Effect	NN	O
of	IN	O
duloxetine	NN	PM
on	IN	O
pain	NN	O
,	,	O
function	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
among	IN	O
patients	NNS	O
with	IN	O
chemotherapy-induced	JJ	O
painful	JJ	O
peripheral	JJ	O
neuropathy	NN	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

IMPORTANCE	NNP	O
There	EX	O
are	VBP	O
no	DT	O
known	JJ	O
effective	JJ	O
treatments	NNS	O
for	IN	O
painful	JJ	O
chemotherapy-induced	JJ	O
peripheral	JJ	O
neuropathy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
duloxetine	NN	PM
,	,	O
60	CD	O
mg	JJ	O
daily	RB	O
,	,	O
on	IN	O
average	JJ	O
pain	NN	O
severity	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
crossover	NN	O
trial	NN	O
at	IN	O
8	CD	O
National	NNP	O
Cancer	NNP	O
Institute	NNP	O
(	(	O
NCI	NNP	O
)	)	O
-funded	VBD	O
cooperative	JJ	O
research	NN	O
networks	NNS	O
that	WDT	O
enrolled	VBD	O
231	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
25	CD	O
years	NNS	O
or	CC	O
older	JJR	O
being	VBG	O
treated	VBN	O
at	IN	O
community	NN	O
and	CC	O
academic	JJ	O
settings	NNS	O
between	IN	O
April	NNP	O
2008	CD	O
and	CC	O
March	NNP	O
2011	CD	O
.	.	O

Study	NNP	O
follow-up	NN	O
was	VBD	O
completed	VBN	O
July	NNP	O
2012	CD	O
.	.	O

Stratified	VBN	O
by	IN	O
chemotherapeutic	JJ	O
drug	NN	O
and	CC	O
comorbid	NN	O
pain	NN	O
risk	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
duloxetine	NN	PM
followed	VBN	O
by	IN	O
placebo	NN	C
or	CC	O
placebo	NN	C
followed	VBN	O
by	IN	O
duloxetine	NN	PM
.	.	O

Eligibility	NN	O
required	VBD	O
that	IN	O
patients	NNS	O
have	VBP	O
grade	VBN	O
1	CD	O
or	CC	O
higher	JJR	O
sensory	NN	O
neuropathy	JJ	O
according	VBG	O
to	TO	O
the	DT	O
NCI	NNP	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNS	O
and	CC	O
at	IN	O
least	JJS	O
4	CD	O
on	IN	O
a	DT	O
scale	NN	O
of	IN	O
0	CD	O
to	TO	O
10	CD	O
,	,	O
representing	VBG	O
average	JJ	O
chemotherapy-induced	JJ	O
pain	NN	O
,	,	O
after	IN	O
paclitaxel	NN	O
,	,	O
other	JJ	O
taxane	NN	O
,	,	O
or	CC	O
oxaliplatin	JJ	O
treatment	NN	O
.	.	O

INTERVENTIONS	VBZ	O
The	DT	O
initial	JJ	O
treatment	NN	O
consisted	VBN	O
of	IN	O
taking	VBG	O
1	CD	O
capsule	JJ	O
daily	RB	O
of	IN	O
either	CC	O
30	CD	O
mg	NN	O
of	IN	O
duloxetine	NN	PM
or	CC	O
placebo	NN	C
for	IN	O
the	DT	O
first	JJ	O
week	NN	O
and	CC	O
2	CD	O
capsules	NNS	O
of	IN	O
either	DT	O
30	CD	O
mg	NN	O
of	IN	O
duloxetine	NN	PM
or	CC	O
placebo	JJ	C
daily	JJ	O
for	IN	O
4	CD	O
additional	JJ	O
weeks	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
primary	JJ	O
hypothesis	NN	O
was	VBD	O
that	IN	O
duloxetine	NN	PM
would	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	C
in	IN	O
decreasing	VBG	O
chemotherapy-induced	JJ	O
peripheral	JJ	O
neuropathic	JJ	O
pain	NN	O
.	.	O

Pain	NNP	O
severity	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Brief	JJ	O
Pain	NNP	O
Inventory-Short	NNP	O
Form	NNP	O
average	NN	O
pain	NN	O
item	NN	O
with	IN	O
0	CD	O
representing	VBG	O
no	DT	O
pain	NN	O
and	CC	O
10	CD	O
representing	VBG	O
as	RB	O
bad	JJ	O
as	IN	O
can	MD	O
be	VB	O
imagined	VBN	O
.	.	O

RESULTS	JJ	O
Individuals	NNS	O
receiving	VBG	O
duloxetine	NN	O
as	IN	O
their	PRP$	O
initial	JJ	O
5-week	JJ	O
treatment	NN	O
reported	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
average	JJ	O
pain	NN	O
of	IN	O
1.06	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.72-1.40	NNP	O
)	)	O
vs	VBZ	O
0.34	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.01-0.66	NNP	O
)	)	O
among	IN	O
those	DT	O
who	WP	O
received	VBD	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
;	:	O
effect	NN	O
size	NN	O
,	,	O
0.513	CD	O
)	)	O
.	.	O

The	DT	O
observed	JJ	O
mean	JJ	O
difference	NN	O
in	IN	O
the	DT	O
average	JJ	O
pain	NN	O
score	NN	O
between	IN	O
duloxetine	NN	PM
and	CC	O
placebo	NN	C
was	VBD	O
0.73	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.26-1.20	NN	O
)	)	O
.	.	O

Fifty-nine	JJ	O
percent	NN	O
of	IN	O
those	DT	O
initially	RB	O
receiving	VBG	O
duloxetine	NN	PM
vs	FW	O
38	CD	O
%	NN	O
of	IN	O
those	DT	O
initially	RB	O
receiving	VBG	O
placebo	NN	O
reported	VBD	O
decreased	JJ	O
pain	NN	O
of	IN	O
any	DT	O
amount	NN	O
.	.	O

CONCLUSION	NNP	O
AND	CC	O
RELEVANCE	NNP	O
Among	IN	O
patients	NNS	O
with	IN	O
painful	JJ	O
chemotherapy-induced	JJ	O
peripheral	JJ	O
neuropathy	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
duloxetine	NN	PM
compared	VBN	O
with	IN	O
placebo	NN	C
for	IN	O
5	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
a	DT	O
greater	JJR	O
reduction	NN	O
in	IN	O
pain	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00489411	NN	O
.	.	O

Need	NN	O
for	IN	O
insulin	NN	PM
therapy	NN	PM
in	IN	O
type	NN	O
II	NNP	O
diabetes	VBZ	O
mellitus	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

To	TO	O
identify	VB	O
patients	NNS	O
with	IN	O
type	JJ	O
II	NNP	O
diabetes	VBZ	O
mellitus	NN	O
for	IN	O
whom	WP	O
insulin	NN	PM
therapy	NN	PM
is	VBZ	O
most	RBS	O
beneficial	JJ	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
in	IN	O
the	DT	O
general	JJ	O
medicine	NN	O
clinic	NN	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
.	.	O

Asymptomatic	NNP	O
,	,	O
obese	JJ	O
,	,	O
insulin-treated	JJ	O
patients	NNS	O
were	VBD	O
given	VBN	O
diet	JJ	E
and	CC	E
diabetes	VBZ	E
education	NN	E
and	CC	O
,	,	O
in	IN	O
half	NN	O
of	IN	O
these	DT	O
patients	NNS	O
,	,	O
insulin	JJ	PM
therapy	NN	PM
was	VBD	O
withdrawn	VBN	O
.	.	O

Over	IN	O
six	CD	O
months	NNS	O
,	,	O
patients	NNS	O
developing	VBG	O
hyperglycemic	JJ	O
symptoms	NNS	O
or	CC	O
acetonemia	NN	O
were	VBD	O
counted	VBN	O
as	IN	O
study	NN	O
failures	NNS	O
.	.	O

Failure	NN	O
criteria	NNS	O
developed	VBD	O
in	IN	O
13	CD	O
of	IN	O
25	CD	O
insulin-withdrawal	JJ	O
patients	NNS	O
,	,	O
at	IN	O
a	DT	O
median	NN	O
of	IN	O
four	CD	O
weeks	NNS	O
after	IN	O
withdrawal	NN	O
,	,	O
compared	VBN	O
with	IN	O
two	CD	O
of	IN	O
24	CD	O
control	NN	O
subjects	NNS	O
.	.	O

Elevated	VBN	O
stimulated	VBD	O
glucose	JJ	O
levels	NNS	O
predicted	VBD	O
the	DT	O
need	NN	O
for	IN	O
insulin	JJ	O
therapy	NN	O
.	.	O

Hyperglycemia	NNP	O
worsened	VBD	O
in	IN	O
insulin-withdrawal	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
meet	VB	O
study	JJ	O
failure	NN	O
criteria	NNS	O
,	,	O
but	CC	O
it	PRP	O
improved	VBD	O
in	IN	O
control	NN	O
patients	NNS	O
.	.	O

Study	NNP	O
patients	NNS	O
were	VBD	O
insulin	JJ	O
deficient	NN	O
as	IN	O
shown	VBN	O
by	IN	O
low	JJ	O
baseline	NN	O
C	NNP	O
peptide	NN	O
values	NNS	O
(	(	O
0.43	CD	O
+/-	JJ	O
0.05	CD	O
nmol/L	NN	O
)	)	O
.	.	O

The	DT	O
prompt	JJ	O
metabolic	JJ	O
decompensation	NN	O
precipitated	VBN	O
by	IN	O
insulin	NN	O
withdrawal	NN	O
suggests	VBZ	O
that	IN	O
insulin-deficient	JJ	O
patients	NNS	O
may	MD	O
benefit	VB	O
from	IN	O
insulin	NN	O
therapy	NN	O
and	CC	O
may	MD	O
need	VB	O
it	PRP	O
to	TO	O
prevent	VB	O
symptomatic	JJ	O
hyperglycemia	NN	O
.	.	O

Short-term	JJ	O
effects	NNS	O
of	IN	O
prednisolone	NN	PM
and	CC	O
dexamethasone	NN	PM
on	IN	O
circulating	VBG	O
concentrations	NNS	O
of	IN	O
leptin	NN	O
and	CC	O
sex	NN	O
hormone-binding	JJ	O
globulin	NN	O
in	IN	O
children	NNS	O
being	VBG	O
treated	VBN	O
for	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukaemia	NN	O
.	.	O

OBJECTIVE	NNP	O
Disturbances	NNPS	O
in	IN	O
body	NN	O
weight	JJ	O
regulation	NN	O
are	VBP	O
often	RB	O
encountered	VBN	O
during	IN	O
glucocorticoid	JJ	PM
treatment	NN	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
increased	JJ	O
insulin	NN	O
resistance	NN	O
and	CC	O
truncal	JJ	O
fat	NN	O
accumulation	NN	O
.	.	O

Children	NNP	O
were	VBD	O
investigated	VBN	O
who	WP	O
were	VBD	O
receiving	VBG	O
glucocorticoid	JJ	PM
treatment	NN	O
for	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukaemia	NN	O
(	(	O
ALL	DT	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	CC	O
prednisolone	VB	PM
or	CC	O
dexamethasone	VB	PM
as	IN	O
part	NN	O
of	IN	O
induction	NN	O
of	IN	O
remission	NN	O
.	.	O

This	DT	O
randomization	NN	O
process	NN	O
provided	VBD	O
a	DT	O
suitable	JJ	O
opportunity	NN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
these	DT	O
two	CD	O
administered	VBD	O
steroid	NN	O
on	IN	O
surrogate	JJ	O
markers	NNS	O
of	IN	O
adipocyte	NN	O
activity	NN	O
(	(	O
leptin	NN	O
)	)	O
and	CC	O
hyperinsulinaemia/insulin	JJ	O
resistance	NN	O
(	(	O
SHBG	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
AND	CC	O
PATIENTS	NNP	O
Prospective	NNP	O
study	NN	O
over	IN	O
16	CD	O
weeks	NNS	O
of	IN	O
children	NNS	O
randomized	VBN	O
to	TO	O
receive	VB	O
prednisolone	NN	PM
(	(	O
40	CD	O
mg/m2	NN	O
)	)	O
or	CC	O
dexamethasone	NN	PM
(	(	O
6.5	CD	O
mg/m2	NN	O
)	)	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
MRC-ALL97/99	NNP	O
induction	NN	PM
chemotherapy	NN	PM
for	IN	O
ALL	NNP	O
.	.	O

Nineteen	NNP	O
children	NNS	O
(	(	O
8	CD	O
male	NN	O
,	,	O
11	CD	O
female	NN	O
)	)	O
with	IN	O
a	DT	O
median	JJ	O
age	NN	O
5.9	CD	O
years	NNS	O
(	(	O
range	VB	O
2.6-13	CD	O
years	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
into	IN	O
the	DT	O
study	NN	O
.	.	O

Main	NNP	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
body	JJ	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
,	,	O
serum	JJ	O
leptin	NN	O
and	CC	O
sex	NN	O
hormone	NN	O
binding	VBG	O
globulin	NN	O
(	(	O
SHBG	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Glucocorticoid	NNP	O
administration	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
increases	NNS	O
in	IN	O
BMI	NNP	O
,	,	O
leptin	NN	O
(	(	O
corrected	VBN	O
for	IN	O
BMI	NNP	O
)	)	O
and	CC	O
the	DT	O
leptin	NN	O
:	:	O
SHBG	NNP	O
ratio	NN	O
and	CC	O
lowering	NN	O
of	IN	O
SHBG	NNP	O
.	.	O

Dose	NNP	O
for	IN	O
dose	NN	O
,	,	O
dexamethasone	NN	PM
was	VBD	O
significantly	RB	O
more	RBR	O
potent	JJ	O
than	IN	O
prednisolone	NN	PM
in	IN	O
altering	VBG	O
these	DT	O
parameters	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Short-term	JJ	O
glucocorticoid	NN	O
treatment	NN	O
has	VBZ	O
significant	JJ	O
effects	NNS	O
on	IN	O
BMI	NNP	O
,	,	O
leptin	NN	O
and	CC	O
SHBG	NNP	O
.	.	O

The	DT	O
leptin	NN	O
:	:	O
SHBG	NNP	O
ratio	NN	O
increase	NN	O
indicates	VBZ	O
that	IN	O
this	DT	O
may	MD	O
be	VB	O
a	DT	O
novel	JJ	O
and	CC	O
sensitive	JJ	O
biochemical	JJ	O
marker	NN	O
of	IN	O
metabolic	JJ	O
change	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
glucocorticoid	JJ	PM
treatment	NN	O
regimens	NNS	O
should	MD	O
be	VB	O
kept	VBN	O
as	RB	O
short	JJ	O
as	IN	O
possible	JJ	O
to	TO	O
avoid	VB	O
possible	JJ	O
detrimental	JJ	O
effects	NNS	O
associated	VBN	O
with	IN	O
increased	JJ	O
adiposity	NN	O
and	CC	O
insulin	NN	O
resistance	NN	O
.	.	O

Safety	NN	O
of	IN	O
ferumoxytol	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
anemia	NN	O
and	CC	O
CKD	NNP	O
.	.	O

BACKGROUND	NNP	O
Iron	NNP	O
deficiency	NN	O
anemia	NN	O
is	VBZ	O
a	DT	O
common	JJ	O
complication	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
CKD	NNP	O
)	)	O
.	.	O

Currently	NNP	O
available	JJ	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
iron	NN	PM
replacement	NN	PM
therapies	NNS	PM
have	VBP	O
either	DT	O
inconvenient	JJ	O
regimens	NNS	O
of	IN	O
administration	NN	O
or	CC	O
adverse	JJ	O
event	NN	O
profiles	NNS	O
that	WDT	O
limit	VBP	O
their	PRP$	O
utility	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
setting	NN	O
.	.	O

Ferumoxytol	NNP	PM
is	VBZ	O
a	DT	O
novel	NN	O
,	,	O
semisynthetic	JJ	O
,	,	O
carbohydrate-coated	JJ	O
,	,	O
superparamagnetic	JJ	O
iron	NN	O
oxide	NN	O
nanoparticle	NN	O
that	WDT	O
is	VBZ	O
administered	VBN	O
IV	NNP	O
as	IN	O
an	DT	O
injection	NN	O
.	.	O

The	DT	O
main	JJ	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
safety	NN	O
of	IN	O
ferumoxytol	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
CKD	NNP	O
stages	VBZ	O
1	CD	O
to	TO	O
5	CD	O
and	CC	O
5D	CD	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Phase	NNP	O
3	CD	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
crossover	NN	O
,	,	O
multicenter	NN	O
study	NN	O
of	IN	O
a	DT	O
single	JJ	O
510-mg	JJ	O
dose	NN	O
of	IN	O
ferumoxytol	JJ	PM
versus	NN	O
saline	NN	C
as	IN	PM
placebo	NN	PM
.	.	O

SETTING	NNP	O
&	CC	O
PARTICIPANTS	NNP	O
750	CD	O
patients	NNS	O
with	IN	O
CKD	NNP	O
stages	VBZ	O
1	CD	O
to	TO	O
5	CD	O
and	CC	O
5D	CD	O
.	.	O

INTERVENTION	NNP	O
An	DT	O
IV	NNP	PM
injection	NN	PM
of	IN	O
either	CC	O
17	CD	O
mL	NN	O
of	IN	O
ferumoxytol	NN	PM
or	CC	O
saline	NN	C
placebo	NN	PM
over	IN	O
17	CD	O
seconds	NNS	O
on	IN	O
day	NN	O
0	CD	O
and	CC	O
the	DT	O
alternate	NN	O
agent	NN	O
on	IN	O
day	NN	O
7	CD	O
.	.	O

OUTCOMES	NNP	O
&	CC	O
MEASUREMENTS	NNP	O
Descriptive	NNP	O
comparison	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
,	,	O
laboratory	NN	O
tests	NNS	O
,	,	O
and	CC	O
vital	JJ	O
signs	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
750	CD	O
randomly	NNS	O
assigned	VBD	O
patients	NNS	O
with	IN	O
CKD	NNP	O
,	,	O
60	CD	O
%	NN	O
were	VBD	O
not	RB	O
on	IN	O
dialysis	NN	PH
therapy	NN	PH
.	.	O

713	CD	O
patients	NNS	O
received	VBD	O
ferumoxytol	JJ	PM
,	,	O
and	CC	O
711	CD	O
received	VBD	O
placebo	NN	C
.	.	O

There	EX	O
were	VBD	O
420	CD	O
adverse	JJ	O
events	NNS	O
reported	VBD	O
;	:	O
242	CD	O
in	IN	O
152	CD	O
patients	NNS	O
(	(	O
21.3	CD	O
%	NN	O
)	)	O
with	IN	O
ferumoxytol	NN	O
and	CC	O
178	CD	O
in	IN	O
119	CD	O
patients	NNS	O
(	(	O
16.7	CD	O
%	NN	O
)	)	O
with	IN	O
placebo	NN	C
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
related	JJ	O
adverse	JJ	O
events	NNS	O
was	VBD	O
5.2	CD	O
%	NN	O
with	IN	O
ferumoxytol	NN	PM
and	CC	O
4.5	CD	O
%	NN	O
with	IN	O
placebo	NN	C
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
related	JJ	O
adverse	JJ	O
events	NNS	O
after	IN	O
each	DT	O
treatment	NN	O
included	VBD	O
symptoms	NNS	O
related	VBN	O
to	TO	O
the	DT	O
injection/infusion	NN	O
site	NN	O
,	,	O
dizziness	NN	O
,	,	O
pruritus	NN	O
,	,	O
headache	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
nausea	NN	O
.	.	O

Serious	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
in	IN	O
21	CD	O
patients	NNS	O
(	(	O
2.9	CD	O
%	NN	O
)	)	O
after	IN	O
ferumoxytol	NN	PM
and	CC	O
13	CD	O
patients	NNS	O
(	(	O
1.8	CD	O
%	NN	O
)	)	O
after	IN	O
placebo	NN	C
.	.	O

Serious	JJ	O
related	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
1	CD	O
patient	NN	O
(	(	O
0.1	CD	O
%	NN	O
)	)	O
after	IN	O
each	DT	O
treatment	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
meaningful	JJ	O
decrease	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
after	IN	O
administration	NN	O
of	IN	O
ferumoxytol	NN	PM
or	CC	O
placebo	NN	C
.	.	O

LIMITATIONS	NNP	O
Follow-up	NNP	O
was	VBD	O
7	CD	O
days	NNS	O
after	IN	O
each	DT	O
study	NN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Ferumoxytol	NNP	PM
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
has	VBZ	O
a	DT	O
safety	NN	O
profile	NN	O
similar	JJ	O
to	TO	O
placebo	VB	C
in	IN	O
anemic	JJ	O
patients	NNS	O
with	IN	O
CKD	NNP	O
stages	VBZ	O
1	CD	O
to	TO	O
5	CD	O
and	CC	O
5D	CD	O
.	.	O

[	JJ	O
Efficacy	NNP	O
of	IN	O
naftopidil	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
overactive	JJ	O
bladder	NN	O
associated	VBN	O
with	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
:	:	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
to	TO	O
compare	VB	O
differences	NNS	O
in	IN	O
efficacy	NN	O
between	IN	O
morning	NN	O
and	CC	O
evening	VBG	O
medication	NN	O
]	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
100	CD	O
patients	NNS	O
with	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
and	CC	O
overactive	JJ	O
bladder	NN	O
(	(	O
OAB	NNP	O
)	)	O
symptoms	NNS	O
(	(	O
BPH/OAB	NNP	O
)	)	O
,	,	O
enrolled	VBN	O
between	IN	O
June	NNP	O
2006	CD	O
to	TO	O
March	NNP	O
2008	CD	O
,	,	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
of	IN	O
morning	NN	O
medication	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
evening	VBG	O
medication	NN	O
(	(	O
E	NNP	O
)	)	O
groups	NNS	O
,	,	O
then	RB	O
50	CD	O
mg	NN	O
of	IN	O
naftopidil	NN	PM
was	VBD	O
given	VBN	O
once	RB	O
a	DT	O
day	NN	O
after	IN	O
breakfast	NN	O
or	CC	O
supper	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
efficacy	NN	O
analysis	NN	O
on	IN	O
80	CD	O
patients	NNS	O
(	(	O
M	NNP	O
group	NN	O
;	:	O
43	CD	O
,	,	O
E	NNP	O
group	NN	O
;	:	O
37	CD	O
)	)	O
.	.	O

Naftopidil	NNP	PM
significantly	RB	O
improved	VBD	O
the	DT	O
overall	JJ	O
international	JJ	O
prostatic	JJ	O
symptom	NN	O
score	NN	O
;	:	O
from	IN	O
19.2?7.9	CD	O
to	TO	O
11.7?5.8	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
and	CC	O
from	IN	O
19.4?6.4	CD	O
to	TO	O
12.3?6.8	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
QOL	NNP	O
score	NN	O
from	IN	O
4.9?0.8	CD	O
to	TO	O
3.2?1.4	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
and	CC	O
from	IN	O
5.0?0.8	CD	O
to	TO	O
3.6?1.3	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
OAB	NNP	O
symptom	VBD	O
score	NN	O
from	IN	O
7.8?2.6	CD	O
to	TO	O
5.0?2.5	CD	O
in	IN	O
the	DT	O
M	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
from	IN	O
8.6?2.9	CD	O
to	TO	O
5.8?	CD	O
3.3	CD	O
in	IN	O
the	DT	O
E	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
between	IN	O
the	DT	O
M	NNP	O
group	NN	O
(	(	O
6.1	CD	O
%	NN	O
)	)	O
and	CC	O
E	NNP	O
group	NN	O
(	(	O
2.2	CD	O
%	NN	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
naftopidil	JJ	O
improves	NNS	O
storage	NN	O
symptoms	NNS	O
as	RB	O
well	RB	O
as	IN	O
voiding	VBG	O
symptoms	NNS	O
regardless	RB	O
of	IN	O
timing	NN	O
of	IN	O
administration	NN	O
.	.	O

Early	JJ	O
combination	NN	O
disease-modifying	JJ	O
antirheumatic	JJ	PM
drug	NN	PM
therapy	NN	PM
and	CC	O
tight	JJ	O
disease	NN	O
control	NN	O
improve	VB	O
long-term	JJ	O
radiologic	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
rheumatoid	NN	O
arthritis	NN	O
:	:	O
the	DT	O
11-year	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Finnish	NNP	O
Rheumatoid	NNP	O
Arthritis	NNP	O
Combination	NNP	O
Therapy	NNP	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
Early	NNP	O
treatment	NN	O
of	IN	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
retard	VB	O
the	DT	O
development	NN	O
of	IN	O
joint	JJ	O
damage	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
up	IN	O
to	TO	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
radiologic	JJ	O
progression	NN	O
beyond	IN	O
that	DT	O
time	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
RA	NNP	O
initially	RB	O
treated	VBD	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
three	CD	PM
disease-modifying	JJ	PM
antirheumatic	JJ	PM
drugs	NNS	PM
(	(	PM
DMARDs	NNP	PM
)	)	PM
or	CC	O
a	DT	O
single	JJ	PM
DMARD	NNP	PM
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
199	CD	O
patients	NNS	O
with	IN	O
early	JJ	O
active	JJ	O
RA	NNP	O
were	VBD	O
initially	RB	O
randomized	VBN	O
to	TO	O
receive	VB	O
treatment	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
methotrexate	NN	PM
,	,	O
sulfasalazine	NN	PM
,	,	O
and	CC	O
hydroxychloroquine	NN	PM
with	IN	PM
prednisolone	NN	PM
(	(	PM
FIN-RACo	NNP	PM
)	)	PM
,	,	O
or	CC	O
treatment	NN	O
with	IN	O
a	DT	O
single	JJ	PM
DMARD	NNP	PM
(	(	PM
initially	RB	PM
,	,	PM
sulfasalazine	NN	PM
)	)	PM
with	IN	O
or	CC	O
without	IN	O
prednisolone	NN	PM
(	(	PM
SINGLE	NNP	PM
)	)	PM
.	.	O

After	IN	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
drug-treatment	JJ	O
strategy	NN	O
became	VBD	O
unrestricted	JJ	O
,	,	O
but	CC	O
still	RB	O
targeted	VBN	O
remission	NN	O
.	.	O

The	DT	O
radiographs	NN	O
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
using	VBG	O
the	DT	O
Larsen	NNP	O
score	NN	O
at	IN	O
baseline	NN	O
,	,	O
2	CD	O
,	,	O
5	CD	O
,	,	O
and	CC	O
11	CD	O
years	NNS	O
,	,	O
and	CC	O
the	DT	O
radiographs	NN	O
of	IN	O
large	JJ	O
joints	NNS	O
,	,	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
Sixty-five	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	PM
and	CC	O
65	CD	O
in	IN	O
the	DT	O
SINGLE	NNP	PM
group	NN	O
had	VBD	O
radiographs	NN	O
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
available	JJ	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
11	CD	O
years	NNS	O
in	IN	O
Larsen	NNP	O
score	NN	O
was	VBD	O
17	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
12	CD	O
to	TO	O
26	CD	O
)	)	O
in	IN	O
the	DT	O
FIN-RACo	NNP	PM
group	NN	O
and	CC	O
27	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
22	CD	O
to	TO	O
33	CD	O
)	)	O
in	IN	O
the	DT	O
SINGLE	NNP	PM
group	NN	O
(	(	O
P=0.037	NNP	O
)	)	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
87	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
74	CD	O
to	TO	O
94	CD	O
)	)	O
and	CC	O
72	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
58	CD	O
to	TO	O
84	CD	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
and	CC	O
the	DT	O
SINGLE	NNP	O
treatment	NN	O
arms	NNS	O
,	,	O
respectively	RB	O
,	,	O
had	VBD	O
no	DT	O
erosive	JJ	O
changes	NNS	O
in	IN	O
large	JJ	O
joints	NNS	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Targeting	VBG	O
to	TO	O
remission	NN	O
with	IN	O
tight	JJ	O
clinical	JJ	O
controls	NNS	O
results	NNS	O
in	IN	O
low	JJ	O
radiologic	JJ	O
progression	NN	O
in	IN	O
most	JJS	O
RA	JJ	O
patients	NNS	O
.	.	O

Patients	NNS	O
treated	VBD	O
initially	RB	O
with	IN	O
a	DT	O
combination	NN	PM
of	IN	PM
DMARDs	NNP	PM
have	VBP	O
less	RBR	O
long-term	JJ	O
radiologic	NN	O
damage	NN	O
than	IN	O
do	VBP	O
those	DT	O
treated	VBN	O
initially	RB	O
with	IN	O
DMARD	NNP	PM
monotherapy	NN	PM
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
ISRCTN18445519	NNP	O
.	.	O

A	DT	O
30-month	JJ	O
longitudinal	JJ	O
study	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
some	DT	O
oral	JJ	PH
hygiene	NN	PH
measures	NNS	PH
on	IN	O
Streptococcus	NNP	O
mutans	NNS	O
and	CC	O
approximal	JJ	O
dental	JJ	O
caries	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
some	DT	O
oral	JJ	PH
hygiene	NN	PH
measures	NNS	PH
on	IN	O
Streptococcus	NNP	O
mutants	NNS	O
and	CC	O
approximal	JJ	O
dental	JJ	O
caries	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eighty-seven	JJ	O
13-year-old	JJ	O
individuals	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
salivary	JJ	O
S.	NNP	O
mutans	NNS	O
(	(	O
greater	JJR	O
than	IN	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/mL	NN	O
)	)	O
were	VBD	O
selected	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
distributed	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
initially	RB	O
received	VBD	O
professional	JJ	PH
mechanical	JJ	PH
tooth-cleaning	NN	PH
,	,	E
tongue-scraping	NN	PH
,	,	E
chlorhexidine	NN	C
treatment	NN	C
,	,	E
and	CC	E
oral	JJ	E
hygiene	NN	E
instructions	NNS	E
concentrated	VBD	O
on	IN	O
the	DT	O
approximal	JJ	O
surfaces	NNS	O
most	RBS	O
colonized	VBN	O
by	IN	O
S.	NNP	O
mutans	NNS	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
given	VBN	O
four	CD	O
times	NNS	O
with	IN	O
intervals	NNS	O
of	IN	O
two	CD	O
days	NNS	O
,	,	O
followed	VBN	O
by	IN	O
one	CD	O
single	JJ	O
treatment	NN	O
every	DT	O
six	CD	O
months	NNS	O
throughout	IN	O
the	DT	O
experimental	JJ	O
period	NN	O
.	.	O

The	DT	O
initial	JJ	O
treatment	NN	O
period	NN	O
for	IN	O
group	NN	O
II	NNP	O
,	,	O
also	RB	O
consisting	VBG	O
of	IN	O
four	CD	O
visits	NNS	O
,	,	O
included	VBD	O
the	DT	O
same	JJ	O
oral	JJ	E
hygiene	NN	E
instructions	NNS	E
as	IN	O
for	IN	O
group	NN	O
I	PRP	O
.	.	O

The	DT	O
instructions	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
six	CD	O
months	NNS	O
.	.	O

Group	NNP	O
III	NNP	O
was	VBD	O
maintained	VBN	O
in	IN	O
the	DT	O
preventive	JJ	E
program	NN	E
provided	VBN	E
by	IN	E
the	DT	E
local	JJ	E
Dental	NNP	E
Health	NNP	E
Office	NNP	E
,	,	O
based	VBN	O
on	IN	O
mechanical	JJ	PH
plaque	NN	PH
control	NN	PH
and	CC	O
topical	JJ	PM
use	NN	PM
of	IN	PM
fluorides	NNS	PM
and	CC	PM
chlorhexidine	NN	PM
at	IN	O
individualized	JJ	O
intervals	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
showed	VBD	O
a	DT	O
significant	JJ	O
immediate	JJ	O
reduction	NN	O
of	IN	O
S.	NNP	O
mutans	NNS	O
in	IN	O
saliva	NN	O
as	RB	O
well	RB	O
as	IN	O
an	DT	O
approximal	JJ	O
tooth	NN	O
surfaces	NNS	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
regarding	VBG	O
these	DT	O
variables	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
baseline	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
S.	NNP	O
mutans	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
caries	NNS	O
progression	NN	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
selected	VBN	O
high-risk	JJ	O
individuals	NNS	O
in	IN	O
group	NN	O
I	PRP	O
developed	VBD	O
0.25	CD	O
new	JJ	O
manifest	NN	O
caries	NNS	O
lesions	NNS	O
approximally/year	VBP	O
,	,	O
compared	VBN	O
with	IN	O
0.27	CD	O
for	IN	O
all	DT	O
children	NNS	O
of	IN	O
the	DT	O
same	JJ	O
age	NN	O
group	NN	O
in	IN	O
the	DT	O
area	NN	O
.	.	O

Seventeen	JJ	O
individuals	NNS	O
had	VBD	O
approximal	JJ	O
surfaces	NNS	O
with	IN	O
consistently	RB	O
high	JJ	O
or	CC	O
consistently	RB	O
low	JJ	O
S.	NNP	O
mutans	NN	O
levels	NNS	O
.	.	O

Forty-six	CD	O
percent	NN	O
of	IN	O
the	DT	O
surfaces	NNS	O
with	IN	O
high	JJ	O
values	NNS	O
developed	VBD	O
new	JJ	O
or	CC	O
progressive	JJ	O
caries	NNS	O
,	,	O
compared	VBN	O
with	IN	O
2	CD	O
%	NN	O
of	IN	O
the	DT	O
surfaces	NNS	O
with	IN	O
low	JJ	O
values	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	PM
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
:	:	O
neuropsychological	JJ	O
measures	NNS	O
.	.	O

OBJECTIVE	NNP	O
There	EX	O
has	VBZ	O
been	VBN	O
recent	JJ	O
interest	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
cognitive	JJ	PM
enhancing	VBG	PM
drugs	NNS	PM
,	,	O
such	JJ	O
as	IN	O
cholinesterase	NN	PH
inhibitors	NNS	PH
,	,	O
as	IN	O
a	DT	O
possible	JJ	O
treatment	NN	O
for	IN	O
executive	NN	O
functioning	NN	O
(	(	O
EF	NNP	O
)	)	O
deficits	NNS	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
tolerability	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	O
on	IN	O
EF	NNP	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

METHOD	NNP	O
Thirty-four	JJ	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
age	NN	O
range	NN	O
8-17	CD	O
years	NNS	O
;	:	O
IQ	NNP	O
>	NNP	O
75	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
10-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
of	IN	O
donepezil	NN	PM
(	(	O
doses	NNS	O
of	IN	O
5	CD	O
and	CC	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
10-week	JJ	O
open	JJ	O
label	NN	O
trial	NN	O
for	IN	O
placebo	NN	O
nonresponders	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
effect	NN	O
of	IN	O
donepezil	NN	O
treatment	NN	O
on	IN	O
EF	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

Despite	IN	O
improvement	NN	O
on	IN	O
a	DT	O
number	NN	O
of	IN	O
EF	NNP	O
measures	NNS	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
between-group	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
(	(	O
with	IN	O
gains	NNS	O
observed	VBN	O
for	IN	O
both	DT	O
the	DT	O
placebo	NN	O
and	CC	O
donepezil	NN	O
groups	NNS	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
donepezil	NN	O
may	MD	O
have	VB	O
limited	VBN	O
impact	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
ASD	NNP	O
.	.	O

Future	NNP	O
controlled	VBD	O
trials	NNS	O
may	MD	O
need	VB	O
to	TO	O
consider	VB	O
a	DT	O
longer	RBR	O
treatment	NN	O
period	NN	O
to	TO	O
detect	VB	O
significant	JJ	O
gains	NNS	O
on	IN	O
EF	NNP	O
measures	NNS	O
.	.	O

Predictors	NNS	O
of	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
and	CC	O
negative	JJ	O
caregiving	NN	O
experiences	NNS	O
in	IN	O
carers	NNS	O
of	IN	O
adolescents	NNS	O
with	IN	O
bulimia	NN	O
nervosa	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
exploratory	NN	O
study	NN	O
focuses	VBZ	O
on	IN	O
the	DT	O
mental	JJ	E
health	NN	E
(	(	E
MH	NNP	E
)	)	E
and	CC	E
caregiving	VBG	E
experience	NN	E
of	IN	E
carers	NNS	E
of	IN	E
adolescents	NNS	E
with	IN	O
Bulimia	NNP	O
Nervosa	NNP	O
(	(	O
BN	NNP	O
)	)	O
/Eating	VBG	O
Disorder	NNP	O
not	RB	O
otherwise	RB	O
specified	VBN	O
(	(	O
EDNOS	NNP	O
)	)	O
,	,	O
aiming	VBG	O
to	TO	O
determine	VB	O
:	:	O
levels	NNS	O
of	IN	O
MH	NNP	O
problems	NNS	O
in	IN	O
carers	NNS	O
and	CC	O
if	IN	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
predicts	NNS	O
carer	VBP	O
MH	NNP	O
status	NN	O
and	CC	O
which	WDT	O
factors	NNS	O
predict	VBP	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
.	.	O

METHOD	NNP	O
Hundred	NNP	O
and	CC	O
twelve	VB	O
carers	NNS	O
and	CC	O
68	CD	O
adolescents	NNS	O
with	IN	O
BN/EDNOS	NNP	O
completed	VBD	O
self-report	JJ	E
measures	NNS	E
(	(	E
General	NNP	E
Health	NNP	E
Questionnaire	NNP	E
,	,	O
Experience	NNP	E
of	IN	E
Caregiving	NNP	E
Inventory	NNP	E
,	,	O
Level	NNP	E
of	IN	E
Expressed	JJ	E
Emotion	NNP	E
,	,	O
Self-report	NNP	E
Family	NNP	E
Inventory	NNP	E
,	,	O
Inventory	NNP	E
of	IN	E
Interpersonal	NNP	E
Problems	NNP	E
)	)	O
.	.	O

RESULTS	NNP	O
Over	IN	O
half	NN	O
of	IN	O
the	DT	O
carers	NNS	O
reported	VBD	O
some	DT	O
MH	NNP	O
problems	NNS	O
and	CC	O
a	DT	O
minority	NN	O
(	(	O
5.4	CD	O
%	NN	O
)	)	O
were	VBD	O
experiencing	VBG	O
considerable	JJ	O
difficulties	NNS	O
.	.	O

A	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
predicted	VBN	O
carer	NN	O
MH	NNP	O
status	NN	O
.	.	O

Higher	JJR	O
weekly	JJ	O
contact	NN	O
hours	NNS	O
and	CC	O
patient	JJ	O
ratings	NNS	O
of	IN	O
expressed	VBN	O
emotion	NN	O
(	(	O
EE	NNP	O
)	)	O
predicted	VBD	O
a	DT	O
negative	JJ	O
experience	NN	O
of	IN	O
caregiving	VBG	O
.	.	O

CONCLUSIONS	NNP	O
Interventions	NNPS	E
focusing	VBG	E
on	IN	E
reducing	VBG	E
EE	NNP	E
and	CC	E
contact	NN	E
hours	NNS	E
could	MD	O
prove	VB	O
beneficial	JJ	O
for	IN	O
both	DT	O
patient	NN	O
and	CC	O
caregiver	NN	O
outcomes	NNS	O
.	.	O

The	DT	O
instruction	NN	O
to	TO	O
refrain	VB	E
from	IN	E
blinking	VBG	E
affects	NNS	O
auditory	JJ	O
P3	NNP	O
and	CC	O
N1	NNP	O
amplitudes	NNS	O
.	.	O

Often	NNP	O
subjects	VBZ	O
have	VBP	O
been	VBN	O
instructed	VBN	O
to	TO	O
refrain	VB	E
from	IN	E
blinking	VBG	E
lest	JJS	O
their	PRP$	O
evoked	JJ	O
EEG	NNP	O
potentials	NNS	O
should	MD	O
be	VB	O
distorted	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
whether	IN	O
these	DT	O
very	RB	O
instructions	NNS	O
have	VBP	O
any	DT	O
impact	NN	O
on	IN	O
P3	NNP	O
amplitude	NN	O
.	.	O

Two	CD	O
tones	NNS	O
were	VBD	O
presented	VBN	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
and	CC	O
subjects	NNS	O
had	VBD	O
to	TO	O
count	VB	O
the	DT	O
high-pitched	JJ	O
tones	NNS	O
.	.	O

Half	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
instructed	VBN	E
not	RB	E
to	TO	E
blink	VB	E
,	,	O
whereas	IN	O
this	DT	O
instruction	NN	O
was	VBD	O
omitted	VBN	O
for	IN	O
the	DT	O
other	JJ	O
subjects	NNS	O
.	.	O

Target	NNP	O
tones	NNS	O
evoked	VBD	O
larger	JJR	O
P3s	NNP	O
than	IN	O
non-targets	NNS	O
in	IN	O
the	DT	O
latter	JJ	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
former	JJ	O
,	,	O
in	IN	O
particular	JJ	O
not	RB	O
in	IN	O
those	DT	O
subjects	NNS	O
that	WDT	O
actually	RB	O
blinked	VBD	O
rarely	RB	O
.	.	O

The	DT	O
groups	NNS	O
also	RB	O
differed	VBN	O
in	IN	O
their	PRP$	O
N1	NNP	O
amplitudes	NNS	O
.	.	O

These	DT	O
findings	NNS	O
might	MD	O
be	VB	O
relevant	JJ	O
to	TO	O
P3	NNP	O
studies	NNS	O
working	VBG	O
with	IN	O
patients	NNS	O
and	CC	O
controls	NNS	O
:	:	O
the	DT	O
harder	NN	O
some	DT	O
frequently	RB	O
blinking	JJ	O
subjects	NNS	O
try	VBP	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	NN	O
,	,	O
the	DT	O
smaller	JJR	O
might	MD	O
become	VB	O
their	PRP$	O
P3	NNP	O
amplitudes	NNS	O
.	.	O

Omitting	VBG	O
the	DT	O
instruction	NN	O
and	CC	O
using	VBG	O
off-line	JJ	O
blink	NN	O
subtraction	NN	O
procedures	NNS	O
seems	VBZ	O
a	DT	O
viable	JJ	O
alternative	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
actually	RB	O
motivated	VBN	O
by	IN	O
discrepant	JJ	O
findings	NNS	O
on	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
preceding	VBG	O
tone	NN	O
sequence	NN	O
on	IN	O
P3	NNP	O
.	.	O

These	DT	O
discrepancies	NNS	O
could	MD	O
be	VB	O
largely	RB	O
resolved	VBN	O
by	IN	O
the	DT	O
instructional	JJ	O
variable	NN	O
,	,	O
in	IN	O
conjunction	NN	O
with	IN	O
different	JJ	O
tone	NN	O
intensities	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
subjects	NNS	E
who	WP	E
are	VBP	E
discouraged	VBN	E
from	IN	E
blinking	VBG	E
try	NN	O
to	TO	O
protect	VB	O
themselves	PRP	O
against	IN	O
the	DT	O
arousing	JJ	O
effects	NNS	O
of	IN	O
stimuli	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
a	DT	O
psychological	JJ	E
intervention	NN	E
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
non-metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
psychological	JJ	PS
intervention	NN	PS
had	VBD	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
behaviour	NN	O
of	IN	O
women	NNS	O
diagnosed	VBN	O
with	IN	O
breast	NN	O
cancer	NN	O
.	.	O

36	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
non-metastatic	JJ	O
breast	NN	O
cancer	NN	O
assigned	VBD	O
to	TO	O
surgery	VB	O
and	CC	O
systemic	VB	O
chemotherapy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
psychological	JJ	PS
intervention	NN	PS
(	(	PS
weekly	JJ	PS
cognitive	VBP	PS
individual	JJ	PS
psychotherapy	NN	PS
and	CC	PS
bimonthly	JJ	PS
family	NN	PS
counselling	VBG	PS
)	)	PS
or	CC	O
standard	JJ	C
follow-up	NN	C
.	.	O

Personality	NNP	O
(	(	O
16-PF	JJ	O
and	CC	O
IIQ	NNP	O
)	)	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
FLIC	NNP	O
)	)	O
,	,	O
and	CC	O
depression	NN	O
(	(	O
BDI	NNP	O
)	)	O
scores	NNS	O
were	VBD	O
the	DT	O
endpoints	NNS	O
for	IN	O
this	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
at	IN	O
diagnosis	NN	O
,	,	O
and	CC	O
up	RB	O
to	TO	O
9	CD	O
months	NNS	O
after	IN	O
diagnosis	NN	O
.	.	O

Cognitive	JJ	O
psychotherapy	NN	O
and	CC	O
family	NN	O
counselling	NN	O
improved	VBD	O
both	DT	O
depression	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
indexes	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Better	NNP	O
emotional	JJ	O
coping	NN	O
behaviours	NNS	O
were	VBD	O
also	RB	O
revealed	VBN	O
by	IN	O
some	DT	O
changes	NNS	O
in	IN	O
personality	NN	O
traits	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

[	JJ	O
European	JJ	O
topic	NN	O
:	:	O
liver	NN	PM
surgery	NN	PM
II	NNP	PM
--	:	PM
regional	JJ	PM
chemotherapy	NN	PM
]	NN	O
.	.	O

The	DT	O
most	RBS	O
important	JJ	O
methods	NNS	O
of	IN	O
regional	JJ	PM
chemotherapy	NN	PM
are	VBP	O
exemplified	VBN	O
by	IN	O
657	CD	O
cases	NNS	O
of	IN	O
primary	JJ	O
and	CC	O
secondary	JJ	O
liver	NN	O
only	RB	O
malignancies	VBZ	O
.	.	O

I	PRP	O
.	.	O

Adjuvant	JJ	S
portal	JJ	S
therapy	NN	S
of	IN	S
the	DT	S
liver	NN	S
with	IN	S
resection	NN	S
of	IN	S
the	DT	S
colorectal	JJ	S
primary	JJ	S
malignancy	NN	S
seems	VBZ	O
to	TO	O
be	VB	O
advantageous	JJ	O
for	IN	O
advanced	JJ	O
tumors	NNS	O
.	.	O

II	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
still	RB	O
unresolved	JJ	O
whether	IN	O
survival	NN	O
is	VBZ	O
prolonged	VBN	O
by	IN	O
adjuvant	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
liver	NN	O
following	VBG	O
curative	JJ	S
resection	NN	S
of	IN	S
colorectal	JJ	S
liver	NN	S
metastases	NNS	S
.	.	O

III	NNP	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
time	NN	O
(	(	O
FUDR	NNP	O
,	,	O
pump	NN	O
)	)	O
is	VBZ	O
17	CD	O
months	NNS	O
for	IN	O
palliative	JJ	PM
local	JJ	PM
chemotherapy	NN	PM
of	IN	O
unresectable	JJ	O
colorectal	JJ	O
liver	NN	O
metastases	NNS	O
.	.	O

IV	NNP	O
.	.	O

Primary	NNP	O
non-resectable	JJ	O
liver	NN	O
malignancies	NNS	O
show	VBP	O
the	DT	O
best	JJS	O
results	NNS	O
after	IN	O
chemoembolisation	NN	O
(	(	O
Frankfurt	NNP	O
method	NN	O
)	)	O
.	.	O

Isoniazid	NNP	O
prophylaxis	NN	O
for	IN	O
tuberculosis	NN	O
in	IN	O
HIV	NNP	O
infection	NN	O
:	:	O
a	DT	O
meta-analysis	NN	O
of	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
isoniazid	NN	PM
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
tuberculosis	NN	O
in	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
individuals	NNS	O
with	IN	O
HIV	NNP	O
infection	NN	O
.	.	O

DESIGN	NNP	O
Meta-analysis	NN	O
of	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
.	.	O

SETTING	NNP	O
Seven	NNP	O
trials	NNS	O
from	IN	O
Mexico	NNP	O
,	,	O
Haiti	NNP	O
,	,	O
the	DT	O
United	NNP	O
States	NNPS	O
,	,	O
Zambia	NNP	O
,	,	O
Uganda	NNP	O
and	CC	O
Kenya	NNP	O
.	.	O

PATIENTS	NNP	O
Individuals	NNP	O
free	JJ	O
from	IN	O
tuberculosis	NN	O
,	,	O
2367	CD	O
persons	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
and	CC	O
2162	CD	O
in	IN	O
the	DT	O
control	NN	O
groups	NNS	O
.	.	O

INTERVENTION	NNP	O
Comparison	NNP	O
of	IN	O
isoniazid	NN	PM
with	IN	O
placebo	NN	C
or	CC	O
no	DT	O
prophylaxis	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
systematic	JJ	O
search	NN	O
of	IN	O
the	DT	O
literature	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
from	IN	O
1985	CD	O
to	TO	O
October	NNP	O
1997	CD	O
for	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
of	IN	O
isoniazid	JJ	PM
prophylaxis	NN	O
in	IN	O
HIV-infected	JJ	O
persons	NNS	O
.	.	O

Two	CD	O
reviewers	NNS	O
evaluated	VBD	O
the	DT	O
relevance	NN	O
of	IN	O
each	DT	O
candidate	NN	O
study	NN	O
and	CC	O
the	DT	O
validity	NN	O
of	IN	O
eligible	JJ	O
trials	NNS	O
.	.	O

Studies	NNS	O
were	VBD	O
pooled	VBN	O
using	VBG	O
a	DT	O
random	JJ	O
effect	NN	O
model	NN	O
,	,	O
conducting	VBG	O
secondary	JJ	O
analyses	NNS	O
for	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
persons	NNS	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
follow-up	NN	O
in	IN	O
trials	NNS	O
varied	VBD	O
between	IN	O
0.4	CD	O
and	CC	O
3.2	CD	O
years	NNS	O
.	.	O

Pooling	VBG	O
all	DT	O
seven	CD	O
trials	NNS	O
,	,	O
a	DT	O
risk	NN	O
ratio	NN	O
was	VBD	O
found	VBN	O
for	IN	O
persons	NNS	O
treated	VBN	O
with	IN	O
isoniazid	NN	PM
for	IN	O
developing	VBG	O
tuberculosis	NN	O
of	IN	O
0.58	CD	O
[	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
0.43-0.80	JJ	O
]	NN	O
and	CC	O
0.94	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.83-1.07	NNP	O
)	)	O
for	IN	O
death	NN	O
.	.	O

In	IN	O
groups	NNS	O
of	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
persons	NNS	O
,	,	O
the	DT	O
risk	NN	O
ratio	NN	O
of	IN	O
tuberculosis	NN	O
was	VBD	O
0.40	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.24-0.65	NNP	O
)	)	O
and	CC	O
0.84	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.54-1.30	NNP	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
isoniazid	JJ	PM
versus	NN	O
placebo	NN	C
between	IN	O
these	DT	O
groups	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
,	,	O
for	IN	O
the	DT	O
difference	NN	O
of	IN	O
summary	JJ	O
estimates	NNS	O
)	)	O
.	.	O

Consistency	NN	O
of	IN	O
results	NNS	O
was	VBD	O
found	VBN	O
across	IN	O
trials	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.10	CD	O
,	,	O
heterogeneity	NN	O
value	NN	O
)	)	O
for	IN	O
all	DT	O
comparisons	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Prophylaxis	NNP	O
with	IN	O
isoniazid	JJ	PM
reduces	NNS	O
the	DT	O
risk	NN	O
of	IN	O
tuberculosis	NN	O
in	IN	O
persons	NNS	O
with	IN	O
HIV	NNP	O
infection	NN	O
.	.	O

The	DT	O
effect	NN	O
is	VBZ	O
restricted	VBN	O
to	TO	O
tuberculin	VB	O
skin	JJ	O
test-positive	JJ	O
persons	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
1-	JJ	O
and	CC	O
3-minute	JJ	O
lockout	NN	O
periods	NNS	O
during	IN	O
patient-controlled	JJ	O
sedation	NN	O
with	IN	O
midazolam	NN	PM
.	.	PM

PURPOSE	VB	O
The	DT	O
maximum	JJ	O
effect	NN	O
of	IN	O
midazolam	NN	PM
injected	VBN	O
intravenously	RB	O
occurs	VBZ	O
in	IN	O
about	IN	O
3	CD	O
minutes	NNS	O
.	.	O

Patient-controlled	JJ	O
sedation	NN	O
carried	VBD	O
out	RP	O
with	IN	O
1-mg	JJ	O
increments	NNS	O
of	IN	O
midazolam	NN	PM
at	IN	O
3-minute	JJ	O
intervals	NNS	O
provides	VBZ	O
comparable	JJ	O
conditions	NNS	O
to	TO	O
that	DT	O
of	IN	O
doctor-controlled	JJ	O
sedation	NN	O
carried	VBD	O
out	RP	O
with	IN	O
1-mg	JJ	O
increments	NNS	O
at	IN	O
1-minute	JJ	O
intervals	NNS	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
longer	JJR	O
duration	NN	O
taken	VBN	O
for	IN	O
the	DT	O
patients	NNS	O
to	TO	O
achieve	VB	O
satisfactory	JJ	O
sedation	NN	O
prior	RB	O
to	TO	O
surgery	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
find	VB	O
out	RP	O
how	WRB	O
safe	JJ	O
it	PRP	O
would	MD	O
be	VB	O
to	TO	O
shorten	VB	O
the	DT	O
interval	NN	O
of	IN	O
increments	NNS	O
of	IN	O
midazolam	NN	PM
to	TO	O
1	CD	O
minute	NN	O
in	IN	O
patient-controlled	JJ	PM
sedation	NN	PM
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
26	CD	O
patients	NNS	O
undergoing	JJ	O
bilateral	JJ	O
lower	JJR	O
third	JJ	O
molar	JJ	O
surgery	NN	O
at	IN	O
two	CD	O
visits	NNS	O
had	VBD	O
patient-controlled	JJ	O
sedation	NN	O
with	IN	O
1	CD	O
mg	NNS	O
midazolam	JJ	PM
increments	NNS	O
at	IN	O
1-minute	JJ	O
or	CC	O
3-minute	JJ	O
intervals	NNS	O
at	IN	O
one	CD	O
visit	NN	O
and	CC	O
the	DT	O
alternative	NN	O
at	IN	O
the	DT	O
other	JJ	O
visit	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
time	NN	O
taken	VBN	O
for	IN	O
patients	NNS	O
to	TO	O
achieve	VB	O
a	DT	O
degree	NN	O
of	IN	O
sedation	NN	O
that	IN	O
they	PRP	O
thought	VBD	O
was	VBD	O
sufficient	JJ	O
to	TO	O
tolerate	VB	O
the	DT	O
surgery	NN	O
was	VBD	O
significantly	RB	O
longer	RBR	O
when	WRB	O
the	DT	O
increment	NN	O
interval	NN	O
was	VBD	O
3	CD	O
minutes	NNS	O
(	(	O
t	JJ	O
=	NNP	O
-4.8	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Both	DT	O
techniques	NNS	O
provided	VBD	O
good	JJ	O
operating	NN	O
conditions	NNS	O
,	,	O
stable	JJ	O
vital	JJ	O
signs	NNS	O
,	,	O
mild	NN	O
to	TO	O
moderate	VB	O
sedation	NN	O
,	,	O
without	IN	O
loss	NN	O
of	IN	O
verbal	JJ	O
contact	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
significant	JJ	O
majority	NN	O
preferred	VBD	O
the	DT	O
sedation	NN	O
technique	NN	O
with	IN	O
1-minute	JJ	O
increment	NN	O
intervals	NNS	O
(	(	O
chi	VB	O
2	CD	O
=	JJ	O
4.6	CD	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
effect	NN	O
of	IN	O
a	DT	O
focused	JJ	E
imitation	NN	E
intervention	NN	E
on	IN	O
social	JJ	O
functioning	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Imitation	NNP	O
is	VBZ	O
an	DT	O
early	JJ	O
skill	NN	O
thought	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
social	JJ	O
development	NN	O
,	,	O
leading	VBG	O
some	DT	O
to	TO	O
suggest	VB	O
that	IN	O
teaching	VBG	O
imitation	NN	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
should	MD	O
lead	VB	O
to	TO	O
improvements	NNS	O
in	IN	O
social	JJ	O
functioning	NN	O
.	.	O

This	DT	O
study	NN	O
used	VBD	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
focused	JJ	E
imitation	NN	E
intervention	NN	E
on	IN	O
initiation	NN	O
of	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
social-emotional	JJ	O
functioning	NN	O
in	IN	O
27	CD	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
the	DT	O
treatment	NN	O
group	NN	O
made	VBD	O
significantly	RB	O
more	RBR	O
gains	NNS	O
in	IN	O
joint	JJ	O
attention	NN	O
initiations	NNS	O
at	IN	O
post-treatment	JJ	O
and	CC	O
follow-up	JJ	O
and	CC	O
social-emotional	JJ	O
functioning	NN	O
at	IN	O
follow-up	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Although	IN	O
gains	NNS	O
in	IN	O
social	JJ	O
functioning	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
treatment	NN	O
,	,	O
a	DT	O
mediation	NN	O
analysis	NN	O
did	VBD	O
not	RB	O
support	VB	O
imitation	NN	O
as	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
the	DT	O
intervention	NN	O
improves	VBZ	O
social	JJ	O
functioning	NN	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
synthetic	JJ	PM
appeasing	VBG	PM
pheromone	NN	PM
on	IN	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
in	IN	O
dogs	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
synthetic	JJ	PM
,	,	PM
dog-appeasing	JJ	PM
pheromone	NN	PM
(	(	PM
sDAP	NN	PM
)	)	PM
on	IN	O
the	DT	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
in	IN	O
dogs	NNS	O
undergoing	VBG	O
elective	JJ	O
orchiectomy	NN	O
or	CC	O
ovariohysterectomy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

ANIMALS	$	O
46	CD	O
dogs	NNS	O
housed	VBN	O
in	IN	O
animal	NN	O
shelters	NNS	O
and	CC	O
undergoing	VBG	O
elective	JJ	O
orchiectomy	NN	O
or	CC	O
ovariohysterectomy	NN	O
.	.	O

PROCEDURES	NNP	O
Intensive	NNP	O
care	NN	O
unit	NN	O
cages	NNS	O
were	VBD	O
sprayed	VBN	O
with	IN	O
sDAP	JJ	PH
solution	NN	PH
or	CC	O
sham	NN	C
treated	VBN	C
with	IN	C
the	DT	C
carrier	NN	C
used	VBN	O
in	IN	O
the	DT	O
solution	NN	O
20	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

Dogs	NNS	O
(	(	O
n	JJ	O
=	NN	O
24	CD	O
and	CC	O
22	CD	O
in	IN	O
the	DT	O
sDAP	NN	PH
and	CC	O
sham	JJ	C
treatment	NN	C
exposure	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
placed	VBN	O
in	IN	O
treated	JJ	O
cages	NNS	O
for	IN	O
30	CD	O
minutes	NNS	O
before	IN	O
and	CC	O
after	IN	O
surgery	NN	O
.	.	O

Indicators	NNS	O
of	IN	O
stress	NN	O
(	(	O
ie	NN	O
,	,	O
alterations	NNS	O
in	IN	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
responses	NNS	O
)	)	O
were	VBD	O
evaluated	VBN	O
perioperatively	RB	O
.	.	O

Behavioral	JJ	O
response	NN	O
variables	NNS	O
,	,	O
salivary	JJ	O
cortisol	NN	O
concentration	NN	O
,	,	O
WBC	NNP	O
count	NN	O
,	,	O
and	CC	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
glucose	NN	O
,	,	O
prolactin	NN	O
,	,	O
haptoglobin	NN	O
,	,	O
and	CC	O
C-reactive	JJ	O
protein	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

RESULTS	NNP	O
Behavioral	NNP	O
response	NN	O
variables	NNS	O
and	CC	O
serum	NN	O
prolactin	NN	O
concentration	NN	O
were	VBD	O
influenced	VBN	O
by	IN	O
sDAP	NN	O
exposure	NN	O
.	.	O

Dogs	NNS	O
exposed	VBD	O
to	TO	O
sDAP	VB	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
alertness	NN	O
and	CC	O
visual	JJ	O
exploration	NN	O
behaviors	NNS	O
after	IN	O
surgery	NN	O
than	IN	O
were	VBD	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
sham	VB	O
treatment	NN	O
.	.	O

Decreases	VBZ	O
in	IN	O
serum	NN	O
prolactin	NN	O
concentrations	NNS	O
in	IN	O
response	NN	O
to	TO	O
perioperative	JJ	O
stress	NN	O
were	VBD	O
significantly	RB	O
smaller	JJR	O
in	IN	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
sDAP	VB	O
,	,	O
compared	VBN	O
with	IN	O
findings	NNS	O
in	IN	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
the	DT	O
sham	NN	O
treatment	NN	O
.	.	O

Variables	NNS	O
examined	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
axis	NN	O
,	,	O
immune	JJ	O
system	NN	O
,	,	O
and	CC	O
acute-phase	JJ	O
responses	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
sDAP	NN	O
appeared	VBD	O
to	TO	O
affect	VB	O
behavioral	JJ	O
and	CC	O
neuroendocrine	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
by	IN	O
modification	NN	O
of	IN	O
lactotropic	JJ	O
axis	NN	O
activity	NN	O
.	.	O

Use	NN	O
of	IN	O
sDAP	NN	PM
in	IN	O
a	DT	O
clinical	JJ	O
setting	NN	O
may	MD	O
improve	VB	O
the	DT	O
recovery	NN	O
and	CC	O
welfare	NN	O
of	IN	O
dogs	NNS	O
undergoing	VBG	O
surgery	NN	O
.	.	O

Virtual	JJ	E
reality	NN	E
intervention	NN	E
for	IN	O
older	JJR	O
women	NNS	O
with	IN	O
breast	NN	O
cancer	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
virtual	JJ	E
reality	NN	E
distraction	NN	E
intervention	NN	E
on	IN	O
chemotherapy-related	JJ	O
symptom	NN	O
distress	NN	O
levels	NNS	O
in	IN	O
16	CD	O
women	NNS	O
aged	VBD	O
50	CD	O
and	CC	O
older	JJR	O
.	.	O

A	DT	O
cross-over	JJ	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
answer	VB	O
the	DT	O
following	JJ	O
research	NN	O
questions	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
Is	VBZ	O
virtual	JJ	O
reality	NN	O
an	DT	O
effective	JJ	O
distraction	NN	O
intervention	NN	O
for	IN	O
reducing	VBG	O
chemotherapy-related	JJ	O
symptom	NN	O
distress	NN	O
levels	NNS	O
in	IN	O
older	JJR	O
women	NNS	O
with	IN	O
breast	NN	O
cancer	NN	O
?	.	O
(	(	O
2	CD	O
)	)	O
Does	NNP	O
virtual	JJ	E
reality	NN	E
have	VBP	O
a	DT	O
lasting	JJ	O
effect	NN	O
?	.	O
Chemotherapy	NN	O
treatments	NNS	O
are	VBP	O
intensive	JJ	O
and	CC	O
difficult	JJ	O
to	TO	O
endure	VB	O
.	.	O

One	CD	O
way	NN	O
to	TO	O
cope	VB	O
with	IN	O
chemotherapy-related	JJ	O
symptom	NN	O
distress	NN	O
is	VBZ	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
distraction	NN	O
.	.	O

For	IN	O
this	DT	O
study	NN	O
,	,	O
a	DT	O
head-mounted	JJ	O
display	NN	O
(	(	O
Sony	NNP	O
PC	NNP	O
Glasstron	NNP	O
PLM	NNP	O
-	:	O
S700	NN	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
display	VB	O
encompassing	VBG	O
images	NNS	O
and	CC	O
block	NN	O
competing	VBG	O
stimuli	NNS	O
during	IN	O
chemotherapy	JJ	O
infusions	NNS	O
.	.	O

The	DT	O
Symptom	NNP	O
Distress	NNP	O
Scale	NNP	O
(	(	O
SDS	NNP	O
)	)	O
,	,	O
Revised	VBN	O
Piper	NNP	O
Fatigue	NNP	O
Scale	NNP	O
(	(	O
PFS	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
State	NNP	O
Anxiety	NNP	O
Inventory	NNP	O
(	(	O
SAI	NNP	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
symptom	JJ	O
distress	NN	O
.	.	O

For	IN	O
two	CD	O
matched	JJ	O
chemotherapy	NN	O
treatments	NNS	O
,	,	O
one	CD	O
pre-test	NN	O
and	CC	O
two	CD	O
post-test	JJ	O
measures	NNS	O
were	VBD	O
employed	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
the	DT	O
VR	NNP	E
distraction	NN	E
intervention	NN	E
during	IN	E
one	CD	E
chemotherapy	NN	PS
treatment	NN	E
and	CC	O
received	VBD	O
no	DT	C
distraction	NN	C
intervention	NN	C
(	(	C
control	VB	C
condition	NN	C
)	)	C
during	IN	O
an	DT	O
alternate	JJ	O
chemotherapy	NN	O
treatment	NN	O
.	.	O

Analysis	NN	O
using	VBG	O
paired	VBN	O
t-tests	NNS	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
SAI	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.10	CD	O
)	)	O
scores	NNS	O
immediately	RB	O
following	VBG	O
chemotherapy	NN	O
treatments	NNS	O
when	WRB	O
participants	NNS	O
used	VBD	O
VR	NNP	O
.	.	O

No	NNP	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
SDS	NNP	O
or	CC	O
PFS	NNP	O
values	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
consistent	JJ	O
trend	NN	O
toward	IN	O
improved	VBN	O
symptoms	NNS	O
on	IN	O
all	DT	O
measures	NNS	O
48	CD	O
h	NN	O
following	VBG	O
completion	NN	O
of	IN	O
chemotherapy	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
intervention	NN	O
indicated	VBD	O
that	IN	O
women	NNS	O
thought	VBD	O
the	DT	O
head	NN	O
mounted	VBD	O
device	NN	O
was	VBD	O
easy	JJ	O
to	TO	O
use	VB	O
,	,	O
they	PRP	O
experienced	VBD	O
no	DT	O
cybersickness	NN	O
,	,	O
and	CC	O
100	CD	O
%	NN	O
would	MD	O
use	VB	O
VR	NNP	O
again	RB	O
.	.	O

Primary	JJ	O
prophylaxis	NN	O
with	IN	O
pyrimethamine	NN	PM
for	IN	O
toxoplasmic	JJ	O
encephalitis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
disease	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

Terry	NNP	O
Beirn	NNP	O
Community	NNP	O
Programs	NNP	O
for	IN	O
Clinical	NNP	O
Research	NNP	O
on	IN	O
AIDS	NNP	O
.	.	O

Pyrimethamine	NNP	PM
,	,	O
25	CD	O
mg	NN	O
thrice	NN	O
weekly	RB	O
,	,	O
was	VBD	O
evaluated	VBN	O
as	IN	O
primary	JJ	O
prophylaxis	NN	O
for	IN	O
toxoplasmic	JJ	O
encephalitis	NN	O
(	(	O
TE	NNP	O
)	)	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
disease	NN	O
,	,	O
absolute	JJ	O
CD4	NNP	O
lymphocyte	NN	O
count	NN	O
of	IN	O
<	$	O
200/microL	CD	O
(	(	O
or	CC	O
prior	RB	O
AIDS-defining	NNP	O
opportunistic	JJ	O
infection	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
serum	NN	O
IgG	NNP	O
to	TO	O
Toxoplasma	NNP	O
gondii	NN	O
.	.	O

Leucovorin	NNP	PM
was	VBD	O
coadministered	VBN	O
only	RB	O
for	IN	O
hematologic	JJ	O
toxicity	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
death	NN	O
rate	NN	O
among	IN	O
patients	NNS	O
receiving	VBG	O
pyrimethamine	NN	PM
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
,	,	O
2.5	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.3-4.8	JJ	O
;	:	O
P	NNP	O
=	NNP	O
.006	NNP	O
)	)	O
,	,	O
even	RB	O
after	IN	O
adjusting	VBG	O
for	IN	O
factors	NNS	O
predictive	CD	O
of	IN	O
survival	NN	O
.	.	O

The	DT	O
TE	NNP	O
event	NN	O
rate	NN	O
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

Only	RB	O
1	CD	O
of	IN	O
218	CD	O
patients	NNS	O
taking	VBG	O
trimethoprim-sulfamethoxazole	JJ	PM
but	CC	O
7	CD	O
of	IN	O
117	CD	O
taking	VBG	O
aerosolized	JJ	PM
pentamidine	NN	PM
for	IN	O
prophylaxis	NN	O
against	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
developed	VBD	O
TE	NNP	O
(	(	O
adjusted	VBN	O
RR	NNP	O
for	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	PM
group	NN	O
,	,	O
0.16	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.01-1.79	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.14	NNP	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
for	IN	O
HIV-infected	JJ	O
patients	NNS	O
receiving	VBG	O
trimethoprim-sulfamethoxazole	JJ	PM
,	,	O
additional	JJ	O
prophylaxis	NN	O
for	IN	O
TE	NNP	O
appears	VBZ	O
unnecessary	JJ	O
.	.	O

Comparison	NNP	O
of	IN	O
maintenance	NN	O
treatment	NN	O
regimens	NNS	O
for	IN	O
first	JJ	O
central	JJ	O
nervous	JJ	O
system	NN	O
relapse	NN	O
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
.	.	O

A	DT	O
Pediatric	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

Eighty-seven	JJ	O
children	NNS	O
with	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
(	(	O
CNS	NNP	O
)	)	O
leukemia	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
induction	NN	PH
intrathecal	JJ	PH
chemotherapy	NN	PH
(	(	PM
ITC	NNP	PM
)	)	PM
and	CC	O
cranial	JJ	PH
irradiation	NN	PH
(	(	PH
CRT	NNP	PH
)	)	PH
plus	CC	PM
maintenance	NN	PH
ITC	NNP	PH
,	,	O
or	CC	O
induction	NN	PH
ITC	NNP	PH
and	CC	PM
craniospinal	JJ	PM
irradiation	NN	PM
(	(	PM
CSpRT	NNP	PM
)	)	PM
with	IN	PM
no	DT	PM
maintenance	NN	PM
ITC	NNP	PM
.	.	O

ITC	NNP	O
consisted	VBD	O
of	IN	O
six	CD	O
weekly	JJ	O
injections	NNS	O
of	IN	O
methotrexate	NN	PM
,	,	O
hydrocortisone	NN	PM
,	,	O
and	CC	O
arabinosylcytosine	NN	PM
.	.	O

Also	RB	O
,	,	O
intensification	NN	PH
of	IN	PH
systemic	JJ	PH
induction	NN	PH
and	CC	O
maintenance	NN	PH
chemotherapy	NN	PH
was	VBD	O
given	VBN	O
.	.	O

CRT	NNP	PH
+	NNP	PM
ITC	NNP	PH
was	VBD	O
given	VBN	O
as	IN	O
CRT	NNP	PH
,	,	O
2400	CD	O
rad	NN	O
in	IN	O
12	CD	O
fractions	NNS	O
followed	VBN	O
by	IN	O
ITC	NNP	PH
maintenance	NN	O
bimonthly	NN	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

Craniospinal	JJ	PH
irradiation	NN	PH
consisted	VBD	PH
of	IN	PH
CRT	NNP	PH
+	NNP	O
1400	CD	O
rad	NN	O
in	IN	O
ten	JJ	O
fractions	NNS	O
to	TO	O
the	DT	O
spine	NN	O
.	.	O

Randomization	NN	O
was	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
whether	IN	O
CNS	NNP	O
leukemia	NN	O
occurred	VBD	O
at	IN	O
initial	JJ	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
(	(	O
ALL	DT	O
)	)	O
(	(	O
Stratum	NNP	O
I	PRP	O
,	,	O
15	CD	O
patients	NNS	O
)	)	O
,	,	O
during	IN	O
first	JJ	O
bone	NN	O
marrow	NN	O
(	(	O
BM	NNP	O
)	)	O
remission	NN	O
(	(	O
Stratum	NNP	O
II	NNP	O
,	,	O
49	CD	O
patients	NNS	O
)	)	O
,	,	O
simultaneous	JJ	O
with	IN	O
first	JJ	O
BM	NNP	O
relapse	NN	O
(	(	O
Stratum	NNP	O
III	NNP	O
,	,	O
12	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
during	IN	O
second	JJ	O
BM	NNP	O
remission	NN	O
(	(	O
Stratum	NNP	O
IV	NNP	O
,	,	O
11	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
follow-up	NN	O
for	IN	O
patients	NNS	O
who	WP	O
remain	VBP	O
at	IN	O
risk	NN	O
is	VBZ	O
15	CD	O
+	JJ	O
months	NNS	O
.	.	O

Eight	NNP	O
children	NNS	O
(	(	O
seven	CD	O
on	IN	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
,	,	O
one	CD	O
on	IN	O
CSpRT	NNP	O
)	)	O
developed	VBD	O
presumed	VBN	O
therapy	RB	O
related	VBN	O
encephalopathy	NN	O
.	.	O

In	IN	O
Stratum	NNP	O
II	NNP	O
,	,	O
16	CD	O
of	IN	O
29	CD	O
(	(	O
55	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
experienced	VBD	O
adverse	JJ	O
events	NNS	O
:	:	O
3	CD	O
deaths	NNS	O
during	IN	O
continuous	JJ	O
complete	JJ	O
remission	NN	O
(	(	O
CCR	NNP	O
)	)	O
and	CC	O
13	CD	O
relapses	NNS	O
(	(	O
2	CD	O
CNS	NNP	O
,	,	O
1	CD	O
CNS	NNP	O
+	NNP	O
BM	NNP	O
,	,	O
1	CD	O
BM	NNP	O
+	NNP	O
testes	VBZ	O
,	,	O
and	CC	O
2	CD	O
testes	NNS	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
only	RB	O
5	CD	O
relapses	NNS	O
in	IN	O
20	CD	O
(	(	O
25	CD	O
%	NN	O
)	)	O
patients	NNS	O
on	IN	O
CSpRT	NNP	O
(	(	O
1	CD	O
CNS	NNP	O
,	,	O
1	CD	O
CNS	NNP	O
+	NNP	O
BM	NNP	O
,	,	O
1	CD	O
BM	NNP	O
,	,	O
and	CC	O
2	CD	O
testes	NNS	O
)	)	O
.	.	O

The	DT	O
children	NNS	O
on	IN	O
both	DT	O
regimens	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
sex	NN	O
,	,	O
race	NN	O
,	,	O
age	NN	O
at	IN	O
initial	JJ	O
ALL	NNP	O
diagnosis	NN	O
,	,	O
time	NN	O
from	IN	O
ALL	NNP	O
diagnosis	NN	O
to	TO	O
first	JJ	O
episode	NN	O
of	IN	O
CNS	NNP	O
leukemia	NN	O
,	,	O
systemic	JJ	O
therapy	NN	O
both	DT	O
before	IN	O
and	CC	O
after	IN	O
CNS	NNP	O
relapse	NN	O
,	,	O
and	CC	O
number	NN	O
of	IN	O
blasts	NNS	O
in	IN	O
the	DT	O
spinal	JJ	O
fluid	NN	O
at	IN	O
diagnosis	NN	O
of	IN	O
CNS	NNP	O
leukemia	NN	O
.	.	O

The	DT	O
conclusion	NN	O
is	VBZ	O
that	IN	O
children	NNS	O
with	IN	O
isolated	JJ	O
CNS	NNP	O
leukemia	NN	O
can	MD	O
achieve	VB	O
prolonged	JJ	O
survival	NN	O
with	IN	O
aggressive	JJ	O
therapy	NN	O
,	,	O
and	CC	O
that	IN	O
CSpRT	NNP	O
is	VBZ	O
possibly	RB	O
less	RBR	O
toxic	JJ	O
and	CC	O
more	RBR	O
likely	JJ	O
than	IN	O
is	VBZ	O
CRT	NNP	O
+	NNP	O
ITC	NNP	O
to	TO	O
prevent	VB	O
subsequent	JJ	O
BM	NNP	O
and	CC	O
testicular	JJ	O
relapse	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
subsequent	JJ	O
CNS	NNP	O
relapse	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.7	CD	O
)	)	O
.	.	O

A	DT	O
possible	JJ	O
systemic	JJ	O
therapy	NN	O
effect	NN	O
of	IN	O
spinal	JJ	O
irradiation	NN	O
is	VBZ	O
postulated	VBN	O
to	TO	O
explain	VB	O
the	DT	O
superiority	NN	O
of	IN	O
CSpRT	NNP	PH
.	.	O

Hypnosis	NNP	PS
treatment	NN	PS
for	IN	O
severe	JJ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
:	:	O
investigation	NN	O
of	IN	O
mechanism	NN	O
and	CC	O
effects	NNS	O
on	IN	O
symptoms	NNS	O
.	.	O

Hypnosis	NNP	PS
improves	VBZ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
(	(	O
IBS	NNP	O
)	)	O
,	,	O
but	CC	O
the	DT	O
mechanism	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

Possible	JJ	O
physiological	JJ	O
and	CC	O
psychological	JJ	O
mechanisms	NNS	O
were	VBD	O
investigated	VBN	O
in	IN	O
two	CD	O
studies	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
severe	JJ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
received	VBD	O
seven	CD	O
biweekly	JJ	PS
hypnosis	NN	PS
sessions	NNS	PS
and	CC	PS
used	VBD	PS
hypnosis	NN	PS
audiotapes	NNS	PS
at	IN	O
home	NN	O
.	.	O

Rectal	JJ	O
pain	NN	O
thresholds	NNS	O
and	CC	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
barostat	NN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
in	IN	O
18	CD	O
patients	NNS	O
(	(	O
study	VB	O
I	PRP	O
)	)	O
,	,	O
and	CC	O
treatment	NN	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
conductance	NN	O
,	,	O
finger	NN	O
temperature	NN	O
,	,	O
and	CC	O
forehead	JJ	O
electromyographic	JJ	O
activity	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
24	CD	O
patients	NNS	O
(	(	O
study	VB	O
II	NNP	O
)	)	O
.	.	O

Somatization	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
depression	NN	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

All	DT	O
central	JJ	O
IBS	NNP	O
symptoms	NNS	O
improved	VBN	O
substantially	RB	O
from	IN	O
treatment	NN	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

Rectal	JJ	O
pain	NN	O
thresholds	NNS	O
,	,	O
rectal	JJ	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
,	,	O
and	CC	O
autonomic	JJ	O
functioning	NN	O
(	(	O
except	IN	O
sweat	NN	O
gland	VBP	O
reactivity	NN	O
)	)	O
were	VBD	O
unaffected	VBN	O
by	IN	O
hypnosis	NN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
somatization	NN	O
and	CC	O
psychological	JJ	O
distress	NN	O
showed	VBD	O
large	JJ	O
decreases	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
hypnosis	NN	E
improves	NNS	O
IBS	NNP	O
symptoms	NNS	O
through	IN	O
reductions	NNS	O
in	IN	O
psychological	JJ	O
distress	NN	O
and	CC	O
somatization	NN	O
.	.	O

Improvements	NNS	O
were	VBD	O
unrelated	JJ	O
to	TO	O
changes	NNS	O
in	IN	O
the	DT	O
physiological	JJ	O
parameters	NNS	O
measured	VBD	O
.	.	O

Environmental	JJ	O
enrichment	NN	O
as	IN	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
autism	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Enriched	NNP	O
sensorimotor	NN	O
environments	NNS	O
enable	JJ	O
rodents	NNS	O
to	TO	O
compensate	VB	O
for	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
neurological	JJ	O
challenges	NNS	O
,	,	O
including	VBG	O
those	DT	O
induced	VBN	O
in	IN	O
animal	JJ	O
models	NNS	O
of	IN	O
autism	NN	O
.	.	O

Given	VBN	O
the	DT	O
sensorimotor	NN	O
deficits	NNS	O
in	IN	O
most	JJS	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
we	PRP	O
attempted	VBD	O
to	TO	O
translate	VB	O
that	DT	O
approach	NN	O
to	TO	O
their	PRP$	O
treatment	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
3-12	JJ	O
year-old	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
sensorimotor	NN	PH
enrichment	NN	PH
group	NN	PH
,	,	O
which	WDT	O
received	VBD	O
daily	RB	O
olfactory/tactile	JJ	PH
stimulation	NN	PH
along	IN	O
with	IN	O
exercises	NNS	PH
that	WDT	O
stimulated	VBD	O
other	JJ	O
paired	JJ	O
sensory	JJ	O
modalities	NNS	O
,	,	O
or	CC	O
to	TO	O
a	DT	O
control	NN	C
group	NN	C
.	.	O

We	PRP	O
administered	VBD	O
tests	NNS	O
of	IN	O
cognitive	JJ	O
performance	NN	O
and	CC	O
autism	NN	O
severity	NN	O
to	TO	O
both	DT	O
groups	NNS	O
at	IN	O
the	DT	O
initiation	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Severity	NNP	O
of	IN	O
autism	NN	O
,	,	O
as	IN	O
assessed	VBN	O
with	IN	O
the	DT	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
improved	VBN	O
significantly	RB	O
in	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
controls	NNS	O
.	.	O

Indeed	RB	O
,	,	O
42	CD	O
%	NN	O
of	IN	O
the	DT	O
enriched	VBN	O
group	NN	O
and	CC	O
only	RB	O
7	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
had	VBD	O
what	WP	O
we	PRP	O
considered	VBD	O
to	TO	O
be	VB	O
a	DT	O
clinically	RB	O
significant	JJ	O
improvement	NN	O
of	IN	O
5	CD	O
points	NNS	O
on	IN	O
that	DT	O
scale	NN	O
.	.	O

Sensorimotor	NNP	O
enrichment	NN	O
also	RB	O
produced	VBD	O
a	DT	O
clear	JJ	O
improvement	NN	O
in	IN	O
cognition	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
their	PRP$	O
Leiter-R	JJ	O
Visualization	NNP	O
and	CC	O
Reasoning	NNP	O
scores	NNS	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
change	NN	O
in	IN	O
average	JJ	O
scores	NNS	O
for	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
was	VBD	O
11.3	CD	O
points	NNS	O
higher	JJR	O
than	IN	O
that	DT	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Finally	RB	O
,	,	O
69	CD	O
%	NN	O
of	IN	O
parents	NNS	O
in	IN	O
the	DT	O
enriched	JJ	O
group	NN	O
and	CC	O
31	CD	O
%	NN	O
of	IN	O
parents	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
reported	VBD	O
improvement	NN	O
in	IN	O
their	PRP$	O
child	NN	O
over	IN	O
the	DT	O
6-month	JJ	O
study	NN	O
.	.	O

Environmental	JJ	O
enrichment	NN	O
therefore	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
ameliorating	VBG	O
some	DT	O
of	IN	O
the	DT	O
symptoms	NNS	O
of	IN	O
autism	NN	O
in	IN	O
children	NNS	O
.	.	O

Divalproex	NNP	PM
sodium	NN	PM
vs.	FW	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	O
behaviours	NNS	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Autism	NNP	O
is	VBZ	O
a	DT	O
neurodevelopmental	JJ	O
disorder	NN	O
characterized	VBN	O
by	IN	O
impairment	NN	O
in	IN	O
three	CD	O
core	NN	O
symptom	NN	O
domains	NNS	O
:	:	O
socialization	NN	O
,	,	O
communication	NN	O
,	,	O
and	CC	O
repetitive/stereotyped	VBD	O
behaviours	NNS	O
.	.	O

Other	JJ	O
associated	JJ	O
symptom	NN	O
domains	NNS	O
are	VBP	O
also	RB	O
affected	JJ	O
including	VBG	O
impulsivity/aggression	NN	O
,	,	O
self-injury	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
mood	NN	O
lability	NN	O
.	.	O

Divalproex	NNP	PM
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
efficacy	NN	O
in	IN	O
treating	VBG	O
epilepsy	NN	O
,	,	O
bipolar	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
lability	NN	O
,	,	O
and	CC	O
impulsive	JJ	O
aggression	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
use	NN	O
of	IN	O
divalproex	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	O
,	,	O
compulsive-like	JJ	O
symptoms	NNS	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Thirteen	JJ	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
participated	VBD	O
in	IN	O
an	DT	O
8-wk	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
of	IN	O
divalproex	NN	PM
sodium	NN	PM
vs.	FW	O
placebo	NN	C
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
group	NN	O
difference	NN	O
on	IN	O
improvement	NN	O
in	IN	O
repetitive	JJ	O
behaviours	NNS	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scale	NNP	O
(	(	O
C-YBOCS	NNP	O
)	)	O
(	(	O
p=0.037	NN	O
)	)	O
and	CC	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
(	(	O
d=1.616	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
preliminary	JJ	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
divalproex	NN	PM
in	IN	O
treating	VBG	O
repetitive	JJ	O
behaviours	NNS	O
in	IN	O
ASD	NNP	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
specificity	NN	O
and	CC	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
these	DT	O
findings	NNS	O
.	.	O

Relief	NN	O
of	IN	O
periorbital	JJ	O
pain	NN	O
after	IN	O
acute	JJ	O
angle	JJ	O
closure	NN	O
glaucoma	NN	O
attack	NN	O
by	IN	O
botulinum	NN	PM
toxin	NN	PM
type	NN	PM
A	NNP	PM
.	.	PM

PURPOSE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
botulinum	NN	PM
toxin	NN	PM
type	NN	PM
A	NNP	PM
(	(	PM
BoNT-A	NNP	PM
)	)	PM
injection	NN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
intractable	JJ	O
periorbital	NN	O
pain	NN	O
after	IN	O
acute	JJ	O
angle	JJ	O
closure	NN	O
glaucoma	NN	O
(	(	O
AACG	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
randomized	VBN	O
intervention	NN	O
study	NN	O
,	,	O
19	CD	O
patients	NNS	O
suffering	VBG	O
from	IN	O
periorbital	JJ	O
pain	NN	O
after	IN	O
an	DT	O
AACG	NNP	O
attack	NN	O
were	VBD	O
injected	VBN	PM
with	IN	PM
BoNT-A	NNP	PM
or	CC	O
placebo	NN	C
for	IN	O
pain	NN	O
relief	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
7	CD	O
,	,	O
14	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
,	,	O
and	CC	O
90	CD	O
.	.	O

The	DT	O
main	JJ	O
outcomes	NNS	O
were	VBD	O
mean	JJ	O
change	NN	O
of	IN	O
visual	JJ	O
analog	NN	O
rating	NN	O
scale	NN	O
(	(	O
VARS	NNP	O
)	)	O
and	CC	O
index	NN	O
scores	NNS	O
measured	VBN	O
through	IN	O
a	DT	O
quality-of-life	JJ	O
questionnaire	NN	O
(	(	O
EQ-5D	NNP	O
)	)	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
the	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
were	VBD	O
assessed	VBN	O
at	IN	O
each	DT	O
visit	NN	O
.	.	O

A	DT	O
secondary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
and	CC	O
nature	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
withdrew	VBP	O
from	IN	O
the	DT	O
study	NN	O
as	IN	O
a	DT	O
result	NN	O
.	.	O

RESULTS	NN	O
In	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
n=10	NN	O
)	)	O
,	,	O
the	DT	O
mean	JJ	O
index	NN	O
score	NN	O
of	IN	O
EQ-5D	NNP	O
and	CC	O
VAS	NNP	O
changed	VBD	O
significantly	RB	O
from	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
by	IN	O
0.299	CD	O
and	CC	O
2.61	CD	O
,	,	O
respectively	RB	O
)	)	O
from	IN	O
day	NN	O
2	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
VARS	NNP	O
of	IN	O
EQ-5D	NNP	O
also	RB	O
disclosed	VBD	O
significant	JJ	O
changes	NNS	O
from	IN	O
day	NN	O
2	CD	O
(	(	O
17	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
efficacy	NN	O
was	VBD	O
maintained	VBN	O
mainly	RB	O
between	IN	O
days	NNS	O
2	CD	O
and	CC	O
60	CD	O
but	CC	O
declined	VBD	O
slightly	RB	O
by	IN	O
day	NN	O
90	CD	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
treatment-related	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
were	VBD	O
local	JJ	O
tenderness	NN	O
(	(	O
21	CD	O
%	NN	O
)	)	O
,	,	O
subcutaneous	JJ	O
hemorrhage	NN	O
(	(	O
10.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
conjunctivitis	NN	O
(	(	O
10.5	CD	O
%	NN	O
)	)	O
.	.	O

No	UH	O
severe	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
during	IN	O
the	DT	O
study	NN	O
or	CC	O
follow-up	JJ	O
period	NN	O
.	.	O

CONCLUSIONS	NNP	O
BoNT-A	NNP	PM
is	VBZ	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
periorbital	JJ	O
pain	NN	O
after	IN	O
an	DT	O
AACG	NNP	O
attack	NN	O
.	.	O

Its	PRP$	O
effects	NNS	O
may	MD	O
be	VB	O
maintained	VBN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
arbutamine	NN	PM
and	CC	O
exercise	NN	PH
echocardiography	NN	PH
in	IN	O
diagnosing	VBG	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

Arbutamine	NNP	PM
is	VBZ	O
a	DT	O
new	JJ	O
catecholamine	NN	O
designed	VBN	O
for	IN	O
use	NN	O
as	IN	O
a	DT	O
pharmacologic	JJ	O
stress	NN	O
agent	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
sensitivity	NN	O
of	IN	O
arbutamine	NN	PM
with	IN	O
symptom-limited	JJ	PH
exercise	NN	PH
to	TO	O
induce	VB	O
echocardiographic	JJ	O
signs	NNS	O
of	IN	O
ischemia	NN	O
.	.	O

Arbutamine	NNP	PM
was	VBD	O
administered	VBN	O
by	IN	O
a	DT	O
computerized	JJ	O
closed-loop	NN	O
delivery	NN	O
system	NN	O
that	WDT	O
controls	VBZ	O
the	DT	O
infusion	NN	O
rate	NN	O
of	IN	O
arbutamine	NN	PM
toward	IN	O
a	DT	O
predefined	JJ	O
rate	NN	O
of	IN	O
heart	NN	O
rate	NN	O
increase	NN	O
and	CC	O
maximum	JJ	O
heart	NN	O
rate	NN	O
limit	NN	O
.	.	O

Beta	NNP	O
blockers	NNS	O
were	VBD	O
stopped	VBN	O
>	CD	O
or	CC	O
=	VB	O
48	CD	O
hours	NNS	O
before	IN	O
both	DT	O
tests	NNS	O
.	.	O

Stress	NN	O
was	VBD	O
stopped	VBN	O
for	IN	O
intolerable	JJ	O
symptoms	NNS	O
,	,	O
or	CC	O
clinical	JJ	O
,	,	O
electrocardiographic	JJ	O
or	CC	O
echocardiographic	JJ	O
signs	NNS	O
of	IN	O
ischemia	NN	O
(	(	O
new	JJ	O
or	CC	O
worsening	VBG	O
wall	JJ	O
motion	NN	O
abnormality	NN	O
)	)	O
,	,	O
target	VB	O
heart	NN	O
rate	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
85	CD	O
%	NN	O
age	NN	O
predicted	VBD	O
maximum	JJ	O
heart	NN	O
rate	NN	O
)	)	O
,	,	O
or	CC	O
plateau	NN	O
of	IN	O
heart	NN	O
rate	NN	O
response	NN	O
.	.	O

Thirty-seven	JJ	O
patients	NNS	O
were	VBD	O
entered	VBN	O
into	IN	O
the	DT	O
study	NN	O
(	(	O
35	CD	O
arbutamine	NN	PM
and	CC	O
exercise	NN	PH
,	,	O
1	CD	O
arbutamine	NN	O
only	RB	O
,	,	O
1	CD	O
exercise	NN	PH
only	RB	O
)	)	O
,	,	O
of	IN	O
which	WDT	O
30	CD	O
had	VBD	O
angiographic	JJ	O
evidence	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
50	CD	O
%	NN	O
lumen	NNS	O
diameter	RB	O
narrowing	VBG	O
)	)	O
.	.	O

Rate-pressure	JJ	O
product	NN	O
increased	VBN	O
significantly	RB	O
in	IN	O
response	NN	O
to	TO	O
both	DT	O
stress	JJ	O
modalities	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
was	VBD	O
significantly	RB	O
greater	JJR	O
with	IN	O
exercise	NN	O
(	(	O
11,308	CD	O
+/-	JJ	O
2,443	CD	O
)	)	O
than	IN	O
with	IN	O
arbutamine	NN	O
(	(	O
9,486	CD	O
+/-	JJ	O
2,479	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
maximum	VB	O
heart	NN	O
rate	NN	O
was	VBD	O
longer	RBR	O
during	IN	O
arbutamine	JJ	PM
stress	NN	O
echocardiography	NN	O
than	IN	O
during	IN	O
exercise	NN	PH
testing	NN	O
(	(	O
17.3	CD	O
+/-	JJ	O
9.4	CD	O
versus	NN	O
9.3	CD	O
+/-	JJ	O
4.2	CD	O
minutes	NNS	O
,	,	O
respectively	RB	O
,	,	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
more	JJR	O
patients	NNS	O
with	IN	O
interpretable	JJ	O
echo	NN	O
data	NNS	O
for	IN	O
arbutamine	NN	PM
(	(	O
82	CD	O
%	NN	O
)	)	O
than	IN	O
for	IN	O
exercise	NN	PH
(	(	O
67	CD	O
%	NN	O
)	)	O
.	.	O

Sensitivity	NN	O
for	IN	O
recognition	NN	O
of	IN	O
myocardial	JJ	O
ischemia	NN	O
was	VBD	O
94	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
70	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
)	)	O
and	CC	O
88	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
62	CD	O
%	NN	O
to	TO	O
98	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
most	RBS	O
frequent	JJ	O
adverse	JJ	O
events	NNS	O
during	IN	O
arbutamine	NN	PM
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
were	VBD	O
dyspnea	VBN	O
(	(	O
5.6	CD	O
%	NN	O
)	)	O
and	CC	O
tremor	NN	O
(	(	O
5.6	CD	O
%	NN	O
)	)	O
.	.	O

Two	CD	O
arbutamine	JJ	PM
stress	NN	O
tests	NNS	O
were	VBD	O
discontinued	VBN	O
due	JJ	O
to	TO	O
arrhythmias	VB	O
:	:	O
1	CD	O
patient	NN	O
had	VBD	O
premature	JJ	O
atrial	JJ	O
and	CC	O
ventricular	JJ	O
beats	NNS	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
had	VBD	O
premature	JJ	O
atrial	JJ	O
contractions	NNS	O
and	CC	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

Arrhythmias	NNP	O
were	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
resolved	VBN	O
without	IN	O
sequelae	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
arbutamine	NN	PM
to	TO	O
induce	VB	O
echocardiographic	JJ	O
signs	NNS	O
of	IN	O
ischemia	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
exercise	NN	PH
despite	IN	O
a	DT	O
lower	JJR	O
rate-pressure	NN	O
product	NN	O
.	.	O

Arbutamine	NNP	PM
was	VBD	O
well	RB	O
tolerated	JJ	O
and	CC	O
provides	VBZ	O
a	DT	O
reliable	JJ	O
alternative	NN	O
to	TO	O
exercise	VB	PH
echocardiography	NN	PH
.	.	O

Comparison	NNP	O
of	IN	O
three	CD	O
solutions	NNS	O
of	IN	O
ropivacaine/fentanyl	NN	PM
for	IN	O
postoperative	JJ	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
.	.	O

BACKGROUND	NNP	O
Ropivacaine	NNP	PM
,	,	O
0.2	CD	O
%	NN	O
,	,	O
is	VBZ	O
a	DT	O
new	JJ	O
local	JJ	O
anesthetic	JJ	O
approved	VBN	O
for	IN	O
epidural	JJ	O
analgesia	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
4	CD	O
microg/ml	NNS	O
fentanyl	JJ	PM
improves	NNS	O
analgesia	VBP	O
from	IN	O
epidural	JJ	O
ropivacaine	NN	O
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
lower	JJR	O
concentration	NN	O
of	IN	O
ropivacaine-fentanyl	NN	PM
may	MD	O
further	VB	O
improve	VB	O
analgesia	NN	O
or	CC	O
decrease	JJ	O
side	NN	O
effects	NNS	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
undergoing	VBG	O
lower	JJR	O
abdominal	JJ	O
surgery	NN	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blinded	JJ	O
manner	NN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
three	CD	O
solutions	NNS	O
:	:	O
0.2	CD	PM
%	NN	PM
ropivacaine-4	JJ	PM
microg	NN	PM
fentanyl	VBD	PM
0.1	CD	PM
%	NN	PM
ropivacaine-2	JJ	PM
microg	NN	PM
fentanyl	NN	PM
,	,	O
or	CC	O
0.05	CD	PM
%	NN	PM
ropivacaine-1	JJ	PM
microg	NN	PM
fentanyl	NN	PM
for	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
after	IN	O
standardized	VBN	O
combined	JJ	O
epidural	JJ	O
and	CC	O
general	JJ	O
anesthesia	NN	O
.	.	O

Patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
settings	NNS	O
and	CC	O
adjustments	NNS	O
for	IN	O
the	DT	O
three	CD	O
solutions	NNS	O
were	VBD	O
standardized	VBN	O
to	TO	O
deliver	VB	O
equivalent	JJ	O
drug	NN	O
doses	NNS	O
.	.	O

Pain	NN	O
scores	NNS	O
(	(	O
rest	NN	O
,	,	O
cough	NN	O
,	,	O
and	CC	O
ambulation	NN	O
)	)	O
,	,	O
side	JJ	O
effects	NNS	O
(	(	O
nausea	NN	O
,	,	O
pruritus	NN	O
,	,	O
sedation	NN	O
,	,	O
motor	NN	O
block	NN	O
,	,	O
hypotension	NN	O
,	,	O
and	CC	O
orthostasis	NN	O
)	)	O
,	,	O
and	CC	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
consumption	NN	O
were	VBD	O
measured	VBN	O
for	IN	O
48	CD	O
h.	JJ	O
RESULTS	NNP	O
All	NNP	O
three	CD	O
solutions	NNS	O
produced	VBD	O
equivalent	JJ	O
analgesia	NN	O
.	.	O

Motor	NNP	O
block	NN	O
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
(	(	O
30	CD	O
vs.	FW	O
0	CD	O
%	NN	O
)	)	O
and	CC	O
more	JJR	O
intense	JJ	O
with	IN	O
the	DT	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	PM
microg	NN	O
fentanyl	JJ	O
solution	NN	O
.	.	O

Other	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
equivalent	JJ	O
between	IN	O
solutions	NNS	O
and	CC	O
mild	NN	O
in	IN	O
severity	NN	O
.	.	O

A	DT	O
significantly	RB	O
smaller	JJR	O
volume	NN	O
of	IN	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	PM
microg	NN	O
fentanyl	JJ	O
solution	NN	O
was	VBD	O
used	VBN	O
,	,	O
whereas	IN	O
the	DT	O
0.1	CD	O
%	NN	O
ropivacaine-2	JJ	O
microg	NN	O
fentanyl	NN	O
group	NN	O
used	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
amount	NN	O
of	IN	O
ropivacaine	NN	PM
and	CC	O
fentanyl	NN	PM
.	.	O

CONCLUSIONS	NNP	O
Lesser	NNP	O
concentrations	NNS	O
of	IN	O
ropivacaine	NN	PM
and	CC	O
fentanyl	JJ	PM
provide	NN	O
comparable	JJ	O
analgesia	NN	O
with	IN	O
less	JJR	O
motor	NN	O
block	NN	O
despite	IN	O
the	DT	O
use	NN	O
of	IN	O
similar	JJ	O
amounts	NNS	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	NN	O
.	.	O

This	DT	O
finding	NN	O
suggests	VBZ	O
that	IN	O
concentration	NN	O
of	IN	O
local	JJ	O
anesthetic	JJ	O
solution	NN	O
at	IN	O
low	JJ	O
doses	NNS	O
is	VBZ	O
a	DT	O
primary	JJ	O
determinant	NN	O
of	IN	O
motor	NN	O
block	NN	O
with	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
after	IN	O
lower	JJR	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Behavioral	NNP	O
and	CC	O
physiological	JJ	O
effects	NNS	O
of	IN	O
remifentanil	NN	PM
and	CC	O
alfentanil	NN	PM
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

BACKGROUND	IN	O
The	DT	O
subjective	JJ	O
and	CC	O
psychomotor	JJ	O
effects	NNS	O
of	IN	O
remifentanil	NNS	PM
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
authors	NNS	O
used	VBD	O
mood	NN	O
inventories	NNS	O
and	CC	O
psychomotor	NN	O
tests	NNS	O
to	TO	O
characterize	VB	O
the	DT	O
effects	NNS	O
of	IN	O
remifentanil	NN	PM
in	IN	O
healthy	JJ	O
,	,	O
non-drug-abusing	JJ	O
volunteers	NNS	O
.	.	O

Alfentanil	NNP	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
comparator	NN	O
drug	NN	O
.	.	O

METHODS	NNP	O
Ten	NNP	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
crossover	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
they	PRP	O
received	VBD	O
an	DT	O
infusion	NN	O
of	IN	O
saline	NN	PM
,	,	O
remifentanil	NN	PM
,	,	O
or	CC	O
alfentanil	NN	PM
for	IN	O
120	CD	O
min	NN	O
.	.	O

The	DT	O
age-	JJ	O
and	CC	O
weight-adjusted	JJ	O
infusions	NNS	O
(	(	O
determined	VBN	O
with	IN	O
STANPUMP	NNP	PM
,	,	O
a	DT	O
computer	NN	PM
modeling	VBG	PM
software	NN	PM
package	NN	PM
)	)	O
were	VBD	O
given	VBN	O
to	TO	O
achieve	VB	O
three	CD	O
predicted	VBN	O
constant	JJ	O
plasma	NN	O
levels	NNS	O
for	IN	O
40	CD	O
min	NNS	O
each	DT	O
of	IN	O
remifentanil	NN	PM
(	(	O
0.75	CD	O
,	,	O
1.5	CD	O
,	,	O
and	CC	O
3	CD	O
ng/ml	NN	O
)	)	O
and	CC	O
alfentanil	NN	O
(	(	O
16	CD	O
,	,	O
32	CD	O
,	,	O
and	CC	O
64	CD	O
ng/ml	NN	O
)	)	O
.	.	O

Mood	NN	O
forms	NNS	O
and	CC	O
psychomotor	NN	O
tests	NNS	O
were	VBD	O
completed	VBN	O
,	,	O
and	CC	O
miosis	NN	O
was	VBD	O
assessed	VBN	O
,	,	O
during	IN	O
and	CC	O
after	IN	O
the	DT	O
infusions	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
analgesia	NN	O
was	VBD	O
tested	VBN	O
at	IN	O
each	DT	O
dose	JJ	O
level	NN	O
using	VBG	O
a	DT	O
cold-pressor	JJ	O
test	NN	O
.	.	O

RESULTS	NNP	O
Remifentanil	NNP	PM
had	VBD	O
prototypic	VBN	O
micro-like	JJ	O
opioid	JJ	O
subjective	JJ	O
effects	NNS	O
,	,	O
impaired	JJ	O
psychomotor	NN	O
performance	NN	O
,	,	O
and	CC	O
produced	VBD	O
analgesia	NN	O
.	.	O

Alfentanil	NNP	O
at	IN	O
the	DT	O
dose	JJ	O
range	NN	O
tested	VBD	O
had	VBD	O
more	RBR	O
mild	JJ	O
effects	NNS	O
on	IN	O
these	DT	O
measures	NNS	O
,	,	O
and	CC	O
the	DT	O
analgesia	NN	O
data	NNS	O
indicated	VBD	O
that	IN	O
a	DT	O
40:1	CD	O
potency	NN	O
ratio	NN	O
,	,	O
rather	RB	O
than	IN	O
the	DT	O
20:1	CD	O
ratio	NN	O
we	PRP	O
used	VBD	O
,	,	O
may	MD	O
exist	VB	O
between	IN	O
remifentanil	NN	O
and	CC	O
alfentanil	NN	O
.	.	O

A	DT	O
psychomotor	NN	O
test	NN	O
administered	VBD	O
60	CD	O
min	NN	O
after	IN	O
the	DT	O
remifentanil	NN	O
infusion	NN	O
was	VBD	O
discontinued	VBN	O
showed	VBD	O
that	IN	O
the	DT	O
volunteers	NNS	O
were	VBD	O
still	RB	O
impaired	VBN	O
,	,	O
although	IN	O
they	PRP	O
reported	VBD	O
feeling	VBG	O
no	DT	O
drug	NN	O
effects	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
notion	NN	O
that	IN	O
the	DT	O
pharmacodynamic	JJ	O
effects	NNS	O
of	IN	O
remifentanil	NN	PM
are	VBP	O
extremely	RB	O
short-lived	JJ	O
after	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
no	DT	O
longer	RB	O
administered	VBN	O
must	MD	O
be	VB	O
questioned	VBN	O
given	VBN	O
our	PRP$	O
findings	NNS	O
that	IN	O
psychomotor	NN	O
effects	NNS	O
were	VBD	O
still	RB	O
apparent	JJ	O
1	CD	O
h	NN	O
after	IN	O
the	DT	O
infusion	NN	O
was	VBD	O
discontinued	VBN	O
.	.	O

Dexamethasone	NNP	PM
effectively	RB	O
reduces	VBZ	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
a	DT	O
general	JJ	O
surgical	JJ	O
adult	NN	O
patient	JJ	O
population	NN	O
.	.	O

BACKGROUND	NNP	O
Postoperative	NNP	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
is	VBZ	O
still	RB	O
a	DT	O
common	JJ	O
and	CC	O
major	JJ	O
complication	NN	O
for	IN	O
surgical	JJ	O
patients	NNS	O
,	,	O
which	WDT	O
may	MD	O
delay	VB	O
post-anesthetic	JJ	O
care	NN	O
unit	NN	O
discharge	NN	O
,	,	O
prolong	JJ	O
hospital	NN	O
stay	NN	O
and	CC	O
thus	RB	O
increase	VB	O
the	DT	O
cost	NN	O
of	IN	O
hospitalization	NN	O
.	.	O

It	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
PONV	NNP	O
is	VBZ	O
a	DT	O
multi-factorial	JJ	O
outcome	NN	O
and	CC	O
occurs	VBZ	O
more	RBR	O
often	RB	O
with	IN	O
general	JJ	O
anesthesia	NN	O
than	IN	O
with	IN	O
other	JJ	O
anesthetic	JJ	O
methods	NNS	O
.	.	O

Prophylactic	JJ	O
administration	NN	O
of	IN	O
antihistamines	NNS	O
,	,	O
antidopaminergics	NNS	O
,	,	O
anticholinergics	NNS	O
,	,	O
phenothiazines	NNS	O
,	,	O
serotonin	JJ	O
antagonist	NN	O
,	,	O
steroids	NNS	O
and	CC	O
even	RB	O
acupuncture	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

However	RB	O
,	,	O
expenses	NNS	O
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
a	DT	O
concern	NN	O
for	IN	O
clinical	JJ	O
doctors	NNS	O
.	.	O

The	DT	O
aim	NN	O
for	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
was	VBD	O
to	TO	O
find	VB	O
an	DT	O
agent	NN	O
that	WDT	O
is	VBZ	O
cost	RBS	O
effective	JJ	O
and	CC	O
side	JJ	O
effect	NN	O
free	JJ	O
(	(	O
or	CC	O
at	IN	O
least	JJS	O
with	IN	O
a	DT	O
low	JJ	O
incidence	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
)	)	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
PONV	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
700	CD	O
adult	NN	O
surgical	JJ	O
patients	NNS	O
who	WP	O
planned	VBD	O
to	TO	O
have	VB	O
surgery	NN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
double-blinded	JJ	O
,	,	O
randomized	JJ	O
and	CC	O
placebo-controlled	JJ	PM
study	NN	O
.	.	O

Group	NNP	O
P	NNP	O
received	VBD	O
the	DT	O
placebo	NN	C
(	(	O
0.9	CD	O
%	NN	O
normal	JJ	C
saline	JJ	C
2	CD	O
ml	NN	O
)	)	O
and	CC	O
Group	NNP	O
D	NNP	O
received	VBD	O
10	CD	O
mg	NNS	O
dexamethasone	RB	PM
intravenously	RB	O
right	JJ	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
that	IN	O
during	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
1-8	JJ	O
h	NN	O
,	,	O
patients	NNS	O
in	IN	O
Group	NNP	O
D	NNP	O
reported	VBD	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
PONV	NNP	O
(	(	O
24	CD	O
%	NN	O
)	)	O
than	IN	O
those	DT	O
in	IN	O
Group	NNP	O
P	NNP	O
(	(	O
39	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
Group	NNP	O
D	NNP	O
also	RB	O
requested	VBD	O
less	JJR	O
rescue	JJ	O
anti-emetic	JJ	O
(	(	O
17	CD	O
%	NN	O
)	)	O
than	IN	O
those	DT	O
in	IN	O
Group	NNP	O
P	NNP	O
(	(	O
30	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
same	JJ	O
phenomenon	NN	O
was	VBD	O
also	RB	O
noted	VBN	O
in	IN	O
the	DT	O
8-to-24-hour	JJ	O
interval	NN	O
(	(	O
PONV	NNP	O
4	CD	O
%	NN	O
vs.	FW	O
12	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
and	CC	O
rescue	VB	O
anti-emetic	JJ	O
3	CD	O
%	NN	O
vs.	FW	O
9	CD	O
%	NN	O
,	,	O
p	NN	O
<	VBD	O
0.05	CD	O
in	IN	O
Group	NNP	O
D	NNP	O
vs.	FW	O
Group	NNP	O
P	NNP	O
,	,	O
respectively	RB	O
.	.	O

)	)	O
CONCLUSIONS	IN	O
We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
prophylactic	JJ	O
intravenous	JJ	O
administration	NN	O
of	IN	O
10	CD	O
mg	NNS	O
dexamethasone	VBP	O
immediately	RB	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
preventing	VBG	O
PONV	NNP	O
in	IN	O
the	DT	O
general	JJ	O
surgical	JJ	O
adult	NN	O
patient	JJ	O
population	NN	O
.	.	O

Effect	NN	O
of	IN	O
micronutrient	NN	PM
supplement	NN	PM
on	IN	O
health	NN	O
and	CC	O
nutritional	JJ	O
status	NN	O
of	IN	O
schoolchildren	NNS	O
:	:	O
study	NN	O
design	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
supplementation	NN	O
with	IN	O
a	DT	O
micronutrient-fortified	JJ	PM
beverage	NN	PM
improves	VBZ	O
micronutrient	JJ	O
status	NN	O
and	CC	O
physical	JJ	O
and	CC	O
mental	JJ	O
development	NN	O
in	IN	O
apparently	RB	O
healthy	JJ	O
schoolchildren	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
middle-income	JJ	O
students	NNS	O
in	IN	O
two	CD	O
residential	JJ	O
schools	NNS	O
that	WDT	O
catered	VBD	O
to	TO	O
children	NNS	O
from	IN	O
a	DT	O
semi-urban	JJ	O
population	NN	O
near	IN	O
Hyderabad	NNP	O
,	,	O
India	NNP	O
.	.	O

Included	NNP	O
were	VBD	O
869	CD	O
children	NNS	O
who	WP	O
were	VBD	O
6	CD	O
to	TO	O
16	CD	O
y	NN	O
of	IN	O
age	NN	O
in	IN	O
grades	NNS	O
1	CD	O
to	TO	O
10	CD	O
.	.	O

Because	IN	O
children	NNS	O
at	IN	O
each	DT	O
grade	NN	O
were	VBD	O
distributed	VBN	O
across	IN	O
two	CD	O
classrooms	NNS	O
(	(	O
clusters	NNS	O
)	)	O
and	CC	O
were	VBD	O
homogeneous	JJ	O
,	,	O
each	DT	O
grade	NN	O
was	VBD	O
considered	VBN	O
to	TO	O
consist	VB	O
of	IN	O
a	DT	O
matched	JJ	O
pair	NN	O
.	.	O

There	EX	O
were	VBD	O
thus	RB	O
10	CD	O
pairs	NNS	O
available	JJ	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

Classes	NNS	O
in	IN	O
each	DT	O
grade	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
micronutrient-enriched	JJ	PM
beverage	NN	PM
or	CC	O
a	DT	O
placebo	NN	C
without	IN	C
added	JJ	C
micronutrients	NNS	C
.	.	O

The	DT	O
study	NN	O
was	VBD	O
double	RB	O
blinded	VBN	O
and	CC	O
the	DT	O
duration	NN	O
was	VBD	O
14	CD	O
mo	NN	O
,	,	O
with	IN	O
supervised	JJ	O
feeding	NN	O
of	IN	O
the	DT	O
micronutrient-enriched	JJ	PM
beverage	NN	PM
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
micronutrients	NNS	PM
on	IN	O
the	DT	O
outcome	NN	O
variables	NNS	O
growth	NN	O
,	,	O
biochemical	JJ	O
status	NN	O
,	,	O
mental	JJ	O
function	NN	O
,	,	O
and	CC	O
bone	NN	O
health	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
number	NN	O
of	IN	O
matched	JJ	O
pairs	NNS	O
varied	VBD	O
between	IN	O
seven	CD	O
and	CC	O
eight	CD	O
,	,	O
and	CC	O
the	DT	O
required	JJ	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
treatment	NN	O
group	NN	O
ranged	VBD	O
from	IN	O
32	CD	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
bone	NN	O
heath	NN	O
to	TO	O
177	CD	O
for	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
power	NN	O
of	IN	O
the	DT	O
outcome	NN	O
variables	NNS	O
ranged	VBD	O
from	IN	O
74	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
and	CC	O
was	VBD	O
adequate	NN	O
for	IN	O
successful	JJ	O
pairing	NN	O
.	.	O

The	DT	O
effect	NN	O
assessed	VBD	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
supplementation	NN	PM
showed	VBD	O
that	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
beneficial	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Designing	VBG	O
an	DT	O
intervention	NN	O
,	,	O
choosing	VBG	O
outcome	NN	O
variables	NNS	O
,	,	O
and	CC	O
implementing	VBG	O
the	DT	O
protocol	NN	O
in	IN	O
a	DT	O
typical	JJ	O
Indian	JJ	O
school	NN	O
setting	VBG	O
were	VBD	O
achieved	VBN	O
.	.	O

Family	RB	E
economic	JJ	E
empowerment	NN	E
and	CC	O
mental	JJ	O
health	NN	O
among	IN	O
AIDS-affected	JJ	O
children	NNS	O
living	VBG	O
in	IN	O
AIDS-impacted	JJ	O
communities	NNS	O
:	:	O
evidence	NN	O
from	IN	O
a	DT	O
randomised	JJ	O
evaluation	NN	O
in	IN	O
southwestern	JJ	O
Uganda	NNP	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
authors	NNS	O
examine	VBP	O
whether	IN	O
an	DT	O
innovative	JJ	O
family	NN	E
economic	JJ	E
empowerment	NN	E
intervention	NN	O
addresses	VBZ	O
mental	JJ	O
health	NN	O
functioning	NN	O
of	IN	O
AIDS-affected	JJ	O
children	NNS	O
in	IN	O
communities	NNS	O
heavily	RB	O
impacted	VBN	O
by	IN	O
HIV/AIDS	NNP	O
in	IN	O
Uganda	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
cluster	NN	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
consisting	VBG	O
of	IN	O
two	CD	O
study	NN	O
arms	NNS	O
,	,	O
a	DT	O
treatment	NN	O
condition	NN	O
(	(	O
n=179	JJ	O
)	)	O
and	CC	O
a	DT	O
control	NN	C
condition	NN	C
(	(	O
n=118	JJ	O
)	)	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
family	NN	E
economic	JJ	E
empowerment	NN	E
intervention	NN	E
on	IN	O
children	NNS	O
's	POS	O
levels	NNS	O
of	IN	O
hopelessness	NN	O
and	CC	O
depression	NN	O
.	.	O

The	DT	O
intervention	NN	O
comprised	VBD	O
matched	JJ	E
children	NNS	E
savings	NNS	E
accounts	NNS	E
,	,	E
financial	JJ	E
management	NN	E
workshops	NNS	E
and	CC	E
mentorship	NN	E
.	.	E

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

RESULTS	NNP	O
Using	VBG	O
multivariate	JJ	O
analysis	NN	O
with	IN	O
several	JJ	O
socioeconomic	JJ	O
controls	NNS	O
,	,	O
the	DT	O
authors	NNS	O
find	VBP	O
that	IN	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
condition	NN	O
(	(	O
receiving	VBG	O
the	DT	O
intervention	NN	O
)	)	O
report	NN	O
significant	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
mental	JJ	O
health	NN	O
functioning	NN	O
.	.	O

Specifically	RB	O
,	,	O
the	DT	O
intervention	NN	O
reduces	VBZ	O
hopelessness	NN	O
and	CC	O
depression	NN	O
levels	NNS	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
control	NN	O
condition	NN	O
(	(	O
not	RB	O
receiving	VBG	O
the	DT	O
intervention	NN	O
)	)	O
report	NN	O
no	DT	O
changes	NNS	O
on	IN	O
both	DT	O
measures	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
children	NNS	O
with	IN	O
poor	JJ	O
mental	JJ	O
health	NN	O
functioning	VBG	O
living	NN	O
in	IN	O
communities	NNS	O
affected	VBN	O
by	IN	O
HIV/AIDS	NNP	O
may	MD	O
benefit	VB	O
from	IN	O
innovative	JJ	O
family	NN	O
economic	JJ	O
empowerment	NN	O
interventions	NNS	O
.	.	O

As	IN	O
measures	NNS	O
of	IN	O
mental	JJ	O
health	NN	O
functioning	NN	O
,	,	O
both	DT	O
hopelessness	NN	O
and	CC	O
depression	NN	O
have	VBP	O
long-term	JJ	O
negative	JJ	O
psychosocial	NN	O
and	CC	O
developmental	JJ	O
impacts	NNS	O
on	IN	O
children	NNS	O
.	.	O

These	DT	O
findings	NNS	O
have	VBP	O
implications	NNS	O
for	IN	O
public	JJ	O
health	NN	O
programmes	NNS	O
intended	VBN	O
for	IN	O
long-term	JJ	O
care	NN	O
and	CC	O
support	NN	O
of	IN	O
children	NNS	O
living	VBG	O
in	IN	O
resource	JJ	O
poor	JJ	O
AIDS-impacted	JJ	O
communities	NNS	O
.	.	O

Effect	NN	O
of	IN	O
prophylactic	JJ	PM
amiodarone	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
rheumatic	JJ	O
valve	NNS	O
disease	NN	O
undergoing	VBG	O
valve	JJ	O
replacement	NN	O
surgery	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
prophylactic	JJ	O
single-dose	JJ	O
intravenous	JJ	O
amiodarone	NN	PM
in	IN	O
patients	NNS	O
undergoing	VBG	O
valve	JJ	O
replacement	NN	O
surgery	NN	O
.	.	O

Maintenance	NN	O
of	IN	O
sinus	NN	O
rhythm	NN	O
is	VBZ	O
better	JJR	O
than	IN	O
maintenance	NN	O
of	IN	O
fixed	JJ	O
ventricular	JJ	O
rate	NN	O
in	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
especially	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
irritable	JJ	O
left	NN	O
or	CC	O
right	JJ	O
atrium	NN	O
because	IN	O
of	IN	O
enlargement	NN	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
with	IN	O
valvular	JJ	O
heart	NN	O
disease	NN	O
with	IN	O
or	CC	O
without	IN	O
AF	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
or	CC	O
the	DT	O
amiodarone	NN	PM
group	NN	PM
(	(	O
n=28	NN	O
)	)	O
received	VBD	O
amiodarone	NN	PM
(	(	O
3	CD	O
mg/kg	NN	O
in	IN	O
100	CD	O
ml	NNS	O
normal	JJ	O
saline	NN	O
)	)	O
and	CC	O
group	NN	O
II	NNP	O
or	CC	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
same	JJ	O
volume	NN	O
of	IN	O
normal	JJ	PM
saline	NN	PM
.	.	O

The	DT	O
standardized	JJ	O
protocol	NN	O
for	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
was	VBD	O
maintained	VBN	O
for	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
.	.	O

AF	NNP	O
occurred	VBD	O
in	IN	O
7.14	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
,	,	O
and	CC	O
in	IN	O
group	NN	O
II	NNP	O
,	,	O
28.57	CD	O
%	NN	O
(	(	O
P=0.035	NNP	O
)	)	O
;	:	O
ventricular	JJ	O
tachycardia/fibrillation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
21.43	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
46.43	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
II	NNP	O
(	(	O
P=0.089	NNP	O
)	)	O
after	IN	O
release	NN	O
of	IN	O
aortic	JJ	O
clamp	NN	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
(	(	O
92.86	CD	O
%	NN	O
)	)	O
maintained	VBD	O
sinus	JJ	O
rhythm	NN	O
without	IN	O
cardioversion	NN	O
or	CC	O
defibrillation	NN	O
after	IN	O
release	NN	O
of	IN	O
aortic	JJ	O
cross	NN	O
clamp	NN	O
(	(	O
P=0.002	NNP	O
)	)	O
.	.	O

Defibrillation	NN	O
or	CC	O
cardio	NN	O
version	NN	O
was	VBD	O
needed	VBN	O
in	IN	O
7.14	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
28.57	CD	O
%	NN	O
patients	NNS	O
in	IN	O
group	NN	O
II	NNP	O
(	(	O
P=0.078	NNP	O
)	)	O
.	.	O

A	DT	O
single	JJ	O
prophylactic	JJ	O
intraoperative	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
amiodarone	NN	PM
decreased	VBD	O
post	NN	O
bypass	NN	O
arrhythmia	NN	O
in	IN	O
this	DT	O
study	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Single	NNP	O
dose	NN	O
of	IN	O
intraoperative	JJ	O
amiodarone	NN	PM
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
decrease	VB	O
postoperative	JJ	O
arrhythmia	NN	O
in	IN	O
open	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

A	DT	O
web-based	JJ	E
patient	NN	E
activation	NN	E
intervention	NN	E
to	TO	O
improve	VB	O
hypertension	NN	O
care	NN	O
:	:	O
study	NN	O
design	NN	O
and	CC	O
baseline	NN	O
characteristics	NNS	O
in	IN	O
the	DT	O
web	NN	O
hypertension	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
the	DT	O
known	JJ	O
health	NN	O
risks	NNS	O
of	IN	O
hypertension	NN	O
,	,	O
many	JJ	O
hypertensive	JJ	O
patients	NNS	O
still	RB	O
have	VBP	O
uncontrolled	VBN	O
blood	NN	O
pressure	NN	O
.	.	O

Clinical	JJ	O
inertia	NN	O
,	,	O
the	DT	O
tendency	NN	O
of	IN	O
physicians	NNS	O
not	RB	O
to	TO	O
intensify	VB	O
treatment	NN	O
,	,	O
is	VBZ	O
a	DT	O
common	JJ	O
barrier	NN	O
in	IN	O
controlling	VBG	O
chronic	JJ	O
diseases	NNS	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
aimed	VBN	O
at	IN	O
determining	VBG	O
the	DT	O
impact	NN	O
of	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
ask	VB	O
providers	NNS	O
to	TO	O
make	VB	O
changes	NNS	O
to	TO	O
their	PRP$	O
care	NN	O
through	IN	O
tailored	VBN	O
feedback	NN	O
.	.	O

METHODS	NNP	O
Diagnosed	VBD	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
RCT	NNP	O
and	CC	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
study	NN	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
the	DT	E
intervention	NN	E
condition	NN	E
--	:	E
Web-based	JJ	E
hypertension	NN	E
feedback	NN	E
,	,	E
based	VBN	E
on	IN	E
the	DT	E
individual	JJ	E
patient	NN	E
's	POS	E
self-report	NN	E
of	IN	E
health	NN	E
variables	NNS	E
and	CC	E
previous	JJ	E
BP	NNP	E
measurements	NNS	E
,	,	E
to	TO	E
prompt	VB	E
them	PRP	E
to	TO	E
ask	VB	E
questions	NNS	E
during	IN	E
their	PRP$	E
next	JJ	E
physician	NN	E
's	POS	E
visit	NN	E
about	IN	E
hypertension	NN	E
care	NN	E
(	(	O
2	CD	O
)	)	O
the	DT	E
control	NN	E
condition	NN	E
--	:	E
Web-based	JJ	E
preventive	JJ	E
health	NN	E
feedback	NN	E
,	,	E
based	VBN	E
on	IN	E
the	DT	E
individual	NN	E
's	POS	E
self-report	NN	E
of	IN	E
receiving	VBG	E
preventive	JJ	E
care	NN	E
(	(	O
e.g.	UH	O
,	,	O
pap	JJ	O
testing	VBG	O
)	)	O
,	,	O
to	TO	E
prompt	VB	E
them	PRP	E
to	TO	E
ask	VB	E
questions	NNS	E
during	IN	E
their	PRP$	E
next	JJ	E
physician	NN	E
's	POS	E
visit	NN	E
about	IN	E
preventive	JJ	E
care	NN	E
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
the	DT	O
study	NN	O
is	VBZ	O
change	VBN	O
in	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
change	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
with	IN	O
controlled	VBN	O
blood	NN	O
pressure	NN	O
.	.	O

CONCLUSION	NNP	O
Five	CD	O
hundred	VBD	O
participants	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
baseline	JJ	O
characteristics	NNS	O
include	VBP	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
60.0	CD	O
years	NNS	O
;	:	O
57.6	CD	O
%	NN	O
female	NN	O
;	:	O
and	CC	O
77.6	CD	O
%	NN	O
white	JJ	O
.	.	O

Overall	JJ	O
37.7	CD	O
%	NN	O
participants	NNS	O
had	VBD	O
uncontrolled	VBN	O
blood	NN	O
pressure	NN	O
;	:	O
the	DT	O
mean	NN	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
was	VBD	O
in	IN	O
the	DT	O
obese	JJ	O
range	NN	O
(	(	O
32.4	CD	O
)	)	O
and	CC	O
21.8	CD	O
%	NN	O
had	VBD	O
diabetes	NNS	O
.	.	O

By	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
become	VB	O
involved	VBN	O
in	IN	O
their	PRP$	O
own	JJ	O
care	NN	O
,	,	O
we	PRP	O
believe	VBP	O
the	DT	O
addition	NN	O
of	IN	O
the	DT	O
web-based	JJ	O
intervention	NN	O
will	MD	O
improve	VB	O
blood	NN	O
pressure	NN	O
control	NN	O
compared	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
who	WP	O
receive	VBP	O
web-based	JJ	O
preventive	JJ	O
messages	NNS	O
unrelated	VBN	O
to	TO	O
hypertension	NN	O
.	.	O

Anecortave	NNP	PM
acetate	NN	PM
treatment	NN	PM
for	IN	O
retinal	JJ	O
angiomatous	JJ	O
proliferation	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
anecortave	JJ	PM
acetate	JJ	PM
treatment	NN	PM
of	IN	O
retinal	JJ	O
angiomatous	JJ	O
proliferation	NN	O
(	(	O
RAP	NNP	O
)	)	O
,	,	O
a	DT	O
neovascular	JJ	O
form	NN	O
of	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
with	IN	O
specific	JJ	O
regard	NN	O
to	TO	O
inhibition	NN	O
of	IN	O
neovascularization	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
vision	NN	O
.	.	O

METHODS	NNP	O
Thirty-four	JJ	O
patients	NNS	O
with	IN	O
RAP	NNP	O
with	IN	O
any	DT	O
stage	NN	O
of	IN	O
neovascularization	NN	O
were	VBD	O
randomized	VBN	O
1:1:1	CD	O
for	IN	O
treatment	NN	O
with	IN	O
three	CD	O
different	JJ	O
quantities	NNS	O
(	(	O
30	CD	O
mg	NN	O
,	,	O
15	CD	O
mg	NN	O
,	,	O
3	CD	O
mg	NN	O
)	)	O
of	IN	O
anecortave	NN	PM
acetate	NN	PM
sterile	JJ	PM
suspension	NN	PM
for	IN	PM
juxtascleral	JJ	PM
administration	NN	PM
.	.	O

Best-corrected	JJ	O
visual	JJ	O
acuity	NN	O
(	(	O
Early	JJ	O
Treatment	NNP	O
Diabetic	NNP	O
Retinopathy	NNP	O
Study	NNP	O
chart	NN	O
)	)	O
,	,	O
intraocular	JJ	O
pressure	NN	O
measurement	NN	O
,	,	O
biomicroscopy	NN	O
,	,	O
funduscopy	NN	O
,	,	O
digital	JJ	O
fluorescein	NN	O
,	,	O
and	CC	O
indocyanine	NN	O
green	JJ	O
angiography	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

A	DT	O
6-month	JJ	O
retreatment	NN	O
interval	NN	O
was	VBD	O
established	VBN	O
for	IN	O
this	DT	O
study	NN	O
with	IN	O
a	DT	O
follow-up	NN	O
of	IN	O
12	CD	O
months	NNS	O
.	.	O

In	IN	O
selected	JJ	O
patients	NNS	O
optical	JJ	O
coherence	NN	O
tomography	NN	O
was	VBD	O
performed	VBN	O
.	.	O

The	DT	O
outcomes	NNS	O
were	VBD	O
mean	JJ	O
changes	NNS	O
in	IN	O
visual	JJ	O
acuity	NN	O
and	CC	O
lesion	NN	O
size	NN	O
at	IN	O
1	CD	O
year	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
detachment	NN	O
of	IN	O
the	DT	O
neurosensory	JJ	O
retina	NN	O
and	CC	O
retinal	JJ	O
pigment	NN	O
epithelium	NN	O
improved	VBN	O
in	IN	O
all	DT	O
eyes	NNS	O
,	,	O
but	CC	O
all	DT	O
neovascular	JJ	O
lesions	NNS	O
increased	VBD	O
in	IN	O
size	NN	O
.	.	O

Vision	NNP	O
loss	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
study	NN	O
eyes	NNS	O
(	(	O
22	CD	O
out	IN	O
of	IN	O
34	CD	O
eyes	NNS	O
,	,	O
64.7	CD	O
%	NN	O
)	)	O
independent	JJ	O
of	IN	O
the	DT	O
concentration	NN	O
administered	VBD	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
posterior	JJ	O
juxtascleral	JJ	O
injection	NN	O
of	IN	O
anecortave	JJ	PM
acetate	NN	PM
reduces	NNS	O
capillary	JJ	O
permeability	NN	O
in	IN	O
patients	NNS	O
with	IN	O
RAP	NNP	O
.	.	O

However	RB	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
improvement	NN	O
of	IN	O
the	DT	O
exudation	NN	O
there	EX	O
is	VBZ	O
a	DT	O
progression	NN	O
of	IN	O
neovascularization	NN	O
and	CC	O
a	DT	O
significant	JJ	O
loss	NN	O
of	IN	O
vision	NN	O
in	IN	O
all	PDT	O
these	DT	O
patients	NNS	O
.	.	O

Like	IN	O
other	JJ	O
monotherapeutic	JJ	O
methods	NNS	O
used	VBN	O
to	TO	O
treat	VB	O
this	DT	O
variant	NN	O
of	IN	O
neovascular	JJ	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
,	,	O
anecortave	VBP	PM
acetate	JJ	PM
alone	RB	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
benefit	VB	O
these	DT	O
patients	NNS	O
.	.	O

Future	JJ	O
studies	NNS	O
should	MD	O
investigate	VB	O
a	DT	O
combination	NN	O
form	NN	O
of	IN	O
therapy	NN	O
.	.	O

MDM2	NNP	O
and	CC	O
Ki-67	NNP	O
predict	NN	O
for	IN	O
distant	JJ	O
metastasis	NN	O
and	CC	O
mortality	NN	O
in	IN	O
men	NNS	O
treated	VBN	O
with	IN	O
radiotherapy	NN	PH
and	CC	O
androgen	NN	PM
deprivation	NN	PM
for	IN	O
prostate	JJ	O
cancer	NN	O
:	:	O
RTOG	NNP	O
92-02	CD	O
.	.	O

PURPOSE	NNP	O
MDM2	NNP	O
regulates	VBZ	O
p53	NN	O
,	,	O
which	WDT	O
controls	VBZ	O
cell	NN	O
cycle	NN	O
arrest	NN	O
and	CC	O
apoptosis	NN	O
.	.	O

Both	DT	O
proteins	NNS	O
,	,	O
along	IN	O
with	IN	O
Ki-67	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
an	DT	O
established	VBN	O
strong	JJ	O
determinant	NN	O
of	IN	O
metastasis	NN	O
,	,	O
have	VBP	O
shown	VBN	O
promise	NN	O
in	IN	O
predicting	VBG	O
the	DT	O
outcome	NN	O
of	IN	O
men	NNS	O
treated	VBN	O
with	IN	O
radiation	NN	PH
therapy	NN	PH
(	(	PH
RT	NNP	PH
)	)	PH
with	IN	O
or	CC	O
without	IN	O
short-term	JJ	PM
androgen	NN	PM
deprivation	NN	PM
(	(	PM
STAD	NNP	PM
)	)	PM
.	.	O

This	DT	O
report	NN	O
compares	VBZ	O
the	DT	O
utility	NN	O
of	IN	O
abnormal	JJ	O
expression	NN	O
of	IN	O
these	DT	O
biomarkers	NNS	O
in	IN	O
estimating	VBG	O
progression	NN	O
in	IN	O
a	DT	O
cohort	NN	O
of	IN	O
men	NNS	O
treated	VBN	O
on	IN	O
RTOG	NNP	O
92-02	CD	O
.	.	O

PATIENTS	NNPS	O
AND	CC	O
METHODS	NNP	O
Adequate	NNP	O
tissue	NN	O
for	IN	O
immunohistochemistry	NN	O
was	VBD	O
available	JJ	O
for	IN	O
p53	NN	O
,	,	O
Ki-67	NNP	O
,	,	O
and	CC	O
MDM2	NNP	O
analyses	NNS	O
in	IN	O
478	CD	O
patient	JJ	O
cases	NNS	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
tumor	NN	O
nuclei	NN	O
staining	VBG	O
positive	JJ	O
(	(	O
PSP	NNP	O
)	)	O
was	VBD	O
quantified	VBN	O
manually	RB	O
or	CC	O
by	IN	O
image	NN	O
analysis	NN	O
,	,	O
and	CC	O
the	DT	O
per-sample	JJ	O
mean	JJ	O
intensity	NN	O
score	NN	O
(	(	O
MIS	NNP	O
)	)	O
was	VBD	O
quantified	VBN	O
by	IN	O
image	NN	O
analysis	NN	O
.	.	O

Cox	NNP	O
regression	NN	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
overall	JJ	O
mortality	NN	O
(	(	O
OM	NNP	O
)	)	O
,	,	O
and	CC	O
Fine	NNP	O
and	CC	O
Gray	NNP	O
's	POS	O
regressions	NNS	O
were	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
end	NN	O
points	NNS	O
of	IN	O
distant	JJ	O
metastasis	NN	O
(	(	O
DM	NNP	O
)	)	O
and	CC	O
cause-specific	JJ	O
mortality	NN	O
(	(	O
CSM	NNP	O
)	)	O
.	.	O

Results	NNS	O
In	IN	O
multivariate	JJ	O
analyses	NNS	O
that	WDT	O
adjusted	VBD	O
for	IN	O
all	DT	O
markers	NNS	O
and	CC	O
treatment	NN	O
covariates	NNS	O
,	,	O
MDM2	NNP	O
overexpression	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
DM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
and	CC	O
OM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
,	,	O
and	CC	O
Ki-67	NNP	O
overexpression	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
DM	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
CSM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.0007	NNP	O
)	)	O
,	,	O
and	CC	O
OM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

P53	NNP	O
overexpression	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
OM	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

When	WRB	O
considered	VBN	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
overexpression	NN	O
of	IN	O
both	DT	O
Ki-67	NNP	O
and	CC	O
MDM2	NNP	O
at	IN	O
high	JJ	O
levels	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
increased	VBN	O
failure	NN	O
rates	NNS	O
for	IN	O
all	DT	O
end	NN	O
points	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
for	IN	O
DM	NNP	O
,	,	O
CSM	NNP	O
,	,	O
and	CC	O
OM	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Combined	VBD	O
MDM2	NNP	O
and	CC	O
Ki-67	NNP	O
expression	NN	O
levels	NNS	O
were	VBD	O
independently	RB	O
related	VBN	O
to	TO	O
distant	JJ	O
metastasis	NN	O
and	CC	O
mortality	NN	O
and	CC	O
,	,	O
if	IN	O
validated	VBN	O
,	,	O
could	MD	O
be	VB	O
considered	VBN	O
for	IN	O
risk	NN	O
stratification	NN	O
of	IN	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
self-administered	JJ	PM
vaginal	JJ	PM
misoprostol	NN	PM
versus	NN	O
placebo	NN	C
for	IN	O
cervical	JJ	O
ripening	VBG	O
prior	JJ	O
to	TO	O
operative	JJ	O
hysteroscopy	NN	O
using	VBG	O
a	DT	O
sequential	JJ	O
trial	NN	O
design	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
impact	NN	O
of	IN	O
1000-microgram	JJ	O
self-administered	JJ	PM
vaginal	JJ	PM
misoprostol	NN	PM
versus	IN	O
self-administered	JJ	O
vaginal	JJ	C
placebo	NN	C
at	IN	O
home	NN	O
on	IN	O
preoperative	JJ	O
cervical	JJ	O
ripening	NN	O
in	IN	O
both	DT	O
premenopausal	NN	O
and	CC	O
postmenopausal	JJ	O
women	NNS	O
prior	RB	O
to	TO	O
outpatient	VB	O
resectoscopy	NN	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
sequential	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Norwegian	JJ	O
university	NN	O
teaching	VBG	O
hospital	NN	O
.	.	O

SAMPLE	NNP	O
Premenopausal	NNP	O
and	CC	O
postmenopausal	JJ	O
women	NNS	O
referred	VBD	O
to	TO	O
outpatient	VB	O
resectoscopy	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
women	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
either	DT	O
1000	CD	O
micrograms	NNS	O
of	IN	O
self-administered	JJ	PM
vaginal	JJ	PM
misoprostol	NN	PM
or	CC	O
self-administered	JJ	O
vaginal	JJ	C
placebo	NN	C
the	DT	O
evening	NN	O
before	IN	O
outpatient	JJ	O
resectoscopy	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Preoperative	NNP	O
cervical	JJ	O
dilatation	NN	O
,	,	O
acceptability	NN	O
and	CC	O
complications	NNS	O
.	.	O

RESULTS	NNP	O
(	(	O
a	DT	O
)	)	O
Intraoperative	JJ	O
findings	NNS	O
and	CC	O
distribution	NN	O
of	IN	O
cervical	JJ	O
dilatation	NN	O
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
median	JJ	O
(	(	O
range	NN	O
)	)	O
or	CC	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
b	NN	O
)	)	O
Acceptability	NN	O
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
completely	RB	O
acceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
;	:	O
fairly	RB	O
acceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
;	:	O
fairly	RB	O
unacceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
and	CC	O
completely	RB	O
unacceptable	JJ	O
,	,	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
c	NN	O
)	)	O
Pain	NN	O
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Pain	NNP	O
was	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
score	NN	O
,	,	O
scale	JJ	O
ranges	NNS	O
from	IN	O
0	CD	O
(	(	O
no	DT	O
pain	NN	O
)	)	O
to	TO	O
10	CD	O
(	(	O
unbearable	JJ	O
pain	NN	O
)	)	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
median	JJ	O
(	(	O
range	NN	O
)	)	O
.	.	O

(	(	O
d	NN	O
)	)	O
Occurrence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Values	NNS	O
are	VBP	O
given	VBN	O
as	IN	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

(	(	O
e	NN	O
)	)	O
Complications	NNPS	O
,	,	O
given	VBN	O
as	IN	O
n	JJ	O
(	(	O
%	NN	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
surgical	JJ	O
trauma	NN	O
and	CC	O
insulin	NN	PM
on	IN	O
whole-body	NN	O
protein	NN	O
turnover	NN	O
in	IN	O
parenterally-fed	JJ	O
undernourished	JJ	O
patients	NNS	O
.	.	O

Ten	CD	O
undernourished	JJ	O
patients	NNS	O
receiving	VBG	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
and	CC	O
undergoing	JJ	O
major	JJ	O
intestinal	JJ	O
surgery	NN	O
were	VBD	O
restarted	VBN	O
on	IN	O
intravenous	JJ	O
feeds	NNS	O
identical	JJ	O
to	TO	O
their	PRP$	O
pre-operative	JJ	O
regimens	NNS	O
within	IN	O
24	CD	O
h	NNS	O
of	IN	O
their	PRP$	O
operation	NN	O
.	.	O

Five	CD	O
,	,	O
chosen	VBN	O
at	IN	O
random	NN	O
,	,	O
received	VBD	O
post-operatively	RB	O
1-2	JJ	PM
units	NNS	PM
insulin/kg	VBP	PM
body	NN	PM
weight/24	JJ	PM
h	NN	PM
with	IN	PM
their	PRP$	PM
feed	NN	PM
,	,	O
while	IN	O
the	DT	O
other	JJ	O
five	CD	O
received	VBD	C
the	DT	C
feed	NN	C
only	RB	C
.	.	O

Pre-operatively	RB	O
,	,	O
and	CC	O
2	CD	O
h	NN	O
after	IN	O
commencing	VBG	O
their	PRP$	O
post-operative	JJ	O
feeds	NNS	O
,	,	O
rates	NNS	O
of	IN	O
whole-body	NN	O
protein	NN	O
synthesis	NN	O
and	CC	O
breakdown	NN	O
were	VBD	O
measured	VBN	O
over	IN	O
a	DT	O
9-h	JJ	O
period	NN	O
following	VBG	O
intravenous	JJ	O
injection	NN	O
of	IN	O
a	DT	O
single	JJ	O
tracer	NN	O
dose	NN	O
of	IN	O
15N-glycine	JJ	PM
by	IN	O
the	DT	O
ammonia	NN	O
and	CC	O
urea	JJ	O
end-product	NN	O
methods	NNS	O
.	.	O

During	IN	O
these	DT	O
9-h	CD	O
study	NN	O
periods	NNS	O
measurements	NNS	O
were	VBD	O
also	RB	O
made	VBN	O
of	IN	O
blood	NN	O
glucose	NN	O
,	,	O
plasma	JJ	O
insulin	NN	PM
and	CC	O
glucagon	NN	O
,	,	O
urinary	JJ	O
ammonia	NN	O
,	,	O
nitrogen	NN	O
,	,	O
creatinine	NN	O
and	CC	O
3-methylhistidine	JJ	O
.	.	O

Blood	NNP	O
glucose	NN	O
and	CC	O
plasma	JJ	O
insulin	NN	PM
and	CC	O
glucagon	NN	O
concentrations	NNS	O
rose	VBD	O
post-operatively	RB	O
whether	IN	O
or	CC	O
not	RB	O
insulin	NN	PM
was	VBD	O
given	VBN	O
,	,	O
but	CC	O
the	DT	O
increment	NN	O
in	IN	O
insulin	NN	PM
concentration	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
when	WRB	O
insulin	NN	PM
was	VBD	O
given	VBN	O
.	.	O

Apparent	JJ	O
nitrogen	NN	O
balance	NN	O
was	VBD	O
positive	JJ	O
pre-operatively	RB	O
and	CC	O
became	VBD	O
less	RBR	O
so	RB	O
post-operatively	RB	O
whether	IN	O
insulin	NN	PM
was	VBD	O
given	VBN	O
or	CC	O
not	RB	O
.	.	O

Similarly	RB	O
,	,	O
post-operative	JJ	O
increments	NNS	O
in	IN	O
urinary	JJ	O
excretion	NN	O
of	IN	O
ammonia	NN	O
,	,	O
creatinine	NN	O
and	CC	O
3-methylhistidine	JJ	O
were	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
addition	NN	O
of	IN	O
insulin	NN	PM
.	.	O

Protein	NNP	O
turnover	NN	O
,	,	O
as	IN	O
estimated	VBN	O
by	IN	O
the	DT	O
ammonia	JJ	O
end-product	NN	O
method	NN	O
,	,	O
tended	VBD	O
to	TO	O
rise	VB	O
post-operatively	RB	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
increases	NNS	O
observed	VBD	O
with	IN	O
or	CC	O
without	IN	O
insulin	NN	PM
.	.	O

The	DT	O
urea	JJ	O
end-product	NN	O
method	NN	O
suggested	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
change	NN	O
in	IN	O
whole-body	NN	O
protein	NN	O
turnover	NN	O
after	IN	O
surgery	NN	O
,	,	O
whether	IN	O
or	CC	O
not	RB	O
insulin	NN	PM
was	VBD	O
given	VBN	O
.	.	O

This	DT	O
study	NN	O
does	VBZ	O
not	RB	O
support	VB	O
the	DT	O
clinical	JJ	O
use	NN	O
of	IN	O
insulin	NN	PM
as	IN	O
a	DT	O
means	NN	O
of	IN	O
modifying	VBG	O
protein	JJ	O
metabolic	JJ	O
losses	NNS	O
after	IN	O
major	JJ	O
surgery	NN	O
.	.	O

Effect	NN	O
of	IN	O
systemic	JJ	O
nitric	JJ	PM
oxide	IN	PM
synthase	JJ	PM
inhibition	NN	O
on	IN	O
postexercise	NN	O
hypotension	NN	O
in	IN	O
humans	NNS	O
.	.	O

An	DT	O
acute	JJ	O
bout	NN	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
results	NNS	O
in	IN	O
a	DT	O
reduced	JJ	O
blood	NN	O
pressure	NN	O
that	WDT	O
lasts	VBZ	O
several	JJ	O
hours	NNS	O
.	.	O

Animal	NNP	O
studies	NNS	O
suggest	VBP	O
this	DT	O
response	NN	O
is	VBZ	O
mediated	VBN	O
by	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
[	NNP	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-monomethyl-L-arginine	NN	O
(	(	O
L-NMMA	NNP	O
)	)	O
]	NN	O
can	MD	O
reverse	VB	O
the	DT	O
drop	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
that	WDT	O
occurs	VBZ	O
after	IN	O
exercise	NN	O
in	IN	O
humans	NNS	O
.	.	O

Eight	NNP	O
healthy	JJ	O
subjects	NNS	O
underwent	JJ	O
parallel	JJ	O
experiments	NNS	O
on	IN	O
2	CD	O
separate	JJ	O
days	NNS	O
.	.	O

The	DT	O
order	NN	O
of	IN	O
the	DT	O
experiments	NNS	O
was	VBD	O
randomized	VBN	O
between	IN	O
sham	NN	O
(	(	O
60	CD	O
min	NN	O
of	IN	O
seated	JJ	PH
upright	JJ	PH
rest	NN	PH
)	)	O
and	CC	O
exercise	NN	O
(	(	O
60	CD	PH
min	NN	PH
of	IN	PH
upright	JJ	PH
cycling	NN	PH
at	IN	O
60	CD	O
%	NN	O
peak	NN	O
aerobic	JJ	O
capacity	NN	O
)	)	O
.	.	O

After	IN	O
both	DT	O
sham	NN	O
and	CC	O
exercise	NN	O
,	,	O
subjects	VBZ	O
received	VBN	O
,	,	O
in	IN	O
sequence	NN	O
,	,	O
systemic	JJ	O
alpha-adrenergic	JJ	O
blockade	NN	O
(	(	O
phentolamine	NN	O
)	)	O
and	CC	O
L-NMMA	NNP	O
.	.	O

Phentolamine	NNP	O
was	VBD	O
given	VBN	O
first	RB	O
to	TO	O
isolate	VB	O
the	DT	O
contribution	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
to	TO	O
postexercise	VB	O
hypotension	NN	O
by	IN	O
preventing	VBG	O
reflex	JJ	O
changes	NNS	O
in	IN	O
sympathetic	JJ	O
tone	NN	O
that	WDT	O
result	NN	O
from	IN	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
and	CC	O
to	TO	O
control	VB	O
for	IN	O
alterations	NNS	O
in	IN	O
resting	VBG	O
sympathetic	JJ	O
activity	NN	O
after	IN	O
exercise	NN	O
.	.	O

During	IN	O
each	DT	O
condition	NN	O
,	,	O
systemic	JJ	O
and	CC	O
regional	JJ	O
hemodynamics	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Throughout	IN	O
the	DT	O
study	NN	O
,	,	O
arterial	JJ	O
pressure	NN	O
and	CC	O
vascular	JJ	O
resistances	NNS	O
remained	VBD	O
lower	JJR	O
postexercise	NN	O
vs.	FW	O
postsham	NN	O
despite	IN	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
inhibition	NN	O
(	(	O
e.g.	JJ	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
after	IN	O
L-NMMA	NNP	O
was	VBD	O
108.0+/-2.4	JJ	O
mmHg	NN	O
postsham	NN	O
vs.	FW	O
102.1+/-3.3	JJ	O
mmHg	NN	O
postexercise	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Thus	VB	O
it	PRP	O
does	VBZ	O
not	RB	O
appear	VB	O
that	IN	O
postexercise	NN	O
hypotension	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
in	IN	O
humans	NNS	O
.	.	O

Effect	NN	O
of	IN	O
acarbose	NN	PM
on	IN	O
additional	JJ	O
insulin	NN	PM
therapy	NN	PM
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
late	JJ	O
failure	NN	O
of	IN	O
sulphonylurea	JJ	O
therapy	NN	O
.	.	O

AIM	VB	O
The	DT	O
present	JJ	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
acarbose	NN	PM
on	IN	O
insulin	NN	O
requirements	NNS	O
and	CC	O
glycaemic	JJ	O
control	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
receiving	VBG	O
exogenous	JJ	O
insulin	NN	PM
due	JJ	O
to	TO	O
secondary	JJ	O
failure	NN	O
of	IN	O
maximum	NN	O
dose	JJ	O
sulphonylurea	JJ	O
therapy	NN	O
.	.	O

METHODS	VB	O
A	DT	O
single-centre	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
48	CD	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
late-term	JJ	O
failure	NN	O
following	VBG	O
at	IN	O
least	JJS	O
3	CD	O
years	NNS	O
of	IN	O
sulphonylurea	JJ	PM
therapy	NN	O
requiring	VBG	O
additional	JJ	O
insulin	NN	PM
therapy	NN	O
to	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
acarbose	NN	PM
on	IN	O
glycaemic	JJ	O
control	NN	O
and	CC	O
insulin	NN	O
requirements	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
glycaemic	JJ	O
response	NN	O
rate	NN	O
(	(	O
responders	NNS	O
being	VBG	O
predefined	VBN	O
as	IN	O
patients	NNS	O
who	WP	O
achieve	VBP	O
a	DT	O
decrease	NN	O
in	IN	O
HbA1c	NNP	O
to	TO	O
less	JJR	O
than	IN	O
8	CD	O
%	NN	O
or	CC	O
a	DT	O
reduction	NN	O
by	IN	O
at	IN	O
least	JJS	O
15	CD	O
%	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
baseline	NN	O
values	NNS	O
)	)	O
and	CC	O
the	DT	O
daily	JJ	O
insulin	NN	PM
dose	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Secondary	JJ	O
parameters	NNS	O
assessed	VBD	O
included	VBN	O
postprandial	JJ	O
changes	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
,	,	O
serum	JJ	O
insulin	NN	PM
and	CC	O
C-peptide	NNP	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
significantly	RB	O
more	JJR	O
responders	NNS	O
in	IN	O
the	DT	O
acarbose-treated	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
20/24	CD	O
patients	NNS	O
vs.	FW	O
10/19	CD	O
patients	NNS	O
;	:	O
p	VB	O
<	$	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
daily	JJ	O
insulin	NN	PM
dose	NN	O
after	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
was	VBD	O
16.4	CD	O
+/-	JJ	O
10.1	CD	O
IU	NNP	O
in	IN	O
the	DT	O
acarbose	JJ	PM
group	NN	O
and	CC	O
22.4	CD	O
+/-	JJ	O
12.2	CD	O
IU	NNP	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
s.d	NN	O
.	.	O

;	:	O
p	JJ	O
<	NNP	O
0.07	CD	O
)	)	O
.	.	O

Postprandial	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
,	,	O
insulin	NN	O
and	CC	O
C-peptide	NNP	O
were	VBD	O
consistently	RB	O
lower	JJR	O
in	IN	O
the	DT	O
acarbose-treated	JJ	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
the	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
2-h	JJ	O
postprandial	JJ	O
serum	NN	O
insulin	NN	PM
remained	VBD	O
almost	RB	O
unchanged	JJ	O
in	IN	O
the	DT	O
acarbose	JJ	O
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
compared	VBN	O
to	TO	O
an	DT	O
increase	NN	O
to	TO	O
43	CD	O
+/-	JJ	O
29	CD	O
microU/ml	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
s.d	NN	O
.	.	O

)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
period	NN	O
for	IN	O
the	DT	O
placebo	NN	C
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
the	DT	O
addition	NN	O
of	IN	O
acarbose	NN	PM
to	TO	O
sulphonylurea/insulin	VB	PM
combination	NN	PM
therapy	NN	PM
can	MD	O
improve	VB	O
glycaemic	JJ	O
control	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
.	.	O

Acarbose	NNP	PM
may	MD	O
also	RB	O
reduce	VB	O
insulin	NN	O
resistance	NN	O
and	CC	O
hyperinsulinaemia	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
intravenous	JJ	O
granisetron	NN	PM
to	TO	O
control	VB	O
nausea	NN	O
and	CC	O
vomiting	VBG	O
during	IN	O
multiple	JJ	O
cycles	NNS	O
of	IN	O
cisplatin-based	JJ	PM
chemotherapy	NN	PM
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
granisetron	NN	PM
(	(	O
10	CD	O
micrograms/kg	NN	O
and	CC	O
40	CD	O
micrograms/kg	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
during	IN	O
a	DT	O
second	JJ	O
(	(	O
n	JJ	O
=	NNP	O
393	CD	O
)	)	O
and	CC	O
third	JJ	O
(	(	O
n	JJ	O
=	NNP	O
200	CD	O
)	)	O
cycle	NN	O
of	IN	O
chemotherapy	NN	O
in	IN	O
this	DT	O
multicenter	NN	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
study	NN	O
.	.	O

Granisetron	NNP	PM
was	VBD	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
cisplatin	NN	PM
chemotherapy	NN	PM
(	(	O
>	CD	O
or	CC	O
=	VB	O
60	CD	O
mg/m2	NN	O
)	)	O
.	.	O

Total	JJ	O
control	NN	O
(	(	O
no	DT	O
vomiting	NN	O
,	,	O
no	DT	O
retching	NN	O
,	,	O
no	DT	O
nausea	NN	O
,	,	O
and	CC	O
no	DT	O
use	NN	O
of	IN	O
antiemetic	JJ	O
rescue	NN	O
medication	NN	O
)	)	O
after	IN	O
the	DT	O
first	JJ	O
24	CD	O
hr	NN	O
following	VBG	O
chemotherapy	NN	PM
was	VBD	O
achieved	VBN	O
in	IN	O
40	CD	O
%	NN	O
and	CC	O
49	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
Cycles	NNP	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
10	CD	O
micrograms/kg	NN	O
group	NN	O
,	,	O
and	CC	O
in	IN	O
42	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
Cycles	NNP	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
40	CD	O
micrograms/kg	NN	O
group	NN	O
.	.	O

Both	DT	O
dose	JJ	O
levels	NNS	O
of	IN	O
granisetron	NN	PM
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
comparable	JJ	O
efficacy	NN	O
between	IN	O
the	DT	O
10	CD	O
micrograms/kg	NN	O
and	CC	O
40	CD	O
micrograms/kg	NN	O
doses	NNS	O
of	IN	O
granisetron	NN	PM
in	IN	O
preventing	VBG	O
nausea	NN	O
and	CC	O
vomiting	VBG	O
during	IN	O
repeat	NN	O
cycles	NNS	O
of	IN	O
high-dose	JJ	O
cisplatin-based	JJ	PM
chemotherapy	NN	PM
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
granisetron	VBZ	PM
10	CD	O
micrograms/kg	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
remains	VBZ	O
effective	JJ	O
with	IN	O
repeat	NN	O
cycle	NN	O
use	NN	O
.	.	O

Action	NNP	O
observation	NN	O
treatment	NN	O
improves	VBZ	O
recovery	NN	O
of	IN	O
postsurgical	JJ	O
orthopedic	JJ	O
patients	NNS	O
:	:	O
evidence	NN	O
for	IN	O
a	DT	O
top-down	JJ	O
effect	NN	O
?	.	O
OBJECTIVE	UH	O
To	TO	O
assess	VB	O
whether	IN	O
action	NN	PH
observation	NN	PH
treatment	NN	PH
(	(	PH
AOT	NNP	PH
)	)	PH
may	MD	O
also	RB	O
improve	VB	O
motor	NN	O
recovery	NN	O
in	IN	O
postsurgical	JJ	O
orthopedic	JJ	O
patients	NNS	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
conventional	JJ	O
physiotherapy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NNP	O
Department	NNP	O
of	IN	O
rehabilitation	NN	O
.	.	O

PARTICIPANTS	JJ	O
Patients	NNPS	O
(	(	O
N=60	NNP	O
)	)	O
admitted	VBD	O
to	TO	O
our	PRP$	O
department	NN	O
postorthopedic	NN	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
case	NN	O
(	(	O
n=30	NN	O
)	)	O
or	CC	O
control	NN	C
(	(	O
n=30	JJ	O
)	)	O
group	NN	O
.	.	O

Exclusion	NN	O
criteria	NNS	O
were	VBD	O
age	NN	O
18	CD	O
years	NNS	O
or	CC	O
younger	JJR	O
and	CC	O
90	CD	O
years	NNS	O
or	CC	O
older	JJR	O
,	,	O
Mini-Mental	JJ	O
State	NNP	O
Examination	NNP	O
score	NN	O
of	IN	O
21	CD	O
of	IN	O
30	CD	O
or	CC	O
lower	JJR	O
,	,	O
no	DT	O
ambulating	VBG	O
order	NN	O
,	,	O
advanced	JJ	O
vision	NN	O
impairment	NN	O
,	,	O
malignancy	NN	O
,	,	O
pneumonia	NN	O
,	,	O
or	CC	O
heart	NN	O
failure	NN	O
.	.	O

INTERVENTIONS	NNP	O
All	NNP	O
participants	NNS	O
underwent	JJ	O
conventional	JJ	O
physiotherapy	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
observe	VB	E
video	JJ	E
clips	NNS	E
showing	VBG	E
daily	JJ	E
actions	NNS	E
and	CC	E
to	TO	E
imitate	VB	E
them	PRP	E
afterward	RB	E
.	.	PH

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
observe	VB	E
video	JJ	E
clips	NNS	E
with	IN	E
no	DT	E
motor	NN	E
content	NN	E
and	CC	E
to	TO	E
execute	VB	E
the	DT	E
same	JJ	E
actions	NNS	E
as	IN	E
patients	NNS	E
in	IN	E
the	DT	E
case	NN	E
group	NN	E
afterward	RB	O
.	.	O

Participants	NNS	O
were	VBD	O
scored	VBN	O
on	IN	O
functional	JJ	O
scales	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
treatment	NN	O
by	IN	O
a	DT	O
physician	NN	O
blinded	VBD	O
to	TO	O
group	NN	O
assignment	NN	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
MEASURES	NNP	O
Changes	NNP	O
in	IN	O
FIM	NNP	O
and	CC	O
Tinetti	NNP	O
scale	NN	O
scores	NNS	O
,	,	O
and	CC	O
dependence	NN	O
on	IN	O
walking	VBG	O
aids	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
clinical	JJ	O
and	CC	O
functional	JJ	O
scale	NN	O
scores	NNS	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
scored	VBD	O
better	JJR	O
than	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
FIM	NNP	O
total	NN	O
score	NN	O
,	,	O
P=.02	NNP	O
;	:	O
FIM	NNP	O
motor	NN	O
subscore	NN	O
,	,	O
P=.001	NNP	O
;	:	O
Tinetti	NNP	O
scale	NN	O
score	NN	O
,	,	O
P=.04	NNP	O
)	)	O
;	:	O
patients	NNS	O
in	IN	O
the	DT	O
case	NN	O
group	NN	O
were	VBD	O
assigned	VBN	O
more	RBR	O
frequently	RB	O
to	TO	O
1	CD	O
crutch	NN	O
(	(	O
P=.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
addition	NN	O
to	TO	O
conventional	JJ	O
physiotherapy	NN	O
,	,	O
AOT	NNP	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
rehabilitation	NN	O
of	IN	O
postsurgical	JJ	O
orthopedic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
present	JJ	O
results	NNS	O
strongly	RB	O
support	VB	O
top-down	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
treatment	NN	O
in	IN	O
motor	NN	O
recovery	NN	O
,	,	O
even	RB	O
in	IN	O
nonneurologic	JJ	O
patients	NNS	O
.	.	O

[	JJ	O
Clinical	NNP	O
observation	NN	O
on	IN	O
acupuncture	NN	PH
combined	VBN	O
with	IN	O
Yizhi	NNP	PM
Jiannao	NNP	PM
granules	NNS	PM
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
clinical	JJ	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
acupuncture	NN	PH
combined	VBN	O
with	IN	O
Yizhi	NNP	PM
Jiannao	NNP	PM
Granules	NNP	PM
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
and	CC	O
its	PRP$	O
effects	NNS	O
on	IN	O
intelligence	NN	O
,	,	O
daily	JJ	O
life	NN	O
and	CC	O
social	JJ	O
activity	NN	O
ability	NN	O
.	.	O

METHODS	NNP	O
Eighty-four	JJ	O
cases	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
,	,	O
28	CD	O
cases	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
combined	JJ	O
acupuncture	NN	PH
and	CC	O
medication	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
acupuncture	NN	PH
at	IN	O
Baihui	NNP	O
(	(	O
GV	NNP	O
20	CD	O
)	)	O
,	,	O
Sishencong	NNP	O
(	(	O
EX-HN	NNP	O
1	CD	O
)	)	O
,	,	O
Dazhui	NNP	O
(	(	O
GV	NNP	O
14	CD	O
)	)	O
,	,	O
Guanyuan	NNP	O
(	(	O
CV	NNP	O
4	CD	O
)	)	O
,	,	O
etc	FW	O
.	.	O

and	CC	O
oral	JJ	O
administration	NN	O
of	IN	O
Yizhi	NNP	PM
Jiannao	NNP	PM
Granules	NNP	PM
;	:	O
the	DT	O
Chinese	NNP	O
herb	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
Yizhi	NNP	PM
Jiannao	NNP	PM
Granules	NNP	PM
,	,	O
and	CC	O
the	DT	O
western	JJ	PM
medicine	NN	PM
group	NN	PM
with	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
Aricept	NNP	PM
.	.	O

The	DT	O
scores	NNS	O
for	IN	O
the	DT	O
Mini-Mental	JJ	O
State	NNP	O
Examination	NNP	O
(	(	O
MMSE	NNP	O
)	)	O
,	,	O
Ability	NNP	O
of	IN	O
Daily	NNP	O
Life	NNP	O
(	(	O
ADL	NNP	O
)	)	O
and	CC	O
the	DT	O
therapeutic	JJ	O
effects	NNS	O
were	VBD	O
assessed	VBN	O
and	CC	O
compared	VBN	O
before	IN	O
treatment	NN	O
and	CC	O
after	IN	O
treatment	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
scores	NNS	O
for	IN	O
MMSE	NNP	O
and	CC	O
ADL	NNP	O
were	VBD	O
improved	VBN	O
in	IN	O
the	DT	O
combined	JJ	PH
acupuncture	NN	PH
and	CC	PH
medication	NN	PH
group	NN	O
,	,	O
the	DT	O
Chinese	JJ	PM
herb	NN	PM
group	NN	O
and	CC	O
the	DT	O
western	JJ	PM
medicine	NN	PM
group	NN	O
,	,	O
which	WDT	O
were	VBD	O
better	RBR	O
in	IN	O
the	DT	O
combined	JJ	O
acupuncture	NN	PH
and	CC	PH
medication	NN	PH
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
effective	JJ	O
rate	NN	O
of	IN	O
85.7	CD	O
%	NN	O
in	IN	O
the	DT	O
combined	JJ	PH
acupuncture	NN	PH
and	CC	PH
medication	NN	PH
group	NN	O
was	VBD	O
better	JJR	O
than	IN	O
71.4	CD	O
%	NN	O
in	IN	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
67.9	CD	O
%	NN	O
in	IN	O
the	DT	O
western	JJ	O
medicine	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Acupuncture	NNP	O
combined	VBN	O
with	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
has	VBZ	O
a	DT	O
significant	JJ	O
therapeutic	JJ	O
effect	NN	O
on	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
which	WDT	O
is	VBZ	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
Yizhi	NNP	O
Jiannao	NNP	O
Granules	NNP	O
or	CC	O
Aricept	NNP	O
.	.	O

Comparative	NNP	O
dose	NN	O
efficacy	NN	O
study	NN	O
of	IN	O
atorvastatin	JJ	PM
versus	NN	O
simvastatin	NN	PM
,	,	O
pravastatin	NN	PM
,	,	O
lovastatin	NN	PM
,	,	O
and	CC	O
fluvastatin	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
hypercholesterolemia	NN	O
(	(	O
the	DT	O
CURVES	NNP	O
study	NN	O
)	)	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
open-label	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
8-week	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
comparative	JJ	O
dose	JJ	O
efficacy	NN	O
of	IN	O
the	DT	O
3-hydroxy-3-methylglutaryl	JJ	PM
coenzyme	NN	PM
A	NNP	PM
(	(	PM
HMG-CoA	NNP	PM
)	)	PM
reductase	NN	PM
inhibitor	NN	PM
atorvastatin	VBD	PM
10	CD	PM
,	,	PM
20	CD	PM
,	,	PM
40	CD	PM
,	,	PM
and	CC	PM
80	CD	PM
mg	NNS	PM
compared	VBN	O
with	IN	O
simvastatin	NN	PM
10	CD	PM
,	,	PM
20	CD	PM
,	,	PM
and	CC	PM
40	CD	PM
mg	NN	PM
,	,	O
pravastatin	NN	PM
10	CD	PM
,	,	PM
20	CD	PM
,	,	PM
and	CC	PM
40	CD	PM
mg	NN	PM
,	,	PM
lovastatin	VBZ	PM
20	CD	PM
,	,	PM
40	CD	PM
,	,	PM
and	CC	PM
80	CD	PM
mg	NN	PM
,	,	O
and	CC	O
fluvastatin	$	PM
20	CD	PM
and	CC	PM
40	CD	PM
mg.	NN	PM
Investigators	NNS	O
enrolled	VBD	O
534	CD	O
hypercholesterolemic	JJ	O
patients	NNS	O
(	(	O
low-density	JJ	O
lipoprotein	NN	O
[	NNP	O
LDL	NNP	O
]	NNP	O
cholesterol	NN	O
>	NN	O
or	CC	O
=	$	O
160	CD	O
mg/dl	NN	O
[	VBD	O
4.2	CD	O
mmol/L	NN	O
]	NN	O
and	CC	O
triglycerides	NNS	O
<	VBP	O
or	CC	O
=	VBP	O
400	CD	O
mg/dl	NN	O
[	VBD	O
4.5	CD	O
mmol/L	NNS	O
]	RB	O
)	)	O
.	.	O

The	DT	O
efficacy	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
mean	JJ	O
percent	NN	O
change	NN	O
in	IN	O
plasma	NN	O
LDL	NNP	O
cholesterol	NN	O
(	(	O
primary	JJ	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
,	,	O
triglycerides	NNS	O
,	,	O
and	CC	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
concentrations	NNS	O
from	IN	O
baseline	NN	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
week	NN	O
8	CD	O
)	)	O
.	.	O

Atorvastatin	$	PM
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
produced	VBN	O
greater	JJR	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.01	CD	O
)	)	O
reductions	NNS	O
in	IN	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
-38	CD	O
%	NN	O
,	,	O
-46	CD	O
%	NN	O
,	,	O
and	CC	O
-51	NNP	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
than	IN	O
the	DT	O
milligram	JJ	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
simvastatin	NN	PM
,	,	O
pravastatin	NN	PM
,	,	O
lovastatin	NN	PM
,	,	O
and	CC	O
fluvastatin	NN	PM
.	.	O

Atorvastatin	$	PM
10	CD	O
mg	NN	O
produced	VBN	O
LDL	NNP	O
cholesterol	NN	O
reductions	NNS	O
comparable	JJ	O
to	TO	O
or	CC	O
greater	JJR	O
than	IN	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.02	CD	O
)	)	O
simvastatin	NN	PM
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
pravastatin	NN	PM
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
lovastatin	CC	PM
20	CD	O
and	CC	O
40	CD	O
mg	NN	O
,	,	O
and	CC	O
fluvastatin	$	PM
20	CD	O
and	CC	O
40	CD	O
mg.	NN	O
Atorvastatin	NNP	PM
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
40	CD	O
mg	NN	O
produced	VBN	O
greater	JJR	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.01	CD	O
)	)	O
reductions	NNS	O
in	IN	O
total	JJ	O
cholesterol	NN	O
than	IN	O
the	DT	O
milligram	JJ	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
simvastatin	NN	PM
,	,	O
pravastatin	NN	PM
,	,	O
lovastatin	NN	PM
,	,	O
and	CC	O
fluvastatin	NN	PM
.	.	O

All	DT	O
reductase	NN	O
inhibitors	NNS	O
studied	VBD	O
had	VBD	O
similar	JJ	O
tolerability	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
incidences	NNS	O
of	IN	O
persistent	JJ	O
elevations	NNS	O
in	IN	O
serum	NN	O
transaminases	NNS	O
or	CC	O
myositis	NN	O
.	.	O

Reputation	NNP	O
management	NN	O
:	:	O
evidence	NN	O
for	IN	O
ability	NN	O
but	CC	O
reduced	JJ	O
propensity	NN	O
in	IN	O
autism	NN	O
.	.	O

Previous	JJ	O
research	NN	O
has	VBZ	O
reported	VBN	O
that	IN	O
autistic	JJ	O
adults	NNS	O
do	VBP	O
not	RB	O
manage	VB	O
their	PRP$	O
reputation	NN	O
,	,	O
purportedly	RB	O
due	JJ	O
to	TO	O
problems	NNS	O
with	IN	O
theory	NN	O
of	IN	O
mind	NN	O
[	NNP	O
Izuma	NNP	O
,	,	O
Matsumoto	NNP	O
,	,	O
Camerer	NNP	O
,	,	O
&	CC	O
Adolphs	NNP	O
]	NNP	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
aimed	VBD	O
to	TO	O
test	VB	E
alternative	JJ	E
explanations	NNS	E
for	IN	O
this	DT	O
apparent	JJ	O
lack	NN	O
of	IN	O
reputation	NN	O
management	NN	O
.	.	O

Twenty	NNP	O
typical	JJ	O
and	CC	O
19	CD	O
autistic	JJ	O
adults	NNS	O
donated	VBD	E
to	TO	E
charity	NN	E
and	CC	E
to	TO	E
a	DT	E
person	NN	E
,	,	O
both	DT	O
when	WRB	O
alone	RB	O
and	CC	O
when	WRB	O
observed	VBN	O
.	.	O

In	IN	O
an	DT	O
additional	JJ	O
manipulation	NN	O
,	,	O
for	IN	O
half	NN	O
of	IN	O
the	DT	O
participants	NNS	O
,	,	O
the	DT	O
observer	NN	O
was	VBD	O
also	RB	O
the	DT	O
recipient	NN	O
of	IN	O
their	PRP$	O
donations	NNS	O
,	,	O
and	CC	O
participants	NNS	O
were	VBD	O
told	VBN	O
that	IN	O
this	DT	O
observer	NN	O
would	MD	O
subsequently	RB	O
have	VB	O
the	DT	O
opportunity	NN	O
to	TO	O
donate	VB	E
to	TO	O
them	PRP	O
(	(	O
motivation	NN	O
condition	NN	O
)	)	O
.	.	O

This	DT	O
manipulation	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
encourage	VB	O
an	DT	O
expectation	NN	O
of	IN	O
a	DT	O
reciprocal	JJ	O
tit-for-tat	NN	O
strategy	NN	O
in	IN	O
the	DT	O
participant	NN	O
,	,	O
which	WDT	O
may	MD	O
motivate	VB	O
participants	NNS	O
to	TO	O
change	VB	O
their	PRP$	O
behavior	NN	O
to	TO	O
receive	VB	O
more	JJR	O
donations	NNS	O
.	.	O

The	DT	O
remaining	VBG	O
participants	NNS	O
were	VBD	O
told	VBN	O
that	IN	O
the	DT	O
person	NN	O
watching	NN	O
was	VBD	O
just	RB	O
observing	VBG	O
the	DT	O
procedure	NN	O
(	(	O
no	DT	O
motivation	NN	O
condition	NN	O
)	)	O
.	.	O

Our	PRP$	O
results	NNS	O
replicated	VBD	O
Izuma	NNP	O
et	CC	O
al	NN	O
.	.	O

's	POS	O
finding	VBG	O
that	IN	O
autistic	JJ	O
adults	NNS	O
did	VBD	O
not	RB	O
donate	VB	O
more	JJR	O
to	TO	O
charity	NN	O
when	WRB	O
observed	VBN	O
.	.	O

Yet	CC	O
,	,	O
in	IN	O
the	DT	O
motivation	NN	O
condition	NN	O
,	,	O
both	DT	O
typical	JJ	O
and	CC	O
autistic	JJ	O
adults	NNS	O
donated	VBD	O
significantly	RB	O
more	RBR	O
to	TO	O
the	DT	O
observer	NN	O
when	WRB	O
watched	VBN	O
,	,	O
although	IN	O
this	DT	O
effect	NN	O
was	VBD	O
significantly	RB	O
attenuated	VBN	O
in	IN	O
autistic	JJ	O
individuals	NNS	O
.	.	O

Results	NNS	O
indicate	VBP	O
that	IN	O
,	,	O
while	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
may	MD	O
have	VB	O
the	DT	O
ability	NN	O
to	TO	O
think	VB	O
about	IN	O
reputation	NN	O
,	,	O
a	DT	O
reduced	JJ	O
expectation	NN	O
of	IN	O
reciprocal	JJ	O
behavior	NN	O
from	IN	O
others	NNS	O
may	MD	O
reduce	VB	O
the	DT	O
degree	NN	O
to	TO	O
which	WDT	O
they	PRP	O
engage	VBP	O
in	IN	O
reputation	NN	O
management	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
recombinant	JJ	PM
alpha	JJ	PM
2b-interferon	JJ	PM
with	IN	O
or	CC	O
without	IN	O
indomethacin	NNS	PM
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
malignant	JJ	O
melanoma	NN	O
.	.	O

alpha-Interferon	NN	PM
has	VBZ	O
antitumor	VBN	O
activity	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
malignancies	NNS	O
but	CC	O
is	VBZ	O
frequently	RB	O
associated	VBN	O
with	IN	O
unacceptable	JJ	O
toxic	JJ	O
side-effects	NNS	O
.	.	O

The	DT	O
routine	JJ	O
use	NN	O
of	IN	O
agents	NNS	O
potentially	RB	O
capable	JJ	O
of	IN	O
reducing	VBG	O
these	DT	O
side-effects	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
recommended	VBN	O
out	IN	O
of	IN	O
concern	NN	O
for	IN	O
possible	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
therapeutic	JJ	O
activity	NN	O
of	IN	O
interferon	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
alpha-interferon	JJ	O
given	VBN	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	JJ	PM
to	TO	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
to	TO	O
determine	VB	O
what	WP	O
effect	NN	O
,	,	O
if	IN	O
any	DT	O
,	,	O
indomethacin	NN	PM
might	MD	O
have	VB	O
on	IN	O
the	DT	O
toxic	NN	O
,	,	O
immunomodulatory	NN	O
,	,	O
and	CC	O
therapeutic	JJ	O
properties	NNS	O
of	IN	O
interferon	NN	O
in	IN	O
this	DT	O
disease	NN	O
.	.	O

53	CD	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
performance	NN	O
status	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
alpha	JJ	PM
2b-interferon	CD	PM
,	,	O
20	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
i.v.	NN	O
,	,	O
5	CD	O
days	NNS	O
per	IN	O
week	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
10	CD	O
million	CD	O
units	NNS	O
per	IN	O
m2	NN	O
s.c.	NN	O
three	CD	O
times	NNS	O
per	IN	O
week	NN	O
,	,	O
either	RB	O
with	IN	O
or	CC	O
without	IN	O
indomethacin	NN	PM
,	,	O
25	CD	O
mg	NN	O
orally	RB	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

The	DT	O
overall	JJ	O
major	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
13	CD	O
%	NN	O
(	(	O
three	CD	O
complete	JJ	O
responders	NNS	O
and	CC	O
three	CD	O
partial	JJ	O
responders	NNS	O
among	IN	O
47	CD	O
evaluable	JJ	O
patients	NNS	O
)	)	O
and	CC	O
was	VBD	O
the	DT	O
same	JJ	O
on	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
mean	JJ	O
maximal	JJ	O
temperature	NN	O
elevation	NN	O
induced	VBN	O
by	IN	O
interferon	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
from	IN	O
102.1	CD	O
to	TO	O
100.7	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0002	CD	O
)	)	O
by	IN	O
indomethacin	NN	PM
,	,	O
but	CC	O
the	DT	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
interferon-related	JJ	O
fatigue	NN	O
,	,	O
reduction	NN	O
in	IN	O
performance	NN	O
status	NN	O
,	,	O
headache	NN	O
,	,	O
depression	NN	O
,	,	O
confusion	NN	O
,	,	O
elevations	NNS	O
in	IN	O
liver	JJ	O
function	NN	O
tests	NNS	O
,	,	O
and	CC	O
myelosuppression	NN	O
were	VBD	O
no	DT	O
different	JJ	O
in	IN	O
either	DT	O
arm	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Indomethacin	NNP	PM
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
frequency	NN	O
of	IN	O
dose	JJ	O
reductions	NNS	O
for	IN	O
toxic	JJ	O
side-effects	NNS	O
and	CC	O
did	VBD	O
not	RB	O
permit	VB	O
the	DT	O
administration	NN	O
of	IN	O
higher	JJR	O
interferon	NN	O
doses	NNS	O
.	.	O

Peripheral	NNP	O
blood	VBD	O
natural	JJ	O
killer	NN	O
activity	NN	O
was	VBD	O
significantly	RB	O
enhanced	VBN	O
in	IN	O
patients	NNS	O
during	IN	O
maintenance	NN	O
therapy	NN	O
whether	IN	O
or	CC	O
not	RB	O
they	PRP	O
received	VBD	O
indomethacin	NN	O
.	.	O

Indomethacin	NNP	PM
appeared	VBD	O
to	TO	O
inhibit	VB	O
augmentation	NN	O
of	IN	O
natural	JJ	O
killer	NN	O
activity	NN	O
during	IN	O
high	JJ	O
dose	JJ	O
induction	NN	O
therapy	NN	O
.	.	O

Immunological	JJ	O
changes	NNS	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
response	NN	O
status	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
indomethacin	NN	O
can	MD	O
reduce	VB	O
the	DT	O
fever	NN	O
associated	VBN	O
with	IN	O
interferon	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
without	IN	O
interfering	VBG	O
with	IN	O
its	PRP$	O
therapeutic	JJ	O
or	CC	O
chronic	JJ	O
immunomodulatory	NN	O
activities	NNS	O
.	.	O

Since	IN	O
fever	NN	O
is	VBZ	O
rarely	RB	O
the	DT	O
dose-limiting	JJ	O
toxicity	NN	O
of	IN	O
interferon	NN	O
,	,	O
indomethacin	NN	PM
is	VBZ	O
of	IN	O
marginal	JJ	O
benefit	NN	O
to	TO	O
patients	NNS	O
with	IN	O
malignant	JJ	O
melanoma	NN	O
receiving	VBG	O
interferon	NN	O
at	IN	O
the	DT	O
doses	NNS	O
outlined	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Long	JJ	O
term	NN	O
follow	VBP	O
up	IN	O
of	IN	O
patients	NNS	O
treated	VBN	O
for	IN	O
Helicobacter	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

BACKGROUND	NNP	O
Helicobacter	NNP	O
pylori	POS	O
infection	NN	O
induces	NNS	O
progressive	JJ	O
inflammatory	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
gastric	JJ	O
mucosa	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
gastric	JJ	O
cancer	NN	O
.	.	O

Understanding	VBG	O
long	JJ	O
term	NN	O
effects	NNS	O
resulting	VBG	O
from	IN	O
the	DT	O
cure	NN	O
of	IN	O
this	DT	O
infection	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
design	VB	O
cancer	NN	O
prevention	NN	O
strategies	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
795	CD	O
adults	NNS	O
with	IN	O
preneoplastic	JJ	O
gastric	JJ	O
lesions	NNS	O
was	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	PM
anti-H	JJ	PM
pylori	NN	PM
treatment	NN	PM
and/or	JJ	PM
antioxidants	NNS	PM
.	.	PM

At	IN	O
the	DT	O
end	NN	O
of	IN	O
six	CD	O
years	NNS	O
of	IN	O
intervention	NN	O
,	,	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
anti-H	JJ	O
pylori	NN	O
treatment	NN	O
were	VBD	O
offered	VBN	O
it	PRP	O
.	.	O

Gastric	JJ	O
biopsies	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
years	NNS	O
.	.	O

A	DT	O
histopathology	NN	O
score	NN	O
was	VBD	O
utilised	VBN	O
to	TO	O
document	VB	O
changes	NNS	O
in	IN	O
gastric	JJ	O
lesions	NNS	O
.	.	O

Non-linear	JJ	O
mixed	JJ	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
cumulative	JJ	O
effect	NN	O
of	IN	O
H	NNP	O
pylori	JJ	O
clearance	NN	O
on	IN	O
histopathology	NN	O
scores	NNS	O
adjusted	VBN	O
for	IN	O
follow	VB	O
up	RP	O
time	NN	O
,	,	O
interventions	NNS	O
,	,	O
and	CC	O
confounders	NNS	O
.	.	O

RESULTS	NNP	O
Ninety	NNP	O
seven	CD	O
per	IN	O
cent	NN	O
of	IN	O
subjects	NNS	O
were	VBD	O
H	NNP	O
pylori	JJ	O
positive	JJ	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
53	CD	O
%	NN	O
were	VBD	O
positive	JJ	O
at	IN	O
12	CD	O
years	NNS	O
.	.	O

Subjects	NNS	O
accumulated	JJ	O
1703	CD	O
person	NN	O
years	NNS	O
free	JJ	O
of	IN	O
infection	NN	O
.	.	O

A	DT	O
multivariate	NN	O
model	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
regression	NN	O
in	IN	O
histopathology	NN	O
score	NN	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
square	NN	O
of	IN	O
H	NNP	O
pylori	FW	O
negative	JJ	O
time	NN	O
.	.	O

Subjects	NNS	O
who	WP	O
were	VBD	O
H	NNP	O
pylori	JJ	O
negative	JJ	O
had	VBD	O
14.8	CD	O
%	NN	O
more	JJR	O
regression	NN	O
and	CC	O
13.7	CD	O
%	NN	O
less	JJR	O
progression	NN	O
than	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
positive	JJ	O
at	IN	O
12	CD	O
years	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
healing	NN	O
of	IN	O
gastric	JJ	O
lesions	NNS	O
occurred	VBD	O
more	RBR	O
rapidly	RB	O
as	IN	O
years	NNS	O
free	JJ	O
of	IN	O
infection	NN	O
accumulated	VBN	O
,	,	O
and	CC	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
less	RBR	O
advanced	JJ	O
lesions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Preneoplastic	NNP	O
gastric	JJ	O
lesions	NNS	O
regress	NN	O
at	IN	O
a	DT	O
rate	NN	O
equal	JJ	O
to	TO	O
the	DT	O
square	NN	O
of	IN	O
time	NN	O
in	IN	O
patients	NNS	O
rendered	JJ	O
free	JJ	O
of	IN	O
H	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
preneoplastic	JJ	O
gastric	JJ	O
lesions	NNS	O
should	MD	O
be	VB	O
treated	VBN	O
and	CC	O
cured	VBN	O
of	IN	O
their	PRP$	O
H	NNP	O
pylori	NN	O
infection	NN	O
.	.	O

Aztreonam	NNP	PM
versus	NN	O
gentamicin	NN	PM
for	IN	O
short-term	JJ	O
prophylaxis	NN	O
in	IN	O
biliary	JJ	O
and	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

Short-term	NNP	O
antibiotic	JJ	O
prophylaxis	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
80	CD	O
patients	NNS	O
undergoing	JJ	O
biliary	JJ	O
or	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
g	NN	O
of	IN	O
aztreonam	NN	PM
or	CC	O
80	CD	O
mg	NN	O
of	IN	O
gentamicin	NN	PM
intravenously	RB	O
30	CD	O
minutes	NNS	O
before	IN	O
surgery	NN	O
and	CC	O
8	CD	O
and	CC	O
16	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Of	IN	O
samples	NNS	O
taken	VBN	O
from	IN	O
the	DT	O
abdominal	JJ	O
cavity	NN	O
for	IN	O
bacteriologic	NN	O
study	NN	O
,	,	O
53	CD	O
%	NN	O
were	VBD	O
culture	NN	O
positive	JJ	O
.	.	O

Wound	IN	O
infections	NNS	O
developed	VBN	O
in	IN	O
two	CD	O
(	(	O
4.5	CD	O
%	NN	O
)	)	O
of	IN	O
44	CD	O
patients	NNS	O
receiving	VBG	O
aztreonam	NN	PM
and	CC	O
in	IN	O
seven	CD	O
(	(	O
19.4	CD	O
%	NN	O
)	)	O
of	IN	O
36	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
gentamicin	NN	PM
.	.	PM

Staphylococcus	NNP	O
epidermidis	NN	O
and	CC	O
Enterobacter	NNP	O
species	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
sites	NNS	O
of	IN	O
wound	JJ	O
infection	NN	O
in	IN	O
the	DT	O
aztreonam	JJ	PM
group	NN	O
;	:	O
Escherichia	NNP	O
coli	NNS	O
(	(	O
two	CD	O
isolates	NNS	O
)	)	O
,	,	O
Pseudomonas	NNP	O
aeruginosa	NN	O
(	(	O
two	CD	O
isolates	NNS	O
)	)	O
,	,	O
Enterobacter	NNP	O
species	NNS	O
,	,	O
Klebsiella	NNP	O
species	NNS	O
,	,	O
Enterococcus	NNP	O
faecalis	NN	O
,	,	O
and	CC	O
Aeromonas	NNP	O
hydrophila	NN	O
were	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
gentamicin	NN	O
group	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
aztreonam	NN	PM
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
infections	NNS	O
following	VBG	O
biliary	JJ	O
and	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

Improved	VBN	O
fibrinolysis	NN	O
after	IN	O
1-year	JJ	O
treatment	NN	O
with	IN	O
HMG	NNP	PM
CoA	NNP	PM
reductase	NN	PM
inhibitors	NNS	PM
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
different	JJ	O
statins	NNS	PM
on	IN	O
the	DT	O
levels	NNS	O
of	IN	O
haemostatic	JJ	O
variables	NNS	O
reflecting	VBG	O
procoagulant	NN	O
and	CC	O
fibrinolytic	JJ	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
,	,	O
with	IN	O
the	DT	O
hypothesis	NN	O
that	WDT	O
statins	VBZ	PM
might	MD	O
beneficially	RB	O
modify	VB	O
these	DT	O
levels	NNS	O
.	.	O

Fifty-eight	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
atorvastatin	NN	PM
(	(	O
n=28	JJ	O
)	)	O
or	CC	O
simvastatin	NN	PM
(	(	O
n=30	JJ	O
)	)	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
in	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
20	CD	O
mg/day	NN	O
.	.	O

Fasting	VBG	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
before	IN	O
and	CC	O
after	IN	O
12-month	JJ	O
treatment	NN	O
for	IN	O
determinations	NNS	O
of	IN	O
fibrinogen	NN	O
,	,	O
prothrombin	JJ	O
fragment	NN	O
1+2	CD	O
(	(	O
F1+2	NNP	O
)	)	O
,	,	O
plasma	JJ	O
D-dimer	NNP	O
,	,	O
soluble	JJ	O
tissue	NN	O
factor	NN	O
,	,	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
(	(	O
tPA	NN	O
)	)	O
antigen	NN	O
,	,	O
tPA	NN	O
activity	NN	O
,	,	O
plasminogen	NN	O
activator	NN	O
inhibitor	JJ	O
type-1	JJ	O
activity	NN	O
(	(	O
PAI-1	NNP	O
activity	NN	O
)	)	O
and	CC	O
serum	JJ	O
D-dimer	NNP	O
as	IN	O
a	DT	O
global	JJ	O
test	NN	O
of	IN	O
fibrinolytic	JJ	O
activity	NN	O
.	.	O

In	IN	O
the	DT	O
total	JJ	O
population	NN	O
,	,	O
improved	VBN	O
fibrinolytic	JJ	O
activity	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
1	CD	O
year	NN	O
with	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
D-dimer	NNP	O
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
tPA	JJ	O
activity	NN	O
(	(	O
P=.024	NNP	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
tPA	NN	O
antigen	NN	O
(	(	O
P=.048	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
measured	JJ	O
coagulation	NN	O
variables	NNS	O
.	.	O

Separately	RB	O
examined	VBD	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
atorvastatin	NN	PM
group	NN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
serum	JJ	O
D-dimer	NNP	O
(	(	O
P=.005	NNP	O
)	)	O
,	,	O
a	DT	O
borderline	JJ	O
increase	NN	O
in	IN	O
tPA	JJ	O
activity	NN	O
(	(	O
P=.083	NNP	O
)	)	O
and	CC	O
a	DT	O
borderline	NN	O
reduction	NN	O
in	IN	O
tPA	NN	O
antigen	NN	O
(	(	O
P=.069	NNP	O
)	)	O
.	.	O

Within	IN	O
the	DT	O
simvastatin	NN	PM
group	NN	O
,	,	O
a	DT	O
reduction	NN	O
in	IN	O
prothrombin	NN	O
F1+2	NNP	O
was	VBD	O
observed	VBN	O
(	(	O
P=.038	NNP	O
)	)	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
changes	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
global	JJ	O
fibrinolysis	NN	O
(	(	O
serum	JJ	O
D-dimer	NNP	O
,	,	O
P=.046	NNP	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
statin	NN	PM
treatment	NN	O
,	,	O
most	RBS	O
pronounced	JJ	O
with	IN	O
atorvastatin	NN	PM
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
drugs	NNS	O
promote	VBP	O
a	DT	O
profibrinolytic	JJ	O
profile	NN	O
,	,	O
and	CC	O
may	MD	O
in	IN	O
part	NN	O
explain	VBP	O
the	DT	O
benefit	NN	O
of	IN	O
statin	NN	PM
treatment	NN	O
rendered	VBN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CHD	NNP	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
daily	JJ	O
versus	FW	O
weekly	JJ	O
administration	NN	O
of	IN	O
2-chlorodeoxyadenosine	JJ	PM
in	IN	O
patients	NNS	O
with	IN	O
hairy	JJ	O
cell	NN	O
leukemia	NN	O
:	:	O
a	DT	O
multicenter	NN	O
phase	NN	O
III	NNP	O
trial	NN	O
(	(	O
SAKK	NNP	O
32/98	CD	O
)	)	O
.	.	O

Daily	JJ	O
administration	NN	O
of	IN	O
2-chlorodeoxyadenosine	JJ	PM
(	(	PM
Cladribine	NNP	PM
,	,	PM
CDA	NNP	PM
)	)	PM
is	VBZ	O
a	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
hairy	NN	O
cell	NN	O
leukemia	NN	O
,	,	O
but	CC	O
may	MD	O
cause	VB	O
severe	JJ	O
neutropenia	NN	O
and	CC	O
neutropenic	JJ	O
fever	NN	O
.	.	O

This	DT	O
trial	NN	O
compared	VBN	O
toxicity	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
weekly	JJ	O
versus	NN	O
daily	RB	O
CDA	NNP	PM
administration	NN	O
.	.	O

One	CD	O
hundred	VBD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
standard	NN	O
(	(	O
CDA	NNP	PM
0.14	CD	O
mg/kg/day	JJ	O
day	NN	O
1-5	JJ	O
[	NNP	O
Arm	NNP	O
A	NNP	O
]	NN	O
)	)	O
or	CC	O
experimental	JJ	O
treatment	NN	O
(	(	O
CDA	NNP	PM
0.14	CD	O
mg/kg/day	NN	O
once	RB	O
weekly	JJ	O
for	IN	O
5	CD	O
weeks	NNS	O
[	JJ	O
Arm	NNP	O
B	NNP	O
]	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
average	JJ	O
leukocyte	JJ	O
count	NN	O
within	IN	O
6	CD	O
weeks	NNS	O
from	IN	O
randomization	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
included	VBD	O
response	NN	O
rates	NNS	O
,	,	O
other	JJ	O
acute	JJ	O
hematotoxicity	NN	O
,	,	O
acute	JJ	O
infection	NN	O
rate	NN	O
,	,	O
hospital	NN	O
admission	NN	O
,	,	O
remission	NN	O
duration	NN	O
,	,	O
event-free	JJ	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
average	JJ	O
leukocyte	JJ	O
count	NN	O
.	.	O

Response	JJ	O
rate	NN	O
(	(	O
complete	JJ	O
+	NNP	O
partial	JJ	O
remission	NN	O
)	)	O
at	IN	O
week	NN	O
10	CD	O
was	VBD	O
78	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
64-88	CD	O
%	NN	O
)	)	O
in	IN	O
Arm	NNP	O
A	NNP	O
and	CC	O
68	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
54-80	CD	O
%	NN	O
)	)	O
in	IN	O
Arm	NNP	O
B	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.13	CD	O
)	)	O
.	.	O

Best	JJS	O
response	NN	O
rates	NNS	O
during	IN	O
follow-up	JJ	O
were	VBD	O
identical	JJ	O
(	(	O
86	CD	O
%	NN	O
)	)	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
grade	NN	O
3+4	CD	O
leukocytopenia	NN	O
(	(	O
94	CD	O
%	NN	O
vs	NN	O
.	.	O

84	CD	O
%	NN	O
)	)	O
,	,	O
grade	VBD	O
3+4	CD	O
neutropenia	NN	O
(	(	O
90	CD	O
%	NN	O
vs	NN	O
.	.	O

80	CD	O
%	NN	O
)	)	O
,	,	O
acute	JJ	O
infection	NN	O
(	(	O
44	CD	O
%	NN	O
vs	NN	O
.	.	O

40	CD	O
%	NN	O
)	)	O
,	,	O
hospitalization	NN	O
(	(	O
38	CD	O
%	NN	O
vs	NN	O
.	.	O

34	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
erythrocyte	JJ	O
support	NN	O
(	(	O
22	CD	O
%	NN	O
vs	NN	O
.	.	O

30	CD	O
%	NN	O
)	)	O
within	IN	O
10	CD	O
weeks	NNS	O
.	.	O

Overall	JJ	O
,	,	O
these	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
there	EX	O
are	VBP	O
no	DT	O
apparent	JJ	O
advantages	NNS	O
in	IN	O
toxicity	NN	O
and	CC	O
efficacy	NN	O
by	IN	O
giving	VBG	O
CDA	NNP	PM
weekly	RB	O
rather	RB	O
than	IN	O
daily	RB	O
.	.	O

Activation	NN	O
and	CC	O
intermuscular	JJ	O
coherence	NN	O
of	IN	O
distal	JJ	O
arm	NN	O
muscles	NNS	O
during	IN	O
proximal	JJ	O
muscle	NN	O
contraction	NN	O
.	.	O

In	IN	O
the	DT	O
human	JJ	O
upper	JJ	O
extremity	NN	O
(	(	O
UE	NNP	O
)	)	O
,	,	O
unintended	JJ	O
effects	NNS	O
of	IN	O
proximal	JJ	O
muscle	NN	O
activation	NN	O
on	IN	O
muscles	NNS	O
controlling	VBG	O
the	DT	O
hand	NN	O
could	MD	O
be	VB	O
an	DT	O
important	JJ	O
aspect	NN	O
of	IN	O
motor	NN	O
control	NN	O
due	JJ	O
to	TO	O
the	DT	O
necessary	JJ	O
coordination	NN	O
of	IN	O
distal	NN	O
and	CC	O
proximal	JJ	O
segments	NNS	O
during	IN	O
functional	JJ	O
activities	NNS	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
elucidate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
concurrent	JJ	O
activation	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
on	IN	O
the	DT	O
coordination	NN	O
between	IN	O
hand	NN	O
muscles	NNS	O
performing	VBG	O
a	DT	O
grip	NN	O
task	NN	O
.	.	O

Eleven	NNP	O
healthy	JJ	O
subjects	NNS	O
performed	VBN	O
precision	NN	PH
grip	NN	PH
tasks	NNS	PH
while	IN	PH
a	DT	PH
constant	JJ	PH
extension	NN	PH
or	CC	PH
flexion	NN	PH
moment	NN	PH
was	VBD	PH
applied	VBN	PH
to	TO	PH
their	PRP$	PH
elbow	NN	PH
joints	NNS	PH
,	,	O
inducing	VBG	O
a	DT	O
sustained	VBN	O
submaximal	JJ	O
contraction	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
to	TO	O
counter	VB	O
the	DT	O
applied	JJ	O
torque	NN	O
.	.	O

Activation	NNP	O
of	IN	O
four	CD	O
hand	NN	O
muscles	NNS	O
was	VBD	O
measured	VBN	O
during	IN	O
each	DT	O
task	NN	O
condition	NN	O
using	VBG	O
surface	NN	PH
electromyography	NN	PH
(	(	PH
EMG	NNP	PH
)	)	PH
.	.	PH

When	WRB	O
concurrent	JJ	O
activation	NN	O
of	IN	O
elbow	NN	O
muscles	NNS	O
was	VBD	O
induced	VBN	O
,	,	O
significant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
activation	NN	O
levels	NNS	O
of	IN	O
the	DT	O
hand	NN	O
muscles	NNS	O
were	VBD	O
observed	VBN	O
,	,	O
with	IN	O
greater	JJR	O
effects	NNS	O
on	IN	O
the	DT	O
extrinsic	JJ	O
finger	NN	O
extensor	NN	O
(	(	O
23.2	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
extensor	NN	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.003	CD	O
)	)	O
than	IN	O
extrinsic	JJ	O
finger	NN	O
flexor	NN	O
(	(	O
14.2	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
flexor	JJ	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.130	CD	O
)	)	O
.	.	O

Elbow	NNP	O
muscle	NN	O
activation	NN	O
also	RB	O
induced	VBD	O
involuntary	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
intrinsic	JJ	O
thumb	NN	O
flexor	NN	O
activation	NN	O
(	(	O
44.6	CD	O
%	NN	O
increase	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
extensor	NN	O
activation	NN	O
;	:	O
p	CC	O
=	VB	O
0.005	CD	O
)	)	O
.	.	O

EMG-EMG	JJ	O
coherence	NN	O
analyses	NNS	O
revealed	VBD	O
that	IN	O
elbow	JJ	O
muscle	NN	O
activation	NN	O
significantly	RB	O
reduced	VBD	O
intermuscular	JJ	O
coherence	NN	O
between	IN	O
distal	JJ	O
muscle	NN	O
pairs	NNS	O
,	,	O
with	IN	O
its	PRP$	O
greatest	JJS	O
effects	NNS	O
on	IN	O
coherence	NN	O
in	IN	O
the	DT	O
?-band	NN	O
(	(	O
13-25	JJ	O
Hz	NNP	O
)	)	O
(	(	O
average	NN	O
of	IN	O
17	CD	O
%	NN	O
decrease	NN	O
under	IN	O
30	CD	O
%	NN	O
elbow	NN	O
flexor	JJ	O
activation	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
evidence	NN	O
for	IN	O
involuntary	JJ	O
,	,	O
muscle-specific	JJ	O
interactions	NNS	O
between	IN	O
distal	NN	O
and	CC	O
proximal	JJ	O
UE	NNP	O
muscles	NNS	O
,	,	O
which	WDT	O
may	MD	O
contribute	VB	O
to	TO	O
UE	NNP	O
motor	NN	O
performance	NN	O
in	IN	O
health	NN	O
and	CC	O
disease	NN	O
.	.	O

Effect	NN	O
of	IN	O
antipsychotic	JJ	PM
drugs	NNS	PM
on	IN	O
cortical	JJ	O
thickness	NN	O
.	.	O

A	DT	O
randomized	JJ	O
controlled	VBN	O
one-year	JJ	O
follow-up	NN	O
study	NN	O
of	IN	O
haloperidol	NN	PM
,	,	O
risperidone	NN	PM
and	CC	O
olanzapine	NN	PM
.	.	O

BACKGROUND	NNP	O
Imaging	NNP	O
evidence	NN	O
indicates	VBZ	O
that	IN	O
brain	NN	O
alterations	NNS	O
are	VBP	O
primary	JJ	O
to	TO	O
the	DT	O
full-blown	JJ	O
onset	NN	O
of	IN	O
schizophrenia	NN	O
and	CC	O
seem	VBP	O
to	TO	O
progress	VB	O
across	IN	O
time	NN	O
.	.	O

The	DT	O
potential	JJ	O
effects	NNS	O
of	IN	O
antipsychotic	JJ	PM
medication	NN	PM
on	IN	O
brain	NN	O
structure	NN	O
represent	VBP	O
a	DT	O
key	JJ	O
factor	NN	O
in	IN	O
understanding	VBG	O
brain	NN	O
changes	NNS	O
in	IN	O
psychosis	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
low	JJ	O
doses	NNS	O
of	IN	O
haloperidol	NN	PM
,	,	O
risperidone	NN	PM
and	CC	O
olanzapine	NN	PM
on	IN	O
cortical	JJ	O
thickness	NN	O
.	.	O

METHOD	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
risperidone	NN	PM
(	(	O
N=16	NNP	O
)	)	O
,	,	O
olanzapine	JJ	PM
(	(	O
N=18	NNP	O
)	)	O
and	CC	O
low	JJ	O
doses	NNS	O
of	IN	O
haloperidol	NN	PM
(	(	O
N=18	NNP	O
)	)	O
in	IN	O
cortical	JJ	O
thickness	NN	O
changes	NNS	O
during	IN	O
1-year	JJ	O
follow-up	JJ	O
period	NN	O
in	IN	O
a	DT	O
large	JJ	O
and	CC	O
heterogeneous	JJ	O
sample	NN	O
of	IN	O
schizophrenia	NN	O
spectrum	NN	O
patients	NNS	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
cortical	JJ	O
thickness	NN	O
changes	NNS	O
and	CC	O
clinical	JJ	O
and	CC	O
cognitive	JJ	O
outcome	NN	O
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

A	DT	O
group	NN	O
of	IN	O
45	CD	O
healthy	JJ	O
volunteers	NNS	O
was	VBD	O
also	RB	O
longitudinally	RB	O
evaluated	VBN	O
.	.	O

Magnetic	JJ	O
resonance	NN	O
imaging	VBG	O
brain	NN	O
scans	NNS	O
(	(	O
1.5T	CD	O
)	)	O
were	VBD	O
obtained	VBN	O
and	CC	O
images	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
using	VBG	O
BRAINS2	NNP	O
.	.	O

RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
of	IN	O
time	NN	O
(	(	O
F	NNP	O
(	(	O
1,47	CD	O
)	)	O
<	NN	O
1.66	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.204	CD	O
)	)	O
,	,	O
treatment	NN	O
group	NN	O
(	(	O
F	NNP	O
(	(	O
2,47	CD	O
)	)	O
<	NN	O
1.47	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.242	CD	O
)	)	O
or	CC	O
group-by-time	JJ	O
interaction	NN	O
(	(	O
F	NNP	O
(	(	O
2,47	CD	O
)	)	O
<	NN	O
1.82	CD	O
;	:	O
P	NNP	O
>	NNP	O
0.174	CD	O
)	)	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
cortical	JJ	O
thickness	NN	O
variables	NNS	O
.	.	O

When	WRB	O
the	DT	O
group	NN	O
of	IN	O
healthy	JJ	O
controls	NNS	O
was	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analyses	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
of	IN	O
note	NN	O
that	IN	O
group-by-time	JJ	O
interaction	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
result	NN	O
for	IN	O
the	DT	O
frontal	JJ	O
lobe	NN	O
at	IN	O
trend	NN	O
level	NN	O
(	(	O
F	NNP	O
(	(	O
3,81	CD	O
)	)	O
=2.686	NN	O
;	:	O
P=0.052	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
Bonferroni	NNP	O
adjustment	NN	O
for	IN	O
multiple	JJ	O
comparisons	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
associations	NNS	O
between	IN	O
changes	NNS	O
in	IN	O
cortical	JJ	O
thickness	NN	O
and	CC	O
clinical	JJ	O
and	CC	O
cognitive	JJ	O
outcome	NN	O
.	.	O

CONCLUSIONS	NNP	O
Low	NNP	O
doses	NNS	O
of	IN	O
haloperidol	NN	PM
,	,	O
risperidone	NN	PM
,	,	O
and	CC	O
olanzapine	NN	PM
seem	VBP	O
to	TO	O
equally	RB	O
affect	VB	O
gray	JJ	O
matter	NN	O
cortical	JJ	O
thickness	NN	O
,	,	O
overall	JJ	O
and	CC	O
lobes	JJ	O
,	,	O
at	IN	O
the	DT	O
medium-term	NN	O
(	(	O
1	CD	O
year	NN	O
)	)	O
.	.	O

The	DT	O
clinical	JJ	O
effectiveness	NN	O
of	IN	O
treatments	NNS	O
was	VBD	O
not	RB	O
significantly	RB	O
related	VBN	O
to	TO	O
changes	NNS	O
in	IN	O
cortical	JJ	O
thickness	NN	O
.	.	O

A	DT	O
cost-benefit	JJ	O
comparison	NN	O
of	IN	O
intensive	JJ	PH
diabetes	NNS	PH
management	NN	PH
with	IN	PH
implantable	JJ	PH
pumps	NNS	PH
versus	IN	O
multiple	JJ	PM
subcutaneous	JJ	PM
injections	NNS	PM
in	IN	O
patients	NNS	O
with	IN	O
type	NN	O
I	PRP	O
diabetes	VBZ	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
if	IN	O
intraperitoneal	JJ	PH
(	(	PH
IP	NNP	PH
)	)	PH
insulin	NN	PH
infusion	NN	PH
via	IN	PH
programmable	JJ	PH
implantable	JJ	PH
pumps	NNS	PH
is	VBZ	O
a	DT	O
potential	JJ	O
alternative	NN	O
to	TO	O
subcutaneous	JJ	PM
(	(	PM
SC	NNP	PM
)	)	PM
insulin	NN	PM
via	IN	PM
multiple	JJ	PM
injections	NNS	PM
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
We	PRP	O
compared	VBN	O
the	DT	O
cost-benefits	NNS	O
of	IN	O
the	DT	O
two	CD	O
methods	NNS	O
using	VBG	O
a	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
6-month	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
in	IN	O
10	CD	O
adult	NN	O
type	NN	O
I	PRP	O
diabetic	JJ	O
patients	NNS	O
.	.	O

RESULTS	NNP	O
When	WRB	O
judged	VBN	O
on	IN	O
the	DT	O
last	JJ	O
month	NN	O
of	IN	O
IP	NNP	O
versus	NN	O
SC	NNP	O
periods	NNS	O
in	IN	O
the	DT	O
nine	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
,	,	O
metabolic	JJ	O
data	NN	O
showed	VBD	O
better	JJR	O
glycemic	JJ	O
control	NN	O
(	(	O
HbA1c	NNP	O
:	:	O
7.2	CD	O
+/-	JJ	O
0.2	CD	O
IP	NNP	O
vs.	FW	O
8.5	CD	O
+/-	JJ	O
0.7	CD	O
%	NN	O
SC	NNP	O
,	,	O
mean	JJ	O
+/-	JJ	O
SE	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
reduced	VBN	O
glycemic	JJ	O
fluctuations	NNS	O
(	(	O
SD	NNP	O
of	IN	O
capillary	JJ	O
glucose	JJ	O
values	NNS	O
:	:	O
3.4	CD	O
+/-	JJ	O
0.2	CD	O
IP	NNP	O
vs.	FW	O
4.6	CD	O
+/-	JJ	O
0.2	CD	O
mM	NN	O
SC	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
fewer	JJR	O
mild	JJ	O
hypoglycemic	JJ	O
events	NNS	O
(	(	O
5.7	CD	O
+/-	JJ	O
2.0	CD	O
IP	NNP	O
vs.	FW	O
10.0	CD	O
+/-	JJ	O
3.1	CD	O
events/month	JJ	O
SC	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
,	,	O
judged	VBN	O
by	IN	O
Diabetes	NNP	O
Control	NNP	O
and	CC	O
Complications	NNP	O
Trial	NNP	O
questionnaires	NNS	O
,	,	O
was	VBD	O
unaffected	VBN	O
by	IN	O
pump	NN	PH
therapy	NN	O
.	.	O

Direct	JJ	O
costs	NNS	O
,	,	O
including	VBG	O
pump	JJ	O
acquisition	NN	O
,	,	O
implantation	NN	O
,	,	O
and	CC	O
follow-up	NN	O
,	,	O
were	VBD	O
2.6-fold	JJ	O
higher	JJR	O
with	IN	O
IP	NNP	O
than	IN	O
with	IN	O
SC	NNP	O
delivery	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
implantable	JJ	PH
pump	NN	PH
is	VBZ	O
more	RBR	O
effective	JJ	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
,	,	O
equally	RB	O
accepted	VBN	O
,	,	O
but	CC	O
more	RBR	O
costly	JJ	O
than	IN	O
multiple	JJ	PM
injections	NNS	PM
and	CC	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
unsatisfactory	JJ	O
glycemic	JJ	O
control	NN	O
despite	IN	O
intensive	JJ	O
diabetes	NNS	O
management	NN	O
with	IN	O
SC	NNP	O
insulin	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
longer-term	JJ	O
,	,	O
larger-scale	JJ	O
,	,	O
and	CC	O
comparative	JJ	O
evaluation	NN	O
is	VBZ	O
required	VBN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
melatonin	NN	PM
for	IN	O
sleep	JJ	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
,	,	O
or	CC	O
autism	NN	O
and	CC	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
melatonin	NN	PM
on	IN	O
sleep	NN	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
fragile	JJ	O
X	NNP	O
syndrome	NN	O
(	(	O
FXS	NNP	O
)	)	O
.	.	O

METHODS	VB	O
A	DT	O
4-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
was	VBD	O
conducted	VBN	O
following	VBG	O
a	DT	O
1-week	JJ	O
baseline	NN	O
period	NN	O
.	.	O

Either	CC	O
melatonin	NN	PM
,	,	O
3	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	NN	C
was	VBD	O
given	VBN	O
to	TO	O
participants	NNS	O
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
alternated	VBD	O
for	IN	O
another	DT	O
2	CD	O
weeks	NNS	O
.	.	O

Sleep	JJ	O
variables	NNS	O
,	,	O
including	VBG	O
sleep	JJ	O
duration	NN	O
,	,	O
sleep-onset	JJ	O
time	NN	O
,	,	O
sleep-onset	JJ	O
latency	NN	O
time	NN	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
night	NN	O
awakenings	NNS	O
,	,	O
were	VBD	O
recorded	VBN	O
using	VBG	O
an	DT	O
Actiwatch	NN	O
and	CC	O
from	IN	O
sleep	JJ	O
diaries	NNS	O
completed	VBN	O
by	IN	O
parents	NNS	O
.	.	O

All	DT	O
participants	NNS	O
had	VBD	O
been	VBN	O
thoroughly	RB	O
assessed	VBN	O
for	IN	O
ASD	NNP	O
and	CC	O
also	RB	O
had	VBD	O
DNA	NNP	O
testing	VBG	O
for	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
FXS	NNP	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
were	VBD	O
successfully	RB	O
obtained	VBN	O
from	IN	O
the	DT	O
12	CD	O
of	IN	O
18	CD	O
subjects	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
11	CD	O
males	NNS	O
,	,	O
age	NN	O
range	NN	O
2	CD	O
to	TO	O
15.25	CD	O
years	NNS	O
,	,	O
mean	JJ	O
5.47	CD	O
,	,	O
SD	NNP	O
3.6	CD	O
)	)	O
.	.	O

Five	CD	O
participants	NNS	O
met	VBD	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
ASD	NNP	O
,	,	O
3	CD	O
for	IN	O
FXS	NNP	O
alone	RB	O
,	,	O
3	CD	O
for	IN	O
FXS	NNP	O
and	CC	O
ASD	NNP	O
,	,	O
and	CC	O
1	CD	O
for	IN	O
fragile	JJ	O
X	NNP	O
premutation	NN	O
.	.	O

Eight	CD	O
out	IN	O
of	IN	O
12	CD	O
had	VBD	O
melatonin	VBN	PM
first	RB	O
.	.	O

The	DT	O
conclusions	NNS	O
from	IN	O
a	DT	O
nonparametric	JJ	O
repeated-measures	NNS	O
technique	NN	O
indicate	VBP	O
that	IN	O
mean	JJ	O
night	NN	O
sleep	NN	O
duration	NN	O
was	VBD	O
longer	RBR	O
on	IN	O
melatonin	NN	PM
than	IN	O
placebo	NN	C
by	IN	O
21	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.02	NNP	O
)	)	O
,	,	O
mean	JJ	O
sleep-onset	JJ	O
latency	NN	O
was	VBD	O
shorter	JJR	O
by	IN	O
28	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.0001	NNP	O
)	)	O
,	,	O
and	CC	O
mean	VB	O
sleep-onset	JJ	O
time	NN	O
was	VBD	O
earlier	RB	O
by	IN	O
42	CD	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
support	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
melatonin	NN	PM
treatment	NN	O
for	IN	O
sleep	JJ	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
FXS	NNP	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
pre-	NN	S
and	CC	S
intraoperative	JJ	S
positioning	NN	S
of	IN	S
the	DT	S
condyle	NN	S
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
on	IN	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
disc	NN	O
in	IN	O
orthognathic	JJ	S
surgery	NN	S
.	.	S

A	NNP	O
magnetic	JJ	O
resonance	NN	O
study	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
investigated	VBD	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
temporomandibular	JJ	O
joint	NN	O
(	(	O
TMJ	NNP	O
)	)	O
after	IN	O
bilateral	JJ	S
sagittal	JJ	S
split	NN	S
osteotomy	NN	S
of	IN	S
the	DT	S
mandible	JJ	S
for	IN	O
orthognathic	JJ	O
surgery	NN	O
and	CC	O
the	DT	O
influence	NN	O
of	IN	O
positioning	NN	S
of	IN	S
the	DT	S
condylar	JJ	S
process	NN	S
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
before	IN	O
and	CC	O
during	IN	O
the	DT	O
operation	NN	O
for	IN	O
preventing	VBG	O
changes	NNS	O
in	IN	O
the	DT	O
TMJ	NNP	O
postoperatively	RB	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
28	CD	O
patients	NNS	O
with	IN	O
mandibular	JJ	O
retrognathism	NN	O
had	VBD	O
bilateral	JJ	S
sagittal	JJ	S
split	NN	S
osteotomies	NNS	S
for	IN	S
mandibular	JJ	S
advancement	NN	S
.	.	S

In	IN	O
one	CD	O
group	NN	O
of	IN	O
14	CD	O
patients	NNS	O
(	(	O
28	CD	O
TMJ	NNP	O
)	)	O
,	,	O
the	DT	O
condyles	NNS	S
were	VBD	S
placed	VBN	S
in	IN	S
the	DT	S
centre	NN	S
of	IN	S
the	DT	S
articular	JJ	S
fossa	NN	S
before	IN	S
and	CC	S
during	IN	S
the	DT	S
operation	NN	S
,	,	S
and	CC	S
in	IN	S
the	DT	S
other	JJ	S
group	NN	S
they	PRP	S
were	VBD	S
not	RB	S
.	.	O

Differences	NNS	O
on	IN	O
magnetic	JJ	PH
resonance	NN	PH
imaging	NN	PH
(	(	PH
MRI	NNP	PH
)	)	PH
were	VBD	O
calculated	VBN	O
and	CC	O
the	DT	O
results	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
main	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
at	IN	O
maximal	JJ	O
mouth	NN	O
opening	NN	O
.	.	O

15/28	CD	O
TMJs	NNP	O
(	(	O
54	CD	O
%	NN	O
)	)	O
that	WDT	O
had	VBD	O
not	RB	O
been	VBN	O
positioned	VBN	O
changed	VBD	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
disc	NN	O
from	IN	O
physiological	JJ	O
to	TO	O
anterior	VB	O
disc	JJ	O
derangement	NN	O
with	IN	O
and	CC	O
without	IN	O
reduction	NN	O
postoperatively	RB	O
.	.	O

In	IN	O
the	DT	O
28	CD	O
that	WDT	O
had	VBD	O
been	VBN	O
positioned	VBN	O
,	,	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
only	RB	O
3	CD	O
TMJs	NNP	O
(	(	O
11	CD	O
%	NN	O
)	)	O
postoperatively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Fixing	VBG	PH
the	DT	PH
condylar	JJ	PH
process	NN	PH
in	IN	PH
the	DT	PH
centre	NN	PH
of	IN	PH
the	DT	PH
articular	JJ	PH
fossa	NN	PH
intraoperatively	RB	PH
before	IN	O
bilateral	JJ	O
sagittal	JJ	O
split	NN	O
osteotomy	NN	O
is	VBZ	O
a	DT	O
factor	NN	O
in	IN	O
preventing	VBG	O
postoperative	JJ	O
structural	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
temporomandibular	JJ	O
joint	NN	O
.	.	O

Improved	VBN	O
intraoperative	JJ	O
management	NN	O
of	IN	O
anastomotic	JJ	O
bleeding	NN	O
during	IN	O
aortic	JJ	O
reconstruction	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
polymeric	JJ	S
surgical	JJ	S
sealant	NN	S
(	(	S
CoSeal	NNP	S
)	)	S
was	VBD	O
compared	VBN	O
to	TO	O
Gelfoam/thrombin	NNP	S
for	IN	O
managing	VBG	O
anastomotic	JJ	O
bleeding	NN	O
after	IN	O
implantation	NN	PH
of	IN	S
Dacron	NNP	S
grafts	NNS	S
during	IN	S
aortic	JJ	S
reconstruction	NN	S
for	IN	S
nonruptured	JJ	S
aneurysms	NNS	S
.	.	O

Each	DT	S
treatment	NN	S
was	VBD	S
directly	RB	S
applied	VBN	S
to	TO	S
the	DT	S
suture	NN	S
line	NN	S
after	IN	S
confirmation	NN	S
of	IN	S
anastomotic	JJ	S
bleeding	NN	S
.	.	S

The	DT	O
proportion	NN	O
of	IN	O
suture	NN	O
line	NN	O
sites	VBZ	O
that	IN	O
achieved	VBD	O
immediate	JJ	O
sealing	NN	O
and	CC	O
the	DT	O
proportion	NN	O
sealed	VBD	O
within	IN	O
5	CD	O
minutes	NNS	O
were	VBD	O
determined	VBN	O
among	IN	O
37	CD	O
experimental	JJ	O
(	(	O
59	CD	O
sites	NNS	O
)	)	O
and	CC	O
17	CD	O
control	NN	O
subjects	NNS	O
(	(	O
27	CD	O
sites	NNS	O
)	)	O
.	.	O

A	DT	O
significantly	RB	O
greater	JJR	O
proportion	NN	O
of	IN	O
bleeding	VBG	O
suture	NN	O
line	NN	O
sites	NNS	O
treated	VBD	O
with	IN	O
the	DT	O
polymeric	JJ	S
sealant	NN	S
achieved	VBN	O
immediate	JJ	O
sealing	NN	O
following	VBG	O
reestablishment	NN	O
of	IN	O
blood	NN	O
flow	NN	O
compared	VBN	O
with	IN	O
control-treated	JJ	O
sites	NNS	O
[	VBP	O
48	CD	O
of	IN	O
59	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
vs	VBZ	O
10	CD	O
of	IN	O
27	CD	O
(	(	O
37	CD	O
%	NN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.002	CD	O
]	NN	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
was	VBD	O
maintained	VBN	O
after	IN	O
5	CD	O
minutes	NNS	O
with	IN	O
approximately	RB	O
85	CD	O
per	IN	O
cent	NN	O
(	(	O
50	CD	O
of	IN	O
59	CD	O
)	)	O
of	IN	O
CoSeal	NNP	S
sites	NNS	O
compared	VBN	O
to	TO	O
just	RB	O
over	IN	O
one-half	JJ	O
(	(	O
14	CD	O
of	IN	O
27	CD	O
)	)	O
of	IN	O
control	NN	O
sites	VBZ	O
demonstrating	VBG	O
ultimate	JJ	O
sealing	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
adverse	JJ	O
events	NNS	O
related	VBN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
polymeric	JJ	S
sealant	NN	S
in	IN	O
this	DT	O
study	NN	O
.	.	O

These	DT	O
results	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
this	DT	O
novel	JJ	O
sealant	NN	O
for	IN	O
the	DT	O
intraoperative	JJ	O
management	NN	O
of	IN	O
anastomotic	JJ	O
bleeding	NN	O
during	IN	O
aortic	JJ	O
reconstruction	NN	O
procedures	NNS	O
.	.	O

Dose	NNP	O
dependent	JJ	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	PM
:	:	PM
Michaelis-Menten	JJ	O
parameters	NNS	O
for	IN	O
its	PRP$	O
major	JJ	O
metabolic	JJ	O
pathways	NNS	O
.	.	O

Dose	NNP	O
Dependency	NNP	O
for	IN	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	PM
and	CC	O
the	DT	O
formation	NN	O
of	IN	O
its	PRP$	O
major	JJ	O
metabolites	NNS	O
,	,	O
3-methylxanthine	JJ	O
(	(	O
3-MX	JJ	O
)	)	O
;	:	O
1-methyluric	JJ	O
acid	NN	O
(	(	O
1-MU	JJ	O
)	)	O
;	:	O
1,3-dimethyluric	JJ	O
acid	NN	O
(	(	O
DMU	NNP	O
)	)	O
,	,	O
were	VBD	O
examined	VBN	O
by	IN	O
administering	VBG	O
three	CD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
(	(	O
250	CD	O
,	,	O
375	CD	O
,	,	O
500	CD	O
mg	NN	O
)	)	O
of	IN	O
theophylline	NN	O
to	TO	O
six	CD	O
healthy	JJ	O
adult	NN	O
volunteers	NNS	O
.	.	O

The	DT	O
serum	NN	O
and	CC	O
urine	JJ	O
concentrations	NNS	O
of	IN	O
theophylline	NN	PM
and	CC	O
the	DT	O
metabolites	NNS	O
in	IN	O
serum	NN	O
and	CC	O
urine	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

Total	JJ	O
clearance	NN	O
of	IN	O
theophylline	NN	PM
decreased	VBN	O
and	CC	O
its	PRP$	O
half	JJ	O
life	NN	O
increased	VBD	O
over	IN	O
the	DT	O
range	NN	O
of	IN	O
doses	NNS	O
administered	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
dose	NN	O
related	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
fractional	JJ	O
recovery	NN	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
dose	NN	O
related	JJ	O
increase	NN	O
in	IN	O
fractional	JJ	O
excretion	NN	O
of	IN	O
DMU	NNP	O
and	CC	O
unchanged	JJ	O
theophylline	NN	O
(	(	O
p	JJ	O
<	NN	O
0.01	CD	O
and	CC	O
p	VB	O
<	JJ	O
0.001	CD	O
respectively	RB	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
dose	NN	O
related	VBN	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
renal	JJ	O
clearance	NN	O
of	IN	O
3-MX	JJ	O
,	,	O
1-MU	JJ	O
and	CC	O
DMU	NNP	O
,	,	O
indicating	VBG	O
linear	JJ	O
urinary	JJ	O
excretion	NN	O
kinetics	NNS	O
of	IN	O
the	DT	O
metabolites	NNS	O
.	.	O

Theophylline	NNP	PM
metabolic	JJ	O
clearance	NN	O
to	TO	O
3-MX	JJ	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
1-MU	CD	O
decreased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
but	CC	O
clearance	NN	O
to	TO	O
DMU	NNP	O
remained	VBD	O
unnaffected	JJ	O
by	IN	O
the	DT	O
size	NN	O
of	IN	O
dose	NN	O
.	.	O

The	DT	O
individual	JJ	O
Michaelis-Menten	NNP	O
parameters	NNS	O
Km	NNP	O
and	CC	O
Vmax	NNP	O
were	VBD	O
estimated	VBN	O
for	IN	O
six	CD	O
subjects	NNS	O
receiving	VBG	O
three	CD	O
different	JJ	O
single	JJ	O
doses	NNS	O
.	.	O

The	DT	O
Km	NNP	O
values	NNS	O
for	IN	O
theophylline	JJ	PM
metabolism	NN	O
to	TO	O
3-MX	JJ	O
,	,	O
1-MU	JJ	O
and	CC	O
DMU	NNP	O
were	VBD	O
2.4+/-0.6	JJ	O
,	,	O
5.1+/-1.8+/-	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/L	NN	O
respectively	RB	O
and	CC	O
the	DT	O
Vmax	NNP	O
values	NNS	O
were	VBD	O
3.5+/-0.7	JJ	O
,	,	O
7.5+/-2.6	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/hr	NN	O
respectively	RB	O
.	.	O

The	DT	O
Km	NNP	O
values	NNS	O
for	IN	O
the	DT	O
N-demethylation	NNP	O
pathways	NNS	O
(	(	O
3MX	CD	O
and	CC	O
1-MU	JJ	O
)	)	O
were	VBD	O
lower	JJR	O
corresponding	VBG	O
to	TO	O
therapeutic	JJ	O
serum	NN	O
concentrations	NNS	O
of	IN	O
drug	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
elimination	NN	O
kinetics	NNS	O
of	IN	O
theophylline	NN	PM
is	VBZ	O
nonlinear	JJ	O
in	IN	O
the	DT	O
human	NN	O
in	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
of	IN	O
serum	JJ	O
concenntrations	NNS	O
and	CC	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
saturable	JJ	O
formation	NN	O
kinetics	NNS	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
previous	JJ	O
studies	NNS	O
we	PRP	O
did	VBD	O
n't	RB	O
find	VB	O
obvious	JJ	O
indication	NN	O
for	IN	O
nonlinear	JJ	O
formation	NN	O
of	IN	O
DMU	NNP	O
at	IN	O
therapeutic	JJ	O
concentration	NN	O
range	NN	O
.	.	O

Involvement	NN	O
of	IN	O
cholecystokininA	NN	O
receptors	NNS	O
in	IN	O
transient	NN	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
relaxations	NNS	O
triggered	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

OBJECTIVE	CC	O
Transient	NNP	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
relaxations	NNS	O
(	(	O
TLESRs	NNP	O
)	)	O
are	VBP	O
the	DT	O
main	JJ	O
mechanism	NN	O
underlying	VBG	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
loxiglumide	NN	O
,	,	O
a	DT	O
specific	JJ	O
cholecystokininA	NN	O
(	(	O
CCKA	NNP	O
)	)	O
-receptor	NN	O
antagonist	NN	O
,	,	O
on	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
TLESRs	NNP	O
evoked	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	O
healthy	JJ	O
subjects	NNS	O
underwent	JJ	O
esophageal	JJ	O
manometry	NN	O
using	VBG	O
a	DT	O
10-lumen	JJ	PH
sleeve	NN	PH
assembly	NN	PH
during	IN	PH
placebo	NN	PH
or	CC	O
loxiglumide	NN	PM
(	(	O
10	CD	O
mg/kg/h	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
order	NN	O
.	.	O

Gastric	NNP	O
distension	NN	O
was	VBD	O
induced	VBN	O
by	IN	O
inflation	NN	O
of	IN	O
400	CD	O
ml	NN	O
of	IN	O
air	NN	O
.	.	O

RESULTS	VB	O
Basal	NNP	O
lower	JJR	O
esophageal	NN	O
pressure	NN	O
(	(	O
LESP	NNP	O
)	)	O
and	CC	O
swallow-induced	JJ	O
relaxation	NN	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
loxiglumide	NN	O
.	.	O

Loxiglumide	NNP	O
significantly	RB	O
reduced	VBD	O
the	DT	O
number	NN	O
of	IN	O
TLESRs	NNP	O
,	,	O
from	IN	O
11.5	CD	O
(	(	O
5.8-18.3	JJ	O
)	)	O
to	TO	O
6.0	CD	O
(	(	O
3.3-14.3	JJ	O
)	)	O
during	IN	O
the	DT	O
total	JJ	O
recording	JJ	O
period	NN	O
of	IN	O
1	CD	O
h	NN	O
,	,	O
and	CC	O
from	IN	O
5.5	CD	O
(	(	O
4.25-7.5	JJ	O
)	)	O
to	TO	O
2.0	CD	O
(	(	O
0.5-6.8	JJ	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
15	CD	O
min	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
common	JJ	O
cavities	NNS	O
was	VBD	O
significantly	RB	O
decreased	VBN	O
by	IN	O
loxiglumide	NN	O
,	,	O
from	IN	O
8.0	CD	O
(	(	O
4.0-20.0	JJ	O
)	)	O
to	TO	O
5.0	CD	O
(	(	O
2.0-7.8	JJ	O
)	)	O
.	.	O

TLESRs	NNP	O
represented	VBD	O
the	DT	O
main	JJ	O
mechanism	NN	O
(	(	O
60	CD	O
%	NN	O
during	IN	O
placebo	NN	O
,	,	O
74	CD	O
%	NN	O
during	IN	O
loxiglumide	NN	O
)	)	O
underlying	VBG	O
common	JJ	O
cavities	NNS	O
,	,	O
followed	VBN	O
by	IN	O
swallow-induced	JJ	O
relaxation	NN	O
.	.	O

CONCLUSIONS	NNP	O
Loxiglumide	NNP	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
number	NN	O
of	IN	O
TLESRs	NNP	O
triggered	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
without	IN	O
interfering	VBG	O
with	IN	O
swallow-related	JJ	O
relaxation	NN	O
of	IN	O
the	DT	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
,	,	O
suggesting	VBG	O
the	DT	O
involvement	NN	O
of	IN	O
CCKA	NNP	O
receptors	NNS	O
in	IN	O
the	DT	O
reflex	JJ	O
pathway	NN	O
mediating	VBG	O
TLESRs	NNP	O
.	.	O

Domperidone	NN	O
,	,	O
metoclopramide	NN	O
,	,	O
and	CC	O
placebo	NN	O
.	.	O

All	DT	O
give	JJ	O
symptomatic	JJ	O
improvement	NN	O
in	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
of	IN	O
two	CD	O
gastric	JJ	PM
prokinetic	JJ	PM
drugs	NNS	PM
in	IN	O
23	CD	O
patients	NNS	O
with	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
a	DT	O
dual-isotope	JJ	O
mixed-meal	JJ	O
study	NN	O
of	IN	O
their	PRP$	O
gastric	JJ	O
emptying	NN	O
(	(	O
GE	NNP	O
)	)	O
.	.	O

Group	NNP	O
I	PRP	O
had	VBD	O
normal	JJ	O
GE	NNP	O
and	CC	O
group	NN	O
II	NNP	O
delayed	VBD	O
GE	NNP	O
.	.	O

Nine	NNP	O
gastrointestinal	JJ	O
symptoms	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
frequency	NN	O
and	CC	O
severity	NN	O
before	IN	O
treatment	NN	O
.	.	O

The	DT	O
trial	NN	O
had	VBD	O
three	CD	O
1-month	JJ	O
treatment	NN	O
periods	NNS	O
using	VBG	O
metoclopramide	RB	O
10	CD	O
mg	NN	O
q.i.d.	NN	O
,	,	O
domperidone	NN	PM
20	CD	O
mg	NN	O
q.i.d.	NN	O
,	,	O
or	CC	O
placebo	NN	O
on	IN	O
a	DT	O
random	JJ	O
basis	NN	O
.	.	O

Symptoms	NNS	O
were	VBD	O
reassessed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
month	NN	O
.	.	O

Taken	NNP	O
as	IN	O
a	DT	O
whole	NN	O
,	,	O
the	DT	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
symptomatic	JJ	O
response	NN	O
in	IN	O
all	DT	O
three	CD	O
treatment	NN	O
periods	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
,	,	O
but	CC	O
patients	NNS	O
with	IN	O
delayed	JJ	O
or	CC	O
normal	JJ	O
GE	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
their	PRP$	O
symptomatic	JJ	O
response	NN	O
.	.	O

Eleven	JJ	O
patients	NNS	O
complained	VBD	O
of	IN	O
side	NN	O
effects	NNS	O
with	IN	O
metoclopramide	NN	O
and	CC	O
three	CD	O
stopped	VBD	O
therapy	NN	O
before	IN	O
the	DT	O
1-month	JJ	O
course	NN	O
was	VBD	O
completed	VBN	O
.	.	O

Two	CD	O
patients	NNS	O
described	JJ	O
side	JJ	O
effects	NNS	O
with	IN	O
domperidone	NN	O
,	,	O
including	VBG	O
one	CD	O
woman	NN	O
with	IN	O
galactorrhea	NN	O
after	IN	O
36	CD	O
h	NN	O
of	IN	O
treatment	NN	O
.	.	O

Three	CD	O
patients	NNS	O
on	IN	O
placebo	NN	O
also	RB	O
complained	VBD	O
of	IN	O
important	JJ	O
side	NN	O
effects	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
significant	JJ	O
placebo	NN	O
effect	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
symptomatic	JJ	O
improvement	NN	O
between	IN	O
placebo	NN	O
,	,	O
domperidone	NN	O
,	,	O
and	CC	O
metoclopramide	RB	PM
in	IN	O
this	DT	O
study	NN	O
.	.	O

Effect	NN	O
of	IN	O
chronic	JJ	PH
aerobic	JJ	PH
exercise	NN	PH
and	CC	O
progressive	JJ	PH
relaxation	NN	PH
on	IN	O
motor	NN	O
performance	NN	O
and	CC	O
affect	NN	O
following	VBG	O
acute	JJ	O
stress	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
10-week	JJ	O
aerobic	JJ	PH
exercise	NN	PH
and	CC	O
progressive	JJ	PH
relaxation	NN	PH
training	VBG	O
program	NN	O
on	IN	O
somatic	JJ	O
,	,	O
emotional	JJ	O
,	,	O
and	CC	O
behavioral	JJ	O
responses	NNS	O
to	TO	O
acute	VB	O
stress	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
quality	NN	O
of	IN	O
motor	NN	O
performance	NN	O
and	CC	O
affect	NN	O
,	,	O
were	VBD	O
examined	VBN	O
.	.	O

The	DT	O
participants	NNS	O
consisted	VBD	O
of	IN	O
60	CD	O
unfit	JJ	O
male	NN	O
university	NN	O
undergraduate	JJ	O
students	NNS	O
with	IN	O
no	DT	O
previous	JJ	O
training	NN	O
in	IN	O
stress	JJ	O
management	NN	O
who	WP	O
were	VBD	O
randomly	RB	O
and	CC	O
evenly	RB	O
assigned	VBD	O
to	TO	O
engage	VB	O
in	IN	O
one	CD	E
of	IN	E
four	CD	E
treatments	NNS	E
over	IN	E
10	CD	E
weeks	NNS	E
:	:	O
(	(	O
a	DT	O
)	)	O
moderate	NN	PH
aerobic	JJ	PH
exercise	NN	PH
,	,	O
(	(	O
b	NN	O
)	)	O
progressive	NN	PH
relaxation	NN	PH
,	,	O
(	(	O
c	NN	O
)	)	O
a	DT	O
placebo	NN	C
group	NN	C
that	WDT	C
engaged	VBD	C
in	IN	C
group	NN	C
discussion	NN	C
but	CC	C
did	VBD	C
experience	VB	C
acute	NN	C
stress	NN	C
,	,	O
and	CC	O
(	(	O
d	NN	O
)	)	O
a	DT	O
nonintervention	NN	C
control	NN	C
group	NN	C
that	WDT	C
did	VBD	C
not	RB	C
experience	VB	C
stress	NN	C
while	IN	C
performing	VBG	C
the	DT	C
motor	NN	C
task	NN	C
.	.	O

Acute	NNP	O
stress	NN	O
consisted	VBD	O
of	IN	O
losing	VBG	O
against	IN	O
a	DT	O
competitor	NN	O
of	IN	O
the	DT	O
opposite	JJ	O
sex	NN	O
on	IN	O
the	DT	O
criterion	NN	O
motor	NN	O
task	NN	O
while	IN	O
receiving	VBG	O
unpleasant	JJ	O
information	NN	O
about	IN	O
their	PRP$	O
performance	NN	O
over	IN	O
30	CD	O
preintervention	NN	O
and	CC	O
30	CD	O
postintervention	NN	O
trials	NNS	O
.	.	O

Analyses	NNS	O
indicated	VBD	O
that	IN	O
aerobic	JJ	O
exercisers	NNS	O
,	,	O
in	IN	O
comparisons	NNS	O
with	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
,	,	O
responded	VBD	O
to	TO	O
acute	VB	O
stress	NN	O
with	IN	O
more	RBR	O
positive	JJ	O
affect	NN	O
,	,	O
lower	JJR	O
stressor	NN	O
task	JJ	O
heart	NN	O
rate	NN	O
,	,	O
reduced	VBN	O
systolic	JJ	O
(	(	O
but	CC	O
not	RB	O
diastolic	JJ	O
)	)	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
superior	JJ	O
motor	NN	O
performance	NN	O
.	.	O

Progressive	JJ	O
relaxation	NN	O
markedly	RB	O
reduced	VBD	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
but	CC	O
did	VBD	O
not	RB	O
favorably	RB	O
influence	JJ	O
performance	NN	O
or	CC	O
affect	VB	O
in	IN	O
response	NN	O
to	TO	O
acute	VB	O
stress	NN	O
.	.	O

Placebo	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
statistically	RB	O
similar	JJ	O
on	IN	O
all	DT	O
measures	NNS	O
.	.	O

The	DT	O
findings	NNS	O
indicated	VBD	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
chronic	JJ	O
aerobic	JJ	O
exercise	NN	O
as	IN	O
a	DT	O
strategy	NN	O
for	IN	O
improved	JJ	O
coping	NN	O
with	IN	O
acute	JJ	O
stress	NN	O
.	.	O

Phase	NNP	O
III	NNP	O
study	NN	O
of	IN	O
two	CD	O
different	JJ	O
dosing	VBG	O
schedules	NNS	O
of	IN	O
erythropoietin	NN	PM
in	IN	O
anemic	JJ	O
patients	NNS	O
with	IN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
maintenance	NN	O
epoetin	NN	PM
alfa	NN	PM
administered	VBD	O
once	RB	O
every	DT	O
3	CD	O
weeks	NNS	O
with	IN	O
continued	JJ	O
weekly	JJ	O
epoetin	NN	PM
alfa	NN	PM
for	IN	O
patients	NNS	O
with	IN	O
cancer-associated	JJ	O
anemia	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Eligible	JJ	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
at	IN	O
enrollment	NN	O
to	TO	O
receive	VB	O
three	CD	PM
weekly	JJ	PM
doses	NNS	PM
of	IN	PM
epoetin	NN	PM
alfa	NN	PM
40,000	CD	PM
U	NNP	PM
subcutaneously	RB	PM
(	(	O
SC	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
either	DT	O
standard	JJ	O
weekly	JJ	O
epoetin	NN	PM
alfa	NN	PM
(	(	O
40K	CD	O
arm	NN	O
)	)	O
or	CC	O
120,000	CD	O
U	NNP	O
of	IN	O
epoetin	NN	PM
alfa	NN	PM
(	(	O
120K	CD	O
arm	NN	O
)	)	O
SC	NNP	O
every	DT	O
3	CD	O
weeks	NNS	O
for	IN	O
18	CD	O
additional	JJ	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Three	CD	O
hundred	VBD	O
sixty-five	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
eighty-three	JJ	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
40K	CD	O
arm	NN	O
,	,	O
and	CC	O
182	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
120K	CD	O
arm	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
requiring	VBG	O
transfusions	NNS	O
during	IN	O
the	DT	O
study	NN	O
(	(	O
23	CD	O
%	NN	O
in	IN	O
40K	CD	O
arm	NN	O
and	CC	O
18	CD	O
%	NN	O
in	IN	O
120K	CD	O
arm	NN	O
,	,	O
P	NNP	O
=	NNP	O
.22	NNP	O
)	)	O
or	CC	O
specifically	RB	O
during	IN	O
the	DT	O
maintenance	NN	O
phase	NN	O
(	(	O
13	CD	O
%	NN	O
in	IN	O
40K	CD	O
arm	NN	O
v	NN	O
15	CD	O
%	NN	O
in	IN	O
120K	CD	O
arm	NN	O
,	,	O
P	NNP	O
=	NNP	O
.58	NNP	O
)	)	O
.	.	O

Patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
40K	CD	O
arm	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
>	NN	O
or	CC	O
=	VB	O
2	CD	O
or	CC	O
>	CD	O
or	CC	O
=	VB	O
3	CD	O
g/dL	NN	O
hemoglobin	NN	O
(	(	O
Hb	NNP	O
)	)	O
increment	NN	O
,	,	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
drug	NN	O
dose	RB	O
held	VBD	O
because	IN	O
of	IN	O
high	JJ	O
Hb	NNP	O
,	,	O
and	CC	O
had	VBD	O
higher	JJR	O
mean	JJ	O
end-of-study	JJ	O
Hb	NNP	O
levels	NNS	O
.	.	O

Toxicities	NNS	O
,	,	O
including	VBG	O
thromboembolism	NN	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
similar	JJ	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
40K	CD	O
arm	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
global	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
at	IN	O
baseline	NN	O
for	IN	O
unclear	JJ	O
reasons	NNS	O
,	,	O
whereas	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
120K	CD	O
arm	NN	O
had	VBD	O
a	DT	O
greater	JJR	O
global	JJ	O
QOL	NNP	O
improvement	NN	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
so	IN	O
end-of-study	JJ	O
QOL	NNP	O
was	VBD	O
equivalent	JJ	O
.	.	O

CONCLUSION	NN	O
After	IN	O
three	CD	O
weekly	JJ	O
doses	NNS	O
of	IN	O
epoetin	NN	PM
alfa	NN	PM
40,000	CD	O
U	NNP	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
120,000	CD	O
U	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
safely	RB	O
once	RB	O
every	DT	O
3	CD	O
weeks	NNS	O
without	IN	O
increasing	VBG	O
transfusion	NN	O
needs	NNS	O
or	CC	O
sacrificing	VBG	O
QOL	NNP	O
.	.	O

The	DT	O
Hb	NNP	O
increment	NN	O
is	VBZ	O
somewhat	RB	O
greater	JJR	O
with	IN	O
continued	JJ	O
weekly	JJ	O
epoetin	NN	PM
alfa	NN	PM
.	.	O

Lack	NNP	O
of	IN	O
blinding	VBG	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
different	JJ	O
treatment	NN	O
schedules	NNS	O
may	MD	O
have	VB	O
confounded	VBN	O
results	NNS	O
.	.	O

Methotrexate	NNP	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
steroid-dependent	JJ	O
asthma	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
crossover	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
steroid	JJ	O
requirements	NNS	O
between	IN	O
placebo	NN	C
and	CC	O
methotrexate	NN	PM
(	(	O
MTX	NNP	O
)	)	O
treatment	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
corticosteroid-requiring	JJ	O
asthma	NN	O
.	.	O

Subjects	NNS	O
began	VBD	O
with	IN	O
a	DT	O
steroid	JJ	O
taper	NN	O
and	CC	O
then	RB	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
3-month	JJ	O
trial	NN	O
of	IN	O
drug	NN	O
or	CC	O
placebo	NN	C
therapy	NN	C
.	.	C

Subjects	NNS	O
received	VBD	O
15	CD	O
mg	NN	O
of	IN	O
MTX	NNP	PM
a	DT	O
week	NN	O
or	CC	O
identical	JJ	O
placebo	NN	C
.	.	C

A	DT	O
1-month	JJ	O
washout	NN	O
period	NN	O
was	VBD	O
completed	VBN	O
before	IN	O
the	DT	O
crossover	NN	O
trial	NN	O
.	.	O

Symptom	NNP	O
scores	NNS	O
,	,	O
peak	NN	O
flow	NN	O
rates	NNS	O
,	,	O
spirometry	NN	O
,	,	O
and	CC	O
beta-agonist	JJ	O
frequency	NN	O
were	VBD	O
closely	RB	O
monitored	VBN	O
.	.	O

Ten	CD	O
subjects	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
average	JJ	O
dose	NN	O
of	IN	O
prednisone	NN	O
during	IN	O
the	DT	O
placebo-treatment	JJ	C
period	NN	O
was	VBD	O
11.97	CD	O
mg/day	NN	O
compared	VBN	O
to	TO	O
8.37	CD	O
mg/day	NNS	O
while	IN	O
subjects	NNS	O
were	VBD	O
taking	VBG	O
MTX	NNP	PM
.	.	O

This	DT	O
was	VBD	O
a	DT	O
30	CD	O
%	NN	O
reduction	NN	O
in	IN	O
daily	JJ	O
steroid	JJ	O
requirement	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Symptom	JJ	O
scores	NNS	O
and	CC	O
spirometry	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
crossover	NN	O
trials	NNS	O
,	,	O
and	CC	O
overall	JJ	O
clinical	JJ	O
status	NN	O
was	VBD	O
not	RB	O
altered	VBN	O
.	.	O

Complications	NNS	O
from	IN	O
MTX	NNP	PM
were	VBD	O
mild	JJ	O
and	CC	O
included	VBD	O
anorexia	NN	O
,	,	O
alopecia	NN	O
,	,	O
and	CC	O
stomatitis	NN	O
.	.	O

All	DT	O
complications	NNS	O
resolved	VBN	O
with	IN	O
dose	JJ	O
reduction	NN	O
or	CC	O
when	WRB	O
MTX	NNP	PM
was	VBD	O
stopped	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

No	DT	O
subjects	NNS	O
withdrew	VBD	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
MTX	NNP	PM
complications	NNS	O
.	.	O

Low-dose	JJ	O
MTX	NNP	PM
significantly	RB	O
reduced	VBD	O
the	DT	O
steroid	JJ	O
requirement	NN	O
in	IN	O
this	DT	O
group	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
steroid-dependent	JJ	O
asthma	NN	O
.	.	O

This	DT	O
reduction	NN	O
in	IN	O
steroid	JJ	O
requirement	NN	O
was	VBD	O
obtained	VBN	O
without	IN	O
altering	VBG	O
clinical	JJ	O
status	NN	O
and	CC	O
without	IN	O
significant	JJ	O
complication	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
indomethacin	NN	O
in	IN	O
uremic	JJ	O
pericarditis	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
indomethacin	NN	O
on	IN	O
the	DT	O
course	NN	O
of	IN	O
uremic	JJ	O
pericarditis	NN	O
we	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
double	JJ	O
blind	NN	O
study	NN	O
in	IN	O
which	WDT	O
24	CD	O
patients	NNS	O
with	IN	O
endstage	NN	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
and	CC	O
pericarditis	NN	O
randomly	RB	O
received	VBD	O
indomethacin	JJ	O
,	,	O
25	CD	O
mg	NN	O
four	CD	O
times	NNS	O
daily	RB	O
,	,	O
(	(	O
11	CD	O
patients	NNS	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	C
(	(	O
13	CD	O
patients	NNS	O
)	)	O
for	IN	O
a	DT	O
3-week	JJ	O
period	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBN	O
peritoneal	JJ	O
or	CC	O
hemodialysis	NN	O
treatment	NN	O
concurrently	RB	O
with	IN	O
the	DT	O
study	NN	O
drug	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
the	DT	O
placebo	NN	C
,	,	O
indomethacin	NN	O
produced	VBD	O
an	DT	O
immediate	JJ	O
and	CC	O
sustained	JJ	O
reduction	NN	O
of	IN	O
fever	NN	O
in	IN	O
all	DT	O
but	CC	O
one	CD	O
patient	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
indomethacin	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
chest	NN	O
pain	NN	O
(	(	O
mean	JJ	O
days	NNS	O
+/-	JJ	O
SE	NNP	O
:	:	O
placebo	NN	C
1.4	CD	O
+/-	JJ	O
0.6	CD	O
,	,	O
indomethacin	JJ	PM
5.5	CD	O
+/-	JJ	O
3.3	CD	O
)	)	O
,	,	O
duration	NN	O
of	IN	O
pericardial	JJ	O
friction	NN	O
rub	NN	O
(	(	O
placebo	JJ	O
10.3	CD	O
+/-	JJ	O
1.7	CD	O
,	,	O
indomethacin	JJ	O
16.0	CD	O
+/-	JJ	O
3.8	CD	O
)	)	O
,	,	O
or	CC	O
on	IN	O
the	DT	O
amount	NN	O
of	IN	O
pericardial	JJ	O
effusion	NN	O
.	.	O

Further	NNP	O
,	,	O
indomethacin	NN	O
did	VBD	O
not	RB	O
diminish	VB	O
the	DT	O
need	NN	O
for	IN	O
invasive	JJ	O
surgical	JJ	O
procedures	NNS	O
for	IN	O
relief	NN	O
of	IN	O
tamponade	NN	O
(	(	O
three	CD	O
of	IN	O
13	CD	O
placebo	NN	O
patients	NNS	O
,	,	O
two	CD	O
of	IN	O
11	CD	O
indomethacin	JJ	O
patients	NNS	O
)	)	O
or	CC	O
result	NN	O
in	IN	O
decreased	JJ	O
mortality	NN	O
rate	NN	O
.	.	O

Death	NNP	O
(	(	O
not	RB	O
due	RB	O
to	TO	O
pericarditis	NN	O
)	)	O
occurred	VBD	O
in	IN	O
two	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
indomethacin	NN	O
and	CC	O
one	CD	O
patient	NN	O
who	WP	O
received	VBD	O
the	DT	O
placebo	NN	O
.	.	O

In	IN	O
our	PRP$	O
patients	NNS	O
pericarditis	VBP	O
encompassed	VBD	O
a	DT	O
wide	JJ	O
spectrum	NN	O
ranging	VBG	O
from	IN	O
a	DT	O
mild	JJ	O
illness	NN	O
of	IN	O
several	JJ	O
days	NNS	O
duration	NN	O
to	TO	O
a	DT	O
painful	JJ	O
and	CC	O
debilitating	JJ	O
disease	NN	O
lasting	JJ	O
weeks	NNS	O
and	CC	O
requiring	VBG	O
surgical	JJ	O
intervention	NN	O
.	.	O

Although	IN	O
the	DT	O
size	NN	O
of	IN	O
our	PRP$	O
population	NN	O
prohibits	VBZ	O
definitive	JJ	O
conclusions	NNS	O
,	,	O
it	PRP	O
would	MD	O
appear	VB	O
that	IN	O
,	,	O
except	IN	O
for	IN	O
fever	NN	O
,	,	O
the	DT	O
manifestations	NNS	O
and	CC	O
natural	JJ	O
history	NN	O
of	IN	O
this	DT	O
illness	NN	O
are	VBP	O
unaffected	VBN	O
by	IN	O
indomethacin	NN	O
.	.	O

Digestive	JJ	PM
enzyme	NN	PM
supplementation	NN	PM
for	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
digestive	JJ	PM
enzyme	NN	PM
supplement	NN	PM
in	IN	O
improving	VBG	O
expressive	JJ	O
language	NN	O
,	,	O
behaviour	NN	O
and	CC	O
other	JJ	O
symptoms	NNS	O
in	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorder	NNP	O
.	.	O

Randomized	VBN	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	C
trial	NN	O
using	VBG	O
crossover	NN	O
design	NN	O
over	IN	O
6	CD	O
months	NNS	O
for	IN	O
43	CD	O
children	NNS	O
,	,	O
aged	VBN	O
3-8	CD	O
years	NNS	O
.	.	O

Outcome	NNP	O
measurement	NN	O
tools	NNS	O
included	VBD	O
monthly	JJ	O
Global	NNP	O
Behaviour	NNP	O
Rating	NNP	O
Scales	NNP	O
,	,	O
Additional	NNP	O
Rating	NNP	O
Scales	NNP	O
of	IN	O
other	JJ	O
symptoms	NNS	O
by	IN	O
parents	NNS	O
and	CC	O
therapists	NNS	O
,	,	O
and	CC	O
monthly	JJ	O
completion	NN	O
of	IN	O
the	DT	O
Rescorla	NNP	O
Language	NNP	O
Development	NNP	O
Survey	NNP	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	C
,	,	O
treatment	NN	O
with	IN	O
enzyme	NN	PM
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
clinically	RB	O
significant	JJ	O
improvement	NN	O
in	IN	O
behaviour	NN	O
,	,	O
food	NN	O
variety	NN	O
,	,	O
gastrointestinal	JJ	O
symptoms	NNS	O
,	,	O
sleep	JJ	O
quality	NN	O
,	,	O
engagement	NN	O
with	IN	O
therapist	NN	O
,	,	O
or	CC	O
the	DT	O
Language	NNP	O
Development	NNP	O
Survey	NNP	O
Vocabulary	NNP	O
or	CC	O
Sentence	NNP	O
Complexity	NNP	O
Scores	NNP	O
.	.	O

A	NNP	O
small	JJ	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
on	IN	O
enzyme	NN	O
therapy	NN	O
was	VBD	O
seen	VBN	O
for	IN	O
the	DT	O
food	NN	O
variety	NN	O
scores	NNS	O
.	.	O

No	DT	O
clinically	RB	O
significant	JJ	O
effect	NN	O
improvement	NN	O
of	IN	O
autism	NN	O
symptoms	NNS	O
with	IN	O
enzyme	NN	O
use	NN	O
was	VBD	O
shown	VBN	O
with	IN	O
this	DT	O
trial	NN	O
,	,	O
however	RB	O
,	,	O
possible	JJ	O
effects	NNS	O
on	IN	O
improvement	NN	O
in	IN	O
food	NN	O
variety	NN	O
warrants	NNS	O
further	RBR	O
detailed	JJ	O
investigation	NN	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
ofloxacin	NN	PM
and	CC	O
cefixime	NN	PM
for	IN	O
treatment	NN	O
of	IN	O
typhoid	JJ	O
fever	NN	O
in	IN	O
children	NNS	O
.	.	O

The	DT	O
Dong	NNP	O
Nai	NNP	O
Pediatric	NNP	O
Center	NNP	O
Typhoid	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
concerns	NNS	O
about	IN	O
safety	NN	O
in	IN	O
children	NNS	O
,	,	O
fluoroquinolone	NN	PM
antibiotics	NNS	PM
have	VBP	O
become	VBN	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
in	IN	O
patients	NNS	O
with	IN	O
multidrug-resistant	JJ	O
typhoid	NN	O
fever	NN	O
in	IN	O
Vietnam	NNP	O
.	.	O

However	RB	O
,	,	O
quinolone-resistant	JJ	O
strains	NNS	O
of	IN	O
Salmonella	NNP	O
typhi	NN	O
have	VBP	O
recently	RB	O
been	VBN	O
reported	VBN	O
from	IN	O
Vietnam	NNP	O
;	:	O
and	CC	O
if	IN	O
quinolone	JJ	O
resistance	NN	O
becomes	NNS	O
established	VBN	O
,	,	O
alternative	JJ	O
oral	JJ	O
treatment	NN	O
options	NNS	O
will	MD	O
be	VB	O
needed	VBN	O
.	.	O

OBJECTIVE	NNP	O
Cefixime	NNP	PM
,	,	O
an	DT	O
orally	RB	O
administered	VBN	O
third	JJ	O
generation	NN	O
cephalosporin	NN	PM
,	,	O
was	VBD	O
compared	VBN	O
with	IN	O
ofloxacin	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
uncomplicated	JJ	O
typhoid	NN	O
fever	NN	O
in	IN	O
children	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
an	DT	O
open	JJ	O
trial	NN	O
children	NNS	O
with	IN	O
suspected	JJ	O
typhoid	NN	O
fever	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
ofloxacin	NN	PM
(	(	O
10	CD	O
mg/kg/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
)	)	O
for	IN	O
5	CD	O
days	NNS	O
or	CC	O
cefixime	NN	PM
(	(	O
20	CD	O
mg/kg/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
)	)	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
S.	NNP	O
typhi	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
82	CD	O
patients	NNS	O
(	(	O
44	CD	O
in	IN	O
the	DT	O
cefixime	NN	PM
group	NN	O
,	,	O
38	CD	O
in	IN	O
the	DT	O
ofloxacin	JJ	PM
group	NN	O
)	)	O
and	CC	O
70	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
isolates	NNS	O
were	VBD	O
multidrug-resistant	JJ	O
.	.	O

Median	JJ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
range	NN	O
)	)	O
fever	NN	O
clearance	NN	O
times	NNS	O
were	VBD	O
4.4	CD	O
(	(	O
4	CD	O
to	TO	O
5.2	CD	O
,	,	O
0.2	CD	O
to	TO	O
9.9	CD	O
)	)	O
days	NNS	O
for	IN	O
ofloxacin	JJ	PM
recipients	NNS	O
and	CC	O
8.5	CD	O
(	(	O
4.2	CD	O
to	TO	O
9	CD	O
,	,	O
1.8	CD	O
to	TO	O
15.2	CD	O
)	)	O
days	NNS	O
for	IN	O
cefixime-treated	JJ	PM
patients	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
11	CD	O
treatment	NN	O
failures	NNS	O
(	(	O
10	CD	O
acute	NN	O
and	CC	O
one	CD	O
relapse	NN	O
)	)	O
in	IN	O
the	DT	O
cefixime	NN	PM
group	NN	O
and	CC	O
1	CD	O
acute	NN	O
treatment	NN	O
failure	NN	O
in	IN	O
the	DT	O
ofloxacin	NN	PM
group	NN	O
(	(	O
mean	JJ	O
difference	NN	O
,	,	O
22	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
9	CD	O
to	TO	O
36	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Short	NNP	O
course	NN	O
treatment	NN	O
with	IN	O
cefixime	NN	PM
may	MD	O
provide	VB	O
a	DT	O
useful	JJ	O
alternative	JJ	O
treatment	NN	O
in	IN	O
cases	NNS	O
of	IN	O
uncomplicated	JJ	O
typhoid	NN	O
fever	NN	O
in	IN	O
children	NNS	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
less	RBR	O
effective	JJ	O
than	IN	O
short	JJ	O
course	NN	O
treatment	NN	O
with	IN	O
ofloxacin	NN	PM
.	.	O

Levosulpiride	NNP	PM
in	IN	O
functional	JJ	O
dyspepsia	NN	O
:	:	O
a	DT	O
multicentric	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

Abnormalities	NNS	O
in	IN	O
gastrointestinal	JJ	O
motility	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
a	DT	O
substantial	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
functional	JJ	O
dyspepsia	NN	O
,	,	O
supporting	VBG	O
the	DT	O
use	NN	O
of	IN	O
prokinetic	JJ	PM
drugs	NNS	PM
for	IN	O
treatment	NN	O
of	IN	O
dyspeptic	JJ	O
symptoms	NNS	O
.	.	O

To	TO	O
evaluate	VB	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
levosulpiride	NN	PM
in	IN	O
short-term	JJ	O
treatment	NN	O
,	,	O
1298	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
multicentric	NN	O
study	NN	O
carried	VBD	O
out	IN	O
in	IN	O
45	CD	O
Italian	JJ	O
Gastroenterology	NNP	O
Departments	NNP	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
levosulpiride	NN	PM
(	(	O
25	CD	O
mg	RB	O
tid	NN	O
)	)	O
,	,	O
domperidone	NN	PM
(	(	O
10	CD	O
mg	RB	O
tid	NN	O
)	)	O
,	,	O
metoclopramide	RB	PM
(	(	O
10	CD	O
mg	RB	O
tid	NN	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
1	CD	O
tablet	NN	O
tid	NN	O
)	)	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
selected	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
:	:	O
a	DT	O
)	)	O
occurrence	NN	O
in	IN	O
the	DT	O
last	JJ	O
4	CD	O
weeks	NNS	O
of	IN	O
at	IN	O
least	JJS	O
5/10	CD	O
selected	VBN	O
symptoms	NNS	O
(	(	O
anorexia	NN	O
,	,	O
nausea	NN	O
,	,	O
vomiting	VBG	O
,	,	O
upper	JJ	O
abdominal	JJ	O
pain	NN	O
,	,	O
postprandial	JJ	O
bloating	NN	O
,	,	O
abdominal	JJ	O
fullness	NN	O
,	,	O
early	JJ	O
satiety	NN	O
,	,	O
belching	NN	O
,	,	O
heartburn	NN	O
,	,	O
regurgitation	NN	O
)	)	O
,	,	O
severity	NN	O
of	IN	O
which	WDT	O
should	MD	O
reach/exceed	VB	O
a	DT	O
total	JJ	O
score	NN	O
of	IN	O
8	CD	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
a	DT	O
specific	JJ	O
scale	NN	O
ranging	VBG	O
from	IN	O
0	CD	O
(	(	O
absent	NN	O
)	)	O
to	TO	O
3	CD	O
(	(	O
severe	JJ	O
)	)	O
;	:	O
b	VBN	O
)	)	O
normal	JJ	O
results	NNS	O
of	IN	O
routine	JJ	O
biochemical	NN	O
,	,	O
ultrasound	NN	O
and	CC	O
endoscopic	JJ	O
examinations	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
each	DT	O
patient	NN	O
subjectively	RB	O
evaluated	VBD	O
efficacy	NN	O
of	IN	O
treatment	NN	O
by	IN	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
.	.	O

Significant	JJ	O
improvement	NN	O
was	VBD	O
recorded	VBN	O
for	IN	O
all	DT	O
symptoms	NNS	O
at	IN	O
days	NNS	O
10	CD	O
and	CC	O
28	CD	O
in	IN	O
all	DT	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
levosulpiride	NN	PM
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
superior	NN	O
to	TO	O
domperidone	VB	PM
,	,	O
metoclopramide	NN	PM
and	CC	O
placebo	VB	C
both	DT	O
in	IN	O
the	DT	O
overall	JJ	O
clinical	JJ	O
improvement	NN	O
scale	NN	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
symptoms	NNS	O
(	(	O
postprandial	JJ	O
bloating	NN	O
,	,	O
epigastric	JJ	O
pain	NN	O
,	,	O
heartburn	NN	O
)	)	O
.	.	O

Active	JJ	PM
treatments	NNS	PM
and	CC	O
placebo	NNS	C
were	VBD	O
comparable	JJ	O
as	RB	O
far	RB	O
as	IN	O
concerns	NNS	O
occurrence	IN	O
of	IN	O
side-effects	NNS	O
(	(	O
12-20	CD	O
%	NN	O
)	)	O
including	VBG	O
galactorrhoea	NN	O
,	,	O
breast	NN	O
tenderness	NN	O
and	CC	O
menstrual	JJ	O
changes	NNS	O
.	.	O

Chemoradiation	NN	O
comparing	VBG	O
cisplatin	JJ	PM
versus	NN	O
carboplatin	NN	PM
in	IN	O
locally	RB	O
advanced	JJ	O
nasopharyngeal	JJ	O
cancer	NN	O
:	:	O
randomised	VBN	O
,	,	O
non-inferiority	NN	O
,	,	O
open	JJ	O
trial	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
single	JJ	O
centre	NN	O
,	,	O
open	JJ	O
labelled	VBD	O
,	,	O
randomised	VBD	O
non-inferiority	JJ	O
trial	NN	O
compared	VBN	O
concurrent	JJ	O
chemoradiotherapy	NN	PM
with	IN	PM
carboplatin	JJ	PM
versus	JJ	O
standard	NN	PM
concurrent	NN	PM
chemoradiotherapy	NN	PM
with	IN	PM
cisplatin	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
locoregionally	RB	O
advanced	JJ	O
nasopharyngeal	JJ	O
cancer	NN	O
(	(	O
NPC	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
August	NNP	O
1999	CD	O
to	TO	O
December	NNP	O
2004	CD	O
,	,	O
206	CD	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
NPC	NNP	O
were	VBD	O
randomised	VBN	O
with	IN	O
101	CD	O
to	TO	O
cisplatin	VB	PM
arm	NN	O
and	CC	O
105	CD	O
to	TO	O
carboplatin	VB	PM
arm	NN	O
.	.	O

Planned	VBD	PM
radiotherapy	NN	PM
was	VBD	O
the	DT	O
same	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
toxicity	NN	O
and	CC	O
survival	NN	O
according	VBG	O
to	TO	O
the	DT	O
as-treated	JJ	O
principle	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
26.3	CD	O
months	NNS	O
(	(	O
range	VB	O
3-74.6	JJ	O
months	NNS	O
)	)	O
,	,	O
59	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
cisplatin	NN	O
arm	NN	O
completed	VBD	O
the	DT	O
planned	VBN	O
concurrent	NN	O
chemoradiation	NN	O
treatment	NN	O
,	,	O
compared	VBN	O
to	TO	O
73	CD	O
%	NN	O
in	IN	O
the	DT	O
carboplatin	NN	O
arm	NN	O
.	.	O

Forty-two	JJ	O
percent	NN	O
of	IN	O
cisplatin	NN	O
patients	NNS	O
completed	VBD	O
the	DT	O
3	CD	O
cycles	NNS	O
of	IN	O
adjuvant	JJ	O
therapy	NN	O
compared	VBN	O
to	TO	O
70	CD	O
%	NN	O
in	IN	O
the	DT	O
carboplatin	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
more	JJR	O
renal	JJ	O
toxicity	NN	O
,	,	O
leucopenia	NN	O
,	,	O
and	CC	O
anaemia	NN	O
in	IN	O
the	DT	O
cisplatin	NN	O
group	NN	O
,	,	O
and	CC	O
more	JJR	O
thrombocytopenia	NN	O
in	IN	O
the	DT	O
carboplatin	NN	O
arm	NN	O
.	.	O

The	DT	O
3	CD	O
year	NN	O
disease	NN	O
free	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
63.4	CD	O
%	NN	O
for	IN	O
the	DT	O
cisplatin	NN	O
group	NN	O
and	CC	O
60.9	CD	O
%	NN	O
for	IN	O
the	DT	O
carboplatin	NN	O
group	NN	O
(	(	O
p=0.9613	NN	O
)	)	O
(	(	O
HR	$	O
0.70	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
:	:	O
0.50-0.98	JJ	O
)	)	O
.	.	O

The	DT	O
3	CD	O
year	NN	O
overall	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
77.7	CD	O
%	NN	O
and	CC	O
79.2	CD	O
%	NN	O
for	IN	O
cisplatin	NN	O
and	CC	O
carboplatin	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
p=0.9884	NN	O
)	)	O
(	(	O
HR	$	O
0.83	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.63-1.010	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
concluded	VBD	O
that	IN	O
the	DT	O
tolerability	NN	O
of	IN	O
carboplatin	NN	PM
based	VBN	O
regimen	NNS	O
is	VBZ	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
cisplatin	NN	PM
regimen	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
treatment	NN	O
efficacy	NN	O
of	IN	O
carboplatin	NN	O
arm	NN	O
is	VBZ	O
not	RB	O
different	JJ	O
from	IN	O
the	DT	O
standard	JJ	O
regimen	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
locoregional	JJ	O
advanced	JJ	O
stage	NN	O
NPC	NNP	O
.	.	O

Injection	NNP	PM
sclerotherapy	NN	PM
versus	NN	PH
electrocoagulation	NN	PH
in	IN	O
the	DT	O
management	NN	O
outcome	NN	O
of	IN	O
early	JJ	O
haemorrhoids	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
symptomatology	NN	O
of	IN	O
early	JJ	O
hemorrhoids	NNS	O
and	CC	O
to	TO	O
compare	VB	O
injection	NN	PM
sclerotherapy	NN	PM
(	(	PM
IS	NNP	PM
)	)	PM
with	IN	O
electrocoagulation	NN	PH
(	(	PH
EC	NNP	PH
)	)	PH
in	IN	O
the	DT	O
management	NN	O
outcome	NN	O
of	IN	O
early	JJ	O
haemorrhoids	NNS	O
with	IN	O
respect	NN	O
to	TO	O
pain	VB	O
during	IN	O
the	DT	O
procedure	NN	O
,	,	O
reduction	NN	O
in	IN	O
bleeding	VBG	O
per	IN	O
rectum	NN	O
,	,	O
and	CC	O
overall	JJ	O
patient	NN	O
satisfaction	NN	O
score	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
102	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
experimental	JJ	O
study	NN	O
at	IN	O
the	DT	O
POF	NNP	O
Hospital	NNP	O
,	,	O
Wah	NNP	O
Cantt	NNP	O
from	IN	O
October	NNP	O
2004	CD	O
to	TO	O
June	NNP	O
2005	CD	O
.	.	O

A	DT	O
detailed	JJ	O
history	NN	O
was	VBD	O
taken	VBN	O
and	CC	O
proctoscopic	JJ	O
examination	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
then	RB	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
Lottery	NNP	O
method	NN	O
)	)	O
.	.	O

One	CD	O
group	NN	O
was	VBD	O
subjected	VBN	O
to	TO	O
EC	NNP	O
and	CC	O
the	DT	O
other	JJ	O
to	TO	O
IS	NNP	O
.	.	O

In	IN	O
the	DT	O
EC	NNP	O
,	,	O
using	VBG	O
the	DT	O
EC	NNP	O
machine	NN	O
(	(	O
Wieda	NNP	O
,	,	O
China	NNP	O
)	)	O
,	,	O
direct	JJ	O
current	JJ	O
of	IN	O
10-20	JJ	O
mA	NN	O
was	VBD	O
applied	VBN	O
in	IN	O
the	DT	O
submucosal	JJ	O
plane	NN	O
of	IN	O
each	DT	O
pile	NN	O
core	NN	O
for	IN	O
5-7	JJ	O
minutes	NNS	O
.	.	O

In	IN	O
the	DT	O
IS	NNP	O
1-2	JJ	O
ml	NN	O
of	IN	O
5	CD	O
%	NN	O
phenol	NN	PM
in	IN	PM
almond	NN	PM
oil	NN	PM
was	VBD	O
injected	VBN	O
in	IN	O
the	DT	O
same	JJ	O
plane	NN	O
in	IN	O
each	DT	O
pile	NN	O
core	NN	O
.	.	O

Pain	NN	O
during	IN	O
the	DT	O
procedure	NN	O
,	,	O
reduction	NN	O
in	IN	O
bleeding	VBG	O
per	IN	O
rectum	NN	O
and	CC	O
overall	JJ	O
patient	NN	O
satisfaction	NN	O
,	,	O
were	VBD	O
studied	VBN	O
as	IN	O
outcome	JJ	O
measures	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
was	VBD	O
44	CD	O
years	NNS	O
,	,	O
86	CD	O
were	VBD	O
males	NNS	O
and	CC	O
16	CD	O
were	VBD	O
females	NNS	O
.	.	O

Two	CD	O
thirds	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
having	VBG	O
symptoms	NNS	O
for	IN	O
more	JJR	O
than	IN	O
6	CD	O
months	NNS	O
.	.	O

A	DT	O
third	JJ	O
of	IN	O
patients	NNS	O
had	VBD	O
associated	VBN	O
local	JJ	O
pain	NN	O
while	IN	O
another	DT	O
third	JJ	O
had	VBD	O
associated	VBN	O
mucous	JJ	O
discharge	NN	O
.	.	O

Chronic	JJ	O
constipation	NN	O
was	VBD	O
present	JJ	O
in	IN	O
81	CD	O
%	NN	O
patients	NNS	O
.	.	O

Only	RB	O
24.5	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
positive	JJ	O
family	NN	O
history	NN	O
of	IN	O
haemorrhoids	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
electrocoagulation	NN	O
(	(	O
EC	NNP	O
)	)	O
group	NN	O
experienced	VBD	O
more	JJR	O
pain	NN	O
during	IN	O
the	DT	O
procedure	NN	O
than	IN	O
the	DT	O
injection	NN	O
sclerotherapy	NN	O
(	(	O
IS	NNP	O
)	)	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.000	CD	O
)	)	O
,	,	O
but	CC	O
EC	NNP	O
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
IS	NNP	O
in	IN	O
terms	NNS	O
of	IN	O
reducing	VBG	O
the	DT	O
bleeding	NN	O
per	IN	O
rectum	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
,	,	O
and	CC	O
also	RB	O
significantly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
were	VBD	O
fully	RB	O
satisfied	VBN	O
with	IN	O
EC	NNP	O
than	IN	O
with	IN	O
IS	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.04	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
EC	NNP	O
,	,	O
although	IN	O
more	RBR	O
painful	JJ	O
,	,	O
is	VBZ	O
a	DT	O
safe	JJ	O
,	,	O
more	RBR	O
effective	JJ	O
and	CC	O
a	DT	O
highly	RB	O
satisfying	JJ	O
procedure	NN	O
for	IN	O
treating	VBG	O
early	JJ	O
hemorrhoids	NNS	O
.	.	O

Central	JJ	O
5-HT4	JJ	O
receptor	NN	O
binding	NN	O
as	IN	O
biomarker	NN	O
of	IN	O
serotonergic	JJ	O
tonus	NN	O
in	IN	O
humans	NNS	O
:	:	O
a	DT	O
[	$	O
11C	CD	O
]	NNP	O
SB207145	NNP	O
PET	NNP	O
study	NN	O
.	.	O

Identification	NNP	O
of	IN	O
a	DT	O
biomarker	NN	O
that	WDT	O
can	MD	O
inform	VB	O
on	IN	O
extracellular	JJ	O
serotonin	NN	O
(	(	O
5-HT	JJ	O
)	)	O
levels	NNS	O
in	IN	O
the	DT	O
brains	NNS	O
of	IN	O
living	NN	O
humans	NNS	O
would	MD	O
enable	VB	O
greater	JJR	O
understanding	NN	O
of	IN	O
the	DT	O
way	NN	O
brain	NN	O
circuits	NNS	O
are	VBP	O
modulated	VBN	O
by	IN	O
serotonergic	JJ	O
neurotransmission	NN	O
.	.	O

Substantial	JJ	O
evidence	NN	O
from	IN	O
studies	NNS	O
in	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
indicates	VBZ	O
an	DT	O
inverse	NN	O
relationship	NN	O
between	IN	O
central	JJ	O
5-HT	JJ	O
tonus	NN	O
and	CC	O
5-HT	JJ	O
type	NN	O
4	CD	O
receptor	NN	O
(	(	O
5-HT4R	JJ	O
)	)	O
density	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
5-HT4R	JJ	O
receptor	NN	O
density	NN	O
may	MD	O
be	VB	O
a	DT	O
biomarker	NN	O
marker	NN	O
for	IN	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
a	DT	O
3-week	JJ	O
administration	NN	O
of	IN	O
a	DT	O
selective	JJ	O
serotonin	NN	O
reuptake	NN	O
inhibitor	NN	O
,	,	O
expected	VBN	O
to	TO	O
increase	VB	O
brain	NN	O
5-HT	JJ	O
levels	NNS	O
,	,	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decline	NN	O
in	IN	O
brain	NN	O
5-HT4R	JJ	O
binding	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
35	CD	O
healthy	JJ	O
men	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	C
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
3	CD	O
weeks	NNS	O
of	IN	O
oral	JJ	C
dosing	VBG	C
with	IN	C
placebo	NN	C
or	CC	O
fluoxetine	NN	PM
,	,	PM
40	CD	PM
mg	NNS	PM
per	IN	PM
day	NN	PM
.	.	O

Brain	VB	O
5-HT4R	JJ	O
binding	NN	O
was	VBD	O
quantified	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
follow-up	JJ	O
with	IN	O
[	NNP	O
(	(	PH
11	CD	PH
)	)	PH
C	NNP	PH
]	NNP	PH
SB207145	NNP	PH
positron	NN	PH
emission	NN	PH
tomography	NN	PH
(	(	PH
PET	NNP	PH
)	)	PH
.	.	O

Three	CD	O
weeks	NNS	O
of	IN	O
intervention	NN	O
with	IN	O
fluoxetine	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
5.2	CD	O
%	NN	O
reduction	NN	O
in	IN	O
brain	NN	O
5-HT4R	JJ	O
binding	NN	O
(	(	O
P=0.017	NNP	O
)	)	O
,	,	O
whereas	JJ	O
placebo	NN	O
intervention	NN	O
did	VBD	O
not	RB	O
change	VB	O
5-HT4R	JJ	O
binding	NN	O
(	(	O
P=0.52	NNP	O
)	)	O
.	.	O

Our	PRP$	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
a	DT	O
model	NN	O
,	,	O
wherein	VBP	O
the	DT	O
5-HT4R	JJ	O
density	NN	O
adjusts	VBZ	O
to	TO	O
changes	NNS	O
in	IN	O
the	DT	O
extracellular	JJ	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
demonstrate	NN	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
in	IN	O
humans	NNS	O
that	IN	O
the	DT	O
imaging	NN	O
of	IN	O
central	JJ	O
5-HT4R	JJ	O
binding	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
in	IN	O
vivo	NN	O
biomarker	NN	O
of	IN	O
the	DT	O
central	JJ	O
5-HT	JJ	O
tonus	NN	O
.	.	O

Metformin	NNP	PM
does	VBZ	O
not	RB	O
enhance	VB	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
metformin	NN	PM
pretreatment	NN	PM
has	VBZ	O
beneficial	JJ	O
effects	NNS	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
infertile	JJ	O
women	NNS	O
with	IN	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
in	IN	O
an	DT	O
infertility	NN	O
clinic	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
placebo	NN	O
controlled	VBD	O
double-blind	NN	O
crossover	NN	O
study	NN	O
of	IN	O
3	CD	O
months	NNS	O
metformin	RB	PM
(	(	O
1500	CD	O
mg	IN	O
day-1	NN	O
)	)	O
/placebo	NN	C
,	,	O
followed	VBN	O
by	IN	O
3	CD	O
months	NNS	O
metformin/placebo	VBN	PM
together	RB	O
with	IN	O
clomiphene	NN	PM
(	(	O
50-100	JJ	O
mg	NN	O
for	IN	O
5	CD	O
days	NNS	O
)	)	O
for	IN	O
three	CD	O
cycles	NNS	O
in	IN	O
clomiphene	NN	O
resistant	JJ	O
women	NNS	O
with	IN	O
PCOS	NNP	O
.	.	O

The	DT	O
primary	JJ	O
outcomes	NNS	O
were	VBD	O
restoration	NN	O
of	IN	O
spontaneous	JJ	O
menses	NNS	O
,	,	O
ovulation	NN	O
induction	NN	O
(	(	O
spontaneous	JJ	O
or	CC	O
clomiphene	NN	O
induced	VBN	O
)	)	O
and	CC	O
pregnancy	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
were	VBD	O
changes	NNS	O
in	IN	O
biochemical	JJ	O
parameters	NNS	O
related	VBN	O
to	TO	O
androgens	NNS	O
and	CC	O
insulin	NN	O
.	.	O

RESULTS	NNP	O
Twelve	NNP	O
women	NNS	O
completed	VBD	O
the	DT	O
metformin	NN	PM
arm	NN	O
and	CC	O
14	CD	O
the	DT	O
placebo	NN	C
arm	NN	O
.	.	O

Spontaneous	JJ	O
menstruation	NN	O
resumed	VBD	O
in	IN	O
five	CD	O
metformin	NNS	PM
treated	VBD	O
patients	NNS	O
and	CC	O
in	IN	O
six	CD	O
placebo	NN	C
treated	VBN	O
women	NNS	O
,	,	O
P=0.63	NNP	O
.	.	O

No	NNP	O
women	NNS	O
given	VBN	O
metformin	NNS	O
spontaneously	RB	O
ovulated	VBD	O
,	,	O
although	IN	O
one	CD	O
patient	NN	O
given	VBN	O
placebo	NN	C
did	VBD	O
,	,	O
P=0.30	NNP	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
clomiphene	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
with	IN	O
ovulation	NN	O
being	VBG	O
induced	VBN	O
in	IN	O
five	CD	O
(	(	O
out	IN	O
of	IN	O
12	CD	O
)	)	O
metformin	NN	PM
treated	VBN	O
women	NNS	O
and	CC	O
four	CD	O
(	(	O
out	IN	O
of	IN	O
14	CD	O
)	)	O
placebo	NN	C
treated	VBN	O
women	NNS	O
,	,	O
P=0.63	NNP	O
.	.	O

Pregnancy	NN	O
occurred	VBD	O
in	IN	O
three	CD	O
(	(	O
out	IN	O
of	IN	O
12	CD	O
)	)	O
women	NNS	O
given	VBN	O
metformin	NNS	PM
and	CC	O
two	CD	O
(	(	O
out	IN	O
of	IN	O
14	CD	O
)	)	O
women	NNS	O
given	VBN	O
placebo	NNS	C
,	,	O
P=0.59	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Metformin	NNP	PM
is	VBZ	O
not	RB	O
always	RB	O
beneficial	JJ	O
when	WRB	O
given	VBN	O
to	TO	O
clomiphene	VB	O
resistant	JJ	O
infertile	JJ	O
women	NNS	O
with	IN	O
PCOS	NNP	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Allopurinol	NNP	PM
use	NN	O
yields	NNS	O
potentially	RB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
inflammatory	JJ	O
indices	NNS	O
in	IN	O
those	DT	O
with	IN	O
recent	JJ	O
ischemic	JJ	O
stroke	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Elevated	NNP	O
serum	NN	O
uric	JJ	O
acid	NN	O
level	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
poor	JJ	O
outcome	NN	O
and	CC	O
increased	VBD	O
risk	NN	O
of	IN	O
recurrent	NN	O
events	NNS	O
after	IN	O
stroke	NN	O
.	.	O

The	DT	O
xanthine	JJ	O
oxidase	NN	O
inhibitor	NN	O
allopurinol	NN	PM
lowers	NNS	O
uric	JJ	O
acid	NN	O
but	CC	O
also	RB	O
attenuates	VBZ	O
expression	NN	O
of	IN	O
inflammatory	JJ	O
adhesion	NN	O
molecules	NNS	O
in	IN	O
murine	NN	O
models	NNS	O
,	,	O
reduces	NNS	O
oxidative	VBP	O
stress	NN	O
in	IN	O
the	DT	O
vasculature	NN	O
,	,	O
and	CC	O
improves	VBZ	O
endothelial	JJ	O
function	NN	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
allopurinol	JJ	PM
alters	NNS	O
expression	NN	O
of	IN	O
inflammatory	NN	O
markers	NNS	O
after	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
effect	NN	O
of	IN	O
6	CD	PM
weeks	NNS	PM
'	POS	PM
treatment	NN	PM
with	IN	PM
high-	NN	PM
(	(	PM
300	CD	PM
mg	NN	PM
once	RB	PM
a	DT	PM
day	NN	PM
)	)	PM
or	CC	PM
low-	JJ	PM
(	(	PM
100	CD	PM
mg	NN	PM
once	RB	PM
a	DT	PM
day	NN	PM
)	)	PM
dose	NN	PM
allopurinol	NN	PM
on	IN	O
levels	NNS	O
of	IN	O
uric	JJ	O
acid	NN	O
and	CC	O
circulating	VBG	O
inflammatory	JJ	O
markers	NNS	O
after	IN	O
ischemic	JJ	O
stroke	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
enrolled	VBD	O
50	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
(	(	O
17	CD	O
,	,	O
17	CD	O
,	,	O
and	CC	O
16	CD	O
in	IN	O
the	DT	O
high	JJ	O
,	,	O
low	JJ	O
,	,	O
and	CC	O
placebo	NN	C
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Mean	NNP	O
(	(	O
+/-SD	NNP	O
)	)	O
age	NN	O
was	VBD	O
70	CD	O
(	(	O
+/-13	JJ	O
)	)	O
years	NNS	O
.	.	O

Groups	NNP	O
had	VBD	O
similar	JJ	O
characteristics	NNS	O
at	IN	O
baseline	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Uric	NNP	O
acid	NN	O
levels	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
at	IN	O
both	DT	O
7	CD	O
days	NNS	O
and	CC	O
6	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
by	IN	O
0.14	CD	O
mmol/L	NNS	O
at	IN	O
6	CD	O
weeks	NNS	O
,	,	O
P=0.002	NNP	O
)	)	O
.	.	O

Intercellular	JJ	O
adhesion	NN	O
molecule-1	JJ	O
concentration	NN	O
(	(	O
ng/mL	JJ	O
)	)	O
rose	VBD	O
by	IN	O
51.2	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
rose	VBD	O
slightly	RB	O
(	(	O
by	IN	O
10.6	CD	O
)	)	O
in	IN	O
the	DT	O
low-dose	JJ	O
allopurinol	NN	PM
group	NN	O
,	,	O
but	CC	O
fell	VBD	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
by	IN	O
2.6	CD	O
;	:	O
difference	NN	O
between	IN	O
groups	NNS	O
P=0.012	NNP	O
,	,	O
Kruskal-Wallis	NNP	O
test	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Allopurinol	NNP	PM
treatment	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
attenuates	VBZ	O
the	DT	O
rise	NN	O
in	IN	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
levels	NNS	O
seen	VBN	O
after	IN	O
stroke	NN	O
.	.	O

Uric	JJ	O
acid	NN	O
levels	NNS	O
were	VBD	O
lowered	VBN	O
with	IN	O
high	JJ	O
doses	NNS	O
.	.	O

These	DT	O
findings	NNS	O
support	NN	O
further	JJ	O
evaluation	NN	O
of	IN	O
allopurinol	NN	PM
as	IN	O
a	DT	O
preventive	JJ	O
measure	NN	O
after	IN	O
stroke	NN	O
.	.	O

Screening	VBG	PH
,	,	PH
brief	JJ	PH
intervention	NN	PH
,	,	PH
and	CC	PH
referral	JJ	PH
to	TO	PH
treatment	NN	PH
(	(	PH
SBIRT	NNP	PH
)	)	PH
in	IN	O
a	DT	O
Polish	JJ	O
emergency	NN	O
department	NN	O
:	:	O
three-month	JJ	O
outcomes	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
A	DT	O
randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
screening	NN	PH
,	,	PH
brief	JJ	PH
intervention	NN	PH
,	,	PH
and	CC	PH
referral	JJ	PH
to	TO	PH
treatment	NN	PH
(	(	PH
SBIRT	NNP	PH
)	)	PH
for	IN	O
drinking	NN	O
and	CC	O
related	JJ	O
problems	NNS	O
among	IN	O
at-risk	JJ	O
and	CC	O
dependent	JJ	O
drinkers	NNS	O
was	VBD	O
conducted	VBN	O
in	IN	O
an	DT	O
emergency	NN	O
department	NN	O
(	(	O
ED	NNP	O
)	)	O
in	IN	O
Sosnowiec	NNP	O
,	,	O
Poland	NNP	O
,	,	O
among	IN	O
patients	NNS	O
ages	VBZ	O
18	CD	O
years	NNS	O
and	CC	O
older	JJR	O
.	.	O

METHOD	NNP	O
Data	NNP	O
were	VBD	O
collected	VBN	O
over	IN	O
a	DT	O
23-week	JJ	O
period	NN	O
,	,	O
from	IN	O
4:00	CD	O
PM	NNP	O
to	TO	O
midnight	VB	O
,	,	O
and	CC	O
resulted	VBD	O
in	IN	O
446	CD	O
patients	NNS	O
being	VBG	O
recruited	VBN	O
into	IN	O
the	DT	O
study	NN	O
(	(	O
90	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
screened	VBD	O
positive	JJ	O
)	)	O
and	CC	O
randomized	VBN	O
to	TO	O
three	CD	O
conditions	NNS	O
following	VBG	O
a	DT	O
two-stage	JJ	O
process	NN	O
:	:	O
screened	VBN	PH
only	RB	PH
(	(	O
n	JJ	O
=	NNP	O
147	CD	O
)	)	O
,	,	O
assessed	VBN	E
(	(	O
n	JJ	O
=	NNP	O
152	CD	O
)	)	O
,	,	O
and	CC	O
received	VBN	PH
intervention	NN	PH
(	(	O
n	JJ	O
=	NNP	O
147	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
assessment	NN	O
(	(	O
85	CD	O
%	NN	O
)	)	O
and	CC	O
intervention	NN	PH
(	(	O
83	CD	O
%	NN	O
)	)	O
conditions	NNS	O
were	VBD	O
blindly	RB	O
reassessed	VBN	O
at	IN	O
3	CD	O
months	NNS	O
via	IN	O
a	DT	O
telephone	NN	O
interview	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
3-month	JJ	O
follow-up	NN	O
,	,	O
both	DT	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
the	DT	O
proportion	NN	O
who	WP	O
were	VBD	O
positive	JJ	O
for	IN	O
at-risk	JJ	O
drinking	NN	O
,	,	O
the	DT	O
primary	JJ	O
outcome	NN	O
variable	NN	O
.	.	O

Both	DT	O
groups	NNS	O
also	RB	O
showed	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
drinking	NN	O
days	NNS	O
per	IN	O
week	NN	O
,	,	O
drinks	NNS	O
per	IN	O
drinking	NN	O
day	NN	O
,	,	O
maximum	JJ	O
drinks	NNS	O
per	IN	O
occasion	NN	O
,	,	O
and	CC	O
negative	JJ	O
consequences	NNS	O
of	IN	O
drinking	NN	O
.	.	O

Using	VBG	O
analysis	NN	O
of	IN	O
covariance	NN	O
to	TO	O
control	VB	O
for	IN	O
baseline	NN	O
measures	NNS	O
and	CC	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
no	DT	O
difference	NN	O
in	IN	O
outcome	JJ	O
measures	NNS	O
was	VBD	O
found	VBN	O
between	IN	O
intervention	NN	Ot
and	CC	O
assessment	JJ	E
conditions	NNS	O
.	.	O

Subgroup	NNP	O
analysis	NN	O
found	VBD	O
some	DT	O
significant	JJ	O
interactions	NNS	O
between	IN	O
intervention	NN	PH
and	CC	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
main	JJ	O
findings	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
from	IN	O
other	JJ	O
brief-intervention	NN	O
studies	NNS	O
in	IN	O
Western	JJ	O
cultures	NNS	O
,	,	O
findings	NNS	O
here	RB	O
also	RB	O
suggest	VBP	O
that	IN	O
intervention	NN	O
may	MD	O
have	VB	O
differential	JJ	O
benefits	NNS	O
for	IN	O
specific	JJ	O
subgroups	NNS	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
ED	NNP	O
,	,	O
an	DT	O
area	NN	O
of	IN	O
research	NN	O
that	WDT	O
may	MD	O
warrant	VB	O
additional	JJ	O
study	NN	O
of	IN	O
brief	JJ	O
intervention	NN	O
in	IN	O
the	DT	O
ED	NNP	O
setting	NN	O
.	.	O

Effect	NN	O
of	IN	O
pravastatin	NN	PM
on	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
women	NNS	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
:	:	O
the	DT	O
cholesterol	NN	O
and	CC	O
recurrent	JJ	O
events	NNS	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
pravastatin	NN	PM
on	IN	O
recurrent	NN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
women	NNS	O
with	IN	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Little	JJ	O
information	NN	O
is	VBZ	O
available	JJ	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
lipid	JJ	O
lowering	VBG	O
in	IN	O
secondary	JJ	O
prevention	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
in	IN	O
women	NNS	O
;	:	O
in	IN	O
particular	JJ	O
,	,	O
those	DT	O
with	IN	O
CHD	NNP	O
and	CC	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
the	DT	O
Cholesterol	NNP	O
and	CC	O
Recurrent	NNP	O
Events	NNP	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
,	,	O
576	CD	O
postmenopausal	NN	O
women	NNS	O
,	,	O
between	IN	O
3	CD	O
and	CC	O
20	CD	O
months	NNS	O
after	IN	O
MI	NNP	O
,	,	O
with	IN	O
a	DT	O
total	JJ	O
cholesterol	NN	O
level	NN	O
<	VBD	O
240	CD	O
mg/dl	NN	O
and	CC	O
a	DT	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
level	NN	O
115	CD	O
to	TO	O
174	CD	O
mg/dl	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
pravastatin	NN	PM
40	CD	PM
mg/day	NN	PM
or	CC	O
matching	VBG	O
placebo	NN	C
for	IN	O
a	DT	O
median	JJ	O
follow-up	JJ	O
period	NN	O
of	IN	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
combined	VBN	O
coronary	JJ	O
events	NNS	O
(	(	O
coronary	JJ	O
death	NN	O
,	,	O
nonfatal	JJ	O
MI	NNP	O
,	,	O
percutaneous	JJ	O
transluminal	JJ	O
coronary	NN	O
angioplasty	NN	O
[	NNP	O
PTCA	NNP	O
]	NNP	O
or	CC	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
[	NNP	O
CABG	NNP	O
]	NNP	O
)	)	O
,	,	O
the	DT	O
primary	JJ	O
trial	NN	O
end	NN	O
point	NN	O
(	(	O
coronary	JJ	O
death	NN	O
or	CC	O
nonfatal	JJ	O
MI	NNP	O
)	)	O
and	CC	O
stroke	NN	O
.	.	O

RESULTS	NNP	O
Women	NNP	O
treated	VBD	O
with	IN	O
pravastatin	NN	O
had	VBD	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
43	CD	O
%	NN	O
for	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.035	CD	O
)	)	O
,	,	O
46	CD	O
%	NN	O
for	IN	O
combined	JJ	O
coronary	JJ	O
events	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
48	CD	O
%	NN	O
for	IN	O
PTCA	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.025	CD	O
)	)	O
,	,	O
40	CD	O
%	NN	O
for	IN	O
CABG	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.14	CD	O
)	)	O
and	CC	O
56	CD	O
%	NN	O
for	IN	O
stroke	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

The	DT	O
3,583	CD	O
men	NNS	O
in	IN	O
the	DT	O
CARE	NNP	O
trial	NN	O
also	RB	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
risk	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
tended	VBD	O
to	TO	O
be	VB	O
less	JJR	O
.	.	O

Pravastatin	NNP	PM
improved	VBD	O
plasma	JJ	O
lipids	NNS	O
similarly	RB	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
risk	NN	O
of	IN	O
coronary	JJ	O
events	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
between	IN	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

Minor	JJ	O
differences	NNS	O
between	IN	O
men	NNS	O
and	CC	O
women	NNS	O
were	VBD	O
present	JJ	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
and	CC	O
treatment	NN	O
for	IN	O
MI	NNP	O
,	,	O
in	IN	O
general	JJ	O
,	,	O
conferring	VBG	O
a	DT	O
higher	JJR	O
risk	NN	O
status	NN	O
and	CC	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
CABG	NNP	O
in	IN	O
the	DT	O
women	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Pravastatin	NNP	PM
led	VBD	O
to	TO	O
significant	JJ	O
early	JJ	O
reduction	NN	O
of	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
post-MI	JJ	O
women	NNS	O
with	IN	O
average	JJ	O
cholesterol	NN	O
levels	NNS	O
.	.	O

Penetration	NN	O
and	CC	O
accumulation	NN	O
of	IN	O
moxifloxacin	NN	PM
in	IN	O
uterine	JJ	O
tissue	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
moxifloxacin	NN	PM
penetrates	VBZ	O
the	DT	O
uterine	JJ	O
tissue	NN	O
and	CC	O
accumulates	NNS	O
at	IN	O
levels	NNS	O
sufficient	JJ	O
to	TO	O
eradicate	VB	O
the	DT	O
major	JJ	O
pathogens	NNS	O
causing	VBG	O
pelvic	JJ	O
inflammatory	JJ	O
disease	NN	O
(	(	O
PID	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
multicenter	NN	O
,	,	O
open-label	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
we	PRP	O
determined	VBD	O
the	DT	O
concentration	NN	O
of	IN	O
moxifloxacin	NN	O
in	IN	O
plasma	NN	O
and	CC	O
uterine	JJ	O
tissue	NN	O
after	IN	O
a	DT	O
single	JJ	O
,	,	O
400-mg	JJ	PM
intravenous	JJ	PM
dose	NN	PM
of	IN	PM
moxifloxacin	NN	PM
.	.	O

Study	NN	O
participants	NNS	O
were	VBD	O
randomized	VBN	O
for	IN	O
time	NN	O
of	IN	O
tissue	NN	O
sampling	NN	O
,	,	O
which	WDT	O
was	VBD	O
performed	VBN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
7	CD	O
,	,	O
or	CC	O
24	CD	O
hours	NNS	O
following	VBG	O
the	DT	O
moxifloxacin	JJ	PM
infusion	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
43	CD	O
participants	NNS	O
,	,	O
40	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
tissue	VB	O
sampling	VBG	O
.	.	O

Moxifloxacin	NNP	O
accumulated	VBD	O
in	IN	O
uterine	JJ	O
tissue	NN	O
and	CC	O
concentrations	NNS	O
were	VBD	O
highest	JJS	O
1	CD	O
hour	NN	O
after	IN	O
infusion	NN	O
in	IN	O
both	DT	O
plasma	NN	O
and	CC	O
tissue	NN	O
.	.	O

Tissue	NN	O
to	TO	O
plasma	VB	O
ratios	NNS	O
remained	VBD	O
between	IN	O
1.7	CD	O
and	CC	O
2.1	CD	O
for	IN	O
24	CD	O
hours	NNS	O
.	.	O

Moxifloxacin	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	NNP	O
Based	VBD	O
on	IN	O
known	VBN	O
minimum	JJ	O
inhibitory	JJ	O
concentration	NN	O
data	NNS	O
,	,	O
the	DT	O
uterine	JJ	O
tissue	NN	O
concentrations	NNS	O
of	IN	O
moxifloxacin	NN	O
achieved	VBN	O
over	IN	O
24	CD	O
hours	NNS	O
would	MD	O
be	VB	O
sufficient	JJ	O
to	TO	O
eradicate	VB	O
the	DT	O
range	NN	O
of	IN	O
bacterial	JJ	O
pathogens	NNS	O
responsible	JJ	O
for	IN	O
PID	NNP	O
.	.	O

Sublingual	JJ	O
administration	NN	O
of	IN	O
micronized	JJ	PM
estradiol	NN	PM
and	CC	O
progesterone	NN	PM
,	,	O
with	IN	O
and	CC	O
without	IN	O
micronized	VBN	PM
testosterone	NN	PM
:	:	O
effect	NN	O
on	IN	O
biochemical	JJ	O
markers	NNS	O
of	IN	O
bone	NN	O
metabolism	NN	O
and	CC	O
bone	JJ	O
mineral	JJ	O
density	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
investigation	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
relative	JJ	O
efficacy	NN	O
of	IN	O
the	DT	O
sublingual	JJ	O
administration	NN	O
of	IN	O
micronized	JJ	PM
estradiol	NN	PM
(	(	PM
E2	NNP	PM
)	)	PM
,	,	O
progesterone	NN	PM
(	(	PM
P4	NNP	PM
)	)	PM
,	,	O
and	CC	O
testosterone	NN	PM
(	(	PM
T	NNP	PM
)	)	PM
on	IN	O
bone	NN	O
mineral	JJ	O
density	NN	O
and	CC	O
biochemical	JJ	O
markers	NNS	O
of	IN	O
bone	NN	O
metabolism	NN	O
.	.	O

DESIGN	NN	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
prospective	JJ	O
study	NN	O
,	,	O
postmenopausal	JJ	O
women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
hysterectomized	VBN	O
women	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	DT	O
1	CD	O
)	)	O
micronized	VBN	PM
E2	NNP	PM
(	(	O
0.5	CD	O
mg	NN	O
)	)	O
or	CC	O
2	CD	O
)	)	O
micronized	VBN	PM
E2	NNP	PM
(	(	O
0.5	CD	O
mg	NN	O
)	)	O
+	VBZ	O
micronized	VBN	PM
T	NNP	PM
(	(	O
1.25	CD	O
mg	NN	O
)	)	O
.	.	O

Women	NNS	O
with	IN	O
intact	JJ	O
uteri	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	DT	O
3	CD	O
)	)	O
micronized	VBN	PM
E2	NNP	PM
(	(	O
0.5	CD	O
mg	NN	O
)	)	O
+	VBZ	O
micronized	VBN	PM
P4	NNP	PM
(	(	O
100	CD	O
mg	NN	O
)	)	O
or	CC	O
4	CD	O
)	)	O
micronized	VBN	PM
E2	NNP	PM
(	(	O
0.5	CD	O
mg	NN	O
)	)	O
+	VBZ	PM
micronized	VBN	PM
P4	NNP	PM
(	(	O
100	CD	O
mcg	NN	O
)	)	O
+	VBZ	PM
micronized	VBN	PM
T	NNP	PM
(	(	O
1.25	CD	O
mg	NN	O
)	)	O
.	.	O

For	IN	O
the	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
,	,	O
the	DT	O
four	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
combined	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
for	IN	O
all	DT	O
comparisons	NNS	O
.	.	O

The	DT	O
E2	NNP	PM
and	CC	O
E2+P4	NNP	PM
groups	NNS	O
were	VBD	O
combined	VBN	O
into	IN	O
the	DT	O
HRT	NNP	O
alone	RB	O
group	NN	O
(	(	O
n=30	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
E2+T	NNP	PM
and	CC	O
E2+P4+T	NNP	PM
groups	NNS	O
were	VBD	O
combined	VBN	O
into	IN	O
the	DT	O
HRT	NNP	PM
+	NNP	PM
T	NNP	PM
group	NN	O
(	(	O
n=27	RB	O
)	)	O
.	.	O

Hormones	NNPS	O
were	VBD	O
administered	VBN	O
sublingually	RB	O
as	IN	O
a	DT	O
single	JJ	O
tablet	NN	O
twice	RB	O
a	DT	O
day	NN	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

Bone	NNP	O
mineral	JJ	O
density	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
the	DT	O
anterior-posterior	JJ	O
lumbar	NN	O
spine	NN	O
and	CC	O
total	JJ	O
left	JJ	O
hip	NN	O
via	IN	O
dual	JJ	O
energy	NN	O
x-ray	JJ	O
absorptiometry	NN	O
.	.	O

Bone	NNP	O
metabolism	NN	O
was	VBD	O
assessed	VBN	O
via	IN	O
serum	JJ	O
bone-specific	JJ	O
alkaline	NN	O
phosphatase	NN	O
and	CC	O
urinary	JJ	O
deoxypyridinoline	NN	O
and	CC	O
cross-linked	JJ	O
N-telopeptide	NNP	O
of	IN	O
type	NN	O
I	PRP	O
collagen	VBP	O
,	,	O
both	DT	O
normalized	VBN	O
to	TO	O
creatinine	VB	O
.	.	O

Data	NNP	O
were	VBD	O
analyzed	VBN	O
via	IN	O
a	DT	O
repeated	JJ	O
measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
and	CC	O
a	DT	O
Student	NN	O
's	POS	O
t	JJ	O
test	NN	O
(	(	O
alpha=0.05	NN	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
subjects	NNS	O
were	VBD	O
of	IN	O
similar	JJ	O
age	NN	O
(	(	O
54.0	CD	O
+/-	JJ	O
0.8	CD	O
years	NNS	O
)	)	O
,	,	O
height	VBD	O
(	(	O
64.0	CD	O
+/-	JJ	O
0.3	CD	O
in	IN	O
)	)	O
,	,	O
weight	VBD	O
(	(	O
157.6	CD	O
+/-	JJ	O
4.2	CD	O
lb	NN	O
)	)	O
,	,	O
and	CC	O
had	VBD	O
similar	JJ	O
baseline	NN	O
follicle-stimulating	NN	O
hormone	NN	O
(	(	O
66.4	CD	O
+/-	JJ	O
3.2	CD	O
mIU/L	NN	O
)	)	O
,	,	O
E2	NNP	O
(	(	O
26.4	CD	O
+/-	JJ	O
1.5	CD	O
pg/ml	NN	O
)	)	O
,	,	O
P4	NNP	O
(	(	O
0.3	CD	O
+/-	JJ	O
0.1	CD	O
ng/ml	NN	O
)	)	O
,	,	O
total	JJ	O
T	NNP	O
(	(	O
19.0	CD	O
+/-	JJ	O
1.5	CD	O
ng/dL	NN	O
)	)	O
,	,	O
and	CC	O
bioavailable	JJ	O
T	NNP	O
(	(	O
3.7	CD	O
+/-	JJ	O
0.3	CD	O
ng/dL	NN	O
)	)	O
levels	NNS	O
.	.	O

During	IN	O
therapy	NN	O
,	,	O
serum	NN	O
levels	NNS	O
increased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
each	DT	O
hormone	NN	O
.	.	O

Bone	NNP	O
mineral	JJ	O
density	NN	O
and	CC	O
bone	NN	O
markers	NNS	O
at	IN	O
baseline	NN	O
were	VBD	O
similar	JJ	O
for	IN	O
each	DT	O
treatment	NN	O
group	NN	O
.	.	O

Bone-specific	JJ	O
alkaline	JJ	O
phosphatase	NN	O
decreased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
by	IN	O
-14.3	JJ	O
+/-	JJ	O
4.1	CD	O
%	NN	O
in	IN	O
the	DT	O
HRT	NNP	PM
alone	RB	O
group	NN	O
and	CC	O
by	IN	O
-8.2	NNP	O
+/-	JJ	O
4.6	CD	O
%	NN	O
in	IN	O
the	DT	O
HRT	NNP	PM
+	NNP	PM
T	NNP	PM
group	NN	O
.	.	O

Deoxypyridinoline	NNP	O
levels	NNS	O
decreased	VBN	O
significantly	RB	O
in	IN	O
the	DT	O
HRT	NNP	PM
alone	RB	PM
and	CC	O
HRT	NNP	PM
+	NNP	PM
T	NNP	PM
groups	NNS	O
,	,	O
-	:	O
14.4	CD	O
+/-	JJ	O
6.8	CD	O
%	NN	O
and	CC	O
-26.9	JJ	O
+/-	JJ	O
7.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Significant	JJ	O
reductions	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
cross-linked	JJ	O
N-telopeptide	NNP	O
of	IN	O
type	NN	O
I	PRP	O
collagen	VBP	O
were	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
-24.4	VBD	O
+/-	JJ	O
6.5	CD	O
%	NN	O
and	CC	O
-39.5	JJ	O
+/-	JJ	O
8.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Bone	NNP	O
mineral	JJ	O
density	NN	O
in	IN	O
the	DT	O
lumbar	NN	O
spine	NN	O
increased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
by	IN	O
+2.2	JJ	O
+/-	JJ	O
0.5	CD	O
%	NN	O
the	DT	O
HRT	NNP	PM
alone	RB	PM
group	NN	O
and	CC	O
by	IN	O
+	JJ	O
1.8	CD	O
+/-	JJ	O
0.6	CD	O
%	NN	O
in	IN	O
the	DT	O
HRT	NNP	PM
+	NNP	PM
T	NNP	PM
group	NN	O
.	.	O

Total	JJ	O
hip	NN	O
bone	NN	O
mineral	JJ	O
density	NN	O
was	VBD	O
maintained	VBN	O
in	IN	O
the	DT	O
HRT	NNP	PM
alone	RB	PM
group	NN	O
(	(	O
+0.4	JJ	O
+/-	JJ	O
0.4	CD	O
%	NN	O
)	)	O
and	CC	O
increased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
HRT	NNP	PM
+	NNP	PM
T	NNP	PM
group	NN	O
(	(	O
+	JJ	O
1.8	CD	O
+/-	JJ	O
0.5	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Sublingual	NNP	O
micronized	VBD	O
HRT	NNP	PM
favorably	RB	O
decreases	VBZ	O
serum	NN	O
and	CC	O
urine	JJ	O
markers	NNS	O
of	IN	O
bone	NN	O
metabolism	NN	O
,	,	O
prevents	VBZ	O
bone	JJ	O
loss	NN	O
,	,	O
and	CC	O
results	NNS	O
in	IN	O
a	DT	O
slight	JJ	O
increase	NN	O
in	IN	O
spine	NN	O
and	CC	O
hip	NN	O
bone	NN	O
mineral	JJ	O
density	NN	O
.	.	O

Although	IN	O
the	DT	O
addition	NN	O
of	IN	O
testosterone	NN	O
to	TO	O
HRT	NNP	PM
for	IN	O
1	CD	O
year	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
added	JJ	O
benefit	NN	O
to	TO	O
the	DT	O
spine	NN	O
bone	NN	O
mineral	JJ	O
density	NN	O
,	,	O
it	PRP	O
did	VBD	O
result	VB	O
in	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
hip	NN	O
bone	NN	O
mineral	JJ	O
density	NN	O
.	.	O

Longer	JJR	O
duration	NN	O
of	IN	O
therapy	NN	O
may	MD	O
have	VB	O
further	JJR	O
improved	VBN	O
these	DT	O
outcomes	NNS	O
.	.	O

Transitions	NNS	O
during	IN	O
effective	JJ	O
treatment	NN	O
for	IN	O
cocaine-abusing	JJ	O
homeless	JJ	O
persons	NNS	O
:	:	O
establishing	VBG	O
abstinence	NN	O
,	,	O
lapse	NN	O
,	,	O
and	CC	O
relapse	NN	O
,	,	O
and	CC	O
reestablishing	VBG	O
abstinence	NN	O
.	.	O

Data	NNS	O
are	VBP	O
reported	VBN	O
on	IN	O
drug	NN	O
use	NN	O
among	IN	O
cocaine-dependent	JJ	O
homeless	NN	O
persons	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
that	WDT	O
compared	VBN	O
day	NN	C
treatment	NN	C
only	RB	C
(	(	O
DT	NNP	O
,	,	O
n	JJ	O
=	NNP	O
69	CD	O
)	)	O
with	IN	O
day	NN	C
treatment	NN	C
plus	CC	O
abstinent-contingent	JJ	C
housing	NN	C
and	CC	C
work	NN	C
(	(	O
DT+	NNP	O
,	,	O
n	JJ	O
=	NNP	O
72	CD	O
)	)	O
.	.	O

Drug	NNP	O
use	NN	O
was	VBD	O
measured	VBN	O
with	IN	O
multiple	JJ	O
weekly	JJ	O
urine	NN	O
toxicologies	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
DT	NNP	O
participants	NNS	O
,	,	O
more	JJR	O
DT+	JJ	O
participants	NNS	O
established	VBN	O
abstinence	NN	E
,	,	O
maintained	VBD	O
abstinence	NN	O
for	IN	O
longer	JJR	O
durations	NNS	O
,	,	O
were	VBD	O
marginally	RB	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
lapse	VB	O
,	,	O
and	CC	O
significantly	RB	O
less	RBR	O
likely	JJ	O
to	TO	O
relapse	VB	O
.	.	O

Of	IN	O
all	DT	O
participants	NNS	O
who	WP	O
established	VBD	O
abstinence	NN	O
and	CC	O
then	RB	O
relapsed	VBD	O
,	,	O
DT+	NNP	O
participants	NNS	O
relapsed	VBD	O
later	RB	O
and	CC	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
reestablish	VB	O
abstinence	NN	O
.	.	O

These	DT	O
analyses	NNS	O
yield	VBP	O
information	NN	O
on	IN	O
the	DT	O
processes	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
manner	NN	O
in	IN	O
which	WDT	O
drug	NN	O
use	NN	O
changes	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
abstinent-contingent	JJ	E
housing	NN	E
and	CC	E
work	NN	E
.	.	O

Olanzapine	NNP	PM
versus	NN	O
haloperidol	NN	PM
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
:	:	O
an	DT	O
open	JJ	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
Conventional	NNP	O
neuroleptics	NNS	PM
ameliorate	VBP	O
symptoms	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
;	:	O
however	RB	O
,	,	O
they	PRP	O
are	VBP	O
known	VBN	O
to	TO	O
cause	VB	O
dyskinesias	NN	O
.	.	O

Atypical	JJ	PM
neuroleptics	NNS	PM
,	,	O
including	VBG	O
olanzapine	NN	O
,	,	O
may	MD	O
have	VB	O
less	JJR	O
risk	NN	O
for	IN	O
dyskinesia	NN	O
,	,	O
but	CC	O
their	PRP$	O
efficacy	NN	O
in	IN	O
autistic	JJ	O
disorder	NN	O
is	VBZ	O
not	RB	O
established	VBN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
and	CC	O
effectiveness	NN	O
of	IN	O
open-label	JJ	O
olanzapine	NN	PM
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
by	IN	O
using	VBG	O
haloperidol	NN	PM
as	IN	O
a	DT	O
standard	JJ	O
comparator	NN	O
treatment	NN	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
parallel	JJ	O
groups	NNS	O
design	NN	O
,	,	O
12	CD	O
children	NNS	O
with	IN	O
DSM-IV	NNP	O
autistic	JJ	O
disorder	NN	O
(	(	O
mean	JJ	O
age	NN	O
7.8+/-2.1	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
6	CD	O
weeks	NNS	O
of	IN	O
open	JJ	PM
treatment	NN	PM
with	IN	PM
olanzapine	NN	PM
or	CC	O
haloperidol	NN	PM
.	.	O

Mean	NNP	O
final	JJ	O
dosages	NNS	O
were	VBD	O
7.9+/-2.5	JJ	O
mg/day	NN	O
for	IN	O
olanzapine	NN	PM
and	CC	O
1.4+/-0.7	JJ	O
mg/day	NN	O
for	IN	O
haloperidol	NN	PM
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
(	(	O
CGI	NNP	O
)	)	O
and	CC	O
the	DT	O
Children	NNP	O
's	POS	O
Psychiatric	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
CPRS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
had	VBD	O
symptom	VBN	O
reduction	NN	O
.	.	O

Five	CD	O
of	IN	O
six	CD	O
in	IN	O
the	DT	O
olanzapine	NN	PM
group	NN	O
and	CC	O
three	CD	O
of	IN	O
six	CD	O
in	IN	O
the	DT	O
haloperidol	NN	PM
group	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
responders	NNS	O
according	VBG	O
to	TO	O
the	DT	O
CGI	NNP	O
Improvement	NNP	O
item	NN	O
.	.	O

Subjects	NNS	O
showed	VBD	O
improvement	NN	O
on	IN	O
the	DT	O
CPRS	NNP	O
Autism	NNP	O
Factor	NNP	O
(	(	O
F1,9	NNP	O
=	NNP	O
24.4	CD	O
,	,	O
p	NN	O
=	NNP	O
.0008	NNP	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
included	VBD	O
drowsiness	NN	O
and	CC	O
weight	JJ	O
gain	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
olanzapine	NN	PM
is	VBZ	O
a	DT	O
promising	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Further	JJ	O
placebo-controlled	JJ	O
and	CC	O
long-term	JJ	O
studies	NNS	O
of	IN	O
olanzapine	NN	PM
in	IN	O
autistic	JJ	O
disorder	NN	O
are	VBP	O
required	VBN	O
.	.	O

Combination	NNP	O
hydrocodone	NN	PM
and	CC	PM
ibuprofen	JJ	PM
versus	NN	O
combination	NN	O
codeine	NN	PM
and	CC	PM
acetaminophen	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
pain	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
combination	NN	O
hydrocodone	NN	PM
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	PM
200	CD	O
mg	NN	O
with	IN	O
that	DT	O
of	IN	O
combination	NN	O
codeine	NN	PM
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	PM
300	CD	O
mg	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
pain	NN	O
.	.	O

BACKGROUND	NNP	O
Hydrocodone	NNP	PM
7.5	CD	O
mg	NN	O
with	IN	O
ibuprofen	JJ	PM
200	CD	O
mg	NN	O
is	VBZ	O
the	DT	O
only	JJ	O
approved	VBD	O
fixed-dose	JJ	O
combination	NN	O
analgesic	IN	O
containing	VBG	O
an	DT	O
opioid	NN	O
and	CC	O
ibuprofen	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
repeated-dose	JJ	O
,	,	O
active-comparator	JJ	O
,	,	O
4-week	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
,	,	O
469	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
1-tablet	JJ	O
(	(	O
n	JJ	O
=	NNP	O
156	CD	O
)	)	O
or	CC	O
2-tablet	JJ	O
(	(	O
n	JJ	O
=	NNP	O
153	CD	O
)	)	O
dose	NN	O
of	IN	O
combination	NN	PM
hydrocodone	NN	PM
7.5	CD	PM
mg	NN	PM
and	CC	PM
ibuprofen	$	PM
200	CD	PM
mg	NN	PM
(	(	O
HI1	NNP	O
and	CC	O
HI2	NNP	O
,	,	O
respectively	RB	O
)	)	O
or	CC	O
a	DT	O
2-tablet	JJ	O
dose	NN	O
of	IN	O
combination	NN	O
codeine	NN	PM
30	CD	PM
mg	NN	PM
and	CC	PM
acetaminophen	$	PM
300	CD	PM
mg	NN	PM
(	(	O
CA	NNP	O
,	,	O
n	RB	O
=	VBZ	O
160	CD	O
)	)	O
,	,	O
the	DT	O
active	JJ	O
comparator	NN	O
,	,	O
every	DT	O
6	CD	O
to	TO	O
8	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Efficacy	NN	O
was	VBD	O
measured	VBN	O
through	IN	O
pain	NN	O
relief	NN	O
scores	NNS	O
,	,	O
number	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
study	NN	O
medication	NN	O
,	,	O
number	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
supplemental	JJ	O
analgesics	NNS	O
,	,	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
discontinued	VBD	O
therapy	NN	O
due	JJ	O
to	TO	O
an	DT	O
unsatisfactory	JJ	O
analgesic	JJ	O
response	NN	O
,	,	O
and	CC	O
global	JJ	O
assessment	NN	O
scores	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
469	CD	O
patients	NNS	O
,	,	O
255	CD	O
(	(	O
54.4	CD	O
%	NN	O
)	)	O
were	VBD	O
female	JJ	O
and	CC	O
214	CD	O
(	(	O
45.6	CD	O
%	NN	O
)	)	O
were	VBD	O
male	JJ	O
.	.	O

The	DT	O
mean	JJ	O
age	NN	O
was	VBD	O
51.1	CD	O
years	NNS	O
.	.	O

Types	NNS	O
of	IN	O
chronic	NN	O
pain	NN	O
included	VBD	O
back	RB	O
(	(	O
214	CD	O
;	:	O
45.6	CD	O
%	NN	O
)	)	O
,	,	O
arthritic	JJ	O
(	(	O
145	CD	O
;	:	O
30.9	CD	O
%	NN	O
)	)	O
,	,	O
other	JJ	O
musculoskeletal	NN	O
(	(	O
65	CD	O
;	:	O
13.9	CD	O
%	NN	O
)	)	O
,	,	O
cancer	NN	O
(	(	O
6	CD	O
;	:	O
1.3	CD	O
%	NN	O
)	)	O
,	,	O
diabetic	JJ	O
neuropathic	NN	O
(	(	O
3	CD	O
;	:	O
0.6	CD	O
%	NN	O
)	)	O
,	,	O
postherpetic	JJ	O
neuralgic	NN	O
(	(	O
5	CD	O
;	:	O
1.1	CD	O
%	NN	O
)	)	O
,	,	O
other	JJ	O
neurologic	NN	O
(	(	O
21	CD	O
;	:	O
4.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
other	JJ	O
unclassified	JJ	O
chronic	JJ	O
pain	NN	O
(	(	O
10	CD	O
;	:	O
2.1	CD	O
%	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
48	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
the	DT	O
study	NN	O
,	,	O
351	CD	O
(	(	O
74.8	CD	O
%	NN	O
)	)	O
patients	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
opioid	JJ	O
or	CC	O
opioid-nonopioid	JJ	O
combination	NN	O
analgesics	NNS	O
.	.	O

The	DT	O
overall	JJ	O
mean	JJ	O
daily	JJ	O
pain	NN	O
relief	NN	O
score	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2.25+/-0.89	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
1.98+/-0.87	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
or	CC	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
1.85+/-0.96	JJ	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
mean	JJ	O
number	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
study	NN	O
medication	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2.94+/-0.99	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
3.23+/-0.76	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.036	CD	O
)	)	O
or	CC	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
3.26+/-0.75	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.014	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
mean	JJ	O
number	NN	O
of	IN	O
daily	JJ	O
doses	NNS	O
of	IN	O
supplemental	JJ	O
analgesics	NNS	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
0.24+/-0.49	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
0.34+/-0.58	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
or	CC	O
CA	NNP	O
group	NN	O
(	(	O
0.49+/-0.85	JJ	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.010	CD	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
discontinued	VBD	O
treatment	NN	O
due	JJ	O
to	TO	O
an	DT	O
unsatisfactory	JJ	O
analgesic	JJ	O
response	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
2	CD	O
;	:	O
1.3	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
CA	NNP	O
group	NN	O
(	(	O
12	CD	O
;	:	O
7.5	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

HI2	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
as	IN	O
measured	VBN	O
by	IN	O
pain	NN	O
relief	NN	O
scores	NNS	O
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
,	,	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
,	,	O
and	CC	O
week	NN	O
3	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.008	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
;	:	O
daily	JJ	O
doses	NNS	O
of	IN	O
study	NN	O
medication	NN	O
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.019	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
=	NNP	O
0.011	CD	O
vs	NN	O
CA	NNP	O
)	)	O
;	:	O
daily	JJ	O
doses	NNS	O
of	IN	O
supplemental	JJ	O
analgesics	NNS	O
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.010	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
)	)	O
;	:	O
and	CC	O
global	JJ	O
assessment	NN	O
scores	NNS	O
for	IN	O
week	NN	O
1	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.018	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
,	,	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.005	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
0.001	CD	O
vs	NN	O
CA	NNP	O
)	)	O
,	,	O
and	CC	O
week	NN	O
4	CD	O
(	(	O
P	NNP	O
=	VBZ	O
0.013	CD	O
vs	NN	O
HI1	NNP	O
and	CC	O
P	NNP	O
=	NNP	O
0.023	CD	O
vs	NN	O
CA	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
HI1	NNP	O
and	CC	O
CA	NNP	O
in	IN	O
any	DT	O
efficacy	NN	O
variable	JJ	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
experiencing	VBG	O
adverse	JJ	O
events	NNS	O
in	IN	O
the	DT	O
HI2	NNP	O
(	(	O
127	CD	O
;	:	O
83	CD	O
%	NN	O
)	)	O
,	,	O
HI1	NNP	O
(	(	O
124	CD	O
;	:	O
79.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
CA	NNP	O
(	(	O
129	CD	O
;	:	O
80.6	CD	O
%	NN	O
)	)	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
mean	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
discontinued	VBD	O
treatment	NN	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
HI2	NNP	O
group	NN	O
(	(	O
40	CD	O
;	:	O
26.1	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
HI1	NNP	O
group	NN	O
(	(	O
23	CD	O
;	:	O
14.7	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
hydrocodone	NN	PM
7.5	CD	O
mg	NN	O
and	CC	O
ibuprofen	$	PM
200	CD	O
mg	NN	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
either	DT	O
1-tablet	JJ	O
doses	NNS	O
of	IN	O
this	DT	O
combination	NN	O
or	CC	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
codeine	NN	PM
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	PM
300	CD	O
mg	NN	O
.	.	O

Moreover	RB	O
,	,	O
1-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	PM
hydrocodone	NN	PM
7.5	CD	PM
mg	NN	PM
and	CC	PM
ibuprofen	$	PM
200	CD	O
mg	NN	O
may	MD	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
2-tablet	JJ	O
doses	NNS	O
of	IN	O
combination	NN	O
codeine	NN	PM
30	CD	O
mg	NN	O
and	CC	O
acetaminophen	$	PM
300	CD	O
mg	NN	O
.	.	O

Partial-area	JJ	O
method	NN	O
in	IN	O
bioequivalence	NN	O
assessment	NN	O
:	:	O
naproxen	NN	PM
.	.	O

Regulatory	NNP	O
authorities	NNS	O
require	VBP	O
demonstration	NN	O
of	IN	O
bioequivalence	NN	O
through	IN	O
comparisons	NNS	O
of	IN	O
different	JJ	O
pharmacokinetic	JJ	O
parameters	NNS	O
,	,	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
plasma	JJ	O
concentration-time	JJ	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
,	,	O
the	DT	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
reach	VB	O
peak	JJ	O
concentration	NN	O
(	(	O
Tmax	NNP	O
)	)	O
.	.	O

The	DT	O
applicability	NN	O
and	CC	O
validity	NN	O
of	IN	O
regulatory	JJ	O
requirements	NNS	O
have	VBP	O
been	VBN	O
widely	RB	O
criticized	VBN	O
on	IN	O
statistical	JJ	O
and	CC	O
clinical	JJ	O
relevance	NN	O
grounds	NNS	O
.	.	O

For	IN	O
most	JJS	O
noncomplicated	JJ	O
absorption	NN	O
models	NNS	O
,	,	O
the	DT	O
AUC	NNP	O
correlates	VBZ	O
well	RB	O
with	IN	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
nonlinear	JJ	O
models	NNS	O
of	IN	O
absorption	NN	O
,	,	O
in	IN	O
mechanisms	NN	O
involving	VBG	O
recycling	NN	O
of	IN	O
drugs	NNS	O
,	,	O
and	CC	O
for	IN	O
drugs	NNS	O
with	IN	O
long	JJ	O
half-life	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
(	(	O
from	IN	O
zero	CD	O
to	TO	O
infinity	NN	O
)	)	O
can	MD	O
give	VB	O
erroneous	JJ	O
and	CC	O
clinically	RB	O
irrelevant	JJ	O
results	NNS	O
since	IN	O
the	DT	O
area	NN	O
is	VBZ	O
mostly	RB	O
determined	VBN	O
by	IN	O
elimination	NN	O
phase	NN	O
or	CC	O
by	IN	O
recycling	VBG	O
.	.	O

The	DT	O
calculation	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
also	RB	O
involves	VBZ	O
prolonged	JJ	O
sampling	NN	O
,	,	O
adding	VBG	O
to	TO	O
the	DT	O
cost	NN	O
and	CC	O
risks	NNS	O
associated	VBN	O
with	IN	O
bioequivalence	NN	O
studies	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
Cmax	NNP	O
or	CC	O
Tmax	NNP	O
as	IN	O
a	DT	O
measure	NN	O
of	IN	O
rate	NN	O
of	IN	O
absorption	NN	O
,	,	O
to	TO	O
correlate	VB	O
with	IN	O
clinical	JJ	O
relevance	NN	O
,	,	O
is	VBZ	O
widely	RB	O
criticized	VBN	O
on	IN	O
logical	JJ	O
,	,	O
technical	JJ	O
,	,	O
and	CC	O
statistical	JJ	O
grounds	NNS	O
.	.	O

For	IN	O
drugs	NNS	O
used	VBN	O
on	IN	O
a	DT	O
multiple-dose	JJ	O
basis	NN	O
,	,	O
Cmax	NNP	O
and	CC	O
Tmax	NNP	O
evaluations	NNS	O
become	VBP	O
redundant	JJ	O
since	IN	O
the	DT	O
average	JJ	O
plateau	NN	O
concentration	NN	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
these	DT	O
parameters	NNS	O
.	.	O

To	TO	O
resolve	VB	O
the	DT	O
drawbacks	NNS	O
in	IN	O
the	DT	O
traditional	JJ	O
methodology	NN	O
of	IN	O
bioequivalence	NN	O
evaluation	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
partial	JJ	O
areas	NNS	O
in	IN	O
lieu	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
,	,	O
Tmax	NNP	O
,	,	O
and	CC	O
Cmax	NNP	O
is	VBZ	O
suggested	VBN	O
.	.	O

This	DT	O
study	NN	O
investigates	VBZ	O
the	DT	O
logic	NN	O
and	CC	O
robustness	NN	O
of	IN	O
the	DT	O
partial-area	JJ	O
method	NN	O
in	IN	O
establishing	VBG	O
bioequivalence	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
5h	CD	O
AUC	NNP	O
is	VBZ	O
a	DT	O
more	RBR	O
relevant	JJ	O
parameter	NN	O
to	TO	O
establish	VB	O
naproxen	NNS	PM
bioequivalence	NN	O
than	IN	O
AUCinf	NNP	O
.	.	O

We	PRP	O
recommend	VBP	O
against	IN	O
using	VBG	O
symmetrical	JJ	O
confidence	NN	O
intervals	NNS	O
and	CC	O
report	NN	O
excellent	JJ	O
agreement	NN	O
among	IN	O
several	JJ	O
methods	NNS	O
of	IN	O
calculating	VBG	O
confidence	NN	O
intervals	NNS	O
,	,	O
probability	NN	O
values	NNS	O
,	,	O
and	CC	O
nonparametric	JJ	O
tests	NNS	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
a	DT	O
single-point	JJ	O
short-term	JJ	O
AUC	NNP	O
is	VBZ	O
a	DT	O
better	JJR	O
indicator	NN	O
of	IN	O
the	DT	O
bioequivalence	NN	O
of	IN	O
generic	JJ	O
products	NNS	O
than	IN	O
the	DT	O
total	JJ	O
AUC	NNP	O
,	,	O
Cmax	NNP	O
,	,	O
and	CC	O
Tmax	NNP	O
as	IN	O
required	VBN	O
currently	RB	O
by	IN	O
the	DT	O
regulatory	JJ	O
authorities	NNS	O
.	.	O

Randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
oral	JJ	O
phytonadione	NN	PM
for	IN	O
excessive	JJ	O
anticoagulation	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
managing	VBG	O
excessive	JJ	O
anticoagulation	NN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
bleeding	NN	O
by	IN	O
either	DT	O
omitting	VBG	O
warfarin	JJ	O
therapy	NN	O
alone	RB	O
or	CC	O
administering	VBG	O
oral	JJ	O
phytonadione	NN	PM
in	IN	O
addition	NN	O
to	TO	O
omitting	VBG	O
warfarin	JJ	O
therapy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
Clinical	JJ	O
pharmacy	NN	O
anticoagulation	NN	O
service	NN	O
in	IN	O
a	DT	O
group	NN	O
model	NN	O
health	NN	O
maintenance	NN	O
organization	NN	O
.	.	O

SUBJECTS	NNP	O
Thirty	NNP	O
nonbleeding	VBG	O
patients	NNS	O
with	IN	O
international	JJ	O
normalized	JJ	O
ratios	NNS	O
(	(	O
INRs	NNP	O
)	)	O
ranging	VBG	O
from	IN	O
6.0-10.0	JJ	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	CC	O
a	DT	O
single	JJ	PM
oral	JJ	PM
dose	NN	PM
of	IN	PM
phytonadione	NN	PM
2.5	CD	PM
mg	NN	PM
or	CC	O
placebo	NN	C
.	.	O

Both	DT	O
groups	NNS	O
omitted	VBD	PM
warfarin	JJ	PM
doses	NNS	PM
until	IN	PM
the	DT	PM
INR	NNP	PM
became	VBD	PM
less	RBR	PM
than	IN	PM
or	CC	PM
equal	JJ	PM
to	TO	PM
4.0	CD	PM
.	.	O

MEASUREMENTS	NNS	O
AND	CC	O
RESULTS	NNP	O
The	DT	O
mean	NN	O
calculated	VBD	O
time	NN	O
to	TO	O
reach	VB	O
an	DT	O
INR	NNP	O
of	IN	O
4.0	CD	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
placebo	NN	O
than	IN	O
the	DT	O
phytonadione	NN	O
group	NN	O
(	(	O
2.6	CD	O
vs	RB	O
1.4	CD	O
days	NNS	O
,	,	O
p=0.006	NN	O
)	)	O
.	.	O

Overcorrection	NN	O
of	IN	O
anticoagulation	NN	O
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
phytonadione	NN	O
.	.	O

Overt	NNP	O
warfarin	VBD	O
resistance	NN	O
was	VBD	O
not	RB	O
observed	VBN	O
in	IN	O
either	DT	O
group	NN	O
after	IN	O
reinitiating	VBG	O
warfarin	JJ	O
therapy	NN	O
.	.	O

No	DT	O
major	JJ	O
bleeding	NN	O
or	CC	O
thromboembolic	JJ	O
complications	NNS	O
occurred	VBD	O
,	,	O
and	CC	O
minor	JJ	O
bleeding	NN	O
episodes	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
addition	NN	O
of	IN	O
oral	JJ	O
phytonadione	NN	O
2.5	CD	O
mg	NN	O
reduced	VBD	O
the	DT	O
time	NN	O
to	TO	O
achieve	VB	O
an	DT	O
INR	NNP	O
of	IN	O
4.0	CD	O
by	IN	O
approximately	RB	O
1	CD	O
day	NN	O
compared	VBN	O
with	IN	O
omitting	VBG	O
warfarin	JJ	O
therapy	NN	O
alone	RB	O
.	.	O

Adverse	JJ	O
events	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Both	DT	O
strategies	NNS	O
were	VBD	O
effective	JJ	O
in	IN	O
managing	VBG	O
asymptomatic	JJ	O
patients	NNS	O
with	IN	O
INRs	NNP	O
of	IN	O
6.0-10.0	NNP	O
.	.	O

Oral	NNP	O
phytonadione	NN	O
may	MD	O
be	VB	O
most	RBS	O
appropriate	JJ	O
for	IN	O
patients	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
bleeding	VBG	O
in	IN	O
whom	WP	O
the	DT	O
benefit	NN	O
of	IN	O
prompt	JJ	O
INR	NNP	O
reduction	NN	O
would	MD	O
outweigh	VB	O
the	DT	O
thromboembolic	JJ	O
risk	NN	O
associated	VBN	O
with	IN	O
INR	NNP	O
overcorrection	NN	O
.	.	O

Parent	NNP	E
management	NN	E
training	NN	E
and	CC	O
Asperger	NNP	O
syndrome	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
a	DT	O
parent	NN	E
based	VBN	E
intervention	NN	E
.	.	O

This	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
a	DT	O
parent	NN	E
management	NN	E
intervention	NN	E
aimed	VBN	O
to	TO	O
increase	VB	O
parental	JJ	O
competence	NN	O
in	IN	O
management	NN	O
of	IN	O
problem	NN	O
behaviours	NNS	O
associated	VBN	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
.	.	O

The	DT	O
intervention	NN	O
compared	VBN	O
two	CD	O
formats	NNS	O
,	,	O
a	DT	O
1	CD	E
day	NN	E
workshop	NN	E
and	CC	E
six	CD	E
individual	JJ	E
sessions	NNS	E
.	.	E

Measures	NNS	O
were	VBD	O
taken	VBN	O
on	IN	O
three	CD	O
occasions	NNS	O
:	:	O
pre-intervention	NN	O
,	,	O
at	IN	O
4	CD	O
weeks	NNS	O
,	,	O
and	CC	O
at	IN	O
3	CD	O
month	NN	O
follow-up	NN	O
.	.	O

Variables	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
number	NN	O
and	CC	O
intensity	NN	O
of	IN	O
problem	NN	O
behaviours	NN	O
,	,	O
and	CC	O
parent	JJ	O
evaluation	NN	O
of	IN	O
social	JJ	O
interaction	NN	O
skills	NNS	O
.	.	O

Results	NNS	O
showed	VBD	O
parents	NNS	O
reporting	VBG	O
fewer	JJR	O
and	CC	O
lower	JJR	O
intensity	NN	O
of	IN	O
problem	NN	O
behaviours	NNS	O
and	CC	O
increased	VBD	O
social	JJ	O
interactions	NNS	O
at	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
.	.	O

Results	NNS	O
held	VBD	O
across	IN	O
formats	NNS	O
and	CC	O
suggest	VBP	O
that	IN	O
parent	NN	O
management	NN	O
training	NN	O
can	MD	O
provide	VB	O
an	DT	O
effective	JJ	O
intervention	NN	O
for	IN	O
parents	NNS	O
of	IN	O
a	DT	O
child	NN	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
.	.	O

Group	NNP	O
differences	VBZ	O
on	IN	O
outcome	NN	O
measures	NNS	O
and	CC	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
strategies	NNS	O
are	VBP	O
discussed	VBN	O
along	IN	O
with	IN	O
limitations	NNS	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Independent	NNP	O
prognostic	JJ	O
information	NN	O
provided	VBN	O
by	IN	O
sphygmomanometrically	RB	PH
determined	VBN	PH
pulse	JJ	PH
pressure	NN	PH
and	CC	O
mean	JJ	O
arterial	JJ	PH
pressure	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
relationship	NN	O
of	IN	O
baseline	NN	O
pulse	JJ	O
pressure	NN	O
and	CC	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
to	TO	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

BACKGROUND	NNP	O
Increased	VBD	O
conduit	NN	O
vessel	NN	O
stiffness	NN	O
increases	VBZ	O
pulse	JJ	O
pressure	NN	O
and	CC	O
pulsatile	NN	O
load	NN	O
,	,	O
potentially	RB	O
contributing	VBG	O
to	TO	O
adverse	VB	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

METHODS	NNP	O
Pulse	NNP	O
and	CC	O
mean	VB	O
arterial	JJ	O
pressure	NN	O
were	VBD	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
mortality	NN	O
,	,	O
adjusting	VBG	O
for	IN	O
other	JJ	O
modifiers	NNS	O
of	IN	O
risk	NN	O
,	,	O
using	VBG	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
regression	NN	O
analysis	NN	O
of	IN	O
data	NNS	O
collected	VBN	O
from	IN	O
6,781	CD	O
patients	NNS	O
randomized	VBN	O
into	IN	O
the	DT	O
Studies	NNPS	O
of	IN	O
Left	NNP	O
Ventricular	NNP	O
Dysfunction	NNP	O
trials	NNS	O
.	.	O

RESULTS	NNP	O
Pulse	NNP	O
and	CC	O
mean	VB	O
arterial	JJ	O
pressure	NN	O
were	VBD	O
related	VBN	O
positively	RB	O
to	TO	O
each	DT	O
other	JJ	O
,	,	O
age	NN	O
,	,	O
ejection	NN	O
fraction	NN	O
and	CC	O
prevalence	NN	O
of	IN	O
diabetes	NNS	O
and	CC	O
hypertension	NN	O
and	CC	O
inversely	RB	O
to	TO	O
prior	VB	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
beta-adrenergic	JJ	O
blocking	NN	O
agent	NN	O
use	NN	O
.	.	O

Higher	JJR	O
pulse	JJ	O
pressure	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
prevalence	NN	O
of	IN	O
female	JJ	O
gender	NN	O
,	,	O
greater	JJR	O
calcium	NN	PM
channel	NN	PM
blocking	VBG	PM
agent	NN	PM
,	,	O
digoxin	NN	PM
and	CC	O
diuretic	JJ	PM
use	NN	O
,	,	O
lower	JJR	O
heart	NN	O
rate	NN	O
and	CC	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
reported	VBN	O
smoking	NN	O
history	NN	O
.	.	O

Higher	JJR	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
heart	NN	O
rate	NN	O
,	,	O
lower	JJR	O
calcium	NN	PM
channel	NN	PM
blocker	NN	PM
and	CC	O
digoxin	NN	PM
use	NN	O
and	CC	O
lower	JJR	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
functional	JJ	O
class	NN	O
.	.	O

Over	IN	O
a	DT	O
61-month	JJ	O
follow-up	JJ	O
1,582	CD	O
deaths	NNS	O
(	(	O
1,397	CD	O
cardiovascular	NN	O
)	)	O
occurred	VBD	O
.	.	O

In	IN	O
a	DT	O
multivariate	NN	O
analysis	NN	O
adjusting	VBG	O
for	IN	O
the	DT	O
above	JJ	O
covariates	NNS	O
and	CC	O
treatment	NN	O
assignment	NN	O
,	,	O
higher	JJR	O
pulse	JJ	O
pressure	NN	O
remained	VBD	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
total	JJ	O
and	CC	O
cardiovascular	JJ	O
mortality	NN	O
(	(	O
total	JJ	O
mortality	NN	O
relative	NN	O
risk	NN	O
,	,	O
1.05	CD	O
per	IN	O
10	CD	O
mm	NN	O
Hg	NNP	O
increment	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.01	CD	O
to	TO	O
1.10	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.02	CD	O
)	)	O
.	.	O

Mean	JJ	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
inversely	RB	O
related	VBN	O
to	TO	O
total	JJ	O
and	CC	O
cardiovascular	JJ	O
mortality	NN	O
(	(	O
total	JJ	O
mortality	NN	O
relative	NN	O
risk	NN	O
,	,	O
0.89	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.85	CD	O
to	TO	O
0.94	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
One	CD	O
noninvasive	JJ	PH
blood	NN	PH
pressure	NN	PH
measurement	NN	PH
provides	VBZ	O
two	CD	O
independent	JJ	O
prognostic	JJ	O
factors	NNS	O
for	IN	O
survival	NN	O
.	.	O

Increased	VBD	O
conduit	NN	O
vessel	NN	O
stiffness	NN	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
pulse	JJ	O
pressure	NN	O
,	,	O
may	MD	O
contribute	VB	O
to	TO	O
increased	VBN	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
,	,	O
independent	JJ	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
Selaginella	NNP	PM
combined	VBD	O
with	IN	O
radiotherapy	NN	PH
on	IN	O
nasopharyngeal	JJ	O
carcinoma	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
Chinese	JJ	O
herbal	JJ	O
medicine	NN	O
Selaginella-induced	NNP	O
radiosensitization	NN	O
of	IN	O
terminal	JJ	O
nasopharyngeal	JJ	O
carcinoma	NN	O
(	(	O
NPC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Totally	RB	O
180	CD	O
patients	NNS	O
with	IN	O
NPC	NNP	O
were	VBD	O
divided	VBN	O
equally	RB	O
into	IN	O
3	CD	O
groups	NNS	O
with	IN	O
the	DT	O
same	JJ	O
radiotherapeutic	JJ	O
protocols	NNS	O
.	.	O

The	DT	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
received	VBD	O
radiotherapy	NN	PH
alone	RB	PH
,	,	O
those	DT	O
in	IN	O
group	NN	O
B	NNP	O
were	VBD	O
given	VBN	O
daily	JJ	PM
Selaginella	NNP	PM
(	(	PM
30	CD	PM
g	NN	PM
)	)	PM
prepared	VBD	PM
into	IN	PM
50	CD	PM
ml	JJ	PM
decoction	NN	PM
during	IN	PM
the	DT	PM
entire	JJ	PM
course	NN	PM
of	IN	PM
radiotherapy	NN	PM
,	,	O
and	CC	O
those	DT	O
in	IN	O
group	NN	PM
C	NNP	PM
had	VBD	PM
Selaginella	NNP	PM
30	CD	PM
g	JJ	PM
daily	RB	PM
in	IN	O
the	DT	O
late	JJ	O
course	NN	O
of	IN	O
radiotherapy	NN	PM
.	.	O

RESULTS	VB	O
The	DT	O
complete	JJ	O
remission	NN	O
rate	NN	O
of	IN	O
nasopharyngeal	JJ	O
primary	JJ	O
lesions	NNS	O
in	IN	O
groups	NNS	O
B	NNP	O
and	CC	O
C	NNP	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
with	IN	O
also	RB	O
significantly	RB	O
higher	JJR	O
complete	JJ	O
remission	NN	O
rates	NNS	O
of	IN	O
the	DT	O
cervical	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

The	DT	O
acute	JJ	O
toxicity	NN	O
of	IN	O
the	DT	O
skin	NN	O
and	CC	O
mucous	JJ	O
membrane	NN	O
was	VBD	O
milder	RBR	O
in	IN	O
the	DT	O
latter	JJ	O
two	CD	O
groups	NNS	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Selaginella	NNP	PM
may	MD	O
induce	VB	O
radiosensitization	NN	O
for	IN	O
terminal	JJ	O
NPC	NNP	O
and	CC	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
acute	JJ	O
toxicity	NN	O
of	IN	O
radiotherapy	NN	O
.	.	O

Treatment	NN	O
of	IN	O
recurrent	NN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
demonstrate	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
intranasal	JJ	O
furosemide	NN	PM
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
the	DT	O
sodium	NN	O
chloride	NN	O
cotransporter	NN	O
channel	NN	O
at	IN	O
the	DT	O
basolateral	JJ	O
surface	NN	O
of	IN	O
the	DT	O
respiratory	JJ	O
epithelial	JJ	O
cell	NN	O
,	,	O
vs	VBZ	O
no	DT	C
therapeutic	JJ	C
intervention	NN	C
vs	NN	O
intranasal	NN	O
mometasone	NN	PM
furoate	NN	PM
,	,	PM
a	DT	PM
corticosteroid	NN	PM
,	,	O
in	IN	O
preventing	VBG	O
relapses	NNS	O
of	IN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
prospective	NN	O
controlled	VBD	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
examined	VBN	O
every	DT	O
6	CD	O
months	NNS	O
during	IN	O
follow-up	NN	O
(	(	O
range	NN	O
,	,	O
1-9	JJ	O
years	NNS	O
)	)	O
.	.	O

PATIENTS	VB	O
One	CD	O
hundred	JJ	O
seventy	NN	O
patients	NNS	O
with	IN	O
bilateral	JJ	O
obstructive	CD	O
or	CC	O
minimally	RB	O
obstructive	JJ	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

INTERVENTION	NNP	O
All	DT	O
patients	NNS	O
were	VBD	O
surgically	RB	O
treated	VBN	O
in	IN	O
the	DT	O
ENT	NNP	O
Department	NNP	O
,	,	O
University	NNP	O
of	IN	O
Siena	NNP	O
Medical	NNP	O
School	NNP	O
.	.	O

One	CD	O
month	NN	O
after	IN	O
surgery	NN	O
,	,	O
group	NN	O
1	CD	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
97	CD	O
)	)	O
started	VBD	O
treatment	NN	O
with	IN	O
intranasal	JJ	PM
furosemide	NN	PM
,	,	O
group	NN	O
2	CD	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
received	VBD	C
no	DT	C
therapeutic	JJ	C
treatment	NN	C
,	,	O
and	CC	O
group	NN	O
3	CD	O
(	(	O
n	JJ	O
=	NNP	O
33	CD	O
)	)	O
were	VBD	O
treated	VBN	O
with	IN	O
mometasone	NN	PM
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Clinical	NNP	O
and	CC	O
instrumental	JJ	O
evaluation	NN	O
of	IN	O
postoperative	JJ	O
outcomes	NNS	O
.	.	O

RESULTS	NNP	O
Seventeen	NNP	O
(	(	O
17.5	CD	O
%	NN	O
)	)	O
of	IN	O
97	CD	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
12	CD	O
(	(	O
30.0	CD	O
%	NN	O
)	)	O
of	IN	O
40	CD	O
patients	NNS	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
and	CC	O
8	CD	O
(	(	O
24.2	CD	O
%	NN	O
)	)	O
of	IN	O
33	CD	O
patients	NNS	O
in	IN	O
group	NN	O
3	CD	O
experienced	VBD	O
nasal	JJ	O
polyposis	NN	O
relapses	NNS	O
.	.	O

We	PRP	O
noted	VBD	O
a	DT	O
prevalence	NN	O
of	IN	O
early-stage	JJ	O
relapse	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
furosemide	NN	PM
or	CC	O
mometasone	NN	PM
,	,	O
whereas	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
any	DT	O
treatment	NN	O
experienced	VBD	O
more	JJR	O
severe	JJ	O
grades	NNS	O
of	IN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
intranasal	NN	O
furosemide	JJ	PM
represents	VBZ	O
a	DT	O
valid	JJ	O
therapeutic	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
chronic	JJ	O
hyperplastic	JJ	O
sinusitis	NN	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
.	.	O

A	DT	O
limited	JJ	O
sampling	NN	O
method	NN	O
for	IN	O
the	DT	O
estimation	NN	O
of	IN	O
flunarizine	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
and	CC	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
.	.	O

A	DT	O
limited	JJ	O
sampling	NN	O
model	NN	O
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
flunarizine	NN	O
following	VBG	O
a	DT	O
30	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
in	IN	O
epileptic	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
receiving	VBG	O
phenytoin	NN	PM
or	CC	O
carbamazepine	NN	PM
or	CC	O
both	DT	O
,	,	O
to	TO	O
estimate	VB	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
and	CC	O
maximum	JJ	PH
plasma	JJ	PH
concentration	NN	PH
(	(	PH
Cmax	NNP	PH
)	)	PH
.	.	O

The	DT	O
model	NN	O
was	VBD	O
developed	VBN	O
using	VBG	O
training	VBG	O
data	NNS	O
sets	NNS	O
from	IN	O
30	CD	O
,	,	O
20	CD	O
,	,	O
15	CD	O
,	,	O
or	CC	O
10	CD	O
patients	NNS	O
at	IN	O
one	CD	O
or	CC	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

The	DT	O
equations	NNS	O
describing	VBG	O
the	DT	O
models	NNS	O
for	IN	O
AUC	NNP	O
using	VBG	O
two	CD	O
time	NN	O
points	NNS	O
(	(	O
3	CD	O
and	CC	O
24h	CD	O
)	)	O
and	CC	O
Cmax	NNP	O
for	IN	O
the	DT	O
training	NN	O
data	NNS	O
set	NN	O
of	IN	O
30	CD	O
subjects	NNS	O
were	VBD	O
AUCpredicted	NNP	O
=	NNP	O
11.1	CD	O
C3h	NNP	O
+	VBD	O
121.4	CD	O
C24h	NNP	O
-	:	O
157	CD	O
(	(	O
r	NN	O
=	RB	O
0.80	CD	O
)	)	O
Cmax	NNP	O
(	(	O
predicted	VBN	O
)	)	O
=	$	O
0.036	CD	O
AUC	NNP	O
+	$	O
42.9	CD	O
(	(	O
r	NN	O
=	RB	O
0.74	CD	O
)	)	O
The	DT	O
model	NN	O
was	VBD	O
validated	VBN	O
on	IN	O
64	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
flunarizine	JJ	O
orally	RB	O
.	.	O

The	DT	O
model	NN	O
provided	VBD	O
reasonably	RB	O
good	JJ	O
estimates	NNS	O
for	IN	O
both	DT	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
.	.	O

The	DT	O
mean	NN	O
predicted	VBD	O
AUC	NNP	O
of	IN	O
flunarizine	NN	O
was	VBD	O
1230	CD	O
+/-	JJ	O
717	CD	O
ng	JJ	O
h	NN	O
mL-1	NN	O
,	,	O
whereas	IN	O
the	DT	O
observed	JJ	O
AUC	NNP	O
was	VBD	O
1203	CD	O
+/-	JJ	O
900	CD	O
ng	JJ	O
h	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	O
of	IN	O
the	DT	O
prediction	NN	O
was	VBD	O
2	CD	O
%	NN	O
and	CC	O
precision	NN	O
was	VBD	O
28	CD	O
%	NN	O
.	.	O

The	DT	O
mean	NN	O
predicted	VBD	O
Cmax	NNP	O
of	IN	O
flunarizine	NN	O
was	VBD	O
86	CD	O
+/-	JJ	O
32	CD	O
ng	JJ	O
mL-1	NN	O
as	IN	O
compared	VBN	O
to	TO	O
an	DT	O
observed	JJ	O
mean	NN	O
Cmax	NNP	O
of	IN	O
90	CD	O
+/-	JJ	O
42	CD	O
ng	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	O
and	CC	O
precision	NN	O
of	IN	O
the	DT	O
prediction	NN	O
were	VBD	O
4	CD	O
%	NN	O
and	CC	O
24	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
method	NN	O
described	VBD	O
here	RB	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
estimate	VB	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
for	IN	O
flunarizine	NN	O
without	IN	O
detailed	JJ	O
pharmacokinetic	JJ	O
studies	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
terazosin	NN	PM
and	CC	O
enalapril	NN	PM
on	IN	O
laboratory	NN	O
stress	NN	O
testing	VBG	O
blood	NN	O
pressure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

It	PRP	O
is	VBZ	O
the	DT	O
current	JJ	O
opinion	NN	O
that	IN	O
an	DT	O
ideal	JJ	O
antihypertensive	JJ	PM
drug	NN	PM
should	MD	O
reduce	VB	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
not	RB	O
only	RB	O
at	IN	O
rest	NN	O
but	CC	O
also	RB	O
during	IN	O
stressful	JJ	O
situations	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
selective	JJ	PM
alpha	NN	PM
1-adrenergic	JJ	PM
blocker	NN	PM
terazosin	NN	PM
(	(	O
5	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
)	)	O
and	CC	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	PM
enzyme	NN	PM
inhibitor	NN	PM
enalapril	NN	PM
(	(	O
20	CD	O
mg	NN	O
once	RB	O
daily	RB	O
)	)	O
on	IN	O
cardiovascular	JJ	O
response	NN	O
to	TO	O
a	DT	O
set	NN	O
of	IN	O
standardized	JJ	O
laboratory	NN	O
stressors	NNS	O
,	,	O
such	JJ	O
as	IN	O
mental	JJ	O
arithmetic	JJ	O
,	,	O
handgrip	JJ	O
test	NN	O
and	CC	O
cycle	NN	O
ergometry	NN	O
,	,	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
16	CD	O
essential	JJ	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
trial	NN	O
preceded	VBN	O
by	IN	O
a	DT	O
placebo	JJ	C
run-in	JJ	O
period	NN	O
.	.	O

Terazosin	NNP	PM
and	CC	O
enalapril	VB	PM
had	VBD	O
a	DT	O
comparable	JJ	O
effect	NN	O
on	IN	O
resting	VBG	O
BP	NNP	O
,	,	O
reducing	VBG	O
systolic	JJ	O
(	(	O
SBP	NNP	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
DBP	NNP	O
)	)	O
blood	NN	O
pressure	NN	O
from	IN	O
159.5	CD	O
+/-	JJ	O
13.9/101.6	CD	O
+/-	JJ	O
8.8	CD	O
mm	NN	O
Hg	NNP	O
during	IN	O
placebo	NN	O
by	IN	O
7.8	CD	O
%	NN	O
/6.7	CC	O
%	NN	O
and	CC	O
by	IN	O
11.3	CD	O
%	NN	O
/10.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
to	TO	O
the	DT	O
two	CD	O
treatments	NNS	O
was	VBD	O
approximately	RB	O
the	DT	O
same	JJ	O
,	,	O
being	VBG	O
69	CD	O
%	NN	O
and	CC	O
75	CD	O
%	NN	O
after	IN	O
terazosin	NN	PM
and	CC	O
enalapril	NN	PM
,	,	O
respectively	RB	O
.	.	O

During	IN	O
mental	JJ	O
arithmetic	JJ	O
,	,	O
from	IN	O
an	DT	O
average	NN	O
of	IN	O
181.6	CD	O
+/-	JJ	O
17.8/118.6	CD	O
+/-	JJ	O
11.5	CD	O
mm	NN	O
Hg	NNP	O
during	IN	O
placebo	NN	C
,	,	O
BP	NNP	O
was	VBD	O
reduced	VBN	O
by	IN	O
11.5	CD	O
%	NN	O
/7.9	CD	O
%	NN	O
after	IN	O
terazosin	NN	PM
and	CC	O
by	IN	O
13.6	CD	O
%	NN	O
/8.5	CD	O
%	NN	O
after	IN	O
enalapril	NN	PM
;	:	O
during	IN	O
handgrip	NN	O
test	NN	O
,	,	O
BP	NNP	O
decreased	VBD	O
from	IN	O
207.2	CD	O
+/-	JJ	O
22.2/142.2	CD	O
+/-	JJ	O
13.6	CD	O
mm	NN	O
Hg	NNP	O
by	IN	O
7.3	CD	O
%	NN	O
/8.4	CD	O
%	NN	O
after	IN	O
terazosin	NN	PM
and	CC	O
by	IN	O
7.7	CD	O
%	NN	O
/7.1	CD	O
%	NN	O
after	IN	O
enalapril	NN	PM
;	:	O
finally	RB	O
,	,	O
during	IN	O
cycle	NN	O
ergometry	NN	O
,	,	O
terazosin	NN	O
and	CC	O
enalapril	NN	O
lowered	VBN	O
BP	NNP	O
by	IN	O
5.4	CD	O
%	NN	O
/6.7	CC	O
%	NN	O
and	CC	O
7	CD	O
%	NN	O
/3.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
from	IN	O
a	DT	O
placebo	NN	C
value	NN	O
of	IN	O
215.5	CD	O
+/-	JJ	O
17.3/127.6	CD	O
+/-	JJ	O
11.2	CD	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
antihypertensive	JJ	O
efficacy	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
,	,	O
either	RB	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
stress	JJ	O
testing	VBG	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Topical	JJ	PM
treatment	NN	PM
of	IN	O
alopecia	NN	O
areata	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
previously	RB	O
that	IN	O
alopecia	JJ	O
areata	NNS	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
dinitrochlorobenzene	NN	PM
(	(	PM
DNCB	NNP	PM
)	)	PM
and	CC	O
other	JJ	O
contact	NN	PM
allergens	NNS	PM
.	.	O

Whether	IN	O
these	DT	O
agents	NNS	O
work	NN	O
by	IN	O
inducing	VBG	O
immunologic	JJ	O
stimulation	NN	O
or	CC	O
simply	RB	O
a	DT	O
nonspecific	JJ	O
inflammatory	NN	O
reaction	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
definitively	RB	O
demonstrated	VBN	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
these	DT	O
two	CD	O
mechanisms	NNS	O
,	,	O
we	PRP	O
have	VBP	O
randomly	RB	O
studied	VBN	O
22	CD	O
patients	NNS	O
with	IN	O
alopecia	JJ	O
areata	NNS	O
to	TO	O
whom	WP	O
either	DT	O
DNCB	NNP	PM
or	CC	O
croton	VB	PM
oil	NN	PM
was	VBD	O
applied	VBN	O
topically	RB	O
.	.	O

Sixty-three	JJ	O
percent	NN	O
of	IN	O
patients	NNS	O
without	IN	O
spontaneous	JJ	O
regrowth	NN	O
of	IN	O
hair	NN	O
regrew	NNS	O
hair	NN	O
after	IN	O
DNCB	NNP	O
application	NN	O
.	.	O

None	NN	O
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
croton	NN	PM
oil	NN	PM
regrew	VBD	O
hair	NN	O
when	WRB	O
treated	VBN	O
later	RB	O
with	IN	O
DNCB	NNP	PM
.	.	O

Therefore	NNP	O
,	,	O
a	DT	O
proved	JJ	O
contact	NN	O
allergen	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
required	VBN	O
for	IN	O
therapeutic	JJ	O
success	NN	O
.	.	O

Patient	JJ	O
acceptance	NN	O
of	IN	O
the	DT	O
induced	JJ	O
contact	NN	O
dermatitis	NN	O
was	VBD	O
excellent	JJ	O
.	.	O

In	IN	O
light	NN	O
of	IN	O
recent	JJ	O
data	NNS	O
on	IN	O
the	DT	O
mutagenicity	NN	O
of	IN	O
DNCB	NNP	PM
to	TO	O
bacteria	NNS	O
,	,	O
other	JJ	O
contact	NN	O
allergens	NNS	O
for	IN	O
topical	JJ	O
immunotherapy	NN	O
are	VBP	O
being	VBG	O
sought	VBN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
a	DT	O
stage-of-change	NN	E
oriented	VBN	E
smoking	VBG	E
cessation	NN	E
intervention	NN	E
in	IN	O
infertile	NN	O
and	CC	O
pregnant	JJ	O
women	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
a	DT	O
stage-of-change	NN	E
oriented	VBN	E
smoking	VBG	E
cessation	NN	E
intervention	NN	E
for	IN	O
infertile	NN	O
and	CC	O
pregnant	JJ	O
women	NNS	O
,	,	O
compared	VBN	O
with	IN	O
standard	NN	O
of	IN	O
care	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NNP	O
Three	CD	O
university	NN	O
teaching	VBG	O
hospitals	NNS	O
in	IN	O
Hamilton	NNP	O
,	,	O
Ontario	NNP	O
,	,	O
Canada	NNP	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Infertile	NNP	O
women	NNS	O
at	IN	O
their	PRP$	O
first	JJ	O
visit	NN	O
to	TO	O
a	DT	O
tertiary	JJ	O
referral	JJ	O
infertility	NN	O
clinic	NN	O
(	(	O
n	JJ	O
=	NNP	O
94	CD	O
)	)	O
and	CC	O
new	JJ	O
patients	NNS	O
seeking	VBG	O
pre-natal	JJ	O
care	NN	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	O
)	)	O
who	WP	O
had	VBD	O
smoked	VBN	O
>	NNP	O
/=	$	O
3	CD	O
cigarettes	NNS	O
in	IN	O
the	DT	O
past	JJ	O
six	CD	O
months	NNS	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
three	CD	E
to	TO	E
five	CD	E
minute	NN	E
scripted	VBN	E
intervention	NN	E
and	CC	E
booklet	NN	E
specific	NN	E
to	TO	E
the	DT	E
woman	NN	E
's	POS	E
stage-of-change	NN	E
in	IN	E
the	DT	E
smoking	NN	E
continuum	NN	E
,	,	E
versus	JJ	E
standard	NN	Ot
of	IN	Ot
care	NN	Ot
.	.	O

Exhaled	VBN	PH
carbon-monoxide	NN	PH
(	(	PH
CO	NNP	PH
)	)	PH
monitoring	NN	O
was	VBD	O
used	VBN	O
to	TO	O
validate	VB	O
exposure	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Delta	NNP	O
stage-of-change	NN	O
and	CC	O
rate	NN	O
of	IN	O
maintained	VBN	O
cessation	NN	O
at	IN	O
12	CD	O
months	NNS	O
post	VBN	O
follow-up	JJ	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Intervention	NNP	O
and	CC	O
control	NN	O
were	VBD	O
similarly	RB	O
effective	JJ	O
for	IN	O
infertile	JJ	O
women	NNS	O
:	:	O
the	DT	O
rate	NN	O
of	IN	O
maintained	VBN	O
cessation	NN	O
rose	VBD	O
significantly	RB	O
from	IN	O
4	CD	O
%	NN	O
to	TO	O
24	CD	O
%	NN	O
over	IN	O
twelve	JJ	O
months	NNS	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
delta	NN	O
stage-of-change	NN	O
0.28	CD	O
.	.	O

In	IN	O
prenatal	JJ	O
women	NNS	O
,	,	O
neither	CC	O
approach	NN	O
was	VBD	O
effective	JJ	O
.	.	O

Maintained	VBN	O
cessation	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
from	IN	O
0	CD	O
to	TO	O
12	CD	O
months	NNS	O
(	(	O
19	CD	O
%	NN	O
to	TO	O
18	CD	O
%	NN	O
)	)	O
.	.	O

Mean	JJ	O
delta	JJ	O
stage-of-change	NN	O
declined	VBN	O
by	IN	O
-0.62	NNP	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
For	IN	O
infertile	JJ	O
women	NNS	O
,	,	O
basic	JJ	O
information	NN	O
describing	VBG	O
the	DT	O
impact	NN	O
of	IN	O
smoking	VBG	O
on	IN	O
fertility	NN	O
,	,	O
along	IN	O
with	IN	O
exhaled	JJ	O
CO	NNP	O
monitoring	NN	O
and	CC	O
a	DT	O
more	RBR	O
intensive	JJ	O
intervention	NN	O
were	VBD	O
both	DT	O
highly	RB	O
effective	JJ	O
.	.	O

In	IN	O
pregnant	JJ	O
women	NNS	O
neither	CC	O
approach	NN	O
was	VBD	O
beneficial	JJ	O
,	,	O
with	IN	O
some	DT	O
evidence	NN	O
of	IN	O
post-partum	JJ	O
relapse	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
study	NN	O
of	IN	O
valproate	NN	PM
for	IN	O
aggression	NN	O
in	IN	O
youth	NN	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
study	VB	O
valproate	JJ	PM
efficacy	NN	O
and	CC	O
safety	NN	O
for	IN	O
aggression	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
study	NN	O
,	,	O
30	CD	O
subjects	NNS	O
(	(	O
20	CD	O
boys	NNS	O
,	,	O
10	CD	O
girls	NNS	O
)	)	O
6-20	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
PDD	NNP	O
and	CC	O
significant	JJ	O
aggression	NN	O
were	VBD	O
randomized	VBN	O
and	CC	O
received	VBN	O
treatment	NN	O
with	IN	O
valproate	NN	PM
(	(	PM
VPA	NNP	PM
)	)	PM
or	CC	O
placebo	NN	C
(	(	PM
PBO	NNP	PM
)	)	PM
for	IN	O
8	CD	O
weeks	NNS	O
as	IN	O
outpatients	NNS	O
.	.	O

Mean	NNP	O
VPA	NNP	O
trough	IN	O
blood	NN	O
levels	NNS	O
were	VBD	O
75.5	CD	O
mcg/mL	NNS	O
at	IN	O
week	NN	O
4	CD	O
and	CC	O
77.8	CD	O
mcg/mL	NN	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

RESULTS	VB	O
No	DT	O
treatment	NN	O
difference	NN	O
was	VBD	O
observed	VBN	O
statistically	RB	O
between	IN	O
VPA	NNP	PM
and	CC	O
PBO	NNP	PM
groups	NNS	O
.	.	O

The	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
--	:	O
Community	NNP	O
Scale	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
Irritability	NNP	O
subscale	NN	O
was	VBD	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.65	CD	O
)	)	O
,	,	O
and	CC	O
CGI	NNP	O
--	:	O
Improvement	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.16	CD	O
)	)	O
and	CC	O
OAS	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.96	CD	O
)	)	O
were	VBD	O
secondary	JJ	O
outcome	NN	O
measures	NNS	O
.	.	O

Increased	VBN	O
appetite	NN	O
and	CC	O
skin	NN	O
rash	NN	O
were	VBD	O
significant	JJ	O
side	NN	O
effects	NNS	O
.	.	O

Only	RB	O
1	CD	O
subject	NN	O
was	VBD	O
dropped	VBN	O
from	IN	O
the	DT	O
study	NN	O
owing	VBG	O
to	TO	O
side	VB	O
effects	NNS	O
,	,	O
notably	RB	O
a	DT	O
spreading	NN	O
skin	NN	O
rash	NN	O
,	,	O
which	WDT	O
then	RB	O
resolved	VBD	O
spontaneously	RB	O
.	.	O

Two	CD	O
subjects	NNS	O
receiving	VBG	O
VPA	NNP	PM
developed	VBD	O
increased	VBN	O
serum	NN	O
ammonia	NN	O
levels	NNS	O
,	,	O
one	CD	O
with	IN	O
an	DT	O
associated	JJ	O
parent	NN	O
report	NN	O
of	IN	O
slurred	JJ	O
speech	NN	O
and	CC	O
mild	JJ	O
cognitive	JJ	O
slowing	NN	O
.	.	O

Poststudy	NNP	O
,	,	O
of	IN	O
16	CD	O
VPA	NNP	PM
and	CC	O
PBO	NNP	PM
subjects	NNS	O
receiving	VBG	O
VPA	NNP	PM
,	,	O
10	CD	O
subjects	NNS	O
demonstrated	VBD	O
sustained	JJ	O
response	NN	O
,	,	O
4	CD	O
of	IN	O
whom	WP	O
later	RB	O
attempted	VBN	O
taper	NN	O
,	,	O
with	IN	O
significant	JJ	O
relapse	NN	O
of	IN	O
aggression	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
present	JJ	O
negative	JJ	O
findings	NNS	O
can	MD	O
not	RB	O
be	VB	O
viewed	VBN	O
as	IN	O
conclusive	JJ	O
,	,	O
partly	RB	O
owing	VBG	O
to	TO	O
the	DT	O
large	JJ	O
placebo	NN	C
response	NN	O
,	,	O
subject	JJ	O
heterogeneity	NN	O
,	,	O
and	CC	O
size	NN	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

Larger	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
expand	VB	O
upon	IN	O
these	DT	O
findings	NNS	O
.	.	O

Brief	JJ	O
Report	NNP	O
:	:	O
social	JJ	O
disability	NN	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
results	NNS	O
from	IN	O
Research	NNP	O
Units	NNP	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
)	)	O
Autism	NNP	O
Network	NNP	O
trials	NNS	O
.	.	O

There	EX	O
is	VBZ	O
growing	VBG	O
interest	NN	O
in	IN	O
measuring	VBG	O
social	JJ	O
disability	NN	O
as	IN	O
a	DT	O
core	NN	O
element	NN	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
medication	NN	O
trials	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
secondary	JJ	O
analysis	NN	O
on	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
Social	NNP	O
Withdrawal	NNP	O
subscale	JJ	O
using	VBG	O
data	NNS	O
from	IN	O
two	CD	O
federally-funded	JJ	O
,	,	O
multi-site	JJ	O
,	,	O
randomized	JJ	O
trials	NNS	O
with	IN	O
risperidone	NN	PM
.	.	O

Study	NNP	O
1	CD	O
included	VBD	O
52	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
placebo	VB	C
and	CC	O
49	CD	O
subjects	NNS	O
to	TO	O
risperidone	VB	PM
under	IN	O
double-blind	JJ	O
conditions	NNS	O
.	.	O

Study	NNP	O
2	CD	O
included	VBD	O
49	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
risperidone	VB	PM
only	RB	PM
and	CC	O
75	CD	O
subjects	NNS	O
assigned	VBN	O
to	TO	O
risperidone	VB	PM
plus	JJ	PM
parent	NN	E
training	NN	E
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
all	DT	O
active	JJ	O
treatments	NNS	O
were	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	O
(	(	O
effect	NN	O
sizes	VBZ	O
ranging	VBG	O
from	IN	O
0.42	CD	O
to	TO	O
0.65	CD	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
Social	NNP	O
Withdrawal	NNP	O
subscale	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
measure	NN	O
of	IN	O
social	JJ	O
disability	NN	O
in	IN	O
acute	JJ	O
treatment	NN	O
trials	NNS	O
.	.	O

Phonophoresis	NNP	PM
versus	NN	O
topical	JJ	O
application	NN	O
of	IN	O
ketoprofen	NN	PM
:	:	O
comparison	NN	O
between	IN	O
tissue	NN	O
and	CC	O
plasma	NN	O
levels	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Over	IN	O
the	DT	O
last	JJ	O
few	JJ	O
decades	NNS	O
,	,	O
application	NN	O
of	IN	O
ultrasound	NN	O
has	VBZ	O
been	VBN	O
attempted	VBN	O
to	TO	O
enhance	VB	O
transdermal	JJ	O
transport	NN	O
of	IN	O
several	JJ	O
drugs	NNS	O
,	,	O
a	DT	O
method	NN	O
referred	VBD	O
to	TO	O
as	IN	O
phonophoresis	NN	O
.	.	O

The	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
examine	VB	O
the	DT	O
influence	NN	O
of	IN	O
ultrasound	NN	O
on	IN	O
the	DT	O
transdermal	JJ	O
delivery	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
humans	NNS	O
and	CC	O
to	TO	O
compare	VB	O
the	DT	O
concentrations	NNS	O
found	VBD	O
after	IN	O
continuous	JJ	O
and	CC	O
pulsed	JJ	O
application	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
Twenty-six	NNP	O
patients	NNS	O
with	IN	O
knee	NN	O
disorders	NNS	O
requiring	VBG	O
arthroscopy	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
.	.	O

Just	NNP	O
before	IN	O
surgery	NN	O
,	,	O
phonophoresis	NN	PM
of	IN	PM
a	DT	PM
ketoprofen	NN	PM
gel	NN	PM
(	(	O
Fastum	NNP	O
gel	NN	O
)	)	O
was	VBD	O
given	VBN	O
to	TO	O
group	NN	O
A	NNP	O
using	VBG	O
continuous	JJ	PH
ultrasound	NN	PH
(	(	O
1	CD	O
MHz	NNP	O
,	,	O
1.5	CD	O
W/cm2	NNP	O
,	,	O
for	IN	O
5	CD	O
minutes	NNS	O
)	)	O
.	.	O

Group	NNP	O
B	NNP	O
received	VBD	O
the	DT	O
same	JJ	O
treatment	NN	O
but	CC	O
with	IN	O
pulsed	JJ	PH
ultrasound	NN	PH
(	(	O
100	CD	O
Hz	NNP	O
,	,	O
20	CD	O
%	NN	O
duty	NN	O
cycle	NN	O
)	)	O
.	.	O

Group	NNP	O
C	NNP	O
received	VBD	O
5	CD	O
minutes	NNS	O
of	IN	O
sham	NN	C
ultrasound	NN	C
with	IN	C
the	DT	C
ketoprofen	NN	C
gel	NN	C
.	.	O

The	DT	O
ultrasound	JJ	O
head	NN	O
was	VBD	O
moved	VBN	O
over	IN	O
a	DT	O
10-cm2	JJ	O
area	NN	O
using	VBG	O
small	JJ	O
,	,	O
continuous	JJ	O
,	,	O
circular	JJ	O
movements	NNS	O
.	.	O

Biopsies	NNS	O
of	IN	O
adipose	JJ	O
tissue	NN	O
and	CC	O
synovial	JJ	O
tissue	NN	O
were	VBD	O
taken	VBN	O
during	IN	O
surgery	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
local	JJ	O
penetration	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
also	RB	O
were	VBD	O
collected	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
ketoprofen	NN	O
entered	VBD	O
the	DT	O
systemic	JJ	O
circulation	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
concentration	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
plasma	NN	O
was	VBD	O
negligible	JJ	O
in	IN	O
all	DT	O
3	CD	O
groups	NNS	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
synovial	JJ	O
tissue	NN	O
differed	VBD	O
from	IN	O
that	IN	O
in	IN	O
fat	JJ	O
tissue	NN	O
.	.	O

A	DT	O
difference	NN	O
in	IN	O
concentration	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
synovial	JJ	O
tissue	NN	O
was	VBD	O
found	VBN	O
between	IN	O
group	NN	O
C	NNP	O
and	CC	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
fat	JJ	O
tissue	NN	O
and	CC	O
synovial	JJ	O
tissue	NN	O
was	VBD	O
consistently	RB	O
higher	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

DISCUSSION	NNP	O
AND	CC	O
CONCLUSION	NNP	O
This	DT	O
study	NN	O
confirms	VBZ	O
that	IN	O
phonophoresis	NN	O
of	IN	O
ketoprofen	NN	O
allows	VBZ	O
the	DT	O
attainment	NN	O
of	IN	O
higher	JJR	O
local	JJ	O
concentrations	NNS	O
,	,	O
whereas	JJ	O
systemic	JJ	O
exposure	NN	O
is	VBZ	O
lower	JJR	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
,	,	O
in	IN	O
contrast	NN	O
to	TO	O
sham	VB	O
phonopheresis	NN	O
,	,	O
ultrasound	NN	O
can	MD	O
increase	VB	O
the	DT	O
transdermal	JJ	O
delivery	NN	O
of	IN	O
ketoprofen	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
7-day	JJ	PM
and	CC	PM
14-day	JJ	PM
proton	NN	PM
pump	IN	PM
inhibitor-containing	JJ	PM
triple	JJ	PM
therapy	NN	PM
for	IN	O
Helicobacter	NNP	O
pylori	JJ	O
eradication	NN	O
:	:	O
neither	CC	O
treatment	NN	O
duration	NN	O
provides	VBZ	O
acceptable	JJ	O
eradication	NN	O
rate	NN	O
in	IN	O
Korea	NNP	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
Although	IN	O
triple	JJ	PM
combination	NN	PM
therapy	NN	PM
containing	VBG	O
a	DT	O
proton	NN	PM
pump	NN	PM
inhibitor	NN	PM
(	(	PM
PPI	NNP	PM
)	)	PM
and	CC	O
two	CD	PM
antibiotics	NNS	PM
is	VBZ	O
considered	VBN	O
as	IN	O
a	DT	O
standard	JJ	O
regimen	NN	O
for	IN	O
the	DT	O
first-line	JJ	O
anti-Helicobacter	JJ	O
pylori	NN	O
treatment	NN	O
,	,	O
there	EX	O
are	VBP	O
still	RB	O
debates	NNS	O
on	IN	O
the	DT	O
ideal	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacies	NNS	O
of	IN	O
7-day	JJ	PM
and	CC	PM
14-day	JJ	PM
PPI-containing	JJ	PM
triple	NN	PM
therapy	NN	PM
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
multicenter	NN	O
,	,	O
prospective	JJ	O
manner	NN	O
.	.	O

After	IN	O
upper	JJ	S
gastrointestinal	JJ	S
endoscopy	NN	S
,	,	O
H.	NNP	O
pylori-infected	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
gastric	JJ	O
ulcer	NN	O
and/or	VBZ	O
a	DT	O
duodenal	JJ	O
ulcer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
PAC7	NNP	PM
group	NN	O
(	(	O
omeprazole	JJ	PM
20	CD	PM
mg	NN	PM
or	CC	PM
equivalent	JJ	PM
dose	NN	PM
of	IN	PM
other	JJ	PM
PPIs	NNP	PM
,	,	PM
amoxicillin	NN	PM
1000	CD	PM
mg	NN	PM
,	,	PM
and	CC	PM
clarithromycin	VBZ	PM
500	CD	PM
mg	NN	PM
twice	RB	PM
daily	RB	PM
for	IN	PM
7	CD	PM
days	NNS	PM
)	)	PM
or	CC	O
to	TO	O
a	DT	O
PAC14	NNP	PM
group	NN	O
(	(	O
the	DT	PM
same	JJ	PM
regimen	NN	PM
as	IN	PM
the	DT	PM
PAC7	NNP	PM
group	NN	PM
but	CC	PM
for	IN	PM
14	CD	PM
days	NNS	PM
)	)	O
.	.	O

H.	NNP	O
pylori	NN	O
status	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
(	(	O
13	CD	O
)	)	O
C	NNP	O
urea	JJ	O
breath	NN	O
test	NN	O
5	CD	O
weeks	NNS	O
after	IN	O
anti-ulcer	JJ	O
treatment	NN	O
completion	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
598	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
;	:	O
337	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
PAC7	NNP	PM
group	NN	O
and	CC	O
261	CD	O
to	TO	O
the	DT	O
PAC14	NNP	PM
group	NN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
baseline	NN	O
characteristics	NNS	O
.	.	O

The	DT	O
eradication	NN	O
rates	NNS	O
of	IN	O
the	DT	O
PAC7	NNP	PM
group	NN	O
were	VBD	O
not	RB	O
inferior	JJ	O
to	TO	O
those	DT	O
of	IN	O
the	DT	O
PAC14	NNP	PM
group	NN	O
in	IN	O
both	DT	O
intention-to-treat	JJ	O
analysis	NN	O
(	(	O
71.2	CD	O
%	NN	O
vs.	FW	O
75.5	CD	O
%	NN	O
)	)	O
and	CC	O
per-protocol	JJ	O
analysis	NN	O
(	(	O
83.6	CD	O
%	NN	O
vs.	FW	O
86.6	CD	O
%	NN	O
)	)	O
.	.	O

Incidences	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
comparable	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
7-day	JJ	O
PPI-containing	JJ	O
triple	JJ	O
anti-H.	JJ	O
pylori	NN	O
therapy	NN	O
is	VBZ	O
not	RB	O
inferior	JJ	O
to	TO	O
the	DT	O
14-day	JJ	Ot
therapy	NN	O
,	,	O
neither	CC	O
treatment	NN	O
duration	NN	O
provides	VBZ	O
acceptable	JJ	O
eradication	NN	O
rate	NN	O
reaching	VBG	O
90	CD	O
%	NN	O
in	IN	O
per-protocol	JJ	O
analysis	NN	O
.	.	O

New	NNP	O
combination	NN	O
regimen	NNS	O
with	IN	O
higher	JJR	O
efficacy	NN	O
should	MD	O
be	VB	O
developed	VBN	O
as	IN	O
a	DT	O
first-line	JJ	O
eradication	NN	O
therapy	NN	O
for	IN	O
H.	NNP	O
pylori	NN	O
in	IN	O
Korea	NNP	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
nifedipine	NN	PM
sustained	VBN	PM
release	NN	PM
with	IN	O
Ginkgo	NNP	PM
biloba	NN	PM
extract	NN	PM
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
primary	JJ	O
Raynaud	NNP	O
's	POS	O
phenomenon	NN	O
in	IN	O
South	NNP	O
Korea	NNP	O
;	:	O
Korean	NNP	O
Raynaud	NNP	O
study	NN	O
(	(	O
KOARA	NNP	O
study	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
nifedipine	NN	PM
sustained	VBN	PM
release	NN	PM
(	(	PM
nifedipine	JJ	PM
SR	NNP	PM
)	)	PM
compared	VBN	O
with	IN	O
Ginkgo	NNP	PM
biloba	NN	PM
extract	NN	PM
as	IN	O
treatment	NN	O
for	IN	O
primary	JJ	O
Raynaud	NNP	O
's	POS	O
phenomenon	NN	O
(	(	O
RP	NNP	O
)	)	O
in	IN	O
Korea	NNP	O
.	.	O

Primary	NNP	O
RP	NNP	O
were	VBD	O
screened	VBN	O
and	CC	O
assigned	VBN	O
to	TO	O
either	CC	O
the	DT	O
nifedipine	JJ	PM
SR	NNP	PM
group	NN	O
(	(	O
Group	NNP	O
N	NNP	O
)	)	O
or	CC	O
the	DT	O
Ginkgo	NNP	PM
biloba	NN	PM
extract	NN	PM
group	NN	PM
(	(	O
Group	NNP	O
G	NNP	O
)	)	O
in	IN	O
the	DT	O
ratio	NN	O
of	IN	O
2:1	CD	O
.	.	O

After	IN	O
a	DT	O
run-in	JJ	O
period	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
,	,	O
patients	NNS	O
received	VBD	O
treatment	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

We	PRP	O
observed	VBD	O
the	DT	O
percent	NN	O
improvement	NN	O
of	IN	O
the	DT	O
RP	NNP	O
attack	NN	O
rate	NN	O
between	IN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
8-week	JJ	O
treatment	NN	O
.	.	O

Ninety-three	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
.	.	O

The	DT	O
percent	NN	O
improvement	NN	O
in	IN	O
Group	NNP	O
N	NNP	O
was	VBD	O
50.1	CD	O
%	NN	O
at	IN	O
8	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
31.0	CD	O
%	NN	O
in	IN	O
Group	NNP	O
G	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

No	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
,	,	O
and	CC	O
almost	RB	O
adverse	JJ	O
events	NNS	O
were	VBD	O
mild	JJ	O
and	CC	O
improved	VBN	O
without	IN	O
specific	JJ	O
treatment	NN	O
.	.	O

nifedipine	JJ	PM
SR	NNP	PM
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
Ginkgo	NNP	PM
biloba	NN	PM
extract	NN	PM
for	IN	O
treatment	NN	O
of	IN	O
primary	JJ	O
RP	NNP	O
in	IN	O
Korean	JJ	O
patients	NNS	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
tolerable	JJ	O
with	IN	O
primary	JJ	O
RP	NNP	O
patients	NNS	O
.	.	O

Automatic	JJ	O
detection	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
in	IN	O
digital	JJ	O
color	NN	O
fundus	NN	O
photographs	NN	O
.	.	O

The	DT	O
robust	JJ	O
detection	NN	PH
of	IN	PH
red	JJ	PH
lesions	NNS	PH
in	IN	PH
digital	JJ	Ot
color	NN	Ot
fundus	NN	Ot
photographs	NN	Ot
is	VBZ	O
a	DT	O
critical	JJ	O
step	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
automated	JJ	O
screening	VBG	O
systems	NNS	O
for	IN	O
diabetic	JJ	O
retinopathy	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
,	,	O
a	DT	O
novel	NN	Ot
red	JJ	Ot
lesion	NN	Ot
detection	NN	Ot
method	NN	Ot
is	VBZ	O
presented	VBN	O
based	VBN	O
on	IN	O
a	DT	O
hybrid	JJ	O
approach	NN	O
,	,	O
combining	VBG	O
prior	JJ	O
works	NNS	O
by	IN	O
Spencer	NNP	O
et	CC	O
al	NN	O
.	.	O

(	(	O
1996	CD	O
)	)	O
and	CC	O
Frame	NNP	O
et	NNP	O
al	NN	O
.	.	O

(	(	O
1998	CD	O
)	)	O
with	IN	O
two	CD	O
important	JJ	O
new	JJ	O
contributions	NNS	O
.	.	O

The	DT	O
first	JJ	O
contribution	NN	O
is	VBZ	O
a	DT	O
new	JJ	O
red	JJ	Ot
lesion	NN	Ot
candidate	NN	Ot
detection	NN	Ot
system	NN	Ot
based	VBN	O
on	IN	O
pixel	JJ	O
classification	NN	O
.	.	O

Using	VBG	O
this	DT	O
technique	NN	O
,	,	O
vasculature	NN	O
and	CC	O
red	JJ	O
lesions	NNS	O
are	VBP	O
separated	VBN	O
from	IN	O
the	DT	O
background	NN	O
of	IN	O
the	DT	O
image	NN	O
.	.	O

After	IN	O
removal	NN	O
of	IN	O
the	DT	O
connected	JJ	O
vasculature	NN	O
the	DT	O
remaining	VBG	O
objects	NNS	O
are	VBP	O
considered	VBN	O
possible	JJ	O
red	JJ	O
lesions	NNS	O
.	.	O

Second	NNP	O
,	,	O
an	DT	O
extensive	JJ	O
number	NN	O
of	IN	O
new	JJ	O
features	NNS	O
are	VBP	O
added	VBN	O
to	TO	O
those	DT	O
proposed	VBN	O
by	IN	O
Spencer-Frame	NNP	O
.	.	O

The	DT	O
detected	JJ	O
candidate	NN	O
objects	NNS	O
are	VBP	O
classified	VBN	O
using	VBG	O
all	DT	O
features	NNS	O
and	CC	O
a	DT	O
k-nearest	JJ	O
neighbor	NN	O
classifier	NN	O
.	.	O

An	DT	O
extensive	JJ	O
evaluation	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
test	NN	O
set	NN	O
composed	VBN	O
of	IN	O
images	NNS	O
representative	NN	O
of	IN	O
those	DT	O
normally	RB	O
found	VBN	O
in	IN	O
a	DT	O
screening	NN	O
set	NN	O
.	.	O

When	WRB	O
determining	VBG	O
whether	IN	O
an	DT	O
image	NN	O
contains	VBZ	O
red	JJ	O
lesions	NNS	O
the	DT	O
system	NN	O
achieves	VBZ	O
a	DT	O
sensitivity	NN	O
of	IN	O
100	CD	O
%	NN	O
at	IN	O
a	DT	O
specificity	NN	O
of	IN	O
87	CD	O
%	NN	O
.	.	O

The	DT	O
method	NN	O
is	VBZ	O
compared	VBN	O
with	IN	O
several	JJ	O
different	JJ	O
automatic	JJ	O
systems	NNS	O
and	CC	O
is	VBZ	O
shown	VBN	O
to	TO	O
outperform	VB	O
them	PRP	O
all	DT	O
.	.	O

Performance	NNP	O
is	VBZ	O
close	RB	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
human	JJ	O
expert	NN	O
examining	VBG	O
the	DT	O
images	NNS	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
.	.	O

Tailored	NNP	E
,	,	E
iterative	JJ	E
,	,	E
printed	JJ	E
dietary	JJ	E
feedback	NN	E
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
group	NN	O
education	NN	O
in	IN	O
improving	VBG	O
dietary	JJ	O
behaviours	NNS	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomised	VBN	O
control	NN	O
trial	NN	O
in	IN	O
middle-aged	JJ	O
adults	NNS	O
with	IN	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

BACKGROUND	NNP	O
Tailored	NNP	O
nutrition	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
non-tailored	JJ	O
materials	NNS	O
in	IN	O
changing	VBG	O
dietary	JJ	O
behaviours	NNS	O
,	,	O
particularly	RB	O
fat	JJ	O
intake	NN	O
and	CC	O
fruit	NN	O
and	CC	O
vegetable	JJ	O
intake	NN	O
.	.	O

But	CC	O
further	JJ	O
research	NN	O
examining	VBG	O
efficacy	NN	O
of	IN	O
tailored	JJ	O
nutrition	NN	O
education	NN	O
in	IN	O
comparison	NN	O
to	TO	O
other	JJ	O
nutrition	JJ	O
education	NN	O
methods	NNS	O
and	CC	O
across	IN	O
a	DT	O
wider	NN	O
range	NN	O
of	IN	O
dietary	JJ	O
behaviours	NNS	O
is	VBZ	O
needed	VBN	O
.	.	O

The	DT	O
Stages	NNPS	O
to	TO	O
Healthy	NNP	O
Eating	NNP	O
Patterns	NNP	O
Study	NNP	O
(	(	O
STEPs	NNP	O
)	)	O
was	VBD	O
an	DT	O
intervention	NN	O
study	NN	O
,	,	O
in	IN	O
middle-aged	JJ	O
adults	NNS	O
with	IN	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
printed	VBN	O
,	,	O
tailored	VBN	O
,	,	O
iterative	JJ	O
dietary	JJ	O
feedback	NN	O
delivered	VBN	O
by	IN	O
mail	NN	O
in	IN	O
improving	VBG	O
short-term	JJ	O
dietary	JJ	O
behaviour	NN	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
saturated	JJ	O
fat	NN	O
,	,	O
fruit	NN	O
,	,	O
vegetable	JJ	O
and	CC	O
grain	NN	O
and	CC	O
cereal	NN	O
intake	NN	O
.	.	O

METHODS	NNP	O
STEPs	NNP	O
was	VBD	O
a	DT	O
3-month	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
with	IN	O
a	DT	O
pre	NN	O
and	CC	O
post-test	JJ	O
design	NN	O
.	.	O

There	EX	O
were	VBD	O
three	CD	O
experimental	JJ	O
conditions	NNS	O
:	:	O
1	CD	O
)	)	O
tailored	VBN	E
,	,	E
iterative	JJ	E
,	,	E
printed	JJ	E
dietary	JJ	E
feedback	NN	E
(	(	E
TF	NNP	E
)	)	E
with	IN	O
three	CD	O
instalments	NNS	O
mail-delivered	JJ	O
over	IN	O
a	DT	O
3-month	JJ	O
period	NN	O
that	WDT	O
were	VBD	O
re-tailored	VBN	O
to	TO	O
most	RBS	O
recent	JJ	O
assessment	NN	O
of	IN	O
dietary	JJ	O
intake	NN	O
,	,	O
intention	NN	O
to	TO	O
change	VB	O
and	CC	O
assessment	NN	O
of	IN	O
self-adequacy	NN	O
of	IN	O
dietary	JJ	O
intake	NN	O
.	.	O

Tailoring	VBG	O
for	IN	O
dietary	JJ	O
intake	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
data	NNS	O
from	IN	O
a	DT	O
validated	JJ	O
63-item	JJ	O
combination	NN	O
FFQ	NNP	O
designed	VBN	O
for	IN	O
the	DT	O
purpose	JJ	O
2	CD	O
)	)	O
small	JJ	O
group	NN	O
nutrition	NN	E
education	NN	E
sessions	NNS	E
(	(	O
GE	NNP	O
)	)	O
:	:	O
consisting	NN	O
of	IN	O
two	CD	O
90-minute	JJ	O
dietitian-led	JJ	O
small	JJ	O
group	NN	O
nutrition	NN	O
education	NN	O
sessions	NNS	O
and	CC	O
3	CD	O
)	)	O
and	CC	O
a	DT	O
wait-listed	JJ	O
control	NN	O
(	(	O
C	NNP	O
)	)	O
group	NN	O
who	WP	O
completed	VBD	O
the	DT	O
dietary	JJ	E
measures	NNS	E
and	CC	E
socio-demographic	JJ	E
questionnaires	NNS	E
at	IN	O
baseline	NN	O
and	CC	O
3-months	JJ	O
later	NN	O
.	.	O

Dietary	NNP	O
outcome	NN	O
measures	NNS	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
saturated	JJ	O
fat	JJ	O
intake	NN	O
(	(	O
g	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
intake	NN	O
of	IN	O
fruit	NN	O
(	(	O
serves	NNS	O
)	)	O
,	,	O
vegetables	NNS	O
(	(	O
serves	NNS	O
)	)	O
,	,	O
grain	NN	O
and	CC	O
cereals	NNS	O
as	IN	O
total	JJ	O
and	CC	O
wholegrain	NN	O
(	(	O
serves	NNS	O
)	)	O
were	VBD	O
collected	VBN	O
using	VBG	O
7-day	JJ	O
estimated	VBN	O
dietary	JJ	O
records	NNS	O
.	.	O

Descriptive	JJ	O
statistics	NNS	O
,	,	O
paired	VBD	O
t-tests	NNS	O
and	CC	O
general	JJ	O
linear	JJ	O
models	NNS	O
adjusted	VBN	O
for	IN	O
baseline	NN	O
dietary	JJ	O
intake	NN	O
,	,	O
age	NN	O
and	CC	O
gender	NN	O
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
different	JJ	O
nutrition	NN	O
interventions	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
TF	NNP	E
group	NN	O
reported	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
increase	NN	O
in	IN	O
fruit	JJ	O
intake	NN	O
(	(	O
0.3	CD	O
serves/d	NN	O
P	NNP	O
=	NNP	O
0.031	CD	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
GE	NNP	O
and	CC	O
the	DT	O
C	NNP	O
group	NN	O
.	.	O

All	DT	O
three	CD	O
intervention	NN	O
groups	NNS	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
total	JJ	O
saturated	JJ	O
fat	JJ	O
intake	NN	O
.	.	O

GE	NNP	O
also	RB	O
had	VBD	O
a	DT	O
within-group	JJ	O
increase	NN	O
in	IN	O
mean	JJ	O
vegetable	JJ	O
intake	NN	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
but	CC	O
this	DT	O
increase	NN	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
changes	NNS	O
in	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
printed	VBN	O
,	,	O
tailored	VBN	O
,	,	O
iterative	JJ	O
dietary	JJ	O
feedback	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
small	JJ	O
group	NN	O
nutrition	NN	O
education	NN	O
in	IN	O
improving	VBG	O
the	DT	O
short-term	JJ	O
fruit	NN	O
intake	VB	O
behaviour	NN	O
,	,	O
and	CC	O
as	IN	O
effective	JJ	O
in	IN	O
improving	VBG	O
saturated	VBN	O
fat	JJ	O
intake	NN	O
of	IN	O
middle-aged	JJ	O
adults	NNS	O
with	IN	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

This	DT	O
showed	VBD	O
that	IN	O
a	DT	O
low-level	JJ	O
dietary	JJ	O
intervention	NN	O
could	MD	O
achieve	VB	O
modest	JJ	O
dietary	JJ	O
behaviour	NN	O
changes	NNS	O
that	WDT	O
are	VBP	O
of	IN	O
public	JJ	O
health	NN	O
significance	NN	O
.	.	O

Sunlight	JJ	C
exposure	NN	C
or	CC	O
vitamin	NN	PM
D	NNP	PM
supplementation	NN	PM
for	IN	O
vitamin	JJ	O
D-deficient	JJ	O
non-western	JJ	O
immigrants	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

UNLABELLED	NNP	O
Vitamin	NNP	PM
D	NNP	PM
deficiency	NN	O
is	VBZ	O
very	RB	O
common	JJ	O
in	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

In	IN	O
this	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
vitamin	NN	PM
D	NNP	PM
800	CD	O
IU/day	NNP	O
or	CC	O
100,000	CD	O
IU/3	JJ	O
months	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
advised	JJ	PH
sunlight	NN	PH
exposure	NN	PH
.	.	O

Vitamin	NNP	PM
D	NNP	PM
supplementation	NN	PM
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
advised	JJ	C
sunlight	JJ	C
exposure	NN	C
in	IN	O
improving	VBG	O
vitamin	NN	O
D	NNP	O
status	NN	O
and	CC	O
lowering	VBG	O
parathyroid	JJ	O
hormone	NN	O
levels	NNS	O
.	.	O

INTRODUCTION	NNP	O
Vitamin	NNP	O
D	NNP	O
deficiency	NN	O
(	(	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
<	VBD	O
25	CD	O
nmol/l	NN	O
)	)	O
is	VBZ	O
common	JJ	O
among	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

It	PRP	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
or	CC	O
sunlight	JJ	O
exposure	NN	O
.	.	O

METHODS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
(	(	O
3	CD	O
)	)	O
supplementation	NN	O
(	(	O
daily	JJ	O
800	CD	O
IU	NNP	O
or	CC	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
)	)	O
or	CC	O
sunlight	JJ	O
exposure	NN	O
advice	NN	O
is	VBZ	O
similar	JJ	O
with	IN	O
regard	NN	O
to	TO	O
serum	VB	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
and	CC	O
parathyroid	VB	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
concentrations	NNS	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
in	IN	O
11	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
The	DT	O
Netherlands	NNP	O
.	.	O

Non-western	JJ	O
immigrants	NNS	O
,	,	O
aged	VBN	O
18-65	CD	O
years	NNS	O
(	(	O
n	JJ	O
=	NNP	O
232	CD	O
)	)	O
and	CC	O
serum	$	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
<	$	O
25	CD	O
nmol/l	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
supplementation	NN	O
(	(	O
daily	JJ	O
800	CD	O
IU	NNP	O
or	CC	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
)	)	O
or	CC	O
advice	NN	O
for	IN	O
sunlight	JJ	O
exposure	NN	O
for	IN	O
6	CD	O
months	NNS	O
(	(	O
March-September	NNP	O
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
,	,	O
during	IN	O
treatment	NN	O
(	(	O
3	CD	O
months	NNS	O
,	,	O
6	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
(	(	O
12	CD	O
months	NNS	O
)	)	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
multilevel	JJ	O
regression	NN	O
modelling	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
intention-to-treat	JJ	O
analysis	NN	O
included	VBD	O
211	CD	O
persons	NNS	O
.	.	O

Baseline	NNP	O
serum	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
was	VBD	O
22.5	CD	O
?	.	O
11.1	CD	O
nmol/l	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
mean	VBP	O
serum	JJ	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
increased	VBD	O
to	TO	O
53	CD	O
nmol/l	NNS	O
with	IN	O
800	CD	O
IU/day	NNP	O
,	,	O
to	TO	O
50.5	CD	O
nmol/l	NNS	O
with	IN	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
,	,	O
and	CC	O
to	TO	O
29.1	CD	O
nmol/l	NNS	O
with	IN	O
advised	JJ	O
sunlight	NN	O
exposure	NN	O
(	(	O
supplementation	NN	O
vs	FW	O
sunshine	NN	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Serum	NNP	O
PTH	NNP	O
decreased	VBD	O
significantly	RB	O
in	IN	O
all	DT	O
groups	NNS	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
more	RBR	O
in	IN	O
the	DT	O
supplementation	NN	O
groups	NNS	O
than	IN	O
in	IN	O
the	DT	O
advised	JJ	O
sunlight	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
physical	JJ	O
performance	NN	O
and	CC	O
functional	JJ	O
limitations	NNS	O
.	.	O

CONCLUSION	NNP	O
Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
advised	JJ	O
sunlight	JJ	O
exposure	NN	O
for	IN	O
treating	VBG	O
vitamin	NN	O
D	NNP	O
deficiency	NN	O
in	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

Eltrombopag	NNP	PM
for	IN	O
management	NN	O
of	IN	O
chronic	JJ	O
immune	NN	O
thrombocytopenia	NN	O
(	(	O
RAISE	NNP	O
)	)	O
:	:	O
a	DT	O
6-month	JJ	O
,	,	O
randomised	VBN	O
,	,	O
phase	VB	O
3	CD	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Eltrombopag	NNP	PM
is	VBZ	O
an	DT	O
oral	JJ	PM
thrombopoietin	NN	PM
receptor	NN	PM
agonist	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
thrombocytopenia	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
response	NN	O
to	TO	O
once	RB	O
daily	JJ	O
eltrombopag	NNS	PM
versus	VBP	O
placebo	NN	C
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
immune	JJ	O
thrombocytopenia	NN	O
during	IN	O
a	DT	O
6-month	JJ	O
period	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
undertook	VBD	O
a	DT	O
phase	NN	O
3	CD	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
study	NN	O
in	IN	O
adults	NNS	O
with	IN	O
previously	RB	O
treated	VBN	O
immune	JJ	O
thrombocytopenia	NN	O
of	IN	O
more	JJR	O
than	IN	O
6	CD	O
months	NNS	O
'	POS	O
duration	NN	O
who	WP	O
had	VBD	O
baseline	NN	O
platelet	NN	O
counts	VBZ	O
lower	JJR	O
than	IN	O
30,000	CD	O
per	IN	O
?L	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
(	(	O
in	IN	O
a	DT	O
2:1	CD	O
ratio	NN	O
)	)	O
treatment	NN	O
with	IN	O
local	JJ	O
standard	NN	O
of	IN	O
care	NN	O
plus	CC	O
50	CD	O
mg	NN	O
eltrombopag	NN	O
or	CC	O
matching	VBG	O
placebo	JJ	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
done	VBN	O
centrally	RB	O
with	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
schedule	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
baseline	JJ	O
platelet	NN	O
count	NN	O
(	(	O
?	.	O
15,000	CD	O
per	IN	O
?L	NN	O
)	)	O
,	,	O
use	NN	O
of	IN	O
treatment	NN	O
for	IN	O
immune	JJ	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
splenectomy	JJ	O
status	NN	O
.	.	O

Patients	NNS	O
,	,	O
investigators	NNS	O
,	,	O
and	CC	O
those	DT	O
assessing	VBG	O
data	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
allocation	NN	O
.	.	O

Dose	JJ	O
modifications	NNS	O
were	VBD	O
made	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
platelet	NN	O
response	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
response	NN	O
to	TO	O
treatment	NN	O
(	(	O
defined	VBN	O
as	IN	O
a	DT	O
platelet	NN	O
count	NN	O
of	IN	O
50,000-400,000	CD	O
per	IN	O
?L	NN	O
)	)	O
weekly	NN	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
weeks	NNS	O
and	CC	O
at	IN	O
least	JJS	O
once	RB	O
every	DT	O
4	CD	O
weeks	NNS	O
thereafter	RB	O
;	:	O
the	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
odds	NNS	O
of	IN	O
response	NN	O
to	TO	O
eltrombopag	VB	O
versus	NN	O
placebo	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00370331	NNP	O
.	.	O

FINDINGS	NNP	O
Between	NNP	O
Nov	NNP	O
22	CD	O
,	,	O
2006	CD	O
,	,	O
and	CC	O
July	NNP	O
31	CD	O
,	,	O
2007	CD	O
,	,	O
197	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
treatment	NN	O
groups	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
intention-to-treat	JJ	O
analysis	NN	O
(	(	O
135	CD	O
eltrombopag	NN	O
,	,	O
62	CD	O
placebo	NN	O
)	)	O
.	.	O

106	CD	O
(	(	O
79	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
eltrombopag	NN	O
group	NN	O
responded	VBD	O
to	TO	O
treatment	NN	O
at	IN	O
least	JJS	O
once	RB	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
compared	VBN	O
with	IN	O
17	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

The	DT	O
odds	NNS	O
of	IN	O
responding	VBG	O
were	VBD	O
greater	JJR	O
in	IN	O
patients	NNS	O
in	IN	O
the	DT	O
eltrombopag	NN	O
group	NN	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
throughout	IN	O
the	DT	O
6-month	JJ	O
treatment	NN	O
period	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
8?2	CD	O
,	,	O
99	CD	O
%	NN	O
CI	NNP	O
3?59-18?73	CD	O
;	:	O
p	CC	O
<	VB	O
0?0001	CD	O
)	)	O
.	.	O

37	CD	O
(	(	O
59	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
reduced	VBD	O
concomitant	JJ	O
treatment	NN	O
versus	NN	O
ten	NN	O
(	(	O
32	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p=0?016	NN	O
)	)	O
.	.	O

24	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
needed	VBN	O
rescue	NN	O
treatment	NN	O
compared	VBN	O
with	IN	O
25	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
p=0?001	NN	O
)	)	O
.	.	O

Three	NNP	O
(	(	O
2	CD	O
%	NN	O
)	)	O
patients	NNS	O
receiving	VBG	O
eltrombopag	NN	O
had	VBD	O
thromboembolic	JJ	O
events	NNS	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
patients	NNS	O
on	IN	O
placebo	NN	O
.	.	O

Nine	NNP	O
(	(	O
7	CD	O
%	NN	O
)	)	O
eltrombopag-treated	JJ	O
patients	NNS	O
and	CC	O
two	CD	O
(	(	O
3	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
had	VBD	O
mild	VBN	O
increases	NNS	O
in	IN	O
alanine	JJ	O
aminotransferase	NN	O
concentration	NN	O
,	,	O
and	CC	O
five	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
eltrombopag-treated	JJ	O
patients	NNS	O
(	(	O
vs	IN	O
none	NN	O
allocated	VBN	O
to	TO	O
placebo	VB	O
)	)	O
had	VBD	O
increases	NNS	O
in	IN	O
total	JJ	O
bilirubin	NN	O
.	.	O

Four	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
patients	NNS	O
taking	VBG	O
placebo	NN	O
had	VBD	O
serious	JJ	O
bleeding	VBG	O
events	NNS	O
,	,	O
compared	VBN	O
with	IN	O
one	CD	O
(	(	O
<	VB	O
1	CD	O
%	NN	O
)	)	O
patient	NN	O
treated	VBN	O
with	IN	O
eltrombopag	NN	O
.	.	O

INTERPRETATION	NNP	O
Eltrombopag	NNP	O
is	VBZ	O
effective	JJ	O
for	IN	O
management	NN	O
of	IN	O
chronic	JJ	O
immune	NN	O
thrombocytopenia	NN	O
,	,	O
and	CC	O
could	MD	O
be	VB	O
particularly	RB	O
beneficial	JJ	O
for	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
not	RB	O
responded	VBN	O
to	TO	O
splenectomy	VB	O
or	CC	O
previous	JJ	O
treatment	NN	O
.	.	O

These	DT	O
benefits	NNS	O
should	MD	O
be	VB	O
balanced	VBN	O
with	IN	O
the	DT	O
potential	JJ	O
risks	NNS	O
associated	VBN	O
with	IN	O
eltrombopag	JJ	O
treatment	NN	O
.	.	O

FUNDING	NN	O
GlaxoSmithKline	NNP	O
.	.	O

A	DT	O
high	JJ	O
intake	NN	O
of	IN	O
trans	NNS	PM
fatty	JJ	PM
acids	NNS	PM
has	VBZ	O
little	JJ	O
effect	NN	O
on	IN	O
markers	NNS	O
of	IN	O
inflammation	NN	O
and	CC	O
oxidative	JJ	O
stress	NN	O
in	IN	O
humans	NNS	O
.	.	O

Consumption	NN	O
of	IN	O
industrial	JJ	PM
trans	NNS	PM
fatty	JJ	PM
acids	NNS	PM
(	(	PM
iTFA	NN	PM
)	)	PM
increases	VBZ	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
decreases	VBZ	O
HDL	NNP	O
cholesterol	NN	O
,	,	O
and	CC	O
is	VBZ	O
strongly	RB	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
(	(	O
CVD	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
changes	NNS	O
in	IN	O
circulating	VBG	O
cholesterol	NN	O
can	MD	O
not	RB	O
explain	VB	O
the	DT	O
entire	JJ	O
effect	NN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
studied	VBD	O
whether	IN	O
iTFA	NN	PM
and	CC	O
conjugated	VBD	PM
linoleic	JJ	PM
acid	NN	PM
(	(	PM
CLA	NNP	PM
)	)	PM
affect	VBP	O
markers	NNS	O
of	IN	O
inflammation	NN	O
and	CC	O
oxidative	JJ	O
stress	NN	O
.	.	O

Sixty-one	CD	O
healthy	JJ	O
adults	NNS	O
consumed	VBD	O
each	DT	O
of	IN	O
3	CD	O
diets	NNS	Ot
for	IN	O
3	CD	O
wk	NN	O
,	,	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Diets	NNS	O
were	VBD	O
identical	JJ	O
except	IN	O
for	IN	O
7	CD	O
%	NN	O
of	IN	O
energy	NN	O
provided	VBN	O
by	IN	O
oleic	JJ	C
acid	NN	C
(	(	C
control	VB	C
diet	NN	C
)	)	C
,	,	O
iTFA	JJ	PM
,	,	O
or	CC	O
CLA	NNP	PM
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
3	CD	O
wk	NN	O
,	,	O
we	PRP	O
measured	VBD	O
plasma	JJ	O
inflammatory	JJ	O
markers	NNS	O
IL-6	NNP	O
,	,	O
C-reactive	NNP	O
protein	NN	O
,	,	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
receptors	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
(	(	O
TNF-RI	NNP	O
and	CC	O
-RII	NNP	O
)	)	O
,	,	O
monocyte	JJ	O
chemotactic	JJ	O
protein-1	NN	O
and	CC	O
E-selectin	NNP	O
,	,	O
and	CC	O
urinary	JJ	O
8-iso-PGF	NN	O
(	(	O
2?	CD	O
)	)	O
,	,	O
a	DT	O
marker	NN	O
of	IN	O
lipid	JJ	O
peroxidation	NN	O
.	.	O

Consumption	NN	O
of	IN	O
iTFA	NN	O
caused	VBD	O
4	CD	O
%	NN	O
lower	JJR	O
TNF-RI	NNP	O
concentrations	NNS	O
and	CC	O
6	CD	O
%	NN	O
higher	JJR	O
E-selectin	JJ	O
concentrations	NNS	O
compared	VBN	O
with	IN	O
oleic	JJ	O
acid	NN	O
(	(	O
control	NN	O
)	)	O
and	CC	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
other	JJ	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

CLA	NNP	O
did	VBD	O
not	RB	O
significantly	RB	O
affect	JJ	O
inflammatory	NN	O
markers	NNS	O
.	.	O

The	DT	O
urine	JJ	O
concentration	NN	O
of	IN	O
8-iso-PGF	JJ	O
(	(	O
2?	CD	O
)	)	O
[	NN	O
geometric	JJ	O
mean	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
]	NN	O
was	VBD	O
greater	JJR	O
after	IN	O
the	DT	O
iTFA	NN	O
[	VBZ	O
0.54	CD	O
(	(	O
0.48	CD	O
,	,	O
0.60	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
]	NN	O
and	CC	O
the	DT	O
CLA	NNP	O
[	NNP	O
1.2	CD	O
(	(	O
1.1	CD	O
,	,	O
1.3	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
]	NNP	O
diet	VBZ	O
periods	NNS	O
than	IN	O
after	IN	O
the	DT	O
control	NN	O
period	NN	O
[	VBD	O
0.45	CD	O
(	(	O
0.41	CD	O
,	,	O
0.50	CD	O
)	)	O
nmol/mmol	FW	O
creatinine	NN	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
]	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
high	JJ	O
intakes	NNS	O
of	IN	O
iTFA	NN	O
and	CC	O
CLA	NNP	O
did	VBD	O
not	RB	O
substantially	RB	O
affect	JJ	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
inflammatory	JJ	O
markers	NNS	O
,	,	O
but	CC	O
they	PRP	O
increased	VBD	O
the	DT	O
urine	JJ	O
8-iso-PGF	JJ	O
(	(	O
2?	CD	O
)	)	O
concentration	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
unlikely	JJ	O
this	DT	O
plays	VBZ	O
a	DT	O
major	JJ	O
role	NN	O
in	IN	O
the	DT	O
mechanism	NN	O
by	IN	O
which	WDT	O
iTFA	JJ	O
increase	NN	O
the	DT	O
risk	NN	O
of	IN	O
CVD	NNP	O
.	.	O

However	RB	O
,	,	O
more	JJR	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
fully	RB	O
understand	VB	O
the	DT	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
.	.	O

Wheelchair	NNP	PH
skills	VBZ	PH
training	NN	PH
to	TO	O
improve	VB	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
among	IN	O
older	JJR	O
adults	NNS	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
wheelchair	NN	PH
skills	NNS	PH
training	VBG	PH
on	IN	O
confidence	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
who	WP	O
are	VBP	O
inexperienced	VBN	O
wheelchair	JJ	O
users	NNS	O
.	.	O

DESIGN	NNP	O
Parallel	NNP	O
group	NN	O
,	,	O
single-blind	JJ	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Research	NNP	O
laboratory	NN	O
in	IN	O
a	DT	O
rehabilitation	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
(	(	O
N=20	NNP	O
)	)	O
who	WP	O
were	VBD	O
community-living	JJ	O
older	JJR	O
adults	NNS	O
at	IN	O
least	JJS	O
65	CD	O
years	NNS	O
old	JJ	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
70y	CD	O
)	)	O
,	,	O
50	CD	O
%	NN	O
women	NNS	O
,	,	O
and	CC	O
who	WP	O
had	VBD	O
no	DT	O
experience	NN	O
of	IN	O
using	VBG	O
a	DT	O
wheelchair	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n=10	JJ	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n=10	JJ	O
)	)	O
group	NN	O
.	.	O

INTERVENTIONS	VBZ	O
The	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
two	CD	PH
1-hour	JJ	PH
training	NN	PH
sessions	NNS	PH
that	WDT	PH
followed	VBD	PH
the	DT	PH
Wheelchair	NNP	PH
Skills	NNP	PH
Training	NNP	PH
Program	NNP	PH
(	(	PH
WSTP	NNP	PH
)	)	PH
protocol	NN	PH
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
a	DT	O
single	JJ	E
socialization	NN	E
contact	NN	E
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
Wheelchair	NNP	O
Use	NNP	O
Confidence	NNP	O
Scale-Manual	JJ	O
(	(	O
WheelCon-M	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
.	.	O

The	DT	O
WheelCon-M	NNP	O
is	VBZ	O
a	DT	O
self-report	JJ	O
questionnaire	NN	O
that	WDT	O
comprises	VBZ	O
65	CD	O
items	NNS	O
in	IN	O
6	CD	O
conceptual	JJ	O
areas	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
1-way	JJ	O
between-groups	JJ	O
analysis	NN	O
of	IN	O
covariance	NN	O
revealed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
postintervention	NN	O
WheelCon-M	JJ	O
scores	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
F1,17=10.9	NNP	O
,	,	O
P=.004	NNP	O
)	)	O
after	IN	O
controlling	VBG	O
for	IN	O
baseline	JJ	O
WheelCon-M	JJ	O
scores	NNS	O
.	.	O

A	DT	O
large	JJ	O
effect	NN	O
size	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
(	(	O
partial	JJ	O
?	.	O
(	(	O
2	CD	O
)	)	O
=.39	NN	O
)	)	O
.	.	O

Secondary	JJ	O
analyses	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
WSTP	NNP	O
had	VBD	O
greater	JJR	O
effects	NNS	O
on	IN	O
confidence	NN	O
in	IN	O
areas	NNS	O
related	VBN	O
to	TO	O
maneuvering	VBG	O
around	IN	O
the	DT	O
physical	JJ	O
environment	NN	O
,	,	O
knowledge	NN	O
and	CC	O
problem	NN	O
solving	NN	O
,	,	O
advocacy	NN	O
,	,	O
and	CC	O
managing	VBG	O
emotions	NNS	O
than	IN	O
in	IN	O
areas	NNS	O
related	VBN	O
to	TO	O
performing	VBG	O
activities	NNS	O
and	CC	O
behaving	VBG	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

CONCLUSION	NNP	O
Two	CD	O
1-hour	JJ	O
WSTP	NNP	O
sessions	NNS	O
improve	VBP	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
among	IN	O
older	JJR	O
adults	NNS	O
who	WP	O
are	VBP	O
inexperienced	VBN	O
wheelchair	JJ	O
users	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
single-dose	JJ	PM
versus	NN	O
conventional-dose	JJ	C
antibiotic	JJ	C
treatment	NN	C
of	IN	O
bacteriuria	NN	O
in	IN	O
elderly	JJ	O
women	NNS	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
single-dose	JJ	PM
antibiotic	JJ	PM
therapy	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bacteriuria	NN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
non-catheterized	JJ	O
elderly	JJ	O
women	NNS	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
conventional	JJ	PM
7-10	JJ	PM
day	NN	PM
courses	NNS	PM
of	IN	PM
antibiotic	JJ	PM
therapy	NN	PM
.	.	O

Thirty-one	JJ	O
women	NNS	O
received	VBD	O
single-dose	JJ	C
treatment	NN	C
and	CC	O
22	CD	O
conventional-dose	JJ	C
treatment	NN	C
.	.	O

The	DT	O
cure	NN	O
rates	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
single-dose	JJ	O
treatments	NNS	O
were	VBD	O
52	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
cure	NN	O
rates	NNS	O
for	IN	O
the	DT	O
conventional-dose	JJ	O
treatments	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
were	VBD	O
59	CD	O
%	NN	O
and	CC	O
52	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
place	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
single-dose	JJ	PM
antibiotic	JJ	PM
therapy	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
selected	VBN	O
elderly	JJ	O
women	NNS	O
with	IN	O
bacteriuria	NN	O
,	,	O
but	CC	O
larger	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Anticholinergic	NNP	PM
drugs	NNS	PM
:	:	O
effects	NNS	O
on	IN	O
oxygen	NN	O
consumption	NN	O
and	CC	O
energy	NN	O
expenditure	NN	O
.	.	O

Premedication	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
affect	VB	O
both	DT	O
oxygen	NN	O
consumption	NN	O
(	(	O
VO2	NNP	O
)	)	O
and	CC	O
energy	NN	O
expenditure	NN	O
(	(	O
EE	NNP	O
)	)	O
.	.	O

The	DT	O
metabolic	JJ	O
responses	NNS	O
to	TO	O
anticholinergic	VB	O
drugs	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
the	DT	O
effects	NNS	O
of	IN	O
anticholinergic	JJ	PM
drugs	NNS	PM
on	IN	O
VO2	NNP	O
and	CC	O
EE	NNP	O
(	(	O
calculated	VBN	O
from	IN	O
the	DT	O
measured	VBN	O
rates	NNS	O
of	IN	O
VO2	NNP	O
and	CC	O
carbon	NN	O
dioxide	NN	O
production	NN	O
[	NNP	O
VCO2	NNP	O
]	NN	O
:	:	O
EE	NNP	O
[	NNP	O
kcal/d	NNP	O
]	NNP	O
=	VBD	O
3.581	CD	O
x	NNP	O
VO2	NNP	O
[	NNP	O
L/d	NNP	O
]	NNP	O
+	VBD	O
1.448	CD	O
x	NNP	O
VCO2	NNP	O
[	NNP	O
L/d	NNP	O
]	NNP	O
-	:	O
32.4	CD	O
)	)	O
were	VBD	O
measured	VBN	O
in	IN	O
six	CD	O
healthy	JJ	O
female	NN	O
volunteers	NNS	O
.	.	O

They	PRP	O
were	VBD	O
given	VBN	O
intramuscular	JJ	O
atropine	NN	PM
(	(	O
15	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
glycopyrrolate	NN	PM
(	(	O
8	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
scopolamine	NN	PM
(	(	O
8	CD	O
micrograms/kg	NN	O
)	)	O
,	,	O
and	CC	O
placebo	NN	C
in	IN	O
a	DT	O
random	JJ	O
double-blind	JJ	O
cross-over	NN	O
design	NN	O
.	.	O

The	DT	O
consecutive	JJ	O
sessions	NNS	O
were	VBD	O
at	IN	O
least	JJS	O
1	CD	O
wk	JJ	O
apart	RB	O
for	IN	O
each	DT	O
subject	NN	O
.	.	O

VO2	NNP	O
and	CC	O
EE	NNP	O
were	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
indirect	JJ	O
calorimetry	NN	O
(	(	O
Deltatrac	NNP	O
)	)	O
.	.	O

Cardiovascular	JJ	O
responses	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
standard	JJ	O
noninvasive	JJ	O
monitoring	NN	O
.	.	O

Plasma	NNP	O
drug	NN	O
concentrations	NNS	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
a	DT	O
sensitive	JJ	O
modification	NN	O
of	IN	O
radioreceptor	NN	O
assay	NN	O
.	.	O

Subjective	JJ	O
responses	NNS	O
were	VBD	O
measured	VBN	O
with	IN	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
.	.	O

Atropine	NNP	PM
and	CC	O
glycopyrrolate	NN	PM
induced	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
heart	NN	O
rate	NN	O
with	IN	O
a	DT	O
simultaneous	JJ	O
decrease	NN	O
in	IN	O
pressure	NN	O
rate	NN	O
quotient	NN	O
(	(	O
PRQ	NNP	O
)	)	O
,	,	O
while	IN	O
scopolamine	NN	O
caused	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
heart	NN	O
rate	NN	O
with	IN	O
a	DT	O
simultaneous	JJ	O
increase	NN	O
in	IN	O
PRQ	NNP	O
.	.	O

Scopolamine	NNP	PM
significantly	RB	O
decreased	VBD	O
both	DT	O
VO2	NNP	O
and	CC	O
EE	NNP	O
,	,	O
whereas	JJ	O
glycopyrrolate	NN	PM
increased	VBD	O
VO2	NNP	O
.	.	O

Atropine	NNP	PM
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
metabolic	JJ	O
variables	NNS	O
.	.	O

Only	RB	O
scopolamine	NN	O
induced	JJ	O
sedation	NN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
atropine	NN	PM
,	,	O
glycopyrrolate	NN	PM
,	,	O
and	CC	O
scopolamine	NN	PM
differ	NN	O
not	RB	O
only	RB	O
in	IN	O
their	PRP$	O
cardiovascular	NN	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
effects	NNS	O
,	,	O
but	CC	O
also	RB	O
in	IN	O
their	PRP$	O
effects	NNS	O
on	IN	O
metabolism	NN	O
.	.	O

Anti-angiogenic	JJ	O
effect	NN	O
of	IN	O
tamoxifen	NN	PM
combined	VBN	PM
with	IN	PM
epirubicin	NN	PM
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

Vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
A	NNP	O
(	(	O
VEGF-A	NNP	O
)	)	O
and	CC	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
2	CD	O
(	(	O
VEGFR2	NNP	O
)	)	O
are	VBP	O
the	DT	O
key	JJ	O
factors	NNS	O
mediating	VBG	O
neo-vascularization	NN	O
.	.	O

They	PRP	O
are	VBP	O
often	RB	O
coexpressed	VBN	O
in	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Sex	NNP	O
steroids	NNS	O
may	MD	O
stimulate	VB	O
angiogenesis	NN	O
via	IN	O
the	DT	O
estrogen	NN	O
receptor	NN	O
(	(	O
ER	NNP	O
)	)	O
pathway	RB	O
.	.	O

We	PRP	O
investigated	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
addition	NN	O
of	IN	O
tamoxifen	NN	PM
to	TO	PM
epirubicin	VB	PM
versus	NN	PM
epirubicin	FW	PM
alone	RB	PM
on	IN	O
VEGF	NNP	O
and	CC	O
VEGFR2	NNP	O
expression	NN	O
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

The	DT	O
expression	NN	O
of	IN	O
VEGF	NNP	O
and	CC	O
VEGFR2	NNP	O
was	VBD	O
assessed	VBN	O
on	IN	O
tissue	NN	O
microarray	NN	O
by	IN	O
immunohistochemistry	NN	O
at	IN	O
baseline	JJ	O
conditions	NNS	O
and	CC	O
after	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
191	CD	O
patients	NNS	O
with	IN	O
T2-4	NNP	O
N0-1	NNP	O
breast	NN	O
cancer	NN	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
four	CD	O
cycles	NNS	O
of	IN	O
single	JJ	O
agent	NN	O
epirubicin	NN	O
versus	NN	O
epirubicin	NN	O
plus	CC	O
tamoxifen	NN	O
as	IN	O
primary	JJ	O
systemic	JJ	O
treatment	NN	O
.	.	O

Epirubicin	NNP	O
alone	RB	O
failed	VBD	O
to	TO	O
induce	VB	O
changes	NNS	O
in	IN	O
VEGF	NNP	O
expression	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.54	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
addition	NN	O
of	IN	O
tamoxifen	NN	PM
to	TO	PM
epirubicin	VB	PM
resulted	VBN	O
in	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
VEGF	NNP	O
expression	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

As	IN	O
a	DT	O
consequence	NN	O
,	,	O
baseline	NN	O
VEGF	NNP	O
had	VBD	O
a	DT	O
negative	JJ	O
prognostic	JJ	O
role	NN	O
in	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
epirubicin	JJ	O
alone	RB	O
but	CC	O
not	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
epirubicin	JJ	PM
plus	CC	PM
tamoxifen	JJ	PM
(	(	O
interaction	JJ	O
test	NN	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

VEGFR2	NNP	O
expression	NN	O
increased	VBD	O
at	IN	O
residual	JJ	O
tumor	NN	O
histology	NN	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
,	,	O
with	IN	O
a	DT	O
lesser	JJR	O
extent	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
tamoxifen	JJ	PM
plus	CC	PM
epirubicin	JJ	PM
.	.	O

Decrease	NNP	O
in	IN	O
VEGFR2	NNP	O
expression	NN	O
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
response	NN	O
rate	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
addition	NN	PM
of	IN	PM
tamoxifen	NN	PM
to	TO	PM
epirubicin	VB	PM
resulted	VBN	O
in	IN	O
a	DT	O
suppression	NN	O
of	IN	O
a	DT	O
key	JJ	O
angiogenic	JJ	O
pathway	NN	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
a	DT	O
potential	JJ	O
synergism	NN	O
of	IN	O
these	DT	O
two	CD	O
drugs	NNS	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
early	JJ	E
discharge	NN	E
after	IN	O
uncomplicated	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Out	IN	O
of	IN	O
383	CD	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
patients	NNS	O
aged	VBN	O
below	IN	O
70	CD	O
years	NNS	O
,	,	O
252	CD	O
(	(	O
66	CD	O
%	NN	O
)	)	O
were	VBD	O
judged	VBN	O
after	IN	O
the	DT	O
third	JJ	O
day	NN	O
in	IN	O
hospital	NN	O
to	TO	O
have	VB	O
had	VBN	O
uncomplicated	VBN	O
infarctions	NNS	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
at	IN	O
random	NN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
one	CD	E
of	IN	E
which	WDT	E
was	VBD	E
given	VBN	E
treatment	NN	E
for	IN	E
8	CD	E
days	NNS	E
and	CC	E
the	DT	E
other	JJ	E
for	IN	E
15	CD	E
days	NNS	E
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
mortality	NN	O
,	,	O
morbidity	NN	O
or	CC	O
incapacity	NN	O
for	IN	O
work	NN	O
could	MD	O
be	VB	O
detected	VBN	O
during	IN	O
the	DT	O
three-month	JJ	O
period	NN	O
of	IN	O
follow-up	NN	O
.	.	O

The	DT	O
findings	NNS	O
thus	RB	O
support	VBP	O
previous	JJ	O
conclusions	NNS	O
that	WDT	O
early	RB	E
discharge	VBP	E
from	IN	O
hospital	NN	O
after	IN	O
uncomplicated	JJ	O
MI	NNP	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
greater	JJR	O
risk	NN	O
for	IN	O
the	DT	O
patient	NN	O
than	IN	O
later	RB	O
discharge	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
n3	JJ	PM
fatty	JJ	PM
acid	NN	PM
ethyl	NN	PM
esters	NNS	PM
increases	VBZ	O
large	JJ	O
and	CC	O
small	JJ	O
artery	NN	O
elasticity	NN	O
in	IN	O
obese	JJ	O
adults	NNS	O
on	IN	O
a	DT	O
weight	JJ	O
loss	NN	O
diet	NN	O
.	.	O

Increased	VBN	O
arterial	JJ	O
stiffness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
enhanced	JJ	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
obese	JJ	O
individuals	NNS	O
.	.	O

Whether	NNP	O
n3	JJ	PM
fatty	RB	PM
acid	JJ	PM
ethyl	NN	PM
ester	NN	PM
(	(	PM
FAEE	NNP	PM
)	)	PM
supplementation	NN	PM
improves	VBZ	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
obese	JJ	O
participants	NNS	O
on	IN	O
a	DT	O
weight	JJ	O
loss	NN	O
diet	NN	O
has	VBZ	O
not	RB	O
yet	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
carry	VB	O
out	RP	O
a	DT	O
12-wk	JJ	O
randomized	NN	O
,	,	O
single-blind	JJ	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
25	CD	O
%	NN	O
energy	NN	PH
deficit	NN	PH
weight	VBD	PH
loss	NN	PH
diet	NN	PH
alone	RB	O
(	(	O
WL	NNP	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
or	CC	O
WL	NNP	Ot
plus	CC	PM
4	CD	PM
g/d	NN	PM
Omacor	NNP	PM
(	(	O
46	CD	PM
%	NN	PM
EPA	NNP	PM
and	CC	O
38	CD	PM
%	NN	PM
DHA	NNP	PM
)	)	PM
supplementation	NN	PM
(	(	PM
WL+FAEE	NNP	PM
)	)	PM
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
on	IN	O
arterial	JJ	O
elasticity	NN	O
in	IN	O
obese	JJ	O
adults	NNS	O
.	.	O

Large	NNP	O
(	(	O
C1	NNP	O
)	)	O
and	CC	O
small	JJ	O
artery	NN	O
elasticity	NN	O
(	(	O
C2	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
by	IN	O
pulse	JJ	O
contour	NN	O
analysis	NN	O
of	IN	O
the	DT	O
radial	JJ	O
artery	NN	O
.	.	O

WL	NNP	O
alone	RB	O
reduced	VBD	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
in	IN	O
all	DT	O
)	)	O
body	NN	O
weight	NN	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
,	,	O
waist	JJ	O
circumference	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
systolic	JJ	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
-3	CD	O
%	NN	O
)	)	O
blood	NN	O
pressures	NNS	O
,	,	O
cardiac	JJ	O
output	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
TG	NNP	O
concentration	NN	O
(	(	O
-25	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
homeostasis	NN	O
model	NN	O
assessment	NN	O
(	(	O
HOMA	NNP	O
)	)	O
score	NN	O
(	(	O
-12	CD	O
%	NN	O
)	)	O
and	CC	O
increased	VBD	O
plasma	NN	O
HDL	NNP	O
cholesterol	NN	O
(	(	O
+9	CD	O
%	NN	O
)	)	O
and	CC	O
adiponectin	NN	O
(	(	O
+18	CD	O
%	NN	O
)	)	O
concentrations	NNS	O
.	.	O

However	RB	O
,	,	O
WL	NNP	PH
alone	RB	O
did	VBD	O
not	RB	O
alter	VB	O
C1	NNP	O
and	CC	O
C2	NNP	O
.	.	O

The	DT	O
WL+FAEE	NNP	PM
intervention	NN	PM
significantly	RB	O
reduced	VBN	O
body	NN	O
weight	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
waist	JJ	O
circumference	NN	O
(	(	O
-4	CD	O
%	NN	O
)	)	O
,	,	O
systolic	JJ	O
(	(	O
-8	CD	O
%	NN	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
-5	CD	O
%	NN	O
)	)	O
blood	NN	O
pressures	NNS	O
,	,	O
pulse	JJ	O
pressure	NN	O
(	(	O
-5	CD	O
%	NN	O
)	)	O
,	,	O
heart	NN	O
rate	NN	O
(	(	O
-8	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
TG	NNP	O
concentration	NN	O
(	(	O
-36	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
HOMA	NNP	O
score	NN	O
(	(	O
-12	CD	O
%	NN	O
)	)	O
and	CC	O
increased	JJ	O
stroke	NN	O
volume	NN	O
(	(	O
+3	CD	O
%	NN	O
)	)	O
,	,	O
plasma	JJ	O
HDL	NNP	O
cholesterol	NN	O
(	(	O
+6	CD	O
%	NN	O
)	)	O
and	CC	O
adiponectin	JJ	O
concentrations	NNS	O
(	(	O
+28	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
C1	NNP	O
(	(	O
+20	NNP	O
%	NN	O
)	)	O
and	CC	O
C2	NNP	O
(	(	O
+22	NNP	O
%	NN	O
)	)	O
artery	NN	O
elasticity	NN	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
plasma	NN	O
TGs	NNP	O
,	,	O
C1	NNP	O
,	,	O
and	CC	O
C2	NNP	O
were	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
WL+FAEE	NNP	PM
group	NN	O
than	IN	O
in	IN	O
the	DT	O
WL	NNP	PH
group	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
n3	JJ	PM
FAEEs	NNP	PM
improves	VBZ	O
C1	NNP	O
and	CC	O
C2	NNP	O
independently	RB	O
of	IN	O
weight	JJ	O
loss	NN	O
in	IN	O
obese	JJ	O
adults	NNS	O
.	.	O

Blood	NNP	PH
purification	NN	PH
for	IN	O
critical	JJ	O
care	NN	O
medicine	NN	O
:	:	O
endotoxin	NN	O
adsorption	NN	O
.	.	O

Many	JJ	O
kinds	NNS	O
of	IN	O
blood	NN	PH
purifying	VBG	PH
technologies	NNS	PH
have	VBP	O
been	VBN	O
applied	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
since	IN	O
1979	CD	O
when	WRB	O
plasma	JJ	O
exchange	NN	O
with	IN	O
hollow-fiber	JJ	O
membranes	NNS	O
was	VBD	O
developed	VBN	O
.	.	O

These	DT	O
technologies	NNS	O
have	VBP	O
been	VBN	O
applied	VBN	O
not	RB	O
only	RB	O
to	TO	O
the	DT	O
removal	NN	O
of	IN	O
toxic	JJ	O
substances	NNS	O
,	,	O
but	CC	O
also	RB	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
objective	JJ	O
diseases	NNS	O
and	CC	O
the	DT	O
removal	NN	O
of	IN	O
the	DT	O
factors	NNS	O
relating	VBG	O
to	TO	O
the	DT	O
associated	VBN	O
inflammation	NN	O
.	.	O

This	DT	O
article	NN	O
summarizes	VBZ	O
these	DT	O
methods	NNS	O
and	CC	O
their	PRP$	O
efficacies	NNS	O
for	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
,	,	O
especially	RB	O
those	DT	O
with	IN	O
severe	JJ	O
sepsis	NN	O
.	.	O

Attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
remove	VB	O
endotoxin	NN	O
,	,	O
the	DT	O
main	JJ	O
cause	NN	O
of	IN	O
sepsis	NN	O
,	,	O
from	IN	O
the	DT	O
circulation	NN	O
using	VBG	O
polymyxin	NN	O
B	NNP	O
immobilized	VBD	O
fiber	NN	O
,	,	O
charcoal	NN	O
hemoperfusion	NN	O
,	,	O
and	CC	O
plasma	NN	PH
or	CC	PH
whole	JJ	PH
blood	NN	PH
exchange	NN	PH
.	.	O

Attempts	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
made	VBN	O
to	TO	O
remove	VB	O
proinflammatory	NN	O
cytokines	NNS	O
,	,	O
eicosanoides	NNS	O
,	,	O
and	CC	O
coagulative	JJ	O
factors	NNS	O
from	IN	O
the	DT	O
circulation	NN	O
in	IN	O
the	DT	O
human	JJ	O
body	NN	O
.	.	O

Continuous	JJ	O
hemofiltration	NN	O
or	CC	O
hemodiafiltration	NN	O
is	VBZ	O
the	DT	O
representative	JJ	O
technology	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
these	DT	O
methods	NNS	O
has	VBZ	O
been	VBN	O
established	VBN	O
,	,	O
but	CC	O
several	JJ	O
issues	NNS	O
remain	VBP	O
unresolved	JJ	O
.	.	O

All	DT	O
methods	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
of	IN	O
severe	JJ	O
sepsis	NN	O
are	VBP	O
discussed	VBN	O
with	IN	O
reference	NN	O
to	TO	O
treatment	NN	O
indications	NNS	O
,	,	O
efficacy	NN	O
,	,	O
and	CC	O
outcome	JJ	O
parameters	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
clinical	JJ	O
results	NNS	O
of	IN	O
endotoxin	JJ	O
removal	NN	O
with	IN	O
polymyxin	NN	O
B	NNP	O
immobilized	JJ	O
fiber	NN	O
are	VBP	O
summarized	VBN	O
in	IN	O
this	DT	O
article	NN	O
.	.	O

A	DT	O
randomised	JJ	O
open	JJ	O
multicentre	NN	O
comparative	JJ	O
trial	NN	O
of	IN	O
lamotrigine	NN	PM
and	CC	O
carbamazepine	NN	PM
as	IN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
or	CC	O
recurrent	JJ	O
epilepsy	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
lamotrigine	NN	PM
and	CC	O
carbamazepine	NN	PM
as	IN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
untreated	JJ	O
,	,	O
newly	RB	O
diagnosed	VBN	O
or	CC	O
recurrent	JJ	O
partial	JJ	O
and/or	NN	O
generalised	VBD	O
tonic-clonic	JJ	O
seizures	NNS	O
,	,	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
open	JJ	O
,	,	O
multicentre	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
received	VBD	O
24	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
with	IN	O
oral	JJ	PM
lamotrigine	NN	PM
100	CD	PM
mg	NN	PM
(	(	PM
LTG	NNP	PM
100	CD	PM
,	,	PM
n	RB	PM
=	VBZ	PM
115	CD	PM
)	)	PM
or	CC	O
200	CD	PM
mg	NN	PM
(	(	PM
LTG	NNP	PM
200	CD	PM
,	,	PM
n	RB	PM
=	VBZ	PM
111	CD	PM
)	)	PM
or	CC	O
carbamazepine	$	PM
600	CD	PM
mg	NN	PM
(	(	PM
CBZ	NNP	PM
600	CD	O
,	,	O
n	RB	O
=	VBZ	O
117	CD	O
)	)	O
.	.	O

Efficacy	NN	O
measurements	NNS	O
were	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
three	CD	O
treatment	NN	O
groups	NNS	O
,	,	O
although	IN	O
the	DT	O
higher	JJR	O
lamotrigine	NN	PM
dose	NN	O
was	VBD	O
possibly	RB	O
most	RBS	O
effective	JJ	O
,	,	O
with	IN	O
60.4	CD	O
%	NN	O
completing	VBG	O
seizure	NN	O
free	JJ	O
compared	VBN	O
with	IN	O
51.3	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
54.7	CD	O
%	NN	O
(	(	O
CBZ	NNP	O
600	CD	O
)	)	O
.	.	O

Both	DT	O
dosage	NN	O
regimens	NNS	O
of	IN	O
lamotrigine	NN	PM
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

More	JJR	O
patients	NNS	O
on	IN	O
CBZ	NNP	PM
600	CD	O
reported	VBD	O
adverse	JJ	O
experiences	NNS	O
,	,	O
66	CD	O
%	NN	O
versus	IN	O
53	CD	O
%	NN	O
(	(	O
LTG	NNP	PM
100	CD	O
)	)	O
and	CC	O
58	CD	O
%	NN	O
(	(	O
LTG	NNP	PM
200	CD	O
)	)	O
,	,	O
and	CC	O
of	IN	O
these	DT	O
a	DT	O
greater	JJR	O
proportion	NN	O
were	VBD	O
attributed	VBN	O
to	TO	O
CBZ	NNP	PM
600	CD	O
treatment	NN	O
,	,	O
53	CD	O
%	NN	O
versus	IN	O
23	CD	O
%	NN	O
(	(	O
LTG	NNP	O
100	CD	O
)	)	O
and	CC	O
28	CD	O
%	NN	O
(	(	O
LTG	NNP	O
200	CD	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
the	DT	O
CBZ	NNP	PM
600	CD	O
group	NN	O
required	VBD	O
a	DT	O
change	NN	O
in	IN	O
dose	NN	O
,	,	O
47	CD	O
%	NN	O
versus	IN	O
20	CD	O
%	NN	O
(	(	O
LTG	NNP	PM
100	CD	O
)	)	O
and	CC	O
17	CD	O
%	NN	O
(	(	O
LTG	NNP	PM
200	CD	O
)	)	O
or	CC	O
withdrew	$	O
completely	RB	O
due	JJ	O
to	TO	O
adverse	JJ	O
experiences	NNS	O
,	,	O
10.3	CD	O
%	NN	O
versus	IN	O
4.3	CD	O
%	NN	O
(	(	O
LTG	NNP	PM
100	CD	O
)	)	O
and	CC	O
4.5	CD	O
%	NN	O
(	(	O
LTG	NNP	PM
200	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
experience	NN	O
leading	VBG	O
to	TO	O
withdrawal	VB	O
was	VBD	O
rash	NN	O
,	,	O
with	IN	O
approximately	RB	O
double	JJ	O
the	DT	O
proportion	NN	O
of	IN	O
reports	NNS	O
occurring	VBG	O
in	IN	O
patients	NNS	O
on	IN	O
CBZ	NNP	PM
600	CD	O
(	(	O
5.1	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
lamotrigine	NN	PM
(	(	O
1.7	CD	O
%	NN	O
on	IN	O
LTG	NNP	PM
100	CD	O
and	CC	O
2.7	CD	O
%	NN	O
on	IN	O
LTG	NNP	PM
200	CD	O
)	)	O
.	.	O

Overall	JJ	O
lamotrigine	NN	PM
appeared	VBD	O
equally	RB	O
effective	JJ	O
but	CC	O
better	RB	O
tolerated	VBD	O
compared	VBN	O
with	IN	O
carbamazepine	NN	PM
.	.	O

Unpacking	VBG	O
attitude	JJ	O
certainty	NN	O
:	:	O
attitude	NN	O
clarity	NN	O
and	CC	O
attitude	NN	O
correctness	NN	O
.	.	O

Attitude	NNP	O
certainty	NN	O
has	VBZ	O
been	VBN	O
the	DT	O
subject	NN	O
of	IN	O
considerable	JJ	O
attention	NN	O
in	IN	O
the	DT	O
attitudes	NNS	O
and	CC	O
persuasion	NN	O
literature	NN	O
.	.	O

The	DT	O
present	JJ	O
research	NN	O
identifies	VBZ	O
2	CD	O
aspects	NNS	O
of	IN	O
attitude	NN	O
certainty	NN	O
and	CC	O
provides	VBZ	O
evidence	NN	O
for	IN	O
the	DT	O
distinctness	NN	O
of	IN	O
the	DT	O
constructs	NNS	O
.	.	O

Specifically	RB	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
attitude	JJ	O
certainty	NN	O
can	MD	O
be	VB	O
conceptualized	VBN	O
,	,	O
and	CC	O
empirically	RB	O
separated	VBN	O
,	,	O
in	IN	O
terms	NNS	O
of	IN	O
attitude	NN	O
clarity	NN	O
(	(	O
the	DT	O
subjective	NN	O
sense	NN	O
that	WDT	O
one	CD	O
knows	VBZ	O
what	WP	O
one	CD	O
's	POS	O
attitude	NN	O
is	VBZ	O
)	)	O
and	CC	O
attitude	JJ	O
correctness	NN	O
(	(	O
the	DT	O
subjective	NN	O
sense	NN	O
that	IN	O
one	CD	O
's	POS	O
attitude	NN	O
is	VBZ	O
correct	JJ	O
or	CC	O
valid	JJ	O
)	)	O
.	.	O

Experiment	JJ	O
1	CD	O
uses	NNS	O
factor	NN	O
analysis	NN	O
and	CC	O
correlational	JJ	O
data	NNS	O
to	TO	O
provide	VB	O
evidence	NN	O
for	IN	O
viewing	VBG	O
attitude	JJ	O
clarity	NN	O
and	CC	O
attitude	NN	O
correctness	NN	O
as	IN	O
separate	JJ	O
constructs	NNS	O
.	.	O

Experiments	NNS	O
2	CD	O
and	CC	O
3	CD	O
demonstrate	NN	O
that	WDT	O
attitude	VBP	E
clarity	NN	E
and	CC	O
attitude	NN	E
correctness	NN	E
can	MD	O
have	VB	O
distinct	JJ	O
antecedents	NNS	O
(	(	O
repeated	VBN	O
expression	NN	O
and	CC	O
consensus	NN	O
feedback	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Experiment	JJ	O
4	CD	O
reveals	NNS	O
that	IN	O
these	DT	O
constructs	NNS	O
each	DT	O
play	VBP	O
an	DT	O
independent	JJ	O
role	NN	O
in	IN	O
persuasion	NN	O
and	CC	O
resistance	NN	O
situations	NNS	O
.	.	O

As	IN	O
clarity	NN	O
and	CC	O
correctness	JJ	O
increase	NN	O
,	,	O
attitudes	VBZ	O
become	VBP	O
more	RBR	O
resistant	JJ	O
to	TO	O
counterattitudinal	JJ	O
persuasive	JJ	O
messages	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
existing	VBG	O
attitude	NN	O
strength	NN	O
literature	NN	O
.	.	O

Benefits	NNS	O
of	IN	O
adding	VBG	O
fluticasone	NN	PM
propionate/salmeterol	NN	PM
to	TO	O
tiotropium	VB	PM
in	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
COPD	NNP	O
.	.	O

BACKGROUND	NNP	O
Combining	NNP	O
maintenance	NN	O
medications	NNS	O
with	IN	O
different	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
may	MD	O
improve	VB	O
outcomes	NNS	O
in	IN	O
COPD	NNP	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
fluticasone/salmeterol	NN	PM
(	(	PM
FSC	NNP	PM
)	)	PM
(	(	O
250/50	CD	O
mcg	NN	O
twice	RB	O
daily	RB	O
)	)	O
when	WRB	O
added	VBN	O
to	TO	O
tiotropium	VB	PM
(	(	O
18	CD	O
mcg	NN	O
once	RB	O
daily	RB	O
)	)	O
(	(	O
TIO	NNP	O
)	)	O
in	IN	O
subjects	NNS	O
with	IN	O
symptomatic	JJ	O
moderate	NN	O
to	TO	O
severe	VB	O
COPD	NNP	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
24-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
,	,	O
multi-center	NN	O
study	NN	O
.	.	O

Subjects	VBZ	O
40	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
cigarette	NN	O
smoking	VBG	O
history	NN	O
?10	JJ	O
pack-years	NNS	O
and	CC	O
with	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
COPD	NNP	O
and	CC	O
post-bronchodilator	NN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
?40	NN	O
to	TO	O
?	.	O
80	CD	O
%	NN	O
of	IN	O
predicted	VBN	O
normal	JJ	O
and	CC	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
/FVC	NN	O
of	IN	O
?0.70	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Following	VBG	O
a	DT	O
4-week	JJ	O
treatment	NN	O
with	IN	O
open-label	JJ	O
TIO	NNP	O
18	CD	O
mcg	NN	O
once	RB	O
daily	JJ	O
,	,	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
to	TO	O
either	VB	O
the	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
250/50	CD	O
DISKUS	NNP	O
twice	RB	O
daily	RB	O
or	CC	O
matching	VBG	O
placebo	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
AM	NNP	O
pre-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
and	CC	O
secondary	JJ	O
endpoints	NNS	O
included	VBD	O
other	JJ	O
measures	NNS	O
of	IN	O
lung	NN	O
function	NN	O
,	,	O
rescue	NN	O
albuterol	NN	O
use	NN	O
,	,	O
health	NN	O
status	NN	O
and	CC	O
exacerbations	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
to	TO	O
TIO	NNP	O
significantly	RB	O
improved	VBD	O
lung	JJ	O
function	NN	O
indices	NNS	O
including	VBG	O
AM	NNP	O
pre-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
2	CD	O
h	NN	O
post-dose	JJ	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
,	,	O
AM	NNP	O
pre-dose	JJ	O
FVC	NNP	O
,	,	O
2	CD	O
h	NN	O
post-dose	JJ	O
FVC	NNP	O
and	CC	O
AM	NNP	O
pre-dose	JJ	O
IC	NNP	O
compared	VBN	O
with	IN	O
TIO	NNP	O
alone	RB	O
.	.	O

Furthermore	RB	O
,	,	O
this	DT	O
combination	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
TIO	VB	O
alone	RB	O
in	IN	O
reducing	VBG	O
rescue	NN	O
albuterol	NN	O
use	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
in	IN	O
health	NN	O
status	NN	O
or	CC	O
COPD	NNP	O
exacerbations	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
FSC	NNP	O
to	TO	O
subjects	NNS	O
with	IN	O
COPD	NNP	O
treated	VBD	O
with	IN	O
TIO	NNP	O
significantly	RB	O
improves	VBZ	O
lung	JJ	O
function	NN	O
without	IN	O
increasing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

NCT00784550	NNP	O
.	.	O

Effect	NN	O
of	IN	O
daily	JJ	O
etidronate	NN	PM
on	IN	O
the	DT	O
osteolysis	NN	O
of	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Progressive	NNP	O
bone	NN	O
disease	NN	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
frequently	RB	O
leads	VBZ	O
to	TO	O
osteolysis	VB	O
,	,	O
bone	NN	O
resorption	NN	O
,	,	O
pathologic	JJ	O
fractures	NNS	O
,	,	O
vertebral	JJ	O
compression	NN	O
,	,	O
and	CC	O
hypercalcemia	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
double-blind	NN	O
study	NN	O
in	IN	O
173	CD	O
newly	RB	O
diagnosed	VBN	O
multiple	JJ	O
myeloma	NN	O
patients	NNS	O
of	IN	O
etidronate	JJ	O
disodium	NN	O
(	(	O
EHDP	NNP	O
)	)	O
,	,	O
a	DT	O
diphosphonate	NN	O
compound	NN	O
that	WDT	O
reduces	VBZ	O
bone	NN	O
resorption	NN	O
by	IN	O
inhibiting	VBG	O
osteoclastic	JJ	O
activity	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
oral	JJ	PM
EHDP	NNP	PM
5	CD	PM
mg/kg/d	NN	PM
or	CC	O
placebo	NN	C
until	IN	O
death	NN	O
or	CC	O
discontinuation	NN	O
due	JJ	O
to	TO	O
intolerance	VB	O
or	CC	O
refusal	VB	O
.	.	O

The	DT	O
extent	NN	O
of	IN	O
vertebral	JJ	O
deformity	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
vertebral	JJ	O
index	NN	O
as	RB	O
well	RB	O
as	IN	O
height	NN	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
pathologic	JJ	O
fractures	NNS	O
,	,	O
hypercalcemia	NN	O
,	,	O
and	CC	O
bone	NN	O
pain	NN	O
was	VBD	O
regularly	RB	O
assessed	VBN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
size	NN	O
and	CC	O
number	NN	O
of	IN	O
osteolytic	JJ	O
lesions	NNS	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
melphalan	JJ	PM
and	CC	O
prednisone	JJ	PM
daily	JJ	O
for	IN	O
4	CD	O
days	NNS	O
every	DT	O
4	CD	O
weeks	NNS	O
as	IN	O
the	DT	O
primary	JJ	O
chemotherapy	NN	O
for	IN	O
their	PRP$	O
disease	NN	O
.	.	O

Although	IN	O
the	DT	O
repeated	JJ	O
measures	NNS	O
analysis	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
height	JJ	O
loss	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
arms	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.98	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
bone	NN	O
pain	NN	O
,	,	O
episodes	NNS	O
of	IN	O
hypercalcemia	NN	O
,	,	O
or	CC	O
development	NN	O
of	IN	O
pathologic	JJ	O
fractures	NNS	O
.	.	O

Patients	NNS	O
on	IN	O
EHDP	NNP	PM
showed	VBD	O
less	JJR	O
deterioration	NN	O
in	IN	O
their	PRP$	O
vertebral	JJ	O
index	NN	O
,	,	O
but	CC	O
this	DT	O
difference	NN	O
only	RB	O
approached	VBD	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
.07	NNP	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
EHDP	NNP	PM
therapy	NN	O
used	VBN	O
in	IN	O
this	DT	O
dosage	NN	O
schedule	NN	O
does	VBZ	O
not	RB	O
have	VB	O
a	DT	O
clinically	RB	O
significant	JJ	O
impact	NN	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Bevacizumab	NNP	PM
compared	VBN	O
with	IN	O
macular	JJ	PH
laser	NN	PH
grid	JJ	PH
photocoagulation	NN	PH
for	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
in	IN	O
branch	JJ	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

INTRODUCTION	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
outcome	NN	O
of	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
treated	VBN	O
with	IN	O
intravitreal	JJ	PM
injections	NNS	PM
of	IN	PM
bevacizumab	NN	PM
and	CC	O
macular	JJ	PH
grid	NN	PH
laser	NN	PH
photocoagulation	NN	PH
(	(	PH
GLP	NNP	PH
)	)	PH
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
perfused	JJ	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
eyes	NNS	O
of	IN	O
30	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
secondary	JJ	O
to	TO	O
nonischemic	JJ	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	DT	O
GLP	NNP	PH
group	NN	O
or	CC	O
to	TO	O
intravitreal	VB	PM
bevacizumab	NN	PM
(	(	PM
IB	NNP	PM
)	)	PM
group	NN	O
.	.	O

Complete	NNP	O
ophthalmologic	JJ	O
examinations	NNS	O
were	VBD	O
performed	VBN	O
just	RB	O
before	IN	O
GLP	NNP	PH
and	CC	O
IB	NNP	PM
injection	NN	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
.	.	O

Changes	NNS	O
in	IN	O
logarithm	NN	O
of	IN	O
minimum	JJ	O
angle	NN	O
of	IN	O
resolution	NN	O
(	(	O
logMAR	JJ	O
)	)	O
best-corrected	JJ	O
visual	JJ	O
acuity	NN	O
(	(	O
BCVA	NNP	O
)	)	O
,	,	O
central	JJ	O
macular	JJ	O
thickness	NN	O
(	(	O
CMT	NNP	O
)	)	O
shown	VBN	O
by	IN	O
optical	JJ	O
coherence	NN	O
tomography-3	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
BCVA	NNP	O
(	(	O
logMAR	NN	O
)	)	O
and	CC	O
CMT	NNP	O
were	VBD	O
,	,	O
respectively	RB	O
,	,	O
0.89	CD	O
+/-	JJ	O
0.13	CD	O
and	CC	O
650	CD	O
+/-	JJ	O
140	CD	O
microm	NN	O
for	IN	O
the	DT	O
GLP	NNP	PH
group	NN	O
,	,	O
0.87	CD	O
+/-	JJ	O
0.16	CD	O
and	CC	O
690	CD	O
+/-	JJ	O
120	CD	O
microm	NN	O
for	IN	O
the	DT	O
IB	NNP	PM
group	NN	O
.	.	O

After	IN	O
the	DT	O
treatment	NN	O
,	,	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
in	IN	O
the	DT	O
GLP	NNP	PH
group	NN	O
,	,	O
BCVA	NNP	O
had	VBD	O
improved	VBN	O
by	IN	O
0.19	CD	O
,	,	O
0.22	CD	O
,	,	O
0.21	CD	O
,	,	O
and	CC	O
0.20	CD	O
logMAR	NN	O
,	,	O
CMT	NNP	O
had	VBD	O
decreased	VBN	O
by	IN	O
40	CD	O
%	NN	O
,	,	O
41.3	CD	O
%	NN	O
,	,	O
40.5	CD	O
%	NN	O
,	,	O
and	CC	O
42	CD	O
%	NN	O
.	.	O

In	IN	O
the	DT	O
IB	NNP	PM
group	NN	O
,	,	O
BCVA	NNP	O
had	VBD	O
improved	VBN	O
by	IN	O
0.31	CD	O
,	,	O
0.32	CD	O
,	,	O
0.30	CD	O
,	,	O
and	CC	O
0.31	CD	O
logMAR	NN	O
and	CC	O
CMT	NNP	O
had	VBD	O
decreased	VBN	O
by	IN	O
59.5	CD	O
%	NN	O
,	,	O
59	CD	O
%	NN	O
,	,	O
60	CD	O
%	NN	O
,	,	O
and	CC	O
60.3	CD	O
%	NN	O
.	.	O

The	DT	O
group	NN	O
receiving	VBG	O
bevacizumab	NN	PM
had	VBD	O
better	JJR	O
BCVA	NNP	O
and	CC	O
lower	JJR	O
CMT	NNP	O
values	NNS	O
at	IN	O
all	DT	O
time	NN	O
points	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Intravitreal	NNP	O
bevacizumab	NN	PM
injection	NN	O
improves	VBZ	O
BCVA	NNP	O
and	CC	O
reduces	NNS	O
CMT	NNP	O
more	JJR	O
than	IN	O
GLP	NNP	O
.	.	O

Intravitreal	NNP	O
bevacizumab	JJ	PM
injection	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
could	MD	O
be	VB	O
used	VBN	O
as	IN	O
primary	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
secondary	JJ	O
to	TO	O
perfused	VBN	O
branch	NN	O
retinal	JJ	O
vein	NN	O
occlusion	NN	O
.	.	O

Effect	NN	O
of	IN	O
total	JJ	O
enteral	JJ	O
nutrition	NN	O
on	IN	O
the	DT	O
short-term	JJ	O
outcome	NN	O
of	IN	O
severely	RB	O
malnourished	VBN	O
cirrhotics	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

Thirty-five	JJ	O
severely	RB	O
malnourished	VBN	O
cirrhotic	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
enteral-tube	JJ	PM
feeding	NN	PM
as	IN	PM
the	DT	PM
sole	JJ	PM
nutritional	JJ	PM
support	NN	PM
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
or	CC	O
an	DT	O
isocaloric	JJ	PM
,	,	O
isonitrogenous	JJ	PM
,	,	O
low-sodium	JJ	PM
standard	JJ	PM
oral	JJ	PM
diet	NN	PM
(	(	O
n	JJ	O
=	NNP	O
19	CD	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
homogeneous	JJ	O
regarding	VBG	O
age	NN	O
,	,	O
sex	NN	O
distribution	NN	O
,	,	O
etiology	NN	O
of	IN	O
liver	JJ	O
cirrhosis	NN	O
,	,	O
history	NN	O
of	IN	O
previous	JJ	O
complications	NNS	O
,	,	O
clinical	JJ	O
status	NN	O
,	,	O
liver	RB	O
and	CC	O
renal	JJ	O
function	NN	O
,	,	O
modified	VBD	O
Child	NNP	O
's	POS	O
score	NN	O
,	,	O
and	CC	O
nutritional	JJ	O
status	NN	O
at	IN	O
admission	NN	O
.	.	O

The	DT	O
enteral	JJ	O
formula	NN	O
diet	NN	O
was	VBD	O
energy	NN	O
dense	NN	O
,	,	O
containing	VBG	O
40	CD	O
mmol	NN	O
Na/day	NNP	O
,	,	O
whole	JJ	PM
protein	NN	PM
plus	CC	PM
branched-chain	JJ	PM
amino	NN	PM
acids	NNS	PM
,	,	O
medium-	JJ	PM
and	CC	PM
long-chain	JJ	PM
triglycerides	NNS	PM
,	,	O
and	CC	O
maltodextrin	NN	PM
.	.	O

It	PRP	PH
supplied	VBD	PH
2115	CD	PH
kcal/day	NN	PH
.	.	O

The	DT	O
amount	NN	O
of	IN	O
vitamins	NNS	O
and	CC	O
trace	NN	O
elements	NNS	O
was	VBD	O
at	IN	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
the	DT	O
recommended	JJ	O
dietary	JJ	O
allowances	NNS	O
.	.	O

The	DT	E
orally	RB	E
fed	JJ	E
patients	NNS	E
were	VBD	E
encouraged	VBN	E
to	TO	E
eat	VB	E
all	DT	E
meals	NNS	E
served	VBD	E
.	.	O

Total	JJ	O
enteral	JJ	O
nutrition	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
without	IN	O
major	JJ	O
complications	NNS	O
.	.	O

Serum	NNP	O
albumin	NN	O
and	CC	O
Child	NNP	O
's	POS	O
score	NN	O
improved	VBD	O
in	IN	O
the	DT	O
enterally	RB	O
fed	JJ	O
patients	NNS	O
but	CC	O
not	RB	O
in	IN	O
controls	NNS	O
.	.	O

Mortality	NNP	O
rate	NN	O
while	IN	O
in	IN	O
the	DT	O
hospital	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
on	IN	O
enteral	JJ	O
feeding	NN	O
than	IN	O
in	IN	O
controls	NNS	O
(	(	O
12	CD	O
%	NN	O
vs	JJ	O
47	CD	O
%	NN	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
total	JJ	O
enteral	JJ	O
nutrition	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
improving	VBG	O
the	DT	O
short-term	JJ	O
clinical	JJ	O
outcome	NN	O
in	IN	O
severely	RB	O
malnourished	JJ	O
cirrhotics	NNS	O
.	.	O

Emotional	JJ	O
reactivity	NN	O
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
among	IN	O
persons	NNS	O
with	IN	O
borderline	JJ	O
personality	NN	O
features	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
emotional	JJ	O
reactivity	NN	O
of	IN	O
persons	NNS	O
with	IN	O
heightened	JJ	O
borderline	NN	O
personality	NN	O
(	(	O
BP	NNP	O
)	)	O
features	VBZ	O
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
in	IN	O
the	DT	O
laboratory	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
BP	NNP	O
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
and	CC	O
controls	NNS	O
with	IN	O
low	JJ	O
levels	NNS	O
of	IN	O
BP	NNP	O
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
44	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
condition	NN	E
involving	VBG	E
negative	JJ	E
evaluation	NN	E
based	VBN	E
on	IN	E
writing	NN	E
(	(	E
negative	JJ	E
evaluation/academic	NN	E
)	)	E
,	,	E
or	CC	E
a	DT	E
condition	NN	E
involving	VBG	E
negative	JJ	E
evaluation	NN	E
based	VBN	E
on	IN	E
personal	JJ	E
characteristics	NNS	E
as	RB	E
well	RB	E
as	IN	E
social	JJ	E
rejection	NN	E
(	(	E
negative	JJ	E
evaluation/social	JJ	E
rejection	NN	E
)	)	E
.	.	E

Hypothesis	$	O
1	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
,	,	O
but	CC	O
not	RB	O
low-BP	JJ	O
controls	NNS	O
,	,	O
would	MD	O
show	VB	O
greater	JJR	O
emotional	JJ	O
reactivity	NN	O
to	TO	O
the	DT	O
negative	JJ	Ot
evaluation/social	JJ	Ot
rejection	NN	Ot
stressor	NN	Ot
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	Ot
evaluation/academic	JJ	Ot
(	(	Ot
writing	VBG	Ot
)	)	Ot
stressor	NN	Ot
.	.	O

Hypothesis	$	O
2	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
would	MD	O
specifically	RB	O
show	VB	O
greater	JJR	O
reactivity	NN	O
of	IN	O
shame-	JJ	O
and	CC	O
anger-related	JJ	O
emotions	NNS	O
to	TO	O
the	DT	O
negative	JJ	E
evaluation/social	JJ	E
rejection	NN	E
stressor	NN	E
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	Ot
evaluation/academic	JJ	Ot
stressor	NN	Ot
.	.	O

Findings	NNS	O
indicated	VBD	O
that	IN	O
high-BP	JJ	O
individuals	NNS	O
showed	VBD	O
heightened	VBN	O
emotional	JJ	O
reactivity	NN	O
to	TO	O
the	DT	O
social	JJ	E
rejection	NN	E
stressor	NN	E
but	CC	O
not	RB	O
to	TO	O
the	DT	O
negative	JJ	Ot
evaluation	NN	Ot
stressor	NN	Ot
,	,	O
but	CC	O
the	DT	O
opposite	JJ	O
pattern	NN	O
occurred	VBD	O
for	IN	O
controls	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
evidence	NN	O
for	IN	O
heightened	JJ	O
reactivity	NN	O
of	IN	O
irritability	NN	O
,	,	O
distress	NN	O
,	,	O
and	CC	O
shame	NN	O
for	IN	O
the	DT	O
high-BP	JJ	O
group	NN	O
,	,	O
specifically	RB	O
in	IN	O
the	DT	O
social	JJ	O
rejection	NN	O
condition	NN	O
.	.	O

Nutrient	JJ	O
retention	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
fed	VBN	O
standard	JJ	O
infant	NN	O
formulas	NN	O
.	.	O

Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
compare	VB	O
nitrogen	NN	O
,	,	O
mineral	NN	O
,	,	O
and	CC	O
zinc	NN	O
balance	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
fed	VBN	O
standard	JJ	PM
infant	NN	PM
formulas	NNS	PM
,	,	O
Similac	NNP	PM
With	IN	PM
Iron	NNP	PM
and	CC	PM
Similac	NNP	PM
With	IN	PM
Whey	NNP	PM
+	NNP	PM
Iron	NNP	PM
.	.	O

Nitrogen	NNP	O
and	CC	O
magnesium	NN	O
balances	NNS	O
were	VBD	O
similar	JJ	O
during	IN	O
both	DT	O
feeds	NNS	O
,	,	O
and	CC	O
met	VBD	O
estimated	VBN	O
fetal	JJ	O
requirements	NNS	O
.	.	O

Infants	NNS	O
absorbed	VBD	O
and	CC	O
retained	VBD	O
(	(	O
milligrams	FW	O
per	IN	O
kilogram	FW	O
per	IN	O
day	NN	O
)	)	O
more	JJR	O
calcium	NN	O
,	,	O
phosphorus	NN	O
,	,	O
and	CC	O
zinc	NN	O
when	WRB	O
fed	VBN	O
Similac	NNP	PM
With	IN	PM
Iron	NNP	PM
.	.	O

However	RB	O
,	,	O
retention	NN	O
of	IN	O
calcium	NN	O
,	,	O
phosphorus	NN	O
(	(	O
both	DT	O
formulas	NN	O
)	)	O
,	,	O
and	CC	O
zinc	NN	O
(	(	O
Similac	NNP	O
With	IN	O
Whey	NNP	O
+	NNP	O
Iron	NNP	O
)	)	O
was	VBD	O
inadequate	JJ	O
to	TO	O
meet	VB	O
estimated	JJ	O
fetal	JJ	O
requirements	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
important	JJ	O
in	IN	O
the	DT	O
rapidly	RB	O
growing	VBG	O
preterm	JJ	O
infant	NN	O
,	,	O
who	WP	O
is	VBZ	O
already	RB	O
at	IN	O
risk	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
rickets	NNS	O
and	CC	O
zinc	NN	O
deficiency	NN	O
and	CC	O
may	MD	O
be	VB	O
fed	VBN	O
either	DT	O
formula	NN	O
on	IN	O
discharge	NN	O
from	IN	O
the	DT	O
newborn	JJ	O
nursery	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
sclerotherapy	NN	S
with	IN	O
staple	JJ	S
transection	NN	S
of	IN	S
the	DT	S
esophagus	NN	S
for	IN	O
the	DT	O
emergency	NN	O
control	NN	O
of	IN	O
bleeding	VBG	O
from	IN	O
esophageal	JJ	O
varices	NNS	O
.	.	O

We	PRP	O
compared	VBN	O
two	CD	O
procedures	NNS	O
for	IN	O
the	DT	O
emergency	NN	O
treatment	NN	O
of	IN	O
bleeding	VBG	O
esophageal	JJ	O
varices	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
blood	VB	O
transfusion	NN	O
and	CC	O
vasoactive	JJ	O
drugs	NNS	O
.	.	O

We	PRP	O
randomly	VBP	O
assigned	VBD	O
101	CD	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
of	IN	O
the	DT	O
liver	NN	O
and	CC	O
bleeding	VBG	O
esophageal	JJ	O
varices	NNS	O
to	TO	O
undergo	VB	S
either	DT	S
emergency	NN	S
sclerotherapy	NN	S
(	(	O
n	JJ	O
=	NNP	O
50	CD	O
)	)	O
or	CC	O
staple	JJ	S
transection	NN	S
of	IN	S
the	DT	S
esophagus	NN	S
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
.	.	O

Four	CD	O
patients	NNS	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	S
and	CC	O
12	CD	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
did	VBD	O
not	RB	O
actually	RB	O
undergo	VBP	O
those	DT	O
procedures	NNS	O
,	,	O
but	CC	O
all	DT	O
analyses	NNS	O
were	VBD	O
made	VBN	O
on	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
.	.	O

Total	JJ	O
mortality	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
;	:	O
the	DT	O
relative	JJ	O
risk	NN	O
of	IN	O
death	NN	O
for	IN	O
staple	JJ	O
transection	NN	O
as	IN	O
compared	VBN	O
with	IN	O
sclerotherapy	NN	O
was	VBD	O
0.88	CD	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.51	CD	O
to	TO	O
1.54	CD	O
)	)	O
.	.	O

Mortality	NN	O
at	IN	O
six	CD	O
weeks	NNS	O
was	VBD	O
44	CD	O
percent	NN	O
among	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	S
and	CC	O
35	CD	O
percent	NN	O
among	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
.	.	O

Complication	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

An	DT	O
interval	NN	O
of	IN	O
five	CD	O
days	NNS	O
without	IN	O
bleeding	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
88	CD	O
percent	NN	O
of	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
staple	VB	O
transection	NN	O
and	CC	O
in	IN	O
62	CD	O
percent	NN	O
of	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
sclerotherapy	VB	S
after	IN	O
a	DT	O
single	JJ	O
injection	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
and	CC	O
82	CD	O
percent	NN	O
after	IN	O
three	CD	O
injections	NNS	O
.	.	O

In	IN	O
only	RB	O
2	CD	O
of	IN	O
the	DT	O
11	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
a	DT	O
third	JJ	O
sclerotherapy	NN	S
injection	NN	O
was	VBD	O
bleeding	VBG	O
controlled	VBN	O
for	IN	O
more	JJR	O
than	IN	O
five	CD	O
days	NNS	O
,	,	O
and	CC	O
9	CD	O
died	VBD	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
staple	JJ	O
transection	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
is	VBZ	O
as	RB	O
safe	JJ	O
as	IN	O
sclerotherapy	NN	O
for	IN	O
the	DT	O
emergency	NN	O
treatment	NN	O
of	IN	O
bleeding	VBG	O
esophageal	JJ	O
varices	NNS	O
and	CC	O
that	IN	O
it	PRP	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
a	DT	O
single	JJ	O
sclerotherapy	NN	S
procedure	NN	O
.	.	O

We	PRP	O
currently	RB	O
recommend	VBP	O
surgery	NN	O
after	IN	O
two	CD	O
injection	NN	O
treatments	NNS	O
have	VBP	O
failed	VBN	O
.	.	O

Development	NNP	O
of	IN	O
an	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
for	IN	O
the	DT	O
identification	NN	O
of	IN	O
auditory	NN	O
processing	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	CC	O
One	CD	O
type	NN	O
of	IN	O
test	NN	O
commonly	RB	O
used	VBD	O
to	TO	O
examine	VB	O
auditory	JJ	O
processing	NN	O
disorders	NNS	O
(	(	O
APD	NNP	O
)	)	O
is	VBZ	O
the	DT	O
low-pass	NN	PH
filtered	VBD	PH
speech	JJ	PH
test	NN	PH
(	(	O
LPFST	NNP	O
)	)	O
,	,	O
of	IN	O
which	WDT	O
there	EX	O
are	VBP	O
various	JJ	O
versions	NNS	O
.	.	O

In	IN	O
LPFSTs	NNP	O
,	,	O
a	DT	O
monaural	JJ	O
,	,	O
low-redundancy	JJ	O
speech	NN	O
sample	NN	O
is	VBZ	O
distorted	VBN	O
by	IN	O
using	VBG	O
filtering	VBG	O
to	TO	O
modify	VB	O
its	PRP$	O
frequency	NN	O
content	NN	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
richness	NN	O
of	IN	O
the	DT	O
neural	JJ	O
pathways	NNS	O
in	IN	O
the	DT	O
auditory	NN	O
system	NN	O
and	CC	O
the	DT	O
redundancy	NN	O
of	IN	O
acoustic	JJ	O
information	NN	O
in	IN	O
spoken	JJ	O
language	NN	O
,	,	O
a	DT	O
normal	JJ	O
listener	NN	O
is	VBZ	O
able	JJ	O
to	TO	O
recognize	VB	O
speech	NN	O
even	RB	O
when	WRB	O
parts	NNS	O
of	IN	O
the	DT	O
signal	NN	O
are	VBP	O
missing	VBG	O
,	,	O
whereas	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
often	RB	O
impaired	VBN	O
in	IN	O
listeners	NNS	O
with	IN	O
APD	NNP	O
.	.	O

One	CD	O
limitation	NN	O
of	IN	O
the	DT	O
various	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
LPFST	NNP	PH
is	VBZ	O
that	IN	O
they	PRP	O
are	VBP	O
carried	VBN	O
out	IN	O
using	VBG	O
a	DT	O
constant	JJ	O
level	NN	O
of	IN	O
low-pass	JJ	O
filtering	NN	O
(	(	O
e.g	NN	O
.	.	O

a	DT	O
fixed	JJ	O
1kHz	CD	O
corner	NN	O
frequency	NN	O
)	)	O
which	WDT	O
makes	VBZ	O
them	PRP	O
prone	VB	O
to	TO	O
ceiling	NN	O
and	CC	O
floor	NN	O
effects	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
counter	VB	O
these	DT	O
effects	NNS	O
by	IN	O
modifying	VBG	O
the	DT	O
LPFST	NNP	O
using	VBG	O
a	DT	O
computer-based	JJ	O
adaptive	JJ	O
procedure	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
performance	NN	O
of	IN	O
normal-hearing	JJ	O
participants	NNS	O
of	IN	O
varying	VBG	O
ages	NNS	O
on	IN	O
the	DT	O
test	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
preliminary	JJ	O
study	NN	O
,	,	O
33	CD	O
adults	NNS	O
and	CC	O
30	CD	O
children	NNS	O
(	(	O
aged	VBN	O
8-11	CD	O
years	NNS	O
)	)	O
with	IN	O
no	DT	O
known	JJ	O
history	NN	O
of	IN	O
listening	VBG	O
difficulties	NNS	O
were	VBD	O
tested	VBN	O
.	.	O

The	DT	E
University	NNP	E
of	IN	E
Canterbury	NNP	E
Adaptive	NNP	E
Speech	NNP	E
Test	NNP	E
(	(	E
UCAST	NNP	E
)	)	E
platform	NN	E
was	VBD	E
used	VBN	E
to	TO	E
administer	VB	E
a	DT	E
four-alternative	JJ	E
forced-choice	JJ	E
adaptive	JJ	E
test	NN	E
that	WDT	E
altered	VBD	E
a	DT	E
low-pass	JJ	E
filter	NN	E
(	(	E
LPF	NNP	E
)	)	E
to	TO	E
track	VB	E
the	DT	E
corner	NN	E
frequency	NN	E
at	IN	E
which	WDT	E
participants	NNS	E
correctly	RB	E
identified	VBN	E
a	DT	E
certain	JJ	E
percentage	NN	E
of	IN	E
the	DT	E
word	NN	E
stimuli	NN	E
.	.	E

RESULTS	NNP	O
Findings	NNP	O
on	IN	O
the	DT	O
University	NNP	O
of	IN	O
Canterbury	NNP	O
Adaptive	NNP	O
Speech	NNP	O
Test-Filtered	NNP	O
Words	NNP	O
(	(	O
UCAST-FW	NNP	O
)	)	O
indicated	VBD	O
a	DT	O
significant	JJ	O
maturational	JJ	O
effect	NN	O
.	.	O

Adult	NN	O
participants	NNS	O
performed	VBD	O
significantly	RB	O
better	RBR	O
on	IN	O
the	DT	O
UCAST-FW	NNP	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
child	NN	O
participants	NNS	O
.	.	O

The	DT	O
UCAST-FW	JJ	O
test	NN	O
was	VBD	O
reliable	JJ	O
over	IN	O
repeated	JJ	O
administrations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
An	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
such	JJ	O
as	IN	O
the	DT	O
UCAST-FW	NNP	O
is	VBZ	O
sensitive	JJ	O
to	TO	O
maturational	JJ	O
changes	NNS	O
in	IN	O
auditory	NN	O
processing	NN	O
ability	NN	O
.	.	O

Endobronchial	JJ	O
ultrasonography-guided	JJ	O
transbronchial	JJ	S
needle	JJ	S
aspiration	NN	S
increases	VBZ	O
the	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
peripheral	JJ	O
pulmonary	JJ	O
lesions	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
endobronchial	JJ	S
ultrasonography	NN	S
(	(	S
EBUS	NNP	S
)	)	S
-guided	VBD	S
transbronchial	JJ	S
needle	JJ	S
aspiration	NN	S
(	(	S
TBNA	NNP	S
)	)	S
for	IN	O
peripheral	JJ	O
pulmonary	JJ	O
lesions	NNS	O
(	(	O
PPLs	NNP	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

The	DT	O
diagnostic	JJ	O
impact	NN	O
of	IN	O
TBNA	NNP	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
is	VBZ	O
adjacent	JJ	O
to	TO	O
lesions	NNS	O
remains	VBZ	O
to	TO	O
be	VB	O
determined	VBN	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
with	IN	O
PPLs	NNP	O
and	CC	O
positive	JJ	O
EBUS	NNP	O
findings	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
classified	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
EBUS	NNP	O
conventional	JJ	O
diagnostic	JJ	O
procedures	NNS	O
(	(	O
CDPs	NNP	O
)	)	O
group	NN	O
(	(	O
103	CD	O
patients	NNS	O
)	)	O
,	,	O
both	DT	O
transbronchial	JJ	PH
biopsy	NN	PH
(	(	O
TBB	NNP	O
)	)	O
and	CC	O
bronchial	JJ	O
washing	NN	O
(	(	O
BW	NNP	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

In	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
(	(	O
99	CD	O
patients	NNS	O
)	)	O
,	,	O
TBNA	NNP	O
,	,	O
TBB	NNP	O
,	,	O
and	CC	O
BW	NNP	O
were	VBD	O
performed	VBN	O
.	.	O

The	DT	O
diagnostic	JJ	O
yield	NN	O
in	IN	O
each	DT	O
group	NN	O
was	VBD	O
compared	VBN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
182	CD	O
patients	NNS	O
(	(	O
94	CD	O
in	IN	O
the	DT	O
EBUS	NNP	O
CDPs	NNP	O
group	NN	O
and	CC	O
88	CD	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
)	)	O
were	VBD	O
analyzed	VBN	O
.	.	O

The	DT	O
yield	NN	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
(	(	O
78.4	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
the	DT	O
EBUS	NNP	O
CDPs	NNP	O
group	NN	O
(	(	O
60.6	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.015	CD	O
)	)	O
.	.	O

Cases	NNS	O
in	IN	O
which	WDT	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
located	VBN	O
within	IN	O
the	DT	O
lesions	NNS	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	RBR	O
diagnostic	JJ	O
yield	NN	O
(	(	O
78.3	CD	O
%	NN	O
)	)	O
than	IN	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
them	PRP	O
(	(	O
47.2	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Concerning	VBG	O
the	DT	O
three	CD	O
different	JJ	O
techniques	NNS	O
,	,	O
TBNA	NNP	O
showed	VBD	O
the	DT	O
highest	JJS	O
diagnostic	JJ	O
yield	NN	O
(	(	O
62.5	CD	O
%	NN	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
TBB	NNP	O
(	(	O
48.9	CD	O
%	NN	O
)	)	O
and	CC	O
to	TO	O
BW	NNP	O
(	(	O
19.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
TBNA	NNP	O
remained	VBD	O
unchanged	JJ	O
even	RB	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
the	DT	O
lesions	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
.	.	O

No	DT	O
additional	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Applying	NNP	O
TBNA	NNP	O
to	TO	O
EBUS-guided	NNP	O
CDPs	NNP	O
further	RBR	O
increased	VBD	O
the	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
PPLs	NNP	O
without	IN	O
additional	JJ	O
risk	NN	O
.	.	O

The	DT	O
diagnostic	JJ	O
advantage	NN	O
of	IN	O
TBNA	NNP	O
became	VBD	O
more	RBR	O
obvious	JJ	O
if	IN	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
the	DT	O
lesions	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinicaltrials.gov	NNP	O
Identifier	NNP	O
:	:	O
NCT00626587	NN	O
.	.	O

Controlled	VBN	O
trial	NN	O
of	IN	O
induction	NN	O
of	IN	O
labor	NN	O
by	IN	O
vaginal	JJ	O
suppositories	NNS	PM
containing	VBG	O
prostaglandin	NN	PM
E2	NNP	PM
.	.	O

A	NNP	O
group	NN	O
of	IN	O
84	CD	O
women	NNS	O
at	IN	O
39-43	JJ	O
weeks	NNS	O
of	IN	O
pregnancy	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
a	DT	O
blind	JJ	O
trial	NN	O
of	IN	O
induction	NN	O
of	IN	O
labor	NN	O
with	IN	O
vaginal	JJ	O
suppositories	NNS	PM
containing	VBG	O
inert	JJ	C
material	NN	C
or	CC	O
either	CC	O
0.2	CD	O
mg	NN	O
or	CC	O
0.4	CD	O
mg	NN	O
of	IN	O
prostaglandin	NN	PM
E2	NNP	PM
.	.	O

The	DT	O
suppositories	NNS	O
were	VBD	O
self-administered	JJ	O
every	DT	O
two	CD	O
hours	NNS	O
during	IN	O
waking	VBG	O
hours	NNS	O
on	IN	O
two	CD	O
successive	JJ	O
days	NNS	O
until	IN	O
labor	NN	O
started	VBD	O
or	CC	O
15	CD	O
had	VBD	O
been	VBN	O
used	VBN	O
.	.	O

Side-effects	NNS	O
were	VBD	O
absent	JJ	O
.	.	O

Labor	NN	O
was	VBD	O
established	VBN	O
within	IN	O
48	CD	O
hr	NN	O
of	IN	O
insertion	NN	O
of	IN	O
the	DT	O
first	JJ	O
suppository	NN	O
in	IN	O
9.3	CD	O
%	NN	O
of	IN	O
control	NN	O
patients	NNS	O
,	,	O
65.4	CD	O
%	NN	O
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
0.2	CD	O
mg	NNS	O
PGE2	NNP	PM
and	CC	O
85.7	CD	O
%	NN	O
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
0.4	CD	O
mg	NNS	O
PGE2	NNP	PM
.	.	O

The	DT	O
mean	JJ	O
Apgar	NNP	O
scores	NNS	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
were	VBD	O
the	DT	O
same	JJ	O
.	.	O

The	DT	O
mean	JJ	O
total	NN	O
dose	NN	O
of	IN	O
PGE2	NNP	PM
were	VBD	O
2.0	CD	O
mg	NN	O
(	(	O
0.2	CD	O
mg	NNS	O
group	NN	O
)	)	O
and	CC	O
2.3	CD	O
mg	NN	O
(	(	O
0.4	CD	O
mg	NNS	O
group	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
vaginal	JJ	O
PGE2	NNP	PM
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
acceptable	JJ	O
method	NN	O
of	IN	O
inducing	VBG	O
labor	NN	O
at	IN	O
term	NN	O
.	.	O

Epidural	JJ	PM
fentanyl-bupivacaine	JJ	PM
compared	VBN	O
with	IN	O
clonidine-bupivacaine	NN	PM
for	IN	O
analgesia	NN	O
in	IN	O
labour	NN	O
.	.	O

Alpha-adrenergic	JJ	O
agonists	NNS	O
produce	VBP	O
pain	NN	O
relief	NN	O
through	IN	O
an	DT	O
opioid	JJ	O
independent	JJ	O
mechanism	NN	O
and	CC	O
may	MD	O
be	VB	O
alternatives	NNS	O
to	TO	O
opioids	NNS	O
for	IN	O
combination	NN	O
with	IN	O
local	JJ	O
anaesthetics	NNS	O
for	IN	O
analgesia	NN	O
during	IN	O
labour	NN	O
.	.	O

We	PRP	O
studied	VBD	O
41	CD	O
pregnant	JJ	O
women	NNS	O
.	.	O

Epidural	JJ	O
block	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
75	CD	O
microg	NNS	O
clonidine	NN	PM
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
50	CD	PM
microg	NNS	PM
fentanyl	NN	PM
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
combined	VBN	PM
with	IN	PM
0.125	CD	PM
%	NN	PM
bupivacaine	NN	PM
(	(	O
10	CD	O
mL	NN	O
)	)	O
.	.	O

Maternal	JJ	O
vital	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
;	:	O
sedation	NN	O
was	VBD	O
scored	VBN	O
using	VBG	O
a	DT	O
five-point	JJ	O
scale	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
maternal	JJ	O
vital	JJ	O
parameters	NNS	O
,	,	O
fetal	JJ	O
heart	NN	O
rate	NN	O
(	(	O
FHR	NNP	O
)	)	O
or	CC	O
Apgar	NNP	O
scores	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Analgesia	NNP	O
lasted	VBD	O
longer	RBR	O
in	IN	O
the	DT	O
bupivacaine-clonidine	JJ	PM
group	NN	O
(	(	O
139.4	CD	O
+/-	JJ	O
31	CD	O
min	NN	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
bupivacaine-fentanyl	JJ	PM
group	NN	O
(	(	O
127.9	CD	O
+/-	JJ	O
48	CD	O
min	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.42	CD	O
)	)	O
.	.	O

Additional	JJ	O
analgesic	JJ	O
requirement	NN	O
was	VBD	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
fentanyl-bupivacaine	JJ	PM
group	NN	O
and	CC	O
total	JJ	O
bupivacaine	NN	O
requirement	NN	O
was	VBD	O
less	RBR	O
in	IN	O
the	DT	O
clonidine-bupivacaine	JJ	PM
group	NN	O
(	(	O
22.5	CD	O
+/-	JJ	O
12.5	CD	O
mg	NN	O
vs.	FW	O
30.9	CD	O
+/-	JJ	O
12.8	CD	O
mg	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

This	DT	O
small	JJ	O
study	NN	O
confirms	VBZ	O
that	IN	O
this	DT	O
combination	NN	O
of	IN	O
bupivacaine	NN	PM
and	CC	O
clonidine	NN	PM
provides	VBZ	O
satisfactory	JJ	O
analgesia	NN	O
for	IN	O
first-stage	JJ	O
labour	NN	O
,	,	O
and	CC	O
of	IN	O
longer	JJR	O
duration	NN	O
than	IN	O
bupivacaine-fentanyl	NN	PM
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
oral	JJ	O
DMSA	NNP	PM
therapy	NN	PM
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
part	NN	O
B	NNP	O
-	:	O
behavioral	JJ	O
results	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
oral	JJ	PM
dimercapto	NN	PM
succinic	JJ	PM
acid	NN	PM
(	(	PM
DMSA	NNP	PM
)	)	PM
therapy	NN	PM
on	IN	O
the	DT	O
behavioural	JJ	O
symptoms	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
ages	VBZ	O
3-8	JJ	O
years	NNS	O
.	.	O

METHODS	NNP	O
Phase	NNP	O
1	CD	O
involved	VBD	O
65	CD	O
children	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
received	VBD	O
one	CD	O
round	NN	O
of	IN	O
DMSA	NNP	O
(	(	O
3	CD	O
days	NNS	O
)	)	O
.	.	O

Participants	NNS	O
who	WP	O
had	VBD	O
high	JJ	O
urinary	JJ	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
were	VBD	O
selected	VBN	O
to	TO	O
continue	VB	O
on	IN	O
to	TO	O
phase	VB	O
2	CD	O
.	.	O

In	IN	O
phase	NN	O
2	CD	O
,	,	O
49	CD	O
participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
design	NN	O
to	TO	O
receive	VB	O
an	DT	O
additional	JJ	O
6	CD	PM
rounds	NNS	PM
of	IN	PM
either	DT	PM
DMSA	NNP	PM
or	CC	O
placebo	NN	C
.	.	O

RESULTS	VB	O
The	DT	O
groups	NNS	O
receiving	VBG	O
one	CD	O
round	NN	O
and	CC	O
seven	CD	O
rounds	NNS	O
of	IN	O
DMSA	NNP	PM
had	VBD	O
significant	JJ	O
improvements	NNS	O
on	IN	O
all	PDT	O
the	DT	O
assessment	JJ	O
measures	NNS	O
.	.	O

For	IN	O
the	DT	O
seven	CD	O
round	NN	O
group	NN	O
,	,	O
the	DT	O
degree	NN	O
of	IN	O
improvement	NN	O
on	IN	O
the	DT	O
assessment	NN	O
measures	NNS	O
could	MD	O
be	VB	O
partially	RB	O
explained	VBN	O
by	IN	O
a	DT	O
regression	NN	O
analysis	NN	O
based	VBN	O
on	IN	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
and	CC	O
changes	NNS	O
in	IN	O
glutathione	NN	O
(	(	O
adjusted	VBN	O
R2	NNP	O
of	IN	O
0.28-0.75	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.02	CD	O
in	IN	O
all	DT	O
cases	NNS	O
)	)	O
.	.	O

One	CD	O
round	NN	O
of	IN	O
DMSA	NNP	O
had	VBD	O
nearly	RB	O
the	DT	O
same	JJ	O
benefit	NN	O
as	IN	O
seven	CD	O
rounds	NNS	O
.	.	O

The	DT	O
assessment	JJ	O
measures	NNS	O
correlated	VBN	O
reasonably	RB	O
with	IN	O
one	CD	O
another	DT	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.60-0.87	NN	O
)	)	O
and	CC	O
even	RB	O
better	JJR	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.63-0.94	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
both	DT	O
one	CD	O
and	CC	O
seven	CD	O
rounds	NNS	O
of	IN	O
DMSA	NNP	PM
therapy	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
reasonably	RB	O
safe	JJ	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
have	VBP	O
high	JJ	O
urinary	JJ	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
,	,	O
and	CC	O
possibly	RB	O
helpful	JJ	O
in	IN	O
reducing	VBG	O
some	DT	O
of	IN	O
the	DT	O
symptoms	NNS	O
of	IN	O
autism	NN	O
in	IN	O
those	DT	O
children	NNS	O
.	.	O

Effect	NN	O
of	IN	O
simvastatin	NN	PM
on	IN	O
hemostasis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
.	.	O

BACKGROUNDS/AIMS	NNP	O
Elevated	NNP	O
triglyceride	NN	O
levels	NNS	O
seem	VBP	O
to	TO	O
predispose	VB	O
to	TO	O
the	DT	O
earlier	JJR	O
development	NN	O
and	CC	O
accelerated	JJ	O
progression	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

In	IN	O
our	PRP$	O
study	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
whether	IN	O
simvastatin	JJ	PM
treatment	NN	O
affects	NNS	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
39	CD	O
patients	NNS	O
with	IN	O
elevated	JJ	O
triglyceride	NN	O
levels	NNS	O
and	CC	O
peripheral	JJ	O
artery	NN	O
sclerosis	NN	O
,	,	O
treated	VBD	O
for	IN	O
90	CD	O
days	NNS	O
with	IN	O
either	DT	O
simvastatin	NN	PM
(	(	O
40	CD	O
mg	NNS	O
daily	RB	O
)	)	O
or	CC	O
placebo	NN	C
.	.	O

Plasma	NNP	O
lipids	NNS	O
,	,	O
glucose	JJ	O
homeostasis	NN	O
markers	NNS	O
and	CC	O
hemostasic	JJ	O
variables	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Simvastatin	NNP	PM
,	,	O
but	CC	O
not	RB	O
placebo	VB	C
,	,	O
administered	VBN	O
to	TO	O
these	DT	O
patients	NNS	O
reduced	VBD	O
plasma	JJ	O
levels/activity	NN	O
of	IN	O
fibrinogen	NN	O
(	(	O
from	IN	O
3.5	CD	O
?	.	O
0.4	CD	O
to	TO	O
2.8	CD	O
?	.	O
0.3	CD	O
g/l	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
factor	NN	O
VII	NNP	O
(	(	O
from	IN	O
144.2	CD	O
?	.	O
16.9	CD	O
to	TO	O
112.5	CD	O
?	.	O
14.0	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
plasminogen	JJ	O
activator	NN	O
inhibitor-1	NN	O
(	(	O
from	IN	O
76.9	CD	O
?	.	O
13.5	CD	O
to	TO	O
50.2	CD	O
?	.	O
9.2	CD	O
ng/ml	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
without	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
von	NN	O
Willebrand	NNP	O
factor	NN	O
levels	NNS	O
,	,	O
and	CC	O
tended	VBD	O
to	TO	O
prolong	VB	O
the	DT	O
prothrombin	NN	O
and	CC	O
partial	JJ	O
thromboplastin	NN	O
times	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
statin	NN	O
treatment	NN	O
produces	VBZ	O
a	DT	O
multidirectional	JJ	O
effect	NN	O
on	IN	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
and	CC	O
that	IN	O
this	DT	O
treatment	NN	O
may	MD	O
bring	VB	O
some	DT	O
benefits	NNS	O
to	TO	O
patients	NNS	O
with	IN	O
elevated	JJ	O
triglyceride	NN	O
levels	NNS	O
.	.	O

Omega-3	JJ	PM
fatty	JJ	PM
acids	NNS	PM
supplementation	NN	PM
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
,	,	O
placebo-controlled	JJ	C
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
increasing	VBG	O
evidence	NN	O
that	IN	O
fatty	JJ	O
acid	JJ	O
deficiencies	NNS	O
or	CC	O
imbalances	NNS	O
may	MD	O
contribute	VB	O
to	TO	O
childhood	VB	O
neurodevelopmental	JJ	O
disorders	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
6-week	JJ	O
pilot	NN	O
trial	NN	O
investigating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
1.5	CD	PM
g/d	NN	PM
of	IN	PM
omega-3	JJ	PM
fatty	JJ	PM
acids	NNS	PM
(	(	PM
.84	JJ	PM
g/d	NN	PM
eicosapentaenoic	NN	PM
acid	NN	PM
,	,	PM
.7	NNP	PM
g/d	NN	PM
docosahexaenoic	NN	PM
acid	NN	PM
)	)	PM
supplementation	NN	PM
in	IN	O
13	CD	O
children	NNS	O
(	(	O
aged	VBN	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
)	)	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
accompanied	VBN	O
by	IN	O
severe	JJ	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
.	.	O

The	DT	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
at	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
observed	VBD	O
an	DT	O
advantage	NN	O
of	IN	O
omega-3	JJ	PM
fatty	JJ	PM
acids	NNS	PM
compared	VBN	O
with	IN	O
placebo	NN	PM
for	IN	O
hyperactivity	NN	O
and	CC	O
stereotypy	NN	O
,	,	O
each	DT	O
with	IN	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
.	.	O

Repeated-measures	NNS	O
ANOVA	NNP	O
indicated	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
superiority	NN	O
of	IN	O
omega-3	JJ	PM
fatty	JJ	PM
acids	NNS	PM
over	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	O
.	.	O

No	DT	O
clinically	RB	O
relevant	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
elicited	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	VBZ	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
preliminary	JJ	O
evidence	NN	O
that	IN	O
omega-3	JJ	PM
fatty	JJ	PM
acids	NNS	PM
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Variations	NNS	O
in	IN	O
EEG	NNP	PH
discharges	NNS	PH
predict	VBP	O
ADHD	NNP	O
severity	NN	O
within	IN	O
individual	JJ	O
Smith-Lemli-Opitz	JJ	O
patients	NNS	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
examine	VB	O
the	DT	O
prevalence	NN	O
of	IN	O
EEG	NNP	O
abnormalities	NNS	O
in	IN	O
Smith-Lemli-Opitz	NNP	O
syndrome	NN	O
(	(	O
SLOS	NNP	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
relationship	NN	O
between	IN	O
interictal	JJ	O
epileptiform	NN	O
discharges	NNS	O
(	(	O
IEDs	NNP	O
)	)	O
and	CC	O
within-subject	JJ	O
variations	NNS	O
in	IN	O
attentional	JJ	O
symptom	NN	O
severity	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
for	IN	O
SLOS	NNP	O
,	,	O
we	PRP	O
performed	VBD	O
cross-sectional	JJ	O
and	CC	O
repeated-measure	JJ	O
observational	JJ	O
studies	NNS	O
of	IN	O
the	DT	O
relationship	NN	O
between	IN	O
EEG	NNP	PH
findings	NNS	O
and	CC	O
cognitive/behavioral	JJ	O
factors	NNS	O
on	IN	O
23	CD	O
children	NNS	O
(	(	O
aged	VBN	O
4-17	CD	O
years	NNS	O
)	)	O
.	.	O

EEGs	NNP	PH
were	VBD	O
reviewed	VBN	O
for	IN	O
clinical	JJ	O
abnormalities	NNS	O
,	,	O
including	VBG	O
IEDs	NNP	O
,	,	O
by	IN	O
readers	NNS	O
blinded	VBD	O
to	TO	O
participants	NNS	O
'	POS	O
behavioral	NN	O
symptoms	NNS	O
.	.	O

Between-group	JJ	O
differences	NNS	O
in	IN	O
baseline	JJ	O
characteristics	NNS	O
of	IN	O
participants	NNS	O
with	IN	O
and	CC	O
without	IN	O
IEDs	NNP	O
were	VBD	O
analyzed	VBN	O
.	.	O

Within-subject	JJ	O
analyses	NNS	O
examined	VBD	O
the	DT	O
association	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
IEDs	NNP	O
and	CC	O
changes	NNS	O
in	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
symptoms	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
85	CD	O
EEGs	NNP	O
,	,	O
43	CD	O
(	(	O
51	CD	O
%	NN	O
)	)	O
were	VBD	O
abnormal	JJ	O
,	,	O
predominantly	RB	O
because	IN	O
of	IN	O
IEDs	NNP	O
.	.	O

Only	RB	O
one	CD	O
subject	NN	O
had	VBD	O
documented	VBN	O
clinical	JJ	O
seizures	NNS	O
.	.	O

IEDs	NNP	O
clustered	VBD	O
in	IN	O
13	CD	O
subjects	NNS	O
(	(	O
57	CD	O
%	NN	O
)	)	O
,	,	O
whereas	$	O
9	CD	O
subjects	NNS	O
(	(	O
39	CD	O
%	NN	O
)	)	O
had	VBD	O
EEGs	NNP	O
consistently	RB	O
free	JJ	O
of	IN	O
IEDs	NNP	O
.	.	O

While	IN	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
group	NN	O
differences	NNS	O
in	IN	O
sex	NN	O
,	,	O
age	NN	O
,	,	O
intellectual	JJ	O
disability	NN	O
,	,	O
language	NN	O
level	NN	O
,	,	O
or	CC	O
baseline	VB	O
ADHD	NNP	O
symptoms	NNS	O
,	,	O
autistic	JJ	O
symptoms	NNS	O
tended	VBD	O
to	TO	O
be	VB	O
more	RBR	O
prevalent	JJ	O
in	IN	O
the	DT	O
IED	NNP	O
group	NN	O
(	(	O
according	VBG	O
to	TO	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule-2	NNP	O
criteria	NNS	O
)	)	O
.	.	O

Within	JJ	O
individuals	NNS	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
IEDs	NNP	O
on	IN	O
a	DT	O
particular	JJ	O
EEG	NNP	O
predicted	VBD	O
,	,	O
on	IN	O
average	NN	O
,	,	O
a	DT	O
27	CD	O
%	NN	O
increase	NN	O
in	IN	O
ADHD	NNP	O
symptom	NN	O
severity	NN	O
.	.	O

CONCLUSIONS	NNP	O
Epileptiform	NNP	O
discharges	NNS	O
are	VBP	O
common	JJ	O
in	IN	O
SLOS	NNP	O
,	,	O
despite	IN	O
a	DT	O
relatively	RB	O
low	JJ	O
prevalence	NN	O
of	IN	O
epilepsy	NN	O
.	.	O

Fluctuations	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
epileptiform	NN	O
discharges	NNS	O
within	IN	O
individual	JJ	O
children	NNS	O
with	IN	O
a	DT	O
developmental	JJ	O
disability	NN	O
syndrome	NN	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
fluctuations	NNS	O
in	IN	O
ADHD	NNP	O
symptomatology	NN	O
,	,	O
even	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
clinical	JJ	O
seizures	NNS	O
.	.	O

A	DT	O
placebo-controlled	JJ	C
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
using	VBG	O
testosterone	NN	PM
undecanoate	NN	PM
with	IN	PM
injectable	JJ	PM
norethisterone	JJ	PM
enanthate	NN	PM
:	:	PM
effect	NN	O
on	IN	O
anthropometric	NN	O
,	,	O
metabolic	JJ	O
and	CC	O
biochemical	JJ	O
parameters	NNS	O
.	.	O

Testosterone	CD	O
administered	VBD	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
progestogens	NNS	O
in	IN	O
male	JJ	O
contraception	NN	O
induces	NNS	O
reversible	JJ	O
oligo-azoospermia	JJ	O
,	,	O
but	CC	O
its	PRP$	O
effects	NNS	O
on	IN	O
body	NN	O
composition	NN	O
and	CC	O
metabolism	NN	O
are	VBP	O
less	RBR	O
known	JJ	O
.	.	O

We	PRP	O
analysed	VBD	O
anthropometric	JJ	O
and	CC	O
metabolic	JJ	O
parameters	NNS	O
in	IN	O
five	CD	O
groups	NNS	O
of	IN	O
10	CD	O
males	NNS	O
:	:	O
four	CD	O
receiving	VBG	O
testosterone	NN	PM
undecanoate	NN	PM
(	(	O
TU	NNP	O
:	:	O
1000	CD	O
mg	NN	O
)	)	O
plus	CC	PM
norethisterone	JJ	PM
enanthate	NN	PM
(	(	O
NETE	NNP	O
:	:	O
200	CD	O
mg	NN	O
)	)	O
at	IN	O
different	JJ	O
intervals	NNS	O
(	(	O
every	DT	O
8	CD	O
weeks	NNS	O
:	:	O
NETE-8	JJ	O
;	:	O
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-12	NN	O
;	:	O
every	DT	O
6	CD	O
weeks	NNS	O
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-6/12	JJ	O
;	:	O
every	DT	O
6	CD	O
weeks	NNS	O
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
then	RB	O
TU	NNP	PM
plus	CC	PM
placebo	JJ	PM
every	DT	O
12	CD	O
weeks	NNS	O
:	:	O
NETE-6/12/0	NNP	O
)	)	O
and	CC	O
one	CD	O
placebo	NN	C
(	(	O
NETE-0/0	NNP	O
)	)	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
48	CD	O
weeks	NNS	O
.	.	O

Body	NNP	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
and	CC	O
waist	JJ	O
circumference	NN	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
any	DT	O
groups	NNS	O
except	IN	O
for	IN	O
the	DT	O
NETE-8	NNP	O
in	IN	O
which	WDT	O
BMI	NNP	O
increased	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

Lean	JJ	O
body	NN	O
mass	NN	O
(	(	O
MAMC	NNP	O
or	CC	O
AMA	NNP	O
)	)	O
increased	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
highest	JJS	O
hormonal	JJ	O
dose	NN	O
groups	NNS	O
(	(	O
p	JJ	O
=	NN	O
0.04	CD	O
,	,	O
NETE-6/12	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.004	CD	O
,	,	O
NETE-8	NNP	O
)	)	O
.	.	O

No	UH	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
glucose	JJ	O
levels	NNS	O
,	,	O
insulin	NN	O
sensitivity	NN	O
index	NN	O
and	CC	O
lipid	JJ	O
profile	NN	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
biochemical	JJ	O
and	CC	O
cell	NN	O
count	NN	O
parameters	NNS	O
in	IN	O
any	DT	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
NETE	NNP	O
and	CC	O
TU	NNP	O
for	IN	O
48	CD	O
weeks	NNS	O
were	VBD	O
not	RB	O
accompanied	VBN	O
by	IN	O
any	DT	O
metabolic	JJ	O
changes	NNS	O
and	CC	O
any	DT	O
adverse	JJ	O
effects	NNS	O
.	.	O

The	DT	O
weight	JJ	O
gain	NN	O
of	IN	O
the	DT	O
highest	JJS	O
NETE	JJ	O
plus	CC	O
TU	JJ	O
dosage	NN	O
was	VBD	O
mainly	RB	O
because	IN	O
of	IN	O
gain	NN	O
in	IN	O
muscle	NN	O
mass	NN	O
.	.	O

Can	MD	O
acupuncture	VB	PH
ease	VB	O
the	DT	O
symptoms	NNS	O
of	IN	O
menopause	NN	O
?	.	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
2-group	JJ	O
clinical	JJ	O
study	NN	O
,	,	O
acupuncture	NN	PH
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
menopausal	NN	O
hot	JJ	O
flushes	NNS	O
,	,	O
sleep	JJ	O
disturbances	NNS	O
,	,	O
and	CC	O
mood	NN	O
changes	NNS	O
.	.	O

The	DT	O
experimental	JJ	O
acupuncture	NN	PH
treatment	NN	O
consisted	VBD	O
of	IN	O
specific	JJ	O
acupuncture	NN	PH
body	NN	O
points	NNS	O
related	VBN	O
to	TO	O
menopausal	VB	O
symptoms	NNS	O
.	.	O

The	DT	O
comparison	JJ	O
acupuncture	NN	PH
treatment	NN	O
consisted	VBN	O
of	IN	O
a	DT	O
treatment	NN	O
designated	VBN	O
as	IN	O
a	DT	O
general	JJ	O
tonic	NN	O
specifically	RB	O
designed	VBN	O
to	TO	O
benefit	VB	O
the	DT	O
flow	NN	O
of	IN	O
Ch'i	NNP	O
(	(	O
energy	NN	O
)	)	O
.	.	O

Results	NNS	O
from	IN	O
the	DT	O
experimental	JJ	O
acupuncture	NN	PH
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
mean	JJ	O
monthly	JJ	O
hot	JJ	O
flush	NN	O
severity	NN	O
for	IN	O
site-specific	JJ	O
acupuncture	NN	O
.	.	O

The	DT	O
comparison	JJ	O
acupuncture	NN	PH
treatment	NN	O
group	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
in	IN	O
severity	NN	O
from	IN	O
baseline	NN	O
over	IN	O
the	DT	O
treatment	NN	O
phase	NN	O
.	.	O

Sleep	JJ	O
disturbances	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
acupuncture	NN	PH
treatment	NN	O
group	NN	O
declined	VBD	O
over	IN	O
the	DT	O
study	NN	O
.	.	O

Mood	NNP	O
changes	NNS	O
in	IN	O
both	DT	O
the	DT	O
experimental	JJ	O
acupuncture	NN	PH
treatment	NN	O
group	NN	O
and	CC	O
the	DT	O
comparison	NN	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
baseline	NN	O
and	CC	O
the	DT	O
third	JJ	O
month	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Acupuncture	NNP	PH
using	VBG	O
menopausal-specific	JJ	O
sites	NNS	O
holds	VBZ	O
promise	NN	O
for	IN	O
nonhormonal	JJ	O
relief	NN	O
of	IN	O
hot	JJ	O
flushes	NNS	O
and	CC	O
sleep	JJ	O
disturbances	NNS	O
.	.	O

First-line	JJ	PM
cisplatin	NN	PM
with	IN	PM
docetaxel	NN	PM
or	CC	O
vinorelbine	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
:	:	O
a	DT	O
quality	NN	O
of	IN	O
life	NN	O
directed	VBN	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
of	IN	O
Gruppo	NNP	O
Oncologico	NNP	O
Italia	NNP	O
Meridionale	NNP	O
.	.	O

BACKGROUND	NNP	O
Quality	NNP	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
has	VBZ	O
gained	VBN	O
greater	JJR	O
importance	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
metastatic	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
due	JJ	O
to	TO	O
the	DT	O
palliative	JJ	O
nature	NN	O
of	IN	O
treatment	NN	O
.	.	O

Docetaxel	NNP	PM
(	(	PM
DCT	NNP	PM
)	)	PM
and	CC	O
cisplatin	NN	PM
(	(	PM
CDDP	NNP	PM
)	)	PM
doublet	NN	PM
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
to	TO	O
a	DT	O
better	JJR	O
QoL	NNP	O
than	IN	O
the	DT	O
weekly	JJ	O
vinorelbine	NN	PM
(	(	PM
VNR	NNP	PM
)	)	PM
and	CC	O
CDDP	NNP	PM
regimen	NNS	O
.	.	O

Recently	RB	O
a	DT	O
newer	NN	O
more	RBR	O
tolerated	JJ	O
schedule	NN	O
of	IN	O
the	DT	O
VNR/CDDP	NNP	PH
regimen	NN	O
has	VBZ	O
been	VBN	O
published	VBN	O
and	CC	O
is	VBZ	O
widely	RB	O
employed	VBN	O
in	IN	O
medical	JJ	O
practice	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
these	DT	O
regimens	NNS	O
on	IN	O
patients	NNS	O
'	POS	O
QoL	NNP	O
as	RB	O
well	RB	O
as	IN	O
symptoms	NNS	O
control	NN	O
and	CC	O
type	NN	O
and	CC	O
grading	VBG	O
chemo-related	JJ	O
side-effects	NNS	O
has	VBZ	O
been	VBN	O
compared	VBN	O
prospectically	RB	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
received	VBD	O
CDDP	NNP	PM
75	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
plus	CC	PM
DCT	NNP	PM
75	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
on	IN	O
day	NN	O
1	CD	O
every	DT	O
weeks	NNS	O
(	(	O
arm	IN	O
A	NNP	O
)	)	O
or	CC	O
CDDP	$	PM
80	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
on	IN	PM
day	NN	PM
1	CD	PM
plus	CC	PM
VNR	NNP	PM
30	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
day	NN	O
1	CD	O
and	CC	O
8	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
(	(	O
arm	NN	O
B	NNP	O
)	)	O
.	.	O

G-CSF	NNP	PM
and/or	JJ	O
EPO	NNP	PM
were	VBD	O
employed	VBN	O
as	IN	O
needed	VBN	O
.	.	O

Health-related	JJ	O
QoL	NNP	O
was	VBD	O
assessed	VBN	O
at	IN	O
entry	NN	O
and	CC	O
after	IN	O
every	DT	O
cycle	NN	O
by	IN	O
the	DT	O
EORTC-QLQ-C30	NNP	O
and	CC	O
LC13	NNP	O
questionnaires	NNS	O
,	,	O
toxicity	NN	O
by	IN	O
the	DT	O
NCI-NCCN	NNP	O
CTC	NNP	O
vs	NN	O
2	CD	O
,	,	O
and	CC	O
intent-to-treat	JJ	O
objective	JJ	O
response	NN	O
by	IN	O
the	DT	O
Recist	NNP	O
criteria	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
QoL	NNP	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
37	CD	O
pts	NNS	O
(	(	O
88	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	PM
arm	NN	O
and	CC	O
39	CD	O
pts	NNS	O
(	(	O
87	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	PM
one	NN	O
.	.	O

Baseline	JJ	O
mean	JJ	O
scores	NNS	O
and	CC	O
rates	NNS	O
at	IN	O
which	WDT	O
pts	NNS	O
failed	VBD	O
to	TO	O
complete	VB	O
QoL	NNP	O
assessment	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Global	NNP	O
health	NN	O
status	NN	O
of	IN	O
the	DT	O
EORTC	NNP	O
QLQ-C30	NNP	O
scale	NN	O
and	CC	O
specific	JJ	O
symptoms	NNS	O
control	NN	O
(	(	O
LC13	NNP	O
module	NN	O
)	)	O
improved	VBD	O
during	IN	O
treatment	NN	O
without	IN	O
any	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Emotional	JJ	O
functioning	NN	O
remained	VBD	O
stable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
during	IN	O
treatment	NN	O
,	,	O
whereas	JJ	O
physical	JJ	O
and	CC	O
role	NN	O
improved	VBN	O
slightly	RB	O
.	.	O

In	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
14	CD	O
pts	NNS	O
(	(	O
33	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CL	NNP	O
24-40	CD	O
%	NN	O
)	)	O
had	VBD	O
PR	NNP	O
,	,	O
and	CC	O
10	CD	O
(	(	O
24	CD	O
%	NN	O
)	)	O
SD	NNP	O
for	IN	O
a	DT	O
57	CD	O
%	NN	O
TGCR	NNP	O
.	.	O

In	IN	O
the	DT	O
VNR/CDDP	NNP	PM
arm	NN	O
12	CD	O
pts	NNS	O
(	(	O
27	CD	O
%	NN	O
)	)	O
achieved	VBD	O
PR	NNP	O
,	,	O
18	CD	O
(	(	O
41	CD	O
%	NN	O
)	)	O
SD	VBZ	O
a	DT	O
68	CD	O
%	NN	O
TGCR	NNP	O
.	.	O

Differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Median	JJ	O
time-to-progression	NN	O
was	VBD	O
4.2	CD	O
months	NNS	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	PM
arm	NN	O
and	CC	O
4.5	CD	O
months	NNS	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	PM
one	CD	O
,	,	O
and	CC	O
median	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
12.1	CD	O
(	(	O
range	VB	O
1-26+	JJ	O
months	NNS	O
)	)	O
and	CC	O
12.5	CD	O
months	NNS	O
(	(	O
range	VB	O
1-28+	JJ	O
months	NNS	O
)	)	O
for	IN	O
DCT/CDDP	NNP	PM
and	CC	O
VNR/CDDP	NNP	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Febrile	NNP	O
neutropenia	JJ	O
rate	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	PM
arm	NN	O
(	(	O
p=0.02	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
G3-4	NNP	O
anemia	NN	O
(	(	O
p=0.005	NN	O
)	)	O
and	CC	O
G-CSF/EPO	NNP	O
use	NN	O
(	(	O
p=0.019	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Global	NNP	O
and	CC	O
specific	JJ	O
health-related	JJ	O
QoL	NNP	O
data	NNS	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
with	IN	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
.	.	O

Efficacy	NN	O
measures	NNS	O
,	,	O
overall	JJ	O
response	NN	O
rate	NN	O
,	,	O
time-to-progression	NN	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
equivalent	JJ	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

However	RB	O
,	,	O
severe	JJ	O
anemia	NN	O
and	CC	O
febrile	JJ	O
neutropenia	NN	O
are	VBP	O
statistically	RB	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	PM
arm	NN	O
than	IN	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	PM
one	NN	O
.	.	O

These	DT	O
data	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
treatment	NN	O
decision-making	NN	O
for	IN	O
pts	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
and	CC	O
for	IN	O
the	DT	O
design	NN	O
of	IN	O
future	JJ	O
trials	NNS	O
with	IN	O
chemotherapy	NN	O
plus	CC	O
biologics	NNS	O
.	.	O

Can	MD	O
incentives	VB	E
undermine	JJ	O
intrinsic	JJ	O
motivation	NN	O
to	TO	O
participate	VB	O
in	IN	O
epidemiologic	JJ	O
surveys	NNS	O
?	.	O
Response	JJ	O
rates	NNS	O
to	TO	O
surveys	NNS	O
are	VBP	O
decreasing	VBG	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
use	NN	E
of	IN	E
lottery	JJ	E
tickets	NNS	E
as	IN	E
incentives	NNS	E
in	IN	O
an	DT	O
epidemiologic	JJ	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
self-administered	JJ	O
questionnaire	NN	O
was	VBD	O
sent	VBN	O
to	TO	O
parents	NNS	O
in	IN	O
the	DT	O
municipality	NN	O
of	IN	O
Stockholm	NNP	O
,	,	O
Sweden	NNP	O
,	,	O
who	WP	O
were	VBD	O
to	TO	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
in	IN	O
a	DT	O
study	NN	O
addressing	VBG	O
stress	NN	O
in	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
cancer	NN	O
.	.	O

A	DT	O
stratified	JJ	O
random	JJ	O
sample	NN	O
of	IN	O
450	CD	O
parents	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
incentive	JJ	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
no	DT	C
incentive	NN	C
;	:	O
(	(	O
b	NN	O
)	)	O
a	DT	O
promised	JJ	E
incentive	NN	E
of	IN	E
one	CD	E
lottery	NN	E
ticket	NN	E
to	TO	E
be	VB	E
received	VBN	E
upon	IN	E
reply	NN	E
;	:	O
(	(	O
c	NN	O
)	)	O
a	DT	O
promised	JJ	E
incentive	NN	E
of	IN	E
one	CD	E
lottery	NN	E
ticket	NN	E
to	TO	E
be	VB	E
received	VBN	E
upon	IN	E
reply	NN	E
and	CC	E
an	DT	E
additional	JJ	E
lottery	NN	E
ticket	NN	E
upon	IN	E
reply	NN	E
within	IN	E
1	CD	E
week	NN	E
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
across	IN	O
the	DT	O
three	CD	O
groups	NNS	O
was	VBD	O
65.3	CD	O
%	NN	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
was	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
no	DT	C
incentive	NN	C
group	NN	C
(	(	O
69.3	CD	O
%	NN	O
)	)	O
and	CC	O
lowest	JJS	O
in	IN	O
the	DT	O
one	CD	E
plus	CC	E
one	CD	E
lottery	NN	E
ticket	NN	E
group	NN	E
(	(	O
62.0	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
a	DT	O
survival	JJ	O
analysis	NN	O
,	,	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
response	NN	O
curves	NNS	O
was	VBD	O
significant	JJ	O
by	IN	O
the	DT	O
log-rank	JJ	O
test	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
with	IN	O
the	DT	O
no	DT	O
incentive	NN	O
group	NN	O
having	VBG	O
a	DT	O
shorter	JJR	O
time	NN	O
to	TO	O
response	NN	O
than	IN	O
the	DT	O
incentive	NN	E
group	NN	E
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
lottery	JJ	E
tickets	NNS	E
as	IN	O
incentives	NNS	O
to	TO	O
increase	VB	O
participation	NN	O
in	IN	O
a	DT	O
mail	NN	O
questionnaire	NN	O
among	IN	O
parents	NNS	O
may	MD	O
be	VB	O
less	RBR	O
valuable	JJ	O
or	CC	O
even	RB	O
harmful	JJ	O
.	.	O

Incentives	NNS	E
may	MD	O
undermine	VB	O
motivation	NN	O
in	IN	O
studies	NNS	O
in	IN	O
which	WDT	O
the	DT	O
intrinsic	JJ	O
motivation	NN	O
of	IN	O
the	DT	O
respondents	NNS	O
is	VBZ	O
already	RB	O
high	JJ	O
.	.	O

Impact	NN	O
of	IN	O
a	DT	O
controlled	VBN	PH
heated	VBN	PH
breathing	VBG	PH
tube	NN	PH
humidifier	NN	PH
on	IN	O
sleep	JJ	O
quality	NN	O
during	IN	O
CPAP	NNP	PH
therapy	NN	PH
in	IN	O
a	DT	O
cool	JJ	O
sleeping	NN	O
environment	NN	O
.	.	O

There	EX	O
are	VBP	O
conflicting	VBG	O
data	NNS	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
adding	VBG	O
a	DT	O
heated	VBN	PH
humidifier	NN	PH
to	TO	O
nasal	RB	O
continuous	JJ	PH
positive	JJ	PH
airway	NN	PH
pressure	NN	PH
(	(	PH
CPAP	NNP	PH
)	)	PH
therapy	NN	PH
for	IN	O
patients	NNS	O
with	IN	O
obstructive	JJ	O
sleep	JJ	O
apnoea	NN	O
syndrome	NN	O
(	(	O
OSAS	NNP	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
heated	JJ	O
humidification	NN	O
on	IN	O
sleep	JJ	O
quality	NN	O
and	CC	O
treatment	NN	O
side-effects	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
prefer	VBP	O
a	DT	O
cold	JJ	O
bedroom	NN	O
environment	NN	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

A	DT	O
randomised	JJ	O
,	,	O
controlled	VBD	O
crossover	RB	O
trial	NN	O
involving	VBG	O
19	CD	O
patients	NNS	O
with	IN	O
a	DT	O
first-ever	JJ	O
diagnosis	NN	O
of	IN	O
OSAS	NNP	O
measured	VBD	O
the	DT	O
effect	NN	O
of	IN	O
conventional	JJ	PH
heated	JJ	PH
humidification	NN	PH
added	VBD	PH
to	TO	PH
CPAP	NNP	PH
compared	VBN	O
with	IN	O
a	DT	O
controlled	VBN	PH
heated	VBN	PH
breathing	VBG	PH
tube	NN	PH
humidifier	NN	PH
(	(	PH
ThermoSmart	NNP	PH
(	(	PH
R	NNP	PH
)	)	PH
;	:	PH
Fisher	NNP	O
and	CC	O
Paykel	NNP	O
Healthcare	NNP	O
,	,	O
Auckland	NNP	O
,	,	O
New	NNP	O
Zealand	NNP	O
)	)	O
on	IN	O
sleep	JJ	O
quality	NN	O
.	.	O

During	IN	O
the	DT	O
night	NN	O
in	IN	O
the	DT	O
sleep	JJ	O
laboratory	NN	O
at	IN	O
a	DT	O
mean	JJ	O
room	NN	O
temperature	NN	O
of	IN	O
14	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
less	JJR	O
condensation	NN	O
formed	VBN	O
with	IN	O
the	DT	O
controlled	VBN	PH
heated	VBD	PH
breathing	VBG	PH
tube	NN	PH
humidifier	NN	PH
(	(	O
1.9	CD	O
mL	NN	O
versus	NN	O
35.3	CD	O
mL	NN	O
)	)	O
in	IN	O
the	DT	O
delivery	NN	O
system	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
total	JJ	O
sleep	JJ	O
time	NN	O
,	,	O
time	NN	O
spent	VBN	O
in	IN	O
sleep	JJ	O
stages	NNS	O
3	CD	O
and	CC	O
4	CD	O
,	,	O
and	CC	O
rapid	JJ	O
eye	NN	O
movement	NN	O
sleep	JJ	O
phases	NNS	O
were	VBD	O
significantly	RB	O
longer	RBR	O
and	CC	O
the	DT	O
overall	JJ	O
side-effect	JJ	O
score	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
with	IN	O
conventional	JJ	O
heated	JJ	O
humidification	NN	O
.	.	O

Patients	NNS	O
on	IN	O
nasal	JJ	O
continuous	JJ	O
positive	JJ	O
airway	NN	O
pressure	NN	O
desiring	VBG	O
a	DT	O
cool	JJ	O
bedroom	NN	O
temperature	NN	O
could	MD	O
benefit	VB	O
from	IN	O
controlled	VBN	PH
heated	VBN	PH
breathing	VBG	PH
tube	JJ	PH
humidification	NN	PH
technology	NN	PH
(	(	O
with	IN	O
inputs	NNS	O
from	IN	O
ambient	JJ	O
temperature	NN	O
,	,	O
set	VBN	O
pressure	NN	O
and	CC	O
flow	NN	O
)	)	O
.	.	O

Use	NNP	O
of	IN	O
the	DT	O
electrothermal	JJ	S
bipolar	JJ	S
vessel	NN	S
system	NN	S
(	(	S
EBVS	NNP	S
)	)	S
in	IN	O
laparoscopic	JJ	O
adrenalectomy	NN	O
:	:	O
a	DT	O
prospective	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Since	IN	O
laparoscopic	NN	O
adrenalectomy	NN	O
(	(	O
LA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
adopted	VBN	O
as	IN	O
the	DT	O
gold	JJ	O
standard	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adrenal	JJ	O
diseases	NNS	O
,	,	O
the	DT	O
development	NN	O
of	IN	O
technology	NN	O
for	IN	O
vascular	JJ	O
control	NN	O
and	CC	O
dissection	NN	O
manoeuvres	NNS	O
,	,	O
amongst	VBZ	O
other	JJ	O
things	NNS	O
,	,	O
may	MD	O
play	VB	O
a	DT	O
pivotal	JJ	O
role	NN	O
in	IN	O
its	PRP$	O
further	JJ	O
improvement	NN	O
.	.	O

We	PRP	O
report	VBP	O
our	PRP$	O
experience	NN	O
with	IN	O
the	DT	O
electrothermal	JJ	S
bipolar	JJ	S
vessel	NN	S
sealing	NN	S
(	(	S
EBVS	NNP	S
)	)	S
device	NN	O
for	IN	O
LA	NNP	O
.	.	O

METHODS	NNP	O
From	IN	O
January	NNP	O
2004	CD	O
to	TO	O
January	NNP	O
2006	CD	O
,	,	O
50	CD	O
patients	NNS	O
(	(	O
pts	NNS	O
)	)	O
undergoing	VBG	O
LA	NNP	O
were	VBD	O
selected	VBN	O
and	CC	O
randomized	VBN	O
for	IN	O
use	NN	O
of	IN	O
the	DT	O
EBVS	NNP	S
(	(	PH
25	CD	PH
pts	NNS	PH
,	,	PH
group	NN	PH
A	NNP	PH
)	)	PH
versus	IN	PH
the	DT	PH
UltraSonic	NNP	PH
Shears	NNP	PH
(	(	PH
USS	NNP	PH
)	)	PH
device	NN	PH
(	(	O
25	CD	O
pts	NNS	O
,	,	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Age	NNP	O
,	,	O
sex	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
,	,	O
previous	JJ	O
surgery	NN	O
and	CC	O
associated	VBN	O
diseases	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
main	JJ	O
surgical	JJ	O
parameters	NNS	O
collected	VBN	O
for	IN	O
each	DT	O
patient	NN	O
(	(	O
pt	NN	O
)	)	O
concerned	VBD	O
operative	JJ	O
time	NN	O
,	,	O
major	JJ	O
and	CC	O
minor	JJ	O
complications	NNS	O
,	,	O
conversion	NN	O
rate	NN	O
,	,	O
blood	NN	O
loss	NN	O
,	,	O
hospital	JJ	O
stay	NN	O
and	CC	O
histology	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
mortality	NN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
right	JJ	O
adrenalectomy	NN	O
mean	VB	O
operative	JJ	O
time	NN	O
(	(	O
OpT	NNP	O
)	)	O
was	VBD	O
51.8	CD	O
mins	NNS	O
(	(	O
range	VB	O
40-90	JJ	O
mins	NNS	O
)	)	O
and	CC	O
68.6	CD	O
mins	NNS	O
(	(	O
range	VB	O
50-130	NNP	O
mins	NNS	O
)	)	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
left	JJ	O
adrenalectomy	JJ	O
mean	JJ	O
OpT	NNP	O
was	VBD	O
72.2	CD	O
mins	NNS	O
(	(	O
range	VB	O
55-100	NNP	O
mins	NNS	O
)	)	O
and	CC	O
94	CD	O
mins	NNS	O
(	(	O
range	VB	O
65-140	NNP	O
mins	NNS	O
)	)	O
for	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
83	CD	O
ml	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
210	CD	O
ml	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Complications	NNS	O
were	VBD	O
not	RB	O
different	JJ	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	O
hospital	NN	O
stay	NN	O
was	VBD	O
2.9	CD	O
and	CC	O
3.1	CD	O
days	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
EBVS	NNP	O
in	IN	O
LA	NNP	O
may	MD	O
provide	VB	O
a	DT	O
significantly	RB	O
short	JJ	O
operating	NN	O
time	NN	O
and	CC	O
blood	NN	O
loss	NN	O
.	.	O

Untoward	NNP	O
effects	NNS	O
of	IN	O
fenfluramine	NN	PM
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

Several	JJ	O
recent	JJ	O
studies	NNS	O
have	VBP	O
described	VBN	O
the	DT	O
benefits	NNS	O
of	IN	O
fenfluramine	NN	PM
for	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
infantile	JJ	O
autism	NN	O
.	.	O

No	DT	O
large	JJ	O
surveys	NNS	O
of	IN	O
side	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
drug	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
untoward	JJ	O
effects	NNS	O
of	IN	O
fenfluramine	NN	PM
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
12	CD	O
subjects	NNS	O
were	VBD	O
systematically	RB	O
studied	VBN	O
.	.	O

Medication	NNP	O
was	VBD	O
administered	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
cross-over	NN	O
study	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
trained	VBN	O
in	IN	O
monitoring	VBG	O
untoward	JJ	O
effects	NNS	O
.	.	O

These	DT	O
observations	NNS	O
were	VBD	O
compiled	VBN	O
in	IN	O
detailed	JJ	O
daily	JJ	O
notes	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
four	CD	O
cases	NNS	O
describing	VBG	O
unusual	JJ	O
effects	NNS	O
found	VBN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
170	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
fenfluramine	NN	PM
are	VBP	O
also	RB	O
reported	VBN	O
.	.	O

In	IN	O
the	DT	O
initial	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
active	JJ	O
drug	NN	O
listlessness	NN	O
,	,	O
food	NN	O
refusal	NN	O
,	,	O
and	CC	O
stomach	NN	O
upset	NN	O
were	VBD	O
frequently	RB	O
seen	VBN	O
.	.	O

A	DT	O
different	JJ	O
pattern	NN	O
of	IN	O
untoward	JJ	O
effects	NNS	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
final	JJ	O
14	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Irritability	NNP	O
,	,	O
agitation	NN	O
,	,	O
and	CC	O
crying	VBG	O
along	RB	O
with	IN	O
continued	VBN	O
food	NN	O
refusal	NN	O
were	VBD	O
noted	VBN	O
.	.	O

The	DT	O
subjects	NNS	O
lost	VBD	O
2.1	CD	O
%	NN	O
of	IN	O
body	NN	O
weight	NN	O
during	IN	O
active	JJ	O
drug	NN	O
phase	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
rebound	NN	O
weight	NN	O
gain	NN	O
during	IN	O
the	DT	O
subsequent	JJ	O
placebo	NN	C
phase	NN	O
.	.	O

A	DT	O
thorough	JJ	O
understanding	NN	O
of	IN	O
fenfluramine	NN	PM
's	POS	PM
side	NN	O
effects	NNS	O
and	CC	O
adverse	JJ	O
reactions	NNS	O
is	VBZ	O
necessary	JJ	O
so	RB	O
as	IN	O
to	TO	O
differentiate	VB	O
them	PRP	O
from	IN	O
the	DT	O
multiple	NN	O
symptoms	NNS	O
inherent	NN	O
in	IN	O
the	DT	O
syndrome	NN	O
of	IN	O
autism	NN	O
.	.	O

Impact	NN	O
of	IN	O
different	JJ	O
platelet	NN	O
glycoprotein	NN	O
IIb/IIIa	NNP	O
receptor	NN	O
inhibitors	NNS	O
among	IN	O
diabetic	JJ	O
patients	NNS	O
undergoing	VBG	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
:	:	O
:	:	O
Do	VB	O
Tirofiban	NNP	O
and	CC	O
ReoPro	NNP	O
Give	NNP	O
Similar	NNP	O
Efficacy	NNP	O
Outcomes	NNP	O
Trial	NNP	O
(	(	O
TARGET	NNP	O
)	)	O
1-year	JJ	O
follow-up	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
platelet	NN	O
glycoprotein	NN	O
IIb/IIIa	NNP	O
receptor	NN	O
inhibitor	NN	O
abciximab	NN	O
,	,	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
,	,	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
improve	VB	O
early	JJ	O
and	CC	O
late	JJ	O
outcomes	NNS	O
among	IN	O
diabetic	JJ	O
patients	NNS	O
undergoing	VBG	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
unknown	JJ	O
whether	IN	O
small-molecule	JJ	O
agents	NNS	O
confer	VBP	O
similar	JJ	O
benefits	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
In	IN	O
18	CD	O
countries	NNS	O
,	,	O
4809	CD	O
patients	NNS	O
undergoing	VBG	O
PCI	NNP	O
with	IN	O
stent	JJ	O
implantation	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
tirofiban	VB	PM
or	CC	O
abciximab	VB	PM
.	.	O

At	IN	O
the	DT	O
time	NN	O
of	IN	O
enrollment	NN	O
,	,	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
diabetes	NNS	O
status	NN	O
.	.	O

As	IN	O
compared	VBN	O
with	IN	O
non-diabetic	JJ	O
patients	NNS	O
,	,	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
(	(	O
n=1117	NN	O
)	)	O
showed	VBD	O
similar	JJ	O
30-day	JJ	O
ischemic	JJ	O
outcomes	NNS	O
,	,	O
an	DT	O
increased	JJ	O
incidence	NN	O
of	IN	O
any	DT	O
target	NN	O
vessel	NN	O
revascularization	NN	O
(	(	O
TVR	NNP	O
)	)	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
10.3	CD	O
%	NN	O
versus	IN	O
7.8	CD	O
%	NN	O
;	:	O
P=	NNP	O
0.008	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
trend	NN	O
toward	IN	O
higher	JJR	O
1-year	JJ	O
mortality	NN	O
(	(	O
2.5	CD	O
%	NN	O
versus	IN	O
1.6	CD	O
%	NN	O
;	:	O
P=0.056	NNP	O
)	)	O
.	.	O

Among	IN	O
diabetic	JJ	O
patients	NNS	O
randomized	VBN	O
to	TO	O
tirofiban	VB	O
(	(	O
n=560	NN	O
)	)	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
,	,	O
or	CC	O
urgent	JJ	O
TVR	NNP	O
at	IN	O
30	CD	O
days	NNS	O
was	VBD	O
6.2	CD	O
%	NN	O
,	,	O
and	CC	O
among	IN	O
those	DT	O
randomized	VBN	O
to	TO	O
abciximab	VB	O
(	(	O
n=557	NN	O
)	)	O
it	PRP	O
was	VBD	O
5.4	CD	O
%	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
1.16	CD	O
;	:	O
P=0.540	NNP	O
)	)	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
composite	NN	O
of	IN	O
death	NN	O
,	,	O
MI	NNP	O
,	,	O
or	CC	O
any	DT	O
TVR	NNP	O
occurred	VBD	O
in	IN	O
15.7	CD	O
%	NN	O
and	CC	O
in	IN	O
16.9	CD	O
%	NN	O
of	IN	O
tirofiban	NN	O
and	CC	O
abciximab	NN	O
patients	NNS	O
,	,	O
respectively	RB	O
(	(	O
HR	NNP	O
0.93	CD	O
;	:	O
P=0.610	NNP	O
)	)	O
.	.	O

Any	DT	O
TVR	NNP	O
occurred	VBD	O
in	IN	O
9.5	CD	O
%	NN	O
and	CC	O
11.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
HR	NNP	O
0.84	CD	O
;	:	O
P=	NNP	O
0.366	CD	O
)	)	O
.	.	O

The	DT	O
1-year	JJ	O
mortality	NN	O
was	VBD	O
2.1	CD	O
%	NN	O
in	IN	O
the	DT	O
tirofiban	NN	O
group	NN	O
and	CC	O
2.9	CD	O
%	NN	O
in	IN	O
the	DT	O
abciximab	NN	O
group	NN	O
(	(	O
HR	NNP	O
0.74	CD	O
;	:	O
P=	NNP	O
0.436	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Among	IN	O
diabetic	JJ	O
patients	NNS	O
undergoing	VBG	O
PCI	NNP	O
,	,	O
tirofiban	NN	O
and	CC	O
abciximab	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
comparable	JJ	O
event	NN	O
rates	NNS	O
,	,	O
including	VBG	O
similar	JJ	O
rates	NNS	O
of	IN	O
6-month	JJ	O
TVR	NNP	O
and	CC	O
1-year	JJ	O
mortality	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
non-glycoprotein	JJ	O
IIb/IIIa	NNP	O
properties	NNS	O
of	IN	O
abciximab	NNS	O
do	VBP	O
not	RB	O
translate	VB	O
into	IN	O
a	DT	O
discernible	JJ	O
long-term	JJ	O
clinical	JJ	O
benefit	NN	O
among	IN	O
diabetic	JJ	O
patients	NNS	O
.	.	O

Locomoting-to-reach	NN	PH
:	:	O
information	NN	O
variables	NNS	O
and	CC	O
control	NN	O
strategies	NNS	O
for	IN	O
nested	JJ	O
actions	NNS	O
.	.	O

Locomoting-to-reach	NNP	PH
is	VBZ	O
a	DT	O
basic	JJ	O
perception/action	NN	O
behavior	NN	O
that	WDT	O
requires	VBZ	O
visual	JJ	O
information	NN	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
both	DT	O
locomotion	NN	O
and	CC	O
reaching	VBG	O
components	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
visual	JJ	O
information	NN	O
and	CC	O
the	DT	O
control	NN	O
strategies	NNS	O
used	VBN	O
to	TO	O
guide	VB	O
both	PDT	O
the	DT	O
head	NN	O
and	CC	O
the	DT	O
hand	NN	O
on	IN	O
approach	NN	O
to	TO	O
a	DT	O
target	NN	O
in	IN	O
a	DT	O
locomotion-to-reach	JJ	PH
task	NN	PH
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
participants	NNS	O
were	VBD	O
required	VBN	O
to	TO	O
locomote	VB	O
in	IN	O
the	DT	O
dark	NN	O
to	TO	O
a	DT	O
lit	NN	O
target	NN	O
in	IN	O
three	CD	O
different	JJ	O
conditions	NNS	O
:	:	O
monocular	JJ	O
vision/target	NN	O
with	IN	O
image	NN	O
size	NN	O
,	,	O
binocular	JJ	O
vision/target	NN	O
with	IN	O
image	NN	O
size	NN	O
,	,	O
and	CC	O
binocular	JJ	O
vision/point-light	JJ	O
target	NN	O
(	(	O
without	IN	O
image	NN	O
size	NN	O
)	)	O
.	.	O

In	IN	O
task	NN	O
one	CD	O
,	,	O
participants	NNS	O
brought	VBD	O
their	PRP$	O
eyes	NNS	O
to	TO	O
the	DT	O
target	NN	O
.	.	O

In	IN	O
task	NN	O
two	CD	O
,	,	O
participants	NNS	O
brought	VBD	O
their	PRP$	O
outstretched	JJ	O
hand	NN	O
to	TO	O
the	DT	O
target	NN	O
.	.	O

Movement	JJ	O
trajectories	NNS	O
for	IN	O
both	DT	O
tasks	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

Results	NNP	O
show	VBP	O
that	IN	O
participants	NNS	O
were	VBD	O
significantly	RB	O
more	RBR	O
accurate	JJ	O
when	WRB	O
binocular	JJ	O
information	NN	O
was	VBD	O
present	JJ	O
.	.	O

In	IN	O
both	DT	O
tasks	NNS	O
,	,	O
participants	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
use	VB	O
a	DT	O
proportional	JJ	O
rate	NN	O
control	NN	O
strategy	NN	O
rather	RB	O
than	IN	O
a	DT	O
constant	JJ	O
?	.	O
strategy	NN	O
.	.	O

In	IN	O
the	DT	O
walk-to-reach	NN	O
task	NN	O
,	,	O
they	PRP	O
used	VBD	O
monocular	JJ	O
and/or	NN	O
binocular	NN	O
?	.	O
information	NN	O
to	TO	O
guide	VB	O
the	DT	O
head	NN	O
and	CC	O
then	RB	O
switched	VBD	O
to	TO	O
using	VBG	O
relative	JJ	O
disparity	NN	O
?	.	O
to	TO	O
guide	VB	O
the	DT	O
hand	NN	O
to	TO	O
final	JJ	O
target	NN	O
acquisition	NN	O
,	,	O
switching	VBG	O
when	WRB	O
the	DT	O
hand	NN	O
centric	NN	O
?	.	O
became	VBD	O
less	JJR	O
than	IN	O
the	DT	O
head	NN	O
centric	JJ	O
?.	NNP	O
Dynamical	NNP	O
models	NNS	O
of	IN	O
the	DT	O
information	NN	O
and	CC	O
control	NN	O
strategies	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
perform	VB	O
simulations	NNS	O
that	WDT	O
were	VBD	O
found	VBN	O
to	TO	O
fit	VB	O
the	DT	O
data	NN	O
well	RB	O
.	.	O

The	DT	O
conclusion	NN	O
is	VBZ	O
that	IN	O
proportional	JJ	O
rate	NN	O
control	NN	O
is	VBZ	O
used	VBN	O
sequentially	RB	O
with	IN	O
head	NN	O
centric	NN	O
,	,	O
then	RB	O
hand-centric	JJ	O
?-based	JJ	O
information	NN	O
,	,	O
using	VBG	O
at	IN	O
each	DT	O
moment	NN	O
the	DT	O
?	.	O
with	IN	O
the	DT	O
smallest	JJS	O
value	NN	O
.	.	O

Direct	JJ	O
evidence	NN	O
for	IN	O
spinal	JJ	O
cord	NN	O
involvement	NN	O
in	IN	O
placebo	NN	O
analgesia	NN	O
.	.	O

Placebo	NNP	O
analgesia	NN	O
is	VBZ	O
a	DT	O
prime	JJ	O
example	NN	O
of	IN	O
the	DT	O
impact	NN	O
that	WDT	O
psychological	JJ	O
factors	NNS	O
have	VBP	O
on	IN	O
pain	NN	O
perception	NN	O
.	.	O

We	PRP	O
used	VBD	O
functional	JJ	PH
magnetic	JJ	PH
resonance	NN	PH
imaging	NN	PH
of	IN	O
the	DT	O
human	JJ	O
spinal	JJ	O
cord	NN	O
to	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
placebo	VBZ	O
analgesia	JJ	O
results	NNS	O
in	IN	O
a	DT	O
reduction	NN	O
of	IN	O
nociceptive	JJ	O
processing	NN	O
in	IN	O
the	DT	O
spinal	JJ	O
cord	NN	O
.	.	O

In	IN	O
line	NN	O
with	IN	O
behavioral	JJ	O
data	NNS	O
that	WDT	O
show	VBP	O
decreased	VBN	O
pain	NN	O
responses	NNS	O
under	IN	O
placebo	NN	O
,	,	O
pain-related	JJ	O
activity	NN	O
in	IN	O
the	DT	O
spinal	JJ	O
cord	NN	O
is	VBZ	O
strongly	RB	O
reduced	VBN	O
under	IN	O
placebo	NN	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
direct	JJ	O
evidence	NN	O
for	IN	O
spinal	JJ	O
inhibition	NN	O
as	IN	O
one	CD	O
mechanism	NN	O
of	IN	O
placebo	NN	O
analgesia	NN	O
and	CC	O
highlight	NN	O
that	WDT	O
psychological	JJ	O
factors	NNS	O
can	MD	O
act	VB	O
on	IN	O
the	DT	O
earliest	JJS	O
stages	NNS	O
of	IN	O
pain	NN	O
processing	NN	O
in	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
comparing	VBG	O
induction	NN	PM
chemotherapy	NN	PM
versus	NN	O
induction	NN	PM
chemotherapy	NN	PM
followed	VBN	O
by	IN	O
maintenance	NN	PM
chemotherapy	NN	PM
in	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
.	.	O

European	JJ	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
.	.	O

PURPOSE	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
European	NNP	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
(	(	O
ELCWP	NNP	O
)	)	O
performed	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
with	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
to	TO	O
determine	VB	O
if	IN	O
maintenance	NN	O
chemotherapy	NN	O
with	IN	O
12	CD	O
courses	NNS	O
of	IN	O
etoposide	NN	PM
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
3	CD	O
)	)	O
and	CC	O
vindesine	NN	PM
(	(	O
3	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
3	CD	O
)	)	O
could	MD	O
improve	VB	O
progression-free	JJ	O
survival	NN	O
in	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
SCLC	NNP	O
)	)	O
patients	NNS	O
who	WP	O
responded	VBD	O
to	TO	O
six	CD	O
courses	NNS	O
of	IN	O
induction	NN	PM
chemotherapy	NN	PM
with	IN	O
ifosfamide	NN	PM
,	,	O
etoposide	RB	PM
,	,	O
and	CC	O
an	DT	O
anthracycline	NN	PM
(	(	O
doxorubicin	NN	PM
or	CC	O
epirubicin	NN	PM
)	)	O
.	.	O

RESULTS	NNP	O
Among	IN	O
235	CD	O
eligible	JJ	O
patients	NNS	O
initially	RB	O
registered	VBD	O
,	,	O
91	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
maintenance	NN	O
therapy	NN	O
,	,	O
including	VBG	O
seven	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
no	RB	O
longer	RBR	O
responding	VBG	O
.	.	O

Among	IN	O
84	CD	O
randomized	JJ	O
responders	NNS	O
,	,	O
progression-free	JJ	O
survival	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
by	IN	O
maintenance	NN	O
therapy	NN	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
(	(	O
maintenance	NN	O
v	IN	O
follow-up	JJ	O
)	)	O
of	IN	O
25	CD	O
versus	NNS	O
12	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
second	JJ	O
randomization	NN	O
,	,	O
but	CC	O
survival	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
increased	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.10	NNP	O
)	)	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
of	IN	O
48	CD	O
and	CC	O
38	CD	O
weeks	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
a	DT	O
multi-variate	JJ	O
analysis	NN	O
that	WDT	O
took	VBD	O
into	IN	O
account	NN	O
disease	NN	O
extent	NN	O
,	,	O
maintenance	NN	O
therapy	NN	O
,	,	O
Karnofsky	NNP	O
performance	NN	O
status	NN	O
(	(	O
PS	NNP	O
)	)	O
,	,	O
and	CC	O
absolute	JJ	O
dose-intensity	NN	O
(	(	O
ADI	NNP	O
)	)	O
of	IN	O
anthracycline	NN	O
given	VBN	O
during	IN	O
induction	NN	O
,	,	O
limited	JJ	O
disease	NN	O
(	(	O
LD	NNP	O
)	)	O
and	CC	O
maintenance	NN	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
independent	JJ	O
positive	JJ	O
predictors	NNS	O
of	IN	O
survival	NN	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
conclude	VBP	O
that	DT	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
responding	VBG	O
patients	NNS	O
is	VBZ	O
beneficial	JJ	O
in	IN	O
SCLC	NNP	O
.	.	O

Long	JJ	O
term	NN	O
response	NN	O
to	TO	O
therapy	NN	O
of	IN	O
chronic	JJ	O
anti-HBe-positive	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
poor	JJ	O
independent	JJ	O
of	IN	O
type	NN	O
and	CC	O
schedule	NN	O
of	IN	O
interferon	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
response	NN	O
rate	NN	O
to	TO	O
alpha	VB	PM
interferon	NN	PM
(	(	PM
IFN	NNP	PM
)	)	PM
of	IN	O
chronic	JJ	O
anti-HBe-positive	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
variable	JJ	O
.	.	O

We	PRP	O
studied	VBD	O
whether	IN	O
type	NN	O
,	,	O
dose	NN	O
,	,	O
and	CC	O
schedule	NN	O
of	IN	O
IFN	NNP	PM
,	,	O
and	CC	O
type	NN	O
and	CC	O
frequency	NN	O
of	IN	O
posttreatment	NN	O
monitoring	NN	O
,	,	O
influence	VB	O
the	DT	O
response	NN	O
rate	NN	O
.	.	O

METHODS	NNP	O
Seventy-two	JJ	O
consecutive	JJ	O
anti-HBe-positive	JJ	O
chronic	NN	O
hepatitis	NN	O
B	NNP	O
patients	NNS	O
(	(	O
59	CD	O
male	NN	O
and	CC	O
13	CD	O
female	NN	O
,	,	O
median	JJ	O
age	NN	O
41	CD	O
yr	NN	O
)	)	O
stratified	VBN	O
by	IN	O
sex	NN	O
and	CC	O
histology	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
three	CD	O
treatment	NN	O
arms	NNS	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
(	(	O
A	DT	O
)	)	O
received	VBD	O
10	CD	O
million	CD	O
units	NNS	O
alpha-N1	JJ	PM
IFN	NNP	PM
i.m	NN	PM
.	.	PM

t.w	NN	O
.	.	O

for	IN	O
24	CD	O
wk	NN	O
(	(	O
total	JJ	O
dose	NN	O
:	:	O
720	CD	O
million	CD	O
units	NNS	O
)	)	O
;	:	O
21	CD	O
(	(	O
B	NNP	O
)	)	O
received	VBD	O
9	CD	O
million	CD	O
units	NNS	O
alpha-2a	JJ	PM
IFN	NNP	PM
i.m	NN	PM
.	.	PM

t.w	NN	O
.	.	O

for	IN	O
4	CD	O
wk	NN	O
,	,	O
followed	VBN	O
by	IN	O
18	CD	O
million	CD	O
units	NNS	O
for	IN	O
12	CD	O
wk	NN	O
and	CC	O
9	CD	O
million	CD	O
units	NNS	O
for	IN	O
8	CD	O
wk	NN	O
(	(	O
972	CD	O
million	CD	O
units	NNS	O
)	)	O
;	:	O
24	CD	O
(	(	O
C	NNP	O
)	)	O
received	VBD	O
2	CD	PM
alpha-2a	JJ	PM
IFN	NNP	PM
courses	NNS	O
(	(	O
9	CD	O
million	CD	O
units	NNS	O
i.m	RB	O
.	.	O

t.w	NN	O
.	.	O

for	IN	O
16	CD	O
and	CC	O
12	CD	O
wk	NN	O
separated	VBN	O
by	IN	O
a	DT	O
6-month	JJ	O
interval	NN	O
[	$	O
756	CD	O
million	CD	O
units	NNS	O
]	NNP	O
)	)	O
.	.	O

Primary	JJ	O
response	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
normal	JJ	O
ALT	NNP	O
and	CC	O
serum	VB	O
HBV-DNA	NNP	O
levels	NNS	O
below	IN	O
10	CD	O
pg/ml	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
therapy	NN	O
and	CC	O
sustained	VBN	O
response	NN	O
by	IN	O
normal	JJ	O
ALT	NNP	O
(	(	O
tested	VBN	O
monthly	RB	O
)	)	O
,	,	O
undetectable	JJ	O
HBV-DNA	NN	O
and	CC	O
IgM	NNP	O
anti-HBc	NN	O
(	(	O
<	JJ	O
7	CD	O
I.U	NNP	O
.	.	O

Paul	NNP	O
Ehrlich	NNP	O
Institute	NNP	O
)	)	O
(	(	O
tested	VBN	O
every	DT	O
3	CD	O
months	NNS	O
)	)	O
during	IN	O
the	DT	O
posttreatment	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
,	,	O
12	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
13	CD	O
patients	NNS	O
from	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
and	CC	O
C	NNP	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
responders	NNS	O
.	.	O

At	IN	O
the	DT	O
18-month	JJ	O
follow-up	JJ	O
,	,	O
two	CD	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
only	RB	O
one	CD	O
in	IN	O
groups	NNS	O
B	NNP	O
and	CC	O
C	NNP	O
maintained	VBD	O
the	DT	O
response	NN	O
.	.	O

Overall	NNP	O
,	,	O
after	IN	O
34	CD	O
months	NNS	O
(	(	O
median	JJ	O
posttreatment	NN	O
follow-up	NN	O
)	)	O
,	,	O
three	CD	O
patients	NNS	O
were	VBD	O
long	JJ	O
term	NN	O
responders	NNS	O
,	,	O
whereas	NNS	O
three	CD	O
showed	VBD	O
a	DT	O
sustained	VBN	O
remission	NN	O
after	IN	O
relapse	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
rate	NN	O
of	IN	O
long	JJ	O
term	NN	O
response	NN	O
to	TO	O
interferon	VB	O
of	IN	O
anti-HBe-positive	JJ	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
poor	JJ	O
,	,	O
independent	JJ	O
of	IN	O
IFN	NNP	O
type	NN	O
,	,	O
dose	VB	O
,	,	O
or	CC	O
schedule	NN	O
;	:	O
the	DT	O
more	RBR	O
stringent	JJ	O
the	DT	O
monitoring	NN	O
,	,	O
the	DT	O
higher	JJR	O
the	DT	O
relapse	NN	O
rate	NN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
tolerance	NN	O
of	IN	O
single-	JJ	O
and	CC	O
multiple-dose	JJ	O
oral	JJ	O
or	CC	O
intravenous	JJ	O
linezolid	NNS	PM
,	,	O
an	DT	O
oxazolidinone	NN	O
antibiotic	JJ	O
,	,	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
tolerance	NN	O
of	IN	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
linezolid	NN	PM
,	,	O
an	DT	O
oxazolidinone	NN	O
antibiotic	JJ	O
,	,	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
following	VBG	O
single-	JJ	O
and	CC	O
multiple-dose	JJ	O
administration	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
two	CD	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
dose-escalating	JJ	O
trials	NNS	O
,	,	O
subjects	NNS	O
were	VBD	O
exposed	VBN	O
either	RB	O
to	TO	O
oral	JJ	O
(	(	O
375	CD	O
,	,	O
500	CD	O
or	CC	O
625	CD	O
mg	NN	O
)	)	O
or	CC	O
intravenous	JJ	O
(	(	O
500	CD	O
or	CC	O
625	CD	O
mg	NN	O
)	)	O
linezolid	VBD	PM
or	CC	O
placebo	VB	C
twice	JJ	O
daily	RB	O
.	.	O

Serial	JJ	O
blood	NN	O
and	CC	O
urine	JJ	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
after	IN	O
the	DT	O
first-	JJ	O
and	CC	O
multiple-dose	JJ	O
administrations	NNS	O
for	IN	O
up	IN	O
to	TO	O
18	CD	O
days	NNS	O
.	.	O

Non-compartmental	JJ	O
pharmacokinetic	JJ	O
analyses	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
describe	VB	O
the	DT	O
disposition	NN	O
of	IN	O
linezolid	JJ	PM
.	.	PM

RESULTS	NNP	O
Plasma	NNP	O
linezolid	JJ	PM
concentrations	NNS	O
and	CC	O
area	NN	O
under	IN	O
the	DT	O
concentration-time	JJ	O
curves	NNS	O
increased	VBD	O
proportionally	RB	O
with	IN	O
dose	JJ	O
irrespective	NN	O
of	IN	O
the	DT	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O

Plasma	NNP	O
linezolid	JJ	PM
concentrations	NNS	O
remained	VBN	O
above	IN	O
the	DT	O
MIC90	NNP	O
for	IN	O
susceptible	JJ	O
target	NN	O
pathogens	NNS	O
(	(	O
4.0	CD	O
mg/L	NN	O
)	)	O
for	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
12	CD	O
h	NN	O
dosing	VBG	O
interval	NN	O
.	.	O

Mean	JJ	O
clearance	NN	O
,	,	O
half-life	JJ	O
and	CC	O
volume	NN	O
of	IN	O
distribution	NN	O
were	VBD	O
similar	JJ	O
irrespective	NN	O
of	IN	O
dose	NN	O
for	IN	O
both	DT	O
the	DT	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
routes	NNS	O
.	.	O

Linezolid	NNP	PM
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
the	DT	O
frequency	NN	O
of	IN	O
drug-related	JJ	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
linezolid	JJ	PM
and	CC	O
placebo	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Oral	NNP	O
and	CC	O
intravenous	JJ	O
linezolid	JJ	PM
exhibit	NN	O
linear	JJ	O
pharmacokinetics	NNS	O
,	,	O
with	IN	O
concentrations	NNS	O
remaining	VBG	O
above	IN	O
the	DT	O
target	NN	O
MIC90	NNP	O
for	IN	O
most	JJS	O
of	IN	O
the	DT	O
dosing	NN	O
interval	NN	O
.	.	O

These	DT	O
results	NNS	O
support	VBD	O
a	DT	O
twice-daily	JJ	O
schedule	NN	O
for	IN	O
linezolid	JJ	O
and	CC	O
demonstrate	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
converting	VBG	O
from	IN	O
intravenous	JJ	O
to	TO	O
oral	JJ	O
dosing	NN	O
without	IN	O
a	DT	O
dose	JJ	O
adjustment	NN	O
.	.	O

Torasemide	NNP	PM
versus	NN	O
furosemide	NN	PM
in	IN	O
cirrhosis	NN	O
:	:	O
a	DT	O
long-term	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
study	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
long-term	JJ	O
therapy	NN	O
(	(	O
70	CD	O
days	NNS	O
)	)	O
with	IN	O
torasemide	NN	PM
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
,	,	O
a	DT	O
new	JJ	O
loop	NN	O
diuretic	JJ	O
,	,	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
of	IN	O
furosemide	NN	PM
(	(	O
50	CD	O
mg/day	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
administered	VBN	O
in	IN	O
association	NN	O
with	IN	O
spironolactone	NN	PM
(	(	O
200	CD	O
mg/day	NN	O
)	)	O
in	IN	O
28	CD	O
nonazotemic	JJ	O
cirrhotic	JJ	O
patients	NNS	O
with	IN	O
controlled	JJ	O
ascites	NNS	O
.	.	O

The	DT	O
treatments	NNS	O
did	VBD	O
not	RB	O
modify	VB	O
creatinine	JJ	O
clearance	NN	O
and	CC	O
exhibited	VBD	O
a	DT	O
similar	JJ	O
effect	NN	O
on	IN	O
body	NN	O
weight	NN	O
,	,	O
urinary	JJ	O
volume	NN	O
,	,	O
and	CC	O
fractional	JJ	O
excretion	NN	O
of	IN	O
uric	JJ	O
acid	NN	O
,	,	O
sodium	NN	O
,	,	O
and	CC	O
chloride	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
torasemide	NN	PM
on	IN	O
fractional	JJ	O
potassium	NN	O
excretion	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
of	IN	O
furosemide	NN	PM
.	.	O

Torasemide	VB	PM
showed	VBD	O
higher	JJR	O
sparing	VBG	O
effect	NN	O
than	IN	O
furosemide	NN	PM
on	IN	O
calcium	NN	O
,	,	O
inorganic	JJ	O
phosphate	NN	O
,	,	O
and	CC	O
magnesium	NN	O
excretion	NN	O
and	CC	O
stronger	JJR	O
action	NN	O
on	IN	O
free	JJ	O
water	NN	O
clearance	NN	O
.	.	O

No	DT	O
changes	NNS	O
in	IN	O
serum	NN	O
parameters	NNS	O
were	VBD	O
induced	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
.	.	O

Two	CD	O
episodes	NNS	O
of	IN	O
hepatic	JJ	O
encephalopathy	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
torasemide	NN	PM
group	NN	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
sodium	NN	O
and	CC	O
water	NN	O
excretion	NN	O
and	CC	O
on	IN	O
other	JJ	O
urinary	JJ	O
parameters	NNS	O
,	,	O
torasemide	NN	PM
can	MD	O
represent	VB	O
an	DT	O
alternative	JJ	O
tool	NN	O
for	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
ascites	NNS	O
.	.	O

Gemcitabine	NNP	PM
and	CC	O
split-dose	JJ	O
paclitaxel	NN	PM
or	CC	O
docetaxel	NN	PM
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
randomised	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
activity	NN	O
and	CC	O
toxicity	NN	O
of	IN	O
split-dose	JJ	PM
paclitaxel	NN	PM
or	CC	O
docetaxel	NN	PM
in	IN	O
combination	NN	PM
with	IN	PM
gemcitabine	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
(	(	O
MBC	NNP	O
)	)	O
who	WP	O
had	VBD	O
previously	RB	O
received	VBN	O
anthracyclines	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
210	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
gemcitabine	NN	PM
1,250	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
Days	VBZ	PM
1	CD	PM
and	CC	PM
8	CD	PM
and	CC	PM
paclitaxel	VB	PM
175	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
as	IN	PM
a	DT	PM
3-h	JJ	PM
infusion	NN	PM
on	IN	PM
Day	NNP	PM
1	CD	PM
(	(	PM
GP1	NNP	PM
)	)	PM
;	:	O
gemcitabine	$	PM
1,000	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
Days	VBZ	PM
1	CD	PM
and	CC	PM
8	CD	PM
and	CC	PM
paclitaxel	VB	PM
100	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
as	IN	PM
a	DT	PM
1-h	JJ	PM
infusion	NN	PM
on	IN	PM
Days	NNP	PM
1	CD	PM
and	CC	PM
8	CD	PM
(	(	PM
GP2	NNP	PM
)	)	PM
;	:	O
gemcitabine	$	PM
1,000	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
Days	VBZ	PM
1	CD	PM
and	CC	PM
8	CD	PM
and	CC	PM
docetaxel	VB	PM
40	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
as	IN	PM
a	DT	PM
1-h	JJ	PM
infusion	NN	PM
on	IN	PM
Days	NNP	PM
1	CD	PM
and	CC	PM
8	CD	PM
(	(	PM
GD	NNP	PM
)	)	O
.	.	O

Cycles	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
3	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
204	CD	O
patients	NNS	O
evaluable	JJ	O
for	IN	O
response	NN	O
assessment	NN	O
,	,	O
the	DT	O
response	NN	O
rates	NNS	O
were	VBD	O
48.6	CD	O
%	NN	O
for	IN	O
GP1	NNP	O
,	,	O
52.2	CD	O
%	NN	O
for	IN	O
GP2	NNP	O
,	,	O
and	CC	O
52.3	CD	O
%	NN	O
for	IN	O
GD	NNP	O
.	.	O

Median	JJ	O
response	NN	O
duration	NN	O
,	,	O
time	NN	O
to	TO	O
treatment	NN	O
failure	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
each	DT	O
arm	NN	O
.	.	O

Median	JJ	O
TTP	NNP	O
for	IN	O
GP1	NNP	O
,	,	O
GP2	NNP	O
and	CC	O
GD	NNP	O
was	VBD	O
7.5	CD	O
,	,	O
7.0	CD	O
and	CC	O
7.4	CD	O
months	NNS	O
,	,	O
respectively	RB	O
.	.	O

For	IN	O
the	DT	O
208	CD	O
patients	NNS	O
evaluable	JJ	O
for	IN	O
safety	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
grade	NN	O
3/4	CD	O
toxicity	NN	O
for	IN	O
each	DT	O
regimen	NN	O
was	VBD	O
neutropaenia	RB	O
,	,	O
with	IN	O
64	CD	O
%	NN	O
,	,	O
57	CD	O
%	NN	O
,	,	O
and	CC	O
68	CD	O
%	NN	O
for	IN	O
GP1	NNP	O
,	,	O
GP2	NNP	O
,	,	O
and	CC	O
GD	NNP	O
,	,	O
respectively	RB	O
.	.	O

Grade	VB	O
4	CD	O
neutropaenia	NN	O
,	,	O
grade	VBD	O
3/4	CD	O
anaemia	NN	O
,	,	O
febrile	JJ	O
neutropaenia	NN	O
,	,	O
and	CC	O
diarrhoea	NNS	O
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
docetaxel	NN	O
arm	NN	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
use	NN	O
of	IN	O
intravenous	JJ	O
antibiotics	NNS	O
and	CC	O
blood	NN	O
transfusions	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
study	NN	O
confirmed	VBD	O
the	DT	O
high	JJ	O
activity	NN	O
of	IN	O
gemcitabine-taxane	JJ	PM
combinations	NNS	PM
in	IN	O
MBC	NNP	O
.	.	O

Split-dose	JJ	O
paclitaxel	NN	PM
had	VBD	O
similar	JJ	O
activity	NN	O
and	CC	O
toxicity	NN	O
to	TO	O
the	DT	O
3-weekly	JJ	O
administration	NN	O
.	.	O

The	DT	O
split-dose	JJ	O
docetaxel	NN	PM
regimen	NNS	O
had	VBD	O
similar	JJ	O
activity	NN	O
to	TO	O
the	DT	O
paclitaxel	NN	PM
combinations	NNS	PM
though	IN	O
associated	VBN	O
with	IN	O
higher	JJR	O
toxicity	NN	O
.	.	O

Prognostic	JJ	O
value	NN	O
of	IN	O
postoperative	JJ	S
CEA	NNP	S
clearance	NN	S
in	IN	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
with	IN	O
high	JJ	O
preoperative	JJ	O
CEA	NNP	O
levels	NNS	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
determined	VBD	O
the	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
carcinoembryonic	JJ	O
antigen	NN	O
(	(	O
CEA	NNP	O
)	)	O
clearance	NN	O
after	IN	O
tumor	NN	S
resection	NN	S
with	IN	O
serial	JJ	O
evaluation	NN	O
of	IN	O
postoperative	JJ	O
CEA	NNP	O
levels	NNS	O
in	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
1994	CD	O
and	CC	O
2004	CD	O
,	,	O
we	PRP	O
retrospectively	RB	O
reviewed	VBD	O
122	CD	O
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
whose	WP$	O
serum	JJ	O
CEA	NNP	O
levels	NNS	O
were	VBD	O
measured	VBN	O
on	IN	O
the	DT	O
preoperative	JJ	O
day	NN	O
and	CC	O
postoperative	JJ	O
days	NNS	O
7	CD	O
and	CC	O
30	CD	O
.	.	O

Patients	NNS	O
with	IN	O
preoperative	JJ	O
CEA	NNP	O
levels	NNS	O
<	VBP	O
5.0	CD	O
ng/ml	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

An	DT	O
exponential	JJ	O
trend	NN	O
line	NN	O
was	VBD	O
drawn	VBN	O
using	VBG	O
the	DT	O
three	CD	O
CEA	NNP	O
values	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
categorized	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
based	VBN	O
on	IN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
values	NNS	O
calculated	VBN	O
through	IN	O
trend	NN	O
line	NN	O
,	,	O
which	WDT	O
indicates	VBZ	O
the	DT	O
correlation	NN	O
coefficient	NN	O
between	IN	O
exponential	JJ	O
graph	NN	O
and	CC	O
measured	VBD	O
CEA	NNP	O
values	NNS	O
:	:	O
exponential	JJ	O
decrease	NN	O
group	NN	O
(	(	O
group	NN	O
1	CD	O
:	:	O
0.9	CD	O
<	NN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
1.0	CD	O
)	)	O
,	,	O
nearly	RB	O
exponential	JJ	O
decrease	NN	O
group	NN	O
(	(	O
group	NN	O
2	CD	O
:	:	O
0.5	CD	O
<	NN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
0.9	CD	O
)	)	O
,	,	O
and	CC	O
randomized	JJ	O
clearance	NN	O
group	NN	O
(	(	O
group	NN	O
3	CD	O
:	:	O
0.5	CD	O
<	NN	O
or	CC	O
=	VB	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

We	PRP	O
then	RB	O
analyzed	VBD	O
the	DT	O
CEA	NNP	O
clearance	NN	O
pattern	NN	O
as	IN	O
a	DT	O
prognostic	JJ	O
indicator	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
57	CD	O
months	NNS	O
,	,	O
the	DT	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
62.3	CD	O
%	NN	O
vs.	FW	O
48.1	CD	O
%	NN	O
vs.	FW	O
25	CD	O
%	NN	O
and	CC	O
the	DT	O
5-year	JJ	O
disease-free	JJ	O
survival	NN	O
was	VBD	O
58.6	CD	O
%	NN	O
vs.	FW	O
52.7	CD	O
%	NN	O
vs.	FW	O
25	CD	O
%	NN	O
among	IN	O
groups	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.014	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.027	CD	O
,	,	O
respectively	RB	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	O
III	NNP	O
rectal	JJ	O
cancer	NN	O
.	.	O

For	IN	O
those	DT	O
with	IN	O
stage	NN	O
II	NNP	O
rectal	NN	O
cancer	NN	O
,	,	O
the	DT	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
rate	NN	O
of	IN	O
group	NN	O
1	CD	O
was	VBD	O
significantly	RB	O
better	JJR	O
than	IN	O
groups	NNS	O
2	CD	O
and	CC	O
3	CD	O
(	(	O
88.8	CD	O
%	NN	O
vs.	FW	O
74.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
postoperative	JJ	S
pattern	NN	S
of	IN	S
CEA	NNP	S
clearance	NN	S
is	VBZ	O
a	DT	O
useful	JJ	O
prognostic	JJ	O
determinant	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
randomized	JJ	O
pattern	NN	O
of	IN	O
CEA	NNP	O
clearance	NN	O
after	IN	O
tumor	NN	O
resection	NN	O
should	MD	O
be	VB	O
regarded	VBN	O
as	IN	O
having	VBG	O
the	DT	O
possibility	NN	O
of	IN	O
a	DT	O
persistent	JJ	O
CEA	NNP	O
source	NN	O
and	CC	O
may	MD	O
require	VB	O
consideration	NN	O
of	IN	O
intensive	JJ	O
follow-up	NN	O
or	CC	O
adjuvant	JJ	O
therapy	NN	O
.	.	O

An	DT	O
exploratory	NN	O
,	,	O
pragmatic	JJ	O
,	,	O
cluster	NN	O
randomised	VBD	O
trial	NN	O
of	IN	O
practice	NN	E
nurse	JJ	E
training	NN	E
in	IN	O
the	DT	O
use	NN	O
of	IN	O
asthma	JJ	O
action	NN	O
plans	NNS	O
.	.	O

INTRODUCTION	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
improving	VBG	O
asthma	JJ	O
management	NN	O
-	:	O
in	IN	O
particular	JJ	O
,	,	O
the	DT	O
implementation	NN	O
of	IN	O
individualised	JJ	PH
asthma	JJ	PH
action	NN	PH
plans	NNS	PH
(	(	PH
AAPs	NNP	PH
)	)	PH
for	IN	O
poorly-controlled	JJ	O
adult	NN	O
asthma	NN	O
patients	NNS	O
-	:	O
by	IN	O
providing	VBG	O
training	NN	O
in	IN	O
asthma-focused	JJ	O
clinical	JJ	O
and	CC	O
communication	NN	O
skills	NNS	O
for	IN	O
practice	NN	O
nurses	NNS	O
who	WP	O
deliver	VBP	O
asthma	JJ	O
clinics	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
pragmatic	JJ	O
,	,	O
cluster	NN	O
randomised	VBD	O
trial	NN	O
with	IN	O
an	DT	O
intervention	NN	O
(	(	O
an	DT	O
interactive	JJ	O
seminar	NN	O
)	)	O
delivered	VBD	O
at	IN	O
practice	NN	O
level	NN	O
(	(	O
n=13	JJ	O
practices	NNS	O
;	:	O
6=intervention	CD	O
,	,	O
7=control	CD	O
)	)	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
assessed	VBN	O
against	IN	O
patient	JJ	O
outcomes	NNS	O
:	:	O
routinely	RB	O
available	JJ	O
asthma	JJ	O
outcome	NN	O
measures	NNS	O
(	(	O
beta2-agonist	JJ	O
prescription	NN	O
rate	NN	O
and	CC	O
number	NN	O
of	IN	O
oral	JJ	O
steroid	NN	O
courses	NNS	O
)	)	O
for	IN	O
asthma	NN	O
patients	NNS	O
identified	VBN	O
as	IN	O
being	VBG	O
poorly-controlled	JJ	O
from	IN	O
practice	NN	O
records	NNS	O
;	:	O
and	CC	O
questionnaire	VB	O
data	NNS	O
-	:	O
Mini	NNP	O
Asthma	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
Questionnaire	NNP	O
(	(	O
AQLQ	NNP	O
)	)	O
and	CC	O
the	DT	O
Asthma	NNP	O
Control	NNP	O
Questionnaire	NNP	O
(	(	O
ACQ	NNP	O
)	)	O
-	:	O
from	IN	O
a	DT	O
subset	NN	O
of	IN	O
consenting	VBG	O
patients	NNS	O
.	.	O

Data	NNP	O
was	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

ANALYSISs	NN	O
:	:	O
Routine	NNP	O
data	NN	O
was	VBD	O
analysed	VBN	O
for	IN	O
629	CD	O
patients	NNS	O
.	.	O

236	CD	O
(	(	O
37	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
patients	NNS	O
consented	VBD	O
to	TO	O
provide	VB	O
questionnaire	NN	O
data	NNS	O
at	IN	O
baseline	NN	O
,	,	O
with	IN	O
75	CD	O
%	NN	O
returning	VBG	O
questionnaires	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

After	IN	O
adjustment	NN	O
for	IN	O
baseline	NN	O
and	CC	O
practice	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
at	IN	O
followup	NN	O
between	IN	O
intervention	NN	O
and	CC	O
control	NN	O
practices	NNS	O
on	IN	O
the	DT	O
Mini	NNP	O
AQLQ	NNP	O
only	RB	O
(	(	O
p=0.03	NN	O
)	)	O
.	.	O

Estimates	NNS	O
for	IN	O
subsequent	JJ	O
sample	NN	O
sizes	NNS	O
to	TO	O
inform	VB	O
future	JJ	O
trials	NNS	O
of	IN	O
asthma	JJ	O
training	NN	O
were	VBD	O
identified	VBN	O
.	.	O

CONCLUSION	NNP	O
Training	NNP	O
designed	VBD	O
to	TO	O
support	VB	O
practice	NN	O
nurses	NNS	O
in	IN	O
implementing	VBG	O
individualised	JJ	O
AAPs	NNP	O
impacted	VBD	O
on	IN	O
one	CD	O
patient	NN	O
outcome	NN	O
only	RB	O
.	.	O

This	DT	O
disappointing	JJ	O
outcome	NN	O
may	MD	O
have	VB	O
been	VBN	O
due	JJ	O
to	TO	O
many	JJ	O
different	JJ	O
factors	NNS	O
such	JJ	O
as	IN	O
outcome	JJ	O
measure	NN	O
limitations	NNS	O
,	,	O
data	NNS	O
collection	NN	O
problems	NNS	O
,	,	O
and	CC	O
underestimating	VBG	O
the	DT	O
complexity	NN	O
of	IN	O
supporting	VBG	O
practice	NN	O
nurses	NNS	O
in	IN	O
behaviour	JJ	O
change	NN	O
.	.	O

Effect	NN	O
of	IN	O
light-cured	JJ	O
filled	VBN	O
sealant	NN	O
on	IN	O
shear	JJ	O
bond	NN	O
strength	NN	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
a	DT	O
resin-modified	JJ	O
glass	NN	O
ionomer	NN	O
cement	NN	O
.	.	O

INTRODUCTION	NNP	O
Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
highly	RB	O
filled	VBN	O
light-cured	JJ	PH
sealant	NN	PH
(	(	PH
HFLCS	NNP	PH
)	)	PH
on	IN	O
the	DT	O
shear	JJ	O
bond	NN	O
strength	NN	O
and	CC	O
bond	NN	O
failure	NN	O
site	NN	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
resin-modified	JJ	O
glass	NN	O
ionomer	NN	O
cement	NN	O
(	(	O
RMGIC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Eighty	NNP	O
freshly	RB	O
extracted	VBD	O
maxillary	JJ	O
premolars	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
4	CD	O
groups	NNS	O
(	(	O
20	CD	O
in	IN	O
each	DT	O
group	NN	O
)	)	O
.	.	O

In	IN	O
all	DT	O
groups	NNS	O
,	,	O
the	DT	O
teeth	NNS	O
were	VBD	O
etched	VBN	O
with	IN	O
37	CD	PH
%	NN	PH
phosphoric	JJ	PH
acid	NN	PH
for	IN	PH
20	CD	PH
seconds	NNS	PH
,	,	O
and	CC	O
RMGIC	NNP	PH
(	(	PH
Fuji	NNP	PH
Ortho	NNP	PH
LC	NNP	PH
,	,	PH
GC	NNP	PH
Europe	NNP	PH
,	,	PH
Leuven	NNP	PH
,	,	PH
Belgium	NNP	PH
)	)	PH
was	VBD	O
used	VBN	O
for	IN	O
bracket	NN	O
bonding	NN	O
.	.	O

In	IN	O
groups	NNS	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
the	DT	O
brackets	NNS	O
were	VBD	O
bonded	VBN	O
directly	RB	O
to	TO	O
etched	VB	O
enamel	JJ	O
surfaces	NNS	O
;	:	O
in	IN	O
groups	NNS	O
2	CD	O
and	CC	O
4	CD	O
,	,	O
the	DT	O
etched	JJ	O
enamel	NN	O
was	VBD	O
covered	VBN	O
with	IN	O
HFLCS	NNP	PH
(	(	PH
Pro	NNP	PH
Seal	NNP	PH
,	,	PH
Reliance	NNP	PH
Orthodontic	NNP	PH
Products	NNP	PH
,	,	PH
Itasca	NNP	PH
,	,	PH
Ill	NNP	PH
)	)	PH
.	.	O

Groups	$	O
1	CD	O
and	CC	O
2	CD	O
received	VBD	O
metal	JJ	PH
brackets	NNS	PH
,	,	O
and	CC	O
groups	NNS	O
3	CD	O
and	CC	O
4	CD	O
had	VBD	O
ceramic	JJ	PH
brackets	NNS	PH
.	.	O

The	DT	O
specimens	NNS	O
were	VBD	O
stored	VBN	O
in	IN	O
distilled	JJ	O
water	NN	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
24	CD	O
hours	NNS	O
and	CC	O
subsequently	RB	O
tested	VBN	O
in	IN	O
shear	JJ	O
mode	NN	O
with	IN	O
a	DT	O
universal	JJ	O
testing	NN	O
machine	NN	O
.	.	O

After	IN	O
debonding	VBG	O
,	,	O
the	DT	O
teeth	NNS	O
and	CC	O
the	DT	O
brackets	NNS	O
were	VBD	O
examined	VBN	O
under	IN	O
a	DT	O
stereomicroscope	NN	O
(	(	O
model	JJ	O
SMZ-1B	NNP	O
,	,	O
Nikon	NNP	O
,	,	O
Osaka	NNP	O
,	,	O
Japan	NNP	O
)	)	O
at	IN	O
20-times	JJ	O
magnification	NN	O
to	TO	O
assess	VB	O
the	DT	O
residual	JJ	O
adhesive	NN	O
on	IN	O
the	DT	O
tooth	NN	O
surfaces	NNS	O
.	.	O

RESULTS	NNP	O
Interaction	NNP	O
between	IN	O
HFLCS	NNP	O
and	CC	O
bracket	NN	O
type	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
.	.	O

Pretreatment	NN	O
with	IN	O
HFLCS	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
a	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
in	IN	O
the	DT	O
shear	JJ	O
bond	NN	O
values	NNS	O
of	IN	O
either	DT	O
metal	NN	O
or	CC	O
ceramic	JJ	O
brackets	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
.	.	O

Shear	JJ	O
bond	NN	O
values	NNS	O
of	IN	O
the	DT	O
ceramic	JJ	O
brackets	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
metal	JJ	O
brackets	NNS	O
independent	JJ	O
of	IN	O
HFLCS	NNP	O
application	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
bond	NN	O
failure	NN	O
modes	VBZ	O
in	IN	O
the	DT	O
4	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
HFLCS	NNP	O
application	NN	O
on	IN	O
enamel	NN	O
etched	VBN	O
with	IN	O
37	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
bond	NN	O
strength	NN	O
values	NNS	O
and	CC	O
the	DT	O
bond	NN	O
failure	NN	O
modes	NNS	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
RMGIC	NNP	O
.	.	O

RESULTS	NNP	O
Interaction	NNP	O
between	IN	O
HFLCS	NNP	O
and	CC	O
bracket	NN	O
type	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
.	.	O

Pretreatment	NN	O
with	IN	O
HFLCS	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
a	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
in	IN	O
the	DT	O
shear	JJ	O
bond	NN	O
values	NNS	O
of	IN	O
either	DT	O
metal	NN	O
or	CC	O
ceramic	JJ	O
brackets	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
.	.	O

Shear	JJ	O
bond	NN	O
values	NNS	O
of	IN	O
the	DT	O
ceramic	JJ	O
brackets	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
metal	JJ	O
brackets	NNS	O
independent	JJ	O
of	IN	O
HFLCS	NNP	O
application	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
bond	NN	O
failure	NN	O
modes	VBZ	O
in	IN	O
the	DT	O
4	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
HFLCS	NNP	O
application	NN	O
on	IN	O
enamel	NN	O
etched	VBN	O
with	IN	O
37	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
bond	NN	O
strength	NN	O
values	NNS	O
and	CC	O
the	DT	O
bond	NN	O
failure	NN	O
modes	NNS	O
of	IN	O
metal	NN	O
and	CC	O
ceramic	JJ	O
brackets	NNS	O
bonded	VBN	O
with	IN	O
RMGIC	NNP	O
.	.	O

Selected	VBN	O
polymorphisms	NNS	O
of	IN	O
GSTP1	NNP	O
and	CC	O
TERT	NNP	O
were	VBD	O
associated	VBN	O
with	IN	O
glioma	NN	O
risk	NN	O
in	IN	O
Han	NNP	O
Chinese	NNP	O
.	.	O

BACKGROUND	NNP	O
Current	NNP	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
a	DT	O
majority	NN	O
of	IN	O
the	DT	O
inherited	JJ	O
risks	NNS	O
play	VBP	O
a	DT	O
major	JJ	O
role	NN	O
in	IN	O
glioma	JJ	O
susceptibility	NN	O
,	,	O
and	CC	O
glioma	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
the	DT	O
co-inheritance	NN	O
of	IN	O
multiple	JJ	O
low-risk	JJ	O
variants	NNS	O
.	.	O

These	DT	O
variants	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
through	IN	O
association	NN	O
studies	NNS	O
including	VBG	O
such	JJ	O
as	IN	O
genome-wide	JJ	O
association	NN	O
studies	NNS	O
(	(	O
GWAS	NNP	O
)	)	O
,	,	O
which	WDT	O
has	VBZ	O
led	VBN	O
the	DT	O
glioma	NN	O
epidemiology	NN	O
researchers	NNS	O
to	TO	O
focus	VB	O
on	IN	O
identifying	VBG	O
potential	JJ	O
disease-causing	JJ	O
factors	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
evaluated	VBD	O
and	CC	O
validated	VBD	O
10	CD	O
tag	NN	O
single	JJ	O
nucleotide	JJ	O
polymorphisms	NN	O
(	(	O
tSNPs	NN	O
)	)	O
in	IN	O
seven	CD	O
genes	NNS	O
associated	VBN	O
with	IN	O
glioma	NN	O
susceptibility	NN	O
in	IN	O
a	DT	O
Han	NNP	O
Chinese	NNP	O
population	NN	O
,	,	O
including	VBG	O
301	CD	O
glioma	NN	O
cases	NNS	O
and	CC	O
302	CD	O
controls	NNS	O
,	,	O
using	VBG	O
a	DT	O
multiplexed	JJ	Ot
single	JJ	Ot
nucleotide	NN	Ot
polymorphism	NN	Ot
(	(	Ot
SNP	NNP	Ot
)	)	Ot
MassEXTEND	NNP	Ot
assay	NN	Ot
.	.	O

We	PRP	O
ascertained	VBD	O
the	DT	O
genotypic	NN	O
frequencies	NNS	O
for	IN	O
each	DT	O
tSNP	NN	O
in	IN	O
control	NN	O
subjects	NNS	O
were	VBD	O
within	IN	O
Hardy-Weinberg	NNP	O
equilibrium	NN	O
(	(	O
HWE	NNP	O
)	)	O
using	VBG	O
an	DT	O
exact	JJ	O
test	NN	O
,	,	O
and	CC	O
then	RB	O
compared	VBN	O
the	DT	O
genotype	NN	O
and	CC	O
allele	JJ	O
frequencies	NNS	O
of	IN	O
glioma	NN	O
patients	NNS	O
and	CC	O
control	NN	O
subjects	NNS	O
using	VBG	O
the	DT	O
?2	JJ	O
test	NN	O
.	.	O

We	PRP	O
then	RB	O
applied	VBD	O
three	CD	O
genetic	JJ	O
models	NNS	O
(	(	O
dominant	JJ	O
,	,	O
recessive	JJ	O
,	,	O
and	CC	O
additive	JJ	O
)	)	O
using	VBG	O
PLINK	NNP	O
software	NN	O
to	TO	O
assess	VB	O
the	DT	O
association	NN	O
of	IN	O
each	DT	O
tSNP	NN	O
with	IN	O
glioma	NN	O
risk	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
identified	VBD	O
two	CD	O
tSNPs	NN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
glioma	NN	O
susceptibility	NN	O
(	(	O
rs1695	NN	O
,	,	O
GSTP1	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.019	CD	O
;	:	O
rs2853676	NN	O
,	,	O
TERT	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
,	,	O
which	WDT	O
we	PRP	O
confirmed	VBD	O
using	VBG	O
dominant	NN	O
and	CC	O
additive	JJ	O
model	NN	O
analyses	NNS	O
.	.	O

The	DT	O
genotype	NN	O
&	CC	O
ldquo	NN	O
;	:	O
GA	NNP	O
&	CC	O
rdquo	NN	O
;	:	O
for	IN	O
rs1695	NN	O
was	VBD	O
recognized	VBN	O
to	TO	O
be	VB	O
a	DT	O
protective	JJ	O
genotype	NN	O
for	IN	O
glioma	NN	O
(	(	O
OR	NNP	O
,	,	O
0.67	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.47-0.96	NNP	O
;	:	O
P	NNP	O
=	NNP	O
0.027	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
genotype	NN	O
&	CC	O
ldquo	NN	O
;	:	O
AG	NNP	O
&	CC	O
rdquo	NN	O
;	:	O
for	IN	O
rs2853676	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
risk	NN	O
genotype	NN	O
for	IN	O
glioma	NN	O
(	(	O
OR	NNP	O
,	,	O
1.50	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.05-2.15	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
,	,	O
and	CC	O
those	DT	O
from	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
suggest	VBP	O
potential	JJ	O
genetic	JJ	O
contributes	NNS	O
for	IN	O
GSTP1	NNP	O
and	CC	O
TERT	NNP	O
in	IN	O
glioma	NN	O
development	NN	O
.	.	O

A	DT	O
placebo-controlled	JJ	C
trial	NN	O
of	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
fluconazole	JJ	PM
after	IN	O
treatment	NN	O
of	IN	O
cryptococcal	JJ	O
meningitis	NN	O
in	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
.	.	O

California	NNP	O
Collaborative	NNP	O
Treatment	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
relapse	NN	O
after	IN	O
primary	JJ	O
treatment	NN	O
for	IN	O
cryptococcal	JJ	O
meningitis	NN	O
remains	VBZ	O
high	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
controlled	VBN	O
,	,	O
double-blind	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
fluconazole	NN	O
.	.	O

At	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
,	,	O
all	DT	O
participants	NNS	O
had	VBD	O
sterile	JJ	O
cultures	NNS	O
of	IN	O
cerebrospinal	JJ	O
fluid	NN	O
,	,	O
blood	NN	O
,	,	O
and	CC	O
urine	JJ	O
after	IN	O
following	VBG	O
a	DT	O
standardized	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
for	IN	O
culture-proved	JJ	O
cryptococcal	JJ	O
meningitis	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
take	VB	O
either	DT	O
fluconazole	NN	PM
or	CC	O
placebo	NN	C
as	IN	O
maintenance	NN	O
therapy	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
fluconazole	NN	PM
was	VBD	O
100	CD	O
mg	JJ	O
daily	RB	O
in	IN	O
the	DT	O
first	JJ	O
phase	NN	O
of	IN	O
study	NN	O
and	CC	O
200	CD	O
mg	NNS	O
daily	RB	O
in	IN	O
the	DT	O
second	JJ	O
phase	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
84	CD	O
patients	NNS	O
initially	RB	O
enrolled	VBD	O
,	,	O
16	CD	O
(	(	O
19	CD	O
percent	NN	O
)	)	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
silent	JJ	O
,	,	O
persistent	JJ	O
infection	NN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
cultures	NNS	O
that	WDT	O
became	VBD	O
positive	JJ	O
after	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
;	:	O
7	CD	O
other	JJ	O
patients	NNS	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	NNS	O
shortly	RB	O
after	IN	O
entry	NN	O
.	.	O

Of	IN	O
the	DT	O
remaining	VBG	O
61	CD	O
patients	NNS	O
,	,	O
10	CD	O
of	IN	O
27	CD	O
assigned	VBN	O
to	TO	O
placebo	VB	C
(	(	O
37	CD	O
percent	NN	O
)	)	O
and	CC	O
1	CD	O
of	IN	O
34	CD	O
assigned	VBN	O
to	TO	O
fluconazole	VB	PM
(	(	O
3	CD	O
percent	NN	O
)	)	O
had	VBD	O
a	DT	O
recurrence	NN	O
of	IN	O
cryptococcal	JJ	O
infection	NN	O
at	IN	O
any	DT	O
site	NN	O
(	(	O
difference	NN	O
in	IN	O
risk	NN	O
,	,	O
34	CD	O
percent	NN	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
15	CD	O
to	TO	O
53	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
11	CD	O
recurrent	NN	O
infections	NNS	O
,	,	O
7	CD	O
were	VBD	O
detected	VBN	O
in	IN	O
urine	NN	O
obtained	VBN	O
after	IN	O
prostatic	JJ	O
massage	NN	O
.	.	O

There	EX	O
were	VBD	O
four	CD	O
recurrent	NN	O
meningeal	NN	O
infections	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
taking	VBG	O
placebo	NN	C
,	,	O
but	CC	O
none	NN	O
in	IN	O
those	DT	O
taking	VBG	O
fluconazole	JJ	PM
(	(	O
mean	JJ	O
duration	NN	O
of	IN	O
follow-up	NN	O
,	,	O
164	CD	O
days	NNS	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

In	IN	O
multivariate	NN	O
analyses	NNS	O
,	,	O
the	DT	O
best	JJS	O
predictors	NNS	O
of	IN	O
recurrence-free	JJ	O
survival	NN	O
were	VBD	O
fluconazole	JJ	PM
treatment	NN	PM
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
13.2	CD	O
)	)	O
,	,	O
a	DT	O
lower	JJR	O
serum	NN	O
cryptococcal-antigen	NN	O
titer	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
1.2	CD	O
)	)	O
,	,	O
and	CC	O
more	JJR	O
prolonged	JJ	O
primary	JJ	O
therapy	NN	O
with	IN	O
flucytosine	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.09	CD	O
;	:	O
relative	JJ	O
hazard	NN	O
,	,	O
1.1	CD	O
)	)	O
.	.	O

Survival	NNP	O
and	CC	O
toxicity	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
maintenance-treatment	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
,	,	O
silent	JJ	O
persistent	JJ	O
infection	NN	O
is	VBZ	O
common	JJ	O
after	IN	O
clinically	RB	O
successful	JJ	O
treatment	NN	O
for	IN	O
cryptococcal	JJ	O
meningitis	NN	O
.	.	O

Maintenance	NNP	O
therapy	NN	O
with	IN	O
fluconazole	NN	PM
is	VBZ	O
highly	RB	O
effective	JJ	O
in	IN	O
preventing	VBG	O
recurrent	JJ	O
cryptococcal	JJ	O
infection	NN	O
.	.	O

Effects	NNS	O
of	IN	O
vacuum-compression	NN	PH
therapy	NN	PH
on	IN	O
healing	NN	O
of	IN	O
diabetic	JJ	O
foot	NN	O
ulcers	NNS	O
:	:	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

A	DT	O
single-blind	JJ	O
,	,	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
vacuum-compression	NN	PH
therapy	NN	PH
(	(	PH
VCT	NNP	PH
)	)	PH
for	IN	O
the	DT	O
healing	NN	O
of	IN	O
diabetic	JJ	O
foot	NN	O
ulcers	NNS	O
.	.	O

Eighteen	NNP	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
foot	JJ	O
ulcers	NNS	O
were	VBD	O
recruited	VBN	O
through	IN	O
simple	JJ	O
nonprobability	NN	O
sampling	VBG	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
experimental	JJ	O
or	CC	O
a	DT	O
control	NN	C
group	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
,	,	O
the	DT	O
foot	NN	O
ulcer	JJ	O
surface	NN	O
area	NN	O
was	VBD	O
estimated	VBN	O
stereologically	RB	O
,	,	O
based	VBN	O
on	IN	O
Cavalieri	NNP	O
's	POS	O
principle	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
VCT	NNP	PH
in	IN	PH
addition	NN	PH
to	TO	PH
conventional	JJ	PH
therapy	NN	PH
for	IN	O
10	CD	O
sessions	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
only	RB	O
conventional	JJ	C
therapy	NN	C
,	,	C
including	VBG	C
debridement	NN	C
,	,	C
blood	NN	C
glucose	NNS	C
control	NN	C
agents	NNS	C
,	,	C
systemic	JJ	C
antibiotics	NNS	C
,	,	C
wound	IN	C
cleaning	VBG	C
with	IN	C
normal	JJ	C
saline	NN	C
,	,	C
offloading	VBG	PH
(	(	PH
pressure	NN	PH
relief	NN	PH
)	)	PH
,	,	C
and	CC	C
daily	RB	PH
wound	JJ	PH
dressings	NNS	PH
.	.	O

The	DT	O
mean	JJ	O
foot	NN	O
ulcer	JJ	O
surface	NN	O
area	NN	O
decreased	VBD	O
from	IN	O
46.88	CD	O
+/-	JJ	O
9.28	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
35.09	CD	O
+/-	JJ	O
4.09	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
from	IN	O
46.62	CD	O
+/-	JJ	O
10.03	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
42.89	CD	O
+/-	JJ	O
8.1	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
experimental	JJ	O
group	NN	O
significantly	RB	O
improved	VBN	O
in	IN	O
measures	NNS	O
of	IN	O
foot	NN	O
ulcer	JJ	O
surface	NN	O
area	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.024	CD	O
)	)	O
.	.	O

VCT	NNP	PH
enhances	VBZ	O
diabetic	JJ	O
foot	NN	O
ulcer	NN	O
healing	VBG	O
when	WRB	O
combined	VBN	O
with	IN	O
appropriate	JJ	O
wound	NN	O
care	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
live	JJ	O
and	CC	O
videotape	JJ	O
ratings	NNS	O
:	:	O
clomipramine	NN	PM
and	CC	O
haloperidol	NN	PM
in	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
live	JJ	O
ratings	NNS	O
with	IN	O
ratings	NNS	O
of	IN	O
videotapes	NNS	O
and	CC	O
compared	VBN	O
response	NN	O
to	TO	O
clomipramine	VB	PM
with	IN	O
response	NN	O
to	TO	O
haloperidol	VB	PM
in	IN	O
8	CD	O
subjects	NNS	O
,	,	O
mean	JJ	O
age	NN	O
5.62	CD	O
years	NNS	O
,	,	O
who	WP	O
met	VBD	O
criteria	NNS	O
for	IN	O
autism	NN	O
.	.	O

They	PRP	O
were	VBD	O
consecutive	JJ	O
admissions	NNS	O
to	TO	O
a	DT	O
pilot	NN	O
study	NN	O
of	IN	O
clomipramine	NN	PM
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
or	CC	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo	NN	C
controlled	VBD	O
study	NN	O
of	IN	O
haloperidol	NN	PM
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
.	.	O

Live	JJ	O
ratings	NNS	O
were	VBD	O
performed	VBN	O
by	IN	O
two	CD	O
raters	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
pre-treatment	JJ	O
placebo	NN	C
baseline	NN	O
period	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
drug	NN	O
treatment	NN	O
period	NN	O
on	IN	O
the	DT	O
CPRS	NNP	O
and	CC	O
the	DT	O
CGI	NNP	O
and	CC	O
were	VBD	O
videotaped	VBN	O
.	.	O

Employing	VBG	O
the	DT	O
same	JJ	O
instruments	NNS	O
,	,	O
these	DT	O
videotapes	NNS	O
were	VBD	O
rated	VBN	O
by	IN	O
two	CD	O
raters	NNS	O
who	WP	O
did	VBD	O
not	RB	O
know	VB	O
the	DT	O
subjects	NNS	O
and	CC	O
were	VBD	O
blind	NNS	O
to	TO	O
study	VB	O
design	NN	O
,	,	O
treatment	NN	O
,	,	O
and	CC	O
study	NN	O
phase	NN	O
.	.	O

Ratings	NNS	O
of	IN	O
videotapes	NNS	O
significantly	RB	O
differed	VBN	O
from	IN	O
live	JJ	O
ratings	NNS	O
.	.	O

A	DT	O
treatment	NN	O
effect	NN	O
for	IN	O
haloperidol	NN	O
was	VBD	O
detected	VBN	O
only	RB	O
on	IN	O
live	JJ	O
ratings	NNS	O
and	CC	O
not	RB	O
on	IN	O
ratings	NNS	O
of	IN	O
videotapes	NNS	O
.	.	O

No	DT	O
treatment	NN	O
effect	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
clomipramine	NN	PM
in	IN	O
either	CC	O
live	JJ	O
or	CC	O
videotape	JJ	O
ratings	NNS	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
crossover	NN	O
study	NN	O
investigating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
porcine	NN	PM
secretin	NN	PM
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

OBJECTIVES	CC	O
A	DT	O
recent	JJ	O
patient	NN	O
series	NN	O
reported	VBD	O
the	DT	O
incidental	JJ	O
findings	NNS	O
of	IN	O
improved	VBN	O
social	JJ	O
and	CC	O
language	NN	O
skills	NNS	O
in	IN	O
3	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
secretin	NN	PM
,	,	O
a	DT	O
peptide	NN	O
hormone	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
subsequent	JJ	O
study	NN	O
did	VBD	O
not	RB	O
find	VB	O
evidence	NN	O
for	IN	O
a	DT	O
drug	NN	O
effect	NN	O
.	.	O

Parents	NNS	O
are	VBP	O
seeking	VBG	O
treatment	NN	O
with	IN	O
secretin	JJ	PM
despite	IN	O
the	DT	O
absence	NN	O
of	IN	O
empirical	JJ	O
investigations	NNS	O
demonstrating	VBG	O
amelioration	NN	O
in	IN	O
autism	NN	O
symptomology	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
more	RBR	O
precisely	RB	O
measure	VB	O
the	DT	O
effects	NNS	O
of	IN	O
secretin	NN	PM
,	,	O
this	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	PM
dose	NN	PM
of	IN	PM
porcine	NN	PM
secretin	NN	PM
on	IN	O
12	CD	O
autistic	JJ	O
children	NNS	O
through	IN	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Children	NNP	O
were	VBD	O
assessed	VBN	O
on	IN	O
objective	JJ	O
language	NN	O
and	CC	O
on	IN	O
social	JJ	O
,	,	O
neuropsychological	JJ	O
,	,	O
and	CC	O
gastrointestinal	JJ	O
measures	NNS	O
to	TO	O
evaluate	VB	O
drug	NN	O
effects	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
over	IN	O
a	DT	O
16-week	JJ	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
significant	JJ	O
differences	NNS	O
were	VBD	O
not	RB	O
observed	VBN	O
on	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
dependent	JJ	O
variables	NNS	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
on	IN	O
measures	NNS	O
of	IN	O
positive	JJ	O
affect	NN	O
and	CC	O
activity	NN	O
level	NN	O
following	VBG	O
secretin	JJ	PM
infusion	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
autistic	JJ	O
children	NNS	O
did	VBD	O
not	RB	O
demonstrate	VB	O
the	DT	O
improvements	NNS	O
described	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
retrospective	JJ	O
report	NN	O
.	.	O

Cost-effectiveness	NN	O
of	IN	O
cognitive-behavioral	JJ	PS
group	NN	PS
therapy	NN	PS
for	IN	O
dysfunctional	JJ	O
fear	NN	O
of	IN	O
progression	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

Anxiety	NNP	O
and	CC	O
fear	NN	O
are	VBP	O
often	RB	O
associated	VBN	O
with	IN	O
chronic	JJ	O
conditions	NNS	O
such	JJ	O
as	IN	O
cancer	NN	O
.	.	O

This	DT	O
paper	NN	O
targets	VBZ	O
the	DT	O
cost-effectiveness	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
cognitive-behavioral	JJ	PS
group	NN	PS
therapy	NN	PS
(	(	PS
CBT	NNP	PS
)	)	PS
in	IN	O
comparison	NN	O
to	TO	O
a	DT	O
client-centered	JJ	PS
,	,	PS
supportive-experiential	JJ	PS
group	NN	PS
therapy	NN	PS
(	(	PS
SET	NNP	PS
)	)	PS
in	IN	O
cancer	NN	O
patients	NNS	O
with	IN	O
dysfunctional	JJ	O
fear	NN	O
of	IN	O
progression	NN	O
.	.	O

An	DT	O
incremental	JJ	O
cost-effectiveness	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
data	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
among	IN	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
inpatient	JJ	O
rehabilitation	NN	O
.	.	O

The	DT	O
means	NNPS	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
[	VBP	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
,	,	O
incremental	JJ	O
cost-effectiveness	JJ	O
graphic	NN	O
and	CC	O
acceptability	NN	O
curve	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
1,000	CD	O
bootstrap	NN	O
replications	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
174	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
economic	JJ	O
evaluation	NN	O
.	.	O

The	DT	O
estimated	JJ	O
means	VBZ	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
of	IN	O
direct	JJ	O
costs	NNS	O
and	CC	O
reduction	NN	O
of	IN	O
fear	NN	O
of	IN	O
progression	NN	O
were	VBD	O
<	JJ	O
euro	JJ	O
>	NN	O
9,045.03	CD	O
[	JJ	O
6,359.07	CD	O
;	:	O
12,091.87	CD	O
]	NN	O
and	CC	O
1.41	CD	O
[	JJ	O
0.93	CD	O
;	:	O
1.92	CD	O
]	NN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
SET	NNP	O
and	CC	O
<	NNP	O
euro	VBP	O
>	$	O
6,682.78	CD	O
[	JJ	O
4,998.09	CD	O
;	:	O
8,440.95	CD	O
]	NN	O
and	CC	O
1.44	CD	O
[	JJ	O
1.02	CD	O
;	:	O
1.09	CD	O
]	NN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
CBT	NNP	PS
.	.	O

The	DT	O
incremental	JJ	O
cost-effectiveness	JJ	O
ratio	NN	O
[	VBD	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
amounts	NNS	O
to	TO	O
minus	NNS	O
<	NNP	O
euro	VBP	O
>	$	O
78,741.66	CD	O
[	NNP	O
-154,987.20	NNP	O
;	:	O
110,486.32	CD	O
]	NN	O
for	IN	O
an	DT	O
additional	JJ	O
unit	NN	O
of	IN	O
effect	NN	O
.	.	O

Given	VBN	O
the	DT	O
acceptability	NN	O
curve	NN	O
,	,	O
there	EX	O
is	VBZ	O
a	DT	O
92.4	CD	O
%	NN	O
chance	NN	O
that	IN	O
the	DT	O
CBT	NNP	E
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
SET	NNP	E
,	,	O
is	VBZ	O
cost-effective	JJ	O
without	IN	O
the	DT	O
need	NN	O
of	IN	O
additional	JJ	O
costs	NNS	O
to	TO	O
payers	NNS	O
.	.	O

Our	PRP$	O
main	JJ	O
result	NN	O
is	VBZ	O
the	DT	O
superior	JJ	O
cost-effectiveness	NN	O
of	IN	O
the	DT	O
cognitive-behavioral	JJ	E
intervention	NN	E
program	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
non-directive	JJ	O
encounter	NN	O
group	NN	O
for	IN	O
our	PRP$	O
sample	NN	O
of	IN	O
cancer	NN	O
patients	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
anxiety	NN	O
.	.	O

[	JJ	O
Effect	NNP	O
analysis	NN	O
on	IN	O
non-and-low	JJ	O
response	NN	O
infants	NNS	O
after	IN	O
revaccinated	VBN	O
hepatitis	NN	PM
B	NNP	PM
vaccine	NN	PM
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
booster	NN	O
immunization	NN	O
effect	NN	O
to	TO	O
non-and-low	JJ	O
response	NN	O
children	NNS	O
after	IN	O
3	CD	O
doses	NNS	O
HepB	NNP	O
immunization	NN	O
.	.	O

METHODS	NNP	O
Non-and-low	JJ	O
response	NN	O
infants	NNS	O
born	VBN	O
in	IN	O
2004	CD	O
2005	CD	O
administered	VBD	O
3	CD	PM
doses	NNS	PM
of	IN	PM
HepB	NNP	PM
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
6	CD	O
months	NNS	O
in	IN	O
Guangzhou	NNP	O
,	,	O
Beijing	NNP	O
and	CC	O
Zhejiang	NNP	O
were	VBD	O
divided	VBN	O
into	IN	O
4	CD	O
groups	NNS	O
randomly	RB	O
,	,	O
and	CC	O
boosted	VBD	O
3	CD	O
dose	NN	O
of	IN	O
4	CD	O
different	JJ	O
types	NNS	O
of	IN	O
HepB	NNP	PM
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
GMC	NNP	O
of	IN	O
non-and-low	JJ	O
response	NN	O
children	NNS	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
before	IN	O
booster	NN	O
)	)	O
,	,	O
group	NN	O
B	NNP	O
(	(	O
after	IN	O
1	CD	O
dose	JJ	O
booster	NN	O
)	)	O
and	CC	O
group	NN	O
C	NNP	O
(	(	O
after	IN	O
3	CD	O
dose	JJ	O
booster	NN	O
)	)	O
were	VBD	O
18.66	CD	O
mIUml	NN	O
,	,	O
88.82	CD	O
mIU/ml	NN	O
,	,	O
178.24	CD	O
mIU/ml	NN	O
respectively	RB	O
;	:	O
the	DT	O
proportion	NN	O
of	IN	O
non-responders	NNS	O
in	IN	O
three	CD	O
groups	NNS	O
were	VBD	O
20.4	CD	O
%	NN	O
,	,	O
9.1	CD	O
%	NN	O
,	,	O
1.9	CD	O
%	NN	O
respectively	RB	O
.	.	O

In	IN	O
103	CD	O
non-and-low	JJ	O
response	NN	O
children	NNS	O
,	,	O
proportion	NN	O
of	IN	O
titers	NNS	O
of	IN	O
more	JJR	O
than	IN	O
100	CD	O
mIU/ml	NN	O
of	IN	O
group	NN	O
B	NNP	O
and	CC	O
group	NN	O
C	NNP	O
were	VBD	O
61.2	CD	O
%	NN	O
and	CC	O
84.5	CD	O
%	NN	O
,	,	O
and	CC	O
there	RB	O
was	VBD	O
statistical	JJ	O
significant	JJ	O
difference	NN	O
(	(	O
chi2	JJ	O
=	NN	O
14.13	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
GMC	NNP	O
after	IN	O
3	CD	O
doses	NNS	O
revaccination	NN	PM
with	IN	O
four	CD	O
kinds	NNS	O
of	IN	O
HepB	NNP	O
,	,	O
included	VBD	O
5	CD	O
microg	NN	O
HepB-Y	NNP	PM
,	,	O
10	CD	O
microg	NN	O
HepB-Y	NNP	PM
,	,	O
l0	JJ	O
microg	NN	O
HepB-CHO	NNP	PM
,	,	O
10	CD	O
microg	JJ	O
HepB-HY	NNP	PM
were	VBD	O
168.8	CD	O
mJU/ml	NN	O
,	,	O
174.7	CD	O
mIU/ml	NN	O
,	,	O
184.9	CD	O
mIU/ml	NN	O
,	,	O
182.9	CD	O
mIU/ml	NN	O
respectively	RB	O
.	.	O

Proportion	NN	O
of	IN	O
titers	NNS	O
of	IN	O
more	JJR	O
than	IN	O
100	CD	O
mIU/ml	NNS	O
for	IN	O
four	CD	O
kinds	NNS	O
HepB	NNP	O
were	VBD	O
79.0	CD	O
%	NN	O
,	,	O
85.7	CD	O
%	NN	O
,	,	O
88.2	CD	O
%	NN	O
and	CC	O
84.6	CD	O
%	NN	O
respectively	RB	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
(	(	O
chi2	JJ	O
=	NN	O
0.75	CD	O
,	,	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
There	EX	O
were	VBD	O
no	DT	O
different	JJ	O
of	IN	O
seroconversion	NN	O
rate	NN	O
between	IN	O
study	NN	O
population	NN	O
received	VBD	O
1	CD	O
dose	NN	O
and	CC	O
3	CD	O
dose	JJ	O
booster	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
high	JJ	O
titer	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
3	CD	O
dose	JJ	O
booster	NN	O
.	.	O

The	DT	O
four	CD	O
kinds	NNS	O
of	IN	O
HepB	NNP	O
,	,	O
including	VBG	O
5	CD	O
microg	JJ	O
HepB-Y,10	NNP	O
microg	NN	O
HepB-Y	NNP	O
,	,	O
10	CD	O
microg	NN	O
HepB-CHO	NNP	O
,	,	O
10	CD	O
microg	NN	O
HepB-HY	NNP	O
had	VBD	O
the	DT	O
same	JJ	O
immunization	NN	O
effect	NN	O
after	IN	O
3	CD	O
doses	NNS	O
revaccination	NN	O
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
6	CD	O
months	NNS	O
to	TO	O
non-and-low	JJ	O
response	NN	O
children	NNS	O
.	.	O

Pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
YM17E	NNP	PM
,	,	PM
an	DT	PM
inhibitor	NN	PM
of	IN	PM
acyl	NN	PM
coenzyme	NN	PM
A	DT	O
:	:	O
cholesterol	NN	O
acyl	NN	O
transferase	NN	O
,	,	O
and	CC	O
serum	VB	O
cholesterol	NN	O
levels	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
single	JJ	O
and	CC	O
repeat	JJ	O
oral	JJ	O
dose	NN	PM
study	NN	PM
of	IN	PM
YM17E	NNP	PM
,	,	O
a	DT	O
novel	JJ	O
inhibitor	NN	O
of	IN	O
acyl	NN	O
coenzyme	NN	O
A	NNP	O
(	(	O
CoA	NNP	O
)	)	O
:	:	O
cholesterol	NN	O
acyltransferase	NN	O
,	,	O
in	IN	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
pharmacokinetic	JJ	O
profile	NN	O
,	,	O
tolerability	NN	O
and	CC	O
effect	NN	O
of	IN	O
the	DT	O
drug	NN	O
on	IN	O
serum	NN	O
cholesterol	NN	O
.	.	O

In	IN	O
the	DT	O
single	JJ	O
administration	NN	O
study	NN	O
,	,	O
YM17E	NNP	PM
was	VBD	PM
administered	VBN	PM
after	IN	PM
a	DT	PM
meal	NN	PM
to	TO	PM
two	CD	PM
groups	NNS	PM
of	IN	PM
subjects	NNS	PM
(	(	O
each	DT	PM
containing	VBG	PM
six	CD	PM
subjects	NNS	PM
taking	VBG	PM
the	DT	PM
drug	NN	PM
and	CC	O
three	CD	C
taking	VBG	C
placebo	NN	C
)	)	O
receiving	VBG	O
3	CD	O
,	,	O
60	CD	O
and	CC	O
300	CD	O
mg	NN	O
or	CC	O
15	CD	O
,	,	O
60	CD	O
and	CC	O
450	CD	O
mg	NN	O
YM17E	NNP	O
,	,	O
respectively	RB	O
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
unchanged	JJ	O
drug	NN	O
following	VBG	O
single	JJ	O
oral	JJ	O
administration	NN	O
at	IN	O
3-300	JJ	O
mg	NN	O
after	IN	O
a	DT	O
meal	NN	O
increased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
plasma	NN	O
concentrations	NNS	O
after	IN	O
administration	NN	O
of	IN	O
450	CD	O
mg	NNS	O
were	VBD	O
almost	RB	O
the	DT	O
same	JJ	O
as	IN	O
after	IN	O
300	CD	O
mg	NN	O
.	.	O

Unchanged	VBD	O
YM17E	NNP	PM
was	VBD	O
not	RB	O
detected	VBN	O
in	IN	O
urine	NN	O
after	IN	O
single	JJ	O
administration	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
it	PRP	O
was	VBD	O
excreted	VBN	O
via	IN	O
the	DT	O
bile	NN	O
or	CC	O
urine	NN	O
after	IN	O
metabolism	NN	O
.	.	O

Five	CD	O
active	JJ	O
metabolites	NNS	O
(	(	O
M1	NNP	O
,	,	O
M2-a	NNP	O
,	,	O
M2-b	NNP	O
,	,	O
M3	NNP	O
and	CC	O
M4	NNP	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
plasma	NN	O
at	IN	O
concentrations	NNS	O
comparable	JJ	O
to	TO	O
those	DT	O
of	IN	O
unchanged	JJ	O
YM17E	NNP	PM
.	.	PM

Their	PRP$	O
plasma	JJ	O
concentrations	NNS	O
increased	VBD	O
in	IN	O
a	DT	O
slightly	RB	O
greater	JJR	O
than	IN	O
dose-dependent	JJ	O
manner	NN	O
from	IN	O
3	CD	O
to	TO	O
300	CD	O
mg	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
food	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
an	DT	O
open	JJ	O
crossover	NN	O
design	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
washout	NN	O
period	NN	O
.	.	O

Twelve	NNP	O
subjects	VBZ	O
received	VBD	O
150	CD	PM
mg	NNS	PM
YM17E	VBN	PM
in	IN	O
both	DT	O
the	DT	O
fasted	VBN	O
and	CC	O
post-prandial	JJ	O
states	NNS	O
.	.	O

The	DT	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
after	IN	O
fasting	VBG	O
were	VBD	O
closely	RB	O
similar	JJ	O
to	TO	O
those	DT	O
after	IN	O
a	DT	O
meal	NN	O
,	,	O
showing	VBG	O
that	IN	O
bioavailability	NN	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
food	NN	O
intake	NN	O
.	.	O

In	IN	O
the	DT	O
repeated	JJ	O
oral	JJ	O
dose	NN	O
study	NN	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
test	JJ	PM
drug	NN	PM
at	IN	PM
150	CD	PM
mg	NN	PM
or	CC	PM
300	CD	PM
mg	NN	PM
(	(	O
n	JJ	O
=	RB	O
6	CD	O
each	DT	O
)	)	O
or	CC	O
placebo	NN	C
(	(	C
n	JJ	C
=	NNP	C
3	CD	C
)	)	C
twice	RB	C
a	DT	C
day	NN	C
(	(	O
after	IN	O
breakfast	NN	O
and	CC	O
after	IN	O
dinner	NN	O
)	)	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

On	IN	O
days	NNS	O
1	CD	O
and	CC	O
7	CD	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
YM17E	NNP	PM
once	RB	PM
a	DT	PM
day	NN	PM
(	(	O
after	IN	O
breakfast	NN	O
)	)	O
for	IN	O
evaluation	NN	O
of	IN	O
pharmacokinetic	JJ	O
properties	NNS	O
.	.	O

After	IN	O
repeated	VBN	O
oral	JJ	O
administration	NN	O
of	IN	O
150	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
reached	VBD	O
steady	JJ	O
state	NN	O
by	IN	O
day	NN	O
5	CD	O
(	(	O
mean	JJ	O
Cmin	NNP	O
48.6	CD	O
ng.ml-1	NN	O
)	)	O
.	.	O

After	IN	O
repeated	JJ	O
administration	NN	O
of	IN	O
300	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
prior	RB	O
to	TO	O
each	DT	O
daily	JJ	O
morning	NN	O
dose	NN	O
increased	VBD	O
up	RB	O
to	TO	O
the	DT	O
5th	JJ	O
day	NN	O
(	(	O
mean	JJ	O
Cmin	NNP	O
166.6	CD	O
ng.ml-1	NN	O
)	)	O
and	CC	O
then	RB	O
tended	VBD	O
to	TO	O
decrease	VB	O
until	IN	O
the	DT	O
7th	JJ	O
day	NN	O
.	.	O

No	DT	O
significant	JJ	O
signs	NNS	O
,	,	O
symptoms	NNS	O
or	CC	O
changes	NNS	O
in	IN	O
serum	NN	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
single	JJ	O
and	CC	O
repeated	JJ	O
oral	JJ	O
dose	NN	O
studies	NNS	O
at	IN	O
150	CD	O
mg	NN	O
b.d	NN	O
.	.	O

Although	IN	O
statistical	JJ	O
analysis	NN	O
was	VBD	O
not	RB	O
conducted	VBN	O
because	IN	O
of	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
subjects	NNS	O
,	,	O
all	DT	O
subjects	NNS	O
receiving	VBG	O
repeated	VBD	O
oral	JJ	O
administration	NN	O
of	IN	O
300	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
showed	VBD	O
a	DT	O
25	CD	O
%	NN	O
decrease	NN	O
in	IN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
on	IN	O
day	NN	O
7	CD	O
,	,	O
but	CC	O
also	RB	O
the	DT	O
simultaneous	JJ	O
occurrence	NN	O
of	IN	O
diarrhoea	NN	O
.	.	O

Mouth	NNP	O
closing	NN	O
device	NN	O
(	(	O
chinstrap	NN	O
)	)	O
reduces	VBZ	O
mouth	JJ	O
leak	NN	O
during	IN	O
nasal	JJ	O
CPAP	NNP	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Mouth	NNP	O
leak	VBP	O
occasionally	RB	O
complicates	VBZ	O
continuous	JJ	O
positive	JJ	O
airway	NN	O
pressure	NN	O
(	(	O
CPAP	NNP	O
)	)	O
therapy	NN	O
,	,	O
which	WDT	O
leads	VBZ	O
to	TO	O
discomfort	VB	O
.	.	O

While	IN	O
a	DT	O
chinstrap	NN	O
prevents	VBZ	O
the	DT	O
mouth	NN	O
from	IN	O
opening	VBG	O
during	IN	O
sleep	NN	O
,	,	O
its	PRP$	O
efficacy	NN	O
in	IN	O
diminishing	VBG	O
mouth	NN	O
leak	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Fifteen	NNP	O
patients	NNS	O
with	IN	O
mouth	JJ	O
leak	JJ	O
complaining	NN	O
of	IN	O
mouth	NN	O
dryness	NN	O
and	CC	O
nasal	JJ	O
obstruction	NN	O
underwent	JJ	O
two	CD	PH
consecutive	JJ	PH
overnight	JJ	PH
polysomnographies	NNS	PH
,	,	O
one	CD	O
with	IN	O
a	DT	O
chinstrap	NN	PH
,	,	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Cephalometry	NN	PH
with	IN	PH
and	CC	PH
without	IN	PH
a	DT	PH
chinstrap	NN	PH
was	VBD	O
randomly	RB	O
performed	VBN	O
on	IN	O
six	CD	O
patients	NNS	O
.	.	O

RESULTS	NNP	O
With	IN	O
the	DT	O
chinstrap	NN	O
,	,	O
both	DT	O
mouth	FW	O
leak	NN	O
and	CC	O
the	DT	O
arousal	NN	O
index	NN	O
decreased	VBD	O
significantly	RB	O
,	,	O
from	IN	O
(	(	O
mean+/-SD	JJ	O
)	)	O
42.9+/-23.5	CD	O
to	TO	O
23.8+/-13.3	CD	O
%	NN	O
of	IN	O
total	JJ	O
sleep	JJ	O
time	NN	O
(	(	O
TST	NNP	O
)	)	O
,	,	O
and	CC	O
from	IN	O
33.4+/-18.6	JJ	O
to	TO	O
23.6+/-9.3/sleep	JJ	O
hour	NN	O
,	,	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
snoring	VBG	O
time	NN	O
showed	VBD	O
a	DT	O
concomitant	JJ	O
increase	NN	O
from	IN	O
6.7+/-14.3	JJ	O
to	TO	O
24.0+/-13.2	CD	O
%	NN	O
of	IN	O
TST	NNP	O
.	.	O

The	DT	O
arousal	JJ	O
index	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
during	IN	O
leak	JJR	O
periods	NNS	O
,	,	O
and	CC	O
its	PRP$	O
changes	NNS	O
correlated	VBN	O
positively	RB	O
with	IN	O
changes	NNS	O
in	IN	O
mouth	NN	O
leak	NN	O
.	.	O

Cephalometric	JJ	O
measures	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
anterior	JJ	O
lower	JJR	O
facial	JJ	O
height	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
chinstrap	NN	O
,	,	O
by	IN	O
closing	VBG	O
the	DT	O
mouth	NN	O
during	IN	O
CPAP	NNP	O
,	,	O
reduces	VBZ	O
mouth	JJ	O
leak	NN	O
and	CC	O
therefore	RB	O
the	DT	O
arousal	NN	O
index	NN	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

Nevertheless	NNP	O
,	,	O
the	DT	O
indices	NNS	O
remained	VBD	O
unacceptably	RB	O
high	JJ	O
.	.	O

The	DT	O
chinstrap	NN	O
may	MD	O
also	RB	O
increase	VB	O
snoring	NN	O
and	CC	O
,	,	O
in	IN	O
rare	JJ	O
cases	NNS	O
,	,	O
can	MD	O
worsen	VB	O
the	DT	O
respiratory	NN	O
disturbance	NN	O
index	NN	O
.	.	O

Consideration	NN	O
of	IN	O
these	DT	O
potential	JJ	O
effects	NNS	O
is	VBZ	O
important	JJ	O
before	IN	O
instituting	VBG	O
regular	JJ	O
home	NN	O
use	NN	O
of	IN	O
the	DT	O
chinstrap	NN	O
.	.	O

B-type	JJ	O
natriuretic	JJ	O
peptide	NN	O
and	CC	O
risk	NN	O
of	IN	O
contrast-induced	JJ	O
acute	JJ	O
kidney	NN	O
injury	NN	O
in	IN	O
acute	JJ	O
ST-segment-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
:	:	O
a	DT	O
substudy	NN	O
from	IN	O
the	DT	O
HORIZONS-AMI	NNP	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Contrast-induced	NNP	O
acute	NN	O
kidney	NN	O
injury	NN	O
(	(	O
CI-AKI	NNP	O
)	)	O
after	IN	O
percutaneous	JJ	S
coronary	JJ	S
intervention	NN	S
is	VBZ	O
associated	VBN	O
with	IN	O
adverse	JJ	O
short-	NN	O
and	CC	O
long-term	JJ	O
outcomes	NNS	O
.	.	O

However	RB	O
,	,	O
identification	NN	O
of	IN	O
patients	NNS	O
at	IN	O
risk	NN	O
for	IN	O
CI-AKI	NNP	O
is	VBZ	O
challenging	VBG	O
.	.	O

Using	VBG	O
a	DT	O
large	JJ	O
contemporary	JJ	O
randomized	VBN	O
trial	NN	O
database	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ST-segment-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
,	,	O
we	PRP	O
therefore	RB	O
sought	VBD	O
to	TO	O
examine	VB	O
whether	IN	O
admission	NN	O
B-type	NNP	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
BNP	NNP	O
)	)	O
levels	NNS	O
predict	VBP	O
the	DT	O
development	NN	O
of	IN	O
CI-AKI	NNP	O
.	.	O

METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
979	CD	O
ST-segment-elevation	JJ	O
myocardial	JJ	O
infarction	NN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
Harmonizing	NNP	O
Outcomes	NNP	O
with	IN	O
Revascularization	NNP	O
and	CC	O
Stents	NNP	O
in	IN	O
Acute	NNP	O
Myocardial	NNP	O
Infarction	NNP	O
(	(	O
HORIZONS-AMI	NNP	O
)	)	O
trial	NN	O
had	VBD	O
BNP	NNP	PH
levels	NNS	PH
measured	VBN	O
in	IN	O
the	DT	O
emergency	NN	O
room	NN	O
prior	RB	O
to	TO	O
primary	JJ	O
percutaneous	JJ	S
coronary	JJ	S
intervention	NN	S
as	IN	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
protocol	NN	O
.	.	O

CI-AKI	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
relative	JJ	O
increase	NN	O
in	IN	O
serum	JJ	O
creatinine	NN	O
of	IN	O
?25	NNP	O
%	NN	O
,	,	O
or	CC	O
an	DT	O
absolute	JJ	O
increase	NN	O
of	IN	O
?0.5	NNP	O
mg/dL	NN	O
,	,	O
occurring	VBG	O
within	IN	O
48	CD	O
hours	NNS	O
after	IN	O
contrast	NN	O
administration	NN	O
.	.	O

Logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
association	NN	O
of	IN	O
admission	NN	O
BNP	NNP	O
with	IN	O
development	NN	O
of	IN	O
CI-AKI	NNP	O
.	.	O

CI-AKI	NNP	O
occurred	VBD	O
in	IN	O
131	CD	O
patients	NNS	O
(	(	O
13.3	CD	O
%	NN	O
)	)	O
.	.	O

Baseline	NNP	O
BNP	NNP	O
was	VBD	O
a	DT	O
significant	JJ	O
univariable	JJ	O
correlate	NN	O
of	IN	O
CI-AKI	NNP	O
(	(	O
odds	NNS	O
ratio	VBP	O
1.31	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.14-1.51	JJ	O
;	:	O
P=0.0001	NNP	O
)	)	O
.	.	O

After	IN	O
multivariable	JJ	O
adjustment	NN	O
for	IN	O
clinical	JJ	O
,	,	O
laboratory	NN	O
,	,	O
and	CC	O
angiographic	JJ	O
variables	NNS	O
,	,	O
BNP	NNP	O
remained	VBD	O
a	DT	O
significant	JJ	O
independent	JJ	O
predictor	NN	O
of	IN	O
CI-AKI	NNP	O
(	(	O
1.29	CD	O
[	RB	O
1.10	CD	O
,	,	O
1.51	CD	O
]	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Significant	JJ	O
net	JJ	O
reclassification	NN	O
improvement	NN	O
was	VBD	O
achieved	VBN	O
by	IN	O
addition	NN	O
of	IN	O
BNP	NNP	O
to	TO	O
the	DT	O
current	JJ	O
clinical	JJ	O
risk	NN	O
prediction	NN	O
model	NN	O
(	(	O
net	JJ	O
reclassification	NN	O
improvement=0.177	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
to	TO	O
the	DT	O
Mehran	NNP	O
Risk	NNP	O
Score	NNP	O
(	(	O
net	JJ	O
reclassification	NN	O
improvement=0.100	NN	O
;	:	O
P=0.015	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Measurement	NNP	O
of	IN	O
serum	NN	O
BNP	NNP	O
at	IN	O
hospital	JJ	O
admission	NN	O
may	MD	O
help	VB	O
identify	VB	O
patients	NNS	O
who	WP	O
are	VBP	O
at	IN	O
risk	NN	O
for	IN	O
developing	VBG	O
CI-AKI	NNP	O
after	IN	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
in	IN	O
ST-segment-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
URL	NNP	O
:	:	O
http	NN	O
:	:	O
//www.clinicaltrials.gov	NN	O
.	.	O

Unique	NNP	O
identifier	NN	O
:	:	O
NCT00433966	NNP	O
.	.	O

Therapy	NNP	O
effect	NN	O
of	IN	O
either	CC	O
paclitaxel	NN	C
or	CC	O
cyclophosphamide	JJ	C
combination	NN	C
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
epithelial	JJ	O
ovarian	JJ	O
cancer	NN	O
and	CC	O
relation	NN	O
to	TO	O
TP53	NNP	O
gene	NN	O
status	NN	O
.	.	O

Cell	NNP	O
death	NN	O
after	IN	O
treatment	NN	O
with	IN	O
chemotherapy	NN	PM
is	VBZ	O
exerted	VBN	O
by	IN	O
activation	NN	O
of	IN	O
apoptosis	NN	O
,	,	O
and	CC	O
the	DT	O
p53	NN	O
protein	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
actively	RB	O
participate	VB	O
in	IN	O
this	DT	O
process	NN	O
.	.	O

This	DT	O
recent	JJ	O
focus	NN	O
on	IN	O
TP53	NNP	O
status	NN	O
as	IN	O
a	DT	O
possible	JJ	O
determinant	NN	O
of	IN	O
cancer	NN	O
therapy	NN	O
response	NN	O
has	VBZ	O
raised	VBN	O
the	DT	O
question	NN	O
of	IN	O
whether	IN	O
or	CC	O
not	RB	O
mutations	NNS	O
in	IN	O
the	DT	O
TP53	NNP	O
gene	NN	O
have	VBP	O
an	DT	O
influence	NN	O
on	IN	O
paclitaxel	NN	PM
therapy	NN	O
.	.	O

The	DT	O
TP53	NNP	O
status	NN	O
has	VBZ	O
been	VBN	O
analysed	VBN	O
at	IN	O
the	DT	O
DNA	NNP	O
level	NN	O
in	IN	O
tumours	NNS	O
from	IN	O
45	CD	O
ovarian	JJ	O
cancer	NN	O
patients	NNS	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
paclitaxel	NN	PM
and	CC	O
cisplatin	NN	O
or	CC	O
cyclophosphamide	NN	PM
and	CC	O
cisplatin	NN	PM
.	.	O

Therapy	NNP	O
response	NN	O
was	VBD	O
obtained	VBN	O
for	IN	O
38	CD	O
patients	NNS	O
with	IN	O
clinically	RB	O
evaluable	JJ	O
disease	NN	O
after	IN	O
initial	JJ	O
surgery	NN	O
.	.	O

The	DT	O
positive	JJ	O
response	NN	O
rate	NN	O
to	TO	O
the	DT	O
paclitaxel/cisplatin	NN	PM
therapy	NN	O
was	VBD	O
85	CD	O
%	NN	O
vs	JJ	O
61	CD	O
%	NN	O
for	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
the	DT	O
cyclophosphamide/cisplatin	JJ	PM
regimen	NNS	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
relapse-free	JJ	O
survival	NN	O
in	IN	O
favour	NN	O
of	IN	O
paclitaxel/cisplatin	NN	PM
chemotherapy	NN	PM
was	VBD	O
found	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
33	CD	O
tumour	NN	O
samples	NNS	O
(	(	O
73	CD	O
%	NN	O
)	)	O
had	VBD	O
detectable	JJ	O
sequence	NN	O
alterations	NNS	O
in	IN	O
the	DT	O
TP53	NNP	O
gene	NN	O
.	.	O

When	WRB	O
relapse-free	JJ	O
survival	NN	O
was	VBD	O
estimated	VBN	O
for	IN	O
all	DT	O
patients	NNS	O
with	IN	O
TP53	NNP	O
alterations	NNS	O
in	IN	O
their	PRP$	O
tumours	NNS	O
,	,	O
a	DT	O
significant	JJ	O
better	RBR	O
outcome	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	PM
group	NN	O
was	VBD	O
found	VBN	O
compared	VBN	O
with	IN	O
the	DT	O
patient	NN	O
group	NN	O
receiving	VBG	O
cyclophosphamide	NN	PM
and	CC	O
cisplatin	NN	PM
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

We	PRP	O
did	VBD	O
not	RB	O
observe	VB	O
an	DT	O
association	NN	O
between	IN	O
TP53	NNP	O
tumour	NN	O
status	NN	O
and	CC	O
prognosis	NN	O
for	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
paclitaxel/cisplatin	JJ	PM
combination	NN	O
treatment	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
effect	NN	O
of	IN	O
this	DT	O
therapy	NN	O
is	VBZ	O
not	RB	O
influenced	VBN	O
by	IN	O
this	DT	O
parameter	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
patient	JJ	E
education	NN	E
and	CC	O
supervised	VBD	PH
exercise	NN	PH
vs	NN	O
patient	JJ	E
education	NN	E
alone	RB	E
in	IN	O
patients	NNS	O
with	IN	O
hip	JJ	O
osteoarthritis	NN	O
:	:	O
a	DT	O
single	JJ	O
blind	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
patient	JJ	E
education	NN	E
and	CC	O
supervised	VBD	Ot
exercise	NN	Ot
with	IN	O
that	DT	O
of	IN	O
patient	JJ	E
education	NN	E
alone	RB	E
for	IN	O
the	DT	O
management	NN	O
of	IN	O
pain	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hip	NN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Single	NNP	O
blind	IN	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Recruitment	NNP	O
of	IN	O
patients	NNS	O
from	IN	O
hospitals	NNS	O
,	,	O
primary	JJ	O
health	NN	O
care	NN	O
and	CC	O
advertisement	NN	O
,	,	O
Oslo	NNP	O
,	,	O
Norway	NNP	O
.	.	O

PARTICIPANTS	NNP	O
109	CD	O
patients	NNS	O
with	IN	O
radiographic	JJ	O
and	CC	O
symptomatic	JJ	O
hip	NN	O
OA	NNP	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
symptoms	NNS	O
.	.	O

INTERVENTIONS	NNP	O
Patient	NNP	E
education	NN	E
(	(	E
PE	NNP	E
)	)	E
.	.	O

Patient	JJ	E
education	NN	E
and	CC	O
supervised	VBN	PH
exercise	NN	PH
(	(	O
PE+SE	NNP	O
)	)	O
.	.	O

PRIMARY	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
pain	NN	O
subscale	NN	O
of	IN	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
pain	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
between	IN	O
group	NN	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	O
pain	NN	O
over	IN	O
the	DT	O
16-month	JJ	O
follow-up	NN	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
secondary	JJ	O
outcome	NN	O
WOMAC	NNP	O
physical	JJ	O
function	NN	O
(	(	O
P=0.011	NNP	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
PE+SE	NNP	PH
compared	VBN	O
to	TO	O
the	DT	O
group	NN	O
receiving	VBG	O
PE	NNP	E
only	RB	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	O
stiffness	NN	O
,	,	O
the	DT	O
SF-36	JJ	O
subscales	NNS	O
or	CC	O
the	DT	O
activity	NN	O
scale	NN	O
.	.	O

The	DT	O
effect	NN	O
sizes	VBZ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
for	IN	O
WOMAC	NNP	O
pain	NN	O
were	VBD	O
-0.26	NNP	O
(	(	O
0.11	CD	O
,	,	O
-0.64	NN	O
)	)	O
,	,	O
-0.35	NNP	O
(	(	O
0.07	CD	O
,	,	O
-0.77	NN	O
)	)	O
,	,	O
and	CC	O
-0.30	NNP	O
(	(	O
0.15	CD	O
,	,	O
-0.75	NN	O
)	)	O
,	,	O
and	CC	O
for	IN	O
WOMAC	NNP	O
physical	JJ	O
function	NN	O
-0.29	NNP	O
(	(	O
0.09	CD	O
,	,	O
-0.67	NN	O
)	)	O
,	,	O
-0.48	NNP	O
(	(	O
-0.06	NNP	O
,	,	O
-0.91	NNP	O
)	)	O
,	,	O
and	CC	O
-0.47	NNP	O
(	(	O
-0.02	NNP	O
,	,	O
-0.93	NNP	O
)	)	O
at	IN	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
16	CD	O
months	NNS	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
both	DT	O
PE	NNP	E
and	CC	O
SE	NNP	PH
.	.	O

All	DT	O
patients	NNS	O
attended	VBD	O
the	DT	O
three-session	JJ	O
PE	NNP	E
program	NN	E
,	,	O
and	CC	O
75	CD	O
%	NN	O
performed	VBN	O
?16	JJ	O
sessions	NNS	O
of	IN	O
the	DT	O
12-week	JJ	O
SE	NNP	O
program	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
study	NN	O
could	MD	O
not	RB	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
pain	NN	O
reduction	NN	O
over	IN	O
time	NN	O
between	IN	O
PE+SE	NNP	O
vs	NNP	O
PE	NNP	O
alone	RB	O
.	.	O

Adding	VBG	O
SE	NNP	O
to	TO	O
PE	NNP	O
may	MD	O
improve	VB	O
physical	JJ	O
function	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
possible	JJ	O
benefit	NN	O
is	VBZ	O
unknown	JJ	O
as	IN	O
the	DT	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
around	IN	O
the	DT	O
mean	JJ	O
difference	NN	O
were	VBD	O
wide	JJ	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinical	NNP	O
Trials	NNP	O
NCT00319423	NNP	O
.	.	O

Moclobemide	NNP	O
,	,	O
imipramine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depression	NN	O
.	.	O

Moclobemide	NNP	PM
was	VBD	O
compared	VBN	O
with	IN	O
imipramine	NN	PM
and	CC	O
placebo	NN	C
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depressive	JJ	O
episodes	NNS	O
in	IN	O
75	CD	O
outpatients	NNS	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
moclobemide	NN	PM
(	(	PM
25	CD	PM
patients	NNS	PM
)	)	PM
was	VBD	PM
300	CD	PM
mg	JJ	PM
daily	RB	PM
for	IN	PM
the	DT	PM
first	JJ	PM
5	CD	PM
days	NNS	PM
,	,	PM
after	IN	PM
which	WDT	PM
it	PRP	PM
could	MD	PM
be	VB	PM
increased	VBN	PM
to	TO	PM
600	CD	PM
mg.	NNS	PM
Imipramine	NNP	PM
(	(	PM
25	CD	PM
patients	NNS	PM
)	)	PM
was	VBD	PM
given	VBN	PM
in	IN	PM
a	DT	PM
dosage	NN	PM
starting	VBG	PM
with	IN	PM
33	CD	PM
mg	NNS	PM
and	CC	PM
gradually	RB	PM
increased	VBD	PM
to	TO	PM
100	CD	PM
mg/day	NN	PM
in	IN	PM
the	DT	PM
first	JJ	PM
5	CD	PM
days	NNS	PM
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
could	MD	O
be	VB	O
further	RB	O
increased	VBN	O
;	:	O
25	CD	O
patients	NNS	O
received	VBD	O
placebo	NN	C
.	.	C

Both	DT	O
drugs	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Hamilton	NNP	O
Rating	NNP	O
Scale	NNP	O
for	IN	O
Depression	NNP	O
,	,	O
the	DT	O
overall	JJ	O
assessment	NN	O
of	IN	O
efficacy	NN	O
and	CC	O
the	DT	O
Zung	NNP	O
Self-rating	NNP	O
Scale	NNP	O
,	,	O
and	CC	O
clearly	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
2	CD	O
active	JJ	O
drugs	NNS	O
.	.	O

Moclobemide	NNP	PM
was	VBD	O
better	RBR	O
tolerated	VBN	O
than	IN	O
imipramine	NN	PM
,	,	O
and	CC	O
was	VBD	O
almost	RB	O
comparable	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
this	DT	O
respect	NN	O
.	.	O

[	JJ	O
Clinical	NNP	O
application	NN	O
of	IN	O
irradiated	JJ	O
drug-containing	JJ	PM
porcine-cornea	NN	PM
to	TO	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
]	FW	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
explore	VB	O
a	DT	O
new	JJ	O
method	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
.	.	O

METHODS	NNP	O
Fifty-five	JJ	O
cases	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
(	(	O
in	IN	O
88	CD	O
eyes	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Thirty	NNP	O
cases	NNS	O
in	IN	O
treatment	NN	O
group	NN	O
with	IN	O
49	CD	O
eyes	NNS	O
were	VBD	O
transplanted	VBN	O
with	IN	O
irradiated	JJ	PM
drug-containing	NN	PM
(	(	PM
ofloxacin	UH	PM
,	,	PM
acetyl	JJ	PM
cysteine	NN	PM
and	CC	PM
reduced	JJ	PM
glutathione	NN	PM
)	)	PM
porcine-cornea	NN	PM
.	.	O

25	CD	O
cases	NNS	O
in	IN	O
control	NN	O
group	NN	O
with	IN	O
39	CD	O
eyes	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
routine	JJ	O
program	NN	O
.	.	O

RESULTS	NNP	O
Thirty-two	JJ	O
eyes	NNS	O
were	VBD	O
rescued	VBN	O
in	IN	O
treatment	NN	O
group	NN	O
with	IN	O
the	DT	O
cure	NN	O
rate	NN	O
of	IN	O
65.3	CD	O
%	NN	O
.	.	O

But	CC	O
only	RB	O
17	CD	O
eyes	NNS	O
were	VBD	O
saved	VBN	O
in	IN	O
control	NN	O
group	NN	O
with	IN	O
the	DT	O
cure	NN	O
rate	NN	O
of	IN	O
43.59	CD	O
%	NN	O
,	,	O
indicating	VBG	O
significant	JJ	O
difference	NN	O
of	IN	O
the	DT	O
cure	NN	O
rate	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Irradiated	VBD	O
drug-containing	JJ	O
porcine-cornea	NN	PH
might	MD	O
well	RB	O
be	VB	O
an	DT	O
ideal	JJ	O
therapeutic	JJ	O
material	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ocular	JJ	O
burns	NNS	O
.	.	O

[	RB	O
Dexmedetomidine	NNP	PM
use	NN	O
for	IN	O
postoperative	JJ	O
adrenergic	JJ	O
analgesia	NN	O
and	CC	O
sedation	NN	O
in	IN	O
abdominal	JJ	O
surgery	NN	O
]	NN	O
.	.	O

Comparative	NNP	O
study	NN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
and	CC	O
sedation	NN	O
with	IN	O
trimeperidine	NN	PM
and	CC	O
dexmedetomidine	NN	PM
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
haemodynamics	NNS	O
and	CC	O
vegetative	VBP	O
nervous	JJ	O
system	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Assessment	NNP	O
of	IN	O
analgesia	NN	O
and	CC	O
sedation	NN	O
during	IN	O
vagotonia	NN	O
(	(	O
first	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
and	CC	O
hypokinetic	JJ	O
type	NN	O
of	IN	O
haemodynamics	NNS	O
(	(	O
second	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
was	VBD	O
carried	VBN	O
out	RP	O
with	IN	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
and	CC	O
Richmond	NNP	O
scale	NN	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
showed	VBD	O
that	IN	O
dexmedetomidine	NN	PM
is	VBZ	O
more	RBR	O
effective	JJ	O
and	CC	O
safer	JJR	O
than	IN	O
trimeperidine	NN	PM
for	IN	O
analgesia	NN	O
and	CC	O
sedation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
spontaneous	JJ	O
breathing	NN	O
after	IN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Dexmedetomidine	NNP	PM
use	NN	O
allows	VBZ	O
keeping	VBG	O
optimal	JJ	O
type	NN	O
of	IN	O
haemodynamics	NNS	O
and	CC	O
vegetative	VBP	O
nervous	JJ	O
system	NN	O
parameters	NNS	O
on	IN	O
first	JJ	O
day	NN	O
of	IN	O
postoperative	JJ	O
period	NN	O
.	.	O

Butorphanol	NNP	PM
and	CC	O
meperidine	NN	PM
compared	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
ureteral	JJ	O
colic	NN	O
.	.	O

Pain	NNP	O
relief	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
81	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
ureteral	JJ	O
colic	NN	O
and	CC	O
the	DT	O
confirmed	JJ	O
presence	NN	O
of	IN	O
a	DT	O
calculus	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
comparison	NN	O
of	IN	O
intramuscular	JJ	O
2	CD	O
and	CC	O
4	CD	O
mg.	NN	O
butorphanol	NN	PM
and	CC	O
80	CD	O
mg.	NNS	O
meperidine	NN	PM
was	VBD	O
used	VBN	O
.	.	O

Pain	NNP	O
intensity	NN	O
and	CC	O
pain	NN	O
relief	NN	O
were	VBD	O
evaluated	VBN	O
at	IN	O
half	JJ	O
hour	NN	O
and	CC	O
hourly	JJ	O
intervals	NNS	O
for	IN	O
4	CD	O
hours	NNS	O
.	.	O

A	DT	O
2	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	PM
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
analgesically	RB	O
equivalent	JJ	O
to	TO	O
80	CD	O
mg.	NNS	O
meperidine	NN	PM
,	,	O
while	IN	O
a	DT	O
4	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	PM
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
80	CD	O
mg.	JJ	O
meperidine	NN	PM
and	CC	O
2	CD	O
mg.	NN	O
butorphanol	NN	PM
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
up	RB	O
to	TO	O
2	CD	O
doses	NNS	O
of	IN	O
analgesic	JJ	O
medication	NN	O
when	WRB	O
necessary	JJ	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
among	IN	O
treatments	NNS	O
.	.	O

One	CD	O
patient	NN	O
had	VBD	O
visual	JJ	O
hallucinations	NNS	O
after	IN	O
a	DT	O
2	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	PM
,	,	O
possibly	RB	O
owing	VBG	O
to	TO	O
its	PRP$	O
antagonistic	JJ	O
activity	NN	O
to	TO	O
significant	JJ	O
narcotic	JJ	O
experience	NN	O
given	VBN	O
previously	RB	O
at	IN	O
another	DT	O
hospital	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
other	JJ	O
evidence	NN	O
of	IN	O
toxicity	NN	O
with	IN	O
butorphanol	NN	PM
.	.	O

It	PRP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
,	,	O
effective	JJ	O
and	CC	O
wall	RB	O
tolerated	JJ	O
drug	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ureteral	JJ	O
colic	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
in	IN	O
place	NN	O
of	IN	O
narcotics	NNS	O
.	.	O

Long-term	JJ	O
use	NN	O
of	IN	O
Viozan	NNP	PM
(	(	PM
sibenadet	JJ	PM
HCl	NNP	PM
)	)	PM
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
study	NN	O
.	.	O

Viozan	NNP	PM
(	(	O
sibenadet	JJ	PM
HCl	NNP	PM
,	,	O
AR-C68397AA	NNP	PM
)	)	O
is	VBZ	O
a	DT	O
novel	JJ	O
dual	JJ	O
D2	NNP	O
dopamine	NN	O
receptor	NN	O
,	,	O
beta2-adrenoceptor	JJ	O
agonist	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
investigated	VBN	O
for	IN	O
efficacy	NN	O
in	IN	O
alleviating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

The	DT	O
slowly	RB	O
progressive	JJ	O
nature	NN	O
of	IN	O
this	DT	O
disease	NN	O
means	VBZ	O
that	IN	O
patients	NNS	O
will	MD	O
require	VB	O
ongoing	JJ	O
therapeutic	JJ	O
management	NN	O
for	IN	O
many	JJ	O
years	NNS	O
,	,	O
or	CC	O
even	RB	O
decades	NNS	O
.	.	O

With	IN	O
such	JJ	O
long-term	JJ	O
treatment	NN	O
,	,	O
the	DT	O
safety	NN	O
profile	NN	O
of	IN	O
new	JJ	O
agents	NNS	O
will	MD	O
be	VB	O
of	IN	O
paramount	JJ	O
importance	NN	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
the	DT	O
large-scale	JJ	O
assessment	NN	O
of	IN	O
sibenadet	NN	PM
,	,	O
a	DT	O
12-month	JJ	O
safety	NN	O
study	NN	O
has	VBZ	O
been	VBN	O
conducted	VBN	O
.	.	O

Following	VBG	O
completion	NN	O
of	IN	O
a	DT	O
2-week	JJ	O
baseline	NN	O
period	NN	O
,	,	O
435	CD	O
adults	NNS	O
with	IN	O
stable	JJ	O
,	,	O
symptomatic	JJ	O
,	,	O
smoking-related	JJ	O
COPD	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
500	CD	PM
microg	NN	PM
sibenadet	NN	PM
or	CC	O
placebo	NN	C
delivered	VBN	O
via	IN	O
pressurized	VBN	O
metered	VBD	O
dose	JJ	O
inhaler	NN	O
(	(	O
pMDI	NN	O
)	)	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
52	CD	O
weeks	NNS	O
.	.	O

Sibenadet	NNP	PM
therapy	NN	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
the	DT	O
only	JJ	O
notable	JJ	O
differences	NNS	O
seen	VBN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
tremor	NN	O
and	CC	O
taste	NN	O
of	IN	O
treatment	NN	O
(	(	O
16.9	CD	O
%	NN	O
vs.	FW	O
4.1	CD	O
%	NN	O
and	CC	O
14.5	CD	O
%	NN	O
vs.	FW	O
4.1	CD	O
%	NN	O
in	IN	O
the	DT	O
sibenadet	NN	O
and	CC	O
placebo	NN	C
groups	NNS	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
a	DT	O
total	NN	O
of	IN	O
79	CD	O
patients	NNS	O
with	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
SAEs	NNP	O
)	)	O
,	,	O
43	CD	O
(	(	O
14.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
sibenadet	NN	O
pMDI	NN	O
group	NN	O
and	CC	O
36	CD	O
(	(	O
24.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
.	.	O

No	DT	O
clinically	RB	O
significant	JJ	O
abnormal	JJ	O
laboratory	NN	O
values	NNS	O
or	CC	O
overall	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
were	VBD	O
noted	VBN	O
.	.	O

Similarly	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
clinically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
for	IN	O
cardiac	JJ	O
variables	NNS	O
,	,	O
or	CC	O
in	IN	O
vital	JJ	O
signs	NNS	O
.	.	O

The	DT	O
secondary	JJ	O
variables	NNS	O
showed	VBD	O
no	DT	O
notable	JJ	O
differences	NNS	O
with	IN	O
respect	NN	O
to	TO	O
lung	NN	O
function	NN	O
,	,	O
exacerbations	NNS	O
or	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
effective	JJ	O
beta2-agonist	NN	O
properties	NNS	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
sibenadet	NN	O
group	NN	O
did	VBD	O
,	,	O
however	RB	O
,	,	O
report	NN	O
reduced	VBD	O
rescue	JJ	O
medication	NN	O
usage	NN	O
at	IN	O
all	DT	O
timepoints	NNS	O
.	.	O

While	IN	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
,	,	O
overall	JJ	O
,	,	O
sibenadet	JJ	O
therapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
the	DT	O
lack	NN	O
of	IN	O
sustained	JJ	O
benefit	NN	O
reported	VBD	O
in	IN	O
large-scale	JJ	O
clinical	JJ	O
efficacy	NN	O
studies	NNS	O
means	VBZ	O
that	IN	O
sibenadet	NN	O
development	NN	O
will	MD	O
not	RB	O
be	VB	O
continued	VBN	O
.	.	O

The	DT	O
relationship	NN	O
of	IN	O
alexithymia	NN	O
to	TO	O
emotional	JJ	O
dysregulation	NN	O
within	IN	O
an	DT	O
alcohol	NN	O
dependent	JJ	O
treatment	NN	O
sample	NN	O
.	.	O

Difficulties	NNS	O
regulating	VBG	O
emotions	NNS	O
have	VBP	O
implications	NNS	O
for	IN	O
the	DT	O
development	NN	O
,	,	O
maintenance	NN	O
,	,	O
and	CC	O
recovery	NN	O
from	IN	O
alcohol	NN	O
problems	NNS	O
.	.	O

One	CD	O
construct	NN	O
thought	NN	O
to	TO	O
impede	VB	O
the	DT	O
regulation	NN	O
of	IN	O
emotion	NN	O
is	VBZ	O
alexithymia	JJ	O
.	.	O

Alexithymia	NNP	O
is	VBZ	O
characterized	VBN	O
by	IN	O
difficulties	NNS	O
identifying	VBG	O
,	,	O
differentiating	VBG	O
and	CC	O
expressing	VBG	O
feelings	NNS	O
,	,	O
a	DT	O
limited	JJ	O
imagination	NN	O
and	CC	O
fantasy	JJ	O
life	NN	O
,	,	O
and	CC	O
an	DT	O
externally-oriented	JJ	O
thinking	NN	O
style	NN	O
(	(	O
e.g.	UH	O
,	,	O
prefer	VBP	O
talking	VBG	O
about	IN	O
daily	JJ	O
activities	NNS	O
rather	RB	O
than	IN	O
feelings	NNS	O
)	)	O
.	.	O

Given	VBN	O
that	IN	O
poor	JJ	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
to	TO	O
predict	VB	O
posttreatment	NN	O
levels	NNS	O
of	IN	O
alcohol	NN	O
use	NN	O
,	,	O
and	CC	O
that	IN	O
several	JJ	O
defining	VBG	O
characteristics	NNS	O
of	IN	O
alexithymia	JJ	O
bear	JJ	O
similarity	NN	O
to	TO	O
deficits	NNS	O
in	IN	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
alexithymia	NN	O
may	MD	O
predict	VB	O
poorer	JJR	O
alcohol	NN	O
treatment	NN	O
outcomes	NNS	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
present	JJ	O
study	NN	O
first	RB	O
examined	VBD	O
the	DT	O
relationship	NN	O
of	IN	O
alexithymia	NN	Ot
to	TO	O
several	JJ	O
other	JJ	O
emotion	NN	PS
regulation	NN	PS
measures	NNS	PS
and	CC	O
then	RB	O
investigated	VBD	O
the	DT	O
impact	NN	O
of	IN	O
alexithymia	NN	Ot
on	IN	O
attrition	NN	O
and	CC	O
alcohol	NN	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
(	(	O
N=77	NNP	O
)	)	O
enrolled	VBD	O
in	IN	O
a	DT	O
12-week	JJ	PS
cognitive-behavioral	JJ	PS
intervention	NN	PS
for	IN	PS
alcohol	NN	PS
dependence	NN	PS
.	.	O

At	IN	O
baseline	NN	O
,	,	O
higher	JJR	O
scores	NNS	O
on	IN	O
alexithymia	NN	O
were	VBD	O
associated	VBN	O
poorer	JJR	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
,	,	O
fewer	JJR	O
percent	NN	O
days	NNS	O
abstinent	NN	O
,	,	O
greater	JJR	O
alcohol	NN	O
dependence	NN	O
severity	NN	O
,	,	O
and	CC	O
several	JJ	O
high-risk	JJ	O
drinking	NN	O
situations	NNS	O
.	.	O

Alexithymia	NNP	O
was	VBD	O
unrelated	JJ	O
to	TO	O
attrition	NN	O
and	CC	O
to	TO	O
level	NN	O
of	IN	O
alcohol	NN	O
consumption	NN	O
at	IN	O
posttreatment	NN	O
.	.	O

Overall	UH	O
,	,	O
the	DT	O
construct	NN	O
of	IN	O
alexithymia	NN	O
is	VBZ	O
shown	VBN	O
to	TO	O
be	VB	O
related	VBN	O
to	TO	O
several	JJ	O
theoretically-related	JJ	O
constructs	NNS	O
(	(	O
e.g.	NN	O
,	,	O
emotion	NN	O
regulation	NN	O
,	,	O
mindfulness	NN	O
)	)	O
but	CC	O
demonstrated	VBD	O
a	DT	O
limited	JJ	O
relationship	NN	O
to	TO	O
drinking	VBG	O
outcomes	NNS	O
in	IN	O
those	DT	O
seeking	VBG	O
treatment	NN	O
for	IN	O
alcohol	NN	O
dependence	NN	O
.	.	O

Short-term	JJ	O
fluoxetine	NN	PM
monotherapy	NN	PM
for	IN	O
bipolar	JJ	O
type	NN	O
II	NNP	O
or	CC	O
bipolar	JJ	O
NOS	NNP	O
major	JJ	O
depression	NN	O
-	:	O
low	JJ	O
manic	JJ	O
switch	NN	O
rate	NN	O
.	.	O

OBJECTIVES	CC	O
Current	NNP	O
guidelines	NNS	O
for	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
of	IN	O
bipolar	JJ	O
type	NN	O
II	NNP	O
(	(	O
BP	NNP	O
II	NNP	O
)	)	O
major	JJ	O
depressive	JJ	O
episode	NN	O
(	(	O
MDE	NNP	O
)	)	O
recommend	VBP	O
using	VBG	O
either	CC	O
a	DT	O
mood	NN	O
stabilizer	NN	O
alone	RB	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
a	DT	O
mood	NN	O
stabilizer	NN	O
plus	CC	O
a	DT	O
selective	JJ	O
serotonin	NN	O
re-uptake	NN	O
inhibitor	NN	O
(	(	O
SSRI	NNP	O
)	)	O
.	.	O

This	DT	O
recommendation	NN	O
is	VBZ	O
the	DT	O
result	NN	O
of	IN	O
concern	NN	O
over	IN	O
antidepressant-induced	JJ	O
manic	JJ	O
switch	NN	O
episodes	NNS	O
.	.	O

However	RB	O
,	,	O
recent	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
manic	JJ	O
switch	NN	O
rate	NN	O
may	MD	O
be	VB	O
low	JJ	O
in	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
during	IN	O
SSRI	NNP	O
therapy	NN	O
.	.	O

METHODS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
relapse-prevention	NN	O
study	NN	O
of	IN	O
fluoxetine	JJ	PH
monotherapy	NN	PH
in	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
,	,	O
37	CD	O
patients	NNS	O
received	VBD	O
open-label	JJ	PM
fluoxetine	NN	PM
20	CD	PM
mg	NN	PM
every	DT	E
day	NN	E
for	IN	E
up	IN	E
to	TO	E
8	CD	E
weeks	NNS	E
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
(	(	O
HAM-D	NNP	O
17	CD	O
)	)	O
rating	NN	O
and	CC	O
the	DT	O
Young	NNP	O
Mania	NNP	O
Rating	NNP	O
(	(	O
YMR	NNP	O
)	)	O
scale	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
of	IN	O
23	CD	O
patients	NNS	O
(	(	O
48	CD	O
%	NN	O
)	)	O
who	WP	O
completed	VBD	O
8	CD	O
weeks	NNS	O
of	IN	O
fluoxetine	NN	PM
treatment	NN	O
showed	VBD	O
a	DT	O
HAM-D	JJ	O
17	CD	O
reduction	NN	O
of	IN	O
>	NN	O
or	CC	O
=50	CD	O
%	NN	O
,	,	O
while	IN	O
14	CD	O
(	(	O
38	CD	O
%	NN	O
)	)	O
of	IN	O
all	DT	O
treated	JJ	O
patients	NNS	O
had	VBD	O
>	VBN	O
or	CC	O
=50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
baseline	JJ	O
HAM-D	JJ	O
17	CD	O
score	NN	O
.	.	O

Using	VBG	O
a	DT	O
conservative	JJ	O
YMR	NNP	O
score	NN	O
of	IN	O
>	NN	O
or	CC	O
=8	VB	O
to	TO	O
identify	VB	O
hypomanic	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
patients	NNS	O
with	IN	O
YMR	NNP	O
score	NN	O
>	NN	O
or	CC	O
=8	NN	O
during	IN	O
fluoxetine	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
seen	VBN	O
during	IN	O
the	DT	O
screen	NN	O
and	CC	O
baseline	JJ	O
period	NN	O
.	.	O

Only	RB	O
three	CD	O
patients	NNS	O
(	(	O
7.3	CD	O
%	NN	O
)	)	O
had	VBD	O
symptoms	NNS	O
suggestive	JJ	O
of	IN	O
hypomania	NN	O
,	,	O
and	CC	O
only	RB	O
one	CD	O
patient	NN	O
stopped	VBD	O
treatment	NN	O
because	IN	O
of	IN	O
a	DT	O
rapid	JJ	O
mood	NN	O
swing	VBG	O
into	IN	O
depression	NN	O
.	.	O

LIMITATIONS	NNP	O
Fluoxetine	NNP	PM
was	VBD	O
given	VBN	O
at	IN	O
a	DT	O
fixed	JJ	O
dose	NN	O
of	IN	O
20	CD	O
mg	NNS	O
everyday	JJ	O
.	.	O

Fluoxetine	NNP	PM
was	VBD	O
prescribed	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
manner	NN	O
,	,	O
and	CC	O
the	DT	O
sample	NN	O
size	NN	O
was	VBD	O
limited	VBN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
observations	NNS	O
support	VBP	O
the	DT	O
findings	NNS	O
of	IN	O
a	DT	O
low	JJ	O
manic	JJ	O
switch	NN	O
rate	NN	O
during	IN	O
SSRI	NNP	O
monotherapy	NN	O
of	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
,	,	O
and	CC	O
suggest	VBP	O
that	IN	O
fluoxetine	JJ	PM
monotherapy	NN	PM
may	MD	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
initial	JJ	O
treatment	NN	O
of	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
.	.	O

Seven-star	NNP	PH
needle	JJ	PH
stimulation	NN	PH
improves	VBZ	O
language	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
that	WDT	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
Seven-star	NNP	PH
Needle	NNP	PH
Stimulation	NNP	PH
treatment	NN	O
on	IN	O
children	NNS	O
with	IN	O
Autistic	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Thirty-two	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
into	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
underwent	VBD	O
30	CD	O
sessions	NNS	O
of	IN	O
stimulation	NN	O
over	IN	O
6	CD	O
weeks	NNS	O
,	,	O
while	IN	O
children	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
on	IN	O
a	DT	O
waiting	VBG	O
list	NN	O
and	CC	O
did	VBD	O
not	RB	O
receive	VB	O
treatment	NN	O
during	IN	O
this	DT	O
period	NN	O
of	IN	O
time	NN	O
.	.	O

Intervention	NNP	O
consisted	VBD	O
of	IN	O
a	DT	O
treatment	NN	O
regime	NN	O
comprising	NN	O
of	IN	O
30	CD	PH
sessions	NNS	PH
of	IN	PH
Seven-star	NNP	PH
Needle	NNP	PH
Stimulation	NNP	PH
,	,	O
delivered	VBD	O
over	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Each	DT	O
session	NN	O
lasted	VBD	O
5	CD	O
to	TO	O
10	CD	O
min	NN	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
were	VBD	O
stimulated	VBN	O
at	IN	O
the	DT	O
front	NN	O
and	CC	O
back	RB	O
sides	NNS	O
of	IN	O
their	PRP$	O
body	NN	O
and	CC	O
the	DT	O
head	NN	O
by	IN	O
using	VBG	O
Seven-star	JJ	PH
Needles	NNP	PH
.	.	O

The	DT	O
change	NN	O
in	IN	O
the	DT	O
children	NNS	O
's	POS	O
behavior	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
parents	NNS	O
'	POS	O
report	NN	O
and	CC	O
neurophysiological	JJ	O
changes	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
quantitative	JJ	O
EEG	NNP	O
(	(	O
qEEG	NN	O
)	)	O
.	.	O

Results	CC	O
showed	VBD	O
that	IN	O
the	DT	O
treatment	NN	O
group	NN	O
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
language	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
stereotyped	JJ	O
behavior	NN	O
or	CC	O
motor	NN	O
function	NN	O
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

qEEG	JJ	O
spectral	JJ	O
amplitudes	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
were	VBD	O
also	RB	O
reduced	VBN	O
significantly	RB	O
.	.	O

The	DT	O
results	NNS	O
suggested	VBD	O
that	IN	O
Seven-star	NNP	PH
Needle	NNP	PH
Stimulation	NNP	PH
might	MD	O
be	VB	O
an	DT	O
effective	JJ	O
intervention	NN	O
to	TO	O
improve	VB	O
language	NN	O
and	CC	O
social	JJ	O
functioning	NN	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

A	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
on	IN	O
the	DT	O
influence	NN	O
of	IN	O
acetaminophen	NN	PM
,	,	O
diclofenac	NN	PM
,	,	O
or	CC	O
naproxen	RB	PM
on	IN	O
aspirin-induced	JJ	O
inhibition	NN	O
of	IN	O
platelet	NN	O
aggregation	NN	O
.	.	O

Nonsteroidal	NNP	PM
anti-inflammatory	JJ	PM
drugs	NNS	PM
(	(	PM
NSAID	NNP	PM
)	)	PM
may	MD	O
interfere	VB	O
with	IN	O
aspirin	NN	PM
(	(	PM
acetylsalicylic	JJ	PM
acid	NN	PM
)	)	PM
and	CC	O
increase	VB	O
the	DT	O
risk	NN	O
for	IN	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
relevance	NN	O
is	VBZ	O
uncertain	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
influence	NN	O
of	IN	O
a	DT	O
co-administration	NN	O
of	IN	O
aspirin	NN	PM
and	CC	O
NSAID	NNP	PM
on	IN	O
platelet	NN	O
aggregation	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
,	,	O
eleven	RB	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
studied	VBN	O
during	IN	O
4	CD	O
separate	JJ	O
study	NN	O
periods	NNS	O
of	IN	O
4	CD	O
days	NNS	O
each	DT	O
.	.	O

Individuals	NNS	O
were	VBD	O
treated	VBN	O
on	IN	O
each	DT	O
occasion	NN	O
with	IN	O
100	CD	O
mg	NNS	O
aspirin	JJ	PM
daily	RB	O
in	IN	O
combination	NN	O
with	IN	O
either	DT	O
3	CD	O
x	VBD	O
1	CD	O
g	NN	O
acetaminophen	NN	PM
,	,	O
3	CD	O
x	NN	O
50	CD	O
mg	NN	O
diclofenac	NN	PM
,	,	O
3	CD	O
x	NN	O
250	CD	O
mg	NN	O
naproxen	NN	PM
,	,	O
or	CC	O
3	CD	O
x	JJ	O
1	CD	O
placebo	NN	C
.	.	O

Primary	JJ	O
hemostasis	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
platelet	NN	O
function	NN	O
analyser	NN	O
(	(	O
PFA-100	NNP	O
)	)	O
,	,	O
which	WDT	O
measures	VBZ	O
the	DT	O
closure	NN	O
time	NN	O
(	(	O
CT	NNP	O
)	)	O
of	IN	O
a	DT	O
collagen-	JJ	O
and	CC	O
epinephrine-coated	JJ	O
pore	NN	O
by	IN	O
aggregating	VBG	O
platelets	NNS	O
in	IN	O
flowing	VBG	O
blood	NN	O
.	.	O

Naproxen	NNP	PM
enhanced	VBD	O
the	DT	O
anti-aggregatory	JJ	O
action	NN	O
of	IN	O
aspirin	NN	PM
after	IN	O
24	CD	O
h	NN	O
(	(	O
CT	NNP	O
rising	VBG	O
from	IN	O
104+/-16	JJ	O
s	NN	O
at	IN	O
baseline	NN	O
to	TO	O
212+/-69	JJ	O
s	NN	O
at	IN	O
24	CD	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
any	DT	O
other	JJ	O
drug	NN	O
combination	NN	O
.	.	O

Diclofenac	NNP	PM
reduced	VBD	O
the	DT	O
anti-aggregatory	JJ	O
action	NN	O
of	IN	O
aspirin	NN	PM
in	IN	O
the	DT	O
first	JJ	O
two	CD	O
days	NNS	O
,	,	O
since	IN	O
the	DT	O
CT	NNP	O
did	VBD	O
not	RB	O
rise	VB	O
significantly	RB	O
(	(	O
109+/-19	JJ	O
s	NN	O
,	,	O
148+/-56	JJ	O
s	NN	O
,	,	O
and	CC	O
168+/-66	JJ	O
s	NN	O
at	IN	O
0	CD	O
h	NN	O
,	,	O
24	CD	O
h	NN	O
,	,	O
48	CD	O
h	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Acetaminophen	NNP	PM
had	VBD	O
no	DT	O
effect	NN	O
compared	VBN	O
with	IN	O
placebo	NN	C
.	.	O

After	IN	O
4	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
platelet	NN	O
aggregation	NN	O
was	VBD	O
similarly	RB	O
inhibited	VBN	O
by	IN	O
all	DT	O
combinations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
co-administration	NN	O
of	IN	O
NSAID	NNP	PM
and	CC	O
aspirin	NN	PM
may	MD	O
interfere	VB	O
with	IN	O
platelet	NN	O
inhibition	NN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
a	DT	O
treatment	NN	O
with	IN	O
an	DT	O
increase	NN	O
of	IN	O
naproxen	JJ	PM
and	CC	O
a	DT	O
decrease	NN	O
of	IN	O
diclofenac	NN	PM
.	.	O

This	DT	O
effect	NN	O
is	VBZ	O
lost	VBN	O
after	IN	O
4	CD	O
days	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
a	DT	O
regular	JJ	O
daily	JJ	O
co-administration	NN	O
of	IN	O
NSAID	NNP	PM
does	VBZ	O
not	RB	O
have	VB	O
an	DT	O
influence	NN	O
on	IN	O
platelet	NN	O
inhibition	NN	O
by	IN	O
aspirin	NN	PM
.	.	O

Effect	NN	O
of	IN	O
adhesive	JJ	O
system	NN	O
type	NN	O
and	CC	O
tooth	DT	O
region	NN	O
on	IN	O
the	DT	O
bond	NN	O
strength	NN	O
to	TO	O
dentin	VB	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
bond	NN	O
strength	NN	O
of	IN	O
two	CD	O
etch-and-rinse	JJ	PH
adhesive	JJ	PH
systems	NNS	PH
(	(	O
two-	JJ	O
and	CC	O
three-step	NN	O
)	)	O
and	CC	PH
a	DT	PH
self-etching	JJ	PH
system	NN	PH
to	TO	O
coronal	VB	O
and	CC	O
root	VB	O
canal	JJ	O
dentin	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
root	NN	O
canals	NNS	O
of	IN	O
30	CD	O
human	JJ	O
incisors	NNS	O
and	CC	O
canines	NNS	O
were	VBD	O
instrumented	VBN	O
and	CC	O
prepared	VBN	O
with	IN	O
burs	NNS	O
.	.	O

The	DT	O
posts	NNS	PH
used	VBD	PH
for	IN	PH
luting	VBG	PH
were	VBD	PH
duplicated	VBN	PH
with	IN	PH
dual	JJ	PH
resin	NN	PH
cement	NN	PH
(	(	PH
Duo-link	NNP	PH
)	)	PH
inside	IN	PH
Aestheti	NNP	PH
Plus	NNP	PH
#	#	PH
2	CD	PH
molds	NNS	PH
.	.	O

Thus	RB	O
,	,	O
three	CD	O
groups	NNS	O
were	VBD	O
formed	VBN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
adhesive	JJ	O
system	NN	O
employed	VBN	O
:	:	O
All-Bond	JJ	Ot
2	CD	Ot
(	(	Ot
TE3	NNP	Ot
)	)	Ot
+	VBP	Ot
resin	JJ	Ot
cement	NN	Ot
post	NN	Ot
(	(	Ot
rcp	NN	Ot
)	)	Ot
+	VBZ	Ot
Duo-link	NNP	Ot
(	(	Ot
Dl	NNP	Ot
)	)	Ot
;	:	O
One-Step	JJ	Ot
Plus	NNP	Ot
(	(	Ot
TE2	NNP	Ot
)	)	Ot
+	VBP	Ot
rcp	JJ	Ot
+	NNP	Ot
Dl	NNP	Ot
;	:	Ot
Tyrian/One-Step	JJ	Ot
Plus	NNP	Ot
(	(	Ot
SE	NNP	Ot
)	)	Ot
+	VBP	Ot
rcp	JJ	Ot
+	NNP	Ot
Dl	NNP	Ot
.	.	O

Afterwards	NNP	O
,	,	O
8	CD	O
transverse	NN	O
sections	NNS	O
(	(	O
1.5	CD	O
mm	NN	O
)	)	O
were	VBD	O
cut	VBN	O
from	IN	O
4	CD	O
mm	NNS	O
above	IN	O
the	DT	O
CEJ	NNP	O
up	RB	O
to	TO	O
4	CD	O
mm	NNS	O
short	JJ	O
of	IN	O
the	DT	O
root	NN	O
canal	JJ	O
apex	NN	O
,	,	O
comprising	VBG	O
coronal	JJ	O
and	CC	O
root	JJ	O
canal	JJ	O
dentin	NN	O
.	.	O

The	DT	O
sections	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
push-out	JJ	O
testing	NN	O
in	IN	O
a	DT	O
universal	JJ	O
testing	VBG	O
machine	NN	O
EMIC	NNP	O
(	(	O
1	CD	O
mm/min	NN	O
)	)	O
.	.	O

Bond	NNP	O
strength	NN	O
data	NNS	O
were	VBD	O
analyzed	VBN	O
with	IN	O
two-way	JJ	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
and	CC	O
Tukey	NNP	O
's	POS	O
test	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
relationship	NN	O
between	IN	O
the	DT	O
adhesives	NNS	O
was	VBD	O
not	RB	O
the	DT	O
same	JJ	O
in	IN	O
the	DT	O
different	JJ	O
regions	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
means	NNS	O
achieved	VBN	O
with	IN	O
the	DT	O
adhesives	NNS	O
in	IN	O
each	DT	O
region	NN	O
(	(	O
Tukey	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.05	CD	O
)	)	O
revealed	VBD	O
that	IN	O
TE3	NNP	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
deviation	NN	O
:	:	O
5.22	CD	O
+/-	JJ	O
1.70	CD	O
)	)	O
was	VBD	O
higher	JJR	O
than	IN	O
TE2	NNP	O
(	(	O
2.60	CD	O
+/-	JJ	O
1.74	CD	O
)	)	O
and	CC	O
SE	NNP	O
(	(	O
1.68	CD	O
+/-	JJ	O
1.85	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Under	IN	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
,	,	O
better	JJR	O
bonding	VBG	O
to	TO	O
dentin	VB	O
was	VBD	O
achieved	VBN	O
using	VBG	O
the	DT	O
three-step	JJ	O
etch-and-rinse	JJ	O
system	NN	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
coronal	JJ	O
region	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
traditional	JJ	O
etch-and-rinse	JJ	O
three-step	NN	O
adhesive	JJ	O
system	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
best	JJS	O
choice	NN	O
for	IN	O
teeth	NN	O
needing	VBG	O
adhesive	JJ	O
endodontic	JJ	O
restorations	NNS	O
.	.	O

Amphotericin	NNP	PM
B	NNP	PM
in	IN	O
children	NNS	O
with	IN	O
malignant	JJ	O
disease	NN	O
:	:	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
toxicities	NNS	O
and	CC	O
pharmacokinetics	NNS	O
of	IN	O
amphotericin	NN	PM
B	NNP	PM
administered	VBN	PM
in	IN	PM
dextrose	JJ	PM
versus	NN	O
lipid	JJ	PM
emulsion	NN	PM
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
toxicity	NN	O
of	IN	O
1	CD	O
mg	NN	O
of	IN	O
amphotericin	NN	PM
B	NNP	PM
(	(	PM
AmB	NNP	PM
)	)	PM
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
day	NN	O
infused	VBN	O
in	IN	O
5	CD	O
%	NN	O
dextrose	NN	PM
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
AmB	NNP	PM
infused	VBD	PM
in	IN	PM
lipid	JJ	PM
emulsion	NN	PM
in	IN	O
children	NNS	O
with	IN	O
malignant	JJ	O
disease	NN	O
.	.	O

In	IN	O
an	DT	O
analysis	NN	O
of	IN	O
82	CD	O
children	NNS	O
who	WP	O
received	VBD	O
a	DT	O
full	JJ	O
course	NN	O
of	IN	O
6	CD	O
days	NNS	O
or	CC	O
more	JJR	O
of	IN	O
AmB	NNP	PM
(	(	O
117	CD	O
courses	NNS	O
)	)	O
,	,	O
it	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
there	EX	O
were	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
plasma	JJ	O
urea	JJ	O
and	CC	O
creatinine	JJ	O
concentrations	NNS	O
and	CC	O
in	IN	O
potassium	NN	O
requirement	NN	O
after	IN	O
6	CD	O
days	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
both	DT	O
AmB	NNP	PM
infused	VBN	O
in	IN	O
dextrose	NN	PM
and	CC	O
AmB	NNP	PM
infused	VBD	O
in	IN	O
lipid	JJ	PM
emulsion	NN	PM
,	,	O
with	IN	O
there	EX	O
being	VBG	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
of	IN	O
AmB	NNP	PM
administration	NN	O
.	.	O

An	DT	O
intent-to-treat	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
numbers	NNS	O
of	IN	O
courses	NNS	O
affected	VBN	O
by	IN	O
acute	JJ	O
toxicity	NN	O
(	(	O
fever	NN	O
,	,	O
rigors	NNS	O
)	)	O
and	CC	O
chronic	JJ	O
toxicity	NN	O
(	(	O
nephrotoxicity	NN	O
)	)	O
also	RB	O
indicated	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
AmB	NNP	PM
infused	VBD	O
in	IN	O
dextrose	NN	PM
(	(	O
78	CD	O
courses	NNS	O
)	)	O
and	CC	O
AmB	NNP	PM
infused	VBD	PM
in	IN	PM
lipid	JJ	PM
emulsion	NN	PM
(	(	O
84	CD	O
courses	NNS	O
)	)	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
of	IN	O
AmB	NNP	PM
were	VBD	O
investigated	VBN	O
in	IN	O
20	CD	O
children	NNS	O
who	WP	O
received	VBD	O
AmB	NNP	PM
in	IN	O
dextrose	NN	PM
and	CC	O
15	CD	O
children	NNS	O
who	WP	O
received	VBD	O
AmB	NNP	PM
in	IN	PM
lipid	JJ	PM
emulsion	NN	PM
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
up	RB	O
to	TO	O
24	CD	O
h	NN	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
first	JJ	O
dose	NN	O
,	,	O
and	CC	O
the	DT	O
concentration	NN	O
of	IN	O
AmB	NNP	PM
in	IN	O
plasma	NN	O
was	VBD	O
analyzed	VBN	O
by	IN	O
a	DT	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
assay	NN	O
.	.	O

The	DT	O
clearance	NN	O
(	(	O
CL	NNP	O
)	)	O
of	IN	O
AmB	NNP	PM
in	IN	PM
dextrose	NN	PM
(	(	O
0.039	CD	O
+/-	JJ	O
0.016	CD	O
liter	NN	O
.	.	O

h-1	NN	O
.	.	O

kg-1	NN	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
than	IN	O
the	DT	O
CL	NNP	O
of	IN	O
AmB	NNP	PM
in	IN	PM
lipid	JJ	PM
emulsion	NN	PM
(	(	O
0.062	CD	O
+/-	JJ	O
0	CD	O
.	.	O

024	CD	O
liter	NN	O
.	.	O

h-1	NN	O
.	.	O

kg-1	NN	O
)	)	O
.	.	O

The	DT	O
steady-state	JJ	O
volume	NN	O
of	IN	O
distribution	NN	O
for	IN	O
AmB	NNP	O
in	IN	O
dextrose	NN	O
(	(	O
0.83	CD	O
+/-	JJ	O
0.33	CD	O
liter	NN	O
.	.	O

kg-1	NN	O
)	)	O
was	VBD	O
also	RB	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
than	IN	O
that	DT	O
for	IN	O
AmB	NNP	PM
in	IN	PM
lipid	JJ	PM
emulsion	NN	PM
(	(	O
1.47	CD	O
+/-	JJ	O
0.77	CD	O
liter	NN	O
.	.	O

kg-1	NN	O
)	)	O
.	.	O

Although	IN	O
AmB	NNP	PM
in	IN	PM
lipid	JJ	PM
emulsion	NN	PM
is	VBZ	O
apparently	RB	O
cleared	VBN	O
faster	RBR	O
and	CC	O
distributes	VBZ	O
more	RBR	O
widely	RB	O
than	IN	O
AmB	NNP	PM
in	IN	PM
dextrose	NN	PM
,	,	O
this	DT	O
study	NN	O
did	VBD	O
not	RB	O
reveal	VB	O
any	DT	O
significant	JJ	O
advantage	NN	O
with	IN	O
respect	NN	O
to	TO	O
safety	NN	O
and	CC	O
tolerance	NN	O
in	IN	O
the	DT	O
administration	NN	O
of	IN	O
AmB	NNP	PM
in	IN	O
lipid	JJ	O
emulsion	NN	O
compared	VBN	O
to	TO	O
its	PRP$	O
administration	NN	O
in	IN	O
dextrose	NN	PM
in	IN	O
children	NNS	O
with	IN	O
malignant	JJ	O
disease	NN	O
.	.	O

Randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
crossover	NN	O
study	NN	O
of	IN	O
methylphenidate	NN	PM
for	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
symptoms	NNS	O
in	IN	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
methylphenidate	NN	PM
(	(	PM
MPH	NNP	PM
)	)	PM
to	TO	O
treat	VB	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
symptoms	NNS	O
in	IN	O
an	DT	O
understudied	JJ	O
population	NN	O
of	IN	O
preschoolers	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
(	(	O
PDD	NNP	O
)	)	O
or	CC	O
intellectual	JJ	O
disability	NN	O
(	(	O
ID	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Fourteen	NNP	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
(	(	O
DD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
14	CD	O
;	:	O
PDD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
12	CD	O
;	:	O
ID	NNP	O
,	,	O
n	JJ	O
=	NNP	O
2	CD	O
)	)	O
underwent	NN	O
MPH	NNP	PM
titration	NN	PM
in	IN	O
a	DT	O
single-blind	JJ	O
manner	NN	O
followed	VBN	O
by	IN	O
a	DT	O
4-week	JJ	O
double-blind	NN	O
crossover	NN	O
phase	NN	O
.	.	O

Each	DT	O
child	NN	O
was	VBD	O
administered	VBN	O
placebo	NN	C
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
optimal	JJ	PM
dose	NN	PM
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
4	CD	O
(	(	O
th	NN	O
)	)	O
edition	NN	O
(	(	O
DSM-IV	NNP	O
)	)	O
ADHD	NNP	O
subscale	NN	O
of	IN	O
the	DT	O
Conners	NNP	O
'	POS	O
Parent	NN	O
Rating	VBG	O
Scale-Revised	JJ	O
(	(	O
CPRS-R-DSM-IV-ADHD	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
MPH	NNP	PM
improved	VBD	O
parent-rated	JJ	O
ADHD	NNP	O
symptoms	NNS	O
of	IN	O
the	DT	O
preschoolers	NNS	O
;	:	O
50	CD	O
%	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
responders	NNS	O
.	.	O

The	DT	O
CPRS-R-DSM-IV-ADHD	JJ	O
subscale	NN	O
was	VBD	O
significant	JJ	O
for	IN	O
the	DT	O
PDD	NNP	O
subgroup	NN	O
(	(	O
p	JJ	O
=	NN	O
0.005	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.97	CD	O
)	)	O
and	CC	O
marginally	RB	O
significant	JJ	O
for	IN	O
the	DT	O
entire	JJ	O
DD	NNP	O
sample	NN	O
(	(	O
p	JJ	O
=	NN	O
0.08	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.50	CD	O
)	)	O
.	.	O

Half	NN	O
of	IN	O
the	DT	O
preschoolers	NNS	O
experienced	VBD	O
side	JJ	O
effects	NNS	O
with	IN	O
MPH	NNP	PM
,	,	O
including	VBG	O
reports	NNS	O
of	IN	O
increased	VBN	O
stereotypic	NN	O
behavior	NN	O
,	,	O
upset	JJ	O
stomach	NN	O
,	,	O
sleep-related	JJ	O
difficulties	NNS	O
,	,	O
and	CC	O
emotional	JJ	O
lability	NN	O
.	.	O

One	CD	O
child	NN	O
discontinued	VBN	O
during	IN	O
titration	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
predominant	JJ	O
direction	NN	O
of	IN	O
response	NN	O
in	IN	O
these	DT	O
preschoolers	NNS	O
with	IN	O
both	DT	O
ADHD	NNP	O
and	CC	O
PDD/ID	NNP	O
favored	VBD	O
MPH	NNP	PM
,	,	O
even	RB	O
though	IN	O
the	DT	O
response	NN	O
was	VBD	O
more	RBR	O
subtle	JJ	O
and	CC	O
variable	JJ	O
than	IN	O
in	IN	O
older	JJR	O
and	CC	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

Due	NNP	O
to	TO	O
high	JJ	O
rates	NNS	O
of	IN	O
adverse	JJ	O
effects	NNS	O
,	,	O
preschoolers	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
.	.	O

Effect	NN	O
of	IN	O
intravenous	JJ	PM
fructose-1,6-diphosphate	NN	PM
on	IN	O
myocardial	JJ	O
contractility	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
dysfunction	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
fructose-1,6-diphosphate	NN	PM
on	IN	O
myocardial	JJ	O
performance	NN	O
using	VBG	O
nuclear	JJ	O
scintigraphy	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
single-blind	JJ	O
,	,	O
parallel	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
Urban	NNP	O
teaching	VBG	O
hospital	JJ	O
clinical	JJ	O
research	NN	O
center	NN	O
.	.	O

PATIENTS	JJ	O
Individuals	NNS	O
with	IN	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
functional	JJ	O
class	NN	O
II-III	NNP	O
heart	NN	O
failure	NN	O
(	(	O
mild	JJ	O
to	TO	O
moderate	VB	O
)	)	O
.	.	O

INTERVENTIONS	JJ	O
Subjects	NNPS	O
received	VBD	O
either	DT	O
intravenous	JJ	PM
fructose-1,6-diphosphate	JJ	PM
125	CD	PM
mg/kg	NN	PM
or	CC	O
normal	JJ	PM
saline	JJ	PM
1.3	CD	O
ml/kg	NN	O
every	DT	O
12	CD	O
hours	NNS	O
over	IN	O
10	CD	O
minutes	NNS	O
for	IN	O
four	CD	O
consecutive	JJ	O
doses	NNS	O
.	.	O

Left	NNP	O
ventricular	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
radionuclide	NN	PH
ventriculography	NN	PH
at	IN	O
baseline	NN	O
and	CC	O
within	IN	O
60	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
fourth	JJ	O
infusion	NN	O
.	.	O

Vital	JJ	O
signs	NNS	O
were	VBD	O
monitored	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Fructose-1,6-diphosphate	NNP	PM
resulted	VBD	O
in	IN	O
a	DT	O
modest	JJ	O
7	CD	O
%	NN	O
increase	NN	O
in	IN	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Peak	JJ	O
ejection	NN	O
rate	NN	O
and	CC	O
peak	VB	O
diastolic	JJ	O
filling	VBG	O
rate	NN	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
changes	NNS	O
in	IN	O
blood	NN	O
pressure	NN	O
or	CC	O
heart	NN	O
rate	NN	O
with	IN	O
either	DT	O
fructose-1,6-diphosphate	JJ	PM
or	CC	O
placebo	NN	C
.	.	O

CONCLUSIONS	NNP	O
Fructose-1,6-diphosphate	NNP	PM
produces	VBZ	O
a	DT	O
modest	JJ	O
but	CC	O
significant	JJ	O
increase	NN	O
in	IN	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
heart	NN	O
failure	NN	O
.	.	O

Preschool	NNP	O
based	VBN	O
JASPER	NNP	E
intervention	NN	E
in	IN	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
pilot	NN	O
RCT	NNP	O
.	.	O

In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
we	PRP	O
tested	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
novel	JJ	O
intervention	NN	O
(	(	E
JASPER	NNP	E
,	,	E
Joint	NNP	E
Attention	NNP	E
Symbolic	NNP	E
Play	NNP	E
Engagement	NNP	E
and	CC	E
Regulation	NNP	E
)	)	E
on	IN	O
3	CD	O
to	TO	O
5	CD	O
year	NN	O
old	JJ	O
,	,	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
who	WP	O
were	VBD	O
attending	VBG	O
a	DT	O
non-public	JJ	O
preschool	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
treatment	NN	O
as	IN	O
usual	JJ	O
,	,	O
30	CD	O
h	NN	O
of	IN	O
ABA-based	JJ	O
therapy	NN	O
per	IN	O
week	NN	O
)	)	O
or	CC	O
a	DT	O
treatment	NN	O
group	NN	O
(	(	O
substitution	NN	O
of	IN	O
30	CD	O
min	NN	O
of	IN	O
JASPER	NNP	O
treatment	NN	O
,	,	O
twice	RB	O
weekly	RB	O
during	IN	O
their	PRP$	O
regular	JJ	O
program	NN	O
)	)	O
.	.	O

A	DT	O
baseline	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
in	IN	O
which	WDT	O
no	DT	O
changes	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
core	NN	O
deficits	NNS	O
was	VBD	O
followed	VBN	O
by	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
intervention	NN	O
for	IN	O
children	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
JASPER	NNP	O
treatment	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
demonstrated	VBD	O
greater	JJR	O
play	NN	O
diversity	NN	O
on	IN	O
a	DT	O
standardized	JJ	O
assessment	NN	O
.	.	O

Effects	NNS	O
also	RB	O
generalized	VBD	O
to	TO	O
the	DT	O
classroom	NN	O
,	,	O
where	WRB	O
participants	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
initiated	VBD	O
more	JJR	O
gestures	NNS	O
and	CC	O
spent	VB	O
less	JJR	O
time	NN	O
unengaged	JJ	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
further	JJ	O
support	NN	O
that	WDT	O
even	RB	O
brief	VBP	O
,	,	O
targeted	JJ	O
interventions	NNS	O
on	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
play	NN	O
can	MD	O
improve	VB	O
core	NN	O
deficits	NNS	O
in	IN	O
minimally	RB	O
verbal	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Serum	NNP	O
selenium	NN	PM
concentration	NN	O
and	CC	O
antioxidant	JJ	O
activity	NN	O
in	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

AIM	NNP	O
In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
chemo	NN	O
and	CC	O
radio	NN	O
therapies	NNS	O
on	IN	O
serum	NN	O
trace	NN	O
elements	NNS	O
content	NN	O
and	CC	O
antioxidant	JJ	O
activity	NN	O
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
was	VBD	O
evaluated	VBN	O
.	.	O

METHODS	NNP	O
Among	IN	O
104	CD	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
selected	VBN	O
for	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
54	CD	O
and	CC	O
50	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
chemo-	JJ	PH
and	CC	PH
radiotherapy	NN	PH
respectively	RB	O
.	.	O

Plasma	NNP	O
Se	NNP	O
,	,	O
Zn	NNP	O
,	,	O
Cu	NNP	O
and	CC	O
some	DT	O
enzymatic	JJ	O
antioxidants	NNS	O
activities	NNS	O
were	VBD	O
estimated	VBN	O
in	IN	O
serum	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
decreased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
trace	NN	O
elements	NNS	O
,	,	O
glutathione	NN	O
peroxidase	NN	O
activity	NN	O
and	CC	O
total	JJ	O
antioxidant	JJ	O
capacity	NN	O
,	,	O
and	CC	O
increased	VBD	O
malondialdehyde	NN	O
,	,	O
glutathion	NN	O
reductase	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
healthy	JJ	O
controls	NNS	O
.	.	O

The	DT	O
increased	JJ	O
concentration	NN	O
of	IN	O
serum	NN	O
Se	NNP	O
,	,	O
Zn	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	PM
.	.	O

Simultaneously	RB	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
increase	NN	O
in	IN	O
glutathione	JJ	O
peroxidase	NN	O
and	CC	O
total	JJ	O
antioxidant	JJ	O
capacity	NN	O
,	,	O
and	CC	O
significant	JJ	O
decrease	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
malondialdehyde	NN	O
and	CC	O
glutathion	NN	O
reductase	NN	O
levels	NNS	O
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	PM
compared	VBN	O
to	TO	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
radiotherapy	NN	PH
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
chemotherapy	NN	PM
but	CC	O
not	RB	O
radiotherapy	JJ	PH
results	NNS	O
in	IN	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
trace	NN	O
elements	NNS	O
levels	NNS	O
and	CC	O
antioxidant	JJ	O
activities	NNS	O
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

Caudal	NNP	O
analgesia	NN	O
for	IN	O
perianal	JJ	O
surgery	NN	O
.	.	O

A	DT	O
comparison	NN	O
between	IN	O
bupivacaine	NN	PM
and	CC	O
diamorphine	NN	PM
.	.	O

Seventy-three	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
perianal	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
control	NN	O
group	NN	O
,	,	O
a	DT	O
group	NN	O
who	WP	O
received	VBD	O
a	DT	O
caudal	JJ	O
injection	NN	O
of	IN	O
20	CD	O
ml	NNS	O
bupivacaine	VBP	PM
0.5	CD	O
%	NN	O
plain	NN	O
and	CC	O
a	DT	O
group	NN	O
who	WP	O
received	VBD	O
diamorphine	JJ	PM
2.5	CD	O
mg	NN	O
in	IN	O
10	CD	O
ml	NNS	O
normal	JJ	O
saline	NN	O
by	IN	O
caudal	JJ	PM
injection	NN	PM
;	:	O
a	DT	O
comparison	NN	O
was	VBD	O
then	RB	O
made	VBN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
requirements	NNS	O
.	.	O

The	DT	O
bupivacaine	NN	PM
group	NN	O
had	VBD	O
better	JJR	O
analgesia	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
first	JJ	O
8	CD	O
hours	NNS	O
,	,	O
after	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
.	.	O

The	DT	O
diamorphine	NN	PM
group	NN	O
had	VBD	O
better	JJR	O
analgesia	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
postoperatively	RB	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
less	RBR	O
in	IN	O
the	DT	O
diamorphine	NN	PM
group	NN	O
than	IN	O
the	DT	O
control	NN	O
,	,	O
or	CC	O
the	DT	O
bupivacaine	NN	PM
group	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
41	CD	O
%	NN	O
of	IN	O
the	DT	O
bupivacaine	NN	PM
group	NN	O
complained	VBD	O
of	IN	O
some	DT	O
degree	NN	O
of	IN	O
urinary	JJ	O
retention	NN	O
and	CC	O
one	CD	O
patient	NN	O
required	VBN	O
temporary	JJ	O
catheterisation	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
caudal	JJ	O
diamorphine	NN	PM
gives	VBZ	O
good	JJ	O
postoperative	JJ	O
analgesia	NN	O
for	IN	O
perianal	JJ	O
operations	NNS	O
,	,	O
particularly	RB	O
when	WRB	O
motor	NN	O
blockade	NN	O
is	VBZ	O
not	RB	O
wanted	VBN	O
by	IN	O
the	DT	O
surgeon	NN	O
.	.	O

Cognitive	JJ	E
behavioral	JJ	E
therapy	NN	E
for	IN	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
often	RB	O
present	JJ	O
with	IN	O
comorbid	NN	O
anxiety	NN	O
disorders	NNS	O
that	WDT	O
cause	VBP	O
significant	JJ	O
functional	JJ	O
impairment	NN	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
a	DT	O
modular	JJ	O
cognitive	JJ	E
behavioral	JJ	E
therapy	NN	E
(	(	E
CBT	NNP	E
)	)	E
program	NN	O
for	IN	O
children	NNS	O
with	IN	O
this	DT	O
profile	NN	O
.	.	O

A	DT	O
standard	JJ	O
CBT	NNP	E
program	NN	O
was	VBD	O
augmented	VBN	O
with	IN	O
multiple	JJ	O
treatment	NN	O
components	NNS	O
designed	VBN	O
to	TO	O
accommodate	VB	O
or	CC	O
remediate	VB	O
the	DT	O
social	JJ	O
and	CC	O
adaptive	JJ	O
skill	NN	O
deficits	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
that	WDT	O
could	MD	O
pose	VB	O
barriers	NNS	O
to	TO	O
anxiety	VB	O
reduction	NN	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
(	(	O
7-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
CBT	NNP	E
or	CC	O
a	DT	O
3-month	JJ	E
waitlist	NN	E
(	(	O
36	CD	O
completed	VBN	O
treatment	NN	O
or	CC	O
waitlist	NN	O
)	)	O
.	.	O

Therapists	NNS	O
worked	VBD	O
with	IN	O
individual	JJ	O
families	NNS	O
.	.	O

The	DT	O
CBT	NNP	E
model	NN	O
emphasized	VBD	O
behavioral	JJ	O
experimentation	NN	O
,	,	O
parent-training	NN	O
,	,	O
and	CC	O
school	NN	O
consultation	NN	O
.	.	O

Independent	JJ	O
evaluators	NNS	O
blind	VBP	O
to	TO	O
treatment	NN	O
condition	NN	O
conducted	VBN	O
structured	JJ	O
diagnostic	JJ	O
interviews	NNS	O
and	CC	O
parents	NNS	O
and	CC	O
children	NNS	O
completed	VBN	O
anxiety	NN	O
symptom	NN	O
checklists	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
posttreatment/postwaitlist	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
intent-to-treat	JJ	O
analyses	NNS	O
,	,	O
78.5	CD	O
%	NN	O
of	IN	O
the	DT	O
CBT	NNP	E
group	NN	O
met	VBD	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NNP	O
scale	NN	O
criteria	NNS	O
for	IN	O
positive	JJ	O
treatment	NN	O
response	NN	O
at	IN	O
posttreatment	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
only	RB	O
8.7	CD	O
%	NN	O
of	IN	O
the	DT	O
waitlist	NN	E
group	NN	O
.	.	O

CBT	NNP	E
also	RB	O
outperformed	VBD	O
the	DT	O
waitlist	NN	E
on	IN	O
diagnostic	JJ	O
outcomes	NNS	O
and	CC	O
parent	NN	O
reports	NNS	O
of	IN	O
child	NN	O
anxiety	NN	O
,	,	O
but	CC	O
not	RB	O
children	NNS	O
's	POS	O
self-reports	NNS	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
CBT	NNP	E
manual	JJ	O
employed	VBN	O
in	IN	O
this	DT	O
study	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
adaptations	NNS	O
of	IN	O
an	DT	O
evidence-based	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Remission	NN	O
of	IN	O
anxiety	NN	O
disorders	NNS	O
appears	VBZ	O
to	TO	O
be	VB	O
an	DT	O
achievable	JJ	O
goal	NN	O
among	IN	O
high-functioning	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Reversal	NNP	O
of	IN	O
skeletal	JJ	O
effects	NNS	O
of	IN	O
endocrine	NN	O
treatments	NNS	O
in	IN	O
the	DT	O
Intergroup	NNP	O
Exemestane	NNP	O
Study	NNP	O
.	.	O

The	DT	O
adjuvant	JJ	O
use	NN	O
of	IN	O
aromatase	NN	PM
inhibitors	NNS	PM
in	IN	O
breast	NN	O
cancer	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
adverse	JJ	O
effects	NNS	O
on	IN	O
bone	NN	O
health	NN	O
.	.	O

We	PRP	O
previously	RB	O
reported	VBD	O
a	DT	O
decline	NN	O
in	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
following	VBG	O
the	DT	O
switch	NN	O
from	IN	O
tamoxifen	NN	PM
to	TO	O
exemestane	VB	PM
in	IN	O
the	DT	O
Intergroup	NNP	O
Exemestane	NNP	O
Study	NNP	O
(	(	O
IES	NNP	O
)	)	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
effects	NNS	O
of	IN	O
endocrine	JJ	PM
treatment	NN	PM
withdrawal	NN	O
on	IN	O
BMD	NNP	O
,	,	O
bone	NN	O
turnover	NN	O
markers	NNS	O
(	(	O
BTM	NNP	O
)	)	O
and	CC	O
fracture	JJ	O
rates	NNS	O
.	.	O

4,724	CD	O
patients	NNS	O
took	VBD	O
part	NN	O
in	IN	O
IES	NNP	O
,	,	O
and	CC	O
206	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
bone	NN	O
sub-study	NN	O
.	.	O

BMD	NNP	O
and	CC	O
BTM	NNP	O
were	VBD	O
assessed	VBN	O
pre-randomization	NN	O
,	,	O
during	IN	O
and	CC	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
EOT	NNP	O
)	)	O
.	.	O

To	TO	O
evaluate	VB	O
treatment	NN	O
withdrawal	NN	O
effects	NNS	O
,	,	O
12-	JJ	O
and	CC	O
24-month	JJ	O
post	NN	O
EOT	NNP	O
BMD	NNP	O
results	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
122	CD	O
and	CC	O
126	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

Similar	JJ	O
patient	NN	O
numbers	NNS	O
had	VBD	O
BTM	NNP	O
measured	VBD	O
post	NN	O
EOT	NNP	O
.	.	O

Following	VBG	O
treatment	NN	O
withdrawal	NN	O
,	,	O
the	DT	O
differences	NNS	O
in	IN	O
BMD	NNP	O
observed	VBD	O
between	IN	O
the	DT	O
two	CD	O
endocrine	NN	O
strategies	NNS	O
were	VBD	O
partially	RB	O
reversed	VBN	O
.	.	O

At	IN	O
24	CD	O
months	NNS	O
from	IN	O
EOT	NNP	O
,	,	O
spine	JJ	O
BMD	NNP	O
increased	VBN	O
by	IN	O
1.53	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.63-2.43	CD	O
;	:	O
p	CC	O
=	VB	O
0.001	CD	O
)	)	O
after	IN	O
stopping	VBG	O
exemestane	NN	O
and	CC	O
fell	VBD	O
by	IN	O
1.93	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-2.91	NNP	O
to	TO	O
0.95	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.0002	CD	O
)	)	O
following	VBG	O
tamoxifen	NN	PM
withdrawal	NN	O
.	.	O

A	DT	O
similar	JJ	O
pattern	NN	O
of	IN	O
changes	NNS	O
was	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
hip	NN	O
.	.	O

At	IN	O
2	CD	O
years	NNS	O
post	RB	O
EOT	NNP	O
,	,	O
BMD	NNP	O
changes	NNS	O
from	IN	O
baseline	NN	O
were	VBD	O
similar	JJ	O
with	IN	O
both	DT	O
treatment	NN	O
strategies	NNS	O
.	.	O

Corresponding	VBG	O
inverse	JJ	O
changes	NNS	O
in	IN	O
BTM	NNP	O
were	VBD	O
seen	VBN	O
,	,	O
with	IN	O
an	DT	O
increase	NN	O
following	VBG	O
tamoxifen	JJ	O
withdrawal	NN	O
and	CC	O
a	DT	O
reduction	NN	O
after	IN	O
exemestane	NN	O
.	.	O

A	DT	O
higher	JJR	O
number	NN	O
of	IN	O
fractures	NNS	O
occurred	VBD	O
during	IN	O
exemestane	NN	PM
treatment	NN	O
,	,	O
but	CC	O
fracture	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
after	IN	O
treatment	NN	O
withdrawal	NN	O
.	.	O

With	IN	O
the	DT	O
switch	NN	O
strategy	NN	O
used	VBN	O
in	IN	O
IES	NNP	O
,	,	O
the	DT	O
on	IN	O
treatment	NN	O
adverse	JJ	O
bone	NN	O
effects	NNS	O
of	IN	O
exemestane	NN	PM
are	VBP	O
reversed	VBN	O
.	.	O

Ongoing	VBG	O
monitoring	NN	O
of	IN	O
BMD	NNP	O
is	VBZ	O
therefore	RB	O
not	RB	O
routinely	RB	O
required	VBN	O
.	.	O

Osteopontin	NNP	PM
is	VBZ	O
a	DT	O
prognostic	JJ	O
factor	NN	O
for	IN	O
survival	NN	O
of	IN	O
acute	JJ	O
myeloid	JJ	O
leukemia	NN	O
patients	NNS	O
.	.	O

Osteopontin	NNP	PM
(	(	O
OPN	NNP	O
)	)	O
is	VBZ	O
a	DT	O
glycoprotein	NN	O
that	WDT	O
is	VBZ	O
secreted	VBN	O
by	IN	O
osteoblasts	NNS	O
and	CC	O
hematopoietic	JJ	O
cells	NNS	O
.	.	O

OPN	NNP	PM
suppresses	VBZ	O
the	DT	O
proliferation	NN	O
of	IN	O
hematopoietic	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
vitro	NN	O
and	CC	O
may	MD	O
regulate	VB	O
the	DT	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
pool	NN	O
.	.	O

Increased	VBN	O
serum	NN	O
OPN	NNP	O
concentrations	NNS	O
occur	VBP	O
in	IN	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
,	,	O
multiple	JJ	O
myeloma	NN	O
,	,	O
and	CC	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
(	(	O
AML	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
we	PRP	O
analyzed	VBD	O
the	DT	O
prognostic	JJ	O
impact	NN	O
of	IN	O
OPN	NNP	O
in	IN	O
AML	NNP	O
by	IN	O
investigating	VBG	O
the	DT	O
expression	NN	O
and	CC	O
relevance	NN	O
of	IN	O
OPN	NNP	PM
in	IN	O
newly	RB	O
diagnosed	VBN	O
AML	NNP	O
patients	NNS	O
from	IN	O
2	CD	O
large	JJ	O
study	NN	O
groups	NNS	O
(	(	O
the	DT	O
German	JJ	O
AML	NNP	O
Cooperative	NNP	O
Group	NNP	O
and	CC	O
the	DT	O
Dutch-Belgian	JJ	O
Hematology	NNP	O
Oncology	NNP	O
Cooperative	NNP	O
group	NN	O
)	)	O
.	.	O

IHC	NNP	O
(	(	O
n	JJ	O
=	NNP	O
84	CD	O
)	)	O
,	,	O
ELISAs	NNP	O
of	IN	O
blood/BM	NN	O
sera	NN	O
(	(	O
n	JJ	O
=	NNP	O
41	CD	O
)	)	O
,	,	O
and	CC	O
microarray	NN	PM
data	NNS	PM
for	IN	PM
mRNA	NN	PM
levels	NNS	PM
(	(	O
n	JJ	O
=	NNP	O
261	CD	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

Expression	NN	O
of	IN	O
OPN	NNP	PM
protein	NN	O
was	VBD	O
increased	VBN	O
in	IN	O
AML	NNP	O
patients	NNS	O
both	DT	O
in	IN	O
BM	NNP	O
blasts	NNS	O
(	(	O
IHC	NNP	O
)	)	O
and	CC	O
in	IN	O
BM	NNP	O
serum	NN	O
(	(	O
ELISA	NNP	O
)	)	O
compared	VBN	O
with	IN	O
healthy	JJ	O
controls	NNS	O
.	.	O

Patients	NNS	O
expressing	VBG	O
high	JJ	O
levels	NNS	O
of	IN	O
OPN	NNP	O
within	IN	O
the	DT	O
BM	NNP	O
(	(	O
IHC	NNP	O
)	)	O
experienced	VBD	O
shortened	VBN	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.025	NNP	O
)	)	O
.	.	O

Multivariate	NNP	O
analysis	NN	O
identified	VBD	O
karyotype	NN	O
,	,	O
blast	JJ	O
clearance	NN	O
(	(	O
day	NN	O
16	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
level	NN	O
of	IN	O
OPN	NNP	O
expression	NN	O
as	IN	O
independent	JJ	O
prognostic	JJ	O
factors	NNS	O
for	IN	O
OS	NNP	O
.	.	O

This	DT	O
prompted	VBD	O
us	PRP	O
to	TO	O
analyze	VB	O
microarray	NN	O
data	NNS	O
from	IN	O
261	CD	O
patients	NNS	O
from	IN	O
a	DT	O
third	JJ	O
cohort	NN	O
.	.	O

The	DT	O
analysis	NN	O
confirmed	VBD	O
OPN	NNP	O
as	IN	O
a	DT	O
prognostic	JJ	O
marker	NN	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
high	JJ	O
OPN	NNP	PM
mRNA	NN	O
expression	NN	O
indicated	VBD	O
decreased	JJ	O
event-free	JJ	O
survival	NN	O
(	(	O
P	NNP	O
=	NNP	O
.0002	NNP	O
)	)	O
and	CC	O
OS	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
prognostic	JJ	O
role	NN	O
of	IN	O
OPN	NNP	O
was	VBD	O
most	RBS	O
prominent	JJ	O
in	IN	O
intermediate-risk	JJ	O
AML	NNP	O
.	.	O

These	DT	O
data	NNS	O
provide	VBP	O
evidence	NN	O
that	IN	O
OPN	NNP	O
expression	NN	O
is	VBZ	O
an	DT	O
independent	JJ	O
prognostic	JJ	O
factor	NN	O
in	IN	O
AML	NNP	O
.	.	O

Pazopanib	NNP	PM
in	IN	O
locally	RB	O
advanced	JJ	O
or	CC	O
metastatic	JJ	O
renal	NN	O
cell	NN	O
carcinoma	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Pazopanib	NNP	PM
is	VBZ	O
an	DT	O
oral	JJ	PM
angiogenesis	NN	PM
inhibitor	NN	PM
targeting	VBG	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
platelet-derived	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
and	CC	O
c-Kit	NN	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
phase	NN	O
III	NNP	O
study	NN	O
evaluated	VBD	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
pazopanib	JJ	PM
monotherapy	NN	PM
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	PM
patients	NNS	O
with	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
(	(	O
RCC	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Adult	NNP	O
patients	NNS	O
with	IN	O
measurable	JJ	O
,	,	O
locally	RB	O
advanced	JJ	O
,	,	O
and/or	JJ	O
metastatic	JJ	O
RCC	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
2:1	CD	O
to	TO	O
receive	VB	O
oral	JJ	PM
pazopanib	NN	PM
or	CC	O
placebo	NN	C
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
overall	JJ	O
survival	NN	O
,	,	O
tumor	NN	O
response	NN	O
rate	NN	O
(	(	O
Response	NNP	O
Evaluation	NNP	O
Criteria	NNP	O
in	IN	O
Solid	NNP	O
Tumors	NNP	O
)	)	O
,	,	O
and	CC	O
safety	NN	O
.	.	O

Radiographic	JJ	O
assessments	NNS	O
of	IN	O
tumors	NNS	O
were	VBD	O
independently	RB	O
reviewed	VBN	O
.	.	O

Results	NNS	O
Of	IN	O
435	CD	O
patients	NNS	O
enrolled	VBD	O
,	,	O
233	CD	O
were	VBD	O
treatment	NN	O
naive	JJ	O
(	(	O
54	CD	O
%	NN	O
)	)	O
and	CC	O
202	CD	O
were	VBD	O
cytokine	NN	O
pretreated	VBN	O
(	(	O
46	CD	O
%	NN	O
)	)	O
.	.	O

PFS	NNP	O
was	VBD	O
significantly	RB	O
prolonged	VBN	O
with	IN	O
pazopanib	NNS	PM
compared	VBN	O
with	IN	O
placebo	NN	C
in	IN	O
the	DT	O
overall	JJ	O
study	NN	O
population	NN	O
(	(	O
median	JJ	O
,	,	O
PFS	NNP	O
9.2	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
hazard	PRP$	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
,	,	O
0.46	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.34	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
the	DT	O
treatment-naive	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
11.1	CD	O
v	NN	O
2.8	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.40	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.27	CD	O
to	TO	O
0.60	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
cytokine-pretreated	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
,	,	O
7.4	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.54	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.35	CD	O
to	TO	O
0.84	CD	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
objective	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
30	CD	O
%	NN	O
with	IN	O
pazopanib	NN	PM
compared	VBN	O
with	IN	O
3	CD	O
%	NN	O
with	IN	O
placebo	NN	C
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
response	NN	O
was	VBD	O
longer	JJR	O
than	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
diarrhea	RB	O
,	,	O
hypertension	NN	O
,	,	O
hair	NN	O
color	NN	O
changes	NNS	O
,	,	O
nausea	NN	O
,	,	O
anorexia	NN	O
,	,	O
and	CC	O
vomiting	VBG	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
differences	NNS	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
for	IN	O
pazopanib	JJ	PM
versus	NN	O
placebo	NN	C
.	.	O

CONCLUSION	NNP	O
Pazopanib	NNP	PM
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
PFS	NNP	O
and	CC	O
tumor	NN	O
response	NN	O
compared	VBN	O
with	IN	O
placebo	NN	C
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	PM
patients	NNS	O
with	IN	O
advanced	JJ	O
and/or	NNS	O
metastatic	JJ	O
RCC	NNP	O
.	.	O

Randomized	VBN	O
controlled	JJ	O
trial	NN	O
:	:	O
Multimodal	NNP	E
Anxiety	NNP	E
and	CC	E
Social	NNP	PS
Skill	NNP	PS
Intervention	NNP	PS
for	IN	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Anxiety	NN	O
is	VBZ	O
common	JJ	O
among	IN	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
may	MD	O
amplify	VB	O
the	DT	O
core	NN	O
social	JJ	O
disability	NN	O
,	,	O
thus	RB	O
necessitating	VBG	O
combined	VBN	O
treatment	NN	O
approaches	NNS	O
.	.	O

This	DT	O
pilot	NN	O
,	,	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
evaluated	VBD	O
the	DT	O
feasibility	NN	O
and	CC	O
preliminary	JJ	O
outcomes	NNS	O
of	IN	O
the	DT	O
Multimodal	NNP	E
Anxiety	NNP	E
and	CC	E
Social	NNP	PS
Skills	NNP	PS
Intervention	NNP	PS
(	(	PS
MASSI	NNP	PS
)	)	PS
program	NN	PS
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
30	CD	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
anxiety	NN	O
symptoms	NNS	O
of	IN	O
moderate	JJ	O
or	CC	O
greater	JJR	O
severity	NN	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
acceptable	JJ	O
to	TO	O
families	NNS	O
,	,	O
subject	JJ	O
adherence	NN	O
was	VBD	O
high	JJ	O
,	,	O
and	CC	O
therapist	JJ	O
fidelity	NN	O
was	VBD	O
high	JJ	O
.	.	O

A	DT	O
16	CD	O
%	NN	O
improvement	NN	O
in	IN	O
ASD	NNP	O
social	JJ	O
impairment	NN	O
(	(	O
within-group	JJ	O
effect	NN	O
size	NN	O
=	NNP	O
1.18	CD	O
)	)	O
was	VBD	O
observed	VBN	O
on	IN	O
a	DT	O
parent-reported	JJ	O
scale	NN	O
.	.	O

Although	IN	O
anxiety	NN	O
symptoms	NNS	O
declined	VBD	O
by	IN	O
26	CD	O
%	NN	O
,	,	O
the	DT	O
change	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
MASSI	NNP	PS
is	VBZ	O
a	DT	O
feasible	JJ	O
treatment	NN	O
program	NN	O
and	CC	O
further	JJ	O
evaluation	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Efficacy	NN	O
of	IN	O
bepotastine	NN	PM
besilate	NN	PM
ophthalmic	JJ	PM
solution	NN	PM
1.5	CD	O
%	NN	O
for	IN	O
seasonal	JJ	O
allergic	JJ	O
conjunctivitis	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
natural	JJ	O
exposure	NN	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

Allergic	NNP	O
conjunctivitis	NN	O
(	(	O
AC	NNP	O
)	)	O
affects	VBZ	O
an	DT	O
estimated	JJ	O
20	CD	O
%	NN	O
of	IN	O
the	DT	O
population	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
,	,	O
with	IN	O
a	DT	O
large	JJ	O
fraction	NN	O
suffering	VBG	O
due	JJ	O
to	TO	O
seasonal	JJ	O
or	CC	O
perennial	JJ	O
allergen	NN	O
exposures	NNS	O
.	.	O

Bepotastine	NNP	PM
besilate	NN	PM
ophthalmic	JJ	PM
solution	NN	PM
(	(	PM
BBOS	NNP	PM
)	)	PM
1.5	CD	O
%	NN	O
,	,	O
a	DT	O
dual-acting	JJ	PM
histamine	NN	PM
(	(	O
H	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
receptor	NN	O
antagonist	NN	O
and	CC	O
mast	NN	O
cell	NN	O
stabilizer	NN	O
,	,	O
is	VBZ	O
indicated	VBN	O
for	IN	O
itching	VBG	O
associated	VBN	O
with	IN	O
AC	NNP	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
for	IN	O
reducing	VBG	O
ocular	JJ	O
itching	NN	O
associated	VBN	O
with	IN	O
AC	NNP	O
in	IN	O
subjects	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
natural	JJ	O
exposure	NN	O
trial	NN	O
.	.	O

Eligible	JJ	O
subjects	NNS	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-masked	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
natural	JJ	O
exposure	NN	O
clinical	JJ	O
trial	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
BBOS	NNP	PM
1.5	CD	O
%	NN	O
or	CC	O
placebo	NN	C
eyedrops	NNS	C
on	IN	O
a	DT	O
1:1	CD	O
basis	NN	O
and	CC	O
instilled	VBD	O
1	CD	O
drop	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
into	IN	O
both	DT	O
eyes	NNS	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
ocular	JJ	O
itching	NN	O
scores	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
were	VBD	O
evaluated	VBN	O
based	VBN	O
on	IN	O
subject-assessed	JJ	O
severity	NN	O
of	IN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
itching	NN	O
.	.	O

Subject-reported	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
also	RB	O
recorded	VBN	O
for	IN	O
safety	NN	O
.	.	O

Treatment	NN	O
with	IN	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
significantly	RB	O
reduced	VBN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
ocular	JJ	O
itching	NN	O
scores	NNS	O
from	IN	O
baseline	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
over	IN	O
the	DT	O
2-week	JJ	O
study	NN	O
period	NN	O
(	(	O
p	JJ	O
=	NN	O
0.007	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.005	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

BBOS	$	O
1.5	CD	O
%	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
AEs	NNP	O
were	VBD	O
generally	RB	O
transient	JJ	O
and	CC	O
mild	JJ	O
.	.	O

This	DT	O
clinical	JJ	O
study	NN	O
indicates	VBZ	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
effectively	RB	O
and	CC	O
safely	RB	O
treated	VBD	O
ocular	JJ	O
itching	NN	O
in	IN	O
a	DT	O
natural	JJ	O
exposure	NN	O
allergy	NN	O
study	NN	O
and	CC	O
is	VBZ	O
a	DT	O
useful	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
ocular	JJ	O
itching	NN	O
associated	VBN	O
with	IN	O
AC	NNP	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
identifier	VBZ	O
number	NN	O
:	:	O
NCT01174823	NNP	O
.	.	O

)	)	O
Poylmerized	VBN	PM
whole	JJ	PM
ragweed	NN	PM
:	:	O
an	DT	O
improved	JJ	O
method	NN	O
of	IN	O
immunotherapy	NN	O
.	.	O

A	DT	O
single-blind	JJ	O
study	NN	O
compared	VBN	O
the	DT	O
effectiveness	NN	O
of	IN	O
glutaraldehyde-treated	JJ	PM
polymerized	NNS	PM
ragweed	VBP	PM
with	IN	O
nonpolymerized	JJ	PM
monomeric	JJ	PM
ragweed	NN	PM
.	.	PM

These	DT	O
studies	NNS	O
are	VBP	O
an	DT	O
extension	NN	O
of	IN	O
those	DT	O
previously	RB	O
reported	VBN	O
for	IN	O
polymerized	JJ	O
AgE	NNP	O
using	VBG	O
a	DT	O
readily	RB	O
available	JJ	O
ragweed	NN	O
preparation	NN	O
containing	VBG	O
all	DT	O
ragweed	NN	PM
antigens	NNS	O
.	.	O

Nineteen	JJ	O
ragweed-sensitive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
;	:	O
10	CD	O
received	VBD	O
the	DT	O
polymerized	JJ	PM
form	NN	PM
and	CC	O
9	CD	O
received	VBD	O
the	DT	O
monomeric	JJ	PM
form	NN	PM
.	.	O

Four	CD	O
parameters	NNS	O
were	VBD	O
followed	VBN	O
:	:	O
serum-specific	JJ	O
IgE	NNP	O
against	IN	O
antigen	NN	O
E	NNP	O
,	,	O
total	JJ	O
blocking	VBG	O
antibody	NN	O
against	IN	O
antigen	NN	O
E	NNP	O
,	,	O
local	JJ	O
and	CC	O
systemic	JJ	O
reactions	NNS	O
to	TO	O
injection	NN	O
therapy	NN	O
,	,	O
and	CC	O
symptom	NN	O
score	NN	O
indices	NNS	O
.	.	O

Pretreatment	NNP	O
levels	NNS	O
of	IN	O
antigen	NN	O
E	NNP	O
--	:	O
specific	JJ	O
IgE	NNP	O
and	CC	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

After	IN	O
a	DT	O
total	NN	O
of	IN	O
15,000	CD	O
protein	NNS	O
nitrogen	JJ	O
units	NNS	O
(	(	O
PNU	NNP	O
)	)	O
had	VBD	O
been	VBN	O
given	VBN	O
,	,	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
in	IN	O
the	DT	O
monomer	NN	O
group	NN	O
rose	VBD	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
170	CD	O
ng	JJ	O
AgE	NNP	O
bound	NN	O
per	IN	O
ml	NN	O
to	TO	O
a	DT	O
mean	NN	O
of	IN	O
2,813	CD	O
.	.	O

The	DT	O
rise	NN	O
in	IN	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
in	IN	O
the	DT	O
polymer	NN	O
group	NN	O
was	VBD	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
181	CD	O
ng	JJ	O
AgE	NNP	O
bound	NN	O
per	IN	O
ml	NN	O
to	TO	O
1,574	CD	O
.	.	O

At	IN	O
15,000	CD	O
PNU	NNP	O
,	,	O
blocking	VBG	O
antibody	NN	O
activity	NN	O
levels	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

After	IN	O
1	CD	O
year	NN	O
of	IN	O
treatment	NN	O
,	,	O
no	DT	O
consistent	JJ	O
decrease	NN	O
in	IN	O
postseasonal	JJ	O
specific	JJ	O
IgE	NNP	O
rise	NN	O
could	MD	O
be	VB	O
shown	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Forty	NNP	O
times	NNS	O
less	RBR	O
erythema	JJ	O
and	CC	O
15	CD	O
times	NNS	O
less	JJR	O
induration	NN	O
were	VBD	O
found	VBN	O
with	IN	O
polymerized	JJ	PM
ragweed	NN	PM
.	.	O

There	EX	O
were	VBD	O
7	CD	O
systemic	JJ	O
reactions	NNS	O
with	IN	O
the	DT	O
monomer	NN	O
and	CC	O
none	NN	O
with	IN	O
the	DT	O
polymer	NN	O
.	.	O

Both	DT	O
groups	NNS	O
experienced	VBD	O
symptomatic	JJ	O
improvement	NN	O
with	IN	O
treatment	NN	O
.	.	O

Most	RBS	O
effective	JJ	O
regimen	NNS	O
of	IN	O
tranexamic	JJ	PM
acid	NN	PM
in	IN	O
knee	NN	O
arthroplasty	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
in	IN	O
240	CD	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
antifibrinolytic	JJ	PM
tranexamic	JJ	PM
acid	NN	PM
reduces	NNS	O
surgical	JJ	O
blood	NN	O
loss	NN	O
,	,	O
but	CC	O
studies	NNS	O
have	VBP	O
not	RB	O
identified	VBN	O
an	DT	O
optimal	JJ	O
regimen	NNS	O
.	.	O

QUESTIONS/PURPOSES	NNP	O
We	PRP	O
studied	VBD	O
different	JJ	O
dosages	NNS	O
,	,	O
timings	NNS	O
,	,	O
and	CC	O
modes	NNS	O
of	IN	O
administration	NN	O
to	TO	O
identify	VB	O
the	DT	O
most	RBS	O
effective	JJ	O
regimen	NNS	O
of	IN	O
tranexamic	JJ	PM
acid	NN	PM
in	IN	O
achieving	VBG	O
maximum	JJ	O
reduction	NN	O
of	IN	O
blood	NN	O
loss	NN	O
in	IN	O
TKA	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
prospectively	RB	O
studied	VBD	O
five	CD	O
regimens	NNS	O
(	(	O
four	CD	O
intravenous	NN	PH
,	,	O
one	CD	O
local	JJ	PH
;	:	O
40	CD	O
patients	NNS	O
each	DT	O
)	)	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
no	DT	O
tranexamic	JJ	O
acid	NN	O
)	)	O
.	.	O

The	DT	O
four	CD	O
intravenous	JJ	PH
(	(	O
10-mg/kg	JJ	O
dose	NN	O
)	)	O
regimens	VBZ	O
included	VBN	O
(	(	O
1	CD	O
)	)	O
intraoperative	NN	S
dose	NN	S
(	(	S
IO	NNP	S
)	)	S
given	VBN	O
before	IN	O
tourniquet	JJ	O
deflation	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
additional	JJ	PM
preoperative	NN	PM
dose	NN	PM
(	(	PM
POIO	NNP	PM
)	)	PM
,	,	O
(	(	O
3	CD	O
)	)	O
additional	JJ	PM
postoperative	NN	PM
dose	NN	PM
(	(	PM
IOPO	NNP	PM
)	)	PM
,	,	O
and	CC	O
(	(	O
4	CD	O
)	)	O
all	DT	O
three	CD	O
doses	NNS	O
(	(	O
POIOPO	NNP	O
)	)	O
.	.	O

The	DT	O
fifth	JJ	O
regimen	NN	O
was	VBD	O
a	DT	O
single	JJ	O
local	JJ	PM
application	NN	PM
(	(	O
LA	NNP	O
)	)	O
.	.	O

Two	CD	O
independent	JJ	O
parameters	NNS	O
of	IN	O
drain	NN	O
loss	NN	O
and	CC	O
total	JJ	O
blood	NN	O
loss	NN	O
,	,	O
calculated	VBN	O
by	IN	O
the	DT	O
hemoglobin	NN	O
balance	NN	O
method	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
statistically	RB	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
parameters	NNS	O
were	VBD	O
reduced	VBN	O
in	IN	O
all	DT	O
five	CD	O
regimens	NNS	O
as	IN	O
against	IN	O
the	DT	O
control	NN	O
.	.	O

A	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
drain	NN	O
loss	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
POIO	NNP	O
,	,	O
IOPO	NNP	O
,	,	O
and	CC	O
POIOPO	NNP	O
groups	NNS	O
whereas	VBP	O
total	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
the	DT	O
POIO	NNP	O
,	,	O
POIOPO	NNP	O
,	,	O
and	CC	O
LA	NNP	O
groups	NNS	O
.	.	O

The	DT	O
POIOPO	NNP	O
group	NN	O
had	VBD	O
the	DT	O
least	JJS	O
drain	JJ	O
loss	NN	O
(	(	O
303	CD	O
mL	NN	O
)	)	O
and	CC	O
least	JJS	O
total	JJ	O
blood	NN	O
loss	NN	O
(	(	O
688	CD	O
mL	NN	O
)	)	O
.	.	O

The	DT	O
IO	NNP	O
group	NN	O
had	VBD	O
the	DT	O
greatest	JJS	O
drain	NN	O
loss	NN	O
and	CC	O
the	DT	O
IOPO	NNP	O
group	NN	O
the	DT	O
greatest	JJS	O
total	JJ	O
blood	NN	O
loss	NN	O
.	.	O

CONCLUSIONS	NNP	O
Single-dose	JJ	O
tranexamic	JJ	PM
acid	NN	PM
did	VBD	O
not	RB	O
give	VB	O
effective	JJ	O
results	NNS	O
.	.	O

The	DT	O
two-dose	JJ	O
regimen	NNS	O
of	IN	O
POIO	NNP	O
was	VBD	O
the	DT	O
least	JJS	O
amount	NN	O
necessary	JJ	O
for	IN	O
effective	JJ	O
results	NNS	O
.	.	O

When	WRB	O
compared	VBN	O
against	IN	O
the	DT	O
control	NN	O
,	,	O
this	DT	O
regimen	NNS	O
produced	VBD	O
reduction	NN	O
of	IN	O
drain	NN	O
loss	NN	O
and	CC	O
total	JJ	O
blood	NN	O
loss	NN	O
,	,	O
whereas	IN	O
the	DT	O
IOPO	NNP	O
regimen	NNS	O
did	VBD	O
not	RB	O
.	.	O

The	DT	O
three-dose	JJ	O
regimen	NNS	O
of	IN	O
POIOPO	NNP	O
produced	VBD	O
maximum	JJ	O
effective	JJ	O
reduction	NN	O
of	IN	O
drain	NN	O
loss	NN	O
and	CC	O
total	JJ	O
blood	NN	O
loss	NN	O
.	.	O

Osteoporosis	NN	PM
and	CC	O
gait	NN	O
and	CC	O
balance	NN	O
disturbances	NNS	O
in	IN	O
older	JJR	O
sarcopenic	JJ	O
obese	JJ	O
New	NNP	O
Zealanders	NNP	O
.	.	O

UNLABELLED	NNP	O
Bone	NNP	O
,	,	O
muscle	NN	O
,	,	O
and	CC	O
fat	NN	O
may	MD	O
affect	VB	O
gait	NN	O
and	CC	O
balance	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
.	.	O

Osteoporosis	NN	O
was	VBD	O
prevalent	JJ	O
in	IN	O
low	JJ	O
muscle	NN	O
mass	NN	O
participants	NNS	O
and	CC	O
related	VBN	O
to	TO	O
gait	VB	O
and	CC	O
balance	VB	O
deficits	NNS	O
.	.	O

Low	JJ	O
muscle	NN	O
combined	VBN	O
with	IN	O
high	JJ	O
fat	JJ	O
mass	NN	O
had	VBD	O
more	RBR	O
functional	JJ	O
deficits	NNS	O
and	CC	O
poorer	JJR	O
bone	NN	O
health	NN	O
,	,	O
which	WDT	O
has	VBZ	O
implications	NNS	O
for	IN	O
falls	NNS	O
risk	NN	O
and	CC	O
fractures	NNS	O
.	.	O

INTRODUCTION	NNP	O
Decreasing	VBG	O
bone	NN	O
density	NN	O
and	CC	O
muscle	NN	O
mass	NN	O
and	CC	O
increasing	VBG	O
fat	JJ	O
mass	NN	O
may	MD	O
act	VB	O
synergistically	RB	O
to	TO	O
affect	VB	O
gait	NN	O
and	CC	O
balance	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
eighty-three	JJ	O
older	NN	O
adults	NNS	O
(	(	O
age	NN	O
72.7	CD	O
+/-	JJ	O
6	CD	O
years	NNS	O
,	,	O
range	VBP	O
56-93	JJ	O
;	:	O
body	NN	O
mass	NN	O
index	NN	O
28.2	CD	O
+/-	JJ	O
4.9	CD	O
,	,	O
range	VBP	O
16.6-46.0	JJ	O
)	)	O
were	VBD	O
recruited	VBN	O
from	IN	O
a	DT	O
New	NNP	O
Zealand	NNP	O
falls	VBZ	O
prevention	NN	O
intervention	NN	O
trial	NN	O
.	.	O

Total	JJ	O
and	CC	O
appendicular	JJ	O
skeletal	JJ	O
muscle	NN	O
mass	NN	O
(	(	O
ASM	NNP	O
)	)	O
,	,	O
percent	JJ	O
fat	NN	O
,	,	O
and	CC	O
bone	NN	O
mineralization	NN	O
were	VBD	O
assessed	VBN	O
by	IN	O
dual	JJ	PH
energy	NN	PH
X-ray	JJ	PH
absorptiometry	NN	PH
and	CC	O
used	VBD	O
to	TO	O
characterize	VB	O
normal	JJ	O
lean	JJ	O
(	(	O
NL	NNP	O
,	,	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
,	,	O
sarcopenic	JJ	O
(	(	O
SS	NNP	O
,	,	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
,	,	O
sarcopenic	JJ	O
obese	NN	O
(	(	O
SO	NNP	O
,	,	O
n	JJ	O
=	NNP	O
29	CD	O
)	)	O
,	,	O
and	CC	O
obese	JJ	O
(	(	O
OO	NNP	O
,	,	O
n	JJ	O
=	NNP	O
85	CD	O
)	)	O
phenotypes	NNS	O
.	.	O

Functional	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
,	,	O
chair	NN	O
stand	NN	O
,	,	O
single	JJ	O
leg	NN	O
stand	NN	O
,	,	O
and	CC	O
step	VB	Ot
test	NN	Ot
.	.	O

Regression	NN	O
models	NNS	O
were	VBD	O
adjusted	VBN	O
for	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
medications	NNS	O
,	,	O
and	CC	O
physical	JJ	O
activity	NN	O
.	.	O

RESULTS	NNP	O
Femoral	NNP	O
neck	NN	O
osteoporosis	NN	O
was	VBD	O
present	JJ	O
in	IN	O
22	CD	O
%	NN	O
SS	NNP	O
,	,	O
17	CD	O
%	NN	O
SO	NNP	O
,	,	O
12	CD	O
%	NN	O
NL	NNP	O
,	,	O
and	CC	O
7	CD	O
%	NN	O
OO	NNP	O
.	.	O

Femoral	NNP	O
neck	NN	O
osteoporosis	NN	O
with	IN	O
low	JJ	O
ASM	NNP	O
predicted	VBD	O
poor	JJ	O
chair	NN	O
stand	VBP	O
performance	NN	O
(	(	O
beta	JJ	O
-3.3	NNP	O
,	,	O
standard	JJ	O
error	NN	O
1.6	CD	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

SO	RB	O
scored	JJ	O
lowest	NN	O
on	IN	O
the	DT	O
chair	NN	O
stand	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
step	JJ	O
test	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Higher	JJR	O
ASM	NNP	O
predicted	VBD	O
faster	RBR	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
performance	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Osteoporosis	NNP	O
was	VBD	O
prevalent	VBN	O
in	IN	O
low	JJ	O
ASM	NNP	O
groups	NNS	O
(	(	O
SS	NNP	O
and	CC	O
SO	NNP	O
)	)	O
and	CC	O
related	VBN	O
to	TO	O
gait	VB	O
and	CC	O
balance	VB	O
deficits	NNS	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
SO	NNP	O
.	.	O

This	DT	O
has	VBZ	O
implications	NNS	O
for	IN	O
falls	NNS	O
risk	NN	O
,	,	O
fractures	NNS	O
,	,	O
and	CC	O
interventions	NNS	O
.	.	O

[	NN	O
Encephalopathy	NNP	PH
therapeutic	JJ	PH
tongue	NN	PH
acupoint	NN	PH
apparatus	NN	PH
(	(	O
ETTAA	NNP	O
)	)	O
for	IN	O
42	CD	O
cases	NNS	O
of	IN	O
autism	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
encephalopathy	JJ	PH
therapeutic	JJ	PH
tongue	NN	PH
acupoint	NN	PH
apparatus	NN	PH
(	(	PH
ETTAA	NNP	PH
)	)	PH
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHODS	NNP	O
Eighty-four	JJ	O
children	NNS	O
of	IN	O
autism	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
tongue	JJ	PH
acupuncture	NN	PH
group	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
a	DT	O
conventional	JJ	E
training	NN	E
group	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
,	,	O
42	CD	O
cases	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

The	DT	O
behavior	JJ	O
training	NN	O
and	CC	O
sensory	JJ	O
integration	NN	O
training	NN	O
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
group	NN	O
B	NNP	O
and	CC	O
the	DT	O
ETTAA	NNP	O
was	VBD	O
added	VBN	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

The	DT	O
apparatus	NN	O
was	VBD	O
switched	VBN	O
on	IN	O
for	IN	O
20	CD	O
min	NN	O
every	DT	O
time	NN	O
and	CC	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

Treatment	NN	O
of	IN	O
two	CD	O
months	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
score	NN	O
of	IN	O
childhood	NN	O
autism	NN	O
rating	NN	O
scale	NN	O
(	(	O
CARS	NNP	O
)	)	O
and	CC	O
clinical	JJ	O
efficacy	NN	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
observed	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
CARS	NNPS	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
(	(	O
42.39	CD	O
+/-	JJ	O
6.86	CD	O
vs	JJ	O
32.15	CD	O
+/-	JJ	O
5.12	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
44.58	CD	O
+/-	JJ	O
6.76	CD	O
vs	JJ	O
39.72	CD	O
+/-	JJ	O
7.11	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
more	RBR	O
significant	JJ	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
totally	RB	O
effective	JJ	O
rate	NN	O
in	IN	O
group	NN	O
A	NNP	O
[	RB	O
90.5	CD	O
%	NN	O
(	(	O
38/42	CD	O
)	)	O
]	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
that	DT	O
in	IN	O
group	NN	O
B	NNP	O
[	VBZ	O
66.7	CD	O
%	NN	O
(	(	O
28/42	CD	O
)	)	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
clinical	JJ	O
efficacy	NN	O
in	IN	O
tongue	JJ	PH
acupuncture	NN	PH
group	NN	O
is	VBZ	O
apparently	RB	O
superior	JJ	O
to	TO	O
that	DT	O
in	IN	O
conventional	JJ	E
training	NN	E
group	NN	O
,	,	O
ETTAA	NNP	O
combined	VBD	O
with	IN	O
conventional	JJ	O
training	NN	O
have	VBP	O
a	DT	O
better	JJR	O
curative	JJ	O
effect	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

Effects	NNS	O
of	IN	O
fenoterol	NN	PM
on	IN	O
inspiratory	JJ	O
effort	NN	O
sensation	NN	O
and	CC	O
fatigue	NN	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
fenoterol	NN	PM
on	IN	O
the	DT	O
relationship	NN	O
between	IN	O
inspiratory	NN	O
effort	NN	O
sensation	NN	O
(	(	O
IES	NNP	O
)	)	O
and	CC	O
inspiratory	JJ	O
muscle	NN	O
fatigue	NN	O
induced	VBN	O
by	IN	O
inspiratory	NN	O
threshold	NN	O
loading	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
threshold	NN	O
was	VBD	O
60	CD	O
%	NN	O
of	IN	O
maximal	JJ	O
static	JJ	O
inspiratory	NN	O
mouth	NN	O
pressure	NN	O
(	(	O
PI	NNP	O
,	,	O
mmax	NN	O
)	)	O
at	IN	O
functional	JJ	O
residual	JJ	O
capacity	NN	O
,	,	O
and	CC	O
the	DT	O
duty	NN	O
cycle	NN	O
was	VBD	O
0.5	CD	O
.	.	O

Subjects	NNS	O
continued	VBD	O
the	DT	O
threshold	NN	O
loaded	VBD	O
breathing	NN	O
until	IN	O
the	DT	O
target	NN	O
mouth	NN	O
pressure	NN	O
could	MD	O
no	RB	O
longer	RB	O
be	VB	O
maintained	VBN	O
(	(	O
endurance	JJ	O
time	NN	O
)	)	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
IES	NNP	O
was	VBD	O
scored	VBN	O
with	IN	O
a	DT	O
modified	JJ	O
Borg	NNP	O
scale	NN	O
.	.	O

Either	CC	O
fenoterol	NN	PM
(	(	PM
5	CD	PM
mg	NN	PM
)	)	PM
or	CC	O
a	DT	O
placebo	NN	PM
was	VBD	O
given	VBN	O
orally	RB	O
2	CD	O
h	NN	O
before	IN	O
loading	VBG	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
crossover	NN	O
protocol	NN	O
.	.	O

The	DT	O
endurance	NN	O
time	NN	O
with	IN	O
fenoterol	NN	O
(	(	O
34.4	CD	O
+/-	JJ	O
8.6	CD	O
min	NN	O
)	)	O
was	VBD	O
longer	JJR	O
than	IN	O
that	DT	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
22.2	CD	O
+/-	JJ	O
7.1	CD	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	O
of	IN	O
high-	JJ	O
to	TO	O
low-frequency	JJ	O
power	NN	O
of	IN	O
the	DT	O
diaphragmatic	JJ	O
electromyogram	NN	O
(	(	O
EMGdi	NNP	O
)	)	O
decreased	VBD	O
during	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
less	RBR	O
with	IN	O
fenoterol	NN	PM
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
EMGdi	NNP	O
also	RB	O
decreased	VBD	O
with	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
greater	JJR	O
on	IN	O
fenoterol	NN	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
PI	NNP	O
,	,	O
mmax	NN	O
and	CC	O
maximal	JJ	O
transdiaphragmatic	JJ	O
pressure	NN	O
(	(	O
Pdi	NNP	O
)	)	O
were	VBD	O
similarly	RB	O
decreased	VBN	O
after	IN	O
loading	VBG	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
IES	NNP	O
rose	VBD	O
with	IN	O
time	NN	O
during	IN	O
loading	VBG	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
was	VBD	O
lower	JJR	O
with	IN	O
fenoterol	NN	PM
than	IN	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	O
of	IN	O
Pdi	NNP	O
to	TO	O
integrated	JJ	O
activity	NN	O
of	IN	O
the	DT	O
EMGdi	NNP	O
increased	VBD	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Fenoterol	NNP	O
treatment	NN	O
increased	VBD	O
both	DT	O
superimposed	VBN	O
Pdi	NNP	O
twitch	NN	O
and	CC	O
Pdi	NNP	O
twitch	NN	O
of	IN	O
relaxed	JJ	O
diaphragm	NN	O
and	CC	O
decreased	VBD	O
the	DT	O
value	NN	O
of	IN	O
(	(	O
1-superimposed	JJ	O
Pdi	NNP	O
twitch/Pdi	NN	O
twitch	NN	O
of	IN	O
relaxed	JJ	O
diaphragm	NN	O
)	)	O
.	.	O

Thus	IN	O
we	PRP	O
conclude	VBP	O
that	IN	O
in	IN	O
normal	JJ	O
subjects	NNS	O
fenoterol	JJ	O
reduces	NNS	O
diaphragmatic	JJ	O
fatigue	NN	O
and	CC	O
decreases	VBZ	O
the	DT	O
motor	NN	O
command	NN	O
to	TO	O
the	DT	O
diaphragm	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
IES	NNP	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
and	CC	O
a	DT	O
prolongation	NN	O
of	IN	O
endurance	NN	O
.	.	O

Anesthesia	NNP	O
for	IN	O
in	IN	O
vitro	JJ	O
fertilization	NN	O
:	:	O
the	DT	O
addition	NN	O
of	IN	O
fentanyl	NN	PM
to	TO	O
1.5	CD	O
%	NN	O
lidocaine	NN	PM
.	.	PM

UNLABELLED	NNP	O
Ultrasonically	RB	O
guided	VBD	O
transvaginal	JJ	O
oocyte	NN	O
retrieval	NN	O
is	VBZ	O
relatively	RB	O
short	JJ	O
procedure	NN	O
that	WDT	O
is	VBZ	O
performed	VBN	O
on	IN	O
an	DT	O
out-patient	JJ	O
basis	NN	O
.	.	O

The	DT	O
optimal	JJ	O
anesthetic	JJ	O
technique	NN	O
should	MD	O
allow	VB	O
good	JJ	O
surgical	JJ	O
anesthesia	NN	O
with	IN	O
minimal	JJ	O
side	NN	O
effects	NNS	O
,	,	O
a	DT	O
short	JJ	O
recovery	NN	O
time	NN	O
,	,	O
and	CC	O
,	,	O
if	IN	O
possible	JJ	O
,	,	O
a	DT	O
high	JJ	O
rate	NN	O
of	IN	O
successful	JJ	O
pregnancy	NN	O
.	.	O

Spinal	JJ	PM
anesthesia	NN	PM
is	VBZ	O
often	RB	O
used	VBN	O
in	IN	O
this	DT	O
institution	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
many	JJ	O
others	NNS	O
,	,	O
for	IN	O
this	DT	O
procedure	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
fentanyl	NN	O
may	MD	O
be	VB	O
effective	JJ	O
for	IN	O
both	DT	O
intraoperative	JJ	O
and	CC	O
postoperative	JJ	O
pain	NN	O
relief	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
effect	NN	O
of	IN	O
adding	VBG	O
fentanyl	NN	O
to	TO	O
1.5	CD	O
%	NN	O
lidocaine	NN	O
in	IN	O
women	NNS	O
undergoing	VBG	O
ultrasonically	RB	O
guided	VBN	O
oocyte	NN	O
retrieval	NN	O
.	.	O

Seventy-eight	JJ	O
women	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
45	CD	PM
mg	NN	PM
of	IN	PM
hyperbaric	JJ	PM
1.5	CD	PM
%	NN	PM
lidocaine	NN	PM
with	IN	PM
or	CC	PM
without	IN	PM
10	CD	PM
microg	NN	PM
of	IN	PM
fentanyl	NN	PM
.	.	PM

Visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
pain	NN	O
scores	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
operating	NN	O
room	NN	O
(	(	O
OR	NNP	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
postanesthesia	$	O
care	NN	O
unit	NN	O
(	(	O
PACU	NNP	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.0005	CD	O
)	)	O
for	IN	O
the	DT	O
group	NN	O
that	WDT	O
received	VBD	O
fentanyl	RB	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
narcotic	JJ	O
required	VBN	O
in	IN	O
the	DT	O
PACU	NNP	O
was	VBD	O
less	RBR	O
in	IN	O
the	DT	O
fentanyl	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
VAS	NNP	O
scores	VBZ	O
the	DT	O
evening	NN	O
of	IN	O
or	CC	O
24	CD	O
h	NN	O
after	IN	O
the	DT	O
procedure	NN	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
analgesics	NNS	O
and	CC	O
narcotics	NNS	O
required	VBN	O
after	IN	O
discharge	NN	O
was	VBD	O
the	DT	O
same	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Timed	NNP	O
variables	NNS	O
,	,	O
such	JJ	O
as	IN	O
time	NN	O
to	TO	O
urination	NN	O
,	,	O
ambulation	NN	O
,	,	O
and	CC	O
discharge	NN	O
,	,	O
were	VBD	O
the	DT	O
same	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
of	IN	O
women	NNS	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
fentanyl	NN	O
to	TO	O
lidocaine	VB	O
for	IN	O
transvaginal	JJ	O
oocyte	NN	O
retrieval	NN	O
results	NNS	O
in	IN	O
a	DT	O
more	RBR	O
comfortable	JJ	O
patient	NN	O
in	IN	O
the	DT	O
OR	NNP	O
and	CC	O
PACU	NNP	O
.	.	O

IMPLICATIONS	NNP	O
This	DT	O
study	NN	O
demonstrates	VBZ	O
that	IN	O
when	WRB	O
fentanyl	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
a	DT	O
local	JJ	O
anesthetic	NN	O
,	,	O
lidocaine	NN	O
,	,	O
with	IN	O
spinal	JJ	O
anesthesia	NN	O
for	IN	O
egg	NN	O
retrieval	NN	O
procedures	NNS	O
,	,	O
patients	NNS	O
are	VBP	O
more	RBR	O
comfortable	JJ	O
during	IN	O
the	DT	O
procedure	NN	O
compared	VBN	O
with	IN	O
those	DT	O
who	WP	O
receive	VBP	O
lidocaine	NN	O
alone	RB	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
narcotic	JJ	O
requirements	NNS	O
of	IN	O
patients	NNS	O
are	VBP	O
less	RBR	O
in	IN	O
the	DT	O
postanesthesia	NN	O
care	NN	O
unit	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
intranasal	NN	O
beclomethasone	NN	PM
dipropionate	NN	PM
after	IN	O
polypectomy	NN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
of	IN	O
intranasal	NN	PM
beclomethasone	NN	PM
dipropionate	NN	PM
(	(	PM
Bdp	NNP	PM
)	)	PM
in	IN	O
patients	NNS	O
with	IN	O
nasal	JJ	O
polyposis	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
earlier	RBR	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
investigate	VB	O
whether	IN	O
long-term	JJ	O
treatment	NN	O
with	IN	O
Bdp	NNP	PM
after	IN	O
polypectomy	NN	O
could	MD	O
prevent	VB	O
formation	NN	O
of	IN	O
new	JJ	O
polyps	NNS	O
and	CC	O
reduce	VB	O
the	DT	O
number	NN	O
of	IN	O
surgical	JJ	O
removals	NNS	O
.	.	O

Forty	NNP	O
consecutive	JJ	O
patients	NNS	O
without	IN	O
laboratory	NN	O
or	CC	O
other	JJ	O
clinical	JJ	O
signs	NNS	O
of	IN	O
allergy	NN	O
but	CC	O
with	IN	O
severe	JJ	O
nasal	JJ	O
polyposis	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Twenty	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
intranasal	JJ	PM
Bdp	NNP	PM
and	CC	O
twenty	JJ	O
patients	NNS	O
received	VBD	O
no	DT	O
treatment	NN	O
after	IN	O
polypectomy	NN	S
.	.	S

All	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
at	IN	O
least	JJS	O
2.5	CD	O
years	NNS	O
.	.	O

The	DT	O
size	NN	O
of	IN	O
the	DT	O
polyps	NNS	O
that	WDT	O
recurred	VBD	O
was	VBD	O
estimated	VBN	O
at	IN	O
different	JJ	O
time-intervals	NNS	O
by	IN	O
the	DT	O
examining	VBG	O
doctor	NN	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
there	RB	O
was	VBD	O
already	RB	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
favour	NN	O
of	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
intranasal	JJ	O
Bdp	NNP	PM
.	.	O

Further	NNP	O
results	NNS	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
the	DT	O
clinical	JJ	O
implications	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Intervention	NN	PH
for	IN	PH
ineffective	JJ	PH
airway	JJ	PH
clearance	NN	PH
in	IN	PH
asthmatic	JJ	PH
children	NNS	PH
:	:	PH
a	DT	O
controlled	VBN	O
and	CC	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
intervention	NN	O
for	IN	O
the	DT	O
nursing	NN	O
diagnosis	NN	O
of	IN	O
ineffective	JJ	O
airway	JJ	O
clearance	NN	O
in	IN	O
asthmatic	JJ	O
children	NNS	O
.	.	O

A	DT	O
blinded	JJ	O
,	,	O
randomized	VBN	O
and	CC	O
controlled	VBN	O
clinical	JJ	O
trial	NN	O
was	VBD	O
developed	VBN	O
in	IN	O
a	DT	O
paediatric	JJ	O
hospital	NN	O
located	VBN	O
on	IN	O
northeast	NN	O
of	IN	O
Brazil	NNP	O
with	IN	O
42	CD	O
asthmatic	JJ	O
children	NNS	O
aged	VBN	O
?	.	O
36	CD	O
months	NNS	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
(	(	O
intervention	NN	O
and	CC	O
control	NN	O
)	)	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
simple	JJ	O
drawing	NN	O
.	.	O

The	DT	O
applied	JJ	O
intervention	NN	O
included	VBD	O
actions	NNS	O
related	VBN	O
to	TO	O
change	VB	O
of	IN	O
positioning	NN	O
and	CC	O
stimulation	NN	O
of	IN	O
cough	NN	O
.	.	O

The	DT	O
main	JJ	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	VBP	O
that	IN	O
before	IN	O
the	DT	O
intervention	NN	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
health	NN	O
status	NN	O
of	IN	O
the	DT	O
children	NNS	O
.	.	O

After	IN	O
the	DT	O
intervention	NN	O
,	,	O
the	DT	O
indicators	NNS	O
of	IN	O
choking	VBG	O
(	(	O
16.83	CD	O
vs.	FW	O
26.17	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.007	CD	O
)	)	O
and	CC	O
adventitious	JJ	O
breath	NN	O
sounds	NNS	O
(	(	O
16.4	CD	O
vs.	FW	O
26.6	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
were	VBD	O
higher	JJR	O
,	,	O
on	IN	O
average	NN	O
,	,	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

It	PRP	O
was	VBD	O
observed	VBN	O
an	DT	O
improvement	NN	O
in	IN	O
obstructive	JJ	O
symptoms	NNS	O
in	IN	O
children	NNS	O
who	WP	O
received	VBD	O
the	DT	O
intervention	NN	O
proposed	VBN	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
of	IN	O
risperidone	NN	PM
plus	CC	PM
amantadine	NN	PM
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
10-week	JJ	O
randomized	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
adding	VBG	O
amantadine	NN	PM
to	TO	PM
risperidone	VB	PM
for	IN	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
outpatients	NNS	O
aged	VBD	O
4	CD	O
to12	NN	O
years	NNS	O
,	,	O
who	WP	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
based	VBN	O
on	IN	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
,	,	O
Text	NNP	O
Revision	NNP	O
criteria	NNS	O
,	,	O
were	VBD	O
assigned	VBN	O
to	TO	O
this	DT	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
2	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
risperidone	JJ	PM
plus	CC	PM
amantadine	JJ	PM
,	,	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
received	VBD	O
risperidone	JJ	PM
plus	CC	PM
placebo	NN	C
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	O
was	VBD	O
titrated	VBN	O
between	IN	O
1	CD	O
and	CC	O
2.0	CD	O
mg/d	NN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
amantadine	NN	PM
was	VBD	O
100	CD	O
or	CC	O
150	CD	O
mg/d	NNS	O
for	IN	O
patients	NNS	O
less	JJR	O
than	IN	O
30	CD	O
kg	NN	O
or	CC	O
more	JJR	O
than	IN	O
30	CD	O
kg	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Aberrant	NNP	O
Behavioral	NNP	O
Checklist-Community	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
and	CC	O
adverse	JJ	O
effects	NNS	O
checklist	NN	O
as	RB	O
well	RB	O
as	IN	O
clinical	JJ	O
global	JJ	O
impression-improvement	NN	O
(	(	O
CGI-I	NNP	O
)	)	O
at2	VBZ	O
checkpoints	NNS	O
of	IN	O
5-week	JJ	O
intervals	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
.	.	O

Informed	NNP	O
consentwas	NN	O
obtained	VBN	O
from	IN	O
the	DT	O
parents	NNS	O
of	IN	O
each	DT	O
participant	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
ABC-C	NNP	O
subscales	NNS	O
,	,	O
Hyperactivity	NNP	O
and	CC	O
Irritability	NNP	O
showed	VBD	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
adverse	JJ	O
effects	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
CGI-I	JJ	O
scores	NNS	O
show	VBP	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
amantadine	NN	PM
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
present	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
amantadine	NN	PM
may	MD	O
be	VB	O
a	DT	O
potential	JJ	O
adjunctive	JJ	O
treatment	NN	O
strategy	NN	O
for	IN	O
autism	NN	O
and	CC	O
it	PRP	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

Body	NN	O
size	NN	O
indexes	NNS	O
for	IN	O
optimizing	VBG	O
iodine	NN	PM
dose	NN	O
for	IN	O
aortic	JJ	O
and	CC	O
hepatic	JJ	O
enhancement	NN	O
at	IN	O
multidetector	NN	O
CT	NNP	O
:	:	O
comparison	NN	O
of	IN	O
total	JJ	O
body	NN	O
weight	NN	O
,	,	O
lean	JJ	O
body	NN	O
weight	NN	O
,	,	O
and	CC	O
blood	NN	O
volume	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
total	JJ	O
body	NN	O
weight	NN	O
(	(	O
TBW	NNP	O
)	)	O
,	,	O
lean	JJ	O
body	NN	O
weight	NN	O
(	(	O
LBW	NNP	O
)	)	O
,	,	O
and	CC	O
estimated	VBD	O
blood	NN	O
volume	NN	O
(	(	O
BV	NNP	O
)	)	O
for	IN	O
the	DT	O
adjustment	NN	O
of	IN	O
the	DT	O
iodine	NN	PM
dose	NN	PM
required	VBN	O
for	IN	O
contrast	NN	O
material-enhanced	JJ	O
multidetector	NN	O
computed	VBD	O
tomography	NN	O
(	(	O
CT	NNP	O
)	)	O
of	IN	O
the	DT	O
aorta	NN	O
and	CC	O
liver	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Institutional	NNP	O
review	NN	O
committee	NN	O
approval	NN	O
and	CC	O
written	VBN	O
informed	JJ	O
consent	NN	O
were	VBD	O
obtained	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
twenty	NN	O
patients	NNS	O
(	(	O
54	CD	O
men	NNS	O
,	,	O
66	CD	O
women	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
64.1	CD	O
years	NNS	O
;	:	O
range	NN	O
,	,	O
19-88	CD	O
years	NNS	O
)	)	O
who	WP	O
underwent	JJ	O
multidetector	NN	PH
CT	NNP	PH
of	IN	O
the	DT	O
upper	JJ	O
abdomen	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
of	IN	O
40	CD	O
patients	NNS	O
each	DT	O
:	:	O
(	(	O
a	DT	O
)	)	O
TBW	NNP	O
group	NN	O
(	(	O
0.6	CD	O
g	NN	O
of	IN	O
iodine	NN	PM
per	IN	O
kilogram	NN	O
of	IN	O
TBW	NNP	O
)	)	O
,	,	O
(	(	O
b	NN	O
)	)	O
LBW	NNP	O
group	NN	O
(	(	O
0.821	CD	O
g	NN	O
of	IN	O
iodine	NN	PM
per	IN	O
kilogram	NN	O
of	IN	O
LBW	NNP	O
)	)	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
BV	NNP	O
group	NN	O
(	(	O
men	NNS	O
,	,	O
8.6	CD	O
g	NN	O
of	IN	O
iodine	NN	PM
per	IN	O
liter	NN	O
of	IN	O
BV	NNP	O
;	:	O
women	NNS	O
,	,	O
9.9	CD	O
g	NN	O
of	IN	O
iodine	NN	O
per	IN	O
liter	NN	O
of	IN	O
BV	NNP	O
)	)	O
.	.	O

Change	NN	O
in	IN	O
CT	NNP	O
number	NN	O
between	IN	O
unenhanced	JJ	O
and	CC	O
contrast-enhanced	JJ	O
images	NNS	O
per	IN	O
gram	NN	O
of	IN	O
iodine	NN	O
and	CC	O
maximum	JJ	O
hepatic	JJ	O
enhancement	NN	O
(	(	O
MHE	NNP	O
)	)	O
adjusted	VBD	O
for	IN	O
iodine	NN	PM
dose	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
correlation	NN	O
with	IN	O
TBW	NNP	O
,	,	O
LBW	NNP	O
,	,	O
and	CC	O
BV	NNP	O
by	IN	O
using	VBG	O
linear	JJ	O
regression	NN	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
portal	JJ	O
venous	JJ	O
phase	NN	O
,	,	O
correlation	NN	O
coefficients	NNS	O
for	IN	O
the	DT	O
correlation	NN	O
of	IN	O
change	NN	O
in	IN	O
CT	NNP	O
number	NN	O
per	IN	O
gram	NN	O
of	IN	O
iodine	NN	PM
with	IN	O
TBW	NNP	O
for	IN	O
the	DT	O
aorta	NN	O
and	CC	O
liver	NN	O
were	VBD	O
-0.71	NNP	O
and	CC	O
-0.79	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
TBW	NNP	O
group	NN	O
;	:	O
-0.80	CC	O
and	CC	O
-0.86	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
LBW	NNP	O
group	NN	O
;	:	O
and	CC	O
-0.68	VB	O
and	CC	O
-0.66	NNP	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
BV	NNP	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
liver	NN	O
,	,	O
they	PRP	O
were	VBD	O
marginally	RB	O
higher	JJR	O
in	IN	O
the	DT	O
LBW	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BV	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

Adjusted	VBN	O
MHE	NNP	O
remained	VBD	O
constant	JJ	O
at	IN	O
77.9	CD	O
HU	NNP	O
+/-	JJ	O
10.2	CD	O
(	(	O
standard	JJ	O
deviation	NN	O
)	)	O
in	IN	O
the	DT	O
LBW	NNP	O
group	NN	O
with	IN	O
respect	NN	O
to	TO	O
TBW	NNP	O
,	,	O
but	CC	O
it	PRP	O
increased	VBD	O
in	IN	O
the	DT	O
TBW	NNP	O
(	(	O
r	VB	O
=	RB	O
0.80	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
BV	NNP	O
(	(	O
r	VB	O
=	RB	O
0.70	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
groups	NNS	O
as	IN	O
TBW	NNP	O
increased	VBD	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
LBW	NNP	O
,	,	O
rather	RB	O
than	IN	O
TBW	NNP	O
or	CC	O
BV	NNP	O
,	,	O
is	VBZ	O
used	VBN	O
,	,	O
the	DT	O
iodine	NN	PM
dose	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
consistent	JJ	O
hepatic	JJ	O
enhancement	NN	O
may	MD	O
be	VB	O
estimated	VBN	O
more	RBR	O
precisely	RB	O
and	CC	O
with	IN	O
reduced	JJ	O
patient-to-patient	JJ	O
variability	NN	O
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
nutrition	NN	PH
intervention	NN	PH
during	IN	O
early	JJ	O
childhood	NN	O
on	IN	O
economic	JJ	O
productivity	NN	O
in	IN	O
Guatemalan	NNP	O
adults	NNS	O
.	.	O

BACKGROUND	NNP	O
Substantial	NNP	O
,	,	O
but	CC	O
indirect	JJ	O
,	,	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
improving	VBG	O
nutrition	NN	O
in	IN	O
early	JJ	O
childhood	NN	O
in	IN	O
developing	VBG	O
countries	NNS	O
is	VBZ	O
a	DT	O
long-term	JJ	O
economic	JJ	O
investment	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
direct	JJ	O
effect	NN	O
of	IN	O
a	DT	O
nutrition	NN	PH
intervention	NN	PH
in	IN	O
early	JJ	O
childhood	NN	O
on	IN	O
adult	JJ	O
economic	JJ	O
productivity	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
obtained	VBD	O
economic	JJ	O
data	NNS	O
from	IN	O
1424	CD	O
Guatemalan	NNP	O
individuals	NNS	O
(	(	O
aged	VBN	O
25-42	CD	O
years	NNS	O
)	)	O
between	IN	O
2002	CD	O
and	CC	O
2004	CD	O
.	.	O

They	PRP	O
accounted	VBD	O
for	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
2392	CD	O
children	NNS	O
(	(	O
aged	VBN	O
0-7	CD	O
years	NNS	O
)	)	O
who	WP	O
had	VBD	O
been	VBN	O
enrolled	VBN	O
in	IN	O
a	DT	O
nutrition	NN	PM
intervention	NN	PM
study	NN	O
during	IN	O
1969-77	JJ	O
.	.	O

In	IN	O
this	DT	O
initial	JJ	O
study	NN	O
,	,	O
two	CD	O
villages	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
a	DT	O
nutritious	JJ	PM
supplement	NN	PM
(	(	PM
atole	JJ	PM
)	)	PM
for	IN	PM
all	DT	PM
children	NNS	PM
and	CC	O
two	CD	PM
villages	NNS	PM
a	DT	PM
less	RBR	PM
nutritious	JJ	PM
one	CD	PM
(	(	PM
fresco	NN	PM
)	)	PM
.	.	O

We	PRP	O
estimated	VBD	O
annual	JJ	O
income	NN	O
,	,	O
hours	NNS	O
worked	VBD	O
,	,	O
and	CC	O
average	JJ	O
hourly	JJ	O
wages	NNS	O
from	IN	O
all	DT	O
economic	JJ	O
activities	NNS	O
.	.	O

We	PRP	O
used	VBD	O
linear	JJ	O
regression	NN	O
models	NNS	O
,	,	O
adjusting	VBG	O
for	IN	O
potentially	RB	O
confounding	VBG	O
factors	NNS	O
,	,	O
to	TO	O
assess	VB	O
the	DT	O
relation	NN	O
between	IN	O
economic	JJ	O
variables	NNS	O
and	CC	O
exposure	NN	O
to	TO	O
atole	VB	PM
or	CC	O
fresco	VB	PM
at	IN	O
specific	JJ	O
ages	NNS	O
between	IN	O
birth	NN	O
and	CC	O
7	CD	O
years	NNS	O
.	.	O

FINDINGS	NNP	O
Exposure	NN	O
to	TO	O
atole	VB	PM
before	IN	O
,	,	O
but	CC	O
not	RB	O
after	IN	O
,	,	O
age	NN	O
3	CD	O
years	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
hourly	NN	O
wages	NNS	O
,	,	O
but	CC	O
only	RB	O
for	IN	O
men	NNS	O
.	.	O

For	IN	O
exposure	NN	O
to	TO	O
atole	VB	O
from	IN	O
0	CD	O
to	TO	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
increase	NN	O
was	VBD	O
US	NNP	O
$	$	O
0.67	CD	O
per	IN	O
hour	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.16-1.17	NN	O
)	)	O
,	,	O
which	WDT	O
meant	VBD	O
a	DT	O
46	CD	O
%	NN	O
increase	NN	O
in	IN	O
average	JJ	O
wages	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
non-significant	JJ	O
tendency	NN	O
for	IN	O
hours	NNS	O
worked	VBN	O
to	TO	O
be	VB	O
reduced	VBN	O
and	CC	O
for	IN	O
annual	JJ	O
incomes	NNS	O
to	TO	O
be	VB	O
greater	JJR	O
for	IN	O
those	DT	O
exposed	VBN	O
to	TO	O
atole	VB	PM
from	IN	O
0	CD	O
to	TO	O
2	CD	O
years	NNS	O
.	.	O

INTERPRETATION	NNP	O
Improving	VBG	O
nutrition	NN	O
in	IN	O
early	JJ	O
childhood	NN	O
led	VBD	O
to	TO	O
substantial	JJ	O
increases	NNS	O
in	IN	O
wage	NN	O
rates	NNS	O
for	IN	O
men	NNS	O
,	,	O
which	WDT	O
suggests	VBZ	O
that	IN	O
investments	NNS	O
in	IN	O
early	JJ	O
childhood	NN	O
nutrition	NN	O
can	MD	O
be	VB	O
long-term	JJ	O
drivers	NNS	O
of	IN	O
economic	JJ	O
growth	NN	O
.	.	O

Azelnidipine	NNP	PM
and	CC	O
amlodipine	VB	PM
anti-coronary	JJ	O
atherosclerosis	NN	O
trial	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
intervention	NN	O
by	IN	O
serial	JJ	O
volumetric	JJ	O
intravascular	NN	O
ultrasound	NN	O
analysis	NN	O
in	IN	O
Juntendo	NNP	O
university	NN	O
(	(	O
ALPS-J	NNP	O
)	)	O
.	.	O

PURPOSE	NNP	O
Many	JJ	O
trials	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
calcium	NN	O
channel	NN	O
blockers	NNS	O
(	(	O
CCBs	NNP	O
)	)	O
can	MD	O
reduce	VB	O
the	DT	O
cardiovascular	NN	O
(	(	O
CV	NNP	O
)	)	O
events	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

The	DT	O
mechanisms	NN	O
of	IN	O
this	DT	O
effect	NN	O
could	MD	O
be	VB	O
associated	VBN	O
with	IN	O
plaque	JJ	O
regression	NN	O
due	JJ	O
to	TO	O
the	DT	O
anti-atherosclerotic	JJ	O
properties	NNS	O
of	IN	O
CCBs	NNP	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
CCB	NNP	O
on	IN	O
volumetric	JJ	O
quantitative	JJ	O
changes	NNS	O
of	IN	O
coronary	JJ	O
plaques	NNS	O
accessed	VBN	O
by	IN	O
intravascular	JJ	O
ultrasound	NN	O
(	(	O
IVUS	NNP	O
)	)	O
.	.	O

To	TO	O
confirm	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
trial	NN	O
of	IN	O
CCBs	NNP	O
treatment	NN	O
with	IN	O
azelnidipine	NN	PM
or	CC	O
amlodipine	NN	PM
will	MD	O
be	VB	O
conducted	VBN	O
in	IN	O
hypertensive	JJ	O
CAD	NNP	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Patients	NNPS	O
who	WP	O
have	VBP	O
hypertension	NN	O
and	CC	O
are	VBP	O
scheduled	VBN	O
for	IN	O
PCI	NNP	O
will	MD	O
be	VB	O
enrolled	VBN	O
.	.	O

Subjects	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
to	TO	O
azelnidipine	VB	PM
or	CC	O
amlodipine	VB	PM
and	CC	O
observed	VB	O
for	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
will	MD	O
be	VB	O
the	DT	O
percent	NN	O
change	NN	O
of	IN	O
coronary	JJ	O
plaque	NN	O
volume	NN	O
.	.	O

The	DT	O
secondary	JJ	O
endpoint	NN	O
will	MD	O
include	VB	O
inflammatory	JJ	O
markers	NNS	O
,	,	O
antioxidant	JJ	O
activity	NN	O
,	,	O
and	CC	O
incidence	NN	O
of	IN	O
composite	JJ	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
will	MD	O
investigate	VB	O
the	DT	O
improvement	NN	O
of	IN	O
coronary	JJ	O
plaque	NN	O
with	IN	O
IVUS	NNP	O
by	IN	O
treatment	NN	O
with	IN	O
two	CD	O
dihydropyridine	NN	O
CCBs	NNP	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

This	DT	O
result	NN	O
will	MD	O
lead	VB	O
to	TO	O
the	DT	O
discovery	NN	O
of	IN	O
more	RBR	O
effective	JJ	O
drug	NN	O
therapy	NN	O
for	IN	O
inhibition	NN	O
of	IN	O
coronary	JJ	O
events	NNS	O
.	.	O

[	NNP	O
Medical	NNP	O
safety	NN	O
and	CC	O
staff	NN	O
mental	JJ	O
health	NN	O
]	NNP	O
.	.	O

Improvement	NNP	O
in	IN	O
patient	JJ	O
safety	NN	O
is	VBZ	O
a	DT	O
high-priority	JJ	O
issue	NN	O
of	IN	O
great	JJ	O
social	JJ	O
import	NN	O
.	.	O

Several	JJ	O
studies	NNS	O
have	VBP	O
reported	VBN	O
that	IN	O
most	JJS	O
adverse	JJ	O
events	NNS	O
are	VBP	O
due	JJ	O
to	TO	O
errors	NNS	O
of	IN	O
hospital	JJ	O
staff	NN	O
,	,	O
and	CC	O
emphasized	VBD	O
the	DT	O
necessity	NN	O
of	IN	O
promoting	VBG	O
countermeasures	NNS	O
against	IN	O
medical	JJ	O
errors	NNS	O
.	.	O

Root	NNP	O
cause	NN	O
analysis	NN	O
(	(	O
RCA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
implemented	VBN	O
to	TO	O
prevent	VB	O
such	JJ	O
errors	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
retrospective	NN	O
and	CC	O
qualitative	JJ	O
nature	NN	O
of	IN	O
RCA	NNP	O
is	VBZ	O
a	DT	O
limitation	NN	O
in	IN	O
scientific	JJ	O
analyses	NNS	O
examining	VBG	O
causal	JJ	O
relationships	NNS	O
.	.	O

We	PRP	O
showed	VBD	O
that	IN	O
prospective	JJ	O
design	NN	O
path	NN	O
analysis	NN	O
using	VBG	O
structural	JJ	E
equation	NN	E
modeling	NN	E
(	(	E
SEM	NNP	E
)	)	E
model	NN	O
for	IN	O
both	DT	O
direct	JJ	O
and	CC	O
indirect	JJ	O
effects	NNS	O
enabled	VBD	O
statistical	JJ	O
exploration	NN	O
of	IN	O
root	NN	O
causes	NNS	O
and	CC	O
estimation	NN	O
of	IN	O
their	PRP$	O
impact	NN	O
on	IN	O
the	DT	O
outcome	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggested	VBD	O
such	JJ	O
analysis	NN	O
to	TO	O
be	VB	O
useful	JJ	O
in	IN	O
devising	VBG	O
countermeasures	NNS	O
against	IN	O
medical	JJ	O
errors	NNS	O
.	.	O

The	DT	O
SEM	NNP	O
model	NN	O
constructed	VBN	O
in	IN	O
this	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
one	CD	O
of	IN	O
the	DT	O
potential	JJ	O
root	NN	O
causes	NNS	O
was	VBD	O
sleep	JJ	O
disturbance	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
whether	IN	O
or	CC	O
not	RB	O
brief	JJ	O
bright	JJ	O
light	NN	O
(	(	O
BL	NNP	PH
)	)	O
exposure	NN	O
on	IN	O
workday	JJ	O
mornings	NNS	O
can	MD	O
improve	VB	O
health	NN	O
,	,	O
performance	NN	O
and	CC	O
safety	NN	O
in	IN	O
nurses	NNS	O
with	IN	O
rapidly	RB	O
rotating	VBG	O
shifts	NNS	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
BL	NNP	O
periods	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
for	IN	O
self-assessed	JJ	O
sleepiness	NN	O
at	IN	O
10	CD	O
:	:	O
00	CD	O
on	IN	O
day-shift	JJ	O
days	NNS	O
,	,	O
self-assessment	NN	O
of	IN	O
night	NN	O
sleep	NN	O
for	IN	O
day-shift	JJ	O
days	NNS	O
and	CC	O
for	IN	O
fatigue	NN	O
.	.	O

Mean	NNP	O
response	NN	O
time	NN	O
evaluated	VBN	O
using	VBG	O
the	DT	O
psychomotor	NN	O
vigilance	NN	O
task	NN	O
test	NN	O
(	(	O
PVT	NNP	O
)	)	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
BL	NNP	O
periods	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
perceived	JJ	O
adverse	JJ	O
events	NNS	O
and	CC	O
near	JJ	O
misses	NNS	O
was	VBD	O
also	RB	O
lower	JJR	O
in	IN	O
the	DT	O
BL	NNP	O
than	IN	O
in	IN	O
the	DT	O
non-BL	JJ	O
periods	NNS	O
,	,	O
but	CC	O
not	RB	O
significantly	RB	O
so	RB	O
,	,	O
possibly	RB	O
indicating	VBG	O
that	IN	O
the	DT	O
one-month	JJ	O
observation	NN	O
period	NN	O
was	VBD	O
too	RB	O
short	JJ	O
to	TO	O
achieve	VB	O
any	DT	O
significant	JJ	O
success	NN	O
.	.	O

Despite	IN	O
our	PRP$	O
study	NN	O
's	POS	O
limitations	NNS	O
,	,	O
we	PRP	O
have	VBP	O
effectively	RB	O
demonstrated	VBN	O
the	DT	O
potential	NN	O
for	IN	O
preventing	VBG	O
medical	JJ	O
error	NN	O
risk	NN	O
among	IN	O
night-shift	JJ	O
workers	NNS	O
.	.	O

Heart	NNP	O
rate	NN	O
variability	NN	O
and	CC	O
QT	NNP	O
dispersion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
subclinical	JJ	O
hypothyroidism	NN	O
.	.	O

UNLABELLED	IN	O
The	DT	O
effect	NN	O
of	IN	O
subclinical	JJ	O
hypothyroidism	NN	O
(	(	O
SH	NNP	O
)	)	O
on	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
ventricular	JJ	O
repolarization	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
yet	RB	O
elucidated	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
dispersion	NN	O
of	IN	O
QT	NNP	O
interval	NN	O
,	,	O
i.e	NN	O
.	.	O

an	DT	O
index	NN	O
of	IN	O
inhomogeneity	NN	O
of	IN	O
repolarization	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
,	,	O
i.e	RB	O
.	.	O

a	DT	O
measure	NN	O
of	IN	O
cardiac	JJ	O
autonomic	JJ	O
modulation	NN	O
,	,	O
in	IN	O
SH	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
42	CD	O
patients	NNS	O
(	(	O
29	CD	O
women	NNS	O
and	CC	O
13	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
53.2+/-14.2	JJ	O
years	NNS	O
;	:	O
body	NN	O
surface	JJ	O
area	NN	O
1.76+/-0.14	JJ	O
m2	NN	O
)	)	O
with	IN	O
SH	NNP	O
,	,	O
as	IN	O
judged	VBN	O
by	IN	O
elevated	JJ	O
serum	NN	O
TSH	NNP	O
levels	NNS	O
(	(	O
>	$	O
3.6	CD	O
mIU/l	NN	O
;	:	O
range	NN	O
,	,	O
3.8-12.0	JJ	O
)	)	O
and	CC	O
normal	JJ	O
free	JJ	O
thyroid	NN	O
hormones	NNS	O
(	(	O
FT4	NNP	O
and	CC	O
FT3	NNP	O
)	)	O
and	CC	O
30	CD	O
euthyroid	JJ	O
volunteer	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
cardiac	JJ	O
,	,	O
metabolic	JJ	O
,	,	O
neurological	JJ	O
disease	NN	O
or	CC	O
any	DT	O
other	JJ	O
systemic	JJ	O
disease	NN	O
that	WDT	O
could	MD	O
affect	VB	O
autonomic	JJ	O
activity	NN	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
with	IN	O
SH	NNP	O
and	CC	O
control	VB	O
subjects	NNS	O
underwent	VB	O
a	DT	O
full	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
,	,	O
standard	JJ	O
12-lead	JJ	PH
ECG	NNP	PH
,	,	PH
and	CC	PH
24-h	JJ	PH
ambulatory	NN	PH
ECG	NNP	PH
monitoring	NN	PH
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
L-thyroxine	NNP	PM
on	IN	O
QT	NNP	O
dispersion	NN	O
and	CC	O
HRV	NNP	O
,	,	O
15	CD	O
patients	NNS	O
with	IN	O
SH	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
therapy	NN	O
with	IN	O
L-thyroxine	NNP	PM
.	.	O

All	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
enrolment	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Patients	NNPS	O
with	IN	O
SH	NNP	O
showed	VBD	O
higher	JJR	O
QT	NNP	O
dispersion	NN	O
and	CC	O
lower	JJR	O
HRV	NNP	O
measures	NNS	O
than	IN	O
healthy	JJ	O
controls	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.01	CD	O
for	IN	O
all	DT	O
)	)	O
.	.	O

In	IN	O
SH	NNP	O
patients	NNS	O
,	,	O
the	DT	O
standard	JJ	O
deviation	NN	O
of	IN	O
N-Ns	NNP	O
(	(	O
SDNN	NNP	O
)	)	O
was	VBD	O
negatively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=-0.42	JJ	O
,	,	O
P=0.006	NNP	O
)	)	O
,	,	O
while	IN	O
low	JJ	O
frequency	NN	O
(	(	O
LF	NNP	O
)	)	O
/high	VBP	O
frequency	NN	O
(	(	O
HF	NNP	O
)	)	O
ratio	NN	O
was	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=0.42	NN	O
,	,	O
P=0.006	NNP	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
in	IN	O
SH	NNP	O
patients	NNS	O
both	DT	O
QT	NNP	O
dispersion	NN	O
and	CC	O
QTc	NNP	O
dispersion	NN	O
were	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=0.64	NN	O
and	CC	O
r=0.63	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
L-tiroxine	NNP	PM
exhibited	VBD	O
a	DT	O
reduction	NN	O
of	IN	O
QT	NNP	O
dispersion	NN	O
and	CC	O
an	DT	O
increase	NN	O
of	IN	O
HRV	NNP	O
parameters	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
demonstrated	VBD	O
that	IN	O
SH	NNP	O
can	MD	O
alter	VB	O
autonomic	JJ	O
modulation	NN	O
of	IN	O
heart	NN	O
rate	NN	O
and	CC	O
cause	NN	O
increased	VBD	O
inhomogeneity	NN	O
of	IN	O
ventricular	JJ	O
recovery	NN	O
times	NNS	O
.	.	O

Accordingly	RB	O
,	,	O
early	JJ	O
L-thyroxine	JJ	PM
treatment	NN	O
may	MD	O
be	VB	O
advised	VBN	O
not	RB	O
only	RB	O
to	TO	O
prevent	VB	O
progression	NN	O
to	TO	O
overt	VB	O
hypothyroidism	NN	O
but	CC	O
also	RB	O
to	TO	O
improve	VB	O
abnormal	JJ	O
cardiac	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
ventricular	JJ	O
repolarization	NN	O
inhomogeneity	NN	O
.	.	O

Randomized	VBN	O
controlled	VBD	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
dose	NN	O
of	IN	O
adjuvant	JJ	PM
chemotherapy	NN	PM
after	IN	O
curative	JJ	S
resection	NN	S
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
Adjuvant	NNP	PM
locoregional	JJ	PM
chemotherapy	NN	PM
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
useful	JJ	O
to	TO	O
prevent	VB	O
recurrence	NN	O
after	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
(	(	O
HCC	NNP	O
)	)	O
in	IN	O
some	DT	O
retrospective	JJ	O
studies	NNS	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
dose	JJ	O
effect	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
tumor	NN	O
recurrence	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
curative	JJ	O
resection	NN	O
of	IN	O
HCC	NNP	O
;	:	O
they	PRP	O
were	VBD	O
given	VBN	O
either	DT	O
one	CD	O
intra-arterial	JJ	O
dose	NN	O
of	IN	O
cisplatin/lipiodol	NN	PM
,	,	O
or	CC	O
received	VBD	O
four	CD	O
doses	NNS	O
,	,	O
once	RB	O
every	DT	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
rates	NNS	O
of	IN	O
recurrence	NN	O
,	,	O
disease-free	JJ	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
During	IN	O
a	DT	O
median	JJ	O
follow	NN	O
up	IN	O
of	IN	O
818	CD	O
days	NNS	O
,	,	O
21	CD	O
patients	NNS	O
received	VBD	O
one	CD	O
dose	NN	O
and	CC	O
19	CD	O
received	VBD	O
four	CD	O
doses	NNS	O
,	,	O
with	IN	O
10	CD	O
(	(	O
47.6	CD	O
%	NN	O
)	)	O
and	CC	O
eight	CD	O
(	(	O
42.1	CD	O
%	NN	O
)	)	O
recurrences	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
1-year	JJ	O
,	,	O
2-year	JJ	O
and	CC	O
3-year	JJ	O
disease-free	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
71	CD	O
%	NN	O
,	,	O
54	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
for	IN	O
the	DT	O
one-dose	JJ	O
group	NN	O
and	CC	O
74	CD	O
%	NN	O
,	,	O
60	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
for	IN	O
the	DT	O
four-dose	JJ	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.78	CD	O
)	)	O
.	.	O

The	DT	O
respective	JJ	O
overall	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
85	CD	O
%	NN	O
,	,	O
74	CD	O
%	NN	O
,	,	O
55	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
,	,	O
71	CD	O
%	NN	O
,	,	O
40	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.64	CD	O
)	)	O
.	.	O

The	DT	O
only	JJ	O
prognostic	JJ	O
factor	NN	O
was	VBD	O
presence	NN	O
of	IN	O
vascular	JJ	O
permeation	NN	O
.	.	O

The	DT	O
side-effects	NNS	O
were	VBD	O
mild	JJ	O
and	CC	O
tolerable	JJ	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
survival	NN	O
rates	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Adjuvant	NNP	PM
chemotherapy	NN	PM
may	MD	O
not	RB	O
be	VB	O
useful	JJ	O
.	.	O

A	DT	O
randomized	JJ	O
placebo-controlled	JJ	C
trial	NN	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
etoricoxib	$	PM
30	CD	O
mg	NN	O
and	CC	O
ibuprofen	NN	PM
2400	CD	O
mg	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
osteoarthritis	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
etoricoxib	$	PM
30	CD	O
mg	NN	O
to	TO	O
placebo	VB	C
and	CC	O
ibuprofen	VB	PM
2400	CD	O
mg	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
of	IN	O
the	DT	O
hip	NN	O
and	CC	O
knee	NN	O
.	.	O

DESIGN	NN	O
In	IN	O
this	DT	O
12-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-	JJ	C
and	CC	O
active-comparator-controlled	JJ	O
trial	NN	O
,	,	O
548	CD	O
patients	NNS	O
(	(	O
median	JJ	O
age	NN	O
63	CD	O
years	NNS	O
)	)	O
with	IN	O
OA	NNP	O
of	IN	O
the	DT	O
hip	NN	O
or	CC	O
knee	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
placebo	NN	C
,	,	O
etoricoxib	VBZ	PM
30	CD	O
mg	NN	O
q.d.	NN	O
,	,	O
or	CC	O
ibuprofen	VB	PM
800	CD	O
mg	NN	O
t.i.d	NN	O
.	.	O

Demonstration	NN	O
of	IN	O
etoricoxib	NN	PM
's	POS	PM
efficacy	NN	O
vs	NN	O
placebo	NN	C
and	CC	O
comparison	NN	O
of	IN	O
its	PRP$	O
efficacy	NN	O
to	TO	O
ibuprofen	VB	PM
were	VBD	O
assessed	VBN	O
using	VBG	O
three	CD	O
co-primary	JJ	O
endpoints	NNS	O
:	:	O
Western	JJ	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
's	POS	O
University	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
Pain	NNP	O
Subscale	NNP	O
(	(	O
WOMAC-PS	NNP	O
)	)	O
;	:	O
WOMAC	NNP	O
Physical	NNP	O
Function	NNP	O
Subscale	NNP	O
(	(	O
WOMAC-PFS	NNP	O
)	)	O
;	:	O
and	CC	O
Patient	NNP	O
Global	NNP	O
Assessment	NNP	O
of	IN	O
Disease	NNP	O
Status	NNP	O
(	(	O
PGADS	NNP	O
)	)	O
.	.	O

Each	DT	O
primary	JJ	O
endpoint	NN	O
utilizes	VBZ	O
a	DT	O
0-100	JJ	O
mm	NN	O
visual	JJ	O
analog	NN	O
scale	NN	O
.	.	O

To	TO	O
demonstrate	VB	O
comparable	JJ	O
efficacy	NN	O
of	IN	O
etoricoxib	JJ	PM
vs	NN	O
ibuprofen	NN	PM
,	,	O
the	DT	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
for	IN	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
least	JJS	O
squares	NNS	O
(	(	O
LS	NNP	O
)	)	O
mean	VBP	O
change	NN	O
over	IN	O
12	CD	O
weeks	NNS	O
for	IN	O
all	DT	O
three	CD	O
co-primary	JJ	O
endpoints	NNS	O
had	VBD	O
to	TO	O
fall	VB	O
within	IN	O
+/-10	JJ	O
mm	NN	O
.	.	O

Safety	NNP	O
and	CC	O
tolerability	NN	O
data	NNS	O
were	VBD	O
collected	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
baseline	NN	O
values	NNS	O
for	IN	O
the	DT	O
three	CD	O
co-primary	JJ	O
endpoints	NNS	O
ranged	VBD	O
from	IN	O
62.52	CD	O
to	TO	O
70.14	CD	O
mm	NN	O
.	.	O

Both	DT	O
etoricoxib	JJ	PM
and	CC	O
ibuprofen	JJ	PM
demonstrated	VBN	O
superior	JJ	O
(	(	O
P	NNP	O
<	NNP	O
or	CC	O
=0.002	NNP	O
)	)	O
efficacy	NN	O
for	IN	O
all	DT	O
primary	JJ	O
endpoints	NNS	O
.	.	O

The	DT	O
LS	NNP	O
mean	NN	O
(	(	O
mm	NN	O
)	)	O
changes	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
over	IN	O
12	CD	O
weeks	NNS	O
for	IN	O
etoricoxib	NN	PM
and	CC	O
ibuprofen	NN	PM
,	,	O
respectively	RB	O
,	,	O
compared	VBN	O
to	TO	O
placebo	VB	C
were	VBD	O
given	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
WOMAC-PS	JJ	O
:	:	O
-11.66	NN	O
(	(	O
-16.31	UH	O
,	,	O
-7.01	NNP	O
)	)	O
and	CC	O
-7.62	NNP	O
(	(	O
-12.30	NNP	O
,	,	O
-2.94	NNP	O
)	)	O
;	:	O
WOMAC-PFS	JJ	O
:	:	O
-10.15	NN	O
(	(	O
-14.74	UH	O
,	,	O
-5.57	NNP	O
)	)	O
and	CC	O
-7.23	NNP	O
(	(	O
-11.85	NNP	O
,	,	O
-2.61	NNP	O
)	)	O
;	:	O
PGADS	NNP	O
:	:	O
-11.65	NN	O
(	(	O
-16.81	UH	O
,	,	O
-6.50	NNP	O
)	)	O
and	CC	O
-8.11	NNP	O
(	(	O
-13.30	NNP	O
,	,	O
-2.92	NNP	O
)	)	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
etoricoxib	$	PM
30	CD	O
mg	NN	O
was	VBD	O
comparable	JJ	O
to	TO	O
ibuprofen	VB	PM
2400	CD	O
mg.	NN	O
All	DT	O
treatments	NNS	O
were	VBD	O
similarly	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	NNP	O
Treatment	NNP	O
with	IN	O
etoricoxib	JJ	PM
30	CD	O
mg	NN	O
q.d	NN	O
.	.	O

provides	VBZ	O
superior	JJ	O
efficacy	NN	O
vs	NN	O
placebo	NN	C
and	CC	O
comparable	JJ	O
clinical	JJ	O
efficacy	NN	O
vs	NN	O
ibuprofen	NN	PM
2400	CD	O
mg	NN	O
(	(	O
800	CD	O
mg	NN	O
t.i.d	NN	O
.	.	O

)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
OA	NNP	O
of	IN	O
the	DT	O
hip	NN	O
and	CC	O
knee	NN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
six	CD	O
epoetin	JJ	PM
alfa	NN	PM
dosing	VBG	O
regimens	NNS	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
without	IN	O
acute	JJ	O
blood	NN	O
loss	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
describe	VB	O
the	DT	O
pharmacokinetic	JJ	O
profiles	NNS	O
of	IN	O
six	CD	O
different	JJ	O
dosing	VBG	O
regimens	NNS	O
for	IN	O
epoetin	NN	PM
alfa	NN	PM
,	,	O
and	CC	O
whether	IN	O
more	JJR	O
rapid	JJ	O
and	CC	O
robust	JJ	O
reticulocytosis	NN	O
can	MD	O
be	VB	O
elicited	VBN	O
with	IN	O
more	RBR	O
frequent	JJ	O
administration	NN	O
of	IN	O
epoetin	JJ	PM
alfa	NN	PM
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
open-label	NN	O
,	,	O
multicenter	NN	O
,	,	O
28-day	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Ten	CD	O
centers	NNS	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PATIENTS	VB	O
Adult	NNP	O
(	(	O
age	NN	O
>	VBN	O
or=18	CD	O
years	NNS	O
)	)	O
critically	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
hemoglobin	JJ	O
<	NNP	O
or=12	NN	O
g/dL	NN	O
,	,	O
expected	VBN	O
hospitalization	NN	O
of	IN	O
>	NNP	O
or=7	NNP	O
days	NNS	O
,	,	O
with	IN	O
no	DT	O
ongoing	VBG	O
acute	RB	O
blood	NN	O
loss	NN	O
.	.	O

INTERVENTIONS	NNP	O
One	CD	O
of	IN	O
six	CD	PM
dosing	VBG	PM
epoetin	NN	PM
alfa	NN	PM
regimens	VBZ	PM
for	IN	O
15	CD	O
days	NNS	O
,	,	O
as	IN	O
follows	VBZ	O
:	:	O
40,000	CD	PM
IU	NNP	PM
once	RB	PM
weekly	RB	PM
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
intravenously	RB	O
(	(	O
IV	NNP	O
)	)	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
;	:	O
15,000	CD	PM
IU	NNP	PM
every	DT	PM
other	JJ	PM
day	NN	PM
,	,	PM
subcutaneously	RB	PM
(	(	O
group	NN	O
C	NNP	O
)	)	O
or	CC	O
IV	NNP	O
(	(	O
group	NN	O
D	NNP	O
)	)	O
;	:	O
or	CC	O
40,000	CD	PM
IU	NNP	PM
day	NN	PM
1	CD	O
and	CC	O
3	CD	O
,	,	O
subcutaneously	RB	PM
(	(	O
group	NN	O
E	NNP	O
)	)	O
or	CC	O
IV	NNP	O
(	(	O
group	NN	O
F	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
15,000	CD	O
IU	NNP	O
once	RB	O
every	DT	O
other	JJ	O
day	NN	O
on	IN	O
[	NN	O
corrected	VBN	O
]	JJ	O
days	NNS	O
5-15	JJ	O
[	NNP	O
corrected	VBD	O
]	NN	O
MEASUREMENTS	NNP	O
Serum	NNP	O
erythropoietin	NN	O
concentration	NN	O
,	,	O
absolute	JJ	O
reticulocyte	NN	O
count	NN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Of	IN	O
the	DT	O
60	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
enrolled	VBN	O
(	(	O
60	CD	O
%	NN	O
men	NNS	O
,	,	O
mean	JJ	O
age	NN	O
53	CD	O
years	NNS	O
,	,	O
mean	VBP	O
Acute	NNP	O
Physiology	NNP	O
and	CC	O
Chronic	NNP	O
Health	NNP	O
Evaluation	NNP	O
II	NNP	O
score	NN	O
,	,	O
19.5	CD	O
)	)	O
,	,	O
30	CD	O
were	VBD	O
evaluable	JJ	O
for	IN	O
both	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
.	.	O

Erythropoietin	NNP	PH
exposure	NN	PH
was	VBD	O
approximately	RB	O
ten	JJ	O
times	NNS	O
greater	JJR	O
for	IN	O
IV	NNP	O
dosing	VBG	O
than	IN	O
for	IN	O
subcutaneous	JJ	PM
dosing	NN	PM
.	.	PM

Mean	NNP	O
absolute	JJ	O
reticulocyte	NN	O
count	NN	O
peaked	VBD	O
at	IN	O
day	NN	O
11	CD	O
or	CC	O
15	CD	O
in	IN	O
each	DT	O
group	NN	O
and	CC	O
appeared	VBD	O
to	TO	O
be	VB	O
greater	JJR	O
for	IN	O
subcutaneous	JJ	O
dosing	NN	PM
(	(	O
mean	JJ	O
peak	NN	O
response	NN	O
149-169	JJ	O
x	NN	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
compared	VBN	O
with	IN	O
IV	NNP	O
dosing	VBG	O
(	(	O
mean	JJ	O
peak	NN	O
response	NN	O
138-147	JJ	O
x	NN	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
at	IN	O
most	JJS	O
visits	NNS	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
were	VBD	O
pyrexia	NNS	O
(	(	O
18	CD	O
%	NN	O
)	)	O
,	,	O
hypokalemia	NN	O
(	(	O
15	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
hypophosphatemia	NN	O
(	(	O
15	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
of	IN	O
anemic	JJ	O
critically	NN	O
ill	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
epoetin	JJ	PM
alfa	NN	PM
,	,	O
all	DT	O
dosing	VBG	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
appeared	VBN	O
to	TO	O
effect	NN	O
reticulocytosis	NN	O
,	,	O
with	IN	O
a	DT	O
peak	NN	O
at	IN	O
day	NN	O
11	CD	O
or	CC	O
15	CD	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
of	IN	O
epoetin	JJ	PM
alfa	NN	PM
did	VBD	O
not	RB	O
predict	VB	O
pharmacodynamic	JJ	O
response	NN	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
.	.	O

Effectiveness	NN	O
of	IN	O
web-based	JJ	E
tailored	JJ	E
smoking	NN	E
cessation	NN	E
advice	NN	O
reports	NNS	O
(	(	O
iQuit	NN	O
)	)	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
web-based	JJ	O
tailored	JJ	O
cessation	NN	O
advice	NN	O
,	,	O
based	VBN	O
on	IN	O
social	JJ	O
cognitive	JJ	O
theory	NN	O
and	CC	O
the	DT	O
perspectives	NNS	O
on	IN	O
change	NN	O
model	NN	O
,	,	O
was	VBD	O
more	RBR	O
effective	JJ	O
in	IN	O
aiding	VBG	O
a	DT	O
quit	NN	O
attempt	NN	O
than	IN	O
broadly	RB	O
similar	JJ	O
web-based	JJ	O
advice	NN	O
that	WDT	O
was	VBD	O
not	RB	O
tailored	VBN	O
.	.	O

DESIGN	JJ	O
Participants	NNS	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
,	,	O
to	TO	E
receive	VB	E
either	CC	E
a	DT	E
cessation	NN	E
advice	NN	E
report	NN	E
and	CC	E
progress	JJ	E
report	NN	E
that	WDT	E
were	VBD	E
tailored	VBN	E
to	TO	E
individual-level	JJ	E
characteristics	NNS	E
or	CC	E
a	DT	E
cessation	NN	E
advice	NN	E
report	NN	E
that	WDT	E
presented	VBD	E
standardized	JJ	E
(	(	E
non-tailored	JJ	E
)	)	E
content	NN	E
.	.	E

Tailoring	NNP	O
was	VBD	O
based	VBN	O
on	IN	O
smoking-related	JJ	O
beliefs	NN	O
,	,	O
personal	JJ	O
characteristics	NNS	O
and	CC	O
smoking	NN	O
patterns	NNS	O
,	,	O
self-efficacy	NN	O
and	CC	O
outcome	JJ	O
expectations	NNS	O
.	.	O

SETTING	NN	O
Participant	JJ	O
enrolment	NN	O
and	CC	O
baseline	NN	E
assessments	NNS	E
were	VBD	O
conducted	VBN	O
remotely	RB	O
online	JJ	O
via	IN	O
the	DT	O
study	NN	O
website	NN	O
,	,	O
with	IN	O
the	DT	O
advice	NN	O
reports	NNS	O
presented	VBN	O
by	IN	O
the	DT	O
same	JJ	O
website	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
(	(	O
n	IN	O
=	NNP	O
1758	CD	O
)	)	O
were	VBD	O
visitors	NNS	O
to	TO	O
the	DT	O
QUIT	NNP	O
website	NN	O
who	WP	O
were	VBD	O
based	VBN	O
in	IN	O
the	DT	O
United	NNP	O
Kingdom	NNP	O
,	,	O
aged	VBD	O
18	CD	O
years	NNS	O
or	CC	O
over	RB	O
and	CC	O
who	WP	O
smoked	VBD	O
cigarettes	NNS	O
or	CC	O
hand-rolled	JJ	O
tobacco	NN	O
.	.	O

MEASUREMENTS	NNP	O
Follow-up	JJ	O
assessments	NNS	O
were	VBD	O
made	VBN	O
at	IN	O
6	CD	O
months	NNS	O
by	IN	O
telephone	NN	O
interview	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
self-reported	JJ	O
3	CD	O
months	NNS	O
prolonged	VBN	O
abstinence	NN	O
,	,	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
were	VBD	O
1	CD	O
month	NN	O
prolonged	VBD	O
abstinence	NN	O
,	,	O
7-day	JJ	O
and	CC	O
24-hour	JJ	O
point	NN	O
prevalence	NN	O
abstinence	NN	O
.	.	O

FINDINGS	IN	O
The	DT	O
intervention	NN	O
group	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
the	DT	O
control	NN	O
group	NN	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
(	(	O
9.1	CD	O
%	NN	O
versus	IN	O
9.3	CD	O
%	NN	O
;	:	O
odds	NNS	O
ratio	VBP	O
=	$	O
1.02	CD	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.73-1.42	NN	O
)	)	O
or	CC	O
on	IN	O
any	DT	O
of	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

Intervention	NN	O
participants	NNS	O
gave	VBD	O
more	RBR	O
positive	JJ	O
evaluations	NNS	O
of	IN	O
the	DT	O
materials	NNS	O
than	IN	O
control	NN	O
participants	NNS	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
web-based	JJ	O
intervention	NN	O
that	WDT	O
tailored	VBD	O
content	JJ	O
according	VBG	O
to	TO	O
smoking-related	JJ	O
beliefs	NN	O
,	,	O
personal	JJ	O
characteristics	NNS	O
and	CC	O
smoking	NN	O
patterns	NNS	O
,	,	O
self-efficacy	NN	O
and	CC	O
outcome	NN	O
expectations	NNS	O
,	,	O
was	VBD	O
not	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
web-based	JJ	O
materials	NNS	O
presenting	VBG	O
broadly	RB	O
similar	JJ	O
non-tailored	JJ	O
information	NN	O
.	.	O

Why	WRB	O
are	VBP	O
there	RB	O
sometimes	RB	O
concreteness	JJ	O
effects	NNS	O
in	IN	O
memory	NN	O
for	IN	O
prose	NN	O
?	.	O
Four	CD	O
experiments	NNS	O
explored	VBD	O
on-line	JJ	O
encoding	NN	O
strategies	NNS	O
and	CC	O
memory	NN	O
for	IN	O
high	JJ	O
imagery	NN	O
and	CC	O
low	JJ	O
imagery	NN	O
texts	NN	O
.	.	O

Results	NNP	O
consistently	RB	O
indicated	VBD	O
that	IN	O
concreteness	NN	O
effects	NNS	O
in	IN	O
memory	NN	O
for	IN	O
text	JJ	O
depend	NN	O
on	IN	O
how	WRB	O
materials	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
several	JJ	O
different	JJ	O
respects	NNS	O
.	.	O

Most	JJS	O
importantly	RB	O
,	,	O
the	DT	O
experiments	NNS	O
clarified	VBD	O
apparently	RB	O
contradictory	JJ	O
results	NNS	O
of	IN	O
previous	JJ	O
studies	NNS	O
by	IN	O
indicating	VBG	O
that	IN	O
concreteness	NN	O
effects	NNS	O
generally	RB	O
do	VBP	O
not	RB	O
occur	VB	O
in	IN	O
memory	NN	O
for	IN	O
prose	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
between-subjects	NNS	O
,	,	O
and	CC	O
that	IN	O
their	PRP$	O
occurrence	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
within-subjects	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
order	NN	O
occurrence	NN	O
when	WRB	O
imageability	NN	O
is	VBZ	O
manipulated	VBN	O
within-subjects	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
order	NN	O
of	IN	O
presentation	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
moving	VBG	O
window	JJ	O
analyses	NNS	O
of	IN	O
text	JJ	E
processing	NN	E
strategies	NNS	E
indicated	VBD	O
that	IN	O
differential	JJ	O
strategies	NNS	O
observed	VBN	O
in	IN	O
previous	JJ	O
studies	NNS	O
when	WRB	O
subjects	NNS	O
listened	VBD	O
to	TO	O
high	JJ	O
vs	NN	O
low	JJ	O
imagery	NN	O
text	NN	O
do	VBP	O
not	RB	O
generalize	VB	O
to	TO	O
reading	NN	O
of	IN	O
the	DT	O
same	JJ	O
materials	NNS	O
.	.	O

Potential	JJ	O
explanations	NNS	O
for	IN	O
the	DT	O
pattern	NN	O
of	IN	O
results	NNS	O
are	VBP	O
evaluated	VBN	O
,	,	O
and	CC	O
implications	NNS	O
for	IN	O
theories	NNS	O
of	IN	O
mental	JJ	O
imagery	NN	O
and	CC	O
memory	NN	O
are	VBP	O
considered	VBN	O
.	.	O

Determinants	NNS	O
of	IN	O
exclusive	JJ	E
breastfeeding	NN	E
in	IN	O
an	DT	O
urban	JJ	O
population	NN	O
of	IN	O
primiparas	NNS	O
in	IN	O
Lebanon	NNP	O
:	:	O
a	DT	O
cross-sectional	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
proportion	NN	O
of	IN	O
mothers	NNS	O
who	WP	O
exclusively	RB	E
breastfeed	VBP	E
their	PRP$	O
babies	NNS	O
up	IN	O
to	TO	O
6	CD	O
months	NNS	O
remains	VBZ	O
low	JJ	O
.	.	O

Determinants	NNS	O
of	IN	O
breastfeeding	VBG	O
practices	NNS	O
have	VBP	O
been	VBN	O
largely	RB	O
documented	VBN	O
in	IN	O
high-income	JJ	O
countries	NNS	O
.	.	O

Little	JJ	O
evidence	NN	O
exists	NNS	O
on	IN	O
possible	JJ	O
predictors	NNS	O
of	IN	O
breastfeeding	VBG	O
behaviors	NNS	O
in	IN	O
the	DT	O
Middle	NNP	O
East	NNP	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
prevalence	NN	O
of	IN	O
breastfeeding	VBG	E
in	IN	O
Beirut	NNP	O
and	CC	O
determine	VB	O
the	DT	O
factors	NNS	O
that	WDT	O
impact	VBP	O
breastfeeding	VBG	O
behavior	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

METHODS	NNP	O
Data	NNP	O
for	IN	O
this	DT	O
longitudinal	JJ	O
study	NN	O
is	VBZ	O
nested	VBN	O
within	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
assessing	VBG	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
24-hour	JJ	E
hotline	NN	E
and	CC	E
postpartum	NN	E
support	NN	E
film	NN	E
on	IN	O
postpartum	NN	O
stress	NN	O
.	.	O

Healthy	JJ	O
first-time	JJ	O
mothers	NNS	O
delivering	VBG	O
in	IN	O
the	DT	O
capital	NN	O
Beirut	NNP	O
between	IN	O
March	NNP	O
and	CC	O
July	NNP	O
2009	CD	O
,	,	O
were	VBD	O
interviewed	VBN	O
at	IN	O
1-3	JJ	O
days	NNS	O
and	CC	O
8-12	JJ	O
weeks	NNS	O
post	NN	O
delivery	NN	O
.	.	O

A	DT	O
multiple	JJ	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
factors	NNS	O
associated	VBN	O
with	IN	O
exclusive	JJ	O
breastfeeding	NN	E
at	IN	O
8-12	JJ	O
weeks	NNS	O
postpartum	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
overall	JJ	O
breastfeeding	NN	O
rate	NN	O
at	IN	O
8-12	JJ	O
weeks	NNS	O
postpartum	NN	O
was	VBD	O
67	CD	O
%	NN	O
.	.	O

The	DT	O
exclusive	JJ	O
breastfeeding	NN	O
rate	NN	O
was	VBD	O
27.4	CD	O
%	NN	O
.	.	O

Factors	NNS	O
associated	VBD	O
with	IN	O
exclusive	JJ	O
breastfeeding	NN	O
included	VBD	O
maternal	JJ	O
work	NN	O
(	(	O
OR=3.92	NNP	O
;	:	O
p-value	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
planned	VBN	O
pregnancy	NN	O
(	(	O
OR=2.42	NNP	O
,	,	O
p-value=0.010	NN	O
)	)	O
,	,	O
intention	NN	O
to	TO	O
breastfeed	VB	O
(	(	O
OR=3.28	NNP	O
;	:	O
p-value=0.043	NN	O
)	)	O
,	,	O
source	NN	O
of	IN	O
maternal	JJ	O
emotional	JJ	O
support	NN	O
(	(	O
OR=1.87	NNP	O
,	,	O
p-value=0.039	NN	O
)	)	O
and	CC	O
the	DT	O
use	NN	O
the	DT	O
postpartum	NN	O
support	NN	O
video	NN	O
,	,	O
the	DT	O
hotline	NN	O
service	NN	O
or	CC	O
both	DT	O
(	(	O
OR=2.55	NNP	O
,	,	O
p-value=0.044	NN	O
;	:	O
OR=3.87	NNP	O
,	,	O
p-value=0.004	NN	O
and	CC	O
OR=4.13	NNP	O
,	,	O
p-value=0.003	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
proportion	NN	O
of	IN	O
healthy	JJ	O
first-time	JJ	O
mothers	NNS	O
who	WP	O
exclusively	RB	O
breastfeed	VBP	O
in	IN	O
Beirut	NNP	O
is	VBZ	O
extremely	RB	O
low	JJ	O
.	.	O

Factors	NNS	O
associated	VBD	O
with	IN	O
breastfeeding	NN	O
behavior	NN	O
are	VBP	O
diverse	JJ	O
.	.	O

Future	JJ	O
research	NN	O
and	CC	O
interventions	NNS	O
should	MD	O
target	VB	O
different	JJ	O
levels	NNS	O
of	IN	O
the	DT	O
maternal-child	JJ	O
pair	NN	O
's	POS	O
ecosystem	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
,	,	O
NCT00857051	NNP	O
.	.	O

Immunologic	NNP	O
profiles	NNS	O
of	IN	O
persons	NNS	O
recruited	VBN	O
for	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	C
clinical	JJ	O
trial	NN	O
of	IN	O
hookworm	NN	O
infection	NN	O
.	.	O

Data	NNS	O
from	IN	O
epidemiologic	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
hookworm	NN	O
infections	NNS	O
,	,	O
in	IN	O
establishing	VBG	O
an	DT	O
immunologic	JJ	O
phenotype	NN	O
conducive	NN	O
to	TO	O
parasite	VB	O
survival	NN	O
,	,	O
may	MD	O
protect	VB	O
against	IN	O
the	DT	O
development	NN	O
of	IN	O
allergic	JJ	O
disease	NN	O
.	.	O

We	PRP	O
describe	VBP	O
immunologic	JJ	O
findings	NNS	O
from	IN	O
a	DT	O
clinical	JJ	O
study	NN	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
of	IN	O
iatrogenic	JJ	PH
hookworm	NN	PH
infection	NN	PH
in	IN	O
participants	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

The	DT	O
low	JJ	O
,	,	O
relatively	RB	O
safe	JJ	O
level	NN	O
of	IN	O
hookworm	NN	PH
infection	NN	PH
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
was	VBD	O
immunogenic	JJ	O
,	,	O
inducing	VBG	O
eosinophilia	NNS	O
and	CC	O
a	DT	O
significant	JJ	O
specific	JJ	O
IgG	NNP	O
response	NN	O
.	.	O

Importantly	RB	O
,	,	O
no	DT	O
potentiation	NN	O
of	IN	O
IgE	NNP	O
responses	NNS	O
to	TO	O
the	DT	O
environmental	JJ	O
allergens	NNS	O
to	TO	O
which	WDT	O
the	DT	O
participants	NNS	O
were	VBD	O
sensitized	VBN	O
was	VBD	O
seen	VBN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
evidence	NN	O
of	IN	O
systemic	JJ	O
immune	JJ	O
regulation	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
infected	JJ	O
participants	NNS	O
.	.	O

This	DT	O
finding	NN	O
may	MD	O
indicate	VB	O
that	IN	O
the	DT	O
level	NN	O
of	IN	O
infection	NN	O
or	CC	O
the	DT	O
frequency	NN	O
of	IN	O
infection	NN	O
may	MD	O
have	VB	O
to	TO	O
be	VB	O
altered	VBN	O
in	IN	O
future	JJ	O
trials	NNS	O
to	TO	O
induce	VB	O
a	DT	O
therapeutically	RB	O
conducive	JJ	O
immunologic	NN	O
phenotype	NN	O
.	.	O

Combining	VBG	O
weight-loss	JJ	O
counseling	NN	O
with	IN	O
the	DT	O
weight	NN	O
watchers	NNS	O
plan	VBP	O
for	IN	O
obese	JJ	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
develop	VB	O
effective	JJ	O
weight-loss	JJ	O
methods	NNS	O
for	IN	O
women	NNS	O
who	WP	O
have	VBP	O
had	VBN	O
breast	VBN	O
cancer	NN	O
,	,	O
because	IN	O
obesity	NN	O
may	MD	O
result	VB	O
in	IN	O
an	DT	O
adverse	JJ	O
prognosis	NN	O
.	.	O

RESEARCH	NNP	O
METHODS	NNP	O
AND	NNP	O
PROCEDURES	NNP	O
This	DT	O
randomized	VBN	O
pilot	NN	O
study	NN	O
tested	VBD	O
an	DT	O
individualized	JJ	O
approach	NN	O
toward	IN	O
weight	JJ	O
loss	NN	O
in	IN	O
obese	JJ	O
women	NNS	O
who	WP	O
have	VBP	O
had	VBD	O
a	DT	O
diagnosis	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
.	.	O

An	DT	O
individualized	JJ	O
approach	NN	O
was	VBD	O
applied	VBN	O
either	CC	O
alone	RB	E
or	CC	E
combined	VBN	E
with	IN	E
the	DT	E
commercial	JJ	E
Weight	NNP	E
Watchers	NNP	E
program	NN	E
.	.	E

Forty-eight	JJ	O
women	NNS	O
(	(	O
body	NN	O
mass	NN	O
index	NN	O
of	IN	O
30	CD	O
to	TO	O
44	CD	O
kg/m	NNS	O
(	(	O
2	CD	O
)	)	O
)	)	O
were	VBD	O
enrolled	VBN	O
.	.	O

RESULTS	NNP	O
Weight	NNP	O
change	NN	O
after	IN	O
12	CD	O
months	NNS	O
of	IN	O
intervention	NN	O
was	VBD	O
as	IN	O
follows	VBZ	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
:	:	O
0.85	CD	O
+/-	JJ	O
6.0	CD	O
kg	NN	O
in	IN	O
the	DT	O
control	NN	C
group	NN	C
,	,	O
-2.6	VBZ	O
+/-	JJ	O
5.9	CD	O
kg	NN	O
in	IN	O
the	DT	O
Weight	NNP	E
Watchers	NNP	E
group	NN	E
,	,	O
-8.0	VBZ	O
+/-	JJ	O
5.5	CD	O
kg	NN	O
in	IN	O
the	DT	O
individualized	JJ	O
group	NN	O
,	,	O
and	CC	O
-9.4	VBD	O
+/-	JJ	O
8.6	CD	O
kg	NN	O
in	IN	O
the	DT	O
comprehensive	JJ	E
group	NN	E
that	WDT	E
used	VBD	E
both	DT	E
individualized	JJ	E
counseling	NN	E
and	CC	E
Weight	NNP	E
Watchers	NNP	E
.	.	E

Weight	NNP	O
loss	NN	O
relative	NN	O
to	TO	O
control	VB	O
was	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
randomization	NN	O
,	,	O
whereas	JJ	O
weight	NN	O
loss	NN	O
in	IN	O
the	DT	O
individualized	JJ	O
group	NN	O
was	VBD	O
significant	JJ	O
only	RB	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

Weight	NNP	O
loss	NN	O
of	IN	O
10	CD	O
%	NN	O
or	CC	O
more	JJR	O
of	IN	O
initial	JJ	O
body	NN	O
weight	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
6	CD	O
of	IN	O
10	CD	O
women	NNS	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
comprehensive	JJ	O
and	CC	O
Weight	NNP	O
Watchers-only	NNP	O
groups	NNS	O
,	,	O
weight	JJ	O
loss	NN	O
was	VBD	O
significantly	RB	O
related	VBN	O
to	TO	O
frequency	NN	O
of	IN	O
attendance	NN	O
at	IN	O
Weight	NNP	O
Watchers	NNP	O
meetings	NNS	O
,	,	O
and	CC	O
attendance	NN	O
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
comprehensive	JJ	O
group	NN	O
.	.	O

DISCUSSION	NNP	O
These	DT	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
most	RBS	O
weight	JJ	O
loss	NN	O
was	VBD	O
achieved	VBN	O
when	WRB	O
the	DT	O
counseling	NN	O
approach	NN	O
combined	VBD	O
both	DT	O
Weight	NNP	O
Watchers	NNPS	O
and	CC	O
individualized	JJ	O
contacts	NNS	O
.	.	O

This	DT	O
was	VBD	O
effective	JJ	O
even	RB	O
though	IN	O
most	JJS	O
of	IN	O
the	DT	O
individualized	JJ	O
contacts	NNS	O
were	VBD	O
by	IN	O
telephone	NN	O
.	.	O

Zinc	NNP	PM
and	CC	PM
copper	NN	PM
balances	NNS	PM
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

Preterm	NNP	O
infants	NNS	O
are	VBP	O
at	IN	O
risk	NN	O
for	IN	O
copper	NN	O
and	CC	O
zinc	NN	O
depletion	NN	O
if	IN	O
sufficient	JJ	O
quantities	NNS	O
of	IN	O
these	DT	O
nutrients	NNS	O
are	VBP	O
not	RB	O
provided	VBN	O
in	IN	O
a	DT	O
bioavailable	JJ	O
form	NN	O
in	IN	O
postnatal	JJ	O
life	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
whey-predominant	JJ	PM
,	,	PM
50	CD	PM
%	NN	PM
medium	NN	PM
chain	NN	PM
triglyceride	IN	PM
formula	NN	PM
with	IN	PM
relatively	RB	PM
high	JJ	PM
concentrations	NNS	PM
of	IN	PM
zinc	NN	PM
and	CC	O
copper	NN	PM
would	MD	O
promote	VB	O
the	DT	O
achievement	NN	O
of	IN	O
the	DT	O
in	IN	O
utero	JJ	O
accretion	NN	O
rate	NN	O
for	IN	O
zinc	NN	O
and	CC	O
copper	NN	O
in	IN	O
the	DT	O
preterm	NN	O
infant	NN	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
five	CD	O
preterm	JJ	O
infants	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
diet	JJ	O
containing	VBG	O
12.5	CD	PM
mg/L	NN	PM
of	IN	PM
zinc	NN	PM
and	CC	O
either	DT	O
0.9	CD	PM
mg/L	NN	PM
or	CC	PM
2.1	CD	PM
mg/L	NN	PM
of	IN	PM
copper	NN	PM
.	.	PM

Seventy-two-hour	JJ	O
metabolic	JJ	O
balance	NN	O
studies	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
an	DT	O
average	JJ	O
postconceptual	JJ	O
age	NN	O
of	IN	O
34	CD	O
weeks	NNS	O
and	CC	O
an	DT	O
average	JJ	O
weight	NN	O
of	IN	O
1,549	CD	O
g.	NN	O
All	DT	O
infants	NNS	O
were	VBD	O
in	IN	O
positive	JJ	O
zinc	NN	O
balance	NN	O
and	CC	O
nine	CD	O
of	IN	O
ten	NNS	O
achieved	VBN	O
the	DT	O
in	IN	O
utero	JJ	O
accretion	NN	O
rate	NN	O
for	IN	O
zinc	NN	O
for	IN	O
a	DT	O
34-week	JJ	O
gestation	NN	O
fetus	NN	O
(	(	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.432	CD	O
mg/d	NN	O
)	)	O
.	.	O

Three	CD	O
infants	NNS	O
receiving	VBG	O
the	DT	O
high	JJ	O
copper	NN	O
formula	NN	O
and	CC	O
two	CD	O
receiving	VBG	O
the	DT	O
lower	JJR	O
copper	NN	O
formula	NN	O
were	VBD	O
in	IN	O
positive	JJ	O
copper	NN	O
balance	NN	O
.	.	O

Two	CD	O
infants	NNS	O
from	IN	O
each	DT	O
group	NN	O
achieved	VBD	O
the	DT	O
in	IN	O
utero	JJ	O
accretion	NN	O
rate	NN	O
for	IN	O
copper	NN	O
for	IN	O
a	DT	O
34-week	JJ	O
gestation	NN	O
fetus	NN	O
(	(	O
0.088	CD	O
mg/d	NN	O
)	)	O
.	.	O

A	DT	O
formula	NN	O
that	WDT	O
provides	VBZ	O
12.5	CD	O
mg/L	NN	O
of	IN	O
zinc	NN	O
permits	NNS	O
positive	JJ	O
zinc	NN	O
balance	NN	O
and	CC	O
zinc	NN	O
retention	NN	O
similar	JJ	O
to	TO	O
in	IN	O
utero	JJ	O
rates	NNS	O
.	.	O

A	DT	O
formula	NN	O
that	WDT	O
provides	VBZ	O
as	RB	O
much	JJ	O
as	IN	O
2.1	CD	O
mg/L	NN	O
of	IN	O
copper	NN	O
,	,	O
however	RB	O
,	,	O
may	MD	O
not	RB	O
always	RB	O
permit	VBP	O
positive	JJ	O
copper	NN	O
balance	NN	O
.	.	O

Association	NNP	O
of	IN	O
severity	NN	O
of	IN	O
coexisting	VBG	O
patellofemoral	JJ	O
disease	NN	O
with	IN	O
increased	JJ	O
impairments	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
knee	JJ	O
osteoarthritis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
association	NN	O
between	IN	O
severity	NN	O
of	IN	O
coexisting	VBG	O
patellofemoral	JJ	O
(	(	O
PF	NNP	O
)	)	O
disease	NN	O
with	IN	O
lower	JJR	O
extremity	NN	O
impairments	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
tibiofemoral	JJ	O
(	(	O
TF	NNP	O
)	)	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Radiographic	NNP	PH
views	NNS	PH
of	IN	O
the	DT	O
TF	NNP	O
and	CC	O
PF	NNP	O
compartments	NNS	O
,	,	O
knee	VB	PH
extension	NN	PH
strength	NN	PH
,	,	O
and	CC	O
knee	VB	PH
range	NN	PH
of	IN	PH
motion	NN	PH
were	VBD	O
obtained	VBN	O
for	IN	O
167	CD	O
patients	NNS	O
with	IN	O
knee	JJ	O
OA	NNP	O
.	.	O

Additionally	RB	O
,	,	O
knee-specific	JJ	O
symptoms	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
and	CC	O
the	DT	O
Activities	NNS	O
of	IN	O
Daily	NNP	O
Living	NNP	O
Scale	NNP	O
(	(	O
ADLS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Moderate/severe	NNP	O
PFOA	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
knee	NN	O
extension	NN	O
strength	NN	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
1.4	CD	O
?	.	O
0.5	CD	O
Nm/body	NN	O
weight	VBD	O
[	NNP	O
BW	NNP	O
]	NNP	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
1.8	CD	O
?	.	O
0.5	CD	O
Nm/BW	NNP	O
)	)	O
.	.	O

Additionally	RB	O
,	,	O
total	JJ	O
knee	NN	O
range	NN	O
of	IN	O
motion	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
patients	NNS	O
with	IN	O
moderate/severe	JJ	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
120.8?	CD	O
?	.	O
14.4?	CD	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
133.5?	CD	O
?	.	O
10.7?	CD	O
)	)	O
and	CC	O
mild	JJ	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
125.8?	CD	O
?	.	O
13.0?	CD	O
)	)	O
.	.	O

Moderate/severe	NNP	O
PFOA	NNP	O
and	CC	O
mild	JJ	O
PFOA	NNP	O
were	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
less	JJR	O
pain	NN	O
while	IN	O
standing	VBG	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	$	O
0.2	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	VBD	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
0.1-0.7	JJ	O
and	CC	O
OR	NNP	O
0.2	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.1-0.6	CD	O
,	,	O
respectively	RB	O
)	)	O
on	IN	O
the	DT	O
WOMAC	NNP	O
,	,	O
and	CC	O
moderate/severe	RB	O
PFOA	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
difficulty	NN	O
with	IN	O
going	VBG	O
downstairs	NNS	O
(	(	O
OR	NNP	O
2.9	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.0-8.1	CD	O
)	)	O
on	IN	O
the	DT	O
ADLS	NNP	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
appears	VBZ	O
that	IN	O
knees	NNS	O
with	IN	O
more	RBR	O
severe	JJ	O
coexisting	VBG	O
PF	NNP	O
disease	NN	O
demonstrate	NN	O
features	NNS	O
distinct	VBP	O
from	IN	O
those	DT	O
observed	VBN	O
in	IN	O
TFOA	NNP	O
in	IN	O
isolation	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
mild	JJ	O
PF	NNP	O
disease	NN	O
.	.	O

Treatment	NNP	O
strategies	VBZ	O
targeting	VBG	O
the	DT	O
PF	NNP	O
joint	NN	O
may	MD	O
be	VB	O
warranted	VBN	O
to	TO	O
mitigate	VB	O
the	DT	O
specific	JJ	O
lower	JJR	O
extremity	NN	O
impairments	NNS	O
and	CC	O
functional	JJ	O
problems	NNS	O
present	JJ	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

Treatment	NN	O
with	IN	O
the	DT	O
dipeptidyl	JJ	PM
peptidase-4	JJ	PM
inhibitor	NN	PM
vildagliptin	NN	PM
improves	VBZ	O
fasting	VBG	O
islet-cell	JJ	O
function	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

CONTEXT	NNP	O
Dipeptidyl	NNP	PM
peptidase	NN	PM
4	CD	PM
(	(	PM
DPP-4	NNP	PM
)	)	PM
inhibitors	NNS	PM
are	VBP	O
proposed	VBN	O
to	TO	O
lower	VB	O
blood	NN	O
glucose	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
mellitus	FW	O
(	(	O
T2DM	NNP	O
)	)	O
by	IN	O
prolonging	VBG	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
circulating	NN	O
incretins	NNS	O
,	,	O
glucose-dependent	JJ	O
insulinotropic	NN	O
polypeptide	NN	O
(	(	O
GIP	NNP	O
)	)	O
and	CC	O
glucagon-like	JJ	O
peptide	NN	O
1	CD	O
(	(	O
GLP-1	NNP	O
)	)	O
.	.	O

Consistent	JJ	O
with	IN	O
this	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
,	,	O
DPP-4	NNP	PM
inhibitors	NNS	PM
improve	VBP	O
glucose	JJ	O
tolerance	NN	O
after	IN	O
meals	NNS	O
by	IN	O
increasing	VBG	O
insulin	NN	O
and	CC	O
reducing	VBG	O
glucagon	NN	O
levels	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
.	.	O

However	RB	O
,	,	O
DPP-4	NNP	PM
inhibitors	NNS	PM
also	RB	O
reduce	VB	O
fasting	VBG	O
blood	NN	O
glucose	NN	O
,	,	O
an	DT	O
unexpected	JJ	O
effect	NN	O
because	IN	O
circulating	VBG	O
levels	NNS	O
of	IN	O
active	JJ	O
GIP	NNP	O
and	CC	O
GLP-1	NNP	O
are	VBP	O
low	JJ	O
in	IN	O
the	DT	O
postabsorptive	JJ	O
state	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
DPP-4	NNP	O
inhibition	NN	O
on	IN	O
fasting	VBG	O
islet	NN	O
function	NN	O
.	.	O

DESIGN	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
.	.	O

SETTING	VB	O
The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
General	NNP	O
Clinical	NNP	O
Research	NNP	O
Centers	NNPS	O
at	IN	O
two	CD	O
University	NNP	O
Hospitals	NNP	O
.	.	O

SUBJECTS	NNP	O
Forty-one	JJ	O
subjects	NNS	O
with	IN	O
T2DM	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
metformin	NN	PM
or	CC	O
diet	NN	O
,	,	O
having	VBG	O
good	JJ	O
glycemic	NNS	O
control	NN	O
with	IN	O
glycosylated	JJ	O
hemoglobin	NN	O
values	NNS	O
of	IN	O
6.2-7.5	JJ	O
%	NN	O
.	.	O

INTERVENTION	JJ	O
Subjects	NNPS	O
were	VBD	O
treated	VBN	O
with	IN	O
vildagliptin	NN	PM
(	(	O
50	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
or	CC	O
placebo	NN	C
for	IN	O
3	CD	O
months	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
2-wk	JJ	O
washout	NN	O
.	.	O

Major	JJ	O
Outcome	JJ	O
Measure	NN	O
:	:	O
We	PRP	O
measured	VBD	O
insulin	JJ	O
secretion	NN	O
in	IN	O
response	NN	O
to	TO	O
iv	VB	O
glucose	JJ	O
and	CC	O
arginine	JJ	O
before	NN	O
and	CC	O
after	IN	O
treatment	NN	O
and	CC	O
after	IN	O
drug	NN	O
washout	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
small	JJ	O
and	CC	O
comparable	JJ	O
reductions	NNS	O
in	IN	O
glycosylated	JJ	O
hemoglobin	NN	O
in	IN	O
both	DT	O
groups	NNS	O
over	IN	O
3	CD	O
months	NNS	O
.	.	O

Vildagliptin	NNP	O
increased	VBD	O
fasting	VBG	O
GLP-1	NNP	O
levels	NNS	O
in	IN	O
subjects	NNS	O
taking	VBG	O
metformin	NN	PM
,	,	O
but	CC	O
not	RB	O
those	DT	O
managed	VBN	O
with	IN	O
diet	JJ	O
,	,	O
and	CC	O
raised	VBD	O
active	JJ	O
GIP	NNP	O
levels	NNS	O
slightly	RB	O
.	.	O

DPP-4	JJ	PM
inhibitor	NN	PM
treatment	NN	O
improved	VBD	O
the	DT	O
acute	JJ	O
insulin	NN	O
and	CC	O
C-peptide	JJ	O
responses	NNS	O
to	TO	O
glucose	VB	O
(	(	O
50	CD	O
and	CC	O
100	CD	O
%	NN	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
increased	VBD	O
the	DT	O
slope	NN	O
of	IN	O
the	DT	O
C-peptide	NNP	O
response	NN	O
to	TO	O
glucose	VB	O
(	(	O
33	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.023	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Vildagliptin	NNP	PM
improves	VBZ	O
islet	JJ	O
function	NN	O
in	IN	O
T2DM	NNP	O
under	IN	O
fasting	VBG	O
conditions	NNS	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
DPP-4	NNP	O
inhibition	NN	O
has	VBZ	O
metabolic	JJ	O
benefits	NNS	O
in	IN	O
addition	NN	O
to	TO	O
enhancing	VBG	O
meal-induced	JJ	O
GLP-1	NNP	O
and	CC	O
GIP	NNP	O
activity	NN	O
.	.	O

Safety	NN	O
and	CC	O
acceptability	NN	O
of	IN	O
cellulose	JJ	PM
sulfate	NN	PM
as	IN	O
a	DT	O
vaginal	JJ	O
microbicide	NN	O
in	IN	O
HIV-infected	JJ	O
women	NNS	O
.	.	O

OBJECTIVES	NNP	O
Few	JJ	O
studies	NNS	O
of	IN	O
topical	JJ	O
microbicides	NNS	O
have	VBP	O
assessed	VBN	O
their	PRP$	O
safety	NN	O
in	IN	O
HIV-infected	JJ	O
women	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
this	DT	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
acceptability	NN	O
of	IN	O
6	CD	O
%	NN	O
cellulose	JJ	PM
sulfate	NN	PM
(	(	PM
CS	NNP	PM
)	)	PM
gel	NN	O
as	IN	O
a	DT	O
vaginal	JJ	O
microbicide	NN	O
in	IN	O
sexually	RB	O
abstinent	JJ	O
and	CC	O
active	JJ	O
HIV-infected	JJ	O
women	NNS	O
.	.	O

METHODS	NNP	O
Fifty-nine	JJ	O
HIV-infected	JJ	O
women	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	C
study	NN	O
comparing	VBG	O
6	CD	O
%	NN	O
CS	NNP	PM
to	TO	O
placebo	VB	C
gel	NNS	C
used	VBN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Sexually	NNP	O
abstinent	JJ	O
women	NNS	O
applied	VBD	O
gel	JJ	O
once	RB	O
or	CC	O
twice	JJ	O
daily	JJ	O
and	CC	O
sexually	RB	O
active	JJ	O
women	NNS	O
used	VBN	O
gel	JJ	O
once	RB	O
daily	JJ	O
.	.	O

RESULTS	NNP	O
CS	NNP	O
gel	NN	O
was	VBD	O
safe	JJ	O
with	IN	O
no	DT	O
reported	VBN	O
severe	RB	O
or	CC	O
life-threatening	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AE	NNP	O
)	)	O
.	.	O

Thirty-nine	NNP	O
(	(	O
66	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
participants	NNS	O
experienced	VBD	O
urogenital	JJ	O
AE	NNP	O
judged	VBD	O
as	IN	O
probably	RB	O
or	CC	O
possibly	RB	O
related	VBN	O
to	TO	O
gel	VB	O
.	.	O

The	DT	O
majority	NN	O
(	(	O
51	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
participants	NNS	O
reported	VBD	O
only	RB	O
mild	JJ	O
events	NNS	O
.	.	O

Fewer	JJR	O
women	NNS	O
(	(	O
62	CD	O
%	NN	O
)	)	O
who	WP	O
used	VBD	O
CS	NNP	O
experienced	VBD	O
urogenital	JJ	O
AE	NNP	O
than	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
placebo	VB	C
gel	NN	O
(	(	O
70	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.59	CD	O
)	)	O
.	.	O

Eleven	NNP	O
(	(	O
19	CD	O
%	NN	O
)	)	O
women	NNS	O
experienced	VBD	O
intermenstrual	JJ	O
bleeding	NN	O
judged	VBD	O
to	TO	O
be	VB	O
probably	RB	O
or	CC	O
possibly	RB	O
related	VBN	O
to	TO	O
gel	VB	O
use	NN	O
(	(	O
four	CD	O
in	IN	O
the	DT	O
CS	NNP	O
and	CC	O
seven	CD	O
in	IN	O
the	DT	O
placebo	NN	O
gel	NN	O
group	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
AE	NNP	O
by	IN	O
frequency	NN	O
of	IN	O
gel	NN	O
use	NN	O
or	CC	O
sexual	JJ	O
activity	NN	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
abdominal/pelvic	NN	O
pain	NN	O
which	WDT	O
was	VBD	O
noted	VBN	O
more	RBR	O
frequently	RB	O
with	IN	O
twice	RB	O
daily	JJ	O
use	NN	O
among	IN	O
sexually	RB	O
abstinent	JJ	O
women	NNS	O
.	.	O

Women	NNS	O
and	CC	O
men	NNS	O
found	VBD	O
the	DT	O
gel	NN	O
highly	RB	O
acceptable	JJ	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
Phase	NNP	O
I	PRP	O
study	VBP	O
demonstrated	VBD	O
that	IN	O
CS	NNP	PM
vaginal	JJ	PM
gel	NN	PM
was	VBD	O
safe	JJ	O
,	,	O
well	RB	O
tolerated	VBN	O
and	CC	O
acceptable	JJ	O
by	IN	O
HIV-infected	JJ	O
women	NNS	O
and	CC	O
their	PRP$	O
male	JJ	O
partners	NNS	O
.	.	O

Thus	RB	O
,	,	O
further	JJ	O
development	NN	O
of	IN	O
CS	NNP	O
is	VBZ	O
warranted	VBN	O
as	IN	O
a	DT	O
potential	JJ	O
method	NN	O
to	TO	O
prevent	VB	O
HIV	NNP	O
transmission	NN	O
and	CC	O
acquisition	NN	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
of	IN	O
cutting	VBG	S
balloon	NN	S
angioplasty	JJ	S
versus	NN	O
high-pressure	NN	S
balloon	NN	S
angioplasty	NN	S
in	IN	O
hemodialysis	NN	O
arteriovenous	JJ	O
fistula	NN	O
stenoses	VBZ	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
balloon	NN	O
angioplasty	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
cutting	VBG	S
balloon	NN	S
angioplasty	NN	S
(	(	S
CBA	NNP	S
)	)	S
versus	IN	S
high-pressure	NN	S
balloon	NN	S
angioplasty	NN	S
(	(	S
HPBA	NNP	S
)	)	S
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hemodialysis	NN	O
autogenous	JJ	O
fistula	NN	O
stenoses	VBZ	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
percutaneous	JJ	O
transluminal	JJ	O
angioplasty	NN	O
(	(	O
PTA	NNP	O
)	)	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
involving	VBG	O
patients	NNS	O
with	IN	O
dysfunctional	JJ	O
,	,	O
stenotic	JJ	O
hemodialysis	NN	O
arteriovenous	JJ	O
fistulas	NNS	O
(	(	O
AVFs	NNP	O
)	)	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
CBA	NNP	S
or	CC	O
HPBA	NNP	S
if	IN	O
conventional	JJ	O
PTA	NNP	O
had	VBD	O
suboptimal	JJ	O
results	NNS	O
(	(	O
ie	JJ	O
,	,	O
residual	JJ	O
stenosis	NN	O
>	VBD	O
30	CD	O
%	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
516	CD	O
patients	NNS	O
consented	VBN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
study	NN	O
from	IN	O
October	NNP	O
2008	CD	O
to	TO	O
September	NNP	O
2011	CD	O
,	,	O
85	CD	O
%	NN	O
of	IN	O
whom	WP	O
(	(	O
n	JJ	O
=	NNP	O
439	CD	O
)	)	O
had	VBD	O
technically	RB	O
successful	JJ	O
conventional	JJ	O
PTA	NNP	O
.	.	O

The	DT	O
remaining	VBG	O
71	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
60	CD	O
y	NN	O
;	:	O
49	CD	O
men	NNS	O
)	)	O
with	IN	O
suboptimal	JJ	O
PTA	NNP	O
results	NNS	O
were	VBD	O
eventually	RB	O
randomized	VBN	O
:	:	O
36	CD	O
to	TO	O
the	DT	O
CBA	NNP	PH
arm	NN	O
and	CC	O
35	CD	O
to	TO	O
the	DT	O
HPBA	NNP	O
arm	NN	O
.	.	O

Primary	JJ	O
and	CC	O
secondary	JJ	O
target	NN	O
lesion	NN	O
patencies	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
Kaplan-Meier	NNP	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
Clinical	JJ	O
success	NN	O
rates	NNS	O
were	VBD	O
100	CD	O
%	NN	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

Primary	JJ	O
target	NN	O
lesion	NN	O
patency	NN	O
rates	NNS	O
at	IN	O
6	CD	O
months	NNS	O
were	VBD	O
66.4	CD	O
%	NN	O
and	CC	O
39.9	CD	O
%	NN	O
for	IN	O
CBA	NNP	PH
and	CC	O
HPBA	NNP	PH
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
target	NN	O
lesion	NN	O
patency	NN	O
rates	NNS	O
at	IN	O
6	CD	O
months	NNS	O
were	VBD	O
96.5	CD	O
%	NN	O
for	IN	O
CBA	NNP	PH
and	CC	O
80.0	CD	O
%	NN	O
for	IN	O
HPBA	NNP	PH
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
single	JJ	O
major	JJ	O
complication	NN	O
of	IN	O
venous	JJ	O
perforation	NN	O
following	VBG	O
CBA	NNP	PH
.	.	O

The	DT	O
30-day	JJ	O
mortality	NN	O
rate	NN	O
was	VBD	O
1.4	CD	O
%	NN	O
,	,	O
with	IN	O
one	CD	O
non-procedure-related	JJ	O
death	NN	O
in	IN	O
the	DT	O
HPBA	NNP	PH
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Primary	NNP	O
and	CC	O
secondary	JJ	O
target	NN	O
lesion	NN	O
patency	NN	O
rates	NNS	O
of	IN	O
CBA	NNP	PH
were	VBD	O
statistically	RB	O
superior	JJ	O
to	TO	O
those	DT	O
of	IN	O
HPBA	NNP	PH
following	VBG	O
suboptimal	JJ	O
conventional	JJ	O
PTA	NNP	O
.	.	O

For	IN	O
AVF	NNP	O
stenoses	VBZ	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
PTA	NNP	O
,	,	O
CBA	NNP	PH
may	MD	O
be	VB	O
a	DT	O
better	JJR	O
second-line	JJ	O
treatment	NN	O
given	VBN	O
its	PRP$	O
superior	JJ	O
patency	NN	O
rates	NNS	O
.	.	O

Dexamethasone	NNP	PM
therapy	NN	PM
and	CC	O
cortisol	JJ	O
excretion	NN	O
in	IN	O
severe	JJ	O
pediatric	JJ	O
head	NN	O
injury	NN	O
.	.	O

Glucocorticoids	NNS	PM
are	VBP	O
used	VBN	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
reduce	VB	O
brain	NN	O
edema	NN	O
secondary	JJ	O
to	TO	O
head	VB	O
injury	NN	O
.	.	O

Nevertheless	RB	O
,	,	O
their	PRP$	O
usefulness	JJ	O
remains	NNS	O
uncertain	JJ	O
and	CC	O
contradictory	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
of	IN	O
24	CD	O
children	NNS	O
with	IN	O
severe	JJ	O
head	NN	O
injury	NN	O
,	,	O
urinary	JJ	O
free	JJ	O
cortisol	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
radioimmunoassay	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
(	(	O
group	NN	O
1	CD	O
)	)	O
received	VBD	O
dexamethasone	NN	PM
and	CC	O
12	CD	O
(	(	O
group	NN	O
2	CD	O
)	)	O
did	VBD	O
not	RB	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
standardized	JJ	O
regimen	NN	O
.	.	O

In	IN	O
group	NN	O
1	CD	O
there	EX	O
was	VBD	O
complete	JJ	O
suppression	NN	O
of	IN	O
endogenous	JJ	O
cortisol	NN	O
production	NN	O
.	.	O

In	IN	O
group	NN	O
2	CD	O
free	JJ	O
cortisol	NN	O
was	VBD	O
up	RB	O
to	TO	O
20-fold	CD	O
higher	JJR	O
than	IN	O
under	IN	O
basal	JJ	O
conditions	NNS	O
and	CC	O
reached	VBN	O
maximum	JJ	O
values	NNS	O
on	IN	O
days	NNS	O
1-3	RB	O
.	.	O

Since	IN	O
the	DT	O
excretion	NN	O
of	IN	O
cortisol	NN	O
in	IN	O
urine	JJ	O
reflects	VBZ	O
the	DT	O
production	NN	O
rate	NN	O
closely	RB	O
and	CC	O
is	VBZ	O
not	RB	O
influenced	VBN	O
by	IN	O
liver	NN	O
function	NN	O
and	CC	O
barbiturates	NNS	O
,	,	O
the	DT	O
results	NNS	O
in	IN	O
group	NN	O
2	CD	O
show	NN	O
that	IN	O
the	DT	O
endogenous	JJ	O
production	NN	O
of	IN	O
steroids	NNS	O
is	VBZ	O
an	DT	O
adequate	JJ	O
reaction	NN	O
to	TO	O
severe	VB	O
head	JJ	O
injury	NN	O
.	.	O

Exogenous	JJ	O
glucocorticoids	NNS	PM
are	VBP	O
thus	RB	O
unlikely	JJ	O
to	TO	O
have	VB	O
any	DT	O
more	JJR	O
beneficial	JJ	O
effects	NNS	O
than	IN	O
endogenous	JJ	O
cortisol	NN	PM
.	.	O

Feasibility	NN	O
of	IN	O
two	CD	O
dose-dense	JJ	O
FEC	NNP	PM
regimens	VBZ	O
with	IN	O
growth	NN	PH
factor	NN	PH
support	NN	PH
for	IN	O
adjuvant	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomised	JJ	O
study	NN	O
of	IN	O
the	DT	O
Central	NNP	O
European	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
CECOG	NNP	O
)	)	O
.	.	O

Addition	NN	O
of	IN	O
epirubicin	NN	PM
to	TO	O
adjuvant	VB	O
chemotherapy	NN	O
can	MD	O
provide	VB	O
important	JJ	O
benefits	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
but	CC	O
the	DT	O
optimal	JJ	O
dose	NN	O
remains	VBZ	O
unclear	JJ	O
.	.	O

Further	JJ	O
improvements	NNS	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
dose-dense	JJ	O
regimens	NNS	O
,	,	O
but	CC	O
densification	NN	O
of	IN	O
fluorouracil/epirubicin/cyclophosphamide	NN	PM
(	(	PM
FEC	NNP	PM
)	)	PM
has	VBZ	O
proved	VBN	O
difficult	JJ	O
,	,	O
with	IN	O
FEC	NNP	O
(	(	O
60	CD	O
)	)	O
providing	VBG	O
little	JJ	O
benefit	NN	O
over	IN	O
standard	JJ	O
chemotherapy	NN	O
and	CC	O
FEC	NNP	PM
(	(	PM
100	CD	PM
)	)	PM
associated	VBN	O
with	IN	O
toxicity	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
two	CD	O
intermediate	JJ	O
dose-dense	JJ	PH
FEC	NNP	PH
regimens	NNS	PH
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
six	CD	O
cycles	NNS	O
of	IN	O
FEC	NNP	PM
(	(	PM
75	CD	PM
)	)	PM
or	CC	O
FEC	NNP	PM
(	(	PM
90	CD	PM
)	)	PM
,	,	O
with	IN	O
all	DT	O
three	CD	O
drugs	NNS	O
given	VBN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
14-day	JJ	O
cycle	NN	O
.	.	O

Patients	NNS	O
also	RB	O
received	VBD	O
pegfilgrastim	JJ	PM
6	CD	O
mg	NN	O
as	IN	O
a	DT	O
single	JJ	O
subcutaneous	JJ	O
injection	NN	O
on	IN	O
day	NN	O
2	CD	O
of	IN	O
each	DT	O
cycle	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
subjects	NNS	O
receiving	VBG	O
>	NN	O
or	CC	O
=85	CD	O
%	NN	O
relative	JJ	O
dose	JJ	O
intensity	NN	O
and	CC	O
was	VBD	O
achieved	VBN	O
by	IN	O
96	CD	O
%	NN	O
and	CC	O
88	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
and	CC	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Of	IN	O
147	CD	O
FEC	NNP	PM
(	(	PM
75	CD	PM
)	)	PM
infusions	NNS	O
,	,	O
4.1	CD	O
%	NN	O
were	VBD	O
delayed	VBN	O
,	,	O
while	IN	O
9.8	CD	O
%	NN	O
of	IN	O
143	CD	O
FEC	NNP	PM
(	(	PM
90	CD	PM
)	)	PM
infusions	NNS	O
were	VBD	O
delayed	VBN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
reasons	NNS	O
for	IN	O
delay	NN	O
were	VBD	O
adverse	JJ	O
events	NNS	O
and	CC	O
personal/logistical	JJ	O
reasons	NNS	O
.	.	O

One	CD	O
dose	JJ	O
reduction	NN	O
occurred	VBD	O
during	IN	O
the	DT	O
study	NN	O
(	(	PM
FEC	NNP	PM
(	(	PM
90	CD	PM
)	)	PM
)	)	PM
,	,	O
related	VBN	O
to	TO	O
diarrhoea	VB	O
.	.	O

Grade	VB	O
3-4	JJ	O
haematological	JJ	O
toxicities	NNS	O
were	VBD	O
reported	VBN	O
in	IN	O
two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
FEC	NNP	PM
(	(	PM
90	CD	PM
)	)	PM
arm	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
incidences	NNS	O
of	IN	O
febrile	JJ	O
neutropenia	NN	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
increases	NNS	O
in	IN	O
liver	NN	O
enzymes	NNS	O
and	CC	O
gastrointestinal	JJ	O
events	NNS	O
;	:	O
no	DT	O
event	NN	O
resulted	VBD	O
in	IN	O
discontinuation	NN	O
.	.	O

Only	RB	O
one	CD	O
patient	NN	O
(	(	PM
FEC	NNP	PM
(	(	PM
90	CD	PM
)	)	PM
)	)	PM
experienced	VBD	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
vomiting	VBG	O
and	CC	O
throat	VB	O
oedema	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
dose-dense	JJ	O
FEC	NNP	PM
(	(	PM
75	CD	PM
)	)	O
and	CC	O
FEC	NNP	PM
(	(	PM
90	CD	PM
)	)	PM
are	VBP	O
feasible	JJ	O
with	IN	O
pegfilgrastim	JJ	O
support	NN	O
.	.	O

These	DT	O
regimens	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
very	RB	O
low	JJ	O
risk	NN	O
of	IN	O
Grade	NNP	O
3-4	JJ	O
toxicity	NN	O
.	.	O

The	DT	O
accuracy	NN	O
of	IN	O
clinical	JJ	PH
neurosensory	NN	PH
testing	VBG	PH
for	IN	O
nerve	JJ	O
injury	NN	O
diagnosis	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
accuracy	NN	O
of	IN	O
the	DT	O
clinical	JJ	PH
neurosensory	JJ	PH
test	NN	PH
to	TO	O
diagnose	VB	O
trigeminal	JJ	O
nerve	NN	O
injuries	NNS	O
has	VBZ	O
never	RB	O
been	VBN	O
statistically	RB	O
evaluated	VBN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
statistical	JJ	O
efficacy	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
neurosensory	JJ	O
test	NN	O
using	VBG	O
surgical	JJ	O
findings	NNS	O
as	IN	O
the	DT	O
gold	JJ	O
standard	NN	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
whether	IN	O
a	DT	O
correlation	NN	O
existed	VBN	O
between	IN	O
the	DT	O
sensory	JJ	O
impairment	NN	O
score	NN	O
obtained	VBN	O
by	IN	O
preoperative	JJ	O
testing	NN	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
nerve	NN	O
injury	NN	O
found	VBD	O
at	IN	O
surgery	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
multisite	NN	O
,	,	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
blinded	VBD	O
,	,	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
130	CD	O
patients	NNS	O
with	IN	O
inferior	JJ	O
alveolar	JJ	O
nerve	NN	O
(	(	O
IAN	NNP	O
)	)	O
and	CC	O
lingual	JJ	O
nerve	NN	O
(	(	O
LN	NNP	O
)	)	O
injuries	NNS	O
.	.	O

Preoperatively	RB	O
,	,	O
patients	NNS	O
were	VBD	O
provided	VBN	O
a	DT	O
sensory	JJ	O
impairment	NN	O
score	NN	O
using	VBG	O
a	DT	O
three-level	JJ	O
drop-out	JJ	O
clinical	JJ	O
neurosensory	NN	O
test	NN	O
(	(	O
NST	NNP	O
)	)	O
,	,	O
and	CC	O
blind	IN	S
comparisons	NNS	S
were	VBD	S
made	VBN	S
with	IN	S
the	DT	S
surgical	JJ	S
findings	NNS	S
postoperatively	RB	S
.	.	O

RESULTS	VB	O
The	DT	O
positive	JJ	O
predictive	NN	O
and	CC	O
negative	JJ	O
predictive	NN	O
values	NNS	O
for	IN	O
LN-injured	JJ	O
patients	NNS	O
were	VBD	O
95	CD	O
%	NN	O
and	CC	O
100	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
positive	JJ	O
predictive	NN	O
and	CC	O
negative	JJ	O
predictive	NN	O
values	NNS	O
for	IN	O
IAN	NNP	O
patients	NNS	O
were	VBD	O
77	CD	O
%	NN	O
and	CC	O
60	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
distribution	NN	O
of	IN	O
age	NN	O
,	,	O
duration	NN	O
of	IN	O
injury	NN	O
,	,	O
cause	NN	O
of	IN	O
injury	NN	O
,	,	O
presence	NN	O
of	IN	O
neuropathic	JJ	O
pain	NN	O
,	,	O
presence	NN	O
of	IN	O
trigger	NN	O
pain	NN	O
,	,	O
and	CC	O
degree	NN	O
of	IN	O
injury	NN	O
between	IN	O
the	DT	O
IAN	NNP	O
and	CC	O
LN	NNP	O
patient	JJ	O
populations	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
positive	JJ	O
relationship	NN	O
found	VBD	O
between	IN	O
the	DT	O
sensory	JJ	O
impairment	NN	O
score	NN	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
nerve	NN	O
injury	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
NST	NNP	PH
is	VBZ	O
a	DT	O
clinically	RB	O
useful	JJ	O
method	NN	O
to	TO	O
diagnose	VB	O
IAN	NNP	O
and	CC	O
LN	NNP	O
injuries	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
NST	NNP	O
results	NNS	O
are	VBP	O
less	RBR	O
efficient	JJ	O
for	IN	O
IAN	NNP	O
injuries	NNS	O
than	IN	O
LN	NNP	O
injuries	NNS	O
,	,	O
and	CC	O
have	VBP	O
a	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
false-positive	JJ	O
(	(	O
23	CD	O
%	NN	O
)	)	O
and	CC	O
false-negative	JJ	O
(	(	O
40	CD	O
%	NN	O
)	)	O
results	NNS	O
when	WRB	O
testing	VBG	O
patients	NNS	O
with	IN	O
IAN	NNP	O
injuries	NNS	O
.	.	O

The	DT	O
different	JJ	O
rates	NNS	O
of	IN	O
statistical	JJ	O
efficiency	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
may	MD	O
be	VB	O
attributable	JJ	O
to	TO	O
differences	NNS	O
in	IN	O
prevalence	NN	O
and	CC	O
biologic	NN	O
covariates	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
individualized	JJ	PS
breast	NN	PS
cancer	NN	PS
risk	NN	PS
counseling	NN	PS
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Studies	NNPS	O
have	VBP	O
shown	VBN	O
that	IN	O
a	DT	O
majority	NN	O
of	IN	O
women	NNS	O
with	IN	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
have	VBP	O
exaggerated	VBN	O
perceptions	NNS	O
of	IN	O
their	PRP$	O
own	JJ	O
risk	NN	O
of	IN	O
this	DT	O
disease	NN	O
and	CC	O
experience	NN	O
excessive	JJ	O
anxiety	NN	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
the	DT	O
need	NN	O
to	TO	O
communicate	VB	O
more	JJR	O
accurate	JJ	O
risk	NN	O
information	NN	O
to	TO	O
these	DT	O
women	NNS	O
,	,	O
specialized	JJ	O
programs	NNS	O
for	IN	O
breast	NN	E
cancer	NN	E
risk	NN	E
counseling	VBG	E
have	VBP	O
been	VBN	O
initiated	VBN	O
in	IN	O
medical	JJ	O
centers	NNS	O
across	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PURPOSE	VB	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
1	CD	O
)	)	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
standardized	JJ	O
protocol	NN	O
for	IN	O
individualized	JJ	PS
breast	NN	PS
cancer	NN	PS
risk	NN	PS
counseling	VBG	PS
on	IN	O
comprehension	NN	O
of	IN	O
personal	JJ	O
risk	NN	O
among	IN	O
first-degree	JJ	O
relatives	NNS	O
of	IN	O
index	NN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
and	CC	O
2	CD	O
)	)	O
to	TO	O
identify	VB	O
women	NNS	O
most	RBS	O
and	CC	O
least	JJS	O
likely	JJ	O
to	TO	O
benefit	VB	O
from	IN	O
such	JJ	O
counseling	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
individualized	VBN	PS
breast	NN	PS
cancer	NN	PS
risk	NN	PS
counseling	VBG	PS
to	TO	O
general	JJ	C
health	NN	C
counseling	NN	C
(	(	C
control	NN	C
)	)	C
.	.	O

We	PRP	O
studied	VBD	O
200	CD	O
women	NNS	O
aged	VBN	O
35	CD	O
years	NNS	O
and	CC	O
older	JJR	O
who	WP	O
had	VBD	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
in	IN	O
a	DT	O
first-degree	JJ	O
relative	NN	O
.	.	O

Women	NNS	O
with	IN	O
a	DT	O
personal	JJ	O
history	NN	O
of	IN	O
cancer	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

Risk	NNP	O
comprehension	NN	O
was	VBD	O
assessed	VBN	O
as	IN	O
the	DT	O
concordance	NN	O
between	IN	O
perceived	VBN	O
subjective	JJ	O
lifetime	NN	O
breast	NN	O
cancer	NN	O
risk	NN	O
and	CC	O
estimated	VBN	O
objective	JJ	O
lifetime	NN	O
risk	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
results	NNS	O
of	IN	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
women	NNS	O
who	WP	O
received	VBD	O
risk	NN	E
counseling	NN	E
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
improve	VB	O
their	PRP$	O
risk	NN	O
comprehension	NN	O
,	,	O
compared	VBN	O
with	IN	O
women	NNS	O
in	IN	O
the	DT	O
control	NN	O
condition	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
=	VBZ	O
3.5	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
=	NNP	O
1.3-9.5	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
about	RB	O
two	CD	O
thirds	NNS	O
of	IN	O
women	NNS	O
continued	VBN	O
to	TO	O
overestimate	VB	O
their	PRP$	O
lifetime	NN	O
risks	NNS	O
substantially	RB	O
following	VBG	O
counseling	VBG	O
.	.	O

Examination	NN	O
of	IN	O
subjects	NNS	O
by	IN	O
treatment	NN	O
interaction	NN	O
effects	NNS	O
indicated	VBD	O
that	IN	O
risk	NN	PS
counseling	VBG	PS
did	VBD	O
not	RB	O
produce	VB	O
improved	JJ	O
comprehension	NN	O
among	IN	O
the	DT	O
large	JJ	O
proportion	NN	O
of	IN	O
women	NNS	O
who	WP	O
had	VBD	O
high	JJ	O
levels	NNS	O
of	IN	O
anxious	JJ	O
preoccupation	NN	O
with	IN	O
breast	NN	O
cancer	NN	O
at	IN	O
base	NN	O
line	NN	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
white	JJ	O
women	NNS	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
benefit	VB	O
than	IN	O
African-American	JJ	O
women	NNS	O
(	(	O
OR	NNP	O
=	VBZ	O
0.34	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.11-0.99	NN	O
;	:	O
P	NNP	O
=	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Efforts	NNPS	O
to	TO	O
counsel	NN	O
women	NNS	O
about	IN	O
their	PRP$	O
breast	NN	O
cancer	NN	O
risks	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
be	VB	O
effective	JJ	O
unless	IN	O
their	PRP$	O
breast	NN	O
cancer	NN	O
anxieties	NNS	O
are	VBP	O
also	RB	O
addressed	VBN	O
.	.	O

IMPLICATIONS	NNP	O
Attention	NNP	O
to	TO	O
the	DT	O
psychological	JJ	O
aspects	NNS	O
of	IN	O
breast	NN	O
cancer	NN	O
risk	NN	O
will	MD	O
be	VB	O
critical	JJ	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
risk-counseling	JJ	E
programs	NNS	E
that	WDT	O
incorporate	VBP	O
testing	VBG	O
for	IN	O
the	DT	O
recently	RB	O
cloned	VBN	O
breast	NN	O
cancer	NN	O
susceptibility	NN	O
gene	NN	O
,	,	O
BRCA1	NNP	O
(	(	O
and	CC	O
BRCA2	NNP	O
when	WRB	O
that	DT	O
gene	NN	O
has	VBZ	O
also	RB	O
been	VBN	O
cloned	VBN	O
)	)	O
.	.	O

Financial	JJ	O
and	CC	O
quality-of-life	JJ	O
burden	NN	O
of	IN	O
dysfunctional	JJ	O
uterine	JJ	O
bleeding	NN	O
among	IN	O
women	NNS	O
agreeing	VBG	O
to	TO	O
obtain	VB	O
surgical	JJ	O
treatment	NN	O
.	.	O

PURPOSE	NN	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
sought	VBD	O
to	TO	O
1	CD	O
)	)	O
describe	NN	O
elements	NNS	O
of	IN	O
the	DT	O
financial	JJ	E
and	CC	E
quality-of-life	JJ	E
burden	NN	E
of	IN	O
dysfunctional	JJ	O
uterine	JJ	O
bleeding	NN	O
(	(	O
DUB	NNP	O
)	)	O
from	IN	O
the	DT	O
perspective	NN	O
of	IN	O
women	NNS	O
who	WP	O
agreed	VBD	O
to	TO	O
obtain	VB	O
surgical	JJ	O
treatment	NN	O
;	:	O
2	CD	O
)	)	O
explore	NN	O
associations	NNS	O
between	IN	O
DUB	NNP	O
symptom	NN	O
characteristics	NNS	O
and	CC	O
the	DT	O
financial	JJ	E
and	CC	E
quality-of-life	JJ	E
burden	NN	E
;	:	O
3	CD	O
)	)	O
estimate	VBP	O
the	DT	O
annual	JJ	O
dollar	NN	O
value	NN	O
of	IN	O
the	DT	O
financial	JJ	O
burden	NN	O
;	:	O
and	CC	O
4	CD	O
)	)	O
estimate	VBP	O
the	DT	O
most	RBS	O
that	DT	O
could	MD	O
be	VB	O
spent	VBN	O
on	IN	O
surgery	NN	O
to	TO	O
eliminate	VB	O
DUB	NNP	O
symptoms	NNS	O
for	IN	O
which	WDT	O
medical	JJ	O
treatment	NN	O
has	VBZ	O
been	VBN	O
unsuccessful	JJ	O
that	WDT	O
would	MD	O
result	VB	O
in	IN	O
a	DT	O
$	$	O
50,000/quality-adjusted	JJ	O
life-year	JJ	O
incremental	JJ	O
cost-effectiveness	NN	O
ratio	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
collected	VBD	O
baseline	NN	E
data	NNS	E
on	IN	E
DUB	NNP	E
symptoms	NNS	E
and	CC	E
aspects	NNS	E
of	IN	E
the	DT	E
financial	JJ	E
and	CC	E
quality-of-life	JJ	E
burden	NN	E
for	IN	O
237	CD	O
women	NNS	O
agreeing	VBG	O
to	TO	O
surgery	VB	O
for	IN	O
DUB	NNP	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
hysterectomy	NN	O
with	IN	O
endometrial	JJ	O
ablation	NN	O
.	.	O

Measures	NNS	O
included	VBD	O
out-of-pocket	JJ	O
pharmaceutical	JJ	O
expenditures	NNS	O
,	,	O
excess	JJ	O
expenditures	NNS	O
on	IN	O
pads	NNS	O
or	CC	O
tampons	NNS	O
,	,	O
the	DT	O
value	NN	O
of	IN	O
time	NN	O
missed	VBN	O
from	IN	O
paid	VBN	O
work	NN	O
and	CC	O
home	NN	O
management	NN	O
activities	NNS	O
,	,	O
and	CC	O
health	NN	O
utility	NN	O
.	.	O

We	PRP	O
used	VBD	O
chi2	NN	O
and	CC	O
t	NN	O
tests	NNS	O
to	TO	O
assess	VB	O
the	DT	O
statistical	JJ	O
significance	NN	O
of	IN	O
associations	NNS	O
between	IN	O
DUB	NNP	O
characteristics	NNS	O
and	CC	O
the	DT	O
financial	JJ	E
and	CC	E
quality-of-life	JJ	E
burden	NN	E
.	.	O

The	DT	O
annual	JJ	O
financial	JJ	O
burden	NN	O
was	VBD	O
estimated	VBN	O
.	.	O

RESULTS	NNP	O
Pelvic	NNP	O
pain	NN	O
and	CC	O
cramps	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
activity	NN	O
limitations	NNS	O
and	CC	O
tiredness	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
health	NN	O
utility	NN	O
.	.	O

Excess	NNP	O
pharmaceutical	JJ	O
and	CC	O
pad	NN	O
and	CC	O
tampon	NN	O
costs	NNS	O
were	VBD	O
$	$	O
333	CD	O
per	IN	O
patient	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
$	$	O
263-	JJ	O
$	$	O
403	CD	O
)	)	O
.	.	O

Excess	NNP	O
paid	VBD	O
work	NN	O
and	CC	O
home	NN	O
management	NN	O
loss	NN	O
costs	NNS	O
were	VBD	O
$	$	O
2,291	CD	O
per	IN	O
patient	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
$	$	O
1847-	JJ	O
$	$	O
2752	CD	O
)	)	O
.	.	O

Effective	JJ	O
surgical	JJ	O
treatment	NN	O
costing	VBG	O
$	$	O
40,000	CD	O
would	MD	O
be	VB	O
cost-effective	JJ	O
compared	VBN	O
with	IN	O
unsuccessful	JJ	O
medical	JJ	O
treatment	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
financial	JJ	E
and	CC	E
quality-of-life	JJ	E
effects	NNS	E
of	IN	O
DUB	NNP	O
represent	VBP	O
a	DT	O
substantial	JJ	O
burden	NN	O
.	.	O

A	DT	O
short-term	JJ	C
cognitive	JJ	C
group	NN	C
treatment	NN	C
program	NN	C
gives	VBZ	O
substantial	JJ	O
weight	NN	O
reduction	NN	O
up	RB	O
to	TO	O
18	CD	O
months	NNS	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

A	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
describe	VB	O
and	CC	O
evaluate	VB	O
long-term	JJ	O
efficacy	NN	O
(	(	O
18	CD	O
months	NNS	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
)	)	O
of	IN	O
a	DT	O
new	JJ	O
cognitive	JJ	C
short-term	JJ	C
weight	NN	C
reducing	VBG	C
treatment	NN	C
program	NN	C
for	IN	O
obese	JJ	O
patients	NNS	O
.	.	O

SUBJECTS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
five	CD	O
obese	JJ	O
[	NN	O
Body	NNP	O
Mass	NNP	O
Index	NNP	O
(	(	O
BMI	NNP	O
)	)	O
>	VBD	O
or	CC	O
=	$	O
30	CD	O
]	JJ	O
patients	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
62	CD	O
took	VBD	O
part	NN	O
in	IN	O
the	DT	O
treatment	NN	O
program	NN	O
and	CC	O
43	CD	O
served	VBD	O
as	IN	O
controls	NNS	O
.	.	O

METHOD	NNP	O
From	IN	O
an	DT	O
obesity	NN	O
unit	NN	O
's	POS	O
waiting	VBG	O
list	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
treatment	NN	O
group	NN	O
or	CC	O
remained	VBN	O
in	IN	O
the	DT	O
waiting	VBG	O
list	NN	O
to	TO	O
serve	VB	O
as	IN	O
a	DT	O
control	NN	C
group	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
participated	VBD	O
in	IN	O
a	DT	O
10-week	JJ	C
(	(	C
30	CD	C
hours	NNS	C
)	)	C
cognitive	VBP	C
group	NN	C
treatment	NN	C
program	NN	C
.	.	O

All	DT	O
participants	NNS	O
were	VBD	O
weighed	VBN	O
at	IN	O
the	DT	O
outset	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
directly	RB	O
after	IN	O
treatment	NN	O
and	CC	O
at	IN	O
a	DT	O
6-	JJ	O
,	,	O
12-	JJ	O
and	CC	O
18-month	JJ	O
post-treatment	JJ	O
follow-up	NN	O
without	IN	O
any	DT	O
booster	NN	O
treatment	NN	O
after	IN	O
the	DT	O
10-week	JJ	O
program	NN	O
.	.	O

RESULTS	NNP	O
Fifty-seven	NNP	O
(	(	O
92	CD	O
%	NN	O
)	)	O
patients	NNS	O
completed	VBN	O
treatment	NN	C
.	.	O

For	IN	O
the	DT	O
34	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
18	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
was	VBD	O
terminated	VBN	O
,	,	O
the	DT	O
mean	JJ	O
weight	NN	O
loss	NN	O
at	IN	O
treatment	NN	O
's	POS	O
end	NN	O
was	VBD	O
8.5	CD	O
kg	NN	O
(	(	O
SD=16.1	NNP	O
)	)	O
.	.	O

Eighteen	JJ	O
months	NNS	O
later	RB	O
their	PRP$	O
mean	JJ	O
weight	NN	O
loss	NN	O
was	VBD	O
10.4	CD	O
kg	NN	O
(	(	O
SD=10.8	NNP	O
)	)	O
.	.	O

The	DT	O
control	NN	O
patients	NNS	O
(	(	O
n=31.72	JJ	O
%	NN	O
)	)	O
that	WDT	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
during	IN	O
the	DT	O
same	JJ	O
period	NN	O
increased	VBD	O
in	IN	O
weight	NN	O
by	IN	O
2.3	CD	O
kg	NNS	O
(	(	O
SD=7.0	NNP	O
)	)	O
.	.	O

The	DT	O
weight	NN	O
difference	NN	O
between	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
group	NN	O
at	IN	O
the	DT	O
18-month	JJ	O
follow-up	NN	O
was	VBD	O
highly	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
cognitive	JJ	O
group	NN	O
treatment	NN	O
program	NN	O
was	VBD	O
highly	RB	O
acceptable	JJ	O
among	IN	O
the	DT	O
participants	NNS	O
and	CC	O
was	VBD	O
completed	VBN	O
by	IN	O
nearly	RB	O
all	PDT	O
the	DT	O
patients	NNS	O
.	.	O

The	DT	O
10-week	JJ	O
treatment	NN	O
program	NN	O
resulted	VBD	O
in	IN	O
satisfactory	JJ	O
weight	JJ	O
loss	NN	O
.	.	O

The	DT	O
weight	NN	O
difference	NN	O
between	IN	O
the	DT	O
treatment	NN	C
group	NN	O
and	CC	O
controls	NNS	O
was	VBD	O
nearly	RB	O
the	DT	O
same	JJ	O
at	IN	O
18	CD	O
months	NNS	O
after	IN	O
end	NN	O
of	IN	O
treatment	NN	O
as	IN	O
at	IN	O
six	CD	O
months	NNS	O
.	.	O

The	DT	O
study	NN	O
,	,	O
therefore	RB	O
,	,	O
does	VBZ	O
not	RB	O
provide	VB	O
support	NN	O
for	IN	O
the	DT	O
contention	NN	O
that	IN	O
a	DT	O
lengthy	JJ	O
therapy	NN	O
for	IN	O
obesity	NN	O
is	VBZ	O
necessary	JJ	O
if	IN	O
treatment	NN	O
results	NNS	O
are	VBP	O
lasting	VBG	O
.	.	O

Dose-response	JJ	O
effect	NN	O
of	IN	O
flecainide	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
paroxysmal	JJ	O
atrial	JJ	O
fibrillation	NN	O
and/or	NN	O
flutter	NN	O
monitored	VBD	O
with	IN	O
trans-telephonic	JJ	O
electrocardiography	NN	O
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
paroxysmal	JJ	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
flutter	NN	O
(	(	O
PAF/PAFL	NNP	O
)	)	O
experiencing	VBG	O
2	CD	O
or	CC	O
more	JJR	O
episodes	NNS	O
of	IN	O
symptomatic	JJ	O
PAF/PAFL	NNP	O
during	IN	O
a	DT	O
28-day	JJ	O
observation	NN	O
period	NN	O
to	TO	O
determine	VB	O
the	DT	O
dose-response	JJ	O
effect	NN	O
and	CC	O
safety	NN	O
of	IN	O
flecainide	NN	PM
.	.	O

METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
143	CD	O
patients	NNS	O
at	IN	O
30	CD	O
centers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
25	CD	O
,	,	O
50	CD	O
,	,	O
or	CC	O
100	CD	O
mg	NN	O
of	IN	O
flecainide	NN	PM
or	CC	O
placebo	VB	C
twice	JJ	O
daily	JJ	O
(	(	O
BID	NNP	O
)	)	O
.	.	O

In	IN	O
123	CD	O
patients	NNS	O
(	(	O
per	IN	O
protocol	NN	O
set	NN	O
)	)	O
,	,	O
those	DT	O
remaining	VBG	O
free	JJ	O
from	IN	O
PAF/PAFL	NNP	O
after	IN	O
the	DT	O
treatment	NN	O
were	VBD	O
3.1	CD	O
%	NN	O
on	IN	O
placebo	NN	C
,	,	O
7.7	CD	O
%	NN	O
on	IN	O
25	CD	O
mg/BID	NN	O
,	,	O
9.4	CD	O
%	NN	O
on	IN	O
50	CD	O
mg/BID	NN	O
,	,	O
and	CC	O
39.4	CD	O
%	NN	O
on	IN	O
100	CD	O
mg/BID	NN	O
of	IN	O
flecainide	NN	PM
.	.	O

As	IN	O
a	DT	O
whole	JJ	O
group	NN	O
,	,	O
a	DT	O
significant	JJ	O
linear	JJ	O
dose-response	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
was	VBD	O
observed	VBN	O
and	CC	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
placebo	NN	O
and	CC	O
100	CD	O
mg/BID	NN	O
was	VBD	O
observed	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
similar	JJ	O
dose-response	NN	O
between	IN	O
the	DT	O
present	JJ	O
study	NN	O
and	CC	O
Caucasian	NNP	O
study	NN	O
was	VBD	O
demonstrated	VBN	O
.	.	O

Although	IN	O
there	EX	O
were	VBD	O
5	CD	O
patients	NNS	O
who	WP	O
needed	VBD	O
cardioversion	NN	O
or	CC	O
ablation	NN	O
because	IN	O
of	IN	O
frequent	JJ	O
episodes	NNS	O
of	IN	O
PAF/PAFL	NNP	O
(	(	O
2	CD	O
in	IN	O
25	CD	O
mg/BID	NN	O
,	,	O
1	CD	O
in	IN	O
50	CD	O
mg/BID	NN	O
,	,	O
and	CC	O
2	CD	O
in	IN	O
100	CD	O
mg/BID	NN	O
of	IN	O
flecainide	NN	PM
)	)	O
,	,	O
neither	CC	O
death	NN	O
nor	CC	O
ventricular	JJ	O
proarrhythmic	JJ	O
event	NN	O
was	VBD	O
reported	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
indicated	VBD	O
that	IN	O
flecainide	NN	PM
exerted	VBD	O
a	DT	O
significant	JJ	O
dose-dependent	JJ	O
effect	NN	O
on	IN	O
the	DT	O
prevention	NN	O
of	IN	O
symptomatic	JJ	O
PAF/PAFL	NNP	O
recurrence	NN	O
and	CC	O
showed	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
inter-ethnic	JJ	O
difference	NN	O
in	IN	O
the	DT	O
clinical	JJ	O
effect	NN	O
of	IN	O
flecainide	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
PAF/PAFL	NNP	O
.	.	O

Herpes	NNP	PM
simplex	JJ	PM
virus	NN	PM
vaccine	NN	PM
in	IN	O
recurrent	JJ	O
herpetic	JJ	O
ocular	JJ	O
infection	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
antiherpetic	JJ	PM
vaccine	NN	PM
in	IN	O
recurrent	JJ	O
herpetic	JJ	O
ocular	JJ	O
infections	NNS	O
.	.	O

METHODS	NNP	O
Twenty	NNP	O
patients	NNS	O
with	IN	O
herpes	NNS	O
simplex	JJ	O
virus	IN	O
1-related	JJ	O
recurrent	NN	O
keratitis/keratouveitis	NN	O
were	VBD	O
prospectively	RB	O
enrolled	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	CC	O
a	DT	O
specific	JJ	PM
vaccination	NN	PM
with	IN	PM
heat	NN	PM
shock-inactivated	JJ	PM
herpes	NNS	PM
simplex	JJ	PM
virus	NN	PM
type	NN	PM
1	CD	PM
(	(	O
10	CD	O
patients	NNS	O
)	)	O
or	CC	O
to	TO	O
be	VB	O
observed	VBN	O
as	IN	O
controls	NNS	C
(	(	O
10	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
number	NN	O
,	,	O
duration	NN	O
,	,	O
and	CC	O
anatomic	JJ	O
localization	NN	O
of	IN	O
relapses	NNS	O
were	VBD	O
recorded	VBN	O
in	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
for	IN	O
12	CD	O
months	NNS	O
before	IN	O
inclusion	NN	O
in	IN	O
the	DT	O
study	NN	O
and	CC	O
for	IN	O
a	DT	O
similar	JJ	O
period	NN	O
after	IN	O
the	DT	O
assignment	NN	O
of	IN	O
each	DT	O
subject	NN	O
to	TO	O
vaccine	VB	O
or	CC	O
control	VB	O
group	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
vaccine	NN	O
group	NN	O
,	,	O
we	PRP	O
observed	VBD	O
a	DT	O
reduction	NN	O
both	DT	O
in	IN	O
the	DT	O
number	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.016	CD	O
)	)	O
and	CC	O
average	JJ	O
duration	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.050	CD	O
)	)	O
of	IN	O
recurrences	NNS	O
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
no	DT	O
significant	JJ	O
change	NN	O
was	VBD	O
found	VBN	O
comparing	VBG	O
a	DT	O
12-month	JJ	O
period	NN	O
before	IN	O
and	CC	O
after	IN	O
inclusion	NN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
comparison	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
highlighted	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.013	CD	O
)	)	O
and	CC	O
average	JJ	O
duration	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.051	CD	O
)	)	O
of	IN	O
relapses	NNS	O
in	IN	O
treated	JJ	O
subjects	NNS	O
,	,	O
who	WP	O
did	VBD	O
not	RB	O
show	VB	O
any	DT	O
significant	JJ	O
vaccine-induced	JJ	O
side	NN	O
effects	NNS	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
use	NN	O
of	IN	O
a	DT	O
vaccination	NN	PM
with	IN	O
heat	NN	O
shock-inactivated	JJ	O
herpes	NNS	O
simplex	JJ	O
virus	NN	O
1	CD	O
seems	VBZ	O
to	TO	O
be	VB	O
able	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
number	NN	O
and	CC	O
duration	NN	O
of	IN	O
relapses	NNS	O
in	IN	O
herpes	NNS	O
simplex	JJ	O
virus	IN	O
1-related	JJ	O
keratitis/keratouveitis	NN	O
.	.	O

Midazolam	NNP	PM
vs	NN	O
ondansetron	NN	PM
for	IN	O
preventing	VBG	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
prophylactic	JJ	O
anti-emetic	JJ	O
efficacy	NN	O
of	IN	O
midazolam	NN	PM
and	CC	O
ondansetron	NN	PM
in	IN	O
90	CD	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
minor	JJ	O
gynaecological	JJ	O
(	(	O
hysteroscopy	NN	O
)	)	O
or	CC	O
urological	JJ	O
(	(	O
ureteroscopy	JJ	O
)	)	O
procedures	NNS	O
planned	VBN	O
to	TO	O
last	JJ	O
1-2	JJ	O
h	NN	O
under	IN	O
sevoflurane	NN	O
anaesthesia	NN	O
with	IN	O
spontaneous	JJ	O
ventilation	NN	O
of	IN	O
the	DT	O
lungs	NNS	O
via	IN	O
a	DT	O
laryngeal	JJ	O
mask	NN	O
airway	NN	O
.	.	O

Midazolam	NNP	PM
2	CD	PM
mg	NN	PM
or	CC	O
ondansetron	$	PM
4	CD	PM
mg	NN	PM
were	VBD	O
administered	VBN	O
intravenously	RB	O
30	CD	O
min	NN	O
before	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
.	.	O

The	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
experienced	VBD	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
h	NN	O
(	(	O
30	CD	O
%	NN	O
and	CC	O
27	CD	O
%	NN	O
for	IN	O
the	DT	O
midazolam	NN	PM
and	CC	O
ondansetron	NN	PM
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
was	VBD	O
significantly	RB	O
smaller	JJR	O
in	IN	O
both	DT	O
groups	NNS	O
than	IN	O
predicted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
patients	NNS	O
'	POS	O
underlying	JJ	O
risks	NNS	O
(	(	O
midazolam	JJ	PM
group	NN	O
:	:	O
p	NN	O
=	VBZ	O
0.018	CD	O
;	:	O
ondansetron	VBN	PM
group	NN	O
:	:	O
p	NN	O
=	VBZ	O
0.017	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
average	JJ	O
sedation	NN	O
scores	NNS	O
or	CC	O
pain	NN	O
scores	NNS	O
.	.	O

Treatment	NNP	O
using	VBG	O
ondansetron	NN	PM
for	IN	O
anti-emetic	JJ	O
prophylaxis	NN	O
did	VBD	O
not	RB	O
provide	VB	O
a	DT	O
superior	JJ	O
benefit	NN	O
compared	VBN	O
to	TO	O
midazolam	VB	PM
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
dopexamine	NN	PM
in	IN	O
splanchnic	JJ	O
perfusion	NN	O
during	IN	O
surgery	NN	O
of	IN	O
the	DT	O
abdominal	JJ	O
aorta	NN	O
]	NNP	O
.	.	O

Abdominal	NNP	O
aortic	JJ	O
surgery	NN	O
has	VBZ	O
significant	JJ	O
effects	NNS	O
on	IN	O
cardiac	NN	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
dopexamine	NN	O
,	,	O
an	DT	O
inodilator	JJ	O
drug	NN	O
,	,	O
on	IN	O
hemodynamic	JJ	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
with	IN	O
measurement	NN	O
of	IN	O
gastric	JJ	O
intramucosal	NN	O
pH	NN	O
,	,	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
gastric	JJ	O
tonometry	NN	O
,	,	O
during	IN	O
abdominal	JJ	O
aneurysm	JJ	O
resection	NN	O
.	.	O

Twenty-five	JJ	O
patients	NNS	O
undergoing	VBG	O
excision	NN	O
of	IN	O
an	DT	O
aortic	JJ	O
abdominal	JJ	O
aneurysm	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
Group	NNP	O
II	NNP	O
patients	NNS	O
received	VBD	O
dopexamine	JJ	PM
infusion	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
microgram/kg/m	NN	O
,	,	O
and	CC	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	O
micrograms/kg/m	NN	O
from	IN	O
declamping	VBG	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
surgery	NN	O
.	.	O

Whereas	NNP	O
Group	NNP	O
I	PRP	O
patients	NNS	O
did	VBD	C
not	RB	C
receive	VB	C
a	DT	C
dopexamine	JJ	C
infusion	NN	C
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	VBG	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
decreased	VBN	O
in	IN	O
Group	NNP	O
I	PRP	O
patients	NNS	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
Group	NNP	O
II	NNP	O
patients	NNS	O
.	.	O

Heart	NNP	O
rate	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
,	,	O
and	CC	O
mixed	JJ	O
venous	JJ	O
oxygen	NN	O
saturation	NN	O
increased	VBD	O
significantly	RB	O
during	IN	O
dopexamine	JJ	O
infusion	NN	O
,	,	O
whereas	JJ	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
was	VBD	O
reduced	VBN	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
dopexamine	NN	PM
was	VBD	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
improving	VBG	O
splanchnic	JJ	O
blood	NN	O
flow	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
venous	JJ	O
saturation	NN	O
.	.	O

Also	RB	O
,	,	O
since	IN	O
the	DT	O
drug	NN	O
produces	VBZ	O
dose	RB	O
related	JJ	O
hemodynamic	JJ	O
changes	NNS	O
of	IN	O
rapid	JJ	O
onset	NN	O
and	CC	O
reversibility	NN	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
interrupt	VB	O
the	DT	O
infusion	NN	O
before	IN	O
aortic	JJ	O
declamping	NN	O
to	TO	O
avoid	VB	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
.	.	O

Effect	NN	O
of	IN	O
resistance	NN	PH
exercise	NN	PH
contraction	NN	PH
mode	NN	PH
and	CC	O
protein	JJ	PH
supplementation	NN	PH
on	IN	O
members	NNS	O
of	IN	O
the	DT	O
STARS	NNP	O
signalling	VBG	O
pathway	RB	O
.	.	O

The	DT	O
striated	JJ	O
muscle	NN	O
activator	NN	O
of	IN	O
Rho	NNP	O
signalling	VBG	O
(	(	O
STARS	NNP	O
)	)	O
pathway	NN	O
is	VBZ	O
suggested	VBN	O
to	TO	O
provide	VB	O
a	DT	O
link	NN	O
between	IN	O
external	JJ	O
stress	NN	O
responses	NNS	O
and	CC	O
transcriptional	JJ	O
regulation	NN	O
in	IN	O
muscle	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
STARS	NNP	O
signalling	VBG	O
to	TO	O
different	JJ	O
mechanical	JJ	O
stresses	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

In	IN	O
a	DT	O
comparative	JJ	O
study	NN	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
regulation	NN	O
of	IN	O
the	DT	O
STARS	NNP	O
signalling	VBG	O
pathway	RB	O
in	IN	O
response	NN	O
to	TO	O
unilateral	JJ	O
resistance	NN	PH
exercise	NN	PH
performed	VBN	O
as	IN	O
either	DT	O
eccentric	JJ	E
(	(	PH
ECC	NNP	PH
)	)	PH
or	CC	PH
concentric	JJ	PH
(	(	PH
CONC	NNP	PH
)	)	PH
contractions	NNS	PH
as	RB	O
well	RB	O
as	IN	O
prolonged	JJ	E
training	NN	E
;	:	O
with	IN	O
and	CC	O
without	IN	O
whey	JJ	PH
protein	NN	PH
supplementation	NN	PH
.	.	O

Skeletal	JJ	O
muscle	NN	O
STARS	NNP	O
,	,	O
myocardian-related	JJ	O
transcription	NN	O
factor-A	NN	O
(	(	O
MRTF-A	NNP	O
)	)	O
and	CC	O
serum	JJ	O
response	NN	O
factor	NN	O
(	(	O
SRF	NNP	O
)	)	O
mRNA	NN	O
and	CC	O
protein	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
muscle	NN	O
cross-sectional	JJ	O
area	NN	O
and	CC	O
maximal	JJ	O
voluntary	JJ	O
contraction	NN	O
,	,	O
were	VBD	O
measured	VBN	O
.	.	O

A	DT	O
single-bout	NN	O
of	IN	O
exercise	NN	PH
produced	VBN	O
increases	NNS	O
in	IN	O
STARS	NNP	O
and	CC	O
SRF	NNP	O
mRNA	NN	O
and	CC	O
decreases	NNS	O
in	IN	O
MRTF-A	NNP	O
mRNA	NN	O
with	IN	O
both	DT	O
ECC	NNP	PH
and	CC	O
CONC	NNP	PH
exercise	NN	PH
,	,	O
but	CC	O
with	IN	O
an	DT	O
enhanced	JJ	O
response	NN	O
occurring	VBG	O
following	VBG	O
ECC	NNP	PH
exercise	NN	PH
.	.	O

A	DT	O
31	CD	O
%	NN	O
increase	NN	O
in	IN	O
STARS	NNP	O
protein	NN	O
was	VBD	O
observed	VBN	O
exclusively	RB	O
after	IN	O
CONC	NNP	PH
exercise	NN	PH
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
while	IN	O
pSRF	JJ	O
protein	NN	O
levels	NNS	O
increased	VBD	O
similarly	RB	O
by	IN	O
48	CD	O
%	NN	O
with	IN	O
both	DT	O
CONC	NNP	O
and	CC	O
ECC	NNP	O
exercise	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Prolonged	VBN	O
ECC	NNP	O
and	CC	O
CONC	NNP	O
training	VBG	O
equally	RB	O
stimulated	VBN	O
muscle	NN	O
hypertrophy	NN	O
and	CC	O
produced	VBD	O
increases	NNS	O
in	IN	O
MRTF-A	NNP	O
protein	NN	O
of	IN	O
125	CD	O
%	NN	O
and	CC	O
99	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	UH	O
changes	NNS	O
occurred	VBD	O
for	IN	O
total	JJ	O
SRF	NNP	O
protein	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
effect	NN	O
of	IN	O
whey	NN	PH
protein	NN	PH
supplementation	NN	PH
.	.	O

These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
resistance	NN	O
exercise	NN	O
provides	VBZ	O
an	DT	O
acute	JJ	O
stimulation	NN	O
of	IN	O
the	DT	O
STARS	NNP	O
pathway	NN	O
that	WDT	O
is	VBZ	O
contraction	JJ	O
mode	NN	O
dependent	NN	O
.	.	O

The	DT	O
responses	NNS	O
to	TO	O
acute	VB	PH
exercise	NN	PH
were	VBD	O
more	RBR	O
pronounced	JJ	O
than	IN	O
responses	NNS	O
to	TO	O
accumulated	JJ	E
training	NN	E
,	,	O
suggesting	VBG	O
that	IN	O
STARS	NNP	O
signalling	VBG	O
is	VBZ	O
primarily	RB	O
involved	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
phase	NN	O
of	IN	O
exercise-induced	JJ	O
muscle	NN	O
adaptations	NNS	O
.	.	O

A	DT	O
phase	NN	O
III	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
multicenter	NN	O
study	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
recombinant	JJ	PM
human	JJ	PM
antithrombin	NN	PM
in	IN	O
heparin-resistant	JJ	O
patients	NNS	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
cardiac	JJ	O
surgery	NN	O
necessitating	VBG	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
recombinant	JJ	PM
human	JJ	PM
antithrombin	NN	PM
(	(	PM
rhAT	NN	PM
)	)	PM
for	IN	O
restoring	VBG	O
heparin	NN	O
responsiveness	NN	O
in	IN	O
heparin	NN	O
resistant	JJ	O
patients	NNS	O
undergoing	VBG	O
cardiac	JJ	O
surgery	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
heparin-resistant	JJ	O
patients	NNS	O
undergoing	VBG	O
cardiac	JJ	O
surgery	NN	O
with	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

Heparin	NNP	PM
resistance	NN	O
was	VBD	O
diagnosed	VBN	O
when	WRB	O
the	DT	O
activated	VBN	O
clotting	NN	O
time	NN	O
was	VBD	O
less	JJR	O
than	IN	O
480	CD	O
s	NNS	O
after	IN	O
400	CD	O
U/kg	NNP	O
heparin	NN	PM
.	.	O

Fifty-four	JJ	O
heparin-resistant	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

One	CD	O
cohort	NN	O
received	VBD	PM
75	CD	PM
U/kg	NNP	PM
rhAT	NN	PM
,	,	O
and	CC	O
the	DT	O
other	JJ	O
received	VBD	PM
normal	JJ	PM
saline	NN	PM
.	.	O

If	IN	O
the	DT	O
activated	JJ	O
clotting	NN	O
time	NN	O
remained	VBD	O
less	JJR	O
than	IN	O
480	CD	O
s	NN	O
,	,	O
this	DT	O
was	VBD	O
considered	VBN	O
treatment	NN	O
failure	NN	O
,	,	O
and	CC	O
2	CD	O
units	NNS	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
was	VBD	O
transfused	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
Only	RB	O
19	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
rhAT	NN	PM
group	NN	O
received	VBD	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
,	,	O
compared	VBN	O
with	IN	O
81	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

During	IN	O
their	PRP$	O
hospitalization	NN	O
,	,	O
48	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
rhAT	NN	PM
group	NN	O
received	VBD	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
,	,	O
compared	VBN	O
with	IN	O
85	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.009	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
required	VBD	O
higher	JJR	O
heparin	NN	PM
doses	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
for	IN	O
anticoagulation	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
associated	VBN	O
with	IN	O
rhAT	NN	PM
.	.	O

There	EX	O
was	VBD	O
increased	VBN	O
blood	NN	O
loss	NN	O
12	CD	O
h	NN	O
postoperatively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
with	IN	O
a	DT	O
trend	NN	O
toward	IN	O
increased	VBN	O
24-h	JJ	O
bleeding	NN	O
in	IN	O
the	DT	O
rhAT	NN	PM
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
blood	NN	O
and	CC	O
platelet	NN	O
transfusions	NNS	O
.	.	O

CONCLUSION	NNP	O
Treatment	NNP	O
with	IN	O
75	CD	O
U/kg	NNP	O
rhAT	NN	PM
is	VBZ	O
effective	JJ	O
in	IN	O
restoring	VBG	O
heparin	NN	O
responsiveness	NN	O
and	CC	O
promoting	VBG	O
therapeutic	JJ	O
anticoagulation	NN	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
heparin-resistant	JJ	O
patients	NNS	O
.	.	O

Treating	VBG	O
heparin-resistant	JJ	O
patients	NNS	O
with	IN	O
rhAT	NN	PM
may	MD	O
decrease	VB	O
the	DT	O
requirement	NN	O
for	IN	O
heparin	NN	O
and	CC	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
.	.	O

Effect	NN	O
of	IN	O
entacapone	NN	PM
,	,	O
a	DT	O
peripherally	RB	O
acting	VBG	O
catechol-O-methyltransferase	NN	O
inhibitor	NN	O
,	,	O
on	IN	O
the	DT	O
motor	NN	O
response	NN	O
to	TO	O
acute	VB	O
treatment	NN	O
with	IN	O
levodopa	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Catechol-O-methyltransferase	NNP	O
(	(	O
COMT	NNP	O
)	)	O
inhibitors	NNS	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
by	IN	O
improving	VBG	O
the	DT	O
bioavailability	NN	O
of	IN	O
levodopa	NN	O
and	CC	O
by	IN	O
prolonging	VBG	O
its	PRP$	O
effects	NNS	O
.	.	O

Entacapone	NNP	PM
(	(	PM
OR-611	NNP	PM
)	)	PM
,	,	O
a	DT	O
novel	JJ	PM
COMT	NNP	PM
inhibitor	NN	PM
,	,	O
which	WDT	O
does	VBZ	O
not	RB	O
cross	VB	O
the	DT	O
blood	NN	O
brain	NN	O
barrier	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
and	CC	O
motor	NN	O
fluctuations	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
,	,	O
single	JJ	O
dose	NN	O
study	NN	O
.	.	O

The	DT	O
magnitude	NN	O
and	CC	O
duration	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
response	NN	O
to	TO	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
levodopa/50	JJ	PM
mg	FW	O
carbidopa	NN	PM
was	VBD	O
evaluated	VBN	O
after	IN	O
concomitant	JJ	O
placebo	NN	C
,	,	O
or	CC	O
200	CD	O
or	CC	O
800	CD	O
mg	NN	O
entacapone	NN	PM
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
motor	NN	O
response	NN	O
to	TO	O
levodopa	NN	O
was	VBD	O
seen	VBN	O
when	WRB	O
200	CD	O
mg	NN	O
entacapone	NN	O
was	VBD	O
given	VBN	O
with	IN	O
levodopa/carbidopa	NN	O
.	.	O

Plasma	NNP	O
levodopa	JJ	O
concentrations	NNS	O
were	VBD	O
increased	VBN	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
the	DT	O
COMT	NNP	O
inhibitor	NN	O
.	.	O

The	DT	O
latency	NN	O
to	TO	O
onset	VB	O
of	IN	O
motor	NN	O
response	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
active	JJ	O
drug	NN	O
and	CC	O
placebo	NN	O
.	.	O

Entacapone	NN	O
may	MD	O
prove	VB	O
useful	JJ	O
in	IN	O
prolonging	VBG	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
benefit	NN	O
obtained	VBN	O
from	IN	O
individual	JJ	O
doses	NNS	O
of	IN	O
levodopa	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
24-h	JJ	O
psychological	JJ	E
training	NN	E
program	NN	E
on	IN	O
attitudes	NNS	O
,	,	O
communication	NN	O
skills	NNS	O
and	CC	O
occupational	JJ	O
stress	NN	O
in	IN	O
oncology	NN	O
:	:	O
a	DT	O
randomised	JJ	O
study	NN	O
.	.	O

The	DT	O
usefulness	NN	O
of	IN	O
psychological	JJ	E
training	NN	E
programs	NNS	E
(	(	E
P.T.P	NNP	E
.	.	E

)	)	E
in	IN	O
health	NN	O
care	NN	O
settings	NNS	O
devoted	VBN	O
to	TO	O
cancer	NN	O
care	NN	O
is	VBZ	O
beginning	VBG	O
to	TO	O
be	VB	O
recognised	VBN	O
but	CC	O
their	PRP$	O
content	NN	O
,	,	O
form	NN	O
and	CC	O
effectiveness	VB	O
need	NN	O
further	JJ	O
investigation	NN	O
.	.	O

Seventy-two	JJ	O
oncology	NN	O
nurses	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
24-h	JJ	E
P.T.P	NNP	E
.	.	E

or	CC	C
to	TO	C
a	DT	C
waiting	VBG	C
list	NN	C
period	NN	C
.	.	O

Attitudes	NNS	O
were	VBD	O
assessed	VBN	E
by	IN	E
a	DT	E
semantic	JJ	E
differential	NN	E
questionnaire	NN	E
,	,	O
occupational	JJ	E
stress	NN	E
was	VBD	E
assessed	VBN	E
by	IN	E
the	DT	E
Nursing	NNP	E
Stress	NNP	E
Scale	NNP	E
and	CC	E
communication	NN	E
skills	NNS	E
were	VBD	E
assessed	VBN	E
by	IN	E
standardised	JJ	E
videotaped	VBD	E
role-playing	NN	E
exercises	NNS	E
.	.	O

These	DT	O
were	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
trained	JJ	O
(	(	O
T.S	NNP	O
.	.	O

)	)	O
and	CC	O
control	NN	O
subjects	NNS	O
(	(	O
C.S.	NNP	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
a	DT	O
significant	JJ	O
training	NN	O
effect	NN	O
on	IN	O
attitudes	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
especially	RB	O
on	IN	O
those	DT	O
related	VBN	O
to	TO	O
self	VB	O
concept	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
level	NN	O
of	IN	O
occupational	JJ	O
stress	NN	O
related	VBN	O
to	TO	O
inadequate	VB	O
preparation	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Limited	VBN	O
changes	NNS	O
were	VBD	O
found	VBN	O
regarding	VBG	O
post-training	JJ	O
communication	NN	O
skills	NNS	O
.	.	O

T.S	NNP	O
.	.	O

were	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
control	NN	O
of	IN	O
the	DT	O
interview	NN	O
than	IN	O
C.S	NNP	O
.	.	O

(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
24-h	JJ	O
P.T.P	NNP	E
.	.	O

assessed	VBN	O
here	RB	O
are	VBP	O
effective	JJ	O
.	.	O

The	DT	O
data	NN	O
also	RB	O
demonstrate	VBP	O
the	DT	O
need	NN	O
to	TO	O
consolidate	VB	O
the	DT	O
skills	NNS	O
acquired	VBN	O
by	IN	O
regular	JJ	O
post-training	JJ	O
sessions	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
seven	CD	O
antiarrhythmic	JJ	PM
drugs	NNS	PM
in	IN	O
patients	NNS	O
with	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
.	.	O

Electrophysiologic	NNP	O
Study	NNP	O
versus	VBD	O
Electrocardiographic	NNP	O
Monitoring	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
relative	JJ	O
efficacies	NNS	O
of	IN	O
various	JJ	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
are	VBP	O
not	RB	O
well	RB	O
known	VBN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
imipramine	NN	PM
,	,	O
mexiletine	NN	PM
,	,	O
pirmenol	NN	PM
,	,	O
procainamide	NN	PM
,	,	O
propafenone	NN	PM
,	,	O
quinidine	NN	PM
,	,	O
and	CC	O
sotalol	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
who	WP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
Electrophysiologic	NNP	O
Study	NNP	O
versus	VBD	O
Electrocardiographic	NNP	O
Monitoring	NNP	O
trial	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
serial	JJ	O
testing	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
seven	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
by	IN	O
one	CD	O
of	IN	O
two	CD	O
strategies	NNS	O
:	:	O
electrophysiologic	NN	PH
study	NN	PH
or	CC	PH
Holter	NNP	PH
monitoring	VBG	PH
together	RB	PH
with	IN	PH
exercise	NN	PH
testing	NN	PH
.	.	O

The	DT	O
seven	CD	O
drugs	NNS	O
were	VBD	O
then	RB	O
tested	VBN	O
for	IN	O
efficacy	NN	O
in	IN	O
random	JJ	O
order	NN	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
eligible	JJ	O
to	TO	O
receive	VB	O
them	PRP	O
.	.	O

The	DT	O
frequencies	NNS	O
of	IN	O
predictions	NNS	O
of	IN	O
drug	NN	O
efficacy	NN	O
and	CC	O
of	IN	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
during	IN	O
the	DT	O
initial	JJ	O
drug	NN	O
titration	NN	O
were	VBD	O
tabulated	VBN	O
for	IN	O
all	DT	O
486	CD	O
randomized	VBN	O
subjects	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
long-term	JJ	O
treatment	NN	O
with	IN	O
the	DT	O
first	JJ	O
antiarrhythmic	JJ	O
drug	NN	O
that	WDT	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
drug	NN	O
testing	NN	O
.	.	O

Recurrences	NNS	O
of	IN	O
arrhythmia	NN	O
,	,	O
deaths	NNS	O
,	,	O
and	CC	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
during	IN	O
long-term	JJ	O
follow-up	NNS	O
were	VBD	O
recorded	VBN	O
for	IN	O
the	DT	O
296	CD	O
patients	NNS	O
in	IN	O
whom	WP	O
an	DT	O
antiarrhythmic	JJ	O
drug	NN	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
electrophysiologic-study	JJ	O
group	NN	O
,	,	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
predictions	NNS	O
of	IN	O
drug	NN	O
efficacy	NN	O
was	VBD	O
higher	JJR	O
with	IN	O
sotalol	NN	O
(	(	O
35	CD	O
percent	NN	O
)	)	O
than	IN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
16	CD	O
percent	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
among	IN	O
the	DT	O
drugs	NNS	O
in	IN	O
the	DT	O
Holter-monitoring	NNP	O
group	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
was	VBD	O
lowest	JJS	O
among	IN	O
those	DT	O
receiving	VBG	O
sotalol	NN	O
.	.	O

The	DT	O
actuarial	JJ	O
probability	NN	O
of	IN	O
a	DT	O
recurrence	NN	O
of	IN	O
arrhythmia	NN	O
after	IN	O
a	DT	O
prediction	NN	O
of	IN	O
drug	NN	O
efficacy	NN	O
by	IN	O
either	DT	O
strategy	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
sotalol	NN	O
than	IN	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
risk	NN	O
ratio	NN	O
,	,	O
0.43	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.29	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

With	IN	O
sotalol	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
combined	VBN	O
,	,	O
there	EX	O
were	VBD	O
lower	JJR	O
risks	NNS	O
of	IN	O
death	NN	O
from	IN	O
any	DT	O
cause	NN	O
(	(	O
risk	NN	O
ratio	NN	O
,	,	O
0.50	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.30	CD	O
to	TO	O
0.80	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
death	NN	O
from	IN	O
cardiac	JJ	O
causes	NNS	O
,	,	O
(	(	O
0.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
death	NN	O
from	IN	O
arrhythmia	NN	O
(	(	O
0.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

The	DT	O
cumulative	JJ	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
whom	WP	O
a	DT	O
drug	NN	O
was	VBD	O
predicted	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
and	CC	O
in	IN	O
whom	WP	O
it	PRP	O
remained	VBD	O
effective	JJ	O
and	CC	O
tolerated	VBD	O
was	VBD	O
higher	JJR	O
for	IN	O
sotalol	JJR	O
than	IN	O
for	IN	O
the	DT	O
other	JJ	O
drugs	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Sotalol	NNP	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
other	JJ	O
six	CD	O
antiarrhythmic	JJ	O
drugs	NNS	O
in	IN	O
preventing	VBG	O
death	NN	O
and	CC	O
recurrences	NNS	O
of	IN	O
arrhythmia	NN	O
.	.	O

In	IN	O
patients	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
in	IN	O
this	DT	O
study	NN	O
,	,	O
if	IN	O
antiarrhythmic-drug	JJ	O
therapy	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
to	TO	O
prevent	VB	O
recurrences	NNS	O
of	IN	O
ventricular	JJ	O
tachyarrhythmias	NNS	O
,	,	O
treatment	NN	O
with	IN	O
sotalol	NN	O
and	CC	O
assessment	NN	O
of	IN	O
its	PRP$	O
potential	JJ	O
efficacy	NN	O
by	IN	O
Holter	NNP	O
monitoring	NN	O
are	VBP	O
a	DT	O
reasonable	JJ	O
initial	JJ	O
strategy	NN	O
.	.	O

Baseline	NNP	O
factors	NNS	O
predicting	VBG	O
placebo	NN	C
response	NN	O
to	TO	O
treatment	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
multisite	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

IMPORTANCE	VBZ	O
The	DT	O
finding	NN	O
of	IN	O
factors	NNS	O
that	WDT	O
differentially	RB	O
predict	VBP	O
the	DT	O
likelihood	NN	O
of	IN	O
response	NN	O
to	TO	O
placebo	VB	O
over	IN	O
that	DT	O
of	IN	O
an	DT	O
active	JJ	O
drug	NN	O
could	MD	O
have	VB	O
a	DT	O
significant	JJ	O
impact	NN	O
on	IN	O
study	NN	O
design	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
identify	VB	O
possible	JJ	O
nonspecific	NN	O
,	,	O
baseline	JJ	O
predictors	NNS	O
of	IN	O
response	NN	O
to	TO	O
intervention	NN	O
in	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
of	IN	O
citalopram	NN	PM
hydrobromide	NN	PM
for	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
prominent	JJ	O
repetitive	JJ	O
behavior	NN	O
.	.	O

Baseline	NNP	O
data	NN	O
at	IN	O
study	NN	O
entry	NN	O
were	VBD	O
examined	VBN	O
with	IN	O
respect	NN	O
to	TO	O
final	JJ	O
outcome	NN	O
to	TO	O
determine	VB	O
if	IN	O
response	NN	O
predictors	NNS	O
could	MD	O
be	VB	O
identified	VBN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
149	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
of	IN	O
age	NN	O
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
,	,	O
9.4	CD	O
[	NN	O
3.1	CD	O
]	CD	O
years	NNS	O
)	)	O
from	IN	O
6	CD	O
academic	JJ	O
centers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
citalopram	VB	PM
(	(	O
n	JJ	O
=	NNP	O
73	CD	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
76	CD	O
)	)	O
.	.	O

Participants	NNS	O
had	VBD	O
autistic	JJ	O
disorder	NN	O
,	,	O
Asperger	NNP	O
syndrome	NN	O
,	,	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
,	,	O
not	RB	O
otherwise	RB	O
specified	VBN	O
;	:	O
had	VBD	O
illness	JJ	O
severity	NN	O
ratings	NNS	O
that	WDT	O
were	VBD	O
moderate	JJ	O
or	CC	O
more	JJR	O
than	IN	O
moderate	VB	O
on	IN	O
the	DT	O
Clinical	JJ	O
Global	NNP	O
Impression-Severity	NNP	O
scale	NN	O
;	:	O
and	CC	O
scored	VBD	O
moderate	JJ	O
or	CC	O
more	JJR	O
than	IN	O
moderate	VB	O
on	IN	O
compulsive	JJ	O
behaviors	NNS	O
measured	VBN	O
with	IN	O
the	DT	O
modified	JJ	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive-Compulsive	JJ	O
Scale	NNP	O
.	.	O

INTERVENTIONS	NNP	O
Twelve	NNP	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
citalopram	NN	PM
(	(	O
10	CD	O
mg/5	RB	O
mL	NN	O
)	)	O
or	CC	O
placebo	NN	C
.	.	O

The	DT	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
maximum	VBD	O
dose	NN	O
of	IN	O
citalopram	NN	O
was	VBD	O
16.5	CD	O
(	(	O
6.5	CD	O
)	)	O
mg	NN	O
by	IN	O
mouth	JJ	O
daily	JJ	O
(	(	O
maximum	JJ	O
dose	NN	O
,	,	O
20	CD	O
mg/d	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
AND	NNP	O
MEASURES	NNP	O
A	NNP	O
positive	JJ	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
having	VBG	O
a	DT	O
score	NN	O
of	IN	O
at	IN	O
least	JJS	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
Clinical	JJ	O
Global	NNP	O
Impression-Improvement	NNP	O
scale	NN	O
at	IN	O
week	NN	O
12	CD	O
.	.	O

Baseline	NNP	O
measures	VBZ	O
included	VBN	O
demographic	JJ	O
(	(	O
sex	NN	O
,	,	O
age	NN	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
pubertal	JJ	O
status	NN	O
)	)	O
,	,	O
clinical	JJ	O
,	,	O
and	CC	O
family	NN	O
measures	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
included	VBD	O
baseline	NN	O
illness	NN	O
severity	NN	O
ratings	NNS	O
(	(	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
,	,	O
the	DT	O
Child	NNP	O
and	CC	O
Adolescent	NNP	O
Symptom	NNP	O
Inventory	NNP	O
,	,	O
the	DT	O
Vineland	NNP	O
Adaptive	NNP	O
Behavior	NNP	O
Scales	NNP	O
,	,	O
the	DT	O
Repetitive	JJ	O
Behavior	NNP	O
Scale-Revised	JJ	O
,	,	O
and	CC	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive-Compulsive	JJ	O
Scale	NNP	O
)	)	O
.	.	O

Family	JJ	O
measures	NNS	O
included	VBD	O
the	DT	O
Caregiver	NNP	O
Strain	NNP	O
Questionnaire	NNP	O
.	.	O

RESULTS	NNP	O
Several	JJ	O
baseline	JJ	O
predictors	NNS	O
of	IN	O
response	NN	O
were	VBD	O
identified	VBN	O
,	,	O
and	CC	O
a	DT	O
principal	JJ	O
component	NN	O
analysis	NN	O
yielded	VBD	O
3	CD	O
composite	JJ	O
measures	NNS	O
(	(	O
disruptive	JJ	O
behavior	NN	O
,	,	O
autism/mood	NN	O
,	,	O
and	CC	O
caregiver	RB	O
strain	NN	O
)	)	O
that	WDT	O
significantly	RB	O
predicted	VBD	O
response	NN	O
at	IN	O
week	NN	O
12	CD	O
.	.	O

Specifically	RB	O
,	,	O
participants	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
significantly	RB	O
less	RBR	O
likely	JJ	O
than	IN	O
participants	NNS	O
in	IN	O
the	DT	O
citalopram	NN	O
group	NN	O
to	TO	O
respond	VB	O
at	IN	O
week	NN	O
12	CD	O
if	IN	O
they	PRP	O
entered	VBD	O
the	DT	O
study	NN	O
more	RBR	O
symptomatic	JJ	O
on	IN	O
each	DT	O
of	IN	O
the	DT	O
3	CD	O
composite	JJ	O
measures	NNS	O
,	,	O
and	CC	O
they	PRP	O
were	VBD	O
at	IN	O
least	JJS	O
2	CD	O
times	NNS	O
less	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
responders	NNS	O
.	.	O

CONCLUSIONS	NNP	O
AND	CC	O
RELEVANCE	NNP	O
This	DT	O
analysis	NN	O
suggests	VBZ	O
strategies	NNS	O
that	WDT	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
anticipating	VBG	O
and	CC	O
potentially	RB	O
mitigating	VBG	O
the	DT	O
nonspecific	JJ	O
response	NN	O
in	IN	O
randomized	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00086645	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
sequential	JJ	O
annual	JJ	O
vaccination	NN	PM
and	CC	O
of	IN	O
DHEA	NNP	PM
administration	NN	PM
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	O
vaccine	NN	O
in	IN	O
the	DT	O
elderly	JJ	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
repeated	VBN	O
vaccination	NN	PM
and	CC	O
of	IN	O
dehydroepiandrosterone	NN	PM
(	(	PM
DHEA	NNP	PM
)	)	PM
treatment	NN	O
on	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	PM
vaccine	NN	PM
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

Seventy-one	CD	O
elderly	JJ	O
volunteers	NNS	O
,	,	O
aged	VBN	O
61-89	CD	O
years	NNS	O
,	,	O
enrolled	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
to	TO	O
receive	VB	O
either	DT	O
DHEA	NNP	PM
(	(	O
50	CD	O
mg	NN	O
qd	NN	O
p.o	NN	O
.	.	O

for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
starting	VBG	O
2	CD	O
days	NNS	O
before	IN	O
immunization	NN	O
)	)	O
or	CC	O
placebo	NN	C
.	.	C

Antibody	NNP	O
response	NN	O
against	IN	O
the	DT	O
three	CD	O
strains	NNS	O
of	IN	O
vaccine	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
vaccination	NN	O
,	,	O
and	CC	O
compared	VBN	O
between	IN	O
previously	RB	O
vaccinated	VBN	O
and	CC	O
non-vaccinated	JJ	O
subjects	NNS	O
.	.	O

DHEA	NNP	PM
treatment	NN	PM
did	VBD	O
not	RB	O
enhance	VB	O
established	VBN	O
immunity	NN	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
attainment	NN	O
of	IN	O
protective	JJ	O
antibody	NN	O
titer	NN	O
(	(	O
titer	NN	O
of	IN	O
1:40	CD	O
or	CC	O
greater	JJR	O
)	)	O
against	IN	O
A/Texas	NNP	O
in	IN	O
subjects	NNS	O
with	IN	O
non-protective	JJ	O
baseline	NN	O
antibody	NN	O
titer	NN	O
was	VBD	O
recorded	VBN	O
following	VBG	O
DHEA	NNP	PM
treatment	NN	PM
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
52	CD	O
vs.	FW	O
84	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Post-immunization	NN	O
titers	NNS	O
against	IN	O
influenza	VBP	O
A	DT	O
strains	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
immunized	VBN	O
before	RB	O
.	.	O

Additionally	RB	O
,	,	O
post-vaccination	JJ	O
protective	JJ	O
titers	NNS	O
against	IN	O
the	DT	O
A/Johannesburg	NNP	O
strain	NN	O
were	VBD	O
more	RBR	O
prevalent	JJ	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
vaccinated	VBN	O
before	RB	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
not	RB	O
the	DT	O
same	JJ	O
for	IN	O
anti-B/Harbin	JJ	O
antibodies-repeated	JJ	O
vaccination	NN	O
caused	VBD	O
a	DT	O
non-significant	JJ	O
increase	NN	O
in	IN	O
HI	NNP	O
titer	NN	O
in	IN	O
previously	RB	O
vaccinated	VBN	O
subjects	NNS	O
.	.	O

[	JJ	O
Metastatic	NNP	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
tamoxifen	NN	PM
and	CC	O
the	DT	O
sequential	JJ	O
administration	NN	O
of	IN	O
tamoxifen	NN	PM
and	CC	O
medroxyprogesterone	NN	PM
acetate	NN	PM
]	NNP	O
.	.	O

Seventy-nine	JJ	O
patients	NNS	O
with	IN	O
an	DT	O
histologically	RB	O
proven	RB	O
disseminated	VBN	O
breast	NN	O
cancer	NN	O
,	,	O
never	RB	O
treated	VBN	O
before	IN	O
with	IN	O
additive	JJ	O
hormonal	JJ	O
therapy	NN	O
,	,	O
entered	VBD	O
into	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
between	IN	O
june	NN	O
1981	CD	O
and	CC	O
december	VB	O
1982	CD	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
group	NN	O
44	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
continually	RB	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
tamoxifen	NN	PM
(	(	PM
TAM	NNP	PM
)	)	O
of	IN	O
20	CD	O
mg/m2	NN	O
.	.	O

In	IN	O
the	DT	O
2nd	CD	O
group	NN	O
35	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
TAM	NNP	PM
of	IN	O
20	CD	O
mg/m2	NN	O
for	IN	O
15	CD	O
days	NNS	O
and	CC	O
then	RB	O
an	DT	O
oral	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
medroxyprogesterone	NN	PM
acetate	NN	PM
of	IN	O
350	CD	O
mg/m2	NN	O
for	IN	O
the	DT	O
next	JJ	O
15	CD	O
days	NNS	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
stopped	VBN	O
at	IN	O
the	DT	O
first	JJ	O
manifestation	NN	O
of	IN	O
progression	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

The	DT	O
hormonal	JJ	O
receptor	NN	O
status	NN	O
was	VBD	O
determined	VBN	O
in	IN	O
30	CD	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
I	PRP	O
and	CC	O
23	CD	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
II	NNP	O
.	.	O

An	DT	O
objective	JJ	O
response	NN	O
to	TO	O
treatment	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
48	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
of	IN	O
the	DT	O
group	NN	O
I	PRP	O
and	CC	O
60	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
group	NN	O
II	NNP	O
.	.	O

This	DT	O
difference	NN	O
is	VBZ	O
not	RB	O
significant	JJ	O
(	(	O
X2	NNP	O
=	NNP	O
1,05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
mean	JJ	O
duration	NN	O
of	IN	O
therapeutic	JJ	O
response	NN	O
is	VBZ	O
significantly	RB	O
higher	RBR	O
in	IN	O
the	DT	O
group	NN	O
II	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0,01	CD	O
)	)	O
.	.	O

[	RB	O
Comparative	NNP	O
study	NN	O
between	IN	O
5	CD	PM
%	NN	PM
prilocaine	NN	PM
and	CC	O
2	CD	PM
%	NN	PM
mepivacaine	NN	PM
by	IN	O
the	DT	O
subarachnoid	JJ	O
route	NN	O
in	IN	O
transurethral	JJ	O
resections	NNS	O
]	VBP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
duration	NN	O
of	IN	O
spinal	JJ	O
block	NN	O
with	IN	O
5	CD	PM
%	NN	PM
prilocaine	NN	PM
and	CC	O
2	CD	PM
%	NN	PM
mepivacaine	NN	PM
in	IN	O
short	JJ	O
procedures	NNS	O
for	IN	O
transurethral	JJ	O
resection	NN	O
and	CC	O
to	TO	O
assess	VB	O
possible	JJ	O
complications	NNS	O
in	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Fifty-seven	NNP	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
transurethral	JJ	O
resection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
or	CC	O
a	DT	O
vesical	JJ	O
tumor	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
ASA	NNP	O
I-III	NNP	O
,	,	O
over	IN	O
55	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	PM
groups	NNS	PM
to	TO	PM
receive	VB	PM
5	CD	PM
%	NN	PM
prilocaine	NN	PM
(	(	PM
1	CD	PM
mg/kg	NN	PM
,	,	PM
n	JJ	PM
=	NNP	PM
27	CD	PM
)	)	PM
or	CC	O
2	CD	PM
%	NN	PM
mepivacaine	NN	PM
(	(	PM
0.8	CD	PM
mg/kg	NN	PM
,	,	PM
n	JJ	PM
=	NNP	PM
30	CD	PM
)	)	PM
.	.	O

We	PRP	S
collected	VBD	S
data	NNS	S
on	IN	S
anesthetic	JJ	S
technique	NN	S
,	,	S
levels	NNS	S
of	IN	S
extension	NN	S
of	IN	S
motor	NN	S
and	CC	S
sensory	JJ	S
blockades	NNS	S
,	,	S
duration	NN	S
of	IN	S
blockades	NNS	S
and	CC	S
complications	NNS	S
within	IN	S
the	DT	S
first	JJ	S
24	CD	S
hours	NNS	S
after	IN	S
surgery	NN	S
.	.	O

RESULTS	NNP	O
Demographic	NNP	O
data	NNS	O
,	,	O
ASA	NNP	O
classification	NN	O
and	CC	O
duration	NN	O
of	IN	O
surgery	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

We	PRP	O
found	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
duration	NN	O
of	IN	O
sensory	JJ	O
blockade	NN	O
(	(	O
120.92	CD	O
+/-	JJ	O
36.21	CD	O
min	NN	O
with	IN	O
prilocaine	NN	PM
and	CC	O
145.83	CD	O
+/-	JJ	O
35.81	CD	O
min	NN	O
with	IN	O
mepivacaine	NN	PM
)	)	O
and	CC	O
in	IN	O
motor	NN	O
blockade	NN	O
(	(	O
106.29	CD	O
+/-	JJ	O
38.16	CD	O
min	NN	O
with	IN	O
prilocaine	NN	O
and	CC	O
133.16	CD	O
+/-	JJ	O
42.21	CD	O
min	NN	O
with	IN	O
mepivacaine	NN	O
)	)	O
.	.	O

Five	JJ	O
cases	NNS	O
of	IN	O
hypotension	NN	O
and	CC	O
4	CD	O
of	IN	O
bradycardia	NN	O
occurred	VBN	O
in	IN	O
each	DT	O
group	NN	O
and	CC	O
one	CD	O
patient	NN	O
in	IN	O
the	DT	O
mepivacaine	NN	O
group	NN	O
suffered	VBD	O
slight	JJ	O
postoperative	JJ	O
cephalea	NN	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
local	JJ	O
anesthetics	NNS	O
offer	VBP	O
good	JJ	O
surgical	JJ	O
conditions	NNS	O
with	IN	O
hemodynamic	JJ	O
stability	NN	O
and	CC	O
few	JJ	O
complications	NNS	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
sensory	NN	O
and	CC	O
motor	NN	O
blockade	NN	O
is	VBZ	O
shorter	JJR	O
with	IN	O
prilocaine	NN	O
than	IN	O
with	IN	O
mepivacaine	NN	O
,	,	O
making	VBG	O
prilocaine	NN	O
more	JJR	O
appropriate	JJ	O
for	IN	O
short	JJ	O
interventions	NNS	O
.	.	O

Granulocyte-macrophage	JJ	PM
colony-stimulating	JJ	PM
factor	NN	PM
as	IN	O
immunomodulating	VBG	O
factor	NN	O
together	RB	O
with	IN	O
influenza	JJ	PM
vaccination	NN	PM
in	IN	O
stem	NN	O
cell	NN	O
transplant	NN	O
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
granulocyte-macrophage	JJ	PH
colony-stimulating	JJ	PH
factor	NN	PH
(	(	PH
GM-CSF	NNP	PH
)	)	PH
on	IN	O
the	DT	O
serological	JJ	O
response	NN	O
at	IN	O
influenza	JJ	PM
vaccination	NN	PM
was	VBD	O
studied	VBN	O
in	IN	O
117	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
undergone	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
SCT	NNP	O
)	)	O
.	.	O

The	DT	O
vaccine	NN	O
response	NN	O
was	VBD	O
evaluated	VBN	O
as	IN	O
significant	JJ	O
increases	NNS	O
in	IN	O
levels	NNS	O
of	IN	O
influenza	JJ	O
hemagglutination-inhibition	NN	O
(	(	O
HAI	NNP	O
)	)	O
antibodies	NNS	O
and	CC	O
of	IN	O
IgG	NNP	O
antibodies	NNS	O
measured	VBN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
antibody	NN	O
response	NN	O
to	TO	O
either	DT	O
influenza	VB	O
A	NNP	O
or	CC	O
B	NNP	O
in	IN	O
64	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
GM-CSF	NNP	PH
at	IN	O
vaccination	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
53	NNS	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

In	IN	O
the	DT	O
subgroup	NN	O
of	IN	O
allogeneic	JJ	O
SCT	NNP	O
patients	NNS	O
,	,	O
HAI	NNP	O
showed	VBD	O
that	IN	O
the	DT	O
response	NN	O
rate	NN	O
to	TO	O
the	DT	O
influenza	NN	PM
B	NNP	PM
vaccine	NN	PM
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

ELISA	NN	O
showed	VBD	O
that	IN	O
autologous	JJ	O
SCT	NNP	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
who	WP	O
received	VBD	O
GM-CSF	NNP	O
had	VBD	O
a	DT	O
better	JJR	O
response	NN	O
to	TO	O
influenza	VB	O
A	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

At	IN	O
early	JJ	O
vaccination	NN	O
,	,	O
4-12	JJ	O
months	NNS	O
after	IN	O
stem	NN	O
cell	NN	O
transplantation	NN	O
,	,	O
these	DT	O
responses	NNS	O
were	VBD	O
more	RBR	O
pronounced	JJ	O
.	.	O

GM-CSF	JJ	PM
appears	VBZ	O
to	TO	O
improve	VB	O
the	DT	O
response	NN	O
to	TO	O
influenza	VB	O
vaccination	NN	O
in	IN	O
some	DT	O
groups	NNS	O
of	IN	O
SCT	NNP	O
patients	NNS	O
,	,	O
but	CC	O
only	RB	O
to	TO	O
a	DT	O
limited	JJ	O
extent	NN	O
.	.	O

Engagement	NN	E
with	IN	E
electronic	JJ	E
screen	JJ	E
media	NNS	E
among	IN	O
students	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
relative	JJ	O
engagement	JJ	O
potential	NN	O
of	IN	O
four	CD	O
types	NNS	O
of	IN	O
electronic	JJ	E
screen	JJ	E
media	NNS	E
(	(	E
ESM	NNP	E
)	)	E
:	:	E
animated	VBN	E
video	NN	E
,	,	E
video	NN	E
of	IN	E
self	NN	E
,	,	E
video	NN	E
of	IN	E
a	DT	E
familiar	JJ	E
person	NN	E
engaged	VBD	E
with	IN	E
an	DT	E
immersive	JJ	E
virtual	JJ	E
reality	NN	E
(	(	E
VR	NNP	E
)	)	E
game	NN	E
,	,	E
and	CC	E
immersion	NN	E
of	IN	E
self	NN	E
in	IN	E
the	DT	E
VR	NNP	E
game	NN	E
.	.	E

Forty-two	JJ	O
students	NNS	O
with	IN	O
autism	NN	O
,	,	O
varying	VBG	O
in	IN	O
age	NN	O
and	CC	O
expressive	JJ	O
communication	NN	O
ability	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
.	.	O

Gaze	NNP	O
duration	NN	O
and	CC	O
vocalization	NN	O
served	VBD	O
as	IN	O
dependent	JJ	O
measures	NNS	O
of	IN	O
engagement	NN	O
.	.	O

The	DT	O
results	NNS	O
reveal	VBP	O
differential	JJ	O
responding	NN	O
across	IN	O
ESM	NNP	E
,	,	O
with	IN	O
some	DT	O
variation	NN	O
related	VBN	O
to	TO	O
the	DT	O
engagement	NN	O
metric	JJ	O
employed	VBN	O
.	.	O

Preferences	NNS	O
for	IN	O
seeing	VBG	O
themselves	PRP	O
on	IN	O
the	DT	O
screen	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
viewing	VBG	O
the	DT	O
VR	NNP	E
scenarios	NNS	O
,	,	O
emerged	VBD	O
from	IN	O
the	DT	O
data	NNS	O
.	.	O

While	IN	O
the	DT	O
study	NN	O
did	VBD	O
not	RB	O
yield	VB	O
definitive	JJ	O
data	NNS	O
about	IN	O
the	DT	O
relative	JJ	O
engagement	JJ	O
potential	NN	O
of	IN	O
ESM	NNP	E
alternatives	NNS	O
,	,	O
it	PRP	O
does	VBZ	O
provide	VB	O
a	DT	O
foundation	NN	O
for	IN	O
future	JJ	O
research	NN	O
,	,	O
including	VBG	O
guidance	NN	O
related	VBN	O
to	TO	O
participant	JJ	O
profiles	NNS	O
,	,	O
stimulus	NN	O
characteristics	NNS	O
,	,	O
and	CC	O
data	NNS	O
coding	NN	O
challenges	NNS	O
.	.	O

Long-stay	JJ	PH
versus	NN	O
short-stay	JJ	PH
hospital	NN	PH
treatment	NN	PH
of	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
protein-energy	JJ	O
malnutrition	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
contrast	VB	O
early	JJ	Ot
discharge	NN	Ot
versus	NN	O
attempted	VBD	Ot
full	JJ	Ot
nutritional	JJ	Ot
rehabilitation	NN	Ot
in	IN	O
hospital	NN	O
of	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
protein-energy	JJ	O
malnutrition	NN	O
(	(	O
PEM	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Field	NNP	O
experiment	NN	O
,	,	O
two-way	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
with	IN	O
one	CD	O
between	IN	O
group	NN	O
(	(	O
short-	JJ	Ot
versus	IN	O
long-stay	NN	Ot
)	)	O
and	CC	O
one	CD	O
repeated	VBN	O
measures	NNS	O
factor	NN	O
(	(	O
admission	NN	O
,	,	O
then	RB	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
,	,	O
30	CD	O
and	CC	O
36	CD	O
months	NNS	O
post-admission	NN	O
)	)	O
.	.	O

Covariates	NNPS	O
introduced	VBD	O
.	.	O

SETTING	NNP	O
Primary	NNP	O
health	NN	O
care	NN	O
,	,	O
Kingston	NNP	O
,	,	O
Jamaica	NNP	O
.	.	O

SUBJECTS	NNP	O
n	JJ	O
=	NNP	O
81	CD	O
;	:	O
mean	JJ	O
age	NN	O
11	CD	O
months	NNS	O
;	:	O
79	CD	O
contribute	VBP	O
longitudinal	JJ	O
data	NNS	O
;	:	O
44	CD	O
every	DT	O
measurement	NN	O
.	.	O

INTERVENTIONS	NNP	O
When	WRB	O
concurrent	NN	O
illnesses	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
and	CC	O
normal	JJ	O
feeding	VBG	O
re-established	JJ	O
(	(	O
weight	JJ	O
gain	NN	O
5	CD	O
g/kg.day-1	NN	O
)	)	O
,	,	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
short-stay	NN	PH
(	(	PH
SS	NNP	PH
)	)	PH
or	CC	O
long-stay	JJ	PH
(	(	PH
LS	NNP	PH
)	)	PH
group	NN	O
.	.	O

LS	NNP	PH
retained	VBD	O
in	IN	O
hospital	NN	O
for	IN	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
mean	VB	O
40	CD	O
days	NNS	O
)	)	O
.	.	O

SS	NNP	PH
discharged	VBD	O
immediately	RB	O
(	(	O
mean	JJ	O
18	CD	O
days	NNS	O
)	)	O
for	IN	O
standard	JJ	O
Health	NNP	O
Service	NNP	O
care	NN	O
at	IN	O
home	NN	O
for	IN	O
6	CD	O
months	NNS	O
plus	CC	O
high-energy	JJ	O
supplement	NN	O
(	(	O
3.31	CD	O
MJ	NNP	O
with	IN	O
20.6	CD	O
g	NNS	O
protein	JJ	O
daily	JJ	O
)	)	O
for	IN	O
first	JJ	O
3	CD	O
months	NNS	O
.	.	O

After	IN	O
discharge	NN	O
LS	NNP	PH
received	VBD	O
6	CD	O
months	NNS	O
home	NN	O
care	NN	O
,	,	O
but	CC	O
without	IN	O
supplementation	NN	O
.	.	O

RESULTS	NNP	O
Significant	NNP	O
advantages	VBZ	O
for	IN	O
LS	NNP	O
group	NN	O
on	IN	O
NCHS	NNP	O
weight	NN	O
&	CC	O
length	NN	O
for	IN	O
age	NN	O
at	IN	O
discharge	NN	O
,	,	O
and	CC	O
at	IN	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
and	CC	O
for	IN	O
length	NN	O
also	RB	O
30	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
to	TO	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Weight	NNP	O
advantage	NN	O
peaked	VBD	O
at	IN	O
12	CD	O
and	CC	O
18	CD	O
months	NNS	O
,	,	O
length	NN	O
later	RB	O
at	IN	O
18	CD	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Contrary	NNP	O
to	TO	O
earlier	VB	O
reports	NNS	O
,	,	O
full	JJ	O
nutritional	JJ	O
rehabilitation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
hospital	NN	O
for	IN	O
children	NNS	O
suffering	VBG	O
from	IN	O
PEM	NNP	O
.	.	O

Although	IN	O
in	IN	O
the	DT	O
long-term	JJ	O
both	DT	O
groups	NNS	O
move	VBP	O
towards	NNS	O
expected	VBN	O
levels	NNS	O
in	IN	O
their	PRP$	O
home	NN	O
community	NN	O
,	,	O
a	DT	O
significant	JJ	O
advantage	NN	O
maintained	VBD	O
for	IN	O
approximately	RB	O
2	CD	O
years	NNS	O
is	VBZ	O
developmentally	RB	O
advantageous	JJ	O
during	IN	O
the	DT	O
critical	JJ	O
time	NN	O
after	IN	O
weaning	VBG	O
.	.	O

Prevention	NN	O
of	IN	O
postoperative	JJ	O
hypocalcemia	NN	O
with	IN	O
routine	JJ	O
oral	JJ	O
calcium	NN	PM
and	CC	O
vitamin	NN	PM
D	NNP	PM
supplements	NNS	PM
in	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
papillary	JJ	O
thyroid	NN	O
carcinoma	NN	O
undergoing	JJ	O
total	JJ	O
thyroidectomy	NN	O
plus	CC	O
central	JJ	O
neck	NN	O
dissection	NN	O
.	.	O

BACKGROUND	NNP	O
Routine	NNP	O
oral	JJ	PM
calcium	NN	PM
and	CC	O
vitamin	NN	PM
D	NNP	PM
supplementation	NN	PM
may	MD	O
prevent	VB	O
hypocalcemic	JJ	O
crisis	NN	O
,	,	O
but	CC	O
its	PRP$	O
efficacy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
thyroidectomy	JJ	O
plus	JJ	O
central	JJ	O
neck	NN	O
dissection	NN	O
(	(	O
CND	NNP	O
)	)	O
.	.	O

The	DT	O
authors	NNS	O
therefore	VBP	O
prospectively	RB	O
evaluated	VBN	O
the	DT	O
clinical	JJ	O
usefulness	NN	O
of	IN	O
routine	JJ	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
for	IN	O
prevention	NN	O
of	IN	O
hypocalcemia	NN	O
after	IN	O
total	JJ	O
thyroidectomy	NN	O
and	CC	O
CND	NNP	O
.	.	O

METHODS	NNP	O
Of	IN	O
197	CD	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
papillary	JJ	O
thyroid	NN	O
carcinoma	NN	O
,	,	O
49	CD	O
underwent	JJ	O
total	JJ	O
thyroidectomy	NN	O
alone	RB	O
,	,	O
and	CC	O
148	CD	O
underwent	JJ	O
total	JJ	PM
thyroidectomy	NN	PM
plus	CC	PM
CND	NNP	PM
.	.	O

The	DT	O
latter	JJ	O
were	VBD	O
randomized	VBN	O
to	TO	O
oral	JJ	PM
calcium	NN	PM
(	(	O
3	CD	O
g/day	NN	O
)	)	O
plus	CC	O
vitamin	JJ	PM
D	NNP	PM
(	(	O
1	CD	O
mg/day	NN	O
)	)	O
(	(	O
Group	NNP	O
A	NNP	O
,	,	O
n=49	NN	O
)	)	O
,	,	O
calcium	NN	PM
alone	RB	PM
(	(	O
Group	NNP	O
B	NNP	O
,	,	O
n=49	NN	O
)	)	O
,	,	O
or	CC	O
no	DT	PM
supplements	NNS	PM
(	(	O
Group	NNP	O
C	NNP	O
,	,	O
n=50	RB	O
)	)	O
.	.	O

Hypocalcemic	NNP	O
symptoms	NNS	O
,	,	O
serum	JJ	O
calcium	NN	O
,	,	O
and	CC	O
parathyroid	VB	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
levels	NNS	O
were	VBD	O
compared	VBN	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Group	NNP	O
C	NNP	O
had	VBD	O
significantly	RB	O
higher	JJR	O
incidences	NNS	O
of	IN	O
symptomatic	JJ	O
(	(	O
26.0	CD	O
%	NN	O
vs	JJ	O
6.1	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.015	NNP	O
)	)	O
and	CC	O
laboratory	NN	O
(	(	O
44.0	CD	O
%	NN	O
vs	JJ	O
14.3	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.015	NNP	O
)	)	O
hypocalcemia	NN	O
than	IN	O
the	DT	O
group	NN	O
without	IN	O
CND	NNP	O
.	.	O

The	DT	O
incidences	NNS	O
of	IN	O
symptomatic	JJ	O
and	CC	O
laboratory	JJ	O
hypocalcemia	NN	O
were	VBD	O
significantly	RB	O
decreased	VBN	O
in	IN	O
Groups	NNP	O
A	NNP	O
(	(	O
2.0	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
12.2	CD	O
%	NN	O
and	CC	O
24.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Serum	NNP	O
calcium	NN	O
levels	NNS	O
decreased	VBN	O
in	IN	O
most	JJS	O
patients	NNS	O
after	IN	O
surgery	NN	O
,	,	O
but	CC	O
recovered	VBD	O
earliest	JJS	O
in	IN	O
Group	NNP	O
A.	NNP	O
Hypercalcemia	NNP	O
and	CC	O
PTH	NNP	O
inhibition	NN	O
did	VBD	O
not	RB	O
occur	VB	O
in	IN	O
gs	NN	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Compared	NNP	O
with	IN	O
total	JJ	O
thyroidectomy	NN	O
alone	RB	O
,	,	O
CND	NNP	O
significantly	RB	O
increases	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
postoperative	JJ	O
hypocalcemia	NN	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
by	IN	O
routine	JJ	O
postoperative	JJ	O
supplementation	NN	O
with	IN	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
remifentanil	NN	PM
with	IN	O
fentanyl	NN	PM
for	IN	O
deep	JJ	O
sedation	NN	O
in	IN	O
oral	JJ	O
surgery	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
recovery	NN	O
for	IN	O
oral	JJ	O
surgery	NN	O
patients	NNS	O
given	VBN	O
a	DT	O
deep	JJ	O
sedation	NN	O
regimen	NNS	O
of	IN	O
midazolam	NN	PM
,	,	PM
propofol	NN	PM
,	,	O
and	CC	O
remifentanil	NN	PM
with	IN	O
a	DT	O
standard	JJ	O
control	NN	O
of	IN	O
fentanyl	NN	O
in	IN	O
place	NN	O
of	IN	O
remifentanil	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
investigation	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
randomized	NN	O
,	,	O
prospective	JJ	O
,	,	O
single-blinded	JJ	O
controlled	VBD	O
study	NN	O
.	.	O

Group	NNP	O
1	CD	O
,	,	O
the	DT	O
control	NN	O
,	,	O
received	VBD	O
midazolam	JJ	PM
0.03	CD	PM
mg/kg	NN	PM
,	,	PM
fentanyl	VBP	PM
1	CD	PM
microg/kg	NN	PM
,	,	PM
and	CC	PM
propofol	VB	PM
initially	RB	PM
at	IN	PM
140	CD	PM
microg/kg/min	NN	PM
.	.	PM

Group	NNP	O
2	CD	O
received	VBD	O
midazolam	RB	PM
0.03	CD	PM
mg/kg	NN	PM
,	,	PM
remifentanil	NN	PM
:	:	PM
propofol	NN	PM
(	(	PM
1:500	CD	PM
)	)	PM
given	VBN	PM
at	IN	PM
an	DT	PM
initial	JJ	PM
propofol	JJ	PM
infusion	NN	PM
rate	NN	PM
of	IN	PM
40	CD	PM
microg/kg/min	NN	PM
.	.	PM

Outcome	NNP	O
measures	NNS	O
included	VBD	O
time	NN	O
to	TO	O
response	NN	O
to	TO	O
verbal	JJ	O
command	NN	O
,	,	O
Aldrete	NNP	O
score	VBD	O
=	JJ	O
9	CD	O
,	,	O
Postanesthesia	NNP	O
Discharge	NNP	O
Scoring	NNP	O
System	NNP	O
=	VBD	O
7	CD	O
,	,	O
and	CC	O
assessment	NN	O
by	IN	O
the	DT	O
Digit	NNP	O
Symbol	NNP	O
Substitution	NNP	O
Test	NNP	O
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
subjects	NNS	O
were	VBD	O
entered	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Baseline	NNP	O
findings	NNS	O
were	VBD	O
homogenous	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
group	NN	O
2	CD	O
recovered	VBN	O
earlier	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
and	CC	O
required	VBN	O
less	JJR	O
propofol	NN	PM
for	IN	O
both	DT	O
the	DT	O
induction	NN	O
(	(	O
0.8	CD	O
+/-	JJ	O
0.4	CD	O
versus	NN	O
1.2	CD	O
+/-	JJ	O
0.6	CD	O
mg/kg	NN	O
;	:	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
maintenance	NN	O
of	IN	O
deep	JJ	O
sedation	NN	O
(	(	O
46	CD	O
+/-	JJ	O
9	CD	O
versus	NN	O
131	CD	O
+/-	JJ	O
17	CD	O
microg/kg/min	NN	O
;	:	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
minor	JJ	O
differences	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
this	DT	O
remifentanil	JJ	O
regimen	NNS	O
provided	VBD	O
significantly	RB	O
more	RBR	O
rapid	JJ	O
recovery	NN	O
and	CC	O
used	VBD	O
significantly	RB	O
less	JJR	O
propofol	JJ	PM
compared	VBN	O
with	IN	O
the	DT	O
fentanyl	JJ	PM
regimen	NNS	O
.	.	O

Group	NNP	E
cognitive	JJ	E
behavior	NN	E
therapy	NN	E
for	IN	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
anxiety	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
are	VBP	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
developing	VBG	O
significant	JJ	O
anxiety	NN	O
.	.	O

Anxiety	NN	O
can	MD	O
adversely	RB	O
impact	VB	O
functioning	VBG	O
across	IN	O
school	NN	O
,	,	O
home	NN	O
and	CC	O
community	NN	O
environments	NNS	O
.	.	O

Cognitive	JJ	E
behavioral	JJ	E
therapies	NNS	E
(	(	E
CBT	NNP	E
)	)	E
are	VBP	O
frequently	RB	O
used	VBN	O
with	IN	O
success	NN	O
for	IN	O
children	NNS	O
with	IN	O
anxiety	NN	O
symptoms	NNS	O
.	.	O

Modified	NNP	E
CBT	NNP	E
interventions	NNS	E
for	IN	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
have	VBP	O
also	RB	O
yielded	VBN	O
promising	JJ	O
results	NNS	O
.	.	O

METHODS	NNP	O
Fifty	NNP	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
ASD	NNP	O
and	CC	O
anxiety	NN	O
were	VBD	O
randomizedto	JJ	O
group	NN	E
CBT	NNP	E
or	CC	O
treatment-as-usual	JJ	E
(	(	E
TAU	NNP	E
)	)	E
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Independent	NNP	O
clinical	JJ	O
evaluators	NNS	O
,	,	O
blind	NN	O
to	TO	O
condition	NN	O
,	,	O
completed	VBN	O
structured	JJ	O
interviews	NNS	O
(	(	O
Anxiety	NNP	O
Disorders	NNP	O
Interview	NNP	O
Schedule	NNP	O
?	.	O
Parent	NNP	O
Version	NNP	O
;	:	O
ADIS-P	NNP	O
)	)	O
pre-	NN	O
and	CC	O
post-intervention	NN	O
condition	NN	O
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
children	NNS	O
completed	VBN	O
either	CC	O
the	DT	O
CBT	NNP	E
or	CC	O
TAU	NNP	E
condition	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
markedly	RB	O
better	RBR	O
outcomes	NNS	O
for	IN	O
the	DT	O
CBT	NNP	E
group	NN	O
.	.	O

Significant	JJ	O
differences	NNS	O
by	IN	O
group	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
Clinician	JJ	O
Severity	NNP	O
Ratings	NNP	O
,	,	O
diagnostic	JJ	O
status	NN	O
,	,	O
and	CC	O
clinician	JJ	O
ratings	NNS	O
of	IN	O
global	JJ	O
improvement	NN	O
.	.	O

In	IN	O
the	DT	O
intent-to-treat	JJ	O
sample	NN	O
,	,	O
10	CD	O
of	IN	O
20	CD	O
children	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
had	VBD	O
a	DT	O
clinically	RB	O
meaningful	JJ	O
positive	JJ	O
treatment	NN	O
response	NN	O
,	,	O
compared	VBN	O
to	TO	O
2	CD	O
of	IN	O
23	CD	O
children	NNS	O
(	(	O
8.7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
TAU	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Initial	JJ	O
results	NNS	O
from	IN	O
this	DT	O
randomized	VBN	O
,	,	O
designed	VBN	O
treatment	NN	O
study	NN	O
suggest	VBP	O
that	IN	O
agroup	NN	O
CBT	NNP	O
intervention	NN	O
specifically	RB	O
developed	VBD	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
may	MD	O
be	VB	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
anxiety	NN	O
.	.	O

Limitations	NNS	O
of	IN	O
this	DT	O
study	NN	O
include	VBP	O
small	JJ	O
sample	JJ	O
size	NN	O
,	,	O
lack	NN	O
of	IN	O
an	DT	O
attention	NN	O
control	NN	O
group	NN	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
outcome	NN	O
measures	NNS	O
normed	VBN	O
with	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
[	JJ	O
Treatment	NNP	O
of	IN	O
autism	NN	O
children	NNS	O
:	:	O
observation	NN	O
on	IN	O
efficacy	NN	O
of	IN	O
behavior	JJ	E
training	NN	E
with	IN	O
retention	NN	PH
of	IN	PH
needles	NNS	PH
on	IN	PH
head	NN	PH
]	NN	PH
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
the	DT	O
effect	NN	O
difference	NN	O
of	IN	O
behavior	JJ	E
training	NN	E
with	IN	E
head	NN	E
needling	VBG	E
retention	NN	E
and	CC	E
behavior	NN	E
training	NN	E
after	IN	E
acupuncture	NN	E
for	IN	O
autism	NN	O
children	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
qualified	VBD	O
autism	NN	O
children	NNS	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
simultaneous	JJ	O
head	NN	E
needling	VBG	E
retention	NN	E
and	CC	E
behavior	JJ	E
training	NN	E
group	NN	E
(	(	O
trial	NN	O
group	NN	O
)	)	O
and	CC	O
behavior	JJ	E
training	NN	E
after	IN	E
acupuncture	NN	E
treatment	NN	E
group	NN	E
(	(	O
control	VB	O
group	NN	O
)	)	O
with	IN	O
30	CD	O
case	NN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Retention	NNP	PH
needles	NNS	PH
on	IN	O
the	DT	O
head	NN	O
with	IN	O
simultaneous	JJ	O
behavior	NN	O
training	NN	O
was	VBD	O
applied	VBN	O
for	IN	O
the	DT	O
trial	NN	O
group	NN	O
.	.	O

The	DT	O
main	JJ	O
acupoints	NNS	O
included	VBD	O
Sishen	NNP	O
Xue	NNP	O
,	,	O
Dingshen	NNP	O
Sanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
tranquilization	NN	O
)	)	O
,	,	O
Nao	NNP	O
Sanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
the	DT	O
function	NN	O
of	IN	O
brain	NN	O
)	)	O
,	,	O
Shou	NNP	O
Zhisanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
activities	NNS	O
on	IN	O
hand	NN	O
)	)	O
and	CC	O
Zozhi	NNP	O
Sonxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
activities	NNS	O
on	IN	O
foot	NN	O
)	)	O
.	.	O

Other	JJ	O
points	NNS	O
were	VBD	O
combined	VBN	O
according	VBG	O
to	TO	O
conditions	NNS	O
of	IN	O
patients	NNS	O
.	.	O

Needles	NNS	O
on	IN	O
the	DT	O
4	CD	O
extremities	NNS	O
were	VBD	O
withdrawn	VBN	O
first	RB	O
after	IN	O
30	CD	O
minutes	NNS	O
,	,	O
needles	NNS	O
on	IN	O
head	NN	O
were	VBD	O
remained	VBN	O
during	IN	O
behavior	JJ	E
training	NN	E
.	.	E

While	IN	O
behavior	JJ	E
training	NN	E
was	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
when	WRB	O
acupuncture	NN	O
treatment	NN	O
was	VBD	O
completely	RB	O
accomplished	VBN	O
.	.	O

Treatments	NNS	O
were	VBD	O
applied	VBN	O
once	RB	O
a	DT	O
day	NN	O
to	TO	O
both	DT	O
groups	NNS	O
.	.	O

And	CC	O
3	CD	O
months	NNS	O
was	VBD	O
taken	VBN	O
as	IN	O
one	CD	O
observation	NN	O
cycle	NN	O
.	.	O

Estimation	NN	O
was	VBD	O
made	VBN	O
on	IN	O
therapeutic	JJ	O
effect	NN	O
and	CC	O
developing	VBG	O
level	NN	O
of	IN	O
autism	NN	O
children	NNS	O
with	IN	O
CARS	NNP	O
and	CC	O
PEP	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
effective	JJ	O
rate	NN	O
of	IN	O
the	DT	O
trial	NN	O
group	NN	O
was	VBD	O
83.3	CD	O
%	NN	O
(	(	O
25/30	CD	O
)	)	O
,	,	O
better	JJR	O
than	IN	O
66.7	CD	O
%	NN	O
(	(	O
20/30	CD	O
)	)	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
CARS	NNPS	O
scores	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
declined	VBD	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

And	CC	O
the	DT	O
score	NN	O
of	IN	O
trail	NN	O
group	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

While	IN	O
the	DT	O
PEP	NNP	O
scores	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
increased	VBD	O
,	,	O
and	CC	O
the	DT	O
score	NN	O
of	IN	O
trail	NN	O
group	NN	O
was	VBD	O
higher	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increasing	VBG	O
level	NN	O
of	IN	O
scores	NNS	O
of	IN	O
cognitive	JJ	O
understanding	NN	O
and	CC	O
cognitive	JJ	O
expression	NN	O
were	VBD	O
all	DT	O
better	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
effect	NN	O
of	IN	O
behavior	JJ	E
training	NN	E
with	IN	O
head	NN	O
needle	JJ	O
retention	NN	O
on	IN	O
autism	NN	O
children	NNS	O
is	VBZ	O
better	JJR	O
than	IN	O
behavior	JJ	O
training	NN	O
after	IN	O
acupuncture	NN	O
treatment	NN	O
,	,	O
especially	RB	O
in	IN	O
enhancing	VBG	O
cognition	NN	O
understanding	NN	O
and	CC	O
cognition	NN	O
expression	NN	O
.	.	O

Noradrenergic	NNP	O
moderation	NN	O
of	IN	O
working	VBG	O
memory	NN	O
impairments	NNS	O
in	IN	O
adults	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
having	VBG	O
difficulties	NNS	O
with	IN	O
social	JJ	O
communications	NNS	O
,	,	O
individuals	NNS	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
often	RB	O
also	RB	O
experience	JJ	O
impairment	NN	O
in	IN	O
higher-order	NN	O
,	,	O
executive	NN	O
skills	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
pharmacological	JJ	O
modulation	NN	O
of	IN	O
the	DT	O
norepinephrine	NN	O
system	NN	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
such	JJ	O
impairments	NNS	O
.	.	O

A	DT	O
sample	NN	O
of	IN	O
14	CD	O
high-functioning	JJ	O
adults	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
a	DT	O
demographically-matched	JJ	O
comparison	NN	O
group	NN	O
of	IN	O
13	CD	O
typically	RB	O
developing	VBG	O
individuals	NNS	O
participated	VBN	O
.	.	O

An	DT	O
AX	NNP	O
continuous	JJ	O
performance	NN	O
test	NN	O
(	(	O
AX-CPT	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
working	VBG	O
memory	NN	O
and	CC	O
inhibitory	NN	O
control	NN	O
.	.	O

AX-CPT	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
following	VBG	O
administration	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
propranolol	NN	PM
(	(	PM
a	DT	PM
beta	NN	PM
adrenergic	JJ	PM
antagonist	NN	PM
)	)	PM
and	CC	O
following	VBG	O
placebo	NN	C
(	(	O
sugar	NN	O
pill	NN	O
)	)	O
administration	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
ASD	NNP	O
performed	VBD	O
more	RBR	O
poorly	RB	O
than	IN	O
non-ASD	JJ	O
individuals	NNS	O
in	IN	O
the	DT	O
working	JJ	O
memory	NN	O
condition	NN	O
(	(	O
BX	NNP	O
trials	NNS	O
)	)	O
.	.	O

Importantly	RB	O
,	,	O
administration	NN	O
of	IN	O
propranolol	NN	PM
attenuated	VBN	O
this	DT	O
impairment	NN	O
,	,	O
with	IN	O
the	DT	O
ASD	NNP	O
group	NN	O
performing	VBG	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
propranolol	NN	O
condition	NN	O
than	IN	O
the	DT	O
placebo	JJ	O
condition	NN	O
.	.	O

Working	VBG	O
memory	NN	O
performance	NN	O
of	IN	O
the	DT	O
non-ASD	JJ	O
group	NN	O
was	VBD	O
unaffected	VBN	O
by	IN	O
propranolol/placebo	JJ	O
administration	NN	O
.	.	O

No	DT	O
group	NN	O
or	CC	O
medication	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
inhibition	NN	O
condition	NN	O
(	(	O
AY	NNP	O
trials	NNS	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
findings	NNS	O
suggest	VBP	O
that	IN	O
norepinephrine	NN	O
may	MD	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
some	DT	O
,	,	O
but	CC	O
not	RB	O
necessarily	RB	O
all	RB	O
,	,	O
cognitive	JJ	O
impairments	NNS	O
associated	VBN	O
with	IN	O
ASD	NNP	O
.	.	O

Additional	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
fully	RB	O
understand	VB	O
whether	IN	O
this	DT	O
role	NN	O
is	VBZ	O
primarily	RB	O
causal	JJ	O
or	CC	O
compensatory	NN	O
in	IN	O
nature	NN	O
.	.	O

BNP-guided	JJ	O
vs	NN	O
symptom-guided	JJ	O
heart	NN	O
failure	NN	O
therapy	NN	O
:	:	O
the	DT	O
Trial	NNP	O
of	IN	O
Intensified	NNP	Ot
vs	FW	Ot
Standard	NNP	Ot
Medical	NNP	Ot
Therapy	NNP	Ot
in	IN	O
Elderly	JJ	O
Patients	NNS	O
With	IN	O
Congestive	NNP	O
Heart	NNP	O
Failure	NNP	O
(	(	O
TIME-CHF	NNP	O
)	)	O
randomized	VBD	O
trial	NN	O
.	.	O

CONTEXT	VB	O
It	PRP	O
is	VBZ	O
uncertain	JJ	O
whether	IN	O
intensified	JJ	O
heart	NN	O
failure	NN	O
therapy	NN	O
guided	VBN	O
by	IN	O
N-terminal	JJ	O
brain	NN	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
BNP	NNP	O
)	)	O
is	VBZ	O
superior	JJ	O
to	TO	O
symptom-guided	JJ	O
therapy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
18-month	JJ	O
outcomes	NNS	O
of	IN	O
N-terminal	JJ	O
BNP-guided	JJ	O
vs	NN	O
symptom-guided	JJ	O
heart	NN	O
failure	NN	O
therapy	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
Randomized	NNP	O
controlled	VBD	O
multicenter	RBR	O
Trial	NNP	O
of	IN	O
Intensified	NNP	O
vs	FW	O
Standard	NNP	O
Medical	NNP	O
Therapy	NNP	O
in	IN	O
Elderly	JJ	O
Patients	NNS	O
With	IN	O
Congestive	NNP	O
Heart	NNP	O
Failure	NNP	O
(	(	O
TIME-CHF	NNP	O
)	)	O
of	IN	O
499	CD	O
patients	NNS	O
aged	VBN	O
60	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
systolic	JJ	O
heart	NN	O
failure	NN	O
(	(	O
ejection	NN	O
fraction	NN	O
<	NN	O
or	CC	O
=	VB	O
45	CD	O
%	NN	O
)	)	O
,	,	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
(	(	O
NYHA	NNP	O
)	)	O
class	NN	O
of	IN	O
II	NNP	O
or	CC	O
greater	JJR	O
,	,	O
prior	JJ	O
hospitalization	NN	O
for	IN	O
heart	NN	O
failure	NN	O
within	IN	O
1	CD	O
year	NN	O
,	,	O
and	CC	O
N-terminal	JJ	O
BNP	NNP	O
level	NN	O
of	IN	O
2	CD	O
or	CC	O
more	JJR	O
times	NNS	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
.	.	O

The	DT	O
study	NN	O
had	VBD	O
an	DT	O
18-month	JJ	O
follow-up	NN	O
and	CC	O
it	PRP	O
was	VBD	O
conducted	VBN	O
at	IN	O
15	CD	O
outpatient	NN	O
centers	NNS	O
in	IN	O
Switzerland	NNP	O
and	CC	O
Germany	NNP	O
between	IN	O
January	NNP	O
2003	CD	O
and	CC	O
June	NNP	O
2008	CD	O
.	.	O

INTERVENTION	NNP	O
Uptitration	NNP	O
of	IN	O
guideline-based	JJ	O
treatments	NNS	O
to	TO	O
reduce	VB	O
symptoms	NNS	O
to	TO	O
NYHA	NNP	O
class	NN	O
of	IN	O
II	NNP	O
or	CC	O
less	JJR	O
(	(	O
symptom-guided	JJ	PH
therapy	NN	PH
)	)	O
and	CC	O
BNP	NNP	O
level	NN	O
of	IN	O
2	CD	O
times	NNS	O
or	CC	O
less	JJR	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
and	CC	O
symptoms	NNS	O
to	TO	O
NYHA	NNP	O
class	NN	O
of	IN	O
II	NNP	O
or	CC	O
less	JJR	O
(	(	O
BNP-guided	JJ	PH
therapy	NN	PH
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Primary	NNP	O
outcomes	NNS	O
were	VBD	O
18-month	JJ	O
survival	JJ	O
free	JJ	O
of	IN	O
all-cause	JJ	O
hospitalizations	NNS	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
as	IN	O
assessed	VBN	O
by	IN	O
structured	JJ	O
validated	JJ	O
questionnaires	NNS	O
.	.	O

RESULTS	NNP	O
Heart	NNP	O
failure	NN	O
therapy	NN	O
guided	VBN	O
by	IN	O
N-terminal	JJ	O
BNP	NNP	O
and	CC	O
symptom-guided	JJ	O
therapy	NN	O
resulted	VBD	O
in	IN	O
similar	JJ	O
rates	NNS	O
of	IN	O
survival	JJ	O
free	JJ	O
of	IN	O
all-cause	JJ	O
hospitalizations	NNS	O
(	(	O
41	CD	O
%	NN	O
vs	JJ	O
40	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
hazard	PRP	O
ratio	VBP	O
[	JJ	O
HR	NNP	O
]	NNP	O
,	,	O
0.91	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.72-1.14	JJ	O
]	NN	O
;	:	O
P	NNP	O
=	NNP	O
.39	NNP	O
)	)	O
.	.	O

Patients	NNS	O
'	POS	O
quality-of-life	JJ	O
metrics	NNS	O
improved	VBN	O
over	IN	O
18	CD	O
months	NNS	O
of	IN	O
follow-up	JJ	O
but	CC	O
these	DT	O
improvements	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
the	DT	O
N-terminal	JJ	O
BNP-guided	JJ	O
and	CC	O
symptom-guided	JJ	O
strategies	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
symptom-guided	JJ	O
group	NN	O
,	,	O
survival	JJ	O
free	JJ	O
of	IN	O
hospitalization	NN	O
for	IN	O
heart	NN	O
failure	NN	O
,	,	O
a	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
,	,	O
was	VBD	O
higher	JJR	O
among	IN	O
those	DT	O
in	IN	O
the	DT	O
N-terminal	JJ	O
BNP-guided	NNP	O
group	NN	O
(	(	O
72	CD	O
%	NN	O
vs	JJ	O
62	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
HR	NNP	O
,	,	O
0.68	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.50-0.92	JJ	O
]	NN	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Heart	NNP	O
failure	NN	O
therapy	NN	O
guided	VBN	O
by	IN	O
N-terminal	NNP	O
BNP	NNP	O
improved	VBD	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
aged	VBD	O
60	CD	O
to	TO	O
75	CD	O
years	NNS	O
but	CC	O
not	RB	O
in	IN	O
those	DT	O
aged	VBN	O
75	CD	O
years	NNS	O
or	CC	O
older	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
for	IN	O
interaction	NN	O
)	)	O
CONCLUSION	NNP	O
Heart	NNP	O
failure	NN	O
therapy	NN	O
guided	VBN	O
by	IN	O
N-terminal	JJ	O
BNP	NNP	O
did	VBD	O
not	RB	O
improve	VB	O
overall	JJ	O
clinical	JJ	O
outcomes	NNS	O
or	CC	O
quality	NN	O
of	IN	O
life	NN	O
compared	VBN	O
with	IN	O
symptom-guided	JJ	O
treatment	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
isrctn.org	NN	O
Identifier	NNP	O
:	:	O
ISRCTN43596477	NNP	O
.	.	O

Skin	NNP	O
manifestations	NNS	O
of	IN	O
inhaled	JJ	O
corticosteroids	NNS	PM
in	IN	O
COPD	NNP	O
patients	NNS	O
:	:	O
results	NNS	O
from	IN	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
define	VB	O
the	DT	O
relationship	NN	O
between	IN	O
skin	NN	O
bruising	NN	O
(	(	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
cutaneous	JJ	O
manifestations	NNS	O
)	)	O
and	CC	O
inhaled	VBN	O
corticosteroid	NN	PM
(	(	PM
ICS	NNP	PM
)	)	PM
therapy	NN	O
vs	NN	O
placebo	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
COPD	NNP	O
who	WP	O
were	VBD	O
participating	VBG	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

To	TO	O
explore	VB	O
the	DT	O
relationship	NN	O
between	IN	O
easy	JJ	O
skin	NN	O
bruising	NN	O
and	CC	O
other	JJ	O
systemic	JJ	O
effects	NNS	O
of	IN	O
ICS	NNP	O
therapy	NN	O
,	,	O
including	VBG	O
adrenal	JJ	O
suppression	NN	O
and	CC	O
loss	NN	O
of	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Double-blind	NNP	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
triamcinolone	NN	PM
acetonide	NN	PM
(	(	O
1200	CD	O
microg	FW	O
daily	RB	O
)	)	O
vs	NN	O
placebo	NN	C
in	IN	O
participants	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
.	.	O

SETTING	NNP	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
,	,	O
a	DT	O
clinical	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ICS	NNP	PM
compared	VBN	O
to	TO	O
placebo	VB	O
in	IN	O
1,116	CD	O
participants	NNS	O
in	IN	O
10	CD	O
centers	NNS	O
over	IN	O
>	$	O
3.5	CD	O
to	TO	O
4.5	CD	O
years	NNS	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1,116	CD	O
smokers	NNS	O
or	CC	O
recent	JJ	O
ex-smokers	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
(	(	O
age	NN	O
range	NN	O
,	,	O
40	CD	O
to	TO	O
69	CD	O
years	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
56.3	CD	O
years	NNS	O
;	:	O
37.2	CD	O
%	NN	O
female	NN	O
)	)	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
RESULTS	NNP	O
Every	NNP	O
6	CD	O
months	NNS	O
,	,	O
a	DT	O
structured	JJ	O
questionnaire	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
elicit	VB	O
reports	NNS	O
of	IN	O
any	DT	O
bruising	NN	O
and/or	NN	O
skin	NN	O
rashes	NNS	O
,	,	O
slow	JJ	O
healing	NN	O
of	IN	O
cuts	NNS	O
or	CC	O
sores	NNS	O
,	,	O
or	CC	O
other	JJ	O
skin	JJ	O
changes	NNS	O
.	.	O

Compliance	NN	O
with	IN	O
inhaler	NN	O
use	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
canister	NN	O
weighing	VBG	O
.	.	O

A	DT	O
significantly	RB	O
higher	JJR	O
proportion	NN	O
of	IN	O
ICS	NNP	PM
than	IN	O
placebo	NN	O
participants	NNS	O
who	WP	O
complied	VBD	O
with	IN	O
using	VBG	O
their	PRP$	O
inhaler	NN	O
reported	VBD	O
easy	JJ	O
bruising	NN	O
(	(	O
11.2	CD	O
%	NN	O
vs	JJ	O
3.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
the	DT	O
slow	JJ	O
healing	NN	O
of	IN	O
skin	NN	O
cuts	NNS	O
or	CC	O
sores	NNS	O
(	(	O
2.4	CD	O
%	NN	O
vs	JJ	O
0.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Older	JJR	O
men	NNS	O
in	IN	O
the	DT	O
ICS	NNP	PM
group	NN	O
with	IN	O
good	JJ	O
inhaler	NN	O
compliance	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
at	IN	O
the	DT	O
greatest	JJS	O
risk	NN	O
of	IN	O
bruising	VBG	O
.	.	O

In	IN	O
those	DT	O
participants	NNS	O
undergoing	VBG	O
serial	JJ	O
measurements	NNS	O
of	IN	O
adrenal	JJ	O
function	NN	O
and	CC	O
BMD	NNP	O
,	,	O
no	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	O
bruising	NN	O
and	CC	O
either	CC	O
the	DT	O
suppression	NN	O
of	IN	O
adrenal	JJ	O
function	NN	O
or	CC	O
the	DT	O
loss	NN	O
of	IN	O
BMD	NNP	O
as	IN	O
systemic	JJ	O
complications	NNS	O
of	IN	O
ICS	NNP	O
use	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
moderate-to-high	JJ	O
doses	NNS	O
of	IN	O
ICSs	NNP	O
result	NN	O
in	IN	O
an	DT	O
increased	JJ	O
incidence	NN	O
of	IN	O
easy	JJ	O
bruising	NN	O
and	CC	O
impairment	NN	O
in	IN	O
skin	NN	O
healing	NN	O
in	IN	O
middle-aged	JJ	O
to	TO	O
elderly	JJ	O
persons	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

No	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	O
bruising	NN	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
systemic	JJ	O
toxicity	NN	O
from	IN	O
the	DT	O
use	NN	O
of	IN	O
ICSs	NNP	O
.	.	O

Plasmakinetic	JJ	S
prostate	NN	S
resection	NN	S
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
benign	JJ	O
prostate	JJ	O
hyperplasia	NN	O
:	:	O
results	NNS	O
of	IN	O
1-year	JJ	O
follow	VBP	O
up	RP	O
.	.	O

AIM	NNP	O
In	IN	O
our	PRP$	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
,	,	O
we	PRP	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficiency	NN	O
of	IN	O
plasmakinetic	JJ	S
resection	NN	S
of	IN	S
prostate	NN	S
(	(	S
PKRP	NNP	S
)	)	S
by	IN	O
comparing	VBG	O
the	DT	O
preoperative	NN	O
and	CC	O
postoperative	JJ	O
results	NNS	O
of	IN	O
the	DT	O
transurethral	JJ	S
resection	NN	S
of	IN	S
prostate	NN	S
(	(	O
TURP	NNP	O
)	)	O
and	CC	O
PKRP	NNP	O
techniques	NNS	O
which	WDT	O
we	PRP	O
administered	VBD	O
in	IN	O
patients	NNS	O
with	IN	O
benign	JJ	O
prostate	NN	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
in	IN	O
our	PRP$	O
clinic	NN	O
.	.	O

METHODS	NNP	O
Of	IN	O
57	CD	O
patients	NNS	O
for	IN	O
whom	WP	O
we	PRP	O
thought	VBD	O
an	DT	O
operative	JJ	O
intervention	NN	O
was	VBD	O
necessary	JJ	O
,	,	O
30	CD	O
cases	NNS	O
in	IN	O
the	DT	O
first	JJ	O
group	NN	O
had	VBD	O
a	DT	O
TURP	NNP	S
and	CC	O
24	CD	O
cases	NNS	O
in	IN	O
the	DT	O
second	JJ	O
group	NN	O
had	VBD	O
a	DT	O
PKRP	NNP	S
.	.	O

International	NNP	O
prostate	JJ	O
symptom	NN	O
scores	NNS	O
(	(	O
I-PSS	NNP	O
)	)	O
,	,	O
uroflowmetry	UH	O
,	,	O
measurement	NN	O
of	IN	O
residual	JJ	O
urine	JJ	O
amount	NN	O
and	CC	O
ultrasonography	NN	O
were	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
patient	NN	O
both	DT	O
preoperatively	RB	O
and	CC	O
postoperatively	RB	O
(	(	O
first	JJ	O
month	NN	O
and	CC	O
first	JJ	O
year	NN	O
)	)	O
.	.	O

Operation	NNP	O
times	NNS	O
,	,	O
urethral	JJ	O
catheterization	NN	O
times	NNS	O
,	,	O
preoperative	JJ	O
and	CC	O
postoperative	JJ	O
Hb	NNP	O
,	,	O
Htc	NNP	O
and	CC	O
serum	VB	O
Na	NNP	O
values	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
compared	VBN	O
and	CC	O
the	DT	O
complications	NNS	O
of	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
also	RB	O
compared	VBN	O
.	.	O

RESULTS	VB	O
On	IN	O
first	JJ	O
month	NN	O
and	CC	O
first	JJ	O
year	NN	O
follow	VBP	O
up	RP	O
between	IN	O
the	DT	O
groups	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
statistical	JJ	O
difference	NN	O
in	IN	O
I-PSS	NNP	O
,	,	O
maximum	JJ	O
flow	NN	O
rate	NN	O
,	,	O
average	NN	O
flow	NN	O
,	,	O
residual	JJ	O
urine	NN	O
and	CC	O
size	NN	O
of	IN	O
the	DT	O
prostate	NN	O
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
serum	NN	O
Na	NNP	O
level	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
TURP	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
operation	NN	O
times	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

While	IN	O
the	DT	O
postoperative	JJ	O
catheterization	NN	O
time	NN	O
was	VBD	O
75.7	CD	O
h	NN	O
in	IN	O
TURP	NNP	O
group	NN	O
,	,	O
it	PRP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
42	CD	O
h	NN	O
in	IN	O
PKRP	NNP	O
group	NN	O
and	CC	O
it	PRP	O
was	VBD	O
clear	JJ	O
that	IN	O
catheterization	NN	O
time	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
is	VBZ	O
obvious	JJ	O
that	IN	O
PKRP	NNP	S
is	VBZ	O
as	RB	O
efficient	JJ	O
as	IN	O
TURP	NNP	O
and	CC	O
it	PRP	O
has	VBZ	O
a	DT	O
similar	JJ	O
morbidity	NN	O
.	.	O

In	IN	O
our	PRP$	O
opinion	NN	O
,	,	O
PKRP	NNP	S
makes	VBZ	O
a	DT	O
promising	JJ	O
treatment	NN	O
for	IN	O
BPH	NNP	O
with	IN	O
its	PRP$	O
advantages	NNS	O
,	,	O
such	JJ	O
as	IN	O
early	JJ	O
removal	NN	O
of	IN	O
postoperative	JJ	O
urethral	JJ	O
catheter	NN	O
,	,	O
a	DT	O
shorter	JJR	O
hospital	NN	O
stay	NN	O
and	CC	O
the	DT	O
absence	NN	O
of	IN	O
TUR	NNP	O
syndrome	NN	O
risk	NN	O
.	.	O

Vaginal	JJ	PH
electrical	JJ	PH
stimulation	NN	PH
of	IN	PH
the	DT	PH
pelvic	JJ	PH
floor	NN	PH
:	:	PH
a	DT	O
randomized	JJ	O
feasibility	NN	O
study	NN	O
in	IN	O
urinary	JJ	O
incontinent	NN	O
elderly	JJ	O
women	NNS	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
intravaginal	JJ	PH
electrical	JJ	PH
stimulation	NN	PH
(	(	PH
ES	NNP	PH
)	)	PH
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
for	IN	O
urinary	JJ	O
incontinence	NN	O
in	IN	O
elderly	JJ	O
women	NNS	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
whether	IN	O
ES	NNP	PH
of	IN	PH
the	DT	PH
pelvic	JJ	PH
floor	NN	PH
is	VBZ	O
a	DT	O
preferable	JJ	O
treatment	NN	O
for	IN	O
urinary	JJ	O
incontinence	NN	O
in	IN	O
elderly	JJ	O
women	NNS	O
.	.	O

METHODS	NNP	O
Postmenopausal	NNP	O
women	NNS	O
(	(	O
age	NN	O
65	CD	O
years	NNS	O
or	CC	O
older	JJR	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
and	CC	O
underwent	JJ	O
every-other-day	JJ	O
ES	NNP	PH
of	IN	PH
the	DT	PH
pelvic	JJ	PH
floor	NN	PH
,	,	O
or	CC	O
a	DT	O
daily	JJ	PH
Kegel	NNP	PH
exercise	NN	PH
(	(	PH
KE	NNP	PH
)	)	PH
program	NN	O
.	.	O

Objective	NNP	O
outcome	NN	O
variables	NNS	O
were	VBD	O
:	:	O
(	(	O
1	CD	O
)	)	O
Urinary	JJ	O
leakage	NN	O
(	(	O
during	IN	O
a	DT	O
standardized	JJ	O
PAD	NNP	O
test	NN	O
)	)	O
,	,	O
(	(	O
2	CD	O
)	)	O
pelvic	NN	O
muscle	NN	O
strength	NN	O
(	(	O
measured	VBN	O
by	IN	O
a	DT	O
perineometer	NN	O
)	)	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
detrusor	NN	O
instability	NN	O
(	(	O
on	IN	O
ambulant	NN	O
urodynamic	JJ	O
registration	NN	O
)	)	O
.	.	O

Subjective	JJ	O
outcome	NN	O
variables	NNS	O
were	VBD	O
women	NNS	O
's	POS	O
subjective	JJ	O
assessment	NN	O
of	IN	O
change	NN	O
in	IN	O
urinary	JJ	O
symptoms	NNS	O
based	VBN	O
on	IN	O
the	DT	O
PRAFAB	NNP	O
score	NN	O
.	.	O

Twenty-four	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
ES	NNP	O
and	CC	O
11	CD	O
women	NNS	O
treated	VBN	O
with	IN	O
Kegel	NNP	O
exercises	NNS	O
completed	VBD	O
the	DT	O
8-week	JJ	O
study	NN	O
program	NN	O
.	.	O

The	DT	O
Chi-square	JJ	O
test	NN	O
was	VBD	O
used	VBN	O
for	IN	O
statistical	JJ	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
improvement	NN	O
in	IN	O
objective	JJ	O
outcome	NN	O
variables	NNS	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
population	NN	O
treated	VBD	O
with	IN	O
ES	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
population	NN	O
treated	VBD	O
with	IN	O
KE	NNP	O
(	(	O
with	IN	O
29.2	CD	O
%	NN	O
vs.	FW	O
36.4	CD	O
%	NN	O
of	IN	O
the	DT	O
women	NNS	O
showing	VBG	O
objective	JJ	O
improvement	NN	O
in	IN	O
measured	JJ	O
urinary	JJ	O
leakage	NN	O
)	)	O
.	.	O

Neither	CC	O
was	VBD	O
subjective	JJ	O
improvement	NN	O
significant	JJ	O
,	,	O
with	IN	O
29.2	CD	O
%	NN	O
vs.	FW	O
27.3	CD	O
%	NN	O
of	IN	O
the	DT	O
women	NNS	O
reporting	VBG	O
improvement	NN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
urinary	JJ	O
leakage	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
number	NN	O
of	IN	O
enrolled	JJ	O
women	NNS	O
was	VBD	O
very	RB	O
small	JJ	O
this	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
:	:	O
1	CD	O
.	.	O

Treating	VBG	O
elderly	JJ	O
women	NNS	O
with	IN	O
vaginal	JJ	O
ES	NNP	O
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
has	VBZ	O
a	DT	O
high	JJ	O
physical	JJ	O
and	CC	O
emotional	JJ	O
cost	NN	O
for	IN	O
the	DT	O
individual	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
ES	NNP	O
of	IN	O
the	DT	O
pelvic	JJ	O
floor	NN	O
in	IN	O
urinary	JJ	O
incontinent	NN	O
elderly	JJ	O
women	NNS	O
is	VBZ	O
low	JJ	O
.	.	O

3	CD	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
great	JJ	O
discrepancy	NN	O
between	IN	O
objective	JJ	O
amelioration	NN	O
(	(	O
PAD	NNP	O
test	NN	O
)	)	O
and	CC	O
subjective	JJ	O
amelioration	NN	O
(	(	O
PRAFAB	NNP	O
score/quantity	NN	O
of	IN	O
urinary	JJ	O
leakage	NN	O
)	)	O
,	,	O
if	IN	O
the	DT	O
objective	JJ	O
improvement	NN	O
is	VBZ	O
adequately	RB	O
defined	VBN	O
.	.	O

4	CD	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
reasonable	JJ	O
to	TO	O
advise	VB	O
elderly	JJ	O
women	NNS	O
with	IN	O
urinary	JJ	O
incontinence	NN	O
to	TO	O
undertake	VB	O
this	DT	O
treatment	NN	O
procedure	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
treatment	NN	O
does	VBZ	O
not	RB	O
compensate	VB	O
for	IN	O
the	DT	O
long-lasting	JJ	O
and	CC	O
intense	JJ	O
treatment	NN	O
protocol	NN	O
.	.	O

5	CD	O
.	.	O

We	PRP	O
terminated	VBD	O
this	DT	O
study	NN	O
because	IN	O
of	IN	O
the	DT	O
negative	JJ	O
outcome	NN	O
with	IN	O
ES	NNP	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
ibuprofen	JJ	PM
arginate	NN	PM
versus	NN	O
dexibuprofen	NN	PM
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

OBJECTIVE	NNP	O
Ibuprofen	NNP	PM
arginate	NN	PM
is	VBZ	O
a	DT	O
salt	JJ	O
formulation	NN	O
of	IN	O
ibuprofen	NN	PM
designed	VBN	O
to	TO	O
reach	VB	O
target	NN	O
concentrations	NNS	O
rapidly	RB	O
.	.	O

The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
12-h	JJ	O
pharmacokinetic	JJ	O
profile	NN	O
of	IN	O
S	NNP	PM
(	(	PM
+	NNP	PM
)	)	PM
-ibuprofen	VBD	PM
following	VBG	O
administration	NN	O
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
ibuprofen	JJ	PM
arginate	NN	PM
(	(	O
600	CD	O
mg	NN	O
)	)	O
and	CC	O
dexibuprofen	NN	PM
(	(	O
400	CD	O
mg	NN	O
)	)	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

METHODS	NNP	O
Twenty-four	JJ	O
volunteers	NNS	O
were	VBD	O
recruited	VBN	O
into	IN	O
an	DT	O
open-label	JJ	O
,	,	O
randomised	JJ	O
,	,	O
two-period	JJ	O
,	,	O
single-centre	JJ	O
study	NN	O
with	IN	O
crossover	NN	O
design	NN	O
.	.	O

RESULTS	NNP	O
Both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Ibuprofen	NNP	PM
arginate	NN	PM
and	CC	O
dexibuprofen	NN	PM
showed	VBD	O
similar	JJ	O
bioavailability	NN	O
for	IN	O
S	NNP	PM
(	(	PM
+	NNP	PM
)	)	PM
-ibuprofen	NN	PM
.	.	O

Compared	VBN	O
with	IN	O
dexibuprofen	NN	PM
,	,	O
ibuprofen	JJ	PM
arginate	NN	PM
demonstrated	VBD	O
a	DT	O
45	CD	O
%	NN	O
higher	JJR	O
maximum	JJ	O
concentration	NN	O
(	(	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
,	,	O
and	CC	O
a	DT	O
time	NN	O
to	TO	O
peak	VB	O
concentration	NN	O
(	(	O
T	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
2	CD	O
h	NN	O
sooner	NN	O
.	.	O

CONCLUSION	NNP	O
Ibuprofen	NNP	PM
arginate	NN	PM
approaches	NNS	O
maximum	JJ	O
concentrations	NNS	O
of	IN	O
S	NNP	O
(	(	O
+	NNP	O
)	)	O
-ibuprofen	VBP	O
faster	RBR	O
and	CC	O
higher	JJR	O
than	IN	O
dexibuprofen	NN	PM
.	.	O

Tomato	NNP	PM
paste	NN	PM
rich	JJ	PM
in	IN	PM
lycopene	JJ	PM
protects	NNS	O
against	IN	O
cutaneous	JJ	O
photodamage	NN	O
in	IN	O
humans	NNS	O
in	IN	O
vivo	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	NNP	O
epidemiological	JJ	O
,	,	O
animal	JJ	O
and	CC	O
human	JJ	O
data	NNS	O
report	NN	O
that	IN	O
lycopene	NN	O
has	VBZ	O
a	DT	O
protective	JJ	O
effect	NN	O
against	IN	O
ultraviolet	NN	O
radiation	NN	O
(	(	O
UVR	NNP	O
)	)	O
-induced	VBD	O
erythema	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
examined	VBD	O
whether	IN	O
tomato	NN	PM
paste	NN	PM
--	:	PM
rich	JJ	PM
in	IN	PM
lycopene	NN	PM
,	,	O
a	DT	O
powerful	JJ	O
antioxidant	NN	O
--	:	O
can	MD	O
protect	VB	O
human	JJ	O
skin	NN	O
against	IN	O
UVR-induced	JJ	O
effects	NNS	O
partially	RB	O
mediated	VBN	O
by	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
i.e	NN	O
.	.	O

erythema	NN	O
,	,	O
matrix	NN	O
changes	NNS	O
and	CC	O
mitochondrial	JJ	O
DNA	NNP	O
(	(	O
mtDNA	NN	O
)	)	O
damage	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
study	NN	O
,	,	O
20	CD	O
healthy	JJ	O
women	NNS	O
(	(	O
median	JJ	O
age	NN	O
33	CD	O
years	NNS	O
,	,	O
range	VBP	O
21-47	JJ	O
;	:	O
phototype	JJ	O
I/II	NNP	O
)	)	O
ingested	VBD	O
55	CD	PH
g	NN	PH
tomato	NN	PH
paste	NN	PH
(	(	PH
16	CD	PH
mg	RB	PH
lycopene	NN	PH
)	)	PH
in	IN	PH
olive	JJ	PH
oil	NN	PH
,	,	PH
or	CC	PH
olive	JJ	PH
oil	NN	PH
alone	RB	PH
,	,	PH
daily	JJ	PH
for	IN	PH
12	CD	PH
weeks	NNS	PH
.	.	PH

Pre-	NNP	O
and	CC	O
postsupplementation	NN	O
,	,	O
UVR	NNP	O
erythemal	JJ	O
sensitivity	NN	O
was	VBD	O
assessed	VBN	O
visually	RB	O
as	IN	O
the	DT	O
minimal	JJ	O
erythema	NN	O
dose	NN	O
(	(	O
MED	NNP	O
)	)	O
and	CC	O
quantified	VBN	O
with	IN	O
a	DT	O
reflectance	NN	O
instrument	NN	O
.	.	O

Biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
unexposed	JJ	O
and	CC	O
UVR-exposed	JJ	O
(	(	O
3	CD	O
?	.	O
MED	NNP	O
24	CD	O
h	NN	O
earlier	RBR	O
)	)	O
buttock	NN	O
skin	JJ	O
pre-	NN	O
and	CC	O
postsupplementation	NN	O
,	,	O
and	CC	O
analysed	VBD	O
immunohistochemically	RB	O
for	IN	O
procollagen	NN	O
(	(	O
pC	NN	O
)	)	O
I	PRP	O
,	,	O
fibrillin-1	JJ	O
and	CC	O
matrix	JJ	O
metalloproteinase	NN	O
(	(	O
MMP	NNP	O
)	)	O
-1	NN	O
,	,	O
and	CC	O
by	IN	O
quantitative	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
for	IN	O
mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
.	.	O

RESULTS	VB	O
Mean	NNP	O
?	.	O
SD	NNP	O
erythemal	JJ	O
D	NNP	O
(	(	O
30	CD	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
following	VBG	O
tomato	JJ	O
paste	NN	O
vs.	FW	O
control	NN	O
(	(	O
baseline	NN	O
,	,	O
26?5	CD	O
?	.	O
7?5	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
23	CD	O
?	.	O
6?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
36?6	CD	O
?	.	O
14?7	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
MED	NNP	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
(	(	O
baseline	NN	O
,	,	O
35?1	CD	O
?	.	O
9?9	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
32?6	CD	O
?	.	O
9?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
42?2	CD	O
?	.	O
11?3	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
.	.	O

Presupplementation	NN	O
,	,	O
UVR	NNP	O
induced	VBD	O
an	DT	O
increase	NN	O
in	IN	O
MMP-1	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
.	.	O

Postsupplementation	NN	O
,	,	O
UVR-induced	JJ	O
MMP-1	NNP	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
tomato	NN	O
paste	NN	O
vs.	FW	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?04	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
UVR-induced	JJ	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
was	VBD	O
similarly	RB	O
abrogated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
pCI	JJ	O
deposition	NN	O
was	VBD	O
seen	VBN	O
following	VBG	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?05	CD	O
)	)	O
.	.	O

mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
following	VBG	O
3	CD	O
?	.	O
MED	NNP	O
UVR	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
postsupplementation	NN	O
with	IN	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Tomato	NNP	O
paste	NN	O
containing	VBG	O
lycopene	NNP	O
provides	VBZ	O
protection	NN	O
against	IN	O
acute	NN	O
and	CC	O
potentially	RB	O
longer-term	JJ	O
aspects	NNS	O
of	IN	O
photodamage	NN	O
.	.	O

Trace	NNP	PM
element	NN	PM
supplementation	NN	PM
after	IN	O
major	JJ	O
burns	NNS	O
modulates	VBZ	O
antioxidant	JJ	O
status	NN	O
and	CC	O
clinical	JJ	O
course	NN	O
by	IN	O
way	NN	O
of	IN	O
increased	JJ	O
tissue	NN	O
trace	NN	O
element	NN	O
concentrations	NNS	O
.	.	O

BACKGROUND	NNP	O
After	IN	O
major	JJ	O
burns	NNS	O
,	,	O
patients	NNS	O
can	MD	O
develop	VB	O
nutritional	JJ	O
deficiencies	NNS	O
including	VBG	O
trace	NN	O
element	NN	O
(	(	O
TE	NNP	O
)	)	O
deficiencies	NNS	O
.	.	O

Various	JJ	O
complications	NNS	O
,	,	O
such	JJ	O
as	IN	O
infections	NNS	O
and	CC	O
delayed	VBN	O
wound	NN	O
healing	NN	O
,	,	O
influence	VB	O
the	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
such	JJ	O
patients	NNS	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
large	JJ	O
,	,	O
intravenous	JJ	O
doses	NNS	O
of	IN	O
TE	NNP	PM
supplements	NNS	PM
on	IN	O
circulating	NN	O
and	CC	O
cutaneous	JJ	O
TE	NNP	O
tissue	NN	O
concentrations	NNS	O
,	,	O
on	IN	O
antioxidant	JJ	O
status	NN	O
,	,	O
and	CC	O
on	IN	O
clinical	JJ	O
outcome	NN	O
after	IN	O
major	JJ	O
burns	NNS	O
.	.	O

DESIGN	NNP	O
This	DT	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
in	IN	O
21	CD	O
patients	NNS	O
aged	VBD	O
35	CD	O
+/-	JJ	O
11	CD	O
y	NN	O
(	(	O
x	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
with	IN	O
burns	NNS	O
on	IN	O
45	CD	O
+/-	JJ	O
21	CD	O
%	NN	O
of	IN	O
their	PRP$	O
body	NN	O
surface	NN	O
area	NN	O
.	.	O

Intravenous	JJ	PM
copper	NN	PM
,	,	PM
selenium	NN	PM
,	,	PM
and	CC	PM
zinc	NN	PM
(	(	PM
TE	NNP	PM
group	NN	PM
)	)	PM
or	CC	O
vehicle	NN	PM
(	(	O
V	NNP	O
group	NN	O
)	)	O
was	VBD	O
given	VBN	O
with	IN	O
a	DT	O
saline	JJ	O
solution	NN	O
for	IN	O
14-21	JJ	O
d.	NN	O
Blood	NNP	O
and	CC	O
urine	JJ	O
samples	NNS	O
were	VBD	O
collected	VBN	O
until	IN	O
day	NN	O
20	CD	O
,	,	O
and	CC	O
skin	FW	O
biopsy	NN	O
specimens	NNS	O
were	VBD	O
collected	VBN	O
on	IN	O
days	NNS	O
3	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
20	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
and	CC	O
the	DT	O
severity	NN	O
of	IN	O
their	PRP$	O
burns	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Plasma	NNP	O
TE	NNP	O
concentrations	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
.	.	O

In	IN	O
burned	JJ	O
areas	NNS	O
,	,	O
skin	JJ	O
contents	NNS	O
of	IN	O
both	DT	O
selenium	NN	O
(	(	O
P=0.05	NNP	O
)	)	O
and	CC	O
zinc	NN	O
(	(	O
P=0.04	NNP	O
)	)	O
increased	VBD	O
significantly	RB	O
by	IN	O
day	NN	O
20	CD	O
.	.	O

Plasma	NNP	O
and	CC	O
tissue	NN	O
antioxidant	NN	O
status	NN	O
was	VBD	O
improved	VBN	O
by	IN	O
supplementation	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
infections	NNS	O
in	IN	O
the	DT	O
first	JJ	O
30	CD	O
d	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
(	(	O
P=0.015	NNP	O
)	)	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
number	NN	O
of	IN	O
2	CD	O
versus	NN	O
4	CD	O
infections	NNS	O
per	IN	O
patient	NN	O
in	IN	O
the	DT	O
TE	NNP	O
and	CC	O
V	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
a	DT	O
reduction	NN	O
in	IN	O
pulmonary	JJ	O
infections	NNS	O
(	(	O
P=0.03	NNP	O
)	)	O
.	.	O

Wound	IN	O
healing	NN	O
was	VBD	O
improved	VBN	O
in	IN	O
the	DT	O
TE	NNP	O
group	NN	O
,	,	O
with	IN	O
lower	JJR	O
requirements	NNS	O
for	IN	O
regrafting	VBG	O
(	(	O
P=0.02	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
TE	NNP	PM
supplementation	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
circulating	NN	O
plasma	NN	O
and	CC	O
skin	JJ	O
tissue	NN	O
contents	NNS	O
of	IN	O
selenium	NN	O
and	CC	O
zinc	NN	O
and	CC	O
improved	VBN	O
antioxidant	JJ	O
status	NN	O
.	.	O

These	DT	O
changes	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
improved	JJ	O
clinical	JJ	O
outcome	NN	O
,	,	O
including	VBG	O
fewer	JJR	O
pulmonary	JJ	O
infections	NNS	O
and	CC	O
better	JJR	O
wound	NN	O
healing	NN	O
.	.	O

Effect	NN	O
of	IN	O
diltiazem	NN	PM
on	IN	O
symptomatic	JJ	O
and	CC	O
asymptomatic	JJ	O
episodes	NNS	O
of	IN	O
ST	NNP	O
segment	NN	O
depression	NN	O
occurring	VBG	O
during	IN	O
daily	JJ	O
life	NN	O
and	CC	O
during	IN	O
exercise	NN	O
.	.	O

BACKGROUND	NNP	O
Silent	NNP	O
myocardial	JJ	O
ischemia	NN	O
is	VBZ	O
an	DT	O
adverse	JJ	O
prognostic	JJ	O
marker	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
disease	NN	O
;	:	O
however	RB	O
,	,	O
controlled	VBN	O
data	NNS	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
are	VBP	O
sparse	JJ	O
and	CC	O
contradictory	NN	O
,	,	O
and	CC	O
the	DT	O
relations	NNS	O
among	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
ST	NNP	O
segment	NN	O
depression	NN	O
,	,	O
drug	NN	O
efficacy	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
are	VBP	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Sixty	NNP	O
patients	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
a	DT	O
positive	JJ	O
treadmill	NN	O
exercise	NN	O
test	NN	O
and	CC	O
asymptomatic	JJ	O
ST	NNP	O
segment	NN	O
depression	NN	O
on	IN	O
ambulatory	JJ	O
electrocardiographic	JJ	O
recording	VBG	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
cross-over	JJ	O
trial	NN	O
.	.	O

Treadmill	NNP	PH
exercise	NN	PH
tests	NNS	O
and	CC	O
72-hour	JJ	O
electrocardiographic	JJ	O
recordings	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
two	CD	O
2-week	JJ	O
treatment	NN	O
periods	NNS	O
with	IN	O
sustained-release	JJ	PM
diltiazem	NN	PM
180	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

or	CC	O
equivalent	JJ	O
placebo	NN	C
.	.	C

Episodes	NNS	O
of	IN	O
asymptomatic	JJ	O
ST	NNP	O
depression	NN	O
decreased	VBN	O
by	IN	O
50	CD	O
%	NN	O
or	CC	O
more	JJR	O
in	IN	O
70	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
from	IN	O
a	DT	O
median	JJ	O
number	NN	O
of	IN	O
4.5	CD	O
(	(	O
range	NN	O
,	,	O
0-19	NN	O
)	)	O
to	TO	O
1.5	CD	O
(	(	O
range	NN	O
,	,	O
0-13	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
;	:	O
their	PRP$	O
cumulative	JJ	O
duration	NN	O
also	RB	O
decreased	VBD	O
from	IN	O
78.5	CD	O
(	(	O
range	NN	O
,	,	O
0-60	NN	O
)	)	O
to	TO	O
24.5	CD	O
(	(	O
range	NN	O
,	,	O
0-411	NN	O
)	)	O
minutes	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
circadian	JJ	O
variation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
diltiazem	NN	PM
.	.	PM

The	DT	O
occurrence	NN	O
of	IN	O
ischemic	JJ	O
type	NN	O
ST	NNP	O
segment	NN	O
depression	NN	O
was	VBD	O
modulated	VBN	O
by	IN	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
rather	RB	O
than	IN	O
by	IN	O
absolute	JJ	O
heart	NN	O
rate	NN	O
.	.	O

Diltiazem	NNP	PM
also	RB	O
improved	VBD	O
exercise	NN	O
test	NN	O
end	NN	O
points	NNS	O
but	CC	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
.	.	O

Time	NN	O
to	TO	O
ST	NNP	O
segment	NN	O
depression	NN	O
increased	VBD	O
to	TO	O
341	CD	O
+/-	JJ	O
148	CD	O
from	IN	O
296	CD	O
+/-	JJ	O
154	CD	O
seconds	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Although	IN	O
less	JJR	O
frequent	JJ	O
with	IN	O
diltiazem	JJ	PM
administration	NN	O
(	(	O
45	CD	O
versus	NN	O
54	CD	O
patients	NNS	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.03	CD	O
)	)	O
,	,	O
exercise-induced	JJ	O
ST	NNP	O
depression	NN	O
was	VBD	O
more	RBR	O
often	RB	O
asymptomatic	JJ	O
(	(	O
98	CD	O
%	NN	O
versus	IN	O
72	CD	O
%	NN	O
of	IN	O
patients	NNS	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Diltiazem	NNP	PM
reduces	VBZ	O
the	DT	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
ischemic	JJ	O
type	NN	O
ST	NNP	O
depression	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Transthoracic	NNP	PH
versus	NN	O
transesophageal	NN	S
cardioversion	NN	S
of	IN	S
atrial	JJ	S
fibrillation	NN	S
under	IN	O
light	JJ	O
sedation	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Electrical	JJ	O
cardioversion	NN	O
(	(	O
ECV	NNP	O
)	)	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
limited	VBN	O
by	IN	O
a	DT	O
5-10	JJ	O
%	NN	O
failure	NN	O
rate	NN	O
and	CC	O
by	IN	O
the	DT	O
expense	NN	O
arising	VBG	O
from	IN	O
a	DT	O
perceived	JJ	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

A	DT	O
transesophageal	JJ	O
approach	NN	O
using	VBG	O
light	JJ	O
sedation	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
augmenting	VBG	O
the	DT	O
success	NN	O
rate	NN	O
and	CC	O
avoiding	VBG	O
the	DT	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
the	DT	O
high	JJ	O
rate	NN	O
of	IN	O
success	NN	O
and	CC	O
the	DT	O
lower	JJR	O
energy	NN	O
requirement	NN	O
associated	VBN	O
with	IN	O
biphasic	JJ	O
cardioversion	NN	O
might	MD	O
eliminate	VB	O
any	DT	O
advantage	NN	O
of	IN	O
the	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
60	CD	O
patients	NNS	O
attending	VBG	O
for	IN	O
ECV	NNP	O
of	IN	O
persistent	JJ	O
AF	NNP	O
to	TO	O
a	DT	O
transesophageal	NN	S
or	CC	O
a	DT	O
transthoracic	JJ	PH
approach	NN	PH
.	.	O

Sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
intravenous	JJ	PM
midazolam	NNS	PM
.	.	O

The	DT	O
dose	NN	O
of	IN	O
midazolam	NN	O
was	VBD	O
titrated	VBN	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Sinus	NNP	O
rhythm	NN	O
was	VBD	O
restored	VBN	O
in	IN	O
29/30	CD	O
patients	NNS	O
(	(	O
97	CD	O
%	NN	O
)	)	O
in	IN	O
each	DT	O
group	NN	O
using	VBG	O
a	DT	O
similar	JJ	O
number	NN	O
of	IN	O
shocks	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
1.3	CD	O
+/-	JJ	O
0.6	CD	O
transesophageal	NN	O
vs	NN	O
1.4	CD	O
+/-	JJ	O
0.7	CD	O
transthoracic	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
with	IN	O
a	DT	O
similar	JJ	O
procedure	NN	O
duration	NN	O
(	(	O
14.1	CD	O
+/-	JJ	O
8.2	CD	O
minutes	NNS	O
vs	JJ	O
13.8	CD	O
+/-	JJ	O
7.5	CD	O
minutes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
similar	JJ	O
doses	NNS	O
of	IN	O
midazolam	NN	O
(	(	O
4.2	CD	O
+/-	JJ	O
2.7	CD	O
mg	NN	O
vs	NN	O
4.4	CD	O
+/-	JJ	O
2.8	CD	O
mg	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
and	CC	O
both	DT	O
reported	VBD	O
a	DT	O
similar	JJ	O
discomfort	NN	O
score	NN	O
in	IN	O
(	(	O
0.9	CD	O
+/-	JJ	O
1.3	CD	O
vs	JJ	O
1.1	CD	O
+/-	JJ	O
1.8	CD	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

No	DT	O
complication	NN	O
occurred	VBD	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
AF	NNP	O
may	MD	O
be	VB	O
cardioverted	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
by	IN	O
either	CC	O
a	DT	O
transthoracic	NN	O
or	CC	O
a	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
renders	NNS	O
cardioversion	NN	O
by	IN	O
either	DT	O
approach	NN	O
acceptable	JJ	O
.	.	O

As	IN	O
transesophageal	NN	O
ECV	NNP	O
shows	VBZ	O
no	DT	O
clear	JJ	O
advantage	NN	O
,	,	O
transthoracic	JJ	O
cardioversion	NN	O
should	MD	O
remain	VB	O
the	DT	O
approach	NN	O
of	IN	O
first	JJ	O
choice	NN	O
.	.	O

A	DT	O
randomised	JJ	O
trial	NN	O
comparing	VBG	O
holmium	NN	S
laser	NN	S
enucleation	NN	S
versus	IN	O
transurethral	JJ	S
resection	NN	S
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
prostates	NNS	O
larger	JJR	O
than	IN	O
40	CD	O
grams	NNS	O
:	:	O
results	NNS	O
at	IN	O
2	CD	O
years	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
compare	VB	O
holmium	NN	S
laser	JJR	S
enucleation	NN	S
of	IN	S
the	DT	S
prostate	NN	S
(	(	S
HoLEP	NNP	S
)	)	S
with	IN	O
transurethral	JJ	S
resection	NN	S
of	IN	S
the	DT	S
prostate	NN	S
(	(	S
TURP	NNP	S
)	)	S
for	IN	O
treatment	NN	O
of	IN	O
men	NNS	O
with	IN	O
bladder	NN	O
outflow	JJ	O
obstruction	NN	O
(	(	O
BOO	NNP	O
)	)	O
secondary	VBP	O
to	TO	O
benign	VB	O
prostatic	JJ	O
hyperplasia	NN	O
with	IN	O
a	DT	O
minimum	NN	O
of	IN	O
24-month	JJ	O
follow-up	JJ	O
.	.	O

PATIENTS	NNPS	O
AND	CC	O
METHODS	NNP	O
Sixty-one	CD	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
either	DT	O
HoLEP	NNP	S
or	CC	O
TURP	NNP	S
.	.	S

All	DT	O
patients	NNS	O
had	VBD	O
BOO	NNP	O
proven	RB	O
on	IN	O
urodynamic	JJ	O
studies	NNS	O
pre-operatively	RB	O
(	(	O
prostate	JJ	O
size	NN	O
40-200	JJ	O
g	NN	O
)	)	O
.	.	O

One	CD	O
patient	NN	O
died	VBD	O
before	IN	O
treatment	NN	O
,	,	O
which	WDT	O
left	VBD	O
30	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Perioperative	NNP	O
data	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
symptom	NN	O
scores	NNS	O
,	,	O
Quality	NNP	O
of	IN	O
Life	NNP	O
(	(	O
QoL	NNP	O
)	)	O
scores	VBZ	O
,	,	O
and	CC	O
maximum	JJ	O
urinary	JJ	O
flow	NN	O
rates	NNS	O
(	(	O
Qmax	NNP	O
)	)	O
were	VBD	O
obtained	VBN	O
at	IN	O
one	CD	O
,	,	O
three	CD	O
,	,	O
six,12	NN	O
,	,	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

Post-void	JJ	O
residual	JJ	O
volumes	NNS	O
,	,	O
transrectal	JJ	O
ultrasound	NN	O
(	(	O
TRUS	NNP	O
)	)	O
volumes	NNS	O
,	,	O
and	CC	O
pressure	NN	O
flow	NN	O
studies	NNS	O
were	VBD	O
obtained	VBN	O
six	CD	O
months	NNS	O
post-operatively	RB	O
.	.	O

Continence	NN	O
and	CC	O
potency	NN	O
data	NNS	O
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
surgical	JJ	O
groups	NNS	O
pre-operatively	RB	O
.	.	O

Mean	JJ	O
pre-operative	JJ	O
TRUS	NNP	O
volume	NN	O
was	VBD	O
77.8+/-5.6	JJ	O
g	NN	O
(	(	O
42-152	JJ	O
)	)	O
in	IN	O
the	DT	O
HoLEP	NNP	O
group	NN	O
and	CC	O
70.0+/-5.0	JJ	O
g	NN	O
(	(	O
46-156	JJ	O
)	)	O
in	IN	O
the	DT	O
TURP	NNP	PH
group	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
HoLEP	NNP	PH
group	NN	O
had	VBD	O
shorter	JJR	O
catheter	NN	O
times	NNS	O
and	CC	O
hospital	NN	O
stays	NNS	O
.	.	O

More	JJR	O
prostate	JJ	O
tissue	NN	O
was	VBD	O
retrieved	VBN	O
in	IN	O
the	DT	O
HoLEP	NNP	PH
group	NN	O
.	.	O

At	IN	O
six	CD	O
months	NNS	O
,	,	O
HoLEP	NNP	PH
was	VBD	O
urodynamically	RB	O
superior	JJ	O
to	TO	O
TURP	NNP	PH
in	IN	O
relieving	VBG	O
BOO	NNP	O
.	.	O

At	IN	O
24	CD	O
months	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
surgical	JJ	O
groups	NNS	O
with	IN	O
respect	NN	O
to	TO	O
American	NNP	O
Urology	NNP	O
Association	NNP	O
scores	NNS	O
,	,	O
QoL	NNP	O
scores	VBZ	O
,	,	O
or	CC	O
Qmax	NNP	O
values	NNS	O
;	:	O
however	RB	O
,	,	O
two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
TURP	NNP	O
group	NN	O
required	VBD	O
re-operation	NN	O
.	.	O

CONCLUSIONS	NNP	O
HoLEP	NNP	PH
has	VBZ	O
less	RBR	O
perioperative	JJ	O
morbidity	NN	O
and	CC	O
produces	VBZ	O
superior	JJ	O
urodynamic	JJ	O
outcomes	NNS	O
than	IN	O
TURP	NNP	PH
,	,	O
when	WRB	O
treating	VBG	O
prostates	NNS	O
>	VBP	O
40	CD	O
g.	NN	O
At	IN	O
24	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
HoLEP	NNP	PH
is	VBZ	O
equivalent	JJ	O
to	TO	O
TURP	NNP	PH
.	.	O

Teaching	VBG	O
picture-to-object	JJ	O
relations	NNS	O
in	IN	O
picture-based	JJ	O
requesting	NN	O
by	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
comparison	NN	O
between	IN	O
error	NN	E
prevention	NN	E
and	CC	O
error	NN	E
correction	NN	E
teaching	NN	E
procedures	NNS	E
.	.	E

BACKGROUND	NNP	O
Children	NNP	O
who	WP	O
have	VBP	O
a	DT	O
combination	NN	O
of	IN	O
language	NN	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
with	IN	O
autism	NN	O
often	RB	O
experience	JJ	O
major	JJ	O
difficulties	NNS	O
in	IN	O
learning	VBG	O
relations	NNS	O
between	IN	O
objects	NNS	O
and	CC	O
their	PRP$	O
graphic	JJ	O
representations	NNS	O
.	.	O

Therefore	RB	O
,	,	O
they	PRP	O
would	MD	O
benefit	VB	O
from	IN	O
teaching	VBG	E
procedures	NNS	E
that	WDT	O
minimize	VBP	O
their	PRP$	O
difficulties	NNS	O
in	IN	O
acquiring	VBG	O
these	DT	O
relations	NNS	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
two	CD	O
teaching	NN	E
procedures	NNS	E
,	,	E
an	DT	E
error	NN	E
prevention	NN	E
procedure	NN	E
and	CC	E
an	DT	E
error	NN	E
correction	NN	E
procedure	NN	E
,	,	E
for	IN	E
teaching	VBG	E
relations	NNS	E
between	IN	E
objects	NNS	E
and	CC	E
pictures	NNS	E
.	.	E

METHOD	JJ	O
Participants	NNS	O
were	VBD	O
two	CD	O
groups	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
aged	VBD	O
between	IN	O
3	CD	O
and	CC	O
7	CD	O
years	NNS	O
.	.	O

In	IN	O
the	DT	O
context	NN	O
of	IN	O
picture-to-object	JJ	O
requesting	NN	O
,	,	O
one	CD	O
group	NN	O
was	VBD	O
taught	VBN	O
using	VBG	O
an	DT	E
error	NN	E
correction	NN	E
method	NN	E
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
with	IN	O
an	DT	E
error	NN	E
prevention	NN	E
method	NN	E
.	.	E

The	DT	O
measures	NNS	O
for	IN	O
each	DT	O
child	NN	O
were	VBD	O
accuracy	NN	O
of	IN	O
correspondences	NNS	O
between	IN	O
taught	JJ	O
picture	NN	O
and	CC	O
object	JJ	O
pairs	NNS	O
and	CC	O
accuracy	NN	O
of	IN	O
delayed	JJ	O
correspondences	NNS	O
in	IN	O
learning	VBG	O
outcome	JJ	O
tests	NNS	O
with	IN	O
all	DT	O
combinations	NNS	O
of	IN	O
object	NN	O
and	CC	O
picture	NN	O
pairs	NNS	O
presented	VBN	O
to	TO	O
them	PRP	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
The	DT	O
group	NN	O
receiving	VBG	O
the	DT	O
error	NN	O
prevention-based	JJ	E
teaching	NN	E
made	VBN	O
significantly	RB	O
fewer	JJR	O
errors	NNS	O
during	IN	O
the	DT	O
teaching	NN	O
phases	NNS	O
and	CC	O
in	IN	O
their	PRP$	O
learning	NN	O
outcome	NN	O
test	NN	O
for	IN	O
correspondences	NNS	O
between	IN	O
all	DT	O
combinations	NNS	O
of	IN	O
pictures	NNS	O
and	CC	O
objects	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
error	NN	O
prevention	NN	E
teaching	NN	E
procedure	NN	E
would	MD	O
seem	VB	O
to	TO	O
provide	VB	O
a	DT	O
more	RBR	O
efficient	JJ	O
and	CC	O
ecologically	RB	O
valid	JJ	O
method	NN	O
than	IN	O
the	DT	O
error	NN	O
correction	NN	O
procedure	NN	O
for	IN	O
teaching	VBG	O
relations	NNS	O
between	IN	O
objects	NNS	O
and	CC	O
their	PRP$	O
graphic-based	JJ	O
referents	NNS	O
.	.	O

Improvements	NNS	O
in	IN	O
the	DT	O
methodology	NN	O
were	VBD	O
suggested	VBN	O
for	IN	O
providing	VBG	O
a	DT	O
stronger	JJR	O
basis	NN	O
for	IN	O
comparison	NN	O
between	IN	O
error	NN	O
correction	NN	O
and	CC	O
error	NN	O
prevention	NN	O
teaching	VBG	O
methods	NNS	O
.	.	O

Combined	VBN	Ot
delivery	NN	Ot
approach	NN	Ot
of	IN	O
bone	NN	PH
marrow	NN	PH
mononuclear	JJ	PH
stem	NN	PH
cells	NNS	PH
early	RB	PH
and	CC	O
late	RB	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
:	:	O
the	DT	O
MYSTAR	NNP	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Combined	VBD	O
intracoronary	JJ	O
and	CC	O
intramyocardial	JJ	O
administration	NN	O
might	MD	O
improve	VB	O
outcomes	NNS	O
for	IN	O
bone-marrow-derived	JJ	PH
stem	NN	PH
cell	NN	PH
therapy	NN	PH
for	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
safety	NN	O
and	CC	O
feasibility	NN	O
of	IN	O
early	JJ	O
and	CC	O
late	JJ	O
delivery	NN	O
of	IN	O
stem	NN	PH
cells	NNS	PH
with	IN	O
combined	JJ	O
therapy	NN	O
approaches	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
less	JJR	O
than	IN	O
45	CD	O
%	NN	O
after	IN	O
AMI	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
stem	NN	S
cell	NN	S
delivery	NN	S
via	IN	S
intramyocardial	JJ	S
injection	NN	S
and	CC	S
intracoronary	JJ	S
infusion	NN	S
3-6	JJ	S
weeks	NNS	S
or	CC	S
3-4	JJ	S
months	NNS	S
after	IN	S
AMI	NNP	S
.	.	O

Primary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
changes	NNS	O
in	IN	O
infarct	NN	O
size	NN	O
and	CC	O
left	VBD	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
3	CD	O
months	NNS	O
after	IN	O
therapy	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
60	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
.	.	O

The	DT	O
mean	JJ	O
changes	NNS	O
in	IN	O
infarct	JJ	O
size	NN	O
at	IN	O
3	CD	O
months	NNS	O
were	VBD	O
-3.5	JJ	O
+/-	JJ	O
5.1	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-5.5	NNP	O
%	NN	O
to	TO	O
-1.5	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
in	IN	O
the	DT	O
early	JJ	O
group	NN	O
and	CC	O
-3.9	VBZ	O
+/-	JJ	O
5.6	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-6.1	NNP	O
%	NN	O
to	TO	O
-1.6	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
in	IN	O
the	DT	O
late	JJ	O
group	NN	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
ejection	NN	O
fraction	NN	O
were	VBD	O
3.5	CD	O
+/-	JJ	O
5.6	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.3-5.6	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
3.4	CD	O
+/-	JJ	O
7.0	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.7-6.1	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.017	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

At	IN	O
9-12	JJ	O
months	NNS	O
after	IN	O
AMI	NNP	O
,	,	O
ejection	NN	O
fraction	NN	O
remained	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
at	IN	O
baseline	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
early	JJ	O
and	CC	O
late	JJ	O
groups	NNS	O
,	,	O
a	DT	O
mean	NN	O
of	IN	O
200.3	CD	O
+/-	JJ	O
68.7	CD	O
x	JJ	O
10	CD	O
(	(	O
6	CD	O
)	)	O
and	CC	O
194.8	CD	O
+/-	JJ	O
60.4	CD	O
x	JJ	O
10	CD	O
(	(	O
6	CD	O
)	)	O
stem	NN	O
cells	NNS	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
delivered	VBN	O
to	TO	O
the	DT	O
myocardium	NN	O
,	,	O
and	CC	O
1.30	CD	O
+/-	JJ	O
0.68	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
and	CC	O
1.29	CD	O
+/-	JJ	O
0.41	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
cells	NNS	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
delivered	VBN	O
into	IN	O
the	DT	O
artery	NN	O
.	.	O

A	DT	O
high	JJ	O
number	NN	O
of	IN	O
cells	NNS	O
was	VBD	O
required	VBN	O
for	IN	O
significant	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
end	NN	O
points	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Combined	VBD	O
cardiac	JJ	S
stem	NN	S
cell	NN	S
delivery	NN	S
induces	VBZ	O
a	DT	O
moderate	JJ	O
but	CC	O
significant	JJ	O
improvement	NN	O
in	IN	O
myocardial	JJ	O
infarct	NN	O
size	NN	O
and	CC	O
left	VBD	O
ventricular	JJ	O
function	NN	O
.	.	O

Outcomes	NNS	O
and	CC	O
biochemical	JJ	O
parameters	NNS	O
following	VBG	O
cardiac	JJ	S
surgery	NN	S
:	:	S
effects	NNS	O
of	IN	O
transfusion	NN	PH
of	IN	PH
residual	JJ	PH
blood	NN	PH
using	VBG	O
centrifugation	NN	PH
and	CC	PH
multiple-pass	NN	PH
hemoconcentration	NN	PH
.	.	PH

OBJECTIVES	UH	O
To	TO	O
determine	VB	O
whether	IN	O
or	CC	O
not	RB	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
methods	NNS	O
of	IN	O
centrifugation	NN	O
(	(	O
CF	NNP	O
)	)	O
and	CC	O
multiple-pass	JJ	O
hemoconcentration	NN	O
(	(	O
MPH	NNP	O
)	)	O
of	IN	O
the	DT	O
residual	JJ	O
cardiopulmonary-bypass	NN	O
volume	NN	O
in	IN	O
relation	NN	O
to	TO	O
biochemical	JJ	O
measurements	NNS	O
and	CC	O
patient	JJ	O
outcomes	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBN	O
,	,	O
and	CC	O
controlled	VBD	O
.	.	O

SETTING	NN	O
Conducted	VBN	O
at	IN	O
a	DT	O
western	JJ	O
Canadian	JJ	O
tertiary	NN	O
care	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	NNP	O
Consisted	NNP	O
of	IN	O
61	CD	O
consecutive	JJ	O
male	NN	O
and	CC	O
female	JJ	O
patients	NNS	O
from	IN	O
ages	NNS	O
40	CD	O
to	TO	O
80	CD	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
cardiac	JJ	S
surgery	NN	S
with	IN	O
cardiopulmonary	JJ	S
bypass	NN	S
.	.	S

INTERVENTIONS	NNP	O
Either	CC	O
the	DT	O
centrifugation	NN	PH
or	CC	O
multiple-pass	NN	PH
hemoconcentration	NN	PH
method	NN	PH
was	VBD	O
used	VBN	O
to	TO	O
process	VB	O
the	DT	O
residual	JJ	O
blood	NN	O
from	IN	O
the	DT	O
cardiopulmonary	JJ	O
bypass	NN	O
circuit	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
12-hour	JJ	O
postoperative	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
hemoglobin	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
the	DT	O
centrifugation	NN	PH
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
multiple-pass	JJ	PH
hemoconcentration	NN	PH
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
serum	NN	O
levels	NNS	O
of	IN	O
total	JJ	O
protein	NN	O
and	CC	O
albumin	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
multiple-pass	JJ	PH
hemoconcentration	NN	PH
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
centrifugation	NN	PH
group	NN	O
.	.	O

Additionally	RB	O
,	,	O
after	IN	O
12-hours	JJ	O
postoperatively	RB	O
,	,	O
the	DT	O
serum	NN	O
fibrinogen	NN	O
and	CC	O
platelet	NN	O
counts	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
multiple-pass	JJ	PH
hemoconcentration	NN	PH
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
those	DT	O
of	IN	O
the	DT	O
centrifugation	NN	PH
group	NN	O
.	.	O

The	DT	O
allogeneic	JJ	O
product	NN	O
transfusion	NN	O
index	NN	O
and	CC	O
the	DT	O
chest-tube	JJ	O
blood	NN	O
drainage	NN	O
indices	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
multiple-pass	JJ	PH
hemoconcentration	NN	PH
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
centrifugation	NN	PH
group	NN	O
.	.	O

CONCLUSION	NNP	O
Although	IN	O
the	DT	O
CF	NNP	PH
method	NN	PH
provided	VBD	O
a	DT	O
product	NN	O
in	IN	O
a	DT	O
shorter	JJR	O
turnaround	NN	O
time	NN	O
,	,	O
with	IN	O
consistent	JJ	O
clearance	NN	O
of	IN	O
heparin	NN	PM
,	,	O
the	DT	O
MPH	NNP	PH
method	NN	PH
trended	VBD	O
towards	NNS	O
enhanced	VBN	O
biochemical	JJ	O
and	CC	O
clinical	JJ	O
patient	NN	O
outcomes	VBZ	O
over	IN	O
the	DT	O
12-hour	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

Capsular	JJ	O
contracture	NN	O
around	IN	O
saline-filled	JJ	PM
fine	NN	PM
textured	VBN	PM
and	CC	O
smooth	JJ	PM
mammary	JJ	PM
implants	NNS	PM
:	:	O
a	DT	O
prospective	JJ	O
7.5-year	JJ	O
follow-up	NN	O
.	.	O

In	IN	O
a	DT	O
previous	JJ	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
study	NN	O
comparing	VBG	O
in	IN	O
the	DT	O
same	JJ	O
patient	NN	O
textured	VBD	O
and	CC	O
smooth	JJ	O
saline-filled	JJ	PM
mammary	JJ	PM
implants	NNS	PM
(	(	PM
Biocell	NNP	PM
)	)	PM
with	IN	O
large	JJ	O
pore	NN	O
size	NN	O
(	(	O
300	CD	O
to	TO	O
600	CD	O
microm	NN	O
)	)	O
,	,	O
we	PRP	O
saw	VBD	O
no	DT	O
difference	NN	O
in	IN	O
capsular	JJ	O
contracture	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
in	IN	O
a	DT	O
similar	JJ	O
way	NN	O
to	TO	O
compare	VB	O
capsular	JJ	O
contracture	NN	O
around	IN	O
smooth	JJ	O
and	CC	O
textured	VBD	O
saline-filled	JJ	PM
prostheses	NNS	PM
with	IN	O
pores	NNS	O
of	IN	O
small	JJ	O
size	NN	O
.	.	O

During	IN	O
a	DT	O
period	NN	O
of	IN	O
7.5	CD	O
years	NNS	O
,	,	O
the	DT	O
breast	NN	O
hardness	NN	O
was	VBD	O
followed	VBN	O
up	RP	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
patient	JJ	O
satisfaction	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

Twenty	NNP	O
healthy	JJ	O
women	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
30	CD	O
years	NNS	O
were	VBD	O
operated	VBN	O
on	IN	O
for	IN	O
breast	NN	O
augmentation	NN	O
.	.	O

Two	CD	O
surgeons	NNS	O
performed	VBD	O
all	DT	O
operations	NNS	O
in	IN	O
a	DT	O
standardized	JJ	O
way	NN	O
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
subglandularly	RB	PM
a	DT	PM
Siltex	NNP	PM
textured	VBD	PM
saline-filled	JJ	PM
prosthesis	NN	PM
with	IN	O
a	DT	O
pore	NN	O
size	NN	O
of	IN	O
30	CD	O
to	TO	O
70	CD	O
microm	NN	O
in	IN	O
one	CD	O
breast	NN	O
,	,	O
and	CC	O
a	DT	O
smooth	JJ	PM
saline-filled	JJ	PM
prosthesis	NN	PM
in	IN	PM
the	DT	PM
other	JJ	PM
.	.	O

The	DT	O
hardness	NN	O
of	IN	O
the	DT	O
breasts	NNS	O
was	VBD	O
evaluated	VBN	O
after	IN	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
and	CC	O
7.5	CD	O
years	NNS	O
using	VBG	O
Baker	NNP	O
grading	NN	O
and	CC	O
applanation	NN	O
tonometry	NN	O
.	.	O

Eighteen	JJ	O
patients	NNS	O
completed	VBN	O
1-year	JJ	O
and	CC	O
7.5-year	JJ	O
follow-up	NN	O
.	.	O

Two	CD	O
breasts	NNS	O
with	IN	O
smooth	JJ	O
prostheses	NNS	O
were	VBD	O
contracted	VBN	O
after	IN	O
6	CD	O
months	NNS	O
(	(	O
Baker	NNP	O
III	NNP	O
or	CC	O
IV	NNP	O
)	)	O
.	.	O

After	IN	O
1	CD	O
year	NN	O
,	,	O
four	CD	O
patients	NNS	O
with	IN	O
smooth	JJ	O
prostheses	NNS	O
and	CC	O
one	CD	O
with	IN	O
a	DT	O
textured	JJ	O
prosthesis	NN	O
had	VBD	O
capsular	JJ	O
contracture	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.34	CD	O
)	)	O
.	.	O

Seven	CD	O
and	CC	O
one-half	JJ	O
years	NNS	O
after	IN	O
surgery	NN	O
,	,	O
six	CD	O
patents	NNS	O
with	IN	O
smooth	DT	O
and	CC	O
four	CD	O
with	IN	O
textured	JJ	O
implants	NNS	PH
had	VBD	O
contracture	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.66	CD	O
)	)	O
.	.	O

On	IN	O
two	CD	O
patients	NNS	O
with	IN	O
smooth	JJ	O
prostheses	NNS	O
and	CC	O
one	CD	O
patient	NN	O
with	IN	O
a	DT	O
textured	JJ	O
prosthesis	NN	O
,	,	O
the	DT	O
capsule	NN	O
around	IN	O
the	DT	O
implant	NN	O
hardened	VBD	O
between	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
.	.	O

Between	NNP	O
1	CD	O
year	NN	O
and	CC	O
7.5	CD	O
years	NNS	O
,	,	O
three	CD	O
breasts	NNS	O
with	IN	O
smooth	JJ	O
and	CC	O
textured	JJ	O
implants	NNS	O
contracted	VBD	O
and	CC	O
one	CD	O
with	IN	O
a	DT	O
textured	JJ	O
implant	NN	O
softened.The	NN	O
patients	NNS	O
reported	VBN	O
on	IN	O
a	DT	O
Visual	NNP	O
Analogue	NNP	O
Scale	NNP	O
(	(	O
1	CD	O
to	TO	O
10	CD	O
)	)	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
augmentation	NN	O
on	IN	O
their	PRP$	O
quality	NN	O
of	IN	O
life	NN	O
to	TO	O
be	VB	O
9	CD	O
+/-	JJ	O
1	CD	O
.	.	O

Four	CD	O
patients	NNS	O
preferred	VBD	O
the	DT	O
breast	NN	O
with	IN	O
the	DT	O
smooth	JJ	O
prosthesis	NN	O
,	,	O
three	CD	O
preferred	VBD	O
the	DT	O
breast	NN	O
with	IN	O
the	DT	O
textured	JJ	O
prosthesis	NN	O
,	,	O
and	CC	O
the	DT	O
others	NNS	O
found	VBD	O
both	DT	O
breasts	NNS	O
equal	VBP	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
of	IN	O
contracture	NN	O
with	IN	O
smooth	JJ	O
versus	FW	O
fine	JJ	O
textured	VBN	O
implants	NNS	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
the	DT	O
patients	NNS	O
preferred	VBD	O
the	DT	O
smooth	JJ	O
implants	NNS	O
.	.	O

The	DT	O
patients	NNS	O
reported	VBD	O
that	IN	O
the	DT	O
breast	NN	O
augmentation	NN	O
had	VBD	O
had	VBN	O
an	DT	O
extremely	RB	O
high	JJ	O
impact	NN	O
on	IN	O
their	PRP$	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Interventions	NNS	O
in	IN	O
the	DT	O
initial	JJ	O
prodromal	JJ	O
states	NNS	O
of	IN	O
psychosis	NN	O
in	IN	O
Germany	NNP	O
:	:	O
concept	NN	O
and	CC	O
recruitment	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
Early	JJ	O
Detection	NN	O
and	CC	O
Intervention	NNP	O
Programme	NNP	O
of	IN	O
the	DT	O
German	JJ	O
Research	NNP	O
Network	NNP	O
on	IN	O
Schizophrenia	NNP	O
(	(	O
GRNS	NNP	O
)	)	O
investigates	VBZ	O
the	DT	O
initial	JJ	O
prodromal	JJ	O
phase	NN	O
of	IN	O
psychosis	NN	O
in	IN	O
a	DT	O
multidimensional	JJ	O
approach	NN	O
.	.	O

Two	CD	O
intervention	NN	O
strategies	NNS	O
are	VBP	O
being	VBG	O
studied	VBN	O
by	IN	O
two	CD	O
large-scale	JJ	O
multicentre	JJ	O
projects	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
present	VB	O
the	DT	O
concept	NN	O
of	IN	O
the	DT	O
intervention	NN	O
studies	NNS	O
,	,	O
and	CC	O
to	TO	O
provide	VB	O
an	DT	O
interim	JJ	O
report	NN	O
of	IN	O
the	DT	O
recruitment	JJ	O
procedure	NN	O
.	.	O

METHOD	NNP	O
Comprehensive	NNP	PS
cognitive-behavioural	JJ	PS
therapy	NN	PS
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
early	JJ	O
initial	JJ	O
prodromal	JJ	O
state	NN	O
.	.	O

For	IN	O
patients	NNS	O
in	IN	O
the	DT	O
late	JJ	O
initial	JJ	O
prodromal	JJ	O
state	NN	O
the	DT	O
atypical	JJ	PM
neuroleptic	JJ	PM
amisulpride	NN	PM
is	VBZ	O
explored	VBN	O
.	.	O

Both	DT	O
interventions	NNS	O
are	VBP	O
evaluated	VBN	O
in	IN	O
randomised	JJ	O
controlled	VBN	O
trials	NNS	O
using	VBG	O
clinical	JJ	O
management	NN	O
as	IN	O
the	DT	O
control	NN	O
condition	NN	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
January	NNP	O
2001	CD	O
and	CC	O
March	NNP	O
2003	CD	O
,	,	O
1212	CD	O
individuals	NNS	O
seeking	VBG	O
help	NN	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
putative	JJ	O
prodromal	NN	O
symptoms	NNS	O
at	IN	O
four	CD	O
university	NN	O
centres	NNS	O
.	.	O

More	JJR	O
than	IN	O
388	CD	O
individuals	NNS	O
fulfilled	VBD	O
criteria	NNS	O
for	IN	O
both	DT	O
interventions	NNS	O
and	CC	O
188	CD	O
(	(	O
48.5	CD	O
%	NN	O
)	)	O
gave	VBD	O
informed	VBN	O
consent	NN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
trials	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
screening	NN	O
procedure	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
feasible	JJ	O
and	CC	O
trial	NN	O
participation	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
acceptable	JJ	O
to	TO	O
a	DT	O
relevant	JJ	O
proportion	NN	O
of	IN	O
people	NNS	O
at	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
developing	VBG	O
psychosis	NN	O
.	.	O

Blood	NNP	PS
pressure	NN	PS
biofeedback	NN	PS
treatment	NN	PS
of	IN	O
white-coat	JJ	O
hypertension	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
biofeedback	NN	PS
treatment	NN	PS
(	(	PS
BF	NNP	PS
)	)	PS
effects	NNS	O
between	IN	O
white-coat	JJ	O
hypertension	NN	O
and	CC	O
essential	JJ	O
hypertension	NN	O
.	.	O

METHODS	NNP	O
Fifteen	NNP	O
white-coat	JJ	O
hypertensive	JJ	O
out-patients	NNS	O
and	CC	O
23	CD	O
essential	JJ	O
hypertensive	JJ	O
out-patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
groups	NNS	O
A	NNP	O
or	CC	O
B	NNP	O
.	.	O

Subjects	NNS	O
in	IN	O
group	NN	O
A	NNP	O
underwent	NN	O
BF	NNP	PS
once	RB	O
a	DT	O
week	NN	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
four	CD	O
sessions	NNS	O
.	.	O

Those	DT	O
in	IN	O
group	NN	O
B	NNP	O
visited	VBD	Ot
the	DT	Ot
clinic	NN	Ot
only	RB	O
to	TO	O
measure	VB	O
BP	NNP	O
and	CC	O
later	RB	O
underwent	VBD	O
the	DT	O
same	JJ	O
BF	NNP	Ot
.	.	O

RESULTS	NNP	O
In	IN	O
group	NN	O
A	NNP	O
,	,	O
BPs	NNP	O
of	IN	O
white-coat	JJ	O
hypertensives	NNS	O
and	CC	O
essential	JJ	O
hypertensives	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
22/11	CD	O
and	CC	O
14/8	CD	O
mmHg	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
group	NN	O
B	NNP	O
,	,	O
they	PRP	O
were	VBD	O
unchanged	JJ	O
during	IN	O
the	DT	O
same	JJ	O
period	NN	O
but	CC	O
later	RB	O
suppressed	VBN	O
by	IN	O
BF	NNP	Ot
.	.	O

Under	IN	O
BF	NNP	O
,	,	O
pulse	NN	O
and	CC	O
respiratory	NN	O
rates	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
,	,	O
and	CC	O
elevation	NN	O
of	IN	O
diastolic	JJ	O
BP	NNP	O
due	JJ	O
to	TO	O
mental	JJ	O
stress	NN	O
testing	NN	O
was	VBD	O
better	RBR	O
suppressed	VBN	O
in	IN	O
white-coat	NN	O
hypertensives	NNS	O
than	IN	O
in	IN	O
essential	JJ	O
hypertensives	NNS	O
.	.	O

CONCLUSION	VB	O
This	DT	O
treatment	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
both	DT	O
types	NNS	O
of	IN	O
hypertension	NN	O
,	,	O
and	CC	O
pressor	NN	O
response	NN	O
to	TO	O
stress	VB	O
seems	VBZ	O
to	TO	O
be	VB	O
important	JJ	O
in	IN	O
the	DT	O
differentiated	JJ	O
BF	NNP	Ot
effect	NN	O
.	.	O

Measurement	NN	O
of	IN	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Nordic	NNP	O
Myeloma	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

When	WRB	O
a	DT	O
randomized	VBN	O
trial	NN	O
(	(	O
NMSG	NNP	O
4/90	CD	O
)	)	O
comparing	VBG	O
treatment	NN	O
with	IN	O
melphalan/prednisone	NN	PM
to	TO	O
melphalan/	VB	PM
prednisone	NN	PM
+	NNP	PM
interferon	VBZ	PM
alpha-2b	NN	PM
in	IN	O
newly	RB	O
diagnosed	VBN	O
multiple	JJ	O
myeloma	NN	O
was	VBD	O
initiated	VBN	O
in	IN	O
1990	CD	O
,	,	O
a	DT	O
quality-of-life	JJ	O
assessment	NN	O
was	VBD	O
integrated	VBN	O
into	IN	O
the	DT	O
study	NN	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
questionnaire	NN	O
(	(	O
QLQ-C30	NNP	O
)	)	O
developed	VBN	O
by	IN	O
the	DT	O
European	JJ	O
Organization	NNP	O
of	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
(	(	O
EORTC	NNP	O
)	)	O
Study	NNP	O
Group	NNP	O
on	IN	O
Quality	NNP	O
of	IN	O
Life	NNP	O
.	.	O

The	DT	O
QLQ-C30	JJ	O
incorporates	NNS	O
five	CD	O
functional	JJ	O
scales	NNS	O
,	,	O
three	CD	O
symptom	NN	O
scales	NNS	O
,	,	O
a	DT	O
global	JJ	O
health	NN	O
and	CC	O
quality-of	JJ	O
life	NN	O
scale	NN	O
and	CC	O
some	DT	O
single	JJ	O
symptom	NN	O
measures	NNS	O
.	.	O

The	DT	O
questionnaire	NN	O
was	VBD	O
completed	VBN	O
prior	JJ	O
to	TO	O
treatment	NN	O
and	CC	O
after	IN	O
1	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
24	CD	O
,	,	O
36	CD	O
and	CC	O
48	CD	O
months	NNS	O
.	.	O

524	CD	O
(	(	O
90.2	CD	O
%	NN	O
)	)	O
of	IN	O
581	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
NMSG	NNP	O
4/90	CD	O
completed	VBD	O
the	DT	O
first	JJ	O
questionnaire	NN	O
,	,	O
and	CC	O
484	CD	O
(	(	O
83.3	CD	O
%	NN	O
)	)	O
completed	VBD	O
all	DT	O
questionnaires	NNS	O
given	VBN	O
to	TO	O
them	PRP	O
.	.	O

All	DT	O
but	CC	O
one	CD	O
of	IN	O
the	DT	O
scales	NNS	O
met	VBD	O
the	DT	O
minimum	JJ	O
criteria	NNS	O
of	IN	O
reliability	NN	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
>	NNP	O
/	NNP	O
0.70	CD	O
)	)	O
.	.	O

Validity	NNP	O
was	VBD	O
shown	VBN	O
by	IN	O
(	(	O
1	CD	O
)	)	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
scales	NNS	O
to	TO	O
discriminate	VB	O
clearly	RB	O
between	IN	O
patients	NNS	O
differing	VBG	O
in	IN	O
clinical	JJ	O
status	NN	O
as	IN	O
defined	VBN	O
by	IN	O
pretreatment	NN	O
W.H.O	NNP	O
.	.	O

performance	NN	O
index	NN	O
and	CC	O
Durie	NNP	O
&	CC	O
Salmon	NNP	O
stage	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
the	DT	O
sensitivity	NN	O
to	TO	O
changes	NNS	O
in	IN	O
objective	JJ	O
disease	NN	O
status	NN	O
(	(	O
response	NN	O
and	CC	O
relapse	NN	O
)	)	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
report	NN	O
of	IN	O
the	DT	O
measurement	NN	O
of	IN	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
the	DT	O
QLQ-C30	NNP	O
is	VBZ	O
a	DT	O
reliable	JJ	O
and	CC	O
valid	JJ	O
instrument	NN	O
for	IN	O
the	DT	O
measurement	NN	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

The	DT	O
data	NN	O
will	MD	O
be	VB	O
used	VBN	O
for	IN	O
a	DT	O
cost-utility	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
NMSG	NNP	O
4/90	CD	O
trial	NN	O
.	.	O

Local	JJ	O
delivery	NN	O
of	IN	O
a	DT	O
recombinant	NN	PM
adenoassociated	VBN	PM
vector	NN	PM
containing	VBG	PM
a	DT	PM
tumour	JJ	PM
necrosis	NN	PM
factor	NN	PM
alpha	IN	PM
antagonist	JJ	PM
gene	NN	PM
in	IN	O
inflammatory	JJ	O
arthritis	NN	O
:	:	O
a	DT	O
phase	NN	O
1	CD	O
dose-escalation	NN	O
safety	NN	O
and	CC	O
tolerability	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	PM
:	:	PM
Fc	NNP	PM
,	,	PM
an	DT	PM
adenoassociated	JJ	PM
virus	NN	PM
serotype	NN	PM
2	CD	PM
vector	NN	PM
containing	VBG	PM
the	DT	PM
cDNA	NN	PM
for	IN	O
the	DT	O
human	JJ	O
tumour	JJ	O
necrosis	NN	O
factor-immunoglobulin	JJ	O
Fc	NNP	O
fusion	NN	O
gene	NN	O
(	(	O
tgAAC94	NN	O
)	)	O
,	,	O
in	IN	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
phase	JJ	O
1	CD	O
,	,	O
dose-escalation	NN	O
study	NN	O
,	,	O
15	CD	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
(	(	O
14	CD	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
and	CC	O
1	CD	O
with	IN	O
ankylosing	VBG	O
spondylitis	NN	O
)	)	O
not	RB	O
receiving	VBG	O
tumour	JJ	O
necrosis	NN	O
factor	NN	O
alpha	NN	O
(	(	O
TNFalpha	NNP	O
)	)	O
inhibitors	NNS	O
with	IN	O
persistent	JJ	O
moderate	NN	O
(	(	O
grade	JJ	O
2	CD	O
)	)	O
or	CC	O
severe	JJ	O
(	(	O
grade	JJ	O
3	CD	O
)	)	O
swelling	NN	O
in	IN	O
a	DT	O
target	NN	O
joint	NN	O
due	JJ	O
to	TO	O
inflammatory	JJ	O
arthritis	NN	O
received	VBD	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	PM
:	:	PM
Fc	NN	PM
at	IN	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
10	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
or	CC	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
11	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
DNase	NNP	O
resistant	JJ	O
particles	NNS	O
per	IN	O
ml	NN	O
joint	NN	O
volume	NN	O
or	CC	C
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
into	IN	O
a	DT	O
knee	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
or	CC	O
ankle	NN	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
.	.	O

Safety	NN	O
was	VBD	O
assessed	VBN	O
through	IN	O
adverse	JJ	O
event	NN	O
monitoring	NN	O
.	.	O

As	IN	O
a	DT	O
secondary	JJ	O
objective	NN	O
,	,	O
changes	NNS	O
in	IN	O
injected	JJ	O
joint	NN	O
tenderness	NN	O
and	CC	O
swelling	VBG	O
scores	NNS	O
,	,	O
each	DT	O
measured	VBN	O
on	IN	O
a	DT	O
four-point	JJ	O
scale	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Intra-articular	JJ	O
injections	NNS	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
no	DT	O
major	JJ	O
safety	NN	O
issues	NNS	O
.	.	O

One	CD	O
event	NN	O
,	,	O
mild	JJ	O
knee	NN	O
pruritus	NN	O
,	,	O
was	VBD	O
considered	VBN	O
probably	RB	O
related	VBN	O
.	.	O

Synovial	JJ	O
fluid	NN	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
protein	NN	O
was	VBD	O
not	RB	O
detected	VBN	O
(	(	O
nor	CC	O
expected	VBN	O
)	)	O
at	IN	O
the	DT	O
doses	NNS	O
used	VBN	O
.	.	O

At	IN	O
12	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
,	,	O
a	DT	O
two-point	JJ	O
decrease	NN	O
in	IN	O
swelling	VBG	O
was	VBD	O
noted	VBN	O
in	IN	O
2/11	CD	O
and	CC	O
2/4	CD	O
subjects	NNS	O
injected	VBN	O
with	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
and	CC	O
placebo	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intra-articular	JJ	O
rAAV2-TNFR	NN	O
:	:	O
Fc	CD	O
appears	VBZ	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
subjects	NNS	O
without	IN	O
concurrent	JJ	O
systemic	JJ	O
TNFalpha	NNP	O
antagonist	NN	O
use	NN	O
.	.	O

It	PRP	O
is	VBZ	O
thus	RB	O
feasible	JJ	O
to	TO	O
proceed	VB	O
with	IN	O
larger	JJR	O
trials	NNS	O
to	TO	O
further	JJ	O
test	NN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
local	JJ	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
gene	NN	O
transfer	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
modality	NN	O
for	IN	O
patients	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

Oral	JJ	O
bioavailability	NN	O
of	IN	O
moxifloxacin	NN	PM
after	IN	O
Roux-en-Y	NNP	S
gastric	JJ	S
bypass	NN	S
surgery	NN	S
.	.	O

OBJECTIVES	CC	O
Roux-en-Y	JJ	S
gastric	JJ	S
bypass	NN	S
surgery	NN	S
is	VBZ	O
the	DT	O
most	RBS	O
commonly	RB	O
performed	JJ	O
procedure	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
morbid	NN	O
obesity	NN	O
.	.	O

This	DT	O
anatomical	JJ	O
alteration	NN	O
may	MD	O
affect	VB	O
the	DT	O
absorption	NN	O
and	CC	O
consequently	RB	O
the	DT	O
bioavailability	NN	O
of	IN	O
oral	JJ	O
drugs	NNS	O
.	.	O

This	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
investigate	VB	O
the	DT	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
moxifloxacin	NN	PM
in	IN	O
12	CD	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
underwent	VBP	O
gastric	JJ	S
bypass	NN	S
surgery	NN	S
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
each	DT	O
subject	NN	O
received	VBD	O
two	CD	O
single	JJ	O
standard	NN	O
doses	NNS	O
of	IN	O
400	CD	PM
mg	NN	PM
of	IN	PM
moxifloxacin	NN	PM
orally	RB	PM
or	CC	PM
intravenously	RB	PM
administered	VBN	O
on	IN	O
two	CD	O
occasions	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
1	CD	O
week	NN	O
.	.	O

Serial	JJ	O
venous	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
up	RB	O
to	TO	O
72	CD	O
h	NN	O
after	IN	O
dosing	VBG	O
and	CC	O
moxifloxacin	JJ	PM
plasma	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
validated	JJ	O
HPLC	NNP	O
method	NN	O
with	IN	O
fluorescence	NN	O
detection	NN	O
.	.	O

[	CC	O
clinicaltrials.gov	JJ	O
database	NN	O
(	(	O
identifier	NN	O
:	:	O
NCT01130922	NNP	O
)	)	O
.	.	O

]	JJ	O
RESULTS	NNP	O
After	IN	O
oral	JJ	O
dosing	NN	O
,	,	O
moxifloxacin	FW	PM
plasma	NN	O
concentrations	NNS	O
reached	VBD	O
a	DT	O
maximum	JJ	O
(	(	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
of	IN	O
3.38	CD	O
?	.	O
1.41	CD	O
mg/L	NN	O
after	IN	O
1.75	CD	O
h	NN	O
(	(	O
0.75-4.00	JJ	O
)	)	O
.	.	O

After	IN	O
intravenous	JJ	O
dosing	NN	O
,	,	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
max	NN	O
)	)	O
were	VBD	O
4.53	CD	O
?	.	O
1.43	CD	O
mg/L	NN	O
and	CC	O
1.03	CD	O
h	NN	O
(	(	O
0.75-2.50	JJ	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	O
areas	NNS	O
under	IN	O
the	DT	O
plasma	JJ	O
concentration	NN	O
time	NN	O
curve	NN	O
extrapolated	VBD	O
to	TO	O
infinity	NN	O
(	(	O
AUC	NNP	O
(	(	O
?	.	O
)	)	O
)	)	O
were	VBD	O
46.2	CD	O
?	.	O
1.4	CD	O
mg	NN	O
?	.	O
h/L	NN	O
after	IN	O
oral	JJ	O
dosing	NN	O
and	CC	O
52.3	CD	O
?	.	O
1.3	CD	O
mg	NN	O
?	.	O
h/L	NN	O
after	IN	O
intravenous	JJ	O
dosing	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
mean	JJ	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
88.32	CD	O
%	NN	O
[	JJ	O
90	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
85.64	CD	O
%	NN	O
-91.08	CD	O
%	NN	O
]	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
confirms	VBZ	O
that	IN	O
exposure	NN	O
to	TO	O
moxifloxacin	VB	O
is	VBZ	O
equivalent	JJ	O
for	IN	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
administration	NN	O
of	IN	O
400	CD	O
mg	NN	O
dosages	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
underwent	VBP	O
gastric	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

But	CC	O
these	DT	O
exposures	NNS	O
were	VBD	O
more	JJR	O
than	IN	O
50	CD	O
%	NN	O
higher	JJR	O
than	IN	O
those	DT	O
described	VBN	O
for	IN	O
subjects	NNS	O
without	IN	O
gastric	JJ	O
bypass	NN	O
.	.	O

This	DT	O
may	MD	O
suggest	VB	O
a	DT	O
higher	JJR	O
enterohepatic	JJ	O
recirculation	NN	O
of	IN	O
moxifloxacin	NN	O
after	IN	O
gastric	JJ	O
bypass	NN	O
.	.	O

A	DT	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
comparing	VBG	O
radiotherapy	NN	PH
with	IN	O
concurrent	JJ	O
weekly	JJ	O
cisplatin	NN	PM
or	CC	O
weekly	JJ	O
paclitaxel	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
cervical	JJ	O
cancer	NN	O
.	.	O

PURPOSE/OBJECTIVE	VB	O
This	DT	O
is	VBZ	O
a	DT	O
prospective	JJ	O
comparison	NN	O
of	IN	O
weekly	JJ	O
cisplatin	NN	PM
to	TO	O
weekly	VB	O
paclitaxel	NN	PM
as	IN	O
concurrent	JJ	O
chemotherapy	NN	O
with	IN	O
standard	JJ	PH
radiotherapy	NN	PH
for	IN	O
locally	RB	O
advanced	JJ	O
cervical	JJ	O
carcinoma	NN	O
.	.	O

MATERIALS/METHODS	NNP	O
Between	NNP	O
May	NNP	O
2000	CD	O
and	CC	O
May	NNP	O
2004	CD	O
,	,	O
31	CD	O
women	NNS	O
with	IN	O
FIGO	NNP	O
stage	NN	O
IB2-IVA	NNP	O
cervical	JJ	O
cancer	NN	O
or	CC	O
with	IN	O
postsurgical	JJ	O
pelvic	JJ	O
recurrence	NN	O
were	VBD	O
enrolled	VBN	O
into	IN	O
this	DT	O
phase	NN	O
II	NNP	O
study	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
on	IN	O
a	DT	O
weekly	JJ	O
basis	NN	O
either	CC	O
40	CD	O
mg/m?	NN	O
Cisplatin	NNP	O
(	(	O
group	NN	O
I	PRP	O
;	:	O
16	CD	O
patients	NNS	O
)	)	O
or	CC	O
50	CD	O
mg/m?	NNS	O
paclitaxel	NN	O
(	(	O
group	NN	O
II	NNP	O
;	:	O
15	CD	O
patients	NNS	O
)	)	O
concurrently	RB	O
with	IN	O
radiotherapy	NN	O
.	.	O

Median	JJ	O
total	NN	O
dose	NN	O
to	TO	O
point	VB	O
A	NNP	O
was	VBD	O
74	CD	O
Gy	NNP	O
(	(	O
range	NN	O
:	:	O
66-92	JJ	O
Gy	NNP	O
)	)	O
for	IN	O
group	NN	O
I	PRP	O
and	CC	O
66	CD	O
Gy	NNP	O
(	(	O
range	NN	O
:	:	O
40-98	JJ	O
Gy	NNP	O
)	)	O
for	IN	O
group	NN	O
II	NNP	O
.	.	O

Median	JJ	O
follow-up	JJ	O
time	NN	O
was	VBD	O
46	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Patient	NNP	O
and	CC	O
tumor	NN	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
chemotherapy	NN	O
cycles	NNS	O
was	VBD	O
also	RB	O
comparable	JJ	O
with	IN	O
87	CD	O
%	NN	O
and	CC	O
80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
at	IN	O
least	JJS	O
4	CD	O
doses	NNS	O
in	IN	O
groups	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
,	,	O
respectively	RB	O
.	.	O

Seven	JJ	O
patients	NNS	O
(	(	O
44	CD	O
%	NN	O
)	)	O
of	IN	O
group	NN	O
I	PRP	O
and	CC	O
8	CD	O
patients	NNS	O
(	(	O
53	CD	O
%	NN	O
)	)	O
of	IN	O
group	NN	O
II	NNP	O
developed	VBD	O
tumor	NN	O
recurrence	NN	O
.	.	O

The	DT	O
Median	JJ	O
Survival	NNP	O
time	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
for	IN	O
Group	NNP	O
I	PRP	O
and	CC	O
53	CD	O
months	NNS	O
for	IN	O
group	NN	O
II	NNP	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
surviving	VBG	O
at	IN	O
2	CD	O
and	CC	O
5	CD	O
years	NNS	O
was	VBD	O
78	CD	O
%	NN	O
and	CC	O
54	CD	O
%	NN	O
for	IN	O
group	NN	O
I	PRP	O
and	CC	O
73	CD	O
%	NN	O
and	CC	O
43	CD	O
%	NN	O
for	IN	O
group	NN	O
II	NNP	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
small	JJ	O
prospective	JJ	O
study	NN	O
shows	NNS	O
that	WDT	O
weekly	VBP	O
paclitaxel	NN	O
does	VBZ	O
not	RB	O
provide	VB	O
any	DT	O
clinical	JJ	O
advantage	NN	O
over	IN	O
weekly	JJ	O
cisplatin	NN	O
for	IN	O
concurrent	JJ	O
chemoradiation	NN	O
for	IN	O
advanced	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
cervix	NN	O
.	.	O

Hysteroscopic	NNP	S
transcervical	JJ	S
endometrial	JJ	S
resection	NN	S
versus	IN	O
thermal	JJ	S
destruction	NN	S
for	IN	O
menorrhagia	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
on	IN	O
satisfaction	NN	O
rate	NN	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
satisfaction	NN	O
rate	NN	O
and	CC	O
the	DT	O
effectiveness	NN	O
of	IN	O
transcervical	JJ	S
hysteroscopic	NN	S
endometrial	JJ	S
resection	NN	S
and	CC	O
thermal	JJ	S
destruction	NN	S
of	IN	O
the	DT	O
endometrium	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menorrhagia	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
with	IN	O
2	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Gynecology	NNP	O
of	IN	O
the	DT	O
University	NNP	O
of	IN	O
Naples	NNP	O
.	.	O

Eighty-two	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
affected	VBN	O
by	IN	O
menorrhagia	NN	O
that	WDT	O
was	VBD	O
unresponsive	JJ	O
to	TO	O
medical	JJ	O
treatment	NN	O
were	VBD	O
respectively	RB	O
randomized	VBN	O
to	TO	O
transcervical	JJ	S
hysteroscopic	NN	S
endometrial	JJ	S
resection	NN	S
or	CC	O
to	TO	O
thermal	JJ	S
destruction	NN	S
of	IN	S
the	DT	S
endometrium	NN	S
.	.	O

Satisfaction	NN	O
rate	NN	O
,	,	O
operative	JJ	O
time	NN	O
,	,	O
discharge	NN	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
,	,	O
reintervention	NN	O
rate	NN	O
,	,	O
and	CC	O
resumption	NN	O
of	IN	O
normal	JJ	O
activity	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
satisfaction	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
thermal	JJ	S
destruction	NN	S
group	NN	O
.	.	O

Operative	JJ	O
time	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
(	(	O
24	CD	O
+/-	JJ	O
4	CD	O
minutes	NNS	O
vs	JJ	O
37	CD	O
+/-	JJ	O
6	CD	O
minutes	NNS	O
)	)	O
.	.	O

Intraoperative	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
(	(	O
7.2	CD	O
+/-	JJ	O
2.8	CD	O
mL	NN	O
vs	NN	O
89	CD	O
+/-	JJ	O
38	CD	O
mL	NN	O
)	)	O
.	.	O

Reintervention	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
transcervical	JJ	S
hysteroscopic	NN	S
endometrial	JJ	S
resection	NN	S
group	NN	O
,	,	O
although	IN	O
postoperative	JJ	O
pain	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Discharge	NNP	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
,	,	O
and	CC	O
resumption	NN	O
of	IN	O
normal	JJ	O
activity	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Thermal	NNP	S
destruction	NN	S
of	IN	S
the	DT	S
endometrium	NN	S
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menorrhagia	NN	O
should	MD	O
be	VB	O
considered	VBN	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
option	NN	O
because	IN	O
of	IN	O
its	PRP$	O
acceptability	NN	O
among	IN	O
patients	NNS	O
,	,	O
shorter	RB	O
operative	JJ	O
time	NN	O
,	,	O
and	CC	O
lower	JJR	O
blood	NN	O
loss	NN	O
.	.	O

Validation	NN	O
of	IN	O
a	DT	O
novel	JJ	O
satisfaction	NN	E
questionnaire	NN	E
for	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
receiving	VBG	O
outpatient	JJ	O
clinical	JJ	O
nurse	NN	O
specialist	NN	O
care	NN	O
,	,	O
inpatient	NN	O
care	NN	O
,	,	O
or	CC	O
day	NN	O
patient	JJ	O
team	NN	O
care	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
develop	VB	O
and	CC	O
validate	VB	O
a	DT	O
questionnaire	NN	O
for	IN	O
measuring	VBG	O
satisfaction	NN	O
with	IN	O
different	JJ	O
forms	NNS	O
of	IN	O
complex	JJ	O
multidisciplinary	JJ	O
care	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
satisfaction	NN	E
questionnaire	NN	E
(	(	O
score	JJ	O
range	NN	O
0-100	NN	O
)	)	O
comprised	VBD	O
28	CD	O
items	NNS	O
covering	VBG	O
11	CD	O
domains	NNS	O
.	.	O

Together	RB	O
with	IN	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
,	,	O
range	VB	O
0-100	NNP	O
)	)	O
on	IN	O
overall	JJ	O
satisfaction	NN	O
,	,	O
the	DT	O
questionnaire	NN	E
was	VBD	O
applied	VBN	O
in	IN	O
210	CD	O
RA	NNP	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
3	CD	O
types	NNS	O
of	IN	O
multidisciplinary	JJ	O
care	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
questionnaire	NN	O
was	VBD	O
returned	VBN	O
by	IN	O
174	CD	O
patients	NNS	O
(	(	O
83	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
questionnaire	NN	O
and	CC	O
VAS	NNP	O
scores	NNS	O
in	IN	O
the	DT	O
total	JJ	O
group	NN	O
were	VBD	O
75	CD	O
(	(	O
SD	NNP	O
12	CD	O
)	)	O
and	CC	O
83	CD	O
(	(	O
SD	NNP	O
20	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Reliability	NNP	O
analysis	NN	O
showed	VBD	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
of	IN	O
the	DT	O
questionnaire	NN	O
was	VBD	O
0.91	CD	O
.	.	O

Spearman	NNP	O
's	POS	O
correlation	NN	O
coefficient	NN	O
between	IN	O
the	DT	O
satisfaction	NN	O
questionnaire	NN	O
score	NN	O
and	CC	O
VAS	NNP	O
score	NN	O
was	VBD	O
0.58	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Mean	JJ	O
total	JJ	O
satisfaction	NN	O
questionnaire	NN	O
scores	NNS	O
were	VBD	O
72	CD	O
(	(	O
SD	NNP	O
9	CD	O
)	)	O
,	,	O
76	CD	O
(	(	O
SD	NNP	O
14	CD	O
)	)	O
,	,	O
and	CC	O
78	CD	O
(	(	O
SD	NNP	O
11	CD	O
)	)	O
,	,	O
in	IN	O
the	DT	O
nurse	JJ	O
specialist	NN	O
,	,	O
inpatient	JJ	O
and	CC	O
day	NN	O
patient	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
nurse	JJ	O
specialist	NN	O
versus	IN	O
day	NN	O
patient	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

Significant	JJ	O
differences	NNS	O
between	IN	O
nurse	JJ	O
specialist	NN	O
and	CC	O
day	NN	O
patients	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
following	JJ	O
domains	NNS	O
:	:	O
waiting	VBG	O
time	NN	O
during	IN	O
the	DT	O
treatment	NN	O
,	,	O
autonomy	NN	O
,	,	O
coordination	NN	O
,	,	O
non-financial	JJ	O
access	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
general	JJ	O
information	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
patients	NNS	O
were	VBD	O
highly	RB	O
satisfied	VBN	O
with	IN	O
the	DT	O
multidisciplinary	JJ	O
care	NN	O
they	PRP	O
received	VBD	O
.	.	O

Major	JJ	O
differences	NNS	O
regarding	VBG	O
the	DT	O
organization	NN	O
of	IN	O
care	NN	O
were	VBD	O
reflected	VBN	O
in	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
questionnaire	NN	O
scores	NNS	O
.	.	O

The	DT	O
satisfaction	NN	O
questionnaire	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
useful	JJ	O
instrument	NN	O
for	IN	O
measuring	VBG	O
satisfaction	NN	O
with	IN	O
complex	JJ	O
multidisciplinary	NN	O
care	NN	O
in	IN	O
RA	NNP	O
patients	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
intensive	JJ	E
early	JJ	E
intervention	NN	E
for	IN	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

Young	NNP	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
intensive	VB	C
treatment	NN	C
or	CC	O
parent	NN	E
training	NN	E
.	.	O

The	DT	O
intensive	JJ	O
treatment	NN	O
group	NN	O
(	(	O
7	CD	O
with	IN	O
autism	NN	O
,	,	O
8	CD	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified	VBN	O
--	:	O
NOS	NNP	O
)	)	O
averaged	VBD	O
24.52	CD	O
hours	NNS	O
per	IN	O
week	NN	O
of	IN	O
individual	JJ	O
treatment	NN	O
for	IN	O
one	CD	O
year	NN	O
,	,	O
gradually	RB	O
reducing	VBG	O
hours	NNS	O
over	IN	O
the	DT	O
next	JJ	O
1	CD	O
to	TO	O
2	CD	O
years	NNS	O
.	.	O

The	DT	O
parent	NN	E
training	NN	E
group	NN	O
(	(	O
7	CD	O
with	IN	O
autism	NN	O
,	,	O
6	CD	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
NOS	NNP	O
)	)	O
received	VBD	O
3	CD	O
to	TO	O
9	CD	O
months	NNS	O
of	IN	O
parent	NN	E
training	NN	E
.	.	O

The	DT	O
groups	NNS	O
appeared	VBD	O
similar	JJ	O
at	IN	O
intake	NN	O
on	IN	O
all	DT	O
measures	NNS	O
;	:	O
however	RB	O
,	,	O
at	IN	O
follow-up	JJ	O
the	DT	O
intensive	JJ	O
treatment	NN	O
group	NN	O
outperformed	VBD	O
the	DT	O
parent	NN	E
training	VBG	E
group	NN	O
on	IN	O
measures	NNS	O
of	IN	O
intelligence	NN	O
,	,	O
visual-spatial	JJ	O
skills	NNS	O
,	,	O
language	NN	O
,	,	O
and	CC	O
academics	NNS	O
,	,	O
though	IN	O
not	RB	O
adaptive	JJ	O
functioning	NN	O
or	CC	O
behavior	NN	O
problems	NNS	O
.	.	O

Children	NNP	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
NOS	NNP	O
may	MD	O
have	VB	O
gained	VBN	O
more	JJR	O
than	IN	O
those	DT	O
with	IN	O
autism	NN	O
.	.	O

Mediterranean	NNP	Ot
diet	NN	Ot
and	CC	O
high	JJ	Ot
dietary	JJ	Ot
acid	NN	Ot
load	NN	Ot
associated	VBN	O
with	IN	O
mixed	JJ	Ot
nuts	NNS	Ot
:	:	O
effect	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
analyze	VB	O
the	DT	O
effect	NN	O
of	IN	O
differing	VBG	O
diet	NN	O
on	IN	O
the	DT	O
acid	JJ	O
load	NN	O
content	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
.	.	O

DESIGN	NNP	O
Multicentric	NNP	O
,	,	O
randomized	VBD	O
,	,	O
single-blind	JJ	O
,	,	O
parallel-group	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	JJ	O
clinics	NNS	O
.	.	O

PARTICIPANTS	VB	O
Two	CD	O
hundred	CD	O
thirty-eight	JJ	O
elderly	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
aged	VBD	O
60	CD	O
to	TO	O
80	CD	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
interventional	JJ	O
groups	NNS	O
:	:	O
a	DT	O
recommended	JJ	C
low-fat	JJ	Ot
diet	NN	Ot
(	(	C
control	VB	C
diet	JJ	C
group	NN	C
)	)	C
,	,	O
a	DT	O
Mediterranean	NNP	Ot
diet	NN	Ot
supplemented	VBD	Ot
with	IN	Ot
virgin	JJ	Ot
olive	JJ	Ot
oil	NN	Ot
,	,	PH
or	CC	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
supplemented	VBD	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
.	.	O

MEASUREMENTS	NNP	O
Main	NNP	O
outcomes	NNS	O
were	VBD	O
12-month	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
bone	NN	O
formation	NN	O
and	CC	O
resorption	NN	O
markers	NNS	O
and	CC	O
bone	NN	O
mass	NN	O
measured	VBD	O
according	VBG	O
to	TO	O
quantitative	JJ	O
ultrasound	JJ	O
scanning	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
baseline	NN	O
data	NNS	O
on	IN	O
the	DT	O
anthropometric	NN	O
,	,	O
bone	NN	O
densitometry	NN	O
,	,	O
and	CC	O
biochemical	JJ	O
variables	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Dietary	NNP	O
potential	JJ	O
renal	JJ	O
acid	NN	O
load	NN	O
(	(	O
PRAL	NNP	O
)	)	O
and	CC	O
daily	JJ	O
net	NN	O
endogenous	JJ	O
acid	NN	O
production	NN	O
(	(	O
NEAP	NNP	O
)	)	O
at	IN	O
baseline	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
groups	NNS	O
.	.	O

After	IN	O
intervention	NN	O
,	,	O
subjects	NNS	O
allocated	VBD	O
to	TO	O
the	DT	O
Mediterranean	NNP	Ot
diet	NN	Ot
with	IN	Ot
mixed	JJ	Ot
nuts	NNS	Ot
had	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
PRAL	NNP	O
and	CC	O
NEAP	NNP	O
.	.	O

In	IN	O
comparison	NN	O
,	,	O
subjects	NNS	O
in	IN	O
the	DT	O
Mediterranean	NNP	Ot
diet	NN	Ot
with	IN	Ot
nuts	NNS	Ot
group	NN	O
had	VBD	O
higher	JJR	O
parathyroid	NN	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
levels	NNS	O
(	(	O
2.63	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
=-1.01-6.35	NN	O
,	,	O
P=.02	NNP	O
)	)	O
and	CC	O
a	DT	O
nonsignificantly	RB	O
higher	JJR	O
(	(	O
0.31	CD	O
,	,	O
95	CD	O
%	NN	O
CI=-0.13-0.74	NNP	O
,	,	O
P=.14	NNP	O
)	)	O
urine	VBP	O
free	JJ	O
deoxypyridoxine	NN	O
:	:	O
creatinine	NN	O
ratio	NN	O
,	,	O
a	DT	O
marker	NN	O
of	IN	O
bone	NN	O
resorption	NN	O
,	,	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
virgin	JJ	O
olive	JJ	O
oil	NN	O
group	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
Mediterranean	NNP	E
dietary	JJ	E
pattern	NN	E
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
dietary	JJ	O
acid	NN	O
load	NN	O
derived	VBN	O
from	IN	O
consumption	NN	O
of	IN	O
mixed	JJ	O
nuts	NNS	O
does	VBZ	O
not	RB	O
seem	VB	O
to	TO	O
have	VB	O
a	DT	O
much	RB	O
greater	JJR	O
effect	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
biomarkers	NNS	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
PTH	NNP	O
levels	NNS	O
,	,	O
than	IN	O
a	DT	O
Mediterranean	NNP	Ot
diet	NN	Ot
without	IN	Ot
mixed	JJ	Ot
nuts	NNS	Ot
or	CC	O
a	DT	O
control	NN	C
diet	NN	C
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

Pentoxifylline	NNP	PM
therapy	NN	O
in	IN	O
HIV	NNP	O
seropositive	JJ	O
subjects	NNS	O
with	IN	O
elevated	JJ	O
TNF	NNP	O
.	.	O

Tumor	NNP	O
necrosis	IN	O
factor-alpha	JJ	O
(	(	O
TNF-alpha	NNP	O
)	)	O
is	VBZ	O
thought	VBN	O
to	TO	O
induce	VB	O
cachexia	NN	O
in	IN	O
subjects	NNS	O
infected	VBN	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
,	,	O
and	CC	O
it	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
HIV-seropositive	JJ	O
patients	NNS	O
would	MD	O
benefit	VB	O
from	IN	O
treatment	NN	O
with	IN	O
pentoxifylline	NN	PM
,	,	O
a	DT	O
known	VBN	O
suppressor	NN	O
of	IN	O
TNF-alpha	NNP	O
production	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
how	WRB	O
pentoxifylline	NN	PM
at	IN	PM
a	DT	PM
dose	NN	PM
of	IN	PM
800	CD	PM
mg	JJ	PM
thrice	JJ	PM
daily	RB	PM
would	MD	O
influence	VB	O
the	DT	O
cellular	JJ	O
immune	NN	O
system	NN	O
in	IN	O
HIV-seropositive	JJ	O
persons	NNS	O
with	IN	O
elevated	JJ	O
TNF-alpha	NNP	O
.	.	O

Six	NNP	O
HIV-seropositive	JJ	O
subjects	NNS	O
with	IN	O
elevated	JJ	O
amounts	NNS	O
of	IN	O
TNF-alpha	NNP	O
in	IN	O
plasma	NN	O
at	IN	O
least	JJS	O
at	IN	O
two	CD	O
occasions	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
an	DT	O
open	JJ	O
,	,	O
controlled	VBN	O
,	,	O
randomized	VBN	O
,	,	O
cross-over	JJ	O
study	NN	O
consisting	VBG	O
of	IN	O
a	DT	O
6	CD	PM
week	NN	PM
treatment	NN	PM
period	NN	PM
and	CC	O
a	DT	O
6	CD	C
week	NN	C
control	NN	C
period	NN	C
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
period	NN	O
.	.	O

Pentoxifylline	NNP	O
treatment	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
concentration	NN	O
of	IN	O
plasma-TNF-alpha	NN	O
,	,	O
subpopulations	NNS	O
of	IN	O
blood	NN	O
mononuclear	NN	O
cells	NNS	O
,	,	O
the	DT	O
proliferative	JJ	O
responses	NNS	O
nor	CC	O
the	DT	O
natural	JJ	O
killer	NN	O
(	(	O
NK	NNP	O
)	)	O
,	,	O
and	CC	O
lymphokine	NN	O
activated	VBN	O
killer	NN	O
(	(	O
LAK	NNP	O
)	)	O
cell	NN	O
activities	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
pentoxifylline	JJ	O
treatment	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
weight	NN	O
,	,	O
temperature	NN	O
,	,	O
well	RB	O
being	VBG	O
,	,	O
or	CC	O
tiredness	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
patients	NNS	O
frequently	RB	O
reported	VBD	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
.	.	O

In	IN	O
vitro	NN	O
,	,	O
however	RB	O
,	,	O
pentoxifylline	NN	O
at	IN	O
suprapharmacological	JJ	O
concentrations	NNS	O
inhibited	VBD	O
the	DT	O
blood	NN	O
mononuclear	NN	O
cell	NN	O
(	(	O
BMNC	NNP	O
)	)	O
proliferative	NN	O
responses	NNS	O
,	,	O
NK	NNP	O
,	,	O
and	CC	O
LAK	NNP	O
cell	NN	O
activities	NNS	O
.	.	O

Improving	VBG	O
emotion	NN	O
regulation	NN	O
with	IN	O
CBT	NNP	PM
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
This	DT	O
pilot	NN	O
study	NN	O
tested	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
developmentally	RB	O
modified	VBN	O
CBT	NNP	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
to	TO	O
teach	VB	O
emotion	NN	O
regulation	NN	O
strategies	NNS	O
for	IN	O
reducing	VBG	O
anger	NN	O
and	CC	O
anxiety	NN	O
,	,	O
commonly	RB	O
noted	VBD	O
problems	NNS	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

METHOD	NNP	O
Eleven	NNP	O
5-7	JJ	O
year-old	JJ	O
children	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
CBT-group	NNP	PM
while	IN	O
parents	NNS	O
participated	VBN	E
in	IN	E
psychoeducation	NN	E
.	.	O

Children	NNP	C
were	VBD	C
randomly	RB	C
assigned	VBN	C
to	TO	C
an	DT	C
experimental	JJ	C
or	CC	C
delayed-treatment	JJ	C
control	NN	C
group	NN	C
.	.	O

RESULTS	CC	O
From	IN	O
pre-	JJ	O
to	TO	O
post-treatment	JJ	O
,	,	O
all	DT	O
children	NNS	O
had	VBD	O
less	RBR	O
parent	NN	O
reported	VBD	O
negativity/lability	NN	O
,	,	O
better	JJR	O
parent	NN	O
reported	VBD	O
emotion	NN	O
regulation	NN	O
,	,	O
and	CC	O
shorter	JJR	O
outbursts	NNS	O
,	,	O
and	CC	O
also	RB	O
generated	VBD	O
more	RBR	O
coping	JJ	O
strategies	NNS	O
in	IN	O
response	NN	O
to	TO	O
vignettes	NNS	O
.	.	O

Parents	NNS	O
also	RB	O
reported	VBD	O
increases	NNS	O
in	IN	O
their	PRP$	O
own	JJ	O
confidence	NN	O
and	CC	O
their	PRP$	O
child	NN	O
's	POS	O
ability	NN	O
to	TO	O
deal	VB	O
with	IN	O
anger	NN	O
and	CC	O
anxiety	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
young	JJ	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
ASD	NNP	O
may	MD	O
benefit	VB	O
from	IN	O
CBT	NNP	PM
to	TO	O
improve	VB	O
regulation	NN	O
of	IN	O
anger	NN	O
and	CC	O
anxiety	NN	O
,	,	O
and	CC	O
parent	NN	O
training	NN	O
may	MD	O
improve	VB	O
parental	JJ	O
self-efficacy	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
make	VB	O
conclusions	NNS	O
about	IN	O
its	PRP$	O
efficacy	NN	O
.	.	O

The	DT	O
injured	JJ	O
colon	NN	O
:	:	O
therapeutic	JJ	O
considerations	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
the	DT	O
Detroit	NNP	O
General	NNP	O
Hospital	NNP	O
over	IN	O
a	DT	O
two	CD	O
year	NN	O
period	NN	O
to	TO	O
evaluate	VB	O
methods	NNS	O
of	IN	O
management	NN	O
in	IN	O
165	CD	O
patients	NNS	O
with	IN	O
colonic	JJ	PH
injuries	NNS	PH
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
show	NN	O
that	IN	O
primary	JJ	PH
closure	NN	PH
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
reiable	JJ	O
method	NN	O
of	IN	O
management	NN	O
when	WRB	O
rigid	JJ	O
criteria	NNS	O
are	VBP	O
incorporated	VBN	O
in	IN	O
an	DT	O
ongoing	JJ	O
protocol	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
technic	NN	O
of	IN	O
exteriorization	NN	PH
is	VBZ	O
a	DT	O
safe	JJ	O
adjunct	NN	O
to	TO	O
management	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
in	IN	O
any	DT	O
patient	NN	O
with	IN	O
a	DT	O
colonic	JJ	O
injury	NN	O
above	IN	O
18	CD	O
cm	NN	O
in	IN	O
which	WDT	O
one	CD	O
suture	NN	O
line	NN	O
is	VBZ	O
required	VBN	O
and	CC	O
in	IN	O
which	WDT	O
the	DT	O
additional	JJ	O
operating	NN	O
time	NN	O
of	IN	O
twenty	NN	O
minutes	NNS	O
will	MD	O
not	RB	O
compromise	VB	O
the	DT	O
management	NN	O
of	IN	O
secondary	JJ	O
injuries	NNS	O
.	.	O

Patients	NNS	O
not	RB	O
fulfilling	VBG	O
these	DT	O
criteria	NNS	O
should	MD	O
have	VB	O
primary	JJ	S
colostomy	NN	S
.	.	O

These	DT	O
principles	NNS	O
make	VBP	O
it	PRP	O
possible	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
need	NN	O
for	IN	O
primary	JJ	S
colostomy	NN	S
to	TO	O
approximately	RB	O
50	CD	O
per	IN	O
cent	NN	O
in	IN	O
a	DT	O
large	JJ	O
ongoing	VBG	O
group	NN	O
of	IN	O
patients	NNS	O
with	IN	O
colonic	JJ	O
injury	NN	O
.	.	O

A	DT	O
randomized	JJ	O
prospective	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	PM
versus	IN	O
oral	JJ	O
valacyclovir	NN	PM
for	IN	O
prophylaxis	NN	O
of	IN	O
cytomegalovirus	NN	O
disease	NN	O
after	IN	O
renal	JJ	O
transplantation	NN	O
.	.	O

Oral	NNP	O
ganciclovir	NN	PM
and	CC	O
valacyclovir	NN	PM
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
cytomegalovirus	NN	O
(	(	O
CMV	NNP	O
)	)	O
disease	NN	O
after	IN	O
renal	JJ	O
transplantation	NN	O
(	(	O
RTx	NNP	O
)	)	O
.	.	O

Our	PRP$	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
,	,	O
costs	NNS	O
,	,	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	PM
and	CC	O
valacyclovir	NN	PM
in	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
over	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
after	IN	O
RTx	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
38	CD	O
patients	NNS	O
was	VBD	O
randomized	VBN	O
to	TO	O
3-month	JJ	O
treatment	NN	O
with	IN	O
either	DT	O
oral	JJ	PM
ganciclovir	NN	PM
(	(	O
1	CD	O
g	NN	O
t.i.d.	NN	O
,	,	O
n=14	RB	O
,	,	O
GAN	NNP	O
group	NN	O
)	)	O
or	CC	O
oral	JJ	PM
valacyclovir	NN	PM
(	(	O
2	CD	O
g	NN	O
q.i.d.	NN	O
,	,	O
n=12	RB	O
,	,	O
VAL	NNP	O
group	NN	O
)	)	O
.	.	O

A	DT	O
third	JJ	O
group	NN	O
(	(	O
C	NNP	O
,	,	O
n=12	NN	O
)	)	O
received	VBD	O
no	DT	C
prophylaxis	NN	C
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
monitored	VBN	O
by	IN	O
CMV-nested	JJ	O
PCR	NNP	O
in	IN	O
whole	JJ	O
blood	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
their	PRP$	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
immunosuppressive	JJ	O
protocols	NNS	O
,	,	O
or	CC	O
donor	NN	O
and	CC	O
recipient	NN	O
CMV	NNP	O
serology	NN	O
.	.	O

Thirty-six	CD	O
out	IN	O
of	IN	O
38	CD	O
(	(	O
94.7	CD	O
%	NN	O
)	)	O
recipients	NNS	O
were	VBD	O
CMV-seropositive	JJ	O
.	.	O

Over	IN	O
the	DT	O
6-month	JJ	O
post-RTx	JJ	O
period	NN	O
,	,	O
there	EX	O
were	VBD	O
13	CD	O
episodes	NNS	O
of	IN	O
CMV	NNP	O
disease	NN	O
in	IN	O
eight	CD	O
(	(	O
66.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
the	DT	O
C	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
and	CC	O
VAL	NNP	O
groups	NNS	O
(	(	O
P=0.0005	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.001	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
CMV	NNP	O
viremia	NN	O
was	VBD	O
30.8	CD	O
%	NN	O
,	,	O
50.0	CD	O
%	NN	O
,	,	O
and	CC	O
91.7	CD	O
%	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.004	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.07	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=NS	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
VAL	NNP	O
)	)	O
.	.	O

Treatment	JJ	O
failure	NN	O
(	(	O
death	NN	O
,	,	O
graft	NN	O
loss	NN	O
,	,	O
CMV	NNP	O
disease	NN	O
,	,	O
or	CC	O
withdrawal	NN	O
from	IN	O
study	NN	O
)	)	O
occurred	VBD	O
in	IN	O
14.3	CD	O
%	NN	O
,	,	O
0	CD	O
%	NN	O
and	CC	O
66.7	CD	O
%	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.014	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.001	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=NS	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
VAL	NNP	O
)	)	O
.	.	O

The	DT	O
average	JJ	O
CMV-associated	JJ	O
costs	NNS	O
per	IN	O
patient	NN	O
(	(	O
in	IN	O
2001	CD	O
euros	NN	O
)	)	O
were	VBD	O
2,449+/-1,178	JJ	O
,	,	O
2,485+/-581	JJ	O
,	,	O
and	CC	O
4,259+/-4,616	JJ	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Ganciclovir	NNP	O
and	CC	O
valacyclovir	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
ganciclovir	JJ	O
having	VBG	O
had	VBD	O
to	TO	O
be	VB	O
withdrawn	VBN	O
shortly	RB	O
in	IN	O
one	CD	O
patient	NN	O
only	RB	O
because	IN	O
of	IN	O
thrombocytopenia	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
oral	JJ	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
are	VBP	O
equally	RB	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
after	IN	O
RTx	NNP	O
.	.	O

Both	DT	O
are	VBP	O
cost-effective	JJ	O
and	CC	O
help	VB	O
reduce	VB	O
CMV-associated	JJ	O
costs	NNS	O
by	IN	O
some	DT	O
40	CD	O
%	NN	O
compared	VBN	O
with	IN	O
patients	NNS	O
without	IN	O
prophylaxis	NN	O
.	.	O

A	DT	O
controlled	VBN	O
comparison	NN	O
between	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
intravenous	JJ	PM
and	CC	PM
intramuscular	JJ	PM
morphine	NN	PM
with	IN	O
respect	NN	O
to	TO	O
analgesic	JJ	O
effects	NNS	O
and	CC	O
patient	JJ	O
safety	NN	O
.	.	O

UNLABELLED	VBN	O
BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
OF	NNP	O
INVESTIGATION	NNP	O
:	:	O
Intramuscular	NNP	O
(	(	O
IM	NNP	O
)	)	O
administration	NN	O
has	VBZ	O
been	VBN	O
considered	VBN	O
to	TO	O
be	VB	O
safer	JJR	O
than	IN	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
for	IN	O
opioids	NNS	PM
on	IN	O
wards	NNS	O
,	,	O
but	CC	O
a	DT	O
comparative	JJ	O
knowledge	NN	O
of	IN	O
patient	JJ	O
safety	NN	O
and	CC	O
analgesic	JJ	O
potency	NN	O
following	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
IV	NNP	O
and	CC	O
IM	NNP	O
administration	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
compare	VB	O
patient	JJ	O
safety	NN	O
and	CC	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
a	DT	O
single	JJ	O
and	CC	O
high	JJ	O
dose	NN	O
of	IN	O
morphine	NN	PM
given	VBN	PM
IM	NNP	PM
or	CC	PM
IV	NNP	PM
for	IN	O
post-operative	JJ	O
pain	NN	O
management	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Thirty-eight	NNP	O
patients	NNS	O
with	IN	O
post-operative	JJ	O
pain	NN	O
following	VBG	O
hip	NN	S
replacement	NN	S
surgery	NN	S
were	VBD	O
given	VBN	O
IM	NNP	PM
or	CC	PM
IV	NNP	PM
morphine	VBP	PM
10	CD	O
mg	NN	O
at	IN	O
a	DT	O
specified	JJ	O
pain	NN	O
level	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
randomized	VBN	O
and	CC	O
double	JJ	O
blinded	VBN	O
.	.	O

Time	NN	O
to	TO	O
onset	VB	O
of	IN	O
analgesic	JJ	O
effect	NN	O
(	(	O
11-point	JJ	O
numeric	NN	O
rating	NN	O
scale	NN	O
)	)	O
,	,	O
respiratory	JJ	O
function	NN	O
(	(	O
p	NN	O
(	(	O
a	DT	O
)	)	O
CO2	NNP	O
,	,	O
p	NN	O
(	(	O
a	DT	O
)	)	O
O2	NNP	O
,	,	O
and	CC	O
respiratory	JJ	O
rate	NN	O
)	)	O
,	,	O
level	NN	O
of	IN	O
sedation	NN	O
(	(	O
5-point	JJ	O
verbal	NN	O
rating	NN	O
scale	NN	O
)	)	O
,	,	O
and	CC	O
hemodynamic	JJ	O
function	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
IV	NNP	O
group	NN	O
there	EX	O
was	VBD	O
a	DT	O
slight	JJ	O
but	CC	O
significant	JJ	O
increase	NN	O
in	IN	O
p	NN	O
(	(	O
a	DT	O
)	)	O
CO2	NNP	O
after	IN	O
5	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
15	CD	O
min	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
IM	NNP	O
group	NN	O
(	(	O
5.2	CD	O
vs.	FW	O
4.8	CD	O
,	,	O
5.4	CD	O
,	,	O
vs.	FW	O
5.0	CD	O
and	CC	O
5.5	CD	O
vs.	FW	O
5.1	CD	O
kPa	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
IV	NNP	O
group	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
faster	RBR	O
onset	NN	O
of	IN	O
analgesic	JJ	O
effect	NN	O
than	IN	O
the	DT	O
IM	NNP	O
group	NN	O
(	(	O
5	CD	O
vs.	FW	O
20	CD	O
min	NN	O
)	)	O
.	.	O

Between	$	O
5	CD	O
and	CC	O
25	CD	O
min	NN	O
after	IN	O
morphine	JJ	PM
administration	NN	O
,	,	O
pain	NN	O
status	NN	O
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
compared	VBN	O
with	IN	O
the	DT	O
IM	NNP	O
group	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
were	VBD	O
slightly	RB	O
more	RBR	O
sedated	JJ	O
than	IN	O
the	DT	O
IM	NNP	O
group	NN	O
5	CD	O
and	CC	O
10	CD	O
min	NN	O
after	IN	O
morphine	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
10	CD	O
mg	NN	O
bolus	NN	O
dose	NN	O
of	IN	O
IV	NNP	O
morphine	NN	O
given	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
moderate	JJ	O
pain	NN	O
after	IN	O
surgery	NN	S
does	VBZ	O
not	RB	O
cause	VB	O
severe	JJ	O
respiratory	NN	O
depression	NN	O
,	,	O
but	CC	O
provides	VBZ	O
more	RBR	O
rapid	JJ	O
and	CC	O
better	RBR	O
initial	JJ	O
analgesia	NN	O
than	IN	O
10	CD	O
mg	NNS	O
given	VBN	O
IM	NNP	O
.	.	O

IV	NNP	O
morphine	VBD	PM
even	RB	O
at	IN	O
a	DT	O
dose	NN	O
as	RB	O
high	JJ	O
as	IN	O
10	CD	O
mg	NN	O
IV	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
certain	JJ	O
level	NN	O
of	IN	O
pain	NN	O
at	IN	O
its	PRP$	O
administration	NN	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
IV	NNP	O
morphine	NN	PM
on	IN	O
the	DT	O
general	JJ	O
ward	NN	O
needs	VBZ	O
to	TO	O
be	VB	O
further	RB	O
explored	VBN	O
in	IN	O
adequately	RB	O
controlled	JJ	O
studies	NNS	O
.	.	O

Postoperative	JJ	O
pain	NN	O
control	NN	O
for	IN	O
outpatient	JJ	O
oral	JJ	O
surgery	NN	O
.	.	O

16	CD	O
healthy	JJ	O
patients	NNS	O
requiring	VBG	O
removal	NN	O
of	IN	O
bilateral	JJ	O
symmetrically-impacted	JJ	O
mandibular	JJ	O
third	JJ	O
molars	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
double-blind	NN	O
randomised	VBN	O
crossover	RB	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
postoperative	JJ	O
pain	NN	O
control	NN	O
using	VBG	O
a	DT	O
long-acting	JJ	O
anti-inflammatory	JJ	O
agent	NN	O
(	(	O
diflunisal	NN	PM
)	)	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
long-acting	JJ	O
local	JJ	O
anaesthetic	JJ	O
agent	NN	O
(	(	PM
bupivacaine	NN	PM
)	)	PM
.	.	O

Results	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
more	RBR	O
traditional	JJ	O
method	NN	O
of	IN	O
using	VBG	O
an	DT	O
oral	JJ	O
analgesic	NN	O
with	IN	O
shorter	JJR	O
duration	NN	O
of	IN	O
action	NN	O
(	(	PM
paracetamol	NN	PM
with	IN	PM
codeine	NN	PM
)	)	PM
with	IN	O
lignocaine	NN	PM
as	IN	O
the	DT	O
local	JJ	O
anaesthetic	NN	O
.	.	O

Using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
pain	NN	O
scale	NN	O
,	,	O
patients	NNS	O
reported	VBD	O
that	IN	O
significantly	RB	O
reduced	VBN	O
pain	NN	O
was	VBD	O
experienced	VBN	O
over	IN	O
the	DT	O
first	JJ	O
4	CD	O
days	NNS	O
postoperatively	RB	O
with	IN	O
the	DT	O
diflunisal/bupivacaine	NN	PM
treatment	NN	PM
and	CC	O
patient	JJ	O
preference	NN	O
for	IN	O
this	DT	O
treatment	NN	O
was	VBD	O
highly	RB	O
significant	JJ	O
.	.	O

This	DT	O
report	NN	O
represents	VBZ	O
the	DT	O
first	JJ	O
such	JJ	O
study	NN	O
of	IN	O
diflunisal	NN	PM
used	VBN	O
for	IN	O
an	DT	O
extended	JJ	O
course	NN	O
in	IN	O
oral	JJ	O
surgery	NN	O
with	IN	O
pain	NN	O
assessment	NN	O
over	IN	O
the	DT	O
same	JJ	O
period	NN	O
.	.	O

No	DT	O
significant	JJ	O
side-effects	NNS	O
or	CC	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
encountered	VBN	O
.	.	O

Comparative	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
calcium	NN	PM
carbasalate	NN	PM
plus	CC	O
metoclopramide	JJ	PM
versus	NN	O
ergotamine	NN	PM
tartrate	NN	PM
plus	CC	O
caffeine	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
migraine	NN	O
attacks	NNS	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
double-dummy	JJ	O
,	,	O
multicenter	NN	O
,	,	O
parallel-group	JJ	O
study	NN	O
aimed	VBN	O
at	IN	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
calcium	NN	PM
carbasalate	NN	PM
(	(	PM
equivalent	JJ	PM
to	TO	PM
900	CD	PM
mg	NNS	PM
aspirin	RB	PM
)	)	PM
plus	CC	O
metoclopramide	$	PM
10	CD	PM
mg	NN	PM
(	(	PM
CM	NNP	PM
)	)	PM
with	IN	O
ergotamine	JJ	PM
tartrate	NN	PM
1	CD	PM
mg	NN	PM
plus	CC	PM
caffeine	JJ	PM
100	CD	PM
mg	NN	PM
(	(	PM
EC	NNP	PM
)	)	PM
administered	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
2	CD	O
acute	JJ	O
migraine	NN	O
attacks	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
296	CD	O
patients	NNS	O
fulfilling	VBG	O
the	DT	O
International	NNP	O
Headache	NNP	O
Society	NNP	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
migraine	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
one	CD	O
or	CC	O
two	CD	O
migraine	NN	O
attacks	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
268	CD	O
and	CC	O
235	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
for	IN	O
the	DT	O
first	JJ	O
treated	VBD	O
attack	NN	O
was	VBD	O
headache	NN	O
relief	NN	O
,	,	O
with	IN	O
intensity	NN	O
decreasing	VBG	O
from	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
to	TO	O
mild	VB	O
or	CC	O
absent	VB	O
2	CD	O
h	NN	O
after	IN	O
drug	NN	O
intake	NN	O
.	.	O

Usual	JJ	O
secondary	JJ	O
efficacy	NN	O
endpoints	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

A	DT	O
superiority	NN	O
of	IN	O
CM	NNP	PM
over	IN	O
EC	NNP	PM
was	VBD	O
observed	VBN	O
for	IN	O
both	DT	O
treated	JJ	O
attacks	NNS	O
for	IN	O
the	DT	O
main	JJ	O
endpoint	NN	O
:	:	O
success	NN	O
in	IN	O
54	CD	O
versus	NN	O
36	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0.003	CD	O
for	IN	O
the	DT	O
first	JJ	O
attack	NN	O
and	CC	O
60	CD	O
versus	NN	O
44	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0.02	CD	O
for	IN	O
the	DT	O
second	JJ	O
attack	NN	O
.	.	O

CM	NNP	PM
was	VBD	O
also	RB	O
significantly	RB	O
superior	JJ	O
to	TO	O
EC	NNP	PM
during	IN	O
the	DT	O
first	JJ	O
attack	NN	O
for	IN	O
complete	JJ	O
headache	NN	O
relief	NN	O
(	(	O
20	CD	O
vs.	FW	O
8	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
nausea	NN	O
(	(	O
42	CD	O
vs.	FW	O
63	CD	O
%	NN	O
,	,	O
p	NN	O
=	VBD	O
0	CD	O
.	.	O

007	CD	O
)	)	O
and	CC	O
willingness	NN	O
to	TO	O
take	VB	O
the	DT	O
drug	NN	O
again	RB	O
(	(	O
90	CD	O
vs.	FW	O
80	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

The	DT	O
global	JJ	O
efficacy	NN	O
evaluation	NN	O
,	,	O
rated	VBN	O
by	IN	O
the	DT	O
investigators	NNS	O
,	,	O
was	VBD	O
significantly	RB	O
more	RBR	O
favorable	JJ	O
to	TO	O
CM	NNP	PM
for	IN	O
both	DT	O
attacks	NNS	O
(	(	O
p	VB	O
=	$	O
0.001	CD	O
for	IN	O
the	DT	O
first	JJ	O
attack	NN	O
and	CC	O
p	NN	O
=	VBP	O
0.02	CD	O
for	IN	O
the	DT	O
second	JJ	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
'	POS	O
evaluation	NN	O
was	VBD	O
significant	JJ	O
for	IN	O
the	DT	O
first	JJ	O
attack	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

The	DT	O
global	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
45	CD	O
%	NN	O
higher	JJR	O
with	IN	O
EC	NNP	PM
,	,	O
though	IN	O
not	RB	O
significant	JJ	O
(	(	O
32	CD	O
vs.	FW	O
22	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.075	CD	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
most	RBS	O
often	RB	O
unspecific	JJ	O
and	CC	O
mild	JJ	O
to	TO	O
moderate	VB	O
in	IN	O
intensity	NN	O
.	.	O

Gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
significantly	RB	O
less	RBR	O
frequent	JJ	O
with	IN	O
CM	NNP	PM
than	IN	O
EC	NNP	O
(	(	O
7	CD	O
vs.	FW	O
21	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
CM	NNP	PM
is	VBZ	O
more	RBR	O
effective	JJ	O
and	CC	O
has	VBZ	O
a	DT	O
better	JJR	O
gastrointestinal	JJ	O
safety	NN	O
than	IN	O
EC	NNP	PM
in	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
attacks	NNS	O
.	.	O

Peripheral	JJ	O
arterial	JJ	O
disease	NN	O
:	:	O
therapeutic	JJ	O
confidence	NN	O
of	IN	O
CT	NNP	Ot
versus	NNP	O
digital	JJ	Ot
subtraction	NN	Ot
angiography	NN	Ot
and	CC	O
effects	NNS	O
on	IN	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
multi-detector	JJ	Ot
row	NN	Ot
computed	VBN	Ot
tomographic	JJ	Ot
(	(	Ot
CT	NNP	Ot
)	)	Ot
angiography	NN	Ot
and	CC	O
digital	JJ	Ot
subtraction	NN	Ot
angiography	NN	Ot
(	(	Ot
DSA	NNP	Ot
)	)	Ot
prior	RB	O
to	TO	O
revascularization	NN	S
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
assessing	VBG	O
recommendations	NNS	O
for	IN	O
additional	JJ	O
imaging	NN	O
and	CC	O
physician	JJ	O
confidence	NN	O
ratings	NNS	O
for	IN	O
chosen	NN	O
therapy	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
73	CD	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
CT	NNP	Ot
angiography	NN	Ot
,	,	O
and	CC	O
72	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
DSA	NNP	PH
.	.	O

Physician	JJ	O
confidence	NN	O
in	IN	O
the	DT	O
treatment	NN	O
decision	NN	O
was	VBD	O
measured	VBN	O
as	IN	O
a	DT	O
continuous	JJ	O
outcome	NN	O
on	IN	O
a	DT	O
scale	NN	O
of	IN	O
0-10	NNP	O
(	(	O
uncertain	JJ	O
to	TO	O
certain	JJ	O
)	)	O
and	CC	O
as	IN	O
a	DT	O
dichotomous	JJ	O
outcome	NN	O
(	(	O
further	JJ	O
imaging	NN	O
recommended	VBD	O
,	,	O
yes	UH	O
or	CC	O
no	DT	O
)	)	O
.	.	O

Mean	JJ	O
confidence	NN	O
scores	NNS	O
and	CC	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
were	VBD	O
compared	VBN	O
between	IN	O
CT	NNP	Ot
and	CC	O
DSA	NNP	Ot
groups	NNS	O
in	IN	O
an	DT	O
intention-to-diagnose-and-treat	JJ	O
analysis	NN	O
.	.	O

To	TO	O
detect	VB	O
trends	NNS	O
in	IN	O
confidence	NN	O
,	,	O
confidence	NN	O
scores	NNS	O
were	VBD	O
plotted	VBN	O
over	IN	O
time	NN	O
,	,	O
and	CC	O
multiple	JJ	O
linear	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
performed	VBN	O
.	.	O

To	TO	O
detect	VB	O
trends	NNS	O
in	IN	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
,	,	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
.	.	O

Data	NNS	O
from	IN	O
eligible	JJ	O
nonrandomized	JJ	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
randomized	VBN	O
groups	NNS	O
was	VBD	O
found	VBN	O
.	.	O

CT	NNP	Ot
had	VBD	O
a	DT	O
lower	JJR	O
confidence	NN	O
score	JJR	O
than	IN	O
did	VBD	O
DSA	NNP	Ot
(	(	O
7.2	CD	O
vs	NN	O
8.2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Further	JJ	O
imaging	NN	O
was	VBD	O
recommended	VBN	O
more	RBR	O
often	RB	O
after	IN	O
CT	NNP	Ot
(	(	O
25	CD	O
of	IN	O
71	CD	O
patients	NNS	O
,	,	O
35	CD	O
%	NN	O
)	)	O
than	IN	O
after	IN	O
DSA	NNP	Ot
(	(	O
nine	CD	O
of	IN	O
66	CD	O
patients	NNS	O
,	,	O
14	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
.	.	O

Analysis	NN	O
of	IN	O
trends	NNS	O
demonstrated	VBN	O
increasing	VBG	O
(	(	O
but	CC	O
not	RB	O
statistically	RB	O
significant	JJ	O
)	)	O
confidence	NN	O
in	IN	O
CT	NNP	Ot
and	CC	O
stable	JJ	O
confidence	NN	O
in	IN	O
DSA	NNP	Ot
.	.	O

No	NNP	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
randomized	VBN	O
and	CC	O
nonrandomized	JJ	O
patients	NNS	O
.	.	O

Among	IN	O
nonrandomized	JJ	O
patients	NNS	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
mean	JJ	O
confidence	NN	O
score	NN	O
(	(	O
8.2	CD	O
vs	NN	O
8.3	CD	O
,	,	O
P	NNP	O
=	NNP	O
.26	NNP	O
)	)	O
was	VBD	O
found	VBN	O
between	IN	O
CT	NNP	Ot
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
and	CC	O
DSA	NNP	Ot
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
With	IN	O
CT	NNP	Ot
angiography	NN	Ot
,	,	O
physician	JJ	O
confidence	NN	O
decreases	NNS	O
with	IN	O
an	DT	O
associated	JJ	O
increase	NN	O
in	IN	O
additional	JJ	O
imaging	NN	O
prior	RB	O
to	TO	O
revascularization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

Given	VBN	O
that	IN	O
CT	NNP	Ot
is	VBZ	O
less	RBR	O
invasive	JJ	O
than	IN	O
DSA	NNP	Ot
,	,	O
results	NNS	O
suggest	VBP	O
that	IN	O
CT	NNP	Ot
may	MD	O
replace	VB	O
DSA	NNP	Ot
in	IN	O
selected	VBN	O
cases	NNS	O
.	.	O

Chronology	NN	O
of	IN	O
panic	NN	O
and	CC	O
avoidance	NN	O
,	,	O
age	NN	O
of	IN	O
onset	NN	O
in	IN	O
panic	JJ	O
disorder	NN	O
,	,	O
and	CC	O
prediction	NN	O
of	IN	O
treatment	NN	O
response	NN	O
.	.	O

A	DT	O
report	NN	O
from	IN	O
the	DT	O
Cross-National	JJ	O
Collaborative	NNP	O
Panic	NNP	O
Study	NNP	O
.	.	O

The	DT	O
relevance	NN	O
of	IN	O
the	DT	O
chronology	NN	O
between	IN	O
panic	JJ	O
disorder	NN	O
and	CC	O
avoidance	NN	O
behavior	NN	O
and	CC	O
of	IN	O
an	DT	O
early	JJ	O
,	,	O
medium	NN	O
or	CC	O
late	JJ	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
was	VBD	O
tested	VBN	O
.	.	O

Groups	NNP	O
from	IN	O
the	DT	O
sample	NN	O
of	IN	O
the	DT	O
cross-national	JJ	E
collaborative	NN	E
panic	NN	E
study	NN	E
(	(	O
CNCPS	NNP	O
)	)	O
were	VBD	O
compared	VBN	O
for	IN	O
differences	NNS	O
in	IN	O
basic	JJ	O
characteristics	NNS	O
and	CC	O
for	IN	O
the	DT	O
ability	NN	O
to	TO	O
predict	VB	O
treatment	NN	O
response	NN	O
.	.	O

Patients	NNS	O
who	WP	O
developed	VBD	O
avoidance	NN	O
behavior	NN	O
before	IN	O
the	DT	O
full	JJ	O
syndrome	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
had	VBD	O
less	RBR	O
often	RB	O
a	DT	O
full	JJ	O
agoraphobia	NN	O
but	CC	O
were	VBD	O
not	RB	O
different	JJ	O
in	IN	O
their	PRP$	O
response	NN	O
to	TO	O
treatment	NN	PM
.	.	O

Patients	NNS	O
with	IN	O
an	DT	O
early	JJ	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
suffered	VBD	O
more	RBR	O
often	RB	O
from	IN	O
agoraphobia	NNS	O
.	.	O

The	DT	O
treatment	NN	PM
response	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
groups	NNS	O
with	IN	O
early	JJ	O
,	,	O
medium	NN	O
or	CC	O
late	JJ	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
.	.	O

Neither	CC	O
the	DT	O
chronology	NN	O
between	IN	O
panic	JJ	O
disorder	NN	O
and	CC	O
avoidance	NN	O
behavior	NN	O
nor	CC	O
the	DT	O
age	NN	O
of	IN	O
onset	NN	O
of	IN	O
panic	JJ	O
disorder	NN	O
predicted	VBD	O
outcome	NN	O
in	IN	O
short-term	JJ	PM
treatment	NN	PM
with	IN	PM
alprazolam	NN	PM
or	CC	O
imipramine	NN	PM
.	.	O

Adult	NNP	O
height	NN	O
in	IN	O
short	JJ	O
children	NNS	O
born	VBN	O
SGA	NNP	O
treated	VBD	O
with	IN	O
growth	NN	PM
hormone	NN	PM
and	CC	O
gonadotropin	NN	PM
releasing	VBG	PM
hormone	NN	PM
analog	NN	PM
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
dose-response	JJ	O
GH	NNP	PM
trial	NN	O
.	.	O

CONTEXT	NNP	O
GH	NNP	PM
treatment	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
improving	VBG	O
height	NN	O
in	IN	O
short	JJ	O
children	NNS	O
born	VBP	O
small	JJ	O
for	IN	O
gestational	JJ	O
age	NN	O
(	(	O
SGA	NNP	O
)	)	O
.	.	O

GH	NNP	O
is	VBZ	O
thought	VBN	O
to	TO	O
have	VB	O
limited	VBN	O
effect	NN	O
when	WRB	O
started	VBD	O
during	IN	O
adolescence	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
GH	NNP	PM
treatment	NN	O
efficacy	NN	O
in	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
when	WRB	O
treatment	NN	O
was	VBD	O
started	VBN	O
during	IN	O
adolescence	NN	O
;	:	O
to	TO	O
assess	VB	O
whether	IN	O
GH	NNP	PM
2	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	JJ	O
improves	NNS	O
adult	VBP	O
height	NN	O
(	(	O
AH	NNP	O
)	)	O
compared	VBN	O
with	IN	O
1	CD	O
mg/m	NNS	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
;	:	O
and	CC	O
to	TO	O
assess	VB	O
whether	IN	O
an	DT	O
additional	JJ	O
2-yr	JJ	O
postponement	NN	O
of	IN	O
puberty	NN	O
by	IN	O
GnRH	NNP	O
analog	NN	O
(	(	O
GnRHa	NNP	O
)	)	O
improves	VBZ	O
AH	NNP	O
in	IN	O
children	NNS	O
who	WP	O
are	VBP	O
short	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
puberty	NN	O
(	(	O
<	JJ	O
140	CD	O
cm	NN	O
)	)	O
,	,	O
with	IN	O
a	DT	O
poor	JJ	O
AH	NNP	O
expectation	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
DESIGN	NNP	O
In	IN	O
this	DT	O
longitudinal	JJ	O
,	,	O
randomized	VBN	O
,	,	O
dose-response	JJ	O
GH	NNP	O
trial	NN	O
,	,	O
we	PRP	O
included	VBD	O
121	CD	O
short	JJ	O
SGA	NNP	O
children	NNS	O
(	(	O
60	CD	O
boys	NNS	O
)	)	O
at	IN	O
least	JJS	O
8	CD	O
yr	NN	O
of	IN	O
age	NN	O
.	.	O

We	PRP	O
performed	VBD	O
intention-to-treat	JJ	O
analyses	NNS	O
on	IN	O
all	DT	O
children	NNS	O
and	CC	O
uncensored	JJ	O
case	NN	O
analyses	VBZ	O
on	IN	O
84	CD	O
children	NNS	O
who	WP	O
reached	VBD	O
AH	NNP	O
.	.	O

Besides	NNP	O
,	,	O
we	PRP	O
evaluated	VBD	O
growth	NN	O
during	IN	O
2	CD	O
yr	NNS	O
of	IN	O
combined	JJ	O
GH/GnRHa	NNP	O
and	CC	O
subsequent	JJ	O
GH	NNP	O
treatment	NN	O
until	IN	O
AH	NNP	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
40	CD	O
pubertal	JJ	O
children	NNS	O
with	IN	O
a	DT	O
height	NN	O
of	IN	O
less	JJR	O
than	IN	O
140	CD	O
cm	NN	O
at	IN	O
the	DT	O
start	NN	O
.	.	O

RESULTS	NNP	O
Short	NNP	O
SGA	NNP	O
children	NNS	O
started	VBD	O
treatment	NN	O
at	IN	O
a	DT	O
median	JJ	O
age	NN	O
of	IN	O
11.2	CD	O
yr	NNS	O
,	,	O
when	WRB	O
46	CD	O
%	NN	O
had	VBD	O
already	RB	O
started	VBN	O
puberty	NN	O
.	.	O

Median	JJ	O
height	NN	O
increased	VBD	O
from	IN	O
-2.9	NN	O
at	IN	O
start	NN	O
to	TO	O
-1.7	VB	O
sd	NN	O
score	NN	O
(	(	O
SDS	NNP	O
)	)	O
at	IN	O
AH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
GH	NNP	O
2	CD	O
vs.	FW	O
1	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	NN	O
resulted	VBD	O
in	IN	O
significantly	RB	O
better	JJR	O
AH	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
also	RB	O
after	IN	O
correction	NN	O
for	IN	O
gender	NN	O
,	,	O
age	NN	O
at	IN	O
start	NN	O
,	,	O
height	VBD	O
SDS	NNP	O
at	IN	O
start	NN	O
,	,	O
treatment	NN	O
years	NNS	O
before	IN	O
puberty	NN	O
,	,	O
and	CC	O
target	VB	O
height	JJ	O
SDS	NNP	O
.	.	O

AH	NNP	O
was	VBD	O
similar	JJ	O
in	IN	O
children	NNS	O
who	WP	O
started	VBD	O
puberty	NN	O
at	IN	O
less	JJR	O
than	IN	O
140	CD	O
cm	NN	O
and	CC	O
received	VBD	O
GH/GnRHa	NNP	O
,	,	O
compared	VBN	O
with	IN	O
children	NNS	O
who	WP	O
started	VBD	O
puberty	NN	O
greater	JJR	O
than	IN	O
140	CD	O
cm	NN	O
and	CC	O
received	VBD	O
GH	NNP	O
only	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.795	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
started	VBN	O
in	IN	O
adolescence	NN	O
,	,	O
GH	NNP	O
treatment	NN	O
significantly	RB	O
improves	VBZ	O
AH	NNP	O
in	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
,	,	O
particularly	RB	O
with	IN	O
GH	NNP	O
2	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
?	.	O
d	NN	O
during	IN	O
puberty	NN	O
.	.	O

When	WRB	O
SGA	NNP	O
children	NNS	O
are	VBP	O
short	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
puberty	NN	O
,	,	O
they	PRP	O
can	MD	O
benefit	VB	O
from	IN	O
combined	JJ	O
GH/GnRHa	NNP	O
treatment	NN	O
.	.	O

The	DT	O
11-beta-hydroxysteroid	JJ	O
dehydrogenase	NN	O
type	NN	O
1	CD	O
inhibitor	NN	O
INCB13739	NNP	PM
improves	VBZ	O
hyperglycemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
metformin	NN	O
monotherapy	NN	O
.	.	O

OBJECTIVE	CC	O
11-Beta-hydroxysteroid	JJ	O
dehydrogenase	NN	O
type	NN	O
1	CD	O
(	(	O
11betaHSD1	CD	O
)	)	O
converts	NNS	O
inactive	JJ	O
cortisone	NN	O
into	IN	O
active	JJ	O
cortisol	NN	O
,	,	O
thereby	RB	O
amplifying	VBG	O
intracellular	JJ	O
glucocorticoid	JJ	O
action	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
11betaHSD1	CD	O
inhibitor	NN	O
INCB13739	NNP	O
were	VBD	O
assessed	VBN	O
when	WRB	O
added	VBN	O
to	TO	O
ongoing	VBG	O
metformin	NN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
exhibiting	VBG	O
inadequate	JJ	O
glycemic	NNS	O
control	NN	O
(	(	O
A1C	NNP	O
7-11	CD	O
%	NN	O
)	)	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
This	DT	O
double-blind	JJ	O
placebo-controlled	JJ	C
paralleled	VBN	O
study	NN	O
randomized	VBD	O
302	CD	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
(	(	O
mean	JJ	O
A1C	NNP	O
8.3	CD	O
%	NN	O
)	)	O
on	IN	O
metformin	NN	PM
monotherapy	NN	PM
(	(	O
mean	JJ	O
1.5	CD	O
g/day	NN	O
)	)	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
five	CD	O
INCB13739	NNP	PM
doses	NNS	PM
or	CC	O
placebo	NN	C
once	RB	O
daily	JJ	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
change	NN	O
in	IN	O
A1C	NNP	O
at	IN	O
study	JJ	O
end	NN	O
.	.	O

Other	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
changes	NNS	O
in	IN	O
fasting	VBG	O
glucose	NN	O
,	,	O
lipids	NNS	O
,	,	O
weight	NN	O
,	,	O
adverse	JJ	O
events	NNS	O
,	,	O
and	CC	O
safety	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
200	CD	O
mg	NN	O
of	IN	O
INCB13739	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
A1C	NNP	O
(	(	O
-0.6	NNP	O
%	NN	O
)	)	O
,	,	O
fasting	VBG	O
plasma	NN	O
glucose	NN	O
(	(	O
-24	NNP	O
mg/dl	NN	O
)	)	O
,	,	O
and	CC	O
homeostasis	NN	O
model	NN	O
assessment-insulin	JJ	O
resistance	NN	O
(	(	O
HOMA-IR	NNP	O
)	)	O
(	(	O
-24	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Total	JJ	O
cholesterol	NN	O
,	,	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
and	CC	O
triglycerides	NNS	O
were	VBD	O
all	DT	O
significantly	RB	O
decreased	VBN	O
in	IN	O
hyperlipidemic	JJ	O
patients	NNS	O
.	.	O

Body	NNP	O
weight	VBD	O
decreased	JJ	O
relative	NN	O
to	TO	O
placebo	VB	O
after	IN	O
INCB13739	NNP	O
therapy	NN	O
.	.	O

A	DT	O
reversible	JJ	O
dose-dependent	JJ	O
elevation	NN	O
in	IN	O
adrenocorticotrophic	JJ	O
hormone	NN	O
,	,	O
generally	RB	O
within	IN	O
the	DT	O
normal	JJ	O
reference	NN	O
range	NN	O
,	,	O
was	VBD	O
observed	VBN	O
.	.	O

Basal	NNP	O
cortisol	JJ	O
homeostasis	NN	O
,	,	O
testosterone	NN	O
in	IN	O
men	NNS	O
,	,	O
and	CC	O
free	JJ	O
androgen	NN	O
index	NN	O
in	IN	O
women	NNS	O
were	VBD	O
unchanged	JJ	O
by	IN	O
INCB13739	NNP	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
similar	JJ	O
across	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
INCB13739	NNP	O
added	VBD	O
to	TO	O
ongoing	VBG	O
metformin	NN	O
therapy	NN	O
was	VBD	O
efficacious	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
who	WP	O
had	VBD	O
inadequate	JJ	O
glycemic	NNS	O
control	NN	O
with	IN	O
metformin	NN	O
alone	RB	O
.	.	O

11BetaHSD1	CD	O
inhibition	NN	O
offers	NNS	O
a	DT	O
new	JJ	O
potential	JJ	O
approach	NN	O
to	TO	O
control	VB	O
glucose	JJ	O
and	CC	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

Cancer	NNP	O
information	NN	O
and	CC	O
anxiety	NN	O
:	:	O
applying	VBG	O
the	DT	O
extended	JJ	O
parallel	NN	O
process	NN	O
model	NN	O
.	.	O

There	EX	O
is	VBZ	O
concern	NN	O
that	IN	O
public	JJ	O
education	NN	O
about	IN	O
testicular	JJ	O
cancer	NN	O
(	(	O
TC	NNP	O
)	)	O
may	MD	O
cause	VB	O
unnecessary	JJ	O
anxiety	NN	O
.	.	O

Psychological	JJ	O
theory	NN	O
suggests	VBZ	O
that	IN	O
if	IN	O
threat	NN	O
(	(	O
eg	JJ	O
,	,	O
TC	NNP	O
)	)	O
information	NN	O
is	VBZ	O
accompanied	VBN	O
with	IN	O
threat	NN	O
control	NN	O
strategies	NNS	O
(	(	O
eg	NN	O
,	,	O
testicular	JJ	PH
self-examination	NN	PH
;	:	E
TSE	NNP	O
)	)	O
anxiety	NN	O
is	VBZ	O
less	RBR	O
likely	JJ	O
.	.	O

Male	JJ	O
students	NNS	O
(	(	O
N=443	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	VB	O
a	DT	O
TC	NNP	E
or	CC	PH
TC	NNP	E
+TSE	NNP	E
information	NN	E
group	NN	E
or	CC	PH
a	DT	PH
no	DT	C
information	NN	C
control	NN	C
group	NN	O
,	,	O
and	CC	O
assessed	VBD	O
at	IN	O
three	CD	O
time	NN	O
points	NNS	O
.	.	O

Anxiety	NN	O
levels	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
groups	NNS	O
and	CC	O
exposure	NN	O
to	TO	O
TC+TSE	NNP	O
resulted	VBD	O
in	IN	O
greater	JJR	O
perceived	JJ	O
message	NN	O
benefit	NN	O
,	,	O
increased	VBN	O
intention	NN	O
to	TO	O
self-examine	NN	O
and	CC	O
lower	JJR	O
message	NN	O
denigration	NN	O
.	.	O

This	DT	O
suggests	VBZ	O
TC	NNP	E
information	NN	O
is	VBZ	O
not	RB	O
anxiogenic	JJ	O
,	,	O
but	CC	O
inclusion	NN	O
of	IN	O
TSE	NNP	O
information	NN	O
may	MD	O
improve	VB	O
acceptance	NN	O
of	IN	O
disease	NN	O
awareness	NN	O
information	NN	O
.	.	O

Long-term	JJ	O
follow-up	NN	O
of	IN	O
a	DT	O
phase	NN	O
I/II	NNP	O
randomized	VBD	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
of	IN	O
palifermin	NN	PM
to	TO	O
prevent	VB	O
graft-versus-host	JJ	O
disease	NN	O
(	(	O
GVHD	NNP	O
)	)	O
after	IN	O
related	VBN	O
donor	NN	O
allogeneic	NN	O
hematopoietic	JJ	O
cell	NN	O
transplantation	NN	O
(	(	O
HCT	NNP	O
)	)	O
.	.	O

We	PRP	O
previously	RB	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
conducted	VBN	O
from	IN	O
2000	CD	O
to	TO	O
2003	CD	O
of	IN	O
palifermin	NN	PM
,	,	O
a	DT	O
recombinant	JJ	O
human	JJ	O
keratinocyte	NN	O
growth	NN	O
factor	NN	O
,	,	O
dosed	VBN	O
from	IN	O
240	CD	O
microg/kg	NNS	O
to	TO	O
720	CD	O
microg/kg	NN	O
,	,	O
in	IN	O
100	CD	O
allogeneic	JJ	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
HCT	NNP	O
)	)	O
recipients	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
palifermin	NN	PM
showed	VBD	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
mucositis	NN	O
,	,	O
but	CC	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
engraftment	NN	O
,	,	O
acute	JJ	O
graft-versus-host	JJ	O
disease	NN	O
(	(	O
GVHD	NNP	O
)	)	O
,	,	O
or	CC	O
early	JJ	O
survival	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
effect	NN	O
of	IN	O
palifermin	NN	PM
on	IN	O
mucosa	NN	O
,	,	O
other	JJ	O
pleotrophic	JJ	O
effects	NNS	O
,	,	O
including	VBG	O
more	RBR	O
rapid	JJ	O
immune	JJ	O
reconstitution	NN	O
,	,	O
have	VBP	O
been	VBN	O
seen	VBN	O
in	IN	O
experimental	JJ	O
transplant	NN	O
models	NNS	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
with	IN	O
longer	JJR	O
follow-up	NN	O
we	PRP	O
could	MD	O
detect	VB	O
additional	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
palifermin-treated	JJ	PM
and	CC	O
placebo	JJ	C
cohorts	NNS	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
CMV	NNP	O
or	CC	O
invasive	JJ	O
fungal	JJ	O
infections	NNS	O
,	,	O
chronic	JJ	O
GVHD	NNP	O
,	,	O
or	CC	O
long-term	JJ	O
survival	NN	O
between	IN	O
cohorts	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
palifermin	NN	PM
appear	VBP	O
primarily	RB	O
to	TO	O
be	VB	O
limited	VBN	O
to	TO	O
ameliorating	VBG	O
mucotoxicity	NN	O
when	WRB	O
given	VBN	O
to	TO	O
allogeneic	VB	O
HCT	NNP	O
recipients	NNS	O
.	.	O

The	DT	O
interobserver	JJ	O
variability	NN	O
of	IN	O
digital	JJ	PH
rectal	JJ	PH
examination	NN	PH
in	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
trial	NN	O
for	IN	O
the	DT	O
screening	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
analyze	VB	O
to	TO	O
what	WP	O
extent	VB	O
the	DT	O
percentage	NN	O
of	IN	O
suspicious	JJ	O
digital	JJ	PH
rectal	JJ	PH
examination	NN	PH
(	(	PH
DRE	NNP	PH
)	)	PH
findings	NNS	O
vary	VBP	O
between	IN	O
examiners	NNS	O
and	CC	O
to	TO	O
what	WP	O
extent	VB	O
the	DT	O
percentage	NN	O
of	IN	O
prostate	NN	O
cancers	NNS	O
(	(	O
PCs	NNS	O
)	)	O
detected	VBN	O
in	IN	O
men	NNS	O
with	IN	O
these	DT	O
suspicious	JJ	O
findings	NNS	O
varies	NNS	O
between	IN	O
examiners	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
the	DT	O
first	JJ	O
screening	NN	O
round	NN	O
of	IN	O
the	DT	O
European	NNP	O
Randomized	NNP	O
study	NN	O
of	IN	O
Screening	VBG	O
for	IN	O
PC	NN	O
(	(	O
ERSPC	NNP	O
)	)	O
Rotterdam	NNP	O
,	,	O
7,280	CD	O
men	NNS	O
underwent	VBD	O
a	DT	O
PSA-determination	NN	PH
and	CC	PH
DRE	NNP	PH
of	IN	PH
whom	WP	PH
2,102	CD	PH
underwent	JJ	PH
prostate	NN	PH
biopsy	NN	PH
(	(	O
biopsy	JJ	O
indication	NN	O
PSA	NNP	O
>	NNP	O
or	CC	O
=	$	O
4.0	CD	O
ng/ml	JJ	O
and/or	RB	O
suspicious	JJ	O
DRE	NNP	O
and/or	NN	O
TRUS	NNP	O
)	)	O
.	.	O

Descriptive	JJ	O
statistics	NNS	O
of	IN	O
DRE-outcome	NNP	O
per	IN	O
PSA-range	NNP	O
were	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
observer	JJ	O
variability	NN	O
of	IN	O
six	CD	O
examiners	NNS	O
.	.	O

Because	IN	O
this	DT	O
analysis	NN	O
did	VBD	O
not	RB	O
correct	VB	O
properly	RB	O
for	IN	O
other	JJ	O
predictors	NNS	O
of	IN	O
a	DT	O
suspicious	JJ	O
DRE	NNP	O
(	(	O
PSA-level	NNP	O
,	,	O
biopsy	NN	O
indication	NN	O
,	,	O
TRUS-outcome	NNP	O
,	,	O
prostate	NN	O
volume	NN	O
and	CC	O
age	NN	O
)	)	O
,	,	O
a	DT	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
controlling	VBG	O
for	IN	O
these	DT	O
explanatory	JJ	O
variables	NNS	O
was	VBD	O
performed	VBN	O
as	RB	O
well	RB	O
.	.	O

RESULTS	NNP	O
In	IN	O
2,102	CD	O
men	NNS	O
biopsied	VBD	O
,	,	O
443	CD	O
PCs	NNS	O
were	VBD	O
detected	VBN	O
(	(	O
PPV	NNP	O
=	RB	O
21	CD	O
%	NN	O
)	)	O
.	.	O

For	IN	O
all	DT	O
PSA	NNP	O
levels	NNS	O
the	DT	O
percentage	NN	O
suspicious	JJ	O
DRE	NNP	O
varied	VBD	O
between	IN	O
examiners	NNS	O
from	IN	O
4	CD	O
%	NN	O
to	TO	O
28	CD	O
%	NN	O
and	CC	O
percentage	NN	O
PC	NN	O
detected	VBN	O
in	IN	O
men	NNS	O
with	IN	O
a	DT	O
suspicious	JJ	O
DRE	NNP	O
varied	VBD	O
from	IN	O
18	CD	O
%	NN	O
to	TO	O
36	CD	O
%	NN	O
.	.	O

Logistic	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
three	CD	O
of	IN	O
six	CD	O
examiners	NNS	O
considered	VBN	O
DRE	NNP	PH
significantly	RB	O
more	RBR	O
often	RB	O
abnormal	JJ	O
than	IN	O
others	NNS	O
(	(	O
ORs	NNP	O
3.48	CD	O
,	,	O
2.80	CD	O
,	,	O
2.47	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

For	IN	O
all	DT	O
examiners	NNS	O
the	DT	O
odds	NNS	O
to	TO	O
have	VB	O
PC	NN	O
was	VBD	O
statistically	RB	O
significantly	RB	O
higher	JJR	O
in	IN	O
case	NN	O
of	IN	O
a	DT	O
suspicious	JJ	O
DRE	NNP	O
(	(	O
ORs	NNP	O
2.21-5.96	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

This	DT	O
increased	VBD	O
chance	NN	O
to	TO	O
find	VB	O
PC	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
observer-dependent	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Three	CD	O
of	IN	O
six	CD	O
examiners	NNS	O
considered	VBN	O
DRE	NNP	PH
significantly	RB	O
more	RBR	O
often	RB	O
suspicious	JJ	O
than	IN	O
the	DT	O
others	NNS	O
.	.	O

However	RB	O
,	,	O
under	IN	O
equal	JJ	O
circumstances	NNS	O
a	DT	O
suspicious	JJ	O
DRE	NNP	O
executed	VBN	O
by	IN	O
each	DT	O
examiner	NN	O
increased	VBD	O
the	DT	O
chance	NN	O
of	IN	O
the	DT	O
presence	NN	O
of	IN	O
PC	NNP	O
similarly	RB	O
.	.	O

Avatar	NNP	O
assistant	NN	O
:	:	O
improving	VBG	O
social	JJ	O
skills	NNS	O
in	IN	O
students	NNS	O
with	IN	O
an	DT	O
ASD	NNP	O
through	IN	O
a	DT	O
computer-based	JJ	E
intervention	NN	E
.	.	O

This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
FaceSay	NNP	E
,	,	E
a	DT	E
computer-based	JJ	E
social	JJ	E
skills	NNS	E
training	VBG	E
program	NN	E
for	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	VBN	O
study	NN	O
(	(	O
N	NNP	O
=	NNP	O
49	CD	O
)	)	O
indicates	VBZ	O
that	IN	O
providing	VBG	O
children	NNS	O
with	IN	O
low-functioning	JJ	O
autism	NN	O
(	(	O
LFA	NNP	O
)	)	O
and	CC	O
high	JJ	O
functioning	NN	O
autism	NN	O
(	(	O
HFA	NNP	O
)	)	O
opportunities	VBZ	O
to	TO	O
practice	NN	O
attending	VBG	O
to	TO	O
eye	NN	O
gaze	NN	O
,	,	O
discriminating	VBG	O
facial	JJ	O
expressions	NNS	O
and	CC	O
recognizing	VBG	O
faces	VBZ	O
and	CC	O
emotions	NNS	O
in	IN	O
FaceSay	NNP	O
's	POS	O
structured	JJ	O
environment	NN	O
with	IN	O
interactive	JJ	O
,	,	O
realistic	JJ	O
avatar	NN	O
assistants	NNS	O
improved	VBD	O
their	PRP$	O
social	JJ	O
skills	NNS	O
abilities	NNS	O
.	.	O

The	DT	O
children	NNS	O
with	IN	O
LFA	NNP	O
demonstrated	VBD	O
improvements	NNS	O
in	IN	O
two	CD	O
areas	NNS	O
of	IN	O
the	DT	O
intervention	NN	O
:	:	O
emotion	NN	O
recognition	NN	O
and	CC	O
social	JJ	O
interactions	NNS	O
.	.	O

The	DT	O
children	NNS	O
with	IN	O
HFA	NNP	O
demonstrated	VBD	O
improvements	NNS	O
in	IN	O
all	DT	O
three	CD	O
areas	NNS	O
:	:	O
facial	JJ	O
recognition	NN	O
,	,	O
emotion	NN	O
recognition	NN	O
,	,	O
and	CC	O
social	JJ	O
interactions	NNS	O
.	.	O

These	DT	O
findings	NNS	O
,	,	O
particularly	RB	O
the	DT	O
measured	JJ	O
improvements	NNS	O
to	TO	O
social	JJ	O
interactions	NNS	O
in	IN	O
a	DT	O
natural	JJ	O
environment	NN	O
,	,	O
are	VBP	O
encouraging	VBG	O
.	.	O

Effects	NNS	O
of	IN	O
creatine	JJ	PM
supplementation	NN	PM
on	IN	O
repetitive	JJ	O
sprint	NN	O
performance	NN	O
and	CC	O
body	NN	O
composition	NN	O
in	IN	O
competitive	JJ	O
swimmers	NNS	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
and	CC	O
randomized	JJ	O
manner	NN	O
,	,	O
18	CD	O
male	NN	O
and	CC	O
female	JJ	O
junior	JJ	O
competitive	JJ	O
swimmers	NNS	O
supplemented	VBD	O
their	PRP$	O
diets	NNS	O
with	IN	O
21	CD	O
g.day-1	NN	O
of	IN	O
creatine	NN	PM
monohydrate	NN	PM
(	(	PM
Cr	NNP	PM
)	)	PM
or	CC	O
a	DT	O
maltodextrin	JJ	PM
placebo	NN	PM
(	(	PM
P	NNP	PM
)	)	PM
for	IN	O
9	CD	O
days	NNS	O
during	IN	O
training	NN	O
.	.	O

Prior	NNP	O
to	TO	O
and	CC	O
following	VBG	O
supplementation	NN	O
,	,	O
subjects	NNS	O
performed	VBD	O
three	CD	O
100-m	JJ	O
freestyle	JJ	O
sprint	NN	O
swims	NNS	O
(	(	O
long	JJ	O
course	NN	O
)	)	O
with	IN	O
60	CD	O
s	JJ	O
rest/recovery	NN	O
between	IN	O
heats	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
subjects	NNS	O
performed	VBD	O
three	CD	O
20-s	JJ	O
arm	NN	O
ergometer	NN	O
maximal-effort	JJ	O
sprint	NN	O
tests	NNS	O
in	IN	O
the	DT	O
prone	NN	O
position	NN	O
with	IN	O
60	CD	O
s	JJ	O
rest/recovery	NN	O
between	IN	O
sprint	NN	O
tests	NNS	O
.	.	O

Significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
among	IN	O
swim	JJ	O
times	NNS	O
,	,	O
with	IN	O
Cr	NNP	O
subjects	NNS	O
swimming	VBG	O
significantly	RB	O
faster	RBR	O
than	IN	O
P	NNP	O
subjects	NNS	O
following	VBG	O
supplementation	NN	O
in	IN	O
Heat	NNP	O
1	CD	O
and	CC	O
significantly	RB	O
decreasing	VBG	O
swim	JJ	O
time	NN	O
in	IN	O
the	DT	O
second	JJ	O
100-m	JJ	O
sprint	NN	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
some	DT	O
evidence	NN	O
that	IN	O
cumulative	JJ	O
time	NN	O
to	TO	O
perform	VB	O
the	DT	O
three	CD	O
100-m	JJ	O
swims	NNS	O
was	VBD	O
decreased	VBN	O
in	IN	O
the	DT	O
Cr	NNP	O
group	NN	O
.	.	O

Results	NNP	O
indicate	VBP	O
that	IN	O
9	CD	O
days	NNS	O
of	IN	O
Cr	NNP	PM
supplementation	NN	O
during	IN	O
swim	JJ	O
training	NN	O
may	MD	O
provide	VB	O
some	DT	O
ergogenic	JJ	O
value	NN	O
to	TO	O
competitive	JJ	O
junior	JJ	O
swimmers	NNS	O
during	IN	O
repetitive	JJ	O
sprint	NN	O
performance	NN	O
.	.	O

[	JJ	O
Myocardial	NNP	O
ischemia	NN	O
with	IN	O
stable	JJ	O
angina	JJ	O
pectoris	NN	O
:	:	O
clinico-ergometric	JJ	O
evaluation	NN	O
after	IN	O
the	DT	O
use	NN	O
of	IN	O
diltiazem	NN	PM
]	NN	PM
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
diltiazem	JJ	PM
versus	NN	O
placebo	NN	C
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NN	O
.	.	O

METHODS	NNP	O
Eight-seven	JJ	O
angina	NNS	O
pectoris	JJ	O
patients	NNS	O
,	,	O
mean	JJ	O
age	NN	O
of	IN	O
57	CD	O
+/-	JJ	O
9	CD	O
,	,	O
82	CD	O
white	JJ	O
and	CC	O
79	CD	O
male	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
of	IN	O
two	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
diltiazem	JJ	PM
and	CC	O
placebo	NN	C
,	,	O
3	CD	O
to	TO	O
4	CD	O
tablets	NNS	O
a	DT	O
day	NN	O
(	(	O
diltiazem	JJ	PM
180	CD	O
to	TO	O
240	CD	O
mg	NNS	O
daily	RB	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
after	IN	O
laboratory	NN	O
tests	NNS	O
and	CC	O
clinical-ergometric	JJ	O
examinations	NNS	O
.	.	O

A	DT	O
coronary	JJ	O
arteriography	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
study	NN	O
entry	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	NN	O
of	IN	O
anginal	JJ	O
attacks	NNS	O
,	,	O
number	NN	O
of	IN	O
weekly	JJ	O
sublingual	JJ	O
nitrate	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
pressure	NN	O
at	IN	O
rest	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
diltiazem	JJ	O
period	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
regarding	VBG	O
same	JJ	O
periods	NNS	O
on	IN	O
placebo	NN	C
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
depression	NN	O
for	IN	O
ST-segment	NNP	O
was	VBD	O
lower	JJR	O
for	IN	O
diltiazem	NN	PM
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	C
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
that	WDT	O
reach	VBP	O
higher	JJR	O
stages	NNS	O
in	IN	O
the	DT	O
ergometric	JJ	O
test	NN	O
was	VBD	O
significantly	RB	O
better	JJR	O
for	IN	O
diltiazem	NN	PM
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
systolic	JJ	O
plus	CC	O
diastolic	JJ	O
pressures	NNS	O
after	IN	O
exercise	NN	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Diltiazem	NNP	PM
reduced	VBD	O
the	DT	O
clinical	JJ	O
and	CC	O
electrocardiographical	JJ	O
aspects	NNS	O
and	CC	O
raises	VBZ	O
the	DT	O
effort	NN	O
tolerance	NN	O
during	IN	O
the	DT	O
ergometric	JJ	O
test	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NN	O
.	.	O

Application	NN	O
of	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
to	TO	O
clinical	JJ	O
therapeutic	JJ	O
decisions	NNS	O
in	IN	O
hypertension	NN	O
.	.	O

The	DT	O
antihypertensive	JJ	O
efficacies	NNS	O
of	IN	O
lisinopril	NN	PM
and	CC	O
captopril	NN	PM
were	VBD	O
compared	VBN	O
using	VBG	O
office	NN	O
sphygmomanometry	NN	O
and	CC	O
24-h	JJ	O
ambulatory	NN	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
prospective	JJ	O
,	,	O
randomly	RB	O
allocated	VBN	O
trial	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
increasing	VBG	O
doses	NNS	O
of	IN	O
captopril	NN	PM
at	IN	O
25-100	JJ	O
mg	NN	O
twice	RB	O
a	DT	O
day	NN	O
or	CC	O
lisinopril	NN	PM
at	IN	O
10-40	JJ	O
mg	NN	O
once	IN	O
a	DT	O
day	NN	O
until	IN	O
a	DT	O
clinical	JJ	O
response	NN	O
was	VBD	O
achieved	VBN	O
or	CC	O
the	DT	O
highest	JJS	O
dose	NN	O
was	VBD	O
reached	VBN	O
.	.	O

A	DT	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
reduction	NN	O
in	IN	O
diastolic	JJ	O
pressure	NN	O
below	IN	O
90	CD	O
mmHg	NN	O
or	CC	O
a	DT	O
fall	NN	O
of	IN	O
at	IN	O
least	JJS	O
10	CD	O
mmHg	NN	O
from	IN	O
baseline	NN	O
.	.	O

The	DT	O
ambulatory	NN	O
monitoring	NN	O
showed	VBD	O
that	IN	O
lisinopril	NN	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
from	IN	O
baseline	NN	O
to	TO	O
the	DT	O
final	JJ	O
value	NN	O
and	CC	O
maintained	VBD	O
the	DT	O
reduction	NN	O
to	TO	O
a	DT	O
greater	JJR	O
degree	NN	O
than	IN	O
captopril	NN	PM
throughout	IN	O
24-h	JJ	O
periods	NNS	O
of	IN	O
observation	NN	O
.	.	O

The	DT	O
office	NN	O
measurements	NNS	O
showed	VBD	O
a	DT	O
similar	JJ	O
trend	NN	O
,	,	O
but	CC	O
the	DT	O
intertreatment	JJ	O
differences	NNS	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

No	DT	O
first-dose	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
either	DT	O
drug	NN	O
.	.	O

Once	IN	O
a	DT	O
day	NN	O
lisinopril	NN	PM
appeared	VBD	O
to	TO	O
be	VB	O
a	DT	O
more	RBR	O
effective	JJ	O
antihypertensive	JJ	PM
regimen	NNS	PM
than	IN	O
twice	RB	O
a	DT	O
day	NN	O
captopril	NN	O
.	.	O

Oxytocin	NNP	PM
promotes	VBZ	O
facial	JJ	O
emotion	NN	O
recognition	NN	O
and	CC	O
amygdala	JJ	O
reactivity	NN	O
in	IN	O
adults	NNS	O
with	IN	O
asperger	JJ	O
syndrome	NN	O
.	.	O

The	DT	O
neuropeptide	JJ	PM
oxytocin	NN	PM
has	VBZ	O
recently	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
enhance	VB	O
eye	NN	O
gaze	NN	O
and	CC	O
emotion	NN	O
recognition	NN	O
in	IN	O
healthy	JJ	O
men	NNS	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
report	VBP	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
that	WDT	O
examined	VBD	O
the	DT	O
neural	JJ	O
and	CC	O
behavioral	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intranasal	JJ	PM
oxytocin	NN	PM
on	IN	O
emotion	NN	O
recognition	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
(	(	O
AS	IN	O
)	)	O
,	,	O
a	DT	O
clinical	JJ	O
condition	NN	O
characterized	VBN	O
by	IN	O
impaired	JJ	O
eye	NN	O
gaze	NN	O
and	CC	O
facial	JJ	O
emotion	NN	O
recognition	NN	O
.	.	O

Using	VBG	O
functional	JJ	PH
magnetic	JJ	PH
resonance	NN	PH
imaging	NN	PH
,	,	O
we	PRP	O
examined	VBD	O
whether	IN	O
oxytocin	NN	PM
would	MD	O
enhance	VB	O
emotion	NN	O
recognition	NN	O
from	IN	O
facial	JJ	O
sections	NNS	O
of	IN	O
the	DT	O
eye	NN	O
vs	VBZ	O
the	DT	O
mouth	JJ	O
region	NN	O
and	CC	O
modulate	JJ	O
regional	JJ	O
activity	NN	O
in	IN	O
brain	NN	O
areas	NNS	O
associated	VBN	O
with	IN	O
face	NN	O
perception	NN	O
in	IN	O
both	DT	O
adults	NNS	O
with	IN	O
AS	NNP	O
,	,	O
and	CC	O
a	DT	O
neurotypical	JJ	C
control	NN	C
group	NN	O
.	.	O

Intranasal	NNP	O
administration	NN	O
of	IN	O
the	DT	O
neuropeptide	JJ	PM
oxytocin	NN	PM
improved	VBD	O
performance	NN	O
in	IN	O
a	DT	O
facial	JJ	O
emotion	NN	O
recognition	NN	O
task	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
AS	NNP	O
.	.	O

This	DT	O
was	VBD	O
linked	VBN	O
to	TO	O
increased	VBN	O
left	JJ	O
amygdala	NN	O
reactivity	NN	O
in	IN	O
response	NN	O
to	TO	O
facial	JJ	O
stimuli	NNS	O
and	CC	O
increased	JJ	O
activity	NN	O
in	IN	O
the	DT	O
neural	JJ	O
network	NN	O
involved	VBN	O
in	IN	O
social	JJ	O
cognition	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
amygdala	NN	O
,	,	O
together	RB	O
with	IN	O
functionally	RB	O
associated	VBN	O
cortical	JJ	O
areas	NNS	O
mediate	VBP	O
the	DT	O
positive	JJ	O
effect	NN	O
of	IN	O
oxytocin	NN	PM
on	IN	O
social	JJ	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
AS	NNP	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
liberal	JJ	O
versus	NN	O
restrictive	JJ	O
guidelines	NNS	O
for	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
transfusion	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

OBJECTIVE	NNP	O
Although	IN	O
many	JJ	O
centers	NNS	O
have	VBP	O
introduced	VBN	O
more	RBR	O
restrictive	JJ	O
transfusion	NN	O
policies	NNS	O
for	IN	O
preterm	JJ	O
infants	NNS	O
in	IN	O
recent	JJ	O
years	NNS	O
,	,	O
the	DT	O
benefits	NNS	O
and	CC	O
adverse	JJ	O
consequences	NNS	O
of	IN	O
allowing	VBG	O
lower	JJR	O
hematocrit	NN	O
levels	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
restrictive	JJ	O
guidelines	NNS	O
for	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
(	(	O
RBC	NNP	O
)	)	O
transfusions	NNS	O
for	IN	O
preterm	JJ	O
infants	NNS	O
can	MD	O
reduce	VB	O
the	DT	O
number	NN	O
of	IN	O
transfusions	NNS	O
without	IN	O
adverse	JJ	O
consequences	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
We	PRP	O
enrolled	VBD	O
100	CD	O
hospitalized	JJ	O
preterm	NN	O
infants	NNS	O
with	IN	O
birth	JJ	O
weights	NNS	O
of	IN	O
500	CD	O
to	TO	O
1300	CD	O
g	NN	O
into	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
2	CD	O
levels	NNS	O
of	IN	O
hematocrit	NN	O
threshold	NN	O
for	IN	O
RBC	NNP	O
transfusion	NN	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
infants	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
either	VB	O
the	DT	O
liberal-	NN	PH
or	CC	PH
the	DT	PH
restrictive-transfusion	NN	PH
group	NN	O
.	.	O

For	IN	O
each	DT	O
group	NN	O
,	,	O
transfusions	NNS	O
were	VBD	O
given	VBN	O
only	RB	O
when	WRB	O
the	DT	O
hematocrit	NN	O
level	NN	O
fell	VBD	O
below	IN	O
the	DT	O
assigned	JJ	O
value	NN	O
.	.	O

In	IN	O
each	DT	O
group	NN	O
,	,	O
the	DT	O
transfusion	NN	O
threshold	NN	O
levels	NNS	O
decreased	VBN	O
with	IN	O
improving	VBG	O
clinical	JJ	O
status	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
We	PRP	O
recorded	VBD	O
the	DT	O
number	NN	O
of	IN	O
transfusions	NNS	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
donor	JJ	O
exposures	NNS	O
,	,	O
and	CC	O
various	JJ	O
clinical	JJ	O
and	CC	O
physiologic	JJ	O
outcomes	NNS	O
.	.	O

RESULTS	JJ	O
Infants	NNS	O
in	IN	O
the	DT	O
liberal-transfusion	NN	O
group	NN	O
received	VBD	O
more	JJR	O
RBC	JJ	PH
transfusions	NNS	PH
(	(	O
5.2	CD	O
+/-	JJ	O
4.5	CD	O
[	JJ	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
]	NNP	O
vs	VBD	O
3.3	CD	O
+/-	JJ	O
2.9	CD	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
donors	NNS	O
to	TO	O
whom	WP	O
the	DT	O
infants	NNS	O
were	VBD	O
exposed	VBN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
2.8	CD	O
+/-	JJ	O
2.5	CD	O
vs	JJ	O
2.2	CD	O
+/-	JJ	O
2.0	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
infants	NNS	O
who	WP	O
avoided	VBD	O
transfusions	NNS	O
altogether	RB	O
(	(	O
12	CD	O
%	NN	O
in	IN	O
the	DT	O
liberal-transfusion	NN	O
group	NN	O
versus	VBD	O
10	CD	O
%	NN	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
)	)	O
.	.	O

Infants	NNS	O
in	IN	O
the	DT	O
restrictive-transfusion	NN	O
group	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
intraparenchymal	JJ	O
brain	NN	O
hemorrhage	NN	O
or	CC	O
periventricular	JJ	O
leukomalacia	NN	O
,	,	O
and	CC	O
they	PRP	O
had	VBD	O
more	RBR	O
frequent	JJ	O
episodes	NNS	O
of	IN	O
apnea	NN	O
,	,	O
including	VBG	O
both	DT	O
mild	JJ	O
and	CC	O
severe	JJ	O
episodes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
both	DT	O
transfusion	NN	O
programs	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
our	PRP$	O
finding	NN	O
of	IN	O
more	RBR	O
frequent	JJ	O
major	JJ	O
adverse	JJ	O
neurologic	NN	O
events	NNS	O
in	IN	O
the	DT	O
restrictive	JJ	O
RBC-transfusion	NNP	O
group	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
practice	NN	O
of	IN	O
restrictive	JJ	O
transfusions	NNS	O
may	MD	O
be	VB	O
harmful	JJ	O
to	TO	O
preterm	VB	O
infants	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
of	IN	O
5-fluorouracil	JJ	PM
,	,	O
with	IN	O
or	CC	O
without	IN	O
human	JJ	PM
interferon-beta	NN	PM
,	,	O
for	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
5-fluorouracil	JJ	PM
(	(	PM
5-FU	JJ	PM
)	)	PM
monotherapy	NN	PM
to	TO	O
that	DT	O
of	IN	O
5-FU	JJ	PM
combined	VBN	PM
with	IN	PM
natural	JJ	PM
human	JJ	PM
interferon-beta	NN	PM
(	(	PM
IFN-beta	NNP	PM
)	)	PM
in	IN	O
patients	NNS	O
with	IN	O
unresectable	JJ	O
,	,	O
advanced	JJ	O
colorectal	JJ	O
carcinoma	NN	O
.	.	O

Forty-nine	JJ	O
chemotherapy-naive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
5-FU	JJ	O
alone	RB	O
or	CC	O
to	TO	O
the	DT	O
combination	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
750	CD	O
mg	NNS	O
m	NN	O
(	(	O
-2	JJ	O
)	)	O
day	NN	O
(	(	O
-1	JJ	O
)	)	O
5-FU	NN	O
for	IN	O
5	CD	O
days	NNS	O
by	IN	O
continuous	JJ	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
infusion	NN	O
,	,	O
followed	VBD	O
after	IN	O
day	NN	O
15	CD	O
by	IN	O
a	DT	O
weekly	JJ	O
i.v	NN	O
.	.	O

bolus	NN	O
of	IN	O
750	CD	O
mg	NNS	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
.	.	O

IFN-beta	NNP	PM
was	VBD	O
injected	VBN	O
intramuscularly	RB	O
three	CD	O
times	NNS	O
weekly	RB	O
at	IN	O
9	CD	O
M	NNP	O
IU	NNP	O
.	.	O

Treatment	NNP	O
continued	VBD	O
for	IN	O
52	CD	O
weeks	NNS	O
,	,	O
or	CC	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
intolerable	JJ	O
toxicity	NN	O
.	.	O

Clinical	JJ	O
endpoints	NNS	O
were	VBD	O
tumor	JJ	O
response	NN	O
,	,	O
time	NN	O
to	TO	O
progression	NN	O
,	,	O
survival	NN	O
and	CC	O
toxicity	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
IFN-3	NNP	PM
to	TO	PM
5-FU	CD	PM
significantly	RB	O
improved	VBN	O
response	NN	O
rate	NN	O
(	(	O
33.3	CD	O
%	NN	O
vs	JJ	O
4.5	CD	O
%	NN	O
for	IN	O
evaluable	JJ	O
patients	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
,	,	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
median	JJ	O
7.2	CD	O
vs	JJ	O
4.2	CD	O
months	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.0435	CD	O
)	)	O
,	,	O
and	CC	O
survival	JJ	O
time	NN	O
(	(	O
median	JJ	O
15.9	CD	O
vs	JJ	O
7.2	CD	O
months	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
without	IN	O
significantly	RB	O
increasing	VBG	O
toxicity	NN	O
compared	VBN	O
to	TO	O
5-FU	JJ	O
alone	RB	O
.	.	O

Cumulative	JJ	O
5-FU	JJ	PM
dose	NN	O
was	VBD	O
higher	JJR	O
with	IN	O
combined	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
:	:	O
more	JJR	O
patients	NNS	O
receiving	VBG	O
monotherapy	JJ	O
discontinued	VBN	O
treatment	NN	O
because	IN	O
of	IN	O
disease	NN	O
progression	NN	O
.	.	O

Fever	NNP	O
was	VBD	O
more	RBR	O
frequent	JJ	O
with	IN	O
combined	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
other	JJ	O
differences	NNS	O
in	IN	O
toxicity	NN	O
.	.	O

The	DT	O
only	JJ	O
grade	NN	O
IV	NNP	O
toxicity	NN	O
observed	VBD	O
was	VBD	O
neutropenia	JJ	O
(	(	O
two	CD	O
patients	NNS	O
per	IN	O
group	NN	O
)	)	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
has	VBZ	O
been	VBN	O
initiated	VBN	O
to	TO	O
confirm	VB	O
the	DT	O
synergy	NN	O
between	IN	O
5-FU	JJ	PM
and	CC	O
IFN-beta	NNP	PM
.	.	O

Cryotherapy	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
peroneal	JJ	O
reaction	NN	O
following	VBG	O
sudden	JJ	O
inversion	NN	O
.	.	O

CONTEXT	NNP	O
If	IN	O
ankle	JJ	O
joint	NN	O
cryotherapy	NN	O
impairs	VBZ	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
ankle	JJ	O
musculature	NN	O
to	TO	O
counteract	VB	O
potentially	RB	O
injurious	JJ	O
forces	NNS	O
,	,	O
the	DT	O
ankle	NN	O
is	VBZ	O
left	VBN	O
vulnerable	JJ	O
to	TO	O
injury	VB	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
peroneal	JJ	O
reaction	NN	O
to	TO	O
sudden	JJ	O
inversion	NN	O
following	VBG	O
ankle	JJ	O
joint	JJ	O
cryotherapy	NN	O
.	.	O

DESIGN	NNP	O
Repeated	VBD	O
measures	NNS	O
design	NN	O
with	IN	O
independent	JJ	O
variables	NNS	O
,	,	O
treatment	NN	O
(	(	O
cryotherapy	NN	PH
and	CC	O
control	NN	C
)	)	O
,	,	O
and	CC	O
time	NN	O
(	(	O
baseline	NN	O
,	,	O
immediately	RB	O
post	NN	O
treatment	NN	O
,	,	O
15	CD	O
minutes	NNS	O
post	RB	O
treatment	NN	O
,	,	O
and	CC	O
30	CD	O
minutes	NNS	O
post	RB	O
treatment	NN	O
)	)	O
.	.	O

SETTING	NNP	O
University	NNP	O
research	NN	O
laboratory	NN	O
.	.	O

PATIENTS	CC	O
OR	CC	O
OTHER	NNP	O
PARTICIPANTS	NNP	O
Twenty-seven	NNP	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
An	DT	O
ice	NN	O
bag	NN	O
was	VBD	O
secured	VBN	O
to	TO	O
the	DT	O
lateral	JJ	O
ankle	NN	O
joint	NN	O
for	IN	O
20	CD	O
minutes	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
onset	NN	O
and	CC	O
average	JJ	O
root	NN	O
mean	JJ	O
square	JJ	O
amplitude	NN	O
of	IN	O
EMG	NNP	O
activity	NN	O
in	IN	O
the	DT	O
peroneal	NN	O
muscles	NNS	O
was	VBD	O
calculated	VBN	O
following	VBG	O
the	DT	O
release	NN	O
of	IN	O
a	DT	O
trap	NN	O
door	NN	O
mechanism	NN	O
causing	VBG	O
inversion	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
for	IN	O
peroneal	JJ	O
reaction	NN	O
time	NN	O
or	CC	O
average	JJ	O
peroneal	JJ	O
muscle	NN	O
activity	NN	O
at	IN	O
any	DT	O
post	NN	O
treatment	NN	O
time	NN	O
.	.	O

CONCLUSIONS	NNP	O
Cryotherapy	NNP	O
does	VBZ	O
not	RB	O
affect	VB	O
peroneal	JJ	O
muscle	NN	O
reaction	NN	O
following	VBG	O
sudden	JJ	O
inversion	NN	O
perturbation	NN	O
.	.	O

RESPECT-PTSD	JJ	O
:	:	O
re-engineering	JJ	O
systems	NNS	O
for	IN	O
the	DT	O
primary	JJ	O
care	NN	O
treatment	NN	O
of	IN	O
PTSD	NNP	O
,	,	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
collaborative	JJ	O
care	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
treating	VBG	O
depression	NN	O
and	CC	O
other	JJ	O
mental	JJ	O
disorders	NNS	O
in	IN	O
primary	JJ	O
care	NN	O
,	,	O
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
randomized	JJ	O
trials	NNS	O
of	IN	O
collaborative	JJ	O
care	NN	O
specifically	RB	O
for	IN	O
patients	NNS	O
with	IN	O
Posttraumatic	NNP	O
stress	NN	O
disorder	NN	O
(	(	O
PTSD	NNP	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
a	DT	O
collaborative	JJ	O
approach	NN	O
,	,	O
the	DT	O
Three	NNP	PS
Component	NNP	PS
Model	NNP	PS
(	(	PS
3CM	CD	PS
)	)	PS
,	,	O
with	IN	O
usual	JJ	C
care	NN	C
for	IN	O
treating	VBG	O
PTSD	NNP	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

DESIGN	VB	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
two-arm	JJ	O
,	,	O
parallel	JJ	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

PTSD	JJ	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
five	CD	O
primary	JJ	O
care	NN	O
clinics	NNS	O
at	IN	O
four	CD	O
Veterans	NNS	O
Affairs	NNP	O
healthcare	NN	O
facilities	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
usual	JJ	C
care	NN	C
or	CC	E
usual	JJ	E
care	NN	E
plus	CC	E
3CM	CD	E
.	.	O

Blinded	VBN	O
assessors	NNS	O
collected	VBD	O
data	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
3-month	JJ	O
and	CC	O
6-month	JJ	O
follow-up	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
were	VBD	O
195	CD	O
Veterans	NNPS	O
.	.	O

Their	PRP$	O
average	JJ	O
age	NN	O
was	VBD	O
45	CD	O
years	NNS	O
,	,	O
91	CD	O
%	NN	O
were	VBD	O
male	JJ	O
,	,	O
58	CD	O
%	NN	O
were	VBD	O
white	JJ	O
,	,	O
40	CD	O
%	NN	O
served	VBN	O
in	IN	O
Iraq	NNP	O
or	CC	O
Afghanistan	NNP	O
,	,	O
and	CC	O
42	CD	O
%	NN	O
served	VBD	O
in	IN	O
Vietnam	NNP	O
.	.	O

INTERVENTION	NNP	O
All	NNP	O
participants	NNS	O
received	VBD	O
usual	JJ	C
care	NN	C
.	.	O

Participants	NNS	O
assigned	VBD	O
to	TO	O
3CM	CD	PS
also	RB	O
received	VBD	O
telephone	NN	E
care	NN	E
management	NN	E
.	.	O

Care	NN	O
managers	NNS	O
received	VBD	O
supervision	NN	E
from	IN	E
a	DT	E
psychiatrist	NN	E
.	.	O

MAIN	NNP	O
MEASURES	NNP	O
PTSD	NNP	O
symptom	NN	O
severity	NN	O
was	VBD	O
the	DT	O
primary	JJ	O
outcome	NN	O
.	.	O

Depression	NNP	O
,	,	O
functioning	NN	O
,	,	O
perceived	VBD	O
quality	NN	O
of	IN	O
care	NN	O
,	,	O
utilization	NN	O
,	,	O
and	CC	O
costs	NNS	O
were	VBD	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

KEY	JJ	O
RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
3CM	CD	O
and	CC	O
usual	JJ	O
care	NN	O
in	IN	O
symptoms	NNS	O
or	CC	O
functioning	VBG	O
.	.	O

Participants	NNS	O
assigned	VBD	O
to	TO	O
3CM	CD	E
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
mental	JJ	O
health	NN	O
visit	NN	O
,	,	O
fill	VB	O
an	DT	O
antidepressant	JJ	O
prescription	NN	O
,	,	O
and	CC	O
have	VBP	O
adequate	VBN	O
antidepressant	JJ	O
refills	NNS	O
.	.	O

3CM	CD	E
participants	NNS	O
also	RB	O
had	VBD	O
more	RBR	O
mental	JJ	O
health	NN	O
visits	NNS	O
and	CC	O
higher	JJR	O
outpatient	NN	O
pharmacy	NN	O
costs	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Results	NNP	O
suggest	VBP	O
the	DT	O
need	NN	O
for	IN	O
careful	JJ	O
examination	NN	O
of	IN	O
the	DT	O
way	NN	O
that	IN	O
collaborative	JJ	O
care	NN	O
models	NNS	O
are	VBP	O
implemented	VBN	O
for	IN	O
treating	VBG	O
PTSD	NNP	O
,	,	O
and	CC	O
for	IN	O
additional	JJ	O
supports	NNS	O
to	TO	O
encourage	VB	O
primary	JJ	O
care	NN	O
providers	NNS	O
to	TO	O
manage	VB	O
PTSD	NNP	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
extended	JJ	S
radical	JJ	S
versus	NN	O
radical	JJ	S
mastectomy	NN	S
.	.	O

Ten-year	JJ	O
results	NNS	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
increasing	VBG	O
debate	NN	O
over	IN	O
possible	JJ	O
benefit	NN	O
of	IN	O
more	JJR	O
complete	JJ	O
surgery	NN	O
compared	VBN	O
to	TO	O
conservative	JJ	O
procedures	NNS	O
,	,	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
contrasting	VBG	O
the	DT	O
then	RB	O
standard	NN	S
Halsted	NNP	S
radical	NN	S
(	(	S
RDL	NNP	S
)	)	S
operation	NN	S
with	IN	O
the	DT	O
more	RBR	O
complete	JJ	S
extended	JJ	S
radical	NN	S
(	(	S
EXT	NNP	S
)	)	S
mastectomy	NN	S
was	VBD	O
initiated	VBN	O
in	IN	O
1973	CD	O
.	.	O

Between	IN	O
November	NNP	O
1973	CD	O
and	CC	O
July	NNP	O
1982	CD	O
,	,	O
123	CD	O
women	NNS	O
younger	JJR	O
than	IN	O
70	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
at	IN	O
clinical	JJ	O
Stages	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
were	VBD	O
enrolled	VBN	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
series	NN	O
,	,	O
112	CD	O
were	VBD	O
treated	VBN	O
by	IN	O
the	DT	O
same	JJ	O
surgeon	NN	O
and	CC	O
confirmed	VBD	O
pathologically	RB	O
as	IN	O
having	VBG	O
invasive	JJ	O
mammary	JJ	O
carcinoma	NN	O
.	.	O

In	IN	O
this	DT	O
more	RBR	O
homogeneous	JJ	O
subgroup	NN	O
,	,	O
the	DT	O
10-year	JJ	O
survival	NN	O
rates	NNS	O
(	(	O
and	CC	O
standard	JJ	O
errors	NNS	O
)	)	O
were	VBD	O
for	IN	O
RDL	NNP	O
,	,	O
60	CD	O
%	NN	O
(	(	O
+/-	JJ	O
7	CD	O
%	NN	O
)	)	O
and	CC	O
for	IN	O
EXT	NNP	O
,	,	O
74	CD	O
%	NN	O
(	(	O
+/-	JJ	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
value	NN	O
for	IN	O
comparison	NN	O
of	IN	O
survival	JJ	O
curves	NNS	O
=	VBP	O
0.13	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
from	IN	O
this	DT	O
subgroup	NN	O
with	IN	O
central-medial	JJ	O
tumors	NNS	O
,	,	O
comprising	VBG	O
62	CD	O
%	NN	O
of	IN	O
the	DT	O
total	NN	O
,	,	O
survival	NN	O
after	IN	O
RDL	NNP	O
at	IN	O
10	CD	O
years	NNS	O
was	VBD	O
60	CD	O
%	NN	O
(	(	O
+/-	JJ	O
8	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
after	IN	O
EXT	NNP	O
86	CD	O
%	NN	O
(	(	O
+/-	JJ	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
patients	NNS	O
with	IN	O
lateral	JJ	O
tumors	NNS	O
,	,	O
survival	JJ	O
rates	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
:	:	O
58	CD	O
%	NN	O
(	(	O
+/-	JJ	O
13	CD	O
%	NN	O
)	)	O
and	CC	O
56	CD	O
%	NN	O
(	(	O
+/-	JJ	O
11	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.62	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
a	DT	O
nonrandomized	JJ	O
series	NN	O
of	IN	O
266	CD	O
RDL	NNP	O
and	CC	O
124	CD	O
EXT	NNP	O
patients	NNS	O
treated	VBD	O
between	IN	O
1960	CD	O
and	CC	O
1978	CD	O
found	VBD	O
differences	NNS	O
consistent	JJ	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
randomized	VBN	O
study	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

A	DT	O
sensory	JJ	PS
integration	NN	PS
therapy	NN	PS
program	NN	PS
on	IN	O
sensory	JJ	O
problems	NNS	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
planned	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
sensory	JJ	PS
integration	NN	PS
therapy	NN	PS
program	NN	PS
on	IN	O
sensory	JJ	O
problems	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Trakya	NNP	O
University	NNP	O
Training	NNP	O
and	CC	O
Research	NNP	O
Center	NNP	O
for	IN	O
Mentally	NNP	O
and	CC	O
Physically	NNP	O
Handicapped	NNP	O
Children	NNP	O
in	IN	O
Turkey	NNP	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
separated	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
each	DT	O
comprising	VBG	O
15	CD	O
children	NNS	O
between	IN	O
7	CD	O
and	CC	O
11	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
autism	NN	O
,	,	O
according	VBG	O
to	TO	O
DSM-IV	NNP	O
criteria	NNS	O
.	.	O

The	DT	O
children	NNS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
assessed	VBN	O
initially	RB	O
on	IN	O
a	DT	O
checklist	NN	O
,	,	O
Sensory	NNP	O
Evaluation	NNP	O
Form	NNP	O
for	IN	O
Children	NNP	O
with	IN	O
Autism	NNP	O
,	,	O
developed	VBD	O
to	TO	O
evaluate	VB	O
sensory	JJ	O
characteristics	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
participants	NNS	O
were	VBD	O
assessed	VBN	O
again	RB	O
on	IN	O
the	DT	O
checklist	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
sensory	JJ	PS
integration	NN	PS
therapy	NN	PS
program	NN	PS
positively	RB	O
affected	VBD	O
treated	JJ	O
children	NNS	O
.	.	O

Comparison	NNP	O
between	IN	O
intermittent	JJ	PH
mandatory	JJ	PH
ventilation	NN	PH
and	CC	O
synchronized	JJ	PH
intermittent	NN	PH
mandatory	JJ	PH
ventilation	NN	PH
with	IN	O
pressure	NN	PH
support	NN	PH
in	IN	O
children	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
compare	VB	O
intermittent	JJ	PH
mandatory	JJ	PH
ventilation	NN	PH
(	(	PH
IMV	NNP	PH
)	)	PH
with	IN	O
synchronized	JJ	PH
intermittent	JJ	PH
mandatory	NN	PH
ventilation	NN	PH
plus	CC	PH
pressure	NN	PH
support	NN	PH
(	(	PH
SIMV+PS	NNP	PH
)	)	PH
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
duration	NN	O
of	IN	O
weaning	VBG	O
and	CC	O
length	NN	O
of	IN	O
stay	NN	O
in	IN	O
a	DT	O
pediatric	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
PICU	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
enrolled	VBD	O
children	NNS	O
aged	VBN	O
28	CD	O
days	NNS	O
to	TO	O
4	CD	O
years	NNS	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
a	DT	O
PICU	NNP	O
between	IN	O
October	NNP	O
of	IN	O
2005	CD	O
and	CC	O
June	NNP	O
of	IN	O
2007	CD	O
and	CC	O
put	VB	O
on	IN	O
mechanical	JJ	PH
ventilation	NN	PH
(	(	PH
MV	NNP	PH
)	)	PH
for	IN	O
more	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
by	IN	O
drawing	VBG	O
lots	NNS	O
:	:	O
IMV	NNP	PH
group	NN	O
(	(	PH
IMVG	NNP	PH
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
and	CC	O
SIMV+PS	NNP	PH
group	NN	O
(	(	O
SIMVG	NNP	PH
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
excluded	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
undergone	JJ	O
tracheotomy	NN	O
or	CC	O
had	VBD	O
chronic	JJ	O
respiratory	NN	O
diseases	NNS	O
.	.	O

Data	NNS	O
on	IN	O
oxygenation	NN	O
and	CC	O
ventilation	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
admission	NN	O
and	CC	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
weaning	VBG	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
indication	NN	O
for	IN	O
MV	NNP	O
,	,	O
PRISM	NNP	O
score	NN	O
,	,	O
Comfort	NNP	O
scale	NN	O
,	,	O
use	NN	O
of	IN	O
sedatives	NNS	O
or	CC	O
ventilation	NN	O
and	CC	O
oxygenation	NN	O
parameters	NNS	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
on	IN	O
MV	NNP	O
was	VBD	O
5	CD	O
days	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.120	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
for	IN	O
duration	NN	O
of	IN	O
weaning	VBG	O
[	JJ	O
IMVG	NNP	PH
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	PH
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.262	CD	O
]	NN	O
or	CC	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
[	JJ	O
IMVG	NNP	PH
:	:	O
8	CD	O
days	NNS	O
(	(	O
2-22	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	PH
:	:	O
6	CD	O
days	NNS	O
(	(	O
3-20	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.113	CD	O
]	NNP	O
.	.	O

CONCLUSION	NNP	O
Among	IN	O
the	DT	O
children	NNS	O
studied	VBN	O
here	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
IMV	NNP	PH
and	CC	O
SIMV+PS	NNP	PH
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
MV	NNP	O
,	,	O
duration	NN	O
of	IN	O
weaning	VBG	O
or	CC	O
time	NN	O
spent	VBN	O
in	IN	O
the	DT	O
PICU	NNP	O
.	.	O

ClinicalTrials.govID	NN	O
:	:	O
NCT00549809	NNP	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	PM
plus	CC	PM
topiramate	NN	PM
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

BACKGROUND	NNP	O
Autism	NNP	O
is	VBZ	O
a	DT	O
complex	JJ	O
neurodevelopmental	JJ	O
disorder	NN	O
that	WDT	O
forms	VBZ	O
part	NN	O
of	IN	O
a	DT	O
spectrum	NN	O
of	IN	O
related	JJ	O
disorders	NNS	O
referred	VBD	O
to	TO	O
as	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
topiramate	NN	PM
plus	CC	PM
risperidone	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
4	CD	O
and	CC	O
12	CD	O
years	NNS	O
with	IN	O
a	DT	O
DSM	NNP	O
IV	NNP	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
autism	NN	O
who	WP	O
were	VBD	O
outpatients	NNS	O
from	IN	O
a	DT	O
specialty	NN	O
clinic	NN	O
for	IN	O
children	NNS	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
children	NNS	O
presented	VBN	O
with	IN	O
a	DT	O
chief	JJ	O
complaint	NN	O
of	IN	O
severely	RB	O
disruptive	JJ	O
symptoms	NNS	O
related	VBN	O
to	TO	O
autistic	JJ	O
disorder	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
topiramate+risperidone	VB	PM
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
or	CC	O
placebo+risperidone	NN	PM
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
for	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	PM
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
2	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
between	IN	O
10	CD	O
and	CC	O
40	CD	O
kg	NN	O
and	CC	O
3	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
weighting	VBG	O
above	IN	O
40	CD	O
kg	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
topiramate	NN	PM
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
200	CD	O
mg/day	NN	O
depending	VBG	O
on	IN	O
weight	NN	O
(	(	O
100	CD	O
mg/day	NN	O
for	IN	O
<	$	O
30	CD	O
kg	NN	O
and	CC	O
200	CD	O
mg/day	NN	O
for	IN	O
>	$	O
30	CD	O
kg	NN	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
after	IN	O
starting	VBG	O
medication	NN	O
.	.	O

Measure	NN	O
of	IN	O
outcome	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
Rating	VBG	O
Scale	NNP	O
.	.	O

RESULTS	NNP	O
Difference	NNP	O
between	IN	O
the	DT	O
two	CD	O
protocols	NNS	O
was	VBD	O
significant	JJ	O
as	IN	O
the	DT	O
group	NN	O
that	WDT	O
received	VBD	O
topiramate	NN	PM
had	VBD	O
a	DT	O
greater	JJR	O
reduction	NN	O
in	IN	O
ABC-C	NNP	O
subscale	NN	O
scores	NNS	O
for	IN	O
irritability	NN	O
,	,	O
stereotypic	JJ	O
behavior	NN	O
and	CC	O
hyperactivity/noncompliance	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
combination	NN	O
of	IN	O
topiramate	NN	PM
with	IN	O
risperidone	NN	O
may	MD	O
be	VB	O
superior	JJ	O
to	TO	O
risperidone	VB	O
monotherapy	NN	O
for	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

However	RB	O
the	DT	O
results	NNS	O
need	VBP	O
to	TO	O
be	VB	O
further	RB	O
confirmed	VBN	O
by	IN	O
a	DT	O
larger	JJR	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

In-season	JJ	O
effect	NN	O
of	IN	O
short-term	JJ	Ot
sprint	NN	Ot
and	CC	E
power	NN	Ot
training	NN	Ot
programs	NNS	Ot
on	IN	O
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
2	CD	O
in-season	JJ	O
short-term	JJ	Ot
sprint	NN	Ot
and	CC	E
power	NN	Ot
training	NN	Ot
protocols	NNS	Ot
on	IN	O
vertical	JJ	O
countermovement	NN	O
jump	NN	O
height	NN	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
arms	NNS	O
)	)	O
,	,	O
sprint	NN	O
(	(	O
Sprint-15m	NNP	O
)	)	O
speed	NN	O
,	,	O
and	CC	O
agility	NN	O
(	(	O
Agility-15m	NNP	O
)	)	O
speed	NN	O
in	IN	O
male	JJ	O
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

Twenty	NNP	O
highly	RB	O
trained	VBD	O
soccer	NN	O
players	NNS	O
(	(	O
age	NN	O
18.3	CD	O
+/-	JJ	O
0.6	CD	O
years	NNS	O
,	,	O
height	VBD	O
177	CD	O
+/-	JJ	O
4	CD	O
cm	NN	O
,	,	O
body	NN	O
mass	VBD	O
71.4	CD	O
+/-	JJ	O
6.9	CD	O
kg	NN	O
,	,	O
sum	NN	O
skinfolds	NNS	O
48.1	CD	O
+/-	JJ	O
11.4	CD	O
mm	NN	O
)	)	O
,	,	O
members	NNS	O
of	IN	O
a	DT	O
professional	JJ	O
soccer	NN	O
academy	NN	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
a	DT	O
CONTRAST	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
SPRINT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
group	NN	O
.	.	O

The	DT	E
training	NN	E
intervention	NN	E
consisted	VBD	O
of	IN	O
6	CD	E
supervised	JJ	E
training	NN	E
sessions	NNS	E
over	IN	O
7	CD	O
weeks	NNS	O
,	,	O
targeting	VBG	O
the	DT	O
improvement	NN	O
of	IN	O
the	DT	O
players	NNS	O
'	POS	O
speed	NN	O
and	CC	O
power	NN	O
.	.	O

CONTRAST	NNP	O
protocol	NN	O
consisted	VBD	O
of	IN	O
alternating	VBG	O
heavy-light	JJ	O
resistance	NN	O
(	(	O
15-50	CD	O
%	NN	O
body	NN	O
mass	NN	O
)	)	O
with	IN	O
soccer-specific	JJ	O
drills	NNS	O
(	(	O
small-sided	JJ	O
games	NNS	O
or	CC	O
technical	JJ	O
skills	NNS	O
)	)	O
.	.	O

SPRINT	NNP	Ot
training	NN	Ot
protocol	NN	Ot
used	VBN	O
line	NN	O
30-m	JJ	O
sprints	NNS	O
(	(	O
2-4	JJ	O
sets	NNS	O
of	IN	O
4	CD	O
x	JJ	O
30	CD	O
m	NN	O
with	IN	O
180	CD	O
and	CC	O
90	CD	O
seconds	NNS	O
of	IN	O
recovery	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

At	IN	O
baseline	JJ	O
no	DT	O
difference	NN	O
between	IN	O
physical	JJ	O
test	NN	O
performance	NN	O
was	VBD	O
evident	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
time	NN	O
x	VBZ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
vertical	JJ	O
jump	NN	O
and	CC	O
Agility-15m	JJ	O
variables	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
time	NN	O
x	JJ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
Sprint-15m	JJ	O
performance	NN	O
with	IN	O
the	DT	O
CONTRAST	NNP	O
group	NN	O
showing	VBG	O
significantly	RB	O
better	JJR	O
scores	NNS	O
than	IN	O
the	DT	O
SPRINT	NNP	O
group	NN	O
(	(	O
7.23	CD	O
+/-	JJ	O
0.18	CD	O
vs.	FW	O
7.09	CD	O
+/-	JJ	O
0.20	CD	O
m.s	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
light	NN	O
of	IN	O
these	DT	O
findings	NNS	O
CONTRAST	NNP	E
training	NN	E
should	MD	O
be	VB	O
preferred	VBN	O
to	TO	O
line	NN	O
sprint	NN	O
training	NN	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
in	IN	O
young	JJ	O
elite	JJ	O
soccer	NN	O
players	NNS	O
when	WRB	O
the	DT	O
aim	NN	O
is	VBZ	O
to	TO	O
improve	VB	O
soccer-specific	JJ	O
sprint	NN	O
performance	NN	O
(	(	O
15	CD	O
m	NN	O
)	)	O
during	IN	O
the	DT	O
competitive	JJ	O
season	NN	O
.	.	O

A	DT	O
program	NN	O
of	IN	O
screening	VBG	O
and	CC	O
prompting	VBG	O
improves	NNS	O
short-term	JJ	O
physician	JJ	O
counseling	NN	O
of	IN	O
dependent	NN	O
and	CC	O
nondependent	JJ	O
harmful	JJ	O
drinkers	NNS	O
.	.	O

BACKGROUND	NNP	O
Physicians	NNPS	O
in	IN	O
the	DT	O
general	JJ	O
medical	JJ	O
setting	VBG	O
commonly	RB	O
encounter	RB	O
but	CC	O
rarely	RB	O
counsel	NN	O
patients	NNS	O
with	IN	O
dependent	JJ	O
or	CC	O
harmful	JJ	O
drinking	NN	O
behaviors	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
whether	IN	O
providing	VBG	O
physicians	NNS	O
with	IN	O
their	PRP$	O
patients	NNS	O
'	POS	O
results	NNS	O
on	IN	O
the	DT	O
alcohol	NN	O
module	NN	O
of	IN	O
the	DT	O
Diagnostic	NNP	O
Interview	NNP	O
Schedule	NNP	O
and	CC	O
counseling	VBG	O
directives	NNS	O
would	MD	O
prompt	VB	O
them	PRP	O
to	TO	O
counsel	NN	O
these	DT	O
patients	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBN	O
83	CD	O
first-	JJ	O
,	,	O
second-	JJ	O
,	,	O
and	CC	O
third-year	JJ	O
medical	JJ	O
residents	NNS	O
to	TO	O
receive	VB	E
or	CC	E
not	RB	E
to	TO	E
receive	VB	E
diagnostic	JJ	E
information	NN	E
and	CC	E
counseling	VBG	E
directives	NNS	E
on	IN	E
214	CD	O
patients	NNS	O
who	WP	O
reported	VBD	O
at	IN	O
least	JJS	O
one	CD	O
symptom	NN	O
of	IN	O
alcohol	NN	O
impairment	NN	O
as	IN	O
defined	VBN	O
in	IN	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Third	NNP	O
Edition	NNP	O
.	.	O

Using	VBG	O
binary	JJ	E
logistic	JJ	E
regression	NN	E
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
specific	JJ	O
covariables	NNS	O
on	IN	O
rates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
.	.	O

These	DT	O
variables	NNS	O
included	VBD	O
physician	JJ	O
information	NN	O
status	NN	O
,	,	O
patient	JJ	O
gender	NN	O
,	,	O
and	CC	O
drinking	VBG	O
disorder	NN	O
severity	NN	O
and	CC	O
recency	NN	O
.	.	O

We	PRP	O
also	RB	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
physician	JJ	O
prompting	VBG	O
on	IN	O
counseling	NN	O
of	IN	O
female	JJ	O
patients	NNS	O
,	,	O
patients	NNS	O
with	IN	O
inactive	JJ	O
disorders	NNS	O
,	,	O
and	CC	O
nondependent	NN	O
but	CC	O
harmful	JJ	O
drinkers	NNS	O
.	.	O

We	PRP	O
determined	VBD	O
counseling	VBG	O
by	IN	O
post-visit	JJ	O
patient	JJ	O
interviews	NNS	O
.	.	O

RESULTS	NNP	O
Physician	JJ	O
prompting	NN	O
,	,	O
dependent	JJ	O
drinking	NN	O
,	,	O
and	CC	O
recent	JJ	O
disorder	NN	O
activity	NN	O
were	VBD	O
significant	JJ	O
correlates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
,	,	O
while	IN	O
male	JJ	O
gender	NN	O
was	VBD	O
a	DT	O
marginally	RB	O
significant	JJ	O
correlate	NN	O
(	(	O
P	NNP	O
=	NNP	O
.08	NNP	O
)	)	O
.	.	O

Informed	VBN	O
physicians	NNS	O
counseled	VBD	O
female	JJ	O
patients	NNS	O
,	,	O
harmful	JJ	O
but	CC	O
nondependent	JJ	O
drinkers	NNS	O
,	,	O
and	CC	O
patients	NNS	O
with	IN	O
inactive	JJ	O
disorders	NNS	O
more	RBR	O
often	RB	O
than	IN	O
their	PRP$	O
uninformed	JJ	O
colleagues	NNS	O
,	,	O
although	IN	O
only	RB	O
the	DT	O
last	JJ	O
variable	JJ	O
achieved	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Providing	VBG	O
physicians	NNS	O
with	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
Diagnostic	NNP	O
Interview	NNP	O
Schedule	NNP	O
and	CC	O
counseling	VBG	O
directives	NNS	O
resulted	VBD	O
in	IN	O
short-term	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
rates	NNS	O
of	IN	O
counseling	VBG	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
dependent	NN	O
or	CC	O
nondependent	NN	O
but	CC	O
harmful	JJ	O
drinking	NN	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
determine	VB	O
long-term	JJ	O
gains	NNS	O
in	IN	O
rates	NNS	O
of	IN	O
physician	JJ	E
counseling	NN	E
and	CC	E
improvements	NNS	E
in	IN	O
the	DT	O
course	NN	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

Antihistamines	NNS	PM
do	VBP	O
not	RB	O
inhibit	VB	O
the	DT	O
wheal	NN	O
induced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
autologous	JJ	O
serum	NN	O
in	IN	O
resistant	JJ	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NN	O
.	.	O

Some	DT	O
patients	NNS	O
with	IN	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NN	O
(	(	O
CIU	NNP	O
)	)	O
are	VBP	O
resistant	JJ	O
to	TO	O
conventional	JJ	O
doses	NNS	O
of	IN	O
antihistamines	NNS	PM
(	(	PM
AHs	NNP	PM
)	)	PM
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
check	VB	O
whether	IN	O
the	DT	O
skin	JJ	O
wheal	NN	O
and	CC	O
flare	JJ	O
reaction	NN	O
produced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
autologous	JJ	PM
serum	NN	PM
(	(	PM
AS	IN	PM
)	)	PM
and	CC	O
by	IN	O
histamine	NN	PM
differs	NNS	O
in	IN	O
AH-resistant	NNP	O
and	CC	O
AH	NNP	O
responder	VBP	O
CIU	NNP	O
patients	NNS	O
.	.	O

CIU	NNP	O
patients	NNS	O
with	IN	O
treatment	NN	O
failure	NN	O
under	IN	O
fexofenadine	NN	PM
at	IN	O
180	CD	O
mg	NN	O
q.d	NN	O
.	.	O

increased	VBD	O
their	PRP$	O
daily	JJ	O
dose	NN	O
of	IN	O
AH	NNP	O
to	TO	O
4	CD	O
tablets	NNS	O
daily	RB	O
.	.	O

Those	DT	O
with	IN	O
significant	JJ	O
improvement	NN	O
of	IN	O
urticaria	JJ	O
activity	NN	O
score	NN	O
under	IN	O
fexofenadine	NN	PM
at	IN	O
180	CD	O
mg	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
CIU	NNP	O
group	NN	O
.	.	O

Subjects	VBZ	O
with	IN	O
treatment	NN	O
failure	NN	O
despite	IN	O
a	DT	O
full	JJ	O
8-week	JJ	O
fourfold	JJ	O
fexofenadine	NN	PM
treatment	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
resistant	JJ	O
CIU	NNP	O
(	(	O
R-CIU	NNP	O
group	NN	O
)	)	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
sex-	JJ	O
and	CC	O
age-matched	JJ	O
patents	NNS	O
with	IN	O
allergic	JJ	O
rhinitis	NN	O
.	.	O

The	DT	O
AS	NNP	O
skin	JJ	O
test	NN	O
and	CC	O
intradermal	JJ	O
histamine-induced	JJ	PM
wheal	NN	O
and	CC	O
flare	JJ	O
reaction	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
(	(	O
without	IN	O
AH	NNP	O
)	)	O
,	,	O
after	IN	O
8	CD	O
and	CC	O
16	CD	O
weeks	NNS	O
(	(	O
under	IN	O
AH	NNP	O
treatment	NN	O
)	)	O
.	.	O

Forty-six	JJ	O
subjects	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
CIU	NNP	O
group	NN	O
,	,	O
21	CD	O
were	VBD	O
in	IN	O
the	DT	O
R-CIU	NNP	O
group	NN	O
,	,	O
and	CC	O
44	CD	O
were	VBD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Under	IN	O
AH	NNP	O
therapy	NN	O
,	,	O
the	DT	O
skin	JJ	O
reaction	NN	O
to	TO	O
intradermal	VB	O
histamine	JJ	O
injection	NN	O
was	VBD	O
significantly	RB	O
diminished	VBN	O
in	IN	O
all	DT	O
study	NN	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
R-CIU	NNP	O
group	NN	O
,	,	O
fexofenadine	NN	PM
at	IN	O
180	CD	O
mg	NNS	O
did	VBD	O
not	RB	O
suppress	VB	O
AS-induced	NNP	O
wheal	JJ	O
reaction	NN	O
(	(	O
5.96	CD	O
?	.	O
2.25	CD	O
mm	NN	O
;	:	O
p	CC	O
=	VB	O
0.85	CD	O
)	)	O
,	,	O
and	CC	O
with	IN	O
a	DT	O
fourfold	JJ	O
AH	NNP	O
dose	VB	O
some	DT	O
reduction	NN	O
of	IN	O
AS-induced	NNP	O
wheal	NN	O
(	(	O
3.79	CD	O
?	.	O
1.74	CD	O
mm	NN	O
;	:	O
p	CC	O
=	VB	O
0.008	CD	O
)	)	O
was	VBD	O
observed	VBN	O
but	CC	O
remained	VBD	O
larger	JJR	O
than	IN	O
in	IN	O
the	DT	O
CIU	NNP	O
(	(	O
2.31	CD	O
?	.	O
1.12	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.006	CD	O
)	)	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
2.52	CD	O
?	.	O
1.36	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.037	CD	O
)	)	O
.	.	O

AHs	NNP	O
do	VBP	O
not	RB	O
inhibit	VB	O
the	DT	O
wheal	NN	O
induced	VBN	O
by	IN	O
the	DT	O
intradermal	JJ	O
injection	NN	O
of	IN	O
AS	NNP	O
in	IN	O
R-CIU	NNP	O
.	.	O

Plasma	NNP	O
pH	NN	O
does	VBZ	O
not	RB	O
influence	VB	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
maximal	JJ	O
whole	JJ	O
body	NN	O
exercise	NN	O
.	.	O

Exercise	NN	O
lowers	VBZ	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
of	IN	O
O2	NNP	O
to	TO	O
carbohydrate	VB	O
(	(	O
glucose+1/2	JJ	O
lactate	NN	O
)	)	O
and	CC	O
metabolic	JJ	O
acidosis	NN	O
appears	VBZ	O
to	TO	O
promote	VB	O
cerebral	JJ	O
lactate	JJ	O
uptake	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
influence	NN	O
of	IN	O
pH	NN	O
on	IN	O
cerebral	JJ	O
lactate	JJ	O
uptake	NN	O
and	CC	O
,	,	O
in	IN	O
turn	NN	O
,	,	O
on	IN	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
exercise	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

Sodium	NN	PM
bicarbonate	NN	PM
(	(	O
Bicarb	NNP	O
,	,	O
1	CD	O
M	NNP	O
;	:	O
350-500	CD	O
ml	NN	O
)	)	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
normal	JJ	PM
saline	NN	PM
(	(	O
Sal	NNP	O
)	)	O
was	VBD	O
infused	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
constant	JJ	O
rate	NN	O
during	IN	O
a	DT	O
'2000	CD	O
m	NN	O
'	''	O
maximal	JJ	O
ergometer	NN	PM
row	NN	PM
in	IN	O
six	CD	O
male	JJ	O
oarsmen	NNS	O
(	(	O
23?2	CD	O
years	NNS	O
;	:	O
mean?S.D.	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
Sal	NNP	O
trial	NN	O
,	,	O
pH	NN	O
decreased	VBD	O
from	IN	O
7.41?0.01	CD	O
at	IN	O
rest	NN	O
to	TO	O
7.02?0.02	CD	O
but	CC	O
only	RB	O
to	TO	O
7.36?0.02	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
during	IN	O
the	DT	O
Bicarb	NNP	O
trial	NN	O
.	.	O

Arterial	JJ	O
lactate	NN	O
increased	VBD	O
to	TO	O
21.4?0.8	CD	O
and	CC	O
32.7?2.3	CD	O
mM	NN	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
arterial-jugular	JJ	O
venous	JJ	O
lactate	NN	O
difference	NN	O
increased	VBD	O
from-0.03?0.01	JJ	O
mM	NN	O
at	IN	O
rest	NN	O
to	TO	O
3.2?0.9	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
3.4?1.4	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
following	VBG	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
cerebral	JJ	O
metabolic	NN	O
ratio	NN	O
decreased	VBD	O
equally	RB	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
:	:	O
from	IN	O
5.8?0.6	CD	O
at	IN	O
rest	NN	O
to	TO	O
1.7?0.1	CD	O
and	CC	O
1.8?0.2	CD	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
enlarged	JJ	O
blood-buffering	NN	O
capacity	NN	O
after	IN	O
infusion	NN	O
of	IN	O
Bicarb	NNP	O
eliminated	VBD	O
metabolic	JJ	O
acidosis	NN	O
during	IN	O
maximal	JJ	O
exercise	NN	O
but	CC	O
that	DT	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
cerebral	JJ	O
lactate	NN	O
uptake	NN	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
cerebral	JJ	O
metabolic	NN	O
ratio	NN	O
.	.	O

Incidence	NN	O
and	CC	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	O
sextant	JJ	O
prostate	NN	O
biopsies	NNS	O
.	.	O

PURPOSE	NNP	O
Since	IN	O
most	JJS	O
patients	NNS	O
do	VBP	O
not	RB	O
undergo	VB	O
repeat	NN	O
sextant	JJ	O
prostate	NN	O
biopsies	NNS	O
after	IN	O
a	DT	O
biopsy	NN	O
is	VBZ	O
positive	JJ	O
for	IN	O
prostate	NN	O
cancer	NN	O
,	,	O
the	DT	O
true	JJ	O
incidence	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
is	VBZ	O
not	RB	O
well	RB	O
defined	VBN	O
.	.	O

We	PRP	O
assess	VBP	O
the	DT	O
incidence	NN	O
and	CC	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	O
sextant	JJ	O
prostate	NN	O
biopsies	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
radical	JJ	S
prostatectomy	NN	S
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
118	CD	O
patients	NNS	O
with	IN	O
biopsy	NN	O
proved	VBN	O
prostate	JJ	O
cancer	NN	O
underwent	JJ	O
repeat	NN	S
sextant	JJ	S
prostate	NN	S
biopsy	NN	S
before	IN	O
enrollment	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
radical	JJ	S
prostatectomy	NN	S
with	IN	O
or	CC	O
without	IN	O
neoadjuvant	JJ	PH
hormonal	JJ	PH
therapy	NN	PH
.	.	O

Clinical	JJ	O
parameters	NNS	O
were	VBD	O
assessed	VBN	O
to	TO	O
determine	VB	O
potential	JJ	O
sources	NNS	O
of	IN	O
bias	NN	O
.	.	O

Pathological	JJ	O
parameters	NNS	O
and	CC	O
prostate	NN	O
specific	JJ	O
antigen	NN	O
relapse-free	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
determine	VB	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
118	CD	O
patients	NNS	O
27	CD	O
(	(	O
23	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
negative	JJ	O
repeat	NN	O
sextant	JJ	O
biopsy	NN	O
.	.	O

Except	IN	O
for	IN	O
initial	JJ	O
clinical	JJ	O
stage	NN	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
clinical	JJ	O
or	CC	O
pathological	JJ	O
parameters	NNS	O
,	,	O
or	CC	O
prostate	VB	O
specific	JJ	O
antigen	NN	O
relapse	NN	O
rates	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
negative	JJ	O
versus	NN	O
positive	JJ	O
repeat	NN	O
biopsies	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
this	DT	O
23	CD	O
%	NN	O
incidence	NN	O
of	IN	O
false-negative	JJ	O
biopsies	NNS	O
represents	VBZ	O
significant	JJ	O
cancer	NN	O
.	.	O

This	DT	O
relatively	RB	O
high	JJ	O
incidence	NN	O
is	VBZ	O
important	JJ	O
to	TO	O
consider	VB	O
in	IN	O
treatment	NN	O
modalities	NNS	O
in	IN	O
which	WDT	O
prostate	VBP	O
biopsy	NN	O
may	MD	O
be	VB	O
performed	VBN	O
to	TO	O
determine	VB	O
response	NN	O
to	TO	O
therapy	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
an	DT	O
allograft	NN	PM
in	IN	O
an	DT	O
experimental	JJ	PH
putty	NN	PH
carrier	NN	PH
and	CC	PH
a	DT	PH
bovine-derived	JJ	PH
xenograft	NN	PH
used	VBN	O
in	IN	O
ridge	JJ	O
preservation	NN	O
:	:	O
a	DT	O
clinical	JJ	O
and	CC	O
histologic	JJ	O
study	NN	O
in	IN	O
humans	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
blinded	VBD	O
clinical	JJ	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
ridge	JJ	O
dimensions	NNS	O
and	CC	O
histologic	JJ	O
characteristics	NNS	O
of	IN	O
ridges	NNS	O
preserved	VBN	O
with	IN	O
2	CD	O
different	JJ	O
graft	NN	PH
materials	NNS	PH
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Twenty-four	NNP	O
subjects	NNS	O
,	,	O
each	DT	O
requiring	VBG	O
a	DT	O
nonmolar	JJ	O
extraction	NN	O
and	CC	O
delayed	JJ	O
implant	NN	O
placement	NN	O
,	,	O
were	VBD	O
randomly	RB	O
selected	VBN	O
to	TO	O
receive	VB	O
ridge	NN	O
preservation	NN	O
treatment	NN	O
with	IN	O
either	DT	O
an	DT	O
allograft	NN	O
in	IN	O
an	DT	O
experimental	JJ	O
putty	NN	O
carrier	NN	O
plus	CC	O
a	DT	O
calcium	NN	PM
sulfate	NN	PM
barrier	NN	PM
(	(	O
PUT	NNP	O
)	)	O
or	CC	O
a	DT	O
bovine-derived	JJ	PM
xenograft	NN	PM
(	(	PM
BDX	NNP	PM
)	)	PM
plus	CC	O
a	DT	O
collagen	NN	O
membrane	NN	O
.	.	O

Horizontal	NNP	O
and	CC	O
vertical	JJ	O
ridge	NN	O
dimensions	NNS	O
were	VBD	O
determined	VBN	O
using	VBG	O
a	DT	O
digital	JJ	O
caliper	NN	O
and	CC	O
a	DT	O
template	NN	O
.	.	O

At	IN	O
4	CD	O
months	NNS	O
postextraction	NN	O
,	,	O
a	DT	O
trephine	NN	O
core	NN	O
was	VBD	O
obtained	VBN	O
for	IN	O
histologic	JJ	O
analysis	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	JJ	O
ridge	NN	O
width	NN	O
decreased	VBN	O
by	IN	O
0.50	CD	O
mm	NN	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

The	DT	O
midbuccal	JJ	O
vertical	JJ	O
change	NN	O
for	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
was	VBD	O
a	DT	O
loss	NN	O
of	IN	O
0.3+/-0.7	JJ	O
mm	NN	O
versus	IN	O
a	DT	O
gain	NN	O
of	IN	O
0.7+/-1.2	JJ	O
mm	NN	O
for	IN	O
the	DT	O
BDX	NNP	PM
group	NN	O
,	,	O
a	DT	O
difference	NN	O
of	IN	O
1.0	CD	O
mm	NN	O
(	(	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
.	.	O

Histologic	NNP	O
analysis	NN	O
revealed	VBD	O
vital	JJ	O
bone	NN	O
in	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
of	IN	O
about	RB	O
61	CD	O
%	NN	O
+/-9	JJ	O
%	NN	O
versus	IN	O
26	CD	O
%	NN	O
+/-20	JJ	O
%	NN	O
for	IN	O
the	DT	O
BDX	NNP	PH
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

DISCUSSION	NNP	O
Greater	NNP	O
vital	JJ	O
bone	NN	O
fill	NN	O
in	IN	O
the	DT	O
PUT	NNP	O
group	NN	O
may	MD	O
be	VB	O
attributable	JJ	O
to	TO	O
earlier	RBR	O
and	CC	O
greater	JJR	O
vascular	JJ	O
invasion	NN	O
of	IN	O
the	DT	O
carrier	NN	O
material	NN	O
.	.	O

The	DT	O
putty	JJ	O
material	NN	O
was	VBD	O
characterized	VBN	O
by	IN	O
ease	NN	O
of	IN	O
handling	VBG	O
,	,	O
simple	JJ	O
placement	NN	O
,	,	O
and	CC	O
enhanced	VBD	O
graft	NN	O
particle	NN	O
containment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Allograft	NNP	O
mixed	VBD	O
with	IN	O
an	DT	O
experimental	JJ	O
putty	NN	O
carrier	NN	O
produced	VBD	O
significantly	RB	O
more	RBR	O
vital	JJ	O
bone	NN	O
fill	NN	O
than	IN	O
did	VBD	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
xenograft	NN	PM
with	IN	O
no	DT	O
carrier	NN	O
material	NN	O
.	.	O

Ridge	NNP	O
width	NN	O
and	CC	O
height	JJ	O
dimensions	NNS	O
were	VBD	O
similarly	RB	O
preserved	VBN	O
with	IN	O
both	DT	O
graft	NN	O
materials	NNS	O
.	.	O

In	IN	O
school-aged	JJ	O
children	NNS	O
a	DT	O
combination	NN	O
of	IN	O
galacto-oligosaccharides	NNS	PM
and	CC	O
Lactobacillus	NNP	PM
GG	NNP	PM
increases	VBZ	O
bifidobacteria	RB	O
more	JJR	O
than	IN	O
Lactobacillus	NNP	PM
GG	NNP	PM
on	IN	O
its	PRP$	O
own	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
a	DT	O
combination	NN	O
of	IN	O
Lactobacillus	NNP	PM
GG	NNP	PM
(	(	PM
LGG	NNP	PM
)	)	PM
and	CC	PM
galacto-oligosaccharides	NNS	PM
(	(	PM
GOS	NNP	PM
)	)	PM
with	IN	PM
LGG	NNP	PM
on	IN	PM
its	PRP$	PM
own	JJ	PM
,	,	O
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
intestinal	JJ	O
microbiota	NN	O
in	IN	O
school-aged	JJ	O
children	NNS	O
.	.	O

The	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
crossover	NN	O
study	NN	O
comprised	VBD	O
30	CD	O
healthy	JJ	O
children	NNS	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
3-week	JJ	O
study	NN	O
periods	NNS	O
with	IN	O
a	DT	O
4-week	JJ	O
wash-out	JJ	O
period	NN	O
in	IN	O
between	IN	O
.	.	O

The	DT	O
children	NNS	O
ingested	VBD	O
daily	RB	O
65	CD	O
ml	NN	O
of	IN	O
milk-based	JJ	PM
fruit	NN	PM
juice	NN	PM
containing	VBG	PM
either	CC	PM
LGG	NNP	PM
alone	RB	PM
(	(	O
6.5	CD	O
x	RB	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU	NNP	O
)	)	O
or	CC	O
LGG	NNP	PM
plus	CC	PM
2	CD	PM
g	NN	PM
of	IN	PM
GOS	NNP	PM
.	.	O

Symptom	NNP	O
diaries	NNS	O
were	VBD	O
filled	VBN	O
during	IN	O
the	DT	O
study	NN	O
periods	NNS	O
.	.	O

Fecal	JJ	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
both	DT	O
study	NN	O
periods	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
both	DT	O
study	NN	O
periods	NNS	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
bifidobacteria	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
after	IN	O
the	DT	O
ingestion	NN	O
of	IN	O
LGG	NNP	PM
+	NNP	PM
GOS	NNP	PM
compared	VBN	O
with	IN	O
LGG	NNP	PM
alone	RB	PM
(	(	O
geometric	JJ	O
mean	VBP	O
9.33	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
vs.	FW	O
4.28	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU/g	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
lactobacilli	NN	O
or	CC	O
LGG	NNP	PM
,	,	O
nor	CC	O
did	VBD	O
gastrointestinal	JJ	O
symptoms	NNS	O
,	,	O
defecation	NN	O
frequency	NN	O
,	,	O
consistency	NN	O
of	IN	O
stools	NNS	O
or	CC	O
ease	NN	O
of	IN	O
defecation	NN	O
differ	NN	O
between	IN	O
the	DT	O
two	CD	O
study	NN	O
periods	NNS	O
.	.	O

Ingestion	NN	O
of	IN	O
LGG	NNP	PM
combined	VBD	PM
with	IN	PM
2	CD	PM
g	NN	PM
of	IN	PM
GOS	NNP	PM
increased	VBD	O
the	DT	O
bifidobacteria	NN	O
more	JJR	O
than	IN	O
LGG	NNP	PM
on	IN	PM
its	PRP$	PM
own	JJ	PM
and	CC	O
thus	RB	O
GOS	NNP	PM
clearly	RB	O
has	VBZ	O
a	DT	O
prebiotic	JJ	O
effect	NN	O
in	IN	O
children	NNS	O
.	.	O

The	DT	O
children	NNS	O
tolerated	VBN	O
well	RB	O
a	DT	O
daily	JJ	O
intake	NN	O
of	IN	O
2	CD	O
g	NN	O
of	IN	O
GOS	NNP	PM
.	.	O

Efficacy	NN	O
of	IN	O
chlorhexidine	NN	PM
gluconate	NN	PM
use	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
perirectal	JJ	O
infections	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
leukemia	NN	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
rectal	JJ	O
infections	NNS	O
is	VBZ	O
increased	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
leukemia	NN	O
.	.	O

Complications	NNS	O
associated	VBN	O
with	IN	O
rectal	JJ	O
lesions	NNS	O
may	MD	O
be	VB	O
severe	JJ	O
enough	RB	O
to	TO	O
cause	VB	O
life-threatening	JJ	O
septicemia	NN	O
.	.	O

Clinical	JJ	O
research	NN	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
preventive	JJ	O
perirectal	NN	O
skin	NN	O
care	NN	O
is	VBZ	O
scarce	JJ	O
.	.	O

This	DT	O
study	NN	O
's	POS	O
purpose	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
using	VBG	O
chlorhexidine	JJ	PM
gluconate	NN	PM
(	(	PM
CHG	NNP	PM
)	)	PM
in	IN	O
a	DT	O
prophylactic	JJ	O
perirectal	JJ	O
skin-care	JJ	O
regimen	NNS	O
decreases	VBZ	O
perirectal	JJ	O
infections	NNS	O
and	CC	O
whether	IN	O
it	PRP	O
produces	VBZ	O
more	JJR	O
skin	JJ	O
irritation	NN	O
than	IN	O
a	DT	O
nonmedicated	JJ	O
skin	NN	O
cleanser	NN	O
.	.	O

The	DT	O
sample	NN	O
consisted	VBD	O
of	IN	O
40	CD	O
patients	NNS	O
,	,	O
16	CD	O
of	IN	O
whom	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
use	VB	O
chlorhexidine	NN	PM
and	CC	O
24	CD	O
of	IN	O
whom	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
use	VB	O
nonmedicated	JJ	PH
skin	NN	PH
cleanser	NN	PH
.	.	O

Chi-square	JJ	O
and	CC	O
t-tests	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
analyze	VB	O
the	DT	O
incidence	NN	O
of	IN	O
skin	JJ	O
breakdown	NN	O
and	CC	O
rectal	JJ	O
infections	NNS	O
;	:	O
the	DT	O
correlation	NN	O
between	IN	O
the	DT	O
two	CD	O
factors	NNS	O
;	:	O
a	DT	O
positive	JJ	O
history	NN	O
of	IN	O
rectal	JJ	O
infections	NNS	O
,	,	O
fissures	NNS	O
,	,	O
or	CC	O
hemorrhoids	NNS	O
;	:	O
presence	NN	O
of	IN	O
hemorrhoids	NNS	O
;	:	O
severity	NN	O
of	IN	O
diarrhea	NN	O
;	:	O
and	CC	O
duration	NN	O
and	CC	O
severity	NN	O
of	IN	O
granulocytopenia	NN	O
.	.	O

A	DT	O
positive	JJ	O
relationship	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
severity	NN	O
of	IN	O
granulocytopenia	NN	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
rectal	JJ	O
infections	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
perirectal	JJ	O
infections	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.35	CD	O
)	)	O
or	CC	O
skin	JJ	O
breakdown	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.18	CD	O
)	)	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
data	NN	O
suggest	NN	O
that	IN	O
CHG	NNP	O
does	VBZ	O
not	RB	O
offer	VB	O
increased	JJ	O
protection	NN	O
against	IN	O
perirectal	JJ	O
infections	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
intensive	JJ	O
chemotherapy	NN	O
,	,	O
nor	CC	O
is	VBZ	O
it	PRP	O
more	RBR	O
irritating	JJ	O
than	IN	O
a	DT	O
nonmedicated	JJ	O
skin	NN	O
cleanser	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
hygienic	JJ	O
measures	NNS	O
such	JJ	O
as	IN	O
using	VBG	O
skin	JJ	O
disinfectants	NNS	O
to	TO	O
prevent	VB	O
infections	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
immunocompromised	VBN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
follicular	JJ	O
dynamics	NNS	O
of	IN	O
corifollitropin	NN	PM
alfa	NN	PM
versus	NN	O
recombinant	JJ	PM
FSH	NNP	PM
during	IN	O
ovarian	JJ	O
stimulation	NN	O
for	IN	O
IVF	NNP	O
.	.	O

A	NNP	O
single	JJ	O
injection	NN	O
of	IN	O
corifollitropin	NN	PM
alfa	NN	PM
can	MD	O
replace	VB	O
seven	CD	O
daily	JJ	O
injections	NNS	O
of	IN	O
recombinant	JJ	PM
FSH	NNP	PM
(	(	PM
rFSH	NN	PM
)	)	PM
using	VBG	O
a	DT	O
gonadotrophin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
protocol	NN	O
in	IN	O
ovarian	JJ	O
stimulation	NN	O
prior	RB	O
to	TO	O
IVF	NNP	O
or	CC	O
intracytoplasmic	JJ	O
sperm	JJ	O
injection	NN	O
.	.	O

This	DT	O
double-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
assessed	VBD	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
150?g	CD	O
corifollitropin	NN	O
alfa	NN	O
versus	IN	O
daily	JJ	O
200IU	CD	O
rFSH	NN	O
in	IN	O
1509	CD	O
patients	NNS	O
.	.	O

Comparative	JJ	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
FSH	NNP	O
immunoreactivity	NN	O
(	(	O
pharmacokinetics	NNS	O
)	)	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
and	CC	O
size	NN	O
of	IN	O
growing	VBG	O
follicles	NNS	O
,	,	O
and	CC	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
as	IN	O
biomarkers	NNS	O
of	IN	O
ovarian	JJ	O
response	NN	O
(	(	O
pharmacodynamics	NNS	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
follicular	JJ	O
development	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

By	IN	O
stimulation	NN	O
day	NN	O
8	CD	O
,	,	O
33	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
corifollitropin	NN	O
alfa	NN	O
reached	VBD	O
the	DT	O
criterion	NN	O
for	IN	O
human	JJ	O
chorionic	NN	O
gonadotrophin	NN	O
(	(	O
HCG	NNP	O
)	)	O
injection	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
follicles	NNS	O
?11mm	NNP	O
was	VBD	O
slightly	RB	O
higher	JJR	O
after	IN	O
corifollitropin	NN	O
alfa	NN	O
compared	VBN	O
with	IN	O
daily	JJ	O
rFSH	NN	O
at	IN	O
stimulation	NN	O
day	NN	O
8	CD	O
(	(	O
difference	NN	O
,	,	O
1.2	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
0.5-1.8	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
HCG	NNP	O
injection	NN	O
(	(	O
difference	NN	O
,	,	O
2.1	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.4-2.8	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
rise	NN	O
of	IN	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Although	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
and	CC	O
rFSH	NN	O
are	VBP	O
quite	RB	O
different	JJ	O
their	PRP$	O
pharmacodynamic	JJ	O
profiles	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
used	VBN	O
are	VBP	O
similar	JJ	O
.	.	O

A	DT	O
single	JJ	O
injection	NN	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
can	MD	O
replace	VB	O
seven	CD	O
daily	JJ	O
injections	NNS	O
of	IN	O
recombinant	JJ	O
FSH	NNP	O
(	(	O
rFSH	NN	O
)	)	O
using	VBG	O
a	DT	O
gonadotrophin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
protocol	NN	O
in	IN	O
ovarian	JJ	O
stimulation	NN	O
prior	RB	O
to	TO	O
IVF	NNP	O
or	CC	O
intracytoplasmic	JJ	O
sperm	JJ	O
injection	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	JJ	O
versus	JJ	O
daily	JJ	O
rFSH	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1509	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
to	TO	O
either	VB	O
a	DT	O
single	JJ	O
injection	NN	O
of	IN	O
150?g	CD	O
corifollitropin	NN	O
alfa	NN	O
or	CC	O
to	TO	O
daily	JJ	O
injections	NNS	O
of	IN	O
200IU	CD	O
rFSH	NN	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
of	IN	O
ovarian	JJ	O
stimulation	NN	O
.	.	O

Serum	NNP	O
levels	NNS	O
of	IN	O
FSH	NNP	O
immunoreactivity	NN	O
were	VBD	O
analysed	VBN	O
(	(	O
pharmacokinetic	JJ	O
analysis	NN	O
)	)	O
,	,	O
together	RB	O
with	IN	O
the	DT	O
number	NN	O
and	CC	O
size	NN	O
of	IN	O
growing	VBG	O
follicles	NNS	O
and	CC	O
serum	NN	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
as	IN	O
biomarkers	NNS	O
of	IN	O
the	DT	O
ovarian	JJ	O
response	NN	O
(	(	O
pharmacodynamic	JJ	O
analysis	NN	O
)	)	O
.	.	O

Serum	NNP	O
FSH	NNP	O
immunoreactivity	NN	O
levels	NNS	O
were	VBD	O
higher	JJR	O
up	RB	O
to	TO	O
stimulation	VB	O
day	NN	O
5	CD	O
for	IN	O
corifollitropin	NN	O
alfa	NN	O
compared	VBN	O
with	IN	O
the	DT	O
daily	JJ	O
rFSH	NN	O
regimen	NNS	O
but	CC	O
were	VBD	O
similar	JJ	O
from	IN	O
day	NN	O
8	CD	O
onwards	NNS	O
,	,	O
when	WRB	O
patients	NNS	O
started	VBD	O
rFSH	RB	O
if	IN	O
the	DT	O
criteria	NN	O
for	IN	O
human	JJ	O
chorionic	NN	O
gonadotrophin	NN	O
were	VBD	O
not	RB	O
yet	RB	O
reached	VBN	O
.	.	O

Corifollitropin	NNP	O
alfa	JJ	O
treatment	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
similar	JJ	O
growth	NN	O
rate	NN	O
of	IN	O
follicles	NNS	O
though	IN	O
a	DT	O
slightly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
follicles	NNS	O
were	VBD	O
recruited	VBN	O
compared	VBN	O
with	IN	O
daily	JJ	O
rFSH	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
corifollitropin	NN	PM
alfa	NN	PM
and	CC	O
rFSH	NN	PM
are	VBP	O
quite	RB	O
different	JJ	O
but	CC	O
their	PRP$	O
induced	JJ	O
pharmacodynamic	JJ	O
effects	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
used	VBN	O
are	VBP	O
similar	JJ	O
.	.	O

14	CD	O
day	NN	O
endoscopy	NN	O
study	NN	O
comparing	VBG	O
risedronate	NN	PM
and	CC	O
alendronate	NN	PM
in	IN	O
postmenopausal	JJ	O
women	NNS	O
stratified	VBN	O
by	IN	O
Helicobacter	NNP	O
pylori	NN	O
status	NN	O
.	.	O

OBJECTIVE	NNP	O
Bisphosphonates	NNPS	PM
are	VBP	O
effective	JJ	O
treatment	NN	O
for	IN	O
osteoporosis	NN	O
but	CC	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
gastrointestinal	JJ	O
(	(	O
GI	NNP	O
)	)	O
mucosal	NN	O
injury	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
incidence	NN	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
after	IN	O
treatment	NN	O
with	IN	O
risedronate	NN	PM
,	,	PM
a	DT	PM
pyridinyl	NN	PM
bisphosphonate	NN	PM
,	,	O
or	CC	O
alendronate	NN	PM
,	,	PM
a	DT	PM
primary	JJ	PM
amino	NN	PM
bisphosphonate	NN	PM
,	,	O
in	IN	O
healthy	JJ	O
postmenopausal	NN	O
women	NNS	O
stratified	VBN	O
by	IN	O
Helicobacter	NNP	O
pylori	NN	O
status	NN	O
.	.	O

METHODS	NNP	O
Subjects	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
risedronate	NN	PM
5	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
318	CD	O
)	)	O
or	CC	O
alendronate	$	PM
10	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
317	CD	O
)	)	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Endoscopy	NNP	S
and	CC	O
evaluator-blind	JJ	O
assessments	NNS	O
of	IN	O
the	DT	O
esophageal	NN	O
,	,	O
gastric	NN	O
,	,	O
and	CC	O
duodenal	JJ	O
mucosa	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
on	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
.	.	O

RESULTS	NNP	O
Overall	NNP	O
,	,	O
gastric	JJ	O
ulcers	NNS	O
>	VBP	O
or	CC	O
=	VBP	O
3	CD	O
mm	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
18	CD	O
(	(	O
6.0	CD	O
%	NN	O
)	)	O
of	IN	O
300	CD	O
evaluable	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
risedronate	NN	PM
group	NN	O
and	CC	O
36	CD	O
(	(	O
12.1	CD	O
%	NN	O
)	)	O
of	IN	O
297	CD	O
in	IN	O
the	DT	O
alendronate	NN	O
group	NN	O
during	IN	O
treatment	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

On	IN	O
Day	NNP	O
8	CD	O
,	,	O
the	DT	O
incidences	NNS	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
in	IN	O
the	DT	O
risedronate	NN	PM
and	CC	O
alendronate	NN	PM
groups	NNS	O
were	VBD	O
3.6	CD	O
%	NN	O
and	CC	O
6.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.133	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
Day	NNP	O
15	CD	O
,	,	O
they	PRP	O
were	VBD	O
3.3	CD	O
%	NN	O
and	CC	O
8.7	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.008	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
H.	NNP	O
pylori	NN	O
status	NN	O
.	.	O

Mean	NNP	O
gastric	JJ	O
endoscopy	NN	O
scores	NNS	O
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
risedronate	NN	PM
group	NN	O
than	IN	O
in	IN	O
the	DT	O
alendronate	NN	PM
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Mean	JJ	O
esophageal	NN	O
and	CC	O
duodenal	JJ	O
endoscopy	NN	O
scores	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
.	.	O

When	WRB	O
the	DT	O
treatment	NN	O
groups	NNS	O
were	VBD	O
combined	VBN	O
,	,	O
gastric	JJ	O
endoscopy	NN	O
scores	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
among	IN	O
H.	NNP	O
pylori	FW	O
negative	JJ	O
than	IN	O
H.	NNP	O
pylori	FW	O
positive	JJ	O
subjects	NNS	O
at	IN	O
Days	NNP	O
8	CD	O
and	CC	O
15	CD	O
(	(	O
p	NN	O
<	RB	O
0.05	CD	O
)	)	O
.	.	O

Upper	NNP	O
GI	NNP	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
by	IN	O
18	CD	O
(	(	O
5.7	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
in	IN	O
the	DT	O
risedronate	NN	PM
group	NN	O
(	(	O
19	CD	O
events	NNS	O
)	)	O
and	CC	O
28	CD	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
in	IN	O
the	DT	O
alendronate	NN	PM
group	NN	O
(	(	O
32	CD	O
events	NNS	O
)	)	O
.	.	O

Symptoms	NNS	O
did	VBD	O
not	RB	O
predict	VB	O
the	DT	O
presence	NN	O
of	IN	O
mucosal	JJ	O
damage	NN	O
.	.	O

CONCLUSION	NNP	O
Risedronate	NNP	PM
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
incidence	NN	O
of	IN	O
gastric	JJ	O
ulcers	NNS	O
than	IN	O
alendronate	NN	PM
.	.	O

H.	NNP	O
pylori	JJ	O
infection	NN	O
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
incidence	NN	O
of	IN	O
bisphosphonate	NN	O
related	VBN	O
gastric	JJ	O
ulcers	NNS	O
.	.	O

The	DT	O
findings	NNS	O
from	IN	O
this	DT	O
14	CD	O
day	NN	O
study	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
support	VBP	O
the	DT	O
hypothesis	NN	O
that	WDT	O
bisphosphonates	VBZ	O
may	MD	O
differ	VB	O
from	IN	O
one	CD	O
another	DT	O
in	IN	O
their	PRP$	O
potential	JJ	O
to	TO	O
produce	VB	O
upper	JJ	O
GI	NNP	O
mucosal	NN	O
damage	NN	O
.	.	O

Prophylactic	JJ	PM
lidocaine	NN	PM
in	IN	O
the	DT	O
early	JJ	O
phase	NN	O
of	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Four	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
with	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
seen	VBN	O
within	IN	O
6	CD	O
hours	NNS	O
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
entered	VBD	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
lidocaine	NN	PM
vs	NN	O
placebo	NN	C
.	.	O

During	IN	O
the	DT	O
1	CD	O
hour	NN	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
the	DT	O
incidence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
or	CC	O
sustained	VBN	O
ventricular	JJ	O
tachycardia	NN	O
among	IN	O
the	DT	O
204	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
low	JJ	O
,	,	O
1.5	CD	O
%	NN	O
.	.	O

Lidocaine	NNP	PM
,	,	O
given	VBN	O
in	IN	O
a	DT	O
300	CD	O
mg	NN	O
dose	VBD	O
intramuscularly	RB	O
followed	VBN	O
by	IN	O
100	CD	O
mg	NN	O
intravenously	RB	O
,	,	O
did	VBD	O
not	RB	O
prevent	VB	O
sustained	JJ	O
ventricular	JJ	O
tachycardia	NN	O
,	,	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
warning	VBG	O
arrhythmias	NNS	O
between	IN	O
15	CD	O
and	CC	O
45	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
lidocaine	NN	PM
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
average	JJ	O
plasma	JJ	O
lidocaine	JJ	PM
level	NN	O
10	CD	O
minutes	NNS	O
after	IN	O
administration	NN	O
for	IN	O
patients	NNS	O
without	IN	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
for	IN	O
patients	NNS	O
with	IN	O
an	DT	O
acute	JJ	O
infarction	NN	O
.	.	O

The	DT	O
mean	JJ	O
plasma	NN	O
lidocaine	JJ	PM
level	NN	O
of	IN	O
patients	NNS	O
on	IN	O
beta-blocking	JJ	O
agents	NNS	O
was	VBD	O
no	DT	O
different	JJ	O
from	IN	O
that	DT	O
in	IN	O
patients	NNS	O
not	RB	O
on	IN	O
beta	NN	O
blocking	VBG	O
agents	NNS	O
.	.	O

During	IN	O
the	DT	O
1-hour	JJ	O
study	NN	O
period	NN	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
side	NN	O
effects	NNS	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
lidocaine	NN	O
group	NN	O
,	,	O
hypotension	NN	O
occurred	VBD	O
in	IN	O
11	CD	O
patients	NNS	O
,	,	O
nine	CD	O
of	IN	O
whom	WP	O
had	VBD	O
received	VBN	O
lidocaine	NN	O
,	,	O
and	CC	O
four	CD	O
patients	NNS	O
died	VBD	O
from	IN	O
asystole	NN	O
,	,	O
three	CD	O
of	IN	O
whom	WP	O
had	VBD	O
had	VBN	O
lidocaine	NN	PM
.	.	O

We	PRP	O
can	MD	O
not	RB	O
advocate	VB	O
the	DT	O
administration	NN	O
of	IN	O
lidocaine	JJ	PM
prophylactically	RB	O
in	IN	O
the	DT	O
early	JJ	O
hours	NNS	O
of	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Intravenous	JJ	O
platelet	NN	O
blockade	NN	O
with	IN	O
cangrelor	NN	PM
during	IN	O
PCI	NNP	O
.	.	O

BACKGROUND	NNP	O
Intravenous	NNP	O
cangrelor	NN	PM
,	,	O
a	DT	O
rapid-acting	NN	O
,	,	O
reversible	JJ	O
adenosine	NN	O
diphosphate	NN	O
(	(	O
ADP	NNP	O
)	)	O
receptor	NN	O
antagonist	NN	O
,	,	O
might	MD	O
reduce	VB	O
ischemic	JJ	O
events	NNS	O
during	IN	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
we	PRP	O
randomly	VBP	O
assigned	JJ	O
5362	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
not	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
clopidogrel	NN	O
to	TO	O
receive	VB	O
either	DT	O
cangrelor	NN	PM
or	CC	O
placebo	NN	C
at	IN	O
the	DT	O
time	NN	O
of	IN	O
PCI	NNP	O
,	,	O
followed	VBN	O
by	IN	O
600	CD	O
mg	NNS	O
of	IN	O
clopidogrel	NN	PM
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
composite	JJ	O
of	IN	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
or	CC	O
ischemia-driven	JJ	O
revascularization	NN	O
at	IN	O
48	CD	O
hours	NNS	O
.	.	O

Enrollment	NN	O
was	VBD	O
stopped	VBN	O
when	WRB	O
an	DT	O
interim	JJ	O
analysis	NN	O
concluded	VBD	O
that	IN	O
the	DT	O
trial	NN	O
would	MD	O
be	VB	O
unlikely	JJ	O
to	TO	O
show	VB	O
superiority	NN	O
for	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
occurred	VBD	O
in	IN	O
185	CD	O
of	IN	O
2654	CD	O
patients	NNS	O
receiving	VBG	O
cangrelor	NN	PM
(	(	O
7.0	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
210	CD	O
of	IN	O
2641	CD	O
patients	NNS	O
receiving	VBG	O
placebo	NN	C
(	(	O
8.0	CD	O
%	NN	O
)	)	O
(	(	O
odds	NNS	O
ratio	NN	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
0.87	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.71	CD	O
to	TO	O
1.07	CD	O
;	:	O
P=0.17	NNP	O
)	)	O
(	(	O
modified	VBN	O
intention-to-treat	NN	O
population	NN	O
adjusted	VBN	O
for	IN	O
missing	VBG	O
data	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
cangrelor	NN	PM
group	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
two	CD	O
prespecified	VBD	O
secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
at	IN	O
48	CD	O
hours	NNS	O
:	:	O
the	DT	O
rate	NN	O
of	IN	O
stent	JJ	O
thrombosis	NN	O
,	,	O
from	IN	O
0.6	CD	O
%	NN	O
to	TO	O
0.2	CD	O
%	NN	O
(	(	O
odds	JJ	O
ratio	NN	O
,	,	O
0.31	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.11	CD	O
to	TO	O
0.85	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
death	NN	O
from	IN	O
any	DT	O
cause	NN	O
,	,	O
from	IN	O
0.7	CD	O
%	NN	O
to	TO	O
0.2	CD	O
%	NN	O
(	(	O
odds	JJ	O
ratio	NN	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.13	CD	O
to	TO	O
0.83	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
blood	NN	O
transfusion	NN	O
(	(	O
1.0	CD	O
%	NN	O
in	IN	O
the	DT	O
cangrelor	NN	PM
group	NN	O
and	CC	O
0.6	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
,	,	O
P=0.13	NNP	O
)	)	O
,	,	O
though	IN	O
major	JJ	O
bleeding	VBG	O
on	IN	O
one	CD	O
scale	NN	O
was	VBD	O
increased	VBN	O
in	IN	O
the	DT	O
cangrelor	NN	O
group	NN	O
,	,	O
from	IN	O
3.5	CD	O
%	NN	O
to	TO	O
5.5	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
because	IN	O
of	IN	O
more	JJR	O
groin	JJ	O
hematomas	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
use	NN	O
of	IN	O
periprocedural	JJ	O
cangrelor	NN	PM
during	IN	O
PCI	NNP	O
was	VBD	O
not	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
reducing	VBG	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
.	.	O

The	DT	O
prespecified	JJ	O
secondary	JJ	O
end	NN	O
points	NNS	O
of	IN	O
stent	JJ	O
thrombosis	NN	O
and	CC	O
death	NN	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
cangrelor	NN	PM
group	NN	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
transfusion	NN	O
.	.	O

Further	NNP	O
study	NN	O
of	IN	O
intravenous	JJ	O
ADP	NNP	PM
blockade	NN	PM
with	IN	PM
cangrelor	NN	PM
may	MD	O
be	VB	O
warranted	VBN	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00385138	NNP	O
.	.	O

)	)	O
Randomized	NNP	O
comparison	NN	O
of	IN	O
two	CD	O
communication	NN	O
interventions	NNS	O
for	IN	O
preschoolers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
randomized	JJ	O
group	NN	O
experiment	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
2	CD	E
communication	NN	E
interventions	NNS	E
(	(	E
Responsive	JJ	E
Education	NN	E
and	CC	E
Prelinguistic	NNP	E
Milieu	NNP	E
Teaching	NNP	E
[	NNP	E
RPMT	NNP	E
]	NNP	E
and	CC	E
the	DT	E
Picture	NNP	E
Exchange	NNP	E
Communication	NNP	E
System	NNP	E
[	NNP	E
PECS	NNP	E
]	NNP	E
)	)	O
in	IN	O
36	CD	O
preschoolers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Each	DT	O
treatment	NN	O
was	VBD	O
delivered	VBN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
,	,	O
in	IN	O
20-min	JJ	O
sessions	NNS	O
,	,	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
results	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
RPMT	NNP	E
facilitated	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
generalized	JJ	O
turn	NN	O
taking	VBG	O
and	CC	O
generalized	VBN	O
initiating	NN	O
joint	JJ	O
attention	NN	O
more	RBR	O
than	IN	O
did	VBD	O
the	DT	O
PECS	NNP	O
.	.	O

The	DT	O
latter	JJ	O
effect	NN	O
occurred	VBD	O
only	RB	O
for	IN	O
children	NNS	O
who	WP	O
began	VBD	O
treatment	NN	O
with	IN	O
at	IN	O
least	JJS	O
some	DT	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
PECS	NNP	PM
facilitated	VBD	O
generalized	JJ	O
requests	NNS	O
more	RBR	O
than	IN	O
the	DT	O
RPMT	NNP	O
in	IN	O
children	NNS	O
with	IN	O
very	RB	O
little	JJ	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
prior	RB	O
to	TO	O
treatment	NN	O
.	.	O

These	DT	O
effect	NN	O
sizes	NNS	O
were	VBD	O
large	JJ	O
.	.	O

Remifentanil	NNP	O
with	IN	O
morphine	JJ	O
transitional	JJ	O
analgesia	NN	O
shortens	VBZ	O
neurological	JJ	O
recovery	NN	O
compared	VBN	O
to	TO	O
fentanyl	VB	O
for	IN	O
supratentorial	JJ	O
craniotomy	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
recovery	NN	O
profiles	NNS	O
,	,	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
remifentanil	NN	O
and	CC	O
morphine	NN	O
for	IN	O
transitional	JJ	O
analgesia	NN	O
with	IN	O
fentanyl	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
craniotomy	NN	O
for	IN	O
supratentorial	JJ	O
mass	NN	O
lesions	NNS	O
.	.	O

METHODS	NNP	O
Ninety-one	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicentre	FW	O
study	NN	O
.	.	O

Anesthesia	NNP	PM
was	VBD	O
induced	VBN	O
with	IN	O
thiopental	JJ	O
and	CC	O
remifentanil	NN	PM
(	(	PM
1.0	CD	PM
micro	NN	PM
g	NN	PM
x	NNP	PM
kg	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
bolus	NN	PM
and	CC	O
a	DT	O
1	CD	PM
micro	NN	PM
g	NN	PM
x	NNP	PM
kg	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
x	VBP	PM
min	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
infusion	NN	PM
)	)	PM
or	CC	O
fentanyl	NN	PM
(	(	PM
1	CD	PM
micro	NN	PM
g	NN	PM
x	NNP	PM
kg	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
bolus	NN	PM
and	CC	O
a	DT	O
1.0	CD	PM
micro	NN	PM
g	NN	PM
x	NNP	PM
kg	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
x	VBP	PM
min	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
infusion	NN	PM
)	)	O
.	.	O

The	DT	O
opioid	JJ	PM
infusion	NN	PM
continued	VBD	O
until	IN	O
the	DT	O
level	NN	O
of	IN	O
anesthesia	NN	PM
was	VBD	O
deemed	VBN	O
appropriate	JJ	O
for	IN	O
intubation	NN	O
.	.	O

Anesthesia	NNP	PM
was	VBD	O
maintained	VBN	O
with	IN	O
N	NNP	O
(	(	O
2	CD	O
)	)	O
O/O	NNP	O
(	(	O
2	CD	O
)	)	O
,	,	O
isoflurane	$	PM
0.5	CD	PM
MAC	NNP	PM
and	CC	O
remifentanil	VB	PM
0.2	CD	PM
micro	NN	PM
g	NN	PM
x	NNP	PM
kg	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
x	VBP	PM
min	NN	PM
(	(	PM
-1	JJ	PM
)	)	PM
or	CC	O
fentanyl	$	PM
0.04	CD	PM
micro	NN	PM
g	NN	PM
x	NNP	PM
kg	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
x	VBP	PM
min	NN	PM
(	(	PM
-1	NNP	PM
)	)	PM
.	.	O

At	IN	PH
bone	NN	PH
flap	NN	PH
replacement	NN	PH
,	,	O
either	DT	PM
morphine	NN	PM
0.08	CD	PM
mg	NN	PM
x	NN	O
kg	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
remifentanil	JJ	PM
group	NN	PM
)	)	PM
or	CC	O
saline	NN	PM
(	(	O
fentanyl	JJ	O
group	NN	O
)	)	O
was	VBD	O
given	VBN	O
.	.	O

RESULTS	NNP	O
Systolic	NNP	O
blood	NN	O
pressure	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
receiving	VBG	O
fentanyl	NN	O
during	IN	O
induction	NN	O
(	(	O
145.6	CD	O
+/-17.5	JJ	O
mmHg	NN	O
vs	NN	O
128.8	CD	O
+/-18.3	JJ	O
mmHg	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
intubation	NN	O
(	(	O
126.9	CD	O
+/-17.1	JJ	O
vs	NN	O
110.9	CD	O
+/-16.5	JJ	O
mmHg	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Median	JJ	O
time	NN	O
to	TO	O
tracheal	VB	O
extubation	NN	O
was	VBD	O
similar	JJ	O
but	CC	O
less	RBR	O
variable	JJ	O
in	IN	O
the	DT	O
remifentanil	NN	O
group	NN	O
(	(	O
remifentanil	JJ	O
=	$	O
8	CD	O
min	NN	O
:	:	O
range	NN	O
=	VBZ	O
2-44	JJ	O
min	NN	O
;	:	O
fentanyl	CC	O
=	$	O
8	CD	O
min	NN	O
:	:	O
range	NN	O
=	VBZ	O
1-732	JJ	O
min	NN	O
)	)	O
.	.	O

The	DT	O
fentanyl	JJ	O
patients	NNS	O
required	VBD	O
a	DT	O
longer	JJR	O
time	NN	O
to	TO	O
achieve	VB	O
the	DT	O
first	JJ	O
normal	JJ	O
neurological	JJ	O
score	NN	O
(	(	O
fentanyl	JJ	O
=	$	O
38.0	CD	O
min	NN	O
;	:	O
remifentanil	CC	O
=	$	O
26.0	CD	O
min	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
.	.	O

Both	CC	O
the	DT	O
anesthesiologists	NNS	O
and	CC	O
the	DT	O
recovery	NN	O
room	NN	O
nurses	NNS	O
rated	VBD	O
remifentanil	JJ	O
better	RBR	O
with	IN	O
respect	NN	O
to	TO	O
level	NN	O
of	IN	O
consciousness	NN	O
.	.	O

Analgesics	NNS	O
were	VBD	O
required	VBN	O
earlier	RBR	O
in	IN	O
patients	NNS	O
receiving	VBG	O
remifentanil	NN	O
;	:	O
median	JJ	O
time	NN	O
0.5	CD	O
vs	NN	O
1.08	CD	O
hr	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
.	.	O

CONCLUSIONS	NNP	O
Remifentanil	NNP	O
is	VBZ	O
a	DT	O
suitable	JJ	O
alternative	NN	O
to	TO	O
fentanyl	VB	O
in	IN	O
supratentorial	JJ	O
craniotomy	NN	O
.	.	O

Time	NN	O
to	TO	O
preoperative	VB	O
neurological	JJ	O
recovery	NN	O
is	VBZ	O
faster	RBR	O
and	CC	O
morphine	VB	O
provides	VBZ	O
some	DT	O
transitional	JJ	O
analgesia	NN	O
without	IN	O
compromising	VBG	O
the	DT	O
quality	NN	O
of	IN	O
recovery	NN	O
.	.	O

Effect	NN	O
of	IN	O
delayed	JJ	S
cord	NN	S
clamping	VBG	S
on	IN	O
iron	NN	O
stores	NNS	O
in	IN	O
infants	NNS	O
born	VBN	O
to	TO	O
anemic	JJ	O
mothers	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
cord	NN	O
clamping	VBG	O
on	IN	O
iron	NN	O
stores	NNS	O
of	IN	O
infants	NNS	O
born	VBN	O
to	TO	O
anemic	VB	O
mothers	NNS	O
at	IN	O
3	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NN	O
Teaching	NNP	O
hospital	NN	O
.	.	O

METHODS	NNP	O
Infants	NNPS	O
born	VBN	O
to	TO	O
mothers	NNS	O
with	IN	O
hemoglobin	NN	O
(	(	O
Hb	NNP	O
)	)	O
<	VBD	O
100	CD	O
g/L	NNS	O
were	VBD	O
randomized	VBN	O
at	IN	O
delivery	NN	O
to	TO	O
either	DT	O
immediate	JJ	S
cord	NN	S
clamping	NN	S
(	(	O
early	JJ	O
group	NN	O
)	)	O
or	CC	O
cord	NN	S
clamping	VBG	S
delayed	VBN	S
till	JJ	S
descent	NN	S
of	IN	S
placenta	NN	S
into	IN	S
vagina	NN	S
(	(	O
delayed	VBN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
outcome	NN	O
measures	NNS	O
were	VBD	O
infant	NN	O
's	POS	O
hemoglobin	NN	O
and	CC	O
serum	NN	O
ferritin	VBP	O
3	CD	O
months	NNS	O
after	IN	O
delivery	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
102	CD	O
neonates	NNS	O
randomized	VBN	O
to	TO	O
early	JJ	O
(	(	O
n	JJ	O
=	NNP	O
43	CD	O
)	)	O
or	CC	O
delayed	VBN	O
cord	NN	O
clamping	NN	O
(	(	O
n	JJ	O
=	NNP	O
59	CD	O
)	)	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
maternal	JJ	O
age	NN	O
,	,	O
parity	NN	O
,	,	O
weight	NN	O
and	CC	O
supplemental	JJ	O
iron	NN	O
intake	NN	O
,	,	O
infant	JJ	O
s	NN	O
birth	NN	O
weight	NN	O
,	,	O
gestation	NN	O
and	CC	O
sex	NN	O
.	.	O

The	DT	O
mean	JJ	O
infant	NN	O
ferritin	NN	O
and	CC	O
Hb	NNP	O
at	IN	O
3	CD	O
months	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
delayed	JJ	S
clamping	NN	S
group	NN	O
(	(	O
118.4	CD	O
microg/L	NN	O
and	CC	O
99	CD	O
g/L	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
early	JJ	S
clamping	NN	S
group	NN	O
(	(	O
73	CD	O
microg/L	NN	O
and	CC	O
88	CD	O
g/L	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
Hb	NNP	O
(	(	O
g/L	NN	O
)	)	O
at	IN	O
3	CD	O
months	NNS	O
adjusted	VBN	O
for	IN	O
co-variates	NNS	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
delayed	JJ	S
clamping	NN	S
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
early	JJ	S
clamping	NN	S
group	NN	O
(	(	O
-1.09	NNP	O
,	,	O
95	CD	O
%	NN	O
CI-1.58	NNP	O
to	TO	O
-0.62	VB	O
,	,	O
p	VB	O
>	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
odds	NNS	O
for	IN	O
anemia	NN	O
(	(	O
<	JJ	O
100	CD	O
g/L	NN	O
)	)	O
at	IN	O
3	CD	O
months	NNS	O
was	VBD	O
7.7	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.84-34.9	CD	O
)	)	O
times	NNS	O
higher	RBR	O
in	IN	O
the	DT	O
early	JJ	O
compared	VBN	O
to	TO	O
the	DT	O
delayed	JJ	S
clamping	NN	S
group	NN	O
.	.	O

CONCLUSION	NNP	O
Iron	NNP	O
stores	NNS	O
and	CC	O
Hb	NNP	O
in	IN	O
infancy	NN	O
can	MD	O
be	VB	O
improved	VBN	O
in	IN	O
neonates	NNS	O
born	VBN	O
to	TO	O
anemic	VB	O
mothers	NNS	O
by	IN	O
delaying	VBG	S
cord	NN	S
clamping	NN	S
at	IN	O
birth	NN	O
.	.	O

Teaching	VBG	PS
emotion	NN	PS
recognition	NN	PS
skills	NNS	PS
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
an	DT	O
emotion	NN	PS
training	NN	PS
programme	NN	PS
.	.	E

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
have	VBP	O
difficulties	NNS	O
in	IN	O
emotion	NN	O
recognition	NN	O
and	CC	O
a	DT	O
number	NN	O
of	IN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
designed	VBN	O
to	TO	O
target	VB	O
these	DT	O
problems	NNS	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
emotion	NN	PS
training	NN	PS
interventions	NNS	PS
have	VBP	O
been	VBN	O
trialled	VBN	O
with	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
co-morbid	JJ	O
ID	NNP	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
emotion	NN	E
training	NN	E
programme	NN	E
for	IN	O
a	DT	O
group	NN	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
range	NN	O
of	IN	O
intellectual	JJ	O
ability	NN	O
.	.	O

METHODS	NNP	O
Participants	NNPS	O
were	VBD	O
55	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBN	O
4-7	CD	O
years	NNS	O
(	(	O
FSIQ	NNP	O
42-107	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
or	CC	O
control	VB	C
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
watched	VBD	O
a	DT	O
DVD	NNP	PS
designed	VBN	PS
to	TO	PS
teach	VB	PS
emotion	NN	PS
recognition	NN	PS
skills	NNS	PS
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
(	(	O
the	DT	O
Transporters	NNPS	E
)	)	O
,	,	O
whereas	IN	O
the	DT	O
control	NN	O
group	NN	O
watched	VBD	C
a	DT	C
DVD	NNP	C
of	IN	C
Thomas	NNP	C
the	DT	C
Tank	NNP	C
Engine	NNP	C
.	.	O

Participants	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
complete	VB	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
tasks	NNS	O
,	,	O
mindreading	VBG	O
and	CC	O
theory	NN	O
of	IN	O
mind	NN	O
(	(	O
TOM	NNP	O
)	)	O
tasks	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
4-week	JJ	O
intervention	NN	O
period	NN	O
,	,	O
and	CC	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Analyses	NNP	O
controlled	VBD	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
chronological	JJ	O
age	NN	O
,	,	O
verbal	JJ	O
intelligence	NN	O
,	,	O
gender	NN	O
and	CC	O
DVD	NNP	O
viewing	VBG	O
time	NN	O
on	IN	O
outcomes	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
improved	JJ	O
performance	NN	O
in	IN	O
the	DT	O
recognition	NN	O
of	IN	O
anger	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
few	JJ	O
improvements	NNS	O
maintained	VBD	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
generalisation	NN	O
of	IN	O
skills	NNS	O
to	TO	O
TOM	NNP	O
or	CC	O
social	JJ	O
skills	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	E
Transporters	NNP	PS
programme	NN	PS
showed	VBD	O
limited	JJ	O
efficacy	NN	O
in	IN	O
teaching	VBG	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
lower	JJR	O
range	NN	O
of	IN	O
cognitive	JJ	O
ability	NN	O
.	.	O

Improvements	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
recognition	NN	O
of	IN	O
expressions	NNS	O
of	IN	O
anger	NN	O
,	,	O
with	IN	O
poor	JJ	O
maintenance	NN	O
of	IN	O
these	DT	O
skills	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

These	DT	O
findings	NNS	O
provide	VBP	O
limited	JJ	O
support	NN	O
for	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
Transporters	NNP	PS
programme	NN	PS
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
of	IN	O
a	DT	O
lower	JJR	O
cognitive	JJ	O
range	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
yoga	NNP	PH
versus	NN	PH
stretching	VBG	PH
for	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
protocol	NN	O
for	IN	O
the	DT	O
Yoga	NNP	O
Exercise	NNP	O
Self-care	NNP	O
(	(	O
YES	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Back	NNP	O
pain	NN	O
,	,	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
prevalent	JJ	O
conditions	NNS	O
afflicting	VBG	O
American	JJ	O
adults	NNS	O
,	,	O
is	VBZ	O
the	DT	O
leading	VBG	O
reason	NN	O
for	IN	O
using	VBG	O
complementary	JJ	PH
and	CC	PH
alternative	JJ	PH
medicine	NN	PH
(	(	PH
CAM	NNP	PH
)	)	PH
therapies	NNS	PH
.	.	O

Yoga	NNP	PH
is	VBZ	O
an	DT	O
increasingly	RB	O
popular	JJ	O
mind-body	NN	O
CAM	NNP	O
therapy	NN	O
often	RB	O
used	VBN	O
for	IN	O
relieving	VBG	O
back	RB	O
pain	NN	O
and	CC	O
several	JJ	O
small	JJ	O
studies	NNS	O
have	VBP	O
found	VBN	O
yoga	RB	O
effective	JJ	O
for	IN	O
this	DT	O
condition	NN	O
.	.	O

This	DT	O
study	NN	O
will	MD	O
assess	VB	O
whether	IN	O
yoga	NN	PH
is	VBZ	O
effective	JJ	O
for	IN	O
treating	VBG	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
compared	VBN	O
with	IN	O
self	PRP	E
care	NN	E
and	CC	O
exercise	NN	PH
and	CC	O
will	MD	O
explore	VB	O
the	DT	O
mechanisms	NNS	O
responsible	JJ	O
for	IN	O
any	DT	O
observed	JJ	O
benefits	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
210	CD	O
participants	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
lasting	NN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
will	MD	O
be	VB	O
recruited	VBN	O
from	IN	O
primary	JJ	O
care	NN	O
clinics	NNS	O
of	IN	O
a	DT	O
large	JJ	O
healthcare	NN	O
system	NN	O
based	VBN	O
in	IN	O
Seattle	NNP	O
.	.	O

They	PRP	O
will	MD	O
be	VB	O
randomized	VBN	O
in	IN	O
a	DT	O
2:2:1	CD	O
ratio	NN	O
to	TO	O
receive	VB	O
12	CD	PH
weekly	JJ	PH
yoga	NN	PH
classes	NNS	PH
,	,	PH
12	CD	PH
weekly	JJ	PH
conventional	JJ	PH
therapeutic	JJ	PH
exercise	NN	PH
classes	NNS	PH
of	IN	PH
comparable	JJ	PH
physical	JJ	PH
exertion	NN	PH
,	,	PH
or	CC	PH
a	DT	PH
self-care	JJ	Ot
book	NN	Ot
.	.	O

Interviewers	NNS	O
masked	VBD	O
to	TO	O
participants	NNS	O
'	POS	O
treatment	NN	O
group	NN	O
will	MD	O
assess	VB	O
outcomes	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
26	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

Primary	JJ	O
outcomes	NNS	O
will	MD	O
be	VB	O
back-related	JJ	O
dysfunction	NN	O
and	CC	O
symptom	NN	O
bothersomeness	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
data	NNS	O
will	MD	O
be	VB	O
collected	VBN	O
on	IN	O
physical	JJ	O
measurements	NNS	O
(	(	O
e.g.	NN	O
,	,	O
flexion	NN	O
)	)	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
and	CC	O
saliva	NN	O
samples	NNS	O
will	MD	O
be	VB	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
6	CD	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O

Information	NN	O
will	MD	O
be	VB	O
collected	VBN	O
on	IN	O
specific	JJ	O
physical	JJ	O
,	,	O
psychological	JJ	O
,	,	O
and	CC	O
physiological	JJ	O
factors	NNS	O
to	TO	O
allow	VB	O
exploration	NN	O
of	IN	O
possible	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
through	IN	O
which	WDT	O
yoga	NN	PH
could	MD	O
relieve	VB	O
back	RB	O
pain	NN	O
and	CC	O
dysfunction	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
yoga	NN	PH
will	MD	O
be	VB	O
assessed	VBN	O
using	VBG	O
analysis	NN	O
of	IN	O
covariance	NN	O
(	(	O
using	VBG	O
general	JJ	O
estimating	VBG	O
equations	NNS	O
-	:	O
GEE	NNP	O
)	)	O
within	IN	O
an	DT	O
intention-to-treat	JJ	O
context	NN	O
.	.	O

If	IN	O
yoga	NN	PH
is	VBZ	O
found	VBN	O
effective	JJ	O
,	,	O
further	JJ	O
analyses	NNS	O
will	MD	O
explore	VB	O
whether	IN	O
yoga	NN	O
's	POS	O
benefits	NNS	O
are	VBP	O
attributable	JJ	O
to	TO	O
physical	JJ	O
,	,	O
psychological	JJ	O
and/or	NN	O
physiological	JJ	O
factors	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
will	MD	O
provide	VB	O
the	DT	O
clearest	JJS	O
evidence	NN	O
to	TO	O
date	NN	O
about	IN	O
the	DT	O
value	NN	O
of	IN	O
yoga	NN	PH
as	IN	O
a	DT	O
therapeutic	JJ	O
option	NN	O
for	IN	O
treating	VBG	O
chronic	JJ	O
back	RB	O
pain	NN	O
,	,	O
and	CC	O
if	IN	O
the	DT	O
results	NNS	O
are	VBP	O
positive	JJ	O
,	,	O
will	MD	O
help	VB	O
focus	VB	O
future	JJ	O
,	,	O
more	RBR	O
in-depth	JJ	O
,	,	O
research	NN	O
on	IN	O
the	DT	O
most	RBS	O
promising	JJ	O
potential	JJ	O
mechanisms	NN	O
of	IN	O
action	NN	O
identified	VBN	O
by	IN	O
this	DT	O
study	NN	O
.	.	O

Effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
paromomycin	NN	PM
on	IN	O
endotoxemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
--	:	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
experimental	JJ	O
and	CC	O
clinical	JJ	O
studies	NNS	O
support	VBP	O
the	DT	O
hypothesis	NN	O
that	IN	O
gut-derived	JJ	O
endotoxins	NNS	O
might	MD	O
be	VB	O
of	IN	O
relevance	NN	O
for	IN	O
the	DT	O
development	NN	O
and	CC	O
course	NN	O
of	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
nonabsorbable	JJ	O
,	,	O
broad-spectrum	JJ	O
antibiotic	NN	O
on	IN	O
endotoxemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

Fifty	JJ	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
(	(	O
27	CD	O
with	IN	O
cirrhosis	NN	O
,	,	O
23	CD	O
without	IN	O
cirrhosis	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
paromomycin	NN	PM
sulfate	NN	PM
(	(	PM
3	CD	PM
x	RB	PM
1	CD	PM
g/day	NN	PM
)	)	PM
or	CC	O
placebo	NN	PM
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
for	IN	O
at	IN	O
least	JJS	O
3	CD	O
weeks	NNS	O
,	,	O
and	CC	O
if	IN	O
possible	JJ	O
4	CD	O
weeks	NNS	O
.	.	O

Endotoxin	NNP	O
concentration	NN	O
,	,	O
liver	JJ	O
function	NN	O
tests	NNS	O
,	,	O
and	CC	O
other	JJ	O
laboratory	NN	O
parameters	NNS	O
were	VBD	O
determined	VBN	O
in	IN	O
weekly	JJ	O
intervals	NNS	O
.	.	O

Endotoxin	NNP	O
concentration	NN	O
was	VBD	O
also	RB	O
determined	VBN	O
in	IN	O
15	CD	O
healthy	JJ	O
controls	NNS	O
.	.	O

Groups	NNP	O
receiving	VBG	O
paromomycin	NN	PM
or	CC	O
placebo	NN	C
were	VBD	O
similar	JJ	O
for	IN	O
clinical	JJ	O
and	CC	O
biological	JJ	O
items	NNS	O
collected	VBN	O
initially	RB	O
.	.	O

Mean	JJ	O
initial	JJ	O
endotoxin	NN	O
concentrations	NNS	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
;	:	O
paromomycin	NN	PM
,	,	O
16.7	CD	O
+/-	JJ	O
5.3	CD	O
pg/ml	NN	O
;	:	O
placebo	NN	C
,	,	O
17.5	CD	O
+/-	JJ	O
6.9	CD	O
pg/ml	NN	O
;	:	O
healthy	JJ	O
controls	NNS	O
,	,	O
2.3	CD	O
+/-	JJ	O
0.4	CD	O
pg/ml	NN	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
mean	JJ	O
endotoxin	NN	O
concentration	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
verum	NN	O
group	NN	O
after	IN	O
1	CD	O
week	NN	O
(	(	O
paromomycin	NN	PM
,	,	O
8.0	CD	O
+/-	JJ	O
1.9	CD	O
pg/ml	NN	O
;	:	O
placebo	NN	C
,	,	O
14.6	CD	O
+/-	JJ	O
3.5	CD	O
pg/ml	NN	O
;	:	O
p	CC	O
>	VB	O
0.05	CD	O
)	)	O
,	,	O
paromomycin	JJ	PM
treatment	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
endotoxin	NN	O
concentration	NN	O
or	CC	O
liver	JJ	O
function	NN	O
tests	NNS	O
during	IN	O
the	DT	O
4-week	JJ	O
period	NN	O
.	.	O

The	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
paromomycin	NN	PM
treatment	NN	O
on	IN	O
endotoxemia	NN	O
in	IN	O
cirrhotics	NNS	O
reported	VBN	O
in	IN	O
earlier	JJR	O
studies	NNS	O
could	MD	O
not	RB	O
be	VB	O
reproduced	VBN	O
under	IN	O
the	DT	O
conditions	NNS	O
of	IN	O
this	DT	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
dose-intensified	JJ	O
MEC	NNP	PM
(	(	O
methotrexate	NN	PM
,	,	O
epirubicin	NN	PM
and	CC	O
cisplatin	NN	PM
)	)	O
chemotherapy	NN	O
for	IN	O
advanced	JJ	O
urothelial	JJ	O
carcinoma	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
MEC	NNP	PM
and	CC	O
M-VAC	NNP	PM
(	(	O
methotrexate	NN	PM
,	,	O
vinblastine	NN	PM
,	,	O
doxorubicin	NN	PM
and	CC	O
cisplatin	NN	PM
)	)	O
.	.	O

Japanese	JJ	O
Urothelial	JJ	O
Cancer	NNP	O
Research	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
antitumor	NN	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
T3b	NNP	O
,	,	O
T4	NNP	O
or	CC	O
metastatic	JJ	O
urothelial	JJ	O
carcinoma	NN	O
treated	VBN	O
with	IN	O
MEC	NNP	PM
or	CC	O
M-VAC	NNP	PM
chemotherapy	NN	O
,	,	O
by	IN	O
performing	VBG	O
a	DT	O
multi-center	JJ	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

METHODS	NNP	O
From	IN	O
1991	CD	O
to	TO	O
1995	CD	O
,	,	O
89	CD	O
patients	NNS	O
with	IN	O
T3b	NNP	O
,	,	O
T4	NNP	O
or	CC	O
metastatic	JJ	O
urothelial	JJ	O
carcinoma	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
a	DT	O
methotrexate	NN	PM
,	,	O
epirubicin	NN	PM
and	CC	O
cisplatin	NN	PM
chemotherapy	NN	O
group	NN	O
(	(	O
arm	JJ	O
1	CD	O
:	:	O
S-MEC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
29	CD	O
)	)	O
,	,	O
a	DT	O
dose-intensified	JJ	O
MEC	NNP	PM
therapy	NN	PM
combined	VBN	O
with	IN	O
G-CSF	NNP	PM
group	NN	O
(	(	O
arm	JJ	O
2	CD	O
:	:	O
I-MEC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
30	CD	O
)	)	O
or	CC	O
a	DT	O
methotrexate	NN	PM
,	,	O
vinblastine	NN	PM
,	,	O
doxorubicin	NN	PM
and	CC	O
cisplatin	NN	PM
chemotherapy	NN	O
(	(	O
arm	JJ	O
3	CD	O
:	:	O
M-VAC	JJ	PM
therapy	NN	PM
;	:	O
n	CC	O
=	VB	O
30	CD	O
)	)	O
.	.	O

At	IN	O
the	DT	O
registration	NN	O
center	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
into	IN	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
recurrence	NN	O
after	IN	O
radical	JJ	O
operation	NN	O
and	CC	O
then	RB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

In	IN	O
each	DT	O
arm	NN	O
,	,	O
two	CD	O
or	CC	O
more	JJR	O
courses	NNS	O
of	IN	O
chemotherapy	NN	O
(	(	O
4-week	JJ	O
cycles	NNS	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
88	CD	O
eligible	JJ	O
patients	NNS	O
,	,	O
four	CD	O
treated	VBN	O
with	IN	O
S-MEC	NNP	PM
therapy	NN	PM
and	CC	O
two	CD	O
treated	VBN	O
with	IN	O
I-MEC	NNP	PM
therapy	NN	O
showed	VBD	O
CR	NNP	O
.	.	O

The	DT	O
response	NN	O
rates	NNS	O
(	(	O
CR	NNP	O
+	NNP	O
PR	NNP	O
)	)	O
were	VBD	O
52	CD	O
%	NN	O
(	(	O
15/29	CD	O
)	)	O
with	IN	O
S-MEC	NNP	PM
therapy	NN	PM
,	,	O
76	CD	O
%	NN	O
(	(	O
22/29	CD	O
)	)	O
with	IN	O
I-MEC	NNP	PM
therapy	NN	O
and	CC	O
47	CD	O
%	NN	O
(	(	O
14/30	CD	O
)	)	O
with	IN	O
M-VAC	NNP	PM
therapy	NN	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
with	IN	O
I-MEC	NNP	PM
therapy	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
with	IN	O
M-VAC	NNP	PM
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
leukopenia	NN	O
was	VBD	O
low	JJ	O
with	IN	O
I-MEC	NNP	PM
therapy	NN	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
thrombocytopenia	NN	O
was	VBD	O
high	JJ	O
with	IN	O
this	DT	O
therapy	NN	O
.	.	O

CONCLUSION	NNP	O
MEC	NNP	PM
therapy	NN	PM
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
is	VBZ	O
promising	VBG	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
antitumor	NN	O
effects	NNS	O
.	.	O

Milk	NNP	O
protein	NN	O
quantity	NN	O
and	CC	O
quality	NN	O
in	IN	O
low-birth-weight	JJ	O
infants	NNS	O
.	.	O

IV	NNP	O
.	.	O

Effects	NNS	O
on	IN	O
tyrosine	NN	O
and	CC	O
phenylalanine	NN	O
in	IN	O
plasma	NN	O
and	CC	O
urine	NN	O
.	.	O

Well	UH	O
,	,	O
appropriate-for-gestational	JJ	O
age	NN	O
,	,	O
low-birth-weight	JJ	O
infants	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
gestational	JJ	O
age	NN	O
groups	NNS	O
and	CC	O
assigned	VBD	O
randomly	RB	O
within	IN	O
each	DT	O
age	NN	O
group	NN	O
to	TO	O
one	CD	O
of	IN	O
five	CD	O
feeding	VBG	O
regimens	NNS	O
:	:	O
pooled	VBN	PM
human	JJ	PM
milk	NN	PM
(	(	PM
BM	NNP	PM
)	)	PM
;	:	PM
formula	$	PM
1	CD	PM
(	(	PM
F1	NNP	PM
)	)	PM
=	VBD	PM
1.5	CD	PM
gm/dl	NN	PM
protein	NN	PM
,	,	PM
60	CD	PM
parts	NNS	PM
bovine	NN	PM
whey	NN	PM
proteins	NNS	PM
:	:	PM
40	CD	PM
parts	NNS	PM
bovine	NN	PM
caseins	NNS	PM
;	:	PM
F2	NNP	PM
=	VBD	PM
3.0	CD	PM
gm/dl	NN	PM
,	,	PM
60:40	CD	PM
;	:	PM
F3	NNP	PM
=	VBD	PM
1.5	CD	PM
gm/dl	NN	PM
,	,	PM
18:82	CD	PM
;	:	PM
F4	NNP	PM
=	VBD	PM
3.0	CD	PM
gm/dl	NN	PM
,	,	O
18:82	CD	O
.	.	O

Plasma	NNP	O
and	CC	O
urine	JJ	O
concentrations	NNS	O
of	IN	O
tyrosine	NN	O
and	CC	O
phenylalanine	NN	O
were	VBD	O
far	RB	O
higher	JJR	O
in	IN	O
the	DT	O
infants	NNS	O
fed	VBP	O
F1	NNP	O
to	TO	O
F4	NNP	O
,	,	O
especially	RB	O
F2	NNP	O
and	CC	O
F4	NNP	O
,	,	O
than	IN	O
in	IN	O
the	DT	O
infants	NNS	O
fed	VBN	O
BM	NNP	O
.	.	O

These	DT	O
findings	NNS	O
offer	VBP	O
further	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
limited	JJ	O
capacity	NN	O
of	IN	O
the	DT	O
low-birth-weight	JJ	O
infant	NN	O
to	TO	O
catabolize	VB	O
tyrosine	NN	O
.	.	O

Infants	NNS	O
fed	VBD	O
F3	NNP	O
had	VBD	O
significantly	RB	O
higher	JJR	O
plasma	JJ	O
tyrosine	NN	O
concentrations	NNS	O
than	IN	O
infants	NNS	O
fed	VBN	O
F1	NNP	O
,	,	O
and	CC	O
those	DT	O
fed	VBN	O
F4	NNP	O
had	VBD	O
higher	JJR	O
concentrations	NNS	O
than	IN	O
those	DT	O
fed	JJ	O
F2	NNP	O
.	.	O

Thus	NNP	O
,	,	O
increased	VBD	O
plasma	JJ	O
tyrosine	NN	O
concentrations	NNS	O
in	IN	O
low-birth-weight	JJ	O
infants	NNS	O
are	VBP	O
related	VBN	O
directly	RB	O
both	DT	O
to	TO	O
the	DT	O
quantity	NN	O
and	CC	O
to	TO	O
the	DT	O
quality	NN	O
of	IN	O
the	DT	O
protein	NN	O
in	IN	O
their	PRP$	O
diets	NNS	O
.	.	O

High-pressure	NN	PH
,	,	PH
rapid-inflation	NN	PH
pneumatic	JJ	PH
compression	NN	PH
improves	VBZ	O
venous	JJ	O
hemodynamics	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
who	WP	O
are	VBP	O
post-thrombotic	JJ	O
.	.	O

PURPOSE	NNP	O
Deep	NNP	O
vein	NN	O
thrombosis	NN	O
(	(	O
DVT	NNP	O
)	)	O
is	VBZ	O
a	DT	O
preventable	JJ	O
cause	NN	O
of	IN	O
morbidity	NN	O
and	CC	O
mortality	NN	O
in	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
hospitalized	VBN	O
.	.	O

An	DT	O
important	JJ	O
part	NN	O
of	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
DVT	NNP	O
prophylaxis	NN	O
with	IN	O
intermittent	JJ	O
pneumatic	JJ	O
compression	NN	O
(	(	O
IPC	NNP	O
)	)	O
is	VBZ	O
reduced	VBN	O
venous	JJ	O
stasis	NN	O
with	IN	O
increased	JJ	O
velocity	NN	O
of	IN	O
venous	JJ	O
return	NN	O
.	.	O

The	DT	O
conventional	JJ	O
methods	NNS	O
of	IN	O
IPC	NNP	O
use	NN	O
low	JJ	O
pressure	NN	O
and	CC	O
slow	JJ	O
inflation	NN	O
of	IN	O
the	DT	O
air	NN	O
bladder	NN	O
on	IN	O
the	DT	O
leg	NN	O
to	TO	O
augment	VB	O
venous	JJ	O
return	NN	O
.	.	O

Recently	RB	O
,	,	O
compression	NN	O
devices	NNS	O
have	VBP	O
been	VBN	O
designed	VBN	O
that	IN	O
produce	VBP	O
high	JJ	O
pressure	NN	O
and	CC	O
rapid	JJ	O
inflation	NN	O
of	IN	O
air	NN	O
cuffs	NNS	O
on	IN	O
the	DT	O
plantar	NN	O
plexus	NN	O
of	IN	O
the	DT	O
foot	NN	O
and	CC	O
the	DT	O
calf	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
evaluate	VB	O
the	DT	O
venous	JJ	O
velocity	NN	O
response	NN	O
to	TO	O
high-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
devices	NNS	O
versus	VBP	O
standard	JJ	O
,	,	O
low-pressure	JJ	O
,	,	O
slow-inflation	JJ	O
compression	NN	O
devices	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
severe	JJ	O
post-thrombotic	JJ	O
venous	JJ	O
disease	NN	O
.	.	O

METHOD	NNP	O
Twenty-two	NNP	O
lower	JJR	O
extremities	NNS	O
from	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
11	CD	O
lower	JJR	O
extremities	NNS	O
from	IN	O
patients	NNS	O
with	IN	O
class	NN	O
4	CD	O
to	TO	O
class	NN	O
6	CD	O
post-thrombotic	JJ	O
chronic	JJ	O
venous	JJ	O
insufficiency	NN	O
were	VBD	O
studied	VBN	O
.	.	O

With	IN	O
duplex	JJ	PH
ultrasound	NN	PH
scanning	NN	PH
(	(	O
ATL-Ultramark	NNP	O
9	CD	O
,	,	O
Advanced	NNP	O
Tech	NNP	O
Laboratory	NNP	O
,	,	O
Bothell	NNP	O
,	,	O
Wash	NNP	O
)	)	O
,	,	O
acute	JJ	O
DVT	NNP	O
was	VBD	O
excluded	VBN	O
before	IN	O
subject	JJ	O
evaluation	NN	O
.	.	O

Venous	JJ	O
velocities	NNS	O
were	VBD	O
monitored	VBN	O
after	IN	O
the	DT	O
application	NN	O
of	IN	O
each	DT	O
of	IN	O
five	CD	O
IPC	NNP	O
devices	NNS	O
,	,	O
with	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
.	.	O

Three	CD	PH
high-pressure	NN	PH
,	,	PH
rapid-compression	NN	PH
devices	NNS	PH
and	CC	PH
two	CD	PH
standard	NN	PH
,	,	PH
low-pressure	JJ	PH
,	,	O
slow-inflation	JJ	PH
compression	NN	PH
devices	NNS	PH
were	VBD	O
applied	VBN	O
in	IN	O
a	DT	O
random	JJ	O
sequence	NN	O
.	.	O

Maximal	NNP	O
venous	JJ	O
velocities	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
the	DT	O
common	JJ	O
femoral	JJ	O
vein	NN	O
and	CC	O
the	DT	O
popliteal	NN	O
vein	NN	O
for	IN	O
all	PDT	O
the	DT	O
devices	NNS	O
and	CC	O
were	VBD	O
recorded	VBN	O
as	IN	O
the	DT	O
mean	JJ	O
peak	JJ	O
velocity	NN	O
of	IN	O
three	CD	O
compression	NN	O
cycles	NNS	O
and	CC	O
compared	VBN	O
with	IN	O
baseline	NN	O
velocities	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
baseline	NN	O
venous	JJ	O
velocities	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
femoral	JJ	O
veins	NNS	O
than	IN	O
in	IN	O
the	DT	O
popliteal	NN	O
veins	NNS	O
in	IN	O
both	DT	O
the	DT	O
volunteers	NNS	O
and	CC	O
the	DT	O
post-thrombotic	JJ	O
subjects	NNS	O
.	.	O

Standard	NNP	O
and	CC	O
high-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
significantly	RB	O
increased	VBD	O
the	DT	O
popliteal	NN	O
and	CC	O
femoral	JJ	O
vein	NN	O
velocities	NNS	O
in	IN	O
healthy	JJ	O
and	CC	O
post-thrombotic	JJ	O
subjects	NNS	O
.	.	O

High-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
produced	VBD	O
significantly	RB	O
higher	JJR	O
maximal	JJ	O
venous	JJ	O
velocities	NNS	O
in	IN	O
the	DT	O
popliteal	NN	O
and	CC	O
femoral	JJ	O
veins	NNS	O
in	IN	O
both	DT	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
as	IN	O
compared	VBN	O
with	IN	O
standard	JJ	O
compression	NN	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
healthy	JJ	O
volunteers	NNS	O
,	,	O
the	DT	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
had	VBD	O
a	DT	O
significantly	RB	O
attenuated	VBN	O
velocity	NN	O
response	NN	O
at	IN	O
both	DT	O
the	DT	O
popliteal	NN	O
and	CC	O
the	DT	O
femoral	JJ	O
vein	NN	O
levels	NNS	O
.	.	O

CONCLUSION	NNP	O
High-pressure	NNP	O
,	,	O
rapid-inflation	NN	O
pneumatic	JJ	O
compression	NN	O
increases	NNS	O
popliteal	NN	O
and	CC	O
femoral	JJ	O
vein	NN	O
velocity	NN	O
as	IN	O
compared	VBN	O
with	IN	O
standard	JJ	O
,	,	O
low-pressure	JJ	O
,	,	O
slow-inflation	JJ	O
pneumatic	JJ	O
compression	NN	O
.	.	O

Patients	NNS	O
with	IN	O
post-thrombotic	JJ	O
venous	JJ	O
disease	NN	O
have	VBP	O
a	DT	O
compromised	JJ	O
hemodynamic	JJ	O
response	NN	O
to	TO	O
all	DT	O
IPC	NNP	O
devices	NNS	O
.	.	O

However	RB	O
,	,	O
an	DT	O
increased	VBN	O
velocity	NN	O
response	NN	O
to	TO	O
the	DT	O
high-pressure	NN	O
,	,	O
rapid-inflation	NN	O
compression	NN	O
device	NN	O
is	VBZ	O
preserved	VBN	O
.	.	O

High-pressure	NN	O
,	,	O
rapid-inflation	NN	O
pneumatic	JJ	O
compression	NN	O
may	MD	O
offer	VB	O
additional	JJ	O
protection	NN	O
from	IN	O
thrombotic	JJ	O
complications	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
an	DT	O
improved	JJ	O
hemodynamic	JJ	O
response	NN	O
,	,	O
both	DT	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
and	CC	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
post-thrombotic	JJ	O
.	.	O

Acute	JJ	O
effects	NNS	O
of	IN	O
caffeine	JJ	PM
ingestion	NN	PM
on	IN	O
signal-averaged	JJ	O
electrocardiograms	NNS	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
moderate	JJ	O
caffeine	NN	O
ingestion	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
arrhythmogenic	JJ	O
,	,	O
caffeine	JJ	O
toxicity	NN	O
can	MD	O
cause	VB	O
severe	JJ	O
cardiac	JJ	O
arrhythmias	NN	O
,	,	O
including	VBG	O
atrial	JJ	O
fibrillation	NN	O
and	CC	O
ventricular	JJ	O
tachycardia	NN	O
.	.	O

Atrial	JJ	O
fibrillation	NN	O
and	CC	O
ventricular	JJ	O
tachycardia	NN	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
prolongation	NN	O
of	IN	O
P-wave	NNP	O
and	CC	O
QRS	NNP	O
complex	JJ	O
durations	NNS	O
on	IN	O
signal-averaged	JJ	O
electrocardiograms	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
acute	JJ	O
effects	NNS	O
of	IN	O
caffeine	JJ	O
ingestion	NN	O
on	IN	O
signal-averaged	JJ	O
P-wave	NNP	O
and	CC	O
QRS	NNP	O
complexes	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Signal-averaged	JJ	O
electrocardiograms	NNS	O
were	VBD	O
obtained	VBN	O
from	IN	O
12	CD	O
normal	JJ	O
subjects	NNS	O
(	(	O
6	CD	O
men	NNS	O
,	,	O
6	CD	O
women	NNS	O
;	:	O
ages	VBZ	O
21	CD	O
to	TO	O
26	CD	O
years	NNS	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
ingestion	NN	O
of	IN	O
caffeine	NN	PM
(	(	O
5	CD	O
mg/kg	NN	O
body	NN	O
weight	NN	O
)	)	O
or	CC	O
placebo	NN	C
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	JJ	O
fashion	NN	O
.	.	O

Electrocardiograms	NNP	O
for	IN	O
signal	JJ	O
averaging	NN	O
were	VBD	O
recorded	VBN	O
from	IN	O
electrodes	NNS	O
left	VBN	O
in	IN	O
a	DT	O
constant	JJ	O
location	NN	O
.	.	O

After	IN	O
bandpass	NN	O
filtering	NN	O
(	(	O
30	CD	O
to	TO	O
300	CD	O
Hz	NNP	O
)	)	O
and	CC	O
amplification	NN	O
,	,	O
signals	NNS	O
were	VBD	O
sampled	VBN	O
over	IN	O
7.2	CD	O
minutes	NNS	O
at	IN	O
2000	CD	O
Hz	NNP	O
.	.	O

Signal-averaged	JJ	O
P-wave	NNP	O
and	CC	O
QRS	NNP	O
complex	JJ	O
durations	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
after	IN	O
placebo	NN	O
ingestion	NN	O
.	.	O

After	IN	O
caffeine	JJ	O
ingestion	NN	O
QRS	NNP	O
duration	NN	O
prolonged	VBD	O
in	IN	O
9	CD	O
of	IN	O
11	CD	O
subjects	NNS	O
at	IN	O
90	CD	O
minutes	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
=	NNP	O
0.8+/-0.3	JJ	O
ms	NN	O
,	,	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
and	CC	O
in	IN	O
8	CD	O
of	IN	O
9	CD	O
after	IN	O
3	CD	O
hours	NNS	O
(	(	O
1.1+/-0.2	JJ	O
ms	NN	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
change	NN	O
in	IN	O
P-wave	NNP	O
duration	NN	O
or	CC	O
heart	NN	O
rate	NN	O
was	VBD	O
found	VBN	O
after	IN	O
caffeine	JJ	O
ingestion	NN	O
at	IN	O
any	DT	O
test	NN	O
interval	NN	O
.	.	O

Average	JJ	O
caffeine	JJ	O
level	NN	O
in	IN	O
saliva	JJ	O
90	CD	O
minutes	NNS	O
after	IN	O
ingestion	NN	O
was	VBD	O
6.6+/-1.6	JJ	O
(	(	O
SD	NNP	O
)	)	O
microg/dL	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
probably	RB	O
not	RB	O
arrhythmogenic	JJ	O
in	IN	O
normal	JJ	O
subjects	NNS	O
,	,	O
moderate	JJ	O
caffeine	NN	O
ingestion	NN	O
does	VBZ	O
produce	VB	O
a	DT	O
small	JJ	O
but	CC	O
statistically	RB	O
significant	JJ	O
prolongation	NN	O
of	IN	O
signal-averaged	JJ	O
QRS	NNP	O
complexes	NNS	O
.	.	O

Further	JJ	O
prolongation	NN	O
caused	VBN	O
by	IN	O
excessive	JJ	O
caffeine	NNS	O
intake	VBP	O
may	MD	O
be	VB	O
a	DT	O
factor	NN	O
in	IN	O
the	DT	O
genesis	NN	O
of	IN	O
arrhythmias	NNS	O
associated	VBN	O
with	IN	O
caffeine	JJ	O
toxicity	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
metronidazole	NN	PM
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
wound	NN	O
infection	NN	O
in	IN	O
elective	JJ	O
colon	NN	O
surgery	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
assessing	VBG	O
the	DT	O
relative	JJ	O
effectiveness	NN	O
of	IN	O
erythromycin-neomycin	JJ	PM
and	CC	O
metronidazole-neomycin	JJ	PM
as	IN	O
a	DT	O
preoperative	JJ	O
bowel	NN	O
preparation	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

Bacteriologic	NNP	O
studies	NNS	O
of	IN	O
feces	NNS	O
and	CC	O
colon	NN	O
content	NN	O
revealed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
reduction	NN	O
of	IN	O
aerobic	JJ	O
bacteria	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
in	IN	O
anaerobic	JJ	O
bacteria	NNS	O
in	IN	O
the	DT	O
feces	NNS	O
and	CC	O
colon	NN	O
contents	NNS	O
of	IN	O
patients	NNS	O
receiving	VBG	O
metronidazole	NN	O
.	.	O

Wound	IN	O
infection	NN	O
rate	NN	O
was	VBD	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
erythromycin	NN	O
group	NN	O
,	,	O
and	CC	O
organisms	NNS	O
recovered	VBN	O
from	IN	O
the	DT	O
wound	NN	O
in	IN	O
all	DT	O
cases	NNS	O
were	VBD	O
fecal	JJ	O
in	IN	O
nature	NN	O
.	.	O

Two	CD	O
wound	IN	O
infections	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
metronidazole	NN	O
group	NN	O
(	(	O
5	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
both	DT	O
cases	NNS	O
the	DT	O
organisms	NNS	O
recovered	VBN	O
were	VBD	O
staphylococci	NNS	O
of	IN	O
presumed	JJ	O
skin	JJ	O
origin	NN	O
.	.	O

These	DT	O
studies	NNS	O
suggest	VBP	O
that	IN	O
anaerobic	JJ	O
bacteria	NNS	O
are	VBP	O
the	DT	O
major	JJ	O
contributors	NNS	O
to	TO	O
wound	VB	O
infection	NN	O
after	IN	O
colon	NN	O
surgery	NN	O
and	CC	O
that	IN	O
their	PRP$	O
specific	JJ	O
reduction	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
wound	JJ	O
infection	NN	O
.	.	O

Effect	NN	O
of	IN	O
chelation	NN	PM
therapy	NN	PM
on	IN	O
progressive	JJ	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
and	CC	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burdens	NNS	O
.	.	O

BACKGROUND	VB	O
A	DT	O
previous	JJ	O
study	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	NN	O
burdens	VBZ	O
showed	VBD	O
that	IN	O
EDTA	NNP	PM
chelation	NN	PM
therapy	NN	PM
for	IN	O
3	CD	O
months	NNS	O
slows	VBZ	O
progressive	JJ	O
diabetic	JJ	O
nephropathy	NN	O
during	IN	O
a	DT	O
12-month	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
a	DT	O
longer	JJR	O
course	NN	O
of	IN	O
therapy	NN	O
on	IN	O
kidney	NN	O
function	NN	O
decrease	NN	O
over	IN	O
a	DT	O
longer	JJR	O
follow-up	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
12-month	JJ	O
run-in	JJ	O
phase	NN	O
,	,	O
then	RB	O
a	DT	O
randomized	VBN	O
single-blind	NN	O
study	NN	O
with	IN	O
a	DT	O
27-month	JJ	O
intervention	NN	O
.	.	O

SETTING	NNP	O
&	CC	O
PARTICIPANTS	NNP	O
University	NNP	O
medical	JJ	O
center	NN	O
;	:	O
50	CD	O
patients	NNS	O
(	(	O
serum	JJ	O
creatinine	NN	O
,	,	O
1.5-3.9	JJ	O
mg/dL	NN	O
)	)	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burden	NN	O
(	(	O
?80-	JJ	O
<	NN	O
600	CD	O
?g	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
weekly	JJ	O
chelation	NN	O
therapy	NN	O
for	IN	O
3	CD	O
months	NNS	O
to	TO	O
reduce	VB	O
their	PRP$	O
body	NN	O
lead	JJ	O
burden	NN	O
to	TO	O
<	VB	O
60	CD	O
?g	NNS	O
and	CC	O
then	RB	O
as	IN	O
needed	VBN	O
for	IN	O
24	CD	O
months	NNS	O
to	TO	O
maintain	VB	O
this	DT	O
level	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
placebo	NN	O
for	IN	O
3	CD	O
months	NNS	O
and	CC	O
then	RB	O
weekly	VB	O
for	IN	O
5	CD	O
weeks	NNS	O
at	IN	O
6-month	JJ	O
intervals	NNS	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

OUTCOMES	IN	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
change	NN	O
in	IN	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
eGFR	NN	O
)	)	O
over	IN	O
time	NN	O
.	.	O

A	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
2-fold	JJ	O
increase	NN	O
in	IN	O
baseline	JJ	O
serum	NN	O
creatinine	NN	O
level	NN	O
or	CC	O
the	DT	O
requirement	NN	O
for	IN	O
renal	JJ	O
replacement	NN	O
therapy	NN	O
.	.	O

MEASUREMENTS	NNP	O
Body	NNP	O
lead	JJ	O
burdens	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
EDTA	NNP	O
mobilization	NN	O
tests	NNS	O
and	CC	O
eGFR	NN	O
was	VBD	O
calculated	VBN	O
using	VBG	O
the	DT	O
equation	NN	O
for	IN	O
Chinese	JJ	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
baseline	NN	O
eGFRs	NN	O
in	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
of	IN	O
chelation	NN	O
therapy	NN	O
,	,	O
the	DT	O
change	NN	O
in	IN	O
eGFR	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
+1.0	NNP	O
?	.	O
4.8	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
differed	VBN	O
significantly	RB	O
from	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
-1.5	NNP	O
?	.	O
4.8	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
subsequent	JJ	O
24-month	JJ	O
intervention	NN	O
,	,	O
the	DT	O
yearly	JJ	O
rate	NN	O
of	IN	O
decrease	NN	O
in	IN	O
eGFR	NN	O
(	(	O
5.6	CD	O
?	.	O
5.0	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
per	IN	O
year	NN	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
slower	JJR	O
than	IN	O
that	DT	O
(	(	O
9.2	CD	O
?	.	O
3.6	CD	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
per	IN	O
year	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

17	CD	O
(	(	O
68	CD	O
%	NN	O
)	)	O
control-group	NN	O
patients	NNS	O
and	CC	O
9	CD	O
(	(	O
36	CD	O
%	NN	O
)	)	O
treatment-group	NN	O
patients	NNS	O
achieved	VBD	O
the	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
.	.	O

LIMITATIONS	NNP	O
Small	NNP	O
sample	NN	O
size	NN	O
,	,	O
not	RB	O
double	JJ	O
blind	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
27-month	JJ	O
course	NN	O
of	IN	O
EDTA	NNP	O
chelation	NN	O
therapy	NN	O
retards	VBZ	O
the	DT	O
progression	NN	O
of	IN	O
diabetic	JJ	O
nephropathy	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
high-normal	JJ	O
body	NN	O
lead	JJ	O
burdens	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
health	NN	E
care	NN	E
program	NN	E
for	IN	E
first-time	JJ	E
adolescent	NN	E
mothers	NNS	E
and	CC	E
their	PRP$	E
infants	NNS	E
.	.	O

To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
special	JJ	E
health	NN	E
care	NN	E
program	NN	E
for	IN	O
adolescent	JJ	O
mothers	NNS	O
(	(	O
17	CD	O
years	NNS	O
old	JJ	O
or	CC	O
younger	JJR	O
)	)	O
and	CC	O
their	PRP$	O
infants	NNS	O
,	,	O
243	CD	O
mother-infant	JJ	O
pairs	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
of	IN	O
the	DT	O
mothers	NNS	O
were	VBD	O
unwed	JJ	O
,	,	O
on	IN	O
Medicaid	NNP	O
,	,	O
and	CC	O
black	JJ	O
.	.	O

The	DT	O
control	NN	E
group	NN	E
received	VBD	E
routine	JJ	E
well-baby	NN	E
care	NN	E
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
received	VBD	O
routine	JJ	E
care	NN	E
and	CC	E
services	NNS	E
that	WDT	E
included	VBD	E
rigorous	JJ	E
follow-up	NN	E
,	,	O
discussions	NNS	E
with	IN	E
the	DT	E
mother	NN	E
about	IN	E
her	PRP$	E
plans	NNS	E
for	IN	E
return	NN	E
to	TO	E
school	NN	E
and	CC	E
use	NN	E
of	IN	E
family	NN	E
planning	NN	E
methods	NNS	E
,	,	O
and	CC	O
extra	JJ	E
health	NN	E
teaching	NN	E
.	.	O

The	DT	O
dropout	NN	O
rate	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
60	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
less	JJR	O
after	IN	O
18	CD	O
months	NNS	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
82	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
spite	NN	O
of	IN	O
the	DT	O
high	JJ	O
dropout	NN	O
rate	NN	O
,	,	O
91	CD	O
%	NN	O
of	IN	O
the	DT	O
mothers	NNS	O
were	VBD	O
located	VBN	O
for	IN	O
the	DT	O
18	CD	O
month	NN	O
follow-up	JJ	O
interview	NN	O
.	.	O

The	DT	O
repeat	JJ	O
pregnancy	NN	O
rate	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
12	CD	O
%	NN	O
after	IN	O
18	CD	O
months	NNS	O
,	,	O
and	CC	O
28	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
percentage	NN	O
returning	VBG	O
to	TO	O
school	NN	O
.	.	O

After	IN	O
12	CD	O
months	NNS	O
,	,	O
the	DT	O
infants	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
fully	RB	O
immunized	VBN	O
(	(	O
33	CD	O
%	NN	O
)	)	O
than	IN	O
the	DT	O
infants	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
18	CD	O
%	NN	O
)	)	O
.	.	O

Mothers	NNS	O
in	IN	O
the	DT	O
special	JJ	E
care	NN	E
program	NN	E
who	WP	O
continued	VBD	O
to	TO	O
attend	VB	O
clinic	NN	O
used	VBN	O
the	DT	O
emergency	NN	O
room	NN	O
less	JJR	O
than	IN	O
the	DT	O
mothers	NNS	O
who	WP	O
continued	VBD	O
to	TO	O
attend	VB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
comprehensive	JJ	E
health	NN	E
care	NN	E
program	NN	E
is	VBZ	O
one	CD	O
way	NN	O
to	TO	O
bring	VB	O
about	RP	O
better	JJR	O
outcomes	NNS	O
for	IN	O
both	DT	O
adolescent	JJ	O
mothers	NNS	O
and	CC	O
their	PRP$	O
infants	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
soy	JJ	PM
intake	NN	PM
on	IN	O
sex	NN	O
hormone	NN	O
metabolism	NN	O
in	IN	O
premenopausal	JJ	O
women	NNS	O
.	.	O

Studies	NNS	O
suggest	VBP	O
that	IN	O
phytoestrogens	NNS	O
in	IN	O
soy	JJ	PM
products	NNS	O
may	MD	O
impart	VB	O
hormonal	JJ	O
effects	NNS	O
that	WDT	O
protect	VBP	O
women	NNS	O
against	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Limited	VBN	O
research	NN	O
suggests	VBZ	O
that	IN	O
intake	NN	O
of	IN	O
soy	NN	PM
products	NNS	O
high	JJ	O
in	IN	O
isoflavonoid	JJ	O
phytoestrogens	NNS	O
affects	VBZ	O
sex	NN	O
hormone	NN	O
metabolism	NN	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
unknown	JJ	O
whether	IN	O
phytoestrogens	NNS	O
in	IN	O
soy	NNS	O
have	VBP	O
any	DT	O
effect	NN	O
on	IN	O
menstrual	JJ	O
function	NN	O
or	CC	O
serum	VB	O
sex	NN	O
hormones	NNS	O
in	IN	O
women	NNS	O
on	IN	O
common	JJ	O
hormone	NN	O
therapies	NNS	O
,	,	O
such	JJ	O
as	IN	O
oral	JJ	O
contraceptives	NNS	O
(	(	O
OC	NNP	O
)	)	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
soy	NN	PM
in	IN	O
36	CD	O
premenopausal	JJ	O
women	NNS	O
,	,	O
20	CD	O
of	IN	O
whom	WP	O
used	VBD	O
OC	NNP	O
.	.	O

Subjects	NNS	O
consumed	VBD	O
their	PRP$	O
normal	JJ	O
diet	NNS	O
for	IN	O
two	CD	O
menstrual	JJ	O
cycles	NNS	O
and	CC	O
added	VBD	O
a	DT	O
soy	JJ	PM
beverage	NN	PM
containing	VBG	PM
20	CD	PM
g	NN	PM
of	IN	PM
protein	NN	PM
and	CC	PM
38	CD	PM
mg	NN	PM
of	IN	PM
total	JJ	PM
isoflavones	NNS	PM
to	TO	O
their	PRP$	O
usual	JJ	O
diet	NN	O
for	IN	O
another	DT	O
two	CD	O
menstrual	JJ	O
cycles	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
serum	NN	O
estrone	NN	O
,	,	O
estradiol	NN	O
,	,	O
sex	NN	O
hormone-binding	JJ	O
globulin	NN	O
,	,	O
dehydroepiandrosterone	NN	O
sulfate	NN	O
,	,	O
prolactin	NN	O
,	,	O
or	CC	O
progesterone	NN	O
concentrations	NNS	O
with	IN	O
soy	JJ	PM
feeding	NN	O
in	IN	O
the	DT	O
non-OC	JJ	O
or	CC	O
the	DT	O
OC	NNP	O
group	NN	O
.	.	O

No	DT	O
changes	NNS	O
in	IN	O
menstrual	JJ	O
cycle	NN	O
length	NN	O
or	CC	O
the	DT	O
urinary	JJ	O
estrogen	NN	O
metabolite	NNS	O
ratio	NN	O
of	IN	O
2-hydroxyestrone	CD	O
to	TO	O
16	CD	O
alpha-hydroxyestrone	NN	O
were	VBD	O
seen	VBN	O
with	IN	O
soy	JJ	O
feeding	NN	O
in	IN	O
the	DT	O
non-OC	JJ	O
or	CC	O
the	DT	O
OC	NNP	O
group	NN	O
.	.	O

Levels	NNP	O
of	IN	O
urinary	JJ	O
estrogen	NN	O
metabolites	NNS	O
were	VBD	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
non-OC	JJ	O
and	CC	O
the	DT	O
OC	NNP	O
group	NN	O
.	.	O

Thus	RB	O
soy	JJ	PM
consumption	NN	PM
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
menstrual	JJ	O
cycle	NN	O
,	,	O
serum	JJ	O
sex	NN	O
hormones	NNS	O
,	,	O
or	CC	O
urinary	JJ	O
estrogen	NN	O
metabolite	NN	O
ratio	NN	O
in	IN	O
premenopausal	NN	O
OC	NNP	O
or	CC	O
non-OC	JJ	O
users	NNS	O
.	.	O

Tetrahydrobiopterin	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	C
crossover	NN	O
study	NN	O
.	.	O

Twelve	NNP	O
children	NNS	O
,	,	O
all	DT	O
boys	NNS	O
,	,	O
aged	VBD	O
4	CD	O
to	TO	O
7	CD	O
years	NNS	O
,	,	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
and	CC	O
low	JJ	O
concentrations	NNS	O
of	IN	O
spinal	JJ	O
6R-l-erythro-5,6,7,8-tetrahydrobiopterin	JJ	O
(	(	O
tetrahydrobiopterin	NN	O
)	)	O
were	VBD	O
selected	VBN	O
to	TO	O
participate	VB	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
crossover	NN	O
study	NN	O
.	.	O

The	DT	O
children	NNS	O
received	VBD	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
3	CD	O
mg	NNS	O
tetrahydrobiopterin	JJ	PM
per	IN	O
kilogram	NN	O
during	IN	O
6	CD	O
months	NNS	O
alternating	VBG	O
with	IN	O
placebo	NN	C
.	.	O

Treatment-induced	JJ	O
effects	NNS	O
were	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
every	DT	O
third	JJ	O
month	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
small	JJ	O
nonsignificant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
total	JJ	O
scores	NNS	O
of	IN	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
after	IN	O
3-	JJ	O
and	CC	O
6-month	JJ	O
treatment	NN	O
.	.	O

Post	NNP	O
hoc	NN	O
analysis	NN	O
looking	VBG	O
at	IN	O
the	DT	O
3	CD	O
core	NN	O
symptoms	NNS	O
of	IN	O
autism	NN	O
,	,	O
that	WDT	O
is	VBZ	O
,	,	O
social	JJ	O
interaction	NN	O
,	,	O
communication	NN	O
,	,	O
and	CC	O
stereotyped	VBD	O
behaviors	NNS	O
,	,	O
revealed	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
of	IN	O
the	DT	O
social	JJ	O
interaction	NN	O
score	NN	O
after	IN	O
6	CD	O
months	NNS	O
of	IN	O
active	JJ	O
treatment	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
high	JJ	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
response	NN	O
of	IN	O
the	DT	O
social	JJ	O
interaction	NN	O
score	NN	O
and	CC	O
IQ	NNP	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
a	DT	O
possible	JJ	O
effect	NN	O
of	IN	O
tetrahydrobiopterin	NN	PM
treatment	NN	O
.	.	O

Instant	JJ	O
Recess?	NNP	O
:	:	O
a	DT	O
practical	JJ	O
tool	NN	O
for	IN	O
increasing	VBG	O
physical	JJ	O
activity	NN	O
during	IN	O
the	DT	O
school	NN	O
day	NN	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
increased	JJ	O
prevalence	NN	O
of	IN	O
overweight/obesity	NN	O
among	IN	O
children	NNS	O
has	VBZ	O
led	VBN	O
to	TO	O
school	NN	O
district	NN	O
level	NN	O
policies	NNS	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
(	(	O
PA	NNP	O
)	)	O
among	IN	O
elementary	JJ	O
school	NN	O
students	NNS	O
.	.	O

Interventions	NNS	O
are	VBP	O
needed	VBN	O
that	IN	O
increase	NN	O
activity	NN	O
levels	NNS	O
without	IN	O
sacrificing	VBG	O
time	NN	O
spent	VBN	O
in	IN	O
academics	NNS	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
evaluated	VBD	O
a	DT	O
policy	NN	O
implementation	NN	O
intervention	NN	O
for	IN	O
to	TO	O
increase	VB	O
in-school	JJ	O
PA	NNP	O
in	IN	O
elementary	JJ	O
schools	NNS	O
in	IN	O
Forsyth	NNP	O
County	NNP	O
,	,	O
North	NNP	O
Carolina	NNP	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
with	IN	O
a	DT	O
delayed	JJ	O
intervention	NN	O
control	NN	O
group	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
third-	JJ	O
through	IN	O
fifth-grade	JJ	O
classrooms	NNS	O
in	IN	O
eight	CD	O
elementary	JJ	O
schools	NNS	O
.	.	O

Instant	NNP	O
Recess?	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
introduce	VB	O
10-minute	JJ	O
PA	NNP	O
breaks	NNS	O
in	IN	O
classrooms	NNS	O
on	IN	O
schedules	NNS	O
determined	VBN	O
by	IN	O
teachers	NNS	O
.	.	O

Direct	JJ	O
observation	NN	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
activity	NN	O
levels	NNS	O
,	,	O
other	JJ	O
student	NN	O
behaviors	NNS	O
,	,	O
and	CC	O
teacher	NN	O
behaviors	NNS	O
related	VBN	O
to	TO	O
PA	NNP	O
in	IN	O
the	DT	O
classrooms	NNS	O
.	.	O

RESULTS	NNP	O
Twenty-eight	JJ	O
visits	NNS	O
to	TO	O
schools	NNS	O
were	VBD	O
made	VBN	O
during	IN	O
the	DT	O
spring	NN	O
and	CC	O
fall	NN	O
semesters	NNS	O
of	IN	O
2009	CD	O
.	.	O

At	IN	O
baseline	JJ	O
11	CD	O
%	NN	O
to	TO	O
44	CD	O
%	NN	O
of	IN	O
intervention	NN	O
and	CC	O
control	NN	O
schools	NNS	O
were	VBD	O
engaged	VBN	O
in	IN	O
classroom-based	JJ	O
PA.	NNP	O
PA	NNP	O
increased	VBD	O
from	IN	O
baseline	NN	O
to	TO	O
spring	VB	O
follow-up	NN	O
in	IN	O
intervention	NN	O
schools	NNS	O
and	CC	O
was	VBD	O
maintained	VBN	O
the	DT	O
following	VBG	O
fall	NN	O
.	.	O

Control	NNP	O
schools	NNS	O
decreased	VBD	O
PA	NNP	O
from	IN	O
baseline	NN	O
to	TO	O
spring	NN	O
and	CC	O
increased	VBD	O
PA	NNP	O
once	RB	O
they	PRP	O
began	VBD	O
the	DT	O
intervention	NN	O
.	.	O

Students	NNS	O
in	IN	O
classrooms	NNS	O
engaged	VBN	O
in	IN	O
Instant	NNP	O
Recess	NNP	O
exhibited	VBD	O
statistically	RB	O
significant	JJ	O
increases	NNS	O
in	IN	O
light	NN	O
(	(	O
51	CD	O
%	NN	O
)	)	O
and	CC	O
moderate-intensity	NN	O
(	(	O
16	CD	O
%	NN	O
)	)	O
PA	NNP	O
and	CC	O
increases	NNS	O
in	IN	O
time	NN	O
spent	VBN	O
in	IN	O
on-task	JJ	O
behavior	NN	O
(	(	O
11	CD	O
%	NN	O
)	)	O
.	.	O

Control	NNP	O
schools	NNS	O
experienced	VBD	O
similar	JJ	O
benefits	NNS	O
after	IN	O
they	PRP	O
began	VBD	O
implementing	VBG	O
Instant	NNP	O
Recess	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Instant	NNP	O
Recess	NNP	O
is	VBZ	O
useful	JJ	O
for	IN	O
increasing	VBG	O
PA	NNP	O
and	CC	O
improving	VBG	O
behavior	NN	O
among	IN	O
elementary	JJ	O
school	NN	O
children	NNS	O
.	.	O

Additional	NNP	O
research	NN	O
may	MD	O
be	VB	O
needed	VBN	O
to	TO	O
understand	VB	O
how	WRB	O
to	TO	O
create	VB	O
policies	NNS	O
supporting	VBG	O
classroom	NN	O
activity	NN	O
breaks	NNS	O
and	CC	O
how	WRB	O
to	TO	O
assess	VB	O
policy	NN	O
adherence	NN	O
.	.	O

Do	NNP	O
heavier	JJR	O
women	NNS	O
benefit	VBP	O
from	IN	O
a	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
leuprolide	JJ	PM
acetate	NN	PM
for	IN	O
suppression	NN	O
of	IN	O
serum	NN	O
estradiol	NN	O
?	.	O
OBJECTIVE	UH	O
To	TO	O
determine	VB	O
if	IN	O
heavier	JJR	O
women	NNS	O
benefit	VBP	O
from	IN	O
a	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
the	DT	O
gonadotropin-releasing	JJ	PM
hormone	NN	PM
analogue	NN	PM
leuprolide	NN	PM
acetate	NN	PM
(	(	PM
LA	NNP	PM
)	)	PM
depot	NN	O
in	IN	O
terms	NNS	O
of	IN	O
suppression	NN	O
of	IN	O
serum	NN	O
estradiol	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
retrospective	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
LA	NNP	PM
depot	FW	PM
3.75	CD	O
mg	NN	O
and	CC	O
7.5	CD	O
mg	NN	O
on	IN	O
serum	NN	PM
estradiol	NN	PM
from	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
12-week	JJ	O
study	NN	O
of	IN	O
women	NNS	O
with	IN	O
anemia	NN	O
due	JJ	O
to	TO	O
bleeding	VBG	O
from	IN	O
uterine	JJ	O
leiomyomata	NN	O
.	.	O

Serum	NNP	O
estradiol	NN	O
levels	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
week	NN	O
12	CD	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
weight	NN	O
quartiles	NNS	O
according	VBG	O
to	TO	O
their	PRP$	O
baseline	NN	O
weight	NN	O
in	IN	O
kilograms	NNS	O
:	:	O
46-	JJ	O
<	NN	O
64	CD	O
,	,	O
64-	JJ	O
<	NN	O
72	CD	O
,	,	O
72-	JJ	O
<	NN	O
89	CD	O
,	,	O
89-159	JJ	O
(	(	O
pounds-102-	JJ	O
<	NN	O
140	CD	O
,	,	O
140-	JJ	O
<	NN	O
159	CD	O
,	,	O
159-	JJ	O
<	NN	O
196	CD	O
,	,	O
196-350	JJ	O
)	)	O
.	.	O

RESULTS	VBN	O
At	IN	O
baseline	NN	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
estradiol	JJ	O
level	NN	O
between	IN	O
groups	NNS	O
as	IN	O
a	DT	O
whole	NN	O
or	CC	O
within	IN	O
weight	JJ	O
quartiles	NNS	O
.	.	O

Within	IN	O
each	DT	O
group	NN	O
there	EX	O
was	VBD	O
no	DT	O
relationship	NN	O
between	IN	O
weight	NN	O
and	CC	O
baseline	NN	O
estradiol	NN	O
.	.	O

At	IN	O
week	NN	O
12	CD	O
,	,	O
whereas	NNS	O
estradiol	VBP	O
levels	NNS	O
were	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
heavier	JJR	O
patients	NNS	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
groups	NNS	O
(	(	O
LA	NNP	O
3.75	CD	O
mg	NN	O
,	,	O
p	NN	O
=	VBD	O
0.044	CD	O
;	:	O
LA	NNP	O
7.5	CD	O
mg	NN	O
,	,	O
p	NN	O
=	NNP	O
0.002	CD	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
estradiol	NN	O
between	IN	O
groups	NNS	O
as	IN	O
a	DT	O
whole	NN	O
or	CC	O
within	IN	O
any	DT	O
of	IN	O
the	DT	O
weight	NN	O
quartiles	NNS	O
.	.	O

Moreover	RB	O
,	,	O
at	IN	O
week	NN	O
12	CD	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
groups	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
estradiol	NNS	O
suppressed	VBN	O
to	TO	O
the	DT	O
menopausal	NN	O
range	NN	O
.	.	O

CONCLUSION	NNP	O
Heavier	NNP	O
women	NNS	O
do	VBP	O
not	RB	O
benefit	VB	O
from	IN	O
a	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
LA	NNP	PM
depot	NNP	O
(	(	O
7.5	CD	O
vs.	FW	O
3.75	CD	O
mg	NN	O
)	)	O
for	IN	O
suppression	NN	O
of	IN	O
serum	NN	O
levels	NNS	O
of	IN	O
estradiol	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
haloperidol	NN	PM
on	IN	O
discrimination	NN	O
learning	NN	O
and	CC	O
behavioral	JJ	O
symptoms	NNS	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

This	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	C
clinical	JJ	O
trial	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
had	VBD	O
three	CD	O
objectives	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
to	TO	O
replicate	VB	O
earlier	JJR	O
findings	NNS	O
that	IN	O
haloperidol	JJ	PM
administration	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
behavioral	JJ	O
symptoms	NNS	O
;	:	O
(	(	O
b	NN	O
)	)	O
to	TO	O
further	JJ	O
assess	NN	O
its	PRP$	O
safety	NN	O
when	WRB	O
given	VBN	O
on	IN	O
a	DT	O
short-term	JJ	O
basis	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
to	TO	O
assess	VB	O
whether	IN	O
it	PRP	O
has	VBZ	O
an	DT	O
effect	NN	O
on	IN	O
discrimination	NN	O
learning	NN	O
.	.	O

Forty-five	JJ	O
children	NNS	O
,	,	O
2.02	CD	O
to	TO	O
7.58	CD	O
years	NNS	O
old	JJ	O
(	(	O
M	NNP	O
=	NNP	O
4.49	CD	O
)	)	O
,	,	O
completed	VBD	O
this	DT	O
crossover	NN	O
design	NN	O
,	,	O
with	IN	O
random	JJ	O
assignment	NN	O
to	TO	O
treatment	NN	O
sequences	NNS	O
.	.	O

Haloperidol	NNP	PM
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
powerful	JJ	O
therapeutic	JJ	O
agent	NN	O
when	WRB	O
administered	VBN	O
for	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
free	JJ	O
of	IN	O
side	JJ	O
effects	NNS	O
;	:	O
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
0.25	CD	O
to	TO	O
4.0	CD	O
mg/day	NN	O
(	(	O
M	NNP	O
=	NNP	O
0.844	CD	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
clinically	RB	O
and	CC	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

Under	IN	O
the	DT	O
given	VBN	O
conditions	NNS	O
,	,	O
the	DT	O
children	NNS	O
failed	VBD	O
to	TO	O
learn	VB	O
on	IN	O
either	DT	O
haloperidol	NN	PM
or	CC	O
placebo	NN	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
trimethoprim-sulfamethoxazole	JJ	PM
or	CC	O
aerosolized	JJ	PM
pentamidine	NN	PM
for	IN	O
secondary	JJ	O
prophylaxis	NN	O
of	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
.	.	O

AIDS	NNP	O
Clinical	JJ	O
Trials	NNP	O
Group	NNP	O
Protocol	NNP	O
021	CD	O
.	.	O

BACKGROUND	NNP	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
(	(	O
PCP	NNP	O
)	)	O
continues	VBZ	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
common	JJ	O
index	NN	O
diagnosis	NN	O
in	IN	O
the	DT	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
clear	JJ	O
which	WDT	O
of	IN	O
several	JJ	O
available	JJ	O
agents	NNS	O
is	VBZ	O
the	DT	O
most	RBS	O
effective	JJ	O
in	IN	O
preventing	VBG	O
a	DT	O
recurrence	NN	O
of	IN	O
PCP	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
comparative	JJ	O
,	,	O
open-label	JJ	O
trial	NN	O
in	IN	O
310	CD	O
adults	NNS	O
with	IN	O
AIDS	NNP	O
who	WP	O
had	VBD	O
recently	RB	O
recovered	VBN	O
from	IN	O
an	DT	O
initial	JJ	O
episode	NN	O
of	IN	O
PCP	NNP	O
and	CC	O
had	VBD	O
no	DT	O
treatment-limiting	JJ	O
toxic	NN	O
effects	NNS	O
of	IN	O
trimethoprim-sulfamethoxazole	JJ	PM
or	CC	O
pentamidine	NN	PM
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
zidovudine	NN	PM
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
800	CD	PM
mg	NN	PM
of	IN	PM
sulfamethoxazole	NN	PM
and	CC	PM
160	CD	PM
mg	NN	PM
of	IN	PM
trimethoprim	JJ	PM
once	JJ	O
daily	JJ	O
or	CC	O
300	CD	PM
mg	NN	PM
of	IN	PM
aerosolized	JJ	PM
pentamidine	NN	PM
administered	VBN	O
every	DT	O
four	CD	O
weeks	NNS	O
by	IN	O
jet	NN	PM
nebulizer	NN	PM
.	.	O

The	DT	O
participants	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
a	DT	O
median	NN	O
of	IN	O
17.4	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	PM
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
154	CD	O
)	)	O
there	EX	O
were	VBD	O
14	CD	O
recurrences	NNS	O
of	IN	O
PCP	NNP	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
36	CD	O
recurrences	NNS	O
(	(	O
including	VBG	O
1	CD	O
extrapulmonary	JJ	O
recurrence	NN	O
)	)	O
in	IN	O
the	DT	O
aerosolized-pentamidine	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
156	CD	O
)	)	O
.	.	O

The	DT	O
estimated	JJ	O
recurrence	NN	O
rates	NNS	O
at	IN	O
18	CD	O
months	NNS	O
were	VBD	O
11.4	CD	O
percent	NN	O
with	IN	O
trimethoprim-sulfamethoxazole	JJ	PM
and	CC	O
27.6	CD	O
percent	NN	O
with	IN	O
pentamidine	NN	PM
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
a	DT	O
recurrence	NN	O
(	(	O
adjusted	VBN	O
for	IN	O
initial	JJ	O
CD4	NNP	O
cell	NN	O
count	NN	O
)	)	O
was	VBD	O
3.25	CD	O
times	NNS	O
higher	RBR	O
in	IN	O
the	DT	O
pentamidine	NN	PM
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
,	,	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.72	CD	O
to	TO	O
6.16	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
survival	NN	O
or	CC	O
in	IN	O
hematologic	JJ	O
or	CC	O
hepatic	JJ	O
toxicity	NN	O
.	.	O

Crossovers	NNS	O
from	IN	O
trimethoprim-sulfamethoxazole	JJ	PM
to	TO	O
aerosolized	JJ	O
pentamidine	NN	PM
were	VBD	O
more	JJR	O
common	JJ	O
than	IN	O
the	DT	O
reverse	NN	O
(	(	O
27	CD	O
vs.	FW	O
4	CD	O
percent	NN	O
)	)	O
,	,	O
partly	RB	O
because	IN	O
of	IN	O
the	DT	O
study	NN	O
protocols	NNS	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
leukopenia	NN	O
.	.	O

There	EX	O
were	VBD	O
19	CD	O
serious	JJ	O
bacterial	JJ	O
infections	NNS	O
in	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	O
group	NN	O
and	CC	O
38	CD	O
in	IN	O
the	DT	O
pentamidine	NN	O
group	NN	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
a	DT	O
first	JJ	O
bacterial	JJ	O
infection	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
for	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
trimethoprim-sulfamethoxazole	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
who	WP	O
are	VBP	O
receiving	VBG	O
zidovudine	NN	PM
,	,	O
trimethoprim-sulfamethoxazole	JJ	PM
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
aerosolized	JJ	PM
pentamidine	NN	PM
in	IN	O
conventional	JJ	O
doses	NNS	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
recurrent	NN	O
pneumocystis	NN	O
infection	NN	O
.	.	O

Effects	NNS	O
of	IN	O
large	JJ	O
doses	NNS	O
of	IN	O
arachidonic	JJ	O
acid	NN	O
added	VBD	O
to	TO	O
docosahexaenoic	VB	O
acid	NN	O
on	IN	O
social	JJ	O
impairment	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

Autism	NNP	O
spectrum	NN	O
disorders	NNS	O
are	VBP	O
a	DT	O
neurodevelopmental	JJ	O
disorders	NNS	O
with	IN	O
reduced	JJ	O
cortical	JJ	O
functional	JJ	O
connectivity	NN	O
relating	VBG	O
to	TO	O
social	JJ	O
cognition	NN	O
.	.	O

Polyunsaturated	VBN	PM
fatty	JJ	PM
acids	NNS	PM
arachidonic	JJ	PM
acid	NN	PM
(	(	PM
ARA	NNP	PM
)	)	PM
and	CC	O
docosahexaenoic	JJ	PM
acid	NN	PM
(	(	PM
DHA	NNP	PM
)	)	PM
may	MD	O
have	VB	O
key	JJ	O
role	NN	O
in	IN	O
brain	NN	O
network	NN	O
maturation	NN	O
.	.	O

In	IN	O
particularly	RB	O
,	,	O
ARA	NNP	PM
is	VBZ	O
important	JJ	O
in	IN	O
signal	JJ	O
transduction	NN	O
related	VBN	O
to	TO	O
neuronal	JJ	O
maturation	NN	O
.	.	O

Supplementation	NN	O
with	IN	O
larger	JJR	O
ARA	NNP	PM
doses	VBZ	PM
added	VBN	PM
to	TO	PM
DHA	NNP	PM
may	MD	O
therefore	VB	O
mitigate	VB	O
social	JJ	O
impairment	NN	O
.	.	O

In	IN	O
a	DT	O
16-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
supplementation	NN	O
with	IN	O
large	JJ	O
doses	NNS	O
of	IN	O
ARA	NNP	PM
added	VBD	PM
to	TO	PM
DHA	NNP	PM
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
in	IN	O
13	CD	O
participants	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
14.6	CD	O
[	NN	O
SD	NNP	O
,	,	O
5.9	CD	O
]	CD	O
years	NNS	O
)	)	O
.	.	O

To	TO	O
examine	VB	O
underlying	JJ	O
mechanisms	NNS	O
underlying	VBG	O
the	DT	O
effect	NN	O
of	IN	O
our	PRP$	O
supplementation	NN	O
regimen	NNS	O
,	,	O
we	PRP	O
examined	VBD	O
plasma	JJ	O
levels	NNS	O
of	IN	O
antioxidants	NNS	O
transferrin	JJ	O
and	CC	O
superoxide	JJ	O
dismutase	NN	O
,	,	O
which	WDT	O
are	VBP	O
useful	JJ	O
markers	NNS	O
of	IN	O
signal	JJ	O
transduction	NN	O
.	.	O

The	DT	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
Social	NNP	O
Responsiveness	NNP	O
Scale	NNP	O
and	CC	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
.	.	O

Repeated-measures	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
revealed	VBD	O
that	IN	O
our	PRP$	O
supplementation	NN	O
regimen	NNS	O
significantly	RB	O
improved	VBN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community-measured	NNP	O
social	JJ	O
withdrawal	NN	O
and	CC	O
Social	NNP	O
Responsiveness	NNP	O
Scale-measured	JJ	O
communication	NN	O
.	.	O

Treatment	NNP	O
effect	NN	O
sizes	NNS	O
were	VBD	O
more	RBR	O
favorable	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
communication	NN	O
:	:	O
treatment	NN	O
groups	NNS	O
,	,	O
0.87	CD	O
vs	NN	O
,	,	O
placebo	NN	C
,	,	O
0.44	CD	O
;	:	O
social	JJ	O
withdrawal	NN	O
:	:	O
treatment	NN	O
groups	NNS	O
,	,	O
0.88	CD	O
,	,	O
vs	NN	O
placebo	NN	C
,	,	O
0.54	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
plasma	NN	O
transferrin	NN	O
levels	NNS	O
and	CC	O
a	DT	O
trend	NN	O
toward	IN	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
plasma	JJ	O
superoxide	JJ	O
dismutase	NN	O
levels	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

This	DT	O
preliminary	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
supplementation	NN	O
with	IN	O
larger	JJR	O
ARA	NNP	PM
doses	VBZ	PM
added	VBN	PM
to	TO	PM
DHA	NNP	PM
improves	NNS	O
impaired	VBD	O
social	JJ	O
interaction	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
by	IN	O
up-regulating	JJ	O
signal	JJ	O
transduction	NN	O
.	.	O

Effect	NN	O
of	IN	O
clinical	JJ	E
pharmacy	NN	E
services	NNS	E
on	IN	O
the	DT	O
blood	NN	O
pressure	NN	O
of	IN	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
who	WP	O
received	VBD	O
direct	JJ	O
patient	NN	O
care	NN	O
from	IN	O
a	DT	O
clinical	JJ	E
pharmacist	NN	E
had	VBD	O
better	RBR	O
blood	NN	O
pressure	NN	O
control	NN	O
compared	VBN	O
to	TO	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
have	VB	O
clinical	JJ	O
pharmacy	NN	O
services	NNS	O
.	.	O

METHODS	NNP	O
Renal	NNP	O
transplant	NN	O
patients	NNS	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
into	IN	O
an	DT	O
intervention	NN	O
group	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
received	VBD	E
clinical	JJ	E
pharmacy	NN	E
services	NNS	E
that	WDT	E
included	VBD	E
a	DT	E
clinical	JJ	E
pharmacist	NN	E
performing	VBG	E
patient	JJ	E
medication	NN	E
reviews	NNS	E
,	,	E
with	IN	E
emphasis	NN	E
on	IN	E
preventing	VBG	E
or	CC	E
resolving	VBG	E
medication-related	JJ	E
problems	NNS	E
and	CC	E
providing	VBG	E
medication	NN	E
recommendations	NNS	E
.	.	E

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	E
routine	JJ	C
clinic	NN	C
services	NNS	C
,	,	E
but	CC	E
had	VBD	E
no	DT	C
clinical	JJ	C
pharmacist	NN	C
interaction	NN	C
.	.	E

Analysis	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
detect	VB	O
differences	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
in	IN	O
baseline	NN	O
and	CC	O
quarterly	JJ	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
SBP	NNP	O
)	)	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
DBP	NNP	O
)	)	O
for	IN	O
one	CD	O
year	NN	O
post-study	NN	O
enrollment	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
(	(	O
N	NNP	O
=	NNP	O
13	CD	O
)	)	O
and	CC	O
control	NN	O
(	(	O
N	NNP	O
=	NNP	O
10	CD	O
)	)	O
groups	NNS	O
in	IN	O
baseline	NN	O
blood	NN	O
pressures	NNS	O
or	CC	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

Significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
SBP	NNP	O
and	CC	O
DBP	NNP	O
from	IN	O
baseline	NN	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
second	JJ	O
,	,	O
third	JJ	O
,	,	O
and	CC	O
fourth	JJ	O
quarters	NNS	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
favoring	VBG	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Mean	NNP	O
SBP	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
at	IN	O
the	DT	O
second	JJ	O
(	(	O
137.8	CD	O
+/-	JJ	O
15.0	CD	O
vs	JJ	O
168.9	CD	O
+/-	JJ	O
15.3	CD	O
)	)	O
,	,	O
third	JJ	O
(	(	O
135.9	CD	O
+/-	JJ	O
11.7	CD	O
vs	JJ	O
164.6	CD	O
+/-	JJ	O
20.1	CD	O
)	)	O
,	,	O
and	CC	O
fourth	JJ	O
(	(	O
145.3	CD	O
+/-	JJ	O
16.8	CD	O
vs	JJ	O
175.8	CD	O
+/-	JJ	O
33.9	CD	O
)	)	O
quarters	NNS	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Mean	NNP	O
DBP	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
at	IN	O
the	DT	O
second	JJ	O
(	(	O
76.0	CD	O
+/-	JJ	O
11.8	CD	O
vs	JJ	O
84.9	CD	O
+/-	JJ	O
6.1	CD	O
)	)	O
and	CC	O
fourth	JJ	O
(	(	O
77.0	CD	O
+/-	JJ	O
10.2	CD	O
vs	JJ	O
91.8	CD	O
+/-	JJ	O
12.0	CD	O
)	)	O
quarters	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Direct	NNP	O
patient	NN	O
care	NN	O
services	NNS	O
provided	VBN	O
by	IN	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
routine	VB	O
clinical	JJ	O
services	NNS	O
,	,	O
have	VBP	O
a	DT	O
positive	JJ	O
effect	NN	O
on	IN	O
the	DT	O
blood	NN	O
pressure	NN	O
of	IN	O
African-American	JJ	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
.	.	O

A	DT	O
multidisciplinary	JJ	O
team	NN	O
that	WDT	O
includes	VBZ	O
a	DT	O
clinical	JJ	O
pharmacist	NN	O
is	VBZ	O
beneficial	JJ	O
to	TO	O
patient	VB	O
care	NN	O
.	.	O

Granulocyte-colony	JJ	PM
stimulating	NN	PM
factor	NN	PM
for	IN	O
mobilizing	VBG	O
bone	NN	O
marrow	NN	O
stem	NN	O
cells	NNS	O
in	IN	O
subacute	JJ	O
stroke	NN	O
:	:	O
the	DT	O
stem	NN	PH
cell	VBP	PH
trial	NN	O
of	IN	O
recovery	NN	O
enhancement	NN	O
after	IN	O
stroke	VBD	O
2	CD	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Granulocyte-colony	NNP	PM
stimulating	VBG	PM
factor	NN	PM
(	(	PM
G-CSF	NNP	PM
)	)	PM
is	VBZ	O
neuroprotective	JJ	O
in	IN	O
experimental	JJ	O
stroke	NN	O
and	CC	O
mobilizes	VBZ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
peripheral	JJ	O
blood	NN	O
stem	NN	O
cells	NNS	O
into	IN	O
the	DT	O
circulation	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
safety	NN	O
of	IN	O
G-CSF	NNP	PM
in	IN	O
recent	JJ	O
stroke	NN	O
in	IN	O
a	DT	O
phase	NN	O
IIb	NNP	O
single-center	NN	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

METHODS	NNP	O
G-CSF	NNP	O
(	(	O
10	CD	O
?g/kg	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
ratio	VB	O
2:1	CD	O
)	)	O
was	VBD	O
given	VBN	O
SC	NNP	O
for	IN	O
5	CD	O
days	NNS	O
to	TO	O
60	CD	O
patients	NNS	O
3	CD	O
to	TO	O
30	CD	O
days	NNS	O
after	IN	O
ischemic	JJ	O
or	CC	O
hemorrhagic	JJ	O
stroke	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Peripheral	NNP	O
blood	NN	O
counts	NNS	O
,	,	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
count	NN	O
,	,	O
and	CC	O
functional	JJ	O
outcome	NN	O
were	VBD	O
measured	VBN	O
.	.	O

MRI	NNP	O
assessed	VBD	O
lesion	NN	O
volume	NN	O
,	,	O
atrophy	NN	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
iron-labeled	JJ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
reinjected	VBN	O
on	IN	O
day	NN	O
6	CD	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
at	IN	O
mean	NN	O
of	IN	O
8	CD	O
days	NNS	O
(	(	O
SD	NNP	O
?	.	O
5	CD	O
)	)	O
post	NN	O
ictus	NN	O
,	,	O
with	IN	O
mean	JJ	O
age	NN	O
71	CD	O
years	NNS	O
(	(	O
?	.	O
12	CD	O
years	NNS	O
)	)	O
and	CC	O
53	CD	O
%	NN	O
men	NNS	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
for	IN	O
baseline	JJ	O
minimization/prognostic	JJ	O
factors	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
participants	NNS	O
with	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
:	:	O
G-CSF	JJ	O
15	CD	O
(	(	O
37.5	CD	O
%	NN	O
)	)	O
of	IN	O
40	CD	O
versus	NN	O
placebo	NN	C
7	CD	O
(	(	O
35	CD	O
%	NN	O
)	)	O
of	IN	O
20	CD	O
,	,	O
death	NN	O
or	CC	O
dependency	NN	O
(	(	O
modified	JJ	O
Rankin	NNP	O
Score	NN	O
:	:	O
G-CSF	JJ	O
3.3	CD	O
?	.	O
1.3	CD	O
,	,	O
placebo	NN	O
3.0	CD	O
?	.	O
1.3	CD	O
)	)	O
at	IN	O
90	CD	O
days	NNS	O
,	,	O
or	CC	O
the	DT	O
number	NN	O
of	IN	O
injections	NNS	O
received	VBN	O
.	.	O

G-CSF	NNP	O
increased	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
total	JJ	O
white	JJ	O
cell	NN	O
counts	NNS	O
of	IN	O
9.5-	CD	O
and	CC	O
4.2-fold	JJ	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
reduction	NN	O
in	IN	O
MRI	NNP	O
ischemic	JJ	O
lesion	NN	O
volume	NN	O
with	IN	O
respect	NN	O
to	TO	O
change	VB	O
from	IN	O
baseline	NN	O
in	IN	O
G-CSF-treated	JJ	O
patients	NNS	O
(	(	O
P=0.06	NNP	O
)	)	O
.	.	O

In	IN	O
1	CD	O
participant	NN	O
,	,	O
there	EX	O
was	VBD	O
suggestion	NN	O
that	IN	O
labeled	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
had	VBD	O
migrated	VBN	O
to	TO	O
the	DT	O
ischemic	JJ	O
lesion	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
suggests	VBZ	O
that	IN	O
G-CSF	NNP	O
is	VBZ	O
safe	JJ	O
when	WRB	O
administered	VBN	O
subacutely	RB	O
.	.	O

It	PRP	O
is	VBZ	O
feasible	JJ	O
to	TO	O
label	VB	O
and	CC	O
readminister	VB	O
iron-labeled	JJ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ischemic	JJ	O
stroke	NN	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
URL	NNP	O
:	:	O
www.controlled-trials.com	NN	O
.	.	O

Unique	NNP	O
identifier	NN	O
:	:	O
ISRCTN63336619	NNP	O
.	.	O

Polymorphisms	NNP	O
of	IN	O
ADORA2A	NNP	O
modulate	NNP	O
psychomotor	NN	O
vigilance	NN	O
and	CC	O
the	DT	O
effects	NNS	O
of	IN	O
caffeine	NN	O
on	IN	O
neurobehavioural	JJ	O
performance	NN	O
and	CC	O
sleep	JJ	O
EEG	NNP	O
after	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Prolonged	NNP	O
wakefulness	NN	O
impairs	NNS	O
sustained	VBD	O
vigilant	JJ	O
attention	NN	O
,	,	O
measured	VBN	O
with	IN	O
the	DT	O
psychomotor	NN	O
vigilance	NN	O
task	NN	O
(	(	O
PVT	NNP	O
)	)	O
,	,	O
and	CC	O
induces	VBZ	O
a	DT	O
compensatory	JJ	O
increase	NN	O
in	IN	O
sleep	JJ	O
intensity	NN	O
in	IN	O
recovery	NN	O
sleep	NN	O
,	,	O
quantified	VBN	O
by	IN	O
slow-wave	JJ	O
activity	NN	O
(	(	O
SWA	NNP	O
)	)	O
in	IN	O
the	DT	O
sleep	JJ	O
electroencephalogram	NN	O
(	(	O
EEG	NNP	O
)	)	O
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
sleep	JJ	O
deprivation	NN	O
are	VBP	O
counteracted	VBN	O
by	IN	O
the	DT	O
adenosine	NN	O
receptor	NN	O
antagonist	JJ	O
caffeine	NN	O
,	,	O
implying	VBG	O
involvement	NN	O
of	IN	O
the	DT	O
adenosine	NN	O
neuromodulator/receptor	NN	O
system	NN	O
.	.	O

To	TO	O
examine	VB	O
a	DT	O
role	NN	O
for	IN	O
adenosine	NN	O
A	NNP	O
(	(	O
2A	CD	O
)	)	O
receptors	NNS	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
variation	NN	O
of	IN	O
the	DT	O
A	NNP	O
(	(	O
2A	CD	O
)	)	O
receptor	NN	O
gene	NN	O
(	(	O
ADORA2A	NNP	O
)	)	O
modified	VBD	O
effects	NNS	O
of	IN	O
caffeine	NN	PM
on	IN	O
PVT	NNP	O
and	CC	O
SWA	NNP	O
after	IN	O
sleep	JJ	PH
deprivation	NN	PH
.	.	O

EXPERIMENTAL	NNP	O
APPROACH	NNP	O
A	NNP	O
haplotype	JJ	O
analysis	NN	O
of	IN	O
eight	CD	O
single-nucleotide	JJ	O
polymorphisms	NNS	O
of	IN	O
ADORA2A	NNP	O
was	VBD	O
performed	VBN	O
in	IN	O
82	CD	O
volunteers	NNS	O
.	.	O

In	IN	O
45	CD	O
young	JJ	O
men	NNS	O
carrying	VBG	O
five	CD	O
different	JJ	O
allele	NN	O
combinations	NNS	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
prolonged	JJ	O
waking	NN	O
and	CC	O
2	CD	O
?	.	O
200	CD	O
mg	JJ	O
caffeine	NN	O
or	CC	O
2	CD	O
?	.	O
100	CD	O
mg	NN	O
modafinil	NN	O
on	IN	O
psychomotor	NN	O
vigilance	NN	O
,	,	O
sleepiness	NN	O
,	,	O
and	CC	O
the	DT	O
waking	NN	O
and	CC	O
sleep	JJ	O
EEG	NNP	O
.	.	O

KEY	NNP	O
RESULTS	NNP	O
Throughout	NNP	O
extended	VBD	O
wakefulness	NN	O
,	,	O
the	DT	O
carriers	NNS	O
of	IN	O
haplotype	NN	O
HT4	NNP	O
performed	VBD	O
faster	RBR	O
on	IN	O
the	DT	O
PVT	NNP	O
than	IN	O
carriers	NNS	O
of	IN	O
non-HT4	JJ	O
haplotype	NN	O
alleles	NNS	O
.	.	O

In	IN	O
haplotype	JJ	O
HT4	NNP	O
,	,	O
caffeine	NN	O
failed	VBD	O
to	TO	O
counteract	VB	O
the	DT	O
waking-induced	JJ	O
impairment	NN	O
of	IN	O
PVT	NNP	O
performance	NN	O
and	CC	O
the	DT	O
rebound	NN	O
of	IN	O
SWA	NNP	O
in	IN	O
recovery	NN	O
sleep	NN	O
.	.	O

However	RB	O
,	,	O
caffeine	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
non-HT4	JJ	O
allele	NN	O
carriers	NNS	O
,	,	O
and	CC	O
modafinil	NN	O
reduced	VBD	O
the	DT	O
consequences	NNS	O
of	IN	O
prolonged	JJ	O
waking	NN	O
,	,	O
independently	RB	O
of	IN	O
ADORA2A	NNP	O
haplotype	NN	O
.	.	O

CONCLUSIONS	NNP	O
AND	CC	O
IMPLICATIONS	NNP	O
Common	NNP	O
genetic	JJ	O
variation	NN	O
of	IN	O
ADORA2A	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
determinant	NN	O
of	IN	O
psychomotor	NN	O
vigilance	NN	O
in	IN	O
rested	JJ	O
and	CC	O
sleep-deprived	JJ	O
state	NN	O
.	.	O

It	PRP	O
also	RB	O
modulates	VBZ	O
individual	JJ	O
responses	NNS	O
to	TO	O
caffeine	VB	O
after	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

These	DT	O
findings	NNS	O
demonstrate	VBP	O
a	DT	O
role	NN	O
for	IN	O
adenosine	NN	O
A	NNP	O
(	(	O
2A	CD	O
)	)	O
receptors	NNS	O
in	IN	O
the	DT	O
effects	NNS	O
of	IN	O
prolonged	JJ	O
wakefulness	NN	O
on	IN	O
vigilant	JJ	O
attention	NN	O
and	CC	O
the	DT	O
sleep	JJ	O
EEG	NNP	O
.	.	O

Effect	NN	O
of	IN	O
device-guided	JJ	E
breathing	NN	E
exercises	NNS	E
on	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NNP	O
Hypertension	NNP	O
is	VBZ	O
a	DT	O
chronic	JJ	O
disorder	NN	O
with	IN	O
a	DT	O
high	JJ	O
prevalence	NN	O
worldwide	NN	O
.	.	O

Despite	IN	O
considerable	JJ	O
efforts	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
sometimes	RB	O
hard	JJ	O
to	TO	O
reach	VB	O
treatment	NN	O
goals	NNS	O
for	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
with	IN	O
classical	JJ	O
treatment	NN	O
options	NNS	O
.	.	O

Reducing	VBG	O
breathing	VBG	O
frequency	NN	O
has	VBZ	O
been	VBN	O
advocated	VBN	O
as	IN	O
a	DT	O
method	NN	O
to	TO	O
reduce	VB	O
BP	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
30	CD	O
non-diabetic	JJ	O
patients	NNS	O
with	IN	O
hypertension	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
9	CD	O
weeks	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
device	NN	E
that	WDT	E
helps	VBZ	E
to	TO	E
slow	VB	E
breathing	NN	E
(	(	E
Resperate	NNP	E
)	)	E
on	IN	O
BP	NNP	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
listened	VBD	E
to	TO	E
music	NN	E
and	CC	E
used	VBN	E
no	DT	E
other	JJ	E
therapeutic	JJ	E
device	NN	E
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
change	NN	O
in	IN	O
BP	NNP	O
between	IN	O
intervention	NN	O
and	CC	O
control	NN	O
;	:	O
BP	NNP	O
-4.2	NNP	O
mmHg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-12.4	NNP	O
to	TO	O
3.9	CD	O
)	)	O
/-2.6	NN	O
mmHg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-8.4	NNP	O
to	TO	O
3.3	CD	O
)	)	O
.	.	O

This	DT	O
result	NN	O
did	VBD	O
not	RB	O
alter	VB	O
in	IN	O
post	NN	O
hoc	NN	O
analyses	NNS	O
,	,	O
when	WRB	O
patients	NNS	O
not	RB	O
achieving	VBG	O
target	NN	O
breathing	NN	O
frequency	NN	O
(	(	O
<	JJ	O
10	CD	O
breaths/min	NN	O
)	)	O
or	CC	O
non-compliant	JJ	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

QoL	NNP	O
did	VBD	O
not	RB	O
change	VB	O
over	IN	O
time	NN	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
found	VBD	O
no	DT	O
effect	NN	O
of	IN	O
the	DT	O
Resperate	NNP	O
on	IN	O
BP	NNP	O
or	CC	O
QoL	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
,	,	O
at	IN	O
this	DT	O
moment	NN	O
,	,	O
this	DT	O
device	NN	O
has	VBZ	O
no	DT	O
added	VBN	O
value	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
.	.	O

Sivelestat	NNP	PM
sodium	NN	PM
hydrate	NN	PM
improves	VBZ	O
septic	JJ	O
acute	NN	O
lung	NN	O
injury	NN	O
by	IN	O
reducing	VBG	O
alveolar	JJ	O
dysfunction	NN	O
.	.	O

Sivelestat	NNP	PM
sodium	NN	PM
hydrate	NN	PM
(	(	PM
sivelestat	NN	PM
)	)	PM
is	VBZ	O
a	DT	O
selective	JJ	O
inhibitor	NN	O
of	IN	O
polymorphonuclear	JJ	O
leukocyte	JJ	O
elastase	NN	O
(	(	O
PMN-E	NNP	O
)	)	O
.	.	O

We	PRP	O
administered	VBD	O
sivelestat	NNS	PM
to	TO	O
patients	NNS	O
with	IN	O
septic	JJ	O
acute	NN	O
lung	NN	O
injury	NN	O
(	(	O
ALI	NNP	O
)	)	O
to	TO	O
examine	VB	O
its	PRP$	O
usefulness	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
in	IN	O
the	DT	O
study	NN	O
were	VBD	O
the	DT	O
duration	NN	O
of	IN	O
artificial	JJ	O
ventilation	NN	O
and	CC	O
pulmonary	JJ	O
oxygenation	NN	O
ability	NN	O
,	,	O
and	CC	O
the	DT	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
mortality	NN	O
and	CC	O
the	DT	O
concentrations	NNS	O
of	IN	O
PMN-E	NNP	O
,	,	O
SP-D	NNP	O
,	,	O
TNF-alpha	NNP	O
and	CC	O
IL-8	NNP	O
in	IN	O
blood	NN	O
.	.	O

In	IN	O
the	DT	O
sivelestat	NN	PM
group	NN	O
,	,	O
the	DT	O
duration	NN	O
of	IN	O
artificial	JJ	O
ventilation	NN	O
,	,	O
pulmonary	JJ	O
oxygenation	NN	O
ability	NN	O
,	,	O
and	CC	O
the	DT	O
blood	NN	O
PMN-E	NNP	O
,	,	O
SP-D	NNP	O
,	,	O
TNF-alpha	NNP	O
and	CC	O
IL-8	NNP	O
concentrations	NNS	O
decreased	VBD	O
significantly	RB	O
.	.	O

Administration	NNP	O
of	IN	O
sivelestat	NN	PM
was	VBD	O
found	VBN	O
to	TO	O
reduce	VB	O
alveolar	JJ	O
dysfunction	NN	O
and	CC	O
improve	VB	O
respiratory	NN	O
function	NN	O
,	,	O
and	CC	O
it	PRP	O
was	VBD	O
suggested	VBN	O
that	IN	O
early	JJ	O
administration	NN	O
might	MD	O
be	VB	O
useful	JJ	O
.	.	O

Rate-modulated	JJ	O
cardiac	NN	O
pacing	NN	O
based	VBN	O
on	IN	O
transthoracic	JJ	O
impedance	NN	O
measurements	NNS	O
of	IN	O
minute	JJ	O
ventilation	NN	O
:	:	O
correlation	NN	O
with	IN	O
exercise	NN	O
gas	NN	O
exchange	NN	O
.	.	O

The	DT	O
relation	NN	O
of	IN	O
pacing	VBG	O
rate	NN	O
to	TO	O
physiologic	VB	O
variables	NNS	O
of	IN	O
metabolic	JJ	O
demand	NN	O
was	VBD	O
examined	VBN	O
in	IN	O
10	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
minute	NN	O
ventilation-sensing	NN	O
,	,	O
rate-modulating	JJ	O
ventricular	JJ	O
pacemaker	NN	O
implanted	VBN	O
for	IN	O
complete	JJ	O
heart	NN	O
block	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
paroxysmal	JJ	O
(	(	O
seven	CD	O
patients	NNS	O
)	)	O
or	CC	O
chronic	JJ	O
(	(	O
three	CD	O
patients	NNS	O
)	)	O
atrial	JJ	O
fibrillation	NN	O
and	CC	O
were	VBD	O
referred	VBN	O
for	IN	O
catheter	JJR	S
ablation	NN	S
of	IN	S
the	DT	S
atrioventricular	JJ	S
junction	NN	S
.	.	O

Treadmill	NNP	PH
exercise	NN	PH
testing	VBG	PH
with	IN	O
measurement	NN	O
of	IN	O
expired	NNP	O
gas	NN	O
exchange	NN	O
and	CC	O
respiratory	NN	O
flow	NN	O
was	VBD	O
performed	VBN	O
before	IN	O
ablation	NN	O
and	CC	O
4	CD	O
weeks	NNS	O
after	IN	O
pacemaker	NN	O
implantation	NN	O
,	,	O
with	IN	O
the	DT	O
pacemaker	NN	O
programmed	VBD	O
to	TO	O
both	DT	O
the	DT	O
fixed-rate	JJ	O
VVI	NNP	O
and	CC	O
rate-modulating	JJ	O
minute	NN	O
ventilation	NN	O
VVIR	NNP	O
pacing	VBG	O
modes	NNS	O
in	IN	O
random	JJ	O
sequence	NN	O
.	.	O

The	DT	O
relation	NN	O
of	IN	O
pacing	VBG	O
rate	NN	O
to	TO	O
oxygen	VB	O
consumption	NN	O
(	(	O
VO2	NNP	O
)	)	O
,	,	O
expired	VBD	O
carbon	NN	O
dioxide	NN	O
concentration	NN	O
(	(	O
VCO2	NNP	O
)	)	O
,	,	O
respiratory	JJ	O
quotient	NN	O
,	,	O
tidal	JJ	O
volume	NN	O
,	,	O
respiratory	NN	O
rate	NN	O
and	CC	O
minute	NN	O
ventilation	NN	O
was	VBD	O
determined	VBN	O
during	IN	O
exercise	NN	O
in	IN	O
the	DT	O
rate-modulating	JJ	O
minute	NN	O
ventilation	NN	O
pacing	VBG	O
mode	NN	O
.	.	O

Pacing	VBG	O
rate	NN	O
was	VBD	O
highly	RB	O
correlated	VBN	O
with	IN	O
minute	JJ	O
ventilation	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
,	,	O
respiratory	JJ	O
quotient	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
,	,	O
VCO2	NNP	O
(	(	O
r	VB	O
=	RB	O
0.87	CD	O
)	)	O
,	,	O
tidal	JJ	O
volume	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.87	CD	O
)	)	O
,	,	O
VO2	NNP	O
(	(	O
r	VB	O
=	RB	O
0.84	CD	O
)	)	O
and	CC	O
respiratory	JJ	O
rate	NN	O
(	(	O
r	NN	O
=	RB	O
0.84	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
exercise	NN	O
duration	NN	O
increased	VBD	O
from	IN	O
8.3	CD	O
+/-	JJ	O
2.8	CD	O
min	NN	O
in	IN	O
the	DT	O
fixed	JJ	O
rate	NN	O
pacing	VBG	O
mode	NN	O
to	TO	O
10.2	CD	O
+/-	JJ	O
3.4	CD	O
min	NN	O
in	IN	O
the	DT	O
rate-modulating	NN	O
,	,	O
minute	NN	O
ventilation	NN	O
mode	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
VO2	NNP	O
increased	VBD	O
from	IN	O
13.4	CD	O
+/-	JJ	O
3.4	CD	O
to	TO	O
16.3	CD	O
+/-	JJ	O
4.1	CD	O
cc/kg	NN	O
per	IN	O
min	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0004	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
heart	NN	O
rate	NN	O
achieved	VBN	O
in	IN	O
the	DT	O
minute	NN	O
ventilation	NN	O
pacing	VBG	O
mode	NN	O
was	VBD	O
136	CD	O
+/-	JJ	O
9.7	CD	O
beats/min	NN	O
,	,	O
similar	JJ	O
to	TO	O
that	DT	O
observed	VBN	O
in	IN	O
the	DT	O
patient	NN	O
's	POS	O
intrinsic	JJ	O
cardiac	JJ	O
rhythm	NN	O
before	IN	O
ablation	NN	O
(	(	O
134.9	CD	O
+/-	JJ	O
30.1	CD	O
beats/min	NN	O
,	,	O
p	NN	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Supporting	VBG	O
families	NNS	O
in	IN	O
challenging	VBG	O
contexts	NN	O
:	:	O
the	DT	O
CAPEDP	NNP	O
project	NN	O
.	.	O

Although	IN	O
France	NNP	O
has	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
generous	JJ	O
health	NN	O
and	CC	O
social	JJ	O
care	NN	O
systems	NNS	O
for	IN	O
infant	NN	O
and	CC	O
maternal	JJ	O
well-being	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
,	,	O
professionals	NNS	O
have	VBP	O
been	VBN	O
increasingly	RB	O
concerned	VBN	O
by	IN	O
the	DT	O
rising	VBG	O
number	NN	O
of	IN	O
children	NNS	O
being	VBG	O
referred	VBN	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
.	.	O

The	DT	O
present	JJ	O
article	NN	O
describes	VBZ	O
the	DT	O
first	JJ	O
home-visiting	JJ	E
program	NN	E
in	IN	O
France	NNP	O
to	TO	O
specifically	RB	O
target	VB	O
mental	JJ	O
health	NN	O
questions	NNS	O
in	IN	O
families	NNS	O
living	VBG	O
in	IN	O
vulnerable	JJ	O
contexts	NN	O
.	.	O

The	DT	O
CAPEDP	NNP	O
project	NN	O
,	,	O
involving	VBG	O
440	CD	O
women	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
,	,	O
took	VBD	O
place	NN	O
in	IN	O
Paris	NNP	O
and	CC	O
its	PRP$	O
inner	JJ	O
suburbs	NNS	O
from	IN	O
2006	CD	O
to	TO	O
2011	CD	O
.	.	O

To	TO	O
be	VB	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
,	,	O
women	NNS	O
had	VBD	O
to	TO	O
be	VB	O
(	(	O
i	NN	O
)	)	O
under	IN	O
26	CD	O
years	NNS	O
old	JJ	O
,	,	O
(	(	O
ii	NN	O
)	)	O
less	JJR	O
that	IN	O
27	CD	O
weeks	NNS	O
pregnant	JJ	O
,	,	O
(	(	O
iii	NN	O
)	)	O
sufficiently	RB	O
fluent	VBN	O
in	IN	O
French	JJ	O
to	TO	O
give	VB	O
truly	NN	O
informed	JJ	O
consent	NN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
study	NN	O
and	CC	O
benefit	NN	O
from	IN	O
the	DT	O
intervention	NN	O
and	CC	O
(	(	O
iv	NN	O
)	)	O
presenting	VBG	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	JJ	O
social	JJ	O
vulnerability	NN	O
factors	NNS	O
:	:	O
low	JJ	O
income	NN	O
,	,	O
low	JJ	O
educational	JJ	O
level	NN	O
,	,	O
and/or	RB	O
intending	VBG	O
to	TO	O
bring	VB	O
up	RP	O
the	DT	O
child	NN	O
without	IN	O
the	DT	O
child	NN	O
's	POS	O
father	NN	O
.	.	O

The	DT	E
intervention	NN	E
consisted	VBD	E
of	IN	E
44	CD	E
home	NN	E
visits	NNS	E
from	IN	E
the	DT	E
third	JJ	E
trimester	NN	E
of	IN	E
pregnancy	NN	E
through	IN	E
to	TO	E
the	DT	E
child	NN	E
's	POS	E
second	JJ	E
birthday	NN	E
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
to	TO	O
promote	VB	O
infant	JJ	O
mental	JJ	O
health	NN	O
and	CC	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
infant	JJ	O
mental	JJ	O
health	NN	O
problems	NNS	O
at	IN	O
the	DT	O
age	NN	O
of	IN	O
two	CD	O
years	NNS	O
.	.	O

The	DT	O
intervention	NN	O
paid	VBD	O
particular	JJ	O
attention	NN	O
to	TO	O
postnatal	JJ	O
maternal	JJ	O
depression	NN	O
and	CC	O
promoting	VBG	O
parenting	VBG	O
skills	NNS	O
and	CC	O
attachment	JJ	O
security	NN	O
,	,	O
particularly	RB	O
through	IN	O
the	DT	O
use	NN	E
of	IN	E
video	NN	E
during	IN	E
home-visits	NNS	E
.	.	O

A	DT	O
major	JJ	O
issue	NN	O
was	VBD	O
that	IN	O
of	IN	O
adapting	VBG	O
international	JJ	O
best	JJS	O
practice	NN	O
recommendations	NNS	O
with	IN	O
regard	NN	O
to	TO	O
home-visiting	JJ	O
programs	NNS	O
to	TO	O
the	DT	O
particularities	NNS	O
of	IN	O
the	DT	O
existing	VBG	O
French	JJ	O
social	JJ	O
and	CC	O
health	NN	O
care	NN	O
system	NN	O
.	.	O

An	DT	O
original	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
to	TO	O
use	VB	O
trained	JJ	O
clinical	JJ	O
psychologists	NNS	O
to	TO	O
conduct	VB	O
all	DT	O
home	NN	O
visits	NNS	O
.	.	O

The	DT	O
Social	NNP	E
Communication	NNP	E
Assessment	NNP	E
for	IN	E
Toddlers	NNP	E
with	IN	E
Autism	NNP	E
(	(	E
SCATA	NNP	E
)	)	E
:	:	O
an	DT	O
instrument	NN	O
to	TO	O
measure	VB	O
the	DT	O
frequency	NN	O
,	,	O
form	NN	O
and	CC	O
function	NN	O
of	IN	O
communication	NN	O
in	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

The	DT	O
Social	NNP	E
Communication	NNP	E
Assessment	NNP	E
for	IN	E
Toddlers	NNP	E
with	IN	E
Autism	NNP	E
(	(	E
SCATA	NNP	E
)	)	E
was	VBD	O
designed	VBN	O
to	TO	O
measure	VB	O
non-verbal	JJ	O
communication	NN	O
,	,	O
including	VBG	O
early	JJ	O
and	CC	O
atypical	JJ	O
communication	NN	O
,	,	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Each	DT	O
communicative	JJ	O
act	NN	O
is	VBZ	O
scored	VBN	O
according	VBG	O
to	TO	O
its	PRP$	O
form	NN	O
,	,	O
function	NN	O
,	,	O
role	NN	O
and	CC	O
complexity	NN	O
.	.	O

The	DT	O
SCATA	NNP	E
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
communicative	JJ	O
ability	NN	O
longitudinally	RB	O
in	IN	O
two	CD	O
samples	NNS	O
of	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Overall	JJ	O
frequency	NN	O
of	IN	O
non-verbal	JJ	O
communicative	JJ	O
acts	NNS	O
did	VBD	O
not	RB	O
change	NN	O
between	IN	O
the	DT	O
two	CD	O
assessments	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
form	NN	O
and	CC	O
complexity	NN	O
,	,	O
the	DT	O
function	NN	O
and	CC	O
the	DT	O
role	NN	O
the	DT	O
child	NN	O
took	VBD	O
in	IN	O
the	DT	O
interaction	NN	O
did	VBD	O
change	VB	O
with	IN	O
time	NN	O
.	.	O

Both	DT	O
frequency	NN	O
and	CC	O
function	NN	O
of	IN	O
communicative	JJ	O
acts	NNS	O
in	IN	O
toddlerhood	NN	O
were	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
later	JJ	O
language	NN	O
ability	NN	O
:	:	O
social	JJ	O
acts	NNS	O
,	,	O
comments	NNS	O
and	CC	O
initiations	NNS	O
showed	VBD	O
greater	JJR	O
predictive	JJ	O
association	NN	O
than	IN	O
requests	NNS	O
and	CC	O
responses	NNS	O
.	.	O

[	JJ	O
Comparative	NNP	O
effects	NNS	O
of	IN	O
nebivolol	NN	PM
and	CC	O
valsartan	NN	PM
on	IN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
in	IN	O
newly	RB	O
diagnosed	VBN	O
stage	NN	O
1	CD	O
hypertensive	JJ	O
patients	NNS	O
]	VBP	O
.	.	O

OBJECTIVES	NNP	O
Hypertension	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
cardiovascular	NN	O
risk	NN	O
factor	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
.	.	O

Increased	VBN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
time	NN	O
interval	NN	O
measured	VBN	O
by	IN	O
tissue	NN	O
Doppler	NNP	O
is	VBZ	O
accepted	VBN	O
as	IN	O
an	DT	O
important	JJ	O
factor	NN	O
for	IN	O
prediction	NN	O
of	IN	O
AF	NNP	O
development	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
valsartan	NN	PM
,	,	O
an	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
,	,	O
and	CC	O
nebivolol	RB	PM
,	,	O
a	DT	O
beta-blocker	NN	O
,	,	O
on	IN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
in	IN	O
newly	RB	O
diagnosed	VBN	O
stage	NN	O
1	CD	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
The	DT	O
study	NN	O
included	VBD	O
60	CD	O
newly	RB	O
diagnosed	VBN	O
stage	NN	O
1	CD	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
no	DT	O
other	JJ	O
systemic	JJ	O
disease	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
nebivolol	JJ	PM
5	CD	PM
mg	NN	PM
(	(	O
30	CD	O
patients	NNS	O
;	:	O
21	CD	O
women	NNS	O
,	,	O
9	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
48.4	CD	O
?	.	O
11.4	CD	O
years	NNS	O
)	)	O
and	CC	O
valsartan	$	O
160	CD	O
mg	NN	O
(	(	O
30	CD	O
patients	NNS	O
;	:	O
21	CD	O
women	NNS	O
,	,	O
9	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
49.8	CD	O
?	.	O
11.3	CD	O
years	NNS	O
)	)	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
underwent	JJ	O
tissue	NN	O
Doppler	NNP	O
echocardiographic	JJ	O
examination	NN	O
before	IN	O
and	CC	O
three	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
on	IN	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
blood	NN	O
pressures	NNS	O
,	,	O
electrocardiographic	JJ	O
and	CC	O
echocardiographic	JJ	O
findings	NNS	O
,	,	O
and	CC	O
atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Both	DT	O
drugs	NNS	O
significantly	RB	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
after	IN	O
treatment	NN	O
,	,	O
with	IN	O
similar	JJ	O
efficacy	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Atrial	JJ	O
electromechanical	JJ	O
coupling	NN	O
time	NN	O
intervals	NNS	O
showed	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Prolonged	VBD	O
interatrial	JJ	O
electromechanical	JJ	O
time	NN	O
intervals	NNS	O
in	IN	O
hypertensives	NNS	O
are	VBP	O
improved	VBN	O
with	IN	O
antihypertensive	JJ	O
treatment	NN	O
.	.	O

Beta-carotene	NNP	PM
in	IN	O
HIV	NNP	O
infection	NN	O
.	.	O

beta-Carotene	NN	PM
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
have	VB	O
an	DT	O
immunostimulatory	JJ	O
effect	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
beta-carotene	JJ	PM
supplementation	NN	PM
can	MD	O
increase	VB	O
CD4	NNP	O
counts	NNS	O
in	IN	O
HIV-infected	JJ	O
patients	NNS	O
.	.	O

Our	PRP$	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
clinical	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
test	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
beta-carotene	NN	PM
in	IN	O
raising	VBG	O
CD4	NNP	O
counts	NNS	O
in	IN	O
HIV-infected	JJ	O
patients	NNS	O
.	.	O

Twenty-one	CD	O
HIV-seropositive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
beta-carotene	NN	PM
,	,	PM
180	CD	PM
mg/day	NN	PM
or	CC	O
placebo	NN	C
for	IN	O
4	CD	O
weeks	NNS	O
,	,	O
and	CC	O
then	RB	O
crossed	VBD	O
over	IN	O
to	TO	O
receive	VB	O
the	DT	O
alternative	JJ	O
treatment	NN	O
for	IN	O
the	DT	O
following	JJ	O
4	CD	O
weeks	NNS	O
.	.	O

beta-Carotene	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
total	JJ	O
WBC	NNP	O
count	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
%	NN	O
change	NN	O
in	IN	O
CD4	NNP	O
count	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
%	NN	O
change	NN	O
in	IN	O
CD4/CD8	NNP	O
ratios	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
absolute	JJ	O
CD4	NNP	O
count	NN	O
,	,	O
absolute	JJ	O
CD4/CD8	NNP	O
ratio	NN	O
,	,	O
and	CC	O
total	JJ	O
and	CC	O
B-lymphocytes	NNP	O
all	DT	O
increased	VBN	O
on	IN	O
carotene	NN	O
and	CC	O
fell	VBD	O
during	IN	O
placebo	NN	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

No	DT	O
toxicity	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

beta-Carotene	JJ	O
appears	VBZ	O
to	TO	O
have	VB	O
an	DT	O
immunostimulatory	JJ	O
effect	NN	O
in	IN	O
HIV-infected	JJ	O
patients	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
demonstrate	VB	O
whether	IN	O
beta-carotene	NN	O
has	VBZ	O
a	DT	O
role	NN	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
treatment	NN	O
of	IN	O
HIV-infected	JJ	O
patients	NNS	O
.	.	O

Randomized	NNP	O
comparison	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
zotarolimus-eluting	JJ	PM
stents	NNS	PM
vs.	IN	O
sirolimus-eluting	JJ	PM
stents	NNS	PM
for	IN	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
in	IN	O
chronic	JJ	O
total	JJ	O
occlusion	NN	O
--	:	O
CAtholic	NNP	O
Total	NNP	O
Occlusion	NNP	O
Study	NNP	O
(	(	O
CATOS	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Limited	NNP	O
data	NNS	O
are	VBP	O
available	JJ	O
regarding	VBG	O
the	DT	O
direct	JJ	O
comparison	NN	O
of	IN	O
angiographic	JJ	O
and	CC	O
clinical	JJ	O
outcomes	NNS	O
after	IN	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
with	IN	O
drug-eluting	JJ	PM
stents	NNS	PM
(	(	O
DESs	NNP	O
)	)	O
for	IN	O
chronic	JJ	O
total	JJ	O
occlusion	NN	O
(	(	O
CTO	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
A	NNP	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicenter	RBR	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
non-inferiority	NN	O
of	IN	O
a	DT	O
zotarolimus-eluting	JJ	PH
stent	NN	PH
(	(	O
ZES	NNP	O
;	:	O
Endeavor	NNP	O
Sprint?	NNP	O
,	,	O
n=80	RB	O
)	)	O
to	TO	O
a	DT	O
sirolimus-eluting	JJ	PH
stent	NN	PH
(	(	O
SES	NNP	O
;	:	O
Cypher?	NNP	O
,	,	O
n=80	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
CTO	NNP	O
lesion	NN	O
with	IN	O
a	DT	O
reference	NN	O
vessel	NN	O
diameter	NN	O
?	.	O
2.5mm	CD	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
in-segment	JJ	O
binary	JJ	O
restenosis	NN	O
rate	NN	O
at	IN	O
9-month	JJ	O
angiographic	JJ	O
follow-up	NN	O
.	.	O

Key	NNP	O
secondary	JJ	O
endpoints	NNS	O
included	VBD	O
target	NN	O
vessel	NN	O
failure	NN	O
(	(	O
TVF	NNP	O
;	:	O
including	VBG	O
cardiac	JJ	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
target	VB	O
vessel	JJ	O
revascularization	NN	O
)	)	O
and	CC	O
Academic	NNP	O
Research	NNP	O
Consortium-defined	NNP	O
definite/probable	JJ	O
stent	NN	O
thrombosis	NN	O
(	(	O
ST	NNP	O
)	)	O
within	IN	O
12	CD	O
months	NNS	O
.	.	O

The	DT	O
ZES	NNP	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
the	DT	O
SES	NNP	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
primary	JJ	O
endpoint	NN	O
,	,	O
which	WDT	O
occurred	VBD	O
in	IN	O
14.1	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
6.0-22.2	JJ	O
)	)	O
and	CC	O
in	IN	O
13.7	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
5.8-21.6	JJ	O
)	)	O
of	IN	O
patients	NNS	O
,	,	O
respectively	RB	O
(	(	O
non-inferiority	JJ	O
margin	NN	O
,	,	O
15.0	CD	O
%	NN	O
;	:	O
P	NNP	O
for	IN	O
non-inferiority	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
between-group	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
TVF	NNP	O
(	(	O
10.0	CD	O
%	NN	O
vs.	FW	O
17.5	CD	O
%	NN	O
;	:	O
P=0.168	NNP	O
)	)	O
nor	CC	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
ST	NNP	O
(	(	O
0.0	CD	O
%	NN	O
vs.	FW	O
1.3	CD	O
%	NN	O
;	:	O
P=0.316	NNP	O
)	)	O
during	IN	O
the	DT	O
12-month	JJ	O
clinical	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
ZES	NNP	O
are	VBP	O
similar	JJ	O
to	TO	O
those	DT	O
of	IN	O
SES	NNP	O
and	CC	O
therefore	VB	O
it	PRP	O
is	VBZ	O
a	DT	O
good	JJ	O
treatment	NN	O
option	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
PCI	NNP	O
for	IN	O
CTO	NNP	O
with	IN	O
DESs	NNP	O
.	.	O

Abstinence	NN	E
or	CC	O
controlled	VBN	E
drinking	NN	E
in	IN	O
clinical	JJ	O
practice	NN	O
:	:	O
indications	NNS	O
at	IN	O
initial	JJ	O
assessment	NN	O
.	.	O

Previous	JJ	O
research	NN	O
has	VBZ	O
suggested	VBN	O
two	CD	O
leading	JJ	O
hypotheses	NNS	O
concerning	VBG	O
which	WDT	O
excessive	JJ	O
drinkers	NNS	O
can	MD	O
re-establish	VB	O
control	NN	O
:	:	O
one	CD	O
based	VBN	O
upon	IN	O
level	NN	O
of	IN	O
dependence	NN	O
,	,	O
the	DT	O
other	JJ	O
upon	IN	O
the	DT	O
client	NN	O
's	POS	O
personal	JJ	O
persuasion	NN	O
.	.	O

Using	VBG	O
initial	JJ	O
assessment	NN	O
data	NNS	O
from	IN	O
46	CD	O
clients	NNS	O
of	IN	O
a	DT	O
clinical	JJ	O
psychology	NN	O
alcohol	NN	O
problems	NNS	O
service	NN	O
(	(	O
30	CD	O
men	NNS	O
,	,	O
16	CD	O
women	NNS	O
)	)	O
,	,	O
an	DT	O
attempt	NN	O
was	VBD	O
made	VBN	O
to	TO	O
operationalize	VB	O
the	DT	O
concepts	NNS	O
of	IN	O
dependence	NN	E
and	CC	O
personal	JJ	E
persuasion	NN	E
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
indicators	NNS	O
of	IN	O
each	DT	O
.	.	O

Although	IN	O
SADQ	NNP	O
scores	NNS	O
and	CC	O
Rand	NNP	O
definite	VBP	O
alcoholism	NN	O
were	VBD	O
in	IN	O
general	JJ	O
agreement	NN	O
,	,	O
there	EX	O
were	VBD	O
a	DT	O
number	NN	O
of	IN	O
borderline	JJ	O
instances	NNS	O
and	CC	O
cases	NNS	O
of	IN	O
disagreement	NN	O
,	,	O
and	CC	O
neither	DT	O
was	VBD	O
in	IN	O
good	JJ	O
agreement	NN	O
with	IN	O
estimates	NNS	O
of	IN	O
problem	NN	O
duration	NN	O
,	,	O
nor	CC	O
with	IN	O
reports	NNS	O
of	IN	O
recent	JJ	O
or	CC	O
earlier	RBR	O
attainment	NN	O
of	IN	O
abstinence	NN	E
or	CC	O
control	NN	E
.	.	E

Indicators	NNS	O
of	IN	O
personal	JJ	E
persuasion	NN	E
were	VBD	O
more	RBR	O
consistent	JJ	O
.	.	O

Those	DT	O
with	IN	O
dependence	NN	E
indicators	NNS	E
for	IN	O
abstinence	NN	E
tended	VBD	O
to	TO	O
prefer	VB	O
abstinence	NN	E
as	IN	O
a	DT	O
goal	NN	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
many	JJ	O
departures	NNS	O
from	IN	O
this	DT	O
pattern	NN	O
particularly	RB	O
for	IN	O
women	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
in	IN	O
clinical	JJ	O
practice	NN	O
it	PRP	O
will	MD	O
be	VB	O
very	RB	O
difficult	JJ	O
to	TO	O
make	VB	O
a	DT	O
clear	JJ	O
cut	NN	O
recommendation	NN	O
about	IN	O
treatment	NN	O
goal	NN	O
at	IN	O
initial	JJ	O
assessment	NN	O
except	IN	O
in	IN	O
a	DT	O
few	JJ	O
cases	NNS	O
.	.	O

Predictors	NNS	O
of	IN	O
recruited	JJ	O
melanoma	NN	O
families	NNS	O
into	IN	O
a	DT	O
behavioral	JJ	E
intervention	NN	E
project	NN	E
.	.	O

BACKGROUND	NNP	O
Examination	NNP	O
of	IN	O
families	NNS	O
represents	VBZ	O
an	DT	O
important	JJ	O
priority	NN	O
in	IN	O
health	NN	O
research	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
we	PRP	O
report	VBP	O
on	IN	O
individual	JJ	O
and	CC	O
family-level	JJ	O
factors	NNS	O
associated	VBN	O
with	IN	O
enrollment	NN	O
in	IN	O
a	DT	O
cancer	NN	O
prevention	NN	O
research	NN	O
project	NN	O
.	.	O

We	PRP	O
approached	VBD	O
families	NNS	O
affected	VBN	O
by	IN	O
melanoma	NN	O
for	IN	O
possible	JJ	O
participation	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
a	DT	O
web-based	JJ	E
communication	NN	E
and	CC	E
support	NN	E
intervention	NN	E
.	.	O

METHODS	NNP	O
We	PRP	O
recruited	VBD	O
three	CD	O
family	NN	O
members	NNS	O
per	IN	O
family	NN	O
for	IN	O
assessment	NN	O
-	:	O
the	DT	O
melanoma	NN	O
case	NN	O
,	,	O
a	DT	O
first-degree	JJ	O
relative	NN	O
(	(	O
FDR	NNP	O
)	)	O
,	,	O
and	CC	O
a	DT	O
relative	NN	O
who	WP	O
is	VBZ	O
a	DT	O
parent	NN	O
of	IN	O
a	DT	O
child	JJ	O
age	NN	O
18	CD	O
or	CC	O
younger	JJR	O
.	.	O

Recruitment	NNP	O
involved	VBD	O
three	CD	O
steps	NNS	O
:	:	O
requesting	VBG	O
the	DT	O
physician	NN	O
's	POS	O
consent	NN	O
to	TO	O
approach	VB	O
the	DT	O
melanoma	NN	O
case	NN	O
,	,	O
approaching	VBG	O
the	DT	O
case	NN	O
to	TO	O
request	VB	O
their	PRP$	O
participation	NN	O
and	CC	O
family	NN	O
contact	NN	O
information	NN	O
,	,	O
and	CC	O
they	PRP	O
approaching	VBG	O
the	DT	O
FDRs	NNP	O
and	CC	O
parents	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
1380	CD	O
families	NNS	O
approached	VBD	O
,	,	O
313	CD	O
were	VBD	O
enrolled	VBN	O
,	,	O
263	CD	O
were	VBD	O
excluded	VBN	O
because	IN	O
we	PRP	O
could	MD	O
not	RB	O
find	VB	O
or	CC	O
contact	VB	O
a	DT	O
family	NN	O
member	NN	O
(	(	O
FDR	CD	O
or	CC	O
parent	NN	O
)	)	O
,	,	O
331	CD	O
did	VBD	O
not	RB	O
have	VB	O
eligible	JJ	O
family	NN	O
members	NNS	O
,	,	O
and	CC	O
473	CD	O
refused	VBD	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
noted	VBD	O
reason	NN	O
for	IN	O
refusal	NN	O
was	VBD	O
being	VBG	O
too	RB	O
busy	JJ	O
or	CC	O
having	VBG	O
no	DT	O
time	NN	O
.	.	O

The	DT	O
primary	JJ	O
predictors	NNS	O
of	IN	O
participation	NN	O
for	IN	O
cases	NNS	O
(	(	O
OR=1.6	NNP	O
;	:	O
CI=1.01-2.51	NNP	O
)	)	O
and	CC	O
FDRs	NNP	O
(	(	O
OR=2.15	NNP	O
;	:	O
CI=1.11-4.13	NNP	O
)	)	O
included	VBD	O
higher	JJR	O
educational	JJ	O
attainment	NN	O
.	.	O

FDRs	NNP	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
enroll	VB	O
if	IN	O
they	PRP	O
were	VBD	O
female	JJ	O
(	(	O
OR=1.77	NNP	O
;	:	O
CI=1.1-.85	NNP	O
)	)	O
and	CC	O
parents	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
enroll	VB	O
if	IN	O
the	DT	O
case	NN	O
had	VBD	O
been	VBN	O
diagnosed	VBN	O
more	RBR	O
recently	RB	O
(	(	O
OR=3.3	NNP	O
;	:	O
CI=1.9-5.93	NNP	O
)	)	O
,	,	O
if	IN	O
the	DT	O
parent	NN	O
was	VBD	O
partnered	VBN	O
(	(	O
OR=4.37	NNP	O
;	:	O
CI=1.86-10.26	NNP	O
)	)	O
,	,	O
and	CC	O
if	IN	O
the	DT	O
parent	NN	O
lived	VBD	O
in	IN	O
the	DT	O
same	JJ	O
city	NN	O
as	IN	O
the	DT	O
case	NN	O
(	(	O
OR=2.88	NNP	O
;	:	O
CI=1.08-7.68	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
can	MD	O
provide	VB	O
information	NN	O
on	IN	O
potential	JJ	O
directions	NNS	O
for	IN	O
future	JJ	O
family	NN	O
recruitment	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
multi-component	JJ	O
higher-functioning	JJ	O
autism	NN	O
anti-stigma	JJ	O
program	NN	O
on	IN	O
adolescent	JJ	O
boys	NNS	O
.	.	O

A	DT	O
six-session	JJ	O
higher-functioning	JJ	O
autism	NN	O
anti-stigma	JJ	O
program	NN	O
incorporating	NN	O
descriptive	NN	O
,	,	O
explanatory	NN	O
and	CC	O
directive	JJ	O
information	NN	O
was	VBD	O
delivered	VBN	O
to	TO	O
adolescent	VB	O
boys	NNS	O
and	CC	O
the	DT	O
impact	NN	O
upon	IN	O
knowledge	NN	O
,	,	O
attitudes	NNS	O
and	CC	O
behavioural	JJ	O
intentions	NNS	O
towards	NNS	O
peers	NNS	O
with	IN	O
autism	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
seventh-	JJ	O
,	,	O
eighth-	JJ	O
and	CC	O
ninth-grade	JJ	O
students	NNS	O
(	(	O
N	NNP	O
=	NNP	O
395	CD	O
)	)	O
from	IN	O
regular	JJ	O
classes	NNS	O
in	IN	O
a	DT	O
mainstream	JJ	O
school	NN	O
.	.	O

Two-eighth-grade	JJ	O
classes	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
condition	NN	O
and	CC	O
all	DT	O
remaining	VBG	O
students	NNS	O
were	VBD	O
either	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
no-intervention	JJ	O
peer	NN	O
or	CC	O
no-intervention	JJ	O
non-peer	JJ	O
condition	NN	O
.	.	O

The	DT	O
anti-stigma	JJ	O
program	NN	O
improved	VBD	O
the	DT	O
knowledge	NN	O
and	CC	O
attitudes	NNS	O
,	,	O
but	CC	O
not	RB	O
the	DT	O
behavioural	JJ	O
intentions	NNS	O
of	IN	O
participants	NNS	O
towards	VBP	O
their	PRP$	O
peers	NNS	O
with	IN	O
autism	NN	O
.	.	O

Knowledge	NNP	O
and	CC	O
attitudinal	JJ	O
changes	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
follow-up	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
spill-over	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
program	NN	O
to	TO	O
non-targeted	JJ	O
students	NNS	O
.	.	O

These	DT	O
results	NNS	O
provide	VBP	O
some	DT	O
preliminary	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
multi-session	NN	O
anti-stigma	JJ	O
programs	NNS	O
incorporating	VBG	O
combined	VBN	O
information	NN	O
for	IN	O
adolescent	NN	O
students	NNS	O
in	IN	O
inclusive	JJ	O
educational	JJ	O
environments	NNS	O
.	.	O

Take	VB	O
a	DT	O
walk	NN	O
in	IN	O
the	DT	O
park	NN	O
?	.	O
A	DT	O
cross-over	NN	O
pilot	NN	O
trial	NN	O
comparing	VBG	O
brisk	JJ	PH
walking	VBG	PH
in	IN	PH
two	CD	PH
different	JJ	PH
environments	NNS	PH
:	:	PH
park	NN	O
and	CC	O
urban	JJ	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
is	VBZ	O
to	TO	O
investigate	VB	O
whether	IN	O
differences	NNS	O
exist	VBP	O
between	IN	O
a	DT	O
30	CD	PH
minute	NN	PH
brisk	NN	PH
walk	VBP	PH
taken	VBN	O
in	IN	O
two	CD	O
different	JJ	O
environments	NNS	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
which	WDT	O
environment	NN	O
best	JJS	O
facilitates	NNS	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
:	:	O
park	NN	O
or	CC	O
urban	JJ	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomised	JJ	O
cross-over	NN	O
pilot	NN	O
study	NN	O
,	,	O
participants	NNS	O
performed	VBD	O
a	DT	O
self-timed	JJ	PH
30	CD	PH
minute	NN	PH
brisk	NN	PH
walk	VBP	PH
in	IN	PH
two	CD	PH
different	JJ	PH
environments	NNS	PH
,	,	PH
park	NN	PH
and	CC	PH
urban	JJ	PH
,	,	O
in	IN	O
Glasgow	NNP	O
,	,	O
Scotland	NNP	O
(	(	O
October	NNP	O
2009	CD	O
to	TO	O
January	NNP	O
2010	CD	O
)	)	O
.	.	O

Cadence	NN	O
,	,	O
recorded	VBD	O
using	VBG	O
the	DT	O
activPAL?	NN	O
activity	NN	O
monitor	NN	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
intensity	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
:	:	O
mean	JJ	O
cadence	NN	O
;	:	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
time	NN	O
accumulated	VBN	O
in	IN	O
bouts	NNS	O
lasting	VBG	O
?	.	O
10	CD	O
min	NN	O
;	:	O
number	NN	O
of	IN	O
walking	VBG	O
breaks	NNS	O
;	:	O
and	CC	O
duration	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
convenience	NN	O
sample	NN	O
of	IN	O
40	CD	O
healthy	JJ	O
adults	NNS	O
was	VBD	O
recruited	VBN	O
:	:	O
16	CD	O
males	NNS	O
,	,	O
24	CD	O
females	NNS	O
,	,	O
mean	JJ	O
age	NN	O
22.9	CD	O
(	(	O
5.5	CD	O
)	)	O
years	NNS	O
.	.	O

The	DT	O
mean	JJ	O
cadence	NN	O
for	IN	O
the	DT	O
whole	JJ	O
walk	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
park	NN	O
:	:	O
119.3	CD	O
(	(	O
8.3	CD	O
)	)	O
vs.	FW	O
110.9	CD	O
(	(	O
8.9	CD	O
)	)	O
steps/min	NN	O
.	.	O

Participants	NNS	O
accumulated	VBD	O
more	RBR	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
in	IN	O
?	.	O
10	CD	O
minute	NN	O
bouts	NNS	O
during	IN	O
park	JJ	O
walks	NNS	O
:	:	O
25.5	CD	O
(	(	O
9.6	CD	O
)	)	O
[	NN	O
median	JJ	O
(	(	O
interquartile	JJ	O
range	NN	O
)	)	O
]	VBZ	O
vs.	FW	O
14.0	CD	O
(	(	O
20.3	CD	O
)	)	O
min	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
self-timed	JJ	O
duration	NN	O
between	IN	O
locations	NNS	O
.	.	O

CONCLUSION	NNP	O
Participants	NNPS	O
accumulated	VBD	O
more	RBR	O
moderate-to-vigorous	JJ	O
physical	JJ	O
activity	NN	O
in	IN	O
bouts	NNS	O
?	.	O
10	CD	O
min	NN	O
in	IN	O
duration	NN	O
on	IN	O
park	NN	O
walks	NNS	O
due	JJ	O
to	TO	O
the	DT	O
lack	NN	O
of	IN	O
interruptions	NNS	O
in	IN	O
walking	VBG	O
.	.	O

Hence	NNP	O
the	DT	O
park	NN	O
environment	NN	O
better	RBR	O
facilitated	VBD	O
the	DT	O
achievement	NN	O
of	IN	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
.	.	O

Further	JJ	O
research	NN	O
involving	VBG	O
a	DT	O
larger	JJR	O
,	,	O
more	RBR	O
heterogeneous	JJ	O
sample	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Predicting	VBG	O
completion	NN	O
of	IN	O
treatment	NN	O
among	IN	O
foreign-born	JJ	O
adolescents	NNS	O
treated	VBN	O
for	IN	O
latent	JJ	O
tuberculosis	NN	O
infection	NN	O
in	IN	O
Los	NNP	O
Angeles	NNP	O
.	.	O

SETTING	NNP	O
Two	CD	O
health	NN	O
clinics	NNS	O
in	IN	O
Los	NNP	O
Angeles	NNP	O
County	NNP	O
,	,	O
California	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
among	IN	O
foreign-born	JJ	O
adolescents	NNS	O
treated	VBN	O
for	IN	O
latent	JJ	O
tuberculosis	NN	O
infection	NN	O
(	(	O
LTBI	NNP	O
)	)	O
.	.	O

DESIGN	VB	O
A	DT	O
total	NN	O
of	IN	O
766	CD	O
low-income	JJ	O
adolescents	NNS	O
(	(	O
79	CD	O
%	NN	O
participation	NN	O
rate	NN	O
)	)	O
,	,	O
including	VBG	O
610	CD	O
foreign-born	JJ	O
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

In	IN	O
prospective	JJ	O
face-to-face	NN	E
interviews	NNS	E
,	,	O
data	NNS	O
were	VBD	O
obtained	VBN	O
on	IN	O
socio-demographic	JJ	O
and	CC	O
lifestyle	JJ	O
characteristics	NNS	O
,	,	O
psychosocial	JJ	O
factors	NNS	O
and	CC	O
clinic-related	JJ	O
variables	NNS	O
.	.	O

Medical	JJ	E
chart	NN	E
data	NNS	E
were	VBD	E
abstracted	VBN	E
regarding	VBG	O
clinic	JJ	O
appointment	NN	O
keeping	VBG	O
and	CC	O
completion	NN	O
of	IN	O
treatment	NN	O
.	.	O

Univariate	NNP	PH
and	CC	PH
multivariate	VB	PH
logistic	JJ	PH
regression	NN	PH
analyses	NNS	PH
were	VBD	O
performed	VBN	O
to	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
.	.	O

RESULTS	NNP	O
Foreign-born	JJ	O
adolescents	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
complete	VB	O
care	NN	O
than	IN	O
US-born	JJ	O
adolescents	NNS	O
,	,	O
with	IN	O
82	CD	O
%	NN	O
completion	NN	O
of	IN	O
care	NN	O
rate	NN	O
.	.	O

In	IN	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
after	IN	O
controlling	VBG	O
for	IN	O
age	NN	O
,	,	O
medication	NN	O
taking	VBG	O
behavior	NN	O
(	(	O
OR	CC	O
1.26	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.15-1.39	CD	O
)	)	O
,	,	O
living	VBG	O
with	IN	O
both	DT	O
parents	NNS	O
(	(	O
OR	NNP	O
1.74	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.02-2.97	CD	O
)	)	O
,	,	O
sexual	JJ	O
intercourse	NN	O
(	(	O
OR	CC	O
0.66	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.36-1.19	NN	O
)	)	O
and	CC	O
speaking	VBG	O
mostly	RB	O
or	CC	O
only	RB	O
English	JJ	O
with	IN	O
parents	NNS	O
(	(	O
OR	NNP	O
0.39	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.15-1.03	NN	O
)	)	O
were	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
contribute	VBP	O
to	TO	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
factors	NNS	O
that	WDT	O
may	MD	O
explain	VB	O
why	WRB	O
some	DT	O
adolescents	NNS	O
complete	JJ	O
care	NN	O
whereas	IN	O
others	NNS	O
do	VBP	O
not	RB	O
.	.	O

They	PRP	O
provide	VBP	O
supportive	JJ	O
evidence	NN	O
that	WDT	O
tailored	VBD	O
intervention	NN	O
programs	NNS	O
should	MD	O
be	VB	O
developed	VBN	O
to	TO	O
support	VB	O
the	DT	O
screening	NN	O
and	CC	O
completion	NN	O
of	IN	O
treatment	NN	O
of	IN	O
foreign-born	JJ	O
adolescents	NNS	O
.	.	O

Accumulated	VBN	PH
brisk	JJ	PH
walking	NN	PH
reduces	NNS	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
overweight	JJ	O
adults	NNS	O
:	:	O
evidence	NN	O
from	IN	O
a	DT	O
randomized	VBN	O
control	NN	O
trial	NN	O
.	.	O

Arterial	JJ	O
stiffness	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
contributor	NN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
atherosclerosis	NN	O
and	CC	O
consequently	RB	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
examine	VB	O
whether	IN	O
6	CD	O
months	NNS	O
of	IN	O
accumulated	VBN	O
(	(	O
3	CD	O
?	.	O
10	CD	O
minutes	NNS	O
,	,	O
5	CD	O
days/week	NN	O
)	)	O
brisk	NN	O
walking	NN	O
was	VBD	O
sufficient	JJ	O
to	TO	O
reduce	VB	O
arterial	JJ	O
stiffness	NN	O
in	IN	O
sedentary	JJ	O
,	,	O
overweight	JJ	O
individuals	NNS	O
.	.	O

Seventy-seven	JJ	O
individuals	NNS	O
(	(	O
19	CD	O
men	NNS	O
,	,	O
58	CD	O
women	NNS	O
;	:	O
age	NN	O
,	,	O
30-55	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
;	:	O
two	CD	O
groups	NNS	O
completed	VBD	O
30	CD	O
minutes	NNS	O
of	IN	O
accumulated	JJ	O
walking	VBG	O
with	IN	O
either	DT	O
monthly	JJ	O
or	CC	O
weekly	JJ	O
telephone	NN	O
support	NN	O
;	:	O
the	DT	O
third	JJ	O
group	NN	O
(	(	O
control	NN	O
)	)	O
performed	VBD	O
stretching	VBG	O
exercises	NNS	O
.	.	O

The	DT	O
walking	VBG	O
groups	NNS	O
were	VBD	O
combined	VBN	O
and	CC	O
telephone	NN	O
support	NN	O
included	VBD	O
as	IN	O
a	DT	O
covariate	NN	O
.	.	O

Anthropometry	NNP	O
,	,	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
blood	NN	O
lipids	NNS	O
,	,	O
pulse	RB	O
wave	VBP	O
velocity	NN	O
(	(	O
PWV	NNP	O
)	)	O
,	,	O
and	CC	O
NOx	NNP	O
(	(	O
surrogate	JJ	O
marker	NN	O
for	IN	O
nitric	JJ	O
oxide	NN	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
,	,	O
post-intervention	NN	O
and	CC	O
4	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

No	CC	O
changes	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
anthropometry	NN	O
,	,	O
BP	NNP	O
,	,	O
or	CC	O
lipids	NNS	O
.	.	O

However	RB	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
PWV	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
accompanied	VBN	O
by	IN	O
an	DT	O
increase	NN	O
in	IN	O
NOx	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
with	IN	O
changes	NNS	O
maintained	VBD	O
4	CD	O
months	NNS	O
post-intervention	NN	O
.	.	O

A	NNP	O
strong	JJ	O
negative	JJ	O
correlation	NN	O
between	IN	O
PWV	NNP	O
and	CC	O
NOx	NNP	O
was	VBD	O
also	RB	O
observed	VBN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
;	:	O
r	NN	O
=	NNP	O
-0.65	NNP	O
)	)	O
.	.	O

A	DT	O
lifestyle	JJ	O
approach	NN	O
to	TO	O
meeting	VBG	O
current	JJ	O
physical	JJ	O
activity	NN	O
guidelines	NNS	O
results	NNS	O
in	IN	O
favorable	JJ	O
alterations	NNS	O
in	IN	O
arterial	JJ	O
function	NN	O
in	IN	O
overweight	JJ	O
individuals	NNS	O
.	.	O

Households	NNS	O
with	IN	O
young	JJ	O
children	NNS	O
and	CC	O
use	NN	O
of	IN	O
freely	RB	O
distributed	VBN	O
bednets	NNS	Ot
in	IN	O
rural	JJ	O
Madagascar	NNP	O
.	.	O

BACKGROUND	NNP	O
Malaria	NNP	O
infections	NNS	O
are	VBP	O
the	DT	O
leading	VBG	O
cause	NN	O
of	IN	O
death	NN	O
for	IN	O
children	NNS	O
in	IN	O
Madagascar	NNP	O
.	.	O

Insecticide-treated	JJ	Ot
bednets	NNS	Ot
offer	VBP	O
effective	JJ	O
prevention	NN	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
unclear	JJ	O
how	WRB	O
well	RB	O
free	JJ	E
bednet	NN	E
distribution	NN	E
programs	NNS	E
reach	VBP	O
young	JJ	O
children	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
secondary	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
free	JJ	Ot
bednet	NN	Ot
distribution	NN	Ot
program	NN	Ot
in	IN	O
Madagascar	NNP	O
from	IN	O
2007-2008	JJ	O
.	.	O

Interviews	NNS	E
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

Principal	JJ	O
components	NNS	O
analysis	NN	O
was	VBD	O
used	VBN	O
to	TO	O
construct	VB	O
a	DT	O
wealth	NN	O
and	CC	O
malaria	NNS	O
knowledge	VBP	O
index	NN	O
.	.	O

Coverage	NNP	O
efficiency	NN	O
was	VBD	O
calculated	VBN	O
as	IN	O
coverage	NN	Ot
of	IN	Ot
children	NNS	Ot
per	IN	Ot
bednet	NN	Ot
owned	VBN	Ot
.	.	O

Univariable	JJ	O
and	CC	O
multivariable	JJ	O
regressions	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
predictors	NNS	O
of	IN	O
bednet	NN	Ot
use	NN	O
.	.	O

RESULTS	NNP	O
Bednet	NNP	O
use	NN	O
,	,	O
among	IN	O
the	DT	O
560	CD	O
households	NNS	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
increased	VBD	O
from	IN	O
6	CD	O
to	TO	O
91	CD	O
%	NN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Coverage	NNP	O
efficiency	NN	O
increased	VBD	O
from	IN	O
1.29	CD	O
to	TO	O
1.56	CD	O
children	NNS	O
covered	VBN	O
per	IN	O
bednet	NN	O
owned	VBN	O
.	.	O

In	IN	O
multivariable	JJ	O
analysis	NN	O
,	,	O
having	VBG	O
a	DT	O
child	NN	O
under	IN	O
5	CD	O
years	NNS	O
of	IN	O
age	NN	O
was	VBD	O
the	DT	O
only	JJ	O
variable	NN	O
associated	VBN	O
with	IN	O
bednet	NN	O
use	NN	O
(	(	O
OR	CC	O
9.10	CD	O
;	:	O
p=0.001	NN	O
)	)	O
,	,	O
yielding	VBG	O
a	DT	O
99	CD	O
%	NN	O
likelihood	NN	O
of	IN	O
using	VBG	O
a	DT	O
bednet	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
96.4	CD	O
to	TO	O
99.9	CD	O
%	NN	O
)	)	O
versus	VBZ	O
82	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
72.2	CD	O
to	TO	O
88.4	CD	O
%	NN	O
)	)	O
in	IN	O
households	NNS	O
without	IN	O
young	JJ	O
children	NNS	O
.	.	O

CONCLUSION	VB	O
This	DT	O
free	JJ	Ot
bednet	NN	Ot
distribution	NN	Ot
program	NN	Ot
achieved	VBN	O
high	JJ	O
levels	NNS	O
of	IN	O
adherence	NN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

Household	NNP	O
presence	NN	O
of	IN	O
children	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
bednet	NN	O
use	NN	O
,	,	O
but	CC	O
not	RB	O
household	JJ	O
income	NN	O
or	CC	O
education	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
distribution	NN	O
to	TO	O
priority	NN	O
groups	NNS	O
may	MD	O
help	VB	O
overcome	VB	O
traditional	JJ	O
barriers	NNS	O
to	TO	O
adoption	NN	O
in	IN	O
some	DT	O
settings	NNS	O
.	.	O

Intranasal	NNP	O
nicotine	NN	PM
for	IN	O
postoperative	JJ	O
pain	NN	O
treatment	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
pharmacological	JJ	O
treatment	NN	O
,	,	O
70-80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
report	NN	O
moderate	VBP	O
to	TO	O
severe	VB	O
pain	NN	O
after	IN	O
surgery	NN	O
.	.	O

Because	IN	O
nicotine	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
have	VB	O
analgesic	JJ	O
properties	NNS	O
in	IN	O
animal	NN	O
and	CC	O
human	JJ	O
volunteer	NN	O
studies	NNS	O
,	,	O
the	DT	O
authors	NNS	O
assessed	VBD	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
a	DT	O
single	JJ	O
3	CD	O
mg	NN	O
dose	NN	O
of	IN	O
nicotine	JJ	PM
nasal	NN	O
spray	NN	O
administered	VBD	O
before	IN	O
emergence	NN	O
from	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
authors	NNS	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	C
controlled	VBD	O
trial	NN	O
of	IN	O
20	CD	O
healthy	JJ	O
women	NNS	O
(	(	O
mean	JJ	O
age	NN	O
45	CD	O
(	(	O
SD	NNP	O
8	CD	O
)	)	O
yr	NN	O
)	)	O
who	WP	O
were	VBD	O
to	TO	O
undergo	VB	O
uterine	JJ	S
surgery	NN	S
through	IN	O
a	DT	O
low	JJ	S
transverse	NN	S
incision	NN	S
.	.	O

After	IN	O
the	DT	O
conclusion	NN	O
of	IN	O
surgery	NN	O
but	CC	O
before	IN	O
emergence	NN	O
from	IN	O
general	JJ	O
anesthesia	NN	O
,	,	O
the	DT	O
anesthesiologist	NN	O
administered	VBD	O
either	CC	O
nicotine	JJ	PM
nasal	NN	PM
spray	NN	PM
or	CC	O
a	DT	O
placebo	NN	C
.	.	O

Numerical	JJ	O
analog	NN	O
pain	NN	O
score	NN	O
and	CC	O
morphine	JJ	O
utilization	NN	O
and	CC	O
hemodynamic	JJ	O
values	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
24	CD	O
h.	NN	O
RESULTS	NNP	O
The	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
nicotine	NN	O
reported	VBN	O
lower	JJR	O
pain	NN	O
scores	NNS	O
during	IN	O
the	DT	O
first	JJ	O
hour	NN	O
after	IN	O
surgery	NN	O
(	(	O
peak	JJ	O
numerical	JJ	O
analog	NN	O
score	NN	O
,	,	O
7.6	CD	O
(	(	O
SD	NNP	O
1.4	CD	O
)	)	O
versus	NN	O
5.3	CD	O
(	(	O
SD	NNP	O
1.6	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
used	VBN	O
half	PDT	O
the	DT	O
amount	NN	O
of	IN	O
morphine	NN	O
as	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
12	CD	O
(	(	O
SD	NNP	O
6	CD	O
)	)	O
versus	NN	O
6	CD	O
(	(	O
SD	NNP	O
5	CD	O
)	)	O
mg	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Patients	NNPS	O
who	WP	O
received	VBD	O
nicotine	NN	O
still	RB	O
reported	VBD	O
less	RBR	O
pain	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
24	CD	O
h	NN	O
after	IN	O
surgery	NN	O
(	(	O
1.5	CD	O
(	(	O
SD	NNP	O
0.5	CD	O
)	)	O
versus	NN	O
4.9	CD	O
(	(	O
SD	NNP	O
1.4	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Systolic	JJ	O
blood	NN	O
pressure	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
received	VBD	O
nicotine	JJ	O
(	(	O
105	CD	O
(	(	O
SD	NNP	O
3	CD	O
)	)	O
versus	NN	O
122	CD	O
(	(	O
SD	NNP	O
3	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
or	CC	O
heart	NN	O
rate	NN	O
.	.	O

CONCLUSIONS	NNP	O
Treatment	NNP	O
with	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
nicotine	JJ	O
immediately	RB	O
before	IN	O
emergence	NN	O
from	IN	O
anesthesia	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
lower	JJR	O
reported	VBD	O
pain	JJ	O
scores	NNS	O
during	IN	O
the	DT	O
first	JJ	O
day	NN	O
after	IN	O
surgery	NN	O
.	.	O

The	DT	O
decreased	JJ	O
pain	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
morphine	JJ	O
utilization	NN	O
and	CC	O
the	DT	O
analgesic	JJ	O
effect	NN	O
of	IN	O
nicotine	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
hypertension	NN	O
or	CC	O
tachycardia	NN	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
a	DT	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
Logiparin	NNP	O
)	)	O
versus	NN	O
dextran	NN	O
as	IN	O
prophylaxis	NN	O
against	IN	O
thrombosis	NN	O
after	IN	O
total	JJ	O
hip	NN	O
replacement	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
study	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
factor	NN	O
XaI	NNP	O
and	CC	O
IIaI	NNP	O
activity	NN	O
an	DT	O
enzymatically	RB	PM
depolymerized	VBN	PM
low	JJ	PM
molecular	JJ	PM
weight	NN	PM
heparin	NN	PM
(	(	PM
LMW-heparin	NNP	PM
;	:	PM
Logiparin	NNP	PM
)	)	PM
was	VBD	O
given	VBN	O
s.c.	NN	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
35	CD	O
XaI	NNP	O
mu/kg	NN	O
b.w	NN	O
.	.	O

once	RB	O
daily	JJ	O
for	IN	O
7	CD	O
days	NNS	O
to	TO	O
10	CD	O
patients	NNS	O
undergoing	JJ	O
total	JJ	O
hip	NN	O
replacement	NN	O
(	(	O
THR	NNP	O
)	)	O
in	IN	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

The	DT	O
XaI	NN	O
activity	NN	O
was	VBD	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.24	CD	O
XaI	NNP	O
units/ml	NN	O
and	CC	O
the	DT	O
IIaI	NNP	O
activity	NN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.043	CD	O
IIaI	NNP	O
mu/ml	NN	O
.	.	O

No	DT	O
accumulation	NN	O
of	IN	O
the	DT	O
activities	NNS	O
were	VBD	O
seen	VBN	O
.	.	O

No	DT	O
phlebographically	RB	O
verified	VBN	O
thrombi	NN	O
or	CC	O
any	DT	O
bleeding	JJ	O
complications	NNS	O
were	VBD	O
registered	VBN	O
.	.	O

From	IN	O
this	DT	O
study	NN	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
the	DT	O
given	VBN	O
dose	NN	O
of	IN	O
Logiparin	NNP	O
was	VBD	O
safe	JJ	O
with	IN	O
regard	NN	O
to	TO	O
bleeding	VBG	O
complications	NNS	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
data	NNS	O
,	,	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
was	VBD	O
started	VBN	O
.	.	O

In	IN	O
this	DT	O
main	JJ	O
study	NN	O
the	DT	O
thromboprophylactic	JJ	O
effect	NN	O
of	IN	O
the	DT	O
LMW-heparin	NNP	O
(	(	O
Logiparin	NNP	O
)	)	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
35	CD	O
XaI	NNP	O
mu/kg	NN	O
b.w	NN	O
.	.	O

once	RB	O
daily	JJ	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
dextran	NN	O
70	CD	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
THR	NNP	O
.	.	O

100	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

The	DT	O
over-all	JJ	O
thrombosis	NN	O
rate	NN	O
was	VBD	O
28	CD	O
%	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
LMW-heparin	NNP	O
and	CC	O
39	CD	O
%	NN	O
in	IN	O
those	DT	O
given	VBN	O
dextran	NN	O
,	,	O
a	DT	O
non-significant	JJ	O
difference	NN	O
.	.	O

No	UH	O
bleeding	VBG	O
complications	NNS	O
,	,	O
deaths	NNS	O
or	CC	O
pulmonary	JJ	O
embolism	NN	O
were	VBD	O
recorded	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Peroperative	JJ	O
blood	NN	O
loss	NN	O
and	CC	O
transfusion	NN	O
requirements	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
investigated	JJ	O
LMW-heparin	NNP	O
(	(	O
Logiparin	NNP	O
)	)	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
preventing	VBG	O
postoperative	JJ	O
thromboembolism	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
total	JJ	O
hip	NN	O
replacement	NN	O
,	,	O
but	CC	O
the	DT	O
dosage	NN	O
can	MD	O
probably	RB	O
be	VB	O
optimized	VBN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
sildenafil	NN	PM
in	IN	O
Asian	JJ	O
males	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
and	CC	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

OBJECTIVE	NNP	O
Assess	NNP	O
the	DT	O
effectiveness	NN	O
of	IN	O
sildenafil	NN	PM
in	IN	O
Asian	JJ	O
males	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
(	(	O
ED	NNP	O
)	)	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
co-morbidities	NNS	O
,	,	O
mild-to-moderate	JJ	O
hypertension	NN	O
,	,	O
dyslipidemia	NN	O
,	,	O
and	CC	O
diabetes	NNS	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHOD	NNP	O
A	NNP	O
six-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
multicenter	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
Thailand	NNP	O
,	,	O
Malaysia	NNP	O
and	CC	O
Singapore	NNP	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
fifty	VB	O
five	CD	O
male	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
2:1	CD	O
)	)	O
to	TO	O
sildenafil	VB	PM
(	(	O
n	JJ	O
=	NNP	O
104	CD	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
.	.	O

Sildenafil	NNP	PM
was	VBD	O
started	VBN	O
at	IN	O
50	CD	O
mg	NN	O
and	CC	O
increased	VBD	O
(	(	O
100	CD	O
mg	NN	O
)	)	O
or	CC	O
decreased	VBN	O
(	(	O
25	CD	O
mg	NN	O
)	)	O
at	IN	O
week	NN	O
2	CD	O
if	IN	O
necessary	JJ	O
.	.	O

RESULTS	VB	O
On	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
,	,	O
sildenafil-treated	JJ	PM
subjects	NNS	O
had	VBD	O
significantly	RB	O
better	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function	NNP	O
(	(	O
IIEF	NNP	O
)	)	O
questions	NNS	O
3	CD	O
and	CC	O
4	CD	O
than	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NN	O
0.001	CD	O
,	,	O
both	DT	O
questions	NNS	O
)	)	O
.	.	O

When	WRB	O
accumulated	VBN	O
into	IN	O
IIEF	NNP	O
domains	NNS	O
,	,	O
all	DT	O
five	CD	O
domains	NNS	O
were	VBD	O
significant	JJ	O
in	IN	O
favor	NN	O
of	IN	O
sildenafil	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
sildenafil-treated	JJ	PM
subjects	NNS	O
were	VBD	O
more	RBR	O
satisfied	JJ	O
with	IN	O
treatment	NN	O
and	CC	O
had	VBD	O
a	DT	O
higher	JJR	O
intercourse	JJ	O
success	NN	O
rate	NN	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
mild	VBN	O
in	IN	O
severity	NN	O
;	:	O
the	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
treatment-related	JJ	O
events	NNS	O
were	VBD	O
dizziness	NN	O
(	(	O
7.7	CD	O
%	NN	O
)	)	O
and	CC	O
tinnitus	NN	O
(	(	O
2.9	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Sildenafil	NNP	O
(	(	O
25	CD	O
,	,	O
50	CD	O
,	,	O
and	CC	O
100	CD	O
mg	NN	O
)	)	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
,	,	O
safe	JJ	O
,	,	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
ED	NNP	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
population	NN	O
of	IN	O
Thai	NNP	O
,	,	O
Malaysian	NNP	O
,	,	O
and	CC	O
Singaporean	NNP	O
males	NNS	O
who	WP	O
also	RB	O
had	VBD	O
increased	VBN	O
cardiovascular	JJ	O
risk	NN	O
T	NNP	O
lymphocyte	JJ	O
subsets	NNS	O
and	CC	O
NK	NNP	O
cell	VBP	O
cytotoxicity	NN	O
in	IN	O
chronic	JJ	O
hemodialysis	NN	O
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
recombinant	JJ	PM
human	JJ	PM
erythropoietin	NN	PM
(	(	PM
rHu-EPO	JJ	PM
)	)	PM
treatment	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
subpopulations	NNS	O
of	IN	O
T	NNP	O
lymphocytes	NNS	O
,	,	O
NK	NNP	O
cell	NN	O
number	NN	O
and	CC	O
cytotoxic	JJ	O
activity	NN	O
in	IN	O
14	CD	O
chronic	JJ	O
uremic	JJ	O
patients	NNS	O
on	IN	O
regular	JJ	C
hemodialysis	NN	C
treatment	NN	C
.	.	O

We	PRP	O
observed	VBD	O
a	DT	O
significantly	RB	O
decreased	VBN	O
absolute	NN	O
lymphocyte	NN	O
number	NN	O
and	CC	O
percentage	NN	O
of	IN	O
CD3	NNP	O
cells	NNS	O
.	.	O

Relative	JJ	O
numbers	NNS	O
of	IN	O
CD16	NNP	O
cells	NNS	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
,	,	O
but	CC	O
NK	NNP	O
cell	VBP	O
cytotoxic	JJ	O
activity	NN	O
was	VBD	O
within	IN	O
a	DT	O
normal	JJ	O
range	NN	O
.	.	O

Nine	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	O
renal	JJ	O
anemia	NN	O
on	IN	O
maintenance	NN	O
hemodialysis	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
rHu-EPO	JJ	PM
treatment	NN	O
trial	NN	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
continued	VBN	O
till	IN	O
the	DT	O
hematocrit	NN	O
level	NN	O
reached	VBD	O
30	CD	O
%	NN	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
corrected	VBN	O
anemia	NN	O
and	CC	O
well-being	NN	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
we	PRP	O
observed	VBD	O
in	IN	O
these	DT	O
patients	NNS	O
decreases	NNS	O
in	IN	O
CD3	NNP	O
,	,	O
CD4	NNP	O
,	,	O
CD8	NNP	O
and	CC	O
CD16	NNP	O
cell	NN	O
numbers	NNS	O
and	CC	O
elevation	NN	O
of	IN	O
CD4/CD8	NNP	O
ratio	NN	O
.	.	O

Cytotoxic	NNP	O
activity	NN	O
of	IN	O
NK	NNP	O
cells	NNS	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
.	.	O

Presented	VBN	O
results	NNS	O
indicate	VBP	O
that	IN	O
chronic	JJ	O
hemodialysis	NN	O
patients	NNS	O
have	VBP	O
significantly	RB	O
diminished	VBN	O
lymphocyte	JJ	O
number	NN	O
.	.	O

rHu	JJ	PM
EPO	NNP	PM
treatment	NN	O
affects	VBZ	O
the	DT	O
T	NNP	O
lymphocyte	NN	O
subsets	NNS	O
inducing	VBG	O
a	DT	O
deep	JJ	O
decrease	NN	O
of	IN	O
CD8	NNP	O
and	CC	O
CD16	NNP	O
cell	NN	O
percentage	NN	O
leading	VBG	O
to	TO	O
normalisation	NN	O
of	IN	O
the	DT	O
CD4/CD8	NNP	O
ratio	NN	O
.	.	O

Superior	JJ	O
fixation	NN	O
of	IN	O
pegged	JJ	PH
trabecular	JJ	PH
metal	NN	PH
over	IN	O
screw-fixed	JJ	PH
pegged	JJ	PH
porous	JJ	PH
titanium	NN	PH
fiber	NN	PH
mesh	NN	PH
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
RSA	NNP	O
study	NN	O
on	IN	O
cementless	JJ	O
tibial	JJ	O
components	NNS	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Lasting	NNP	O
stability	NN	O
of	IN	O
cementless	NN	O
implants	NNS	O
depends	VBZ	O
on	IN	O
osseointegration	NN	O
into	IN	O
the	DT	O
implant	JJ	O
surface	NN	O
,	,	O
and	CC	O
long-term	JJ	O
implant	JJ	O
fixation	NN	O
can	MD	O
be	VB	O
predicted	VBN	O
using	VBG	O
radiostereometric	JJ	O
analysis	NN	O
(	(	O
RSA	NNP	O
)	)	O
with	IN	O
short-term	JJ	O
follow-up	JJ	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
there	EX	O
would	MD	O
be	VB	O
improved	VBN	O
fixation	NN	O
of	IN	O
high-porosity	NN	S
trabecular	JJ	S
metal	NN	S
(	(	S
TM	NNP	S
)	)	S
tibial	JJ	S
components	NNS	S
compared	VBN	O
to	TO	O
low-porosity	JJ	S
titanium	NN	S
pegged	VBD	S
porous	JJ	S
fiber-metal	JJ	S
(	(	S
Ti	NNP	S
)	)	S
polyethylene	NN	S
metal	JJ	S
backings	NNS	S
.	.	S

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
randomized	VBN	O
unblinded	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
we	PRP	O
compared	VBN	O
cementless	JJ	S
tibial	JJ	S
components	NNS	S
in	IN	O
patients	NNS	O
aged	VBN	O
70	CD	O
years	NNS	O
and	CC	O
younger	JJR	O
with	IN	O
osteoarthritis	NN	O
.	.	O

The	DT	O
pre-study	JJ	O
sample	NN	O
size	NN	O
calculation	NN	O
was	VBD	O
22	CD	O
patients	NNS	O
per	IN	O
group	NN	O
.	.	O

25	CD	S
TM	NNP	S
tibial	JJ	S
components	NNS	S
were	VBD	S
fixed	VBN	S
press-fit	JJ	S
by	IN	S
2	CD	O
hexagonal	JJ	O
pegs	NN	O
(	(	O
TM	NNP	O
group	NN	O
)	)	O
and	CC	O
25	CD	S
Ti	NNP	S
tibial	JJ	S
components	NNS	S
were	VBD	S
fixed	VBN	S
press-fit	JJ	S
and	CC	S
by	IN	S
4	CD	S
supplemental	JJ	S
screws	NNS	S
(	(	O
Ti	NNP	O
group	NN	O
)	)	O
.	.	O

Stereo	NNP	O
radiographs	NN	O
for	IN	O
evaluation	NN	O
of	IN	O
absolute	JJ	O
component	NN	O
migration	NN	O
(	(	O
primary	JJ	O
effect	NN	O
size	NN	O
)	)	O
and	CC	O
single-direction	JJ	O
absolute	NN	O
component	NN	O
migration	NN	O
(	(	O
secondary	JJ	O
effect	NN	O
size	NN	O
)	)	O
were	VBD	O
obtained	VBN	O
within	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
week	NN	O
and	CC	O
at	IN	O
6	CD	O
weeks	NNS	O
,	,	O
6	CD	O
months	NNS	O
,	,	O
1	CD	O
year	NN	O
,	,	O
and	CC	O
2	CD	O
years	NNS	O
.	.	O

American	JJ	O
Knee	NNP	O
Society	NNP	O
score	NN	O
was	VBD	O
used	VBN	O
for	IN	O
clinical	JJ	O
assessment	NN	O
preoperatively	RB	O
,	,	O
and	CC	O
at	IN	O
1	CD	O
and	CC	O
2	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
intraoperative	JJ	O
complications	NNS	O
,	,	O
and	CC	O
no	DT	O
postoperative	JJ	O
infections	NNS	O
or	CC	O
revisions	NNS	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
improved	VBN	O
function	NN	O
and	CC	O
regained	VBD	O
full	JJ	O
extension	NN	O
.	.	O

All	DT	O
tibial	JJ	O
components	NNS	O
migrated	VBN	O
initially	RB	O
.	.	O

Most	JJS	O
migration	NN	O
of	IN	O
the	DT	O
TM	NNP	PH
components	NNS	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
occurred	VBD	O
within	IN	O
the	DT	O
first	JJ	O
3	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
whereas	JJ	O
migration	NN	O
of	IN	O
the	DT	O
Ti	NNP	PH
components	NNS	O
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
appeared	VBD	O
to	TO	O
stabilize	VB	O
first	RB	O
after	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
TM	NNP	PH
components	NNS	O
migrated	VBD	O
less	JJR	O
than	IN	O
the	DT	O
Ti	NNP	PH
components	NNS	O
at	IN	O
1	CD	O
year	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
and	CC	O
2	CD	O
years	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
mechanical	JJ	O
fixation	NN	O
of	IN	O
TM	NNP	O
tibial	JJ	O
components	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
that	DT	O
of	IN	O
screw-fixed	JJ	O
Ti	NNP	PH
tibial	JJ	O
components	NNS	O
.	.	O

We	PRP	O
expect	VBP	O
long-term	JJ	O
implant	JJ	O
survival	NN	O
to	TO	O
be	VB	O
better	RB	O
with	IN	O
the	DT	O
TM	NNP	PH
tibial	JJ	O
component	NN	O
.	.	O

Immunologic	NNP	O
and	CC	O
hemodynamic	JJ	O
effects	NNS	O
of	IN	O
low-dose	JJ	PM
hydrocortisone	NN	PM
in	IN	O
septic	JJ	O
shock	NN	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Within	IN	O
the	DT	O
last	JJ	O
few	JJ	O
years	NNS	O
,	,	O
increasing	VBG	O
evidence	NN	O
of	IN	O
relative	JJ	O
adrenal	JJ	O
insufficiency	NN	O
in	IN	O
septic	JJ	O
shock	NN	O
evoked	VBD	O
a	DT	O
reassessment	NN	O
of	IN	O
hydrocortisone	NN	PM
therapy	NN	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
hydrocortisone	NN	PM
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
proinflammatory	NN	O
and	CC	O
antiinflammation	NN	O
,	,	O
40	CD	O
patients	NNS	O
with	IN	O
septic	JJ	O
shock	NN	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
to	TO	O
receive	VB	O
either	CC	O
the	DT	O
first	JJ	O
100	CD	O
mg	NN	O
of	IN	O
hydrocortisone	NN	PM
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
and	CC	O
10	CD	O
mg	NNS	O
per	IN	O
hour	NN	O
until	IN	O
Day	NNP	O
3	CD	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
the	DT	O
opposite	JJ	O
medication	NN	O
until	IN	O
Day	NNP	O
6	CD	O
.	.	O

Hydrocortisone	CD	PM
infusion	NN	O
induced	VBD	O
an	DT	O
increase	NN	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
,	,	O
and	CC	O
a	DT	O
decline	NN	O
of	IN	O
heart	NN	O
rate	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
,	,	O
and	CC	O
norepinephrine	JJ	O
requirement	NN	O
.	.	O

A	DT	O
reduction	NN	O
of	IN	O
plasma	NN	O
nitrite/nitrate	NN	O
indicated	VBD	O
inhibition	NN	O
of	IN	O
nitric	JJ	O
oxide	JJ	O
formation	NN	O
and	CC	O
correlated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
of	IN	O
vasopressor	NN	O
support	NN	O
.	.	O

The	DT	O
inflammatory	JJ	O
response	NN	O
(	(	O
interleukin-6	JJ	O
and	CC	O
interleukin-8	JJ	O
)	)	O
,	,	O
endothelial	JJ	O
(	(	O
soluble	JJ	O
E-selectin	NN	O
)	)	O
and	CC	O
neutrophil	JJ	O
activation	NN	O
(	(	O
expression	NN	O
of	IN	O
CD11b	NNP	O
,	,	O
CD64	NNP	O
)	)	O
,	,	O
and	CC	O
antiinflammatory	JJ	O
response	NN	O
(	(	O
soluble	JJ	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
receptors	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
and	CC	O
interleukin-10	JJ	O
)	)	O
were	VBD	O
attenuated	VBN	O
.	.	O

In	IN	O
peripheral	JJ	O
blood	NN	O
monocytes	NNS	O
,	,	O
human	JJ	O
leukocyte	VBD	O
antigen-DR	JJ	O
expression	NN	O
was	VBD	O
only	RB	O
slightly	RB	O
depressed	VBN	O
,	,	O
whereas	NNS	O
in	IN	O
vitro	JJ	O
phagocytosis	NN	O
and	CC	O
the	DT	O
monocyte-activating	JJ	O
cytokine	JJ	O
interleukin-12	NN	O
increased	VBD	O
.	.	O

Hydrocortisone	NNP	PM
withdrawal	NN	O
induced	VBD	O
hemodynamic	JJ	O
and	CC	O
immunologic	JJ	O
rebound	NN	O
effects	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
hydrocortisone	NN	PM
therapy	NN	O
restored	VBD	O
hemodynamic	JJ	O
stability	NN	O
and	CC	O
differentially	RB	O
modulated	VBD	O
the	DT	O
immunologic	JJ	O
response	NN	O
to	TO	O
stress	VB	O
in	IN	O
a	DT	O
way	NN	O
of	IN	O
antiinflammation	NN	O
rather	RB	O
than	IN	O
immunosuppression	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
Dader	NNP	E
Method	NNP	E
for	IN	O
pharmaceutical	JJ	O
care	NN	O
on	IN	O
control	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
total	JJ	O
cholesterol	NN	O
in	IN	O
outpatients	NNS	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
or	CC	O
cardiovascular	JJ	O
risk	NN	O
:	:	O
EMDADER-CV	JJ	O
randomized	NNS	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
some	DT	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
pharmacist	JJ	E
intervention	NN	E
can	MD	O
improve	VB	O
drug	NN	O
therapy	NN	O
among	IN	O
patients	NNS	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
(	(	O
CVD	NNP	O
)	)	O
,	,	O
more	JJR	O
evidence	NN	O
derived	VBN	O
from	IN	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
(	(	O
RCTs	NNP	O
)	)	O
is	VBZ	O
needed	VBN	O
,	,	O
including	VBG	O
assessment	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
community	NN	E
pharmacist	NN	E
interventions	NNS	E
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
Dader	NNP	E
Method	NNP	E
for	IN	E
pharmaceutical	JJ	E
care	NN	E
on	IN	O
achieving	VBG	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
,	,	O
and	CC	O
both	DT	O
BP	NNP	O
and	CC	O
TC	NNP	O
(	(	O
BP/TC	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
and/or	VBP	O
high	JJ	O
or	CC	O
intermediate	JJ	O
cardiovascular	NN	O
(	(	O
CV	NNP	O
)	)	O
risk	NN	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
in	IN	O
Spain	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
aged	VBD	O
25	CD	O
to	TO	O
74	CD	O
years	NNS	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
with	IN	O
a	DT	O
prescription	NN	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
drug	NN	O
indicated	VBN	O
for	IN	O
CVD	NNP	O
or	CC	O
CV	NNP	O
risk	NN	O
factors	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
:	:	O
an	DT	O
intervention	NN	E
group	NN	E
that	WDT	E
received	VBD	E
pharmaceutical	JJ	E
care	NN	E
,	,	E
which	WDT	E
was	VBD	E
provided	VBN	E
by	IN	E
specially	RB	E
trained	JJ	E
pharmacists	NNS	E
working	VBG	E
in	IN	E
collaboration	NN	E
with	IN	E
physicians	NNS	E
,	,	O
and	CC	O
a	DT	O
control	NN	E
group	NN	E
that	WDT	E
received	VBD	E
usual	JJ	E
care	NN	E
(	(	E
routine	JJ	E
dispensing	VBG	E
counseling	NN	E
)	)	E
and	CC	E
verbal	JJ	E
and	CC	E
written	VBN	E
counseling	VBG	E
regarding	VBG	E
CVD	NNP	E
prevention	NN	E
.	.	O

Patients	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
December	NNP	O
2005	CD	O
to	TO	O
September	NNP	O
2006	CD	O
,	,	O
and	CC	O
both	DT	O
groups	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
8	CD	O
months	NNS	O
.	.	O

Study	NNP	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
16	CD	O
and	CC	O
32	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
achieving	VBG	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
therapeutic	JJ	O
goals	NNS	O
(	(	O
BP	NNP	O
lower	JJR	O
than	IN	O
140/90	CD	O
mm	NNS	O
Hg	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
uncomplicated	JJ	O
hypertension	NN	O
and	CC	O
lower	JJR	O
than	IN	O
130/80	CD	O
mm	NNS	O
Hg	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
,	,	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
,	,	O
or	CC	O
history	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
stroke	NN	O
;	:	O
TC	NNP	O
lower	JJR	O
than	IN	O
200	CD	O
mg	NNS	O
per	IN	O
dL	NN	O
for	IN	O
patients	NNS	O
without	IN	O
CVD	NNP	O
and	CC	O
lower	JJR	O
than	IN	O
175	CD	O
mg	NNS	O
per	IN	O
dL	NN	O
for	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
mean	JJ	O
BP	NNP	O
and	CC	O
TC	NNP	O
values	NNS	O
.	.	O

BP	NNP	O
was	VBD	O
assessed	VBN	O
manually	RB	O
by	IN	O
the	DT	O
pharmacist	NN	O
after	IN	O
a	DT	O
10-minute	JJ	O
rest	NN	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
.	.	O

This	DT	O
measurement	NN	O
was	VBD	O
performed	VBN	O
twice	RB	O
for	IN	O
every	DT	O
participant	NN	O
,	,	O
and	CC	O
the	DT	O
average	NN	O
of	IN	O
the	DT	O
2	CD	O
measurements	NNS	O
was	VBD	O
calculated	VBN	O
.	.	O

TC	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
pharmacist	NN	O
during	IN	O
the	DT	O
study	NN	O
visit	NN	O
using	VBG	O
the	DT	O
enzymatic	JJ	O
dry	JJ	O
method	NN	O
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
2-tailed	JJ	O
McNemar	NNP	O
tests	NNS	O
,	,	O
Pearson	NNP	O
chi-square	NN	O
tests	NNS	O
,	,	O
and	CC	O
Student	NNP	O
's	POS	O
t-tests	NNS	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
was	VBD	O
considered	VBN	O
statistically	RB	O
significant	JJ	O
.	.	O

RESULTS	VB	O
714	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
(	(	O
356	CD	O
intervention	NN	O
,	,	O
358	CD	O
control	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
was	VBD	O
62.8	CD	O
[	JJ	O
8.1	CD	O
]	JJ	O
years	NNS	O
.	.	O

The	DT	O
2	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
at	IN	O
baseline	NN	O
in	IN	O
clinical	JJ	O
and	CC	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
including	VBG	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
at	IN	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
.	.	O

After	IN	O
8	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
there	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
favor	NN	O
of	IN	O
pharmaceutical	JJ	O
care	NN	O
in	IN	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
BP	NNP	O
(	(	O
52.5	CD	O
%	NN	O
vs.	FW	O
43.0	CD	O
%	NN	O
,	,	O
P=0.017	NNP	O
)	)	O
,	,	O
TC	NNP	O
(	(	O
56.5	CD	O
%	NN	O
vs.	FW	O
44.1	CD	O
%	NN	O
,	,	O
P=0.001	NNP	O
)	)	O
,	,	O
and	CC	O
BP/TC	NNP	O
(	(	O
37.1	CD	O
%	NN	O
vs.	FW	O
21.8	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Compared	NNP	O
with	IN	O
usual	JJ	O
care	NN	O
plus	CC	O
written	VBN	O
education	NN	O
,	,	O
pharmaceutical	JJ	O
care	NN	O
focused	VBN	O
on	IN	O
patient	JJ	O
evaluation	NN	O
and	CC	O
follow-up	NN	O
in	IN	O
collaboration	NN	O
with	IN	O
physicians	NNS	O
improved	VBN	O
the	DT	O
achievement	NN	O
of	IN	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
treatment	NN	O
goals	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
and/or	VBP	O
high	JJ	O
or	CC	O
intermediate	JJ	O
CV	NNP	O
risk	NN	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
in	IN	O
Spain	NNP	O
.	.	O

Argatroban	NNP	PM
for	IN	O
elective	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
:	:	O
the	DT	O
ARG-E04	NNP	O
multi-center	NN	O
study	NN	O
.	.	O

UNLABELLED	IN	O
The	DT	O
synthetic	JJ	O
arginine-derived	JJ	O
direct	JJ	O
thrombin	NN	O
inhibitor	NN	O
argatroban	NN	PM
is	VBZ	O
an	DT	O
attractive	JJ	O
anticoagulant	NN	O
for	IN	O
percutaneous	JJ	S
coronary	JJ	S
intervention	NN	S
(	(	S
PCI	NNP	S
)	)	S
,	,	O
because	IN	O
of	IN	O
its	PRP$	O
rapid	JJ	O
onset	NN	O
and	CC	O
offset	NN	O
,	,	O
and	CC	O
its	PRP$	O
hepatic	JJ	O
elimination	NN	O
.	.	O

Argatroban	NNP	PM
was	VBD	O
approved	VBN	O
for	IN	O
PCI	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
heparin-induced	JJ	O
thrombocytopenia	NN	O
(	(	O
HIT	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
limited	VBN	O
data	NNS	O
about	IN	O
argatroban	NN	PM
in	IN	O
non-HIT	JJ	O
patients	NNS	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
open-label	JJ	O
,	,	O
multiple-dose	JJ	O
,	,	O
controlled	VBD	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
argatroban	NN	PM
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Of	IN	O
140	CD	O
patients	NNS	O
randomized	VBN	O
to	TO	O
three	CD	O
argatroban	NNS	PM
dose	JJ	O
groups	NNS	O
(	(	O
ARG250	NNP	PM
,	,	O
ARG300	NNP	PM
,	,	O
and	CC	O
ARG350	NNP	PM
with	IN	O
250	CD	O
,	,	O
300	CD	O
,	,	O
or	CC	O
350	CD	O
?g/kg	JJ	O
bolus	NN	O
,	,	O
followed	VBN	O
by	IN	O
15	CD	O
,	,	O
20	CD	O
,	,	O
or	CC	O
25	CD	O
?g/kg/min	JJ	O
infusion	NN	O
)	)	O
and	CC	O
one	CD	O
unfractionated	JJ	O
heparin	NN	O
(	(	O
UFH	NNP	O
)	)	O
group	NN	O
(	(	O
70-100	JJ	O
IU/kg	NNP	O
bolus	NN	O
)	)	O
,	,	O
138	CD	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

Argatroban	NNP	O
dose-dependently	RB	O
prolonged	VBD	O
activated	VBN	O
clotting	NN	O
time	NN	O
(	(	O
ACT	NNP	O
)	)	O
with	IN	O
more	JJR	O
patients	NNS	O
reaching	VBG	O
the	DT	O
minimum	NN	O
target	NN	O
ACT	NNP	O
after	IN	O
the	DT	O
initial	JJ	O
bolus	NN	O
injection	NN	O
(	(	O
ARG250	NNP	O
:	:	O
86.1	CD	O
%	NN	O
,	,	O
ARG300	NNP	O
:	:	O
89.5	CD	O
%	NN	O
,	,	O
and	CC	O
ARG350	NNP	O
:	:	O
96.8	CD	O
%	NN	O
)	)	O
compared	VBN	O
to	TO	O
45.5	CD	O
%	NN	O
in	IN	O
UFH	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
patient	JJ	O
proportion	NN	O
who	WP	O
did	VBD	O
not	RB	O
require	VB	O
additional	JJ	O
bolus	NN	O
injections	NNS	O
to	TO	O
start	VB	O
PCI	NNP	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
argatroban	NN	O
than	IN	O
in	IN	O
UFH	NNP	O
(	(	O
p	VB	O
?	.	O
0.002	CD	O
)	)	O
.	.	O

Consequently	RB	O
,	,	O
the	DT	O
time	NN	O
to	TO	O
start	VB	O
of	IN	O
PCI	NNP	O
was	VBD	O
shortened	VBN	O
in	IN	O
argatroban	JJ	O
groups	NNS	O
.	.	O

Composite	NNP	O
incidences	NNS	O
of	IN	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
urgent	JJ	O
revascularization	NN	O
until	IN	O
day	NN	O
30	CD	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
(	(	O
ARG250	NNP	O
:	:	O
2.8	CD	O
%	NN	O
,	,	O
ARG300	NNP	O
:	:	O
0.0	CD	O
%	NN	O
,	,	O
ARG350	NNP	O
:	:	O
3.2	CD	O
%	NN	O
vs.	FW	O
UFH	NNP	O
:	:	O
3.0	CD	O
%	NN	O
)	)	O
.	.	O

Major	JJ	O
bleeding	NN	O
was	VBD	O
observed	VBN	O
only	RB	O
in	IN	O
UFH	NNP	O
(	(	O
3.0	CD	O
%	NN	O
)	)	O
,	,	O
while	IN	O
minor	JJ	O
bleeding	NN	O
occurred	VBD	O
in	IN	O
ARG350	NNP	O
(	(	O
3.2	CD	O
%	NN	O
)	)	O
and	CC	O
UFH	NNP	O
(	(	O
6.1	CD	O
%	NN	O
,	,	O
n.s.	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Argatroban	NNP	O
dose-dependently	JJ	O
increases	NNS	O
coagulation	NN	O
parameters	NNS	O
and	CC	O
,	,	O
compared	VBN	O
to	TO	O
UFH	NNP	O
,	,	O
demonstrates	VBZ	O
a	DT	O
superior	JJ	O
predictable	JJ	O
anticoagulant	JJ	O
effect	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
PCI	NNP	O
.	.	O

The	DT	O
lunar	JJ	S
stent	NN	S
characteristics	NNS	O
and	CC	O
clinical	JJ	O
results	NNS	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
frequent	JJ	O
long-term	JJ	O
complications	NNS	O
after	IN	O
stent	JJ	S
implantation	NN	S
is	VBZ	O
restenosis	JJ	O
due	JJ	O
to	TO	O
the	DT	O
building	NN	O
up	IN	O
of	IN	O
a	DT	O
neointima	NN	O
within	IN	O
the	DT	O
artery	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
endovascular	JJ	O
hyperplasia	NN	O
(	(	O
tissue	VB	O
growth	NN	O
)	)	O
.	.	O

The	DT	O
interesting	JJ	O
feature	NN	O
of	IN	O
the	DT	O
Lunar	NNP	S
stent	NN	S
from	IN	S
Inflow	NNP	S
Dynamics	NNP	S
is	VBZ	O
that	IN	O
it	PRP	O
is	VBZ	O
coated	VBN	O
with	IN	O
a	DT	O
layer	NN	O
of	IN	O
iridium	NN	O
oxide	NN	O
.	.	O

The	DT	O
iridium	NN	PM
oxide	IN	PM
coating	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
reduce	VB	O
restenosis	NN	O
by	IN	O
decreasing	VBG	O
the	DT	O
inflammatory	JJ	O
response	NN	O
to	TO	O
the	DT	O
stent	NN	O
via	IN	O
its	PRP$	O
antioxidant	JJ	O
action	NN	O
.	.	O

The	DT	O
MOONLIGHT	NNP	O
(	(	O
Multicenter	NNP	O
Objective	NNP	O
ObservatioNal	NNP	O
Lunar	NNP	PM
Iridiumoxide	NNP	PM
intimal	JJ	O
GrowtH	NNP	O
Trial	NNP	O
)	)	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
immediate	JJ	O
outcome	NN	O
and	CC	O
long-term	JJ	O
angiographic	JJ	O
success	NN	O
after	IN	O
implantation	NN	S
of	IN	S
Lunar	NNP	S
stents	NNS	S
.	.	O

Between	IN	O
March	NNP	O
2001	CD	O
and	CC	O
November	NNP	O
2001	CD	O
,	,	O
87	CD	O
patients	NNS	O
with	IN	O
99	CD	O
lesions	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
and	CC	O
were	VBD	O
treated	VBN	O
with	IN	O
12	CD	O
and	CC	O
16	CD	O
mm	NNS	O
long	JJ	O
iridium-oxide	JJ	PM
coated	VBN	S
Lunar	NNP	S
stents	NNS	S
.	.	O

Delivery	NN	O
of	IN	O
the	DT	O
Lunar	NNP	S
stent	NN	S
was	VBD	O
successful	JJ	O
in	IN	O
most	JJS	O
lesions	NNS	O
and	CC	O
the	DT	O
optimal	JJ	O
radiopacity	NN	O
facilitated	VBN	O
optimal	JJ	O
stent	NN	O
positioning	VBG	O
with	IN	O
optimal	JJ	O
immediate	JJ	O
clinical	JJ	O
and	CC	O
angiographic	JJ	O
results	NNS	O
is	VBZ	O
an	DT	O
unselected	JJ	O
patient	NN	O
and	CC	O
lesion	NN	O
population	NN	O
.	.	O

Preliminary	JJ	O
clinical	JJ	O
and	CC	O
angiographic	JJ	O
follow-up	JJ	O
show	NN	O
a	DT	O
low	JJ	O
rate	NN	O
of	IN	O
cardiac	JJ	O
events	NNS	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
16.1	CD	O
%	NN	O
MACE	NNP	O
)	)	O
and	CC	O
a	DT	O
moderate	JJ	O
hyperplastic	JJ	O
response	NN	O
.	.	O

Probiotics	NNS	PM
prevent	VBP	O
IgE-associated	JJ	O
allergy	NN	O
until	IN	O
age	NN	O
5	CD	O
years	NNS	O
in	IN	O
cesarean-delivered	JJ	O
children	NNS	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
total	JJ	O
cohort	NN	O
.	.	O

BACKGROUND	NNP	O
Less	NNP	O
microbial	JJ	O
exposure	NN	O
in	IN	O
early	JJ	O
childhood	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
more	RBR	O
allergic	JJ	O
disease	NN	O
later	RB	O
.	.	O

Allergic	NNP	O
children	NNS	O
have	VBP	O
a	DT	O
different	JJ	O
fecal	JJ	O
microflora	NN	O
,	,	O
with	IN	O
less	JJR	O
lactobacilli	NN	O
and	CC	O
bifidobacteria	NN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
regarding	VBG	O
the	DT	O
development	NN	O
of	IN	O
allergy	NNS	O
have	VBP	O
been	VBN	O
suggested	VBN	O
to	TO	O
come	VB	O
through	IN	O
probiotic	JJ	O
supplementation	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
probiotic	JJ	PM
and	CC	PM
prebiotic	JJ	PM
supplementation	NN	PM
in	IN	O
preventing	VBG	O
allergies	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	C
study	NN	O
we	PRP	O
randomized	VBD	O
1223	CD	O
mothers	NNS	O
with	IN	O
infants	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
allergy	NN	O
to	TO	O
receive	VB	O
a	DT	O
probiotic	JJ	PM
mixture	NN	PM
(	(	PM
2	CD	PM
lactobacilli	NN	PM
,	,	PM
bifidobacteria	NN	PM
,	,	PM
and	CC	PM
propionibacteria	NN	PM
)	)	PM
or	CC	O
placebo	NN	C
during	IN	O
the	DT	O
last	JJ	O
month	NN	O
of	IN	O
pregnancy	NN	O
and	CC	O
their	PRP$	O
infants	NNS	O
to	TO	O
receive	VB	O
it	PRP	O
from	IN	O
birth	NN	O
until	IN	O
age	NN	O
6	CD	O
months	NNS	O
.	.	O

Infants	NNS	O
also	RB	O
received	VBD	O
a	DT	O
prebiotic	JJ	PM
galacto-oligosaccharide	NN	PM
or	CC	O
placebo	NN	C
.	.	O

At	IN	O
5	CD	O
years	NNS	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
cumulative	JJ	O
incidence	NN	O
of	IN	O
allergic	JJ	O
diseases	NNS	O
(	(	O
eczema	NN	O
,	,	O
food	NN	O
allergy	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
and	CC	O
asthma	NN	O
)	)	O
and	CC	O
IgE	NNP	O
sensitization	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
1018	CD	O
intent-to-treat	NN	O
infants	NNS	O
,	,	O
891	CD	O
(	(	O
88	CD	O
%	NN	O
)	)	O
attended	VBD	O
the	DT	O
5-year	JJ	O
visit	NN	O
.	.	O

Frequencies	NNS	O
of	IN	O
allergic	JJ	O
and	CC	O
IgE-associated	JJ	O
allergic	JJ	O
disease	NN	O
and	CC	O
sensitization	NN	O
in	IN	O
the	DT	O
probiotic	JJ	PM
and	CC	O
placebo	JJ	C
groups	NNS	O
were	VBD	O
similar	JJ	O
:	:	O
52.6	CD	O
%	NN	O
versus	IN	O
54.9	CD	O
%	NN	O
and	CC	O
29.5	CD	O
%	NN	O
versus	IN	O
26.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
41.3	CD	O
%	NN	O
in	IN	O
both	DT	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
appeared	VBD	O
in	IN	O
frequencies	NNS	O
of	IN	O
eczema	NN	O
(	(	O
39.3	CD	O
%	NN	O
vs	JJ	O
43.3	CD	O
%	NN	O
)	)	O
,	,	O
atopic	JJ	O
eczema	NN	O
(	(	O
24.0	CD	O
%	NN	O
vs	JJ	O
25.1	CD	O
%	NN	O
)	)	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
(	(	O
20.7	CD	O
%	NN	O
vs	JJ	O
19.1	CD	O
%	NN	O
)	)	O
,	,	O
or	CC	O
asthma	NN	O
(	(	O
13.0	CD	O
%	NN	O
vs	JJ	O
14.1	CD	O
%	NN	O
)	)	O
between	IN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
less	JJR	O
IgE-associated	JJ	O
allergic	JJ	O
disease	NN	O
occurred	VBD	O
in	IN	O
cesarean-delivered	JJ	O
children	NNS	O
receiving	VBG	O
probiotics	NNS	PM
(	(	O
24.3	CD	O
%	NN	O
vs	JJ	O
40.5	CD	O
%	NN	O
;	:	O
odds	NNS	O
ratio	VBP	O
,	,	O
0.47	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.23	CD	O
%	NN	O
to	TO	O
0.96	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.035	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
allergy-preventive	JJ	O
effect	NN	O
that	WDT	O
extended	VBD	O
to	TO	O
age	NN	O
5	CD	O
years	NNS	O
was	VBD	O
achieved	VBN	O
with	IN	O
perinatal	JJ	O
supplementation	NN	O
of	IN	O
probiotic	JJ	PM
bacteria	NNS	PM
to	TO	O
high-risk	JJ	O
mothers	NNS	O
and	CC	O
children	NNS	O
.	.	O

It	PRP	O
conferred	VBD	O
protection	NN	O
only	RB	O
to	TO	O
cesarean-delivered	JJ	O
children	NNS	O
.	.	O

Prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
diclofenac	NN	PM
and	CC	O
ketorolac	NN	O
after	IN	O
refractive	JJ	O
surgery	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
diclofenac	NN	PM
and	CC	O
ketorolac	NN	PM
in	IN	O
relieving	VBG	O
corneal	NN	O
pain	NN	O
after	IN	O
refractive	JJ	O
surgery	NN	O
,	,	O
and	CC	O
determine	VB	O
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
difference	NN	O
in	IN	O
stinging	VBG	O
on	IN	O
instillation	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
prospectively	RB	O
to	TO	O
postoperative	VB	PM
diclofenac	NN	PM
in	IN	O
one	CD	O
eye	NN	O
and	CC	O
ketorolac	NN	PM
in	IN	PM
the	DT	PM
other	JJ	PM
.	.	O

Patients	NNS	O
and	CC	O
surgeon	NN	O
did	VBD	O
not	RB	O
know	VB	O
which	WDT	O
medications	NNS	O
were	VBD	O
used	VBN	O
.	.	O

Ocular	JJ	O
postoperative	JJ	O
pain	NN	O
and	CC	O
discomfort	NN	O
on	IN	O
instillation	NN	O
of	IN	O
medication	NN	O
were	VBD	O
measured	VBN	O
after	IN	O
radial	JJ	O
keratotomy	NN	O
with	IN	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
and	CC	O
a	DT	O
questionnaire	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
medications	NNS	O
were	VBD	O
highly	RB	O
effective	JJ	O
in	IN	O
relieving	VBG	O
pain	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
pain	NN	O
relief	NN	O
,	,	O
or	CC	O
stinging	VBG	O
on	IN	O
instillation	NN	O
(	(	O
P	NNP	O
=	NNP	O
.29	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistical	JJ	O
difference	NN	O
in	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
medications	NNS	O
on	IN	O
pain	NN	O
relief	NN	O
,	,	O
or	CC	O
in	IN	O
stinging	VBG	O
on	IN	O
instillation	NN	O
.	.	O

Is	VBZ	O
periprostatic	JJ	O
local	JJ	O
anesthesia	NN	PH
for	IN	O
transrectal	JJ	O
ultrasound	NN	O
guided	VBD	O
prostate	NN	O
biopsy	NN	O
associated	VBN	O
with	IN	O
increased	JJ	O
infectious	JJ	O
or	CC	O
hemorrhagic	JJ	O
complications	NNS	O
?	.	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Periprostatic	NNP	O
local	JJ	O
anesthesia	NN	O
for	IN	O
prostate	NN	O
biopsy	NN	O
requires	VBZ	O
2	CD	O
or	CC	O
more	JJR	O
extra	JJ	O
needle	JJ	O
punctures	NNS	O
and	CC	O
injection	NN	O
of	IN	O
the	DT	O
local	JJ	O
anesthetic	NN	O
through	IN	O
the	DT	O
highly	RB	O
colonized	JJ	O
rectum	NN	O
.	.	O

To	TO	O
our	PRP$	O
knowledge	NN	O
we	PRP	O
report	VBP	O
the	DT	O
first	JJ	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
infectious	JJ	O
or	CC	O
hemorrhagic	JJ	O
complications	NNS	O
associated	VBN	O
with	IN	O
this	DT	O
method	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
100	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
sterile	JJ	O
urine	JJ	O
cultures	NNS	O
underwent	JJ	O
transrectal	JJ	S
ultrasound	NN	S
guided	VBD	S
prostate	NN	S
biopsy	NN	S
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
periprostatic	JJ	PH
nerve	NN	PH
block	NN	PH
or	CC	O
no	DT	PH
anesthesia	NN	PH
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
the	DT	O
amount	NN	O
of	IN	O
rectal	NN	PH
and	CC	PH
urethral	JJ	PH
bleeding	NN	PH
,	,	O
and	CC	O
symptoms	NNS	PH
and	CC	PH
signs	NNS	PH
of	IN	PH
infection	NN	PH
after	IN	PH
biopsy	NN	S
.	.	O

RESULTS	VB	O
The	DT	O
amount	NN	O
of	IN	O
urethral	JJ	O
bleeding	NN	O
was	VBD	O
slight	JJ	O
and	CC	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Rectal	JJ	O
bleeding	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
anesthesia	NN	O
.	.	O

High	JJ	O
fever	NN	O
(	(	O
greater	JJR	O
than	IN	O
37.8C	CD	O
)	)	O
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
nerve	NN	O
block	NN	O
group	NN	O
and	CC	O
2	CD	O
patients	NNS	O
in	IN	O
this	DT	O
group	NN	O
required	VBD	O
rehospitalization	NN	O
.	.	O

Bacteriuria	NNP	O
in	IN	O
post-biopsy	JJ	O
urine	JJ	O
cultures	NNS	O
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
anesthesia	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
periprostatic	JJ	O
local	JJ	O
anesthesia	NN	PH
for	IN	O
prostate	JJ	O
biopsy	NN	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
urethral	JJ	O
bleeding	NN	O
.	.	O

It	PRP	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decreased	JJ	O
incidence	NN	O
of	IN	O
rectal	JJ	O
bleeding	NN	O
,	,	O
presumably	RB	O
due	JJ	O
to	TO	O
decreased	JJ	O
patient	NN	O
discomfort	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
bacteriuria	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
anesthesia	NN	O
group	NN	O
.	.	O

High	NNP	O
fever	NN	O
and	CC	O
hospitalization	NN	O
due	JJ	O
to	TO	O
infectious	JJ	O
complications	NNS	O
were	VBD	O
also	RB	O
more	RBR	O
common	JJ	O
in	IN	O
the	DT	O
local	JJ	O
anesthesia	NN	O
group	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Prospective	JJ	O
randomized	JJ	O
trials	NNS	O
seem	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimum	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
regimen	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
biopsy	NN	O
with	IN	O
a	DT	O
periprostatic	JJ	O
nerve	NN	O
block	NN	O
.	.	O

Effects	NNS	O
of	IN	O
short-term	JJ	O
isotonic	JJ	E
&	CC	E
isometric	JJ	E
training	NN	E
on	IN	O
cardiovascular	JJ	O
&	CC	O
pulmonary	JJ	O
function	NN	O
.	.	O

A	DT	O
randomised	JJ	O
control	NN	O
trial	NN	O
of	IN	O
short-term	JJ	PH
exercises	NNS	PH
on	IN	O
specific	JJ	O
cardiovascular	JJ	O
and	CC	O
respiratory	JJ	O
parameters	NNS	O
was	VBD	O
undertaken	VBN	O
in	IN	O
normal	JJ	O
male	JJ	O
college	NN	O
students	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
isotonic	JJ	PH
training	NN	PH
(	(	PH
5BX	CD	PH
programme	NN	PH
)	)	PH
and	CC	E
isometric	JJ	PH
training	NN	PH
(	(	E
a	DT	E
programme	NN	E
of	IN	E
isometric	JJ	E
exercises	NNS	E
working	VBG	E
all	DT	E
major	JJ	E
groups	NNS	E
of	IN	E
muscles	NNS	E
)	)	E
were	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	C
group	NN	O
with	IN	O
no	DT	O
specific	JJ	O
workout	NN	O
.	.	O

Both	DT	O
isotonic	JJ	E
and	CC	E
isometric	JJ	PH
training	NN	PH
resulted	VBD	O
in	IN	O
significant	JJ	O
cardiovascular	JJ	O
improvement	NN	O
but	CC	O
seemed	VBD	O
inadequate	JJ	O
to	TO	O
improve	VB	O
vital	JJ	O
capacity	NN	O
and	CC	O
flow	NN	O
rates	NNS	O
.	.	O

Isotonic	JJ	PH
training	NN	PH
in	IN	O
addition	NN	O
,	,	O
improved	JJ	O
ventilatory	NN	O
efficiency	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
such	JJ	O
isotonic	JJ	E
or	CC	E
isometric	JJ	E
training	NN	E
of	IN	O
thrice	NN	O
a	DT	O
week	NN	O
for	IN	O
ten	JJ	O
weeks	NNS	O
,	,	O
requiring	VBG	O
no	DT	O
equipment	NN	O
,	,	O
less	JJR	O
time	NN	O
and	CC	O
space	NN	O
can	MD	O
be	VB	O
promoted	VBN	O
to	TO	O
improve	VB	O
physical	JJ	O
fitness	NN	O
.	.	O

Neurophysiological	JJ	O
responses	NNS	O
to	TO	O
faces	VBZ	O
and	CC	O
gaze	JJ	O
direction	NN	O
differentiate	NN	O
children	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
ADHD	NNP	O
and	CC	O
ASD+ADHD	NNP	O
.	.	O

Children	NNP	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
demonstrate	VBP	O
face	NN	O
processing	NN	O
abnormalities	NNS	O
that	WDT	O
may	MD	O
underlie	VB	O
social	JJ	O
impairment	NN	O
.	.	O

Despite	IN	O
substantial	JJ	O
overlap	NN	O
between	IN	O
ASD	NNP	O
and	CC	O
ADHD	NNP	O
,	,	O
ERP	NNP	O
markers	NNS	O
of	IN	O
face	NN	O
and	CC	O
gaze	NN	O
processing	NN	O
have	VBP	O
not	RB	O
been	VBN	O
directly	RB	O
compared	VBN	O
across	IN	O
pure	NN	O
and	CC	O
comorbid	NN	O
cases	NNS	O
.	.	O

Children	NNP	O
with	IN	O
ASD	NNP	O
(	(	O
n=19	NN	O
)	)	O
,	,	O
ADHD	NNP	O
(	(	O
n=18	NN	O
)	)	O
,	,	O
comorbid	JJ	O
ASD+ADHD	NNP	O
(	(	O
n=29	NN	O
)	)	O
and	CC	O
typically	RB	O
developing	VBG	O
(	(	O
TD	NNP	O
)	)	O
controls	NNS	O
(	(	O
n=26	NN	O
)	)	O
were	VBD	O
presented	VBN	O
with	IN	O
upright/inverted	JJ	PS
faces	VBZ	PS
with	IN	PS
direct/averted	VBN	PS
gaze	NN	PS
,	,	O
with	IN	O
concurrent	JJ	O
recording	NN	O
of	IN	O
the	DT	O
P1	NNP	O
and	CC	O
N170	NNP	O
components	NNS	O
.	.	O

While	IN	O
the	DT	O
N170	NNP	O
was	VBD	O
predominant	VBN	O
in	IN	O
the	DT	O
right	NN	O
hemisphere	NN	O
in	IN	O
TD	NNP	O
and	CC	O
ADHD	NNP	O
,	,	O
children	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
ASD/ASD+ADHD	NNP	O
)	)	O
showed	VBD	O
a	DT	O
bilateral	JJ	O
distribution	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
children	NNS	O
with	IN	O
ASD	NNP	O
demonstrated	VBD	O
altered	JJ	O
response	NN	O
to	TO	O
gaze	VB	O
direction	NN	O
on	IN	O
P1	NNP	O
latency	NN	O
and	CC	O
no	DT	O
sensitivity	NN	O
to	TO	O
gaze	VB	O
direction	NN	O
on	IN	O
midline-N170	JJ	O
amplitude	NN	O
compared	VBN	O
to	TO	O
TD	NNP	O
and	CC	O
ADHD	NNP	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
children	NNS	O
with	IN	O
ADHD	NNP	O
(	(	O
ADHD/ASD+ADHD	NNP	O
)	)	O
exhibited	VBD	O
a	DT	O
reduced	JJ	O
face	NN	O
inversion	NN	O
effect	NN	O
on	IN	O
P1	NNP	O
latency	NN	O
compared	VBN	O
to	TO	O
TD	NNP	O
and	CC	O
ASD	NNP	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
children	NNS	O
with	IN	O
ASD	NNP	O
have	VBP	O
specific	JJ	O
abnormalities	NNS	O
in	IN	O
gaze	NN	O
processing	NN	O
and	CC	O
altered	JJ	O
neural	JJ	O
specialisation	NN	O
,	,	O
whereas	JJ	O
children	NNS	O
with	IN	O
ADHD	NNP	O
show	NN	O
abnormalities	NNS	O
at	IN	O
early	JJ	O
visual	JJ	O
attention	NN	O
stages	NNS	O
.	.	O

Children	NNP	O
with	IN	O
ASD+ADHD	NNP	O
are	VBP	O
an	DT	O
additive	JJ	O
co-occurrence	NN	O
with	IN	O
deficits	NNS	O
of	IN	O
both	DT	O
disorders	NNS	O
.	.	O

Elucidating	VBG	O
the	DT	O
neural	JJ	O
basis	NN	O
of	IN	O
the	DT	O
overlap	NN	O
between	IN	O
ASD	NNP	O
and	CC	O
ADHD	NNP	O
is	VBZ	O
likely	JJ	O
to	TO	O
inform	VB	O
aetiological	JJ	O
investigation	NN	O
and	CC	O
clinical	JJ	O
assessment	NN	O
.	.	O

Long-term	JJ	O
survival	NN	O
in	IN	O
a	DT	O
phase	NN	O
III	NNP	O
,	,	O
randomised	VBD	O
study	NN	O
of	IN	O
topotecan	JJ	PM
versus	NN	O
paclitaxel	NN	PM
in	IN	O
advanced	JJ	O
epithelial	JJ	O
ovarian	JJ	O
carcinoma	NN	O
.	.	O

BACKGROUND	IN	O
We	PRP	O
have	VBP	O
continued	VBN	O
to	TO	O
monitor	VB	O
the	DT	O
survival	NN	O
of	IN	O
patients	NNS	O
randomised	VBN	O
in	IN	O
a	DT	O
previously	RB	O
reported	VBN	O
multicentre	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
of	IN	O
topotecan	JJ	PM
versus	NN	O
paclitaxel	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
epithelial	JJ	O
ovarian	JJ	O
cancer	NN	O
who	WP	O
had	VBD	O
failed	VBN	O
one	CD	O
prior	JJ	O
platinum-based	JJ	O
regimen	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
with	IN	O
bidimensionally	RB	O
measurable	JJ	O
disease	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
topotecan	VB	PM
(	(	O
1.5	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
for	IN	O
5	CD	O
days	NNS	O
)	)	O
or	CC	O
paclitaxel	NN	PM
(	(	O
175	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
as	IN	O
a	DT	O
3-h	JJ	O
infusion	NN	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
treatment	NN	O
with	IN	O
the	DT	O
alternate	NN	O
therapy	NN	O
at	IN	O
third	JJ	O
line	NN	O
.	.	O

The	DT	O
European	JJ	O
Organisation	NNP	O
for	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
(	(	O
EORTC	NNP	O
QOL	NNP	O
)	)	O
-C30	VBP	O
questionnaire	NN	O
was	VBD	O
also	RB	O
used	VBN	O
to	TO	O
measure	VB	O
eight	CD	O
symptoms	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
during	IN	O
each	DT	O
course	NN	O
(	(	O
pain	NN	O
,	,	O
anorexia	NN	O
,	,	O
diarrhoea	NN	O
,	,	O
fatigue	NN	O
,	,	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
dyspnea	NN	O
,	,	O
constipation	NN	O
and	CC	O
insomnia	NN	O
)	)	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
226	CD	O
patients	NNS	O
were	VBD	O
evaluable	JJ	O
for	IN	O
response	NN	O
.	.	O

Demographic	JJ	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
as	IN	O
were	VBD	O
results	NNS	O
of	IN	O
the	DT	O
EORTC	NNP	O
QOL-30	NNP	O
questionnaire	NN	O
.	.	O

For	IN	O
the	DT	O
topotecan	JJ	PM
group	NN	O
,	,	O
median	JJ	O
time	NN	O
to	TO	O
progression	NN	O
was	VBD	O
18.9	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
92.6+	CD	O
weeks	NNS	O
;	:	O
25	CD	O
%	NN	O
censored	VBN	O
)	)	O
,	,	O
and	CC	O
,	,	O
for	IN	O
paclitaxel	NN	PM
,	,	O
14.7	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
137.3+	CD	O
weeks	NNS	O
;	:	O
12.3	CD	O
%	NN	O
censored	VBN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.076	CD	O
.	.	O

At	IN	O
4	CD	O
years	NNS	O
post-randomisation	NN	O
,	,	O
median	JJ	O
survival	NN	O
in	IN	O
the	DT	O
topotecan	JJ	PM
group	NN	O
was	VBD	O
63.0	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
238.4+	CD	O
weeks	NNS	O
;	:	O
20.5	CD	O
%	NN	O
censored	VBN	O
)	)	O
and	CC	O
,	,	O
for	IN	O
paclitaxel	NN	PM
,	,	O
53.0	CD	O
weeks	NNS	O
(	(	O
range	NN	O
<	RB	O
1	CD	O
to	TO	O
226.3+	CD	O
weeks	NNS	O
;	:	O
12.3	CD	O
%	NN	O
censored	VBN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.44	CD	O
.	.	O

CONCLUSION	NNP	O
Topotecan	NNP	PM
continues	VBZ	O
to	TO	O
demonstrate	VB	O
comparable	JJ	O
efficacy	NN	O
and	CC	O
survival	NN	O
to	TO	O
paclitaxel	VB	PM
with	IN	O
manageable	JJ	O
and	CC	O
non-cumulative	JJ	O
haematological	JJ	O
toxicity	NN	O
.	.	O

Non-haematological	JJ	O
toxicity	NN	O
was	VBD	O
generally	RB	O
mild	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
long-term	JJ	O
survival	NN	O
rate	NN	O
indicates	VBZ	O
substantial	JJ	O
therapeutic	JJ	O
benefit	NN	O
for	IN	O
this	DT	O
group	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
topotecan	JJ	PM
at	IN	O
relapse	NN	O
of	IN	O
ovarian	JJ	O
cancer	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
audiotapes	NNS	E
in	IN	O
promoting	VBG	O
psychological	JJ	O
well-being	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

Open	VB	O
or	CC	O
uncontrolled	JJ	O
studies	NNS	O
have	VBP	O
suggested	VBN	O
that	IN	O
providing	VBG	O
cancer	NN	O
patients	NNS	O
with	IN	O
audiotapes	NNS	E
of	IN	O
their	PRP$	O
clinical	JJ	O
interviews	NNS	O
can	MD	O
improve	VB	O
information	NN	O
recall	NN	O
and	CC	O
reduce	VB	O
psychological	JJ	O
distress	NN	O
.	.	O

We	PRP	O
tested	VBD	O
these	DT	O
hypotheses	NNS	O
in	IN	O
a	DT	O
'clinician-blind	JJ	O
'	''	O
,	,	O
prospective	JJ	O
,	,	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
117	CD	O
patients	NNS	O
newly	RB	O
referred	VBN	O
to	TO	O
a	DT	O
medical	JJ	O
oncology	NN	O
clinic	NN	O
who	WP	O
were	VBD	O
to	TO	O
be	VB	O
given	VBN	O
'bad	CD	O
news	NN	O
'	POS	O
had	VBD	O
their	PRP$	O
consultations	NNS	O
audiotaped	VBN	E
.	.	O

Blind	NNP	O
to	TO	O
the	DT	O
clinician	JJ	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
a	DT	O
copy	NN	E
of	IN	E
the	DT	E
tape	NN	E
to	TO	E
play	VB	E
at	IN	E
home	NN	E
or	CC	E
not	RB	E
(	(	E
control	VB	E
group	NN	E
)	)	E
.	.	O

At	IN	O
6	CD	O
months	NNS	O
follow-up	JJ	O
,	,	O
tape	NN	O
group	NN	O
patients	NNS	O
reported	VBD	O
positive	JJ	O
attitudes	NNS	O
to	TO	O
the	DT	O
audiotape	NN	E
and	CC	O
were	VBD	O
shown	VBN	O
to	TO	O
recall	VB	O
significantly	RB	O
more	JJR	O
information	NN	O
about	IN	O
their	PRP$	O
illness	NN	O
than	IN	O
did	VBD	O
controls	NNS	O
.	.	O

Overall	JJ	O
improvement	NN	O
in	IN	O
psychological	JJ	O
distress	NN	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
months	NNS	O
follow-up	RB	O
,	,	O
as	IN	O
measured	VBN	O
with	IN	O
the	DT	O
30-item	JJ	O
General	NNP	O
Health	NNP	O
Questionnaire	NNP	O
and	CC	O
the	DT	O
Hospital	NNP	O
Anxiety	NNP	O
and	CC	O
Depression	NNP	O
Scale	NNP	O
was	VBD	O
no	DT	O
different	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
a	DT	O
second-order	JJ	O
interaction	NN	O
suggested	VBD	O
that	IN	O
poor-prognosis	NN	O
patients	NNS	O
were	VBD	O
disadvantaged	VBN	O
specifically	RB	O
by	IN	O
access	NN	O
to	TO	O
the	DT	O
audiotape	NN	O
,	,	O
with	IN	O
less	JJR	O
improvement	NN	O
in	IN	O
psychological	JJ	O
distress	NN	O
at	IN	O
6	CD	O
months	NNS	O
follow-up	JJ	O
than	IN	O
non-tape	JJ	O
controls	NNS	O
.	.	O

Patient	JJ	O
access	NN	O
to	TO	O
audiotapes	NNS	E
of	IN	O
clinical	JJ	O
interviews	NNS	O
promotes	VBZ	O
factual	JJ	O
retention	NN	O
but	CC	O
does	VBZ	O
not	RB	O
reliably	RB	O
reduce	VB	O
psychological	JJ	O
distress	NN	O
and	CC	O
may	MD	O
be	VB	O
actively	RB	O
unhelpful	JJ	O
in	IN	O
some	DT	O
subgroups	NNS	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
cost-effectiveness	NN	O
of	IN	O
parasitologic	JJ	O
diagnosis	NN	O
for	IN	O
malaria-suspected	JJ	O
patients	NNS	O
in	IN	O
an	DT	O
era	NN	O
of	IN	O
combination	NN	O
therapy	NN	O
.	.	O

The	DT	O
introduction	NN	O
of	IN	O
artemisinin-based	JJ	PM
combination	NN	PM
therapy	NN	PM
in	IN	O
sub-Saharan	NN	O
Africa	NNP	O
has	VBZ	O
prompted	VBN	O
calls	NNS	O
for	IN	O
increased	VBN	O
use	NN	O
of	IN	O
parasitologic	JJ	O
diagnosis	NN	O
for	IN	O
malaria	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
cost-effectiveness	NN	O
of	IN	O
rapid	JJ	PH
diagnostic	JJ	PH
tests	NNS	PH
(	(	PH
RDTs	NNP	PH
)	)	PH
in	IN	O
comparison	NN	O
to	TO	O
microscopy	VB	Ot
in	IN	O
guiding	VBG	O
treatment	NN	O
of	IN	O
non-severe	JJ	O
febrile	JJ	O
illness	NN	O
at	IN	O
varying	VBG	O
levels	NNS	O
of	IN	O
malaria	NN	O
endemicity	NN	O
using	VBG	O
data	NNS	O
on	IN	O
test	NN	O
accuracy	NN	O
and	CC	O
costs	NNS	O
collected	VBN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
Tanzanian	JJ	O
trial	NN	O
.	.	O

If	IN	O
prescribers	NNS	O
complied	VBD	O
with	IN	O
current	JJ	O
guidelines	NNS	O
,	,	O
microscopy	NN	O
would	MD	O
give	VB	O
rise	NN	O
to	TO	O
lower	JJR	O
average	NN	O
costs	NNS	O
per	IN	O
patient	NN	O
correctly	RB	O
treated	VBD	O
than	IN	O
RDTs	NNP	O
in	IN	O
areas	NNS	O
of	IN	O
both	DT	O
high	JJ	O
and	CC	O
low	JJ	O
transmission	NN	O
.	.	O

RDT	NNP	O
introduction	NN	O
would	MD	O
result	VB	O
in	IN	O
an	DT	O
additional	JJ	O
2.3	CD	O
%	NN	O
and	CC	O
9.4	CD	O
%	NN	O
of	IN	O
patients	NNS	O
correctly	RB	O
treated	VBN	O
,	,	O
at	IN	O
an	DT	O
incremental	JJ	O
cost	NN	O
of	IN	O
$	$	O
25	CD	O
and	CC	O
$	$	O
7	CD	O
in	IN	O
the	DT	O
low	JJ	O
and	CC	O
high	JJ	O
transmission	NN	O
settings	NNS	O
,	,	O
respectively	RB	O
.	.	O

Cost-effectiveness	NNP	O
would	MD	O
be	VB	O
worse	JJR	O
if	IN	O
prescribers	NNS	O
do	VBP	O
not	RB	O
comply	VB	O
with	IN	O
test	NN	O
results	NNS	O
.	.	O

The	DT	O
cost	NN	O
of	IN	O
this	DT	O
additional	JJ	O
benefit	NN	O
may	MD	O
be	VB	O
higher	JJR	O
than	IN	O
many	JJ	O
countries	NNS	O
can	MD	O
afford	VB	O
without	IN	O
external	JJ	O
assistance	NN	O
or	CC	O
lower	JJR	O
RDT	NNP	O
prices	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
hydraulic	JJ	O
circuit	NN	O
training	NN	O
on	IN	O
cardiovascular	JJ	O
function	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hydraulic	JJ	O
circuit	NN	O
training	NN	O
(	(	O
HCT	NNP	O
)	)	O
on	IN	O
cardiovascular	NN	O
(	(	O
CV	NNP	O
)	)	O
function	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
32	CD	O
healthy	JJ	O
middle-aged	JJ	O
males	NNS	O
(	(	O
X	JJ	O
age	NN	O
=	VBD	O
42.2	CD	O
+/-	JJ	O
2.1	CD	O
yr	NN	O
)	)	O
.	.	O

Maximal	NNP	O
aerobic	JJ	O
power	NN	O
(	(	O
VO2max	NNP	O
)	)	O
,	,	O
with	IN	O
simultaneous	JJ	O
measurement	NN	O
of	IN	O
stroke	NN	O
volume	NN	O
(	(	O
SV	NNP	O
)	)	O
and	CC	O
cardiac	JJ	O
output	NN	O
(	(	O
CO	NNP	O
)	)	O
,	,	O
by	IN	O
impedance	NN	O
cardiography	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
pre-	JJ	O
and	CC	O
post-training	JJ	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
nonexercising	JJ	C
control	NN	C
group	NN	C
,	,	C
a	DT	PH
cycle	NN	PH
training	NN	PH
group	NN	PH
(	(	PH
cycle	NN	PH
)	)	PH
,	,	C
or	CC	PH
one	CD	PH
of	IN	PH
the	DT	PH
two	CD	PH
HCT	NNP	PH
groups	NNS	PH
.	.	O

Training	VBG	E
groups	NNS	E
participated	VBN	E
in	IN	E
a	DT	E
9	CD	E
wk	NN	E
program	NN	E
,	,	E
3	CD	E
d.wk-1	NN	E
.	.	O

Subjects	NNS	PH
assigned	VBD	PH
to	TO	PH
HCT	NNP	PH
exercised	VBN	PH
on	IN	PH
a	DT	PH
9	CD	PH
station	NN	PH
circuit	NN	PH
,	,	PH
completing	VBG	PH
3	CD	PH
circuits.d-1	JJ	PH
.	.	O

Each	DT	O
circuit	NN	O
consisted	VBD	O
of	IN	O
three	CD	O
20	CD	O
s	JJ	O
work	NN	O
intervals	NNS	O
at	IN	O
each	DT	O
station	NN	O
with	IN	O
a	DT	O
1:1	CD	O
work	NN	O
:	:	O
rest	NN	O
ratio	NN	O
.	.	O

One	CD	O
HCT	NNP	O
group	NN	O
(	(	O
HCTmax	NNP	O
)	)	O
completed	VBD	O
the	DT	O
maximal	JJ	O
repetitions	NNS	O
possible	JJ	O
(	(	O
RM	NNP	O
)	)	O
during	IN	O
each	DT	O
work	NN	O
interval	NN	O
.	.	O

The	DT	O
other	JJ	O
HCT	NNP	O
group	NN	O
(	(	O
HCTsub	NNP	O
)	)	O
exercised	VBD	O
at	IN	O
70-85	CD	O
%	NN	O
of	IN	O
RM	NNP	O
.	.	O

Following	VBG	O
training	NN	O
VO2max	NNP	O
(	(	O
ml.kg-1	JJ	O
min-1	NN	O
)	)	O
was	VBD	O
significantly	RB	O
increased	VBN	O
in	IN	O
all	DT	O
training	NN	O
groups	NNS	O
(	(	O
18.0	CD	O
,	,	O
12.5	CD	O
,	,	O
and	CC	O
11.3	CD	O
%	NN	O
for	IN	O
cycle	NN	O
,	,	O
HCTsub	NNP	O
,	,	O
and	CC	O
HCTmax	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
VO2max	NNP	O
observed	VBD	O
in	IN	O
the	DT	O
cycle	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
that	DT	O
recorded	VBN	O
by	IN	O
the	DT	O
two	CD	O
HCT	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

For	IN	O
all	DT	O
three	CD	O
training	VBG	O
groups	NNS	O
,	,	O
the	DT	O
increase	NN	O
in	IN	O
VO2max	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
increases	NNS	O
in	IN	O
SVmax	NNP	O
and	CC	O
COmax	NNP	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
both	DT	O
maximal	JJ	O
and	CC	O
submaximal	JJ	O
HCT	NNP	O
programs	NNS	O
can	MD	O
elicit	VB	O
improvements	NNS	O
in	IN	O
cardiovascular	JJ	O
fitness	NN	O
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBD	O
study	NN	O
of	IN	O
various	JJ	O
agents	NNS	O
for	IN	O
endoscopic	NN	O
injection	NN	O
sclerotherapy	NN	O
of	IN	O
bleeding	VBG	O
canine	NN	O
gastric	JJ	O
varices	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
relative	JJ	O
efficacy	NN	O
and	CC	O
technical	JJ	O
ease	NN	O
of	IN	O
use	NN	O
of	IN	O
eight	CD	O
different	JJ	O
agents	NNS	O
for	IN	O
endoscopic	JJ	O
hemostasis	NN	O
and	CC	O
obliteration	NN	O
of	IN	O
bleeding	VBG	O
gastric	JJ	O
varices	NNS	O
in	IN	O
a	DT	O
canine	NN	O
model	NN	O
,	,	O
as	IN	O
no	DT	O
comparative	JJ	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
gastric	JJ	O
variceal	NN	O
sclerotherapy	NN	O
.	.	O

Large	JJ	O
bleeding	VBG	O
gastric	JJ	O
varices	NNS	O
in	IN	O
20	CD	O
heparinized	JJ	O
dogs	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
endoscopic	VB	O
injection	NN	O
treatment	NN	O
with	IN	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
agents	NNS	O
:	:	O
cyanoacrylate	NN	PM
;	:	O
a	DT	PM
1:1:1	CD	PM
mixture	NN	PM
of	IN	PM
sodium	NN	PM
tetradecyl	NN	PM
sulfate	VBP	PM
3	CD	PM
%	NN	PM
,	,	PM
ethanol	RB	PM
98	CD	PM
%	NN	PM
,	,	PM
and	CC	PM
normal	JJ	PM
saline	JJ	PM
solution	NN	PM
;	:	O
ethanolamine	VB	PM
oleate	VBP	PM
5	CD	PM
%	NN	PM
;	:	O
sodium	NN	PM
morrhuate	VBP	PM
5	CD	PM
%	NN	PM
;	:	PM
sodium	NN	PM
tetradecyl	NN	PM
sulfate	VBP	PM
1.5	CD	PM
%	NN	PM
;	:	PM
polidocanol	CC	PM
1	CD	PM
%	NN	PM
;	:	O
normal	JJ	PM
saline	JJ	PM
solution	NN	PM
with	IN	PM
epinephrine	JJ	PM
1:10,000	CD	PM
;	:	O
or	CC	O
normal	JJ	C
saline	JJ	C
solution	NN	C
(	(	C
control	NN	C
)	)	C
.	.	C

The	DT	O
number	NN	O
and	CC	O
volume	NN	O
of	IN	O
injections	NNS	O
and	CC	O
the	DT	O
time	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
complete	JJ	O
hemostasis	NN	O
were	VBD	O
evaluated	VBN	O
;	:	O
follow-up	JJ	O
endoscopy	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
1	CD	O
month	NN	O
to	TO	O
assess	VB	O
gastric	JJ	O
variceal	NN	O
obliteration	NN	O
.	.	O

Cyanoacrylate	NNP	O
was	VBD	O
the	DT	O
best	JJS	O
agent	NN	O
overall	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
immediate	JJ	O
efficacy	NN	O
,	,	O
low	JJ	O
volume	NN	O
requirement	NN	O
,	,	O
time	NN	O
required	VBN	O
for	IN	O
initial	JJ	O
hemostasis	NN	O
,	,	O
and	CC	O
reduction	NN	O
of	IN	O
gastric	JJ	O
variceal	NN	O
size	NN	O
.	.	O

Cyanoacrylate	NNP	O
,	,	O
tetradecyl	NN	O
sulfate	NN	O
,	,	O
and	CC	O
polidocanol	NN	O
were	VBD	O
the	DT	O
most	RBS	O
effective	JJ	O
agents	NNS	O
for	IN	O
reducing	VBG	O
gastric	JJ	O
variceal	NN	O
size	NN	O
.	.	O

Epinephrine	NNP	O
was	VBD	O
effective	JJ	O
for	IN	O
controlling	VBG	O
induced	JJ	O
or	CC	O
secondary	JJ	O
bleeding	NN	O
caused	VBN	O
by	IN	O
puncture	NN	O
of	IN	O
the	DT	O
gastric	JJ	O
varices	NNS	O
with	IN	O
the	DT	O
sclerotherapy	NN	O
needle	NN	O
during	IN	O
intravariceal	JJ	O
injections	NNS	O
.	.	O

Ongoing	VBG	O
studies	NNS	O
are	VBP	O
evaluating	VBG	O
combinations	NNS	O
of	IN	O
agents	NNS	O
with	IN	O
different	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
,	,	O
such	JJ	O
as	IN	O
epinephrine	NN	O
(	(	O
for	IN	O
vasoconstriction	NN	O
to	TO	O
minimize	VB	O
secondary	JJ	O
bleeding	NN	O
)	)	O
plus	CC	O
alcohol	NN	O
,	,	O
and/or	JJ	O
tetradecyl	NN	O
sulfate	NN	O
(	(	O
for	IN	O
variceal	NN	O
thrombosis	NN	O
and	CC	O
sclerosis	NN	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Histamine	NNP	O
intolerance-like	NN	O
symptoms	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
after	IN	O
oral	JJ	O
provocation	NN	O
with	IN	O
liquid	JJ	O
histamine	NN	O
.	.	O

Histamine	NNP	O
in	IN	O
food	NN	O
at	IN	O
non-toxic	JJ	O
doses	NNS	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
to	TO	O
be	VB	O
a	DT	O
major	JJ	O
cause	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
causing	NN	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	O
,	,	O
hypotension	NN	O
,	,	O
headache	NN	O
,	,	O
pruritus	NN	O
and	CC	O
flush	NN	O
(	(	O
histamine	JJ	O
intolerance	NN	O
)	)	O
.	.	O

Histamine-rich	JJ	O
foods	NNS	O
such	JJ	O
as	IN	O
cheese	NN	O
,	,	O
sausages	NNS	O
,	,	O
sauerkraut	NN	O
,	,	O
tuna	NN	O
,	,	O
tomatoes	NNS	O
,	,	O
and	CC	O
alcoholic	JJ	O
beverages	NNS	O
may	MD	O
contain	VB	O
histamine	VB	O
up	IN	O
to	TO	O
500	CD	O
mg/kg	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
cross-over	NN	O
study	NN	O
in	IN	O
10	CD	O
healthy	JJ	O
females	NNS	O
(	(	O
age	NN	O
range	NN	O
22-36	CD	O
years	NNS	O
,	,	O
mean	JJ	O
29.1	CD	O
+/-	JJ	O
5.4	CD	O
)	)	O
who	WP	O
were	VBD	O
hospitalized	VBN	O
and	CC	O
challenged	VBN	O
on	IN	O
two	CD	O
consecutive	JJ	O
days	NNS	O
with	IN	O
placebo	NN	C
(	(	C
peppermint	JJ	C
tea	NN	C
)	)	C
or	CC	O
75	CD	O
mg	NN	O
of	IN	O
pure	JJ	O
histamine	NN	PM
(	(	O
equaling	VBG	O
124	CD	O
mg	JJ	O
histamine	NN	O
dihydrochloride	NN	O
,	,	O
dissolved	VBN	O
in	IN	O
peppermint	NN	O
tea	NN	O
)	)	O
.	.	O

Objective	JJ	O
parameters	NNS	O
(	(	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
temperature	NN	O
,	,	O
peak	VB	O
flow	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
total	JJ	O
clinical	JJ	O
symptom	NN	O
score	NN	O
using	VBG	O
a	DT	O
standardized	VBN	O
protocol	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
received	VBD	O
a	DT	O
histamine-free	JJ	PM
diet	NN	PM
also	RB	O
low	JJ	O
in	IN	O
allergen	NN	O
24	CD	O
hours	NNS	O
before	IN	O
hospitalization	NN	O
and	CC	O
over	IN	O
the	DT	O
whole	JJ	O
observation	NN	O
period	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
histamine	NN	O
and	CC	O
the	DT	O
histamine-degrading	JJ	O
enzyme	NN	O
diamine	NN	O
oxidase	NN	O
(	(	O
DAO	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

After	IN	O
histamine	JJ	O
challenge	NN	O
,	,	O
5	CD	O
of	IN	O
10	CD	O
subjects	NNS	O
showed	VBD	O
no	DT	O
reaction	NN	O
.	.	O

One	CD	O
individual	NN	O
experienced	VBD	O
tachycardia	NN	O
,	,	O
mild	JJ	O
hypotension	NN	O
after	IN	O
20	CD	O
minutes	NNS	O
,	,	O
sneezing	VBG	O
,	,	O
itching	NN	O
of	IN	O
the	DT	O
nose	NN	O
,	,	O
and	CC	O
rhinorrhea	NN	O
after	IN	O
60	CD	O
minutes	NNS	O
.	.	O

Four	CD	O
subjects	NNS	O
experienced	VBD	O
delayed	JJ	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	O
(	(	O
4x	CD	O
)	)	O
,	,	O
flatulence	NN	O
(	(	O
3x	CD	O
)	)	O
,	,	O
headache	NN	O
(	(	O
3x	CD	O
)	)	O
,	,	O
pruritus	NN	O
(	(	O
2x	CD	O
)	)	O
and	CC	O
ocular	JJ	O
symptoms	NNS	O
(	(	O
1x	CD	O
)	)	O
starting	VBG	O
3	CD	O
to	TO	O
24	CD	O
hours	NNS	O
after	IN	O
provocation	NN	O
.	.	O

No	DT	O
subject	NN	O
reacted	VBD	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
histamine	NN	O
and	CC	O
DAO	NNP	O
levels	NNS	O
within	IN	O
the	DT	O
first	JJ	O
80	CD	O
minutes	NNS	O
in	IN	O
non-reactors	NNS	O
as	RB	O
well	RB	O
as	IN	O
reactors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
challenge	NN	O
with	IN	O
histamine	JJ	O
versus	NN	O
challenge	NN	O
with	IN	O
placebo	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
75	CD	O
mg	NN	O
of	IN	O
pure	NN	O
liquid	JJ	O
oral	JJ	O
histamine	NN	O
--	:	O
a	DT	O
dose	JJ	O
found	VBN	O
in	IN	O
normal	JJ	O
meals	NNS	O
--	:	O
can	MD	O
provoke	VB	O
immediate	JJ	O
as	RB	O
well	RB	O
as	IN	O
delayed	VBN	O
symptoms	NNS	O
in	IN	O
50	CD	O
%	NN	O
of	IN	O
healthy	JJ	O
females	NNS	O
without	IN	O
a	DT	O
history	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
.	.	O

The	DT	O
NORwegian	JJ	O
study	NN	O
on	IN	O
DIstrict	NNP	O
treatment	NN	O
of	IN	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
(	(	O
NORDISTEMI	NNP	O
)	)	O
.	.	O

OBJECTIVES	NNP	O
Thrombolysis	NNP	O
is	VBZ	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
patients	NNS	O
with	IN	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
(	(	O
STEMI	NNP	O
)	)	O
living	NN	O
in	IN	O
rural	JJ	O
areas	NNS	O
with	IN	O
long	JJ	O
transfer	NN	O
delays	NNS	O
to	TO	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

This	DT	O
trial	NN	O
compares	VBZ	O
two	CD	O
different	JJ	O
strategies	NNS	O
following	VBG	O
thrombolysis	NN	O
:	:	O
to	TO	O
transfer	VB	O
all	DT	O
patients	NNS	O
for	IN	O
immediate	JJ	O
coronary	JJ	O
angiography	NN	O
and	CC	O
intervention	NN	O
,	,	O
or	CC	O
to	TO	O
manage	VB	O
the	DT	O
patients	NNS	O
more	RBR	O
conservatively	RB	O
.	.	O

DESIGN	VB	O
The	DT	O
NORwegian	JJ	O
study	NN	O
on	IN	O
DIstrict	NNP	O
treatment	NN	O
of	IN	O
STEMI	NNP	O
(	(	O
NORDISTEMI	NNP	O
)	)	O
is	VBZ	O
an	DT	O
open	JJ	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
STEMI	NNP	O
of	IN	O
less	JJR	O
than	IN	O
6	CD	O
hours	NNS	O
of	IN	O
duration	NN	O
and	CC	O
more	JJR	O
than	IN	O
90	CD	O
minutes	NNS	O
expected	VBD	O
time	NN	O
delay	NN	O
to	TO	O
PCI	NNP	S
.	.	O

A	NNP	O
total	NN	O
of	IN	O
266	CD	O
patients	NNS	O
will	MD	O
receive	VB	PH
full-dose	JJ	PM
thrombolysis	NN	PM
,	,	O
preferably	RB	O
pre-hospital	JJ	O
,	,	O
and	CC	O
then	RB	O
be	VB	O
randomized	VBN	O
to	TO	O
either	DT	O
strategy	NN	O
.	.	O

Our	PRP$	O
primary	JJ	O
endpoint	NN	O
is	VBZ	O
the	DT	O
one	CD	O
year	NN	O
combined	VBN	O
incidence	NN	O
of	IN	O
death	NN	O
,	,	O
reinfarction	NN	O
,	,	O
stroke	VBD	O
or	CC	O
new	JJ	O
myocardial	JJ	O
ischaemia	NN	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00161005	NNP	O
.	.	O

RESULTS	VBN	O
By	IN	O
April	NNP	O
2006	CD	O
,	,	O
109	CD	O
patients	NNS	O
have	VBP	O
been	VBN	O
randomized	VBN	O
.	.	O

Thrombolysis	NN	O
has	VBZ	O
been	VBN	O
given	VBN	O
pre-hospital	JJ	O
to	TO	O
52	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
median	JJ	O
transport	NN	O
distance	NN	O
from	IN	O
first	JJ	O
medical	JJ	O
contact	NN	O
to	TO	O
catheterization	NN	O
laboratory	NN	O
was	VBD	O
155	CD	O
km	NN	O
(	(	O
range	JJ	O
90-396	CD	O
km	NN	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
are	VBP	O
expected	VBN	O
in	IN	O
2008	CD	O
.	.	O

Bradykinin-induced	JJ	O
cough	NN	O
reflex	NN	O
markedly	RB	O
increases	VBZ	O
in	IN	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
captopril	NN	O
and	CC	O
enalapril	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
angiotensin	NN	PM
converting	VBG	PM
enzyme	NN	PM
(	(	PM
ACE	NNP	PM
)	)	PM
inhibitors	NNS	PM
on	IN	O
cough	NN	PM
responses	NNS	PM
to	TO	PM
bradykinin	VB	PM
(	(	PM
BK	NNP	PM
)	)	PM
,	,	O
substance	NN	PM
P	NNP	PM
(	(	PM
SP	NNP	PM
)	)	PM
and	CC	O
citric	JJ	PM
acid	NN	PM
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
random	NN	O
study	NN	O
on	IN	O
10	CD	O
hypertensive	JJ	O
patients	NNS	O
receiving	VBG	O
ACE	NNP	PM
inhibitors	NNS	PM
.	.	O

Of	IN	O
these	DT	O
patients	NNS	O
,	,	O
five	CD	O
had	VBD	O
reported	VBN	O
cough	NN	O
with	IN	O
ACE	NNP	PM
inhibitors	NNS	PM
.	.	O

Cough	NNP	O
responses	VBZ	O
to	TO	O
citric	VB	O
acid	NN	O
were	VBD	O
similar	JJ	O
between	IN	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
cough	NN	O
,	,	O
and	CC	O
SP	NNP	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
subjects	NNS	O
.	.	O

BK	NNP	PM
caused	VBD	O
cough	NN	O
at	IN	O
13.4	CD	O
+/-	JJ	O
1.2	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
in	IN	O
5	CD	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
ACE	NNP	PM
inhibitors	NNS	PM
,	,	O
but	CC	O
it	PRP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
at	IN	O
concentrations	NNS	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
in	IN	O
other	JJ	O
5	CD	O
patients	NNS	O
.	.	O

One	CD	O
month	NN	O
after	IN	O
the	DT	O
withdrawal	NN	O
of	IN	O
ACE	NNP	O
inhibitors	NNS	O
,	,	O
5	CD	O
patients	NNS	O
were	VBD	O
free	JJ	O
from	IN	O
cough	NN	O
symptoms	NNS	O
,	,	O
and	CC	O
BK	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
in	IN	O
these	DT	O
patients	NNS	O
,	,	O
except	IN	O
for	IN	O
one	CD	O
who	WP	O
coughed	VBD	O
at	IN	O
10	CD	O
(	(	O
-9	NN	O
)	)	O
M	NNP	O
,	,	O
without	IN	O
changes	NNS	O
in	IN	O
responses	NNS	O
to	TO	O
citric	VB	O
acid	NN	O
.	.	O

BK	NNP	O
caused	VBD	O
cough	NN	O
at	IN	O
14.3	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
although	IN	O
BK1-7	NNP	O
,	,	O
a	DT	O
major	JJ	O
metabolite	NN	O
of	IN	O
BK	NNP	O
by	IN	O
ACE	NNP	O
,	,	O
caused	VBD	O
cough	NN	O
at	IN	O
5.7	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
in	IN	O
another	DT	O
3	CD	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
ACE	NNP	O
inhibitor	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
impaired	JJ	O
metabolism	NN	O
of	IN	O
BK	NNP	O
induced	VBN	O
by	IN	O
ACE	NNP	O
inhibitors	NNS	O
may	MD	O
relate	VB	O
to	TO	O
the	DT	O
manifestation	NN	O
of	IN	O
cough	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
receiving	VBG	O
ACE	NNP	O
inhibitors	NNS	O
.	.	O

Open	JJ	S
flap	NN	S
debridement	NN	S
with	IN	S
or	CC	S
without	IN	S
intentional	JJ	S
cementum	NN	S
removal	NN	S
:	:	S
a	DT	O
4-month	JJ	O
follow-up	NN	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
influence	NN	O
of	IN	O
cementum	NN	S
removal	NN	S
on	IN	S
periodontal	JJ	S
repair	NN	S
.	.	S

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Forty	NNP	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
periodontitis	NN	O
and	CC	O
presenting	NN	O
,	,	O
at	IN	O
least	JJS	O
,	,	O
two	CD	O
proximal	JJ	O
sites	NNS	O
in	IN	O
anterior	JJ	O
teeth	NNS	O
(	(	O
upper	JJ	O
or	CC	O
lower	JJR	O
)	)	O
with	IN	O
probing	VBG	O
depth	JJ	O
>	NN	O
or	CC	O
=5	JJ	O
mm	NNS	O
were	VBD	O
selected	VBN	O
.	.	O

After	IN	O
oral	JJ	O
hygiene	NN	O
instructions	NNS	O
and	CC	O
ultrasonic	JJ	O
supragingival	NN	O
instrumentation	NN	O
,	,	O
the	DT	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
for	IN	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
groups	NNS	O
:	:	O
CIC	NNP	S
,	,	S
scaled	VBD	S
with	IN	S
Gracey	NNP	S
curettes	NNS	S
;	:	S
CIUS	NNP	S
,	,	S
scaled	VBD	S
with	IN	S
ultrasonic	JJ	S
device	NN	S
;	:	O
CDC	NNP	S
,	,	S
calculus	JJ	S
deattachment	NN	S
with	IN	S
Gracey	NNP	S
curettes	NNS	S
and	CC	S
brushing	VBG	S
with	IN	S
saline	JJ	S
solution	NN	S
;	:	O
and	CC	O
CDUS	NNP	S
,	,	S
calculus	JJ	S
deattachment	NN	S
with	IN	S
ultrasonic	JJ	S
device	NN	S
and	CC	S
brushing	VBG	S
with	IN	S
saline	JJ	S
solution	NN	S
.	.	O

Full-thickness	JJ	O
flaps	NNS	O
were	VBD	O
reflected	VBN	O
and	CC	O
the	DT	O
instrumentation	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
a	DT	O
clinical	JJ	O
microscope	NN	O
.	.	O

Probing	VBG	O
depth	NN	O
(	(	O
PD	NNP	O
)	)	O
,	,	O
relative	JJ	O
gingival	NN	O
margin	NN	O
level	NN	O
(	(	O
RGML	NNP	O
)	)	O
and	CC	O
relative	JJ	O
attachment	NN	O
level	NN	O
(	(	O
RAL	NNP	O
)	)	O
were	VBD	O
registered	VBN	O
at	IN	O
five	CD	O
experimental	JJ	O
periods	NNS	O
:	:	O
baseline	NN	O
and	CC	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
and	CC	O
120	CD	O
days	NNS	O
postoperative	JJ	O
.	.	O

RESULTS	VB	O
All	PDT	O
the	DT	O
approaches	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
markedly	RB	O
reduce	VB	O
the	DT	O
PD	NNP	O
values	NNS	O
from	IN	O
the	DT	O
baseline	NN	O
to	TO	O
the	DT	O
other	JJ	O
evaluation	NN	O
periods	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
RGML	NNP	O
values	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
the	DT	O
CDUS	NNP	S
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
baseline	NN	O
and	CC	O
postoperative	JJ	O
values	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
for	IN	O
the	DT	O
RAL	NNP	O
changes	NNS	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
RAL	NNP	O
were	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
among	IN	O
the	DT	O
groups	NNS	O
CDC	NNP	S
and	CC	O
CDUS	NNP	S
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
conventional	JJ	S
scaling	NN	S
and	CC	S
root	NN	S
planing	NN	S
and	CC	S
the	DT	S
calculus	JJ	S
deattachment	NN	S
were	VBD	O
effective	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
probing	VBG	O
depth	NN	O
values	NNS	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
instrumentation	NN	O
method	NN	O
.	.	O

Exposure	NN	O
to	TO	O
the	DT	O
self-face	NN	PH
facilitates	VBZ	PH
identification	NN	O
of	IN	O
dynamic	JJ	O
facial	JJ	O
expressions	NNS	O
:	:	O
influences	NNS	O
on	IN	O
individual	JJ	O
differences	NNS	O
.	.	O

A	DT	O
growing	VBG	O
literature	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
self-face	NN	PH
is	VBZ	O
involved	VBN	O
in	IN	O
processing	VBG	O
the	DT	O
facial	JJ	O
expressions	NNS	O
of	IN	O
others	NNS	O
.	.	O

The	DT	O
authors	NNS	O
experimentally	RB	O
activated	VBD	O
self-face	JJ	PH
representations	NNS	PH
to	TO	O
assess	VB	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
recognition	NN	O
of	IN	O
dynamically	RB	O
emerging	VBG	O
facial	JJ	O
expressions	NNS	O
of	IN	O
others	NNS	O
.	.	O

They	PRP	O
exposed	VBD	O
participants	NNS	O
to	TO	O
videos	NNS	O
of	IN	O
either	DT	O
their	PRP$	O
own	JJ	O
faces	VBZ	O
(	(	O
self-face	JJ	PH
prime	NN	PH
)	)	PH
or	CC	PH
faces	VBZ	PH
of	IN	PH
others	NNS	PH
(	(	PH
nonself-face	JJ	PH
prime	NN	PH
)	)	O
prior	RB	O
to	TO	O
a	DT	O
facial	JJ	O
expression	NN	O
judgment	NN	O
task	NN	O
.	.	O

Their	PRP$	O
results	NNS	O
show	VBP	O
that	IN	O
experimentally	RB	O
activating	VBG	O
self-face	JJ	O
representations	NNS	O
results	NNS	O
in	IN	O
earlier	JJR	O
recognition	NN	O
of	IN	O
dynamically	RB	O
emerging	VBG	O
facial	JJ	O
expression	NN	O
.	.	O

As	IN	O
a	DT	O
group	NN	O
,	,	O
participants	NNS	O
in	IN	O
the	DT	O
self-face	JJ	O
prime	JJ	O
condition	NN	O
recognized	VBD	O
expressions	NNS	O
earlier	RBR	O
(	(	O
when	WRB	O
less	RBR	O
affective	JJ	O
perceptual	JJ	O
information	NN	O
was	VBD	O
available	JJ	O
)	)	O
compared	VBN	O
to	TO	O
participants	NNS	O
in	IN	O
the	DT	O
nonself-face	JJ	O
prime	JJ	O
condition	NN	O
.	.	O

There	EX	O
were	VBD	O
individual	JJ	O
differences	NNS	O
in	IN	O
performance	NN	O
,	,	O
such	JJ	O
that	IN	O
poorer	JJR	O
expression	NN	O
identification	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
autism	NN	O
traits	NNS	O
(	(	O
in	IN	O
this	DT	O
neurocognitively	RB	O
healthy	JJ	O
sample	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
randomized	VBN	O
into	IN	O
the	DT	O
self-face	JJ	O
prime	JJ	O
condition	NN	O
,	,	O
participants	NNS	O
with	IN	O
high	JJ	O
autism	NN	O
traits	NNS	O
performed	VBN	O
as	RB	O
well	RB	O
as	IN	O
those	DT	O
with	IN	O
low	JJ	O
autism	NN	O
traits	NNS	O
.	.	O

Taken	VB	O
together	RB	O
,	,	O
these	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
ability	NN	O
to	TO	O
recognize	VB	O
facial	JJ	O
expressions	NNS	O
in	IN	O
others	NNS	O
is	VBZ	O
linked	VBN	O
with	IN	O
the	DT	O
internal	JJ	O
representations	NNS	O
of	IN	O
our	PRP$	O
own	JJ	O
faces	VBZ	O
.	.	O

Successful	JJ	O
treatment	NN	O
of	IN	O
blepharitis	NN	O
with	IN	O
bibrocathol	NN	O
(	(	O
Posiformin?	NNP	O
2	CD	O
%	NN	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Bibrocathol	NNP	O
is	VBZ	O
a	DT	O
well-established	JJ	O
antiseptic	JJ	O
drug	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	NN	O
eyelid	JJ	O
diseases	NNS	O
like	IN	O
blepharitis	NN	O
.	.	O

Despite	IN	O
its	PRP$	O
frequent	JJ	O
use	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
,	,	O
no	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
bibrocathol	$	O
2	CD	O
%	NN	O
eye	NN	O
ointment	NN	O
has	VBZ	O
been	VBN	O
performed	VBN	O
until	IN	O
now	RB	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
efficacy	NN	O
,	,	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
bibrocathol	NN	O
(	(	O
Posiformin?	NNP	O
2	CD	O
%	NN	O
)	)	O
eye	NN	O
ointment	NN	O
in	IN	O
patients	NNS	O
diagnosed	VBN	O
with	IN	O
blepharitis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
multi-center	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-masked	JJ	O
,	,	O
placebo-controlled	JJ	O
parallel-group	NN	O
comparison	NN	O
,	,	O
the	DT	O
change	NN	O
of	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
(	(	O
sum	VB	O
score	NN	O
)	)	O
of	IN	O
blepharitis	NN	O
in	IN	O
197	CD	O
patients	NNS	O
(	(	O
ITT	NNP	O
(	(	O
intention-to-treat-group	JJ	O
)	)	O
;	:	O
mean	JJ	O
age	NN	O
56	CD	O
?	.	O
18	CD	O
years	NNS	O
,	,	O
56	CD	O
%	NN	O
female	NN	O
,	,	O
active	JJ	O
drug	NN	O
:	:	O
vehicle	NN	O
=	IN	O
97:100	CD	O
)	)	O
over	IN	O
2	CD	O
weeks	NNS	O
treatment	NN	O
with	IN	O
bibrocathol	JJ	O
2	CD	O
%	NN	O
eye	NN	O
ointment	NN	O
was	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
receiving	VBG	O
bibrocathol	RB	O
2	CD	O
%	NN	O
showed	VBD	O
greater	JJR	O
improvement	NN	O
in	IN	O
the	DT	O
sum	NN	O
score	NN	O
than	IN	O
the	DT	O
placebo	NN	O
patients	NNS	O
(	(	O
p	JJ	O
<	NN	O
0.0001	CD	O
,	,	O
Cohen	NNP	O
's	POS	O
effect	NN	O
size	NN	O
d	NN	O
=	NNP	O
0.73	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
results	NNS	O
from	IN	O
further	JJ	O
efficacy	NN	O
assessments	NNS	O
improvement	NN	O
of	IN	O
single	JJ	O
symptoms	NNS	O
and	CC	O
ocular	JJ	O
discomfort	NN	O
measured	VBN	O
by	IN	O
a	DT	O
VAS	NNP	O
(	(	O
visual	JJ	O
analogue	NN	O
scale	NN	O
)	)	O
supported	VBD	O
treatment	NN	O
with	IN	O
bibrocathol	NN	O
.	.	O

Patients	NNS	O
and	CC	O
investigators	NNS	O
provided	VBD	O
favorable	JJ	O
tolerability	NN	O
ratings	NNS	O
preferring	VBG	O
bibrocathol	NN	O
over	IN	O
placebo	NN	O
.	.	O

No	DT	O
safety	NN	O
issues	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
regard	NN	O
to	TO	O
intraocular	JJ	O
pressure	NN	O
,	,	O
visual	JJ	O
acuity	NN	O
,	,	O
or	CC	O
occurrence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Blepharitis	NNP	O
therapy	NN	O
with	IN	O
the	DT	O
antiseptic	JJ	O
bibrocathol	NN	O
2	CD	O
%	NN	O
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
highly	RB	O
efficacious	JJ	O
and	CC	O
safe	JJ	O
.	.	O

Long-term	JJ	O
anticoagulant	NN	O
treatment	NN	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

The	DT	O
Warfarin	NNP	O
Re-Infarction	NNP	O
Study	NNP	O
.	.	O

High	NNP	O
levels	NNS	O
of	IN	O
fibrinogen	NN	O
and	CC	O
clotting	VBG	O
factor	NN	O
VII	NNP	O
are	VBP	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
subsequent	JJ	O
death	NN	O
and	CC	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
apparently	RB	O
healthy	JJ	O
individuals	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
pathoanatomic	JJ	O
studies	NNS	O
and	CC	O
coronary	JJ	O
angiography	NN	O
have	VBP	O
confirmed	VBN	O
a	DT	O
relationship	NN	O
between	IN	O
coronary	JJ	O
thrombus	NN	O
formation	NN	O
and	CC	O
acute	JJ	O
Q-wave	NNP	O
infarction	NN	O
.	.	O

Effective	JJ	O
antithrombotic	JJ	O
agents	NNS	O
may	MD	O
prevent	VB	O
or	CC	O
limit	VB	O
thrombus	JJ	O
formation	NN	O
and	CC	O
events	NNS	O
related	VBN	O
to	TO	O
thrombosis	NN	O
.	.	O

The	DT	O
Warfarin	NNP	O
Re-Infarction	NNP	O
Study	NNP	O
(	(	O
WARIS	NNP	O
)	)	O
studied	VBD	O
the	DT	O
effect	NN	O
of	IN	O
warfarin	NN	PM
in	IN	O
survivors	NNS	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Patients	NNS	O
aged	VBD	O
75	CD	O
years	NNS	O
or	CC	O
less	JJR	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
study	NN	O
to	TO	O
test	VB	O
whether	IN	O
long-term	JJ	O
treatment	NN	O
with	IN	O
warfarin	JJ	PM
reduces	NNS	O
the	DT	O
risk	NN	O
of	IN	O
death	NN	O
,	,	O
reinfarction	NN	O
,	,	O
and	CC	O
thromboembolic	JJ	O
morbidity	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1918	CD	O
patients	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
participation	NN	O
;	:	O
1214	CD	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
mean	JJ	O
follow-up	NN	O
was	VBD	O
37	CD	O
months	NNS	O
.	.	O

Analyzed	VBN	O
on	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
,	,	O
123	CD	O
(	(	O
20	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
died	VBD	O
,	,	O
versus	FW	O
94	CD	O
(	(	O
15	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
warfarin	NN	PM
group	NN	O
,	,	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
24	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.026	CD	O
)	)	O
.	.	O

Considering	VBG	O
patients	NNS	O
on	IN	O
treatment	NN	O
or	CC	O
within	IN	O
28	CD	O
days	NNS	O
after	IN	O
discontinuing	VBG	O
the	DT	O
test	NN	O
medication	NN	O
,	,	O
92	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
died	VBD	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
60	CD	O
of	IN	O
the	DT	O
warfarin-treated	JJ	PM
patients	NNS	O
,	,	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
35	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Relapsing	VBG	O
myocardial	JJ	O
infarction	NN	O
(	(	O
fatal	JJ	O
and	CC	O
nonfatal	JJ	O
)	)	O
was	VBD	O
reduced	VBN	O
by	IN	O
43	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
cerebrovascular	JJ	O
attacks	NNS	O
was	VBD	O
lower	RBR	O
in	IN	O
the	DT	O
warfarin	NN	PM
group	NN	O
(	(	O
16	CD	O
patients	NNS	O
)	)	O
than	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
41	CD	O
patients	NNS	O
)	)	O
,	,	O
a	DT	O
highly	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
61	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

Serious	JJ	O
bleeding	NN	O
occurred	VBD	O
in	IN	O
11	CD	O
patients	NNS	O
taking	VBG	O
warfarin	NN	PM
,	,	O
an	DT	O
incidence	NN	O
of	IN	O
0.6	CD	O
%	NN	O
per	IN	O
year	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
long-term	JJ	O
anticoagulant	JJ	O
therapy	NN	O
may	MD	O
be	VB	O
recommended	VBN	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Conjugated	VBN	O
equine	JJ	O
estrogen	NN	O
influence	NN	O
on	IN	O
mammographic	JJ	O
density	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
in	IN	O
a	DT	O
substudy	NN	O
of	IN	O
the	DT	O
women	NNS	O
's	POS	O
health	NN	O
initiative	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Increased	VBD	O
mammographic	JJ	O
density	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
breast	NN	O
cancer	NN	O
risk	NN	O
and	CC	O
reduced	JJ	O
sensitivity	NN	O
of	IN	O
screening	VBG	O
mammography	NN	O
and	CC	O
is	VBZ	O
related	VBN	O
to	TO	O
hormone	VB	O
exposure	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
conjugated	JJ	PM
equine	NN	PM
estrogens	NNS	PM
(	(	PM
CEEs	NNP	PM
)	)	PM
alone	RB	O
on	IN	O
mammographic	JJ	O
density	NN	O
in	IN	O
diverse	JJ	O
racial/ethnic	JJ	O
populations	NNS	O
are	VBP	O
not	RB	O
established	VBN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
CEE	NNP	O
alone	RB	O
on	IN	O
mammographic	JJ	O
density	NN	O
in	IN	O
a	DT	O
subsample	NN	O
of	IN	O
the	DT	O
Women	NNP	O
's	POS	O
Health	NNP	O
Initiative	NNP	O
(	(	O
WHI	NNP	O
)	)	O
clinical	JJ	O
trial	NN	O
participants	NNS	O
.	.	O

PATIENTS	NNS	O
AND	CC	O
METHODS	NNP	O
In	IN	O
the	DT	O
WHI	NNP	O
trial	NN	O
,	,	O
women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
daily	VB	PM
CEE	NNP	PM
0.625	CD	PM
mg	NN	PM
or	CC	O
placebo	NN	C
.	.	O

The	DT	O
effect	NN	O
of	IN	O
CEE	NNP	O
on	IN	O
mammographic	JJ	O
percent	NN	O
density	NN	O
was	VBD	O
determined	VBN	O
over	IN	O
1	CD	O
and	CC	O
2	CD	O
years	NNS	O
in	IN	O
a	DT	O
stratified	JJ	O
random	JJ	O
sample	NN	O
of	IN	O
435	CD	O
racially	RB	O
and	CC	O
ethnically	RB	O
diverse	JJ	O
participants	NNS	O
from	IN	O
15	CD	O
of	IN	O
40	CD	O
WHI	NNP	O
clinics	NNS	O
.	.	O

RESULTS	NNP	O
Use	NNP	O
of	IN	O
CEE	NNP	O
resulted	VBD	O
in	IN	O
mean	JJ	O
increase	NN	O
in	IN	O
mammographic	JJ	O
percent	NN	O
density	NN	O
of	IN	O
1.6	CD	O
percentage	NN	O
points	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.8	CD	O
to	TO	O
2.4	CD	O
)	)	O
at	IN	O
year	NN	O
1	CD	O
compared	VBN	O
with	IN	O
a	DT	O
mean	JJ	O
decrease	NN	O
of	IN	O
1.0	CD	O
percentage	NN	O
point	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-1.7	NNP	O
to	TO	O
-0.4	VB	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
persisted	VBD	O
for	IN	O
2	CD	O
years	NNS	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
increase	NN	O
of	IN	O
1.7	CD	O
percentage	NN	O
points	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.7	CD	O
to	TO	O
2.7	CD	O
)	)	O
versus	NN	O
a	DT	O
mean	JJ	O
decrease	NN	O
of	IN	O
1.2	CD	O
percentage	NN	O
points	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-1.8	NNP	O
to	TO	O
-0.5	VB	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
in	IN	O
the	DT	O
hormone	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

These	DT	O
effects	NNS	O
were	VBD	O
greater	JJR	O
in	IN	O
women	NNS	O
age	NN	O
60	CD	O
to	TO	O
79	CD	O
years	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
for	IN	O
interaction	NN	O
across	IN	O
age	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
CEE	NNP	O
results	NNS	O
in	IN	O
a	DT	O
modest	JJ	O
but	CC	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
mammographic	JJ	O
density	NN	O
that	WDT	O
is	VBZ	O
sustained	VBN	O
over	IN	O
at	IN	O
least	JJS	O
a	DT	O
2-year	JJ	O
period	NN	O
.	.	O

The	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
the	DT	O
CEE	NNP	O
effect	NN	O
on	IN	O
mammographic	JJ	O
density	NN	O
remains	VBZ	O
to	TO	O
be	VB	O
determined	VBN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
to	TO	O
assess	VB	O
5	CD	O
%	NN	O
imiquimod	JJ	PM
cream	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
multiple	JJ	O
actinic	JJ	O
keratoses	NNS	O
.	.	O

BACKGROUND	NNP	O
Actinic	NNP	O
keratoses	NNS	O
(	(	O
AKs	NNP	O
)	)	O
are	VBP	O
precancerous	JJ	O
epidermal	JJ	O
lesions	NNS	O
found	VBD	O
most	JJS	O
frequently	RB	O
on	IN	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
exposed	VBD	O
to	TO	O
the	DT	O
sun	NN	O
.	.	O

Several	JJ	O
case	NN	O
studies	NNS	O
published	VBN	O
recently	RB	O
have	VBP	O
indicated	VBN	O
that	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
,	,	O
currently	RB	O
licensed	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
genital	JJ	O
warts	NNS	O
,	,	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
AK	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
imiquimod	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
AK	NNP	O
.	.	O

DESIGN	NNP	O
Patients	NNPS	O
in	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
vehicle-controlled	JJ	O
study	NN	O
applied	VBD	O
5	CD	O
%	NN	O
imiquimod	JJ	PM
cream	NN	PM
or	CC	O
vehicle	NN	O
to	TO	O
AK	NNP	O
lesions	NNS	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
or	CC	O
until	IN	O
lesions	NNS	O
had	VBD	O
resolved	VBN	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
an	DT	O
adverse	JJ	O
reaction	NN	O
,	,	O
application	NN	O
of	IN	O
imiquimod	NN	PM
was	VBD	O
reduced	VBN	O
to	TO	O
1	CD	O
or	CC	O
2	CD	O
times	NNS	O
per	IN	O
week	NN	O
.	.	O

Rest	JJS	O
periods	NNS	O
were	VBD	O
also	RB	O
allowed	VBN	O
if	IN	O
necessary	JJ	O
.	.	O

SETTING	VB	O
A	DT	O
specialized	JJ	O
outpatient	NN	O
dermatology	NN	O
clinic	NN	O
within	IN	O
a	DT	O
state-funded	JJ	O
hospital	NN	O
in	IN	O
Germany	NNP	O
.	.	O

PATIENTS	VB	O
The	DT	O
study	NN	O
population	NN	O
was	VBD	O
aged	VBN	O
45	CD	O
to	TO	O
85	CD	O
years	NNS	O
.	.	O

Of	IN	O
52	CD	O
patients	NNS	O
screened	VBD	O
,	,	O
36	CD	O
men	NNS	O
and	CC	O
women	NNS	O
with	IN	O
AK	NNP	O
confirmed	VBN	O
by	IN	O
histological	JJ	O
diagnosis	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
if	IN	O
they	PRP	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
histological	JJ	O
diagnosis	NN	O
for	IN	O
AK	NNP	O
,	,	O
if	IN	O
they	PRP	O
were	VBD	O
older	JJR	O
than	IN	O
85	CD	O
years	NNS	O
,	,	O
or	CC	O
if	IN	O
they	PRP	O
did	VBD	O
not	RB	O
comply	VB	O
with	IN	O
the	DT	O
protocol	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
responded	VBN	O
to	TO	O
a	DT	O
notice	NN	O
asking	VBG	O
for	IN	O
volunteers	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
number	NN	O
and	CC	O
appearance	NN	O
of	IN	O
lesions	NNS	O
were	VBD	O
evaluated	VBN	O
before	RB	O
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

All	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Lesions	NNP	O
treated	VBD	O
with	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	PM
cream	NN	PM
were	VBD	O
clinically	RB	O
cleared	VBN	O
in	IN	O
21	CD	O
(	(	O
84	CD	O
%	NN	O
)	)	O
of	IN	O
25	CD	O
patients	NNS	O
and	CC	O
partially	RB	O
cleared	VBN	O
in	IN	O
2	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
.	.	O

Clearance	NN	O
was	VBD	O
histologically	RB	O
confirmed	VBN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
last	JJ	O
application	NN	O
of	IN	O
imiquimod	NN	PM
in	IN	O
all	DT	O
patients	NNS	O
clinically	RB	O
diagnosed	VBN	O
as	IN	O
lesion	NN	O
free	NN	O
.	.	O

Only	RB	O
10	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
imiquimod	NN	O
were	VBD	O
clinically	RB	O
diagnosed	VBN	O
with	IN	O
recurrence	NN	O
1	CD	O
year	NN	O
after	IN	O
treatment	NN	O
.	.	O

No	DT	O
reduction	NN	O
in	IN	O
the	DT	O
size	NN	O
or	CC	O
number	NN	O
of	IN	O
AK	NNP	O
lesions	NNS	O
was	VBD	O
observed	VBN	O
in	IN	O
vehicle-treated	JJ	O
patients	NNS	O
.	.	O

Adverse	JJ	O
effects	NNS	O
reported	VBN	O
by	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
imiquimod	NN	PM
included	VBD	O
erythema	NN	O
,	,	O
edema	NN	O
,	,	O
induration	NN	O
,	,	O
vesicles	NNS	O
,	,	O
erosion	NN	O
,	,	O
ulceration	NN	O
,	,	O
excoriation	NN	O
,	,	O
and	CC	O
scabbing	VBG	O
.	.	O

However	RB	O
,	,	O
imiquimod	NN	PM
was	VBD	O
well	RB	O
tolerated	VBN	O
since	IN	O
all	DT	O
patients	NNS	O
completed	VBD	O
the	DT	O
12-week	JJ	O
treatment	NN	O
.	.	O

Only	RB	O
a	DT	O
few	JJ	O
,	,	O
mild	JJ	O
adverse	JJ	O
reactions	NNS	O
to	TO	O
the	DT	O
vehicle	NN	O
cream	NN	O
were	VBD	O
reported	VBN	O
.	.	O

CONCLUSION	NNP	O
Application	NNP	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	PM
cream	NN	PM
for	IN	O
12	CD	O
weeks	NNS	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
AK	NNP	O
.	.	O

Analysis	NN	O
of	IN	O
face	NN	Ot
gaze	NN	Ot
in	IN	O
autism	NN	O
using	VBG	O
Bubbles	NNP	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
abnormal	JJ	O
social	JJ	O
functioning	NN	O
in	IN	O
autism	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
ability	NN	O
to	TO	O
direct	VB	O
eye	NN	O
gaze	NN	O
onto	IN	O
other	JJ	O
people	NNS	O
's	POS	O
faces	VBZ	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
gaze	NN	O
onto	IN	O
the	DT	O
eye	NN	O
and	CC	O
mouth	JJ	O
regions	NNS	O
of	IN	O
faces	VBZ	O
,	,	O
and	CC	O
the	DT	O
visual	JJ	O
information	NN	O
that	WDT	O
was	VBD	O
present	JJ	O
within	IN	O
those	DT	O
regions	NNS	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
Bubbles	NNP	Ot
method	NN	Ot
to	TO	O
vary	VB	O
the	DT	O
facial	JJ	O
information	NN	O
available	JJ	O
on	IN	O
any	DT	O
given	VBN	O
trial	NN	O
by	IN	O
revealing	VBG	O
only	RB	O
small	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
and	CC	O
measured	VBD	O
the	DT	O
eye	NN	O
movements	NNS	O
made	VBN	O
as	IN	O
participants	NNS	O
viewed	IN	O
these	DT	O
stimuli	NNS	O
.	.	O

Compared	VBN	O
to	TO	O
ten	VB	O
IQ-	NNP	O
and	CC	O
age-matched	JJ	O
healthy	JJ	O
controls	NNS	O
,	,	O
eight	CD	O
participants	NNS	O
with	IN	O
autism	NN	O
showed	VBD	O
less	JJR	O
fixation	JJ	O
specificity	NN	O
to	TO	O
the	DT	O
eyes	NNS	O
and	CC	O
mouth	NN	O
,	,	O
a	DT	O
greater	JJR	O
tendency	NN	O
to	TO	O
saccade	VB	O
away	RB	O
from	IN	O
the	DT	O
eyes	NNS	O
when	WRB	O
information	NN	O
was	VBD	O
present	JJ	O
in	IN	O
those	DT	O
regions	NNS	O
,	,	O
and	CC	O
abnormal	JJ	O
directionality	NN	O
of	IN	O
saccades	NNS	O
.	.	O

The	DT	O
findings	NNS	O
provide	VBP	O
novel	JJ	O
detail	NN	O
to	TO	O
the	DT	O
abnormal	JJ	O
way	NN	O
in	IN	O
which	WDT	O
people	NNS	O
with	IN	O
autism	NN	O
look	NN	O
at	IN	O
faces	VBZ	O
,	,	O
an	DT	O
impairment	NN	O
that	WDT	O
likely	JJ	O
influences	VBZ	O
all	DT	O
subsequent	JJ	O
face	NN	O
processing	NN	O
.	.	O

Oral	JJ	PM
sildenafil	NN	PM
to	TO	O
control	VB	O
pulmonary	JJ	O
hypertension	NN	O
after	IN	O
congenital	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

This	DT	O
study	NN	O
investigates	VBZ	O
the	DT	O
role	NN	O
of	IN	O
oral	JJ	O
sildenafil	NN	PM
in	IN	O
decreasing	VBG	O
pulmonary	JJ	O
pressure	NN	O
after	IN	O
congenital	JJ	S
heart	NN	S
surgery	NN	S
.	.	S

Between	NNP	O
September	NNP	O
2002	CD	O
and	CC	O
September	NNP	O
2004	CD	O
,	,	O
among	IN	O
a	DT	O
group	NN	O
of	IN	O
postoperative	JJ	O
children	NNS	O
with	IN	O
large	JJ	O
septal	JJ	O
defects	NNS	O
,	,	O
moderate	VBP	O
to	TO	O
severe	VB	O
pulmonary	JJ	O
hypertension	NN	O
[	NNP	O
pulmonary	JJ	O
artery	NN	O
(	(	O
PA	NNP	O
)	)	O
to	TO	O
aortic	JJ	O
(	(	O
Ao	NNP	O
)	)	O
pressure	NN	O
ratio	NN	O
of	IN	O
0.76	CD	O
+/-	JJ	O
0.17	CD	O
]	NN	O
and	CC	O
systemic	JJ	O
desaturation	NN	O
(	(	O
Ao	NNP	O
Sat	NNP	O
=	VBD	O
0.89	CD	O
+/-	JJ	O
0.11	CD	O
)	)	O
,	,	O
oral	JJ	PM
sildenafil	NN	PM
(	(	O
0.3	CD	O
mg	NN	O
x	NN	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
every	DT	O
3	CD	O
hours	NNS	O
)	)	O
was	VBD	O
administered	VBN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
24-48	JJ	O
hours	NNS	O
(	(	O
sildenafil	JJ	PM
group	NN	O
)	)	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
22	CD	O
children	NNS	O
with	IN	O
similar	JJ	O
pathologies	NNS	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
sildenafil	NN	PM
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

Postoperative	JJ	O
PA	NNP	O
pressure	NN	O
(	(	O
28.61	CD	O
+/-	JJ	O
7.80	CD	O
vs	JJ	O
39.40	CD	O
+/-	JJ	O
10.80	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
and	CC	O
PA/Ao	NNP	O
pressure	NN	O
(	(	O
0.28	CD	O
+/-	JJ	O
0.08	CD	O
vs	JJ	O
0.41	CD	O
+/-	JJ	O
0.11	CD	O
)	)	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
sildenafil	NN	PM
group	NN	O
(	(	O
p	JJ	O
=	NN	O
0.001	CD	O
and	CC	O
0.001	CD	O
respectively	RB	O
)	)	O
.	.	O

Pulmonary	JJ	O
hypertensive	JJ	O
crisis	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
4	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
but	CC	O
none	NN	O
in	IN	O
the	DT	O
sildenafil	NN	PM
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
rise	NN	O
in	IN	O
PA	NNP	O
pressure	NN	O
following	VBG	O
discontinuation	NN	O
of	IN	O
the	DT	O
drug	NN	O
(	(	O
26.30	CD	O
+/-	JJ	O
6.66	CD	O
vs	JJ	O
28.49	CD	O
+/-	JJ	O
10.93	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.366	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
complications	NNS	O
were	VBD	O
noticed	VBN	O
regarding	VBG	O
sildenafil	NN	PM
use	NN	O
.	.	O

Low	JJ	O
doses	NNS	O
of	IN	O
oral	JJ	O
sildenafil	NN	PM
appear	VBP	O
to	TO	O
be	VB	O
effective	JJ	O
and	CC	O
safe	JJ	O
to	TO	O
control	VB	O
postoperative	JJ	O
PA	NNP	O
pressure	NN	O
in	IN	O
children	NNS	O
.	.	O

Absence	NN	O
of	IN	O
rebound	NN	O
pulmonary	JJ	O
hypertension	NN	O
,	,	O
availability	NN	O
,	,	O
and	CC	O
low	JJ	O
cost	NN	O
of	IN	O
the	DT	O
drug	NN	O
are	VBP	O
considered	VBN	O
as	IN	O
its	PRP$	O
major	JJ	O
advantages	NNS	O
.	.	O

Bioequivalence	NNP	O
evaluation	NN	O
of	IN	O
a	DT	O
fixed	VBN	O
dose	JJ	O
combination	NN	O
lamivudine	NN	PM
+	NNP	PM
stavudine	NN	PM
tablet	NN	O
with	IN	O
concurrent	JJ	O
administration	NN	O
of	IN	O
lamivudine	JJ	PM
tablet	NN	O
and	CC	O
stavudine	NN	PM
capsule	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
rate	NN	O
and	CC	O
extent	NN	O
of	IN	O
absorption	NN	O
of	IN	O
a	DT	O
fixed	VBN	O
dose	JJ	O
combination	NN	O
tablet	NN	O
of	IN	O
lamivudine	NN	PM
(	(	PM
CAS	NNP	PM
134678-17-4	CD	PM
)	)	PM
and	CC	O
stavudine	NN	PM
(	(	PM
CAS	NNP	PM
3056-17-5	CD	PM
)	)	PM
with	IN	O
the	DT	O
concurrent	JJ	O
administration	NN	O
of	IN	O
lamivudine	JJ	PM
tablet	NN	PM
and	CC	O
stavudine	NN	PM
capsule	NN	PM
in	IN	O
24	CD	O
healthy	JJ	O
volunteers	NNS	O
under	IN	O
fasting	VBG	O
conditions	NNS	O
.	.	O

The	DT	O
volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
test	NN	O
or	CC	O
reference	NN	O
treatment	NN	O
,	,	O
with	IN	O
the	DT	O
two	CD	O
treatment	NN	O
periods	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
7	CD	O
days	NNS	O
.	.	O

Plasma	NNP	O
samples	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
both	DT	O
analytes	NNS	O
lamivudine	VBP	PM
and	CC	O
stavudine	VBP	PM
by	IN	O
a	DT	O
validated	JJ	O
analytical	JJ	O
method	NN	O
.	.	O

Since	IN	O
the	DT	O
90	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
for	IN	O
the	DT	O
test/reference	NN	O
mean	JJ	O
ratio	NN	O
of	IN	O
the	DT	O
In-transformed	NNP	O
pharmacokinetic	JJ	O
variables	NNS	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
AUC	NNP	O
(	(	O
0-t	JJ	O
)	)	O
and	CC	O
AUC	NNP	O
(	(	O
0-infinity	NN	O
)	)	O
were	VBD	O
clearly	RB	O
within	IN	O
the	DT	O
conventional	JJ	O
bioequivalence	NN	O
range	NN	O
of	IN	O
80	CD	O
%	NN	O
to	TO	O
125	CD	O
%	NN	O
,	,	O
the	DT	O
two	CD	O
treatments	NNS	O
were	VBD	O
considered	VBN	O
bioequivalent	NN	O
.	.	O

The	DT	O
safety	NN	O
profiles	NNS	O
of	IN	O
both	DT	O
the	DT	O
test	NN	O
and	CC	O
reference	NN	O
formulations	NNS	O
were	VBD	O
comparable	JJ	O
.	.	O

Multimodal	NNP	O
therapy	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
primary	JJ	O
,	,	O
nonmetastatic	JJ	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
of	IN	O
bone	NN	O
:	:	O
an	DT	O
Intergroup	NNP	O
Study	NNP	O
.	.	O

A	NNP	O
randomized	JJ	O
study	NN	O
of	IN	O
264	CD	O
children	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
localized	JJ	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
of	IN	O
bone	NN	O
was	VBD	O
undertaken	VBN	O
between	IN	O
1973	CD	O
and	CC	O
1978	CD	O
by	IN	O
83	CD	O
institutions	NNS	O
of	IN	O
three	CD	O
national	JJ	O
study	NN	O
groups	NNS	O
:	:	O
Children	NNP	O
's	POS	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
,	,	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
,	,	O
and	CC	O
Cancer	NNP	O
and	CC	O
Leukemia	NNP	O
Group	NNP	O
B	NNP	O
.	.	O

The	DT	O
Intergroup	NNP	O
Study	NNP	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
addition	NN	PM
of	IN	PM
adriamycin	NN	C
(	(	C
ADR	NNP	C
)	)	C
or	CC	C
bilateral	JJ	PH
pulmonary	JJ	PH
radiotherapy	NN	PH
(	(	PH
RT	NNP	PH
)	)	PH
to	TO	C
vincristine	VB	C
,	,	C
dactinomycin	NN	C
,	,	C
and	CC	C
cyclophosphamide	NN	C
(	(	C
VAC	NNP	C
therapy	NN	C
)	)	C
would	MD	O
improve	VB	O
survival	NN	O
and	CC	O
reduce	VB	O
local	JJ	O
recurrences	NNS	O
and	CC	O
metastases	NNS	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
RT	NNP	O
to	TO	O
the	DT	O
primary	JJ	O
lesion	NN	O
,	,	O
and	CC	O
the	DT	O
survival	NN	O
rate	NN	O
after	IN	O
3	CD	O
years	NNS	O
was	VBD	O
65	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
effective	JJ	O
treatment	NN	O
regimen	NNS	O
was	VBD	O
VAC	NNP	O
plus	CC	O
ADR	NNP	O
;	:	O
74	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
free	JJ	O
of	IN	O
disease	NN	O
at	IN	O
2	CD	O
years	NNS	O
.	.	O

The	DT	O
lengths	NNS	O
of	IN	O
disease-free	JJ	O
status	NN	O
and	CC	O
survival	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
VAC	NNP	O
plus	CC	O
ADR	NNP	O
or	CC	O
VAC	NNP	O
plus	CC	O
RT	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

However	RB	O
,	,	O
both	DT	O
regimens	NNS	O
were	VBD	O
significantly	RB	O
superior	JJ	O
to	TO	O
treatment	NN	O
with	IN	O
VAC	NNP	O
alone	RB	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
ADR	NNP	O
or	CC	O
bilateral	JJ	O
pulmonary	JJ	O
RT	NNP	O
to	TO	O
VAC	NNP	O
was	VBD	O
highly	RB	O
advantageous	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
nonpelvic	JJ	O
primaries	NNS	O
.	.	O

Bone	NN	O
and	CC	O
lung	NN	O
were	VBD	O
the	DT	O
major	JJ	O
sites	NNS	O
of	IN	O
distant	JJ	O
relapse	NN	O
,	,	O
but	CC	O
the	DT	O
addition	NN	O
of	IN	O
bilateral	JJ	O
pulmonary	JJ	O
RT	NNP	O
showed	VBD	O
no	DT	O
advantage	NN	O
over	IN	O
that	DT	O
of	IN	O
ADR	NNP	O
in	IN	O
reducing	VBG	O
the	DT	O
occurrence	NN	O
of	IN	O
lung	NN	O
metastases	NNS	O
.	.	O

These	DT	O
recent	JJ	O
results	NNS	O
should	MD	O
eliminate	VB	O
some	DT	O
of	IN	O
the	DT	O
pessimism	NN	O
that	WDT	O
has	VBZ	O
accompanied	VBN	O
a	DT	O
diagnosis	NN	O
of	IN	O
Ewing	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
although	IN	O
distant	JJ	O
metastases	NNS	O
continued	VBD	O
to	TO	O
be	VB	O
a	DT	O
major	JJ	O
reason	NN	O
for	IN	O
failure	NN	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
this	DT	O
tumor	NN	O
.	.	O

Survival	NN	O
of	IN	O
these	DT	O
patients	NNS	O
can	MD	O
be	VB	O
improved	VBN	O
through	IN	O
well-controlled	JJ	O
clinical	JJ	O
trials	NNS	O
designed	VBN	O
to	TO	O
determine	VB	O
optimal	JJ	O
adjuvant	JJ	O
chemotherapy	NN	O
and	CC	O
treatment	NN	O
of	IN	O
the	DT	O
primary	JJ	O
lesion	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
valsartan/hydrochlorothiazide	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
stage-1	JJ	O
or	CC	O
stage-2	JJ	O
hypertension	NN	O
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
6-week	JJ	O
,	,	O
multicenter	NN	O
,	,	O
double-blind	NN	O
study	NN	O
examined	VBD	O
the	DT	O
benefits	NNS	O
of	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
combination	NN	O
valsartan/hydrochlorothiazide	NN	PM
(	(	PM
HCTZ	NNP	PM
)	)	PM
compared	VBN	O
with	IN	O
initial	JJ	O
valsartan	NNS	O
monotherapy	NN	O
for	IN	O
648	CD	O
patients	NNS	O
with	IN	O
stage-1	JJ	O
or	CC	O
stage-2	JJ	O
hypertension	NN	O
(	(	O
age=52.6+/-10	JJ	O
years	NNS	O
;	:	O
54	CD	O
%	NN	O
male	NN	O
;	:	O
baseline	VB	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
=161/98	VBP	O
mm	JJ	O
Hg	NNP	O
,	,	O
32	CD	O
%	NN	O
stage	NN	O
1	CD	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
valsartan	VB	PM
80	CD	PM
mg	NN	PM
(	(	PM
V-low	NNP	PM
)	)	PM
,	,	O
valsartan	$	PM
160	CD	PM
mg	NN	PM
(	(	PM
V-high	NNP	PM
)	)	PM
or	CC	O
valsartan/HCTZ	$	PM
160/12.5	CD	PM
mg	NN	PM
(	(	PM
V/HCTZ	NNP	PM
)	)	PM
,	,	O
and	CC	O
electively	RB	O
titrated	VBN	O
after	IN	O
weeks	NNS	O
2	CD	O
and	CC	O
4	CD	O
to	TO	O
the	DT	O
next	JJ	O
dosage	NN	O
level	NN	O
(	(	O
maximum	JJ	PM
dose	NN	PM
valsartan/HCTZ	NN	PM
160/25	CD	PM
mg	NN	PM
)	)	O
if	IN	O
BP	NNP	PM
remained	VBD	PM
>	JJ	PM
140/90	CD	PM
mm	NN	PM
Hg	NNP	PM
.	.	O

At	IN	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
patients	NNS	O
initiated	VBN	O
with	IN	O
V/HCTZ	NNP	PM
required	VBD	O
less	JJR	O
titration	JJ	O
steps	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
initial	JJ	O
valsartan	NN	O
monotherapy	NN	O
groups	NNS	O
(	(	O
63	CD	O
vs	RB	O
86	CD	O
%	NN	O
required	VBN	O
titration	NN	O
by	IN	O
study	JJ	O
end	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
reached	VBD	O
the	DT	O
target	NN	O
BP	NNP	O
goal	NN	O
of	IN	O
<	$	O
140/90	CD	O
mm	NN	O
Hg	NNP	O
in	IN	O
a	DT	O
shorter	JJ	O
period	NN	O
of	IN	O
time	NN	O
(	(	O
2.8	CD	O
weeks	NNS	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
vs	NN	O
V-low	NNP	O
(	(	O
4.3	CD	O
weeks	NNS	O
)	)	O
and	CC	O
V-high	NNP	O
(	(	O
3.9	CD	O
weeks	NNS	O
)	)	O
.	.	O

Initial	JJ	O
combination	NN	O
therapy	NN	O
was	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
higher	JJR	O
BP	NNP	O
control	NN	O
rates	NNS	O
and	CC	O
greater	JJR	O
reductions	NNS	O
in	IN	O
both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
BP	NNP	O
from	IN	O
baseline	NN	O
(	(	O
63	CD	O
%	NN	O
,	,	O
-27.7+/-13/-15.1+/-8	NNP	O
mm	NNP	O
Hg	NNP	O
)	)	O
compared	VBN	O
with	IN	O
V-low	NNP	O
(	(	O
46	CD	O
%	NN	O
,	,	O
-21.2+/-13/-11.4+/-8	NNP	O
mm	NNP	O
Hg	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
or	CC	O
V-high	NNP	O
(	(	O
51	CD	O
%	NN	O
,	,	O
-24.0+/-13/-12.0+/-10	NNP	O
mm	NNP	O
Hg	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Overall	JJ	O
and	CC	O
drug-related	JJ	O
AEs	NNP	O
were	VBD	O
mild	JJ	O
to	TO	O
moderate	VB	O
and	CC	O
were	VBD	O
similar	JJ	O
between	IN	O
V/HCTZ	NNP	PM
(	(	O
53.1	CD	O
and	CC	O
14.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
the	DT	O
two	CD	O
monotherapy	NN	O
groups	NNS	O
,	,	O
V-low	NNP	O
(	(	O
50.5	CD	O
and	CC	O
13.8	CD	O
%	NN	O
)	)	O
and	CC	O
V-high	NNP	O
(	(	O
50.7	CD	O
and	CC	O
11.8	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
initiating	VBG	O
therapy	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
valsartan	NN	PM
and	CC	O
low-dose	JJ	O
HCTZ	NNP	PM
results	NNS	O
in	IN	O
early	JJ	O
,	,	O
improved	JJ	O
BP	NNP	O
efficacy	NN	O
with	IN	O
similar	JJ	O
tolerability	NN	O
as	IN	O
compared	VBN	O
with	IN	O
starting	VBG	O
treatment	NN	O
with	IN	O
a	DT	O
low	JJ	O
or	CC	O
higher	JJR	O
dose	NN	O
of	IN	O
valsartan	NN	PM
for	IN	O
patients	NNS	O
with	IN	O
stage-1	JJ	O
and	CC	O
stage-2	JJ	O
hypertension	NN	O
.	.	O

Impact	NN	O
of	IN	O
vitamin	NN	PM
D	NNP	PM
supplementation	NN	PM
on	IN	O
inflammatory	JJ	O
markers	NNS	O
in	IN	O
African	JJ	O
Americans	NNPS	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
four-arm	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

African	JJ	O
Americans	NNPS	O
have	VBP	O
a	DT	O
disproportionate	JJ	O
burden	NN	O
of	IN	O
inflammation-associated	JJ	O
chronic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
cancer	NN	O
and	CC	O
lower	JJR	O
circulating	NN	O
levels	NNS	O
of	IN	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
vitamin	NN	PM
D3	NNP	PM
(	(	PM
cholecalciferol	NN	PM
)	)	PM
supplementation	NN	PM
on	IN	O
inflammatory	JJ	O
markers	NNS	O
is	VBZ	O
uncertain	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
supplemental	JJ	PM
oral	JJ	PM
vitamin	NN	PM
D	NNP	PM
(	(	O
placebo	NN	O
,	,	O
1,000	CD	O
,	,	O
2,000	CD	O
,	,	O
or	CC	O
4,000	CD	O
IU/day	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
orally	RB	O
for	IN	O
3	CD	O
months	NNS	O
)	)	O
in	IN	O
328	CD	O
African	JJ	O
Americans	NNPS	O
(	(	O
median	JJ	O
age	NN	O
,	,	O
51	CD	O
years	NNS	O
)	)	O
of	IN	O
public	JJ	O
housing	NN	O
communities	NNS	O
in	IN	O
Boston	NNP	O
,	,	O
MA	NNP	O
,	,	O
who	WP	O
were	VBD	O
enrolled	VBN	O
over	RP	O
three	CD	O
consecutive	JJ	O
winter	NN	O
periods	NNS	O
(	(	O
2007-2010	JJ	O
)	)	O
.	.	O

Change	NN	O
from	IN	O
0	CD	O
to	TO	O
3	CD	O
months	NNS	O
of	IN	O
plasma	NN	O
levels	NNS	O
of	IN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
,	,	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
interleukin	FW	O
(	(	O
IL	NNP	O
)	)	O
-6	NN	O
,	,	O
IL-10	NNP	O
,	,	O
and	CC	O
soluble	JJ	O
TNF-?	NNP	O
receptor	NN	O
type	NN	O
2	CD	O
(	(	O
sTNF-R2	NN	O
)	)	O
in	IN	O
292	CD	O
(	(	O
89	CD	O
%	NN	O
)	)	O
participants	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Overall	NNP	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
CRP	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
IL-10	NNP	O
,	,	O
and	CC	O
sTNF-R2	NNS	O
were	VBD	O
observed	VBN	O
after	IN	O
the	DT	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
period	NN	O
.	.	O

Baseline	NNP	O
CRP	NNP	O
was	VBD	O
significantly	RB	O
inversely	RB	O
associated	VBN	O
with	IN	O
the	DT	O
baseline	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
level	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
in	IN	O
unadjusted	JJ	O
and	CC	O
adjusted	JJ	O
models	NNS	O
.	.	O

An	DT	O
interaction	NN	O
between	IN	O
baseline	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
and	CC	O
vitamin	NNP	O
D	NNP	O
supplementation	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
outcome	JJ	O
change	NN	O
in	IN	O
log	NN	O
CRP	NNP	O
(	(	O
month	NN	O
3-month	RB	O
0	CD	O
;	:	O
P	NNP	O
for	IN	O
interaction	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Within	IN	O
an	DT	O
unselected	JJ	O
population	NN	O
of	IN	O
African	JJ	O
Americans	NNPS	O
,	,	O
short-term	JJ	O
exposure	NN	O
to	TO	O
vitamin	VB	O
D	NNP	O
supplementation	NN	O
produced	VBD	O
no	DT	O
change	NN	O
in	IN	O
circulating	VBG	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

This	DT	O
study	NN	O
confirms	VBZ	O
the	DT	O
strong	JJ	O
independent	JJ	O
association	NN	O
of	IN	O
CRP	NNP	O
with	IN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
status	NN	O
even	RB	O
after	IN	O
adjusting	VBG	O
for	IN	O
body	NN	O
mass	NN	O
index	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
of	IN	O
longer	JJR	O
supplemental	JJ	O
vitamin	NN	O
D3	NNP	O
duration	NN	O
are	VBP	O
necessary	JJ	O
to	TO	O
examine	VB	O
the	DT	O
complex	JJ	O
influence	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
on	IN	O
CRP	NNP	O
and	CC	O
other	JJ	O
chronic	JJ	O
inflammatory	NN	O
cytokines	NNS	O
for	IN	O
possible	JJ	O
reduction	NN	O
of	IN	O
cancer	NN	O
health	NN	O
disparities	NNS	O
in	IN	O
African	JJ	O
Americans	NNPS	O
.	.	O

[	JJ	PM
Local	NNP	PM
therapy	NN	PM
of	IN	PM
grade	NN	PM
1	CD	PM
and	CC	PM
2	CD	PM
hemorrhoids	NNS	PM
.	.	PM

Effectiveness	NN	O
of	IN	O
a	DT	O
combination	NN	PM
preparation	NN	PM
with	IN	PM
standardized	JJ	PM
blood	NN	PM
leech	NN	PM
extract	NN	PM
]	NNP	PM
.	.	O

AIMS	NNP	O
Testing	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
topical	JJ	PM
combination	NN	PM
preparation	NN	PM
containing	VBG	PM
standardized	VBN	PM
leech	JJ	PM
extract	NN	PM
,	,	PM
polidocanol	NN	PM
and	CC	PM
allantoin	NN	PM
.	.	PM

STUDY	NNP	O
DESIGN	NNP	O
Placebo-controlled	NNP	C
,	,	O
double-blind	NN	O
study	NN	O
in	IN	O
80	CD	O
patients	NNS	O
with	IN	O
first	JJ	O
and	CC	O
second	JJ	O
degree	NN	O
hemorrhoids	NNS	O
;	:	O
duration	NN	O
of	IN	O
treatment	NN	O
one	CD	O
week	NN	O
;	:	O
examinations	NNS	O
performed	VBD	O
on	IN	O
admission	NN	O
and	CC	O
on	IN	O
days	NNS	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
and	CC	O
8	CD	O
.	.	O

RESULTS	VB	O
Both	DT	O
the	DT	O
subjective	NN	O
and	CC	O
objective	JJ	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
improved	VBN	O
during	IN	O
the	DT	O
one	CD	O
week	NN	O
of	IN	O
treatment	NN	O
statistically	RB	O
significantly	RB	O
more	RBR	O
rapidly	RB	O
under	IN	O
the	DT	O
test	NN	E
preparation	NN	E
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Histologically	NNP	O
demonstrable	JJ	O
signs	NNS	O
of	IN	O
inflammation	NN	O
were	VBD	O
more	JJR	O
clearly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
preparation	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

No	DT	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
good	JJ	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
topical	JJ	PM
therapeutic	JJ	PM
preparation	NN	PM
in	IN	O
first	JJ	O
and	CC	O
second	JJ	O
degree	NN	O
hemorrhoids	NNS	O
have	VBP	O
been	VBN	O
convincingly	RB	O
demonstrated	VBN	O
.	.	O

Different	NNP	PM
aprotinin	NN	PM
applications	NNS	PM
influencing	VBG	O
hemostatic	JJ	O
changes	NNS	O
in	IN	O
orthotopic	NN	O
liver	NN	O
transplantation	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
different	JJ	O
aprotinin	NN	PM
applications	NNS	PM
on	IN	O
hemostatic	JJ	O
changes	NNS	O
and	CC	O
blood	NN	O
product	NN	O
requirements	NNS	O
in	IN	O
orthotopic	JJ	O
liver	NN	O
transplantation	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
open	JJ	O
,	,	O
and	CC	O
randomized	VBD	O
study	NN	O
.	.	O

From	IN	O
November	NNP	O
1989	CD	O
to	TO	O
June	NNP	O
1990	CD	O
,	,	O
13	CD	O
patients	NNS	O
received	VBD	O
aprotinin	RB	PM
as	IN	O
a	DT	O
bolus	NN	PM
of	IN	PM
0.5	CD	PM
Mill	NNP	PM
.	.	O

Kallikrein	NNP	O
inactivator	JJ	O
units	NNS	O
(	(	O
KIU	NNP	O
)	)	O
on	IN	O
three	CD	O
occasions	NNS	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
an	DT	O
OLT	NNP	O
,	,	O
whereas	RB	O
10	CD	O
other	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
continuous	JJ	PM
aprotinin	JJ	PM
infusion	NN	PM
of	IN	PM
0.1-0.4	JJ	PM
Mill	NNP	PM
.	.	PM

KIU/hr	NNP	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
reperfusion	NN	O
of	IN	O
the	DT	O
graft	NN	O
liver	NN	O
,	,	O
signs	NNS	O
of	IN	O
hyperfibrinolysis	NN	O
,	,	O
measured	VBN	O
by	IN	O
thrombelastography	NN	O
,	,	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Tissue-type	JJ	O
plasminogen	NN	O
activator	NN	O
(	(	O
t-PA	JJ	O
)	)	O
activity	NN	O
increased	VBD	O
during	IN	O
the	DT	O
anhepatic	JJ	O
phase	NN	O
but	CC	O
to	TO	O
a	DT	O
significantly	RB	O
lesser	JJR	O
extent	NN	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Blood	NNP	O
product	NN	O
requirements	NNS	O
during	IN	O
OLT	NNP	O
were	VBD	O
tendentiously	RB	O
higher	JJR	O
in	IN	O
the	DT	O
bolus	NN	O
group	NN	O
but	CC	O
not	RB	O
significantly	RB	O
so	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
packed	JJ	O
red	JJ	O
blood	NN	O
cells	NNS	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
,	,	O
whereas	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
fresh	JJ	O
frozen	NN	O
plasma	NN	O
requirements	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
23	CD	O
patients	NNS	O
have	VBP	O
survived	VBN	O
,	,	O
and	CC	O
only	RB	O
one	CD	O
woman	NN	O
of	IN	O
each	DT	O
group	NN	O
required	VBN	O
retransplantation	NN	O
due	JJ	O
to	TO	O
severe	VB	O
host-versus-graft	JJ	O
reactions	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
perfusate	NN	O
of	IN	O
the	DT	O
graft	NN	O
liver	NN	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
detected	JJ	O
signs	NNS	O
of	IN	O
a	DT	O
decreased	JJ	O
t-PA	JJ	O
release	NN	O
in	IN	O
the	DT	O
infusion	NN	O
group	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
demonstrate	VBP	O
an	DT	O
advantage	NN	O
of	IN	O
aprotinin	NN	PM
given	VBN	O
as	IN	O
continuous	JJ	O
infusion	NN	O
over	IN	O
bolus	JJ	O
application	NN	O
in	IN	O
OLT	NNP	O
.	.	O

The	DT	O
peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	JJ	O
agonist	NN	O
pioglitazone	NN	PM
increases	VBZ	O
number	NN	O
and	CC	O
function	NN	O
of	IN	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

OBJECTIVE	CC	O
Peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	NN	O
(	(	O
PPAR	NNP	O
gamma	NN	O
)	)	O
agonists	VBZ	O
(	(	O
thiazolidinediones	NNS	PM
[	NNP	PM
TZDs	NNP	PM
]	NNP	O
)	)	O
are	VBP	O
used	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

Bone	CD	O
marrow-derived	JJ	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
(	(	O
EPCs	NNP	O
)	)	O
improve	VB	O
vascular	JJ	O
function	NN	O
and	CC	O
predict	NN	O
cardiovascular	NN	O
risk	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
pioglitazone	NN	PM
therapy	NN	O
on	IN	O
EPCs	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
patients	NNS	O
with	IN	O
documented	JJ	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

Of	IN	O
54	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
fasting	VBG	O
glucose	JJ	O
levels	NNS	O
,	,	O
18	CD	O
showed	VBD	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
and	CC	O
36	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
30-day	JJ	O
treatment	NN	O
with	IN	O
pioglitazone	NN	PM
(	(	O
45	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
addition	NN	O
to	TO	O
optimal	VB	O
medical	JJ	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
in	IN	O
the	DT	O
TZD	NNP	PM
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
adiponectin	JJ	O
levels	NNS	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
compliance	NN	O
(	(	O
11.4	CD	O
+/-	JJ	O
1.1	CD	O
to	TO	O
36.8	CD	O
+/-	JJ	O
2.1	CD	O
microg/ml	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

TZD	NNP	PM
,	,	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
decreased	VBN	O
mean	JJ	O
high-sensitivity	NN	O
C-reactive	JJ	O
protein	NN	O
to	TO	O
43	CD	O
+/-	JJ	O
19	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Pioglitazone	NN	O
increased	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
/kinase	NN	O
insert	JJ	O
domain	NN	O
receptor	NN	O
(	(	O
+	NNP	O
)	)	O
EPCs	NNP	O
to	TO	O
142	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
and	CC	O
cultured	VBD	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	JJ	O
acetylated	JJ	O
LDL	NNP	O
(	(	O
+	NNP	O
)	)	O
/lectin	NN	O
(	(	O
+	NNP	O
)	)	O
EPCs	NNP	O
to	TO	O
180	CD	O
+/-	JJ	O
3	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

EPC	JJ	O
numbers	NNS	O
were	VBD	O
not	RB	O
changed	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

TZD	NNP	O
increased	VBD	O
the	DT	O
SDF-1-induced	NNP	O
migratory	NN	O
capacity	NN	O
to	TO	O
146	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
per	IN	O
EPC	NNP	O
number	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
upregulated	VBD	O
the	DT	O
clonogenic	JJ	O
potential	NN	O
of	IN	O
EPCs	NNP	O
,	,	O
increasing	VBG	O
the	DT	O
colony-forming	JJ	O
units	NNS	O
to	TO	O
172	CD	O
+/-	JJ	O
12	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
cultured	JJ	O
human	JJ	O
EPCs	NNP	O
,	,	O
TZD	NNP	PM
increased	VBD	O
EPC	NNP	O
numbers	NNS	O
and	CC	O
migration	NN	O
and	CC	O
reduced	JJ	O
NADPH-oxidase	NNP	O
activity	NN	O
.	.	O

The	DT	O
TZD	NNP	PM
effect	NN	O
was	VBD	O
reversed	VBN	O
by	IN	O
the	DT	O
PPAR	NNP	O
gamma	NN	O
antagonist	NN	O
GW9662	NNP	O
and	CC	O
mimicked	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
adiponectin	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
PPAR	NNP	O
gamma	NN	O
agonist	NN	O
pioglitazone	NN	PM
increases	VBZ	O
the	DT	O
number	NN	O
and	CC	O
function	NN	O
of	IN	O
EPCs	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

The	DT	O
effect	NN	O
represents	VBZ	O
a	DT	O
potential	JJ	O
regenerative	NN	O
mechanism	NN	O
in	IN	O
atherosclerosis	NN	O
and	CC	O
is	VBZ	O
observed	VBN	O
in	IN	O
normoglycemic	JJ	O
individuals	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
Naftidrofuryl	NNP	PM
on	IN	O
ethanol-induced	JJ	O
liver	NN	O
damage	NN	O
in	IN	O
chronic	JJ	O
alcoholic	JJ	O
patients	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	C
trial	NN	O
of	IN	O
intramuscular	JJ	O
Naftidrofuryl	NNP	PM
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
32	CD	O
randomly	RB	O
selected	VBN	O
hospitalized	VBN	O
male	JJ	O
alcoholic	JJ	O
patients	NNS	O
with	IN	O
clinical	JJ	O
,	,	O
biochemical	JJ	O
and	CC	O
histological	JJ	O
evidence	NN	O
of	IN	O
hepatic	JJ	O
damage	NN	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
received	VBD	O
the	DT	O
drug	NN	O
(	(	O
40	CD	O
mg	NN	O
in	IN	O
5	CD	O
ml	NN	O
i.m	NN	O
.	.	O

three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
)	)	O
and	CC	O
15	CD	O
patients	NNS	O
received	VBD	O
a	DT	O
placebo	NN	PM
(	(	O
5	CD	O
ml	NN	O
in	IN	O
normal	JJ	O
saline	JJ	O
i.m	NN	O
.	.	O

three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
drug	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
adverse	JJ	O
side-effects	NNS	O
.	.	O

Naftidrofuryl	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
physiological	JJ	O
function	NN	O
of	IN	O
the	DT	O
liver	NN	O
cells	NNS	O
as	IN	O
reflected	VBN	O
by	IN	O
indocyanine	NN	O
green	NN	O
(	(	O
ICG	NNP	O
)	)	O
clearance	NN	O
by	IN	O
the	DT	O
liver	NN	O
(	(	O
t	JJ	O
=	VBZ	O
2.61	CD	O
;	:	O
p	NN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.02	CD	O
)	)	O
and	CC	O
also	RB	O
caused	VBD	O
a	DT	O
larger	JJR	O
fall	NN	O
in	IN	O
raised	VBN	O
serum	NN	O
levels	NNS	O
of	IN	O
gamma	NN	O
glutamyl	NN	O
transpeptidase	NN	O
(	(	O
GGT	NNP	O
)	)	O
than	IN	O
did	VBD	O
the	DT	O
placebo	NN	O
injections	NNS	O
.	.	O

Overall	JJ	O
clinical	JJ	O
improvement	NN	O
(	(	O
e.g	NN	O
.	.	O

appetite	NN	O
,	,	O
body	NN	O
weight	NN	O
,	,	O
reduced	VBD	O
liver	JJ	O
size	NN	O
,	,	O
general	JJ	O
sense	NN	O
of	IN	O
well-being	NN	O
)	)	O
was	VBD	O
more	RBR	O
clearly	RB	O
evident	JJ	O
in	IN	O
patients	NNS	O
of	IN	O
the	DT	O
treated	VBN	O
group	NN	O
than	IN	O
in	IN	O
those	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Naftidrofuryl	NNP	PM
,	,	O
therefore	RB	O
,	,	O
appears	VBZ	O
to	TO	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
ethanol-induced	JJ	O
liver	NN	O
damage	NN	O
and	CC	O
more	RBR	O
extensive	JJ	O
long-term	JJ	O
trials	NNS	O
are	VBP	O
suggested	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
(	(	O
ALD	NNP	O
)	)	O
.	.	O

?-Blockers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
arterial	JJ	O
hypertension	NN	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
nebivolol	NN	O
or	CC	O
metoprolol	NN	O
in	IN	O
arterial	JJ	O
occlusive	JJ	O
disease	NN	O
trial	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
?-receptor	NN	O
blockers	NNS	O
in	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
is	VBZ	O
controversial	JJ	O
for	IN	O
their	PRP$	O
impact	NN	O
on	IN	O
vasomotor	NN	O
tone	NN	O
.	.	O

The	DT	O
?-blocker	NN	O
nebivolol	NN	O
possesses	VBZ	O
vasodilating	VBG	O
,	,	O
endothelium-dependent	JJ	O
,	,	O
NO-releasing	JJ	O
properties	NNS	O
that	WDT	O
might	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
and	CC	O
tolerability	NN	O
of	IN	O
nebivolol	NN	O
in	IN	O
comparison	NN	O
with	IN	O
metoprolol	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
128	CD	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
essential	JJ	O
hypertension	NN	O
were	VBD	O
included	VBN	O
and	CC	O
double-blind	JJ	O
randomized	VBN	O
to	TO	O
receive	VB	O
5	CD	O
mg	NN	O
of	IN	O
nebivolol	NN	O
(	(	O
N=65	NNP	O
)	)	O
or	CC	O
95	CD	O
mg	NN	O
of	IN	O
metoprolol	NN	O
(	(	O
N=63	NNP	O
)	)	O
once	RB	O
daily	JJ	O
.	.	O

End	NN	O
points	NNS	O
were	VBD	O
changes	NNS	O
in	IN	O
ankle-brachial	JJ	O
index	NN	O
,	,	O
initial	JJ	O
and	CC	O
absolute	JJ	O
claudication	NN	O
distance	NN	O
,	,	O
endothelial	JJ	O
function	NN	O
assessed	VBN	O
by	IN	O
flow-mediated	JJ	O
dilatation	NN	O
of	IN	O
the	DT	O
brachial	JJ	O
artery	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
using	VBG	O
the	DT	O
claudication	NN	O
scale	NN	O
questionnaire	NN	O
.	.	O

End	NN	O
point	NN	O
analysis	NN	O
was	VBD	O
possible	JJ	O
in	IN	O
109	CD	O
patients	NNS	O
(	(	O
85.2	CD	O
%	NN	O
)	)	O
.	.	O

After	IN	O
the	DT	O
48-week	JJ	O
treatment	NN	O
period	NN	O
,	,	O
ankle-brachial	JJ	O
index	NN	O
and	CC	O
absolute	JJ	O
claudication	NN	O
distance	NN	O
improved	VBD	O
significantly	RB	O
in	IN	O
both	DT	O
patient	JJ	O
groups	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
for	IN	O
both	DT	O
)	)	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
across	IN	O
treatments	NNS	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
initial	JJ	O
claudication	NN	O
distance	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
nebivolol	JJ	O
group	NN	O
.	.	O

Adjusted	VBN	O
mean	JJ	O
change	NN	O
of	IN	O
initial	JJ	O
claudication	NN	O
distance	NN	O
was	VBD	O
33.9	CD	O
%	NN	O
after	IN	O
nebivolol	NN	O
(	(	O
P=0.003	NNP	O
)	)	O
and	CC	O
16.6	CD	O
%	NN	O
after	IN	O
metoprolol	NN	O
(	(	O
P=0.12	NNP	O
)	)	O
treatment	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
relevant	JJ	O
change	NN	O
in	IN	O
flow-mediated	JJ	O
dilatation	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
nebivolol	NN	O
or	CC	O
metoprolol	NN	O
(	(	O
P=0.16	NNP	O
)	)	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
lowering	VBG	O
blood	NN	O
pressure	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
?-blocker	JJ	O
therapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
arterial	JJ	O
hypertension	NN	O
during	IN	O
a	DT	O
treatment	NN	O
period	NN	O
of	IN	O
?1	JJ	O
year	NN	O
.	.	O

In	IN	O
the	DT	O
direct	JJ	O
comparison	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
nebivolol	NNS	O
and	CC	O
metoprolol	NN	O
.	.	O

Preliminary	JJ	O
findings	NNS	O
of	IN	O
the	DT	O
minimally-invasive	JJ	S
surgery	NN	S
plus	CC	S
rtPA	NN	S
for	IN	O
intracerebral	JJ	O
hemorrhage	NN	O
evacuation	NN	O
(	(	O
MISTIE	NNP	O
)	)	O
clinical	JJ	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
Compared	VBD	O
to	TO	O
ischemic	VB	O
stroke	NN	O
,	,	O
intracerebral	JJ	O
hemorrhage	NN	O
(	(	O
ICH	NNP	O
)	)	O
is	VBZ	O
easily	RB	O
and	CC	O
rapidly	RB	O
identified	VBN	O
,	,	O
occurs	VBZ	O
in	IN	O
younger	JJR	O
patients	NNS	O
,	,	O
and	CC	O
produces	VBZ	O
relatively	RB	O
small	JJ	O
initial	JJ	O
injury	NN	O
to	TO	O
cerebral	JJ	O
tissues	NNS	O
--	:	O
all	DT	O
factors	NNS	O
suggesting	VBG	O
that	IN	O
interventional	JJ	O
amelioration	NN	O
is	VBZ	O
possible	JJ	O
.	.	O

Investigations	NNS	O
from	IN	O
the	DT	O
last	JJ	O
decade	NN	O
established	VBD	O
that	IN	O
extent	NN	O
of	IN	O
ICH-mediated	NNP	O
brain	NN	O
injury	NN	O
relates	VBZ	O
directly	RB	O
to	TO	O
blood	VB	O
clot	NN	O
volume	NN	O
and	CC	O
duration	NN	O
of	IN	O
blood	NN	O
exposure	NN	O
to	TO	O
brain	NN	O
tissue	NN	O
.	.	O

Using	VBG	O
minimally-invasive	JJ	S
surgery	NN	S
plus	CC	S
recombinant	JJ	S
tissue	NN	S
plasminogen	NN	S
activator	NN	S
(	(	S
rtPA	NN	S
)	)	S
,	,	O
MISTIE	NNP	O
investigators	NNS	O
explored	VBD	O
aggressive	JJ	O
avenues	NNS	O
to	TO	O
treat	VB	O
ICH	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
difference	NN	O
between	IN	O
surgical	JJ	S
intervention	NN	S
plus	CC	S
rtPA	NN	S
and	CC	O
standard	JJ	O
medical	JJ	O
management	NN	O
for	IN	O
ICH	NNP	O
.	.	O

Subjects	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
medically	RB	O
managed	VBN	O
according	VBG	O
to	TO	O
standard	JJ	O
ICU	NNP	O
protocols	NNS	O
.	.	O

Subjects	NNS	O
randomized	VBD	O
to	TO	O
surgery	VB	O
underwent	JJ	O
stereotactic	JJ	S
catheter	NN	S
placement	NN	S
and	CC	S
clot	NN	S
aspiration	NN	S
.	.	O

Injections	NNS	PM
of	IN	PM
rtPA	NN	PM
were	VBD	O
then	RB	O
given	VBN	O
through	IN	O
hematoma	NN	O
catheter	NN	O
every	DT	O
8	CD	O
h	NN	O
,	,	O
up	RB	O
to	TO	O
9	CD	O
doses	NNS	O
,	,	O
or	CC	O
until	IN	O
a	DT	O
clot-reduction	JJ	O
endpoint	NN	O
.	.	O

After	IN	O
each	DT	O
injection	NN	O
the	DT	O
system	NN	O
was	VBD	O
flushed	VBN	O
with	IN	O
sterile	JJ	PM
saline	NN	PM
and	CC	O
closed	VBD	O
for	IN	O
60	CD	O
min	NN	O
before	IN	O
opening	VBG	O
to	TO	O
spontaneous	JJ	O
drainage	NN	O
.	.	O

RESULTS	JJ	O
Average	JJ	O
aspiration	NN	O
of	IN	O
clots	NNS	O
for	IN	O
all	DT	O
patients	NNS	O
randomized	VBN	O
to	TO	O
surgery	VB	O
plus	CC	O
rtPA	VB	O
was	VBD	O
20	CD	O
%	NN	O
of	IN	O
mean	JJ	O
initial	JJ	O
clot	NN	O
size	NN	O
.	.	O

After	IN	O
acute	JJ	O
treatment	NN	O
phase	NN	O
(	(	O
aspiration	NN	O
plus	CC	O
rtPA	NN	O
)	)	O
,	,	O
clot	NN	O
was	VBD	O
reduced	VBN	O
an	DT	O
average	NN	O
of	IN	O
46	CD	O
%	NN	O
.	.	O

Recorded	VBN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
within	IN	O
safety	NN	O
limits	NNS	O
,	,	O
including	VBG	O
30-day	JJ	O
mortality	NN	O
,	,	O
8	CD	O
%	NN	O
;	:	O
symptomatic	JJ	O
re-bleeding	NN	O
,	,	O
8	CD	O
%	NN	O
;	:	O
and	CC	O
bacterial	JJ	O
ventriculitis	NN	O
,	,	O
0	CD	O
%	NN	O
.	.	O

Patients	NNS	O
randomized	VBD	O
to	TO	O
medical	JJ	O
management	NN	O
showed	VBD	O
4	CD	O
%	NN	O
clot	NN	O
resolution	NN	O
in	IN	O
a	DT	O
similar	JJ	O
time	NN	O
window	NN	O
.	.	O

Preliminary	JJ	O
analysis	NN	O
indicates	VBZ	O
that	IN	O
clot	NN	O
resolution	NN	O
rates	NNS	O
are	VBP	O
greatly	RB	O
dependent	JJ	O
on	IN	O
catheter	NN	O
placement	NN	O
.	.	O

Location	NN	O
of	IN	O
ICH	NNP	O
also	RB	O
affects	VBZ	O
efficacy	NN	O
of	IN	O
aggressive	JJ	O
treatment	NN	O
of	IN	O
ICH	NNP	O
.	.	O

CONCLUSION	NNP	O
There	EX	O
is	VBZ	O
tentative	JJ	O
indication	NN	O
that	IN	O
minimally-invasive	JJ	O
surgery	NN	O
plus	CC	O
rtPA	NN	O
shows	NNS	O
greater	JJR	O
clot	NN	O
resolution	NN	O
than	IN	O
traditional	JJ	O
medical	JJ	O
management	NN	O
.	.	O

Hypotensive	JJ	O
effects	NNS	O
and	CC	O
influence	NN	O
on	IN	O
serum	NN	O
lipids	NNS	O
of	IN	O
SQ29,852	NNP	PM
,	,	PM
a	DT	PM
new	JJ	PM
angiotensin	NN	PM
converting	VBG	PM
enzyme	JJ	PM
inhibitor	NN	PM
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
:	:	O
a	DT	O
comparison	NN	O
with	IN	O
atenolol	NN	PM
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
SQ29,852	NNP	PM
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
,	,	O
a	DT	O
new	JJ	O
angiotensin	NN	PM
converting	VBG	PM
enzyme	JJ	PM
inhibitor	NN	PM
,	,	O
and	CC	O
atenolol	NN	PM
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
,	,	O
monotherapies	NNS	O
were	VBD	O
compared	VBN	O
in	IN	O
46	CD	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
essential	JJ	O
hypertension	NN	O
.	.	O

Both	DT	O
SQ29,852	NNP	PM
(	(	O
mean	VBP	O
dose	RB	O
15.0	CD	O
+/-	JJ	O
5.1	CD	O
mg/day	NN	O
)	)	O
and	CC	O
atenolol	$	PM
(	(	O
mean	VB	O
dose	RB	O
37.5	CD	O
+/-	JJ	O
18.5	CD	O
mg/day	NN	O
)	)	O
significantly	RB	O
decreased	VBN	O
both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressures	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
serum	NN	O
lipids	NNS	O
,	,	O
apolipoproteins	NNS	O
,	,	O
lipoproteins	VBZ	O
or	CC	O
atherosclerotic	JJ	O
indices	NNS	O
after	IN	O
both	DT	O
SQ29,852	NNP	PM
and	CC	O
atenolol	RB	PM
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
significant	JJ	O
inter-group	JJ	O
differences	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
side	NN	O
effects	NNS	O
or	CC	O
abnormal	JJ	O
laboratory	NN	O
tests	NNS	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
SQ29,852	NNP	PM
is	VBZ	O
an	DT	O
effective	JJ	O
antihypertensive	JJ	O
drug	NN	O
without	IN	O
adverse	JJ	O
effect	NN	O
on	IN	O
lipid	JJ	O
metabolism	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
random	JJ	PH
modulation	NN	PH
of	IN	PH
functional	JJ	PH
electrical	JJ	PH
stimulation	NN	PH
parameters	NNS	PH
on	IN	O
muscle	NN	O
fatigue	NN	O
.	.	O

Muscle	NNP	O
contractions	NNS	O
induced	VBN	O
by	IN	O
functional	JJ	PH
electrical	JJ	PH
stimulation	NN	PH
(	(	O
FES	NNP	O
)	)	O
tend	VBP	O
to	TO	O
result	VB	O
in	IN	O
rapid	JJ	O
muscle	NN	O
fatigue	NN	O
,	,	O
which	WDT	O
greatly	RB	O
limits	VBZ	O
activities	NNS	O
such	JJ	O
as	IN	O
FES-assisted	JJ	O
standing	NN	O
and	CC	O
walking	NN	O
.	.	O

It	PRP	O
was	VBD	O
hypothesized	VBN	O
that	IN	O
muscle	NN	O
fatigue	NN	O
caused	VBN	O
by	IN	O
FES	NNP	O
could	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
randomly	RB	O
modulating	VBG	O
parameters	NNS	O
of	IN	O
the	DT	O
electrical	JJ	O
stimulus	NN	O
.	.	O

Seven	NNP	O
paraplegic	JJ	O
subjects	NNS	O
participated	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

While	IN	O
subjects	NNS	O
were	VBD	O
seated	VBN	O
,	,	O
FES	NNP	O
was	VBD	O
applied	VBN	O
to	TO	O
quadriceps	NNS	O
and	CC	O
tibialis	JJ	O
anterior	JJ	O
muscles	NNS	O
bilaterally	RB	O
using	VBG	O
surface	NN	O
electrodes	NNS	O
.	.	O

The	DT	O
isometric	JJ	O
force	NN	O
was	VBD	O
measured	VBN	O
,	,	O
and	CC	O
the	DT	O
time	NN	O
for	IN	O
the	DT	O
force	NN	O
to	TO	O
drop	VB	O
by	IN	O
3	CD	O
dB	NN	O
(	(	O
fatigue	JJ	O
time	NN	O
)	)	O
and	CC	O
the	DT	O
normalized	JJ	O
force-time	JJ	O
integral	JJ	O
(	(	O
FTI	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

Four	CD	O
different	JJ	O
modes	NNS	O
of	IN	O
FES	NNP	O
were	VBD	O
applied	VBN	O
in	IN	O
random	JJ	O
order	NN	O
:	:	O
constant	JJ	O
stimulation	NN	O
,	,	O
randomized	VBN	O
frequency	NN	O
(	(	O
mean	JJ	O
40	CD	O
Hz	NNP	O
)	)	O
,	,	O
randomized	VBN	O
current	JJ	O
amplitude	NN	O
,	,	O
and	CC	O
randomized	VBD	O
pulsewidth	NN	O
(	(	O
mean	JJ	O
250	CD	O
micros	NN	O
)	)	O
.	.	O

In	IN	O
randomized	JJ	O
trials	NNS	O
,	,	O
stimulation	NN	O
parameters	NNS	O
were	VBD	O
stochastically	RB	O
modulated	VBN	O
every	DT	O
100	CD	O
ms	NN	O
in	IN	O
a	DT	O
range	NN	O
of	IN	O
+/-15	NNP	O
%	NN	O
using	VBG	O
a	DT	O
uniform	JJ	O
probability	NN	O
distribution	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
fatigue	NN	O
time	NN	O
measurements	NNS	O
for	IN	O
the	DT	O
four	CD	O
modes	NNS	O
of	IN	O
stimulation	NN	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
FTI	NNP	O
measurements	NNS	O
.	.	O

Therefore	RB	O
,	,	O
our	PRP$	O
particular	JJ	O
method	NN	O
of	IN	O
stochastic	JJ	O
modulation	NN	O
of	IN	O
the	DT	O
stimulation	NN	O
parameters	NNS	O
,	,	O
which	WDT	O
involved	VBD	O
moderate	JJ	O
(	(	O
15	CD	O
%	NN	O
)	)	O
variations	NNS	O
updated	VBN	O
every	DT	O
100	CD	O
ms	NN	O
and	CC	O
centered	VBD	O
around	IN	O
40	CD	O
Hz	NNP	O
,	,	O
appeared	VBD	O
to	TO	O
have	VB	O
no	DT	O
effect	NN	O
on	IN	O
muscle	NN	O
fatigue	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
maximum	JJ	O
force	NN	O
measurements	NNS	O
and	CC	O
stimulation	NN	O
order	NN	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
apparent	JJ	O
in	IN	O
the	DT	O
fatigue	JJ	O
time	NN	O
or	CC	O
FTI	NNP	O
measurements	NNS	O
.	.	O

It	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
a	DT	O
10-min	JJ	O
rest	NN	O
period	NN	O
between	IN	O
stimulation	NN	O
trials	NNS	O
was	VBD	O
insufficient	JJ	O
to	TO	O
allow	VB	O
full	JJ	O
recovery	NN	O
of	IN	O
muscle	NN	O
strength	NN	O
.	.	O

The	DT	O
evaluation	NN	O
of	IN	O
pulmonary	JJ	O
hypertension	NN	O
using	VBG	O
right	JJ	PH
ventricular	JJ	PH
myocardial	JJ	PH
isovolumic	JJ	PH
relaxation	NN	PH
time	NN	PH
.	.	O

Right	JJ	O
ventricular	NN	O
(	(	O
RV	NNP	O
)	)	O
blood	VBD	O
pool-derived	JJ	O
isovolumic	JJ	O
relaxation	NN	O
time	NN	O
(	(	O
IVRT	NNP	O
)	)	O
correlates	VBZ	O
well	RB	O
with	IN	O
systolic	JJ	O
pulmonary	JJ	O
arterial	JJ	O
pressure	NN	O
(	(	O
PAP	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
because	IN	O
of	IN	O
complex	JJ	O
parameter	NN	O
derivation	NN	O
,	,	O
the	DT	O
method	NN	O
is	VBZ	O
rarely	RB	O
used	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
validate	VB	O
the	DT	O
measurement	NN	O
of	IN	O
myocardial	JJ	O
velocity	NN	O
imaging-derived	JJ	O
RV	NNP	PH
IVRT	NNP	PH
(	(	PH
IVRT	NNP	PH
'	POS	PH
)	)	PH
against	IN	O
invasively	RB	S
measured	VBN	S
PAP	NNP	S
.	.	S

Transthoracic	NNP	PH
echocardiography	NN	PH
with	IN	PH
myocardial	JJ	PH
velocity	NN	PH
imaging	NN	PH
and	CC	PH
right	JJ	S
heart	NN	S
catheterization	NN	S
were	VBD	O
performed	VBN	O
in	IN	O
33	CD	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
hypertension	NN	O
.	.	O

Blood	NNP	O
pool	NN	O
IVRT	NNP	O
and	CC	O
myocardial	JJ	O
IVRTs	NNP	O
for	IN	O
the	DT	O
tricuspid	JJ	O
valve	NN	O
annulus	NN	O
ring	NN	O
,	,	O
basal	NN	O
and	CC	O
apical	JJ	O
RV	NNP	O
free	JJ	O
wall	NN	O
segments	NNS	O
were	VBD	O
measured	VBN	O
and	CC	O
compared	VBN	O
with	IN	O
data	NNS	O
from	IN	O
33	CD	O
age-	JJ	O
and	CC	O
sex-matched	JJ	O
control	NN	O
subjects	NNS	O
.	.	O

Measured	VBN	O
IVRTs	NNP	O
were	VBD	O
significantly	RB	O
longer	RBR	O
in	IN	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
hypertension	NN	O
than	IN	O
in	IN	O
control	NN	O
subjects	NNS	O
.	.	O

The	DT	O
strongest	JJS	O
correlation	NN	O
(	(	O
R	NNP	O
=	NNP	O
0.74	CD	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
was	VBD	O
found	VBN	O
between	IN	O
systolic	JJ	O
PAP	NNP	O
and	CC	O
the	DT	O
heart	NN	O
rate-corrected	JJ	O
IVRT	NNP	O
'	POS	O
derived	VBN	O
from	IN	O
the	DT	O
basal	NN	O
RV	NNP	O
free	JJ	O
wall	NN	O
segment	NN	O
.	.	O

The	DT	O
basal	NN	O
segment	NN	O
IVRT	NNP	O
'	POS	O
corrected	VBN	O
for	IN	O
heart	NN	O
rate	NN	O
correlates	NNS	O
well	RB	O
with	IN	O
the	DT	O
invasive	JJ	O
PAP	NNP	O
measurement	NN	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
predict	VB	O
systolic	JJ	O
PAP	NNP	O
.	.	O

It	PRP	O
can	MD	O
even	RB	O
be	VB	O
considered	VBN	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
tricuspid	VB	O
regurgitation-derived	JJ	O
PAP	NNP	O
systolic	NN	O
when	WRB	O
tricuspid	JJ	O
regurgitation	NN	O
is	VBZ	O
nonrecordable	JJ	O
.	.	O

A	DT	O
proposed	VBN	O
method	NN	O
to	TO	O
derive	VB	O
systolic	JJ	O
PAP	NNP	O
should	MD	O
be	VB	O
used	VBN	O
while	IN	O
screening	VBG	O
the	DT	O
patients	NNS	O
at	IN	O
risk	NN	O
for	IN	O
pulmonary	JJ	O
hypertension	NN	O
,	,	O
monitoring	VBG	O
the	DT	O
disease	NN	O
progression	NN	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
.	.	O

Treatment	NN	O
of	IN	O
vasculogenic	JJ	O
sexual	JJ	O
dysfunction	NN	O
with	IN	O
pentoxifylline	NN	PM
.	.	PM

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
use	NN	O
of	IN	O
pentoxifylline	NN	PM
to	TO	O
treat	VB	O
impotence	NN	O
in	IN	O
men	NNS	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
penile	IN	O
vascular	JJ	O
insufficiency	NN	O
.	.	O

DESIGN	NNP	O
Double-blind	NNP	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Sexual	JJ	O
Dysfunction	NNP	O
Clinic	NNP	O
at	IN	O
VA	NNP	O
Medical	NNP	O
Center	NNP	O
,	,	O
Sepulveda	NNP	O
,	,	O
CA	NNP	O
.	.	O

PARTICIPANTS	NNP	O
Convenience	NNP	O
sample	NN	O
of	IN	O
couples	NNS	O
.	.	O

INTERVENTION	NNP	O
Twelve	NNP	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
placebo	NN	C
or	CC	O
400	CD	PM
mg	JJ	PM
tid	NN	PM
of	IN	PM
pentoxifylline	NN	PM
.	.	O

MEASUREMENTS	NNP	O
(	(	O
1	CD	O
)	)	O
Report	NN	O
of	IN	O
patient	JJ	O
verified	VBN	O
by	IN	O
partner	NN	O
as	IN	O
to	TO	O
number	NN	O
of	IN	O
coital	JJ	O
episodes	NNS	O
per	IN	O
month	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
penile-brachial	JJ	O
pressure	NN	O
index	NN	O
determinations	NNS	O
.	.	O

RESULTS	NNP	O
Pentoxifylline	NNP	PM
therapy	VBZ	PM
regularly	RB	O
increased	VBN	O
the	DT	O
PBPI	NNP	O
in	IN	O
impotent	JJ	O
men	NNS	O
in	IN	O
comparison	NN	O
with	IN	O
the	DT	O
placebo	NN	O
,	,	O
frequently	RB	O
into	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

Pentoxifylline	NNP	O
therapy	NN	O
was	VBD	O
particularly	RB	O
useful	JJ	O
in	IN	O
restoring	VBG	O
the	DT	O
PBPI	NNP	O
in	IN	O
men	NNS	O
with	IN	O
the	DT	O
pelvic	JJ	O
steal	JJ	O
syndrome	NN	O
;	:	O
six	CD	O
of	IN	O
seven	CD	O
such	JJ	O
subjects	NNS	O
improved	VBN	O
into	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

During	IN	O
the	DT	O
pentoxifylline	JJ	O
treatment	NN	O
period	NN	O
,	,	O
in	IN	O
contrast	NN	O
with	IN	O
the	DT	O
control	NN	O
period	NN	O
,	,	O
nine	CD	O
men	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
reestablish	VB	O
coital	JJ	O
function	NN	O
and	CC	O
three	CD	O
had	VBD	O
no	DT	O
improvement	NN	O
.	.	O

Six	NNP	O
couples	NNS	O
did	VBD	O
not	RB	O
attempt	VB	O
intercourse	JJ	O
despite	IN	O
a	DT	O
professed	JJ	O
interest	NN	O
in	IN	O
sexual	JJ	O
activity	NN	O
;	:	O
however	RB	O
five	CD	O
out	IN	O
of	IN	O
the	DT	O
six	CD	O
men	NNS	O
experienced	VBD	O
erections	NNS	O
during	IN	O
episodes	NNS	O
of	IN	O
fantasy	NN	O
or	CC	O
attempts	NNS	O
at	IN	O
masturbation	NN	O
during	IN	O
treatment	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
complications	NNS	O
of	IN	O
therapy	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
promising	VBG	O
preliminary	JJ	O
results	NNS	O
suggest	VBP	O
a	DT	O
well	RB	O
tolerated	JJ	O
alternative	JJ	O
therapy	NN	O
for	IN	O
erectile	JJ	O
dysfunction	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
penile	IN	O
vascular	JJ	O
disease	NN	O
.	.	O

Removal	NN	O
of	IN	O
inflammatory	JJ	O
cytokines	NNS	O
and	CC	O
endotoxin	NN	O
by	IN	O
veno-venous	JJ	PH
continuous	JJ	PH
renal	JJ	PH
replacement	NN	PH
therapy	NN	PH
for	IN	O
burned	JJ	O
patients	NNS	O
with	IN	O
sepsis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
veno-venous	JJ	PH
continuous	JJ	PH
renal	JJ	PH
replacement	NN	PH
therapy	NN	PH
(	(	PH
CRRT	NNP	PH
)	)	PH
on	IN	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
endotoxin	NN	O
and	CC	O
cytokines	NNS	O
in	IN	O
severely	RB	O
burned	VBN	O
patients	NNS	O
with	IN	O
sepsis	NN	O
.	.	O

METHODS	NNP	O
Twenty	NNP	O
adult	NN	O
severely	RB	O
burned	VBD	O
patients	NNS	O
with	IN	O
sepsis	NN	O
were	VBD	O
studied	VBN	O
.	.	O

For	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
sepsis	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
CRRT	NNP	PH
(	(	O
n=10	NN	O
)	)	O
and	CC	O
Control	NNP	C
(	(	O
n=10	RB	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
conventional	JJ	PH
therapy	NN	PH
after	IN	O
admission	NN	O
.	.	O

Veno-venous	JJ	PH
CRRT	NNP	PH
was	VBD	O
administered	VBN	O
to	TO	O
10	CD	O
patients	NNS	O
in	IN	O
the	DT	O
CRRT	NNP	O
group	NN	O
whenever	WDT	O
patients	NNS	O
were	VBD	O
determined	VBN	O
to	TO	O
be	VB	O
septic	JJ	O
.	.	O

The	DT	O
plasma	JJ	O
level	NN	O
of	IN	O
endotoxin	NN	O
,	,	O
TNF-alpha	NNP	O
,	,	O
IL-1	NNP	O
beta	NN	O
,	,	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
were	VBD	O
measured	VBN	O
at	IN	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
CRRT	NNP	O
initiation	NN	O
,	,	O
and	CC	O
at	IN	O
0	CD	O
,	,	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
diagnosed	VBN	O
as	IN	O
having	VBG	O
sepsis	NN	O
in	IN	O
the	DT	O
Control	NNP	O
group	NN	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Plasma	NNP	O
level	NN	O
of	IN	O
endotoxin	NN	O
and	CC	O
all	PDT	O
the	DT	O
cytokines	NNS	O
after	IN	O
CRRT	NNP	O
initiation	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
before	IN	O
the	DT	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
serial	JJ	O
change	NN	O
of	IN	O
endotoxin	NN	O
,	,	O
IL-1	NNP	O
beta	NN	O
,	,	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
at	IN	O
12	CD	O
,	,	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
treatment	NN	O
compared	VBN	O
with	IN	O
Control	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
plasma	JJ	O
TNF-alpha	JJ	O
levels	NNS	O
was	VBD	O
seen	VBN	O
at	IN	O
36	CD	O
and	CC	O
60	CD	O
h	NN	O
after	IN	O
treatment	NN	O
compared	VBN	O
with	IN	O
Control	NNP	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Plasma	NNP	O
endotoxin	NN	O
and	CC	O
cytokines	NNS	O
(	(	O
TNF-alpha	NNP	O
,	,	O
IL-1	NNP	O
beta	NN	O
,	,	O
IL-6	NNP	O
and	CC	O
IL-8	NNP	O
)	)	O
can	MD	O
be	VB	O
removed	VBN	O
effectively	RB	O
with	IN	O
CRRT	NNP	O
in	IN	O
severely	RB	O
burned	VBN	O
patients	NNS	O
with	IN	O
sepsis	NN	O
.	.	O

Milk	NNP	O
production	NN	O
of	IN	O
dairy	NN	O
cows	NNS	O
fed	VBP	O
wet	JJ	O
corn	NN	O
gluten	NNS	O
feed	VBP	O
during	IN	O
the	DT	O
dry	JJ	O
period	NN	O
and	CC	O
lactation	NN	O
.	.	O

An	DT	O
experiment	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
36	CD	O
primiparous	JJ	O
and	CC	O
40	CD	O
multiparous	JJ	O
Holstein	NNP	O
cows	NNS	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
feeding	VBG	O
wet	JJ	Ot
corn	NN	Ot
gluten	NNS	Ot
feed	VBP	Ot
(	(	Ot
WCGF	NNP	Ot
)	)	Ot
on	IN	O
305-d	JJ	O
milk	NN	O
production	NN	O
,	,	O
dry	JJ	O
matter	NN	O
(	(	O
DM	NNP	O
)	)	O
intake	NN	O
,	,	O
body	NN	O
condition	NN	O
score	NN	O
(	(	O
BCS	NNP	O
)	)	O
,	,	O
and	CC	O
health	NN	O
.	.	O

The	DT	O
experimental	JJ	O
treatments	NNS	O
included	VBD	O
:	:	O
1	CD	O
)	)	O
control	NN	PH
--	:	PH
WCGF	NNP	PH
not	RB	PH
fed	RB	PH
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
;	:	O
2	CD	O
)	)	O
WCGF-L-cows	NNP	O
received	VBD	O
diets	NNS	Ot
containing	VBG	Ot
WCGF	NNP	Ot
(	(	O
38	CD	O
%	NN	O
DM	NNP	O
basis	NN	O
)	)	O
during	IN	O
lactation	NN	O
(	(	O
n	JJ	O
=	NNP	O
23	CD	O
)	)	O
;	:	O
and	CC	O
3	CD	O
)	)	O
WCGF-DL	NNP	O
--	:	O
cows	VBZ	O
received	VBN	O
diets	NNS	Ot
containing	VBG	Ot
WCGF	NNP	Ot
(	(	O
38	CD	O
%	NN	O
DM	NNP	O
basis	NN	O
)	)	O
during	IN	O
the	DT	O
dry	JJ	O
period	NN	O
and	CC	O
lactation	NN	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
.	.	O

During	IN	O
the	DT	O
dry	JJ	O
period	NN	O
,	,	O
cows	VBZ	O
consuming	VBG	O
WCGF	NNP	O
were	VBD	O
observed	VBN	O
to	TO	O
have	VB	O
a	DT	O
significant	JJ	O
gain	NN	O
in	IN	O
BCS	NNP	O
(	(	O
0.07	CD	O
+/-	JJ	O
0.06	CD	O
)	)	O
compared	VBN	O
with	IN	O
a	DT	O
loss	NN	O
in	IN	O
BCS	NNP	O
in	IN	O
cows	NNS	O
fed	VBP	O
the	DT	O
control	NN	O
diet	JJ	O
(	(	O
control	VB	O
=	NNP	O
-0.11	NNP	O
+/-	JJ	O
0.06	CD	O
and	CC	O
WCGF-L	NNP	O
=	NNP	O
-0.04	NNP	O
+/-	JJ	O
0.06	CD	O
)	)	O
.	.	O

During	IN	O
lactation	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
by	IN	O
treatment	NN	O
on	IN	O
BCS	NNP	O
.	.	O

Cows	NNP	O
consuming	VBG	O
WCGF	NNP	O
during	IN	O
lactation	NN	O
consumed	VBN	O
more	RBR	O
feed	JJ	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
:	:	O
25.4	CD	O
,	,	O
23.8	CD	O
,	,	O
and	CC	O
21.2	CD	O
+/-	JJ	O
0.76	CD	O
kg/d	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
.	.	O

Milk	NNP	O
production	NN	O
was	VBD	O
higher	JJR	O
for	IN	O
cows	NNS	O
consuming	VBG	O
WCGF	NNP	O
:	:	O
35.0	CD	O
,	,	O
34.7	CD	O
,	,	O
and	CC	O
31.1	CD	O
+/-	JJ	O
2.1	CD	O
kg/d	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
.	.	O

No	UH	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
either	DT	O
DM	NNP	O
intake	NN	O
or	CC	O
actual	JJ	O
milk	NN	O
yield	NN	O
between	IN	O
the	DT	O
WCGF-L	NNP	O
and	CC	O
WCGF-DL	NNP	O
treatments	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
prepartum	JJ	O
diets	NNS	O
did	VBD	O
not	RB	O
influence	VB	O
lactational	JJ	O
performance	NN	O
.	.	O

The	DT	O
WCGF	NNP	O
diets	NNS	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
concentration	NN	O
of	IN	O
milk	NN	O
fat	NN	O
(	(	O
3.94	CD	O
,	,	O
3.74	CD	O
,	,	O
and	CC	O
4.15	CD	O
+/-	JJ	O
0.08	CD	O
%	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
but	CC	O
because	IN	O
total	JJ	O
milk	NN	O
yield	NN	O
was	VBD	O
increased	VBN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
total	JJ	O
milk	NN	O
fat	JJ	O
yield	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
3.5	CD	O
%	NN	O
of	IN	O
fat-corrected	JJ	O
milk	NN	O
tended	VBN	O
to	TO	O
be	VB	O
affected	VBN	O
by	IN	O
diet	JJ	O
:	:	O
38.9	CD	O
,	,	O
36.3	CD	O
,	,	O
and	CC	O
34.7	CD	O
+/-	JJ	O
1.93	CD	O
kg/d	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
increasing	VBG	O
effect	NN	O
of	IN	O
DM	NNP	O
intake	NN	O
and	CC	O
milk	NN	O
yield	NN	O
in	IN	O
cows	NNS	O
consuming	VBG	O
WCGF	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
similar	JJ	O
efficiency	NN	O
of	IN	O
3.5	CD	O
%	NN	O
fat-corrected	JJ	O
milk	NN	O
production	NN	O
for	IN	O
all	DT	O
treatments	NNS	O
,	,	O
averaging	VBG	O
1.5	CD	O
+/-	JJ	O
0.09	CD	O
.	.	O

Total	JJ	O
protein	JJ	O
yields	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
for	IN	O
cows	NNS	O
consuming	VBG	O
WCGF	NNP	O
diets	NNS	O
during	IN	O
lactation	NN	O
:	:	O
1.15	CD	O
,	,	O
1.10	CD	O
,	,	O
1.00	CD	O
+/-	JJ	O
0.06	CD	O
kg/d	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
diets	NNS	O
may	MD	O
be	VB	O
formulated	VBN	O
to	TO	O
contain	VB	O
as	RB	O
much	JJ	O
as	IN	O
37.5	CD	O
%	NN	O
WCGF	NNP	O
(	(	O
DM	NNP	O
basis	NN	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
PostureJac	NNP	PH
on	IN	O
deep	JJ	O
cervical	JJ	O
flexor	NN	O
endurance	NN	O
:	:	O
implications	NNS	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
cervicogenic	JJ	O
headache	NN	O
and	CC	O
mechanical	JJ	O
neck	NN	O
pain	NN	O
.	.	O

The	DT	O
convergence	NN	O
of	IN	O
cervical	JJ	O
and	CC	O
trigeminal	JJ	O
afferents	NNS	O
on	IN	O
second-order	JJ	O
neurons	NNS	O
in	IN	O
the	DT	O
trigeminocervical	JJ	O
nucleus	NN	O
may	MD	O
refer	VB	O
pain	NN	O
from	IN	O
the	DT	O
upper	JJ	O
cervical	JJ	O
spine	NN	O
into	IN	O
the	DT	O
head	NN	O
and	CC	O
face	NN	O
.	.	O

Furthermore	RB	O
,	,	O
bi-directional	JJ	O
interactions	NNS	O
between	IN	O
trigeminal	JJ	O
and	CC	O
upper	JJ	O
cervical	JJ	O
afferents	NNS	O
may	MD	O
also	RB	O
explain	VB	O
neck	NN	O
symptoms	NNS	O
of	IN	O
trigeminal	JJ	O
origin	NN	O
(	(	O
e.g.	JJ	O
,	,	O
migraine	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
cervicogenic	JJ	O
headache	NN	O
sufferers	NNS	O
present	JJ	O
with	IN	O
several	JJ	O
musculoskeletal	JJ	O
changes	NNS	O
including	VBG	O
poor	JJ	O
endurance	NN	O
of	IN	O
the	DT	O
deep	JJ	O
cervical	JJ	O
flexor	NN	O
muscles	NNS	O
.	.	O

These	DT	O
intrinsic	JJ	O
muscles	NNS	O
of	IN	O
the	DT	O
neck	NN	O
contribute	NN	O
to	TO	O
stabilization	NN	O
and	CC	O
protection	NN	O
of	IN	O
the	DT	O
cervical	JJ	O
spine	NN	O
and	CC	O
are	VBP	O
critical	JJ	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
both	DT	O
intervertebral	JJ	O
motion	NN	O
and	CC	O
the	DT	O
cervical	JJ	O
lordosis	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
PostureJac	NNP	PH
(	(	O
SomatoCentric	NNP	O
Systems	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Toronto	NNP	O
,	,	O
Ontario	NNP	O
,	,	O
Canada	NNP	O
)	)	O
,	,	O
a	DT	O
posture	NN	O
support	NN	O
and	CC	O
exercise	NN	O
jacket	NN	O
,	,	O
was	VBD	O
effective	JJ	O
in	IN	O
enhancing	VBG	O
deep	JJ	O
cervical	JJ	O
muscle	NN	O
endurance	NN	O
.	.	O

Forty-five	JJ	O
(	(	O
45	CD	O
)	)	O
female	NN	O
subjects	NNS	O
,	,	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
18	CD	O
and	CC	O
40	CD	O
years	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
consisting	VBG	O
of	IN	O
the	DT	O
no-treatment	JJ	C
control	NN	C
,	,	O
the	DT	O
treatment-control	NN	C
(	(	C
table	JJ	C
stabilization	NN	C
)	)	C
,	,	O
and	CC	O
the	DT	O
experimental	JJ	PH
(	(	PH
PostureJac	NNP	PH
)	)	PH
group	NN	O
.	.	O

The	DT	O
outcome	JJ	O
measure	NN	O
of	IN	O
deep	JJ	O
cervical	JJ	O
flexor	NN	O
muscle	NN	O
endurance	NN	O
was	VBD	O
based	VBN	O
on	IN	O
the	DT	O
Flexor	NNP	O
Endurance	NNP	O
Test	NNP	O
and	CC	O
was	VBD	O
recorded	VBN	O
in	IN	O
seconds	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
PostureJac	NNP	O
group	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
no-treatment	JJ	O
control	NN	O
(	(	O
p=.001	NN	O
)	)	O
and	CC	O
the	DT	O
treatment-control	NN	O
(	(	O
p=.004	NN	O
)	)	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
increasing	VBG	O
endurance	NN	O
of	IN	O
the	DT	O
deep	JJ	O
cervical	JJ	O
flexors	NNS	O
.	.	O

Consequently	RB	O
,	,	O
the	DT	O
PostureJac	NNP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
therapeutic	JJ	O
tool	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
cervicogenic	JJ	O
headache	NN	O
and	CC	O
mechanical	JJ	O
neck	NN	O
pain	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
quality	NN	O
and	CC	O
amount	NN	O
of	IN	O
dietary	JJ	O
fat	NN	O
on	IN	O
the	DT	O
susceptibility	NN	O
of	IN	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
to	TO	O
oxidation	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
high	JJ	PM
fat	NN	PM
diet	JJ	PM
rich	JJ	PM
in	IN	PM
monounsaturated	JJ	PM
fat	NN	PM
(	(	PM
MUFA-diet	NNP	PM
)	)	PM
and	CC	O
a	DT	O
moderate	JJ	PM
fat	NN	PM
diet	JJ	PM
rich	JJ	PM
in	IN	PM
polyunsaturated	JJ	PM
fat	NN	PM
(	(	PM
PUFA-diet	NNP	PM
)	)	PM
on	IN	O
the	DT	O
susceptibility	NN	O
of	IN	O
LDL	NNP	O
to	TO	O
oxidation	NN	O
.	.	O

SUBJECTS	NNP	O
29	CD	O
subjects	NNS	O
with	IN	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
consuming	VBG	O
a	DT	O
run-in	JJ	O
diet	JJ	O
[	FW	O
37	CD	O
%	NN	O
of	IN	O
energy	NN	O
(	(	O
E	NNP	O
%	NN	O
)	)	O
fat	NN	O
,	,	O
18	CD	O
E	NNP	O
%	NN	O
saturated	VBD	O
fat	JJ	O
]	NN	O
for	IN	O
three	CD	O
weeks	NNS	O
,	,	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
either	RB	O
to	TO	O
a	DT	O
MUFA-diet	JJ	O
(	(	O
40	CD	O
E	NNP	O
%	NN	O
fat	NN	O
,	,	O
19	CD	O
E	NNP	O
%	NN	O
monounsaturated	VBD	O
fatty	JJ	O
acids	NNS	O
)	)	O
or	CC	O
a	DT	O
PUFA-diet	JJ	O
(	(	O
34	CD	O
E	NNP	O
%	NN	O
fat	NN	O
,	,	O
10	CD	O
E	NNP	O
%	NN	O
polyunsaturated	VBD	O
fat	NN	O
)	)	O
for	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

The	DT	O
susceptibility	NN	O
of	IN	O
LDL	NNP	O
to	TO	O
oxidation	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
challenging	VBG	O
LDL	NNP	O
with	IN	O
hemin	NN	O
and	CC	O
H2O2	NNP	O
and	CC	O
measuring	VBG	O
the	DT	O
time	NN	O
for	IN	O
the	DT	O
reaction	NN	O
to	TO	O
reach	VB	O
maximum	JJ	O
velocity	NN	O
.	.	O

Results	NNS	O
are	VBP	O
expressed	VBN	O
as	IN	O
lag	NN	O
time	NN	O
to	TO	O
oxidation	NN	O
in	IN	O
minutes	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
lag	NN	O
time	NN	O
tended	VBD	O
to	TO	O
decrease	VB	O
during	IN	O
the	DT	O
experimental	JJ	O
diet	NN	O
(	(	O
97	CD	O
+/-	JJ	O
28	CD	O
vs	JJ	O
90	CD	O
+/-	JJ	O
25	CD	O
min	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
s.d.	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.073	CD	O
)	)	O
,	,	O
whereas	RB	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
(	(	O
lag	JJ	O
time	NN	O
96	CD	O
+/-	JJ	O
24	CD	O
vs	JJ	O
100	CD	O
+/-	JJ	O
16	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.408	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
in	IN	O
lag	NN	O
time	NN	O
was	VBD	O
-7	JJ	O
+/-	JJ	O
14	CD	O
min	NN	O
(	(	O
-7.2	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
and	CC	O
+4	VBZ	O
+/-	JJ	O
16	CD	O
min	NN	O
(	(	O
+4.0	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.029	CD	O
,	,	O
PUFA-diet	JJ	O
group	NN	O
vs	VBD	O
MUFA-diet	NNP	O
group	NN	O
)	)	O
.	.	O

The	DT	O
alpha-tocopherol	JJ	O
concentration	NN	O
in	IN	O
LDL	NNP	O
increased	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
in	IN	O
both	DT	O
diet	JJ	O
groups	NNS	O
relative	VBP	O
to	TO	O
the	DT	O
run-in	JJ	O
diet	JJ	O
period	NN	O
,	,	O
but	CC	O
LDL	NNP	O
particle	VBD	O
score	RB	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
either	DT	O
of	IN	O
the	DT	O
diet	JJ	O
groups	NNS	O
during	IN	O
the	DT	O
dietary	JJ	O
intervention	NN	O
.	.	O

In	IN	O
subjects	NNS	O
with	IN	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
a	DT	O
PUFA-rich	JJ	PM
diet	NN	O
with	IN	O
a	DT	O
moderate	JJ	O
amount	NN	O
of	IN	O
fat	NN	O
tended	VBN	O
to	TO	O
increase	VB	O
the	DT	O
susceptibility	NN	O
of	IN	O
LDL	NNP	O
to	TO	O
oxidation	NN	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
higher	JJR	O
fat	JJ	O
diet	JJ	O
rich	NN	O
in	IN	O
MUFA	NNP	PM
.	.	O

Furthermore	NNP	O
,	,	O
the	DT	O
negative	JJ	O
mean	NN	O
change	NN	O
in	IN	O
lag	NN	O
time	NN	O
to	TO	O
oxidation	NN	O
found	VBN	O
in	IN	O
the	DT	O
PUFA-diet	JJ	O
group	NN	O
differed	VBD	O
significantly	RB	O
from	IN	O
the	DT	O
slightly	RB	O
positive	JJ	O
mean	NN	O
change	NN	O
found	VBD	O
in	IN	O
the	DT	O
MUFA-diet	JJ	O
group	NN	O
.	.	O

A	DT	O
clinical	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
blood	NN	PH
conservation	NN	PH
device	NN	PH
in	IN	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
patients	NNS	O
.	.	O

OBJECTIVES	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
a	DT	O
)	)	O
document	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
device	NN	O
intended	VBN	O
to	TO	O
conserve	VB	O
blood	NN	O
in	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
;	:	O
b	NN	O
)	)	O
determine	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
this	DT	O
blood	NN	O
conservation	NN	O
on	IN	O
hemoglobin	JJ	O
concentration	NN	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
blood	NN	O
transfusions	NNS	O
;	:	O
c	NNS	O
)	)	O
determine	VBP	O
if	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
resulted	VBD	O
in	IN	O
interference	NN	O
with	IN	O
arterial	JJ	O
pressure	NN	O
waveforms	NNS	O
;	:	O
d	NN	O
)	)	O
determine	NN	O
if	IN	O
use	NN	O
of	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
device	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
difference	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
accidental	JJ	O
needle	JJ	O
punctures	NNS	O
suffered	VBN	O
by	IN	O
healthcare	JJ	O
workers	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
.	.	O

A	DT	O
clinical	JJ	O
trial	NN	O
using	VBG	O
prospective	JJ	O
,	,	O
random	JJ	O
allocation	NN	O
of	IN	O
consecutive	JJ	O
eligible	JJ	O
patients	NNS	O
.	.	O

SETTING	VBG	O
The	DT	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
ICU	NNP	O
)	)	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
located	VBN	O
in	IN	O
a	DT	O
large	JJ	O
metropolitan	JJ	O
area	NN	O
.	.	O

PATIENTS	VB	O
A	DT	O
total	NN	O
of	IN	O
100	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
the	DT	O
medical	JJ	O
ICU	NNP	O
,	,	O
required	VBD	O
arterial	JJ	O
line	NN	O
monitoring	NN	O
for	IN	O
clinical	JJ	O
purposes	NNS	O
,	,	O
and	CC	O
were	VBD	O
managed	VBN	O
by	IN	O
the	DT	O
ICU	NNP	O
medical	JJ	O
service	NN	O
.	.	O

Exclusion	NNP	O
criteria	NNS	O
included	VBD	O
active	JJ	O
bleeding	NN	O
or	CC	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
ICU	NNP	O
admission	NN	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
had	VBD	O
a	DT	O
blood	NN	PH
conservation	NN	PH
device	NN	PH
incorporated	VBN	PH
into	IN	PH
the	DT	PH
arterial	JJ	PH
pressure	NN	PH
monitoring	NN	PH
system	NN	PH
,	,	O
while	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	C
group	NN	C
received	VBD	C
a	DT	C
conventional	JJ	C
arterial	JJ	C
pressure	NN	C
monitoring	NN	C
system	NN	C
.	.	C

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Data	NNP	O
gathered	VBD	O
included	VBN	O
:	:	O
age	NN	O
;	:	O
gender	NN	O
;	:	O
ICU	NNP	O
discharge	NN	O
status	NN	O
;	:	O
the	DT	O
duration	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
;	:	O
time	NN	O
in	IN	O
the	DT	O
study	NN	O
;	:	O
volume	NN	O
of	IN	O
all	DT	O
blood	NN	O
drawn	NN	O
,	,	O
discarded	VBD	O
,	,	O
or	CC	O
lost	VBN	O
due	JJ	O
to	TO	O
leakage	VB	O
;	:	O
hemoglobin	JJ	O
concentrations	NNS	O
;	:	O
blood	NN	O
transfusions	NNS	O
;	:	O
and	CC	O
accidental	JJ	O
needle	JJ	O
injuries	NNS	O
.	.	O

Arterial	JJ	O
pressure	NN	O
waveforms	NNS	O
were	VBD	O
recorded	VBN	O
and	CC	O
inspected	VBN	O
for	IN	O
dampening	VBG	O
or	CC	O
other	JJ	O
deformation	NN	O
.	.	O

Mean	NNP	O
hemoglobin	JJ	O
concentrations	NNS	O
were	VBD	O
compared	VBN	O
on	IN	O
ICU	NNP	O
admission	NN	O
and	CC	O
at	IN	O
12-hr	JJ	O
intervals	NNS	O
.	.	O

Demographic	NNP	O
and	CC	O
clinical	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

The	DT	O
volume	NN	O
of	IN	O
blood	NN	O
drawn	NN	O
and	CC	O
discarded	VBD	O
from	IN	O
arterial	JJ	O
catheters	NNS	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
:	:	O
5.7	CD	O
+/-	JJ	O
7.5	CD	O
mL	NN	O
;	:	O
control	NN	O
:	:	O
96.4	CD	O
+/-	JJ	O
88.5	CD	O
mL	NN	O
;	:	O
p	CC	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
total	JJ	O
volume	NN	O
of	IN	O
blood	NN	O
discarded	VBN	O
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
:	:	O
19.4	CD	O
+/-	JJ	O
47.4	CD	O
mL	NN	O
;	:	O
control	NN	O
:	:	O
103.5	CD	O
+/-	JJ	O
99.9	CD	O
mL	NN	O
;	:	O
p	CC	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

Mean	NNP	O
hemoglobin	JJ	O
concentration	NN	O
on	IN	O
admission	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
blood	NN	O
conservation	NN	O
device	NN	O
group	NN	O
:	:	O
11.8	CD	O
+/-	JJ	O
2.5	CD	O
g/dL	NN	O
;	:	O
control	NN	O
group	NN	O
:	:	O
12.6	CD	O
+/-	JJ	O
2.3	CD	O
g/dL	NN	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
the	DT	O
mean	JJ	O
hemoglobin	NN	O
concentration	NN	O
declined	VBD	O
most	JJS	O
rapidly	RB	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hrs	NN	O
of	IN	O
ICU	NNP	O
care	NN	O
and	CC	O
,	,	O
thereafter	RB	O
,	,	O
declined	VBD	O
more	RBR	O
slowly	RB	O
.	.	O

Although	IN	O
the	DT	O
mean	JJ	O
hemoglobin	NN	O
concentration	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
after	IN	O
6	CD	O
days	NNS	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
until	IN	O
9.5	CD	O
days	NNS	O
of	IN	O
ICU	NNP	O
care	NN	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
in	IN	O
hemoglobin	JJ	O
concentration	NN	O
(	(	O
overall	JJ	O
:	:	O
1.2	CD	O
+/-	JJ	O
2.2	CD	O
g/dL	NN	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
represents	VBZ	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
.0001	NNP	O
)	)	O
decrease	NN	O
of	IN	O
9.7	CD	O
%	NN	O
.	.	O

Hemoglobin	NNP	O
concentration	NN	O
during	IN	O
the	DT	O
study	NN	O
decreased	VBN	O
by	IN	O
1.4	CD	O
+/-	JJ	O
2.2	CD	O
g/dL	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
1.0	CD	O
+/-	JJ	O
2.3	CD	O
g/dL	NN	O
in	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
nonsignificant	NN	O
)	)	O
.	.	O

Univariate	NNP	O
and	CC	O
multiple	JJ	O
regression	NN	O
analysis	NN	O
demonstrated	VBD	O
discarded	JJ	O
blood	NN	O
volume	NN	O
to	TO	O
be	VB	O
a	DT	O
significant	JJ	O
and	CC	O
independent	JJ	O
predictor	NN	O
of	IN	O
the	DT	O
decline	NN	O
in	IN	O
hemoglobin	JJ	O
concentration	NN	O
.	.	O

Transfusion	NN	O
requirements	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
blood	NN	PH
conservation	NN	PH
system	NN	PH
did	VBD	O
not	RB	O
alter	VB	O
or	CC	O
interfere	VB	O
with	IN	O
pressure	NN	O
waveforms	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
accidental	JJ	O
needle	JJ	O
injuries	NNS	O
noted	VBD	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
conservation	NN	O
of	IN	O
blood	NN	O
in	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
must	MD	O
be	VB	O
a	DT	O
high-priority	JJ	O
concern	NN	O
of	IN	O
all	DT	O
healthcare	JJ	O
workers	NNS	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
blood	NN	O
conservation	NN	O
system	NN	O
eliminates	VBZ	O
a	DT	O
significant	JJ	O
factor	NN	O
in	IN	O
the	DT	O
decline	NN	O
in	IN	O
hemoglobin	JJ	O
concentration	NN	O
.	.	O

With	IN	O
devices	NNS	O
as	IN	O
described	NN	O
here	RB	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
reason	NN	O
to	TO	O
continue	VB	O
the	DT	O
practice	NN	O
of	IN	O
wasting	VBG	O
the	DT	O
blood	NN	O
of	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
in	IN	O
order	NN	O
to	TO	O
prevent	VB	O
preanalytic	JJ	O
error	NN	O
.	.	O

Trimetazidine	NN	PM
:	:	O
a	DT	O
new	JJ	O
concept	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
angina	NN	O
.	.	O

Comparison	NNP	O
with	IN	O
propranolol	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NN	O
.	.	O

Trimetazidine	JJ	O
European	JJ	O
Multicenter	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

1	CD	O
.	.	O

Trimetazidine	NN	PM
has	VBZ	O
a	DT	O
direct	JJ	O
anti-ischaemic	JJ	O
effect	NN	O
on	IN	O
the	DT	O
myocardium	NN	O
without	IN	O
altering	VBG	O
the	DT	O
rate	NN	O
x	JJ	O
pressure	NN	O
product	NN	O
or	CC	O
coronary	JJ	O
blood	NN	O
flow	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
trimetazidine	NN	PM
(	(	O
20	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
of	IN	O
propranolol	NN	PM
(	(	O
40	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
)	)	O
in	IN	O
a	DT	O
double-blind	JJ	O
parallel	NN	O
group	NN	O
multicentre	VBD	O
study	NN	O
in	IN	O
149	CD	O
men	NNS	O
with	IN	O
stable	JJ	O
angina	NN	O
.	.	O

3	CD	O
.	.	O

Reproducibility	NN	O
of	IN	O
exercise	NN	O
performance	NN	O
was	VBD	O
verified	VBN	O
during	IN	O
a	DT	O
3	CD	O
week	NN	O
run-in	JJ	O
placebo	NN	O
washout	IN	O
period	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
>	JJ	O
1	CD	O
mm	JJ	O
ST-depression	NN	O
on	IN	O
exercise	NN	O
test	NN	O
.	.	O

4	CD	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
,	,	O
similar	JJ	O
anti-anginal	JJ	O
efficacy	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
trimetazidine	NN	PM
(	(	O
n	JJ	O
=	NNP	O
71	CD	O
)	)	O
and	CC	O
propranolol	NN	PM
(	(	O
n	JJ	O
=	NNP	O
78	CD	O
)	)	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
trimetazidine	NN	PM
and	CC	O
propranolol	NN	PM
as	IN	O
regards	NNS	O
anginal	JJ	O
attack	NN	O
rate	NN	O
per	IN	O
week	NN	O
(	(	O
mean	JJ	O
difference	NN	O
P-TMZ	NN	O
:	:	O
2	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-4.4	NN	O
,	,	O
0.5	CD	O
)	)	O
and	CC	O
exercise	NN	O
duration	NN	O
(	(	O
mean	JJ	O
difference	NN	O
P-TMZ	NN	O
:	:	O
0	CD	O
s	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-33	NN	O
,	,	O
34	CD	O
)	)	O
or	CC	O
time	NN	O
to	TO	O
1	CD	O
mm	NNS	O
ST	NNP	O
segment	NN	O
depression	NN	O
(	(	O
mean	JJ	O
difference	NN	O
P-TMZ	NN	O
:	:	O
13	CD	O
s	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-24	NN	O
,	,	O
51	CD	O
)	)	O
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
rate	NN	O
x	JJ	O
pressure	NN	O
product	NN	O
at	IN	O
rest	NN	O
and	CC	O
at	IN	O
peak	JJ	O
exercise	NN	O
remained	VBD	O
unchanged	JJ	O
in	IN	O
the	DT	O
trimetazidine	NN	PM
group	NN	O
but	CC	O
significantly	RB	O
decreased	VBN	O
with	IN	O
propranolol	NN	PM
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
in	IN	O
all	DT	O
cases	NNS	O
)	)	O
.	.	O

With	IN	O
both	DT	O
drugs	NNS	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
to	TO	O
decreased	VBN	O
ischaemic	JJ	O
episodes	NNS	O
in	IN	O
the	DT	O
46	CD	O
%	NN	O
patients	NNS	O
who	WP	O
experienced	VBD	O
ambulatory	JJ	O
ischaemia	NN	O
on	IN	O
Holter	NNP	O
monitoring	NN	O
.	.	O

Six	CD	O
patients	NNS	O
stopped	VBD	O
trimetazidine	NN	PM
and	CC	O
12	CD	O
propranolol	NN	PM
.	.	O

Of	IN	O
these	DT	O
,	,	O
five	CD	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
withdrawn	VBN	O
because	IN	O
of	IN	O
deterioration	NN	O
in	IN	O
cardiovascular	JJ	O
status	NN	O
.	.	O

5	CD	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
trimetazidine	NN	O
and	CC	O
propranolol	NN	O
at	IN	O
the	DT	O
doses	NNS	O
studied	VBN	O
have	VBP	O
similar	JJ	O
efficacy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	JJ	O
pectoris	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Metabolic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	S
surgery	NN	S
under	IN	O
local	JJ	PM
anesthesia	NN	PM
and	CC	O
sedation	NN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	PM
:	:	O
the	DT	O
effects	NNS	O
of	IN	O
two	CD	O
different	JJ	O
local	JJ	PM
anesthetics	NNS	PM
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
epinephrine-free	JJ	PM
and	CC	PM
epinephrine-containing	JJ	PM
local	JJ	PM
anesthetic	JJ	PM
solutions	NNS	O
on	IN	O
plasma	NN	O
potassium	NN	O
and	CC	O
blood	NN	O
glucose	JJ	O
concentrations	NNS	O
were	VBD	O
investigated	VBN	O
in	IN	O
20	CD	O
patients	NNS	O
undergoing	JJ	O
oral	JJ	O
surgery	NN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	PM
sedation	NN	O
.	.	O

Ten	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
4.4	CD	PM
mL	NN	PM
of	IN	PM
2	CD	PM
%	NN	PM
lidocaine	NN	PM
with	IN	PM
1:80,000	CD	PM
epinephrine	NN	PM
as	IN	PM
a	DT	PM
local	JJ	PM
anesthetic	NN	PM
and	CC	O
10	CD	O
were	VBD	O
given	VBN	O
4.4	CD	PM
mL	NN	PM
of	IN	PM
3	CD	PM
%	NN	PM
prilocaine	NN	PM
with	IN	PM
0.03	CD	PM
IU/mL	NNP	PM
felypressin	NN	PM
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
potassium	NN	O
and	CC	O
glucose	JJ	O
concentrations	NNS	O
both	DT	O
within	IN	O
and	CC	O
between	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
early	JJ	O
postinjection	NN	O
period	NN	O
.	.	O

The	DT	O
epinephrine-containing	JJ	O
local	JJ	O
anesthetic	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
plasma	NN	O
potassium	NN	O
concentration	NN	O
10	CD	O
min	NN	O
after	IN	O
injection	NN	O
,	,	O
by	IN	O
0.16	CD	O
+/-	JJ	O
0.20	CD	O
mmol/L	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
,	,	O
and	CC	O
increased	VBD	O
the	DT	O
blood	NN	O
glucose	JJ	O
concentration	NN	O
at	IN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
30	CD	O
min	NN	O
(	(	O
by	IN	O
0.46	CD	O
+/-	JJ	O
0.37	CD	O
,	,	O
0.63	CD	O
+/-	JJ	O
0.45	CD	O
,	,	O
and	CC	O
0.56	CD	O
+/-	JJ	O
0.28	CD	O
mmol/L	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Conversely	RB	O
,	,	O
plasma	JJ	O
potassium	NN	O
increased	VBD	O
and	CC	O
blood	NN	O
glucose	NN	O
decreased	VBD	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
30	CD	O
min	NN	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
epinephrine-free	JJ	PM
solution	NN	PM
.	.	O

At	IN	O
30	CD	O
min	NN	O
potassium	NN	O
was	VBD	O
increased	VBN	O
by	IN	O
0.24	CD	O
+/-	JJ	O
0.16	CD	O
mmol/L	NN	O
,	,	O
and	CC	O
glucose	NN	O
was	VBD	O
decreased	VBN	O
by	IN	O
0.23	CD	O
+/-	JJ	O
0.16	CD	O
mmol/L	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
epinephrine-free	JJ	PM
and	CC	O
epinephrine-containing	JJ	PM
local	JJ	PM
anesthetics	NNS	PM
differ	VBP	O
in	IN	O
their	PRP$	O
metabolic	JJ	O
effects	NNS	O
during	IN	O
oral	JJ	O
surgery	NN	O
with	IN	O
midazolam	JJ	PM
sedation	NN	PM
.	.	O

Active	JJ	PH
warming	NN	PH
,	,	O
not	RB	O
passive	JJ	O
heat	NN	O
retention	NN	O
,	,	O
maintains	VBZ	O
normothermia	JJ	O
during	IN	O
combined	JJ	O
epidural-general	JJ	O
anesthesia	NN	O
for	IN	O
hip	NN	O
and	CC	O
knee	NN	O
arthroplasty	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
to	TO	O
compare	VB	O
passive	JJ	O
heat	NN	O
retention	NN	O
by	IN	O
low-flow	JJ	O
anesthesia	NN	O
,	,	O
alone	RB	O
and	CC	O
with	IN	O
additional	JJ	O
thermal	JJ	O
insulation	NN	O
by	IN	O
reflective	JJ	O
blankets	NNS	O
,	,	O
with	IN	O
forced-air	JJ	O
warming	VBG	O
preventing	VBG	O
intraoperative	JJ	O
hypothermia	NN	O
during	IN	O
combined	JJ	O
epidural-general	JJ	O
anesthesia	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Inpatient	NNP	O
anesthesia	NN	O
at	IN	O
a	DT	O
university	NN	O
department	NN	O
of	IN	O
orthopedic	JJ	O
surgery	NN	O
.	.	O

PATIENTS	CC	O
30	CD	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
and	CC	O
II	NNP	O
patients	NNS	O
,	,	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
elective	JJ	O
hip	NN	O
or	CC	O
knee	VB	O
arthroplasty	JJ	O
and	CC	O
were	VBD	O
free	JJ	O
from	IN	O
systemic	JJ	O
disease	NN	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
received	VBD	O
epidural	JJ	O
block	NN	O
up	RB	O
to	TO	O
T10	NNP	O
by	IN	O
alkalinized	JJ	PM
lidocaine	JJ	PM
2	CD	PM
%	NN	PM
,	,	O
and	CC	O
then	RB	O
were	VBD	O
administered	VBN	O
standard	JJ	O
general	JJ	O
anesthesia	NN	O
by	IN	O
means	NNS	O
of	IN	O
low-flow	JJ	PH
rebreathing	NN	PH
system	NN	PH
(	(	O
fresh	JJ	O
gas	NN	O
flow	NN	O
=	VBD	O
1	CD	O
L/min	NNP	O
)	)	O
.	.	O

All	DT	O
procedures	NNS	O
started	VBD	O
between	IN	O
8	CD	O
and	CC	O
10	CD	O
AM	NNP	O
,	,	O
and	CC	O
operating	NN	O
room	NN	O
(	(	O
OR	NNP	O
)	)	O
temperature	NN	O
was	VBD	O
maintained	VBN	O
between	IN	O
21	CD	O
degrees	NNS	O
and	CC	O
23	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
with	IN	O
relative	JJ	O
humidity	NN	O
ranging	VBG	O
between	IN	O
40	CD	O
%	NN	O
and	CC	O
45	CD	O
%	NN	O
.	.	O

For	IN	O
heat	NN	O
retention	NN	O
or	CC	O
warming	VBG	O
therapy	NN	O
,	,	O
patients	NNS	O
received	VBD	O
either	RB	O
low-flow	JJ	PH
anesthesia	NN	PH
only	RB	PH
(	(	O
control	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
low-flow	JJ	PH
anesthesia	NN	PH
with	IN	PH
additional	JJ	PH
reflective	JJ	PH
blankets	NNS	PH
(	(	O
blanket	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
or	CC	O
low-flow	JJ	PH
anesthesia	NN	PH
with	IN	PH
active	JJ	PH
forced-air	JJ	PH
warming	NN	PH
(	(	O
forced-air	JJ	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

Tympanic	JJ	O
temperature	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
OR	NNP	O
arrival	NN	O
(	(	O
baseline	NN	O
)	)	O
;	:	O
immediately	RB	O
following	VBG	O
general	JJ	O
anesthesia	JJ	O
induction	NN	O
;	:	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
,	,	O
and	CC	O
120	CD	O
minutes	NNS	O
from	IN	O
general	JJ	O
anesthesia	NN	O
induction	NN	O
;	:	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Duration	NNP	O
of	IN	O
anesthesia	NN	O
,	,	O
invasiveness	NN	O
of	IN	O
surgery	NN	O
,	,	O
and	CC	O
baseline	NN	O
core	NN	O
temperature	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Core	NNP	O
temperature	NN	O
decreased	VBN	O
in	IN	O
all	PDT	O
the	DT	O
three	CD	O
groups	NNS	O
30	CD	O
minutes	NNS	O
after	IN	O
general	JJ	O
anesthesia	NN	O
induction	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
afterwards	NNS	O
,	,	O
it	PRP	O
progressively	RB	O
decreased	VBD	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
blankets	NNS	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
with	IN	O
a	DT	O
reduction	NN	O
from	IN	O
baseline	NN	O
values	NNS	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
of	IN	O
2.0	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
1.6	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
forced-air	JJ	O
group	NN	O
,	,	O
after	IN	O
the	DT	O
initial	JJ	O
significant	JJ	O
decrease	NN	O
(	(	O
p	JJ	O
=	$	O
0.01	CD	O
vs.	FW	O
baseline	NN	O
)	)	O
,	,	O
core	JJ	O
temperature	NN	O
progressively	RB	O
increased	VBD	O
to	TO	O
35.8	CD	O
+/-	JJ	O
0.6	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
which	WDT	O
was	VBD	O
similar	JJ	O
to	TO	O
preoperative	VB	O
values	NNS	O
and	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
either	CC	O
the	DT	O
control	NN	O
or	CC	O
blankets	NNS	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
During	IN	O
combined	VBN	O
epidural-general	JJ	O
anesthesia	NN	O
for	IN	O
elective	JJ	O
hip	NN	O
and	CC	O
knee	NN	O
arthroplasty	NN	O
,	,	O
passive	JJ	O
heat	NN	O
retention	NN	O
by	IN	O
means	NNS	O
of	IN	O
low-flow	JJ	PH
anesthesia	NN	PH
alone	RB	PH
and	CC	PH
in	IN	PH
combination	NN	PH
with	IN	PH
reflective	JJ	PH
blankets	NNS	PH
is	VBZ	O
ineffective	JJ	O
in	IN	O
maintaining	VBG	O
intraoperative	JJ	O
normothermia	NN	O
and	CC	O
definitely	RB	O
inferior	JJ	O
to	TO	O
active	JJ	O
forced-air	JJ	O
warning	NN	O
.	.	O

[	JJ	O
Acute	NNP	O
cardiovascular	NN	O
and	CC	O
metabolic	JJ	O
changes	NNS	O
in	IN	O
interval	NN	O
and	CC	O
endurance	NN	PH
training	NN	PH
in	IN	O
selected	VBN	O
patients	NNS	O
following	VBG	O
aortocoronary	JJ	O
bypass	NN	O
operation	NN	O
]	NNP	O
.	.	O

UNLABELLED	VB	O
This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
acute	NN	O
changes	NNS	O
of	IN	O
cardiovascular	NN	O
and	CC	O
metabolic	JJ	O
reactions	NNS	O
during	IN	O
interval	NN	PH
and	CC	PH
continuous	JJ	PH
training	NN	PH
after	IN	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
9	CD	O
male	JJ	O
patients	NNS	O
(	(	O
age	NN	O
:	:	O
59	CD	O
+/-	JJ	O
4	CD	O
and	CC	O
56	CD	O
+/-	JJ	O
6	CD	O
years	NNS	O
,	,	O
resp	NN	O
.	.	O

)	)	O
each	DT	PH
trained	VBN	PH
on	IN	PH
bicycle	NN	PH
ergometer	JJ	PH
start	NN	PH
on	IN	PH
post-operative	JJ	PH
days	NNS	PH
24	CD	PH
and	CC	PH
26	CD	PH
,	,	PH
resp	NN	PH
.	.	O

In	IN	O
both	DT	O
training	NN	O
groups	NNS	O
training	VBG	O
heart	NN	O
rate	NN	O
was	VBD	O
set	VBN	O
at	IN	O
86	CD	O
%	NN	O
of	IN	O
individual	JJ	O
maximum	JJ	O
heart	NN	O
rate	NN	O
.	.	O

In	IN	PH
the	DT	PH
last	JJ	PH
week	NN	PH
of	IN	PH
training	VBG	PH
the	DT	PH
exercise	NN	PH
intensity	NN	PH
in	IN	PH
the	DT	PH
group	NN	PH
of	IN	PH
patients	NNS	PH
who	WP	PH
were	VBD	PH
trained	VBN	PH
by	IN	PH
the	DT	PH
continuous	JJ	PH
method	NN	PH
was	VBD	PH
at	IN	PH
83	CD	PH
watts	NN	PH
,	,	PH
and	CC	PH
at	IN	PH
20:121	CD	PH
watts	NN	PH
in	IN	PH
the	DT	PH
group	NN	PH
of	IN	PH
patients	NNS	PH
who	WP	PH
were	VBD	PH
trained	VBN	PH
by	IN	PH
interval	JJ	PH
method	NN	PH
(	(	PH
rest	NN	PH
:	:	PH
work	NN	PH
each	DT	PH
1:1	CD	PH
min	NN	PH
)	)	PH
.	.	O

At	IN	O
this	DT	O
exercise	NN	O
training	NN	O
that	WDT	O
lasted	VBD	O
for	IN	O
20	CD	O
min	PDT	O
the	DT	O
acute	JJ	O
response	NN	O
of	IN	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
rate-pressure	JJ	O
product	NN	O
,	,	O
glucose	JJ	O
,	,	O
lactate	JJ	O
and	CC	O
catecholamines	NNS	O
was	VBD	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
both	DT	O
methods	NNS	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
pressure	NN	O
,	,	O
rate-pressure	JJ	O
product	NN	O
,	,	O
in	IN	O
glucose	NN	O
or	CC	O
catecholamine	NN	O
levels	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
rate	NN	O
of	IN	O
lactate	NN	O
in	IN	O
the	DT	O
second	JJ	O
10	CD	O
min	NN	O
of	IN	O
the	DT	O
interval	JJ	O
training	NN	O
.	.	O

And	CC	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
higher	JJR	O
peripheral	JJ	O
exercise	NN	O
intensity	NN	O
by	IN	O
interval	JJ	O
training	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
higher	JJR	O
cardiac	NN	O
work	NN	O
than	IN	O
by	IN	O
the	DT	O
continuous	JJ	O
training	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
interval	JJ	O
training	NN	O
strains	VBZ	O
the	DT	O
oxidative	JJ	O
capacity	NN	O
of	IN	O
the	DT	O
trained	JJ	O
muscles	NNS	O
in	IN	O
a	DT	O
more	RBR	O
intensive	JJ	O
and	CC	O
direct	JJ	O
way	NN	O
than	IN	O
does	VBZ	O
continuous	JJ	O
training	NN	O
.	.	O

Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scale	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
Children	NNP	PS
's	POS	PS
Yale-Brown	JJ	PS
Obsessive	NNP	PS
Compulsive	NNP	PS
Scales	NNP	PS
(	(	PS
CYBOCS	NNP	PS
)	)	PS
modified	VBD	PS
for	IN	PS
pervasive	JJ	PS
developmental	NN	PS
disorders	NNS	PS
(	(	PS
PDDs	NNP	PS
)	)	PS
.	.	O

METHOD	NNP	O
Raters	NNPS	O
from	IN	O
five	CD	O
Research	NNP	O
Units	NNS	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
(	(	O
RUPP	NNP	O
)	)	O
Autism	NNP	O
Network	NNP	O
were	VBD	O
trained	VBN	O
to	TO	O
reliability	NN	O
.	.	O

The	DT	O
modified	JJ	O
scale	NN	O
(	(	PS
CYBOCS-PDD	NNP	PS
)	)	PS
,	,	O
which	WDT	O
contains	VBZ	O
only	RB	O
the	DT	O
five	CD	E
Compulsion	NNP	E
severity	NN	E
items	NNS	E
(	(	O
range	VB	O
0-20	NN	O
)	)	O
,	,	O
was	VBD	O
administered	VBN	O
to	TO	O
172	CD	O
medication-free	JJ	O
children	NNS	O
(	(	O
mean	JJ	O
8.2	CD	O
+/-	JJ	O
2.6	CD	O
years	NNS	O
)	)	O
with	IN	O
PDD	NNP	O
(	(	O
autistic	JJ	O
disorder	NN	O
,	,	O
n	JJ	O
=	VBP	O
152	CD	O
;	:	O
Asperger	NNP	O
's	POS	O
disorder	NN	O
,	,	O
n	JJ	O
=	VBP	O
6	CD	O
;	:	O
PDD	NNP	O
not	RB	O
otherwise	RB	O
specified	VBN	O
,	,	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
participating	NN	O
in	IN	O
RUPP	NNP	O
clinical	JJ	O
trials	NNS	O
.	.	O

Reliability	NNP	O
was	VBD	O
assessed	VBN	O
by	IN	O
intraclass	NN	O
correlation	NN	O
coefficient	NN	O
(	(	O
ICC	NNP	O
)	)	O
and	CC	O
internal	JJ	O
consistency	NN	O
by	IN	O
Cronbach	NNP	O
's	POS	O
alpha	JJ	O
coefficient	NN	O
.	.	O

Correlations	NNS	O
with	IN	O
ratings	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
and	CC	O
disruptive	JJ	O
behavior	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
validity	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
raters	NNS	O
showed	VBD	O
excellent	JJ	O
reliability	NN	O
(	(	O
ICC	NNP	O
=	NNP	O
0.97	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
CYBOCS	NNP	O
score	NN	O
was	VBD	O
14.4	CD	O
(	(	O
+/-	JJ	O
3.86	CD	O
)	)	O
with	IN	O
excellent	JJ	O
internal	JJ	O
consistency	NN	O
(	(	O
alpha	JJ	O
=	NNP	O
.85	NNP	O
)	)	O
.	.	O

Correlations	NNS	O
with	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
ranged	VBD	O
from	IN	O
r	NN	O
=	$	O
0.11	CD	O
to	TO	O
r	VB	O
=	JJ	O
0.28	CD	O
and	CC	O
were	VBD	O
similar	JJ	O
to	TO	O
correlations	NNS	O
with	IN	O
measures	NNS	O
of	IN	O
irritability	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.24	CD	O
)	)	O
and	CC	O
hyperactivity	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.25	CD	O
)	)	O
.	.	O

Children	NNP	O
with	IN	O
higher	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
CYBOCS-PDD	NNP	O
had	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
maladaptive	JJ	O
behaviors	NNS	O
and	CC	O
lower	JJR	O
adaptive	JJ	O
functioning	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
five-item	JJ	O
CYBOCS-PDD	NNP	O
is	VBZ	O
reliable	JJ	O
,	,	O
distinct	JJ	O
from	IN	O
other	JJ	O
measures	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
,	,	O
and	CC	O
sensitive	JJ	O
to	TO	O
change	VB	O
.	.	O

Response	NN	O
of	IN	O
pre-core	NN	O
mutant	NN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
to	TO	O
lamivudine	VB	PM
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
chronic	JJ	O
liver	NN	O
disease	NN	O
associated	VBN	O
with	IN	O
the	DT	O
pre-core	JJ	O
mutant	NN	O
of	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
(	(	O
HBV	NNP	O
)	)	O
infection	NN	O
is	VBZ	O
increasing	VBG	O
,	,	O
particularly	RB	O
in	IN	O
Mediterranean	NNP	O
Europe	NNP	O
and	CC	O
in	IN	O
Asia	NNP	O
.	.	O

The	DT	O
pre-core	JJ	O
mutant	NN	O
HBV	NNP	O
is	VBZ	O
unable	JJ	O
to	TO	O
produce	VB	O
hepatitis	NN	O
B	NNP	O
e	NN	O
antigen	NN	O
(	(	O
HBeAg	NNP	O
)	)	O
,	,	O
so	RB	O
that	IN	O
patients	NNS	O
with	IN	O
this	DT	O
variant	NN	O
do	VBP	O
not	RB	O
present	VB	O
with	IN	O
HBV	NNP	O
characterised	VBN	O
by	IN	O
HBeAg	NNP	O
in	IN	O
the	DT	O
serum	NN	O
.	.	O

Pre-core	NN	O
mutant	JJ	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
usually	RB	O
proceeds	VBZ	O
to	TO	O
serious	JJ	O
liver	JJ	O
disease	NN	O
.	.	O

Wild-type	JJ	O
HBV	NNP	O
infection	NN	O
may	MD	O
be	VB	O
mild	JJ	O
and	CC	O
respond	NN	O
relatively	RB	O
well	RB	O
to	TO	O
interferon	VB	O
(	(	O
IFN	NNP	O
)	)	O
alpha	NN	O
therapy	NN	O
,	,	O
but	CC	O
IFN	NNP	O
alpha	NN	O
is	VBZ	O
not	RB	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
option	NN	O
in	IN	O
pre-core	NN	O
mutant	NN	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
and	CC	O
new	JJ	O
therapeutic	JJ	O
options	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Clinical	JJ	O
data	NNS	O
show	VBP	O
that	IN	O
lamivudine	NN	PM
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
pre-core	JJ	O
mutant	NN	O
hepatitis	NN	O
B	NNP	O
.	.	O

There	EX	O
is	VBZ	O
profound	JJ	O
suppression	NN	O
of	IN	O
HBV	NNP	O
replication	NN	O
and	CC	O
improvement	NN	O
in	IN	O
indicators	NNS	O
of	IN	O
liver	JJ	O
disease	NN	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
lamivudine	NN	PM
is	VBZ	O
suitable	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
,	,	O
including	VBG	O
those	DT	O
with	IN	O
pre-core	JJ	O
mutant	JJ	O
HBV	NNP	O
infection	NN	O
.	.	O

Evolution	NN	O
of	IN	O
coronary	JJ	O
stenoses	NNS	O
is	VBZ	O
related	VBN	O
to	TO	O
baseline	VB	O
severity	NN	O
--	:	O
a	DT	O
prospective	JJ	O
quantitative	JJ	O
angiographic	JJ	O
analysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
coronary	JJ	O
disease	NN	O
.	.	O

INTACT	JJ	O
Investigators	NNPS	O
.	.	O

International	NNP	O
Nifedipine	NNP	O
Trial	NNP	O
on	IN	O
Antiatherosclerotic	NNP	O
Therapy	NNP	O
.	.	O

A	DT	O
correlation	NN	O
of	IN	O
the	DT	O
angiographic	JJ	O
evolution	NN	O
of	IN	O
coronary	JJ	O
stenoses	NNS	O
(	(	O
stenosis	NN	O
diameter	NN	O
>	NN	O
or	CC	O
=	VB	O
20	CD	O
%	NN	O
)	)	O
with	IN	O
morphological	JJ	O
stenosis	NN	O
parameters	NNS	O
at	IN	O
baseline	NN	O
could	MD	O
help	VB	O
to	TO	O
identify	VB	O
the	DT	O
risk	NN	O
of	IN	O
progressive	JJ	O
stenoses	NNS	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
data	NN	O
of	IN	O
the	DT	O
prospective	JJ	O
INTACT	NNP	O
study	NN	O
(	(	O
International	NNP	O
Nifedipine	NNP	O
Trial	NNP	O
on	IN	O
Antiatherosclerotic	NNP	O
Therapy	NNP	O
)	)	O
were	VBD	O
reviewed	VBN	O
.	.	O

In	IN	O
348	CD	O
patients	NNS	O
with	IN	O
moderate	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
standardized	VBD	PH
coronary	JJ	PH
angiograms	NNS	PH
were	VBD	O
taken	VBN	O
3	CD	O
years	NNS	O
apart	RB	O
and	CC	O
were	VBD	O
quantitatively	RB	O
analysed	VBN	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
minimal	JJ	O
diameter	NN	O
of	IN	O
the	DT	O
1063	CD	O
preexisting	VBG	O
coronary	JJ	O
stenoses	NNS	O
compared	VBN	O
between	IN	O
both	DT	O
angiograms	NNS	O
were	VBD	O
set	VBN	O
in	IN	O
relation	NN	O
to	TO	O
a	DT	O
number	NN	O
of	IN	O
conventional	JJ	O
stenosis	NN	O
parameters	NNS	O
at	IN	O
baseline	NN	O
.	.	O

Regression	NNP	O
analysis	NN	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
correlation	NN	O
of	IN	O
the	DT	O
changes	NNS	O
in	IN	O
minimal	JJ	O
diameter	NN	O
with	IN	O
baseline	NN	O
%	NN	O
diameter	NN	O
stenosis	NN	O
(	(	O
r	JJ	O
=	VBZ	O
0.30	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
minimal	JJ	O
diameter	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.28	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
reference	NN	O
diameter	NN	O
of	IN	O
stenoses	NNS	O
(	(	O
r	NN	O
=	NNP	O
-0.14	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
were	VBD	O
not	RB	O
correlated	VBN	O
with	IN	O
stenosis	NN	O
length	NN	O
and	CC	O
plaque	JJ	O
area	NN	O
.	.	O

The	DT	O
baseline	NN	O
parameters	NNS	O
of	IN	O
22	CD	O
preexisting	VBG	O
stenoses	NNS	O
progressing	VBG	O
to	TO	O
occlusions	NNS	O
differed	VBN	O
from	IN	O
those	DT	O
remaining	VBG	O
patent	NN	O
only	RB	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
%	NN	O
diameter	NN	O
stenosis	NN	O
(	(	O
43	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
vs	JJ	O
39	CD	O
+/-	JJ	O
11	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Additional	JJ	O
progression	NN	O
of	IN	O
coronary	JJ	O
disease	NN	O
became	VBD	O
manifest	JJS	O
through	IN	O
development	NN	O
of	IN	O
228	CD	O
stenoses	NNS	O
and	CC	O
19	CD	O
occlusions	NNS	O
at	IN	O
arterial	JJ	O
sites	NNS	O
free	VBP	O
from	IN	O
definitive	JJ	O
stenoses	NNS	O
in	IN	O
the	DT	O
baseline	NN	O
angiograms	NN	O
.	.	O

Thus	RB	O
,	,	O
progression	NN	O
of	IN	O
atherosclerosis	NN	O
predominantly	RB	O
occurred	VBD	O
in	IN	O
mild	NN	O
preexisting	VBG	O
coronary	JJ	O
stenoses	NNS	O
and	CC	O
developed	VBN	O
at	IN	O
previously	RB	O
angiographically	RB	O
normal	JJ	O
sites	NNS	O
.	.	O

Since	IN	O
the	DT	O
conventional	JJ	O
angiographic	JJ	O
parameters	NNS	O
analysed	VBN	O
in	IN	O
this	DT	O
study	NN	O
failed	VBD	O
to	TO	O
identify	VB	O
individual	JJ	O
arterial	JJ	O
sites	NNS	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
progression	NN	O
,	,	O
definition	NN	O
of	IN	O
new	JJ	O
angiographic	JJ	O
parameters	NNS	O
or	CC	O
application	NN	O
of	IN	O
new	JJ	O
techniques	NNS	O
seem	VBP	O
mandatory	JJ	O
to	TO	O
this	DT	O
end	NN	O
.	.	O

Twice-a-day	JJ	O
versus	NN	O
four-times-a-day	JJ	O
ofloxacin	JJ	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
infection	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacies	NNS	O
of	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NNS	O
,	,	O
when	WRB	O
given	VBN	O
twice-a-day	JJ	O
(	(	O
BID	NNP	O
)	)	O
versus	IN	O
four-times-a-day	JJ	O
(	(	O
QID	NNP	O
)	)	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
disease	NN	O
.	.	O

METHOD	NNP	O
Fifty	NNP	O
patients	NNS	O
with	IN	O
blepharitis	NN	O
,	,	O
conjuctivitis	NN	O
,	,	O
or	CC	O
blepharoconjunctivitis	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
0.3	CD	PM
%	NN	PM
ofloxacin	JJ	PM
eyedrops	NNS	PM
,	,	PM
BID	NNP	PM
or	CC	PM
QID	NNP	PM
,	,	PM
for	IN	PM
10	CD	PM
days	NNS	PM
.	.	O

Signs	NNP	O
,	,	O
symptoms	NNS	O
,	,	O
and	CC	O
cultures	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
clinical	JJ	O
outcome	NN	O
was	VBD	O
virtually	RB	O
identical	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
clinical	JJ	O
scores	NNS	O
in	IN	O
the	DT	O
BID	NNP	O
and	CC	O
QID	NNP	O
groups	NNS	O
by	IN	O
days	NNS	O
3	CD	O
to	TO	O
5	CD	O
(	(	O
2.6-3.0	JJ	O
points	NNS	O
)	)	O
and	CC	O
a	DT	O
further	JJ	O
decrease	NN	O
by	IN	O
day	NN	O
11	CD	O
(	(	O
4.3-5.0	JJ	O
points	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
at	IN	O
any	DT	O
time	NN	O
interval	NN	O
.	.	O

Microbiologic	NNP	O
studies	NNS	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
colony-forming	JJ	O
units	NNS	O
in	IN	O
87	CD	O
%	NN	O
of	IN	O
the	DT	O
BID	NNP	O
group	NN	O
and	CC	O
in	IN	O
80	CD	O
%	NN	O
of	IN	O
the	DT	O
QID	NNP	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
treatment	NN	O
of	IN	O
external	JJ	O
ocular	JJ	O
disease	NN	O
with	IN	O
0.3	CD	O
%	NN	O
ofloxacin	JJ	O
eyedrops	NN	O
was	VBD	O
equally	RB	O
effective	JJ	O
when	WRB	O
given	VBN	O
BID	NNP	O
or	CC	O
QID	NNP	O
.	.	O

An	DT	O
open	JJ	O
multicenter	NN	O
efficacy	NN	O
and	CC	O
safety	NN	O
evaluation	NN	O
of	IN	O
amlodipine	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
symptomatic	JJ	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
amlodipine	NN	PM
(	(	O
5-10	JJ	O
mg	NN	O
)	)	O
once	RB	O
daily	JJ	O
were	VBD	O
studied	VBN	O
in	IN	O
an	DT	O
open	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
ongoing	VBG	O
and	CC	O
this	DT	O
report	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
an	DT	O
interim	JJ	O
analysis	NN	O
of	IN	O
data	NNS	O
from	IN	O
78	CD	O
patients	NNS	O
.	.	O

A	DT	O
2-week	JJ	O
baseline	NN	O
period	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
maintained	VBD	O
their	PRP$	O
current	JJ	O
antianginal	JJ	C
therapy	NN	C
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
10-week	JJ	O
treatment	NN	O
period	NN	O
with	IN	O
5-10	JJ	O
mg	NN	O
of	IN	O
amlodipine/day	NN	PM
.	.	O

Both	CC	O
the	DT	O
median	JJ	O
number	NN	O
of	IN	O
angina	JJ	O
attacks	NNS	O
per	IN	O
week	NN	O
and	CC	O
the	DT	O
median	JJ	O
number	NN	O
of	IN	O
nitroglycerin	NN	PM
(	(	O
NTG	NNP	O
)	)	O
tablets	NNS	O
consumed/week	VBP	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
amlodipine	NN	PM
(	(	O
mean	JJ	O
daily	RB	O
dose	NN	O
of	IN	O
8.6	CD	O
mg	NNS	O
)	)	O
when	WRB	O
compared	VBN	O
with	IN	O
baseline	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
98.4	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
63/64	CD	O
)	)	O
experienced	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
frequency	NN	O
of	IN	O
angina	JJ	O
attacks/week	NN	O
and	CC	O
91	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
58/64	CD	O
)	)	O
had	VBD	O
angina	VBN	O
attacks	NNS	O
reduced	VBD	O
to	TO	O
<	VB	O
or	CC	O
=	VB	O
2/week	CD	O
.	.	O

In	IN	O
self-assessments	NNS	O
,	,	O
95	CD	O
%	NN	O
of	IN	O
patients	NNS	O
(	(	O
55/58	CD	O
)	)	O
reported	VBD	O
improved	JJ	O
angina	NNS	O
control	NN	O
and	CC	O
91	CD	O
%	NN	O
(	(	O
53/58	CD	O
)	)	O
felt	VBD	O
their	PRP$	O
ability	NN	O
to	TO	O
perform	VB	O
usual	JJ	O
activities	NNS	O
had	VBD	O
improved	VBN	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
experienced	JJ	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
as	IN	O
drug	NN	O
related	VBN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
event	NN	O
noted	VBD	O
was	VBD	O
edema	RB	O
.	.	O

Amlodipine	NNP	PM
once	RB	O
daily	RB	O
significantly	RB	O
reduced	VBN	O
the	DT	O
incidence	NN	O
of	IN	O
angina	NN	O
attacks	NNS	O
and	CC	O
the	DT	O
concomitant	JJ	O
need	NN	O
of	IN	O
nitroglycerin	NN	PM
for	IN	O
relief	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
thus	RB	O
improved	VBN	O
the	DT	O
patients	NNS	O
'	POS	O
ability	NN	O
to	TO	O
perform	VB	O
daily	JJ	O
activities	NNS	O
.	.	O

Most	JJS	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
were	VBD	O
mild	JJ	O
or	CC	O
moderate	JJ	O
and	CC	O
the	DT	O
incidence	NN	O
is	VBZ	O
as	RB	O
would	MD	O
be	VB	O
expected	VBN	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	PM
enzyme	NN	PM
inhibitor	NN	PM
imidapril	NN	PM
on	IN	O
plasma	NN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
early	JJ	O
treatment	NN	O
with	IN	O
angiotensin-converting	JJ	PM
enzyme	NN	PM
(	(	PM
ACE	NNP	PM
)	)	PM
inhibitors	NNS	PM
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
is	VBZ	O
useful	JJ	O
for	IN	O
the	DT	O
improvement	NN	O
of	IN	O
fibrinolytic	JJ	O
function	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
left	VBN	O
ventricular	JJ	O
function	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
levels	NNS	O
of	IN	O
plasma	NN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
(	(	O
PAI	NNP	O
)	)	O
activity	NN	O
and	CC	O
serum	JJ	O
ACE	NNP	O
activity	NN	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
in	IN	O
40	CD	O
patients	NNS	O
with	IN	O
AMI	NNP	O
within	IN	O
12	CD	O
hours	NNS	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
the	DT	O
symptom	NN	O
and	CC	O
who	WP	O
randomly	VBP	O
received	VBN	O
early	JJ	O
treatment	NN	O
with	IN	O
either	CC	O
the	DT	O
ACE	NNP	PM
inhibitor	NN	PM
imidapril	NN	PM
or	CC	O
a	DT	O
placebo	NN	C
(	(	O
20	CD	O
patients	NNS	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
and	CC	O
20	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
serum	JJ	O
ACE	NNP	O
activity	NN	O
in	IN	O
the	DT	O
imidapril	NN	PM
group	NN	O
decreased	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
8	CD	O
hours	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
imidapril	NN	PM
,	,	O
and	CC	O
the	DT	O
levels	NNS	O
24	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
3.6	CD	O
+/-	JJ	O
0.6	CD	O
IU/L	NNP	O
vs	VBD	O
7.4	CD	O
+/-	JJ	O
0.8	CD	O
IU/L	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
plasma	JJ	O
PAI	NNP	O
activity	NN	O
increased	VBD	O
gradually	RB	O
to	TO	O
peak	VB	O
levels	NNS	O
16	CD	O
hours	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
imidapril	NN	O
and	CC	O
placebo	NN	O
.	.	O

The	DT	O
levels	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
decreased	VBD	O
gradually	RB	O
but	CC	O
remained	VBD	O
high	JJ	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
the	DT	O
levels	NNS	O
of	IN	O
PAI	NNP	O
activity	NN	O
in	IN	O
the	DT	O
imidapril	NN	PM
group	NN	O
decreased	VBD	O
rapidly	RB	O
and	CC	O
those	DT	O
48	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
7.9	CD	O
+/-	JJ	O
1.9	CD	O
IU/ml	NNP	O
vs	VBD	O
18.4	CD	O
+/-	JJ	O
3.5	CD	O
IU/ml	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
about	IN	O
2	CD	O
weeks	NNS	O
after	IN	O
admission	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
65.9	CD	O
%	NN	O
+/-	JJ	O
2.5	CD	O
%	NN	O
vs	JJ	O
49.1	CD	O
%	NN	O
+/-	JJ	O
4.4	CD	O
%	NN	O
;	:	O
p	CC	O
<	VB	O
0.01	CD	O
)	)	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
imidapril	NN	PM
,	,	O
an	DT	O
ACE	NNP	O
inhibitor	NN	O
,	,	O
might	MD	O
be	VB	O
useful	JJ	O
for	IN	O
the	DT	O
improvement	NN	O
of	IN	O
fibrinolytic	JJ	O
function	NN	O
and	CC	O
left	VBD	O
ventricular	JJ	O
function	NN	O
in	IN	O
the	DT	O
acute	JJ	O
phase	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Gonadotropin-releasing	VBG	PM
hormone	NN	PM
agonist	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
premenstrual	JJ	O
symptoms	NNS	O
with	IN	O
and	CC	O
without	IN	O
ongoing	VBG	O
dysphoria	NN	O
:	:	O
a	DT	O
controlled	VBN	O
study	NN	O
.	.	O

Gonadotropin-releasing	VBG	PM
hormone	NN	PM
(	(	PM
GnRH	NNP	PM
)	)	PM
agonists	NNS	PM
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
symptoms	NNS	O
of	IN	O
premenstrual	JJ	O
syndrome	NN	O
(	(	O
PMS	NNP	O
)	)	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
GnRH	NNP	PM
agonist	NN	PM
,	,	O
leuprolide	JJ	O
acetate	NN	O
depot	NN	O
,	,	O
in	IN	O
a	DT	O
clearly	RB	O
defined	VBN	O
PMS	NNP	O
sample	JJ	O
versus	NNS	O
women	NNS	O
with	IN	O
premenstrual	JJ	O
symptoms	NNS	O
in	IN	O
combination	NN	O
with	IN	O
dysphoric	NN	O
symptoms	NNS	O
throughout	IN	O
the	DT	O
cycle	NN	O
,	,	O
termed	VBD	O
the	DT	O
premenstrual	JJ	O
exacerbation	NN	O
(	(	O
PME	NNP	O
)	)	O
group	NN	O
.	.	O

Evaluation	NN	O
included	VBD	O
the	DT	O
Structured	NNP	O
Clinical	NNP	O
Interview	NNP	O
for	IN	O
DSM-III-R	NNP	O
,	,	O
administered	VBN	O
in	IN	O
the	DT	O
follicular	JJ	O
phase	NN	O
,	,	O
and	CC	O
the	DT	O
subject	NN	O
Penn	NNP	O
Dally	NNP	O
Symptoms	NNP	O
Report	NNP	O
(	(	O
DSR	NNP	O
)	)	O
maintained	VBD	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Thirty-three	NNP	O
eligible	JJ	O
women	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
and	CC	O
administered	VBD	O
3.75	CD	PM
mg	NN	PM
of	IN	PM
depot	NN	PM
leuprolide	NN	PM
or	CC	O
a	DT	O
placebo	NN	C
once	RB	O
a	DT	O
month	NN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
seen	VBN	O
for	IN	O
efficacy	NN	O
evaluations	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
cycle	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
the	DT	O
DSRs	NNP	O
and	CC	O
the	DT	O
17-item	JJ	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
HAM-D17	NNP	O
)	)	O
.	.	O

The	DT	O
PMS	NNP	O
leuprolide	JJ	PM
subjects	NNS	O
improved	VBN	O
significantly	RB	O
compared	VBN	O
with	IN	O
the	DT	O
PMS	NNP	O
placebo	NN	O
and	CC	O
PME	NNP	O
leuprolide	RB	O
groups	NNS	O
.	.	O

The	DT	O
PME	NNP	O
leuprolide	NN	PM
group	NN	O
,	,	O
who	WP	O
had	VBD	O
dysphoric	NN	O
symptoms	NNS	O
throughout	IN	O
the	DT	O
cycle	NN	O
,	,	O
did	VBD	O
not	RB	O
improve	VB	O
.	.	O

Depression	NNP	O
symptoms	NNS	O
were	VBD	O
at	IN	O
clinical	JJ	O
levels	NNS	O
premenstrually	RB	O
in	IN	O
the	DT	O
PMS	NNP	O
and	CC	O
PME	NNP	O
groups	NNS	O
;	:	O
following	VBG	O
treatment	NN	O
they	PRP	O
remitted	VBD	O
in	IN	O
the	DT	O
PMS	NNP	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
PME	NNP	O
leuprolide	JJ	PM
subjects	NNS	O
.	.	O

Efficacy	NN	O
did	VBD	O
not	RB	O
occur	VB	O
until	IN	O
after	IN	O
several	JJ	O
months	NNS	O
of	IN	O
leuprolide	JJ	PM
treatment	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
PMS	NNP	O
symptoms	NNS	O
worsened	VBD	O
with	IN	O
the	DT	O
onset	NN	O
of	IN	O
treatment	NN	O
.	.	O

These	DT	O
results	NNS	O
replicate	VBP	O
the	DT	O
findings	NNS	O
in	IN	O
our	PRP$	O
preliminary	JJ	O
open-label	NN	O
study	NN	O
.	.	O

Leuprolide	NNP	PM
reduced	VBD	O
PMS	NNP	O
symptoms	NNS	O
to	TO	O
minimal	JJ	O
levels	NNS	O
where	WRB	O
symptoms	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
luteal	JJ	O
phase	NN	O
.	.	O

Leuprolide	NNP	PM
was	VBD	O
not	RB	O
effective	JJ	O
for	IN	O
women	NNS	O
with	IN	O
ongoing	VBG	O
dysphoric	NN	O
symptoms	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
premenstrual	JJ	O
depression	NN	O
may	MD	O
have	VB	O
mechanisms	NNS	O
different	JJ	O
from	IN	O
those	DT	O
of	IN	O
other	JJ	O
dysphoric	JJ	O
mood	NN	O
disorders	NNS	O
.	.	O

Influence	NN	O
of	IN	O
special-effect	JJ	PH
contact	NN	PH
lenses	NNS	PH
(	(	PH
Crazy	NNP	PH
Lenses	NNP	PH
)	)	PH
on	IN	O
visual	JJ	O
function	NN	O
.	.	O

PURPOSE	NNP	O
Special-effect	JJ	PH
contact	NN	PH
lenses	NNS	PH
(	(	O
opaque	NN	O
,	,	O
tinted	VBD	O
soft	JJ	O
contact	NN	O
lenses	VBZ	O
that	IN	O
incorporate	JJ	O
decorative	JJ	O
images	NNS	O
such	JJ	O
as	IN	O
cateyes	NNS	O
,	,	O
stars	NNS	O
,	,	O
or	CC	O
hearts	NNS	O
to	TO	O
alter	VB	O
eye	NN	O
color	NN	O
and	CC	O
structure	NN	O
)	)	O
have	VBP	O
become	VBN	O
increasingly	RB	O
popular	JJ	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
such	JJ	O
lenses	NNS	O
impair	VBP	O
visual	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
A	DT	PH
clear	JJ	PH
soft	JJ	PH
contact	NN	PH
lens	NNS	PH
and	CC	O
a	DT	PH
special-effect	JJ	PH
soft	JJ	PH
contact	NN	PH
lens	NNS	PH
(	(	PH
Crazy	NNP	PH
lens	VBZ	PH
,	,	PH
)	)	PH
were	VBD	O
fit	JJ	O
in	IN	O
changing	VBG	O
sequence	NN	O
in	IN	O
nine	CD	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
parameters	NNS	O
studied	VBD	O
included	VBN	O
:	:	O
visual	JJ	O
acuity	NN	O
,	,	O
contrast	NN	O
sensitivity	NN	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
)	)	O
,	,	O
visual	JJ	O
field	NN	O
,	,	O
and	CC	O
mesopic	NN	O
vision	NN	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
following	JJ	O
parameters	NNS	O
displayed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Visual	JJ	O
acuity	NN	O
was	VBD	O
decreased	VBN	O
to	TO	O
0.9	CD	O
+/-	JJ	O
0.23	CD	O
in	IN	O
the	DT	O
Crazy	NNP	O
lens	VBZ	O
group	NN	O
as	IN	O
compared	VBN	O
with	IN	O
1.2	CD	O
+/-	JJ	O
0.13	CD	O
in	IN	O
the	DT	O
clear	JJ	PH
lens	NNS	PH
group	NN	O
.	.	O

Goldmann	NNP	O
visual	JJ	O
field	NN	O
displayed	VBD	O
a	DT	O
significant	JJ	O
constriction	NN	O
of	IN	O
the	DT	O
isopters	NNS	O
:	:	O
III/4	NNP	O
,	,	O
I/4	NNP	O
,	,	O
and	CC	O
I/3	NNP	O
.	.	O

Mesopic	NNP	O
vision	NN	O
without	IN	O
glare	NN	O
was	VBD	O
reduced	VBN	O
from	IN	O
1:2.5	CD	O
to	TO	O
1:7.4	CD	O
.	.	O

Contrast	NNP	O
sensitivity	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
a	DT	O
photopic	JJ	O
condition	NN	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
and	CC	O
in	IN	O
a	DT	O
scotopic	JJ	O
condition	NN	O
without	IN	O
glare	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
special-effect	JJ	PH
lenses	NNS	PH
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
lens	NNS	O
wearing	VBG	O
comfort	NN	O
.	.	O

CONCLUSIONS	NNP	O
Special-effect	JJ	PH
contact	NN	PH
lenses	NNS	PH
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
of	IN	O
many	JJ	O
visual	JJ	O
functions	NNS	O
,	,	O
including	VBG	O
visual	JJ	O
acuity	NN	O
and	CC	O
contrast	NN	O
sensitivity	NN	O
.	.	O

For	IN	O
some	DT	O
wearers	NNS	O
this	DT	O
may	MD	O
interfere	VB	O
with	IN	O
activities	NNS	O
where	WRB	O
excellent	JJ	O
vision	NN	O
is	VBZ	O
crucial	JJ	O
,	,	O
such	JJ	O
as	IN	O
driving	VBG	O
a	DT	O
car	NN	O
.	.	O

Response	NNP	O
prediction	NN	O
in	IN	O
metastasised	JJ	O
colorectal	NN	O
cancer	NN	O
using	VBG	O
intratumoural	JJ	O
thymidylate	JJ	O
synthase	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomised	JJ	O
multicentre	NN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Molecular	NNP	O
markers	NNS	O
to	TO	O
predict	VB	O
response	NN	O
to	TO	O
5-fluorouracil	JJ	PM
(	(	PM
FU	NNP	PM
)	)	PM
-based	VBD	PM
treatment	NN	O
of	IN	O
recurrent	NN	O
or	CC	O
metastasised	VBN	O
colorectal	JJ	O
cancer	NN	O
(	(	O
mCRC	NN	O
)	)	O
are	VBP	O
not	RB	O
established	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	O
of	IN	O
thymidylate	JJ	O
synthase	NN	O
(	(	O
TS	NNP	O
)	)	O
,	,	O
a	DT	O
key	JJ	O
enzyme	NN	O
of	IN	O
DNA	NNP	O
synthesis	NN	O
and	CC	O
target	NN	O
of	IN	O
5-FU	JJ	O
,	,	O
to	TO	O
predict	VB	O
response	NN	O
to	TO	O
chemotherapy	NN	O
of	IN	O
mCRC	NN	O
.	.	O

METHODS	NNP	O
Tumour	NNP	O
tissue	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
168	CD	O
patients	NNS	O
with	IN	O
mCRC	NN	O
for	IN	O
relative	JJ	O
thymidylate	NN	PM
synthase	NN	PM
(	(	O
TS	NNP	O
)	)	O
mRNA	NN	O
quantitation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
5-FU/folinic	JJ	PM
acid	NN	PM
(	(	PM
FA	NNP	PM
,	,	PM
FUFA	NNP	PM
)	)	PM
alone	RB	PM
or	CC	PM
in	IN	PM
combination	NN	PM
with	IN	PM
irinotecan	JJ	PM
5-fluorouracil/folinic	JJ	PM
acid	NN	PM
and	CC	PM
irinotecan	JJ	PM
(	(	PM
FOLFIRI	NNP	PM
)	)	PM
stratified	VBN	PM
by	IN	PM
TS	NNP	PM
(	(	PM
low	JJ	PM
versus	RB	PM
high	JJ	PM
)	)	PM
.	.	O

Primary	JJ	O
end-point	NN	O
was	VBD	O
overall	JJ	O
response	NN	O
to	TO	O
first-line	JJ	O
treatment	NN	O
among	IN	O
TS	NNP	O
high	JJ	O
patients	NNS	O
.	.	O

All	DT	O
parties	NNS	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
randomisation	NN	O
centre	NN	O
,	,	O
were	VBD	O
blinded	VBN	O
for	IN	O
TS	NNP	O
status	NN	O
.	.	O

RESULTS	NNP	O
Biopsies	NNP	O
(	(	O
n=168	RB	O
)	)	O
were	VBD	O
taken	VBN	O
without	IN	O
complications	NNS	O
.	.	O

TS	NN	O
levels	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
147	CD	O
patients	NNS	O
(	(	O
87.5	CD	O
%	NN	O
)	)	O
.	.	O

Analysing	VBG	O
response	NN	O
to	TO	O
FUFA	NNP	O
and	CC	O
FOLFIRI	NNP	O
in	IN	O
the	DT	O
per	NN	O
protocol	NN	O
set	VBN	O
(	(	O
n=119	NN	O
)	)	O
after	IN	O
un-blinding	JJ	O
TS	NNP	O
in	IN	O
the	DT	O
data	NN	O
base	NN	O
revealed	VBD	O
a	DT	O
trend	NN	O
to	TO	O
better	JJR	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
(	(	O
9/19	CD	O
,	,	O
47	CD	O
%	NN	O
)	)	O
in	IN	O
TS	NNP	O
high	JJ	O
compared	VBN	O
to	TO	O
FUFA	NNP	O
(	(	O
5/23	CD	O
,	,	O
22	CD	O
%	NN	O
,	,	O
p=0.077	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
biopsies	NNS	O
taken	VBN	O
from	IN	O
liver	JJ	O
lesions	NNS	O
(	(	O
n=91	NN	O
)	)	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
and	CC	O
FUFA	NNP	O
in	IN	O
TS	NNP	O
high	NN	O
was	VBD	O
53	CD	O
%	NN	O
(	(	O
9/17	CD	O
)	)	O
and	CC	O
18	CD	O
%	NN	O
(	(	O
3/17	CD	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p=0.035	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
low	JJ	O
TS	NNP	O
,	,	O
no	DT	O
remarkable	JJ	O
difference	NN	O
in	IN	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
and	CC	O
FUFA	NNP	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Taking	VBG	O
a	DT	O
pre-treatment	JJ	O
biopsy	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
feasible	JJ	O
procedure	NN	O
in	IN	O
mCRC	NN	O
.	.	O

After	IN	O
validation	NN	O
of	IN	O
our	PRP$	O
data	NNS	O
in	IN	O
a	DT	O
larger	JJR	O
group	NN	O
TS	NNP	O
determination	NN	O
may	MD	O
have	VB	O
the	DT	O
potential	NN	O
to	TO	O
better	JJR	O
help	NN	O
direct	VB	O
systemic	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
primarily	RB	O
non-resectable	JJ	O
mCRC	NN	O
.	.	O

[	JJ	O
Intra-arterial	JJ	PM
(	(	PM
5-FU/FA	JJ	PM
and	CC	PH
FUDR	NNP	PM
)	)	PH
versus	VBP	O
systemic	JJ	PM
chemotherapy	NN	PM
(	(	PM
5-FU/FA	JJ	PM
)	)	PM
of	IN	O
non-resectable	JJ	O
colorectal	JJ	O
liver	NN	O
metastases	NNS	O
]	VBP	O
.	.	O

The	DT	O
relative	JJ	O
efficacy	NN	O
of	IN	O
HAI	NNP	PM
FUDR	NNP	PM
,	,	PH
HAI	NNP	PM
5-FU/FA	CD	PM
,	,	PH
and	CC	PH
i.v	NN	PH
.	.	PH

5-FU/FA	JJ	O
chemotherapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
unresectable	JJ	O
colorectal	JJ	O
liver	NN	O
metastases	NNS	O
was	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
after	IN	O
HAI	NNP	PM
treatment	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
as	IN	O
compared	VBN	O
to	TO	O
i.v	VB	O
.	.	O

treatment	NN	O
with	IN	O
no	DT	O
statistical	JJ	O
benefit	NN	O
regarding	VBG	O
survival	NN	O
and	CC	O
time	NN	O
to	TO	O
progression	NN	O
.	.	O

HAI	NNP	PM
FUDR	NNP	PM
treatment	NN	O
was	VBD	O
inferior	JJ	O
as	IN	O
compared	VBN	O
to	TO	O
HAI	NNP	PM
or	CC	O
i.v	NN	O
.	.	O

5-FU/FA	JJ	PM
.	.	PM

i.v	NN	O
.	.	O

5-FU/FA-therapy	NN	PM
is	VBZ	O
therefore	IN	O
the	DT	O
method	NN	O
of	IN	O
choice	NN	O
outside	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

Eberconazole	JJ	PM
1	CD	O
%	NN	O
cream	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
alternative	NN	O
for	IN	O
dermatophytosis	NN	O
treatment	NN	O
:	:	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
comparative	JJ	O
trial	NN	O
with	IN	O
miconazole	JJ	PM
2	CD	O
%	NN	O
cream	NN	O
.	.	O

BACKGROUND	NNP	O
Eberconazole	NNP	PM
is	VBZ	O
a	DT	O
topical	JJ	O
,	,	O
broad-spectrum	JJ	O
imidazole	NN	O
derivative	NN	O
,	,	O
effective	JJ	O
in	IN	O
dermatophytoses	NNS	O
,	,	O
candidiasis	NN	O
,	,	O
and	CC	O
pityriasis	NN	O
treatment	NN	O
.	.	O

In	IN	O
previous	JJ	O
trials	NNS	O
,	,	O
it	PRP	O
showed	VBD	O
a	DT	O
higher	JJR	O
efficacy	NN	O
than	IN	O
clotrimazole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
eberconazole	JJ	PM
1	CD	O
%	NN	O
cream	NN	O
compared	VBN	O
with	IN	O
miconazole	JJ	PM
2	CD	O
%	NN	O
cream	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
multicenter	NN	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
653	CD	O
patients	NNS	O
with	IN	O
dermatophytoses	NNS	O
,	,	O
randomized	VBN	O
to	TO	O
eberconazole	VB	PM
1	CD	O
%	NN	O
cream	NN	O
every	DT	O
12	CD	O
h	NN	O
or	CC	O
miconazole	VB	PM
2	CD	O
%	NN	O
cream	NN	O
every	DT	O
12	CD	O
h	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Treatment	NNP	O
efficacy	NN	O
was	VBD	O
assessed	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
percentage	NN	O
of	IN	O
effective	JJ	O
response	NN	O
after	IN	O
4	CD	O
weeks	NNS	O
through	IN	O
mycologic	NN	O
and	CC	O
clinical	JJ	O
assessment	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
653	CD	O
patients	NNS	O
included	VBN	O
in	IN	O
the	DT	O
trial	NN	O
,	,	O
360	CD	O
produced	VBD	O
positive	JJ	O
baseline	NN	O
mycologic	NN	O
cultures	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
efficacy	NN	O
assessment	NN	O
.	.	O

Clinical	JJ	O
efficacy	NN	O
was	VBD	O
shown	VBN	O
in	IN	O
76.1	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
eberconazole	JJ	O
and	CC	O
in	IN	O
75.0	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
miconazole	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
related	VBN	O
to	TO	O
treatment	NN	O
was	VBD	O
0.91	CD	O
%	NN	O
for	IN	O
eberconazole	NN	O
and	CC	O
0.92	CD	O
%	NN	O
for	IN	O
miconazole	NN	O
,	,	O
none	NN	O
being	VBG	O
serious	JJ	O
,	,	O
and	CC	O
all	DT	O
being	VBG	O
local	JJ	O
and	CC	O
transient	NN	O
.	.	O

CONCLUSIONS	NNP	O
Eberconazole	NNP	O
1	CD	O
%	NN	O
cream	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
fungal	JJ	O
infections	NNS	O
produced	VBN	O
by	IN	O
dermatophytes	NNS	O
,	,	O
with	IN	O
a	DT	O
good	JJ	O
safety	NN	O
and	CC	O
tolerability	NN	O
profile	NN	O
,	,	O
and	CC	O
can	MD	O
be	VB	O
considered	VBN	O
a	DT	O
good	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
dermatophytoses	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
Thai	NNP	O
traditional	JJ	O
massage	NN	O
on	IN	O
autistic	JJ	O
children	NNS	O
's	POS	O
behavior	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
access	NN	O
whether	IN	O
there	EX	O
were	VBD	O
any	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
Thai	NNP	E
Traditional	NNP	E
Massage	NNP	E
(	(	E
TTM	NNP	E
)	)	E
on	IN	O
major	JJ	O
behavioral	JJ	O
and	CC	O
emotional	JJ	O
disturbances	NNS	O
in	IN	O
Thai	NNP	O
autistic	JJ	O
children	NNS	O
.	.	O

DESIGN	NN	O
This	DT	O
was	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
study	NN	O
.	.	O

SETTINGS/LOCATION	NNP	O
The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Rehabilitation	NNP	O
Centre	NNP	O
of	IN	O
the	DT	O
Thai	NNP	O
Red	NNP	O
Cross	NNP	O
Society	NNP	O
.	.	O

SUBJECTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
60	CD	O
autistic	JJ	O
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
3	CD	O
and	CC	O
10	CD	O
completed	VBD	O
this	DT	O
study	NN	O
.	.	O

INTERVENTIONS	NNP	O
Standard	NNP	E
sensory	JJ	E
integration	NN	E
therapy	NN	E
(	(	E
SI	NNP	E
)	)	E
was	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
SI	NNP	O
with	IN	O
TTM	NNP	E
treatments	NNS	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Parents	NNP	O
and	CC	O
teachers	NNS	O
assessed	VBD	O
major	JJ	O
behavior	NN	O
disturbances	NNS	O
using	VBG	O
the	DT	O
Conners	NNPS	O
'	POS	O
Rating	VBG	O
Scales	NNS	O
at	IN	O
0	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
.	.	O

Sleep	JJ	O
Diary	NNP	O
(	(	O
SD	NNP	O
)	)	O
,	,	O
recorded	VBN	O
by	IN	O
the	DT	O
parents	NNS	O
,	,	O
assessed	VBD	O
the	DT	O
patient	NN	O
's	POS	O
sleeping	NN	O
patterns	NNS	O
every	DT	O
week	NN	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
(	(	O
60	CD	O
)	)	O
autistic	JJ	O
children	NNS	O
,	,	O
mean	JJ	O
age	NN	O
4.67	CD	O
+/-	JJ	O
1.82	CD	O
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

No	DT	O
statistical	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
demographic	JJ	O
and	CC	O
baseline	JJ	O
data	NN	O
among	IN	O
both	DT	O
groups	NNS	O
.	.	O

From	IN	O
both	CC	O
the	DT	O
Conners	NNPS	O
'	POS	O
Teacher	NNP	O
Questionnaire	NNP	O
and	CC	O
SD	NNP	O
,	,	O
statistical	JJ	O
improvement	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
conduct	NN	O
problem	NN	O
,	,	O
hyperactivity	NN	O
,	,	O
inattention-passivity	NN	O
,	,	O
hyperactivity	NN	O
index	NN	O
,	,	O
and	CC	O
sleeping	VBG	O
behavior	NN	O
.	.	O

However	RB	O
,	,	O
results	NNS	O
from	IN	O
the	DT	O
Conners	NNP	O
'	POS	O
Parent	NNP	O
Questionnaire	NNP	O
revealed	VBD	O
an	DT	O
improvement	NN	O
only	RB	O
for	IN	O
anxiety	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
the	DT	O
massage	NN	O
group	NN	O
,	,	O
whereas	IN	O
when	WRB	O
both	DT	O
groups	NNS	O
were	VBD	O
compared	VBN	O
,	,	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
conduct	NN	O
problem	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
anxiety	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
was	VBD	O
found	VBN	O
.	.	O

Results	NNS	O
indicated	VBD	O
that	IN	O
TTM	NNP	O
may	MD	O
have	VB	O
a	DT	O
positive	JJ	O
effect	NN	O
in	IN	O
improving	VBG	O
stereotypical	JJ	O
behaviors	NNS	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Over	IN	O
a	DT	O
period	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
,	,	O
our	PRP$	O
findings	NNS	O
suggested	VBD	O
that	IN	O
TTM	NNP	O
could	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
complementary	JJ	O
therapy	NN	O
for	IN	O
autistic	JJ	O
children	NNS	O
in	IN	O
Thailand	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
thin-ideal	JJ	O
media	NNS	O
images	NNS	O
on	IN	O
body	NN	O
dissatisfaction	NN	O
:	:	O
testing	VBG	O
the	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
disclaimer	NN	E
versus	NN	O
warning	VBG	E
label	NN	E
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
disclaimer	NN	O
(	(	O
i.e.	FW	O
,	,	O
Retouched	NNP	O
photograph	NN	O
aimed	VBN	O
at	IN	O
changing	VBG	O
a	DT	O
person	NN	O
's	POS	O
physical	JJ	O
appearance	NN	O
.	.	O

)	)	O
or	CC	O
warning	VBG	O
(	(	O
i.e.	FW	O
,	,	O
Warning	VBG	O
:	:	O
Trying	NN	O
to	TO	O
look	VB	O
as	RB	O
thin	JJ	O
as	IN	O
this	DT	O
model	NN	O
may	MD	O
be	VB	O
dangerous	JJ	O
to	TO	O
your	PRP$	O
health	NN	O
.	.	O

)	)	O
added	VBD	O
to	TO	O
images	NNS	O
of	IN	O
thin/attractive	JJ	O
models	NNS	O
would	MD	O
affect	VB	O
body	NN	O
dissatisfaction	NN	O
and	CC	O
intent	NN	O
to	TO	O
diet	VB	O
in	IN	O
female	JJ	O
undergraduate	JJ	O
students	NNS	O
(	(	O
n=342	NN	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
disclaimer	NN	E
,	,	O
(	(	O
b	NN	O
)	)	O
warning	NN	E
,	,	O
(	(	O
c	NN	O
)	)	O
model	NN	C
control	NN	C
,	,	O
or	CC	O
(	(	O
d	NN	O
)	)	O
car	NN	C
control	NN	C
.	.	O

Results	NNP	O
revealed	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
group	NN	O
and	CC	O
time	NN	O
,	,	O
whereby	WRB	O
only	RB	O
the	DT	O
car	NN	O
control	NN	O
group	NN	O
reported	VBD	O
a	DT	O
significant	JJ	O
change	NN	O
(	(	O
i.e.	FW	O
,	,	O
decrease	NN	O
)	)	O
in	IN	O
body	NN	O
dissatisfaction	NN	O
over	IN	O
time	NN	O
.	.	O

Groups	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
on	IN	O
intent	NN	O
to	TO	O
diet	VB	O
measured	VBN	O
at	IN	O
post-exposure	NN	O
.	.	O

The	DT	O
results	NNS	O
largely	RB	O
replicate	VBP	O
other	JJ	O
findings	NNS	O
in	IN	O
this	DT	O
area	NN	O
and	CC	O
call	VB	O
into	IN	O
question	NN	O
advocacy	NN	O
efforts	NNS	O
to	TO	O
label	VB	O
media	NNS	O
images	NNS	O
as	IN	O
a	DT	O
strategy	NN	O
to	TO	O
decrease	VB	O
women	NNS	O
's	POS	O
identification	NN	O
with	IN	O
the	DT	O
stimuli	NNS	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
for	IN	O
behaviorally	RB	O
disordered	VBN	O
mentally	RB	O
handicapped	JJ	O
patients	NNS	O
on	IN	O
staff	NN	O
personnel	NNS	O
in	IN	O
residential	JJ	O
care	NN	O
]	NNP	O
.	.	O

This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	PS
therapy	NN	PS
program	NN	PS
designed	VBN	O
for	IN	O
mentally	RB	O
handicapped	JJ	O
persons	NNS	O
with	IN	O
severely	RB	O
disturbed	VBN	O
or	CC	O
autistic	JJ	O
behavior	NN	O
on	IN	O
their	PRP$	O
staff	NN	O
personal	JJ	O
which	WDT	O
had	VBD	O
an	DT	O
active	JJ	O
role	NN	O
in	IN	O
the	DT	O
program	NN	O
.	.	O

The	DT	O
staff	NN	O
members	NNS	O
rated	VBD	O
their	PRP$	O
professional	JJ	O
competence	NN	O
,	,	O
quality	NN	O
of	IN	O
interaction	NN	O
with	IN	O
the	DT	O
client	NN	O
,	,	O
team	JJ	O
culture	NN	O
and	CC	O
work	NN	O
satisfaction	NN	O
before	IN	O
and	CC	O
after	IN	O
being	VBG	O
engaged	VBN	O
in	IN	O
the	DT	O
program	NN	O
,	,	O
with	IN	O
additional	JJ	O
ratings	NNS	O
of	IN	O
their	PRP$	O
personal	JJ	O
aims	NNS	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
program	NN	O
.	.	O

Three	NNP	O
sets	NNS	O
of	IN	O
data	NNS	O
were	VBD	O
obtained	VBN	O
with	IN	O
the	DT	O
program	NN	O
being	VBG	O
conducted	VBN	O
three	CD	O
times	NNS	O
in	IN	O
a	DT	O
row	NN	O
.	.	O

The	DT	O
testings	NNS	O
of	IN	O
the	DT	O
related	VBN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
independent	JJ	O
samples	NNS	O
show	VBP	O
differentiated	JJ	O
program	NN	O
effects	NNS	O
.	.	O

The	DT	O
main	JJ	O
effect	NN	O
is	VBZ	O
an	DT	O
increase	NN	O
of	IN	O
the	DT	O
professional	JJ	O
competence	NN	O
and	CC	O
quality	NN	O
of	IN	O
interaction	NN	O
,	,	O
especially	RB	O
by	IN	O
the	DT	O
qualified	JJ	O
staff	NN	O
members	NNS	O
.	.	O

Trainees	NNP	O
put	VBD	O
emphasis	NN	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
their	PRP$	O
personal	JJ	O
relationship	NN	O
with	IN	O
the	DT	O
client	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
impact	NN	O
of	IN	O
learning	VBG	O
processes	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
roles	NNS	O
of	IN	O
the	DT	O
staff	NN	O
members	NNS	O
and	CC	O
motivational	JJ	O
factors	NNS	O
on	IN	O
learning	NN	O
and	CC	O
therapy	NN	O
outcome	NN	O
,	,	O
along	IN	O
with	IN	O
institutional	JJ	O
conditions	NNS	O
influencing	VBG	O
successful	JJ	O
learning	NN	O
.	.	O

Thus	VB	O
the	DT	O
program	NN	O
facilitates	VBZ	O
the	DT	O
professional	JJ	O
and	CC	O
interpersonal	JJ	O
learning	NN	O
process	NN	O
of	IN	O
staff	NN	O
members	NNS	O
in	IN	O
a	DT	O
specific	JJ	O
way	NN	O
with	IN	O
success	NN	O
as	RB	O
well	RB	O
as	IN	O
with	IN	O
limitations	NNS	O
.	.	O

Phase	NNP	O
III	NNP	O
comparative	JJ	O
study	NN	O
of	IN	O
high-dose	JJ	PM
cisplatin	NN	PM
versus	IN	O
a	DT	O
combination	NN	O
of	IN	O
paclitaxel	NN	PM
and	CC	PM
cisplatin	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
New	NNP	O
effective	JJ	O
chemotherapy	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
improve	VB	O
the	DT	O
outcome	NN	O
of	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
.	.	O

Paclitaxel	NNP	PM
administered	VBD	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
cisplatin	NN	PM
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
potentially	RB	O
new	JJ	O
useful	JJ	O
agent	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
NSCLC	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
January	NNP	O
1995	CD	O
and	CC	O
April	NNP	O
1996	CD	O
,	,	O
414	CD	O
patients	NNS	O
with	IN	O
stage	NN	O
IIIB	NNP	O
or	CC	O
IV	NNP	O
NSCLC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
received	VB	O
either	RB	O
a	DT	O
control	NN	O
arm	NN	O
of	IN	O
high-dose	JJ	PM
cisplatin	NN	PM
(	(	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
or	CC	O
a	DT	O
combination	NN	PM
of	IN	PM
paclitaxel	NN	PM
(	(	PM
175	CD	PM
mg/m	NN	PM
(	(	PM
2	CD	PM
)	)	PM
,	,	PM
3-hour	JJ	PM
infusion	NN	PM
)	)	PM
and	CC	PM
cisplatin	NN	PM
(	(	O
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
the	DT	O
cisplatin-only	JJ	O
arm	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
9	CD	O
%	NN	O
improvement	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0	CD	O
%	NN	O
to	TO	O
19	CD	O
%	NN	O
)	)	O
in	IN	O
overall	JJ	O
response	NN	O
rate	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	PM
arm	NN	O
(	(	O
17	CD	O
%	NN	O
v	JJ	O
26	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P=.028	NNP	O
)	)	O
.	.	O

Median	JJ	O
time	NN	O
to	TO	O
progression	NN	O
was	VBD	O
2.7	CD	O
and	CC	O
4.1	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
paclitaxel/cisplatin	NN	PM
arm	NN	O
,	,	O
respectively	RB	O
(	(	O
P=.026	NNP	O
)	)	O
.	.	O

The	DT	O
study	NN	O
,	,	O
however	RB	O
,	,	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
median	JJ	O
survival	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	PM
arm	NN	O
(	(	O
8.6	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
v	NN	O
8.1	CD	O
months	NNS	O
in	IN	O
the	DT	O
paclitaxel/cisplatin	NN	O
arm	NN	O
,	,	O
P=.862	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
more	JJR	O
hematotoxicity	NN	O
,	,	O
peripheral	JJ	O
neuropathy	NN	O
,	,	O
and	CC	O
arthralgia/myalgia	NN	O
on	IN	O
the	DT	O
paclitaxel/cisplatin	NN	PM
arm	NN	O
,	,	O
whereas	IN	O
the	DT	O
high-dose	JJ	O
cisplatin	NN	PM
arm	NN	O
produced	VBD	O
more	JJR	O
ototoxicity	NN	O
,	,	O
nausea	NN	O
,	,	O
vomiting	NN	O
,	,	O
and	CC	O
nephrotoxicity	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
was	VBD	O
similar	JJ	O
overall	JJ	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

CONCLUSION	NN	O
This	DT	O
large	JJ	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
survival	NN	O
for	IN	O
the	DT	O
paclitaxel/cisplatin	NN	PM
combination	NN	O
compared	VBN	O
with	IN	O
high-dose	JJ	O
cisplatin	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
NSCLC	NNP	O
.	.	O

However	RB	O
,	,	O
the	DT	O
paclitaxel/cisplatin	NN	PM
combination	NN	O
did	VBD	O
produce	VB	O
a	DT	O
better	JJR	O
clinical	JJ	O
response	NN	O
,	,	O
resulting	VBG	O
in	IN	O
an	DT	O
increased	JJ	O
time	NN	O
to	TO	O
progression	NN	O
while	IN	O
providing	VBG	O
a	DT	O
similar	JJ	O
QOL	NNP	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
chewing	VBG	PH
versus	NN	O
caffeine	NN	PM
on	IN	O
alertness	NN	O
,	,	O
cognitive	JJ	O
performance	NN	O
and	CC	O
cardiac	JJ	O
autonomic	JJ	O
activity	NN	O
during	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

Chewing	NNP	PH
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
alleviate	VB	O
feelings	NNS	O
of	IN	O
sleepiness	NN	O
and	CC	O
improve	VB	O
cognitive	JJ	O
performance	NN	O
during	IN	O
the	DT	O
day	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
chewing	VBG	PM
on	IN	O
alertness	NN	O
and	CC	O
cognitive	JJ	O
performance	NN	O
across	IN	O
one	CD	O
night	NN	O
without	IN	O
sleep	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
possible	JJ	O
mediating	JJ	O
role	NN	O
of	IN	O
cardiac	JJ	O
autonomic	JJ	O
activity	NN	O
.	.	O

Fourteen	NNP	O
adults	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
counterbalanced	VBD	O
protocol	NN	O
employing	VBG	O
a	DT	O
chewing	NN	PS
,	,	O
placebo	NN	C
and	CC	O
caffeine	JJ	PM
condition	NN	O
.	.	O

Participants	NNS	O
completed	VBD	O
tasks	NNS	O
assessing	VBG	O
psychomotor	NN	O
vigilance	NN	O
,	,	O
tracking	VBG	O
,	,	O
grammatical	JJ	O
reasoning	NN	O
,	,	O
alertness	NN	O
and	CC	O
sleepiness	JJ	O
each	DT	O
hour	NN	O
across	IN	O
the	DT	O
night	NN	O
.	.	O

All	DT	O
participants	NNS	O
received	VBD	O
either	CC	O
placebo	NN	C
or	CC	O
caffeine	NN	PM
(	(	O
200	CD	O
mg	NN	O
)	)	O
,	,	O
while	IN	O
the	DT	O
chewing	VBG	PH
condition	NN	O
also	RB	O
chewed	VBD	PH
on	IN	PH
a	DT	PH
tasteless	NN	PH
and	CC	PH
odorless	JJ	PH
substance	NN	PH
for	IN	O
15	CD	O
min	NNS	O
each	DT	O
hour	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
,	,	O
root	JJ	O
mean	JJ	O
square	NN	O
of	IN	O
the	DT	O
successive	JJ	O
differences	NNS	O
in	IN	O
R-R	NNP	O
intervals	NNS	O
on	IN	O
the	DT	O
ECG	NNP	O
(	(	O
RMSSD	NNP	O
)	)	O
,	,	O
and	CC	O
preejection	NN	O
period	NN	O
(	(	O
PEP	NNP	O
)	)	O
were	VBD	O
simultaneously	RB	O
recorded	VBN	O
.	.	O

Alertness	NNP	O
and	CC	O
cognitive	JJ	O
performance	NN	O
amongst	VBD	O
the	DT	O
chewing	VBG	O
condition	NN	O
did	VBD	O
not	RB	O
differ	VB	O
or	CC	O
were	VBD	O
in	IN	O
fact	NN	O
worse	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Similarly	RB	O
,	,	O
measures	NNS	O
of	IN	O
HR	NNP	O
and	CC	O
RMSSD	NNP	O
remained	VBD	O
the	DT	O
same	JJ	O
between	IN	O
these	DT	O
two	CD	O
conditions	NNS	O
;	:	O
however	RB	O
,	,	O
PEP	NNP	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
later	JJ	O
part	NN	O
of	IN	O
the	DT	O
night	NN	O
in	IN	O
the	DT	O
chewing	VBG	PH
condition	NN	O
compared	VBN	O
with	IN	O
a	DT	O
relative	JJ	O
increase	NN	O
for	IN	O
placebo	NN	O
.	.	O

Caffeine	NNP	PM
led	VBD	O
to	TO	O
improved	VBN	O
speed	NN	O
and	CC	O
accuracy	NN	O
on	IN	O
cognitive	JJ	O
tasks	NNS	O
and	CC	O
increased	VBD	O
alertness	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
chewing	VBG	PH
.	.	O

Relative	JJ	O
increases	NNS	O
in	IN	O
RMSSD	NNP	O
and	CC	O
reductions	NNS	O
in	IN	O
HR	NNP	O
were	VBD	O
demonstrated	VBN	O
following	VBG	O
caffeine	NN	O
;	:	O
however	RB	O
,	,	O
no	DT	O
change	NN	O
in	IN	O
PEP	NNP	O
was	VBD	O
seen	VBN	O
.	.	O

Strong	JJ	O
associations	NNS	O
between	IN	O
cardiac	JJ	O
parasympathetic	JJ	O
activity	NN	O
and	CC	O
complex	JJ	O
cognitive	NN	O
tasks	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
between	IN	O
subjective	JJ	O
alertness	NN	O
and	CC	O
simpler	NN	O
cognitive	JJ	O
tasks	NNS	O
,	,	O
suggest	VBP	O
a	DT	O
differential	JJ	O
process	NN	O
mediating	VBG	O
complex	JJ	O
versus	NN	O
simple	JJ	O
cognitive	JJ	O
performance	NN	O
during	IN	O
sleep	JJ	O
deprivation	NN	O
.	.	O

Relaxation	NN	E
and	CC	E
imagery	NN	E
and	CC	E
cognitive-behavioral	JJ	E
training	NN	E
reduce	VB	O
pain	NN	O
during	IN	O
cancer	NN	O
treatment	NN	O
:	:	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Few	NNP	O
controlled	VBD	O
clinical	JJ	O
trials	NNS	O
of	IN	O
psychological	JJ	O
interventions	NNS	O
for	IN	O
cancer	NN	O
pain	NN	O
relief	NN	O
exist	NN	O
in	IN	O
spite	NN	O
of	IN	O
frequent	JJ	O
support	NN	O
for	IN	O
their	PRP$	O
importance	NN	O
as	IN	O
adjuncts	NNS	O
to	TO	O
medical	JJ	O
treatment	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
oral	JJ	O
mucositis	NN	O
pain	NN	O
levels	NNS	O
in	IN	O
4	CD	O
groups	NNS	O
of	IN	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
bone	NN	O
marrow	NN	O
transplants	NNS	O
(	(	O
BMT	NNP	O
)	)	O
:	:	O
(	(	O
1	CD	O
)	)	O
treatment	NN	C
as	IN	C
usual	JJ	C
control	NN	C
,	,	O
(	(	O
2	CD	O
)	)	O
therapist	NN	E
support	NN	E
,	,	E
(	(	E
3	CD	E
)	)	E
relaxation	NN	E
and	CC	E
imagery	NN	E
training	NN	E
,	,	E
and	CC	E
(	(	E
4	CD	E
)	)	E
training	NN	E
in	IN	E
a	DT	E
package	NN	E
of	IN	E
cognitive-behavioral	JJ	E
coping	NN	E
skills	NNS	E
which	WDT	E
included	VBD	E
relaxation	NN	E
and	CC	E
imagery	NN	E
.	.	O

A	DT	O
total	NN	O
of	IN	O
94	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
which	WDT	O
involved	VBD	O
two	CD	O
training	NN	O
sessions	NNS	O
prior	RB	O
to	TO	O
treatment	NN	O
and	CC	O
twice	RB	O
a	DT	O
week	NN	O
'booster	POS	O
'	POS	O
sessions	NNS	O
during	IN	O
the	DT	O
first	JJ	O
5	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Results	NNS	O
confirmed	VBD	O
our	PRP$	O
hypothesis	NN	O
that	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
either	DT	O
relaxation	NN	O
and	CC	O
imagery	VB	O
alone	RB	O
or	CC	O
patients	NNS	O
who	WP	O
received	VBD	O
the	DT	O
package	NN	O
of	IN	O
cognitive-behavioral	JJ	O
coping	NN	O
skills	NNS	O
would	MD	O
report	VB	O
less	JJR	O
pain	NN	O
than	IN	O
patients	NNS	O
in	IN	O
the	DT	O
other	JJ	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
cognitive-behavioral	JJ	O
skills	NNS	O
package	NN	O
would	MD	O
have	VB	O
an	DT	O
additive	JJ	O
effect	NN	O
beyond	IN	O
relaxation	NN	O
and	CC	O
imagery	NN	O
alone	RB	O
was	VBD	O
not	RB	O
confirmed	VBN	O
.	.	O

Average	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
report	NN	O
of	IN	O
pain	NN	O
within	IN	O
the	DT	O
therapist	JJ	O
support	NN	O
group	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.103	CD	O
)	)	O
nor	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
the	DT	O
training	NN	O
groups	NNS	O
.	.	O

Patient	JJ	O
reports	NNS	O
of	IN	O
relative	JJ	O
helpfulness	NN	O
of	IN	O
the	DT	O
interventions	NNS	O
for	IN	O
managing	VBG	O
pain	NN	O
and	CC	O
nausea	NN	O
matched	VBD	O
the	DT	O
results	NNS	O
of	IN	O
VAS	NNP	O
reports	NNS	O
.	.	O

From	IN	O
these	DT	O
results	NNS	O
,	,	O
we	PRP	O
conclude	VBP	O
that	DT	O
relaxation	NN	O
and	CC	O
imagery	NN	O
training	NN	O
reduces	NNS	O
cancer	NN	O
treatment-related	JJ	O
pain	NN	O
;	:	O
adding	VBG	O
cognitive-behavioral	JJ	O
skills	NNS	O
to	TO	O
the	DT	O
relaxation	NN	O
with	IN	O
imagery	NN	O
does	VBZ	O
not	RB	O
,	,	O
on	IN	O
average	NN	O
,	,	O
further	JJ	O
improve	VB	O
pain	NN	O
relief	NN	O
.	.	O

Stepping	VBG	E
Stones	NNP	E
Triple	NNP	E
P	NNP	E
:	:	E
an	DT	O
RCT	NNP	O
of	IN	O
a	DT	O
parenting	VBG	E
program	NN	E
with	IN	O
parents	NNS	O
of	IN	O
a	DT	O
child	NN	O
diagnosed	VBN	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Whilst	IN	O
the	DT	O
Triple	NNP	E
P	NNP	E
Positive	NNP	E
Parenting	NNP	E
Program	NNP	E
has	VBZ	O
a	DT	O
large	JJ	O
evidence	NN	O
base	NN	O
(	(	O
Sanders	NNP	O
,	,	O
Clinical	NNP	O
Child	NNP	O
and	CC	O
Family	NNP	O
Psychology	NNP	O
Review	NNP	O
2:71-90	CD	O
,	,	O
1999	CD	O
;	:	O
Sanders	NNP	O
,	,	O
Journal	NNP	O
of	IN	O
Consulting	NNP	O
and	CC	O
Clinical	NNP	O
Psychology	NNP	O
68:624-640	CD	O
,	,	O
2000	CD	O
)	)	O
and	CC	O
preliminary	JJ	O
evidence	NN	O
indicates	VBZ	O
that	IN	O
Stepping	VBG	E
Stones	NNP	E
Triple	NNP	E
P	NNP	E
is	VBZ	O
also	RB	O
efficacious	JJ	O
(	(	O
Roberts	NNP	O
,	,	O
Journal	NNP	O
of	IN	O
Clinical	NNP	O
Child	NNP	O
and	CC	O
Adolescent	NNP	O
Psychology	NNP	O
,	,	O
35	CD	O
(	(	O
2	CD	O
)	)	O
:180-193	NN	O
,	,	O
2006	CD	O
)	)	O
,	,	O
to	TO	O
date	NN	O
Stepping	NNP	E
Stones	NNP	E
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
with	IN	O
the	DT	O
ASD	NNP	O
population	NN	O
.	.	O

Fifty-nine	JJ	O
families	NNS	O
with	IN	O
a	DT	O
child	NN	O
with	IN	O
ASD	NNP	O
aged	VBD	O
between	IN	O
2	CD	O
and	CC	O
9	CD	O
participated	VBN	O
in	IN	O
this	DT	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	O
reports	NNS	O
of	IN	O
child	JJ	O
behaviour	NN	O
and	CC	O
parenting	NN	O
styles	NNS	O
with	IN	O
the	DT	O
treatment	NN	O
effects	NNS	O
for	IN	O
child	NN	O
behaviour	NN	O
,	,	O
parental	NN	O
over	IN	O
reactivity	NN	O
and	CC	O
parental	JJ	O
verbosity	NN	O
being	VBG	O
maintained	VBN	O
at	IN	O
follow-up	JJ	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

Further	RBR	O
,	,	O
the	DT	O
results	NNS	O
suggest	VBP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	O
satisfaction	NN	O
and	CC	O
conflict	NN	O
about	RB	O
parenting	VBG	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
sleeper	JJ	O
effect	NN	O
for	IN	O
parental	JJ	O
efficacy	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
Stepping	VBG	E
Stones	NNP	E
Triple	NNP	E
P	NNP	E
is	VBZ	O
a	DT	O
promising	JJ	O
intervention	NN	O
for	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Limitations	NNS	O
and	CC	O
future	JJ	O
research	NN	O
are	VBP	O
also	RB	O
addressed	VBN	O
.	.	O

The	DT	O
adrenocorticotrophic	JJ	PM
hormone	NN	PM
(	(	PM
4-9	JJ	PM
)	)	PM
analog	NN	PM
ORG	IN	PM
2766	CD	PM
benefits	NNS	O
autistic	JJ	O
children	NNS	O
:	:	O
report	NN	O
on	IN	O
a	DT	O
second	JJ	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
second	JJ	O
controlled	VBN	O
crossover	NN	O
trial	NN	O
,	,	O
20	CD	O
autistic	JJ	O
children	NNS	O
received	VBD	O
40	CD	PM
mg/day	NN	PM
of	IN	PM
the	DT	PM
neuropeptide	NN	PM
ORG	NNP	PM
2766	CD	PM
,	,	PM
a	DT	PM
synthetic	JJ	PM
analog	NN	PM
of	IN	PM
ACTH	NNP	PM
(	(	PM
4-9	JJ	PM
)	)	PM
,	,	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Parents	NNS	O
'	POS	O
checklist	NN	O
ratings	NNS	O
(	(	O
ABC	NNP	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
clinicians	NNS	O
'	POS	O
ratings	NNS	O
(	(	O
CGI	NNP	O
)	)	O
pointed	VBD	O
to	TO	O
significant	JJ	O
improvements	NNS	O
after	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
;	:	O
improvements	NNS	O
were	VBD	O
clearest	VBN	O
on	IN	O
the	DT	O
ABC	NNP	O
social	JJ	O
withdrawal	NN	O
subscale	NN	O
.	.	O

The	DT	O
analysis	NN	O
of	IN	O
individual	JJ	O
target	NN	O
symptoms	NNS	O
and	CC	O
the	DT	O
parents	NNS	O
'	POS	O
treatment	NN	O
preferences	NNS	O
substantiated	VBD	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
ORG	NNP	PM
2766	CD	PM
.	.	PM

In	IN	O
an	DT	O
ethologically	RB	O
analyzed	JJ	O
playroom	NN	O
session	NN	O
,	,	O
ORG	NNP	O
2766	CD	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
improvement	NN	O
in	IN	O
the	DT	O
children	NNS	O
's	POS	O
play	NN	O
behavior	NN	O
and	CC	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
social	JJ	O
interaction	NN	O
between	IN	O
child	NN	O
and	CC	O
experimenter	NN	O
.	.	O

Gaze	NNP	O
coordination	NN	O
between	IN	O
child	NN	O
and	CC	O
experimenter	NN	O
also	RB	O
was	VBD	O
improved	VBN	O
.	.	O

Disopyramide-pyridostigmine	JJ	PM
interaction	NN	O
:	:	O
selective	JJ	O
reversal	NN	O
of	IN	O
anticholinergic	NN	O
symptoms	NNS	O
with	IN	O
preservation	NN	O
of	IN	O
antiarrhythmic	JJ	O
effect	NN	O
.	.	O

This	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo	FW	C
crossover	NN	O
study	NN	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
cholinesterase	NN	PM
inhibitor	NN	PM
--	:	PM
slow-release	JJ	PM
pyridostigmine	NN	PM
(	(	O
180	CD	O
mg	NNS	O
orally	RB	O
every	DT	O
12	CD	O
hours	NNS	O
)	)	O
--	:	O
on	IN	O
the	DT	O
anticholinergic	NN	O
and	CC	O
antiarrhythmic	JJ	O
properties	NNS	O
of	IN	O
disopyramide	NN	PM
.	.	O

Quantitative	JJ	O
side	NN	O
effects	NNS	O
questionnaire	VBP	O
scores	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
guide	VB	O
disopyramide	JJ	PM
administration	NN	O
in	IN	O
20	CD	O
men	NNS	O
with	IN	O
ventricular	JJ	O
tachycardia	NN	O
.	.	O

Disopyramide	NNP	PM
was	VBD	O
given	VBN	O
to	TO	O
each	DT	O
patient	NN	O
both	DT	O
with	IN	O
placebo	NN	C
and	CC	O
with	IN	O
active	JJ	O
pyridostigmine	NN	PM
.	.	O

The	DT	O
maximal	JJ	O
administered	VBD	O
dose	NN	O
for	IN	O
each	DT	O
regimen	NN	O
was	VBD	O
used	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
corresponding	JJ	O
questionnaire	NN	O
scores	NNS	O
to	TO	O
calculate	VB	O
an	DT	O
index	NN	O
or	CC	O
estimate	NN	O
of	IN	O
the	DT	O
maximal	JJ	O
tolerable	JJ	O
dose	NN	O
of	IN	O
disopyramide	NN	PM
.	.	O

Additional	JJ	O
evaluations	NNS	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
each	DT	O
maximal	NN	O
administered	VBD	O
dose	JJ	O
regimen	NNS	O
included	VBD	O
tear	JJ	O
and	CC	O
saliva	JJ	O
quantitation	NN	O
,	,	O
24	CD	O
hour	NN	O
electrocardiogram	NN	O
(	(	O
ECG	NNP	O
)	)	O
,	,	O
exercise	VBP	O
testing	VBG	O
and	CC	O
programmed	VBD	O
ventricular	JJ	O
stimulation	NN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
maximal	NN	O
administered	VBD	O
dose	NN	O
of	IN	O
disopyramide	NN	PM
was	VBD	O
greater	JJR	O
with	IN	O
active	JJ	O
pyridostigmine	NN	PM
than	IN	O
with	IN	O
placebo	NN	O
:	:	O
295	CD	O
+/-	JJ	O
75	CD	O
versus	NN	O
245	CD	O
+/-	JJ	O
100	CD	O
mg	NN	O
every	DT	O
6	CD	O
hours	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
calculated	JJ	O
maximal	NN	O
tolerable	JJ	O
dose	NN	O
was	VBD	O
substantially	RB	O
greater	JJR	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
pyridostigmine	NN	PM
:	:	O
355	CD	O
+/-	JJ	O
90	CD	O
versus	NN	O
260	CD	O
+/-	JJ	O
115	CD	O
mg	NN	O
every	DT	O
6	CD	O
hours	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Maximal	JJ	O
side	NN	O
effects	NNS	O
questionnaire	NN	O
scores	NNS	O
also	RB	O
reflected	VBD	O
decreased	JJ	O
anticholinergic	JJ	O
activity	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
pyridostigmine	NN	PM
compared	VBN	O
with	IN	O
placebo	NN	C
:	:	O
101.9	CD	O
+/-	JJ	O
2.2	CD	O
versus	NN	O
104.6	CD	O
+/-	JJ	O
2.8	CD	O
,	,	O
respectively	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
.	.	O

Baseline	NNP	O
tear	NN	O
and	CC	O
saliva	JJ	O
production	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
during	IN	O
disopyramide	JJ	O
therapy	NN	O
,	,	O
but	CC	O
was	VBD	O
restored	VBN	O
toward	IN	O
normal	JJ	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
pyridostigmine	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
MF101	NNP	PM
,	,	PM
a	DT	PM
selective	JJ	PM
estrogen	NN	PM
receptor	NN	PM
beta	NN	O
modulator	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menopausal	NN	O
hot	JJ	O
flushes	NNS	O
:	:	O
a	DT	O
phase	NN	O
II	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
dose	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
efficacy	NN	O
of	IN	O
an	DT	O
estrogen	NN	PM
receptor	NN	PM
beta	NN	PM
selective	JJ	PM
Chinese	NNP	PM
herbal	NN	PM
extract	NN	PM
,	,	O
menopausal	JJ	PM
formula	NN	PM
101	CD	PM
(	(	O
MF101	NNP	O
)	)	O
,	,	O
for	IN	O
treating	VBG	O
hot	JJ	O
flushes	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
blinded	VBD	O
trial	NN	O
in	IN	O
217	CD	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
hot	JJ	O
flushes	NNS	O
randomized	VBD	O
to	TO	O
5	CD	O
or	CC	O
10	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	PM
or	CC	O
placebo	NN	C
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
effects	NNS	O
of	IN	O
5	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
those	DT	O
of	IN	O
placebo	NN	C
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
the	DT	O
mean	JJ	O
percent	NN	O
decrease	NN	O
in	IN	O
frequency	NN	O
of	IN	O
hot	JJ	O
flushes	NNS	O
in	IN	O
the	DT	O
10	CD	O
g/day	NN	O
group	NN	O
was	VBD	O
12.9	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
,	,	O
the	DT	O
median	JJ	O
percent	NN	O
decrease	NN	O
was	VBD	O
11.7	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
with	IN	O
at	IN	O
least	JJS	O
a	DT	O
50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
hot	JJ	O
flushes	NNS	O
was	VBD	O
16.2	CD	O
%	NN	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Treatment	NNP	O
with	IN	O
10	CD	O
g/day	NN	O
of	IN	O
MF101	NNP	PM
reduces	VBZ	O
the	DT	O
frequency	NN	O
of	IN	O
hot	JJ	O
flushes	NNS	O
.	.	O

Trials	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
are	VBP	O
planned	VBN	O
.	.	O

Mapping	VBG	O
from	IN	O
disease-specific	JJ	O
measures	NNS	O
to	TO	O
health-state	JJ	O
utility	NN	O
values	NNS	O
in	IN	O
individuals	NNS	O
with	IN	O
migraine	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
develop	VB	O
empirical	JJ	O
algorithms	NN	O
that	WDT	O
estimate	VBP	O
health-state	JJ	O
utility	NN	O
values	NNS	O
from	IN	O
disease-specific	JJ	O
quality-of-life	JJ	O
scores	NNS	O
in	IN	O
individuals	NNS	O
with	IN	O
migraine	NN	O
.	.	O

METHODS	NNP	O
Data	NNP	O
from	IN	O
a	DT	O
cross-sectional	JJ	O
,	,	O
multicountry	NN	O
study	NN	O
were	VBD	O
used	VBN	O
.	.	O

Individuals	NNS	O
with	IN	O
episodic	NN	O
and	CC	O
chronic	JJ	O
migraine	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
training	NN	O
or	CC	O
validation	NN	O
samples	NNS	O
.	.	O

Spearman	NNP	O
's	POS	O
correlation	NN	O
coefficients	NNS	O
between	IN	O
paired	VBN	O
EuroQol	NNP	E
five-dimensional	JJ	E
(	(	E
EQ-5D	NNP	E
)	)	E
questionnaire	NN	E
utility	NN	O
values	NNS	O
and	CC	O
both	DT	O
Headache	NNP	O
Impact	NNP	O
Test	NNP	O
(	(	O
HIT-6	NNP	O
)	)	O
scores	NNS	O
and	CC	O
Migraine-Specific	NNP	E
Quality-of-Life	NNP	E
Questionnaire	NNP	E
version	NN	E
2.1	CD	E
(	(	E
MSQ	NNP	E
)	)	E
domain	NN	O
scores	NNS	O
(	(	O
role	NN	O
restrictive	NN	O
,	,	O
role	NN	O
preventive	NN	O
,	,	O
and	CC	O
emotional	JJ	O
function	NN	O
)	)	O
were	VBD	O
examined	VBN	O
.	.	O

Regression	NN	O
models	NNS	O
were	VBD	O
constructed	VBN	O
to	TO	O
estimate	VB	O
EQ-5D	NNP	O
questionnaire	NN	O
utility	NN	O
values	NNS	O
from	IN	O
the	DT	O
HIT-6	NNP	O
score	NN	O
or	CC	O
the	DT	O
MSQ	NNP	O
domain	NN	O
scores	NNS	O
.	.	O

Preferred	VBN	O
algorithms	NNS	O
were	VBD	O
confirmed	VBN	O
in	IN	O
the	DT	O
validation	NN	O
samples	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
episodic	JJ	O
migraine	NN	O
,	,	O
the	DT	O
preferred	JJ	O
HIT-6	NNP	E
and	CC	O
MSQ	NNP	E
algorithms	VBP	E
explained	VBD	O
22	CD	O
%	NN	O
and	CC	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
variance	NN	O
(	(	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
in	IN	O
the	DT	O
training	NN	O
samples	NNS	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
had	VBD	O
similar	JJ	O
prediction	NN	O
errors	NNS	O
(	(	O
root	JJ	O
mean	NN	O
square	JJ	O
errors	NNS	O
of	IN	O
0.30	CD	O
)	)	O
.	.	O

In	IN	O
chronic	JJ	O
migraine	NN	O
,	,	O
the	DT	O
preferred	JJ	O
HIT-6	NNP	E
and	CC	O
MSQ	NNP	E
algorithms	VBP	E
explained	VBD	O
36	CD	O
%	NN	O
and	CC	O
45	CD	O
%	NN	O
of	IN	O
the	DT	O
variance	NN	O
in	IN	O
the	DT	O
training	NN	O
samples	NNS	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
had	VBD	O
similar	JJ	O
prediction	NN	O
errors	NNS	O
(	(	O
root	JJ	O
mean	NN	O
square	JJ	O
errors	NNS	O
0.31	CD	O
and	CC	O
0.29	CD	O
)	)	O
.	.	O

In	IN	O
episodic	JJ	O
and	CC	O
chronic	JJ	O
migraine	NN	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
mean	NN	O
observed	VBD	O
and	CC	O
the	DT	O
mean	NN	O
estimated	VBD	O
EQ-5D	NNP	O
questionnaire	NN	O
utility	NN	O
values	NNS	O
for	IN	O
the	DT	O
preferred	JJ	O
HIT-6	NNP	E
and	CC	O
MSQ	NNP	E
algorithms	NN	O
in	IN	O
the	DT	O
validation	NN	O
samples	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
relationship	NN	O
between	IN	O
the	DT	O
EQ-5D	NNP	O
questionnaire	NN	O
and	CC	O
the	DT	O
HIT-6	NNP	O
or	CC	O
the	DT	O
MSQ	NNP	O
is	VBZ	O
adequate	JJ	O
to	TO	O
use	VB	O
regression	NN	O
equations	NNS	O
to	TO	O
estimate	VB	O
EQ-5D	NNP	O
questionnaire	NN	O
utility	NN	O
values	NNS	O
.	.	O

The	DT	O
preferred	JJ	O
HIT-6	NNP	E
and	CC	O
MSQ	NNP	E
algorithms	NN	O
will	MD	O
be	VB	O
useful	JJ	O
in	IN	O
estimating	VBG	O
health-state	JJ	O
utilities	NNS	O
in	IN	O
migraine	NN	O
trials	NNS	O
in	IN	O
which	WDT	O
no	DT	O
preference-based	JJ	O
measure	NN	O
is	VBZ	O
present	JJ	O
.	.	O

Sustained	VBN	O
oral	JJ	O
health	NN	O
improvement	NN	O
and	CC	O
use	NN	O
of	IN	O
toothbrushes	NNS	PH
and	CC	PH
dentifrice	NN	PH
by	IN	O
previous	JJ	O
users	NNS	O
of	IN	O
traditional	JJ	O
materials	NNS	O
in	IN	O
a	DT	O
rural	JJ	O
population	NN	O
in	IN	O
Andhra	NNP	O
Pradesh	NNP	O
,	,	O
India	NNP	O
.	.	O

AIM	NNP	O
To	TO	O
follow-up	NN	O
,	,	O
one	CD	O
year	NN	O
later	RB	O
,	,	O
a	DT	O
double-blind	NN	O
,	,	O
randomised	VBN	O
study	NN	O
,	,	O
which	WDT	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
regular	JJ	PH
brushing	NN	PH
with	IN	PH
dentifrices	NNS	PH
on	IN	O
the	DT	O
oral	JJ	O
health	NN	O
of	IN	O
an	DT	O
economically	RB	O
disadvantaged	JJ	O
rural	JJ	O
population	NN	O
in	IN	O
Andhra	NNP	O
Pradesh	NNP	O
,	,	O
India	NNP	O
who	WP	O
were	VBD	O
primarily	RB	O
users	NNS	O
of	IN	O
traditional	JJ	O
materials	NNS	O
.	.	O

SUBJECTS	NNP	O
150	CD	O
of	IN	O
the	DT	O
original	JJ	O
study	NN	O
population	NN	O
.	.	O

METHOD	NNP	O
Examination	NNP	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
improvements	NNS	O
in	IN	O
oral	JJ	O
health	NN	O
status	NN	O
and	CC	O
oral	JJ	O
health	NN	O
behaviour	NN	O
(	(	O
use	NN	O
of	IN	O
toothbrush	NN	PH
and	CC	PH
dentifrice	NN	PH
)	)	O
,	,	O
being	VBG	O
unsupported	JJ	O
,	,	O
had	VBD	O
been	VBN	O
sustained	VBN	O
since	IN	O
completion	NN	O
of	IN	O
the	DT	O
original	JJ	O
study	NN	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
analysis	NN	O
showed	VBD	O
sustained	VBN	O
,	,	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
gingival	JJ	O
health	NN	O
as	IN	O
measured	VBN	O
by	IN	O
gingival	NN	O
bleeding	NN	O
and	CC	O
plaque	NN	O
indices	NNS	O
(	(	O
GBI	NNP	O
and	CC	O
PI	NNP	O
)	)	O
comparing	VBG	O
users	NNS	O
and	CC	O
non-users	NNS	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrice	NN	O
in	IN	O
the	DT	O
original	JJ	O
study	NN	O
(	(	O
PI	NNP	O
:	:	O
p	NN	O
=	VBZ	O
0.04	CD	O
;	:	O
GBI	NNP	O
:	:	O
p	NN	O
=	VBZ	O
0.03	CD	O
)	)	O
and	CC	O
sustained	VBN	O
use	NN	O
of	IN	O
toothbrushes	NNS	O
and	CC	O
dentifrice	NN	O
by	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
at	IN	O
follow-up	JJ	O
one	CD	O
year	NN	O
later	RB	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
oral	JJ	O
hygiene	NN	O
indices	NNS	O
following	VBG	O
the	DT	O
introduction	NN	PH
of	IN	PH
toothbrushes	NNS	PH
and	CC	PH
dentifrices	NNS	PH
to	TO	O
a	DT	O
community	NN	O
using	VBG	O
traditional	JJ	O
oral	JJ	O
hygiene	NN	O
materials	NNS	O
and	CC	O
sustainability	NN	O
of	IN	O
use	NN	O
of	IN	O
these	DT	O
materials	NNS	O
with	IN	O
motivation	NN	O
and	CC	O
support	NN	O
.	.	O

It	PRP	O
may	MD	O
therefore	RB	O
be	VB	O
concluded	VBN	O
that	IN	O
it	PRP	O
is	VBZ	O
feasible	JJ	O
to	TO	O
achieve	VB	O
significant	JJ	O
use	NN	O
of	IN	O
conventional	JJ	O
toothbrushes	NNS	O
and	CC	O
toothpastes	NNS	O
,	,	O
with	IN	O
consequent	JJ	O
major	JJ	O
and	CC	O
sustained	JJ	O
improvements	NNS	O
in	IN	O
plaque	NN	O
control	NN	O
and	CC	O
gingival	JJ	O
health	NN	O
in	IN	O
a	DT	O
disadvantaged	JJ	O
population	NN	O
hitherto	NN	O
often	RB	O
considered	VBN	O
as	IN	O
not	RB	O
amenable	JJ	O
to	TO	O
conventional	JJ	O
oral	JJ	O
hygiene	NN	O
for	IN	O
cultural	JJ	O
or	CC	O
economic	JJ	O
reasons	NNS	O
.	.	O

Biomarkers	NNS	O
of	IN	O
dietary	JJ	PH
exposure	NN	PH
are	VBP	O
associated	VBN	O
with	IN	O
lower	JJR	O
risk	NN	O
of	IN	O
breast	NN	O
fibroadenomas	NN	O
in	IN	O
Chinese	JJ	O
women	NNS	O
.	.	O

Fibroadenomas	NNP	O
are	VBP	O
the	DT	O
most	RBS	O
common	JJ	O
benign	NN	O
breast	JJ	O
condition	NN	O
among	IN	O
women	NNS	O
and	CC	O
account	NN	O
for	IN	O
up	IN	O
to	TO	O
50	CD	O
%	NN	O
of	IN	O
all	DT	O
breast	NN	O
biopsies	NNS	O
being	VBG	O
performed	VBN	O
.	.	O

Although	IN	O
considered	VBN	O
a	DT	O
benign	JJ	O
condition	NN	O
,	,	O
fibroadenomas	JJ	O
utilize	VBP	O
substantial	JJ	O
resources	NNS	O
for	IN	O
management	NN	O
and	CC	O
treatment	NN	O
to	TO	O
rule	VB	O
out	RP	O
potential	JJ	O
malignancies	NNS	O
.	.	O

Dietary	JJ	PH
factors	NNS	PH
may	MD	O
influence	VB	O
benign	JJ	O
fibrocystic	JJ	O
breast	NN	O
conditions	NNS	O
,	,	O
but	CC	O
little	JJ	O
is	VBZ	O
known	VBN	O
of	IN	O
their	PRP$	O
association	NN	O
with	IN	O
fibroadenomas	NN	O
.	.	O

We	PRP	O
examined	VBD	O
possible	JJ	O
associations	NNS	O
between	IN	O
a	DT	O
broad	JJ	O
spectrum	NN	O
of	IN	O
circulating	VBG	O
biomarkers	NNS	O
of	IN	O
dietary	JJ	O
intake	NN	O
and	CC	O
risk	NN	O
of	IN	O
fibroadenomas	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
women	NNS	O
in	IN	O
a	DT	O
breast	NN	E
self-examination	NN	E
trial	NN	O
in	IN	O
Shanghai	NNP	O
,	,	O
China	NNP	O
who	WP	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
fibroadenomas	NN	O
(	(	O
n	JJ	O
=	NNP	O
258	CD	O
)	)	O
and	CC	O
1035	CD	O
controls	NNS	O
.	.	O

Conditional	NNP	O
logistic	JJ	O
regression	NN	O
was	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
adjusted	VBN	O
odds	NNS	O
ratios	NNS	O
(	(	O
OR	NNP	O
)	)	O
and	CC	O
95	CD	O
%	NN	O
CI	NNP	O
.	.	O

Isoflavone	NNP	O
concentrations	NNS	O
were	VBD	O
inversely	RB	O
associated	VBN	O
with	IN	O
risk	NN	O
of	IN	O
fibroadenomas	NN	O
.	.	O

Adjusted	VBN	O
OR	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
for	IN	O
the	DT	O
highest	JJS	O
versus	NN	O
the	DT	O
lowest	JJS	O
quartile	NN	O
of	IN	O
plasma	JJ	O
concentration	NN	O
were	VBD	O
0.36	CD	O
(	(	O
0.16-0.79	CD	O
;	:	O
P-trend	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
for	IN	O
daidzein	NN	PM
and	CC	O
0.39	CD	O
(	(	O
0.19-0.84	CD	O
;	:	O
P-trend	NNP	O
=	NNP	O
0.010	CD	O
)	)	O
for	IN	O
genistein	NN	PM
.	.	O

We	PRP	O
also	RB	O
observed	VBD	O
inverse	JJ	O
associations	NNS	O
between	IN	O
higher	JJR	O
percentages	NNS	O
of	IN	O
the	DT	O
RBC	NNP	O
(	(	O
n-3	JJ	O
)	)	O
fatty	JJ	O
acids	NNS	O
,	,	O
eicosapentaenoic	JJ	O
acid	NN	O
(	(	O
EPA	NNP	O
)	)	O
(	(	O
[	$	O
0.38	CD	O
(	(	O
0.19-0.77	JJ	O
)	)	O
;	:	O
P-trend	JJ	O
=	NN	O
0.007	CD	O
]	NN	O
and	CC	O
docosapentaenoic	NN	O
acid	NN	O
(	(	O
DPA	NNP	O
)	)	O
[	VBZ	O
0.32	CD	O
(	(	O
0.15-0.70	JJ	O
)	)	O
;	:	O
P-trend	JJ	O
=	NN	O
0.024	CD	O
]	NN	O
,	,	O
and	CC	O
fibroadenoma	NN	O
risk	NN	O
.	.	O

Circulating	VBG	O
concentrations	NNS	O
of	IN	O
carotenoids	NNS	O
,	,	O
vitamin	FW	O
C	NNP	O
,	,	O
retinol	NN	O
,	,	O
and	CC	O
ferritin	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
fibroadenoma	NN	O
risk	NN	O
.	.	O

The	DT	O
inverse	JJ	O
associations	NNS	O
between	IN	O
plasma	NN	O
isoflavone	NN	O
concentrations	NNS	O
and	CC	O
RBC	NNP	O
EPA	NNP	O
and	CC	O
DPA	NNP	O
and	CC	O
fibroadenoma	NN	O
risk	NN	O
suggest	VBP	O
that	IN	O
higher	JJR	O
intakes	NNS	O
of	IN	O
soy	JJ	PM
foods	NNS	PM
and	CC	PM
fatty	JJ	PM
fish	NN	PM
may	MD	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
fibroadenomas	NN	O
.	.	O

A	DT	O
trial	NN	O
with	IN	O
3'-azido-2',3'-dideoxythymidine	JJ	PM
and	CC	O
human	JJ	O
interferon-?	NN	O
in	IN	O
cats	NNS	O
naturally	RB	O
infected	VBN	O
with	IN	O
feline	JJ	O
leukaemia	NN	O
virus	NN	O
.	.	O

Feline	NNP	O
leukaemia	NN	O
virus	NN	O
(	(	O
FeLV	NNP	O
)	)	O
infection	NN	O
is	VBZ	O
still	RB	O
one	CD	O
of	IN	O
the	DT	O
leading	JJ	O
causes	NNS	O
of	IN	O
infection-related	JJ	O
deaths	NNS	O
in	IN	O
domestic	JJ	O
cats	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
various	JJ	O
drugs	NNS	O
has	VBZ	O
been	VBN	O
attempted	VBN	O
,	,	O
but	CC	O
none	NN	O
has	VBZ	O
resulted	VBN	O
in	IN	O
cure	NN	O
or	CC	O
complete	JJ	O
virus	NN	O
elimination	NN	O
.	.	O

Human	JJ	O
interferon-?2a	JJ	O
(	(	O
huIFN-?2a	JJ	O
)	)	O
and	CC	O
3'-azido-2',3'-dideoxythymidine	JJ	O
(	(	O
AZT	NNP	O
)	)	O
have	VBP	O
been	VBN	O
proven	VBN	O
to	TO	O
decrease	VB	O
antigenaemia	NN	O
in	IN	O
cats	NNS	O
infected	VBN	O
experimentally	RB	O
with	IN	O
FeLV	NNP	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
huIFN-?2a	NN	O
,	,	O
AZT	NNP	O
and	CC	O
a	DT	O
combination	NN	O
of	IN	O
both	DT	O
drugs	NNS	O
in	IN	O
cats	NNS	O
infected	VBN	O
naturally	RB	O
with	IN	O
FeLV	NNP	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
double-blinded	JJ	O
trial	NN	O
.	.	O

Fourty-four	CD	O
FeLV-infected	JJ	O
cats	NNS	O
in	IN	O
which	WDT	O
free	JJ	O
FeLV	NNP	O
p27	NN	O
antigen	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
serum	NN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	JJ	O
assay	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Cats	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
treatment	NN	O
groups	NNS	O
that	WDT	O
received	VBD	O
either	RB	O
high	JJ	O
dose	JJ	O
huIFN-?2a	NN	O
(	(	O
10	CD	O
(	(	O
5	CD	O
)	)	O
IU/kg	NNP	O
q24h	NN	O
;	:	O
12	CD	O
cats	NNS	O
)	)	O
,	,	O
AZT	NNP	O
(	(	O
5	CD	O
mg/kg	NN	O
q12h	NN	O
;	:	O
10	CD	O
cats	NNS	O
,	,	O
both	DT	O
of	IN	O
these	DT	O
treatments	NNS	O
(	(	O
12	CD	O
cats	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
10	CD	O
cats	NNS	O
)	)	O
.	.	O

All	DT	O
cats	NNS	O
were	VBD	O
treated	VBN	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
,	,	O
including	VBG	O
stomatitis	NN	O
,	,	O
and	CC	O
laboratory	NN	O
parameters	NNS	O
,	,	O
such	JJ	O
as	IN	O
CD4	NNP	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
CD8	NNP	O
(	(	O
+	NNP	O
)	)	O
counts	NNS	O
and	CC	O
serum	NN	O
FeLV	NNP	O
p	VBZ	O
27	CD	O
antigen	NN	O
concentration	NN	O
,	,	O
were	VBD	O
recorded	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
among	IN	O
the	DT	O
groups	NNS	O
was	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
parameters	NNS	O
.	.	O

Aside	RB	O
from	IN	O
anaemia	NN	O
in	IN	O
one	CD	O
cat	NN	O
treated	VBN	O
with	IN	O
AZT	NNP	O
,	,	O
no	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

It	PRP	O
was	VBD	O
not	RB	O
possible	JJ	O
to	TO	O
demonstrate	VB	O
efficacy	NN	O
of	IN	O
huIFN-?2a	NN	O
or	CC	O
AZT	NNP	O
alone	RB	O
or	CC	O
together	RB	O
in	IN	O
cats	NNS	O
infected	VBN	O
naturally	RB	O
with	IN	O
FeLV	NNP	O
when	WRB	O
given	VBN	O
according	VBG	O
to	TO	O
this	DT	O
regimen	NNS	O
for	IN	O
6	CD	O
weeks	NNS	O
;	:	O
however	RB	O
,	,	O
no	DT	O
notable	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

[	RB	O
Clinical	NNP	O
study	NN	O
on	IN	O
dan	NN	PM
shao	NN	PM
tang	NN	PM
in	IN	O
treating	VBG	O
IgA	NNP	O
nephropathy	NN	O
of	IN	O
deficiency	NN	O
of	IN	O
yin	NN	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
the	DT	O
effect	NN	O
of	IN	O
Dan	NNP	PM
Shao	NNP	PM
Tang	NNP	PM
(	(	PM
DST	NNP	PM
)	)	PM
in	IN	O
treating	VBG	O
IgA	NNP	O
nephropathy	NN	O
(	(	O
IgAN	NNP	O
)	)	O
of	IN	O
deficiency	NN	O
of	IN	O
Yin	NNP	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
.	.	O

METHODS	NNP	O
90	CD	O
patients	NNS	O
with	IN	O
IgAN	NNP	O
of	IN	O
deficiency	NN	O
of	IN	O
Yin	NNP	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

50	CD	O
patients	NNS	O
in	IN	O
treatment	NN	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
DST	NNP	PM
and	CC	O
western	JJ	PM
medicine	NN	PM
and	CC	O
40	CD	O
patients	NNS	O
in	IN	O
control	NN	O
group	NN	O
were	VBD	O
treated	VBN	O
only	RB	O
with	IN	PM
western	JJ	PM
medicine	NN	PM
.	.	O

The	DT	O
effects	NNS	O
and	CC	O
changes	NNS	O
of	IN	O
the	DT	O
indexes	NNS	O
including	VBG	O
renal	JJ	O
function	NN	O
,	,	O
hematuria	NN	O
,	,	O
proteinuria	NN	O
,	,	O
blood	NN	O
IgA	NNP	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
were	VBD	O
observed	VBN	O
.	.	O

RESULTS	NNP	O
After	IN	O
six	CD	O
months	NNS	O
treatment	NN	O
,	,	O
the	DT	O
general	JJ	O
effective	JJ	O
rate	NN	O
in	IN	O
treatment	NN	O
group	NN	O
was	VBD	O
70.00	CD	O
%	NN	O
,	,	O
which	WDT	O
was	VBD	O
markedly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
control	NN	O
group	NN	O
(	(	O
37.50	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Treatment	NNP	O
group	NN	O
is	VBZ	O
obviously	RB	O
better	JJR	O
than	IN	O
control	NN	O
group	NN	O
on	IN	O
decreasing	VBG	O
hematuria	NN	O
,	,	O
proteinuria	NN	O
,	,	O
blood	NN	O
IgA	NNP	O
and	CC	O
improving	VBG	O
renal	JJ	O
function	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
DST	NNP	PM
is	VBZ	O
effective	JJ	O
on	IN	O
IgAN	NNP	O
of	IN	O
deficiency	NN	O
of	IN	O
Yin	NNP	O
with	IN	O
damp-heat	JJ	O
symptom	NN	O
.	.	O

Anti-emetic	JJ	O
efficacy	NN	O
of	IN	O
prophylactic	JJ	PM
granisetron	NNS	PM
compared	VBN	O
with	IN	O
perphenazine	NN	PM
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
post-operative	JJ	O
vomiting	NN	O
in	IN	O
children	NNS	O
.	.	O

We	PRP	O
have	VBP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
granisetron	NN	PM
with	IN	O
perphenazine	NN	PM
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
vomiting	VBG	O
after	IN	O
tonsillectomy	NN	O
with	IN	O
or	CC	O
without	IN	O
adenoidectomy	NN	O
in	IN	O
children	NNS	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
,	,	O
90	CD	O
paediatric	JJ	O
patients	NNS	O
,	,	O
ASA	NNP	O
I	PRP	O
,	,	O
aged	VBN	O
4-10	CD	O
years	NNS	O
,	,	O
received	VBD	O
granisetron	NN	PM
40	CD	O
mg	JJ	O
kg-1	NN	O
or	CC	O
perphenazine	VB	PM
70	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
n	JJ	O
=	RB	O
45	CD	O
each	DT	O
)	)	O
intravenously	RB	O
immediately	RB	O
after	IN	O
an	DT	O
inhalation	NN	O
induction	NN	O
of	IN	O
anaesthesia	NN	PM
.	.	PM

A	DT	O
standard	JJ	O
general	JJ	O
anaesthetic	JJ	O
technique	NN	O
was	VBD	O
employed	VBN	O
throughout	IN	O
.	.	O

A	DT	O
complete	JJ	O
response	NN	O
,	,	O
defined	VBD	O
as	IN	O
no	DT	O
emesis	NN	O
with	IN	O
no	DT	O
need	NN	O
for	IN	O
another	DT	O
rescue	NN	O
antiemetic	JJ	O
,	,	O
during	IN	O
the	DT	O
first	JJ	O
3	CD	O
h	NN	O
(	(	O
0-3	JJ	O
h	NN	O
)	)	O
after	IN	O
anesthesia	NN	O
was	VBD	O
87	CD	O
%	NN	O
with	IN	O
granisetron	NN	PM
and	CC	O
78	CD	O
%	NN	O
with	IN	O
perphenazine	NN	PM
(	(	O
P	NNP	O
=	NNP	O
0.204	CD	O
)	)	O
.	.	O

The	DT	O
corresponding	JJ	O
incidence	NN	O
during	IN	O
the	DT	O
next	JJ	O
21	CD	O
h	NN	O
(	(	O
3-24	JJ	O
h	NN	O
)	)	O
after	IN	O
anaesthesia	NN	O
was	VBD	O
87	CD	O
%	NN	O
and	CC	O
62	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.007	CD	O
)	)	O
.	.	O

No	UH	O
clinically	RB	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
granisetron	NN	PM
is	VBZ	O
a	DT	O
better	JJR	O
anti-emetic	JJ	O
than	IN	O
perphenazine	NN	PM
for	IN	O
the	DT	O
long-term	JJ	O
prevention	NN	O
of	IN	O
post-operative	JJ	O
vomiting	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
general	JJ	O
anaesthesia	NN	O
for	IN	O
tonsillectomy	NN	O
.	.	O

International	NNP	O
Czech	NNP	Ot
and	CC	Ot
Slovak	NNP	Ot
cooperation	NN	Ot
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancer	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
paper	NN	O
is	VBZ	O
to	TO	O
present	VB	O
our	PRP$	O
experience	NN	O
concerning	VBG	O
cooperation	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Slovak	NNP	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancer	NN	O
in	IN	O
Slovak	NNP	O
and	CC	O
Czech	NNP	O
hospitals	NNS	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
demonstrate	VB	O
the	DT	O
means	NNS	O
of	IN	O
this	DT	O
cooperation	NN	Ot
and	CC	O
the	DT	O
results	NNS	O
of	IN	O
therapy	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
September	NNP	O
1991	CD	O
to	TO	O
October	NNP	O
2005	CD	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Ostrava	NNP	O
357	CD	O
patients	NNS	O
from	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
with	IN	O
differentiated	VBN	O
thyroid	NN	O
cancers	NNS	O
(	(	O
follicular	JJ	O
and	CC	O
papillary	JJ	O
)	)	O
underwent	NN	O
complex	JJ	PH
therapy	NN	PH
.	.	O

They	PRP	O
were	VBD	O
diagnosed	VBN	O
and	CC	O
operated	VBN	O
due	JJ	O
to	TO	O
the	DT	O
cancer	NN	O
(	(	O
near-total	JJ	O
thyroidectomy	NN	O
and	CC	O
removal	NN	O
of	IN	O
lymph	JJ	O
node	JJ	O
metastases	NNS	O
)	)	O
in	IN	O
Slovak	NNP	O
hospitals	NNS	O
.	.	O

Then	RB	O
they	PRP	O
were	VBD	O
sent	VBN	O
to	TO	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Ostrava	NNP	O
in	IN	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
.	.	O

In	IN	O
this	DT	O
department	NN	O
a	DT	O
radioiodine	JJ	PM
ablation	NN	O
of	IN	O
thyroid	JJ	O
remnants	NNS	O
,	,	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
amount	NN	O
of	IN	O
radioiodine	NN	PM
of	IN	O
a	DT	O
standard	JJ	O
activity	NN	O
of	IN	O
3.7	CD	O
GBq	NNP	O
,	,	O
was	VBD	O
performed	VBN	O
,	,	O
and	CC	O
then	RB	O
a	DT	O
suppression	NN	O
and	CC	O
substitution	NN	O
therapy	NN	O
of	IN	O
thyroid	JJ	O
hormones	NNS	O
was	VBD	O
started	VBN	O
.	.	O

After	IN	O
3-6	JJ	O
months	NNS	O
some	DT	O
patients	NNS	O
were	VBD	O
examined	VBN	O
by	IN	O
means	NNS	O
of	IN	O
diagnostic	JJ	O
whole	JJ	O
body	NN	O
scintigraphy	NN	O
after	IN	O
application	NN	O
of	IN	O
300	CD	O
MBq	NNP	O
131I	CD	O
.	.	O

Some	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
standard	JJ	O
activity	NN	O
of	IN	O
7.4	CD	O
GBq	NNP	O
131I	CD	O
and	CC	O
after	IN	O
5	CD	O
days	NNS	O
whole	JJ	O
body	NN	O
scintigraphy	NN	O
(	(	O
WBS	NNP	O
)	)	O
was	VBD	O
performed	VBN	O
.	.	O

In	IN	O
both	DT	O
of	IN	O
these	DT	O
groups	NNS	O
of	IN	O
patients	NNS	O
the	DT	O
diagnostic	JJ	O
or	CC	O
therapeutic	JJ	O
radioiodine	NN	PM
application	NN	O
was	VBD	O
done	VBN	O
after	IN	O
withdrawal	NN	O
of	IN	O
thyroid	JJ	O
hormone	NN	O
treatment	NN	O
.	.	O

If	IN	O
thyroglobulin	JJ	O
levels	NNS	O
were	VBD	O
low	JJ	O
and	CC	O
WBSs	NNP	O
were	VBD	O
negative	JJ	O
,	,	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Nuclear	NNP	O
Medicine	NNP	O
in	IN	O
Martin	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
radioiodine	NN	O
accumulated	VBN	O
metastases	NNS	O
were	VBD	O
again	RB	O
treated	VBN	O
with	IN	O
radioiodine	NN	PM
in	IN	O
Ostrava	NNP	O
.	.	O

If	IN	O
indicated	VBN	O
,	,	O
external	JJ	O
radiation	NN	PH
therapy	NN	PH
targeted	VBN	O
on	IN	O
the	DT	O
neck	NN	O
and	CC	O
upper	JJ	O
mediastinum	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
,	,	O
in	IN	O
the	DT	O
University	NNP	O
Hospital	NNP	O
in	IN	O
Martin	NNP	O
.	.	O

Newly	RB	O
formed	VBN	O
lymph	JJ	O
node	NN	O
metastases	NNS	O
were	VBD	O
surgically	RB	O
treated	VBN	O
in	IN	O
Slovakia	NNP	O
,	,	O
too	RB	O
.	.	O

Generally	RB	O
we	PRP	O
have	VBP	O
very	RB	O
good	JJ	O
treatment	NN	O
results	NNS	O
.	.	O

Also	RB	O
,	,	O
economically	RB	O
our	PRP$	O
partnership	NN	O
is	VBZ	O
cost	VBN	O
effective	JJ	O
.	.	O

Our	PRP$	O
collaboration	NN	O
also	RB	O
successfully	RB	O
continues	VBZ	O
after	IN	O
entrance	NN	O
of	IN	O
the	DT	O
Slovak	NNP	O
Republic	NNP	O
and	CC	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
to	TO	O
the	DT	O
European	NNP	O
Union	NNP	O
in	IN	O
2004	CD	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
multi-centre	JJ	O
study	NN	O
show	NN	O
that	IN	O
international	JJ	O
Czech	NNP	O
and	CC	O
Slovak	NNP	O
cooperation	NN	Ot
in	IN	O
the	DT	O
complex	JJ	O
therapy	NN	O
of	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
thyroid	NN	O
cancers	NNS	O
is	VBZ	O
successful	JJ	O
,	,	O
with	IN	O
high	JJ	O
efficacy	NN	O
.	.	O

The	DT	O
treatment	NN	O
results	NNS	O
were	VBD	O
very	RB	O
similar	JJ	O
to	TO	O
therapeutic	JJ	O
results	NNS	O
in	IN	O
our	PRP$	O
patients	NNS	O
from	IN	O
the	DT	O
Czech	NNP	O
Republic	NNP	O
.	.	O

[	JJ	O
Carbohydrate	NNP	O
substitutes	NNS	O
:	:	O
comparative	JJ	O
study	NN	O
of	IN	O
intestinal	JJ	O
absorption	NN	O
of	IN	O
fructose	NN	PM
,	,	O
sorbitol	NN	PM
and	CC	O
xylitol	NNP	PM
]	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
carbohydrate	NN	O
substitutes	NNS	O
fructose	VBP	PM
,	,	O
sorbitol	JJ	PM
and	CC	O
xylitol	NNS	PM
are	VBP	O
gaining	VBG	O
more	JJR	O
and	CC	O
more	JJR	O
importance	NN	O
in	IN	O
the	DT	O
production	NN	O
of	IN	O
dietary	JJ	O
food	NN	O
.	.	O

But	CC	O
they	PRP	O
can	MD	O
provoke	VB	O
gastrointestinal	JJ	O
side-effects	NNS	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
double	JJ	O
blind	NN	O
study	VBD	O
the	DT	O
rate	NN	O
of	IN	O
malabsorption	NN	O
of	IN	O
these	DT	O
sugars	NNS	O
was	VBD	O
compared	VBN	O
and	CC	O
the	DT	O
concomitant	NN	O
symptoms	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
25	CD	O
healthy	JJ	O
controls	NNS	O
received	VBD	O
25	CD	PM
g	NN	PM
of	IN	PM
each	DT	PM
sugar	NN	PM
within	IN	O
3	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

The	DT	O
intestinal	JJ	O
absorption	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
H2-exhalation	NNP	O
tests	NNS	O
and	CC	O
the	DT	O
clinical	JJ	O
symptoms	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
rate	NN	O
of	IN	O
malabsorption	NN	O
was	VBD	O
84	CD	O
%	NN	O
for	IN	O
sorbitol	NN	PM
,	,	O
36	CD	O
%	NN	O
for	IN	O
fructose	JJ	PM
and	CC	O
12	CD	O
%	NN	O
for	IN	O
xylitol	NNP	PM
(	(	O
p	JJ	O
<	VBP	O
0.01	CD	O
for	IN	O
sorbitol	NN	PM
versus	NN	O
fructose	NN	PM
and	CC	O
xylitol	NN	PM
)	)	O
.	.	O

57	CD	O
%	NN	O
of	IN	O
the	DT	O
participants	NNS	O
with	IN	O
pathological	JJ	O
H2-test	NNP	O
after	IN	O
sorbitol	NN	PM
and	CC	O
56	CD	O
%	NN	O
after	IN	O
fructose	JJ	PM
reported	VBD	O
symptoms	NNS	O
,	,	O
while	IN	O
all	DT	O
of	IN	O
the	DT	O
3	CD	O
malabsorbers	NNS	O
of	IN	O
xylitol	NN	PM
were	VBD	O
symptomatic	JJ	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
an	DT	O
advantage	NN	O
to	TO	O
administering	VBG	O
xylitol	NN	PM
and	CC	O
fructose	JJ	PM
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
intestinal	JJ	O
absorption	NN	O
and	CC	O
concomitant	NN	O
symptoms	NNS	O
as	IN	O
compared	VBN	O
with	IN	O
sorbitol	NN	PM
.	.	O

H2-exhalation	NN	O
tests	NNS	O
appear	VBP	O
to	TO	O
be	VB	O
a	DT	O
reliable	JJ	O
diagnostic	JJ	O
tool	NN	O
to	TO	O
detect	VB	O
carbohydrate	JJ	O
malabsorption	NN	O
and	CC	O
should	MD	O
find	VB	O
broader	JJR	O
application	NN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
non-specific	JJ	O
abdominal	JJ	O
complaints	NNS	O
.	.	O

Dietary	NNP	O
patterns	NNS	O
differ	VBP	O
between	IN	O
urban	JJ	O
and	CC	O
rural	JJ	O
older	JJR	O
,	,	O
long-term	JJ	O
survivors	NNS	O
of	IN	O
breast	NN	O
,	,	O
prostate	NN	O
,	,	O
and	CC	O
colorectal	JJ	O
cancer	NN	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
body	NN	O
mass	NN	O
index	NN	O
.	.	O

BACKGROUND	NNP	O
Older	NNP	O
adult	NN	O
cancer	NN	O
survivors	NNS	O
are	VBP	O
at	IN	O
greater	JJR	O
risk	NN	O
of	IN	O
cancer	NN	O
recurrence	NN	O
and	CC	O
other	JJ	O
comorbidities	NNS	O
that	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
through	IN	O
improved	VBN	O
diet	JJ	O
and	CC	O
weight	JJ	O
management	NN	O
.	.	O

The	DT	O
tertiary	JJ	O
prevention	NN	O
needs	NNS	O
of	IN	O
rural-dwelling	JJ	O
survivors	NNS	O
can	MD	O
be	VB	O
even	RB	O
greater	JJR	O
,	,	O
yet	RB	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
rural	JJ	O
and	CC	O
urban	JJ	O
differences	NNS	O
in	IN	O
lifestyle	JJ	O
factors	NNS	O
among	IN	O
this	DT	O
high-risk	JJ	O
population	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	E
dietary	JJ	E
patterns	NNS	E
of	IN	O
urban	JJ	O
and	CC	O
rural	JJ	O
cancer	NN	O
survivors	NNS	O
and	CC	O
to	TO	O
examine	VB	O
associations	NNS	O
of	IN	O
dietary	JJ	O
patterns	NNS	O
with	IN	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
.	.	O

DESIGN	VB	O
A	DT	O
secondary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
of	IN	O
baseline	NN	O
data	NNS	O
from	IN	O
the	DT	O
Reach	NNP	O
Out	NNP	O
to	TO	O
Enhance	VB	O
Wellness	NNP	O
(	(	O
RENEW	NNP	O
)	)	O
trial	NN	O
,	,	O
a	DT	O
diet	JJ	E
and	CC	E
exercise	JJ	E
intervention	NN	E
among	IN	O
overweight	JJ	O
,	,	O
long-term	JJ	O
(	(	O
?5	CD	O
years	NNS	O
)	)	O
,	,	O
older	JJR	O
survivors	NNS	O
of	IN	O
colorectal	NN	O
,	,	O
breast	NN	O
,	,	O
and	CC	O
prostate	NN	O
cancer	NN	O
.	.	O

Survivors	NNS	O
in	IN	O
the	DT	O
present	JJ	O
analysis	NN	O
(	(	O
n=729	JJ	O
)	)	O
underwent	JJ	O
two	CD	O
45-	JJ	O
to	TO	O
60-minute	JJ	O
telephone	NN	O
surveys	NNS	O
,	,	O
which	WDT	O
included	VBD	O
two	CD	O
24-hour	JJ	O
dietary	JJ	O
recalls	NNS	O
.	.	O

Principal	JJ	O
components	NNS	O
analysis	NN	O
and	CC	O
multivariable	JJ	O
general	JJ	O
linear	JJ	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
derive	VB	O
dietary	JJ	O
patterns	NNS	O
and	CC	O
to	TO	O
evaluate	VB	O
associations	NNS	O
between	IN	O
dietary	JJ	O
patterns	NNS	O
and	CC	O
BMI	NNP	O
,	,	O
respectively	RB	O
.	.	O

RESULTS	VB	O
Principal	JJ	O
components	NNS	O
analysis	NN	O
identified	VBD	O
three	CD	O
primary	JJ	O
dietary	JJ	O
patterns	NNS	O
among	IN	O
rural	JJ	O
dwellers	NNS	O
(	(	O
high	JJ	O
sweets	NNS	O
and	CC	O
starches	NNS	O
,	,	O
high	JJ	O
reduced-fat	NN	O
dairy	NN	O
,	,	O
cereal	NN	O
,	,	O
nuts	NNS	O
,	,	O
and	CC	O
fruits	NNS	O
,	,	O
and	CC	O
mixed	JJ	O
)	)	O
and	CC	O
three	CD	O
among	IN	O
urban	JJ	O
dwellers	NNS	O
(	(	O
high	JJ	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
,	,	O
high	JJ	O
meat	NN	O
and	CC	O
refined	VBD	O
grains	NNS	O
,	,	O
and	CC	O
high	JJ	O
sugar-sweetened	JJ	O
beverages	NNS	O
)	)	O
.	.	O

Among	IN	O
rural	JJ	O
survivors	NNS	O
,	,	O
greater	JJR	O
adherence	NN	O
to	TO	O
the	DT	O
high	JJ	O
reduced-fat	NN	O
dairy	NN	O
,	,	O
cereal	NN	O
,	,	O
nuts	NNS	O
,	,	O
and	CC	O
fruits	NNS	O
pattern	NN	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
lower	JJR	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
whereas	IN	O
higher	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
mixed	JJ	O
pattern	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Greater	NNP	O
adherence	NN	O
to	TO	O
the	DT	O
high	JJ	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
pattern	VBP	O
among	IN	O
urban	JJ	O
survivors	NNS	O
was	VBD	O
inversely	RB	O
associated	VBN	O
with	IN	O
BMI	NNP	O
(	(	O
P	NNP	O
trend	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Urban	NNP	O
and	CC	O
rural	JJ	O
differences	NNS	O
in	IN	O
dietary	JJ	O
intake	NN	O
behavior	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
designing	VBG	O
public	JJ	O
health	NN	O
interventions	NNS	O
among	IN	O
the	DT	O
increasing	VBG	O
population	NN	O
of	IN	O
older	JJR	O
cancer	NN	O
survivors	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
targeting	VBG	O
overall	JJ	O
dietary	JJ	O
patterns	NNS	O
might	MD	O
be	VB	O
one	CD	O
approach	NN	O
to	TO	O
help	VB	O
reduce	VB	O
the	DT	O
burden	NN	O
of	IN	O
obesity	NN	O
among	IN	O
this	DT	O
population	NN	O
.	.	O

Cardiovascular	JJ	O
effects	NNS	O
of	IN	O
tamoxifen	NN	PM
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
heart	NN	O
disease	NN	O
:	:	O
breast	NN	O
cancer	NN	O
prevention	NN	O
trial	NN	O
.	.	O

National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
overall	JJ	O
effect	NN	O
of	IN	O
prophylactic	JJ	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
depends	NNS	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
drug	NN	O
,	,	O
which	WDT	O
include	VBP	O
preventing	VBG	O
breast	NN	O
cancer	NN	O
and	CC	O
altering	VBG	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

In	IN	O
a	DT	O
recent	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
postmenopausal	JJ	O
estrogen-progestin	JJ	O
therapy	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
early	JJ	O
cardiovascular	JJ	O
events	NNS	O
among	IN	O
women	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
.	.	O

The	DT	O
cardiovascular	JJ	O
effects	NNS	O
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
CHD	NNP	O
are	VBP	O
not	RB	O
known	VBN	O
.	.	O

The	DT	O
National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
(	(	O
BCPT	NNP	O
)	)	O
is	VBZ	O
the	DT	O
only	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
provides	VBZ	O
data	NNS	O
to	TO	O
assess	VB	O
the	DT	O
cardiovascular	JJ	O
effects	NNS	O
of	IN	O
tamoxifen	NN	O
in	IN	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
CHD	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
13	CD	O
388	CD	O
women	NNS	O
at	IN	O
increased	VBN	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
the	DT	O
BCPT	NNP	O
to	TO	O
receive	VB	O
either	DT	O
tamoxifen	NN	PM
(	(	PM
20	CD	PM
mg/day	NN	PM
)	)	PM
or	CC	O
placebo	NN	C
.	.	O

Cardiovascular	JJ	O
follow-up	NN	O
was	VBD	O
available	JJ	O
for	IN	O
13	CD	O
194	CD	O
women	NNS	O
,	,	O
1048	CD	O
of	IN	O
whom	WP	O
had	VBD	O
prior	RB	O
clinical	JJ	O
CHD	NNP	O
.	.	O

Fatal	NNP	O
and	CC	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
unstable	JJ	O
angina	NN	O
,	,	O
and	CC	O
severe	JJ	O
angina	NN	O
were	VBD	O
tabulated	VBN	O
(	(	O
mean	JJ	O
follow-up	NN	O
:	:	O
49	CD	O
months	NNS	O
)	)	O
.	.	O

All	DT	O
statistical	JJ	O
tests	NNS	O
were	VBD	O
two-sided	JJ	O
.	.	O

RESULTS	NNP	O
Cardiovascular	JJ	O
event	NN	O
rates	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
women	NNS	O
assigned	VBN	O
to	TO	O
receive	VB	O
tamoxifen	NN	O
and	CC	O
those	DT	O
assigned	VBN	O
to	TO	O
receive	VB	O
placebo	NN	O
,	,	O
independent	JJ	O
of	IN	O
pre-existing	JJ	O
CHD	NNP	O
.	.	O

Among	IN	O
women	NNS	O
without	IN	O
CHD	NNP	O
(	(	O
6074	CD	O
on	IN	O
tamoxifen	NN	O
versus	NN	O
6072	CD	O
on	IN	O
placebo	NN	O
)	)	O
,	,	O
risk	JJ	O
ratios	NNS	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
[	VBP	O
CIs	NNP	O
]	NNP	O
)	)	O
for	IN	O
tamoxifen	NN	O
users	NNS	O
were	VBD	O
1.75	CD	O
(	(	O
0.44	CD	O
to	TO	O
8.13	CD	O
)	)	O
for	IN	O
fatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
1.11	CD	O
(	(	O
0.55	CD	O
to	TO	O
2.28	CD	O
)	)	O
for	IN	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
0.69	CD	O
(	(	O
0.29	CD	O
to	TO	O
1.57	CD	O
)	)	O
for	IN	O
unstable	JJ	O
angina	NN	O
,	,	O
and	CC	O
0.83	CD	O
(	(	O
0.32	CD	O
to	TO	O
2.10	CD	O
)	)	O
for	IN	O
severe	JJ	O
angina	NN	O
.	.	O

In	IN	O
women	NNS	O
with	IN	O
CHD	NNP	O
(	(	O
516	CD	O
on	IN	O
tamoxifen	NNS	O
versus	$	O
532	CD	O
on	IN	O
placebo	NN	O
)	)	O
,	,	O
risk	JJ	O
ratios	NNS	O
(	(	O
95	CD	O
%	NN	O
CIs	NNP	O
)	)	O
for	IN	O
tamoxifen	NN	O
users	NNS	O
were	VBD	O
0.00	CD	O
(	(	O
0	CD	O
to	TO	O
1.58	CD	O
)	)	O
for	IN	O
fatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
1.25	CD	O
(	(	O
0.32	CD	O
to	TO	O
5.18	CD	O
)	)	O
for	IN	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
2.26	CD	O
(	(	O
0.87	CD	O
to	TO	O
6.55	CD	O
)	)	O
for	IN	O
unstable	JJ	O
angina	NN	O
,	,	O
and	CC	O
1.39	CD	O
(	(	O
0.23	CD	O
to	TO	O
9.47	CD	O
)	)	O
for	IN	O
severe	JJ	O
angina	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
the	DT	O
lack	NN	O
of	IN	O
association	NN	O
between	IN	O
tamoxifen	NN	O
and	CC	O
cardiovascular	JJ	O
events	NNS	O
was	VBD	O
related	VBN	O
to	TO	O
an	DT	O
early	JJ	O
increase	NN	O
in	IN	O
risk	NN	O
that	WDT	O
may	MD	O
have	VB	O
been	VBN	O
offset	VBN	O
by	IN	O
a	DT	O
late	JJ	O
decrease	NN	O
in	IN	O
risk	NN	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
used	VBN	O
for	IN	O
breast	NN	O
cancer	NN	O
prevention	NN	O
in	IN	O
women	NNS	O
with	IN	O
or	CC	O
without	IN	O
heart	NN	O
disease	NN	O
,	,	O
tamoxifen	NN	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
beneficial	JJ	O
or	CC	O
adverse	JJ	O
cardiovascular	JJ	O
effects	NNS	O
.	.	O

Low-dose	JJ	O
,	,	O
vaginally	RB	O
administered	VBN	O
estrogens	NNS	PM
may	MD	O
enhance	VB	O
local	JJ	O
benefits	NNS	O
of	IN	O
systemic	JJ	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
urogenital	JJ	O
atrophy	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
on	IN	O
hormone	NN	O
therapy	NN	O
.	.	O

BACKGROUND	NNP	O
When	WRB	O
genital	JJ	O
atrophy	NN	O
exists	NNS	O
,	,	O
systemic	JJ	PH
hormone	NN	PH
therapy	NN	PH
(	(	PH
HT	NNP	PH
)	)	PH
has	VBZ	O
a	DT	O
timing	NN	O
until	IN	O
to	TO	O
induce	VB	O
vaginal	JJ	O
proliferation	NN	O
and	CC	O
symptomatic	JJ	O
relieve	NN	O
.	.	O

Thus	RB	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
obtain	VB	O
a	DT	O
prompt	JJ	O
improvement	NN	O
,	,	O
the	DT	O
association	NN	O
of	IN	O
local	JJ	O
therapy	NN	O
acting	VBG	O
on	IN	O
the	DT	O
genital	JJ	O
epithelium	NN	O
to	TO	O
the	DT	O
systemic	JJ	O
treatment	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
combined	JJ	O
therapy	NN	O
consisting	NN	O
of	IN	O
vaginal	JJ	O
estriol	NN	O
with	IN	O
transdermal	JJ	O
17-beta-estradiol	JJ	O
(	(	O
50	CD	O
microg/day	NN	O
)	)	O
plus	CC	O
medroxyprogesterone	JJ	O
acetate	NN	O
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
per	IN	O
os	NN	O
in	IN	O
shortening	VBG	O
the	DT	O
period	NN	O
of	IN	O
uro-genital	JJ	O
symptoms	NNS	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
controlled	VBN	O
with	IN	O
placebo	NN	C
study	NN	O
,	,	O
27	CD	O
women	NNS	O
with	IN	O
climacteric	JJ	O
symptoms	NNS	O
and	CC	O
atrophic	JJ	O
vaginitis	NN	O
were	VBD	O
treated	VBN	O
for	IN	O
4	CD	O
months	NNS	O
with	IN	O
HT	NNP	PM
plus	CC	PM
vaginal	JJ	PM
estriol	NN	PM
0.5	CD	PM
mg/day	NN	PM
(	(	O
group	NN	O
E	NNP	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
group	NN	O
P	NNP	O
)	)	O
.	.	O

Patients	NNS	O
use	VBP	O
the	DT	O
local	JJ	O
medication	NN	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
weeks	NNS	O
and	CC	O
twice-weekly	JJ	O
thereafter	NN	O
.	.	O

Before	IN	O
entering	VBG	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
patients	NNS	O
were	VBD	O
asked	VBN	O
about	IN	O
HT	NNP	O
and	CC	O
selected	VBN	O
for	IN	O
inclusion	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
visit	NN	O
,	,	O
electible	JJ	O
patients	NNS	O
after	IN	O
written	VBN	O
informed	JJ	O
consent	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
HT	NNP	PM
plus	CC	PM
local	JJ	PM
estriol	NN	PM
or	CC	O
placebo	NN	C
.	.	O

All	PDT	O
the	DT	O
subjects	NNS	O
had	VBD	O
baseline	NN	O
studies	NNS	O
,	,	O
including	VBG	O
medical	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
,	,	O
blood	NN	O
and	CC	O
urine	JJ	O
analysis	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
local	JJ	O
treatment	NN	O
on	IN	O
urinary	JJ	O
and	CC	O
genital	JJ	O
symptoms	NNS	O
,	,	O
a	DT	O
score	NN	O
for	IN	O
genital	NN	O
,	,	O
urinary	JJ	O
and	CC	O
colposcopic	JJ	O
complaints	NNS	O
(	(	O
0	CD	O
minimum-100	JJ	O
maximum	NN	O
)	)	O
was	VBD	O
developed	VBN	O
.	.	O

This	DT	O
score	NN	O
and	CC	O
Blatt-Kuperman	NNP	O
were	VBD	O
recorded	VBN	O
and	CC	O
performed	VBN	O
in	IN	O
every	DT	O
control	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
on	IN	O
climacteric	NN	O
symptoms	NNS	O
relief	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Additionally	RB	O
,	,	O
the	DT	O
improvement	NN	O
in	IN	O
urinary	JJ	O
symptoms	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
from	IN	O
16.5	CD	O
+/-	JJ	O
6.1	CD	O
to	TO	O
8.5	CD	O
+/-	JJ	O
2.4	CD	O
for	IN	O
E	NNP	O
group	NN	O
and	CC	O
from	IN	O
15.8	CD	O
+/-	JJ	O
7.8	CD	O
to	TO	O
8.8	CD	O
+/-	JJ	O
2.7	CD	O
for	IN	O
P	NNP	O
group	NN	O
;	:	O
P	NNP	O
<	VBD	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
;	:	O
however	RB	O
,	,	O
those	DT	O
women	NNS	O
in	IN	O
group	NN	O
E	NNP	O
reached	VBD	O
significant	JJ	O
improvement	NN	O
on	IN	O
urinary	JJ	O
complaints	NNS	O
since	IN	O
the	DT	O
first	JJ	O
month	NN	O
of	IN	O
treatment	NN	O
.	.	O

Additionally	RB	O
,	,	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
E	NNP	O
and	CC	O
P	NNP	O
was	VBD	O
observed	VBN	O
at	IN	O
months	NNS	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
although	IN	O
no	DT	O
differences	NNS	O
were	VBD	O
detected	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Papanicolaou	NNP	O
smear	JJ	O
showed	VBD	O
reactive	JJ	O
or	CC	O
reparative	JJ	O
changes	NNS	O
and	CC	O
karyopyknotic	JJ	O
index	NN	O
exhibited	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
superficial	JJ	O
cells	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
Adding	NNP	O
vaginal	JJ	O
estriol	NN	O
to	TO	O
HRT	NNP	O
may	MD	O
shorten	VB	O
the	DT	O
latency	NN	O
period	NN	O
for	IN	O
urinary	JJ	O
symptoms	NNS	O
.	.	O

Timing	NN	O
of	IN	O
death	NN	O
and	CC	O
myocardial	JJ	O
infarction	NN	O
in	IN	O
patients	NNS	O
with	IN	O
non-ST	JJ	O
elevation	NN	O
acute	NN	O
coronary	JJ	O
syndromes	NNS	O
:	:	O
insights	NNS	O
from	IN	O
randomized	VBN	O
clinical	JJ	O
trials	NNS	O
.	.	O

BACKGROUND	NNP	O
Adverse	NNP	O
events	NNS	O
occur	VBP	O
following	VBG	O
non-ST	JJ	O
elevation	NN	O
acute	NN	O
coronary	JJ	O
syndromes	NNS	O
(	(	O
NSTE	NNP	O
ACS	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
timing	NN	O
of	IN	O
these	DT	O
events	NNS	O
in	IN	O
relation	NN	O
to	TO	O
index	NN	O
event	NN	O
is	VBZ	O
less	RBR	O
clear	JJ	O
.	.	O

METHODS	NNP	O
Accordingly	RB	O
,	,	O
we	PRP	O
evaluated	VBD	O
26,466	CD	O
NSTE	NNP	O
ACS	NNP	O
patients	NNS	O
from	IN	O
the	DT	O
Global	NNP	O
Use	NNP	O
of	IN	O
Strategies	NNPS	O
to	TO	O
Open	VB	O
Occluded	NNP	O
Arteries	NNPS	O
in	IN	O
Acute	NNP	O
Coronary	NNP	O
Syndromes	NNP	O
(	(	O
GUSTO-IIb	NNP	O
)	)	O
,	,	O
Platelet	NNP	PM
Glycoprotein	NNP	PM
IIb/IIIa	NNP	PM
in	IN	O
Unstable	JJ	O
Angina	NNP	O
:	:	O
Receptor	NNP	PM
Suppression	NNP	PM
Using	NNP	PM
Integrilin	NNP	PM
Therapy	NNP	PM
(	(	O
PURSUIT	NNP	O
)	)	O
,	,	O
and	CC	O
Platelet	NNP	PM
IIb/IIIa	NNP	PM
Antagonism	NNP	PM
for	IN	O
the	DT	O
Reduction	NNP	O
of	IN	O
Acute	NNP	O
Coronary	NNP	O
Syndrome	NNP	O
Events	NNP	O
in	IN	O
a	DT	O
Global	NNP	O
Organization	NNP	O
Network	NNP	O
(	(	O
PARAGON	NNP	O
)	)	O
A	NNP	O
and	CC	O
B	NNP	O
trials	NNS	O
to	TO	O
ascertain	VB	O
the	DT	O
timing	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

Outcomes	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
,	,	O
and	CC	O
death	NN	O
or	CC	O
MI	NNP	O
at	IN	O
180	CD	O
days	NNS	O
.	.	O

Logistic	JJ	E
regression	NN	E
modeling	VBG	E
for	IN	O
death	NN	O
was	VBD	O
used	VBN	O
to	TO	O
categorize	VB	O
patients	NNS	O
into	IN	O
low-	JJ	O
,	,	O
medium-	JJ	O
,	,	O
and	CC	O
high-risk	JJ	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
6	CD	O
months	NNS	O
,	,	O
6.2	CD	O
%	NN	O
of	IN	O
patients	NNS	O
died	VBD	O
,	,	O
12.1	CD	O
%	NN	O
had	VBD	O
MI	NNP	O
,	,	O
and	CC	O
15.7	CD	O
%	NN	O
suffered	VBD	O
death	NN	O
or	CC	O
MI	NNP	O
.	.	O

From	IN	O
15	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
of	IN	O
these	DT	O
events	NNS	O
occurred	VBD	O
beyond	IN	O
30	CD	O
days	NNS	O
.	.	O

At	IN	O
6	CD	O
months	NNS	O
,	,	O
3	CD	O
%	NN	O
,	,	O
4	CD	O
%	NN	O
,	,	O
and	CC	O
13	CD	O
%	NN	O
of	IN	O
patients	NNS	O
died	VBN	O
in	IN	O
low-	JJ	O
,	,	O
medium-	JJ	O
,	,	O
and	CC	O
high-risk	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
dying	VBG	O
beyond	IN	O
30	CD	O
days	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
(	(	O
44	CD	O
%	NN	O
,	,	O
43	CD	O
%	NN	O
,	,	O
and	CC	O
41	CD	O
%	NN	O
of	IN	O
death	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
whereas	JJ	O
death	NN	O
or	CC	O
MI	NNP	O
increased	VBD	O
with	IN	O
higher	JJR	O
risk	NN	O
(	(	O
11	CD	O
%	NN	O
,	,	O
14	CD	O
%	NN	O
,	,	O
and	CC	O
23	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
this	DT	O
event	NN	O
beyond	IN	O
30	CD	O
days	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
the	DT	O
three	CD	O
strata	NNS	O
(	(	O
22	CD	O
%	NN	O
,	,	O
20	CD	O
%	NN	O
,	,	O
and	CC	O
25	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
study	NN	O
provides	VBZ	O
important	JJ	O
insights	NNS	O
into	IN	O
the	DT	O
timing	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
suggests	VBZ	O
that	IN	O
the	DT	O
substantial	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
suffer	VBP	O
subsequent	JJ	O
adverse	JJ	O
events	NNS	O
after	IN	O
their	PRP$	O
index	NN	O
NSTE	NNP	O
ACS	NNP	O
.	.	O

Thus	RB	O
,	,	O
these	DT	O
data	NNS	O
call	NN	O
for	IN	O
continuous	JJ	O
surveillance	NN	O
for	IN	O
these	DT	O
events	NNS	O
and	CC	O
efforts	NNS	O
beyond	IN	O
the	DT	O
acute	JJ	O
phase	NN	O
at	IN	O
increasing	VBG	O
adherence	NN	O
to	TO	O
evidence-based	JJ	O
therapies	NNS	O
to	TO	O
improve	VB	O
the	DT	O
outcomes	NNS	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

Blind	NNP	S
versus	NN	S
open	JJ	S
approach	NN	S
to	TO	S
laparoscopic	VB	S
cholecystectomy	NN	S
:	:	S
a	DT	O
randomized	JJ	O
study	NN	O
.	.	O

Intraabdominal	NNP	O
structures	NNS	O
may	MD	O
be	VB	O
damaged	VBN	O
during	IN	O
blind	JJ	O
introduction	NN	O
of	IN	O
the	DT	O
first	JJ	O
trocar	NN	O
for	IN	O
laparoscopic	JJ	S
operations	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
150	CD	O
patients	NNS	O
with	IN	O
gallbladder	JJ	O
lithiasis	NN	O
who	WP	O
underwent	JJ	O
laparoscopy	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
a	DT	O
blind	NN	O
(	(	O
V	NNP	O
group	NN	O
)	)	O
or	CC	O
an	DT	O
open	JJ	O
(	(	O
H	NNP	O
group	NN	O
)	)	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
compare	VB	O
the	DT	O
results	NNS	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
complications	NNS	O
.	.	O

No	DT	O
mortality	NN	O
was	VBD	O
observed	VBN	O
.	.	O

Major	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
3/75	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
the	DT	O
V	NNP	O
group	NN	O
and	CC	O
in	IN	O
1/75	CD	O
(	(	O
1.3	CD	O
%	NN	O
)	)	O
patient	NN	O
of	IN	O
the	DT	O
H	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Minor	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
5/75	CD	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
achievement	NN	O
of	IN	O
pneumoperitoneum	NN	O
required	VBN	O
4.5+/-0.4	JJ	O
min	NN	O
in	IN	O
the	DT	O
V	NNP	O
group	NN	O
and	CC	O
3.2+/-0.2	JJ	O
min	NN	O
in	IN	O
the	DT	O
H	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
open	JJ	S
laparoscopic	NN	S
technique	NN	S
is	VBZ	O
safer	JJR	O
and	CC	O
faster	RBR	O
than	IN	O
the	DT	O
blind	JJ	PH
approach	NN	PH
;	:	O
therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
this	DT	O
approach	NN	O
be	VB	O
routinely	RB	O
used	VBN	O
in	IN	O
all	DT	O
laparoscopic	NN	O
procedures	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
transvaginal	JJ	S
synthetic	JJ	S
mesh	NN	S
for	IN	O
anterior	JJ	O
vaginal	JJ	O
wall	NN	O
prolapse	NN	O
repair	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
AND	CC	O
HYPOTHESIS	NNP	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
transvaginal	JJ	S
trocar-guided	JJ	S
polypropylene	NN	S
mesh	JJ	S
insertion	NN	S
with	IN	S
traditional	JJ	S
colporrhaphy	NN	S
for	IN	O
treatment	NN	O
of	IN	O
anterior	JJ	O
vaginal	JJ	O
wall	NN	O
prolapse	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
women	NNS	O
with	IN	O
advanced	JJ	O
anterior	JJ	O
vaginal	NN	O
wall	NN	O
prolapse	NN	O
,	,	O
at	IN	O
least	JJS	O
stage	NN	O
II	NNP	O
with	IN	O
Ba	NNP	O
?	.	O
+1	NN	O
cm	NN	O
according	VBG	O
to	TO	O
the	DT	O
Pelvic	NNP	O
Organ	NNP	O
Prolapse	NNP	O
Quantification	NNP	O
(	(	O
POP-Q	NNP	O
)	)	O
classification	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
have	VB	O
either	DT	O
anterior	JJ	O
colporrhaphy	NN	O
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
or	CC	O
repair	NN	O
using	VBG	O
trocar-guided	JJ	O
transvaginal	JJ	O
mesh	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
objective	JJ	O
cure	NN	O
rate	NN	O
of	IN	O
the	DT	O
anterior	JJ	O
compartment	NN	O
(	(	O
point	NN	O
Ba	NNP	O
)	)	O
assessed	VBD	O
at	IN	O
the	DT	O
12-month	JJ	O
follow-up	JJ	O
visit	NN	O
,	,	O
with	IN	O
stages	NNS	O
0	CD	O
and	CC	O
I	PRP	O
defined	VBD	O
as	IN	O
anatomical	JJ	O
success	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
quantification	NN	O
of	IN	O
other	JJ	O
vaginal	JJ	O
compartments	NNS	O
(	(	O
POP-Q	NNP	O
points	NNS	O
)	)	O
,	,	O
comparison	NN	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
by	IN	O
the	DT	O
prolapse	NN	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
P-QOL	NNP	O
)	)	O
questionnaire	NN	O
,	,	O
and	CC	O
complication	NN	O
rate	NN	O
between	IN	O
the	DT	O
groups	NNS	O
after	IN	O
1	CD	O
year	NN	O
.	.	O

Study	NNP	O
power	NN	O
was	VBD	O
fixed	VBN	O
as	IN	O
80	CD	O
%	NN	O
with	IN	O
5	CD	O
%	NN	O
cutoff	NN	O
point	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
statistical	JJ	O
significance	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
groups	NNS	O
were	VBD	O
similar	JJ	O
regarding	VBG	O
demographic	JJ	O
and	CC	O
clinical	JJ	O
preoperative	NN	O
parameters	NNS	O
.	.	O

Anatomical	JJ	O
success	NN	O
rates	NNS	O
for	IN	O
colporrhaphy	NN	O
and	CC	O
repair	NN	O
with	IN	O
mesh	JJ	O
placement	NN	O
groups	NNS	O
were	VBD	O
56.4	CD	O
vs	JJ	O
82.5	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.068-0.54	NN	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.018	CD	O
)	)	O
.	.	O

Similar	JJ	O
total	JJ	O
complication	NN	O
rates	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
tape	NN	O
exposure	NN	O
observed	VBN	O
in	IN	O
5	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
all	DT	O
P-QOL	NNP	O
domains	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
both	DT	O
procedures	NNS	O
(	(	O
p	VB	O
<	RB	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
they	PRP	O
were	VBD	O
not	RB	O
distinct	JJ	O
between	IN	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Trocar-guided	JJ	O
transvaginal	JJ	O
synthetic	JJ	O
mesh	NN	O
for	IN	O
advanced	JJ	O
anterior	JJ	O
POP	NNP	O
repair	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
anatomical	JJ	O
success	NN	O
rate	NN	O
for	IN	O
the	DT	O
anterior	JJ	O
compartment	NN	O
compared	VBN	O
with	IN	O
traditional	JJ	O
colporrhaphy	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
equally	RB	O
improved	VBN	O
after	IN	O
both	DT	O
techniques	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
trial	NN	O
failed	VBD	O
to	TO	O
detect	VB	O
differences	NNS	O
in	IN	O
P-QOL	NNP	O
scores	NNS	O
and	CC	O
complication	NN	O
rates	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Control	NN	O
of	IN	O
perioperative	JJ	O
hypertension	NN	O
during	IN	O
coronary	JJ	S
artery	NN	S
surgery	NN	S
.	.	O

A	DT	O
randomised	JJ	O
double-blind	NN	O
study	NN	O
comparing	VBG	O
isosorbide	JJ	PM
dinitrate	NN	PM
and	CC	O
nitroglycerin	NN	PM
.	.	O

A	DT	O
reduction	NN	O
in	IN	O
the	DT	O
causes	NNS	O
of	IN	O
myocardial	JJ	O
ischaemia	NN	O
remains	VBZ	O
of	IN	O
prime	JJ	O
importance	NN	O
during	IN	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

Hypertension	NN	O
with	IN	O
the	DT	O
ensuing	VBG	O
increase	NN	O
in	IN	O
myocardial	JJ	O
oxygen	NN	O
demand	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
factor	NN	O
in	IN	O
the	DT	O
aetiology	NN	O
of	IN	O
perioperative	JJ	O
myocardial	JJ	O
ischaemia	NN	O
.	.	O

Nitroglycerin	NNP	PM
(	(	PM
NTG	NNP	PM
)	)	PM
has	VBZ	O
long	RB	O
been	VBN	O
used	VBN	O
beneficially	RB	O
to	TO	O
reduce	VB	O
myocardial	JJ	O
oxygen	NN	O
demand	NN	O
by	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
systemic	JJ	O
and	CC	O
peripheral	JJ	O
vascular	JJ	O
resistances	NNS	O
.	.	O

An	DT	O
alternative	JJ	O
nitrate	NN	PM
,	,	O
isosorbide	JJ	PM
dinitrate	NN	PM
(	(	PM
ISDN	NNP	PM
)	)	PM
is	VBZ	O
now	RB	O
available	JJ	O
as	IN	O
an	DT	O
intravenous	JJ	O
preparation	NN	O
,	,	O
and	CC	O
may	MD	O
offer	VB	O
technical	JJ	O
advantages	NNS	O
,	,	O
both	DT	O
due	JJ	O
to	TO	O
its	PRP$	O
stability	NN	O
in	IN	O
solution	NN	O
and	CC	O
also	RB	O
its	PRP$	O
longer	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
.	.	O

We	PRP	O
designed	VBD	O
and	CC	O
carried	VBD	O
out	RP	O
a	DT	O
multi-centre	JJ	O
study	NN	O
to	TO	O
compare	VB	O
and	CC	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
ISDN	NNP	PM
and	CC	O
NTG	NNP	PM
in	IN	O
the	DT	O
management	NN	O
of	IN	O
perioperative	JJ	O
hypertension	NN	O
in	IN	O
85	CD	O
patients	NNS	O
undergoing	JJ	O
elective	JJ	S
coronary	JJ	S
artery	NN	S
surgery	NN	S
.	.	O

A	DT	O
total	NN	O
of	IN	O
288	CD	O
events	NNS	O
in	IN	O
which	WDT	O
the	DT	O
systolic	NN	O
blood	NN	O
pressure	NN	O
(	(	O
SBP	NNP	O
)	)	O
exceeded	VBD	O
a	DT	O
predetermined	JJ	O
trigger	NN	O
value	NN	O
were	VBD	O
observed	VBN	O
.	.	O

ISDN	NNP	PM
was	VBD	O
successful	JJ	O
in	IN	O
treating	VBG	O
hypertension	NN	O
in	IN	O
63	CD	O
%	NN	O
of	IN	O
the	DT	O
events	NNS	O
,	,	O
whereas	NNS	O
NTG	NNP	PM
had	VBD	O
an	DT	O
83	CD	O
%	NN	O
success	NN	O
.	.	O

The	DT	O
SBP	NNP	O
was	VBD	O
significantly	RB	O
lowered	VBN	O
after	IN	O
treatment	NN	O
with	IN	O
either	DT	O
ISDN	NNP	PM
,	,	O
155	CD	O
mmHg	NN	O
to	TO	O
138	CD	O
mmHg	NN	O
,	,	O
or	CC	O
NTG	NNP	O
,	,	O
160	CD	O
mmHg	NN	O
to	TO	O
130	CD	O
mmHg	NN	O
.	.	O

The	DT	O
mean	JJ	O
successful	JJ	O
dose	NN	O
rate	NN	O
for	IN	O
ISDN	NNP	PM
was	VBD	O
6.5	CD	O
micrograms	JJ	O
kg-1	JJ	O
min-1	NN	O
,	,	O
whereas	NNS	O
for	IN	O
NTG	NNP	PM
this	DT	O
was	VBD	O
3.8	CD	O
micrograms	JJ	O
kg-1	JJ	O
min-1	NN	O
.	.	O

In	IN	O
the	DT	O
ISDN	NNP	PM
group	NN	O
less	JJR	O
events	NNS	O
took	VBD	O
place	NN	O
possibly	RB	O
due	JJ	O
to	TO	O
the	DT	O
longer	JJR	O
duration	NN	O
of	IN	O
this	DT	O
drug	NN	O
.	.	O

In	IN	O
many	JJ	O
previous	JJ	O
studies	NNS	O
NTG	NNP	PM
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
controlling	VBG	O
hypertension	NN	O
;	:	O
ISDN	NNP	PM
offers	NNS	O
and	CC	O
alternative	JJ	O
approach	NN	O
in	IN	O
reducing	VBG	O
hypertension	NN	O
.	.	O

Use	NNP	O
of	IN	O
an	DT	O
inspiratory	JJ	PH
impedance	NN	PH
threshold	JJ	PH
device	NN	PH
on	IN	PH
a	DT	PH
facemask	NN	PH
and	CC	PH
endotracheal	VB	PH
tube	NN	PH
to	TO	O
reduce	VB	O
intrathoracic	JJ	O
pressures	NNS	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
.	.	O

INTRODUCTION	NNP	O
Use	NNP	O
of	IN	O
an	DT	O
inspiratory	JJ	PH
impedance	NN	PH
threshold	NN	PH
device	NN	PH
(	(	PH
ITD	NNP	PH
)	)	PH
significantly	RB	O
increases	VBZ	O
coronary	JJ	O
perfusion	NN	O
pressures	NNS	O
and	CC	O
survival	NN	O
in	IN	O
patients	NNS	O
ventilated	VBN	O
with	IN	O
an	DT	O
endotracheal	JJ	PH
tube	NN	PH
(	(	PH
ETT	NNP	PH
)	)	PH
during	IN	O
active	JJ	PH
compression-decompression	NN	PH
cardiopulmonary	JJ	PH
resuscitation	NN	PH
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
ITD	NNP	PH
could	MD	O
lower	VB	O
intratracheal	NN	O
pressures	NNS	O
when	WRB	O
attached	VBN	O
to	TO	O
either	VB	O
a	DT	O
facemask	NN	PH
or	CC	PH
ETT	NNP	PH
.	.	O

METHODS	NNP	O
An	DT	O
active	JJ	PH
and	CC	PH
sham	JJ	PH
ITD	NNP	PH
were	VBD	O
randomly	RB	O
applied	VBN	O
first	RB	O
to	TO	O
a	DT	O
facemask	NN	PH
and	CC	O
then	RB	O
to	TO	O
an	DT	O
ETT	NNP	PH
during	IN	O
active	JJ	PH
compression-decompression	NN	PH
cardiopulmonary	JJ	PH
resuscitation	NN	PH
in	IN	O
13	CD	O
out-of-hospital	JJ	O
cardiac	JJ	O
arrest	NN	O
patients	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
compression-to-bag-valve	JJ	O
ventilation	NN	O
ratio	NN	O
was	VBD	O
15:2	CD	O
.	.	O

Airway	NN	O
pressures	NNS	O
(	(	O
surrogate	NN	O
for	IN	O
intrathoracic	JJ	O
pressure	NN	O
)	)	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
pressure	NN	O
transducer	NN	O
.	.	O

A	DT	O
sham	NN	PH
and	CC	PH
an	DT	PH
active	JJ	PH
ITD	NNP	PH
were	VBD	O
used	VBN	O
for	IN	O
1	CD	O
min	NNS	O
each	DT	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
,	,	O
first	RB	O
on	IN	O
a	DT	O
facemask	NN	PH
and	CC	O
then	RB	O
on	IN	O
an	DT	O
ETT	NNP	PH
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
made	VBN	O
using	VBG	O
Friedman	NNP	O
's	POS	O
and	CC	O
Wilcoxon	NNP	O
's	POS	O
rank-sum	JJ	O
tests	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
sd	NN	O
maximum	JJ	O
negative	JJ	O
intrathoracic	NN	O
pressures	NNS	O
(	(	O
mm	VB	O
Hg	NNP	O
)	)	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
were	VBD	O
-1.0	JJ	O
+/-	JJ	O
0.73	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
a	DT	O
sham	NN	PH
vs.	FW	O
-4.6	NNP	O
+/-	JJ	O
3.7	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
an	DT	O
active	JJ	PH
ITD	NN	PH
on	IN	O
the	DT	O
facemask	NN	O
(	(	O
p	JJ	O
=	NNP	O
.003	NNP	O
)	)	O
and	CC	O
-1.3	JJ	O
+/-	JJ	O
1.3	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
a	DT	O
sham	NN	O
ITD	NNP	O
vs.	IN	O
-7.3	NNP	O
+/-	JJ	O
4.5	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
an	DT	O
active	JJ	O
ITD	NNP	O
on	IN	O
an	DT	O
ETT	NNP	O
(	(	O
p	JJ	O
=	NNP	O
.0009	NNP	O
)	)	O
.	.	O

Decompression	NNP	O
phase	NN	O
airway	NN	O
pressures	NNS	O
with	IN	O
the	DT	O
facemask	NN	PH
and	CC	PH
ETT	NNP	PH
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
an	DT	O
active	JJ	PH
ITD	NNP	PH
attached	VBD	PH
to	TO	PH
a	DT	PH
facemask	NN	PH
or	CC	PH
an	DT	PH
ETT	NNP	PH
resulted	VBD	O
in	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
negative	JJ	O
intratracheal	JJ	O
pressure	NN	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Airway	NNP	O
pressures	VBZ	O
with	IN	O
an	DT	O
ITD	NNP	PH
on	IN	O
either	CC	O
a	DT	O
facemask	NN	PH
or	CC	O
ETT	NNP	PH
were	VBD	O
similar	JJ	O
.	.	O

The	DT	O
ITD-facemask	JJ	PH
combination	NN	PH
was	VBD	O
practical	JJ	O
and	CC	O
enables	VBZ	O
rapid	JJ	O
deployment	NN	O
of	IN	O
this	DT	O
life-saving	JJ	O
technology	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
dried	JJ	PM
purple	JJ	PM
carrot	NN	PM
on	IN	O
body	NN	O
mass	NN	O
,	,	O
lipids	NNS	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
body	NN	O
composition	NN	O
,	,	O
and	CC	O
inflammatory	JJ	O
markers	NNS	O
in	IN	O
overweight	NN	O
and	CC	O
obese	JJ	O
adults	NNS	O
:	:	O
the	DT	O
QUENCH	NNP	O
trial	NN	O
.	.	O

Obesity	NNP	O
is	VBZ	O
a	DT	O
significant	JJ	O
health	NN	O
issue	NN	O
worldwide	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
chronic	JJ	O
,	,	O
low-grade	JJ	O
inflammation	NN	O
predisposing	VBG	O
the	DT	O
individual	NN	O
to	TO	O
cardiovascular	VB	O
disease	NN	O
and	CC	O
impaired	JJ	O
blood	NN	O
glucose	JJ	O
homeostasis	NN	O
.	.	O

Anthocyanins	NNS	PM
and	CC	PM
phenolic	JJ	PM
acids	NNS	PM
from	IN	PM
purple	JJ	PM
carrots	NNS	PM
are	VBP	O
effective	JJ	O
at	IN	O
reversing	VBG	O
inflammation	NN	O
and	CC	O
metabolic	JJ	O
alterations	NNS	O
in	IN	O
animal	NN	O
models	NNS	O
,	,	O
potentially	RB	O
through	IN	O
inhibition	NN	O
of	IN	O
inflammatory	JJ	O
pathways	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
dried	JJ	PM
purple	JJ	PM
carrot	NN	PM
on	IN	O
body	NN	O
mass	NN	O
,	,	O
body	NN	O
composition	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
lipids	NNS	O
,	,	O
inflammatory	JJ	O
markers	NNS	O
,	,	O
liver	JJ	O
function	NN	O
tests	NNS	O
,	,	O
and	CC	O
appetite	RB	O
were	VBD	O
investigated	VBN	O
in	IN	O
16	CD	O
males	NNS	O
(	(	O
aged	VBN	O
53.1	CD	O
?	.	O
7.6	CD	O
years	NNS	O
and	CC	O
with	IN	O
a	DT	O
mean	JJ	O
BMI	NNP	O
of	IN	O
32.8	CD	O
?	.	O
4.6	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
with	IN	O
normal	JJ	O
lipid	JJ	O
and	CC	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
118.5	CD	O
mg/day	NN	O
of	IN	O
anthocyanins	NNS	O
and	CC	O
259.2	CD	O
mg/day	NN	O
of	IN	O
phenolic	JJ	O
acids	NNS	O
for	IN	O
4	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
body	NN	O
mass	NN	O
,	,	O
body	NN	O
composition	NN	O
,	,	O
appetite	RB	O
,	,	O
dietary	JJ	O
intake	NN	O
,	,	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
,	,	O
total	JJ	O
cholesterol	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
or	CC	O
C-reactive	JJ	O
protein	NN	O
in	IN	O
these	DT	O
obese	JJ	O
participants	NNS	O
at	IN	O
the	DT	O
dose	NN	O
and	CC	O
length	NN	O
of	IN	O
intervention	NN	O
used	VBN	O
in	IN	O
this	DT	O
trial	NN	O
.	.	O

High	JJ	O
density	NN	O
lipoprotein	VBP	O
cholesterol	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Aspartate	NNP	O
amino	NN	O
transferase	NN	O
and	CC	O
alanine	NN	O
amino	NN	O
transferase	NN	O
did	VBD	O
not	RB	O
change	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
safe	JJ	O
.	.	O

More	JJR	O
studies	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
establish	VB	O
the	DT	O
bioavailability	NN	O
and	CC	O
pharmacokinetic	JJ	O
effects	NNS	O
of	IN	O
purple	JJ	O
carrot	NN	O
anthocyanins	NNS	O
and	CC	O
phenolic	JJ	O
acids	NNS	O
prior	RB	O
to	TO	O
further	JJ	O
trials	NNS	O
of	IN	O
efficacy	NN	O
with	IN	O
respect	NN	O
to	TO	O
treating	VBG	O
inflammation	NN	O
and	CC	O
metabolic	JJ	O
alterations	NNS	O
.	.	O

Effect	NN	O
of	IN	O
m-chlorophenylpiperazine	NN	PM
on	IN	O
plasma	NN	O
homovanillic	JJ	O
acid	NN	O
concentrations	NNS	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
abundant	JJ	O
anatomical	JJ	O
and	CC	O
functional	JJ	O
interactions	NNS	O
between	IN	O
serotonin	NN	O
and	CC	O
dopamine	NN	O
systems	NNS	O
,	,	O
this	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
serotonin	JJ	O
agonist	NN	O
,	,	O
m-chlorophenylpiperazine	NN	PM
(	(	PM
mCPP	NN	PM
)	)	PM
on	IN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
the	DT	O
dopamine	NN	O
metabolite	NN	O
,	,	O
homovanillic	JJ	O
acid	NN	O
.	.	O

Plasma	NNP	O
prolactin	NN	O
levels	NNS	O
,	,	O
body	NN	O
temperature	NN	O
,	,	O
and	CC	O
mCPP	RB	O
blood	NN	O
level	NN	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

mCPP	NN	PM
(	(	O
0.35	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
placebo	$	C
were	VBD	O
administered	VBN	O
orally	RB	O
to	TO	O
10	CD	O
healthy	JJ	O
men	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
design	NN	O
.	.	O

Variables	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
210	CD	O
min	NNS	O
after	IN	O
administration	NN	O
of	IN	O
capsules	NNS	O
.	.	O

mCPP	NNS	O
raised	VBD	O
prolactin	NN	O
and	CC	O
temperature	NN	O
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
plasma	NN	O
homovanillic	JJ	O
acid	JJ	O
concentrations	NNS	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
mCPP	NN	O
does	VBZ	O
not	RB	O
alter	VB	O
dopamine	NN	O
function	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo	NN	C
controlled	VBD	O
trial	NN	O
of	IN	O
piracetam	NN	PM
added	VBN	O
to	TO	O
risperidone	VB	PM
in	IN	O
patients	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
that	IN	O
autism	NN	O
is	VBZ	O
a	DT	O
hypoglutamatergic	JJ	O
disorder	NN	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
was	VBD	O
of	IN	O
interest	NN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
piracetam	NN	PM
,	,	O
a	DT	O
positive	JJ	O
modulator	NN	O
of	IN	O
AMPA-sensitive	JJ	O
glutamate	NN	O
receptors	NNS	O
in	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

About	IN	O
40	CD	O
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
three	CD	O
and	CC	O
11	CD	O
years	NNS	O
(	(	O
inclusive	JJ	O
)	)	O
with	IN	O
a	DT	O
DSM	NNP	O
IV	NNP	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
autism	NN	O
and	CC	O
who	WP	O
were	VBD	O
outpatients	NNS	O
from	IN	O
a	DT	O
specialty	NN	O
clinic	NN	O
for	IN	O
children	NNS	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
children	NNS	O
presented	VBN	O
with	IN	O
a	DT	O
chief	JJ	O
complaint	NN	O
of	IN	O
severely	RB	O
disruptive	JJ	O
symptoms	NNS	O
related	VBN	O
to	TO	O
autistic	JJ	O
disorder	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
piracetam	VB	PM
+	NNP	O
risperidone	NN	PM
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
or	CC	O
placebo	JJ	C
+	NN	O
risperidone	NN	PM
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
for	IN	O
a	DT	O
10-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	PM
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
2	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
between	IN	O
10	CD	O
and	CC	O
40	CD	O
kg	NN	O
and	CC	O
3	CD	O
mg/day	NN	O
for	IN	O
children	NNS	O
weighting	VBG	O
above	IN	O
40	CD	O
kg	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
piracetam	NN	PM
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
800	CD	O
mg/day	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
and	CC	O
10	CD	O
weeks	NNS	O
of	IN	O
starting	VBG	O
medication	NN	O
.	.	O

The	DT	O
measure	NN	O
of	IN	O
the	DT	O
outcome	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
Rating	VBG	O
Scale	NNP	O
(	(	O
total	JJ	O
score	NN	O
)	)	O
.	.	O

The	DT	O
ABC-C	JJ	O
Rating	NNP	O
Scale	NNP	O
scores	VBZ	O
improved	VBN	O
with	IN	O
piracetam	NN	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
protocols	NNS	O
was	VBD	O
significant	JJ	O
as	IN	O
indicated	VBN	O
by	IN	O
the	DT	O
effect	NN	O
of	IN	O
group	NN	O
,	,	O
the	DT	O
between	IN	O
subjects	NNS	O
factor	NN	O
(	(	O
F	NNP	O
=	NNP	O
5.85	CD	O
,	,	O
d.f	NN	O
.	.	O

=	CC	O
1	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
at	IN	O
the	DT	O
endpoint	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
were	VBD	O
:	:	O
-11.90	JJ	O
+/-	JJ	O
3.79	CD	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
and	CC	O
-5.15	JJ	O
+/-	JJ	O
3.04	CD	O
for	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
respectively	RB	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
the	DT	O
change	NN	O
in	IN	O
scores	NNS	O
in	IN	O
the	DT	O
ABC-C	NNP	O
Rating	NNP	O
Scale	NNP	O
in	IN	O
week	NN	O
10	CD	O
compared	VBN	O
with	IN	O
baseline	NN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
t	JJ	O
=	NN	O
6.017	CD	O
,	,	O
d.f	NN	O
.	.	O

=	CC	O
38	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
combination	NN	O
of	IN	O
atypical	JJ	O
antipsychotic	JJ	O
medications	NNS	O
and	CC	O
a	DT	O
glutamate	JJ	O
agent	NN	O
such	JJ	O
as	IN	O
piracetam	NNS	O
,	,	O
might	MD	O
have	VB	O
increase	VBN	O
synergistic	JJ	O
effects	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
of	IN	O
amoxycillin	NN	PM
and	CC	PM
omeprazole	NN	PM
with	IN	O
and	CC	O
without	IN	O
metronidazole	NN	PM
in	IN	O
the	DT	O
eradication	NN	O
treatment	NN	O
of	IN	O
Helicobacter	NNP	O
pylori	NN	O
.	.	O

A	DT	O
combination	NN	O
of	IN	O
amoxycillin	NN	PM
and	CC	PM
omeprazole	NN	PM
is	VBZ	O
often	RB	O
used	VBN	O
to	TO	O
treat	VB	O
Helicobacter	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

A	DT	O
three-drug	JJ	O
regimen	NN	O
comprising	VBG	O
metronidazole	NN	PM
,	,	PM
amoxycillin	NN	PM
and	CC	PM
omeprazole	NN	PM
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
an	DT	O
alternative	JJ	O
therapy	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
comparative	JJ	O
study	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
these	DT	O
two	CD	O
regimens	NNS	O
with	IN	O
respect	NN	O
to	TO	O
safety	NN	O
and	CC	O
efficacy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
H.	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

Sixty	JJ	O
patients	NNS	O
with	IN	O
peptic	JJ	O
ulcer	NN	O
(	(	O
gastric	JJ	O
,	,	O
32	CD	O
patients	NNS	O
;	:	O
duodenal	JJ	O
,	,	O
28	CD	O
patients	NNS	O
)	)	O
who	WP	O
had	VBD	O
a	DT	O
history	NN	O
of	IN	O
ulcer	JJ	O
recurrence	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
dual	JJ	O
therapy	NN	O
with	IN	O
amoxycillin	NN	PM
(	(	O
500	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
)	)	O
and	CC	O
omeprazole	JJ	PM
(	(	O
20	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
for	IN	O
8	CD	O
weeks	NNS	O
)	)	O
or	CC	O
to	TO	O
triple	VB	O
therapy	NN	O
with	IN	O
metronidazole	NN	PM
(	(	O
500	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
)	)	O
plus	CC	O
amoxycillin	JJ	PM
and	CC	PM
omeprazole	JJ	PM
,	,	O
given	VBN	O
in	IN	O
the	DT	O
same	JJ	O
dosages	NNS	O
as	IN	O
dual	JJ	O
therapy	NN	O
.	.	O

Forty-eight	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
protocol	NN	O
;	:	O
treatment	NN	O
was	VBD	O
discontinued	VBN	O
because	IN	O
of	IN	O
side	NN	O
effects	NNS	O
in	IN	O
nine	CD	O
patients	NNS	O
,	,	O
and	CC	O
three	CD	O
patients	NNS	O
dropped	VBD	O
out	IN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

On	IN	O
the	DT	O
basis	NN	O
of	IN	O
all	DT	O
patients	NNS	O
treated	VBN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
H.	NNP	O
pylori	FW	O
eradication	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
for	IN	O
triple	JJ	O
therapy	NN	O
20/23	CD	O
cases	NNS	O
,	,	O
87.0	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
0.664-0.972	JJ	O
)	)	O
than	IN	O
for	IN	O
dual	JJ	O
therapy	NN	O
13/25	CD	O
,	,	O
52.0	CD	O
%	NN	O
;	:	O
0.313-0.722	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

On	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
,	,	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
H.	NNP	O
pylori	FW	O
eradication	NN	O
was	VBD	O
marginally	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	VBZ	O
0.06	CD	O
[	JJ	O
0.028-0.512	JJ	O
]	NN	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
reported	VBN	O
by	IN	O
five	CD	O
patients	NNS	O
receiving	VBG	O
triple	JJ	O
therapy	NN	O
(	(	O
skin	JJ	O
rash	NN	O
,	,	O
one	CD	O
;	:	O
nausea	NN	O
,	,	O
two	CD	O
;	:	O
headache	NN	O
,	,	O
one	CD	O
;	:	O
abdominal	JJ	O
pain	NN	O
,	,	O
one	CD	O
)	)	O
,	,	O
and	CC	O
four	CD	O
patients	NNS	O
receiving	VBG	O
dual	JJ	O
therapy	NN	O
(	(	O
skin	JJ	O
rash	NN	O
,	,	O
two	CD	O
;	:	O
abdominal	JJ	O
pain	NN	O
,	,	O
one	CD	O
;	:	O
diarrhoea	NN	O
,	,	O
one	CD	O
)	)	O
.	.	O

All	DT	O
side	NN	O
effects	NNS	O
resolved	VBD	O
spontaneously	RB	O
after	IN	O
termination	NN	O
of	IN	O
treatment	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
safety	NN	O
between	IN	O
the	DT	O
two	CD	O
regimens	NNS	O
.	.	O

Triple	JJ	O
therapy	NN	O
with	IN	O
metronidazole	NN	PM
,	,	PM
amoxycillin	NN	PM
,	,	PM
and	CC	PM
omeprazole	NN	PM
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
for	IN	O
the	DT	O
eradication	NN	O
of	IN	O
H.	NNP	O
pylori	FW	O
than	IN	O
dual	JJ	O
therapy	NN	O
with	IN	O
amoxycillin	NN	PM
and	CC	PM
omeprazole	JJ	PM
alone	RB	PM
.	.	O

The	DT	O
safety	NN	O
of	IN	O
these	DT	O
regimens	NNS	O
was	VBD	O
similar	JJ	O
,	,	O
and	CC	O
triple	JJ	O
therapy	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
clinically	RB	O
acceptable	JJ	O
.	.	O

The	DT	O
clinical	JJ	O
and	CC	O
biochemical	JJ	O
effects	NNS	O
of	IN	O
propofol	JJ	PM
infusion	NN	O
with	IN	PM
and	CC	PM
without	IN	PM
EDTA	NNP	PM
for	IN	O
maintenance	NN	O
anesthesia	NN	O
in	IN	O
healthy	JJ	O
children	NNS	O
undergoing	VBG	O
ambulatory	NN	O
surgery	NN	O
.	.	O

UNLABELLED	IN	O
We	PRP	O
conducted	VBD	O
this	DT	O
randomized	VBN	O
,	,	O
double-blinded	JJ	O
,	,	O
comparative	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
to	TO	O
determine	VB	O
whether	IN	O
adding	VBG	O
EDTA	NNP	PM
to	TO	PM
propofol	VB	PM
would	MD	O
affect	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
,	,	O
calcium	NN	O
and	CC	O
magnesium	NN	O
homeostasis	NN	O
,	,	O
or	CC	O
renal	JJ	O
function	NN	O
in	IN	O
healthy	JJ	O
children	NNS	O
.	.	O

After	IN	O
the	DT	O
induction	NN	PM
of	IN	PM
anesthesia	NN	PM
with	IN	PM
halothane	NN	PM
,	,	O
69	CD	O
ambulatory	JJ	O
surgical	JJ	O
patients	NNS	O
(	(	O
1	CD	O
mo	NN	O
to	TO	O
<	VB	O
17	CD	O
yr	NNP	O
old	JJ	O
)	)	O
,	,	O
received	VBD	O
propofol	NN	PM
without	IN	PM
EDTA	NNP	PM
(	(	O
n	JJ	O
=	NNP	O
33	CD	O
)	)	O
or	CC	O
propofol	NN	PM
with	IN	PM
EDTA	NNP	PM
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
for	IN	O
the	DT	O
measurement	NN	O
of	IN	O
ionized	JJ	O
calcium	NN	O
,	,	O
ionized	JJ	O
magnesium	NN	O
,	,	O
and	CC	O
laboratory	JJ	O
indicators	NNS	O
of	IN	O
renal	JJ	O
function	NN	O
.	.	O

Hemodynamic	NNP	O
measurements	NNS	O
,	,	O
recovery	NN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

Propofol	NNP	PM
with	IN	PM
EDTA	NNP	PM
produced	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
on	IN	O
clinical	JJ	O
efficacy	NN	O
or	CC	O
renal	JJ	O
function	NN	O
.	.	O

Propofol	NNP	PM
and	CC	O
propofol	JJ	PM
EDTA	NNP	PM
produced	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
decrease	NN	O
from	IN	O
baseline	NN	O
in	IN	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
ionized	JJ	O
calcium	NN	O
and	CC	O
magnesium	NN	O
during	IN	O
infusion	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

Hemodynamic	NNP	O
measurements	NNS	O
generally	RB	O
remained	VBD	O
stable	JJ	O
and	CC	O
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Statistically	NNP	O
significant	JJ	O
changes	NNS	O
in	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
were	VBD	O
not	RB	O
considered	VBN	O
clinically	RB	O
significant	JJ	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
mild	JJ	O
or	CC	O
moderate	JJ	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
EDTA	NNP	PM
does	VBZ	O
not	RB	O
alter	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
of	IN	O
propofol	NN	O
in	IN	O
pediatric	JJ	O
ambulatory	JJ	O
surgical	JJ	O
patients	NNS	O
.	.	O

With	IN	O
or	CC	O
without	IN	O
EDTA	NNP	PM
,	,	O
propofol	NN	PM
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
ionized	JJ	O
calcium	NN	O
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

IMPLICATIONS	VBZ	O
The	DT	O
addition	NN	O
of	IN	O
EDTA	NNP	O
does	VBZ	O
not	RB	O
alter	VB	O
the	DT	O
clinical	JJ	O
profile	NN	O
of	IN	O
propofol	NN	O
in	IN	O
pediatric	JJ	O
ambulatory	JJ	O
surgical	JJ	O
patients	NNS	O
.	.	O

With	IN	O
or	CC	O
without	IN	O
EDTA	NNP	O
,	,	O
propofol	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
ionized	JJ	O
calcium	NN	O
with	IN	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

Simulating	VBG	O
a	DT	O
memory	NN	O
impairment	NN	O
:	:	O
can	MD	O
amnesics	VB	O
implicitly	RB	O
outperform	JJ	O
simulators	NNS	O
?	.	O
OBJECTIVES	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
tests	NNS	O
in	IN	O
differentiating	VBG	O
simulating	VBG	O
test	NN	O
performances	NNS	O
from	IN	O
genuine	JJ	O
memory-impaired	JJ	O
and	CC	O
normal	JJ	O
(	(	O
control	NN	O
)	)	O
test	NN	O
performances	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
simulation	NN	E
design	NN	E
was	VBD	O
implemented	VBN	O
,	,	O
based	VBN	O
on	IN	O
an	DT	O
analogue	NN	O
design	NN	O
in	IN	O
which	WDT	O
normal	JJ	O
participants	NNS	O
were	VBD	O
given	VBN	O
experimental	JJ	O
instructions	NNS	O
to	TO	O
feign	VB	O
a	DT	O
mental	JJ	O
impairment	NN	O
and	CC	O
are	VBP	O
compared	VBN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
other	JJ	O
normal	JJ	O
participants	NNS	O
with	IN	O
instructions	NNS	O
to	TO	O
perform	VB	O
honestly	RB	O
,	,	O
and	CC	O
(	(	O
b	NN	O
)	)	O
a	DT	O
comparison	NN	O
group	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
acquired	VBD	O
brain-injured	JJ	O
persons	NNS	O
,	,	O
with	IN	O
similar	JJ	O
instructions	NNS	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
individuals	NNS	O
comprised	VBD	O
the	DT	O
simulating	NN	O
and	CC	O
control	NN	O
group	NN	O
and	CC	O
all	DT	O
participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	E
to	TO	E
the	DT	E
simulating	NN	E
and	CC	O
control	NN	C
groups	NNS	C
.	.	O

Twenty	CD	O
memory-impaired	JJ	O
patients	NNS	O
,	,	O
all	DT	O
of	IN	O
whom	WP	O
had	VBD	O
been	VBN	O
diagnosed	VBN	O
as	IN	O
suffering	VBG	O
from	IN	O
a	DT	O
memory	NN	O
impairment	NN	O
following	VBG	O
acquired	VBD	O
brain	NN	O
damage	NN	O
,	,	O
participated	VBD	O
as	IN	O
the	DT	O
memory-impaired	JJ	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
simulation	NN	O
group	NN	O
was	VBD	O
directed	VBN	E
to	TO	E
imitate	VB	E
a	DT	E
person	NN	E
with	IN	E
a	DT	E
memory	NN	E
impairment	NN	E
.	.	O

The	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
involved	VBN	O
identifying	VBG	O
those	DT	O
tests	NNS	O
,	,	O
if	IN	O
any	DT	O
,	,	O
where	WRB	O
simulators	NNS	O
were	VBD	O
significantly	RB	O
different	JJ	O
from	IN	O
normal	JJ	O
and	CC	O
memory-impaired	JJ	O
participants	NNS	O
.	.	O

RESULTS	VB	O
On	IN	O
5	CD	O
of	IN	O
the	DT	O
15	CD	O
tasks	NNS	O
administered	VBN	O
,	,	O
simulators	NNS	E
performed	VBD	O
significantly	RB	O
differently	RB	O
from	IN	O
normal	JJ	O
and	CC	O
memory-impaired	JJ	O
participants	NNS	O
.	.	O

Of	IN	O
these	DT	O
5	CD	O
tasks	NNS	O
,	,	O
the	DT	O
coin-in-the-hand	NN	O
,	,	O
when	WRB	O
administered	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
autobiographical	JJ	O
interview	NN	O
,	,	O
identified	VBD	O
95	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
simulators	NNS	O
without	IN	O
misclassifying	VBG	O
any	DT	O
of	IN	O
the	DT	O
memory-impaired	JJ	O
or	CC	O
normal	JJ	O
participants	NNS	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
these	DT	O
two	CD	O
tests	NNS	O
,	,	O
when	WRB	O
administered	VBN	O
jointly	RB	O
,	,	O
might	MD	O
be	VB	O
of	IN	O
use	NN	O
in	IN	O
clinical	JJ	O
settings	NNS	O
to	TO	O
assist	VB	O
in	IN	O
the	DT	O
detection	NN	O
of	IN	O
malingerers	NNS	O
.	.	O

Levamisole	NNP	PS
versus	NN	O
placebo	NN	C
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
primary	JJ	O
therapy	NN	O
of	IN	O
laryngopharyngeal	JJ	O
epidermoid	JJ	O
carcinoma	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
immune	JJ	O
status	NN	O
.	.	O

Twenty-four	CD	O
patients	NNS	O
,	,	O
with	IN	O
a	DT	O
biopsy-proven	JJ	O
laryngeal	NN	O
or	CC	O
hypopharyngeal	NN	O
carcinoma	NN	O
,	,	O
received	VBD	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
their	PRP$	O
primary	JJ	O
treatment	NN	O
(	(	O
surgery	JJ	O
and/or	RB	O
radiotherapy	NN	O
)	)	O
,	,	O
levamisole	JJ	PM
(	(	O
150	CD	O
mg	NNS	O
daily	RB	O
during	IN	O
three	CD	O
consecutive	JJ	O
days	NNS	O
,	,	O
every	DT	O
fortnight	NN	O
)	)	O
or	CC	O
placebo	NN	O
,	,	O
following	VBG	O
a	DT	O
single-blind	JJ	O
,	,	O
but	CC	O
randomized	VBD	O
method	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
follow-up	NN	O
,	,	O
an	DT	O
investigation	NN	O
of	IN	O
the	DT	O
immune	NN	O
status	NN	O
was	VBD	O
done	VBN	O
,	,	O
and	CC	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
healthy	JJ	O
control-group	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
immunity	NN	O
is	VBZ	O
disturbed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
laryngo-pharyngeal	JJ	O
cancer	NN	O
,	,	O
but	CC	O
that	IN	O
this	DT	O
disturbance	NN	O
does	VBZ	O
not	RB	O
clearly	RB	O
correlate	NN	O
with	IN	O
the	DT	O
clinical	JJ	O
state	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
immunological	JJ	O
measures	NNS	O
did	VBD	O
not	RB	O
appear	VB	O
relevant	JJ	O
to	TO	O
the	DT	O
significantly	RB	O
favourable	JJ	O
effect	NN	O
of	IN	O
levamisole	NN	O
on	IN	O
the	DT	O
prognosis	NN	O
.	.	O

[	NNS	O
Localised	VBN	O
prostate	JJ	O
cancer	NN	O
:	:	O
the	DT	O
PREFERE	NNP	O
trial	NN	O
]	NNP	O
.	.	O

Prostate	NNP	O
cancer	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
elderly	JJ	O
man	NN	O
and	CC	O
holds	VBZ	O
the	DT	O
third	JJ	O
place	NN	O
in	IN	O
the	DT	O
ranking	NN	O
of	IN	O
cancer-specific	JJ	O
mortality	NN	O
.	.	O

However	RB	O
,	,	O
mortality	NN	O
rates	NNS	O
of	IN	O
3	CD	O
%	NN	O
are	VBP	O
low	JJ	O
,	,	O
and	CC	O
half	NN	O
of	IN	O
the	DT	O
patients	NNS	O
will	MD	O
die	VB	O
from	IN	O
intercurrent	JJ	O
disease	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
significantly	RB	O
improved	VBN	O
diagnostic	JJ	O
methods	NNS	O
and	CC	O
the	DT	O
increasing	VBG	O
use	NN	O
of	IN	O
PSA	NNP	O
screening	NN	O
,	,	O
there	EX	O
has	VBZ	O
been	VBN	O
a	DT	O
stage	NN	O
migration	NN	O
towards	NNS	O
early	RB	O
tumour	VBP	O
stages	NNS	O
that	WDT	O
are	VBP	O
prognostically	RB	O
heterogeneous	JJ	O
and	CC	O
require	NN	O
differentiated	VBN	O
treatment	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
discussions	NNS	O
of	IN	O
the	DT	O
Joint	NNP	O
Federal	NNP	O
Committee	NNP	O
(	(	O
G-BA	NNP	O
)	)	O
and	CC	O
the	DT	O
conceptual	JJ	O
work	NN	O
of	IN	O
the	DT	O
MDS	NNP	O
,	,	O
the	DT	O
Competence	NNP	O
Centre	NNP	O
Oncology	NNP	O
of	IN	O
the	DT	O
MDK	NNP	O
,	,	O
the	DT	O
IQWIG	NNP	O
and	CC	O
the	DT	O
National	NNP	O
Association	NNP	O
of	IN	O
Statutory	NNP	O
Health	NNP	O
Insurance	NNP	O
Funds	NNP	O
(	(	O
GKV-Spitzenverband	NNP	O
)	)	O
,	,	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
multicentre	JJ	O
trial	NN	O
was	VBD	O
developed	VBN	O
comparing	VBG	O
the	DT	O
four	CD	O
treatments	NNS	O
actually	RB	O
recommended	VBN	O
by	IN	O
the	DT	O
German	JJ	O
and	CC	O
European	JJ	O
guidelines	NNS	O
for	IN	O
localised	JJ	O
prostate	NN	O
cancer	NN	O
(	(	O
radical	JJ	S
prostatectomy	NN	S
,	,	O
percutaneous	JJ	PH
radiotherapy	NN	PH
and	CC	O
permanent	JJ	PH
seed	NN	PH
implantation	NN	PH
and	CC	O
active	JJ	PH
surveillance	NN	PH
)	)	O
allowing	VBG	O
a	DT	O
rejection	NN	O
of	IN	O
one	CD	O
or	CC	O
two	CD	O
treatment	NN	O
options	NNS	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
expected	VBN	O
to	TO	O
start	VB	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
next	JJ	O
year	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
combination	NN	O
chemotherapy	NN	PH
in	IN	O
hormone-resistant	JJ	O
metastatic	JJ	O
prostate	NN	O
carcinoma	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
51	CD	O
patients	NNS	O
with	IN	O
stage	JJ	O
D	NNP	O
hormone-resistant	JJ	O
prostatic	JJ	O
carcinoma	NN	O
,	,	O
comparing	VBG	O
a	DT	O
combination	NN	O
of	IN	O
doxorubicin	NN	PM
and	CC	O
lomustine	NN	PM
(	(	O
DC	NNP	O
)	)	O
with	IN	O
cyclophosphamide	NN	PM
and	CC	PM
5-FU	JJ	PM
(	(	PM
CF	NNP	PM
)	)	PM
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
objectively	RB	O
(	(	O
employing	VBG	O
National	NNP	O
Prostate	NNP	O
Cancer	NNP	O
Project	NNP	O
criteria	NNS	O
)	)	O
and	CC	O
subjectively	RB	O
(	(	O
using	VBG	O
a	DT	O
numerical	JJ	O
scoring	NN	O
scheme	NN	O
)	)	O
.	.	O

Each	DT	O
regimen	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
acceptable	JJ	O
levels	NNS	O
of	IN	O
myelosuppression	NN	O
.	.	O

The	DT	O
objective	JJ	O
partial	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
57	CD	O
%	NN	O
for	IN	O
DC	NNP	O
and	CC	O
8	CD	O
%	NN	O
for	IN	O
CF	NNP	O
.	.	O

Objective	NNP	O
stabilization	NN	O
occurred	VBD	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
14	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

Similarly	RB	O
,	,	O
DC	NNP	O
demonstrated	VBD	O
a	DT	O
significantly	RB	O
superior	JJ	O
subjective	JJ	O
response	NN	O
rate	NN	O
(	(	O
partial	JJ	O
plus	CC	O
complete	JJ	O
)	)	O
of	IN	O
82	CD	O
%	NN	O
,	,	O
compared	VBN	O
to	TO	O
48	CD	O
%	NN	O
for	IN	O
CF	NNP	PM
.	.	O

Patients	NNS	O
with	IN	O
poor	JJ	O
initial	JJ	O
performance	NN	O
status	NN	O
or	CC	O
liver	VB	O
involvement	NN	O
had	VBD	O
significantly	RB	O
lower	JJR	O
response	NN	O
rates	NNS	O
and	CC	O
reduced	JJ	O
survival	NN	O
.	.	O

Overall	JJ	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
survival	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
,	,	O
reflecting	VBG	O
the	DT	O
similarity	NN	O
between	IN	O
DC	NNP	PM
and	CC	O
CF	NNP	PM
in	IN	O
total	JJ	O
objective	JJ	O
response	NN	O
rate	NN	O
(	(	O
partial	JJ	O
response	NN	O
plus	CC	O
stable	JJ	O
disease	NN	O
)	)	O
.	.	O

DC	NNP	PM
provided	VBD	O
superior	JJ	O
palliation	NN	O
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	O
by	IN	O
an	DT	O
essentially	RB	O
geriatric	JJ	O
population	NN	O
.	.	O

Improved	VBN	O
frontoparietal	JJ	O
white	JJ	O
matter	NN	O
integrity	NN	O
in	IN	O
overweight	JJ	O
children	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
attendance	NN	O
at	IN	O
an	DT	O
after-school	JJ	E
exercise	NN	E
program	NN	E
.	.	O

Aerobic	NNP	O
fitness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
white	JJ	O
matter	NN	O
integrity	NN	O
(	(	O
WMI	NNP	O
)	)	O
in	IN	O
adults	NNS	O
as	IN	O
measured	VBN	O
by	IN	O
diffusion	NN	O
tensor	NN	O
imaging	NN	O
(	(	O
DTI	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
8-month	JJ	O
exercise	NN	PH
intervention	NN	PH
on	IN	O
WMI	NNP	O
in	IN	O
children	NNS	O
.	.	O

Participants	NNS	O
were	VBD	O
18	CD	O
sedentary	JJ	O
,	,	O
overweight	JJ	O
(	(	O
BMI?85th	NNP	O
percentile	NN	O
)	)	O
8-	CD	O
to	TO	O
11-year-old	JJ	O
children	NNS	O
(	(	O
94	CD	O
%	NN	O
Black	NNP	O
)	)	O
,	,	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
aerobic	JJ	O
exercise	NN	O
(	(	O
n=10	JJ	O
)	)	O
or	CC	O
sedentary	JJ	O
attention	NN	O
control	NN	O
group	NN	O
(	(	O
n=8	RB	O
)	)	O
.	.	O

Each	DT	O
group	NN	O
was	VBD	O
offered	VBN	O
an	DT	O
instructor-led	JJ	O
after-school	JJ	O
program	NN	O
every	DT	O
school	NN	O
day	NN	O
for	IN	O
approximately	RB	O
8	CD	O
months	NNS	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
the	DT	O
program	NN	O
,	,	O
all	DT	O
subjects	NNS	O
participated	VBN	O
in	IN	O
DTI	NNP	O
scans	NNS	O
.	.	O

Tractography	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
isolate	VB	O
the	DT	O
superior	JJ	O
longitudinal	JJ	O
fasciculus	NN	O
and	CC	O
investigate	VB	O
whether	IN	O
the	DT	O
exercise	NN	O
intervention	NN	O
affected	VBD	O
WMI	NNP	O
in	IN	O
this	DT	O
region	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
group	NN	O
by	IN	O
time	NN	O
interaction	NN	O
for	IN	O
WMI	NNP	O
in	IN	O
the	DT	O
superior	JJ	O
longitudinal	JJ	O
fasciculus	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
group	NN	O
by	IN	O
time	NN	O
by	IN	O
attendance	NN	O
interaction	NN	O
,	,	O
however	RB	O
,	,	O
such	JJ	O
that	IN	O
higher	JJR	O
attendance	NN	O
at	IN	O
the	DT	O
exercise	NN	O
intervention	NN	O
,	,	O
but	CC	O
not	RB	O
the	DT	O
control	NN	O
intervention	NN	O
,	,	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
WMI	NNP	O
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
the	DT	O
total	JJ	O
dose	NN	O
of	IN	O
exercise	NN	O
correlated	VBN	O
with	IN	O
WMI	NNP	O
changes	NNS	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
overall	JJ	O
sample	NN	O
,	,	O
increased	VBD	O
WMI	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
improved	JJ	O
scores	NNS	O
on	IN	O
a	DT	O
measure	NN	O
of	IN	O
attention	NN	O
and	CC	O
improved	VBN	O
teacher	JJ	O
ratings	NNS	O
of	IN	O
executive	NN	O
function	NN	O
.	.	O

This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
participating	VBG	O
in	IN	O
an	DT	O
exercise	NN	O
intervention	NN	O
improves	VBZ	O
WMI	NNP	O
in	IN	O
children	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
sedentary	JJ	O
after-school	JJ	O
program	NN	O
.	.	O

Assessment	NN	O
of	IN	O
therapeutic	JJ	O
response	NN	O
of	IN	O
Plasmodium	NNP	O
falciparum	NN	O
to	TO	O
chloroquine	VB	PM
and	CC	O
sulfadoxine-pyrimethamine	VB	PM
in	IN	O
an	DT	O
area	NN	O
of	IN	O
low	JJ	O
malaria	NNS	O
transmission	NN	O
in	IN	O
Colombia	NNP	O
.	.	O

Although	IN	O
chloroquine	NN	PM
(	(	O
CQ	NNP	O
)	)	O
resistance	NN	O
was	VBD	O
first	RB	O
reported	VBN	O
in	IN	O
Colombia	NNP	O
in	IN	O
1961	CD	O
and	CC	O
sulfadoxine-pyrimethamine	JJ	PM
(	(	O
SP	NNP	O
)	)	O
resistance	NN	O
in	IN	O
1981	CD	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
treatment	NN	O
failures	NNS	O
to	TO	O
these	DT	O
drugs	NNS	O
in	IN	O
Colombia	NNP	O
is	VBZ	O
unclear	JJ	O
.	.	O

A	DT	O
modified	JJ	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
14-day	JJ	O
in	IN	O
vivo	JJ	O
drug	NN	O
efficacy	NN	O
test	NN	O
for	IN	O
uncomplicated	JJ	O
Plasmodium	NNP	O
falciparum	NN	O
malaria	NN	O
in	IN	O
areas	NNS	O
with	IN	O
intense	JJ	O
malaria	NNS	O
transmission	NN	O
was	VBD	O
adapted	VBN	O
to	TO	O
reflect	VB	O
the	DT	O
clinical	JJ	O
and	CC	O
epidemiologic	JJ	O
features	NNS	O
of	IN	O
a	DT	O
low-intensity	JJ	O
malaria	NN	O
transmission	NN	O
area	NN	O
in	IN	O
the	DT	O
Pacific	NNP	O
Coast	NNP	O
Region	NNP	O
of	IN	O
Colombia	NNP	O
.	.	O

Patients	NNPS	O
>	JJ	O
or	CC	O
=1	JJ	O
year	NN	O
of	IN	O
age	NN	O
with	IN	O
a	DT	O
parasite	JJ	O
density	NN	O
>	NN	O
or	CC	O
=1,000	CD	O
asexual	JJ	O
parasites	NNS	O
per	IN	O
microliter	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Forty-four	CD	O
percent	NN	O
(	(	O
24	CD	O
of	IN	O
54	CD	O
)	)	O
of	IN	O
the	DT	O
CQ-treated	JJ	PM
patients	NNS	O
were	VBD	O
therapeutic	JJ	O
failures	NNS	O
,	,	O
including	VBG	O
7	CD	O
early	JJ	O
treatment	NN	O
failures	NNS	O
(	(	O
ETFs	NNP	O
)	)	O
and	CC	O
17	CD	O
late	JJ	O
treatment	NN	O
failures	NNS	O
(	(	O
LTFs	NNP	O
)	)	O
.	.	O

Four	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
of	IN	O
67	CD	O
SP-treated	JJ	O
patients	NNS	O
were	VBD	O
therapeutic	JJ	O
failures	NNS	O
(	(	O
2	CD	O
ETFs	NNP	O
and	CC	O
2	CD	O
LTFs	NNP	O
)	)	O
.	.	O

Therapeutic	JJ	O
failure	NN	O
in	IN	O
the	DT	O
CQ-treated	JJ	PM
group	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
age	NN	O
<	VBD	O
15	CD	O
years	NNS	O
old	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
initial	JJ	O
parasite	JJ	O
density	NN	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
CQ	NNP	PM
or	CC	O
sulfa-containing	JJ	O
drugs	NNS	O
in	IN	O
urine	NN	O
,	,	O
or	CC	O
a	DT	O
history	NN	O
of	IN	O
malaria	NN	O
.	.	O

The	DT	O
high	JJ	O
level	NN	O
of	IN	O
therapeutic	JJ	O
failures	NNS	O
to	TO	O
CQ	NNP	PM
detected	VBN	O
in	IN	O
this	DT	O
study	NN	O
underscores	VBZ	O
the	DT	O
need	NN	O
and	CC	O
importance	NN	O
of	IN	O
drug	NN	O
efficacy	NN	O
evaluation	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
rational	JJ	O
national	JJ	O
antimalarial	JJ	O
drug	NN	O
policy	NN	O
.	.	O

The	DT	O
relatively	RB	O
low	JJ	O
level	NN	O
of	IN	O
therapeutic	JJ	O
failures	NNS	O
to	TO	O
SP	NNP	O
compared	VBN	O
with	IN	O
other	JJ	O
South	JJ	O
American	JJ	O
countries	NNS	O
raises	VBZ	O
further	JJ	O
questions	NNS	O
regarding	VBG	O
factors	NNS	O
that	WDT	O
might	MD	O
have	VB	O
prevented	VBN	O
the	DT	O
rapid	JJ	O
development	NN	O
of	IN	O
in	IN	O
vivo	NN	O
resistance	NN	O
to	TO	O
this	DT	O
drug	NN	O
combination	NN	O
.	.	O

Use	NNP	O
of	IN	O
topical	JJ	O
selamectin	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Syphacia	NNP	O
muris	NNP	O
infection	NN	O
in	IN	O
laboratory	NN	O
rats	NNS	O
.	.	O

Efficacy	NN	O
of	IN	O
selamectin	NN	PM
was	VBD	O
studied	VBN	O
in	IN	O
naturally	RB	O
acquired	VBN	O
S.	NNP	O
muris	JJ	O
infections	NNS	O
in	IN	O
rats	NNS	O
.	.	O

Fourty-eight	JJ	O
S.	NNP	O
muris-positive	JJ	O
rats	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
six	CD	O
treated	JJ	O
and	CC	O
two	CD	O
control	NN	O
groups	NNS	O
.	.	O

Selamectin	NNP	PM
(	(	O
6	CD	O
mg/kg	NN	O
)	)	O
was	VBD	O
applied	VBN	O
topically	RB	O
to	TO	O
the	DT	O
skin	NN	O
in	IN	O
a	DT	O
single	JJ	O
spot	NN	O
at	IN	O
the	DT	O
base	NN	O
of	IN	O
the	DT	O
neck	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
rats	NNS	O
of	IN	O
treated	JJ	O
and	CC	O
control	NN	O
groups	NNS	O
were	VBD	O
necropsied	VBN	O
on	IN	O
the	DT	O
24th	CD	O
day	NN	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

Topical	NNP	O
selamectin	NN	PM
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
40.7-63.3	JJ	O
%	NN	O
effective	JJ	O
(	(	O
based	VBN	O
on	IN	O
egg	NN	O
per	IN	O
gram	NN	O
method	NN	O
)	)	O
in	IN	O
eliminating	VBG	O
S.	NNP	O
muris	JJ	O
infection	NN	O
in	IN	O
rats	NNS	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
treatment	NN	O
against	IN	O
S.	NNP	O
muris	NNP	O
(	(	O
based	VBN	O
on	IN	O
adult	NN	O
worm	NN	O
counts	NNS	O
)	)	O
in	IN	O
male	NN	O
and	CC	O
female	JJ	O
rats	NNS	O
was	VBD	O
35.14-58.88	JJ	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
mean	JJ	O
48.39	CD	O
%	NN	O
)	)	O
.	.	O

Effects	NNS	O
of	IN	O
extended	JJ	O
release	NN	O
methylphenidate	NN	PM
treatment	NN	PM
on	IN	O
ratings	NNS	O
of	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
and	CC	O
associated	VBN	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
ADHD	NNP	O
symptoms	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
behavioral	JJ	O
effects	NNS	O
of	IN	O
four	CD	O
doses	NNS	O
of	IN	O
psychostimulant	JJ	O
medication	NN	O
,	,	O
combining	VBG	O
extended-release	JJ	PM
methylphenidate	NN	PM
(	(	PM
MPH	NNP	PM
)	)	PM
in	IN	PM
the	DT	PM
morning	NN	PM
with	IN	O
immediate-release	JJ	PM
MPH	NNP	PM
in	IN	PM
the	DT	PM
afternoon	NN	PM
.	.	O

METHOD	NNP	O
The	DT	O
sample	NN	O
comprised	VBD	O
24	CD	O
children	NNS	O
(	(	O
19	CD	O
boys	NNS	O
;	:	O
5	CD	O
girls	NNS	O
)	)	O
who	WP	O
met	VBD	O
American	NNP	O
Psychiatric	NNP	O
Association	NNP	O
,	,	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
4th	CD	O
ed	NN	O
.	.	O

(	(	O
DSM-IV-TR	NNP	O
)	)	O
criteria	NN	O
for	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
on	IN	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Interview-Revised	JJ	O
(	(	O
ADI-R	NNP	O
)	)	O
and	CC	O
the	DT	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule	NNP	O
(	(	O
ADOS	NNP	O
)	)	O
,	,	O
and	CC	O
had	VBD	O
significant	JJ	O
symptoms	NNS	O
of	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
.	.	O

This	DT	O
sample	NN	O
consisted	VBD	O
of	IN	O
elementary	JJ	O
school-age	NN	O
,	,	O
community-based	JJ	O
children	NNS	O
(	(	O
mean	JJ	O
chronological	JJ	O
age=8.8	NN	O
years	NNS	O
,	,	O
SD=1.7	NNP	O
;	:	O
mean	JJ	O
intelligence	NN	O
quotient	NN	O
[	NNP	O
IQ	NNP	O
]	NNP	O
=85	NNP	O
;	:	O
SD=16.8	NNP	O
)	)	O
.	.	O

Effects	NNS	O
of	IN	O
four	CD	O
dose	NN	O
levels	NNS	O
of	IN	O
MPH	NNP	PM
on	IN	O
parent	NN	O
and	CC	O
teacher	RB	O
behavioral	JJ	O
ratings	NNS	O
were	VBD	O
investigated	VBN	O
using	VBG	O
a	DT	O
within-subject	JJ	O
,	,	O
crossover	NN	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
.	.	O

RESULTS	NNP	O
MPH	NNP	PM
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significant	JJ	O
declines	NNS	O
in	IN	O
hyperactive	JJ	O
and	CC	O
impulsive	JJ	O
behavior	NN	O
at	IN	O
both	DT	O
home	NN	O
and	CC	O
school	NN	O
.	.	O

Parents	NNS	O
noted	VBD	O
significant	JJ	O
declines	NNS	O
in	IN	O
inattentive	JJ	O
and	CC	O
oppositional	JJ	O
behavior	NN	O
,	,	O
and	CC	O
improvements	NNS	O
in	IN	O
social	JJ	O
skills	NNS	O
.	.	O

No	DT	O
exacerbation	NN	O
of	IN	O
stereotypies	NNS	O
was	VBD	O
noted	VBN	O
,	,	O
and	CC	O
side	JJ	O
effects	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
seen	VBN	O
in	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
with	IN	O
ADHD	NNP	O
.	.	O

Dose	NNP	O
response	NN	O
was	VBD	O
primarily	RB	O
linear	JJ	O
in	IN	O
the	DT	O
dose	JJ	O
range	NN	O
studied	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
MPH	NNP	O
formulations	NNS	O
are	VBP	O
efficacious	JJ	O
and	CC	O
well-tolerated	JJ	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
significant	JJ	O
ADHD	NNP	O
symptoms	NNS	O
.	.	O

[	JJ	O
Therapeutic	NNP	O
efficacy	NN	O
of	IN	O
compound	NN	PM
Xuanju	NNP	PM
capsule	NN	O
on	IN	O
type	NN	O
III	NNP	O
prostatitis	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
Compound	NNP	PM
Xuanju	NNP	PM
Capsule	NNP	O
on	IN	O
type	NN	O
III	NNP	O
prostatitis	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
242	CD	O
patients	NNS	O
with	IN	O
type	JJ	O
III	NNP	O
prostatitis	NN	O
diagnosed	VBN	O
by	IN	O
the	DT	O
NIH	NNP	O
criteria	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
an	DT	O
experimental	JJ	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
equal	JJ	O
number	NN	O
,	,	O
the	DT	O
former	JJ	O
treated	VBN	O
with	IN	O
Compound	NNP	PM
Xuanju	NNP	PM
Capsule	NNP	PM
+	NNP	PM
Tamsulosin	NNP	PM
Hydrochloride	NNP	PM
,	,	O
and	CC	O
the	DT	O
latter	NN	O
with	IN	O
Quinolinone	NNP	C
antibiotics	NNS	C
+	VBP	C
Tamsulosin	NNP	C
and	CC	C
Hydrochloride	NNP	C
,	,	O
both	DT	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
therapeutic	JJ	O
effects	NNS	O
based	VBN	O
on	IN	O
the	DT	O
NIH-CPSI	JJ	O
scores	NNS	O
and	CC	O
the	DT	O
improvement	NN	O
of	IN	O
relevant	JJ	O
complications	NNS	O
.	.	O

RESULTS	NNP	O
All	PDT	O
the	DT	O
242	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
treatment	NN	O
.	.	O

The	DT	O
total	JJ	O
effectiveness	NN	O
rate	NN	O
was	VBD	O
77.69	CD	O
%	NN	O
(	(	O
94/121	CD	O
)	)	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
,	,	O
71.56	CD	O
%	NN	O
(	(	O
78/109	CD	O
)	)	O
in	IN	O
those	DT	O
with	IN	O
complications	NNS	O
.	.	O

In	IN	O
comparison	NN	O
,	,	O
it	PRP	O
was	VBD	O
only	RB	O
47.10	CD	O
%	NN	O
(	(	O
57/121	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
31.78	CD	O
%	NN	O
(	(	O
34/107	CD	O
)	)	O
in	IN	O
those	DT	O
with	IN	O
complications	NNS	O
.	.	O

Both	DT	O
the	DT	O
NIH-CPSI	NNP	O
scores	NNS	O
and	CC	O
the	DT	O
improvement	NN	O
of	IN	O
complications	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
experimental	JJ	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Compound	NNP	PM
Xuanju	NNP	PM
Capsule	NNP	O
has	VBZ	O
a	DT	O
good	JJ	O
therapeutic	JJ	O
effect	NN	O
on	IN	O
type	NN	O
III	NNP	O
prostatitis	NN	O
.	.	O

Randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
evaluating	VBG	O
the	DT	O
treatment	NN	O
of	IN	O
plantar	NN	O
fasciitis	NN	O
with	IN	O
an	DT	O
extracoporeal	NN	PH
shockwave	NN	PH
therapy	NN	PH
(	(	O
ESWT	NNP	O
)	)	O
device	NN	O
:	:	O
a	DT	O
North	JJ	O
American	JJ	O
confirmatory	NN	O
study	NN	O
.	.	O

Despite	IN	O
numerous	JJ	O
publications	NNS	O
and	CC	O
clinical	JJ	O
trials	NNS	O
,	,	O
the	DT	O
results	NNS	O
of	IN	O
treatment	NN	O
of	IN	O
recalcitrant	JJ	O
chronic	JJ	O
plantar	NN	O
fasciitis	NN	O
with	IN	O
extracorporeal	JJ	PH
shockwave	JJ	PH
therapy	NN	PH
(	(	PH
ESWT	NNP	PH
)	)	PH
still	RB	O
remain	VBP	O
equivocal	JJ	O
as	IN	O
to	TO	O
whether	IN	O
or	CC	O
not	RB	O
this	DT	O
treatment	NN	O
provides	VBZ	O
relief	NN	O
from	IN	O
the	DT	O
pain	NN	O
associated	VBN	O
with	IN	O
this	DT	O
condition	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
extracorporeal	NN	O
shock	NN	O
wave	VBP	O
therapy	NN	O
can	MD	O
safely	RB	O
and	CC	O
effectively	RB	O
relieve	VB	O
the	DT	O
pain	NN	O
associated	VBN	O
with	IN	O
chronic	JJ	O
plantar	NN	O
fasciitis	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
treatment	NN	O
,	,	O
as	IN	O
demonstrated	VBN	O
by	IN	O
pain	NN	O
with	IN	O
walking	NN	O
in	IN	O
the	DT	O
morning	NN	O
.	.	O

This	DT	O
was	VBD	O
set	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
confirmatory	JJ	O
clinical	JJ	O
study	NN	O
undertaken	VBN	O
in	IN	O
four	CD	O
outpatient	NN	O
orthopedic	NN	O
clinics	NNS	O
.	.	O

The	DT	O
patients	NNS	O
,	,	O
114	CD	O
adult	NN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
plantar	NN	O
fasciitis	NN	O
,	,	O
recalcitrant	JJ	O
to	TO	O
conservative	JJ	O
therapies	NNS	O
for	IN	O
at	IN	O
least	JJS	O
6	CD	O
months	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
.	.	O

Treatment	NNP	O
consisted	VBD	O
of	IN	O
approximately	RB	O
3,800	CD	PH
total	JJ	PH
shock	NN	PH
waves	NNS	PH
(	(	O
+/-10	JJ	O
)	)	O
reaching	VBG	O
an	DT	O
approximated	JJ	O
total	NN	O
energy	NN	O
delivery	NN	O
of	IN	O
1,300	CD	O
mJ/mm	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
ED+	NNP	O
)	)	O
in	IN	O
a	DT	O
single	JJ	O
session	NN	O
versus	IN	O
placebo	NN	C
treatment	NN	C
.	.	O

This	DT	O
study	NN	O
demonstrated	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
3	CD	O
months	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
outcome	NN	O
of	IN	O
pain	NN	O
during	IN	O
the	DT	O
first	JJ	O
few	JJ	O
minutes	NNS	O
of	IN	O
walking	VBG	O
measured	VBN	O
by	IN	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
participants	NNS	O
whose	WP$	O
changes	NNS	O
in	IN	O
Visual	NNP	O
Analog	NNP	O
Scale	NNP	O
scores	VBZ	O
met	VBD	O
the	DT	O
study	NN	O
definition	NN	O
of	IN	O
success	NN	O
at	IN	O
both	DT	O
6	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
posttreatment	NN	O
;	:	O
and	CC	O
between	IN	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
3	CD	O
months	NNS	O
posttreatment	NN	O
in	IN	O
the	DT	O
Roles	NNP	O
and	CC	O
Maudsley	NNP	O
Score	NNP	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
confirm	VBP	O
that	IN	O
ESWT	NNP	PM
administered	VBD	O
with	IN	O
the	DT	O
Dornier	NNP	O
Epos	NNP	O
Ultra	NNP	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
treatment	NN	O
for	IN	O
recalcitrant	JJ	O
plantar	NN	O
fasciitis	NN	O
.	.	O

Serum	NNP	O
bactericidal	NN	O
activities	NNS	O
and	CC	O
comparative	JJ	O
pharmacokinetics	NNS	O
of	IN	O
meropenem	NN	O
and	CC	O
imipenem-cilastatin	NN	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
and	CC	O
serum	NN	O
bactericidal	NN	O
activities	NNS	O
(	(	O
SBAs	NNP	O
)	)	O
of	IN	O
imipenem	NN	PM
and	CC	O
meropenem	NN	PM
were	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
.	.	O

Twelve	NNP	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
received	VBD	O
a	DT	O
constant	JJ	O
30-min	JJ	O
infusion	NN	O
of	IN	O
either	CC	O
1	CD	O
g	NN	O
of	IN	O
imipenem	JJ	PM
plus	CC	PM
1	CD	PM
g	NN	PM
of	IN	PM
cilastatin	NN	PM
or	CC	O
1	CD	PM
g	NN	PM
of	IN	PM
meropenem	NN	PM
.	.	O

The	DT	O
concentrations	NNS	O
of	IN	O
the	DT	O
drugs	NNS	O
in	IN	O
serum	NN	O
and	CC	O
urine	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
bioassay	NN	PH
and	CC	O
high-pressure	NN	PH
liquid	NN	PH
chromatography	NN	PH
.	.	O

Pharmacokinetic	JJ	O
parameters	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
an	DT	O
open	JJ	O
two-compartment	JJ	PH
model	NN	PH
and	CC	O
a	DT	O
noncompartmental	JJ	PH
technique	NN	PH
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
infusion	NN	O
,	,	O
the	DT	O
mean	JJ	O
concentrations	NNS	O
of	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
measured	VBN	O
in	IN	O
serum	NN	O
were	VBD	O
61.2	CD	O
+/-	JJ	O
9.8	CD	O
and	CC	O
51.6	CD	O
+/-	JJ	O
6.5	CD	O
mg/liter	NN	O
,	,	O
respectively	RB	O
;	:	O
urinary	JJ	O
recoveries	NNS	O
were	VBD	O
48.6	CD	O
%	NN	O
+/-	JJ	O
8.2	CD	O
%	NN	O
and	CC	O
60.0	CD	O
%	NN	O
+/-	JJ	O
6.5	CD	O
%	NN	O
of	IN	O
the	DT	O
dose	NN	O
in	IN	O
12	CD	O
h	NN	O
,	,	O
respectively	RB	O
;	:	O
and	CC	O
the	DT	O
areas	NNS	O
under	IN	O
the	DT	O
concentration-time	JJ	O
curve	NN	O
from	IN	O
time	NN	O
zero	CD	O
to	TO	O
infinity	NN	O
were	VBD	O
96.1	CD	O
+/-	JJ	O
14.4	CD	O
and	CC	O
70.5	CD	O
+/-	JJ	O
10.3	CD	O
mg.h/liter	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
or	CC	O
=	VB	O
0.02	CD	O
)	)	O
.	.	O

Imipenem	NNP	O
had	VBD	O
a	DT	O
mean	JJ	O
half-life	NN	O
of	IN	O
66.7	CD	O
+/-	JJ	O
10.4	CD	O
min	NN	O
;	:	O
that	IN	O
of	IN	O
meropenem	NN	O
was	VBD	O
64.4	CD	O
+/-	JJ	O
6.9	CD	O
min	NN	O
.	.	O

The	DT	O
volumes	NNS	O
of	IN	O
distribution	NN	O
at	IN	O
steady	JJ	O
state	NN	O
of	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
were	VBD	O
15.3	CD	O
+/-	JJ	O
3.3	CD	O
and	CC	O
18.6	CD	O
+/-	JJ	O
3.0	CD	O
liters/70	NN	O
kg	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
renal	JJ	O
clearances	NNS	O
per	IN	O
1.73	CD	O
m2	NNS	O
were	VBD	O
85.6	CD	O
+/-	JJ	O
17.6	CD	O
and	CC	O
144.6	CD	O
+/-	JJ	O
26.0	CD	O
ml/min	NN	O
,	,	O
respectively	RB	O
.	.	O

Both	DT	O
antibiotics	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
in	IN	O
this	DT	O
single-dose	JJ	O
administration	NN	O
study	NN	O
.	.	O

The	DT	O
SBAs	NNP	O
were	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
microdilution	NN	O
method	NN	O
of	IN	O
Reller	NNP	O
and	CC	O
Stratton	NNP	O
(	(	O
L.	NNP	O
B.	NNP	O
Reller	NNP	O
and	CC	O
C.	NNP	O
W.	NNP	O
Stratton	NNP	O
,	,	O
J.	NNP	O
Infect	NNP	O
.	.	O

Dis	NNP	O
.	.	O

136:196-204	CD	O
,	,	O
1977	CD	O
)	)	O
against	IN	O
40	CD	O
clinically	RB	O
isolated	JJ	O
strains	NNS	O
.	.	O

Mean	NNP	O
reciprocal	JJ	O
bactericidal	NN	O
titers	NNS	O
were	VBD	O
measured	VBN	O
1	CD	O
and	CC	O
6	CD	O
h	NN	O
after	IN	O
administration	NN	O
.	.	O

After	IN	O
1	CD	O
and	CC	O
6	CD	O
h	NN	O
the	DT	O
median	JJ	O
SBAs	NNP	O
for	IN	O
imipenem	NN	O
and	CC	O
meropenem	NN	O
,	,	O
were	VBD	O
409	CD	O
and	CC	O
34.9	CD	O
and	CC	O
97.9	CD	O
and	CC	O
5.8	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Staphylococcus	NNP	O
aureus	NN	O
,	,	O
19.9	CD	O
and	CC	O
4.4	CD	O
and	CC	O
19.4	CD	O
and	CC	O
4.8	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Pseudomonas	NNP	O
aeruginosa	NN	O
,	,	O
34.3	CD	O
and	CC	O
2.2	CD	O
and	CC	O
232	CD	O
and	CC	O
15.5	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Enterobacter	NNP	O
cloacae	NN	O
,	,	O
and	CC	O
13.4	CD	O
and	CC	O
2.25	CD	O
and	CC	O
90.7	CD	O
and	CC	O
7.9	CD	O
,	,	O
respectively	RB	O
,	,	O
against	IN	O
Proteus	NNP	O
mirabilis	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
had	VBD	O
rather	RB	O
short	JJ	O
biological	JJ	O
elimination	NN	O
half-lives	NNS	O
and	CC	O
a	DT	O
predominantly	RB	O
renal	JJ	O
route	NN	O
of	IN	O
elimination	NN	O
.	.	O

Both	DT	O
carbapenems	NNS	O
revealed	VBD	O
high	JJ	O
SBAs	NNP	O
against	IN	O
clinically	RB	O
important	JJ	O
pathogens	NNS	O
at	IN	O
1	CD	O
h	NN	O
;	:	O
meropenem	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
SBA	NNP	O
against	IN	O
E.	NNP	O
cloacae	NN	O
and	CC	O
P.	NNP	O
mirabilis	NN	O
,	,	O
and	CC	O
the	DT	O
SBA	NNP	O
of	IN	O
imipenem	NN	O
against	IN	O
S.	NNP	O
aureus	NN	O
was	VBD	O
greater	JJR	O
than	IN	O
the	DT	O
SBA	NNP	O
of	IN	O
meropenem	NN	O
.	.	O

Study	NNP	O
protocol	NN	O
:	:	O
Phase	NNP	O
III	NNP	O
single-blinded	JJ	O
fast-track	JJ	O
pragmatic	NN	O
randomised	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
a	DT	O
complex	JJ	O
intervention	NN	O
for	IN	O
breathlessness	NN	O
in	IN	O
advanced	JJ	O
disease	NN	O
.	.	O

BACKGROUND	NNP	O
Breathlessness	NNP	O
in	IN	O
advanced	JJ	O
disease	NN	O
causes	VBZ	O
significant	JJ	O
distress	NN	O
to	TO	O
patients	NNS	O
and	CC	O
carers	NNS	O
and	CC	O
presents	NNS	O
management	NN	O
challenges	VBZ	O
to	TO	O
health	NN	O
care	NN	O
professionals	NNS	O
.	.	O

The	DT	O
Breathlessness	NNP	Ot
Intervention	NNP	Ot
Service	NNP	Ot
(	(	Ot
BIS	NNP	Ot
)	)	Ot
seeks	VBZ	O
to	TO	O
improve	VB	O
the	DT	O
care	NN	O
of	IN	O
breathless	NN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
disease	NN	O
(	(	O
regardless	NN	O
of	IN	O
cause	NN	O
)	)	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
evidence-based	JJ	O
practice	NN	O
and	CC	O
working	VBG	O
with	IN	O
other	JJ	O
healthcare	NN	O
providers	NNS	O
.	.	O

BIS	NNP	E
delivers	VBZ	O
a	DT	O
complex	JJ	Ot
intervention	NN	Ot
(	(	O
of	IN	O
non-pharmacological	JJ	Ot
and	CC	O
pharmacological	JJ	PM
treatments	NNS	PM
)	)	O
via	IN	O
a	DT	O
multi-professional	JJ	O
team	NN	O
.	.	O

BIS	NNP	E
is	VBZ	O
being	VBG	O
continuously	RB	O
developed	VBN	O
and	CC	O
its	PRP$	O
impact	NN	O
evaluated	VBN	O
using	VBG	O
the	DT	O
MRC	NNP	O
's	POS	O
framework	NN	O
for	IN	O
complex	JJ	O
interventions	NNS	O
(	(	O
PreClinical	NNP	O
,	,	O
Phase	NNP	O
I	PRP	O
and	CC	O
Phase	NNP	O
II	NNP	O
completed	VBD	O
)	)	O
.	.	O

This	DT	O
paper	NN	O
presents	VBZ	O
the	DT	O
protocol	NN	O
for	IN	O
Phase	NNP	O
III	NNP	O
.	.	O

METHODS/DESIGN	NNP	O
Phase	NNP	O
III	NNP	O
comprises	VBZ	O
a	DT	O
pragmatic	JJ	O
,	,	O
fast-track	JJ	O
,	,	O
single-blind	JJ	O
randomised	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
BIS	NNP	E
versus	FW	O
standard	NN	C
care	NN	C
.	.	O

Due	NNP	O
to	TO	O
differing	VBG	O
disease	NN	O
trajectories	NNS	O
,	,	O
the	DT	O
service	NN	O
uses	VBZ	O
two	CD	PH
broad	JJ	PH
service	NN	PH
models	NNS	PH
:	:	O
one	CD	O
for	IN	O
patients	NNS	O
with	IN	O
malignant	JJ	O
disease	NN	O
(	(	O
intervention	NN	O
delivered	VBN	O
over	IN	O
two	CD	O
weeks	NNS	O
)	)	O
and	CC	O
one	CD	O
for	IN	O
patients	NNS	O
with	IN	O
non-malignant	JJ	O
disease	NN	O
(	(	O
intervention	NN	O
delivered	VBN	O
over	IN	O
four	CD	O
weeks	NNS	O
)	)	O
.	.	O

The	DT	O
Phase	NNP	O
III	NNP	O
trial	NN	O
therefore	NN	O
consists	VBZ	O
of	IN	O
two	CD	O
sub-protocols	NNS	O
:	:	O
one	CD	O
for	IN	O
patients	NNS	O
with	IN	O
malignant	JJ	O
conditions	NNS	O
(	(	O
four	CD	O
week	NN	O
protocol	NN	O
)	)	O
and	CC	O
one	CD	O
for	IN	O
patients	NNS	O
with	IN	O
non-malignant	JJ	O
conditions	NNS	O
(	(	O
eight	CD	O
week	NN	O
protocol	NN	O
)	)	O
.	.	O

Mixed	JJ	E
method	NN	E
interviews	NNS	E
are	VBP	O
conducted	VBN	O
with	IN	O
patients	NNS	O
and	CC	O
their	PRP$	O
lay	NN	O
carers	NNS	O
at	IN	O
three	CD	O
to	TO	O
five	CD	O
measurement	NN	O
points	NNS	O
depending	VBG	O
on	IN	O
randomisation	NN	O
and	CC	O
sub-protocol	NN	O
.	.	O

Qualitative	JJ	O
interviews	NNS	O
are	VBP	O
conducted	VBN	O
with	IN	O
referring	VBG	O
and	CC	O
non-referring	JJ	O
health	NN	O
care	NN	O
professionals	NNS	O
(	(	O
malignant	JJ	O
disease	NN	O
protocol	NN	O
only	RB	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
is	VBZ	O
'patient	JJ	O
distress	NN	O
due	JJ	O
to	TO	O
breathlessness	VB	O
'	''	O
measured	VBN	O
on	IN	O
a	DT	O
numerical	JJ	O
rating	NN	O
scale	NN	O
(	(	O
0-10	JJ	O
)	)	O
.	.	O

The	DT	O
trial	NN	O
includes	VBZ	O
economic	JJ	O
evaluation	NN	O
.	.	O

Analysis	NN	O
will	MD	O
be	VB	O
on	IN	O
an	DT	O
intention	NN	O
to	TO	O
treat	VB	O
basis	NN	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
breathlessness	NN	O
intervention	NN	O
for	IN	O
advanced	JJ	O
disease	NN	O
to	TO	O
have	VB	O
followed	VBN	O
the	DT	O
MRC	NNP	O
framework	NN	O
and	CC	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
palliative	JJ	O
care	NN	O
trials	NNS	O
to	TO	O
use	VB	O
fast	JJ	O
track	NN	O
methodology	NN	O
and	CC	O
single-blinding	NN	O
.	.	O

The	DT	O
results	NNS	O
will	MD	O
provide	VB	O
evidence	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
the	DT	O
service	NN	O
,	,	O
informing	VBG	O
its	PRP$	O
longer	JJR	O
term	NN	O
development	NN	O
and	CC	O
implementation	NN	O
of	IN	O
the	DT	O
model	NN	O
in	IN	O
other	JJ	O
centres	NNS	O
nationally	RB	O
and	CC	O
internationally	RB	O
.	.	O

It	PRP	O
adds	VBZ	O
to	TO	O
methodological	JJ	O
developments	NNS	O
in	IN	O
palliative	JJ	PH
care	NN	PH
research	NN	O
where	WRB	O
complex	JJ	O
interventions	NNS	O
are	VBP	O
common	JJ	O
but	CC	O
evidence	NN	O
sparse	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
:	:	O
NCT00678405ISRCTN	NN	O
:	:	O
ISRCTN04119516	NNP	O
.	.	O

Additive	JJ	O
IOP-reducing	JJ	O
effect	NN	O
of	IN	O
latanoprost	NN	O
in	IN	O
patients	NNS	O
insufficiently	RB	O
controlled	VBN	O
on	IN	O
timolol	NN	PM
.	.	PM

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
on	IN	O
intraocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
of	IN	O
switching	VBG	O
from	IN	O
timolol	NN	PM
to	TO	PM
latanoprost	VB	PM
or	CC	PM
adding	VBG	PM
latanoprost	NN	PM
to	TO	PM
timolol	VB	PM
in	IN	O
patients	NNS	O
with	IN	O
open	JJ	O
angle	NN	O
glaucoma	NN	O
or	CC	O
ocular	JJ	O
hypertension	NN	O
where	WRB	O
IOP	NNP	O
is	VBZ	O
not	RB	O
adequately	RB	O
controlled	VBN	O
with	IN	O
timolol	NN	PM
.	.	PM

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
6-week	JJ	O
,	,	O
double-masked	JJ	O
,	,	O
randomised	VBD	O
multi-centre	NN	O
study	NN	O
.	.	O

53	CD	O
patients	NNS	O
with	IN	O
primary	JJ	O
open	JJ	O
angle	NN	O
glaucoma	NN	O
,	,	O
capsular	JJ	O
glaucoma	NN	O
,	,	O
or	CC	O
ocular	JJ	O
hypertension	NN	O
with	IN	O
an	DT	O
IOP	NNP	O
of	IN	O
at	IN	O
least	JJS	O
21	CD	O
mmHg	NN	O
on	IN	O
current	JJ	O
therapy	NN	O
were	VBD	O
recruited	VBN	O
.	.	O

After	IN	O
a	DT	O
run-in	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
2	CD	O
weeks	NNS	O
on	IN	O
timolol	NN	PM
,	,	O
5	CD	O
mg/ml	NN	O
twice	RB	O
daily	RB	O
,	,	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
continued	VBD	O
on	IN	O
timolol	NN	PM
,	,	O
one	CD	O
switched	VBN	O
from	IN	O
timolol	NN	PM
to	TO	PM
latanoprost	VB	PM
,	,	O
50	CD	O
microg/ml	NN	O
once	RB	O
daily	JJ	O
,	,	O
and	CC	O
a	DT	O
third	JJ	O
group	NN	O
received	VBD	O
latanoprost	RB	PM
in	IN	PM
addition	NN	PM
to	TO	PM
timolol	VB	PM
.	.	PM

The	DT	O
efficacy	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
comparing	VBG	O
IOP	NNP	O
at	IN	O
9	CD	O
AM	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
IOP	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SEM	NNP	O
)	)	O
were	VBD	O
24.2	CD	O
+/-	JJ	O
0.9	CD	O
and	CC	O
23.8	CD	O
+/-	JJ	O
1.0	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
for	IN	O
patients	NNS	O
continuing	VBG	O
on	IN	O
timolol	NN	O
,	,	O
26.3	CD	O
+/-	JJ	O
1.2	CD	O
and	CC	O
19.6	CD	O
+/-	JJ	O
1.1	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
for	IN	O
patients	NNS	O
switching	VBG	O
to	TO	O
latanoprost	VB	O
,	,	O
and	CC	O
23.2	CD	O
+/-	JJ	O
1.0	CD	O
and	CC	O
17.5	CD	O
+/-	JJ	O
0.8	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
for	IN	O
patients	NNS	O
with	IN	O
combined	JJ	O
treatment	NN	O
.	.	O

Adding	VBG	O
latanoprost	NN	O
to	TO	O
timolol	VB	O
reduced	VBN	O
IOP	NNP	O
with	IN	O
5.9	CD	O
+/-	JJ	O
0.9	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
reduced	VBN	O
IOP	NNP	O
with	IN	O
5.0	CD	O
+/-	JJ	O
0.9	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
which	WDT	O
caused	VBD	O
in	IN	O
each	DT	O
group	NN	O
a	DT	O
significant	JJ	O
IOP	NNP	O
reduction	NN	O
of	IN	O
about	RB	O
25	CD	O
%	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
effect	NN	O
of	IN	O
latanoprost	NN	O
was	VBD	O
additive	JJ	O
to	TO	O
that	DT	O
of	IN	O
timolol	NN	O
,	,	O
and	CC	O
a	DT	O
good	JJ	O
effect	NN	O
on	IN	O
IOP	NNP	O
reduction	NN	O
was	VBD	O
also	RB	O
achieved	VBN	O
by	IN	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
,	,	O
suggesting	VBG	O
that	IN	O
a	DT	O
switch	NN	O
in	IN	O
many	JJ	O
patients	NNS	O
is	VBZ	O
an	DT	O
effective	JJ	O
alternative	NN	O
to	TO	O
combination	NN	O
treatment	NN	O
.	.	O

[	NN	O
Study	NNP	O
on	IN	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
oral	JJ	PM
poliomyelitis	NN	PM
attenuated	VBD	PM
live	JJ	PM
vaccine	NN	PM
(	(	O
human	JJ	O
diploid	NN	O
cell	NN	O
)	)	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
Immunogenicity	NNP	O
of	IN	O
the	DT	O
Poliomyelitis	NNP	PM
vaccine	NN	PM
(	(	O
Human	NNP	O
Diploid	NNP	O
Cell	NNP	O
)	)	O
in	IN	O
>	NN	O
or	CC	O
=2	VB	O
month-old	JJ	O
children	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
random	NN	O
,	,	O
blind	NN	O
and	CC	O
control	NN	O
trial	NN	O
,	,	O
1200	CD	O
healthy	JJ	O
children	NNS	O
of	IN	O
2-5	JJ	O
months	NNS	O
old	JJ	O
in	IN	O
Jiangsu	NNP	O
province	NN	O
were	VBD	O
administered	VBN	O
OPV	NNP	PM
(	(	PM
HDC	NNP	PM
)	)	PM
vaccine	NN	PM
and	CC	O
control	NN	PM
vaccines	NNS	PM
.	.	O

The	DT	O
antibody	NN	O
was	VBD	O
tested	VBN	O
by	IN	O
neutralization	NN	O
test	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
3	CD	O
doses	NNS	O
of	IN	O
the	DT	O
OPV	NNP	PM
(	(	PM
HDC	NNP	PM
)	)	PM
vaccine	NN	PM
,	,	O
the	DT	O
systemic	JJ	O
reactions	NNS	O
were	VBD	O
mild	JJ	O
.	.	O

After	IN	O
1	CD	O
month	NN	O
of	IN	O
vaccination	NN	O
with	IN	O
3	CD	O
doses	NNS	O
of	IN	O
the	DT	O
OPV	NNP	PM
(	(	PM
HDC	NNP	PM
)	)	PM
vaccine	NN	PM
,	,	O
the	DT	O
immune	JJ	O
success	NN	O
rates	NNS	O
of	IN	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
III	NNP	O
type	NN	O
were	VBD	O
98.28	CD	O
%	NN	O
,	,	O
99.45	CD	O
%	NN	O
,	,	O
and	CC	O
95.71	CD	O
%	NN	O
respectively	RB	O
,	,	O
the	DT	O
GMTs	NNP	O
of	IN	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
III	NNP	O
type	NN	O
in	IN	O
susceptible	JJ	O
children	NNS	O
were	VBD	O
1:1243.72	CD	O
,	,	O
1:234.38	CD	O
and	CC	O
1:273.10	CD	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
OPV	NNP	PM
(	(	PM
HDC	NNP	PM
)	)	PM
vaccine	NN	PM
was	VBD	O
safe	JJ	O
and	CC	O
immunogenicity	NN	O
for	IN	O
the	DT	O
children	NNS	O
>	VBP	O
or	CC	O
=2	JJ	O
months	NNS	O
old	JJ	O
.	.	O

Lack	NN	O
of	IN	O
effect	NN	O
of	IN	O
warfarin	NN	PM
on	IN	O
the	DT	O
restenosis	NN	O
rate	NN	O
or	CC	O
on	IN	O
clinical	JJ	O
outcome	NN	O
after	IN	O
balloon	NN	O
coronary	JJ	O
angioplasty	NN	O
.	.	O

Between	NNP	O
September	NNP	O
1985	CD	O
and	CC	O
April	NNP	O
1987	CD	O
,	,	O
110	CD	O
consecutive	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
successful	JJ	O
coronary	JJ	O
angioplasty	NN	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
randomised	JJ	O
prospective	NN	O
controlled	VBN	O
evaluation	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
warfarin	NN	PM
on	IN	O
restenosis	NN	O
.	.	O

The	DT	O
warfarin	NN	PM
(	(	O
n	JJ	O
=	NNP	O
56	CD	O
)	)	O
and	CC	O
the	DT	O
control	NN	C
(	(	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
groups	NNS	O
were	VBD	O
not	RB	O
different	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
previous	JJ	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
or	CC	O
coronary	JJ	O
balloon	NN	O
angioplasty	NN	O
,	,	O
severity	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
and	CC	O
frequency	NN	O
of	IN	O
multivessel	JJ	O
disease	NN	O
or	CC	O
of	IN	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
.	.	O

Warfarin	NNP	PM
was	VBD	O
started	VBN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
the	DT	O
procedure	NN	O
and	CC	O
the	DT	O
dosage	NN	O
was	VBD	O
adjusted	VBN	O
to	TO	O
maintain	VB	O
the	DT	O
thromboplastin	JJ	O
international	JJ	O
normalised	VBN	O
ratio	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
2.5	CD	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
five	CD	O
(	(	O
96	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
verapamil	NNS	PM
and	CC	O
other	JJ	PM
antianginal	JJ	PM
drugs	NNS	PM
were	VBD	O
prescribed	VBN	O
as	IN	O
needed	VBN	O
.	.	O

Low	JJ	PM
molecular	JJ	PM
weight	NN	PM
dextran	NN	PM
and	CC	PM
heparin	NN	PM
were	VBD	O
given	VBN	O
during	IN	O
the	DT	O
procedure	NN	O
and	CC	O
heparin	NN	PM
was	VBD	O
continued	VBN	O
for	IN	O
24	CD	O
hours	NNS	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eight	CD	O
(	(	O
98	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
clinically	RB	O
after	IN	O
a	DT	O
median	NN	O
of	IN	O
five	CD	O
months	NNS	O
(	(	O
range	VB	O
1-20	CD	O
)	)	O
.	.	O

Eighty	NNP	O
five	CD	O
(	(	O
77	CD	O
%	NN	O
)	)	O
had	VBD	O
follow	VBN	O
up	RP	O
angiography	NN	O
at	IN	O
five	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
warfarin	NN	PM
group	NN	O
symptoms	NNS	O
improved	VBN	O
in	IN	O
46	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
patients	NNS	O
by	IN	O
at	IN	O
least	JJS	O
1	CD	O
angina	JJ	O
class	NN	O
and	CC	O
31	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
were	VBD	O
symptom	JJ	O
free	JJ	O
;	:	O
the	DT	O
exercise	NN	O
test	NN	O
remained	VBD	O
positive	JJ	O
in	IN	O
20	CD	O
(	(	O
36	CD	O
%	NN	O
)	)	O
patients	NNS	O
and	CC	O
the	DT	O
angiographic	JJ	O
restenosis	NN	O
rate	NN	O
was	VBD	O
25	CD	O
%	NN	O
per	IN	O
lesion	NN	O
and	CC	O
29	CD	O
%	NN	O
per	IN	O
patient	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
major	JJ	O
bleeding	NN	O
complications	NNS	O
.	.	O

In	IN	O
the	DT	O
control	NN	O
group	NN	O
46	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
patients	NNS	O
were	VBD	O
improved	VBN	O
by	IN	O
at	IN	O
least	JJS	O
1	CD	O
angina	JJ	O
class	NN	O
and	CC	O
31	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
were	VBD	O
symptom	JJ	O
free	JJ	O
;	:	O
the	DT	O
exercise	NN	O
test	NN	O
was	VBD	O
positive	JJ	O
in	IN	O
11	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
patients	NNS	O
and	CC	O
the	DT	O
angiographic	JJ	O
restenosis	NN	O
rate	NN	O
was	VBD	O
33	CD	O
%	NN	O
per	IN	O
lesion	NN	O
and	CC	O
37	CD	O
%	NN	O
per	IN	O
patient	NN	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
angiographic	JJ	O
restenosis	NN	O
tended	VBD	O
to	TO	O
be	VB	O
lower	JJR	O
with	IN	O
warfarin	NN	PM
,	,	O
none	NN	O
of	IN	O
these	DT	O
differences	NNS	O
was	VBD	O
significant	JJ	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
combination	NN	O
of	IN	O
verapamil	NN	PM
and	CC	O
warfarin	NN	PM
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
aspirin	NN	PM
,	,	O
is	VBZ	O
not	RB	O
significantly	RB	O
better	JJR	O
than	IN	O
verapamil	NN	O
alone	RB	O
in	IN	O
preventing	VBG	O
symptom	JJ	O
recurrence	NN	O
or	CC	O
angiographic	JJ	O
restenosis	NN	O
after	IN	O
coronary	JJ	O
angioplasty	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
a	DT	O
new	JJ	E
computer	NN	E
intervention	NN	E
to	TO	O
teach	VB	O
people	NNS	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
to	TO	O
recognize	VB	O
and	CC	O
predict	VB	O
emotions	NNS	O
in	IN	O
others	NNS	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
looked	VBD	O
at	IN	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
new	JJ	E
computer	NN	E
program	NN	E
designed	VBN	O
to	TO	O
teach	VB	O
people	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
to	TO	O
better	JJR	O
recognize	VB	O
and	CC	O
predict	VBP	O
emotional	JJ	O
responses	NNS	O
in	IN	O
others	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
11	CD	O
children	NNS	O
(	(	O
age	NN	O
12-18	CD	O
)	)	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
at	IN	O
two	CD	O
special	JJ	O
schools	NNS	O
participated	VBD	O
:	:	O
one	CD	E
group	NN	E
used	VBD	E
the	DT	E
computer	NN	E
program	NN	E
for	IN	E
10	CD	E
half-hour	JJ	E
sessions	NNS	E
over	IN	E
2	CD	E
weeks	NNS	E
.	.	O

Within-program	NNP	O
data	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
errors	NNS	O
made	VBN	O
from	IN	O
first	JJ	O
to	TO	O
last	JJ	O
use	NN	O
.	.	O

Students	NNS	O
were	VBD	O
assessed	VBN	O
pre-	JJ	O
and	CC	O
post-intervention	NN	O
using	VBG	O
facial	JJ	O
expression	NN	O
photographs	NN	O
,	,	O
cartoons	NNS	O
depicting	VBG	O
emotion-laden	JJ	O
situations	NNS	O
,	,	O
and	CC	O
non-literal	JJ	O
stories	NNS	O
.	.	O

Scores	NNS	O
were	VBD	O
not	RB	O
related	VBN	O
to	TO	O
age	NN	O
or	CC	O
verbal	JJ	O
ability	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
made	VBD	O
gains	NNS	O
relative	JJ	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
on	IN	O
all	DT	O
three	CD	O
measures	NNS	O
.	.	O

Gains	NNP	O
correlated	VBD	O
significantly	RB	O
with	IN	O
the	DT	O
number	NN	O
of	IN	O
times	NNS	O
the	DT	O
computer	NN	E
program	NN	E
was	VBD	O
used	VBN	O
and	CC	O
results	NNS	O
suggest	VBP	O
positive	JJ	O
effects	NNS	O
.	.	O

Further	NNP	O
research	NN	O
could	MD	O
assess	VB	O
whether	IN	O
these	DT	O
gains	NNS	O
generalized	VBD	O
into	IN	O
real	JJ	O
life	NN	O
or	CC	O
improved	VBN	O
performance	NN	O
on	IN	O
theory	NN	O
of	IN	O
mind	NN	O
measures	NNS	O
.	.	O

Perceptual	JJ	O
wind-up	NN	O
in	IN	O
the	DT	O
human	JJ	O
oesophagus	NN	O
is	VBZ	O
enhanced	VBN	O
by	IN	O
central	JJ	O
sensitisation	NN	O
.	.	O

BACKGROUND	NNP	O
Oesophageal	NNP	O
acid	JJ	O
infusion	NN	O
induces	NNS	O
enhanced	VBD	O
pain	NN	O
hypersensitivity	NN	O
in	IN	O
non-acid	JJ	O
exposed	JJ	O
upper	JJ	O
oesophagus	NN	O
(	(	O
secondary	JJ	O
hyperalgesia	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
non-cardiac	JJ	O
chest	NN	O
pain	NN	O
,	,	O
thus	RB	O
suggesting	VBG	O
central	JJ	O
sensitisation	NN	O
contributes	NNS	O
to	TO	O
visceral	JJ	O
pain	NN	O
hypersensitivity	NN	O
in	IN	O
functional	JJ	O
gut	NN	O
disorders	NNS	O
(	(	O
FGD	NNP	O
)	)	O
.	.	O

Perceptual	JJ	O
wind-up	JJ	O
(	(	O
increased	JJ	O
pain	NN	O
perception	NN	O
to	TO	O
constant	JJ	O
intensity	NN	O
sensory	NN	O
stimuli	NN	O
at	IN	O
frequencies	NNS	O
>	VBP	O
or=0.3	JJ	O
Hz	NNP	O
)	)	O
is	VBZ	O
used	VBN	O
as	IN	O
a	DT	O
proxy	NN	O
for	IN	O
central	JJ	O
sensitisation	NN	O
to	TO	O
investigate	VB	O
pain	NN	O
syndromes	NNS	O
where	WRB	O
pain	NN	O
hypersensitivity	NN	O
is	VBZ	O
important	JJ	O
(	(	O
for	IN	O
example	NN	O
,	,	O
fibromyalgia	NN	O
)	)	O
.	.	O

AIMS	$	O
Wind-up	JJ	O
in	IN	O
central	JJ	O
sensitisation	NN	O
induced	VBD	O
human	JJ	O
visceral	JJ	O
pain	NN	O
hypersensitivity	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
explored	VBN	O
.	.	O

We	PRP	O
hypothesised	VBD	O
that	IN	O
if	IN	O
wind-up	NN	O
is	VBZ	O
a	DT	O
proxy	NN	O
for	IN	O
central	JJ	O
sensitisation	NN	O
induced	VBD	O
human	JJ	O
visceral	JJ	O
pain	NN	O
hypersensitivity	NN	O
,	,	O
then	RB	O
oesophageal	JJ	O
wind-up	NN	O
should	MD	O
be	VB	O
enhanced	VBN	O
by	IN	O
secondary	JJ	O
hyperalgesia	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
eight	CD	O
healthy	JJ	O
volunteers	NNS	O
(	(	O
seven	CD	O
males	NNS	O
;	:	O
mean	JJ	O
age	NN	O
32	CD	O
years	NNS	O
)	)	O
,	,	O
perception	NN	O
at	IN	O
pain	NN	O
threshold	NN	O
to	TO	O
a	DT	O
train	NN	O
of	IN	O
20	CD	O
electrical	JJ	PH
stimuli	NNS	PH
applied	VBN	O
to	TO	O
the	DT	O
hand	NN	O
and	CC	O
upper	JJ	O
oesophagus	NN	O
(	(	O
UO	NNP	O
)	)	O
at	IN	O
either	DT	O
0.1	CD	PH
Hz	NNP	PH
(	(	O
control	NN	O
)	)	O
or	CC	O
2	CD	PH
Hz	NNP	PH
was	VBD	O
determined	VBN	O
before	IN	O
and	CC	O
one	CD	O
hour	NN	O
after	IN	O
a	DT	O
30	CD	O
minute	NN	O
lower	JJR	O
oesophageal	NN	O
acid	JJ	O
infusion	NN	O
.	.	O

RESULTS	NNP	O
Wind-up	JJ	O
occurred	VBD	O
only	RB	O
with	IN	O
the	DT	O
2	CD	PH
Hz	NNP	PH
train	NN	O
in	IN	O
the	DT	O
UO	NNP	O
and	CC	O
hand	NN	O
(	(	O
both	DT	O
p=0.01	NN	O
)	)	O
.	.	O

Following	VBG	O
acid	JJ	O
infusion	NN	O
,	,	O
pain	VBP	O
threshold	JJ	O
decreased	VBN	O
(	(	O
17	CD	O
(	(	O
4	CD	O
)	)	O
%	NN	O
;	:	O
p=0.01	NN	O
)	)	O
in	IN	O
the	DT	O
UO	NNP	O
,	,	O
suggesting	VBG	O
the	DT	O
presence	NN	O
of	IN	O
secondary	JJ	O
hyperalgesia	NN	O
.	.	O

Wind-up	UH	O
to	TO	O
the	DT	O
2	CD	PH
Hz	NNP	PH
train	NN	O
increased	VBD	O
in	IN	O
the	DT	O
UO	NNP	O
(	(	O
wind-up	JJ	O
ratio	NN	O
1.4	CD	O
(	(	O
0.1	CD	O
)	)	O
to	TO	O
1.6	CD	O
(	(	O
0.1	CD	O
)	)	O
;	:	O
p=0.03	NN	O
)	)	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
hand	NN	O
(	(	O
wind-up	JJ	O
ratio	NN	O
1.3	CD	O
(	(	O
0.1	CD	O
)	)	O
and	CC	O
1.3	CD	O
(	(	O
0.1	CD	O
)	)	O
;	:	O
p=0.3	NN	O
)	)	O
CONCLUSION	NNP	O
Enhanced	NNP	O
wind-up	NN	O
after	IN	O
secondary	JJ	O
oesophageal	NN	O
hyperalgesia	NN	O
suggests	VBZ	O
that	IN	O
visceral	JJ	O
pain	NN	O
hypersensitivity	NN	O
induced	VBN	O
by	IN	O
central	JJ	O
sensitisation	NN	O
results	NNS	O
from	IN	O
increased	JJ	O
central	JJ	O
neuronal	JJ	O
excitability	NN	O
.	.	O

Wind-up	JJ	O
may	MD	O
offer	VB	O
new	JJ	O
opportunities	NNS	O
to	TO	O
investigate	VB	O
the	DT	O
contribution	NN	O
of	IN	O
central	JJ	O
neuronal	JJ	O
changes	NNS	O
to	TO	O
symptoms	NNS	O
in	IN	O
FGD	NNP	O
.	.	O

Vaginal	NNP	O
pH	NN	O
and	CC	O
microflora	NN	O
related	VBN	O
to	TO	O
yeast	VB	O
infections	NNS	O
and	CC	O
treatment	NN	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
vaginal	JJ	O
pH	NN	O
,	,	O
microflora	NN	O
,	,	O
and	CC	O
yeast	JJS	O
infection	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
93	CD	O
women	NNS	O
randomly	RB	O
treated	VBN	O
with	IN	O
either	DT	O
nystatin	NN	PM
or	CC	O
miconazole	JJ	PM
pessaries	NNS	PM
and	CC	PM
cream	NN	PM
for	IN	O
two	CD	O
weeks	NNS	O
.	.	O

The	DT	O
vaginal	JJ	O
pH	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
48	CD	O
women	NNS	O
.	.	O

In	IN	O
the	DT	O
study	NN	O
group	NN	O
,	,	O
37	CD	O
patients	NNS	O
defaulted	VBD	O
,	,	O
39	CD	O
were	VBD	O
cured	VBN	O
,	,	O
and	CC	O
17	CD	O
required	JJ	O
treatment	NN	O
during	IN	O
the	DT	O
six-month	JJ	O
follow-up	JJ	O
period	NN	O
.	.	O

In	IN	O
both	DT	O
study	NN	O
and	CC	O
control	NN	O
groups	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
the	DT	O
mean	JJ	O
vaginal	JJ	O
pH	NN	O
was	VBD	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
4.3-4.6	JJ	O
.	.	O

Lactobacilli	NNP	O
were	VBD	O
plentiful	JJ	O
in	IN	O
78	CD	O
(	(	O
91	CD	O
%	NN	O
)	)	O
out	IN	O
of	IN	O
86	CD	O
patients	NNS	O
and	CC	O
shows	VBZ	O
that	IN	O
lactobacilli	NN	O
and	CC	O
yeasts	NNS	O
commonly	RB	O
coexist	VBP	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
other	JJ	O
organisms	NNS	O
appeared	VBD	O
to	TO	O
be	VB	O
negligible	JJ	O
.	.	O

The	DT	O
trial	NN	O
showed	VBD	O
that	IN	O
nystatin	NN	O
and	CC	O
micromazole	NN	O
were	VBD	O
equallly	RB	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
vaginal	JJ	O
yeast	NN	O
infection	NN	O
and	CC	O
that	IN	O
the	DT	O
broad-spectrum	JJ	O
activity	NN	O
of	IN	O
micronazole	NN	PM
offered	VBN	O
no	DT	O
advantage	NN	O
in	IN	O
this	DT	O
condition	NN	O
.	.	O

Humoral	NNP	O
immune	JJ	O
response	NN	O
to	TO	O
tetanus-diphtheria	JJ	PM
vaccine	NN	PM
given	VBN	O
during	IN	O
extended	VBN	O
use	NN	O
of	IN	O
chloroquine	NN	PM
or	CC	O
primaquine	NN	PM
malaria	NNS	PM
chemoprophylaxis	NN	PM
.	.	O

Immune	NNP	O
suppression	NN	O
resulting	VBG	O
from	IN	O
prolonged	VBN	O
chemoprophylaxis	NN	O
and	CC	O
potential	JJ	O
drug-vaccine	JJ	O
interaction	NN	O
were	VBD	O
investigated	VBN	O
within	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	C
trial	NN	O
that	WDT	O
compared	VBN	O
daily	RB	O
primaquine	NN	PM
or	CC	O
weekly	JJ	O
chloroquine	NN	PM
administration	NN	O
for	IN	O
malaria	JJ	O
prevention	NN	O
.	.	O

After	IN	O
11	CD	O
months	NNS	O
of	IN	O
prophylaxis	NN	O
,	,	O
adult	VB	O
male	JJ	O
subjects	NNS	O
received	VBD	O
a	DT	O
tetanus-diphtheria	NN	PM
(	(	PM
Td	NNP	PM
)	)	PM
vaccination	NN	PM
.	.	PM

Prophylaxis	NNP	O
continued	VBD	O
4	CD	O
weeks	NNS	O
longer	RBR	O
.	.	O

Anti-tetanus	JJ	O
and	CC	O
anti-diphtheria	JJ	O
antibody	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	PM
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
7	CD	O
,	,	O
and	CC	O
14	CD	O
months	NNS	O
after	IN	O
Td	NNP	O
vaccination	NN	O
.	.	O

All	DT	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
at	IN	O
baseline	NN	O
.	.	O

Immunization	NN	O
triggered	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
anti-tetanus	JJ	O
and	CC	O
anti-diphtheria	JJ	O
IgG	NNP	O
levels	NNS	O
over	IN	O
each	DT	O
group	NN	O
's	POS	O
pre-Td	JJ	O
baseline	NN	O
levels	NNS	O
and	CC	O
those	DT	O
of	IN	O
an	DT	O
unvaccinated	JJ	O
control	NN	O
group	NN	O
.	.	O

Geometric	JJ	O
mean	JJ	O
anti-tetanus	JJ	O
titers	NNS	O
(	(	O
GMTs	NNP	O
)	)	O
in	IN	O
the	DT	O
primaquine	NN	O
group	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
placebo	NN	PM
group	NN	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
14	CD	O
months	NNS	O
.	.	O

Anti-tetanus	NNP	O
GMTs	NNP	O
in	IN	O
placebo	NN	C
and	CC	O
chloroquine	NN	O
groups	NNS	O
declined	VBD	O
over	IN	O
14	CD	O
months	NNS	O
to	TO	O
levels	NNS	O
comparable	JJ	O
to	TO	O
those	DT	O
of	IN	O
unvaccinated	JJ	O
controls	NNS	O
,	,	O
but	CC	O
levels	NNS	O
in	IN	O
the	DT	O
primaquine	NN	O
group	NN	O
remained	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

A	DT	O
six-month	JJ	O
crossover	NN	O
chemoprevention	NN	O
clinical	JJ	O
trial	NN	O
of	IN	O
tea	NN	PH
in	IN	O
smokers	NNS	O
and	CC	O
non-smokers	NNS	O
:	:	O
methodological	JJ	O
issues	NNS	O
in	IN	O
a	DT	O
feasibility	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Chemoprevention	NNP	O
crossover	NN	O
trials	NNS	O
of	IN	O
tea	NN	O
can	MD	O
be	VB	O
more	RBR	O
efficient	JJ	O
than	IN	O
parallel	JJ	O
designs	NNS	O
but	CC	O
the	DT	O
attrition	NN	O
and	CC	O
compliance	NN	O
rates	NNS	O
with	IN	O
such	JJ	O
trials	NNS	O
are	VBP	O
unknown	JJ	O
.	.	O

METHODS	NNP	O
Attrition	NNP	O
(	(	O
dropouts	NNS	O
)	)	O
and	CC	O
compliance	NN	O
with	IN	O
treatment	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
25-week	JJ	O
randomized	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
,	,	O
crossover	NN	O
,	,	O
feasibility	NN	O
clinical	JJ	O
trial	NN	O
of	IN	O
four	CD	PH
tea	NN	PH
treatments	NNS	PH
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
tea	NN	O
on	IN	O
oral	JJ	O
cancer	NN	O
biomarkers	NNS	O
.	.	O

Each	DT	O
treatment	NN	O
lasted	VBD	O
4	CD	O
weeks	NNS	O
with	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
washout	NN	O
in	IN	O
between	IN	O
.	.	O

Participants	NNS	O
were	VBD	O
32	CD	O
smokers	NNS	O
and	CC	O
33	CD	O
non-smokers	NNS	O
without	IN	O
any	DT	O
evidence	NN	O
of	IN	O
premalignant	JJ	O
oral	JJ	O
lesions	NNS	O
.	.	O

The	DT	O
interventions	NNS	O
consisted	VBD	O
of	IN	O
packets	NNS	O
of	IN	O
green	JJ	O
tea	NN	O
,	,	O
black	JJ	O
tea	NN	O
,	,	O
caffeinated	JJ	O
water	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
each	DT	O
treatment	NN	O
for	IN	O
four	CD	O
weeks	NNS	O
,	,	O
and	CC	O
were	VBD	O
instructed	VBN	O
to	TO	O
drink	VB	O
five	CD	O
packets	NNS	O
per	IN	O
day	NN	O
while	IN	O
on	IN	O
the	DT	O
treatment	NN	O
.	.	O

Dropout	IN	O
from	IN	O
the	DT	O
trial	NN	O
and	CC	O
compliance	NN	O
(	(	O
consumption	NN	O
of	IN	O
?85	NNP	O
%	NN	O
of	IN	O
the	DT	O
prescribed	JJ	O
treatment	NN	O
packets	NNS	O
)	)	O
are	VBP	O
the	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
reported	VBN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
high	JJ	O
rate	NN	O
of	IN	O
dropout	NN	O
(	(	O
51	CD	O
%	NN	O
)	)	O
from	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
rates	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
among	IN	O
smokers	NNS	O
(	(	O
64	CD	O
%	NN	O
)	)	O
than	IN	O
non-smokers	NNS	O
(	(	O
36	CD	O
%	NN	O
)	)	O
.	.	O

Among	IN	O
participants	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
the	DT	O
rate	NN	O
of	IN	O
compliance	NN	O
was	VBD	O
72	CD	O
%	NN	O
.	.	O

The	DT	O
highest	JJS	O
rates	NNS	O
of	IN	O
dropouts	NNS	O
occurred	VBD	O
between	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
treatment	NN	O
visits	NNS	O
in	IN	O
both	DT	O
smokers	NNS	O
(	(	O
38	CD	O
%	NN	O
dropout	NN	O
)	)	O
and	CC	O
non-smokers	NNS	O
(	(	O
18	CD	O
%	NN	O
dropout	NN	O
)	)	O
.	.	O

Throughout	IN	O
the	DT	O
study	NN	O
smokers	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
dropout	VB	O
than	IN	O
non-smokers	NNS	O
.	.	O

Black	NNP	O
tea	NN	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
highest	JJS	O
rates	NNS	O
of	IN	O
dropout	NN	O
among	IN	O
smokers	NNS	O
(	(	O
37	CD	O
%	NN	O
)	)	O
,	,	O
but	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
lowest	JJS	O
rate	NN	O
of	IN	O
dropout	NN	O
among	IN	O
non-smokers	NNS	O
(	(	O
4	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
a	DT	O
study	NN	O
conducted	VBN	O
to	TO	O
test	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
a	DT	O
four-treatment	JJ	O
crossover	NN	O
tea	NN	O
trial	NN	O
,	,	O
a	DT	O
high	JJ	O
rate	NN	O
of	IN	O
dropout	NN	O
among	IN	O
smokers	NNS	O
and	CC	O
non-smokers	NNS	O
was	VBD	O
observed	VBN	O
.	.	O

Multi-arm	JJ	O
crossover	NN	O
tea	NN	O
trials	NNS	O
might	MD	O
pose	VB	O
a	DT	O
higher	JJR	O
burden	NN	O
on	IN	O
participants	NNS	O
and	CC	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
improve	VB	O
adherence	NN	O
and	CC	O
treatment	NN	O
compliance	NN	O
in	IN	O
such	JJ	O
trials	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NUMBER	NNP	O
ISRCTN70410203	NNP	O
.	.	O

Risperidone	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	O
:	:	O
a	DT	O
meta-analysis	NN	O
.	.	O

Risperidone	NN	PM
has	VBZ	O
antiserotonergic	VBN	O
and	CC	O
antidopaminergic	JJ	O
properties	NNS	O
that	WDT	O
may	MD	O
make	VB	O
it	PRP	O
more	RBR	O
effective	JJ	O
than	IN	O
conventional	JJ	O
antipsychotic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	O
.	.	O

Clinical	JJ	O
trials	NNS	O
in	IN	O
chronic	JJ	O
schizophrenic	JJ	O
patients	NNS	O
have	VBP	O
shown	VBN	O
trends	NNS	O
in	IN	O
favor	NN	O
of	IN	O
risperidone	NN	PM
in	IN	O
the	DT	O
control	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
compared	VBN	O
with	IN	O
haloperidol	NN	PM
,	,	O
perphenazine	NN	PM
or	CC	O
zuclopenthixol	NN	PM
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
consistently	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

A	DT	O
meta-analysis	NN	O
of	IN	O
the	DT	O
pooled	JJ	O
results	NNS	O
from	IN	O
six	CD	O
double-blind	JJ	O
trials	NNS	O
showed	VBD	O
that	IN	O
risperidone	NN	PM
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
4	CD	O
to	TO	O
8	CD	O
mg/day	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.004	CD	O
)	)	O
higher	JJR	O
negative	JJ	O
symptom	JJ	O
response	NN	O
rate	NN	O
,	,	O
defined	VBN	O
as	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
20	CD	O
%	NN	O
or	CC	O
more	JJR	O
reduction	NN	O
in	IN	O
scores	NNS	O
on	IN	O
the	DT	O
negative	JJ	O
subscale	NN	O
of	IN	O
the	DT	O
Positive	NNP	O
and	CC	O
Negative	NNP	O
Syndrome	NNP	O
Scale	NNP	O
,	,	O
than	IN	O
patients	NNS	O
receiving	VBG	O
active	JJ	O
controls	NNS	O
.	.	O

The	DT	O
combined	JJ	O
patient	JJ	O
population	NN	O
treated	VBN	O
with	IN	O
4-8	JJ	O
mg/day	NN	O
of	IN	O
risperidone	NN	PM
was	VBD	O
1.43	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
had	VBN	O
a	DT	O
clinical	JJ	O
response	NN	O
on	IN	O
the	DT	O
negative	JJ	O
symptom	NN	O
subscale	NN	O
than	IN	O
the	DT	O
combined	JJ	O
population	NN	O
treated	VBN	O
with	IN	O
haloperidol	NN	PM
,	,	O
perphenazine	NN	PM
or	CC	O
zuclopenthixol	NN	PM
.	.	O

Histopathologic	NNP	O
changes	NNS	O
of	IN	O
the	DT	O
eyelid	JJ	O
skin	NN	O
following	VBG	O
trichloroacetic	JJ	PH
acid	JJ	PH
chemical	NN	PH
peel	NN	PH
.	.	O

The	DT	O
use	NN	O
of	IN	O
trichloroacetic	JJ	PM
acid	NN	PM
(	(	PM
TCA	NNP	PM
)	)	PM
as	IN	O
a	DT	O
periorbital	NN	O
and	CC	O
eyelid	JJ	O
peel	NN	O
for	IN	O
skin	JJ	O
rejuvenation	NN	O
is	VBZ	O
gaining	VBG	O
significant	JJ	O
acceptance	NN	O
among	IN	O
oculoplastic	JJ	O
surgeons	NNS	O
,	,	O
dermatologists	NNS	O
,	,	O
and	CC	O
other	JJ	O
surgery	NN	O
groups	NNS	O
.	.	O

In	IN	O
spite	NN	O
of	IN	O
the	DT	O
current	JJ	O
enthusiasm	NN	O
,	,	O
there	EX	O
remain	VBP	O
potentially	RB	O
serious	JJ	O
complications	NNS	O
resulting	VBG	O
from	IN	O
any	DT	O
periorbital	JJ	O
peel	NN	O
.	.	O

Cases	NNS	O
of	IN	O
cicatricial	JJ	O
ectropion	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
phenol-peeled	JJ	O
patients	NNS	O
,	,	O
and	CC	O
lower	JJR	O
eyelid	JJ	O
ectropion	NN	O
has	VBZ	O
reportedly	RB	O
occurred	VBN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
deep	JJ	O
eyelid	NN	O
peel	NN	O
in	IN	O
conjunction	NN	O
with	IN	O
a	DT	O
blepharoplasty	NN	S
(	(	O
1,2	CD	O
)	)	O
.	.	O

To	TO	O
avoid	VB	O
this	DT	O
complication	NN	O
,	,	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
better	RBR	O
understand	VB	O
the	DT	O
depth	NN	O
of	IN	O
the	DT	O
wound	NN	O
produced	VBN	O
by	IN	O
different	JJ	O
strengths	NNS	O
and	CC	O
combinations	NNS	O
of	IN	O
peeling	VBG	O
agents	NNS	O
applied	VBN	O
to	TO	O
living	VBG	O
eyelid	JJ	O
tissue	NN	O
and	CC	O
,	,	O
more	RBR	O
important	JJ	O
,	,	O
to	TO	O
determine	VB	O
the	DT	O
concentrations	NNS	O
of	IN	O
TCA	NNP	PM
that	WDT	O
are	VBP	O
likely	JJ	O
to	TO	O
lead	VB	O
to	TO	O
cicatricial	JJ	O
ectropion	NN	O
when	WRB	O
applied	VBN	O
in	IN	O
a	DT	O
consistent	JJ	O
fashion	NN	O
.	.	O

We	PRP	O
chose	VBD	O
upper-eyelid	JJ	O
skin	NN	O
because	IN	O
it	PRP	O
is	VBZ	O
easier	JJR	O
to	TO	O
obtain	VB	O
for	IN	O
histopathologic	NN	O
study	NN	O
than	IN	O
lower-eyelid	JJ	O
skin	NN	O
and	CC	O
,	,	O
in	IN	O
our	PRP$	O
experience	NN	O
,	,	O
is	VBZ	O
more	RBR	O
sensitive	JJ	O
to	TO	O
hypertrophic	JJ	O
changes	NNS	O
after	IN	O
chemical	NN	O
peeling	NN	O
or	CC	O
carbon	NN	O
dioxide	IN	O
laser	NN	O
resurfacing	NN	O
.	.	O

We	PRP	O
applied	VBD	O
TCA	NNP	PM
to	TO	O
the	DT	O
preseptal	JJ	O
skin	NN	O
of	IN	O
10	CD	O
patients	NNS	O
48	CD	O
h	NN	O
before	IN	O
standard	JJ	O
upper-eyelid	JJ	O
blepharoplasty	NN	O
.	.	O

The	DT	O
acid	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
produce	VB	O
a	DT	O
frost	NN	O
,	,	O
using	VBG	O
varying	VBG	O
concentrations	NNS	O
of	IN	O
acid	NN	O
,	,	O
ranging	VBG	O
from	IN	O
20	CD	O
to	TO	O
50	CD	O
%	NN	O
.	.	O

The	DT	O
treated	JJ	O
skin	NN	O
removed	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
blepharoplasty	NN	O
was	VBD	O
reviewed	VBN	O
in	IN	O
a	DT	O
masked	JJ	O
fashion	NN	O
by	IN	O
a	DT	O
dermatopathologist	NN	O
to	TO	O
determine	VB	O
the	DT	O
depth	NN	O
of	IN	O
necrosis	NN	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
superficial	JJ	O
peels	NNS	O
with	IN	O
necrosis	NN	O
involving	VBG	O
30	CD	O
%	NN	O
of	IN	O
the	DT	O
epidermis	NN	O
were	VBD	O
produced	VBN	O
by	IN	O
the	DT	O
lowest-concentration	JJ	O
combination	NN	O
of	IN	O
TCA	NNP	PM
applied	VBD	O
(	(	O
20	CD	O
%	NN	O
followed	VBN	O
by	IN	O
0	CD	O
%	NN	O
)	)	O
.	.	O

As	IN	O
the	DT	O
strength	NN	O
increased	VBD	O
,	,	O
so	RB	O
did	VBD	O
the	DT	O
depth	NN	O
of	IN	O
peel	NN	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
50	CD	O
%	NN	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
application	NN	O
of	IN	O
50	CD	O
%	NN	O
produced	VBD	O
the	DT	O
deepest	JJS	O
peel	NN	O
,	,	O
with	IN	O
necrosis	NN	O
into	IN	O
the	DT	O
papillary	JJ	O
dermis	NN	O
.	.	O

This	DT	O
finding	NN	O
would	MD	O
indicate	VB	O
that	IN	O
the	DT	O
chance	NN	O
of	IN	O
developing	VBG	O
cicatricial	JJ	O
ectropion	NN	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
tested	JJ	O
combinations	NNS	O
of	IN	O
TCA	NNP	PM
should	MD	O
be	VB	O
very	RB	O
remote	JJ	O
.	.	O

Delayed	VBN	O
perceptual	JJ	O
awareness	NN	O
in	IN	O
rapid	JJ	O
perceptual	JJ	O
decisions	NNS	O
.	.	O

The	DT	O
flourishing	NN	O
of	IN	O
studies	NNS	O
on	IN	O
the	DT	O
neural	JJ	O
correlates	NNS	O
of	IN	O
decision-making	JJ	O
calls	NNS	O
for	IN	O
an	DT	O
appraisal	NN	O
of	IN	O
the	DT	O
relation	NN	O
between	IN	O
perceptual	JJ	O
decisions	NNS	O
and	CC	O
conscious	JJ	O
perception	NN	O
.	.	O

By	IN	O
exploiting	VBG	O
the	DT	O
long	JJ	E
integration	NN	E
time	NN	E
of	IN	E
noisy	JJ	E
motion	NN	E
stimuli	NN	E
,	,	O
and	CC	O
by	IN	O
forcing	VBG	E
human	JJ	E
observers	NNS	E
to	TO	E
make	VB	E
difficult	JJ	E
speeded	VBN	E
decisions	NNS	E
--	:	E
sometimes	RB	E
a	DT	E
blind	JJ	E
guess	NN	E
--	:	E
about	IN	E
stimulus	JJ	E
direction	NN	E
,	,	O
we	PRP	O
traced	VBD	O
the	DT	O
temporal	JJ	O
buildup	NN	O
of	IN	O
motion	NN	O
discrimination	NN	O
capability	NN	O
and	CC	O
perceptual	JJ	O
awareness	NN	O
,	,	O
as	IN	O
assessed	VBN	O
trial	NN	O
by	IN	O
trial	NN	O
through	IN	O
direct	JJ	O
rating	NN	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
both	DT	O
increased	VBN	O
gradually	RB	O
with	IN	O
motion	NN	O
coherence	NN	O
and	CC	O
viewing	NN	O
time	NN	O
,	,	O
but	CC	O
discrimination	NN	O
was	VBD	O
systematically	RB	O
leading	JJ	O
awareness	NN	O
,	,	O
reaching	VBG	O
a	DT	O
plateau	NN	O
much	RB	O
earlier	RBR	O
.	.	O

Sensitivity	NNP	O
and	CC	O
criterion	NN	O
changes	NNS	O
contributed	VBD	O
jointly	RB	O
to	TO	O
the	DT	O
slow	JJ	O
buildup	NN	O
of	IN	O
perceptual	JJ	O
awareness	NN	O
.	.	O

It	PRP	O
made	VBD	O
no	DT	O
difference	NN	O
whether	IN	O
motion	NN	O
discrimination	NN	O
was	VBD	O
accomplished	VBN	O
by	IN	O
saccades	NNS	O
or	CC	O
verbal	JJ	O
responses	NNS	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
perceptual	JJ	O
awareness	NN	O
emerges	VBZ	O
on	IN	O
the	DT	O
top	NN	O
of	IN	O
a	DT	O
developing	NN	O
or	CC	O
even	RB	O
mature	VBP	O
perceptual	JJ	O
decision	NN	O
.	.	O

We	PRP	O
argue	VBP	O
that	IN	O
the	DT	O
middle	JJ	O
temporal	JJ	O
(	(	O
MT	NNP	O
)	)	O
cortical	JJ	O
region	NN	O
does	VBZ	O
not	RB	O
confer	VB	O
us	PRP	O
the	DT	O
full	JJ	O
phenomenic	JJ	O
depth	NN	O
of	IN	O
motion	NN	O
perception	NN	O
,	,	O
although	IN	O
it	PRP	O
may	MD	O
represent	VB	O
a	DT	O
precursor	NN	O
stage	NN	O
in	IN	O
building	VBG	O
our	PRP$	O
subjective	JJ	O
sense	NN	O
of	IN	O
visual	JJ	O
motion	NN	O
.	.	O

Effect	NN	O
of	IN	O
HIV	NNP	O
infection	NN	O
on	IN	O
tolerability	NN	O
and	CC	O
bacteriologic	JJ	O
outcomes	NNS	O
of	IN	O
tuberculosis	NN	O
treatment	NN	O
.	.	O

SETTING	NN	O
Two	CD	O
international	JJ	O
,	,	O
multicenter	JJ	O
Phase	NNP	O
2	CD	O
clinical	JJ	O
trials	NNS	O
examining	VBG	O
fluoroquinolone-containing	JJ	PM
regimens	NNS	PM
in	IN	O
adults	NNS	O
with	IN	O
smear-positive	JJ	O
pulmonary	JJ	O
tuberculosis	NN	O
(	(	O
TB	NNP	O
)	)	O
,	,	O
conducted	VBN	O
from	IN	O
July	NNP	O
2003	CD	O
to	TO	O
March	NNP	O
2007	CD	O
.	.	O

Both	DT	O
trials	NNS	O
enrolled	VBD	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
infected	VBD	O
participants	NNS	O
who	WP	O
were	VBD	O
not	RB	O
receiving	VBG	O
antiretroviral	JJ	O
therapy	NN	O
(	(	O
ART	NNP	O
)	)	O
at	IN	O
TB	NNP	O
treatment	NN	O
initiation	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
HIV	NNP	O
infection	NN	O
on	IN	O
TB	NNP	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
Phase	NNP	O
2	CD	O
clinical	JJ	O
trials	NNS	O
.	.	O

DESIGN	NNP	O
Cross-protocol	JJ	O
analysis	NN	O
comparing	VBG	O
the	DT	O
safety	NN	O
,	,	O
tolerability	NN	O
and	CC	O
outcomes	NNS	O
of	IN	O
anti-tuberculosis	NN	PM
treatment	NN	PM
by	IN	O
HIV	NNP	O
status	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
750	CD	O
participants	NNS	O
who	WP	O
received	VBD	O
at	IN	O
least	JJS	O
one	CD	O
dose	NN	O
of	IN	O
study	NN	O
treatment	NN	O
,	,	O
123	CD	O
(	(	O
16	CD	O
%	NN	O
)	)	O
were	VBD	O
HIV-infected	JJ	O
.	.	O

Treatment	JJ	O
completion	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
by	IN	O
HIV	NNP	O
status	NN	O
(	(	O
81	CD	O
%	NN	O
infected	VBN	O
vs.	IN	O
85	CD	O
%	NN	O
non-infected	JJ	O
)	)	O
,	,	O
as	IN	O
were	VBD	O
rates	NNS	O
of	IN	O
week	NN	O
8	CD	O
culture	NN	O
conversion	NN	O
(	(	O
66	CD	O
%	NN	O
infected	VBN	O
vs.	IN	O
63	CD	O
%	NN	O
non-infected	JJ	O
)	)	O
,	,	O
and	CC	O
treatment	NN	O
failure	NN	O
(	(	O
5	CD	O
%	NN	O
infected	VBN	O
vs.	IN	O
3	CD	O
%	NN	O
non-infected	JJ	O
)	)	O
.	.	O

Among	IN	O
HIV-infected	JJ	O
participants	NNS	O
,	,	O
treatment	NN	O
failure	NN	O
detected	VBD	O
using	VBG	O
liquid	JJ	O
media	NNS	O
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
those	DT	O
treated	JJ	O
thrice	JJ	O
weekly	JJ	O
(	(	O
14	CD	O
%	NN	O
thrice	JJ	O
weekly	JJ	O
vs.	FW	O
2	CD	O
%	NN	O
daily	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

HIV-infected	JJ	O
participants	NNS	O
more	RBR	O
frequently	RB	O
experienced	VBD	O
an	DT	O
adverse	JJ	O
event	NN	O
during	IN	O
the	DT	O
intensive	JJ	O
phase	NN	O
treatment	NN	O
than	IN	O
non-HIV-infected	JJ	O
participants	NNS	O
(	(	O
30	CD	O
%	NN	O
vs.	FW	O
15	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
HIV-infected	JJ	O
persons	NNS	O
not	RB	O
receiving	VBG	O
ART	NNP	O
had	VBD	O
more	RBR	O
adverse	JJ	O
events	NNS	O
during	IN	O
the	DT	O
intensive	JJ	O
phase	NN	O
of	IN	O
anti-tuberculosis	NN	O
treatment	NN	O
,	,	O
but	CC	O
tolerated	VBD	O
treatment	NN	O
well	RB	O
.	.	O

Failure	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
among	IN	O
HIV-infected	JJ	O
persons	NNS	O
treated	VBN	O
with	IN	O
thrice-weekly	JJ	O
intensive	JJ	O
phase	NN	O
therapy	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
a	DT	O
barrier	NN	PH
cream	NN	PH
and	CC	O
its	PRP$	PH
vehicle	NN	PH
as	IN	O
protective	JJ	O
measures	NNS	O
against	IN	O
occupational	JJ	O
irritant	JJ	O
contact	NN	O
dermatitis	NN	O
.	.	O

The	DT	O
actual	JJ	O
advantage	NN	O
of	IN	O
barrier	NN	PM
creams	NNS	PM
over	IN	O
bland	NN	O
emollients	NNS	O
for	IN	O
skin	NN	O
protection	NN	O
is	VBZ	O
still	RB	O
hotly	RB	O
debated	VBN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
study	NN	O
,	,	O
a	DT	O
newly-introduced	JJ	O
barrier	NN	PM
cream	NN	PM
and	CC	O
its	PRP$	O
moisturizing	NN	PM
vehicle	NN	PM
were	VBD	O
compared	VBN	O
regarding	VBG	O
their	PRP$	O
skin	NN	O
compatibility	NN	O
,	,	O
efficacy	NN	O
and	CC	O
resulting	VBG	O
acceptance	NN	O
.	.	O

Thus	NNP	O
,	,	O
2	CD	O
panels	NNS	O
of	IN	O
25	CD	O
hospital	NN	O
nurses	NNS	O
with	IN	O
mild	JJ	O
signs	NNS	O
of	IN	O
skin	JJ	O
irritation	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
use	VB	O
1	CD	O
of	IN	O
the	DT	O
test	NN	O
products	NNS	O
provided	VBN	O
(	(	O
verum	NN	PH
or	CC	PH
vehicle	NN	PH
)	)	PH
over	IN	PH
a	DT	PH
period	NN	PH
of	IN	PH
4	CD	PH
weeks	NNS	PH
.	.	O

Effects	NNS	O
of	IN	O
both	DT	O
types	NNS	O
of	IN	O
preparations	NNS	O
were	VBD	O
studied	VBN	O
weekly	JJ	O
by	IN	O
clinical	JJ	O
examination	NN	O
and	CC	O
the	DT	O
instrumental	JJ	O
assessment	NN	O
of	IN	O
bioengineering	VBG	O
parameters	NNS	O
.	.	O

Results	NNS	O
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
barrier	NN	PM
cream	NN	PM
and	CC	O
vehicle	NN	PH
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
clinical	JJ	O
skin	NN	O
status	NN	O
improved	VBN	O
and	CC	O
stratum	JJ	O
corneum	NN	O
hydration	NN	O
increased	VBD	O
significantly	RB	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

Both	DT	O
preparations	NNS	O
were	VBD	O
tolerated	VBN	O
and	CC	O
accepted	VBN	O
well	RB	O
,	,	O
thus	RB	O
showing	VBG	O
both	DT	O
skin	JJ	O
protection	NN	O
and	CC	O
skin	NN	O
care	NN	O
.	.	O

These	DT	O
results	NNS	O
contribute	VBP	O
to	TO	O
the	DT	O
debate	NN	O
as	IN	O
to	TO	O
whether	IN	O
a	DT	O
strict	JJ	O
distinction	NN	O
between	IN	O
skin	NN	O
care	NN	O
and	CC	O
skin	NN	O
protection	NN	O
products	NNS	O
is	VBZ	O
justified	JJ	O
.	.	O

The	DT	O
vehicle	NN	PM
alone	RB	O
is	VBZ	O
capable	JJ	O
of	IN	O
positively	RB	O
influencing	VBG	O
skin	NN	O
status	NN	O
.	.	O

Emphasis	NN	O
must	MD	O
be	VB	O
laid	VBN	O
on	IN	O
regular	JJ	O
,	,	O
frequent	JJ	O
,	,	O
and	CC	O
correct	JJ	O
application	NN	O
of	IN	O
a	DT	O
product	NN	O
for	IN	O
it	PRP	O
to	TO	O
be	VB	O
effective	JJ	O
.	.	O

Is	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
mobile	JJ	PH
phone	NN	PH
radiofrequency	NN	PH
waves	NNS	PH
on	IN	O
human	JJ	O
skin	JJ	O
perfusion	NN	O
non-thermal	JJ	O
?	.	O
OBJECTIVE	UH	O
To	TO	O
establish	VB	O
whether	IN	O
SkBF	NNP	O
can	MD	O
be	VB	O
modified	VBN	O
by	IN	O
exposure	NN	O
to	TO	O
the	DT	O
radiofrequency	NN	PH
waves	NNS	PH
emitted	VBN	PH
by	IN	PH
a	DT	PH
mobile	JJ	PH
phone	NN	PH
when	WRB	O
the	DT	O
latter	NN	O
is	VBZ	O
held	VBN	O
against	IN	O
the	DT	O
jaw	NN	O
and	CC	O
ear	NN	O
.	.	O

METHODS	NNP	O
Variations	NNP	O
in	IN	O
SkBF	NNP	O
and	CC	O
Tsk	NNP	O
in	IN	O
adult	NN	O
volunteers	NNS	O
were	VBD	O
simultaneously	RB	O
recorded	VBN	PH
with	IN	PH
a	DT	PH
thermostatic	JJ	PH
laser	NN	PH
Doppler	NNP	PH
system	NN	PH
during	IN	PH
a	DT	PH
20-minute	JJ	PH
radiofrequency	NN	PH
exposure	NN	PH
session	NN	PH
and	CC	PH
a	DT	PH
20-minute	JJ	PH
sham	NN	PH
session	NN	PH
.	.	O

The	DT	O
skin	JJ	O
microvessels	NNS	O
'	POS	O
vasodilatory	NN	O
reserve	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
heat	NN	O
challenge	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
protocol	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
the	DT	O
radiofrequency	NN	PH
exposure	NN	PH
session	NN	PH
,	,	O
SkBF	NNP	O
increased	VBD	O
(	(	O
vs.	FW	O
baseline	NN	O
)	)	O
more	JJR	O
than	IN	O
during	IN	O
the	DT	O
sham	JJ	PH
exposure	NN	PH
session	NN	PH
.	.	O

The	DT	O
sessions	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significant	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
Tsk	NNP	O
time-course	JJ	O
response	NN	O
.	.	O

The	DT	O
skin	JJ	O
microvessels	NNS	O
'	POS	O
vasodilatory	NN	O
ability	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
greater	JJR	O
during	IN	O
radiofrequency	NN	O
exposure	NN	O
than	IN	O
during	IN	O
sham	JJ	O
exposure	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
reveal	VBP	O
the	DT	O
existence	NN	O
of	IN	O
a	DT	O
specific	JJ	O
vasodilatory	JJ	O
effect	NN	O
of	IN	O
mobile	JJ	PH
phone	NN	PH
radiofrequency	NN	PH
emission	NN	PH
on	IN	O
skin	JJ	O
perfusion	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
of	IN	O
controlled	JJ	O
release	NN	O
melatonin	NN	PM
treatment	NN	PM
of	IN	O
delayed	JJ	O
sleep	JJ	O
phase	NN	O
syndrome	NN	O
and	CC	O
impaired	JJ	O
sleep	JJ	O
maintenance	NN	O
in	IN	O
children	NNS	O
with	IN	O
neurodevelopmental	JJ	O
disabilities	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
controlled-release	NN	O
(	(	O
CR	NNP	O
)	)	O
melatonin	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
delayed	JJ	O
sleep	JJ	O
phase	NN	O
syndrome	NN	O
and	CC	O
impaired	JJ	O
sleep	JJ	O
maintenance	NN	O
of	IN	O
children	NNS	O
with	IN	O
neurodevelopmental	JJ	O
disabilities	NNS	O
including	VBG	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
crossover	NN	O
trial	NN	O
of	IN	O
CR	NNP	PM
melatonin	NN	PM
(	(	O
5	CD	O
mg	NN	O
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
3-month	JJ	O
open-label	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
during	IN	O
which	WDT	O
the	DT	O
dose	NN	O
was	VBD	O
gradually	RB	O
increased	VBN	O
until	IN	O
the	DT	O
therapy	NN	O
showed	VBD	O
optimal	JJ	O
beneficial	JJ	O
effects	NNS	O
.	.	O

Sleep	JJ	O
characteristics	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
caregiver	NN	O
who	WP	O
completed	VBD	O
somnologs	NNS	O
and	CC	O
wrist	JJ	O
actigraphs	NN	O
.	.	O

Clinician	JJ	O
rating	NN	O
of	IN	O
severity	NN	O
of	IN	O
the	DT	O
sleep	JJ	O
disorder	NN	O
and	CC	O
improvement	NN	O
from	IN	O
baseline	NN	O
,	,	O
along	IN	O
with	IN	O
caregiver	JJ	O
ratings	NNS	O
of	IN	O
global	JJ	O
functioning	NN	O
and	CC	O
family	NN	O
stress	NN	O
were	VBD	O
also	RB	O
obtained	VBN	O
.	.	O

Fifty-one	CD	O
children	NNS	O
(	(	O
age	NN	O
range	NN	O
2-18	CD	O
years	NNS	O
)	)	O
who	WP	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
sleep	VB	O
hygiene	NN	O
intervention	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Fifty	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
crossover	NN	O
trial	NN	O
and	CC	O
47	CD	O
completed	VBD	O
the	DT	O
open-label	JJ	O
phase	NN	O
.	.	O

Recordings	NNS	O
of	IN	O
total	JJ	O
night-time	JJ	O
sleep	NN	O
and	CC	O
sleep	JJ	O
latency	NN	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
of	IN	O
approximately	RB	O
30	CD	O
min	NNS	O
.	.	O

Similarly	RB	O
,	,	O
significant	JJ	O
improvement	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
clinician	JJ	O
and	CC	O
parent	JJ	O
ratings	NNS	O
.	.	O

There	EX	O
was	VBD	O
additional	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
open-label	JJ	O
somnolog	NN	O
measures	NNS	O
of	IN	O
sleep	JJ	O
efficiency	NN	O
and	CC	O
the	DT	O
longest	JJS	O
sleep	JJ	O
episode	NN	O
in	IN	O
the	DT	O
open-label	JJ	O
phase	NN	O
.	.	O

Overall	UH	O
,	,	O
the	DT	O
therapy	NN	O
improved	VBD	O
the	DT	O
sleep	NN	O
of	IN	O
47	CD	O
children	NNS	O
and	CC	O
was	VBD	O
effective	JJ	O
in	IN	O
reducing	VBG	O
family	NN	O
stress	NN	O
.	.	O

Children	NNP	O
with	IN	O
neurodevelopmental	JJ	O
disabilities	NNS	O
,	,	O
who	WP	O
had	VBD	O
treatment	NN	O
resistant	JJ	O
chronic	JJ	O
delayed	VBN	O
sleep	JJ	O
phase	NN	O
syndrome	NN	O
and	CC	O
impaired	JJ	O
sleep	JJ	O
maintenance	NN	O
,	,	O
showed	VBD	O
improvement	NN	O
in	IN	O
melatonin	NN	PM
therapy	NN	PM
.	.	PM

[	JJ	O
Comparison	NNP	O
between	IN	O
anterior	JJ	PH
rhinomanometry	NN	PH
and	CC	O
impulse-oscillometric	JJ	PH
rhinometry	NN	PH
found	VBD	O
within	IN	O
nasal	JJ	O
allergen	JJ	O
provocation	NN	O
]	NNP	O
.	.	O

UNLABELLED	NNP	O
Besides	IN	O
the	DT	O
standard	JJ	O
method	NN	O
of	IN	O
anterior	JJ	PH
rhinomanometry	NN	PH
(	(	PH
aR	NN	PH
)	)	PH
,	,	PH
the	DT	PH
impulse-oscillometric	JJ	PH
rhinometry	NN	PH
(	(	PH
IOS	NNP	PH
)	)	PH
is	VBZ	O
available	JJ	O
for	IN	O
measurements	NNS	O
of	IN	O
the	DT	O
nasal	JJ	O
resistance	NN	O
.	.	O

The	DT	O
aR	NN	O
is	VBZ	O
a	DT	O
procedure	NN	O
dependent	NN	O
on	IN	O
the	DT	O
cooperation	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
whereas	JJ	O
IOS	NNP	O
is	VBZ	O
measured	VBN	O
regardless	RB	O
from	IN	O
the	DT	O
breathing	NN	O
activities	NNS	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

We	PRP	O
examined	VBD	O
weather	RP	O
the	DT	O
resistance-measurement	NN	O
by	IN	O
means	NNS	O
of	IN	O
IOS	NNP	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
aR	NN	O
is	VBZ	O
a	DT	O
more	RBR	O
suitable	JJ	O
method	NN	O
for	IN	O
nasal	JJ	O
allergic	JJ	O
provocation	NN	O
.	.	O

METHOD	NNP	O
17	CD	O
patients	NNS	O
with	IN	O
anamnestic	JJ	O
known	VBN	O
rhinokonjunktivitis	NN	O
(	(	O
6	CD	O
f	NN	O
,	,	O
11	CD	O
m	NN	O
)	)	O
had	VBD	O
a	DT	O
pricktest	NN	PM
and	CC	O
then	RB	O
a	DT	O
nasal	JJ	PM
provocation	NN	PM
testing	VBG	PM
with	IN	O
an	DT	O
allergen	NN	O
which	WDT	O
provoked	VBD	O
a	DT	O
reaction	NN	O
on	IN	O
the	DT	O
skin	NN	O
.	.	O

The	DT	O
complete	JJ	O
resistance	NN	O
of	IN	O
the	DT	O
nose	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
by	IN	O
means	NNS	O
of	IN	O
aR	NN	PM
and	CC	PM
IOS	NNP	PM
.	.	PM

RESULTS	VB	O
The	DT	O
complete	JJ	O
resistance	NN	O
showed	VBD	O
neither	CC	O
in	IN	O
the	DT	O
basic	JJ	O
measurement	NN	O
(	(	O
aR	JJ	O
0,38	CD	O
+/-	JJ	O
0,14	CD	O
kPa/l/s	NN	O
;	:	O
IOS	NNP	O
0,38	CD	O
+/-	JJ	O
0,11	CD	O
kPa/l/s	NN	O
)	)	O
nor	CC	O
in	IN	O
the	DT	O
control	NN	O
solution	NN	O
(	(	O
aR	JJ	O
0,38	CD	O
+/-	JJ	O
0,14	CD	O
;	:	O
IOS	NNP	O
0,39	CD	O
+/-	JJ	O
0,14	CD	O
)	)	O
nor	CC	O
after	IN	O
application	NN	O
of	IN	O
the	DT	O
allergenic	JJ	O
solution	NN	O
(	(	O
15	CD	O
min	NN	O
:	:	O
aR	JJ	O
0,69	CD	O
+/-	JJ	O
0,27	CD	O
;	:	O
IOS	NNP	O
0,77	CD	O
+/-	JJ	O
0,42	CD	O
;	:	O
30	CD	O
min	NN	O
:	:	O
aR	JJ	O
0,65	CD	O
+/-	JJ	O
0,29	CD	O
;	:	O
IOS	NNP	O
0,6	CD	O
+/-	JJ	O
0,38	CD	O
)	)	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
measurement	NN	O
of	IN	O
aR	NN	O
and	CC	O
IOS	NNP	O
after	IN	O
the	DT	O
allergenic	JJ	O
solution	NN	O
showed	VBD	O
a	DT	O
positive	JJ	O
correlation	NN	O
(	(	O
15	CD	O
min	NN	O
:	:	O
r	NN	O
=	VBZ	O
0,63	CD	O
,	,	O
p	NN	O
<	VBD	O
0,01	CD	O
;	:	O
30	CD	O
min	NN	O
:	:	O
r	NN	O
=	VBZ	O
0,67	CD	O
,	,	O
p	NN	O
<	NNP	O
0,01	CD	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
by	IN	O
means	NNS	O
of	IN	O
clinic	NN	O
and	CC	O
measurement	NN	O
methods	NNS	O
in	IN	O
the	DT	O
aR	NN	O
of	IN	O
7	CD	O
patients	NNS	O
a	DT	O
positive	JJ	O
reaction	NN	O
,	,	O
within	IN	O
7	CD	O
patient	NN	O
a	DT	O
negative	JJ	O
reaction	NN	O
,	,	O
3	CD	O
patients	NNS	O
had	VBD	O
a	DT	O
unspecific	JJ	O
nasal	NN	O
hyperreactivity	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
correspondence	NN	O
in	IN	O
6	CD	O
of	IN	O
the	DT	O
7	CD	O
patients	NNS	O
with	IN	O
positive	JJ	O
reaction	NN	O
in	IN	O
aR	NN	O
between	IN	O
both	DT	O
methods	NNS	O
.	.	O

4	CD	O
of	IN	O
the	DT	O
7	CD	O
results	NNS	O
with	IN	O
negative	JJ	O
reaction	NN	O
in	IN	O
the	DT	O
aR	NN	O
would	MD	O
have	VB	O
been	VBN	O
positive	JJ	O
then	RB	O
underlying	VBG	O
the	DT	O
same	JJ	O
criteria	NNS	O
in	IN	O
the	DT	O
IOS	NNP	O
without	IN	O
announcing	VBG	O
the	DT	O
symptomscore	NN	O
a	DT	O
relevant	JJ	O
clinical	JJ	O
symptomatic	NN	O
while	IN	O
testing	VBG	O
.	.	O

CONCLUSION	NNP	O
IOS	NNP	O
is	VBZ	O
a	DT	O
suitable	JJ	O
procedure	NN	O
for	IN	O
nasal	JJ	O
provocation	NN	O
testing	VBG	O
and	CC	O
provides	VBZ	O
results	NNS	O
similar	JJ	O
to	TO	O
the	DT	O
aR	NN	O
.	.	O

In	IN	O
comparison	NN	O
to	TO	O
aR	VB	O
IOS	NNP	O
is	VBZ	O
not	RB	O
dependent	JJ	O
on	IN	O
the	DT	O
patients	NNS	O
cooperation	NN	O
.	.	O

Due	NNP	O
to	TO	O
its	PRP$	O
higher	JJR	O
sensitivity	NN	O
the	DT	O
valid	JJ	O
limits	NNS	O
of	IN	O
the	DT	O
aR	NN	O
at	IN	O
provocation	NN	O
testings	NNS	O
can	MD	O
not	RB	O
be	VB	O
transferred	VBN	O
to	TO	O
IOS	NNP	O
to	TO	O
avoid	VB	O
a	DT	O
false	JJ	O
positive	JJ	O
reaction	NN	O
.	.	O

Cardiovascular	JJ	O
effects	NNS	O
of	IN	O
non-depolarizing	JJ	PM
neuromuscular	JJ	PM
blockers	NNS	PM
in	IN	O
patients	NNS	O
with	IN	O
aortic	JJ	O
valve	NN	O
disease	NN	O
.	.	O

To	TO	O
compare	VB	O
haemodynamic	JJ	O
responses	NNS	O
associated	VBN	O
with	IN	O
equipotent	JJ	O
doses	NNS	O
of	IN	O
neuromuscular	JJ	PM
blockers	NNS	PM
and	CC	O
high-dose	JJ	O
fentanyl	NN	PM
(	(	O
50	CD	O
micrograms.kg-1	NN	O
)	)	O
,	,	O
40	CD	O
patients	NNS	O
with	IN	O
aortic	JJ	O
valve	NNS	O
stenosis	NN	O
(	(	O
AS	IN	O
)	)	O
and	CC	O
20	CD	O
patients	NNS	O
with	IN	O
aortic	JJ	O
insufficiency	NN	O
(	(	O
AI	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
four	CD	O
study	NN	O
groups	NNS	O
to	TO	O
receive	VB	O
the	DT	O
following	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
pancuronium	NN	PM
0.12	CD	PM
mg.kg-1	NN	PM
,	,	PM
(	(	PM
2	CD	PM
)	)	PM
vecuronium	NN	PM
0.12	CD	PM
mg.kg-1	NN	PM
,	,	O
(	(	PM
3	CD	PM
)	)	PM
atracurium	NN	PM
0.4	CD	PM
mg.kg-1	NN	PM
,	,	O
or	CC	O
(	(	PM
4	CD	PM
)	)	PM
pancuronium-metocurine	NN	PM
mixture	NN	PM
(	(	O
0.4	CD	O
mg	NN	O
+	VBD	O
1.6	CD	O
mg/ml	NN	O
)	)	O
:	:	O
1	CD	O
ml/10	NNS	O
kg	NN	O
)	)	O
.	.	O

Neuromuscular	JJ	PM
blockers	NNS	PM
were	VBD	O
injected	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
with	IN	O
the	DT	O
fentanyl	NN	PM
;	:	O
haemodynamics	NNS	O
were	VBD	O
recorded	VBN	O
with	IN	O
the	DT	O
patients	NNS	O
awake	VBP	O
(	(	O
baseline	NN	O
)	)	O
,	,	O
at	IN	O
two	CD	O
minutes	NNS	O
post-induction	NN	O
,	,	O
and	CC	O
at	IN	O
two	CD	O
and	CC	O
five	CD	O
minutes	NNS	O
after	IN	O
intubation	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
AS	NNP	O
,	,	O
pancuronium	NN	PM
increased	VBD	O
heart	NN	O
rate	NN	O
more	JJR	O
than	IN	O
vecuronium	NN	PM
or	CC	O
atracurium	NN	PM
;	:	O
heart	NN	O
rates	NNS	O
were	VBD	O
also	RB	O
higher	JJR	O
with	IN	O
the	DT	O
pancuronium-metocurine	JJ	PM
mixture	NN	PM
than	IN	O
with	IN	O
vecuronium	NN	PM
.	.	O

Although	IN	O
there	EX	O
were	VBD	O
no	DT	O
ECG	NNP	O
signs	NNS	O
of	IN	O
ischaemia	NN	O
,	,	O
one	CD	O
patient	NN	O
given	VBN	O
pancuronium	NN	O
developed	VBD	O
severe	JJ	O
hypotension	NN	O
associated	VBN	O
with	IN	O
tachycardia	NN	O
.	.	O

Reductions	NNS	O
in	IN	O
SVR	NNP	O
after	IN	O
atracurium	NN	O
allowed	VBD	O
small	JJ	O
but	CC	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
decreases	NNS	O
in	IN	O
MAP	NNP	O
which	WDT	O
were	VBD	O
well	RB	O
tolerated	VBN	O
;	:	O
one	CD	O
patient	NN	O
,	,	O
however	RB	O
,	,	O
did	VBD	O
develop	VB	O
severe	JJ	O
hypotension	NN	O
.	.	O

Intubation	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
increases	NNS	O
in	IN	O
MAP	NNP	O
in	IN	O
the	DT	O
pancuronium-metocurine	JJ	PM
mixture	NN	O
group	NN	O
.	.	O

Vecuronium	NNP	PM
permitted	VBD	O
the	DT	O
most	RBS	O
stable	JJ	O
overall	JJ	O
haemodynamic	JJ	O
course	NN	O
at	IN	O
all	DT	O
measurement	JJ	O
times	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
patients	NNS	O
with	IN	O
AI	NNP	O
showed	VBD	O
stable	JJ	O
haemodynamics	NNS	O
after	IN	O
vecuronium	NN	PM
,	,	O
pancuronium	NN	PM
and	CC	O
the	DT	O
pancuronium-metocurine	JJ	PM
mixture	NN	PM
;	:	O
one	CD	O
patient	NN	O
became	VBD	O
tachycardic	JJ	O
following	VBG	O
vecuronium	NN	PM
.	.	O

Atracurium	NNP	PM
caused	VBD	O
unexplained	JJ	O
elevations	NNS	O
in	IN	O
diastolic	JJ	O
and	CC	O
mean	JJ	O
arterial	NN	O
pressures	NNS	O
which	WDT	O
were	VBD	O
significant	JJ	O
when	WRB	O
compared	VBN	O
to	TO	O
vecuronium	VB	PM
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
in	IN	O
increases	NNS	O
in	IN	O
PCWP	NNP	O
;	:	O
mean	JJ	O
PA	NNP	O
pressures	NNS	O
and	CC	O
CVP	NNP	O
were	VBD	O
also	RB	O
increased	VBN	O
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
atracurium	NN	PM
inpatients	NNS	O
with	IN	O
Al	NNP	O
need	VBP	O
further	JJ	O
evaluation	NN	O
.	.	O

Couple-responsible	JJ	PS
therapy	NN	PS
process	NN	PS
:	:	PS
positive	JJ	O
proximal	JJ	O
outcomes	NNS	O
.	.	O

Therapist-couple	JJ	O
struggle	NN	O
vs.	FW	O
cooperation	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
clinical	JJ	O
outcome	NN	O
.	.	O

This	DT	O
research	NN	O
conceptualizes	NN	O
and	CC	O
investigates	VBZ	O
treatment	NN	O
process	NN	O
as	IN	O
it	PRP	O
relates	VBZ	O
to	TO	O
the	DT	O
occurrence	NN	O
of	IN	O
struggle	NN	O
versus	NN	O
cooperation	NN	O
.	.	O

Models	NNS	O
of	IN	O
couple-responsible	JJ	PS
and	CC	PS
therapist-responsible	JJ	PS
process	NN	PS
in	IN	O
couple	NN	PS
therapy	NN	PS
were	VBD	O
developed	VBN	O
.	.	O

Couple-responsible	JJ	PS
process	NN	PS
consists	VBZ	PS
of	IN	PS
enactments	NNS	PS
,	,	PS
accommodation	NN	PS
,	,	PS
and	CC	PS
inductive	JJ	PS
process	NN	PS
.	.	PS

Therapist-responsible	JJ	PS
process	NN	PS
consists	VBZ	PS
of	IN	PS
primary	JJ	PS
therapist-couple	JJ	PS
interaction	NN	PS
,	,	PS
therapist	JJ	PS
interpretation	NN	PS
,	,	PS
and	CC	PS
direct	JJ	PS
instruction	NN	PS
.	.	PS

In	IN	O
counterbalanced	JJ	O
order	NN	O
,	,	O
25	CD	O
couples	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
couple-responsible	JJ	PS
and	CC	PS
therapist-responsible	JJ	PS
episodes	NNS	PS
during	IN	O
one	CD	O
therapy	NN	O
session	NN	O
.	.	O

Couples	NNP	O
reviewed	VBD	O
videotapes	NNS	O
of	IN	O
the	DT	O
episodes	NNS	O
and	CC	O
completed	VBD	O
measures	NNS	O
of	IN	O
responsibility	NN	O
,	,	O
struggle	NN	O
,	,	O
and	CC	O
cooperation	NN	O
.	.	O

Perceived	NNP	O
responsibility	NN	O
was	VBD	O
higher	JJR	O
and	CC	O
struggle	NN	O
was	VBD	O
lower	JJR	O
during	IN	O
couple-responsible	JJ	PS
episodes	NNS	PS
.	.	PS

No	DT	O
difference	NN	O
in	IN	O
cooperation	NN	O
was	VBD	O
found	VBN	O
.	.	O

Presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
a	DT	O
contrast	NN	O
condition	NN	O
,	,	O
where	WRB	O
couples	NNS	O
reported	VBD	O
on	IN	O
one	CD	O
therapist	NN	PH
process	NN	PH
after	IN	O
already	RB	O
experiencing	VBG	O
its	PRP$	O
opposite	NN	O
,	,	O
led	VBN	O
to	TO	O
main	JJ	O
effects	NNS	O
for	IN	O
responsibility	NN	O
and	CC	O
struggle	NN	O
,	,	O
and	CC	O
mediated	VBD	O
effects	NNS	O
of	IN	O
struggle	NN	O
and	CC	O
cooperation	NN	O
.	.	O

Generally	NNP	O
speaking	NN	O
,	,	O
responsibility	NN	O
was	VBD	O
even	RB	O
higher	JJR	O
during	IN	O
couple-responsible	JJ	PS
episodes	NNS	PS
and	CC	O
even	RB	O
lower	JJR	O
during	IN	O
therapist-responsible	JJ	PS
episodes	NNS	PS
when	WRB	O
contrast	NN	O
was	VBD	O
present	JJ	O
.	.	O

Similarly	RB	O
,	,	O
struggle	NN	O
was	VBD	O
even	RB	O
lower	JJR	O
during	IN	O
couple-responsible	JJ	PS
episodes	NNS	PS
and	CC	O
even	RB	O
higher	JJR	O
during	IN	O
therapist-responsible	JJ	PH
episodes	NNS	PH
when	WRB	O
contrast	NN	O
was	VBD	O
present	JJ	O
.	.	O

For	IN	O
both	DT	O
couple-responsible	JJ	O
and	CC	O
therapist-responsible	JJ	O
episodes	NNS	O
,	,	O
cooperation	NN	O
was	VBD	O
negatively	RB	O
affected	VBN	O
by	IN	O
a	DT	O
shift	NN	O
from	IN	O
the	DT	O
prior	JJ	O
,	,	O
opposite	JJ	O
therapist	NN	O
process	NN	O
.	.	O

Significant	JJ	O
proportions	NNS	O
of	IN	O
the	DT	O
variance	NN	O
in	IN	O
responsibility	NN	O
,	,	O
struggle	NN	O
,	,	O
and	CC	O
cooperation	NN	O
,	,	O
however	RB	O
,	,	O
were	VBD	O
not	RB	O
accounted	VBN	O
for	IN	O
by	IN	O
therapist	JJ	O
process	NN	O
alone	RB	O
.	.	O

Addition	NN	O
of	IN	O
fexofenadine	NN	PM
to	TO	O
inhaled	VB	PM
corticosteroid	JJ	PM
therapy	NN	PM
to	TO	O
reduce	VB	O
inflammatory	JJ	O
biomarkers	NNS	O
in	IN	O
atopic	NN	O
asthma	NN	O
.	.	O

BACKGROUND	IN	O
We	PRP	O
previously	RB	O
showed	VBD	O
that	IN	O
H1-antihistamines	NNP	O
may	MD	O
shift	VB	O
the	DT	O
PC20	NNP	O
(	(	O
provocation	NN	O
concentration	NN	O
that	WDT	O
caused	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
1	CD	O
second	NN	O
of	IN	O
20	CD	O
%	NN	O
)	)	O
threshold	NN	O
to	TO	O
adenosine	VB	O
monophosphate	NN	O
(	(	O
AMP	NNP	O
)	)	O
challenge	NN	O
but	CC	O
may	MD	O
paradoxically	RB	O
prolong	VB	O
recovery	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
measure	VB	O
AMP	NNP	O
recovery	NN	O
using	VBG	O
a	DT	O
constant	JJ	O
predetermined	VBN	O
AMP	NNP	O
PC20	NNP	O
and	CC	O
to	TO	O
evaluate	VB	O
whether	IN	O
fexofenadine	NN	PM
use	NN	O
confers	NNS	O
add-on	JJ	O
effects	NNS	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
fluticasone	NN	PM
propionate	NN	PM
alone	RB	O
or	CC	O
combined	VBN	PM
fluticasone	CD	PM
propionate-salmeterol	NN	PM
.	.	O

METHODS	NNP	O
Fourteen	NNP	O
atopic	NN	O
patients	NNS	O
with	IN	O
mild-to-moderate	JJ	O
asthma	NN	O
(	(	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
1	CD	O
second	NN	O
of	IN	O
76	CD	O
%	NN	O
)	)	O
completed	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	NN	O
study	NN	O
consisting	VBG	O
of	IN	O
3-week	JJ	O
treatment	NN	O
blocks	NNS	O
of	IN	O
either	DT	O
fluticasone	JJ	PM
propionate-salmeterol	NN	PM
,	,	O
250	CD	O
microg	NN	O
twice	RB	O
daily	RB	O
,	,	O
or	CC	O
fluticasone	JJ	PM
propionate	NN	PM
alone	RB	PM
,	,	O
250	CD	O
microg	NN	O
twice	RB	O
daily	RB	O
,	,	O
in	IN	O
conjunction	NN	O
with	IN	O
either	DT	O
fexofenadine	NN	PM
,	,	O
180	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
,	,	O
or	CC	O
matched	VBD	O
placebo	NN	C
.	.	O

Recovery	NN	O
after	IN	O
a	DT	O
predetermined	JJ	O
AMP	NNP	O
PC20	NNP	O
challenge	NN	O
was	VBD	O
measured	VBN	O
(	(	O
primary	JJ	O
outcome	NN	O
)	)	O
,	,	O
along	IN	O
with	IN	O
exhaled	JJ	O
nitric	JJ	O
oxide	NN	O
levels	NNS	O
,	,	O
plasma	NN	O
eosinophil	NN	O
cationic	JJ	O
protein	NN	O
levels	NNS	O
,	,	O
peripheral	JJ	O
eosinophil	NN	O
counts	NNS	O
,	,	O
pulmonary	JJ	O
function	NN	O
,	,	O
diary	JJ	O
card	NN	O
outcomes	NNS	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
all	DT	O
secondary	JJ	O
outcomes	NNS	O
)	)	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
primary	JJ	O
or	CC	O
secondary	JJ	O
outcomes	NNS	O
when	WRB	O
fexofenadine	NN	PM
was	VBD	O
added	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
fluticasone	JJ	PM
propionate-salmeterol	NN	PM
or	CC	O
fluticasone	NN	PM
propionate	NN	PM
alone	RB	O
.	.	O

The	DT	O
mean	NN	O
AMP	NNP	O
recovery	NN	O
time	NN	O
was	VBD	O
25.0	CD	O
vs	NN	O
23.4	CD	O
minutes	NNS	O
for	IN	O
fexofenadine	NN	PM
and	CC	O
placebo	NN	C
,	,	O
respectively	RB	O
,	,	O
as	IN	O
add-on	JJ	O
to	TO	O
fluticasone-salmeterol	NN	PM
and	CC	O
22.5	CD	O
vs	NN	O
23.9	CD	O
minutes	NNS	O
,	,	O
respectively	RB	O
,	,	O
as	IN	O
add-on	JJ	O
to	TO	O
fluticasone	VB	PM
alone	RB	O
.	.	O

CONCLUSION	NNP	O
Fexofenadine	NNP	PM
did	VBD	O
not	RB	O
affect	VB	O
recovery	NN	O
to	TO	O
a	DT	O
fixed	VBN	O
dose	NN	O
of	IN	O
AMP	NNP	O
challenge	NN	O
or	CC	O
any	DT	O
other	JJ	O
surrogate	JJ	O
inflammatory	NN	O
markers	NNS	O
when	WRB	O
given	VBN	O
as	IN	O
add-on	JJ	O
therapy	NN	O
to	TO	O
corticosteroid-treatedatopic	JJ	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
whiplash	NN	O
associated	VBN	O
neck	RB	O
pain	VBP	O
[	RB	O
corrected	VBN	O
]	NN	O
with	IN	O
botulinum	JJ	PM
toxin-A	NN	PM
:	:	PM
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Up	NNP	O
to	TO	O
87	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
whiplash	NN	O
associated	VBN	O
disorder	NN	O
(	(	O
WAD	NNP	O
)	)	O
have	VBP	O
some	DT	O
degree	NN	O
of	IN	O
muscle	NN	O
spasm	NN	O
that	WDT	O
is	VBZ	O
contributory	JJ	O
to	TO	O
both	DT	O
pain	NN	O
and	CC	O
dysfunction	NN	O
.	.	O

Botulinum	NNP	PM
toxin	NN	PM
A	NNP	PM
(	(	PM
BTX-A	NNP	PM
)	)	PM
produces	VBZ	O
prolonged	JJ	O
muscle	NN	O
relaxation	NN	O
that	WDT	O
is	VBZ	O
dose-dependent	JJ	O
and	CC	O
can	MD	O
be	VB	O
easily	RB	O
targeted	VBN	O
to	TO	O
affected	JJ	O
muscles	NNS	O
.	.	O

BTX-A	NNP	O
therapy	NN	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
form	NN	O
of	IN	O
therapy	NN	O
offering	VBG	O
an	DT	O
alternative	NN	O
or	CC	O
adjunct	NN	O
to	TO	O
conventional	JJ	O
modalities	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
BTX-A	NNP	PM
as	IN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
WAD	NNP	O
.	.	O

METHODS	NNP	O
This	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	C
controlled	VBD	O
study	NN	O
compares	VBZ	O
outcome	JJ	O
measures	NNS	O
in	IN	O
26	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
neck	NN	O
pain	NN	O
(	(	O
WAD-II	NNP	O
chronic	NN	O
)	)	O
subsequent	NN	O
to	TO	O
a	DT	O
motor	NN	O
vehicle	NN	O
accident	NN	O
.	.	O

One-half	NN	O
of	IN	O
the	DT	O
patients	NNS	O
received	VBD	O
100	CD	PM
units	NNS	PM
BTX-A	NNP	PM
,	,	PM
diluted	VBD	PM
in	IN	PM
1	CD	PM
ml	NNS	PM
saline	NN	PM
,	,	O
while	IN	O
the	DT	O
other	JJ	C
half	NN	C
received	VBD	C
just	RB	C
saline	NN	C
(	(	O
1	CD	O
ml	NN	O
)	)	O
.	.	O

Five	CD	O
trigger	NN	O
points	NNS	O
received	VBD	O
0.2	CD	O
ml	NNS	O
each	DT	O
of	IN	O
injectant	JJ	O
via	IN	O
a	DT	O
30	CD	O
gauge	NN	O
needle	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
total	JJ	O
subjective	JJ	O
neck	NN	O
,	,	O
shoulder	NN	O
,	,	O
and	CC	O
head	NN	O
pain	NN	O
based	VBN	O
on	IN	O
visual	JJ	O
analog	NN	O
scales	NNS	O
;	:	O
objective	JJ	O
total	JJ	O
range	NN	O
of	IN	O
neck	NN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Vernon-Mior	NNP	O
subjective	JJ	O
function	NN	O
index	NN	O
.	.	O

Followup	CD	O
assessments	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
post-treatment	JJ	O
.	.	O

RESULTS	NNP	O
Fourteen	NNP	O
subjects	VBZ	O
receiving	VBG	O
BTX-A	NNP	PM
and	CC	O
12	CD	O
receiving	NN	O
saline	NN	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
improvement	NN	O
in	IN	O
ROM	NNP	O
and	CC	O
reduction	NN	O
in	IN	O
pain	NN	O
at	IN	O
2	CD	O
weeks	NNS	O
post-injection	NN	O
.	.	O

At	IN	O
4	CD	O
weeks	NNS	O
post-injection	NN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
from	IN	O
preinjection	NN	O
levels	NNS	O
(	(	O
p	VB	O
<	RB	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
placebo	NN	O
group	NN	O
showed	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
at	IN	O
any	DT	O
post-treatment	JJ	O
time	NN	O
.	.	O

The	DT	O
Vernon-Mior	JJ	O
scale	NN	O
revealed	VBD	O
a	DT	O
trend	NN	O
to	TO	O
improvement	NN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
BTX-A	NNP	PM
treatment	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
WAD	NNP	O
II	NNP	O
neck	NN	O
pain	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
improvement	NN	O
in	IN	O
ROM	NNP	O
and	CC	O
subjective	JJ	O
pain	NN	O
compared	VBN	O
to	TO	O
a	DT	O
placebo	NN	O
group	NN	O
,	,	O
but	CC	O
only	RB	O
a	DT	O
trend	NN	O
to	TO	O
improvement	NN	O
in	IN	O
subjective	JJ	O
functioning	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
latanoprost	NN	PM
when	WRB	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
ocular	JJ	O
hypotensive	JJ	O
effect	NN	O
for	IN	O
24	CD	O
hours	NNS	O
and	CC	O
the	DT	O
tolerability	NN	O
of	IN	O
latanoprost	NN	PM
stored	VBN	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
30	CD	O
degrees	NNS	O
C.	NNP	O
Seventeen	NNP	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
crossover	NN	O
trial	NN	O
.	.	O

Latanoprost	VB	PM
0.005	CD	O
%	NN	O
(	(	O
Xalatan	NNP	PM
)	)	O
was	VBD	O
stored	VBN	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
or	CC	O
30	CD	O
degrees	NNS	O
C	NNP	O
for	IN	O
4	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
dark	NN	O
.	.	O

The	DT	O
subjects	NNS	O
enrolled	VBD	O
to	TO	O
the	DT	O
study	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
latanoprost	NN	PM
stored	VBD	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
or	CC	O
that	IN	O
stored	VBN	O
at	IN	O
30	CD	O
degrees	NNS	O
C.	NNP	O
The	DT	O
eye	NN	O
drop	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
right	JJ	O
eye	NN	O
of	IN	O
each	DT	O
subject	NN	O
for	IN	O
3	CD	O
days	NNS	O
.	.	O

The	DT	O
left	NN	O
eye	NN	O
served	VBD	O
as	IN	O
a	DT	O
control	NN	O
without	IN	O
administration	NN	O
.	.	O

Slit-lamp	JJ	S
biomicroscopy	NN	S
and	CC	O
circadian	JJ	S
intra	NN	S
ocular	JJ	S
pressure	NN	S
(	(	S
IOP	NNP	S
)	)	S
curve	NN	S
was	VBD	O
performed	VBN	O
at	IN	O
Day	NNP	O
3	CD	O
,	,	O
every	DT	O
3	CD	O
hours	NNS	O
from	IN	O
6	CD	O
pm	NN	O
.	.	O

This	DT	O
procedure	NN	O
was	VBD	O
repeated	VBN	O
7	CD	O
days	NNS	O
after	IN	O
changing	VBG	O
the	DT	O
drug	NN	O
from	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
to	TO	O
30	CD	O
degrees	NNS	O
C	NNP	O
or	CC	O
vice	NN	O
versa	NN	O
,	,	O
and	CC	O
application	NN	O
to	TO	O
the	DT	O
left	NN	O
eye	NN	O
for	IN	O
3	CD	O
days	NNS	O
.	.	O

Eyes	NNS	O
treated	VBD	O
with	IN	O
latanoprost	NN	O
,	,	O
stored	VBD	O
both	DT	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
30	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
achieved	VBD	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
mean	NN	O
IOPs	NNP	O
than	IN	O
untreated	JJ	O
eyes	NNS	O
at	IN	O
all	DT	O
time	NN	O
points	NNS	O
,	,	O
except	IN	O
at	IN	O
21	CD	O
hours	NNS	O
treated	VBN	O
by	IN	O
the	DT	O
drug	NN	O
stored	VBD	O
at	IN	O
30	CD	O
degrees	NNS	O
C.	NNP	O
We	PRP	O
subtracted	VBD	O
the	DT	O
IOP	NNP	O
of	IN	O
eyes	NNS	O
receiving	VBG	O
latanoprost	NN	O
from	IN	O
the	DT	O
IOP	NNP	O
of	IN	O
untreated	JJ	O
eyes	NNS	O
for	IN	O
each	DT	O
time	NN	O
point	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
eye	NN	O
drops	NNS	O
(	(	O
delta	JJ	O
IOP	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
delta	NN	O
IOPs	NNP	O
with	IN	O
the	DT	O
drug	NN	O
stored	VBD	O
at	IN	O
4	CD	O
degrees	NNS	O
C	NNP	O
and	CC	O
30	CD	O
degrees	NNS	O
C.	NNP	O
During	IN	O
the	DT	O
study	NN	O
,	,	O
no	DT	O
subject	NN	O
developed	VBD	O
a	DT	O
serious	JJ	O
adverse	JJ	O
event	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
latanoprost	NN	O
stored	VBN	O
at	IN	O
30	CD	O
degrees	NNS	O
C	NNP	O
for	IN	O
4	CD	O
weeks	NNS	O
after	IN	O
opening	VBG	O
the	DT	O
bottle	NN	O
remains	VBZ	O
as	IN	O
effective	JJ	O
and	CC	O
safe	JJ	O
as	IN	O
latanoprost	NN	O
stored	VBN	O
under	IN	O
cold	JJ	O
conditions	NNS	O
.	.	O

Single	NNP	PH
negative	JJ	PH
colposcopy	NN	PH
:	:	O
is	VBZ	O
it	PRP	O
enough	RB	O
to	TO	O
rule	VB	O
out	IN	O
high-grade	JJ	O
disease	NN	O
?	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
that	IN	O
women	NNS	O
who	WP	O
have	VBP	O
a	DT	O
negative	JJ	O
colposcopic	NN	O
examination	NN	O
or	CC	O
who	WP	O
have	VBP	O
no	DT	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
(	(	O
CIN	NNP	O
)	)	O
on	IN	O
colposcopic	NN	PH
biopsy	NN	PH
can	MD	O
be	VB	O
safely	RB	O
returned	VBN	O
to	TO	O
routine	VB	O
screening	VBG	O
with	IN	O
the	DT	O
next	JJ	O
visit	NN	O
being	VBG	O
three	CD	O
or	CC	O
five	CD	O
years	NNS	O
later	RB	O
.	.	O

We	PRP	O
present	JJ	O
data	NNS	O
regarding	VBG	O
551	CD	O
women	NNS	O
who	WP	O
had	VBD	O
colposcopy	NN	PH
in	IN	O
Wales	NNP	O
for	IN	O
a	DT	O
low-grade	JJ	O
cytological	JJ	O
abnormality	NN	O
and	CC	O
who	WP	O
were	VBD	O
followed	VBN	O
through	IN	O
Cervical	NNP	O
Screening	NNP	O
Wales	NNP	O
for	IN	O
subsequent	JJ	O
CIN	NNP	O
.	.	O

Of	IN	O
436	CD	O
women	NNS	O
declared	VBD	O
CIN	NNP	O
free	JJ	O
initially	RB	O
,	,	O
26	CD	O
(	(	O
6.0	CD	O
%	NN	O
)	)	O
had	VBD	O
high-grade	JJ	O
CIN	NNP	O
diagnosed	VBD	O
on	IN	O
follow-up	NN	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
additional	JJ	O
screening	NN	O
at	IN	O
an	DT	O
interval	NN	O
of	IN	O
less	JJR	O
than	IN	O
three	CD	O
years	NNS	O
should	MD	O
be	VB	O
offered	VBN	O
to	TO	O
women	NNS	O
with	IN	O
a	DT	O
negative	JJ	O
colposcopy	NN	O
or	CC	O
a	DT	O
biopsy	NN	O
without	IN	O
CIN	NNP	O
.	.	O

Bronchodilator	NNP	O
response	NN	O
to	TO	O
salbutamol	VB	PM
after	IN	O
spontaneous	JJ	O
recovery	NN	O
from	IN	O
nonspecific	JJ	O
bronchial	JJ	O
provocation	NN	O
tests	NNS	O
in	IN	O
asthma	NN	O
.	.	O

Assessment	NN	O
of	IN	O
airway	NN	O
responsiveness	NN	O
by	IN	O
bronchoprovocation	NN	O
and	CC	O
bronchodilatation	NN	O
tests	NNS	O
is	VBZ	O
important	JJ	O
in	IN	O
the	DT	O
diagnostic	JJ	O
work-up	JJ	O
protocol	NN	O
of	IN	O
bronchial	JJ	O
asthma	NN	O
and	CC	O
it	PRP	O
would	MD	O
be	VB	O
convenient	JJ	O
to	TO	O
undertake	VB	O
both	DT	O
tests	NNS	O
on	IN	O
the	DT	O
same	JJ	O
occasion	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
this	DT	O
can	MD	O
be	VB	O
done	VBN	O
accurately	RB	O
.	.	O

Therefore	RB	O
,	,	O
this	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
prior	JJ	O
bronchial	JJ	O
provocation	NN	O
test	NN	O
on	IN	O
the	DT	O
bronchodilator	NN	O
response	NN	O
to	TO	O
salbutamol	VB	PM
after	IN	O
spontaneous	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV1	NNP	O
)	)	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
asthmatic	JJ	O
subjects	NNS	O
.	.	O

On	IN	O
two	CD	O
separate	JJ	O
occasions	NNS	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
of	IN	O
day	NN	O
,	,	O
concentration-response	JJ	O
studies	NNS	O
with	IN	O
inhaled	JJ	O
histamine	NN	PM
or	CC	O
methacholine	NN	PM
,	,	O
or	CC	O
a	DT	O
sham	JJ	PM
challenge	NN	PM
with	IN	PM
normal	JJ	PM
saline	NN	PM
were	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
a	DT	O
blinded	JJ	O
,	,	O
randomized	JJ	O
manner	NN	O
.	.	O

Changes	NNS	O
in	IN	O
airway	NN	O
calibre	NN	O
were	VBD	O
followed	VBN	O
as	IN	O
FEV1	NNP	O
and	CC	O
agonist	JJ	O
responsiveness	NN	O
expressed	VBN	O
as	IN	O
the	DT	O
provocative	JJ	O
concentration	NN	O
causing	VBG	O
a	DT	O
20	CD	O
%	NN	O
fall	NN	O
in	IN	O
FEV1	NNP	O
(	(	O
PC20	NNP	O
)	)	O
.	.	O

After	IN	O
either	DT	O
spontaneous	JJ	O
recovery	NN	O
or	CC	O
a	DT	O
fixed-duration	JJ	O
wait	NN	O
of	IN	O
45	CD	O
min	NNS	O
(	(	O
when	WRB	O
appropriate	NN	O
)	)	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
2x100	CD	O
microg	NN	O
of	IN	O
salbutamol	NN	PM
from	IN	O
a	DT	O
metered	VBN	O
dose	NN	O
inhaler	NN	O
with	IN	O
a	DT	O
spacer	NN	O
.	.	O

The	DT	O
bronchodilator	NN	O
response	NN	O
to	TO	O
salbutamol	VB	O
was	VBD	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
of	IN	O
initial	JJ	O
FEV1	NNP	O
(	(	O
deltaFEV1	CD	O
%	NN	O
init	NN	O
)	)	O
.	.	O

Bronchial	JJ	O
challenge	NN	O
with	IN	O
both	DT	O
agonists	NNS	O
failed	VBD	O
to	TO	O
alter	VB	O
significantly	RB	O
the	DT	O
airway	NN	O
response	NN	O
to	TO	O
salbutamol	VB	O
,	,	O
with	IN	O
the	DT	O
deltaFEV1	NN	O
%	NN	O
init	JJ	O
mean	JJ	O
value	NN	O
(	(	O
range	NN	O
)	)	O
being	VBG	O
16.9	CD	O
%	NN	O
(	(	O
9.0-31.9	CD	O
)	)	O
and	CC	O
17.5	CD	O
%	NN	O
(	(	O
11.6-31.2	JJ	O
)	)	O
on	IN	O
the	DT	O
sham	NN	O
and	CC	O
histamine/methacholine	JJ	O
challenge	NN	O
day	NN	O
respectively	RB	O
.	.	O

It	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
the	DT	O
degree	NN	O
of	IN	O
bronchodilatation	NN	O
achieved	VBN	O
after	IN	O
salbutamol	JJ	O
200	CD	O
microg	NN	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
prior	JJ	O
bronchoprovocation	NN	O
testing	VBG	O
when	WRB	O
enough	JJ	O
time	NN	O
is	VBZ	O
allowed	VBN	O
for	IN	O
the	DT	O
airways	NNS	O
to	TO	O
recover	VB	O
spontaneously	RB	O
to	TO	O
baseline	VB	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
.	.	O

Thus	NNP	O
evaluation	NN	O
of	IN	O
airway	NN	O
responsiveness	NN	O
by	IN	O
both	DT	O
bronchial	JJ	O
provocation	NN	O
tests	NNS	O
and	CC	O
bronchodilator	NN	O
testing	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
reliably	RB	O
within	IN	O
a	DT	O
few	JJ	O
hours	NNS	O
in	IN	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
cardiorespiratory	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
combination	NN	O
of	IN	O
ketamine	NN	PM
and	CC	O
propofol	NN	PM
,	,	O
propofol	VB	PM
alone	RB	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
ketamine	NN	PM
and	CC	O
diazepam	NN	PM
before	IN	O
and	CC	O
after	IN	O
induction	NN	PM
of	IN	PM
anesthesia	NN	PM
in	IN	PM
dogs	NNS	PM
sedated	VBN	PM
with	IN	PM
acepromazine	NN	PM
and	CC	PM
oxymorphone	NN	PM
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
cardiorespiratory	JJ	O
effects	NNS	O
of	IN	O
IV	NNP	O
administration	NN	O
of	IN	O
propofol	NN	PM
(	(	O
4	CD	O
mg/kg	NN	O
)	)	O
,	,	O
ketamine	JJ	PM
hydrochloride	NN	PM
and	CC	PM
propofol	NN	PM
(	(	O
2	CD	O
mg/kg	RB	O
each	DT	O
;	:	O
K-P	NNP	O
)	)	O
,	,	O
or	CC	O
ketamine	VB	PM
hydrochloride	NN	PM
(	(	O
5	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
diazepam	NN	PM
(	(	O
0.2	CD	O
mg/kg	NN	O
;	:	O
K-D	NNP	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	PM
(	(	O
IoA	NNP	O
)	)	O
in	IN	O
dogs	NNS	O
sedated	VBN	O
with	IN	O
acepromazine	JJ	PM
maleate	NN	PM
and	CC	O
oxymorphone	NN	PM
hydrochloride	NN	PM
.	.	O

ANIMALS	$	O
10	CD	O
healthy	JJ	O
adult	NN	O
Beagles	NNP	O
.	.	O

PROCEDURES	NNP	O
Each	DT	O
dog	NN	O
was	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
2	CD	O
of	IN	O
3	CD	O
treatments	NNS	O
(	(	O
1-week	JJ	O
interval	NN	O
)	)	O
.	.	O

For	IN	O
instrumentation	NN	O
prior	RB	O
to	TO	O
each	DT	O
treatment	NN	O
,	,	O
each	DT	O
dog	NN	O
was	VBD	O
anesthetized	VBN	PM
with	IN	PM
isoflurane	NN	PM
.	.	O

After	IN	O
full	JJ	O
recovery	NN	O
,	,	O
acepromazine	NN	PM
(	(	O
0.02	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
oxymorphone	NN	PM
(	(	O
0.05	CD	O
mg/kg	NN	O
)	)	O
were	VBD	O
administered	VBN	O
IV	NNP	O
.	.	O

Fifteen	NNP	O
minutes	NNS	O
later	RB	O
(	(	O
before	IN	O
IoA	NNP	O
)	)	O
,	,	O
each	DT	O
dog	NN	O
received	VBD	O
treatment	NN	O
IV	NNP	O
with	IN	O
propofol	NN	PM
,	,	PM
K-P	NNP	PM
,	,	PM
or	CC	PM
K-D.	NNP	PM
Cardiorespiratory	NNP	O
and	CC	O
arterial	JJ	O
blood	NN	O
gas	NN	O
variables	NNS	O
were	VBD	O
assessed	VBN	O
before	RB	O
,	,	O
immediately	RB	O
after	IN	O
,	,	O
and	CC	O
5	CD	O
minutes	NNS	O
after	IN	O
IoA	NNP	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
findings	NNS	O
before	IN	O
IoA	NNP	O
,	,	O
dogs	NNS	O
receiving	VBG	O
the	DT	O
K-P	NNP	PM
or	CC	O
K-D	NNP	PM
treatment	NN	O
had	VBD	O
increased	VBN	O
cardiac	JJ	O
output	NN	O
,	,	O
oxygen	NN	O
delivery	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
5	CD	O
minutes	NNS	O
after	IN	O
IoA	NNP	O
;	:	O
K-P	NNP	PM
administration	NN	O
did	VBD	O
not	RB	O
change	VB	O
mean	JJ	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
or	CC	O
stroke	NN	O
volume	NN	O
and	CC	O
decreased	JJ	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
.	.	O

Propofol	NNP	O
decreased	VBD	O
mean	JJ	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
immediately	RB	O
after	IN	O
IoA	NNP	O
but	CC	O
did	VBD	O
not	RB	O
change	VB	O
heart	NN	O
rate	NN	O
,	,	O
cardiac	JJ	O
output	NN	O
,	,	O
or	CC	O
oxygen	NN	O
delivery	NN	O
.	.	O

All	DT	O
treatments	NNS	O
caused	VBD	O
some	DT	O
degree	NN	O
of	IN	O
apnea	NN	O
,	,	O
hypoventilation	NN	O
,	,	O
and	CC	O
hypoxemia	NN	O
(	(	O
Pao2	NNP	O
<	VBZ	O
80	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
In	IN	O
dogs	NNS	O
,	,	O
K-P	NNP	PM
treatment	NN	O
maintained	VBD	O
mean	JJ	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
better	RBR	O
than	IN	O
propofol	VB	O
alone	JJ	O
and	CC	O
increased	JJ	O
heart	NN	O
rate	NN	O
,	,	O
cardiac	JJ	O
output	NN	O
,	,	O
or	CC	O
oxygen	NN	O
delivery	NN	O
,	,	O
as	IN	O
did	VBD	O
the	DT	O
K-D	NNP	PM
treatment	NN	O
.	.	O

Supplemental	JJ	O
100	CD	O
%	NN	O
oxygen	NN	O
should	MD	O
be	VB	O
provided	VBN	O
during	IN	O
IoA	NNP	O
with	IN	O
all	DT	O
3	CD	O
treatments	NNS	O
.	.	O

Isoflurane	NNP	O
and	CC	O
propofol	NN	O
for	IN	O
long-term	JJ	O
sedation	NN	O
in	IN	O
the	DT	O
intensive	JJ	O
care	NN	O
unit	NN	O
.	.	O

A	DT	O
crossover	NN	O
study	NN	O
.	.	O

Propofol	NNP	PM
and	CC	O
isoflurane	NN	PM
have	VBP	O
been	VBN	O
reported	VBN	O
recently	RB	O
to	TO	O
offer	VB	O
better	JJR	O
sedation	NN	O
than	IN	O
alternative	JJ	O
agents	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
require	VBP	O
long-term	JJ	O
ventilation	NN	O
in	IN	O
the	DT	O
Intensive	NNP	O
Care	NNP	O
Unit	NNP	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
report	NN	O
of	IN	O
a	DT	O
direct	JJ	O
comparison	NN	O
between	IN	O
propofol	NN	PM
and	CC	O
isoflurane	NN	PM
.	.	O

Twenty-four	CD	O
patients	NNS	O
predicted	VBN	O
to	TO	O
require	VB	O
artificial	JJ	O
ventilation	NN	O
for	IN	O
at	IN	O
least	JJS	O
48	CD	O
h	NNS	O
were	VBD	O
entered	VBN	O
into	IN	O
a	DT	O
randomised	VBN	O
crossover	NN	O
study	NN	O
to	TO	O
monitor	VB	O
sedation	NN	O
quality	NN	O
and	CC	O
time	NN	O
to	TO	O
recovery	NN	O
from	IN	O
sedation	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
agents	NNS	O
in	IN	O
either	DT	O
end-point	NN	O
,	,	O
with	IN	O
over	IN	O
95	CD	O
%	NN	O
optimal	JJ	O
sedation	NN	O
achieved	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
each	DT	O
drug	NN	O
.	.	O

Few	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
noted	VBN	O
.	.	O

Technological	JJ	O
advances	NNS	O
in	IN	O
the	DT	O
administration	NN	O
of	IN	O
volatile	JJ	O
agents	NNS	O
as	IN	O
long-term	JJ	O
sedatives	NNS	O
in	IN	O
the	DT	O
Intensive	NNP	O
Care	NNP	O
Unit	NNP	O
may	MD	O
facilitate	VB	O
their	PRP$	O
more	JJR	O
widespread	JJ	O
use	NN	O
.	.	O

Expectancies	NNS	O
,	,	O
not	RB	O
aroma	RB	O
,	,	O
explain	JJ	O
impact	NN	O
of	IN	O
lavender	NN	PM
aromatherapy	NN	PM
on	IN	O
psychophysiological	JJ	O
indices	NNS	O
of	IN	O
relaxation	NN	O
in	IN	O
young	JJ	O
healthy	JJ	O
women	NNS	O
.	.	O

OBJECTIVES	NNP	O
In	IN	O
aromatherapy	NN	PM
,	,	PM
lavender	JJR	PM
aroma	NN	PM
is	VBZ	O
reputed	VBN	O
to	TO	O
assist	VB	O
with	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
while	IN	O
there	EX	O
is	VBZ	O
much	JJ	O
anecdotal	JJ	O
evidence	NN	O
to	TO	O
that	DT	O
effect	NN	O
,	,	O
the	DT	O
empirical	JJ	O
literature	NN	O
is	VBZ	O
very	RB	O
inconsistent	JJ	O
.	.	O

Failure	NN	O
to	TO	O
employ	VB	O
adequate	JJ	O
placebos	NNS	C
,	,	O
proper	JJ	O
blinding	NN	O
,	,	O
objective	JJ	O
measures	NNS	O
,	,	O
or	CC	O
screening	NN	O
of	IN	O
prior	JJ	O
beliefs	NNS	O
about	IN	O
aromatherapy	NN	O
means	NNS	O
that	IN	O
many	JJ	O
previous	JJ	O
findings	NNS	O
could	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
sought	VBD	O
to	TO	O
establish	VB	O
whether	IN	O
lavender	NN	PM
aroma	NN	PM
and/or	JJ	O
expectancies	NNS	O
affect	VBP	O
post-stress	JJ	O
relaxation	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
double-blind	NN	O
,	,	O
3	CD	O
(	(	O
aroma	NN	O
)	)	O
x	VBZ	O
3	CD	O
(	(	O
instruction	NN	O
)	)	O
x	VBZ	O
10	CD	O
(	(	O
time	NN	O
in	IN	O
minutes	NNS	O
)	)	O
mixed-factorial	JJ	C
placebo-controlled	JJ	C
trial	NN	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
laboratory	NN	O
,	,	O
96	CD	O
healthy	JJ	O
undergraduate	JJ	O
women	NNS	O
were	VBD	O
exposed	VBN	PM
to	TO	PM
lavender	VB	PM
,	,	O
placebo	NN	C
,	,	O
or	CC	O
no	DT	Ot
aroma	NN	Ot
during	IN	O
physiologically	RB	O
assessed	VBN	O
relaxation	NN	O
after	IN	O
an	DT	O
arousing	VBG	O
cognitive	JJ	O
task	NN	O
.	.	O

Where	WRB	O
an	DT	O
aroma	NN	O
was	VBD	O
presented	VBN	O
,	,	O
an	DT	O
instructional	JJ	O
priming	NN	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
manipulate	VB	O
participants	NNS	O
'	POS	O
expectancies	NNS	O
about	IN	O
the	DT	O
aroma	NN	O
's	POS	O
likely	JJ	O
impact	NN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
relax	VB	O
.	.	O

RESULTS	NNP	O
Results	NNP	O
showed	VBD	O
no	DT	O
effect	NN	O
of	IN	O
aroma	NN	O
on	IN	O
galvanic	JJ	O
skin	NN	O
response	NN	O
during	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
nature	NN	O
of	IN	O
instructional	JJ	O
prime	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
relaxation	NN	O
patterns	NNS	O
:	:	O
when	WRB	O
expecting	VBG	O
the	DT	O
aroma	NN	O
to	TO	O
inhibit	VB	O
them	PRP	O
,	,	O
participants	NNS	O
relaxed	VBD	O
more	RBR	O
;	:	O
when	WRB	O
expecting	VBG	O
facilitation	NN	O
,	,	O
participants	NNS	O
relaxed	VBD	O
less	RBR	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
regard	NN	O
to	TO	O
self-reported	JJ	O
relaxation	NN	O
(	(	O
as	IN	O
represented	VBN	O
by	IN	O
changes	NNS	O
in	IN	O
state	NN	O
anxiety	NN	O
)	)	O
and	CC	O
was	VBD	O
independent	JJ	O
of	IN	O
ratings	NNS	O
of	IN	O
attitudes	NNS	O
towards	NNS	O
aromatherapy	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
imply	VBP	O
that	IN	O
the	DT	O
previous	JJ	O
associations	NNS	O
of	IN	O
lavender	NN	C
aroma	NN	C
with	IN	O
assisted	JJ	O
relaxation	NN	O
may	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
relevant	JJ	O
expectancies	NNS	O
are	VBP	O
easily	RB	O
manipulable	JJ	O
.	.	O

Primary	JJ	PH
stenting	NN	PH
of	IN	O
occluded	JJ	O
native	JJ	O
coronary	JJ	O
arteries	NNS	O
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Primary	NNP	O
Stenting	NNP	O
of	IN	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
(	(	O
PRISON	NNP	O
)	)	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Primary	NNP	S
intracoronary	JJ	S
stent	NN	S
placement	NN	S
after	IN	O
successfully	RB	O
crossing	VBG	O
chronic	JJ	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
high	JJ	O
restenosis	NN	O
rate	NN	O
at	IN	O
long-term	JJ	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
conventional	JJ	PH
balloon	NN	PH
angioplasty	NN	PH
.	.	PH

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
,	,	O
balloon	NN	PH
angioplasty	NN	PH
was	VBD	O
compared	VBN	O
with	IN	O
stent	JJ	S
implantation	NN	S
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
months	NNS	O
with	IN	O
angiographic	JJ	O
follow-up	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Quantitative	JJ	O
coronary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
core	NN	O
lab	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
200	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Baseline	JJ	O
characteristics	NNS	O
were	VBD	O
evenly	RB	O
distributed	VBN	O
.	.	O

After	IN	O
the	DT	O
procedure	NN	O
the	DT	O
mean	NN	O
minimal	JJ	O
luminal	JJ	O
diameter	NN	O
in	IN	O
the	DT	O
conventional	JJ	PH
group	NN	O
was	VBD	O
2.34	CD	O
+/-	JJ	O
0.46	CD	O
mm	NN	O
versus	NN	O
2.90	CD	O
+/-	JJ	O
0.41	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	S
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

The	DT	O
6-month	JJ	O
angiographic	JJ	O
follow-up	NN	O
showed	VBD	O
a	DT	O
mean	JJ	O
minimal	JJ	O
luminal	JJ	O
diameter	NN	O
of	IN	O
1.57	CD	O
+/-	JJ	O
0.74	CD	O
mm	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
1.93	CD	O
+/-	JJ	O
0.85	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.009	NNP	O
)	)	O
and	CC	O
a	DT	O
mean	JJ	O
diameter	NN	O
stenosis	NN	O
of	IN	O
44.7	CD	O
%	NN	O
+/-	JJ	O
25.0	CD	O
%	NN	O
versus	IN	O
35.5	CD	O
%	NN	O
+/-	JJ	O
26.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=.036	NNP	O
)	)	O
.	.	O

Binary	JJ	O
angiographic	JJ	O
restenosis	NN	O
(	(	O
>	JJ	O
50	CD	O
%	NN	O
diameter	JJ	O
stenosis	NN	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
33	CD	O
%	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
22	CD	O
%	NN	O
in	IN	O
the	DT	O
stented	VBN	S
group	NN	O
(	(	O
P	NNP	O
=.137	NNP	O
)	)	O
.	.	O

The	DT	O
reocclusion	NN	O
rates	NNS	O
were	VBD	O
7.3	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
1.00	CD	O
)	)	O
.	.	O

At	IN	O
12	CD	O
month	NN	O
follow-up	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
conventional	JJ	PM
group	NN	O
(	(	O
29	CD	O
%	NN	O
versus	IN	O
13	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
stenting	VBG	S
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
balloon	VB	PH
angioplasty	JJ	PH
alone	RB	PH
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
need	NN	O
for	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
and	CC	O
a	DT	O
lower	JJR	O
,	,	O
but	CC	O
not	RB	O
significant	JJ	O
,	,	O
restenosis	NN	O
rate	NN	O
.	.	O

Effects	NNS	O
of	IN	O
aspirin	NN	PM
and	CC	O
clopidogrel	NN	PM
in	IN	O
healthy	JJ	O
men	NNS	O
measured	VBN	O
by	IN	O
platelet	NN	O
aggregation	NN	O
and	CC	O
PFA-100	NNP	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
generally	RB	O
accepted	VBN	O
definitions	NNS	O
for	IN	O
low-response	NN	O
(	(	O
frequently	RB	O
called	VBN	O
resistance	NN	O
)	)	O
to	TO	O
the	DT	O
platelet	NN	O
inhibitors	NNS	O
,	,	O
aspirin	NN	PM
and	CC	O
clopidogrel	NN	PM
.	.	PM

Low-response	NN	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
atherosclerotic	JJ	O
patients	NNS	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
define	VB	O
the	DT	O
normal	JJ	O
drug	NN	O
responses	NNS	O
in	IN	O
healthy	JJ	O
men	NNS	O
.	.	O

Platelet	NNP	O
function	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
20	CD	O
healthy	JJ	O
men	NNS	O
during	IN	O
11	CD	O
days	NNS	O
of	IN	O
aspirin	NN	PM
or	CC	O
clopidogrel	NN	PM
intake	NN	O
,	,	O
using	VBG	O
light	JJ	O
transmission	NN	O
aggregometry	NN	O
(	(	O
LTA	NNP	O
)	)	O
and	CC	O
the	DT	O
Platelet	NNP	O
Function	NNP	O
Analyzer	NNP	O
100	CD	O
(	(	O
PFA-100	NNP	O
)	)	O
.	.	O

The	DT	O
lower	JJR	O
limits	NNS	O
for	IN	O
LTA	NNP	O
at	IN	O
baseline	NN	O
were	VBD	O
64	CD	O
%	NN	O
and	CC	O
61	CD	O
%	NN	O
,	,	O
using	VBG	O
arachidonic	JJ	O
acid	NN	O
and	CC	O
ADP	NNP	O
as	IN	O
agonists	NNS	O
,	,	O
respectively	RB	O
.	.	O

During	IN	O
aspirin	JJ	PM
intake	VBP	O
the	DT	O
LTA	NNP	O
results	NNS	O
were	VBD	O
stable	JJ	O
from	IN	O
day	NN	O
to	TO	O
day	NN	O
,	,	O
and	CC	O
an	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
9	CD	O
%	NN	O
arachidonic	JJ	O
acid	NN	O
stimulated	VBD	O
aggregation	NN	O
was	VBD	O
found	VBN	O
.	.	O

Clopidogrel	NNP	PM
intake	NN	O
was	VBD	O
best	RBS	O
shown	VBN	O
by	IN	O
ADP	NNP	O
induced	JJ	O
aggregation	NN	O
.	.	O

However	RB	O
,	,	O
two	CD	O
out	IN	O
of	IN	O
20	CD	O
individuals	NNS	O
exhibited	VBD	O
low-response	NN	O
to	TO	O
clopidogrel	VB	PM
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
18	CD	O
volunteers	NNS	O
an	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
48	CD	O
%	NN	O
aggregation	NN	O
was	VBD	O
found	VBN	O
.	.	O

We	PRP	O
found	VBD	O
an	DT	O
upper	JJ	O
limit	NN	O
for	IN	O
collagen-epinephrine	JJ	O
stimulated	JJ	O
PFA-100	JJ	O
results	NNS	O
of	IN	O
166	CD	O
s	NNS	O
at	IN	O
baseline	NN	O
.	.	O

During	IN	O
aspirin	JJ	PM
intake	NN	O
,	,	O
these	DT	O
results	NNS	O
varied	VBD	O
considerably	RB	O
from	IN	O
day	NN	O
to	TO	O
day	NN	O
in	IN	O
nine	CD	O
out	IN	O
of	IN	O
20	CD	O
men	NNS	O
,	,	O
resulting	VBG	O
in	IN	O
an	DT	O
overlap	NN	O
between	IN	O
the	DT	O
reference	NN	O
ranges	VBZ	O
at	IN	O
baseline	NN	O
and	CC	O
during	IN	O
therapy	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
platelet	NN	O
inhibition	NN	O
by	IN	O
aspirin	NN	PM
and	CC	O
clopidogrel	NN	PM
assessed	VBN	O
by	IN	O
aggregometry	NN	O
was	VBD	O
stable	JJ	O
during	IN	O
11	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
and	CC	O
reference	NN	O
ranges	NNS	O
were	VBD	O
established	VBN	O
.	.	O

The	DT	O
PFA-100	JJ	O
results	NNS	O
varied	VBD	O
greatly	RB	O
and	CC	O
low-response	NN	O
was	VBD	O
not	RB	O
precisely	RB	O
defined	VBN	O
by	IN	O
this	DT	O
method	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
the	DT	O
MA-sensitive	JJ	O
leukocyte	NN	O
chemotaxis	NN	O
in	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
griseofulvin	NN	PM
treatment	NN	O
.	.	O

Polymorphonuclear	JJ	O
leukocyte	NN	O
(	(	O
PMN	NNP	O
)	)	O
chemotaxis	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
play	VB	O
an	DT	O
essential	JJ	O
role	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

PMN	NNP	O
chemotaxis	NN	O
is	VBZ	O
in	IN	O
part	NN	O
sensitive	NN	O
to	TO	O
microtubule	VB	O
antagonists	NNS	O
(	(	O
MAs	NNP	O
)	)	O
,	,	O
e.g	RB	O
.	.	O

colchicine	NN	O
.	.	O

The	DT	O
antimycotic	JJ	O
antibiotic	JJ	O
griseofulvin	NN	PM
inhibits	VBZ	O
the	DT	O
MA-sensitive	JJ	O
PMN	NNP	O
chemotaxis	NN	O
in	IN	O
vitro	NN	O
in	IN	O
concentrations	NNS	O
far	RB	O
below	IN	O
those	DT	O
obtained	VBN	O
in	IN	O
serum	NN	O
during	IN	O
antimycotic	JJ	PH
therapy	NN	PH
.	.	PM

The	DT	O
role	NN	O
of	IN	O
the	DT	O
MA-sensitive	JJ	O
chemotaxis	NN	O
in	IN	O
rheumatoid	JJ	O
arthritis	NN	O
could	MD	O
thus	RB	O
be	VB	O
elucidated	VBN	O
by	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
of	IN	O
griseofulvin	NN	E
treatment	NN	O
.	.	O

Griseofulvin	NNP	PM
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
was	VBD	O
tested	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
study	NN	O
versus	IN	O
placebo	NN	C
(	(	O
m	JJ	O
=	NNP	O
19	CD	O
)	)	O
during	IN	O
one	CD	O
year	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
of	IN	O
mild-moderate	JJ	O
activity	NN	O
.	.	O

No	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
griseofulvin	NN	PM
treatment	NN	O
was	VBD	O
noted	VBN	O
on	IN	O
clinical	JJ	O
symptoms	NNS	O
or	CC	O
laboratory	JJ	O
parameters	NNS	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
placebo-treated	JJ	C
patients	NNS	O
showed	VBD	O
more	RBR	O
improvement	NN	O
than	IN	O
the	DT	O
griseofulvin-treated	JJ	PM
patients	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
therefore	RB	O
suggested	VBN	O
that	IN	O
the	DT	O
MA-sensitive	JJ	O
chemotaxis	NN	O
plays	VBZ	O
a	DT	O
reparative	JJ	O
role	NN	O
in	IN	O
the	DT	O
inflammatory	JJ	O
lesions	NNS	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

Antioxidant	JJ	PM
supplementation	NN	O
and	CC	O
exercise-induced	JJ	O
oxidative	JJ	O
stress	NN	O
in	IN	O
the	DT	O
60-year-old	JJ	O
as	IN	O
measured	VBN	O
by	IN	O
antipyrine	NN	O
hydroxylates	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
antioxidant	JJ	PM
supplementation	NN	PM
on	IN	O
exercise-induced	JJ	O
oxidative	JJ	O
stress	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
older	JJR	O
adults	NNS	O
(	(	O
60	CD	O
(	(	O
SE	NNP	O
1	CD	O
)	)	O
years	NNS	O
;	:	O
BMI	NNP	O
26	CD	O
(	(	O
SE	NNP	O
1	CD	O
)	)	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
in	IN	O
two	CD	O
groups	NNS	O
:	:	O
supplementation	NN	PM
(	(	O
n	JJ	O
11	CD	O
)	)	O
with	IN	O
100	CD	O
mg	NNS	O
dl-alpha-tocopheryl	JJ	PM
acetate	NN	PM
,	,	O
200	CD	O
mg	NN	O
ascorbic	JJ	PM
acid	NN	PM
,	,	O
and	CC	O
2	CD	O
mg	NN	O
beta-carotene	NN	PM
,	,	O
and	CC	O
placebo	NN	C
(	(	O
n	JJ	O
9	CD	O
)	)	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
the	DT	O
12	CD	O
week	NN	O
supplementation	NN	O
period	NN	O
,	,	O
subjects	NNS	O
cycled	VBD	O
for	IN	O
45	CD	O
min	NN	O
at	IN	O
submaximal	JJ	O
intensity	NN	O
(	(	O
50	CD	O
%	NN	O
maximal	JJ	O
workload	NN	O
capacity	NN	O
)	)	O
.	.	O

Antipyrine	NNP	PM
was	VBD	O
used	VBN	O
as	IN	O
marker	NN	O
for	IN	O
oxidative	JJ	O
stress	NN	O
.	.	O

Antipyrine	NNP	O
reacts	VBZ	O
quickly	RB	O
with	IN	O
hydroxyl	JJ	O
radicals	NNS	O
to	TO	O
form	VB	O
para-	JJ	O
and	CC	O
ortho-hydroxyantipyrine	JJ	O
.	.	O

The	DT	O
latter	JJ	O
metabolite	NN	O
is	VBZ	O
not	RB	O
formed	VBN	O
in	IN	O
man	NN	O
through	IN	O
the	DT	O
mono-oxygenase	JJ	O
pathway	NN	O
of	IN	O
cytochrome	JJ	O
P450	NNP	O
.	.	O

Daily	NNP	O
supplementation	NN	PM
significantly	RB	O
increased	VBD	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
alpha-tocopherol	NN	O
and	CC	O
beta-carotene	NN	O
in	IN	O
the	DT	O
supplemented	VBN	O
group	NN	O
(	(	O
Delta	NNP	O
14.4	CD	O
(	(	O
SE	NNP	O
3.2	CD	O
)	)	O
and	CC	O
0.4	CD	O
(	(	O
se	VB	O
0.1	CD	O
)	)	O
micromol/l	NN	O
;	:	O
P	NNP	O
<	VBZ	O
0.001	CD	O
and	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
,	,	O
within	IN	O
and	CC	O
between	IN	O
groups	NNS	O
,	,	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
exercise-induced	JJ	O
increase	NN	O
in	IN	O
the	DT	O
ratios	NNS	O
para-	JJ	O
and	CC	O
ortho-hydroxyantipyrine	JJ	O
to	TO	O
antipyrine	VB	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
supplementation	NN	PM
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
exercise-induced	JJ	O
increase	NN	O
in	IN	O
thiobarbituric	JJ	O
acid	NN	O
reactive	JJ	O
substances	NNS	O
in	IN	O
plasma	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
in	IN	O
60-year-old	JJ	O
subjects	NNS	O
antioxidant	JJ	PM
supplementation	NN	PM
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
exercise-induced	JJ	O
increase	NN	O
in	IN	O
oxidative	JJ	O
stress	NN	O
as	IN	O
measured	VBN	O
by	IN	O
free	JJ	O
radical	JJ	O
products	NNS	O
of	IN	O
antipyrine	NN	O
.	.	O

An	DT	O
empirical	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
and	CC	O
the	DT	O
Chronic	NNP	O
Respiratory	NNP	O
Disease	NNP	O
Questionnaire	NNP	O
(	(	O
CRQ	NNP	O
)	)	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
setting	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
Chronic	NNP	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
CRQ	NNP	O
)	)	O
and	CC	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
are	VBP	O
the	DT	O
two	CD	O
most	JJS	O
widely	RB	O
used	VBN	O
quality	NN	O
of	IN	O
life	NN	O
questionnaires	NNS	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

A	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
compare	VB	O
directly	RB	O
the	DT	O
self-administered	JJ	O
version	NN	O
of	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
the	DT	O
SGRQ	NNP	O
with	IN	O
respect	NN	O
to	TO	O
feasibility	NN	O
,	,	O
internal	JJ	O
consistency	NN	O
,	,	O
validity	NN	O
,	,	O
and	CC	O
sensitivity	NN	O
to	TO	O
changes	NNS	O
resulting	VBG	O
from	IN	O
bronchodilator	NN	O
therapy	NN	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
forty	VB	O
four	CD	O
patients	NNS	O
with	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
COPD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
three	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
either	DT	O
salmeterol	NN	PM
,	,	O
salmeterol	NN	PM
+	NNP	O
ipratropium	NN	PM
bromide	NN	PM
,	,	O
or	CC	O
placebo	NN	C
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
proportions	NNS	O
of	IN	O
missing	VBG	O
values	NNS	O
per	IN	O
patient	NN	O
were	VBD	O
low	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
(	(	O
0.54	CD	O
%	NN	O
for	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
2	CD	O
%	NN	O
for	IN	O
the	DT	O
SGRQ	NNP	O
)	)	O
.	.	O

The	DT	O
internal	JJ	O
consistency	NN	O
was	VBD	O
good	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
coefficients	NNS	O
>	VBP	O
/=	$	O
0.84	CD	O
for	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
>	NNP	O
/=	NNP	O
0.76	CD	O
for	IN	O
the	DT	O
SGRQ	NNP	O
)	)	O
.	.	O

Factor	NNP	O
analysis	NN	O
confirmed	VBD	O
the	DT	O
original	JJ	O
domain	NN	O
structure	NN	O
of	IN	O
the	DT	O
CRQ	NNP	O
but	CC	O
not	RB	O
of	IN	O
the	DT	O
SGRQ	NNP	O
.	.	O

Correlations	NNS	O
with	IN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
%	NN	O
predicted	VBN	O
and	CC	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
rate	NN	O
(	(	O
PEFR	NNP	O
)	)	O
were	VBD	O
low	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
but	CC	O
better	JJR	O
for	IN	O
the	DT	O
SGRQ	NNP	O
than	IN	O
for	IN	O
the	DT	O
CRQ	NNP	O
.	.	O

The	DT	O
ability	NN	O
to	TO	O
discriminate	VB	O
between	IN	O
subjects	NNS	O
with	IN	O
different	JJ	O
levels	NNS	O
of	IN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
was	VBD	O
somewhat	RB	O
better	JJR	O
for	IN	O
the	DT	O
SGRQ	NNP	O
.	.	O

The	DT	O
correlations	NNS	O
with	IN	O
symptom	JJ	O
scores	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
.	.	O

Cross	NNP	O
sectionally	RB	O
,	,	O
the	DT	O
scores	NNS	O
of	IN	O
the	DT	O
two	CD	O
questionnaires	NNS	O
were	VBD	O
moderately	RB	O
to	TO	O
highly	RB	O
correlated	VBN	O
(	(	O
coefficients	NNS	O
ranged	VBD	O
from	IN	O
0.35	CD	O
to	TO	O
0.72	CD	O
)	)	O
.	.	O

Longitudinally	RB	O
,	,	O
these	DT	O
correlations	NNS	O
were	VBD	O
lower	JJR	O
(	(	O
coefficients	NNS	O
ranged	VBD	O
from	IN	O
0.17	CD	O
to	TO	O
0.54	CD	O
)	)	O
but	CC	O
were	VBD	O
still	RB	O
significant	JJ	O
.	.	O

The	DT	O
CRQ	NNP	O
total	NN	O
and	CC	O
emotions	NNS	O
score	NN	O
and	CC	O
the	DT	O
SGRQ	NNP	O
symptoms	NNS	O
score	NN	O
were	VBD	O
the	DT	O
most	RBS	O
responsive	JJ	O
to	TO	O
change	VB	O
.	.	O

The	DT	O
SGRQ	NNP	O
symptoms	NNS	O
domain	NN	O
was	VBD	O
the	DT	O
only	JJ	O
domain	NN	O
where	WRB	O
the	DT	O
improvement	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
combination	NN	O
treatment	NN	O
crossed	VBD	O
the	DT	O
threshold	NN	O
for	IN	O
clinical	JJ	O
relevance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Since	IN	O
this	DT	O
analysis	NN	O
of	IN	O
reliability	NN	O
,	,	O
validity	NN	O
,	,	O
and	CC	O
responsiveness	NN	O
to	TO	O
change	VB	O
did	VBD	O
not	RB	O
clearly	RB	O
favour	VBP	O
one	CD	O
instrument	NN	O
above	IN	O
the	DT	O
other	JJ	O
,	,	O
the	DT	O
choice	NN	O
between	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
the	DT	O
SGRQ	NNP	O
can	MD	O
be	VB	O
based	VBN	O
on	IN	O
other	JJ	O
considerations	NNS	O
such	JJ	O
as	IN	O
the	DT	O
required	JJ	O
sample	NN	O
size	NN	O
or	CC	O
the	DT	O
availability	NN	O
of	IN	O
reference	NN	O
values	NNS	O
.	.	O

The	DT	O
long-term	JJ	O
effect	NN	O
of	IN	O
oxandrolone	NN	PM
on	IN	O
hepatic	JJ	O
acute	NN	O
phase	NN	O
proteins	VBZ	O
in	IN	O
severely	RB	O
burned	JJ	O
children	NNS	O
.	.	O

BACKGROUND	NNP	O
Acute	NNP	O
phase	NN	O
protein	NN	O
production	NN	O
is	VBZ	O
a	DT	O
hallmark	NN	O
of	IN	O
severe	JJ	O
burns	NNS	O
.	.	O

We	PRP	O
wondered	VBD	O
whether	IN	O
anabolic	JJ	O
treatment	NN	O
with	IN	O
oxandrolone	NN	O
would	MD	O
affect	VB	O
these	DT	O
proteins	NNS	O
.	.	O

METHODS	NNP	O
Thirty-five	JJ	O
children	NNS	O
with	IN	O
>	NN	O
or	CC	O
=40	CD	O
%	NN	O
total	JJ	O
body	NN	O
surface	NN	O
area	NN	O
burns	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	C
or	CC	O
oxandrolone	NN	PM
(	(	O
0.1	CD	O
mg/kg	NN	O
by	IN	O
mouth	JJ	O
twice	JJ	O
daily	RB	O
)	)	O
from	IN	O
postoperative	JJ	O
day	NN	O
5	CD	O
to	TO	O
1	CD	O
year	NN	O
postburn	NN	O
.	.	O

Levels	NNP	O
of	IN	O
constitutive	JJ	O
proteins	NNS	O
and	CC	O
acute	JJ	O
phase	NN	O
proteins	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
admission	NN	O
;	:	O
at	IN	O
discharge	NN	O
;	:	O
and	CC	O
at	IN	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
burn	NN	O
.	.	O

Total	JJ	O
albumin	JJ	O
supplementation	NN	O
and	CC	O
hepatic	JJ	O
transaminases	NNS	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Constitutive	JJ	O
proteins	NNS	O
such	JJ	O
as	IN	O
albumin	NN	O
,	,	O
prealbumin	NN	O
,	,	O
and	CC	O
retinol-binding	JJ	O
protein	NN	O
levels	NNS	O
increased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
acute	JJ	O
phase	NN	O
proteins	NNS	O
such	JJ	O
as	IN	O
alpha	JJ	O
1-acid	JJ	O
glycoprotein	NN	O
,	,	O
C3	NNP	O
complement	NN	O
,	,	O
alpha	JJ	O
2-macroglobulin	JJ	O
,	,	O
and	CC	O
fibrinogen	NN	O
levels	NNS	O
significantly	RB	O
decreased	VBN	O
in	IN	O
the	DT	O
oxandrolone	NN	O
group	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Albumin	NNP	O
supplementation	NN	O
during	IN	O
the	DT	O
acute	JJ	O
hospitalization	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
oxandrolone	NN	O
group	NN	O
.	.	O

Hepatic	JJ	O
transaminases	NNS	O
remained	VBD	O
within	IN	O
normal	JJ	O
levels	NNS	O
.	.	O

CONCLUSION	NNP	O
Treatment	NNP	O
with	IN	O
oxandrolone	NN	O
in	IN	O
severe	JJ	O
burns	NNS	O
significantly	RB	O
increases	VBZ	O
constitutive	JJ	O
protein	NN	O
and	CC	O
reduces	NNS	O
acute	JJ	O
phase	NN	O
protein	NN	O
levels	NNS	O
.	.	O

Randomised	VBN	O
trial	NN	O
of	IN	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	PM
ganciclovir	NN	PM
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
cytomegalovirus	NN	O
disease	NN	O
in	IN	O
liver-transplant	JJ	O
recipients	NNS	O
.	.	O

The	DT	O
Oral	NNP	O
Ganciclovir	NNP	PM
International	NNP	O
Transplantation	NNP	O
Study	NNP	O
Group	NNP	O
[	NNP	O
corrected	VBD	O
]	NNP	O
.	.	O

BACKGROUND	NNP	O
Cytomegalovirus	NNP	O
(	(	O
CMV	NNP	O
)	)	O
disease	NN	O
is	VBZ	O
a	DT	O
frequent	JJ	O
cause	NN	O
of	IN	O
serious	JJ	O
morbidity	NN	O
after	IN	O
solid-organ	JJ	O
transplantation	NN	O
.	.	O

The	DT	O
prophylactic	JJ	O
regimens	NNS	O
used	VBN	O
to	TO	O
prevent	VB	O
CMV	NNP	O
infection	NN	O
and	CC	O
disease	NN	O
have	VBP	O
shown	VBN	O
limited	JJ	O
benefit	NN	O
in	IN	O
seronegative	JJ	O
recipients	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
oral	JJ	PM
ganciclovir	NN	PM
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
following	VBG	O
orthotopic	NN	O
liver	JJ	O
transplantation	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
December	NNP	O
,	,	O
1993	CD	O
,	,	O
and	CC	O
April	NNP	O
,	,	O
1995	CD	O
,	,	O
304	CD	O
liver-transplant	JJ	O
recipients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
oral	JJ	PM
ganciclovir	NN	PM
1000	CD	PM
mg	NN	O
or	CC	O
matching	VBG	O
placebo	NN	C
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
.	.	O

Seronegative	JJ	O
recipients	NNS	O
of	IN	O
seronegative	JJ	O
livers	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

Study	NNP	O
drug	NN	O
was	VBD	O
administered	VBN	O
as	RB	O
soon	RB	O
as	IN	O
the	DT	O
patient	NN	O
was	VBD	O
able	JJ	O
to	TO	O
take	VB	O
medication	NN	O
by	IN	O
mouth	NN	O
(	(	O
no	DT	O
later	RB	O
than	IN	O
day	NN	O
10	CD	O
)	)	O
until	IN	O
the	DT	O
98th	CD	O
day	NN	O
after	IN	O
transplantation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
specified	VBN	O
times	NNS	O
throughout	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
for	IN	O
evidence	NN	O
of	IN	O
CMV	NNP	O
infection	NN	O
,	,	O
CMV	NNP	O
disease	NN	O
,	,	O
rejection	NN	O
,	,	O
opportunistic	JJ	O
infections	NNS	O
,	,	O
and	CC	O
possible	JJ	O
drug	NN	O
toxicity	NN	O
.	.	O

FINDINGS	IN	O
The	DT	O
Kaplan-Meier	NNP	O
estimate	NN	O
of	IN	O
the	DT	O
6-month	JJ	O
incidence	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
was	VBD	O
29	CD	O
(	(	O
18.9	CD	O
%	NN	O
)	)	O
of	IN	O
154	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
seven	CD	O
(	(	O
4.8	CD	O
%	NN	O
)	)	O
of	IN	O
150	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	PM
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
high-risk	JJ	O
group	NN	O
of	IN	O
seronegative	JJ	O
recipients	NNS	O
(	(	O
R-	NNP	O
)	)	O
of	IN	O
seropositive	JJ	O
livers	NNS	O
(	(	O
D+	NNP	O
)	)	O
,	,	O
incidence	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
was	VBD	O
11	CD	O
(	(	O
44.0	CD	O
%	NN	O
)	)	O
of	IN	O
25	CD	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
,	,	O
three	CD	O
(	(	O
14.8	CD	O
%	NN	O
)	)	O
of	IN	O
21	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	PM
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Significant	JJ	O
benefit	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
those	DT	O
receiving	VBG	O
antibodies	NNS	O
to	TO	O
lymphocytes	NNS	O
,	,	O
where	WRB	O
the	DT	O
incidence	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
was	VBD	O
12	CD	O
(	(	O
32.9	CD	O
%	NN	O
)	)	O
of	IN	O
37	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
two	CD	O
(	(	O
4.6	CD	O
%	NN	O
)	)	O
of	IN	O
44	CD	O
in	IN	O
the	DT	O
ganciclovir	NN	PM
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Oral	JJ	O
ganciclovir	NN	O
reduced	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
CMV	NNP	O
infection	NN	O
(	(	O
placebo	JJ	O
79	CD	O
[	JJ	O
51.5	CD	O
%	NN	O
]	NN	O
of	IN	O
154	CD	O
;	:	O
ganciclovir	CC	PM
37	CD	O
[	JJ	O
24.5	CD	O
%	NN	O
]	NN	O
of	IN	O
150	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.001	CD	O
)	)	O
and	CC	O
also	RB	O
reduced	VBN	O
symptomatic	JJ	O
herpes-simplex	JJ	O
infections	NNS	O
(	(	O
Kaplan-Meier	NNP	O
estimates	NNS	O
:	:	O
placebo	NN	C
36	CD	O
[	JJ	O
23.5	CD	O
%	NN	O
]	NN	O
of	IN	O
154	CD	O
;	:	O
ganciclovir	JJ	O
five	CD	O
[	JJ	O
3.5	CD	O
%	NN	O
]	NN	O
of	IN	O
150	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.001	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Oral	NNP	O
ganciclovir	NN	PM
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
method	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
after	IN	O
orthotopic	NN	O
liver	NN	O
transplantation	NN	O
.	.	O

Failure	NN	O
of	IN	O
lithium	NN	PM
to	TO	O
reduce	VB	O
period	NN	O
of	IN	O
neutropenia	NN	O
during	IN	O
induction	NN	PH
therapy	NN	PH
of	IN	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
.	.	O

Fifty-four	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
daunorubicin	NN	PM
,	,	O
cytosine	JJ	PM
arabinoside	NN	PM
and	CC	O
thioquanine	NN	PM
for	IN	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
oral	JJ	PM
lithium	NN	PM
carbonate	NN	PM
1200	CD	PM
mg	JJ	PM
daily	JJ	PM
or	CC	O
no	DT	PM
lithium	NN	PM
.	.	O

The	DT	O
duration	NN	O
of	IN	O
neutropenia	NN	O
(	(	O
less	JJR	O
than	IN	O
0.5	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
was	VBD	O
similar	JJ	O
between	IN	O
controls	NNS	O
(	(	O
median	JJ	O
22.5	CD	O
days	NNS	O
)	)	O
and	CC	O
patients	NNS	O
treated	VBN	O
with	IN	O
lithium	NN	PM
(	(	O
median	JJ	O
24	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
remissions	NNS	O
,	,	O
relapse-free	JJ	O
survival	NN	O
and	CC	O
survival	NN	O
were	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
lithium	NN	PM
treated	VBD	O
and	CC	O
control	VB	O
groups	NNS	O
of	IN	O
patients	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
apparent	JJ	O
clinical	JJ	O
efficacy	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
lithium	NN	PM
to	TO	O
reduce	VB	O
the	DT	O
period	NN	O
of	IN	O
neutropenia	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
remission	NN	O
induction	NN	PH
therapy	NN	PH
for	IN	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
.	.	O

The	DT	O
Coping	NNP	O
Cat	NNP	O
program	NN	O
for	IN	O
children	NNS	O
with	IN	O
anxiety	NN	O
and	CC	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
pilot	NN	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
pilot	NN	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
whether	IN	O
a	DT	O
modified	JJ	E
version	NN	E
of	IN	E
the	DT	E
Coping	NNP	E
Cat	NNP	E
program	NN	E
could	MD	O
be	VB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Twenty-two	JJ	O
children	NNS	O
(	(	O
ages	VBZ	O
8-14	NN	O
;	:	O
IQ	NNP	O
?	.	O
70	CD	O
)	)	O
with	IN	O
ASD	NNP	O
and	CC	O
clinically	RB	O
significant	JJ	O
anxiety	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
the	DT	O
Coping	NNP	O
Cat	NNP	O
program	NN	O
(	(	O
cognitive-behavioral	JJ	O
therapy	NN	O
;	:	O
CBT	NNP	O
)	)	O
or	CC	O
a	DT	O
16-week	JJ	O
waitlist	NN	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
CBT	NNP	O
condition	NN	O
evidenced	VBD	O
significantly	RB	O
larger	JJR	O
reductions	NNS	O
in	IN	O
anxiety	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
waitlist	NN	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
largely	RB	O
maintained	VBN	O
at	IN	O
two-month	JJ	O
follow-up	NN	O
.	.	O

Results	NNP	O
provide	VBP	O
preliminary	JJ	O
evidence	NN	O
that	IN	O
a	DT	O
modified	JJ	O
version	NN	O
of	IN	O
the	DT	O
Coping	NNP	O
Cat	NNP	O
program	NN	O
may	MD	O
be	VB	O
a	DT	O
feasible	JJ	O
and	CC	O
effective	JJ	O
program	NN	O
for	IN	O
reducing	VBG	O
clinically	RB	O
significant	JJ	O
levels	NNS	O
of	IN	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
ASD	NNP	O
.	.	O

Impact	NN	O
of	IN	O
preinduced	JJ	O
quadriceps	NNS	O
fatigue	VBP	O
on	IN	O
exercise	NN	O
response	NN	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
and	CC	O
healthy	JJ	O
subjects	NNS	O
.	.	O

Exercise	NN	O
intolerance	NN	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
results	NNS	O
from	IN	O
a	DT	O
complex	JJ	O
interaction	NN	O
between	IN	O
central	JJ	O
(	(	O
ventilatory	NN	O
)	)	O
and	CC	O
peripheral	JJ	O
(	(	O
limb	JJ	O
muscles	NNS	O
)	)	O
components	NNS	O
of	IN	O
exercise	NN	O
limitation	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
influence	NN	O
of	IN	O
quadriceps	NNS	O
muscle	VBP	O
fatigue	NN	O
on	IN	O
exercise	NN	O
tolerance	NN	O
and	CC	O
ventilatory	JJ	O
response	NN	O
during	IN	O
constant-workrate	JJ	PH
cycling	NN	PH
exercise	NN	PH
testing	NN	PH
(	(	PH
CWT	NNP	PH
)	)	PH
in	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
and	CC	O
healthy	JJ	O
subjects	NNS	O
.	.	O

Fifteen	JJ	O
patients	NNS	O
with	IN	O
COPD	NNP	O
and	CC	O
nine	CD	O
age-matched	JJ	O
healthy	JJ	O
subjects	NNS	O
performed	VBN	O
,	,	O
7	CD	O
days	NNS	O
apart	RB	O
,	,	O
two	CD	O
CWTs	NNP	PH
up	RB	O
to	TO	O
exhaustion	NN	O
at	IN	O
80	CD	O
%	NN	O
of	IN	O
their	PRP$	O
predetermined	VBN	O
maximal	JJ	O
work	NN	O
capacity	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
,	,	O
one	CD	O
test	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
preinduced	JJ	O
quadriceps	NNS	O
fatigue	NN	O
and	CC	O
the	DT	O
other	JJ	O
in	IN	O
a	DT	O
fresh	JJ	O
state	NN	O
.	.	O

Quadriceps	NNP	O
fatigue	NN	O
was	VBD	O
produced	VBN	O
by	IN	O
electrostimulation-induced	JJ	O
contractions	NNS	O
and	CC	O
quantified	VBN	O
by	IN	O
maximal	JJ	O
voluntary	JJ	O
contraction	NN	O
and	CC	O
potentiated	VBD	O
twitch	NN	O
force	NN	O
(	(	O
TwQ	NNP	O
(	(	O
pot	NN	O
)	)	O
)	)	O
.	.	O

Endurance	NN	O
time	NN	O
and	CC	O
ventilatory	JJ	O
response	NN	O
during	IN	O
CWT	NNP	O
were	VBD	O
compared	VBN	O
between	IN	O
fatigued	VBN	O
and	CC	O
fresh	JJ	O
state	NN	O
.	.	O

Endurance	NN	O
time	NN	O
significantly	RB	O
decreased	VBN	O
in	IN	O
the	DT	O
fatigued	JJ	O
state	NN	O
compared	VBN	O
with	IN	O
the	DT	O
fresh	JJ	O
condition	NN	O
in	IN	O
COPD	NNP	O
(	(	O
356	CD	O
+/-	JJ	O
69	CD	O
s	NN	O
vs.	FW	O
294	CD	O
+/-	JJ	O
45	CD	O
s	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
controls	NNS	O
(	(	O
450	CD	O
+/-	JJ	O
74	CD	O
s	NN	O
vs.	FW	O
340	CD	O
+/-	JJ	O
45	CD	O
s	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Controls	NNP	O
showed	VBD	O
significantly	RB	O
higher	JJR	O
ventilation	NN	O
and	CC	O
end-exercise	JJ	O
dyspnea	NN	O
scores	NNS	O
in	IN	O
the	DT	O
fatigued	JJ	O
condition	NN	O
,	,	O
whereas	NNS	O
,	,	O
in	IN	O
COPD	NNP	O
,	,	O
fatigue	NN	O
did	VBD	O
not	RB	O
influence	VB	O
ventilation	NN	O
or	CC	O
dyspnea	NN	O
during	IN	O
exercise	NN	O
.	.	O

The	DT	O
degree	NN	O
of	IN	O
ventilatory	NN	O
limitation	NN	O
,	,	O
as	IN	O
expressed	VBN	O
by	IN	O
the	DT	O
Ve/maximum	NNP	O
voluntary	JJ	O
ventilation	NN	O
ratio	NN	O
,	,	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
conditions	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
induce	VB	O
quadriceps	NNS	O
fatigue	VBN	O
by	IN	O
local	JJ	O
electrostimulation-induced	JJ	O
contractions	NNS	O
.	.	O

Our	PRP$	O
findings	NNS	O
demonstrate	VBP	O
that	IN	O
peripheral	JJ	O
muscle	NN	O
fatigue	NN	O
is	VBZ	O
an	DT	O
additional	JJ	O
important	JJ	O
factor	NN	O
,	,	O
besides	IN	O
intense	JJ	O
dyspnea	NN	O
,	,	O
that	IN	O
limits	NNS	O
exercise	VBP	O
tolerance	NN	O
in	IN	O
COPD	NNP	O
.	.	O

Ongoing	VBG	PM
Telmisartan	NNP	PM
Alone	NNP	PM
and	CC	PM
in	IN	PM
Combination	NNP	PM
With	IN	PM
Ramipril	NNP	PM
Global	NNP	PM
Endpoint	NNP	PM
Trial	NNP	PM
(	(	PM
ONTARGET	NNP	PM
)	)	PM
:	:	PM
implications	NNS	O
for	IN	O
reduced	JJ	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

The	DT	O
recently	RB	O
published	VBN	O
Ongoing	NNP	PM
Telmisartan	NNP	PM
Alone	NNP	PM
and	CC	PM
in	IN	PM
Combination	NNP	PM
With	IN	PM
Ramipril	NNP	PM
Global	NNP	PM
Endpoint	NNP	PM
Trial	NNP	PM
(	(	PM
ONTARGET	NNP	PM
)	)	PM
in	IN	O
patients	NNS	O
with	IN	O
vascular	JJ	O
disease	NN	O
or	CC	O
high-risk	JJ	O
diabetes	NNS	O
,	,	O
as	IN	O
the	DT	O
largest	JJS	O
published	VBN	O
comparative	JJ	O
trial	NN	O
of	IN	O
these	DT	O
agent	NN	O
classes	NNS	O
,	,	O
provides	VBZ	O
further	JJ	O
evidence	NN	O
concerning	VBG	O
the	DT	O
comparison	NN	O
between	IN	O
the	DT	O
angiotensin-receptor	NN	PM
blockers	NNS	PM
(	(	PM
ARBs	NNP	PM
)	)	PM
and	CC	O
the	DT	O
angiotensin-converting	JJ	PM
enzyme	NN	PM
inhibitors	NNS	PM
(	(	PM
ACEIs	NNP	PM
)	)	PM
.	.	PM

In	IN	O
this	DT	O
trial	NN	O
,	,	O
telmisartan	NN	PM
(	(	PM
an	DT	PM
ARB	NNP	PM
)	)	PM
was	VBD	O
non-inferior	JJ	O
to	TO	O
ramipril	VB	PM
(	(	PM
an	DT	PM
ACEI	NNP	PM
)	)	PM
in	IN	O
reducing	VBG	O
fatal	JJ	O
and	CC	O
nonfatal	JJ	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

Moreover	RB	O
,	,	O
ONTARGET	NNP	PH
is	VBZ	O
an	DT	O
example	NN	O
of	IN	O
a	DT	O
high-quality	JJ	O
noninferiority	NN	O
trial	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
the	DT	O
2	CD	O
agents	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
more	JJR	O
adverse	JJ	O
effects	NNS	O
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
benefit	NN	O
.	.	O

The	DT	O
study	NN	O
differed	VBD	O
from	IN	O
several	JJ	O
other	JJ	O
comparative	JJ	O
studies	NNS	O
in	IN	O
which	WDT	O
the	DT	O
dose	NN	O
and	CC	O
choice	NN	O
of	IN	O
ACEI	NNP	PH
was	VBD	O
left	VBN	O
to	TO	O
individual	JJ	O
physicians	NNS	O
.	.	O

Further	NNP	O
,	,	O
in	IN	O
ONTARGET	NNP	PM
,	,	O
the	DT	O
ACEI	NNP	PM
was	VBD	O
not	RB	O
titrated	VBN	O
to	TO	O
the	DT	O
maximum	JJ	O
dose	NN	O
and	CC	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

Deliberate	NNP	O
hypotension	NN	O
in	IN	O
patients	NNS	O
with	IN	O
intracranial	JJ	O
arteriovenous	JJ	O
malformations	NNS	O
:	:	O
esmolol	NN	PM
compared	VBN	O
with	IN	O
isoflurane	NN	PM
and	CC	O
sodium	NN	PM
nitroprusside	RB	PM
.	.	O

Thirty	JJ	O
patients	NNS	O
undergoing	VBG	O
resection	NN	O
of	IN	O
arteriovenous	JJ	O
malformations	NNS	O
with	IN	O
deliberate	JJ	O
hypotension	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
of	IN	O
3	CD	O
hypotensive	JJ	O
agents	NNS	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
isoflurane	NN	PM
and	CC	PM
nitrous	JJ	PM
oxide	NN	PM
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

Mean	NNP	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
20	CD	O
%	NN	O
to	TO	O
60-65	JJ	O
mm	NN	O
Hg	NNP	O
with	IN	O
use	NN	O
of	IN	O
either	DT	O
isoflurane	NN	PM
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
4	CD	O
%	NN	O
)	)	O
,	,	O
sodium	JJ	PM
nitroprusside	NN	PM
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
micrograms.kg-1.min-1	NN	O
)	)	O
,	,	O
or	CC	O
esmolol	NN	PM
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
24	CD	O
mg/min	NN	O
)	)	O
.	.	O

Esmolol	NNP	PM
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
from	IN	O
6.2	CD	O
+/-	JJ	O
1.3	CD	O
to	TO	O
3.8	CD	O
+/-	JJ	O
0.8	CD	O
L/min	NNP	O
,	,	O
which	WDT	O
,	,	O
because	IN	O
of	IN	O
a	DT	O
22	CD	O
%	NN	O
increase	NN	O
in	IN	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
,	,	O
far	RB	O
exceeded	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
.	.	O

Systemic	NNP	O
vascular	JJ	O
resistance	NN	O
increased	VBD	O
despite	IN	O
a	DT	O
32	CD	O
%	NN	O
decrease	NN	O
in	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
with	IN	O
sodium	JJ	PM
nitroprusside	NN	PM
or	CC	O
isoflurane	NN	PM
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
decreases	NNS	O
in	IN	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
of	IN	O
similar	JJ	O
magnitude	NN	O
,	,	O
with	IN	O
no	DT	O
change	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

Plasma	NNP	O
renin	NN	O
activity	NN	O
levels	NNS	O
increased	VBD	O
48	CD	O
%	NN	O
with	IN	O
sodium	NN	PM
nitroprusside	NN	PM
and	CC	O
126	CD	O
%	NN	O
with	IN	O
isoflurane	NN	PM
.	.	O

Heart	NNP	O
rate	NN	O
increased	VBD	O
13	CD	O
%	NN	O
with	IN	O
sodium	NN	PM
nitroprusside	NN	PM
,	,	O
remained	VBD	O
unchanged	JJ	O
with	IN	O
isoflurane	NN	O
,	,	O
and	CC	O
decreased	VBD	O
23	CD	O
%	NN	O
with	IN	O
esmolol	NN	PM
.	.	O

Although	IN	O
esmolol	NN	PM
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
primary	JJ	O
hypotensive	JJ	O
agent	NN	O
,	,	O
the	DT	O
potential	NN	O
for	IN	O
marked	JJ	O
myocardial	JJ	O
depression	NN	O
must	MD	O
be	VB	O
recognized	VBN	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
pharmacologic	NN	O
properties	NNS	O
for	IN	O
the	DT	O
different	JJ	O
hypotensive	JJ	O
agents	NNS	O
suggest	VBP	O
that	IN	O
combinations	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
may	MD	O
provide	VB	O
a	DT	O
pharmacologic	NN	O
profile	NN	O
superior	JJ	O
to	TO	O
either	DT	O
agent	NN	O
alone	RB	O
.	.	O

Single	NNP	O
and	CC	O
short-term	JJ	O
dosing	NN	O
effects	NNS	O
of	IN	O
levocetirizine	NN	PM
on	IN	O
adenosine	JJ	O
monophosphate	NN	O
bronchoprovocation	NN	O
in	IN	O
atopic	NN	O
asthma	NN	O
.	.	O

AIMS	NNP	O
Adenosine	NNP	O
monophosphate	NN	O
(	(	O
AMP	NNP	O
)	)	O
acts	VBZ	O
indirectly	RB	O
via	IN	O
primed	VBN	O
airway	RB	O
mast	JJ	O
cells	NNS	O
to	TO	O
induce	VB	O
bronchial	JJ	O
hyper-responsiveness	NN	O
,	,	O
which	WDT	O
in	IN	O
turn	NN	O
correlates	NNS	O
with	IN	O
eosinophilic	JJ	O
asthmatic	JJ	O
inflammation	NN	O
and	CC	O
atopic	JJ	O
disease	NN	O
expression	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
single	JJ	O
and	CC	O
short-term	JJ	O
dosing	NN	O
effects	NNS	O
of	IN	O
a	DT	O
modern	JJ	O
histamine	NN	O
H1-receptor	NNP	O
antagonist	NN	O
,	,	O
levocetirizine	NN	PM
,	,	O
given	VBN	O
at	IN	O
the	DT	O
usual	JJ	O
clinically	RB	O
recommended	VBD	O
dose	NN	O
,	,	O
on	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
AMP	NNP	O
bronchoprovocation	NN	O
.	.	O

METHODS	NNP	O
Fifteen	NNP	O
atopic	NN	O
asthmatics	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
double-blind	NN	O
,	,	O
cross-over	JJ	O
fashion	NN	O
to	TO	O
receive	VB	O
for	IN	O
1	CD	O
week	NN	O
either	CC	O
levocetirizine	JJ	PM
5	CD	PM
mg	NN	PM
or	CC	O
placebo	NN	C
.	.	O

There	EX	O
was	VBD	O
a	DT	O
1-week	JJ	O
washout	NN	O
period	NN	O
prior	RB	O
to	TO	O
each	DT	O
randomized	VBN	O
treatment	NN	O
.	.	O

The	DT	O
provocative	JJ	O
concentration	NN	O
of	IN	O
AMP	NNP	O
producing	VBG	O
a	DT	O
20	CD	O
%	NN	O
fall	NN	O
in	IN	O
FEV1	NNP	O
(	(	O
PC20	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
after	IN	O
each	DT	O
washout	NN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
4-6	JJ	O
h	NN	O
following	VBG	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
of	IN	O
each	DT	O
randomized	VBN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
values	NNS	O
after	IN	O
washout	NN	O
prior	RB	O
to	TO	O
each	DT	O
randomized	VBN	O
treatment	NN	O
comparing	VBG	O
levocetirizine	JJ	PM
vs	NN	O
placebo	NN	C
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
for	IN	O
prechallenge	NN	O
FEV1	NNP	O
(	(	O
%	NN	O
predicted	VBN	O
)	)	O
83	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
82	CD	O
+/-	JJ	O
4	CD	O
,	,	O
or	CC	O
AMP	NNP	O
PC20	NNP	O
(	(	O
mg	JJ	O
ml	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
45	CD	O
+/-	JJ	O
24	CD	O
vs	JJ	O
45	CD	O
+/-	JJ	O
22	CD	O
,	,	O
respectively	RB	O
.	.	O

Airway	NNP	O
calibre	NN	O
as	IN	O
prechallenge	NN	O
FEV1	NNP	O
for	IN	O
levocetirizine	JJ	PM
vs	NN	O
placebo	NN	C
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
following	VBG	O
the	DT	O
first	JJ	O
dose	JJ	O
86	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
82	CD	O
+/-	JJ	O
4	CD	O
,	,	O
or	CC	O
the	DT	O
last	JJ	O
dose	JJ	O
85	CD	O
+/-	JJ	O
4	CD	O
vs	JJ	O
83	CD	O
+/-	JJ	O
4	CD	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
improvements	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
AMP	NNP	O
PC20	NNP	O
comparing	VBG	O
levocetirizine	JJ	O
vs	NN	O
placebo	NN	O
following	VBG	O
the	DT	O
first	JJ	O
dose	JJ	O
123	CD	O
+/-	JJ	O
73	CD	O
vs	JJ	O
48	CD	O
+/-	JJ	O
24	CD	O
,	,	O
a	DT	O
1.4	CD	O
doubling	VBG	O
dilution	NN	O
difference	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.8	CD	O
,	,	O
1.9	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
last	JJ	O
dose	JJ	O
127	CD	O
+/-	JJ	O
74	CD	O
vs	JJ	O
53	CD	O
+/-	JJ	O
29	CD	O
,	,	O
a	DT	O
1.2	CD	O
doubling	VBG	O
dilution	NN	O
difference	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.5	CD	O
,	,	O
2.0	CD	O
)	)	O
.	.	O

AMP	NNP	O
PC20	NNP	O
was	VBD	O
also	RB	O
improved	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
by	IN	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
of	IN	O
levocetirizine	NN	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
vs	FW	O
respective	JJ	O
baseline	NN	O
values	NNS	O
,	,	O
with	IN	O
there	EX	O
being	VBG	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
degree	NN	O
of	IN	O
protection	NN	O
between	IN	O
first	JJ	O
and	CC	O
last	JJ	O
doses	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Single	NNP	O
and	CC	O
short-term	JJ	O
dosing	NN	O
with	IN	O
levocetirizine	NN	PM
conferred	VBN	O
similar	JJ	O
improvements	NNS	O
in	IN	O
bronchial	JJ	O
hyper-responsiveness	NN	O
to	TO	O
AMP	NNP	O
challenge	NN	O
,	,	O
which	WDT	O
was	VBD	O
unrelated	JJ	O
to	TO	O
prechallenge	VB	O
airway	RB	O
calibre	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
indicated	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
longer-term	JJ	O
effects	NNS	O
of	IN	O
levocetirizine	NN	PM
on	IN	O
asthma	JJ	O
exacerbations	NNS	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
effects	NNS	O
of	IN	O
cognitive	JJ	PS
behavioral	JJ	PS
therapy	NN	PS
on	IN	O
parent-reported	JJ	O
autism	NN	O
symptoms	NNS	O
in	IN	O
school-age	JJ	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
.	.	O

This	DT	O
pilot	NN	O
study	NN	O
tested	VBD	O
the	DT	O
effect	NN	O
of	IN	O
cognitive	JJ	PS
behavioral	JJ	PS
therapy	NN	PS
(	(	PS
CBT	NNP	PS
)	)	PS
on	IN	O
parent-reported	JJ	O
autism	NN	O
symptoms	NNS	O
.	.	O

Nineteen	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
an	DT	O
anxiety	NN	O
disorder	NN	O
(	(	O
7-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
CBT	NNP	PS
or	CC	O
a	DT	O
waitlist	JJ	PH
condition	NN	PH
.	.	O

The	DT	O
CBT	NNP	PH
program	NN	O
emphasized	VBN	O
in	IN	O
vivo	NN	O
exposure	NN	O
supported	VBN	O
by	IN	O
parent	NN	O
training	NN	O
and	CC	O
school	NN	O
consultation	NN	O
to	TO	O
promote	VB	O
social	JJ	O
communication	NN	O
and	CC	O
emotion	NN	O
regulation	NN	O
skills	NNS	O
.	.	O

Parents	NNS	O
completed	VBD	O
a	DT	O
standardized	JJ	O
autism	NN	O
symptom	JJ	O
checklist	NN	O
at	IN	O
baseline	NN	O
and	CC	O
posttreatment/postwaitlist	NN	O
and	CC	O
3-month	JJ	O
follow-up	JJ	O
assessments	NNS	O
.	.	O

CBT	NNP	O
outperformed	VBD	O
the	DT	O
waitlist	JJ	O
condition	NN	O
at	IN	O
posttreatment/postwaitlist	NN	O
on	IN	O
total	JJ	O
parent-reported	JJ	O
autism	NN	O
symptoms	NNS	O
(	(	O
Cohen	NNP	O
's	POS	O
d	JJ	O
effect	NN	O
size	NN	O
=	NNP	O
.77	NNP	O
)	)	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

Further	JJ	O
investigation	NN	O
of	IN	O
this	DT	O
intervention	NN	O
modality	NN	O
with	IN	O
larger	JJR	O
samples	NNS	O
and	CC	O
broader	JJR	O
outcome	NN	O
measures	NNS	O
appears	VBZ	O
to	TO	O
be	VB	O
indicated	VBN	O
.	.	O

Impact	NN	O
of	IN	O
disease	NN	O
severity	NN	O
on	IN	O
outcome	NN	O
of	IN	O
antiviral	JJ	PM
therapy	NN	PM
for	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
:	:	O
Lessons	NNS	O
from	IN	O
the	DT	O
HALT-C	NNP	O
trial	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
,	,	O
advanced	VBD	O
fibrosis	NN	O
and	CC	O
cirrhosis	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
lower	JJR	O
rates	NNS	O
of	IN	O
sustained	JJ	O
virologic	JJ	O
response	NN	O
(	(	O
SVR	NNP	O
)	)	O
to	TO	O
interferon	VB	O
(	(	O
IFN	NNP	O
)	)	O
-based	VBD	O
therapy	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
virologic	JJ	O
response	NN	O
to	TO	O
retreatment	VB	O
with	IN	O
peginterferon	JJ	PM
alfa-2a	JJ	PM
and	CC	O
ribavirin	NN	PM
(	(	PM
RBV	NNP	PM
)	)	PM
,	,	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
baseline	NN	O
fibrosis	NN	O
score	NN	O
(	(	O
Ishak	NNP	O
staging	VBG	O
)	)	O
and	CC	O
platelet	NN	O
count	NN	O
,	,	O
in	IN	O
1,046	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
Hepatitis	NNP	O
C	NNP	O
Antiviral	NNP	O
Long-term	NNP	O
Treatment	NNP	O
against	IN	O
Cirrhosis	NNP	O
(	(	O
HALT-C	NNP	O
)	)	O
Trial	NNP	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
failed	VBN	O
prior	RB	O
treatment	NN	O
with	IN	O
IFN	NNP	PM
or	CC	O
peginterferon	VB	PM
+/-	JJ	PM
RBV	NNP	PM
and	CC	O
had	VBD	O
Ishak	NNP	O
fibrosis	NN	O
scores	VBZ	O
>	CD	O
or	CC	O
=	VB	O
3	CD	O
.	.	O

Four	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
increasingly	RB	O
severe	JJ	O
liver	NN	O
disease	NN	O
were	VBD	O
compared	VBN	O
:	:	O
(	(	O
A	DT	O
)	)	O
bridging	NN	O
fibrosis	NN	O
(	(	O
Ishak	NNP	O
3	CD	O
and	CC	O
4	CD	O
)	)	O
with	IN	O
platelet	NN	O
counts	NNS	O
>	VBP	O
125,000/mm3	CD	O
(	(	O
n	JJ	O
=	NNP	O
559	CD	O
)	)	O
;	:	O
(	(	O
B	NNP	O
)	)	O
bridging	VBG	O
fibrosis	NN	O
with	IN	O
platelet	NN	O
counts	NNS	O
<	VBP	O
or	CC	O
=125,000/mm3	NNP	O
(	(	O
n	JJ	O
=	NNP	O
96	CD	O
)	)	O
;	:	O
(	(	O
C	NNP	O
)	)	O
cirrhosis	NN	O
(	(	O
Ishak	NNP	O
5	CD	O
and	CC	O
6	CD	O
)	)	O
with	IN	O
platelet	NN	O
counts	NNS	O
>	VBP	O
125,000/mm3	CD	O
(	(	O
n	JJ	O
=	NNP	O
198	CD	O
)	)	O
;	:	O
and	CC	O
(	(	O
D	NNP	O
)	)	O
cirrhosis	NN	O
with	IN	O
platelet	NN	O
counts	NNS	O
<	VBP	O
or	CC	O
=125,000/mm3	NNP	O
(	(	O
n	JJ	O
=	NNP	O
193	CD	O
)	)	O
.	.	O

SVR	JJ	O
rates	NNS	O
were	VBD	O
23	CD	O
%	NN	O
,	,	O
17	CD	O
%	NN	O
,	,	O
10	CD	O
%	NN	O
,	,	O
and	CC	O
9	CD	O
%	NN	O
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
,	,	O
and	CC	O
D	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
for	IN	O
trend	NN	O
)	)	O
.	.	O

Reduction	NN	O
in	IN	O
SVR	NNP	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
increasingly	RB	O
severe	JJ	O
disease	NN	O
was	VBD	O
independent	JJ	O
of	IN	O
age	NN	O
,	,	O
percent	JJ	O
African	JJ	O
American	NNP	O
,	,	O
HCV	NNP	O
genotype	NN	O
,	,	O
HCV	NNP	O
level	NN	O
,	,	O
and	CC	O
type	NN	O
of	IN	O
prior	JJ	O
therapy	NN	O
.	.	O

Dose	NNP	O
reduction	NN	O
lowered	VBD	O
SVR	NNP	O
frequencies	NNS	O
,	,	O
but	CC	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
than	IN	O
disease	NN	O
severity	NN	O
.	.	O

By	IN	O
logistic	JJ	O
regression	NN	O
,	,	O
cirrhosis	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
was	VBD	O
the	DT	O
major	JJ	O
determinant	NN	O
that	WDT	O
impaired	VBD	O
virologic	JJ	O
response	NN	O
,	,	O
independent	JJ	O
of	IN	O
dose	JJ	O
reduction	NN	O
or	CC	O
platelet	NN	O
count	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
disease	NN	O
severity	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
independent	JJ	O
determinant	NN	O
of	IN	O
rate	NN	O
of	IN	O
SVR	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
chronic	JJ	O
hepatitis	NN	O
C.	NNP	O
New	NNP	O
strategies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
optimize	VB	O
antiviral	JJ	O
therapy	NN	O
in	IN	O
these	DT	O
difficult-to-cure	JJ	O
patients	NNS	O
.	.	O

Randomised	VBN	O
trial	NN	O
of	IN	O
laparoscopic	NN	S
versus	NN	O
open	JJ	S
cholecystectomy	NN	S
for	IN	O
acute	NN	O
and	CC	O
gangrenous	JJ	O
cholecystitis	NN	O
.	.	O

BACKGROUND	NNP	O
Laparoscopic	NNP	S
cholecystectomy	NN	S
(	(	PH
LC	NNP	PH
)	)	PH
has	VBZ	O
become	VBN	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
elective	JJ	S
cholecystectomy	NN	S
,	,	O
but	CC	O
controversy	NN	O
persists	NNS	O
over	IN	O
use	NN	O
of	IN	O
this	DT	O
approach	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
cholecystitis	NN	O
.	.	O

We	PRP	O
undertook	VBD	O
a	DT	O
randomised	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
outcome	NN	O
of	IN	O
LC	NNP	S
and	CC	O
open	JJ	S
cholecystectomy	NN	S
(	(	S
OC	NNP	S
)	)	S
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
cholecystitis	NN	O
.	.	O

METHODS	NNP	O
63	CD	O
of	IN	O
68	CD	O
consecutive	JJ	O
patients	NNS	O
who	WP	O
met	VBD	O
criteria	NNS	O
for	IN	O
acute	JJ	O
cholecystitis	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
OC	NNP	S
(	(	O
31	CD	O
patients	NNS	O
)	)	O
or	CC	O
LC	NNP	S
(	(	O
32	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
were	VBD	O
hospital	JJ	O
mortality	NN	O
and	CC	O
morbidity	NN	O
,	,	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
,	,	O
and	CC	O
length	NN	O
of	IN	O
sick	JJ	O
leave	VBP	O
from	IN	O
work	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

Suspected	VBN	O
bile-duct	NN	O
stones	NNS	O
were	VBD	O
investigated	VBN	O
by	IN	O
preoperative	JJ	O
endoscopic	NN	O
retrograde	NN	O
cholangiography	NN	O
(	(	O
LC	NNP	S
group	NN	O
)	)	O
or	CC	O
intraoperative	JJ	S
cholangiography	NN	S
(	(	O
OC	NNP	O
group	NN	O
)	)	O
.	.	O

FINDINGS	PDT	O
The	DT	O
two	CD	O
randomised	VBD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
demographic	JJ	O
,	,	O
physical	JJ	O
,	,	O
and	CC	O
clinical	JJ	O
characteristics	NNS	O
.	.	O

48	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
OC	NNP	S
group	NN	O
and	CC	O
59	CD	O
%	NN	O
in	IN	O
the	DT	O
LC	NNP	S
group	NN	O
were	VBD	O
older	JJR	O
than	IN	O
60	CD	O
years	NNS	O
.	.	O

13	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
had	VBD	O
gangrene	NN	O
or	CC	O
empyema	NN	O
,	,	O
and	CC	O
one	CD	O
in	IN	O
each	DT	O
group	NN	O
had	VBD	O
perforation	NN	O
of	IN	O
the	DT	O
gallbladder	NN	O
causing	NN	O
diffuse	NN	O
peritonitis	NN	O
.	.	O

Five	CD	O
(	(	O
16	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
LC	NNP	S
group	NN	O
required	VBD	O
conversion	NN	O
to	TO	O
OC	NNP	S
,	,	O
in	IN	O
most	JJS	O
because	IN	O
severe	JJ	O
inflammation	NN	O
distorted	VBD	O
the	DT	O
anatomy	NN	O
of	IN	O
Calot	NNP	O
's	POS	O
triangle	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
deaths	NNS	O
or	CC	O
bile-duct	NN	O
lesions	NNS	O
in	IN	O
either	DT	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
postoperative	JJ	O
complication	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p=0.0048	NN	O
)	)	O
higher	JJR	O
in	IN	O
the	DT	O
OC	NNP	S
than	IN	O
in	IN	O
the	DT	O
LC	NNP	O
group	NN	O
:	:	O
seven	CD	O
(	(	O
23	CD	O
%	NN	O
)	)	O
patients	NNS	O
had	VBD	O
major	JJ	O
and	CC	O
six	CD	O
(	(	O
19	CD	O
%	NN	O
)	)	O
minor	NN	O
complications	NNS	O
after	IN	O
OC	NNP	O
,	,	O
whereas	IN	O
only	RB	O
one	CD	O
(	(	O
3	CD	O
%	NN	O
)	)	O
minor	JJ	O
complication	NN	O
occurred	VBD	O
after	IN	O
LC	NNP	O
.	.	O

The	DT	O
postoperative	JJ	O
hospital	NN	O
stay	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
LC	NNP	S
than	IN	O
the	DT	O
OC	NNP	S
group	NN	O
(	(	O
median	JJ	O
4	CD	O
[	JJ	O
IQR	NNP	O
2-5	JJ	O
]	NNP	O
vs	NN	O
6	CD	O
[	JJ	O
5-8	JJ	O
]	NNP	O
days	NNS	O
;	:	O
p=0.0063	NN	O
)	)	O
.	.	O

Mean	JJ	O
length	NN	O
of	IN	O
sick	JJ	O
leave	NN	O
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
LC	NNP	S
group	NN	O
(	(	O
13.9	CD	O
vs	RB	O
30.1	CD	O
days	NNS	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
10.9-21.7	CD	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Even	RB	O
though	IN	O
LC	NNP	O
for	IN	O
acute	NN	O
and	CC	O
gangrenous	JJ	O
cholecystitis	NN	O
is	VBZ	O
technically	RB	O
demanding	VBG	O
,	,	O
in	IN	O
experienced	JJ	O
hands	NNS	O
it	PRP	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
.	.	O

It	PRP	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
mortality	NN	O
rate	NN	O
,	,	O
and	CC	O
the	DT	O
morbidity	NN	O
rate	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
even	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
OC	NNP	S
.	.	O

However	RB	O
,	,	O
a	DT	O
moderately	RB	O
high	JJ	O
conversion	NN	O
rate	NN	O
must	MD	O
be	VB	O
accepted	VBN	O
.	.	O

Efficacy	NN	O
of	IN	O
nebulized	JJ	PM
flunisolide	NN	PM
combined	VBN	PM
with	IN	PM
salbutamol	NN	PM
and	CC	PM
ipratropium	NN	PM
bromide	NN	PM
in	IN	O
stable	JJ	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
efficacy	NN	O
of	IN	O
nebulized	JJ	O
corticosteroids	NNS	PM
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
exacerbation	NN	O
of	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
poorly	RB	O
studied	VBN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
nebulized	JJ	PM
flunisolide	NN	PM
(	(	O
1	CD	O
mg	NN	O
)	)	O
+	VBZ	PM
salbutamol/ipratropium	JJ	PM
bromide	NN	PM
(	(	O
1,875/375	CD	O
microg	NN	O
)	)	O
b.i.d	NN	O
.	.	O

in	IN	O
comparison	NN	O
with	IN	O
placebo	NN	C
+	NNP	O
salbutamol/ipratropium	NN	C
bromide	NN	C
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
114	CD	O
patients	NNS	O
with	IN	O
COPD	NNP	O
of	IN	O
moderate-to-severe	JJ	O
degree	NN	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
severe	JJ	O
exacerbations	NNS	O
over	IN	O
a	DT	O
6-month	JJ	O
period	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
,	,	O
respiratory	NN	O
symptoms	NNS	O
,	,	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
1	CD	O
s	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
,	,	O
shuttle	JJ	O
walking	VBG	O
test	NN	O
distance	NN	O
and	CC	O
St.	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
scores	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
number	NN	O
of	IN	O
exacerbations	NNS	O
was	VBD	O
slightly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
flunisolide	NN	PM
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	C
group	NN	O
(	(	O
19	CD	O
vs.	FW	O
34	CD	O
,	,	O
p	NN	O
=	NNP	O
0.054	CD	O
)	)	O
;	:	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
experiencing	VBG	O
at	IN	O
least	JJS	O
one	CD	O
exacerbation	NN	O
during	IN	O
the	DT	O
study	NN	O
was	VBD	O
also	RB	O
decreased	VBN	O
(	(	O
16	CD	O
vs.	FW	O
26	CD	O
,	,	O
p	NN	O
=	NNP	O
0.059	CD	O
)	)	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
type	JJ	O
3	CD	O
Anthonisens	NNP	O
's	POS	O
exacerbations	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
flunisolide	NN	PM
(	(	O
p	JJ	O
=	NNP	O
0.044	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	C
group	NN	O
,	,	O
scores	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
in	IN	O
the	DT	O
flunisolide	JJ	PM
group	NN	O
but	CC	O
nonsignificant	NN	O
for	IN	O
dyspnea	NN	O
,	,	O
cough	NN	O
,	,	O
sputum	NN	O
amount	NN	O
and	CC	O
purulence	NN	O
.	.	O

FEV	NNP	O
(	(	O
1	CD	O
)	)	O
was	VBD	O
significantly	RB	O
increased	VBN	O
compared	VBN	O
to	TO	O
baseline	VB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
-time	NN	O
curve	NN	O
during	IN	O
the	DT	O
6-month	JJ	O
period	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
flunisolide	NN	PM
group	NN	O
(	(	O
5.2	CD	O
+/-	JJ	O
10.6	CD	O
vs.	FW	O
2.1	CD	O
+/-	JJ	O
5.0	CD	O
,	,	O
flunisolide	RB	PM
vs.	FW	O
placebo	NN	C
,	,	O
respectively	RB	O
;	:	O
p	VB	O
=	$	O
0.047	CD	O
)	)	O
.	.	O

For	IN	O
shuttle	JJ	O
walking	VBG	O
test	NN	O
distance	NN	O
and	CC	O
scores	NNS	O
of	IN	O
the	DT	O
St.	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
baseline	NN	O
evaluation	NN	O
and	CC	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Nebulized	NNP	PM
flunisolide	NN	PM
is	VBZ	O
a	DT	O
good	JJ	O
alternative	NN	O
to	TO	O
other	JJ	O
inhaled	JJ	O
corticosteroids	NNS	O
when	WRB	O
added	VBN	O
to	TO	O
nebulized	JJ	PM
salbutamol/ipratropium	NN	PM
bromide	NN	PM
in	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
moderate-to-severe	JJ	O
COPD	NNP	O
patients	NNS	O
.	.	O

Abacavir	NNP	PM
once	RB	O
or	CC	O
twice	RB	O
daily	RB	O
combined	VBN	O
with	IN	O
once-daily	JJ	O
lamivudine	NN	PM
and	CC	PM
efavirenz	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
antiretroviral-naive	JJ	O
HIV-infected	JJ	O
adults	NNS	O
:	:	O
results	NNS	O
of	IN	O
the	DT	O
Ziagen	NNP	PM
Once	NNP	O
Daily	NNP	O
in	IN	O
Antiretroviral	NNP	O
Combination	NNP	O
Study	NNP	O
.	.	O

The	DT	O
long	JJ	O
intracellular	JJ	O
half-life	NN	O
of	IN	O
abacavir	NN	PM
(	(	PM
ABC	NNP	PM
)	)	PM
supports	VBZ	O
its	PRP$	O
once-daily	JJ	O
use	NN	O
,	,	O
and	CC	O
this	DT	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
simplify	VB	O
treatment	NN	O
if	IN	O
ABC	NNP	PM
could	MD	O
be	VB	O
given	VBN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
complete	JJ	O
once-daily	JJ	O
regimen	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
600	CD	O
mg	NN	O
of	IN	O
ABC	NNP	PM
administered	VBD	O
once	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
384	CD	O
)	)	O
versus	NN	O
300	CD	O
mg	NN	O
of	IN	O
ABC	NNP	PM
administered	VBD	O
twice	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
386	CD	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
300	CD	O
mg	NNS	O
of	IN	O
lamivudine	NN	PM
(	(	PM
3TC	CD	PM
)	)	PM
and	CC	O
600	CD	O
mg	NN	O
of	IN	O
efavirenz	NN	PM
(	(	PM
EFV	NNP	PM
)	)	PM
administered	VBD	O
once	RB	O
daily	JJ	O
in	IN	O
antiretroviral-naive	JJ	O
patients	NNS	O
over	IN	O
48	CD	O
weeks	NNS	O
.	.	O

The	DT	O
baseline	NN	O
median	JJ	O
plasma	NN	O
HIV-1	NNP	O
RNA	NNP	O
level	NN	O
was	VBD	O
4.89	CD	O
log10	JJ	O
copies/mL	NN	O
(	(	O
44	CD	O
%	NN	O
with	IN	O
viral	JJ	O
load	NN	O
>	VBD	O
100,000	CD	O
copies/mL	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
median	JJ	O
CD4	NNP	O
cell	NN	O
count	NN	O
was	VBD	O
262	CD	O
cells/mm	NN	O
.	.	O

ABC	NNP	PM
administered	VBD	O
once	RB	O
daily	JJ	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
the	DT	O
twice-daily	JJ	O
regimen	NNS	O
,	,	O
with	IN	O
66	CD	O
%	NN	O
and	CC	O
68	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
these	DT	O
respective	JJ	O
treatment	NN	O
arms	NNS	O
achieving	VBG	O
a	DT	O
confirmed	JJ	O
plasma	NN	O
HIV-1	NNP	O
RNA	NNP	O
level	NN	O
<	VBD	O
50	CD	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
-8.4	CD	O
%	NN	O
,	,	O
4.9	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
ABC	NNP	PM
once-daily	JJ	O
and	CC	O
twice-daily	JJ	O
regimens	NNS	O
were	VBD	O
similar	JJ	O
with	IN	O
respect	NN	O
to	TO	O
infrequency	NN	O
of	IN	O
virologic	JJ	O
failure	NN	O
(	(	O
10	CD	O
%	NN	O
vs.	FW	O
8	CD	O
%	NN	O
)	)	O
,	,	O
emergence	NN	O
of	IN	O
resistance	NN	O
mutations	NNS	O
,	,	O
CD4	NNP	O
cell	NN	O
increases	NNS	O
from	IN	O
baseline	NN	O
(	(	O
median	JJ	O
,	,	O
188	CD	O
vs.	FW	O
200	CD	O
cells/mm	NN	O
)	)	O
,	,	O
safety	NN	O
profile	NN	O
,	,	O
and	CC	O
incidence	NN	O
of	IN	O
ABC-related	NNP	PM
hypersensitivity	NN	O
reactions	NNS	O
(	(	O
9	CD	O
%	NN	O
vs.	FW	O
7	CD	O
%	NN	O
)	)	O
.	.	O

ABC	NNP	PM
administered	VBD	O
once	RB	O
daily	JJ	O
in	IN	O
combination	NN	O
with	IN	O
3TC	CD	PM
and	CC	O
EFV	NNP	PM
administered	VBD	O
once	RB	O
daily	JJ	O
was	VBD	O
non-inferior	JJ	O
to	TO	O
the	DT	O
ABC	NNP	PM
twice-daily	JJ	O
dosing	NN	O
schedule	NN	O
when	WRB	O
combined	VBN	O
with	IN	O
3TC	CD	PM
and	CC	O
EFV	NNP	PM
over	IN	O
48	CD	O
weeks	NNS	O
.	.	O

A	DT	O
randomized	VBN	O
study	NN	O
comparing	VBG	O
levofloxacin	NN	PM
,	,	PM
omeprazole	NN	PM
,	,	PM
nitazoxanide	RB	PM
,	,	O
and	CC	O
doxycycline	VB	PM
versus	NN	O
triple	JJ	PM
therapy	NN	PM
for	IN	O
the	DT	O
eradication	NN	O
of	IN	O
Helicobacter	NNP	O
pylori	NN	O
.	.	O

OBJECTIVES	NNP	O
Resistance	NNP	O
to	TO	O
standard	VB	O
Helicobacter	NNP	O
pylori	NN	O
(	(	O
HP	NNP	O
)	)	O
treatment	NN	O
regimens	VBZ	O
has	VBZ	O
led	VBN	O
to	TO	O
unsatisfactory	JJ	O
cure	NN	O
rates	NNS	O
in	IN	O
HP-infected	JJ	O
patients	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
a	DT	O
novel	JJ	O
four-drug	JJ	PM
regimen	NNS	PM
(	(	O
three	CD	O
antibiotics	NNS	O
and	CC	O
a	DT	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
(	(	O
PPI	NNP	O
)	)	O
)	)	O
for	IN	O
eradication	NN	O
of	IN	O
HP	NNP	O
infection	NN	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
HP	NNP	O
gastritis	NN	O
or	CC	O
peptic	JJ	O
ulcer	JJ	O
disease	NN	O
confirmed	VBD	O
using	VBG	O
endoscopy	NN	O
and	CC	O
stool	NN	O
antigen	NN	O
testing	VBG	O
were	VBD	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
underwent	VBD	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
from	IN	O
any	DT	O
prior	JJ	O
antibiotic	JJ	O
or	CC	O
PPI	JJ	O
usage	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
then	RB	O
randomized	VBN	O
to	TO	O
either	DT	O
levofloxacin	NN	PM
,	,	PM
omeprazole	NN	PM
,	,	PM
nitazoxanide	RB	PM
,	,	PM
and	CC	PM
doxycycline	NN	PM
(	(	PM
LOAD	NNP	PM
)	)	PM
therapy	NN	O
for	IN	O
7	CD	O
days	NNS	O
(	(	O
LOAD-7	NNP	O
)	)	O
or	CC	O
10	CD	O
days	NNS	O
(	(	O
LOAD-10	NNP	O
)	)	O
,	,	O
including	VBG	O
levofloxacin	JJ	PM
250	CD	PM
mg	NN	PM
with	IN	PM
breakfast	NN	PM
,	,	PM
omeprazole	JJ	PM
40	CD	PM
mg	NN	PM
before	IN	PM
breakfast	NN	PM
,	,	PM
nitazoxanide	RB	PM
(	(	PM
Alina	NNP	PM
)	)	PM
500	CD	PM
mg	JJ	PM
twice	RB	PM
daily	RB	PM
with	IN	O
meals	NNS	O
and	CC	O
doxycycline	VB	PM
100	CD	PM
mg	NN	PM
at	IN	O
dinner	NN	O
,	,	O
or	CC	O
lansoprozole	NN	PM
,	,	PM
amoxicillin	NN	PM
,	,	PM
and	CC	PM
clarithromycin	NN	PM
(	(	PM
LAC	NNP	PM
)	)	PM
therapy	NN	PM
for	IN	O
10	CD	O
days	NNS	O
,	,	O
which	WDT	O
included	VBD	O
lansoprozole	JJ	PM
30	CD	PM
mg	NN	PM
,	,	PM
amoxicillin	VBZ	PM
1	CD	PM
g	NN	PM
with	IN	PM
breakfast	NN	PM
and	CC	PM
dinner	NN	PM
,	,	PM
and	CC	PM
clarithromycin	VBZ	PM
500	CD	PM
mg	NN	PM
with	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
.	.	O

HP	NNP	O
eradication	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
stool	NN	O
antigen	NN	O
testing	VBG	O
at	IN	O
least	JJS	O
4	CD	O
weeks	NNS	O
after	IN	O
cessation	NN	O
of	IN	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
Intention-to-treat	JJ	O
analysis	NN	O
revealed	VBD	O
significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
respective	JJ	O
eradication	NN	O
rates	NNS	O
of	IN	O
the	DT	O
LOAD	NNP	O
therapies	NNS	O
(	(	O
88.9	CD	O
%	NN	O
(	(	O
80/90	CD	O
)	)	O
LOAD-10	NNP	O
,	,	O
90	CD	O
%	NN	O
(	(	O
81/90	CD	O
)	)	O
LOAD-7	NNP	O
,	,	O
89.4	CD	O
%	NN	O
(	(	O
161/180	CD	O
)	)	O
for	IN	O
combined	VBN	O
LOAD	NNP	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
receiving	VBG	O
LAC	NNP	O
,	,	O
73.3	CD	O
%	NN	O
(	(	O
66/90	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
adverse	JJ	O
effects	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
open-label	JJ	O
,	,	O
prospective	JJ	O
trial	NN	O
demonstrates	VBZ	O
that	IN	O
LOAD	NNP	PM
is	VBZ	O
a	DT	O
highly	RB	O
active	JJ	O
regimen	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HP	NNP	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
.	.	O

A	DT	O
large	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
is	VBZ	O
warranted	VBN	O
to	TO	O
further	RBR	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
this	DT	O
regimen	NNS	O
.	.	O

A	DT	O
two-part	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
cediranib	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
solid	JJ	O
tumours	NN	O
:	:	O
the	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
single-dose	JJ	O
pharmacokinetics	NNS	O
and	CC	O
an	DT	O
evaluation	NN	O
of	IN	O
safety	NN	O
,	,	O
efficacy	NN	O
and	CC	O
imaging	VBG	O
pharmacodynamics	NNS	O
.	.	O

BACKGROUND	NNP	O
Cediranib	NNP	O
(	(	O
RECENTIN?	NNP	O
)	)	O
is	VBZ	O
an	DT	O
oral	JJ	O
,	,	O
highly	RB	O
potent	JJ	O
VEGF	NNP	O
inhibitor	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
cediranib	NN	O
and	CC	O
compared	VBN	O
the	DT	O
administration	NN	O
of	IN	O
continual	JJ	O
cediranib	NN	O
via	IN	O
two	CD	O
dosing	VBG	O
strategies	NNS	O
using	VBG	O
this	DT	O
as	IN	O
a	DT	O
platform	NN	O
to	TO	O
investigate	VB	O
pharmacodynamic	JJ	O
imaging	NN	O
biomarkers	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
two	CD	O
single	JJ	O
doses	NNS	O
of	IN	O
cediranib	NN	O
in	IN	O
either	CC	O
fed/fasted	VBD	O
or	CC	O
fasted/fed	JJ	O
state	NN	O
(	(	O
Part	NNP	O
A	NNP	O
)	)	O
.	.	O

In	IN	O
continual	JJ	O
dosage	NN	O
phase	NN	O
(	(	O
Part	NNP	O
B	NNP	O
)	)	O
,	,	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
a	DT	O
fixed-dose	JJ	O
or	CC	O
dose-escalation	JJ	O
arm	NN	O
.	.	O

Exploratory	JJ	O
pharmacodynamic	JJ	O
assessments	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
DCE-MRI	NNP	O
and	CC	O
CT	NNP	O
enhancing	VBG	O
fraction	NN	O
(	(	O
EnF	NNP	O
)	)	O
.	.	O

RESULTS	VBN	O
In	IN	O
part	NN	O
A	NNP	O
,	,	O
plasma	NN	O
AUC	NNP	O
and	CC	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
of	IN	O
cediranib	NN	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
food	NN	O
by	IN	O
a	DT	O
mean	NN	O
of	IN	O
24	CD	O
and	CC	O
33	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
94	CD	O
%	NN	O
CI	NNP	O
:	:	O
AUC	NNP	O
,	,	O
12-34	CD	O
%	NN	O
and	CC	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
,	,	O
20-43	JJ	O
%	NN	O
)	)	O
,	,	O
indicating	VBG	O
food	NN	O
reduces	NNS	O
cediranib	VBP	O
plasma	JJ	O
exposure	NN	O
.	.	O

In	IN	O
part	NN	O
B	NNP	O
,	,	O
cediranib	VBZ	O
30	CD	O
mg/day	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
sustainable	JJ	O
for	IN	O
chronic	JJ	O
dosing	NN	O
.	.	O

Continuous	JJ	O
cediranib	NN	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
sustained	JJ	O
antivascular	JJ	O
effects	NNS	O
up	RB	O
to	TO	O
16	CD	O
weeks	NNS	O
,	,	O
with	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
DCE-MRI	NNP	O
parameters	NNS	O
and	CC	O
CT	NNP	O
EnF	NNP	O
.	.	O

CONCLUSIONS	VB	O
It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
cediranib	NN	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
1	CD	O
h	NN	O
before	IN	O
or	CC	O
2	CD	O
h	NN	O
after	IN	O
food	NN	O
.	.	O

Evidence	NN	O
of	IN	O
antitumour	JJ	O
activity	NN	O
was	VBD	O
observed	VBN	O
,	,	O
with	IN	O
significant	JJ	O
sustained	JJ	O
effects	NNS	O
upon	IN	O
imaging	VBG	O
vascular	JJ	O
parameters	NNS	O
.	.	O

Effect	NN	O
of	IN	O
L-carnitine	NNP	PM
on	IN	O
myocardial	JJ	O
metabolism	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
balanced	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
open	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
L-carnitine	NNP	PM
on	IN	O
cardiac	JJ	O
performance	NN	O
after	IN	O
open	JJ	O
heart	NN	O
surgery	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
balanced	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
double-blind	JJ	O
study	NN	O
in	IN	O
38	CD	O
patients	NNS	O
.	.	O

Preoperative	JJ	O
haemodynamic	JJ	O
status	NN	O
was	VBD	O
good	JJ	O
in	IN	O
all	DT	O
of	IN	O
them	PRP	O
.	.	O

Seventeen	JJ	O
subjects	NNS	O
underwent	JJ	O
mitral	JJ	S
valve	NN	S
replacement	NN	S
and	CC	O
19	CD	O
patients	NNS	O
coronary	JJ	S
artery	JJ	S
bypass	NN	S
grafting	NN	S
.	.	O

Five	CD	O
grams	NNS	O
L-carnitine	JJ	PM
were	VBD	O
given	VBN	O
intravenously	RB	O
over	IN	O
2	CD	O
h	NNS	O
,	,	O
twice	RB	O
daily	RB	O
for	IN	O
5	CD	O
consecutive	JJ	O
days	NNS	O
;	:	O
moreover	RB	O
,	,	O
10	CD	O
g	JJ	O
L-carnitine	NNP	PM
in	IN	PM
1500	CD	PM
ml	NN	PM
cardioplegia	NN	PM
were	VBD	O
administered	VBN	O
through	IN	O
the	DT	O
aortic	JJ	O
root	NN	O
after	IN	O
aortic	JJ	S
cross-clamping	NN	S
.	.	O

Surgery	NN	O
was	VBD	O
always	RB	O
planned	VBN	O
on	IN	O
treatment	NN	O
day	NN	O
3	CD	O
.	.	O

The	DT	O
post-ischaemic	JJ	O
functional	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
heart	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
clinical	JJ	O
parameters	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
biochemical	JJ	O
and	CC	O
ultrastructure	JJ	O
evaluations	NNS	O
on	IN	O
biopsy	NN	O
specimens	NNS	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
treatment	NN	O
group	NN	O
with	IN	O
respect	NN	O
to	TO	O
all	DT	O
clinical	JJ	O
parameters	NNS	O
of	IN	O
cardiac	JJ	O
performance	NN	O
after	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

At	IN	O
anaesthesia	JJ	O
induction	NN	O
,	,	O
serum	JJ	O
carnitine	NN	O
was	VBD	O
significantly	RB	O
increased	VBN	O
in	IN	O
treated	JJ	O
patients	NNS	O
,	,	O
but	CC	O
carnitine	JJ	O
concentrations	NNS	O
in	IN	O
the	DT	O
right	JJ	O
atrial	JJ	O
biopsy	NN	O
obtained	VBN	O
just	RB	O
before	RB	O
aortic	JJ	O
declamping	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
mitral	JJ	O
valve	FW	O
replacement	NN	O
,	,	O
L-carnitine	JJ	PM
therapy	NN	PM
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
higher	JJR	O
concentrations	NNS	O
of	IN	O
pyruvate	NN	O
,	,	O
ATP	NNP	O
and	CC	O
creatine	JJ	O
phosphate	NN	O
in	IN	O
papillary	JJ	O
muscle	NN	O
.	.	O

Glycogen	NN	O
levels	NNS	O
were	VBD	O
also	RB	O
higher	JJR	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Myocardial	JJ	O
ultrastructure	NN	O
on	IN	O
septal	JJ	O
biopsies	NNS	O
,	,	O
obtained	VBD	O
within	IN	O
5	CD	O
min	NN	O
from	IN	O
weaning	VBG	O
from	IN	O
extracorporeal	JJ	O
circulation	NN	O
,	,	O
showed	VBD	O
better	JJR	O
preservation	NN	O
scores	NNS	O
for	IN	O
all	DT	O
considered	VBN	O
parameters	NNS	O
(	(	O
nucleus	NN	O
,	,	O
sarcoplasmic	JJ	O
reticulum	NN	O
,	,	O
mitochondria	NN	O
and	CC	O
cellular	JJ	O
oedema	NN	O
)	)	O
in	IN	O
the	DT	O
treated	JJ	O
subjects	NNS	O
,	,	O
although	IN	O
the	DT	O
difference	NN	O
reached	VBD	O
statistical	JJ	O
significance	NN	O
only	RB	O
for	IN	O
nuclei	NN	O
.	.	O

When	WRB	O
biochemical	JJ	O
and	CC	O
ultrastructural	JJ	O
data	NNS	O
are	VBP	O
considered	VBN	O
,	,	O
these	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
L-carnitine	NNP	PM
improves	VBZ	O
myocardial	JJ	O
metabolism	NN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
can	MD	O
not	RB	O
be	VB	O
concluded	VBN	O
that	IN	O
L-carnitine	NNP	O
provides	VBZ	O
an	DT	O
advantageous	JJ	O
support	NN	O
therapy	NN	O
for	IN	O
well-compensated	JJ	O
patients	NNS	O
requiring	VBG	O
cardiac	JJ	O
surgery	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
positive	JJ	O
effects	NNS	O
of	IN	O
L-carnitine	NNP	O
on	IN	O
cardiac	JJ	O
recovery	NN	O
after	IN	O
bypass	NN	O
might	MD	O
become	VB	O
clinically	RB	O
relevant	JJ	O
in	IN	O
the	DT	O
surgical	JJ	O
setting	NN	O
for	IN	O
haemodynamically	RB	O
compromised	JJ	O
patients	NNS	O
,	,	O
in	IN	O
which	WDT	O
further	JJ	O
investigations	NNS	O
are	VBP	O
required	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
standardized	JJ	E
pamphlet	NN	E
on	IN	O
insomnia	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
Sleep	NNP	O
difficulties	NNS	O
are	VBP	O
common	JJ	O
reasons	NNS	O
why	WRB	O
parents	NNS	O
seek	VBP	O
medical	JJ	O
intervention	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASDs	NNP	O
)	)	O
.	.	O

We	PRP	O
determined	VBD	O
whether	IN	O
a	DT	O
pamphlet	NN	E
alone	RB	O
could	MD	O
be	VB	O
used	VBN	O
by	IN	O
parents	NNS	O
to	TO	O
help	VB	O
their	PRP$	O
child	NN	O
's	POS	O
insomnia	NN	O
.	.	O

METHODS	NNP	O
Thirty-six	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
ages	VBZ	O
2	CD	O
to	TO	O
10	CD	O
years	NNS	O
,	,	O
were	VBD	O
enrolled	VBN	O
.	.	O

All	DT	O
had	VBD	O
prolonged	VBN	O
sleep	JJ	O
latency	NN	O
confirmed	VBN	O
by	IN	O
actigraphy	NN	O
showing	VBG	O
a	DT	O
mean	JJ	O
sleep	JJ	O
latency	NN	O
of	IN	O
30	CD	O
minutes	NNS	O
or	CC	O
more	JJR	O
.	.	O

Parents	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
the	DT	O
sleep	JJ	E
education	NN	E
pamphlet	NN	E
or	CC	E
no	DT	E
intervention	NN	C
.	.	O

Children	NNP	O
wore	VBD	O
an	DT	O
actigraphy	NN	Ot
device	NN	Ot
to	TO	O
record	VB	O
baseline	NN	O
sleep	JJ	O
parameters	NNS	O
,	,	O
with	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
variable	JJ	O
being	VBG	O
change	NN	O
in	IN	O
sleep	JJ	O
latency	NN	O
.	.	O

Actigraphy	NNP	O
data	NNS	O
were	VBD	O
collected	VBN	O
a	DT	O
second	JJ	O
time	NN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
parent	NN	O
received	VBD	O
the	DT	O
randomization	NN	O
assignment	NN	O
and	CC	O
analyzed	VBN	O
by	IN	O
using	VBG	O
Student	NNP	O
's	POS	O
t	JJ	O
test	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
also	RB	O
asked	VBN	O
a	DT	O
series	NN	O
of	IN	O
questions	NNS	O
to	TO	O
gather	VB	O
information	NN	O
about	IN	O
the	DT	O
pamphlet	NN	E
and	CC	O
its	PRP$	O
usefulness	NN	O
.	.	O

RESULTS	NNP	O
Although	IN	O
participants	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
2	CD	O
arms	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
statistically	RB	O
in	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
socioeconomic	JJ	O
status	NN	O
,	,	O
total	JJ	O
Children	NNP	O
's	POS	O
Sleep	NNP	O
Habits	NNP	O
Questionnaire	NNP	O
score	NN	O
,	,	O
or	CC	O
actigraphy	NN	O
parameters	NNS	O
,	,	O
some	DT	O
differences	NNS	O
may	MD	O
be	VB	O
large	JJ	O
enough	RB	O
to	TO	O
affect	VB	O
results	NNS	O
.	.	O

Mean	JJ	O
change	NN	O
in	IN	O
sleep-onset	JJ	O
latency	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
randomized	VBN	O
groups	NNS	O
(	(	O
pamphlet	VB	E
versus	NN	E
no	DT	C
pamphlet	NN	C
)	)	O
.	.	O

Parents	NNS	O
commented	VBD	O
that	IN	O
the	DT	O
pamphlet	NN	E
contained	VBD	O
good	JJ	O
information	NN	O
,	,	O
but	CC	O
indicated	VBD	O
that	IN	O
it	PRP	O
would	MD	O
have	VB	O
been	VBN	O
more	RBR	O
useful	JJ	O
to	TO	O
be	VB	O
given	VBN	O
specific	JJ	O
examples	NNS	O
of	IN	O
how	WRB	O
to	TO	O
take	VB	O
the	DT	O
information	NN	O
and	CC	O
put	VB	O
it	PRP	O
into	IN	O
practice	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
sleep	JJ	E
education	NN	E
pamphlet	NN	E
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
improve	VB	O
sleep	JJ	O
latency	NN	O
in	IN	O
children	NNS	O
with	IN	O
ASDs	NNP	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
alpha	JJ	PM
dihydroergocryptine	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
fibrocystic	JJ	O
breast	NN	O
disease	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
alpha	JJ	PM
dihidroergocriptine	NN	PM
in	IN	O
patients	NNS	O
with	IN	O
fibrocystic	JJ	O
mastopathy	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
with	IN	O
diagnosis	NN	O
of	IN	O
fibrocystic	JJ	O
breast	NN	O
disease	NN	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
longitudinal	JJ	O
blind	NN	O
double	NN	O
,	,	O
controlled	VBN	O
with	IN	O
placebo	NN	C
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
of	IN	O
treatment	NN	O
group	NN	O
A	DT	O
:	:	O
Alpha	NNP	PM
dihidroergocriptine	VBP	PM
tablets	NNS	PM
of	IN	PM
10	CD	PM
mg	NNS	PM
,	,	O
group	NN	O
B	NNP	O
:	:	O
Placebo	NN	C
,	,	O
during	IN	O
6	CD	O
months	NNS	O
.	.	O

After	IN	O
to	TO	O
basal	VB	O
evaluation	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
revised	VBN	O
in	IN	O
a	DT	O
monthly	JJ	O
way	NN	O
evaluating	VBG	O
the	DT	O
following	NN	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
:	:	O
mastalgia	NN	O
,	,	O
mammary	JJ	O
tension	NN	O
,	,	O
presence	NN	O
of	IN	O
nodules	NNS	O
,	,	O
nipple	JJ	O
secretion	NN	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
39	CD	O
patients	NNS	O
with	IN	O
alpha	JJ	PM
dihidroergocriptine	NN	PM
and	CC	O
38	CD	O
with	IN	O
placebo	NN	C
.	.	O

Mastodinia	NNP	O
,	,	O
a	DT	O
satisfactory	JJ	O
response	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
100	CD	O
%	NN	O
of	IN	O
alpha	JJ	PM
dihidroergocriptine	NN	PM
group	NN	O
vs	VBD	O
61.11	CD	O
%	NN	O
of	IN	O
placebo	NN	C
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0002	CD	O
)	)	O
.	.	O

Mastalgia	NNP	O
responded	VBD	O
in	IN	O
100	CD	O
%	NN	O
of	IN	O
alpha	JJ	O
dihidroergocriptine	NN	O
group	NN	O
vs	VBD	O
64.86	CD	O
%	NN	O
of	IN	O
placebo	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

Galactorrea	NNP	O
responded	VBD	O
100	CD	O
%	NN	O
of	IN	O
alpha	JJ	PM
dihidroergocriptine	NN	PM
group	NN	O
vs	VBD	O
93.33	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
.	.	O

The	DT	O
nodules	NNS	O
in	IN	O
the	DT	O
group	NN	O
alpha	VBZ	O
dihidroergocriptine	NN	O
disappeared	VBD	O
in	IN	O
23.1	CD	O
%	NN	O
and	CC	O
in	IN	O
21.1	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Ultrasound	IN	O
evaluation	NN	O
of	IN	O
the	DT	O
nodules	NNS	O
did	VBD	O
not	RB	O
show	VB	O
significant	JJ	O
differences	NNS	O
between	IN	O
both	DT	O
groups	NNS	O
.	.	O

Prolactin	NNP	O
levels	NNS	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
alpha	JJ	PM
dihidroergocriptine	NN	PM
with	IN	O
an	DT	O
important	JJ	O
difference	NN	O
between	IN	O
both	DT	O
groups	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
6	CD	O
months	NNS	O
study	JJ	O
period	NN	O
.	.	O

There	EX	O
were	VBD	O
not	RB	O
differences	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
between	IN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Alpha	NNP	PM
dihidroergocriptine	NN	PM
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
fribrocystic	JJ	O
breast	NN	O
disease	NN	O
with	IN	O
minimum	JJ	O
adverse	JJ	O
events	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
similar	JJ	O
drugs	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
dalcetrapib	NN	PM
on	IN	O
atherosclerotic	JJ	O
disease	NN	O
using	VBG	O
novel	JJ	S
non-invasive	JJ	S
multimodality	NN	S
imaging	NN	S
(	(	S
dal-PLAQUE	JJ	S
)	)	PH
:	:	O
a	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Dalcetrapib	NNP	PM
modulates	VBZ	O
cholesteryl	VBP	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
activity	NN	O
to	TO	O
raise	VB	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
HDL-C	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
failure	NN	O
of	IN	O
torcetrapib	NN	O
it	PRP	O
was	VBD	O
unknown	JJ	O
if	IN	O
HDL	NNP	O
produced	VBN	O
by	IN	O
interaction	NN	O
with	IN	O
CETP	NNP	O
had	VBD	O
pro-atherogenic	JJ	O
or	CC	O
pro-inflammatory	JJ	O
properties	NNS	O
.	.	O

dal-PLAQUE	NN	O
is	VBZ	O
the	DT	O
first	JJ	O
multicentre	NN	O
study	NN	O
using	VBG	O
novel	JJ	O
non-invasive	JJ	O
multimodality	NN	O
imaging	VBG	O
to	TO	O
assess	VB	O
structural	JJ	O
and	CC	O
inflammatory	JJ	O
indices	NNS	O
of	IN	O
atherosclerosis	NN	O
as	IN	O
primary	JJ	O
endpoints	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
phase	NN	O
2b	CD	O
,	,	O
double-blind	NN	O
,	,	O
multicentre	JJ	O
trial	NN	O
,	,	O
patients	NNS	O
(	(	O
aged	VBN	O
18-75	CD	O
years	NNS	O
)	)	O
with	IN	O
,	,	O
or	CC	O
with	IN	O
high	JJ	O
risk	NN	O
of	IN	O
,	,	O
coronary	JJ	O
heart	NN	O
disease	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
(	(	O
1:1	CD	O
)	)	O
to	TO	O
dalcetrapib	VB	PM
600	CD	PM
mg/day	NN	PM
or	CC	O
placebo	NN	C
for	IN	O
24	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
done	VBN	O
with	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
code	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
centre	NN	O
.	.	O

Patients	NNS	O
and	CC	O
investigators	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
treatment	NN	O
.	.	O

Coprimary	JJ	O
endpoints	NNS	O
were	VBD	O
MRI-assessed	JJ	O
indices	NNS	O
(	(	O
total	JJ	O
vessel	NN	O
area	NN	O
,	,	O
wall	JJ	O
area	NN	O
,	,	O
wall	NN	O
thickness	NN	O
,	,	O
and	CC	O
normalised	VBD	O
wall	NN	O
index	NN	O
[	JJ	O
average	JJ	O
carotid	NN	O
]	NN	O
)	)	O
after	IN	O
24	CD	O
months	NNS	O
and	CC	O
(	(	O
18	CD	O
)	)	O
F-fluorodeoxyglucose	NNP	O
(	(	O
(	(	O
18	CD	O
)	)	O
F-FDG	NN	O
)	)	O
PET/CT	NNP	O
assessment	NN	O
of	IN	O
arterial	JJ	O
inflammation	NN	O
within	IN	O
an	DT	O
index	NN	O
vessel	NN	O
(	(	O
right	JJ	O
carotid	NN	O
,	,	O
left	VBD	O
carotid	NN	O
,	,	O
or	CC	O
ascending	VBG	O
thoracic	JJ	O
aorta	NN	O
)	)	O
after	IN	O
6	CD	O
months	NNS	O
,	,	O
with	IN	O
no-harm	JJ	O
boundaries	NNS	O
established	VBN	O
before	IN	O
unblinding	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
NCT00655473	NNP	O
.	.	O

FINDINGS	NNP	O
189	CD	O
patients	NNS	O
were	VBD	O
screened	VBN	O
and	CC	O
130	CD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	C
(	(	O
66	CD	O
patients	NNS	O
)	)	O
or	CC	O
dalcetrapib	NN	PM
(	(	O
64	CD	O
patients	NNS	O
)	)	O
.	.	O

For	IN	O
the	DT	O
coprimary	JJ	O
MRI	NNP	O
and	CC	O
PET/CT	NNP	O
endpoints	NNS	O
,	,	O
CIs	NNP	O
were	VBD	O
below	IN	O
the	DT	O
no-harm	JJ	O
boundary	NN	O
or	CC	O
the	DT	O
adverse	JJ	O
change	NN	O
was	VBD	O
numerically	RB	O
lower	JJR	O
in	IN	O
the	DT	O
dalcetrapib	NN	PM
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

MRI-derived	JJ	O
change	NN	O
in	IN	O
total	JJ	O
vessel	JJ	O
area	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
patients	NNS	O
given	VBN	O
dalcetrapib	NNS	PM
compared	VBN	O
with	IN	O
those	DT	O
given	VBN	O
placebo	NNS	O
after	IN	O
24	CD	O
months	NNS	O
;	:	O
absolute	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
relative	NN	O
to	TO	O
placebo	VB	C
was	VBD	O
-4?01	JJ	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
90	CD	O
%	NN	O
CI	NNP	O
-7?23	NNP	O
to	TO	O
-0?80	VB	O
;	:	O
nominal	JJ	O
p=0?04	NN	O
)	)	O
.	.	O

The	DT	O
PET/CT	NNP	O
measure	NN	O
of	IN	O
index	NN	O
vessel	JJ	O
most-diseased-segment	JJ	O
target-to-background	NN	O
ratio	NN	O
(	(	O
TBR	NNP	O
)	)	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
,	,	O
but	CC	O
carotid	JJ	O
artery	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
7	CD	O
%	NN	O
reduction	NN	O
in	IN	O
most-diseased-segment	JJ	O
TBR	NNP	O
in	IN	O
the	DT	O
dalcetrapib	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
-7?3	NNP	O
[	RB	O
90	CD	O
%	NN	O
CI	NNP	O
-13?5	NNP	O
to	TO	O
-0?8	VB	O
]	NNP	O
;	:	O
nominal	JJ	O
p=0?07	NN	O
)	)	O
.	.	O

Dalcetrapib	NNP	O
did	VBD	O
not	RB	O
increase	VB	O
office	NN	O
blood	NN	O
pressure	NN	O
and	CC	O
the	DT	O
frequency	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

INTERPRETATION	NNP	O
Dalcetrapib	NNP	O
showed	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
a	DT	O
pathological	JJ	O
effect	NN	O
related	VBN	O
to	TO	O
the	DT	O
arterial	JJ	O
wall	NN	O
over	IN	O
24	CD	O
months	NNS	O
.	.	O

Moreover	RB	O
,	,	O
this	DT	O
trial	NN	O
suggests	VBZ	O
possible	JJ	O
beneficial	JJ	O
vascular	JJ	O
effects	NNS	O
of	IN	O
dalcetrapib	NN	O
,	,	O
including	VBG	O
the	DT	O
reduction	NN	O
in	IN	O
total	JJ	O
vessel	JJ	O
enlargement	NN	O
over	IN	O
24	CD	O
months	NNS	O
,	,	O
but	CC	O
long-term	JJ	O
safety	NN	O
and	CC	O
clinical	JJ	O
outcomes	NNS	O
efficacy	NN	O
of	IN	O
dalcetrapib	NNS	O
need	VBP	O
to	TO	O
be	VB	O
analysed	VBN	O
.	.	O

FUNDING	NN	O
F	NNP	O
Hoffmann-La	NNP	O
Roche	NNP	O
Ltd	NNP	O
.	.	O

Effectiveness	NN	O
of	IN	O
norgestimate	NN	PM
and	CC	O
ethinyl	NN	PM
estradiol	NN	PM
in	IN	O
treating	VBG	O
moderate	JJ	O
acne	NN	O
vulgaris	NN	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
excess	NN	O
of	IN	O
androgen	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
contribute	VB	O
to	TO	O
development	NN	O
of	IN	O
acne	NN	O
in	IN	O
some	DT	O
patients	NNS	O
.	.	O

Because	IN	O
oral	JJ	PM
contraceptives	NNS	PM
(	(	O
OCs	NNP	O
)	)	O
may	MD	O
reduce	VB	O
the	DT	O
active	JJ	O
androgen	NN	O
level	NN	O
,	,	O
hormonal	JJ	O
therapy	NN	O
with	IN	O
OCs	NNP	O
has	VBZ	O
been	VBN	O
used	VBN	O
successfully	RB	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
acne	NN	O
,	,	O
although	IN	O
this	DT	O
treatment	NN	O
has	VBZ	O
previously	RB	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
placebo-controlled	JJ	O
trials	NNS	O
.	.	O

OBJECTIVE	CC	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
triphasic	JJ	PM
,	,	PM
combination	NN	PM
OC	NNP	PM
(	(	PM
ORTHO	NNP	PM
TRI-CYCLEN	NNP	PM
[	NNP	PM
Ortho-McNeil	NNP	PM
Pharmaceutical	NNP	PM
,	,	PM
Raritan	NNP	PM
,	,	PM
N.J.	NNP	PM
]	NNP	PM
,	,	PM
norgestimate/ethinyl	RB	PM
estradiol	NN	PM
)	)	PM
compared	VBN	O
with	IN	O
placebo	NN	C
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
acne	NN	O
vulgaris	NN	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
fifty-seven	RB	O
healthy	JJ	O
female	NN	O
subjects	NNS	O
,	,	O
15	CD	O
to	TO	O
49	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
moderate	JJ	O
acne	NNS	O
vulgaris	NN	O
,	,	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Each	DT	O
month	NN	O
for	IN	O
6	CD	O
months	NNS	O
,	,	O
subjects	VBZ	O
received	VBN	O
either	RB	O
3	CD	O
consecutive	JJ	O
weeks	NNS	O
of	IN	O
the	DT	O
OC	NNP	PM
(	(	O
i.e.	FW	O
,	,	O
tablets	NNS	O
containing	VBG	O
a	DT	O
fixed	VBN	O
dose	NN	O
of	IN	O
ethinyl	JJ	PM
estradiol	NN	PM
[	VBD	O
0.035	CD	O
mg	NN	O
]	NN	O
and	CC	O
increasing	VBG	O
doses	NNS	O
of	IN	O
norgestimate	JJ	PM
[	NNS	O
0.180	CD	O
mg	NNS	O
,	,	O
0.215	CD	O
mg	NN	O
,	,	O
0.250	CD	O
mg	NN	O
]	NN	O
)	)	O
followed	VBN	O
by	IN	O
7	CD	O
days	NNS	O
of	IN	O
inactive	JJ	PM
drug	NN	PM
or	CC	O
placebo	NN	C
(	(	O
color-matched	JJ	O
tablets	NNS	O
)	)	O
.	.	O

Efficacy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
facial	JJ	O
acne	JJ	O
lesion	NN	O
counts	NNS	O
,	,	O
an	DT	O
investigator	NN	O
's	POS	O
global	JJ	O
assessment	NN	O
,	,	O
a	DT	O
subject	NN	O
's	POS	O
self-assessment	NN	O
,	,	O
and	CC	O
an	DT	O
analysis	NN	O
of	IN	O
within-cycle	JJ	O
variation	NN	O
(	(	O
cycle	NN	O
6	CD	O
)	)	O
in	IN	O
lesion	NN	O
counts	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
160	CD	O
subjects	NNS	O
in	IN	O
whom	WP	O
efficacy	NN	O
could	MD	O
be	VB	O
evaluated	VBN	O
,	,	O
the	DT	O
OC	NNP	O
group	NN	O
showed	VBD	O
a	DT	O
statistically	RB	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
for	IN	O
all	DT	O
primary	JJ	O
efficacy	NN	O
measures	NNS	O
.	.	O

The	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
inflammatory	JJ	O
lesion	NN	O
count	NN	O
from	IN	O
baseline	NN	O
to	TO	O
cycle	NN	O
6	CD	O
was	VBD	O
11.8	CD	O
(	(	O
62.0	CD	O
%	NN	O
)	)	O
versus	NN	O
7.6	CD	O
(	(	O
38.6	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
total	JJ	O
lesion	NN	O
count	NN	O
was	VBD	O
29.1	CD	O
(	(	O
53.1	CD	O
%	NN	O
)	)	O
versus	NN	O
14.1	CD	O
(	(	O
26.8	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
in	IN	O
the	DT	O
OC	NNP	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
investigator	NN	O
's	POS	O
global	JJ	O
assessment	NN	O
,	,	O
93.7	CD	O
%	NN	O
of	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
versus	VBD	O
65.4	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
improved	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Six	CD	O
of	IN	O
the	DT	O
seven	CD	O
secondary	JJ	O
efficacy	NN	O
measures	NNS	O
(	(	O
total	JJ	O
comedones	NNS	O
,	,	O
open	JJ	O
comedones	NNS	O
,	,	O
closed	VBD	O
comedones	NNS	O
,	,	O
papules	NNS	O
,	,	O
pustules	NNS	O
,	,	O
and	CC	O
the	DT	O
subject	NN	O
's	POS	O
self-assessment	NN	O
of	IN	O
study	NN	O
treatment	NN	O
)	)	O
were	VBD	O
also	RB	O
significantly	RB	O
more	RBR	O
favorable	JJ	O
in	IN	O
the	DT	O
OC	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
An	DT	O
OC	NNP	O
containing	VBG	O
0.035	CD	O
mg	NN	O
of	IN	O
ethinyl	JJ	PM
estradiol	NN	PM
combined	VBN	O
with	IN	O
the	DT	O
triphasic	JJ	O
regimen	NNS	O
of	IN	O
norgestimate	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
treatment	NN	O
of	IN	O
moderate	JJ	O
acne	NNS	O
vulgaris	VBP	O
in	IN	O
women	NNS	O
with	IN	O
no	DT	O
known	VBN	O
contraindication	NN	O
to	TO	O
OC	NNP	O
therapy	NN	O
.	.	O

The	DT	O
Social	NNP	O
Communication	NNP	O
Intervention	NNP	O
Project	NNP	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
speech	NN	O
and	CC	O
language	NN	O
therapy	NN	O
for	IN	O
school-age	JJ	O
children	NNS	O
who	WP	O
have	VBP	O
pragmatic	JJ	O
and	CC	O
social	JJ	O
communication	NN	O
problems	NNS	O
with	IN	O
or	CC	O
without	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNPS	O
who	WP	O
show	VBP	O
disproportionate	JJ	O
difficulty	NN	O
with	IN	O
the	DT	O
pragmatic	JJ	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
structural	JJ	O
aspects	NNS	O
of	IN	O
language	NN	O
are	VBP	O
described	VBN	O
as	IN	O
having	VBG	O
pragmatic	JJ	O
language	NN	O
impairment	NN	O
(	(	O
PLI	NNP	O
)	)	O
or	CC	O
social	JJ	O
communication	NN	O
disorder	NN	O
(	(	O
SCD	NNP	O
)	)	O
.	.	O

Some	DT	O
children	NNS	O
who	WP	O
have	VBP	O
PLI	NNP	O
also	RB	O
show	VBP	O
mild	JJ	O
social	JJ	O
impairments	NNS	O
associated	VBN	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
or	CC	O
autism	NN	O
spectrum	JJ	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

There	EX	O
is	VBZ	O
little	JJ	O
robust	JJ	O
evidence	NN	O
of	IN	O
effectiveness	NN	O
of	IN	O
speech-language	NN	O
interventions	NNS	O
which	WDT	O
target	VBP	O
the	DT	O
language	NN	O
,	,	O
pragmatic	JJ	O
or	CC	O
social	JJ	O
communication	NN	O
needs	NNS	O
of	IN	O
these	DT	O
children	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
intensive	JJ	E
manualized	VBN	E
social	JJ	E
communication	NN	E
intervention	NN	E
(	(	E
SCIP	NNP	E
)	)	E
for	IN	O
children	NNS	O
who	WP	O
have	VBP	O
PLI	VBN	O
with	IN	O
or	CC	O
without	IN	O
features	NNS	O
of	IN	O
ASD	NNP	O
.	.	O

METHODS	NNP	O
&	CC	O
PROCEDURES	NNP	O
In	IN	O
a	DT	O
single-blind	JJ	O
RCT	NNP	O
design	NN	O
,	,	O
88	CD	O
children	NNS	O
with	IN	O
pragmatic	JJ	O
and	CC	O
social	JJ	O
communication	NN	O
needs	NNS	O
aged	VBD	O
5	CD	O
;	:	O
11-10	JJ	O
;	:	O
8	CD	O
,	,	O
recruited	VBN	O
from	IN	O
UK	NNP	O
speech	NN	O
and	CC	O
language	NN	O
therapy	NN	O
services	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
2:1	CD	O
ratio	NN	O
to	TO	O
SCIP	NNP	E
or	CC	O
to	TO	O
treatment-as-usual	JJ	Ot
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
SCIP	NNP	E
condition	NN	O
received	VBD	O
up	RB	O
to	TO	O
20	CD	E
sessions	NNS	E
of	IN	E
direct	JJ	E
intervention	NN	E
from	IN	E
a	DT	E
specialist	JJ	E
research	NN	E
speech	NN	E
and	CC	E
language	NN	E
therapist	NN	E
working	VBG	E
with	IN	E
supervised	JJ	E
assistants	NNS	E
.	.	O

All	DT	O
therapy	NN	O
content	NN	O
and	CC	O
methodology	NN	O
was	VBD	O
derived	VBN	O
from	IN	O
an	DT	O
intervention	NN	O
manual	NN	O
.	.	O

A	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
of	IN	O
structural	JJ	O
language	NN	O
and	CC	O
secondary	JJ	O
outcome	NN	O
measures	NNS	O
of	IN	O
narrative	JJ	O
,	,	O
parent-reported	JJ	O
pragmatic	JJ	O
functioning	NN	O
and	CC	O
social	JJ	O
communication	NN	O
,	,	O
blind-rated	JJ	O
perceptions	NNS	O
of	IN	O
conversational	JJ	O
competence	NN	O
and	CC	O
teacher-reported	JJ	O
ratings	NNS	O
of	IN	O
classroom	NN	O
learning	VBG	O
skills	NNS	O
were	VBD	O
taken	VBN	O
pre-intervention	NN	O
,	,	O
immediately	RB	O
post-intervention	NN	O
and	CC	O
at	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

OUTCOMES	NNP	O
&	CC	O
RESULTS	NNP	O
No	NNP	O
significant	JJ	O
treatment	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
the	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
of	IN	O
structural	JJ	O
language	NN	O
ability	NN	O
or	CC	O
for	IN	O
a	DT	O
measure	NN	O
of	IN	O
narrative	JJ	O
ability	NN	O
.	.	O

Significant	JJ	O
treatment	NN	O
effects	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
blind-rated	JJ	O
perceptions	NNS	O
of	IN	O
conversational	JJ	O
competence	NN	O
,	,	O
for	IN	O
parent-reported	JJ	O
measures	NNS	O
of	IN	O
pragmatic	JJ	O
functioning	NN	O
and	CC	O
social	JJ	O
communication	NN	O
,	,	O
and	CC	O
for	IN	O
teacher-reported	JJ	O
ratings	NNS	O
of	IN	O
classroom	NN	O
learning	NN	O
skills	NNS	O
.	.	O

CONCLUSIONS	NNP	O
&	CC	O
IMPLICATIONS	NNP	O
There	EX	O
is	VBZ	O
some	DT	O
evidence	NN	O
of	IN	O
an	DT	O
intervention	NN	O
effect	NN	O
on	IN	O
blind	NN	O
and	CC	O
parent/teacher-reported	JJ	O
communication	NN	O
outcomes	NNS	O
,	,	O
but	CC	O
not	RB	O
standardized	JJ	O
language	NN	O
assessment	NN	O
outcomes	NNS	O
,	,	O
for	IN	O
6-11-year-old	JJ	O
children	NNS	O
who	WP	O
have	VBP	O
pragmatic	JJ	O
and	CC	O
social	JJ	O
communication	NN	O
needs	NNS	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
increasingly	RB	O
central	JJ	O
role	NN	O
of	IN	O
service	NN	O
user	NN	O
outcomes	NNS	O
in	IN	O
providing	VBG	O
evidence	NN	O
for	IN	O
an	DT	O
intervention	NN	O
.	.	O

The	DT	O
substantial	JJ	O
overlap	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
PLI	NNP	O
and	CC	O
ASD	NNP	O
(	(	O
75	CD	O
%	NN	O
)	)	O
across	IN	O
the	DT	O
whole	JJ	O
cohort	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
intervention	NN	O
may	MD	O
also	RB	O
be	VB	O
applicable	JJ	O
to	TO	O
some	DT	O
verbally	RB	O
able	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
have	VBP	O
pragmatic	JJ	O
communication	NN	O
needs	NNS	O
.	.	O

Rehabilitation	NNP	O
outcomes	VBZ	O
following	VBG	O
percutaneous	JJ	O
coronary	JJ	O
interventions	NNS	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

This	DT	O
prospective	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
individualized	JJ	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
combining	NN	O
exercise	NN	O
training	NN	O
with	IN	O
risk	NN	O
factor	NN	O
modification	NN	O
and	CC	O
psychosocial	JJ	O
counseling	NN	O
on	IN	O
risk	NN	O
factors	NNS	O
,	,	O
psychological	JJ	O
well-being	NN	O
,	,	O
functional	JJ	O
capacity	NN	O
,	,	O
and	CC	O
work	NN	O
resumption	NN	O
in	IN	O
99	CD	O
post-percutaneous	JJ	E
coronary	JJ	E
interventions	NNS	E
(	(	E
PCI	NNP	E
)	)	E
patients	NNS	O
randomized	VBN	O
to	TO	O
control	VB	C
(	(	C
standard	JJ	C
care	NN	C
plus	CC	C
telephone	NN	C
follow-up	NN	C
,	,	O
n=49	NN	O
)	)	O
or	CC	O
intervention	NN	E
(	(	O
individualized	VBN	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
,	,	O
n=50	NN	O
)	)	O
groups	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
time	NN	O
1	CD	O
(	(	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
during	IN	O
hospital	JJ	O
admission	NN	O
,	,	O
time	NN	O
2	CD	O
(	(	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
approximately	RB	O
2	CD	O
months	NNS	O
post-PCI	JJ	E
,	,	O
and	CC	O
time	NN	O
3	CD	O
(	(	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
)	)	O
approximately	RB	O
12	CD	O
months	NNS	O
post-PCI	JJ	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
the	DT	O
allocation	NN	O
to	TO	O
an	DT	O
individualized	VBN	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
provided	VBD	O
more	RBR	O
advantageous	JJ	O
outcomes	NNS	O
.	.	O

At	IN	O
both	DT	O
follow-ups	NNS	O
,	,	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
within-group	JJ	O
improvement	NN	O
in	IN	O
serum	NN	O
cholesterol	NN	O
levels	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
exercise	JJ	O
participation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
differences	NNS	O
in	IN	O
exercise	NN	O
participation	NN	O
favoring	VBG	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
at	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
.	.	O

Repeated	VBN	O
measures	NNS	O
ANOVA	NNP	O
showed	VBD	O
significant	JJ	O
improvements	NNS	O
over	IN	O
time	NN	O
in	IN	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
psychological	JJ	O
well-being	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
functional	JJ	O
capacity	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

More	JJR	O
patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
had	VBD	O
returned	VBN	O
to	TO	O
work	VB	O
at	IN	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
did	VBD	O
so	RB	O
more	RBR	O
quickly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
an	DT	O
individualized	JJ	O
,	,	O
comprehensive	JJ	O
,	,	O
home-based	JJ	O
cardiac	JJ	O
rehabilitation	NN	O
program	NN	O
improves	VBZ	O
risk	NN	O
factor	NN	O
profiles	NNS	O
and	CC	O
work	NN	O
resumption	NN	O
patterns	NNS	O
for	IN	O
patients	NNS	O
following	VBG	O
PCI	NNP	O
.	.	O

Modulation	NN	PH
of	IN	PH
oxidant	JJ	PH
stress	NN	PH
in	IN	PH
vivo	NN	PH
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

BACKGROUND	NNP	O
Free	JJ	O
radical-induced	JJ	O
oxidative	JJ	O
damage	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
diseases	NNS	O
associated	VBN	O
with	IN	O
cigarette	NN	O
smoking	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
production	NN	O
of	IN	O
8-epi-prostaglandin	JJ	PM
(	(	PM
PG	NNP	PM
)	)	PM
F2	NNP	PM
alpha	NN	PM
,	,	PM
a	DT	PM
stable	JJ	PM
product	NN	PM
of	IN	PM
lipid	JJ	PM
peroxidation	NN	PM
in	IN	PM
vivo	NN	PM
,	,	O
and	CC	O
its	PRP$	O
modulation	NN	O
by	IN	O
aspirin	NN	PM
and	CC	O
antioxidant	JJ	PM
vitamins	NNS	PM
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
the	DT	O
following	JJ	O
studies	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
cross-sectional	JJ	O
comparison	NN	O
of	IN	O
smokers	NNS	O
and	CC	O
control	NN	O
subjects	NNS	O
,	,	O
(	(	O
2	CD	O
)	)	O
an	DT	O
examination	NN	O
of	IN	O
the	DT	O
dose-response	JJ	O
relationship	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
an	DT	O
exploration	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
smoking	VBG	E
cessation	NN	E
(	(	O
3	CD	O
weeks	NNS	O
)	)	O
and	CC	O
nicotine	JJ	PM
patch	NN	PM
supplementation	NN	PM
,	,	O
(	(	O
4	CD	O
)	)	O
the	DT	O
effect	NN	O
of	IN	O
aspirin	NN	PM
consumption	NN	PM
,	,	O
and	CC	O
(	(	O
5	CD	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
5	CD	O
days	NNS	O
'	POS	O
dosing	VBG	O
with	IN	O
vitamin	NN	PM
E	NNP	PM
(	(	O
100	CD	O
and	CC	O
800	CD	O
U	NNP	O
)	)	O
,	,	O
vitamin	FW	PM
C	NNP	PM
(	(	O
2	CD	O
g	NN	O
)	)	O
,	,	O
and	CC	O
their	PRP$	O
combination	NN	O
.	.	O

8-epi-PGF2	JJ	O
alpha	JJ	O
excretion	NN	O
(	(	O
in	IN	O
pmol/mmol	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
)	)	O
was	VBD	O
176.5+/-30.6	JJ	O
in	IN	O
heavy	JJ	O
smokers	NNS	O
,	,	O
92.7+/-4.8	CD	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
in	IN	O
moderate	JJ	O
smokers	NNS	O
,	,	O
and	CC	O
54.1+/-2.7	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
in	IN	O
nonsmokers	NNS	O
.	.	O

Urinary	JJ	O
levels	NNS	O
fell	VBD	O
from	IN	O
145.5+/-24.9	CD	O
to	TO	O
114.6+/-27.1	CD	O
(	(	O
week	NN	O
2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
112.6+/-24.9	JJ	O
(	(	O
week	NN	O
3	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
on	IN	O
cessation	NN	O
of	IN	O
smoking	NN	O
.	.	O

Aspirin	NNP	PM
treatment	NN	PM
failed	VBD	O
to	TO	O
suppress	VB	O
urinary	JJ	O
levels	NNS	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
despite	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
urinary	JJ	O
11-dehydro-TxB2	JJ	O
production	NN	O
and	CC	O
suppression	NN	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
and	CC	O
TxB2	NNP	O
in	IN	O
serum	NN	O
.	.	O

Vitamin	NNP	PM
C	NNP	PM
(	(	O
pre	NN	O
,	,	O
194.6+/-40.9	JJ	O
;	:	O
post	NN	O
,	,	O
137.2+/-34.1	JJ	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
a	DT	O
combination	NN	PM
of	IN	PM
vitamin	JJ	PM
C	NNP	PM
and	CC	PM
E	NNP	PM
(	(	O
pre	NN	O
,	,	O
171.0+/-39.8	JJ	O
;	:	O
post	NN	O
,	,	O
133.5+/-29.6	JJ	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
suppressed	VBD	O
urinary	JJ	O
8-epi-PGF2	JJ	O
alpha	NN	O
,	,	O
whereas	IN	O
vitamin	JJ	PM
E	NNP	PM
alone	RB	O
had	VBD	O
no	DT	O
effect	NN	O
.	.	O

CONCLUSIONS	NNP	O
Urinary	NNP	O
8-epi-PGF2	JJ	O
alpha	NN	O
may	MD	O
represent	VB	O
a	DT	O
noninvasive	JJ	O
,	,	O
quantitative	JJ	O
index	NN	O
of	IN	O
oxidant	JJ	O
stress	NN	O
in	IN	O
vivo	NN	O
.	.	O

Elevated	JJ	O
levels	NNS	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
in	IN	O
smokers	NNS	O
may	MD	O
be	VB	O
modulated	VBN	O
by	IN	O
quitting	VBG	E
cigarettes	NNS	E
and	CC	O
switching	VBG	PM
to	TO	PM
nicotine	VB	PM
patches	NNS	PM
or	CC	O
by	IN	O
antioxidant	JJ	PM
vitamin	NN	PM
therapy	NN	PM
.	.	O

Gastrointestinal	NNP	O
safety	NN	O
of	IN	O
NO-aspirin	NNP	PM
(	(	PM
NCX-4016	NNP	PM
)	)	PM
in	IN	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
:	:	O
a	DT	O
proof	NN	O
of	IN	O
concept	NN	O
endoscopic	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
NCX-4016	NNP	PM
is	VBZ	O
a	DT	O
nitric	JJ	O
oxide-releasing	JJ	O
derivative	NN	O
of	IN	O
aspirin	NN	O
with	IN	O
antiplatelet	NN	O
activity	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
NCX-4016	NNP	PM
on	IN	O
gastrointestinal	JJ	O
mucosa	NN	O
and	CC	O
platelet	NN	O
functions	NNS	O
in	IN	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Forty	NNP	O
healthy	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
7	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
NCX-4016	NNP	PM
(	(	PM
400	CD	PM
and	CC	PM
800	CD	PM
mg	NN	PM
twice	RB	PM
daily	RB	PM
)	)	PM
,	,	O
equimolar	JJ	PM
doses	NNS	PM
of	IN	PM
aspirin	NN	PM
(	(	PM
200	CD	PM
and	CC	PM
420	CD	PM
mg	NN	PM
twice	RB	PM
daily	RB	PM
)	)	O
,	,	O
or	CC	O
placebo	NN	C
.	.	O

Upper	IN	O
endoscopies	NNS	O
were	VBD	O
performed	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
and	CC	O
gastroduodenal	JJ	O
lesions	NNS	O
were	VBD	O
graded	VBN	O
using	VBG	O
a	DT	O
predefined	VBN	O
scoring	NN	O
system	NN	O
.	.	O

Basal	NNP	O
and	CC	O
posttreatment	JJ	O
platelet	NN	O
aggregation	NN	O
in	IN	O
response	NN	O
to	TO	O
arachidonic	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
and	CC	O
serum	JJ	O
thromboxane	NN	O
(	(	O
TX	NNP	O
)	)	O
B	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
AA-stimulated	JJ	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
production	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

RESULTS	NNP	O
Mucosal	NNP	O
endoscopic	JJ	O
injury	NN	O
score	NN	O
on	IN	O
day	NN	O
7	CD	O
was	VBD	O
0.63	CD	O
+/-	JJ	O
0.16	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
11.0	CD	O
+/-	JJ	O
3.0	CD	O
and	CC	O
16.1	CD	O
+/-	JJ	O
1.6	CD	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
treated	VBD	O
with	IN	O
200	CD	O
and	CC	O
420	CD	O
mg	NN	O
aspirin	JJ	O
twice	RB	O
daily	RB	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	NN	O
was	VBD	O
virtually	RB	O
devoid	JJ	O
of	IN	O
gastric	JJ	O
and	CC	O
duodenal	JJ	O
toxicity	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
total	JJ	O
gastric	NN	O
and	CC	O
duodenal	JJ	O
endoscopic	NN	O
score	NN	O
of	IN	O
1.38	CD	O
+/-	JJ	O
0.3	CD	O
and	CC	O
1.25	CD	O
+/-	JJ	O
0.5	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	NN	O
aspirin	NN	O
,	,	O
not	RB	O
significant	JJ	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	JJ	O
inhibited	JJ	O
AA-induced	JJ	O
platelet	NN	O
aggregation	NN	O
as	RB	O
well	RB	O
as	IN	O
serum	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
generation	NN	O
induced	VBN	O
by	IN	O
AA	NNP	O
to	TO	O
the	DT	O
same	JJ	O
extent	NN	O
as	IN	O
aspirin	NN	PM
(	(	O
not	RB	O
significant	JJ	O
vs.	FW	O
aspirin	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
have	VBP	O
proven	VBN	O
the	DT	O
concept	NN	O
that	IN	O
addition	NN	O
of	IN	O
an	DT	O
NO-donating	JJ	O
moiety	NN	O
to	TO	O
aspirin	VB	O
results	NNS	O
in	IN	O
a	DT	O
new	JJ	O
chemical	NN	O
entity	NN	O
that	WDT	O
maintains	VBZ	O
cyclooxygenase-1	NN	O
and	CC	O
platelet	VB	O
inhibitory	JJ	O
activity	NN	O
while	IN	O
nearly	RB	O
avoiding	VBG	O
gastrointestinal	JJ	O
damage	NN	O
.	.	O

Sucralfate	NNP	PM
overcomes	VBZ	O
adverse	JJ	O
effect	NN	O
of	IN	O
cigarette	NN	O
smoking	NN	O
on	IN	O
duodenal	JJ	O
ulcer	NN	O
healing	NN	O
and	CC	O
prolongs	NNS	O
subsequent	JJ	O
remission	NN	O
.	.	O

A	DT	O
unicenter	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
283	CD	O
patients	NNS	O
with	IN	O
active	JJ	O
duodenal	JJ	O
ulcer	NN	O
to	TO	O
compare	VB	O
possible	JJ	O
factors	NNS	O
that	WDT	O
may	MD	O
affect	VB	O
healing	NN	O
and	CC	O
relapse	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
a	DT	O
potent	JJ	O
antisecretory	NN	PM
agent	NN	PM
,	,	O
cimetidine	NN	PM
,	,	O
or	CC	O
a	DT	O
site-protective	JJ	O
and	CC	O
cytoprotective	JJ	O
agent	NN	O
,	,	O
sucralfate	NN	PM
.	.	O

The	DT	O
endoscopic	NN	O
healing	VBG	O
rates	NNS	O
at	IN	O
4	CD	O
wk	NNS	O
were	VBD	O
76	CD	O
%	NN	O
and	CC	O
79	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
cross-over	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
failures	NNS	O
for	IN	O
a	DT	O
further	JJ	O
4	CD	O
wk	NN	O
resulted	VBD	O
in	IN	O
68	CD	O
%	NN	O
healing	VBG	O
with	IN	O
cimetidine	NN	PM
and	CC	O
69	CD	O
%	NN	O
healing	VBG	O
with	IN	O
sucralfate	NN	PM
,	,	O
both	DT	O
differences	NNS	O
being	VBG	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

Unlike	IN	O
cimetidine	NN	PM
,	,	O
healing	VBG	O
by	IN	O
sucralfate	NN	PM
was	VBD	O
unaffected	VBN	O
by	IN	O
cigarette	NN	O
smoking	NN	O
,	,	O
reluctance	NN	O
to	TO	O
give	VB	O
up	RP	O
smoking	NN	O
,	,	O
habitual	JJ	O
use	NN	O
of	IN	O
alcohol	NN	O
,	,	O
high	JJ	O
maximal	JJ	O
acid	NN	O
output	NN	O
,	,	O
and	CC	O
large	JJ	O
ulcer	JJ	O
diameter	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
healing	VBG	O
rate	NN	O
of	IN	O
smokers	NNS	O
treated	VBN	O
with	IN	O
sucralfate	NN	PM
(	(	O
82	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
that	DT	O
of	IN	O
smokers	NNS	O
treated	VBN	O
with	IN	O
cimetidine	NN	PM
(	(	O
63	CD	O
%	NN	O
)	)	O
.	.	O

Duodenal	NNP	O
bulb	NN	O
deformity	NN	O
significantly	RB	O
affected	VBD	O
healing	NN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
was	VBD	O
the	DT	O
only	JJ	O
offsetting	VBG	O
factor	NN	O
identifiable	JJ	O
for	IN	O
sucralfate	NN	PM
out	IN	O
of	IN	O
46	CD	O
factors	NNS	O
examined	VBD	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
with	IN	O
healed	JJ	O
ulcers	NNS	O
,	,	O
238	CD	O
participated	VBN	O
in	IN	O
a	DT	O
24-mo	JJ	O
follow-up	NN	O
study	NN	O
consisting	VBG	O
of	IN	O
interviews	NNS	O
at	IN	O
2-mo	JJ	O
intervals	NNS	O
and	CC	O
endoscopy	NN	O
at	IN	O
4-mo	JJ	O
intervals	NNS	O
or	CC	O
whenever	WRB	O
symptoms	NNS	O
recurred	VBD	O
.	.	O

The	DT	O
cumulative	JJ	O
relapse	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.007	CD	O
)	)	O
greater	JJR	O
in	IN	O
patients	NNS	O
healed	VBN	O
with	IN	O
cimetidine	NN	PM
than	IN	O
with	IN	O
sucralfate	NN	PM
,	,	O
50	CD	O
%	NN	O
relapse	NN	O
occurring	VBG	O
at	IN	O
6	CD	O
and	CC	O
12	CD	O
mo	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
both	DT	O
,	,	O
the	DT	O
cumulative	JJ	O
relapse	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
cigarette	NN	O
smokers	NNS	O
than	IN	O
in	IN	O
nonsmokers	NNS	O
,	,	O
but	CC	O
smokers	NNS	O
and	CC	O
nonsmokers	NNS	O
treated	VBN	O
with	IN	O
cimetidine	NN	PM
relapsed	VBN	O
(	(	O
50	CD	O
%	NN	O
at	IN	O
4	CD	O
and	CC	O
8	CD	O
mo	NN	O
,	,	O
respectively	RB	O
)	)	O
faster	RBR	O
than	IN	O
the	DT	O
corresponding	JJ	O
smokers	NNS	O
and	CC	O
nonsmokers	NNS	O
treated	VBN	O
with	IN	O
sucralfate	NN	PM
(	(	O
50	CD	O
%	NN	O
at	IN	O
8	CD	O
and	CC	O
18	CD	O
mo	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
in	IN	O
cimetidine-	NN	PM
but	CC	O
not	RB	O
sucralfate-healed	JJ	PM
patients	NNS	O
,	,	O
early	JJ	O
ulcer	NN	O
relapse	NN	O
(	(	O
within	IN	O
6	CD	O
mo	NN	O
)	)	O
was	VBD	O
associated	VBN	O
with	IN	O
short	JJ	O
duration	NN	O
of	IN	O
illness	NN	O
,	,	O
short	JJ	O
remission	NN	O
period	NN	O
,	,	O
long	JJ	O
symptomatic	JJ	O
spell	NN	O
,	,	O
and	CC	O
reluctance	NN	O
to	TO	O
give	VB	O
up	RP	O
smoking	VBG	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
smoking	VBG	O
adversely	RB	O
affects	VBZ	O
duodenal	JJ	O
ulcer	NN	O
healing	NN	O
by	IN	O
cimetidine	NN	PM
and	CC	O
hastens	VBZ	O
subsequent	JJ	O
relapse	NN	O
,	,	O
and	CC	O
that	IN	O
sucralfate	NN	PM
overcomes	VBZ	O
the	DT	O
adverse	JJ	O
effect	NN	O
of	IN	O
smoking	VBG	O
on	IN	O
healing	NN	O
as	IN	O
encountered	VBN	O
with	IN	O
cimetidine	NN	PM
,	,	O
and	CC	O
results	NNS	O
in	IN	O
a	DT	O
subsequent	JJ	O
remission	NN	O
period	NN	O
double	JJ	O
that	IN	O
of	IN	O
cimetidine	NN	PM
.	.	O

Effects	NNS	O
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
rabeprazole	JJ	PM
20	CD	O
mg	NN	O
and	CC	O
esomeprazole	JJ	PM
40	CD	O
mg	NN	O
on	IN	O
24-h	JJ	O
intragastric	JJ	O
pH	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
antisecretory	JJ	O
effects	NNS	O
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
rabeprazole	NN	PM
and	CC	O
esomeprazole	NN	PM
.	.	PM

METHODS	NNP	O
Open	NNP	O
,	,	O
randomised	VBD	O
,	,	O
2-way	JJ	O
crossover	NN	O
,	,	O
clinical	JJ	O
pharmacology	NN	O
study	NN	O
.	.	O

24	CD	O
healthy	JJ	O
subjects	NNS	O
(	(	O
10	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
26.2	CD	O
y	NN	O
)	)	O
received	VBD	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
rabeprazole	JJ	PM
20	CD	PM
mg	NN	PM
or	CC	PM
esomeprazole	JJ	PM
40	CD	PM
mg	NN	PM
,	,	O
with	IN	O
a	DT	O
14-day	JJ	O
'washout	NN	O
'	POS	O
.	.	O

Intragastric	NNP	O
pH	NN	O
was	VBD	O
recorded	VBN	O
continuously	RB	O
from	IN	O
24	CD	O
h	NN	O
before	IN	O
to	TO	O
24	CD	O
h	NN	O
after	IN	O
dosing	VBG	O
.	.	O

RESULTS	JJ	O
Mean	NNP	O
intragastric	JJ	O
pH	NN	O
was	VBD	O
higher	JJR	O
after	IN	O
esomeprazole	JJR	PM
than	IN	O
rabeprazole	NN	PM
during	IN	O
0-5	JJ	O
h	NN	O
after	IN	O
dosing	VBG	O
(	(	O
P=0.0001	NNP	O
)	)	O
;	:	O
the	DT	O
reverse	NN	O
was	VBD	O
true	JJ	O
from	IN	O
14-24	JJ	O
h	NN	O
(	(	O
P=0.0002	NNP	O
)	)	O
.	.	O

Mean	VB	O
%	NN	O
time	NN	O
pH	JJ	O
>	$	O
3	CD	O
and	CC	O
>	$	O
4	CD	O
was	VBD	O
greater	JJR	O
after	IN	O
esomeprazole	JJR	PM
than	IN	O
rabeprazole	NN	PM
during	IN	O
0-14	JJ	O
h	NN	O
(	(	O
P=0.041	NNP	O
and	CC	O
0.044	CD	O
)	)	O
,	,	O
but	CC	O
the	DT	O
reverse	NN	O
was	VBD	O
true	JJ	O
during	IN	O
14-24	JJ	O
h	NN	O
(	(	O
P=0.0005	NNP	O
and	CC	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
0-24	JJ	O
h	NN	O
interval	NN	O
as	IN	O
a	DT	O
whole	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
treatments	NNS	O
in	IN	O
mean	JJ	O
pH	NN	O
or	CC	O
%	NN	O
time	NN	O
pH	JJ	O
>	JJ	O
3	CD	O
or	CC	O
>	$	O
4	CD	O
.	.	O

CONCLUSION	NNP	O
Single-dose	JJ	O
rabeprazole	NN	PM
20	CD	O
mg	NN	O
was	VBD	O
as	RB	O
effective	JJ	O
as	IN	O
esomeprazole	JJ	PM
40	CD	O
mg	NN	O
in	IN	O
increasing	VBG	O
intragastric	JJ	O
pH	NN	O
and	CC	O
maintaining	VBG	O
pH	NN	O
>	$	O
3	CD	O
and	CC	O
>	$	O
4	CD	O
,	,	O
despite	IN	O
the	DT	O
2-fold	JJ	O
difference	NN	O
in	IN	O
dose	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
acute	JJ	O
effects	NNS	O
of	IN	O
salbutamol	NN	PM
and	CC	PM
terbutaline	NN	PM
on	IN	O
heart	NN	O
rate	NN	O
variability	NN	O
in	IN	O
adult	JJ	O
asthmatic	JJ	O
patients	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
beta2-adrenergic	JJ	PM
agonist	JJ	O
therapy	NN	O
on	IN	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
in	IN	O
adult	NN	O
asthmatic	JJ	O
patients	NNS	O
by	IN	O
using	VBG	O
frequency	NN	O
domain	NN	O
measures	NNS	O
of	IN	O
HRV	NNP	O
.	.	O

A	NNP	O
randomized	JJ	O
crossover	NN	O
design	NN	O
was	VBD	O
used	VBN	O
.	.	O

Twenty	NNP	O
adult	NN	O
patients	NNS	O
with	IN	O
asthma	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

All	DT	O
patients	NNS	O
showed	VBD	O
a	DT	O
mild-to-moderate	JJ	O
decrease	NN	O
in	IN	O
baseline	NN	O
forced	VBN	O
expiratory	JJ	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
.	.	O

Any	CC	O
diseases	NNS	O
that	WDT	O
might	MD	O
have	VB	O
influenced	VBN	O
the	DT	O
autonomic	JJ	O
function	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
complete	JJ	O
physical	JJ	O
examination	NN	O
and	CC	O
medical	JJ	O
history	NN	O
that	WDT	O
revealed	VBD	O
no	DT	O
cardiovascular	JJ	O
disease	NN	O
or	CC	O
medication	NN	O
.	.	O

The	DT	O
study	NN	O
used	VBD	O
200	CD	O
microg	NN	O
inhaled	VBN	O
salbutamol	NN	PM
and	CC	O
500	CD	O
microg	NN	O
inhaled	VBN	PM
terbutaline	NN	PM
.	.	O

HRV	NNP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
5-min	CD	O
segment	NN	O
,	,	O
5	CD	O
min	NN	O
before	IN	O
inhalation	NN	O
of	IN	O
the	DT	O
study	NN	O
drug	NN	O
and	CC	O
5	CD	O
,	,	O
10	CD	O
,	,	O
15	CD	O
,	,	O
20	CD	O
,	,	O
25	CD	O
and	CC	O
30	CD	O
min	NN	O
after	IN	O
inhalation	NN	O
.	.	O

Total	JJ	O
power	NN	O
(	(	O
TP	NNP	O
:	:	O
<	NN	O
0.40	CD	O
Hz	NNP	O
)	)	O
,	,	O
high-frequency	JJ	O
power	NN	O
(	(	O
HF	NNP	O
:	:	O
0.15-0.40	JJ	O
Hz	NNP	O
)	)	O
,	,	O
low-frequency	JJ	O
power	NN	O
(	(	O
LF	JJ	O
:	:	O
0.04-0.15	JJ	O
Hz	NNP	O
)	)	O
and	CC	O
LF/HF	NNP	O
ratio	NN	O
were	VBD	O
calculated	VBN	O
.	.	O

The	DT	O
LF	NNP	O
and	CC	O
LF/HF	NNP	O
ratio	NN	O
increased	VBD	O
and	CC	O
TP	NNP	O
decreased	VBD	O
at	IN	O
5	CD	O
,	,	O
10	CD	O
,	,	O
15	CD	O
and	CC	O
20	CD	O
min	NN	O
after	IN	O
the	DT	O
salbutamol	NN	PM
and	CC	O
the	DT	O
terbutaline	NN	PM
inhalation	NN	O
,	,	O
HF	NNP	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
after	IN	O
the	DT	O
salbutamol	NN	PM
and	CC	O
terbutaline	JJ	PM
inhalation	NN	O
.	.	O

Acute	NNP	PM
salbutamol	NN	PM
and	CC	PM
terbutaline	JJ	PM
inhalation	NN	PM
produce	VBP	O
similar	JJ	O
effects	NNS	O
on	IN	O
heart	NN	O
rate	NN	O
variability	NN	O
and	CC	O
increase	VB	O
sympathetic	JJ	O
modulation	NN	O
in	IN	O
the	DT	O
cardiac	JJ	O
autonomic	JJ	O
activity	NN	O
.	.	O

Naltrexone	NN	PM
in	IN	O
autistic	JJ	O
children	NNS	O
:	:	O
a	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
critically	RB	O
the	DT	O
effects	NNS	O
of	IN	O
naltrexone	NN	PM
on	IN	O
behavioral	JJ	O
symptoms	NNS	O
and	CC	O
learning	VBG	O
in	IN	O
autistic	JJ	O
children	NNS	O
,	,	O
and	CC	O
its	PRP$	O
safety	NN	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
preliminary	JJ	O
report	NN	O
on	IN	O
18	CD	O
children	NNS	O
,	,	O
ages	VBZ	O
3.08	CD	O
to	TO	O
7.99	CD	O
years	NNS	O
,	,	O
who	WP	O
completed	VBD	O
this	DT	O
ongoing	JJ	O
study	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
naltrexone	CD	PM
or	CC	O
placebo	NN	C
and	CC	O
received	VBD	O
daily	JJ	O
doses	NNS	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
21	CD	O
days	NNS	O
.	.	O

Naltrexone	NN	PM
was	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	C
according	VBG	O
to	TO	O
blind	VB	O
Clinical	JJ	O
Global	NNP	O
Consensus	NNP	O
Ratings	NNP	O
(	(	O
unpublished	JJ	O
scale	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
other	JJ	O
behavioral	JJ	O
rating	NN	O
measures	NNS	O
did	VBD	O
not	RB	O
confirm	VB	O
this	DT	O
result	NN	O
.	.	O

There	EX	O
was	VBD	O
only	RB	O
a	DT	O
suggestion	NN	O
that	IN	O
naltrexone	NN	PM
reduced	VBD	O
fidgety	NN	O
and	CC	O
hyperactive	JJ	O
behavior	NN	O
and	CC	O
tended	VBD	O
to	TO	O
alleviate	VB	O
overall	JJ	O
symptomatology	NN	O
in	IN	O
older	JJR	O
children	NNS	O
.	.	O

Naltrexone	NN	PM
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
affect	VB	O
discrimination	NN	O
learning	VBG	O
.	.	O

Results	NNS	O
are	VBP	O
preliminary	JJ	O
and	CC	O
,	,	O
owing	VBG	O
to	TO	O
the	DT	O
small	JJ	O
sample	NN	O
size	NN	O
,	,	O
can	MD	O
be	VB	O
considered	VBN	O
only	RB	O
suggestive	JJ	O
until	IN	O
this	DT	O
study	NN	O
is	VBZ	O
completed	VBN	O
or	CC	O
replication	NN	O
is	VBZ	O
obtained	VBN	O
from	IN	O
independent	JJ	O
research	NN	O
.	.	O

Intra-operative	JJ	O
antibiotic	JJ	PM
prophylaxis	NN	O
in	IN	O
neurosurgery	NN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
on	IN	O
cefotiam	NN	PM
.	.	PM

In	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
and	CC	O
controlled	VBN	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
cefotiam	NN	PM
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
wound	JJ	O
infections	NNS	O
following	VBG	O
trepanations	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

The	DT	O
main	JJ	O
interest	NN	O
was	VBD	O
centered	VBN	O
on	IN	O
the	DT	O
rate	NN	O
of	IN	O
post-operative	JJ	O
bone	NN	O
flap	NN	O
infections	NNS	O
requiring	VBG	O
operative	JJ	O
revision	NN	O
.	.	O

Administration	NNP	O
of	IN	O
cefotiam	NN	PM
was	VBD	O
randomized	VBN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
major	JJ	O
craniotomies	NNS	O
.	.	O

The	DT	O
antibiotic	NN	PM
was	VBD	O
administered	VBN	O
intravenously	RB	O
in	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
2	CD	O
g	NN	O
with	IN	O
induction	NN	O
of	IN	O
anaesthesia	NN	PM
.	.	PM

Only	JJ	O
clean	JJ	O
or	CC	O
clean	JJ	O
contaminated	VBN	O
cases	NNS	O
were	VBD	O
included	VBN	O
.	.	O

Excluded	VBN	O
were	VBD	O
contaminated	VBN	O
cases	NNS	O
,	,	O
operations	NNS	O
with	IN	O
a	DT	O
transnasal-transsphenoidal	JJ	O
approach	NN	O
,	,	O
shunt-operations	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
any	DT	O
other	JJ	O
preoperative	JJ	O
infection	NN	O
or	CC	O
antibiotic	JJ	PM
therapy	NN	PM
.	.	O

Outpatients	NNS	O
were	VBD	O
excluded	VBN	O
due	JJ	O
to	TO	O
difficulties	NNS	O
in	IN	O
obtaining	VBG	O
sufficient	JJ	O
clinical	JJ	O
information	NN	O
.	.	O

From	NNP	O
originally	RB	O
918	CD	O
consecutive	JJ	O
patients	NNS	O
operated	VBN	O
on	IN	O
711	CD	O
fulfilled	VBD	O
the	DT	O
entry	NN	O
criteria	NNS	O
.	.	O

With	IN	O
regard	NN	O
to	TO	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
diagnosis	NN	O
and	CC	O
the	DT	O
site	NN	O
of	IN	O
te	JJ	O
trepanation	NN	O
,	,	O
control	NN	C
patients	NNS	C
(	(	O
n	JJ	O
=	NNP	O
355	CD	O
)	)	O
and	CC	O
cefotiam	$	O
treated	VBN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
356	CD	O
)	)	O
were	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
comparable	JJ	O
.	.	O

In	IN	O
the	DT	O
various	JJ	O
subgroups	NNS	O
formed	VBN	O
for	IN	O
different	JJ	O
primary	JJ	O
diagnoses	NNS	O
,	,	O
concomitant	JJ	PM
steroidal	NN	PM
therapy	NN	PM
and	CC	O
concomitant	NN	O
severe	JJ	O
internal	JJ	O
medical	JJ	O
diseases	NNS	O
cefotiam	VBP	O
treated	VBN	O
patients	NNS	O
and	CC	O
controls	NNS	O
were	VBD	O
comparable	JJ	O
as	RB	O
well	RB	O
.	.	O

A	DT	O
highly	RB	O
significant	JJ	O
difference	NN	O
for	IN	O
bone	NN	O
flap	NN	O
infection	NN	O
could	MD	O
be	VB	O
shown	VBN	O
with	IN	O
0.3	CD	O
%	NN	O
in	IN	O
the	DT	O
cefotiam	NN	O
group	NN	O
versus	VBD	O
5.1	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
rate	NN	O
of	IN	O
post-operative	JJ	O
deep	JJ	O
wound	NN	O
infections	NNS	O
including	VBG	O
meningitis	NN	O
and	CC	O
abscesses	NNS	O
was	VBD	O
also	RB	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
different	JJ	O
with	IN	O
3.1	CD	O
%	NN	O
in	IN	O
the	DT	O
cefotiam	NN	PM
versus	IN	O
9.0	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Thus	VB	O
it	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
cefotiam	NN	O
significantly	RB	O
reduces	VBZ	O
post-operative	JJ	O
deep	JJ	O
wound	NN	O
infection	NN	O
.	.	O

Intervention	NN	PH
to	TO	PH
lower	VB	PH
household	NN	PH
wood	NN	PH
smoke	NN	PH
exposure	NN	PH
in	IN	O
Guatemala	NNP	O
reduces	NNS	O
ST-segment	NNP	O
depression	NN	O
on	IN	O
electrocardiograms	NNS	O
.	.	O

BACKGROUND	VB	O
A	DT	O
large	JJ	O
body	NN	O
of	IN	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
fine	JJ	O
particulate	NN	O
matter	NN	O
(	(	O
PM	NNP	O
)	)	O
air	NN	O
pollution	NN	O
is	VBZ	O
a	DT	O
cause	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
,	,	O
but	CC	O
little	JJ	O
is	VBZ	O
known	VBN	O
in	IN	O
particular	JJ	O
about	IN	O
the	DT	O
cardiovascular	JJ	O
effects	NNS	O
of	IN	O
indoor	JJ	O
air	NN	O
pollution	NN	O
from	IN	O
household	NN	O
use	NN	O
of	IN	O
solid	JJ	O
fuels	NNS	O
in	IN	O
developing	VBG	O
countries	NNS	O
.	.	O

RESPIRE	NNP	O
(	(	O
Randomized	NNP	O
Exposure	NNP	O
Study	NNP	O
of	IN	O
Pollution	NNP	O
Indoors	NNP	O
and	CC	O
Respiratory	NNP	O
Effects	NNP	O
)	)	O
was	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
chimney	NN	PH
woodstove	NN	PH
that	WDT	O
reduces	VBZ	O
wood	NN	PH
smoke	NN	PH
exposure	NN	PH
.	.	O

OBJECTIVES	IN	O
We	PRP	O
tested	VBD	O
the	DT	O
hypotheses	NNS	O
that	IN	O
the	DT	O
stove	NN	PH
intervention	NN	PH
,	,	O
compared	VBN	O
with	IN	O
open	JJ	PH
fire	NN	PH
use	NN	PH
,	,	O
would	MD	O
reduce	VB	O
ST-segment	NNP	O
depression	NN	O
and	CC	O
increase	VB	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
used	VBD	O
two	CD	O
complementary	JJ	O
study	NN	O
designs	NNS	O
:	:	O
a	DT	O
)	)	O
between-groups	NN	O
comparisons	NNS	O
based	VBN	O
on	IN	O
randomized	JJ	PH
stove	NN	PH
assignment	NN	PH
,	,	O
and	CC	O
b	NN	O
)	)	O
before-and-after	NN	O
comparisons	NNS	O
within	IN	O
control	NN	O
subjects	NNS	O
who	WP	O
used	VBD	PH
open	JJ	PH
fires	NNS	PH
during	IN	PH
the	DT	PH
trial	NN	PH
and	CC	PH
received	VBD	PH
chimney	NN	PH
stoves	NNS	PH
after	IN	PH
the	DT	PH
trial	NN	PH
.	.	O

Electrocardiogram	NNP	PH
sessions	NNS	PH
that	WDT	O
lasted	VBD	O
20	CD	O
hr	NNS	O
were	VBD	O
repeated	VBN	O
up	RP	O
to	TO	O
three	CD	O
times	NNS	O
among	IN	O
49	CD	O
intervention	NN	O
and	CC	O
70	CD	O
control	NN	O
women	NNS	O
38-84	CD	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
and	CC	O
55	CD	O
control	NN	O
subjects	NNS	O
were	VBD	O
also	RB	O
assessed	VBN	O
after	IN	O
receiving	VBG	O
stoves	NNS	PH
.	.	O

HRV	NNP	O
and	CC	O
ST-segment	JJ	O
values	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
each	DT	O
30-min	JJ	O
period	NN	O
.	.	O

ST-segment	JJ	O
depression	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
an	DT	O
average	JJ	O
value	NN	O
below	IN	O
-1.00	NNP	O
mm	NN	O
.	.	O

Personal	JJ	O
fine	JJ	O
PM	NNP	O
[	NNP	O
aerodynamic	JJ	O
diameter	NN	O
?	.	O
2.5	CD	O
?m	NN	O
(	(	O
PM?.?	NNP	O
]	NNP	O
exposures	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
24	CD	O
hr	NN	O
before	IN	O
each	DT	O
electrocardiogram	NN	O
.	.	O

RESULTS	NNP	O
PM?.?	NNP	O
exposure	NN	O
means	NNS	O
were	VBD	O
266	CD	O
and	CC	O
102	CD	O
?g/m?	NN	O
during	IN	O
the	DT	O
trial	NN	O
period	NN	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
intervention	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

During	IN	O
the	DT	O
trial	NN	O
,	,	O
the	DT	O
stove	NN	O
intervention	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
odds	NNS	O
ratio	NN	O
of	IN	O
0.26	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.08-0.90	NN	O
)	)	O
for	IN	O
ST-segment	JJ	O
depression	NN	O
.	.	O

We	PRP	O
found	VBD	O
similar	JJ	O
associations	NNS	O
with	IN	O
the	DT	O
before-and-after	JJ	O
comparison	NN	O
.	.	O

The	DT	O
intervention	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
associated	VBN	O
with	IN	O
HRV	NNP	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
stove	NN	O
intervention	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
reduced	JJ	O
occurrence	NN	O
of	IN	O
nonspecific	JJ	O
ST-segment	JJ	O
depression	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
household	NN	O
wood	NN	O
smoke	NN	O
exposures	NNS	O
affect	VBP	O
ventricular	JJ	O
repolarization	NN	O
and	CC	O
potentially	RB	O
cardiovascular	JJ	O
health	NN	O
.	.	O

Endurance	NN	O
training	NN	O
has	VBZ	O
little	JJ	O
effect	NN	O
on	IN	O
active	JJ	O
muscle	NN	O
free	JJ	O
fatty	NN	O
acid	NN	O
,	,	O
lipoprotein	FW	O
cholesterol	NN	O
,	,	O
or	CC	O
triglyceride	JJ	O
net	JJ	O
balances	NNS	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
net	JJ	O
leg	NN	O
total	JJ	O
FFA	NNP	O
,	,	O
LDL-C	NNP	O
,	,	O
and	CC	O
TG	NNP	O
uptake	JJ	O
and	CC	O
HDL-C	JJ	O
release	NN	O
during	IN	O
moderate-intensity	NN	O
cycling	NN	O
exercise	NN	O
would	MD	O
be	VB	O
increased	VBN	O
following	VBG	O
endurance	NN	O
training	NN	O
.	.	O

Eight	NNP	O
sedentary	JJ	O
men	NNS	O
(	(	O
26	CD	O
+/-	JJ	O
1	CD	O
yr	NN	O
,	,	O
77.4	CD	O
+/-	JJ	O
3.7	CD	O
kg	NN	O
)	)	O
were	VBD	O
studied	VBN	O
in	IN	O
the	DT	O
postprandial	JJ	O
state	NN	O
during	IN	O
90	CD	O
min	NNS	O
of	IN	O
rest	NN	O
and	CC	O
60	CD	O
min	NN	O
of	IN	O
exercise	NN	O
twice	NN	O
before	IN	O
(	(	O
45	CD	O
%	NN	O
and	CC	O
65	CD	O
%	NN	O
V	NNP	O
(	(	O
O2	NNP	O
peak	NN	O
)	)	O
)	)	O
and	CC	O
twice	RB	O
after	IN	O
9	CD	O
wk	NN	O
of	IN	O
endurance	NN	PH
training	NN	PH
(	(	O
55	CD	O
%	NN	O
and	CC	O
65	CD	O
%	NN	O
posttraining	VBG	O
V	NNP	O
(	(	O
O2	NNP	O
peak	NN	O
)	)	O
)	)	O
.	.	O

Measurements	NNS	O
across	IN	O
an	DT	O
exercising	VBG	O
leg	NN	O
were	VBD	O
taken	VBN	O
to	TO	O
be	VB	O
a	DT	O
surrogate	NN	O
for	IN	O
active	JJ	O
skeletal	JJ	O
muscle	NN	O
.	.	O

To	TO	O
determine	VB	O
limb	NN	O
lipid	JJ	O
exchange	NN	O
,	,	O
femoral	JJ	O
arterial	NN	O
and	CC	O
venous	JJ	O
blood	NN	O
samples	NNS	O
drawn	VBP	O
simultaneously	RB	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
were	VBD	O
analyzed	VBN	O
for	IN	O
total	JJ	O
and	CC	O
individual	JJ	O
FFA	NNP	O
(	(	O
e.g.	NN	O
,	,	O
palmitate	NN	O
,	,	O
oleate	NN	O
)	)	O
,	,	O
LDL-C	NNP	O
,	,	O
HDL-C	NNP	O
,	,	O
and	CC	O
TG	NNP	O
concentrations	NNS	O
,	,	O
and	CC	O
limb	NN	O
blood	NN	O
flow	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
thermodilution	NN	O
.	.	O

The	DT	O
transition	NN	O
from	IN	O
rest	NN	O
to	TO	O
exercise	VB	O
resulted	VBN	O
in	IN	O
a	DT	O
shift	NN	O
from	IN	O
net	JJ	O
leg	NN	O
total	JJ	O
FFA	NNP	O
release	NN	O
(	(	O
-44	JJ	O
+/-	JJ	O
16	CD	O
micromol/min	NN	O
)	)	O
to	TO	O
uptake	VB	O
(	(	O
193	CD	O
+/-	JJ	O
49	CD	O
micromol/min	NN	O
)	)	O
that	WDT	O
was	VBD	O
unaffected	VBN	O
by	IN	O
either	DT	O
exercise	NN	O
intensity	NN	O
or	CC	O
endurance	NN	O
training	NN	O
.	.	O

The	DT	O
relative	JJ	O
net	NN	O
leg	NN	O
release	NN	O
and	CC	O
uptake	NN	O
of	IN	O
individual	JJ	O
FFA	NNP	O
closely	RB	O
resembled	VBD	O
their	PRP$	O
relative	JJ	O
abundances	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
with	IN	O
approximately	RB	O
21	CD	O
and	CC	O
41	CD	O
%	NN	O
of	IN	O
net	JJ	O
leg	NN	O
total	JJ	O
FFA	NNP	O
uptake	NN	O
during	IN	O
exercise	NN	O
accounted	VBN	O
for	IN	O
by	IN	O
palmitate	NN	O
and	CC	O
oleate	NN	O
,	,	O
respectively	RB	O
.	.	O

Endurance	NNP	PH
training	NN	PH
resulted	VBD	O
in	IN	O
significant	JJ	O
changes	NNS	O
in	IN	O
arterial	JJ	O
concentrations	NNS	O
of	IN	O
HDL-C	NNP	O
(	(	O
49	CD	O
+/-	JJ	O
5	CD	O
vs.	FW	O
52	CD	O
+/-	JJ	O
5	CD	O
mg/dl	NN	O
,	,	O
pre	NN	O
vs.	FW	O
post	NN	O
)	)	O
and	CC	O
LDL-C	NNP	O
(	(	O
82	CD	O
+/-	JJ	O
9	CD	O
vs.	FW	O
76	CD	O
+/-	JJ	O
9	CD	O
mg/dl	NN	O
,	,	O
pre	NN	O
vs.	FW	O
post	NN	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
net	JJ	O
TG	NN	O
or	CC	O
LDL-C	JJ	O
uptake	NN	O
or	CC	O
HDL-C	JJ	O
release	NN	O
across	IN	O
the	DT	O
resting	NN	O
or	CC	O
active	JJ	O
leg	NN	O
before	IN	O
or	CC	O
after	IN	O
endurance	JJ	O
training	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
endurance	NN	O
training	NN	O
favorably	RB	O
affects	VBZ	O
blood	NN	O
lipoprotein	NN	O
profiles	NNS	O
,	,	O
even	RB	O
in	IN	O
young	JJ	O
,	,	O
healthy	JJ	O
normolipidemic	JJ	O
men	NNS	O
,	,	O
but	CC	O
muscle	NN	O
contractions	NNS	O
per	IN	O
se	NN	O
have	VBP	O
little	JJ	O
effect	NN	O
on	IN	O
net	JJ	O
leg	NN	O
LDL-C	NNP	O
,	,	O
or	CC	O
TG	NNP	O
uptake	VBP	O
or	CC	O
HDL-C	JJ	O
release	NN	O
during	IN	O
moderate-intensity	NN	O
cycling	NN	O
exercise	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
favorable	JJ	O
effects	NNS	O
of	IN	O
physical	JJ	O
activity	NN	O
on	IN	O
the	DT	O
lipid	JJ	O
profiles	NNS	O
of	IN	O
young	JJ	O
,	,	O
healthy	JJ	O
normolipidemic	JJ	O
men	NNS	O
in	IN	O
the	DT	O
postprandial	JJ	O
state	NN	O
are	VBP	O
not	RB	O
attributable	JJ	O
to	TO	O
changes	NNS	O
in	IN	O
HDL-C	NNP	O
or	CC	O
LDL-C	NNP	O
exchange	NN	O
across	IN	O
active	JJ	O
skeletal	JJ	O
muscle	NN	O
.	.	O

Dexamethasone	NN	PM
phosphate	NN	PM
in	IN	O
antibiotic	JJ	PM
ear	NN	PM
drops	NNS	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
bacterial	JJ	O
otitis	NN	O
externa	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
polymyxin	NN	PM
sulfate	NN	PM
7500	CD	PM
IU/neomycin	NNP	PM
sulfate	NN	PM
3500	CD	PM
IU/dexamethasone	NNP	PM
phosphate	VB	PM
0.1	CD	PM
%	NN	PM
(	(	PM
PN+Dx	NNP	PM
)	)	PM
otic	JJ	PM
solution	NN	PM
with	IN	O
polymyxin	NN	PM
sulfate	NN	PM
7500	CD	PM
IU/neomycin	NNP	PM
sulfate	NN	PM
3500	CD	PM
IU	NNP	PM
(	(	PM
PN-Dx	NNP	PM
)	)	PM
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
bacterial	JJ	O
otitis	NN	O
externa	NN	O
(	(	O
AOE	NNP	O
)	)	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
the	DT	O
possible	JJ	O
benefit	NN	O
of	IN	O
the	DT	O
addition	NN	O
of	IN	O
dexamethasone	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Active	NNP	O
controlled	VBD	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
parallel	JJ	O
group	NN	O
,	,	O
multi-center	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
ear	NN	O
,	,	O
nose	RB	O
,	,	O
and	CC	O
throat	NN	O
(	(	O
ENT	NNP	O
)	)	O
specialist	NN	O
practices	NNS	O
with	IN	O
a	DT	O
planned	VBN	O
interim	NN	O
analysis	NN	O
for	IN	O
sample	JJ	O
size	NN	O
adaptation	NN	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
338	CD	O
patients	NNS	O
aged	VBN	O
18-76	NNS	O
who	WP	O
had	VBD	O
a	DT	O
previous	JJ	O
episode	NN	O
of	IN	O
otitis	NN	O
externa	NN	O
within	IN	O
the	DT	O
last	JJ	O
year	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
10	CD	O
+/-	JJ	O
2	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
two	CD	O
drops	NNS	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
,	,	O
of	IN	O
either	DT	O
PN+Dx	NNP	PM
or	CC	O
PN-Dx	NNP	C
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Change	NNP	O
in	IN	O
the	DT	O
clinical	JJ	O
symptom	NN	O
score	NN	O
(	(	O
consisting	VBG	O
of	IN	O
the	DT	O
subscores	NNS	O
redness	NN	O
,	,	O
swelling	VBG	O
,	,	O
pain	NN	O
,	,	O
and	CC	O
secretion	NN	O
)	)	O
and	CC	O
of	IN	O
the	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
rating	NN	O
for	IN	O
pain	NN	O
from	IN	O
Visit	NNP	O
1	CD	O
(	(	O
Day	NNP	O
1	CD	O
)	)	O
to	TO	O
Visit	VB	O
2	CD	O
(	(	O
Day	NNP	O
4	CD	O
+/-	JJ	O
1	CD	O
)	)	O
,	,	O
patient	NN	O
's	POS	O
assessment	NN	O
of	IN	O
efficacy	NN	O
at	IN	O
Visit	NNP	O
3	CD	O
(	(	O
Day	NNP	O
10	CD	O
+/-	JJ	O
2	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
frequency	NN	O
and	CC	O
type	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
of	IN	O
swelling	VBG	O
from	IN	O
Visit	NNP	O
1	CD	O
to	TO	O
Visit	VB	O
2	CD	O
with	IN	O
PN+Dx	NNP	O
,	,	O
and	CC	O
more	JJR	O
patients	NNS	O
rated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
PN+Dx	NNP	O
as	IN	O
'very	RB	O
good	JJ	O
'	''	O
or	CC	O
'good	POS	O
'	''	O
at	IN	O
Visit	NNP	O
3	CD	O
(	(	O
p	NN	O
=	RB	O
0.03	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
a	DT	O
significantly	RB	O
greater	JJR	O
decrease	NN	O
in	IN	O
the	DT	O
clinical	JJ	O
symptom	NN	O
score	NN	O
from	IN	O
Visit	NNP	O
1	CD	O
to	TO	O
Visit	VB	O
2	CD	O
in	IN	O
the	DT	O
PN+Dx	NNP	O
group	NN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
at	IN	O
least	JJS	O
a	DT	O
moderately	RB	O
severe	JJ	O
symptom	NN	O
score	NN	O
with	IN	O
more	JJR	O
than	IN	O
seven	CD	O
points	NNS	O
at	IN	O
Visit	NNP	O
1	CD	O
(	(	O
p	NN	O
=	RB	O
0.01	CD	O
)	)	O
and	CC	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
their	PRP$	O
current	JJ	O
episode	NN	O
of	IN	O
otitis	NN	O
externa	NN	O
for	IN	O
more	JJR	O
than	IN	O
2	CD	O
days	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
14	CD	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
with	IN	O
no	DT	O
related	JJ	O
adverse	JJ	O
drug	NN	O
reactions	NNS	O
for	IN	O
PN+Dx	NNP	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
addition	NN	O
of	IN	O
dexamethasone	NN	PM
phosphate	NN	PM
to	TO	O
polymyxin	VB	PM
B/neomycin	NNP	PM
significantly	RB	O
reduces	VBZ	O
swelling	VBG	O
in	IN	O
patients	NNS	O
with	IN	O
AOE	NNP	O
and	CC	O
leads	VBZ	O
to	TO	O
significantly	RB	O
higher	JJR	O
patient	NN	O
's	POS	O
ratings	NNS	O
of	IN	O
treatment	NN	O
efficacy	NN	O
.	.	O

It	PRP	O
especially	RB	O
leads	VBZ	O
to	TO	O
an	DT	O
overall	JJ	O
reduction	NN	O
of	IN	O
symptoms	NNS	O
in	IN	O
cases	NNS	O
of	IN	O
moderately	RB	O
or	CC	O
more	JJR	O
severe	JJ	O
otitis	NN	O
externa	NN	O
and	CC	O
cases	NNS	O
lasting	VBG	O
for	IN	O
more	JJR	O
than	IN	O
2	CD	O
days	NNS	O
.	.	O

[	JJ	O
Impact	NNP	O
of	IN	O
CCND1	NNP	O
A870G	NNP	O
polymorphism	NN	O
on	IN	O
acute	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
postoperative	JJ	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
adjuvant	JJ	PM
concurrent	NN	PM
chemoradiotherapy	NN	PM
]	NNP	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
association	NN	O
between	IN	O
single	JJ	O
nucleotide	JJ	O
polymorphism	NN	O
(	(	O
SNP	NNP	O
)	)	O
of	IN	O
CCND1	NNP	O
A870G	NNP	O
and	CC	O
acute	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
in	IN	O
postoperative	JJ	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
who	WP	O
received	VBD	O
capecitabine-based	JJ	PM
postoperative	JJ	PM
chemoradiotherapy	NN	PM
(	(	PM
CRT	NNP	PM
)	)	PM
.	.	O

METHODS	NNP	O
Four	CD	O
hundred	VBD	O
patients	NNS	O
with	IN	O
stage	NN	O
II	NNP	O
and	CC	O
III	NNP	O
rectal	JJ	O
cancer	NN	O
received	VBD	O
postoperative	JJ	O
CRT	NNP	PM
of	IN	PM
capecitabine	NN	PM
with	IN	PM
or	CC	PM
without	IN	PM
oxaliplatin	NNS	PM
were	VBD	O
accumulated	VBN	O
and	CC	O
prostectively	RB	O
studied	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Two	CD	O
hundred	CD	O
and	CC	O
twenty-eight	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
concurrent	JJ	PM
capecitabine	NN	PM
and	CC	PM
radiotherapy	NN	PM
(	(	PM
Cap-CRT	NNP	PM
)	)	PM
,	,	O
and	CC	O
172	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
capecitabine	NN	PM
and	CC	PM
oxaliplatin	JJ	PM
plus	CC	PM
radiotherapy	JJ	PM
(	(	PM
Cap-Oxa-CRT	NNP	PM
)	)	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNP	O
,	,	O
v.	NN	O
3.0	CD	O
(	(	O
CTCAE	NNP	O
v3.0	NN	O
)	)	O
.	.	O

The	DT	O
genotype	NN	O
of	IN	O
CCND1	NNP	O
A870G	NNP	O
in	IN	O
the	DT	O
patients	NNS	O
was	VBD	O
detected	VBN	O
by	IN	O
polymerase	NN	O
chain	NN	O
reaction-based	JJ	O
restriction	NN	O
fragment	NN	O
length	NN	O
polymorphism	NN	O
(	(	O
PCR-RFLP	NNP	O
)	)	O
analysis	NN	O
.	.	O

The	DT	O
associations	NNS	O
between	IN	O
the	DT	O
SNP	NNP	O
and	CC	O
acute	JJ	O
AEs	NNP	O
were	VBD	O
indicated	VBN	O
by	IN	O
odds	NNS	O
ratios	NNS	O
(	(	O
ORs	NNP	O
)	)	O
and	CC	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
,	,	O
which	WDT	O
were	VBD	O
computed	VBN	O
with	IN	O
logistic	JJ	O
regression	NN	O
model	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
136	CD	O
patients	NNS	O
presented	VBN	O
severe	JJ	O
AEs	NNP	O
.	.	O

Among	IN	O
them	PRP	O
the	DT	O
frequencies	NNS	O
of	IN	O
the	DT	O
three	CD	O
genotypes	NNS	O
GG	NNP	O
,	,	O
GA	NNP	O
and	CC	O
AA	NNP	O
were	VBD	O
16.9	CD	O
%	NN	O
,	,	O
50.7	CD	O
%	NN	O
and	CC	O
32.4	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
24.6	CD	O
%	NN	O
,	,	O
48.1	CD	O
%	NN	O
and	CC	O
27.3	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
among	IN	O
the	DT	O
patients	NNS	O
without	IN	O
severe	JJ	O
AEs	NNP	O
.	.	O

Diarrhea	NNP	O
was	VBD	O
the	DT	O
most	RBS	O
common	JJ	O
AE	NNP	O
,	,	O
and	CC	O
severe	JJ	O
diarrhea	NN	O
occurred	VBD	O
in	IN	O
109	CD	O
patients	NNS	O
.	.	O

The	DT	O
frequencies	NNS	O
of	IN	O
the	DT	O
three	CD	O
genotypes	NNS	O
GG	NNP	O
,	,	O
GA	NNP	O
and	CC	O
AA	NNP	O
were	VBD	O
15.6	CD	O
%	NN	O
,	,	O
47.7	CD	O
%	NN	O
and	CC	O
36.7	CD	O
%	NN	O
among	IN	O
these	DT	O
patients	NNS	O
,	,	O
compared	VBN	O
with	IN	O
24.4	CD	O
%	NN	O
,	,	O
49.5	CD	O
%	NN	O
and	CC	O
26.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
among	IN	O
patients	NNS	O
without	IN	O
severe	JJ	O
diarrhea	NN	O
.	.	O

Multivariate	NNP	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
1.66-fold	JJ	O
increased	JJ	O
risk	NN	O
for	IN	O
severe	JJ	O
diarrhea	NN	O
in	IN	O
patients	NNS	O
with	IN	O
AA	NNP	O
genotype	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.03	CD	O
-	:	O
2.67	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
cases	NNS	O
with	IN	O
GG	NNP	O
or	CC	O
GA	NNP	O
genotypes	NNS	O
.	.	O

Stratified	VBN	O
analysis	NN	O
showed	VBD	O
that	IN	O
in	IN	O
the	DT	O
Cap-Oxa-CRT	NNP	PM
group	NN	O
,	,	O
patients	NNS	O
with	IN	O
AA	NNP	O
genotype	NN	O
showed	VBD	O
a	DT	O
2.34-fold	JJ	O
increased	JJ	O
risk	NN	O
for	IN	O
severe	JJ	O
diarrhea	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.16	CD	O
-	:	O
4.76	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.018	CD	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
with	IN	O
GG	NNP	O
or	CC	O
GA	NNP	O
genotypes	NNS	O
,	,	O
but	CC	O
in	IN	O
the	DT	O
Cap-CRT	NNP	PM
group	NN	O
,	,	O
the	DT	O
SNP	NNP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
the	DT	O
risk	NN	O
of	IN	O
severe	JJ	O
diarrhea	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
genetic	JJ	O
polymorphism	NN	O
of	IN	O
CCND1	NNP	O
A870G	NNP	O
might	MD	O
be	VB	O
a	DT	O
potential	JJ	O
biomarker	NN	O
for	IN	O
predicting	VBG	O
acute	JJ	O
AEs	NNP	O
in	IN	O
postoperative	JJ	O
stage	NN	O
II	NNP	O
and	CC	O
III	NNP	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
adjuvant	JJ	PM
concurrent	JJ	PM
chemoradiotherapy	NN	PM
of	IN	PM
capecitabine	NN	PM
and	CC	PM
oxaliplatin	NN	PM
.	.	O

Longitudinal	JJ	O
follow-up	NN	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
receiving	VBG	O
targeted	VBN	O
interventions	NNS	O
on	IN	O
joint	JJ	E
attention	NN	E
and	CC	O
play	NN	E
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
examines	VBZ	O
the	DT	O
cognitive	NN	O
and	CC	O
language	NN	O
outcomes	NNS	O
of	IN	O
children	NNS	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
over	IN	O
a	DT	O
5-year	JJ	O
period	NN	O
after	IN	O
receiving	VBG	O
targeted	VBD	E
early	JJ	E
interventions	NNS	E
that	WDT	E
focused	VBD	E
on	IN	E
joint	JJ	E
attention	NN	E
and	CC	E
play	NN	E
skills	NNS	E
.	.	E

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
from	IN	O
the	DT	O
original	JJ	O
study	NN	O
(	(	O
n	JJ	O
=	NNP	O
58	CD	O
)	)	O
had	VBD	O
complete	JJ	O
data	NNS	O
at	IN	O
the	DT	O
5-year	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
all	DT	O
,	,	O
80	CD	O
%	NN	O
of	IN	O
children	NNS	O
had	VBD	O
achieved	VBN	O
functional	JJ	O
use	NN	O
of	IN	O
spoken	JJ	O
language	NN	O
with	IN	O
baseline	JJ	O
play	NN	O
level	NN	O
predicting	VBG	O
spoken	JJ	O
language	NN	O
at	IN	O
the	DT	O
5-year	JJ	O
follow-up	NN	O
.	.	O

Of	IN	O
children	NNS	O
who	WP	O
were	VBD	O
using	VBG	O
spoken	JJ	O
language	NN	O
at	IN	O
age	NN	O
8	CD	O
years	NNS	O
,	,	O
several	JJ	O
baseline	NN	O
behaviors	NNS	O
predicted	VBD	O
their	PRP$	O
later	JJ	O
ability	NN	O
,	,	O
including	VBG	O
earlier	JJR	O
age	NN	O
of	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
,	,	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
skill	NN	O
,	,	O
play	VB	O
level	NN	O
,	,	O
and	CC	O
assignment	NN	O
to	TO	O
either	VB	O
the	DT	O
joint	JJ	E
attention	NN	E
or	CC	E
symbolic	JJ	E
play	NN	E
intervention	NN	O
group	NN	O
.	.	O

Only	RB	O
baseline	JJ	O
play	NN	O
diversity	NN	O
predicted	VBD	O
cognitive	JJ	O
scores	NNS	O
at	IN	O
age	NN	O
8	CD	O
years	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
only	JJ	O
long-term	JJ	O
follow-up	JJ	O
studies	NNS	O
of	IN	O
children	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
preschool	NN	O
early	JJ	O
interventions	NNS	O
aimed	VBN	O
at	IN	O
targeting	VBG	O
core	NN	O
developmental	NN	O
difficulties	NNS	O
.	.	O

The	DT	O
study	NN	O
findings	NNS	O
suggest	VBP	O
that	IN	O
focusing	VBG	O
on	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
play	NN	O
skills	NNS	O
in	IN	O
comprehensive	JJ	O
treatment	NN	O
models	NNS	O
is	VBZ	O
important	JJ	O
for	IN	O
long-term	JJ	O
spoken	JJ	O
language	NN	O
outcomes	NNS	O
.	.	O

Paromomycin	NNP	PM
for	IN	O
cryptosporidiosis	NN	O
in	IN	O
AIDS	NNP	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
effects	NNS	O
of	IN	O
paromomycin	NN	PM
,	,	O
10	CD	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
and	CC	O
cryptosporidiosis	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
paromomycin	VB	PM
or	CC	O
placebo	VB	C
in	IN	O
a	DT	O
double-blind	JJ	O
trial	NN	O
.	.	O

After	IN	O
14	CD	O
days	NNS	O
,	,	O
patients	NNS	O
were	VBD	O
switched	VBN	O
to	TO	O
the	DT	O
other	JJ	O
treatment	NN	O
for	IN	O
14	CD	O
additional	JJ	O
days	NNS	O
.	.	O

Measures	NNS	O
included	VBD	O
the	DT	O
number	NN	O
and	CC	O
character	NN	O
of	IN	O
each	DT	O
stool	NN	O
and	CC	O
weekly	JJ	O
24-h	JJ	O
stool	NN	O
specimens	NNS	O
for	IN	O
weight	NN	O
and	CC	O
oocyst	NN	O
excretion	NN	O
.	.	O

During	IN	O
the	DT	O
paromomycin	NN	PM
treatment	NN	O
phase	NN	O
,	,	O
oocyst	JJ	O
excretion	NN	O
decreased	VBD	O
from	IN	O
314	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
to	TO	O
109	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
24	CD	O
h	NN	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

Oocyst	NNP	O
excretion	NN	O
increased	VBD	O
for	IN	O
the	DT	O
4	CD	O
patients	NNS	O
initially	RB	O
on	IN	O
placebo	NNS	C
compared	VBN	O
to	TO	O
a	DT	O
median	JJ	O
decrease	NN	O
of	IN	O
128	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/24	NN	O
h	NN	O
for	IN	O
the	DT	O
6	CD	O
initially	RB	O
treated	VBN	O
with	IN	O
drug	NN	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

Stool	NNP	O
frequency	NN	O
also	RB	O
decreased	VBD	O
more	RBR	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
drug	NN	PM
(	(	O
3.6	CD	O
fewer	JJR	O
vs.	NN	O
1.25	CD	O
fewer/24	NN	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Trends	NNS	O
favored	JJ	O
drug	NN	O
over	IN	O
placebo	NN	C
for	IN	O
stool	NN	O
weight	NN	O
,	,	O
stool	JJ	O
character	NN	O
,	,	O
and	CC	O
Karnofsky	NNP	O
score	NN	O
.	.	O

Paromomycin	NNP	PM
treatment	NN	O
resulted	VBD	O
in	IN	O
improvement	NN	O
in	IN	O
both	DT	O
clinical	JJ	O
and	CC	O
parasitologic	JJ	O
parameters	NNS	O
in	IN	O
cryptosporidiosis	NN	O
in	IN	O
AIDS	NNP	O
.	.	O

Yohimbine	NN	PM
in	IN	O
neurally	RB	O
mediated	VBN	O
syncope	NN	O
.	.	O

Pathophysiological	JJ	O
implications	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
if	IN	O
increased	VBN	O
sympathetic	JJ	O
stimulation	NN	O
is	VBZ	O
an	DT	O
essential	JJ	O
requirement	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
neurally	RB	O
mediated	VBN	O
syncope	NN	O
(	(	O
NMS	NNP	O
)	)	O
by	IN	O
manipulating	VBG	O
overall	JJ	O
sympathetic	JJ	O
outflow	NN	O
in	IN	O
subjects	NNS	O
susceptible	JJ	O
to	TO	O
tilt-induced	JJ	O
syncope	NN	O
.	.	O

Eight	NNP	O
previously	RB	O
characterized	VBD	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
NMS	NNP	O
(	(	O
five	CD	O
females	NNS	O
and	CC	O
three	CD	O
males	NNS	O
;	:	O
34+/-2	JJ	O
yr	NN	O
)	)	O
were	VBD	O
recruited	VBN	O
from	IN	O
the	DT	O
Vanderbilt	NNP	O
Syncope	NNP	O
Unit	NNP	O
and	CC	O
eight	CD	O
age-matched	JJ	O
controls	NNS	O
underwent	JJ	O
initial	JJ	O
administration	NN	O
of	IN	O
clonidine	NN	PM
(	(	PM
CLO	NNP	PM
)	)	PM
or	CC	O
yohimbine	NN	PM
(	(	O
YHO	NNP	O
)	)	O
.	.	O

This	DT	O
was	VBD	O
done	VBN	O
,	,	O
prospectively	RB	O
,	,	O
to	TO	O
determine	VB	O
doses	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
that	WDT	O
would	MD	O
increase	VB	O
or	CC	O
decrease	VB	O
plasma	JJ	O
norepinephrine	NN	O
levels	NNS	O
by	IN	O
>	NNP	O
/=	NNP	O
30	CD	O
%	NN	O
.	.	O

On	IN	O
a	DT	O
different	JJ	O
day	NN	O
,	,	O
in	IN	O
all	DT	O
subjects	NNS	O
we	PRP	O
determined	VBD	O
intraarterial	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
EKG	NNP	O
and	CC	O
muscle	NN	O
sympathetic	JJ	O
nerve	NN	O
activity	NN	O
(	(	O
MSNA	NNP	O
)	)	O
both	DT	O
supine	JJ	O
and	CC	O
during	IN	O
upright	JJ	O
tilt	NN	O
.	.	O

After	IN	O
this	DT	O
,	,	O
subjects	VBZ	O
randomly	RB	O
received	VBN	O
either	CC	O
CLO	NNP	PM
or	CC	O
YHO	NNP	PM
,	,	O
and	CC	O
3	CD	O
h	NN	O
later	RB	O
another	DT	O
tilt	NN	O
was	VBD	O
performed	VBN	O
.	.	O

After	IN	O
1	CD	O
wk	NN	O
,	,	O
a	DT	O
similar	JJ	O
procedure	NN	O
with	IN	O
the	DT	O
other	JJ	O
drug	NN	O
was	VBD	O
performed	VBN	O
.	.	O

During	IN	O
the	DT	O
two	CD	O
basal	NN	O
tilts	NNS	O
,	,	O
all	PDT	O
the	DT	O
control	NN	O
subjects	VBZ	O
completed	VBN	O
the	DT	O
study	NN	O
,	,	O
whereas	IN	O
all	PDT	O
the	DT	O
NMS	NNP	O
patients	NNS	O
developed	VBD	O
syncope	NN	O
.	.	O

Reduction	NN	O
in	IN	O
sympathetic	JJ	O
tone	NN	O
by	IN	O
CLO	NNP	PM
resulted	VBD	O
in	IN	O
a	DT	O
decreased	JJ	O
tolerance	NN	O
to	TO	O
tilt	VB	O
in	IN	O
three	CD	O
out	IN	O
of	IN	O
eight	CD	O
controls	NNS	O
and	CC	O
in	IN	O
all	PDT	O
the	DT	O
NMS	NNP	O
patients	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
YHO	NNP	O
not	RB	O
only	RB	O
increased	VBD	O
basal	NN	O
plasma	NN	O
NorEpi	NNP	O
levels	NNS	O
and	CC	O
MSNA	NNP	O
,	,	O
but	CC	O
also	RB	O
prevented	VBD	O
syncope	NN	O
in	IN	O
seven	CD	O
out	IN	O
of	IN	O
eight	CD	O
patients	NNS	O
.	.	O

In	IN	O
a	DT	O
selected	JJ	O
population	NN	O
of	IN	O
patients	NNS	O
,	,	O
increased	VBD	O
sympathetic	JJ	O
activity	NN	O
is	VBZ	O
not	RB	O
a	DT	O
prerequisite	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
syncope	NN	O
.	.	O

Yohimbine-induced	JJ	O
enhancement	NN	O
of	IN	O
sympathetic	JJ	O
tone	NN	O
in	IN	O
patients	NNS	O
with	IN	O
NMS	NNP	O
improves	VBZ	O
orthostatic	JJ	O
tolerance	NN	O
and	CC	O
raises	VBZ	O
the	DT	O
possibility	NN	O
that	IN	O
this	DT	O
drug	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
NMS	NNP	O
.	.	O

Myocardial	JJ	O
extracellular	JJ	O
volume	NN	O
by	IN	O
cardiac	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
anthracycline-based	JJ	O
chemotherapy	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
myocardial	JJ	O
extracellular	JJ	O
volume	NN	O
(	(	O
ECV	NNP	O
)	)	O
,	,	O
measured	VBN	O
using	VBG	O
T1	NNP	O
measurements	NNS	O
obtained	VBD	O
during	IN	O
cardiac	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
were	VBD	O
increased	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
anthracyclines	NNS	PM
.	.	O

We	PRP	O
performed	VBD	O
cardiac	JJ	PH
magnetic	JJ	PH
resonance	NN	PH
imaging	NN	PH
and	CC	PH
echocardiography	NN	PH
and	CC	PH
measured	VBD	PH
the	DT	PH
ECV	NNP	PH
in	IN	O
42	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
anthracyclines	NNS	PM
.	.	PM

The	DT	O
data	NN	O
from	IN	O
the	DT	O
cardiac	JJ	O
magnetic	JJ	O
resonance	NN	O
study	NN	O
were	VBD	O
compared	VBN	O
to	TO	O
those	DT	O
from	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
anthracycline-treated	JJ	O
cohort	NN	O
consisted	VBD	O
of	IN	O
21	CD	O
men	NNS	O
and	CC	O
21	CD	O
women	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
55	CD	O
?	.	O
17	CD	O
years	NNS	O
,	,	O
who	WP	O
presented	VBD	O
a	DT	O
median	NN	O
of	IN	O
84	CD	O
months	NNS	O
after	IN	O
chemotherapy	NN	O
with	IN	O
a	DT	O
cumulative	JJ	O
anthracycline	NN	O
exposure	NN	O
of	IN	O
282	CD	O
?	.	O
65	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
and	CC	O
a	DT	O
mean	NN	O
left	VBD	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
of	IN	O
52	CD	O
?	.	O
12	CD	O
%	NN	O
.	.	O

The	DT	O
ECV	NNP	O
was	VBD	O
elevated	VBN	O
in	IN	O
the	DT	O
anthracycline-treated	JJ	O
patients	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
age-	JJ	O
and	CC	O
gender-matched	JJ	O
controls	NNS	O
(	(	O
0.36	CD	O
?	.	O
0.03	CD	O
vs	NN	O
0.28	CD	O
?	.	O
0.02	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	NNP	O
positive	JJ	O
association	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
ECV	NNP	O
and	CC	O
left	VBD	O
atrial	JJ	O
volume	NN	O
(	(	O
ECV	NNP	O
vs	RB	O
indexed	VBD	O
left	JJ	O
atrial	JJ	O
volume	NN	O
,	,	O
r	NN	O
=	VBD	O
0.65	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
negative	JJ	O
association	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
ECV	NNP	O
and	CC	O
diastolic	JJ	O
function	NN	O
(	(	O
E	NNP	O
'	POS	O
lateral	NN	O
,	,	O
r	NN	O
=	NNP	O
-0.64	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
myocardial	JJ	O
ECV	NNP	O
is	VBZ	O
elevated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
previous	JJ	O
anthracycline	NN	O
treatment	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
the	DT	O
diastolic	JJ	O
function	NN	O
and	CC	O
increased	VBD	O
atrial	JJ	O
volumes	NNS	O
.	.	O

Effect	NN	O
of	IN	O
food	NN	PM
on	IN	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
didanosine	JJ	PM
enteric-coated	JJ	PM
capsules	NNS	PM
:	:	O
a	DT	O
pilot	NN	O
comparative	NN	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
food	NN	PM
on	IN	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
enteric-coated	JJ	PM
(	(	PM
EC	NNP	PM
)	)	PM
capsules	NNS	PM
of	IN	PM
didanosine	NN	PM
(	(	PM
ddI	NN	PM
)	)	PM
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
pilot	NN	O
,	,	O
randomized	VBN	O
,	,	O
open-label	JJ	O
study	NN	O
of	IN	O
28-day	JJ	O
ddI-EC	JJ	PM
capsules	NNS	PM
monotherapy-administered	VBN	PM
in	IN	O
a	DT	O
fasted	JJ	E
state	NN	E
(	(	O
group	NN	O
1	CD	O
,	,	O
n=11	NN	O
)	)	O
or	CC	O
with	IN	PM
food	NN	PM
(	(	O
group	NN	O
2	CD	O
,	,	O
n=10	RB	O
)	)	O
to	TO	O
treatment-na?ve	JJ	O
chronically	RB	O
HIV-1-infected	JJ	O
individuals	NNS	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
antiviral	JJ	O
efficacy	NN	O
,	,	O
HIV-1	NNP	O
RNA	NNP	O
was	VBD	O
determined	VBN	O
at	IN	O
baseline	NN	O
,	,	O
day	NN	O
3	CD	O
,	,	O
day	NN	O
7	CD	O
and	CC	O
weekly	JJ	O
thereafter	NN	O
.	.	O

The	DT	O
area	NN	O
under	IN	O
the	DT	O
HIV-1	NNP	O
RNA	NNP	O
curve	NN	O
minus	NN	O
baseline	NN	O
weighted	VBN	O
by	IN	O
time	NN	O
(	(	O
AUCMB/day	NNP	O
)	)	O
was	VBD	O
calculated	VBN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
baseline	JJ	O
HIV-1	NNP	O
RNA	NNP	O
was	VBD	O
4.2	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
3.8	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

After	IN	O
28	CD	O
days	NNS	O
,	,	O
the	DT	O
mean	JJ	O
HIV-1	NNP	O
RNA	NNP	O
reduction	NN	O
was	VBD	O
0.99	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
[	$	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
0.45-1.53	CD	O
]	NN	O
for	IN	O
group	NN	O
1	CD	O
and	CC	O
0.89	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.38-1.40	NN	O
)	)	O
for	IN	O
group	NN	O
2	CD	O
.	.	O

AUCMB/day	JJ	O
values	NNS	O
were	VBD	O
0.775	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.33-1.22	NN	O
)	)	O
and	CC	O
0.774	CD	O
log	NN	O
(	(	O
10	CD	O
)	)	O
copies/mL	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.48-1.07	NN	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
showing	VBG	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
decrease	NN	O
of	IN	O
HIV-1	NNP	O
RNA	NNP	O
(	(	O
P=0.995	NNP	O
)	)	O
.	.	O

Mean	NNP	O
ddI	JJ	O
plasma	NN	O
levels	NNS	O
at	IN	O
day	NN	O
28	CD	O
were	VBD	O
0.0234	CD	O
mg/L	NN	O
for	IN	O
group	NN	O
1	CD	O
and	CC	O
0.0227	CD	O
mg/L	NN	O
for	IN	O
group	NN	O
2	CD	O
(	(	O
P=0.96	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
the	DT	O
administration	NN	O
of	IN	O
food	NN	O
did	VBD	O
not	RB	O
have	VB	O
any	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
ddI-EC	JJ	O
capsules	NNS	O
.	.	O

B-type	JJ	PM
natriuretic	JJ	PM
peptide	NN	PM
for	IN	O
acute	JJ	O
dyspnea	NN	O
in	IN	O
patients	NNS	O
with	IN	O
kidney	JJ	O
disease	NN	O
:	:	O
insights	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
comparison	NN	O
.	.	O

BACKGROUND	NNP	O
B-type	NNP	PM
natriuretic	JJ	PM
peptide	NN	PM
(	(	PM
BNP	NNP	PM
)	)	PM
levels	NNS	PM
are	VBP	O
reliably	RB	O
elevated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
CHF	NNP	O
)	)	O
and	CC	O
therefore	RB	O
helpful	JJ	O
in	IN	O
its	PRP$	O
diagnosis	NN	O
.	.	O

However	RB	O
,	,	O
kidney	FW	O
disease	NN	O
results	NNS	O
in	IN	O
elevated	JJ	O
BNP	NNP	O
levels	NNS	O
independently	RB	O
of	IN	O
CHF	NNP	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
impact	NN	O
of	IN	O
kidney	NN	O
disease	NN	O
on	IN	O
the	DT	O
benefit	NN	O
of	IN	O
BNP	NNP	PM
testing	VBG	O
needs	NNS	O
to	TO	O
be	VB	O
scrutinized	VBN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
kidney	NN	O
disease	NN	O
[	NNP	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
GFR	NNP	O
)	)	O
less	JJR	O
than	IN	O
60	CD	O
mL/min/1.73	JJ	O
m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
presenting	VBG	O
with	IN	O
acute	JJ	O
dyspnea	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
452	CD	O
consecutive	JJ	O
patients	NNS	O
(	(	O
240	CD	O
with	IN	O
kidney	NN	O
disease	NN	O
and	CC	O
212	CD	O
without	IN	O
kidney	NN	O
disease	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
diagnostic	JJ	O
strategy	NN	O
with	IN	O
(	(	O
BNP	NNP	O
group	NN	O
)	)	O
or	CC	O
without	IN	O
(	(	O
control	NN	O
group	NN	O
)	)	O
the	DT	O
use	NN	O
of	IN	O
BNP	NNP	O
levels	NNS	O
provided	VBN	O
by	IN	O
a	DT	O
rapid	JJ	O
bedside	NN	O
assay	NN	O
.	.	O

RESULTS	JJ	O
Patients	NNS	O
with	IN	O
kidney	JJ	O
disease	NN	O
were	VBD	O
older	JJR	O
,	,	O
more	RBR	O
often	RB	O
had	VBD	O
CHF	NNP	O
as	IN	O
the	DT	O
cause	NN	O
of	IN	O
acute	JJ	O
dyspnea	NN	O
,	,	O
and	CC	O
more	RBR	O
often	RB	O
died	JJ	O
in-hospital	JJ	O
or	CC	O
within	IN	O
30	CD	O
days	NNS	O
as	RB	O
compared	VBN	O
to	TO	O
patients	NNS	O
without	IN	O
kidney	NN	O
disease	NN	O
.	.	O

In	IN	O
patients	NNS	O
without	IN	O
kidney	NN	O
disease	NN	O
,	,	O
BNP	NNP	PH
testing	VBG	PH
significantly	RB	O
reduced	VBN	O
median	JJ	O
time	NN	O
to	TO	O
discharge	VB	O
(	(	O
from	IN	O
9.5	CD	O
days	NNS	O
to	TO	O
2.5	CD	O
days	NNS	O
)	)	O
(	(	O
P=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
total	JJ	O
cost	NN	O
of	IN	O
treatment	NN	O
(	(	O
from	IN	O
7184	CD	O
dollars	NNS	O
to	TO	O
4151	CD	O
dollars	NNS	O
)	)	O
(	(	O
P=	NNP	O
0.004	CD	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
kidney	NN	O
disease	NN	O
,	,	O
time	NN	O
to	TO	O
discharge	VB	O
and	CC	O
total	JJ	O
cost	NN	O
of	IN	O
treatment	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
When	WRB	O
applying	VBG	O
BNP	NNP	PM
cut-off	NN	O
values	NNS	O
without	IN	O
adjustment	NN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
kidney	NN	O
disease	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
BNP	NNP	PM
levels	NNS	PM
does	VBZ	O
significantly	RB	O
improve	VB	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
without	IN	O
kidney	NN	O
disease	NN	O
,	,	O
but	CC	O
not	RB	O
of	IN	O
those	DT	O
with	IN	O
kidney	JJ	O
disease	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
endocrine	NN	PM
and	CC	O
radiation	NN	PH
therapy	NN	PH
in	IN	O
locally	RB	O
advanced	JJ	O
prostatic	JJ	O
cancer	NN	O
.	.	O

151	CD	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostatic	JJ	O
cancer	NN	O
(	(	O
T3-4	NNP	O
M0	NNP	O
)	)	O
,	,	O
representing	VBG	O
38	CD	O
%	NN	O
of	IN	O
the	DT	O
404	CD	O
cancer	NN	O
patients	NNS	O
in	IN	O
a	DT	O
Finnish	JJ	O
multicenter	NN	O
study	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
orchiectomy	NN	S
,	,	O
estrogens	VBZ	PM
or	CC	O
radiotherapy	NN	PH
.	.	O

During	IN	O
the	DT	O
4-year	JJ	O
follow-up	JJ	O
period	NN	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
progression	NN	O
rates	NNS	O
(	(	O
appearance	NN	O
of	IN	O
metastases	NNS	O
in	IN	O
bone	NN	O
scan	NN	O
)	)	O
between	IN	O
the	DT	O
therapy	NN	O
groups	NNS	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
thromboembolic	JJ	O
and	CC	O
other	JJ	O
cardiovascular	JJ	O
complications	NNS	O
was	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
estrogen	NN	O
group	NN	O
(	(	O
13/50	CD	O
patients	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
radiotherapy	NN	O
group	NN	O
,	,	O
19	CD	O
of	IN	O
45	CD	O
patients	NNS	O
had	VBD	O
bowel	NN	O
or	CC	O
bladder	NN	O
complications	NNS	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
orchiectomy	NN	O
has	VBZ	O
few	JJ	O
,	,	O
if	IN	O
any	DT	O
,	,	O
complications	NNS	O
.	.	O

The	DT	O
high	JJ	O
risk	NN	O
of	IN	O
complications	NNS	O
associated	VBN	O
with	IN	O
estrogens	NNS	O
and	CC	O
radiotherapy	NN	O
has	VBZ	O
to	TO	O
be	VB	O
taken	VBN	O
into	IN	O
consideration	NN	O
in	IN	O
the	DT	O
selection	NN	O
of	IN	O
treatment	NN	O
.	.	O

Activator	NNP	PM
protein-1	NN	PM
(	(	PM
AP-1	NNP	PM
)	)	PM
signalling	VBG	O
in	IN	O
human	JJ	O
atherosclerosis	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
systematic	JJ	O
evaluation	NN	O
and	CC	O
intervention	NN	O
study	NN	O
.	.	O

Animal	NNP	O
studies	NNS	O
implicate	VBP	O
the	DT	O
AP-1	NNP	PM
(	(	PM
activator	IN	PM
protein-1	NN	PM
)	)	PM
pro-inflammatory	NN	O
pathway	NN	O
as	IN	O
a	DT	O
promising	NN	O
target	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
atherosclerotic	JJ	O
disease	NN	O
.	.	O

It	PRP	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
unclear	JJ	O
whether	IN	O
these	DT	O
observations	NNS	O
apply	VBP	O
to	TO	O
human	JJ	O
atherosclerosis	NN	O
.	.	O

Therefore	IN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
profile	NN	O
of	IN	O
AP-1	NNP	PM
activation	NN	PM
through	IN	O
histological	JJ	O
analysis	NN	O
and	CC	O
tested	VBD	O
the	DT	O
potential	JJ	O
benefit	NN	O
of	IN	O
AP-1	NNP	PM
inhibition	NN	PM
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

AP-1	JJ	PM
activation	NN	PM
was	VBD	O
quantified	VBN	O
by	IN	O
phospho-c-Jun	JJ	O
nuclear	JJ	O
translocation	NN	O
(	(	O
immunohistochemistry	NN	O
)	)	O
on	IN	O
a	DT	O
biobank	NN	O
of	IN	O
aortic	JJ	O
wall	NN	O
samples	NNS	O
from	IN	O
organ	JJ	O
donors	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
AP-1	NNP	PM
inhibition	NN	PM
on	IN	O
vascular	JJ	O
parameters	NNS	O
was	VBD	O
tested	VBN	O
through	IN	O
a	DT	O
double	JJ	O
blind	JJ	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
of	IN	O
28	CD	O
days	NNS	O
doxycycline	NN	O
or	CC	O
placebo	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Vascular	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
brachial	JJ	O
dilation	NN	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
plasma	NN	O
samples	NNS	O
analysed	VBN	O
for	IN	O
hs-CRP	NN	O
(	(	O
high-sensitivity	JJ	O
C-reactive	NNP	O
protein	NN	O
)	)	O
,	,	O
IL-6	NNP	O
(	(	O
interleukin-6	NN	O
)	)	O
,	,	O
IL-8	NNP	O
,	,	O
ICAM-1	NNP	O
(	(	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
)	)	O
,	,	O
vWF	FW	O
(	(	O
von	FW	O
Willebrand	NNP	O
factor	NN	O
)	)	O
,	,	O
MCP-1	NNP	O
(	(	O
monocyte	JJ	O
chemoattractant	NN	O
protein-1	NN	O
)	)	O
,	,	O
PAI-1	NNP	O
(	(	O
plasminogen	JJ	O
activator	NN	O
inhibitor-1	NN	O
)	)	O
and	CC	O
fibrinogen	NN	O
.	.	O

Histological	JJ	O
evaluation	NN	O
of	IN	O
human	JJ	O
atherosclerosis	NN	O
showed	VBD	O
minimal	JJ	O
AP-1	NNP	O
activation	NN	O
in	IN	O
non-diseased	JJ	O
arterial	JJ	O
wall	NN	O
(	(	O
i.e	JJ	O
.	.	O

vessel	NN	O
wall	NN	O
without	IN	O
any	DT	O
signs	NNS	O
of	IN	O
atherosclerotic	JJ	O
disease	NN	O
)	)	O
.	.	O

A	DT	O
gradual	JJ	O
increase	NN	O
of	IN	O
AP-1	NNP	O
activation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
non-progressive	JJ	O
and	CC	O
progressive	JJ	O
phases	NNS	O
of	IN	O
atherosclerosis	NN	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.044	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
progressive	JJ	O
and	CC	O
vulnerable	JJ	O
lesions	NNS	O
.	.	O

The	DT	O
expression	NN	O
of	IN	O
phospho-c-Jun	JJ	O
diminished	VBN	O
as	IN	O
the	DT	O
lesion	NN	O
stabilized	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.016	CD	O
)	)	O
and	CC	O
does	VBZ	O
not	RB	O
significantly	RB	O
differ	VBP	O
from	IN	O
the	DT	O
normal	JJ	O
aortic	JJ	O
wall	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.33	CD	O
)	)	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
doxycycline	NN	O
intervention	NN	O
only	RB	O
revealed	VBD	O
a	DT	O
borderline-significant	JJ	O
reduction	NN	O
of	IN	O
circulating	VBG	O
hs-CRP	JJ	O
levels	NNS	O
(	(	O
-0.51	NNP	O
?g/ml	NNP	O
,	,	O
P=0.05	NNP	O
)	)	O
and	CC	O
did	VBD	O
not	RB	O
affect	VB	O
any	DT	O
of	IN	O
the	DT	O
other	JJ	O
markers	NNS	O
of	IN	O
systemic	JJ	O
inflammation	NN	O
and	CC	O
vascular	JJ	O
function	NN	O
.	.	O

Our	PRP$	O
studies	NNS	O
do	VBP	O
not	RB	O
characterize	VB	O
AP-1	NNP	O
as	IN	O
a	DT	O
therapeutic	JJ	O
target	NN	O
for	IN	O
progressive	JJ	O
human	JJ	O
atherosclerotic	JJ	O
disease	NN	O
.	.	O

The	DT	O
additive	JJ	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
acetaminophen	NN	PM
,	,	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
codeine	NN	PM
,	,	O
60	CD	O
mg	NN	O
,	,	O
in	IN	O
dental	JJ	O
pain	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
single-dose	JJ	O
trial	NN	O
the	DT	O
analgesic	JJ	O
contribution	NN	O
of	IN	O
acetaminophen	NN	PM
,	,	PM
1000	CD	PM
mg	NN	PM
,	,	O
and	CC	O
codeine	NN	PM
,	,	PM
60	CD	PM
mg	NN	PM
,	,	O
was	VBD	O
determined	VBN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
2	CD	O
X	NN	O
2	CD	O
factorial	JJ	O
experiment	NN	O
in	IN	O
which	WDT	O
120	CD	O
patients	NNS	O
suffering	VBG	O
from	IN	O
pain	NN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
oral	JJ	O
surgery	NN	O
rated	VBD	O
their	PRP$	O
pain	NN	O
intensity	NN	O
and	CC	O
pain	NN	O
relief	NN	O
for	IN	O
up	IN	O
to	TO	O
5	CD	O
hours	NNS	O
after	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
one	CD	O
of	IN	O
:	:	O
1000	CD	O
mg	NN	O
acetaminophen	NN	PM
,	,	O
60	CD	O
mg	NN	O
codeine	NN	O
,	,	O
1000	CD	O
mg	NN	O
acetaminophen	NN	PM
plus	CC	PM
60	CD	PM
mg	NN	PM
codeine	NN	PM
,	,	O
or	CC	O
placebo	NN	C
.	.	C

The	DT	O
factorial	JJ	O
analysis	NN	O
showed	VBD	O
that	IN	O
both	DT	O
1000	CD	O
mg	NN	O
acetaminophen	NN	PM
and	CC	O
60	CD	O
mg	NN	O
codeine	NN	PM
made	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
contribution	NN	O
to	TO	O
the	DT	O
analgesic	JJ	O
effectiveness	NN	O
of	IN	O
the	DT	O
combination	NN	O
on	IN	O
all	DT	O
measures	NNS	O
of	IN	O
efficacy	NN	O
(	(	O
sum	NN	O
of	IN	O
pain	NN	O
intensity	NN	O
differences	NNS	O
,	,	O
largest	JJS	O
pain	NN	O
intensity	NN	O
difference	NN	O
,	,	O
total	JJ	O
pain	NN	O
relief	NN	O
,	,	O
largest	JJS	O
pain	NN	O
relief	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
remedication	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
differ	VB	O
among	IN	O
the	DT	O
treatments	NNS	O
,	,	O
including	VBG	O
placebo	NN	O
.	.	O

MSLT	NNP	PH
in	IN	O
primary	JJ	O
insomnia	NN	O
:	:	O
stability	NN	O
and	CC	O
relation	NN	O
to	TO	O
nocturnal	JJ	O
sleep	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVES	NNP	O
To	TO	O
assess	VB	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
multiple	JJ	PH
sleep	JJ	PH
latency	NN	PH
test	NN	PH
(	(	PH
MSLT	NNP	PH
)	)	PH
in	IN	O
primary	JJ	O
insomnia	NN	O
and	CC	O
its	PRP$	O
relation	NN	O
to	TO	O
total	JJ	O
sleep	JJ	O
time	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	NN	O
with	IN	O
sleep	JJ	O
laboratory	NN	O
assessments	NNS	O
in	IN	O
months	NNS	O
1	CD	O
and	CC	O
8	CD	O
of	IN	O
treatment	NN	O
.	.	O

PARTICIPANTS	VB	O
Ninety-five	JJ	O
primary	JJ	O
insomniacs	NN	O
,	,	O
32-64	CD	O
years	NNS	O
old	JJ	O
and	CC	O
55	CD	O
age-	JJ	O
and	CC	O
sex-matched	JJ	O
general	JJ	O
population-based	JJ	O
,	,	O
representative	JJ	O
controls	NNS	O
.	.	O

INTERVENTIONS	NNP	O
After	IN	O
a	DT	O
screening	JJ	O
nocturnal	JJ	PH
polysomnograms	NNS	PH
(	(	PH
NPSG	NNP	PH
)	)	PH
and	CC	O
MSLT	NNP	PH
the	DT	O
following	JJ	O
day	NN	O
,	,	O
participants	NNS	O
with	IN	O
primary	JJ	O
insomnia	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
take	VB	O
zolpidem	NN	PM
10	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
50	CD	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
nightly	RB	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

During	IN	O
months	NNS	O
1	CD	O
and	CC	O
8	CD	O
,	,	O
while	IN	O
taking	VBG	O
their	PRP$	O
prescribed	JJ	O
treatments	NNS	O
,	,	O
NPSGs	NNP	O
and	CC	O
MSLTs	NNP	PH
the	DT	O
following	JJ	O
day	NN	O
were	VBD	O
conducted	VBN	O
.	.	O

A	DT	O
population-based	JJ	O
sample	NN	O
served	VBD	O
as	IN	O
controls	NNS	O
and	CC	O
received	VBD	O
a	DT	O
single	JJ	O
NPSG	NNP	O
followed	VBN	O
by	IN	O
MSLT	NNP	PH
.	.	O

RESULTS	NNP	O
Mean	NNP	O
daily	JJ	O
sleep	NN	O
latency	NN	O
on	IN	O
the	DT	O
screening	VBG	O
MSLT	NNP	PH
of	IN	O
insomniacs	NN	O
was	VBD	O
normally	RB	O
distributed	VBN	O
across	IN	O
the	DT	O
full	JJ	O
range	NN	O
of	IN	O
MSLT	NNP	PH
scores	NNS	O
and	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
a	DT	O
population-based	JJ	O
representative	NN	O
control	NN	O
sample	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.006	CD	O
)	)	O
.	.	O

The	DT	O
insomniacs	NN	O
with	IN	O
the	DT	O
highest	JJS	O
screening	NN	O
MSLTs	NNP	PH
had	VBD	O
the	DT	O
shortest	JJS	O
screening	NN	O
total	JJ	O
sleep	JJ	O
times	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
MSLTs	NNP	PH
of	IN	O
insomniacs	NN	O
during	IN	O
treatment	NN	O
in	IN	O
study	JJ	O
month	NN	O
1	CD	O
were	VBD	O
correlated	VBN	O
(	(	O
r	VB	O
=	RB	O
0.44	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
their	PRP$	O
month	NN	O
8	CD	O
MSLT	NNP	O
.	.	O

The	DT	O
mean	JJ	O
MSLT	NNP	PH
score	NN	O
of	IN	O
the	DT	O
zolpidem	NNP	O
group	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
the	DT	O
stability	NN	O
within	IN	O
treatment	NN	O
groups	NNS	O
also	RB	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
support	NN	O
the	DT	O
hypothesis	NN	O
that	IN	O
some	DT	O
insomniacs	NN	O
show	VBP	O
a	DT	O
reliable	JJ	O
disorder	NN	O
of	IN	O
hyperarousal	NN	O
with	IN	O
increased	JJ	O
wake	NN	O
drive	NN	O
both	DT	O
at	IN	O
night	NN	O
and	CC	O
during	IN	O
the	DT	O
day	NN	O
.	.	O

Can	MD	O
simvastatin	VB	PM
improve	VB	O
erectile	JJ	O
function	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
?	.	O
Results	NNS	O
of	IN	O
the	DT	O
Erectile	NNP	O
Dysfunction	NNP	O
and	CC	O
Statins	NNP	O
Trial	NNP	O
[	NNP	O
ISRCTN66772971	NNP	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
simvastatin	NN	O
on	IN	O
erectile	JJ	O
function	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
(	(	O
ED	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
ED	NNP	O
is	VBZ	O
common	JJ	O
in	IN	O
men	NNS	O
aged	VBN	O
?40	CD	O
years	NNS	O
and	CC	O
impacts	NNS	O
upon	VBP	O
their	PRP$	O
overall	JJ	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
that	IN	O
of	IN	O
their	PRP$	O
partners	NNS	O
.	.	O

Men	NNP	O
aged	VBD	O
?40	CD	O
years	NNS	O
who	WP	O
were	VBD	O
not	RB	O
receiving	VBG	O
lipid	JJ	O
lowering	NN	O
or	CC	O
anti-hypertensive	JJ	O
medication	NN	O
and	CC	O
not	RB	O
at	IN	O
high	JJ	O
cardiovascular	JJ	O
risk	NN	O
were	VBD	O
recruited	VBN	O
from	IN	O
10	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
the	DT	O
East	NNP	O
of	IN	O
England	NNP	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
173	CD	O
eligible	JJ	O
men	NNS	O
with	IN	O
untreated	JJ	O
ED	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
simvastatin	NN	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
three	CD	O
points	NNS	O
over	IN	O
30	CD	O
weeks	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
erectile	JJ	O
function	NN	O
(	(	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function-5	NNP	O
score	NN	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
male	JJ	O
ED-specific	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
MED-QoL	NNP	O
)	)	O
,	,	O
quality-adjusted	JJ	O
life	NN	O
years	NNS	O
(	(	O
QALYs	NNP	O
)	)	O
using	VBG	O
the	DT	O
generic	JJ	O
Euroqol	NNP	O
measure	NN	O
(	(	O
EQ-5D	NNP	O
)	)	O
,	,	O
endothelial	JJ	O
function	NN	O
,	,	O
cardiovascular	JJ	O
risk	NN	O
,	,	O
cholesterol	NN	O
and	CC	O
health	NN	O
service	NN	O
costs	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
erectile	JJ	O
function	NN	O
between	IN	O
the	DT	O
simvastatin	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
(	(	O
mean	JJ	O
change	NN	O
,	,	O
1.28	CD	O
vs	NN	O
0.07	CD	O
,	,	O
z	NN	O
=	VBD	O
1.1	CD	O
,	,	O
p	NN	O
=	NNP	O
0.27	CD	O
)	)	O
,	,	O
although	IN	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
MED-QoL	NNP	O
was	VBD	O
observed	VBN	O
(	(	O
5	CD	O
%	NN	O
vs	JJ	O
2	CD	O
%	NN	O
,	,	O
z	NN	O
=	VBD	O
2.09	CD	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Both	DT	O
10-year	JJ	O
cardiovascular	NN	O
risk	NN	O
and	CC	O
low-density	NN	O
lipoprotein	NN	O
were	VBD	O
reduced	VBN	O
(	(	O
cardiovascular	JJ	O
risk	NN	O
,	,	O
z	NN	O
=	NNP	O
-3.67	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
;	:	O
low-density	JJ	O
lipoprotein	NN	O
,	,	O
z	NN	O
=	NNP	O
-5.46	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
with	IN	O
no	DT	O
consistent	JJ	O
change	NN	O
in	IN	O
endothelial	JJ	O
function	NN	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
sexual	JJ	O
encounters	NNS	O
is	VBZ	O
correlated	VBN	O
with	IN	O
improved	JJ	O
erectile	JJ	O
function	NN	O
.	.	O

The	DT	O
joint	JJ	O
distribution	NN	O
of	IN	O
costs	NNS	O
and	CC	O
QALY	NNP	O
benefits	NNS	O
indicates	VBZ	O
that	IN	O
the	DT	O
probability	NN	O
of	IN	O
simvastatin	NN	O
being	VBG	O
cost-effective	JJ	O
for	IN	O
willingness-to-pay	JJ	O
thresholds	NNS	O
of	IN	O
?20,000	NN	O
and	CC	O
?30,000	NN	O
is	VBZ	O
86	CD	O
%	NN	O
and	CC	O
83	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Identifying	VBG	O
men	NNS	O
with	IN	O
ED	NNP	O
provides	VBZ	O
an	DT	O
opportunity	NN	O
to	TO	O
modify	VB	O
future	JJ	O
cardiovascular	JJ	O
risk	NN	O
and	CC	O
to	TO	O
improve	VB	O
MED-QoL	NNP	O
by	IN	O
treating	VBG	O
them	PRP	O
with	IN	O
40	CD	O
mg	NNS	O
of	IN	O
simvastatin	NN	O
.	.	O

The	DT	O
joint	JJ	O
analysis	NN	O
of	IN	O
costs	NNS	O
and	CC	O
QALY	NNP	O
benefits	NNS	O
suggests	VBZ	O
that	IN	O
there	EX	O
is	VBZ	O
high	JJ	O
probability	NN	O
that	IN	O
simvastatin	NN	O
is	VBZ	O
a	DT	O
cost-effective	JJ	O
strategy	NN	O
in	IN	O
men	NNS	O
with	IN	O
ED	NNP	O
.	.	O

The	DT	O
findings	NNS	O
could	MD	O
influence	VB	O
urological	JJ	O
and	CC	O
primary	JJ	O
care	NN	O
practice	NN	O
by	IN	O
including	VBG	O
questions	NNS	O
on	IN	O
ED	NNP	O
during	IN	O
routine	JJ	O
consultations	NNS	O
and	CC	O
relevant	JJ	O
clinical	JJ	O
protocols	NNS	O
.	.	O

This	DT	O
provides	VBZ	O
an	DT	O
opportunity	NN	O
to	TO	O
impart	VB	O
lifestyle	JJ	O
advice	NN	O
.	.	O

[	RB	O
Accelerated	NNP	PH
postoperative	JJ	PH
radiotherapy	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
larynx	NN	O
cancer	NN	O
]	NNP	O
.	.	O

AIM	NNP	O
The	DT	O
aim	NN	O
of	IN	O
study	NN	O
was	VBD	O
test	JJ	O
efficacy	NN	O
of	IN	O
accelerated	JJ	PH
postoperative	JJ	PH
radiotherapy	NN	PH
--	:	PH
concomitant	JJ	PH
boost	NN	PH
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
larynx	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
The	DT	O
prospective	JJ	O
study	NN	O
included	VBD	O
112	CD	O
patients	NNS	O
with	IN	O
advanced	JJ	O
larynx	NN	O
cancer	NN	O
after	IN	O
radical	JJ	S
surgical	JJ	S
treatment	NN	S
.	.	O

Patients	NNS	O
had	VBD	O
postoperative	JJ	PH
radiation	NN	PH
therapy	NN	PH
,	,	O
conventional	JJ	C
(	(	C
C	NNP	C
)	)	C
or	CC	O
accelerated	VBN	PH
(	(	PH
CB	NNP	PH
)	)	PH
.	.	O

RESULTS	VB	O
The	DT	O
3-year	JJ	O
overall	JJ	O
survival	NN	O
in	IN	O
CB	NNP	PH
was	VBD	O
59	CD	O
%	NN	O
,	,	O
in	IN	O
C	NNP	O
--	:	O
58	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.2	CD	O
)	)	O
,	,	O
3-year	JJ	O
locoregional	JJ	O
control	NN	O
in	IN	O
CB	NNP	PH
--	:	O
83	CD	O
%	NN	O
,	,	O
in	IN	O
C	NNP	O
--	:	O
75	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
the	DT	O
3-year	JJ	O
disease	NN	O
free	JJ	O
survival	NN	O
was	VBD	O
in	IN	O
CB	NNP	PH
--	:	O
72	CD	O
%	NN	O
,	,	O
C	NNP	O
--	:	O
66	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.1	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Concomitant	NNP	PH
boost	VBD	PH
postoperative	JJ	PH
radiation	NN	PH
therapy	NN	PH
did	VBD	O
not	RB	O
improve	VB	O
overall	JJ	O
survival	NN	O
,	,	O
loco-regional	JJ	O
control	NN	O
,	,	O
disease	NN	O
free	JJ	O
survival	NN	O
.	.	O

Patients	NNS	O
with	IN	O
close	JJ	O
surgical	JJ	O
margins	NNS	O
,	,	O
longer	JJR	O
interval	NN	O
between	IN	O
surgery	NN	O
and	CC	O
radiation	NN	O
,	,	O
high	JJ	O
level	NN	O
of	IN	O
hemoglobin	NN	O
,	,	O
T4	NNP	O
had	VBD	O
benefit	VBN	O
from	IN	O
accelerated	VBN	PH
radiotherapy	NN	PH
.	.	O

Effect	NN	O
of	IN	O
two	CD	O
monophasic	JJ	PM
oral	JJ	PM
contraceptives	NNS	PM
containing	VBG	O
gestodene	NN	PM
or	CC	O
desogestrel	NN	PM
on	IN	O
serum	NN	O
lipoprotein	NN	O
lipid	JJ	O
levels	NNS	O
.	.	O

Forty-nine	NNP	O
healthy	JJ	O
women	NNS	O
aged	VBN	O
20-35	JJ	O
years	NNS	O
who	WP	O
had	VBD	O
not	RB	O
been	VBN	O
pregnant	JJ	O
or	CC	O
using	VBG	O
an	DT	O
oral	JJ	PM
contraceptive	NN	PM
(	(	PM
OC	NNP	PM
)	)	PM
for	IN	O
the	DT	O
previous	JJ	O
3	CD	O
months	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
one	CD	O
group	NN	O
taking	VBG	O
an	DT	O
OC	NNP	PM
containing	VBG	O
75	CD	O
micrograms	NNS	O
gestodene	NN	PM
(	(	PM
GTD	NNP	PM
)	)	PM
and	CC	O
30	CD	O
micrograms	NNS	O
ethinyl	VBP	PM
estradiol	NN	PM
(	(	PM
EE	NNP	PM
)	)	PM
,	,	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
using	VBG	O
an	DT	O
OC	NNP	PM
with	IN	O
150	CD	O
micrograms	NNS	O
desogestrel	NN	PM
(	(	PM
DSG	NNP	PM
)	)	PM
and	CC	O
30	CD	O
micrograms	NNS	O
EE	NNP	O
.	.	O

Fasting	VBG	O
blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
before	RB	O
treatment	NN	O
,	,	O
and	CC	O
after	IN	O
cycles	NNS	O
3	CD	O
and	CC	O
6	CD	O
,	,	O
between	IN	O
the	DT	O
18th	CD	O
and	CC	O
the	DT	O
22nd	CD	O
day	NN	O
of	IN	O
the	DT	O
cycle	NN	O
.	.	O

Blood	NNP	O
lipoprotein	JJ	O
lipid	JJ	O
levels	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Serum	NNP	O
total	JJ	O
cholesterol	NN	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
first	JJ	O
three	CD	O
cycles	NNS	O
,	,	O
serum	JJ	O
triglyceride	NN	O
increased	VBN	O
by	IN	O
46	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
and	CC	O
HDL-cholesterol	NNP	O
by	IN	O
14	CD	O
%	NN	O
and	CC	O
8	CD	O
%	NN	O
in	IN	O
the	DT	O
GTD	NNP	PM
and	CC	O
DSG	NNP	PM
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
serum	NN	O
LDL	NNP	O
level	NN	O
decreased	VBN	O
by	IN	O
6.2	CD	O
%	NN	O
and	CC	O
11.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Between	VB	O
the	DT	O
third	JJ	O
and	CC	O
sixth	JJ	O
cycle	NN	O
,	,	O
no	DT	O
further	JJ	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
,	,	O
nor	CC	O
did	VBD	O
these	DT	O
changes	NNS	O
differ	VBP	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
both	DT	O
OC	NNP	PM
preparations	NNS	O
exerted	VBD	O
small	JJ	O
and	CC	O
probably	RB	O
favorable	JJ	O
effects	NNS	O
on	IN	O
serum	NN	O
lipoprotein	NN	O
lipid	JJ	O
levels	NNS	O
.	.	O

Clozapine	NNP	PM
versus	NN	O
placebo	NN	C
in	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
:	:	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
comparative	JJ	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
establish	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
atypical	JJ	O
neuroleptic	JJ	O
clozapine	NN	PM
on	IN	O
chorea	NN	O
,	,	O
voluntary	JJ	O
motor	NN	O
performance	NN	O
,	,	O
and	CC	O
functional	JJ	O
disability	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
three	CD	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
participated	VBD	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
trial	NN	O
.	.	O

A	DT	O
maximum	NN	O
of	IN	O
150	CD	O
mg/day	JJ	O
clozapine	NN	PM
or	CC	O
placebo	NN	C
equivalent	NN	O
was	VBD	O
given	VBN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
31	CD	O
days	NNS	O
.	.	O

Assessments	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
week	NN	O
before	IN	O
and	CC	O
at	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Chorea	NNP	O
was	VBD	O
scored	VBN	O
using	VBG	O
the	DT	O
abnormal	JJ	O
involuntary	JJ	O
movement	NN	O
scale	NN	O
(	(	O
AIMS	NNP	O
)	)	O
,	,	O
the	DT	O
chorea	NN	O
score	NN	O
of	IN	O
the	DT	O
unified	JJ	O
Huntington	NNP	O
's	POS	O
disease	NN	O
rating	NN	O
scale	NN	O
(	(	O
UHDRS	NNP	O
)	)	O
,	,	O
and	CC	O
judgement	NN	O
of	IN	O
video	JJ	O
recordings	NNS	O
.	.	O

Voluntary	JJ	O
motor	NN	O
performance	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
UHDRS	NNP	O
motor	NN	O
scale	NN	O
.	.	O

Patients	NNS	O
and	CC	O
their	PRP$	O
partners	NNS	O
completed	VBD	O
a	DT	O
questionnaire	NN	O
regarding	VBG	O
functional	JJ	O
disability	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
already	RB	O
used	VBD	O
other	JJ	O
neuroleptic	JJ	O
medication	NN	O
,	,	O
which	WDT	O
was	VBD	O
kept	FW	O
unchanged	JJ	O
during	IN	O
the	DT	O
trial	NN	O
period	NN	O
.	.	O

Results	NNS	O
of	IN	O
neuroleptic	JJ	O
naive	JJ	O
and	CC	O
neuroleptic	JJ	O
treated	JJ	O
patients	NNS	O
were	VBD	O
analysed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
Clozapine	NNP	PM
tended	VBD	O
to	TO	O
reduce	VB	O
chorea	NN	O
in	IN	O
neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
only	RB	O
(	(	O
AIMS	NNP	O
)	)	O
;	:	O
improvement	NN	O
seemed	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
higher	JJR	O
doses	NNS	O
of	IN	O
clozapine	NN	O
.	.	O

Other	JJ	O
measures	NNS	O
of	IN	O
chorea	NN	O
(	(	O
UHDRS	NNP	O
chorea	NN	O
score	NN	O
,	,	O
video	JJ	O
ratings	NNS	O
)	)	O
showed	VBD	O
no	DT	O
improvement	NN	O
.	.	O

Clozapine	NNP	PM
had	VBD	O
no	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
chorea	NN	O
in	IN	O
patients	NNS	O
already	RB	O
receiving	VBG	O
neuroleptic	JJ	O
medication	NN	O
.	.	O

Voluntary	JJ	O
motor	NN	O
performance	NN	O
did	VBD	O
not	RB	O
improve	VB	O
with	IN	O
clozapine	NN	O
.	.	O

Neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
reported	VBN	O
aggravation	NN	O
of	IN	O
functional	JJ	O
disability	NN	O
,	,	O
possibly	RB	O
reflecting	VBG	O
the	DT	O
frequent	JJ	O
occurrence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

Adverse	JJ	O
reactions	NNS	O
forced	VBD	O
trial	NN	O
termination	NN	O
in	IN	O
six	CD	O
patients	NNS	O
and	CC	O
dose	JJ	O
reduction	NN	O
in	IN	O
another	DT	O
eight	CD	O
,	,	O
and	CC	O
consisted	VBD	O
mainly	RB	O
of	IN	O
drowsiness	NN	O
,	,	O
fatigue	NN	O
,	,	O
anticholinergic	NN	O
symptoms	NNS	O
,	,	O
and	CC	O
walking	VBG	O
difficulties	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Clozapine	NNP	PM
has	VBZ	O
little	JJ	O
beneficial	JJ	O
effect	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
,	,	O
although	IN	O
individual	JJ	O
patients	NNS	O
may	MD	O
tolerate	VB	O
doses	NNS	O
high	JJ	O
enough	RB	O
to	TO	O
reduce	VB	O
chorea	NN	O
.	.	O

Because	IN	O
adverse	JJ	O
reactions	NNS	O
are	VBP	O
often	RB	O
encountered	VBN	O
,	,	O
clozapine	NN	PM
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
restraint	NN	O
in	IN	O
this	DT	O
patient	NN	O
group	NN	O
.	.	O

Ciprofloxacin	NNP	PM
,	,	O
lomefloxacin	NN	PM
,	,	O
or	CC	O
levofloxacin	CC	PM
as	IN	O
treatment	NN	O
for	IN	O
chronic	JJ	O
osteomyelitis	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
three	CD	O
oral	JJ	PM
fluoroquinolones	NNS	PM
(	(	O
lomefloxacin	NN	PM
,	,	O
levofloxacin	NN	PM
,	,	O
and	CC	O
ciprofloxacin	NN	PM
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
osteomyelitis	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
had	VBD	O
documented	VBN	O
infections	NNS	O
with	IN	O
quinolone-sensitive	JJ	O
organisms	NNS	O
and	CC	O
received	VBD	O
either	DT	O
lomefloxacin	NN	PM
,	,	O
levofloxacin	NN	PM
,	,	O
or	CC	O
ciprofloxacin	NN	PM
.	.	O

Levofloxacin	NNP	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
9	CD	O
of	IN	O
15	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O

Lomefloxacin	NNP	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
five	CD	O
of	IN	O
seven	CD	O
(	(	O
71	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
and	CC	O
ciprofloxacin	NN	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
two	CD	O
of	IN	O
five	CD	O
patients	NNS	O
(	(	O
40	CD	O
%	NN	O
)	)	O
.	.	O

Average	JJ	O
follow-up	NN	O
was	VBD	O
11.8	CD	O
months	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
course	NN	O
of	IN	O
therapy	NN	O
,	,	O
and	CC	O
the	DT	O
average	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
was	VBD	O
60.6	CD	O
days	NNS	O
.	.	O

Gram-positive	JJ	O
bacteria	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
18	CD	O
patients	NNS	O
,	,	O
and	CC	O
11	CD	O
patients	NNS	O
were	VBD	O
cured	VBN	O
.	.	O

Oral	JJ	O
fluoroquinolones	NNS	O
can	MD	O
be	VB	O
safe	JJ	O
,	,	O
effective	JJ	O
therapy	NN	O
if	IN	O
they	PRP	O
are	VBP	O
given	VBN	O
for	IN	O
a	DT	O
prolonged	JJ	O
course	NN	O
as	IN	O
treatment	NN	O
for	IN	O
infections	NNS	O
caused	VBN	O
by	IN	O
susceptible	JJ	O
gram-positive	JJ	O
as	RB	O
well	RB	O
as	IN	O
gram-negative	JJ	O
organisms	NNS	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
adequate	JJ	O
surgical	JJ	O
debridement	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
succinylcholine	NN	PM
with	IN	O
two	CD	O
doses	NNS	O
of	IN	O
rocuronium	NN	PM
using	VBG	O
a	DT	O
new	JJ	O
method	NN	O
of	IN	O
monitoring	VBG	O
neuromuscular	JJ	O
block	NN	O
at	IN	O
the	DT	O
laryngeal	NN	O
muscles	NNS	O
by	IN	O
surface	NN	O
laryngeal	NN	O
electromyography	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
onset	NN	O
of	IN	O
neuromuscular	JJ	O
block	NN	O
with	IN	O
succinylcholine	NN	PM
(	(	PM
1	CD	PM
mg	RB	PM
kg-1	NN	PM
)	)	PM
and	CC	PM
two	CD	PM
doses	NNS	PM
of	IN	PM
rocuronium	NN	PM
(	(	PM
0.6	CD	PM
and	CC	PM
0.9	CD	PM
mg	JJ	PM
kg-1	NN	PM
)	)	PM
at	IN	O
the	DT	O
adductor	NN	O
pollicis	NN	O
muscle	NN	O
using	VBG	O
electromyography	NN	Ot
(	(	Ot
EMG	NNP	Ot
)	)	Ot
and	CC	Ot
acceleromyography	NN	Ot
(	(	O
AMG	NNP	O
)	)	O
,	,	O
and	CC	O
at	IN	O
the	DT	O
adductor	NN	O
laryngeal	NN	O
muscles	NNS	O
with	IN	O
a	DT	O
new	JJ	O
electromyographic	JJ	Ot
method	NN	Ot
using	VBG	O
a	DT	O
disposable	JJ	O
surface	NN	O
electrode	NN	O
attached	VBN	O
to	TO	O
the	DT	O
cuff	NN	O
of	IN	O
a	DT	O
tracheal	JJ	O
tube	NN	O
.	.	O

At	IN	O
the	DT	O
larynx	NN	O
,	,	O
the	DT	O
mean	NN	O
(	(	O
+/-	JJ	O
SD	NNP	O
)	)	O
time	NN	O
to	TO	O
90	CD	O
%	NN	O
block	NN	O
and	CC	O
the	DT	O
onset	JJ	O
time	NN	O
of	IN	O
succinylcholine	NN	PM
(	(	O
38	CD	O
+/-	JJ	O
15	CD	O
and	CC	O
47	CD	O
+/-	JJ	O
19	CD	O
s	NN	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
for	IN	O
rocuronium	NN	PM
0.6	CD	O
mg	NN	O
kg-1	NN	O
(	(	O
92	CD	O
+/-	JJ	O
42	CD	O
and	CC	O
106	CD	O
+/-	JJ	O
38	CD	O
s	NN	O
)	)	O
and	CC	O
rocuronium	$	PM
0.9	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
52	CD	O
+/-	JJ	O
31	CD	O
and	CC	O
64	CD	O
+/-	JJ	O
30	CD	O
s	NN	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
,	,	O
with	IN	O
comparable	JJ	O
degrees	NNS	O
of	IN	O
neuromuscular	JJ	O
block	NN	O
,	,	O
the	DT	O
onset	JJ	O
time	NN	O
of	IN	O
succinylcholine	NN	PM
at	IN	O
the	DT	O
adductor	NN	O
pollicis	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
for	IN	O
rocuronium	NN	PM
0.6	CD	O
mg	NN	O
kg-1	NN	O
and	CC	O
0.9	CD	O
mg	NNS	O
kg-1	JJ	O
(	(	O
EMG	NNP	O
,	,	O
80	CD	O
+/-	JJ	O
39	CD	O
vs	JJ	O
145	CD	O
+/-	JJ	O
48	CD	O
s	NN	O
and	CC	O
99	CD	O
+/-	JJ	O
31	CD	O
s	NN	O
;	:	O
AMG	NNP	O
,	,	O
90	CD	O
+/-	JJ	O
39	CD	O
vs	JJ	O
124	CD	O
+/-	JJ	O
53	CD	O
s	NN	O
and	CC	O
106	CD	O
+/-	JJ	O
38	CD	O
s	NN	O
)	)	O
.	.	O

Clinical	JJ	O
duration	NN	O
at	IN	O
the	DT	O
adductor	NN	O
pollicis	NN	O
(	(	O
AMG	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
longer	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
for	IN	O
both	DT	O
rocuronium	NN	PM
groups	NNS	O
than	IN	O
for	IN	O
succinylcholine	NN	PM
(	(	O
T4	NNP	O
:	:	O
T1	NNP	O
=	VBZ	O
0.7	CD	O
,	,	O
54	CD	O
+/-	JJ	O
18	CD	O
and	CC	O
77	CD	O
+/-	JJ	O
21	CD	O
vs	JJ	O
8	CD	O
+/-	JJ	O
6	CD	O
min	NN	O
)	)	O
.	.	O

The	DT	O
surface	NN	O
laryngeal	JJ	O
electrode	NN	O
proved	VBD	O
non-invasive	JJ	O
,	,	O
easy	JJ	O
to	TO	O
use	VB	O
and	CC	O
reliable	VB	O
in	IN	O
measuring	VBG	O
onset	NN	O
of	IN	O
the	DT	O
neuromuscular	JJ	O
block	NN	O
at	IN	O
the	DT	O
larynx	NN	O
.	.	O

Preventing	VBG	O
disability	NN	O
and	CC	O
managing	VBG	O
chronic	JJ	O
illness	NN	O
in	IN	O
frail	JJ	O
older	NN	O
adults	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
community-based	JJ	O
partnership	NN	O
with	IN	O
primary	JJ	O
care	NN	O
.	.	O

BACKGROUND	NNP	O
Effective	NNP	O
new	JJ	O
strategies	NNS	O
that	WDT	O
complement	VBP	O
primary	JJ	O
care	NN	O
are	VBP	O
needed	VBN	O
to	TO	O
reduce	VB	O
disability	NN	O
risks	NNS	O
and	CC	O
improve	VB	O
self-management	NN	O
of	IN	O
chronic	JJ	O
illness	NN	O
in	IN	O
frail	JJ	O
older	JJR	O
people	NNS	O
living	VBG	O
in	IN	O
the	DT	O
community	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
1-year	JJ	O
,	,	O
senior	JJ	O
center-based	JJ	O
chronic	JJ	O
illness	NN	O
self-management	NN	O
and	CC	O
disability	NN	O
prevention	NN	O
program	NN	O
on	IN	O
health	NN	O
,	,	O
functioning	NN	O
,	,	O
and	CC	O
healthcare	JJ	O
utilization	NN	O
in	IN	O
frail	JJ	O
older	JJR	O
adults	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
A	DT	O
large	JJ	O
senior	JJ	O
center	NN	O
located	VBN	O
in	IN	O
a	DT	O
northeast	NN	O
Seattle	NNP	O
suburb	NN	O
.	.	O

The	DT	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
collaboration	NN	O
with	IN	O
primary	JJ	O
care	NN	O
providers	NNS	O
of	IN	O
two	CD	O
large	JJ	O
managed	VBD	O
care	NN	O
organizations	NNS	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
201	CD	O
chronically	RB	O
ill	JJ	O
older	JJR	O
adults	NNS	O
seniors	NNS	O
aged	VBD	O
70	CD	O
and	CC	O
older	JJR	O
recruited	VBN	O
through	IN	O
medical	JJ	O
practices	NNS	O
.	.	O

INTERVENTION	VB	O
A	NNP	PH
targeted	JJ	PH
,	,	PH
multi-component	JJ	PH
disability	NN	E
prevention	NN	E
and	CC	E
disease	JJ	E
self-management	JJ	E
program	NN	E
led	VBN	PH
by	IN	PH
a	DT	PH
geriatric	JJ	PH
nurse	NN	PH
practitioner	NN	PH
(	(	PH
GNP	NNP	PH
)	)	PH
.	.	O

MEASUREMENTS	NNP	O
Self-reported	JJ	O
Physical	NNP	O
function	NN	O
,	,	O
physical	JJ	O
performance	NN	O
tests	NNS	O
,	,	O
health	NN	O
care	NN	O
utilization	NN	O
,	,	O
and	CC	O
health	NN	O
behaviors	NNS	O
.	.	O

RESULTS	NNP	O
Each	DT	O
of	IN	O
101	CD	O
intervention	NN	O
participants	NNS	O
met	VBD	O
with	IN	O
the	DT	O
GNP	NNP	O
from	IN	O
1	CD	O
to	TO	O
8	CD	O
times	NNS	O
(	(	O
median	JJ	O
=	NNP	O
3	CD	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
year	NN	O
.	.	O

The	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
less	JJR	O
decline	NN	O
in	IN	O
function	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
disability	NN	O
days	NNS	O
and	CC	O
lower	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
Health	NNP	O
Assessment	NNP	O
Questionnaire	NNP	O
.	.	O

Other	JJ	O
measures	NNS	O
of	IN	O
function	NN	O
,	,	O
including	VBG	O
the	DT	O
SF-36	NNP	O
and	CC	O
a	DT	O
battery	NN	O
of	IN	O
physical	JJ	O
performance	NN	O
tests	NNS	O
,	,	O
did	VBD	O
not	RB	O
change	VB	O
with	IN	O
the	DT	O
intervention	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
hospitalized	JJ	O
participants	NNS	O
increased	VBN	O
by	IN	O
69	CD	O
%	NN	O
among	IN	O
the	DT	O
controls	NNS	O
and	CC	O
decreased	VBN	O
by	IN	O
38	CD	O
%	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.083	NNP	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
number	NN	O
of	IN	O
inpatient	JJ	O
hospital	NN	O
days	NNS	O
during	IN	O
the	DT	O
study	NN	O
year	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
compared	VBN	O
with	IN	O
controls	NNS	O
(	(	O
total	JJ	O
days	NNS	O
=	VBP	O
33	CD	O
vs	NN	O
116	CD	O
,	,	O
P	NNP	O
=	NNP	O
.049	NNP	O
)	)	O
.	.	O

The	DT	O
intervention	NN	O
led	VBD	O
to	TO	O
significantly	RB	O
higher	JJR	O
levels	NNS	O
of	IN	O
physical	JJ	O
activity	NN	O
and	CC	O
senior	JJ	O
center	NN	O
participation	NN	O
and	CC	O
significant	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
psychoactive	JJ	O
medications	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
project	NN	O
provides	VBZ	O
evidence	NN	O
that	IN	O
a	DT	O
community-based	JJ	O
collaboration	NN	O
with	IN	O
primary	JJ	O
care	NN	O
providers	NNS	O
can	MD	O
improve	VB	O
function	NN	O
and	CC	O
reduce	VB	O
inpatient	JJ	O
utilization	NN	O
in	IN	O
chronically	RB	O
ill	JJ	O
older	JJR	O
adults	NNS	O
.	.	O

Linking	VBG	O
organized	VBN	O
medical	JJ	O
care	NN	O
with	IN	O
complementary	JJ	O
community-based	JJ	O
interventions	NNS	O
may	MD	O
be	VB	O
a	DT	O
promising	JJ	O
direction	NN	O
for	IN	O
research	NN	O
and	CC	O
practice	NN	O
.	.	O

Onset/offset	NNP	O
characteristics	NNS	O
and	CC	O
intubating	VBG	O
conditions	NNS	O
of	IN	O
rapacuronium	NN	O
:	:	O
a	DT	O
comparison	NN	O
with	IN	O
rocuronium	NN	O
.	.	O

We	PRP	O
compared	VBN	O
onset	PRP	O
and	CC	O
offset	VB	O
of	IN	O
action	NN	O
and	CC	O
tracheal	JJ	O
intubating	NN	O
conditions	NNS	O
after	IN	O
rapacuronium	NN	PM
and	CC	O
rocuronium	NN	PM
in	IN	O
60	CD	O
patients	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
assessor-blinded	JJ	O
study	NN	O
.	.	O

Following	VBG	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
with	IN	O
propofol	JJ	O
2.5	CD	O
mg	JJ	O
kg-1	NN	O
,	,	O
either	CC	O
rapacuronium	NN	PM
1.5	CD	O
mg	NN	O
kg-1	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
or	CC	O
rocuronium	$	PM
0.6	CD	O
mg	JJ	O
kg-1	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
was	VBD	O
administered	VBN	O
to	TO	O
facilitate	VB	O
tracheal	JJ	O
intubation	NN	O
.	.	O

Anaesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
either	CC	O
a	DT	O
propofol	JJ	PH
infusion	NN	PH
(	(	PH
100	CD	PH
micrograms	NNS	PM
kg-1	JJ	PH
min-1	JJ	PH
)	)	PH
or	CC	O
sevoflurane	NN	PM
(	(	PM
1	CD	PM
%	NN	PM
end-tidal	JJ	PM
)	)	PM
with	IN	PM
66	CD	PM
%	NN	PM
nitrous	JJ	PM
oxide	NN	PM
(	(	PM
N2O	NNP	PM
)	)	PM
,	,	O
n	JJ	O
=	VBP	O
15	CD	O
in	IN	O
each	DT	O
subgroup	NN	O
.	.	O

Neuromuscular	JJ	PH
monitoring	NN	PH
was	VBD	O
performed	VBN	O
using	VBG	O
an	DT	O
electromyographic	JJ	PH
(	(	O
EMG	NNP	O
)	)	O
device	NN	O
(	(	O
Datex	NNP	O
Relaxograph	NNP	O
)	)	O
.	.	O

The	DT	O
lag	NN	O
times	NNS	O
(	(	O
mean	JJ	O
42	CD	O
(	(	O
SD	NNP	O
11	CD	O
)	)	O
s	NN	O
and	CC	O
44	CD	O
(	(	O
16	CD	O
)	)	O
s	NN	O
)	)	O
,	,	O
maximum	JJ	O
block	NN	O
(	(	O
99	CD	O
(	(	O
2	CD	O
)	)	O
%	NN	O
and	CC	O
98	CD	O
(	(	O
3	CD	O
)	)	O
%	NN	O
)	)	O
and	CC	O
intubating	JJ	O
conditions	NNS	O
at	IN	O
60	CD	O
s	NN	O
(	(	O
good-to-excellent	JJ	O
in	IN	O
86	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
of	IN	O
patients	NNS	O
)	)	O
were	VBD	O
similar	JJ	O
for	IN	O
rapacuronium	NN	O
and	CC	O
rocuronium	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
onset	JJ	O
time	NN	O
of	IN	O
rapacuronium	NN	O
was	VBD	O
shorter	JJR	O
than	IN	O
rocuronium	NN	O
(	(	O
87	CD	O
(	(	O
20	CD	O
)	)	O
vs	NN	O
141	CD	O
(	(	O
65	CD	O
)	)	O
s	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
block	NN	O
at	IN	O
60	CD	O
s	NN	O
was	VBD	O
greater	JJR	O
(	(	O
69	CD	O
(	(	O
26	CD	O
)	)	O
vs	NN	O
50	CD	O
(	(	O
27	CD	O
)	)	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Twenty-five	JJ	O
per	IN	O
cent	NN	O
recovery	NN	O
was	VBD	O
shorter	JJR	O
with	IN	O
rapacuronium	NN	O
than	IN	O
rocuronium	NN	O
during	IN	O
propofol	NN	O
(	(	O
15.0	CD	O
(	(	O
3.2	CD	O
)	)	O
vs	NN	O
39.1	CD	O
(	(	O
14.2	CD	O
)	)	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
sevoflurane	NN	O
(	(	O
15.1	CD	O
(	(	O
4.2	CD	O
)	)	O
vs	NN	O
47.8	CD	O
(	(	O
19.0	CD	O
)	)	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
anaesthesia	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
rapacuronium	NN	O
1.5	CD	O
mg	NN	O
kg-1	NN	O
had	VBD	O
a	DT	O
more	RBR	O
rapid	JJ	O
onset	NN	O
,	,	O
similar	JJ	O
intubating	NN	O
conditions	NNS	O
,	,	O
and	CC	O
shorter	JJR	O
recovery	NN	O
times	NNS	O
than	IN	O
rocuronium	NN	O
0.6	CD	O
mg	JJ	O
kg-1	NN	O
.	.	O

Single-needle	JJ	PH
acupuncture	NN	PH
alleviates	VBZ	O
gag	JJ	O
reflex	NN	O
during	IN	O
transesophageal	JJ	O
echocardiography	NN	O
:	:	O
a	DT	O
blinded	VBN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
pilot	NN	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
single-needle	JJ	PH
acupuncture	NN	PH
in	IN	O
suppressing	VBG	O
gag-reflex	JJ	O
in	IN	O
transesophageal	JJ	O
echocardiography	NN	O
(	(	O
TEE	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
blinded	VBD	O
trial	NN	O
.	.	O

Settings/locations	NNS	O
:	:	O
Patients	NNS	O
with	IN	O
ischemic	JJ	O
stroke	NN	O
or	CC	O
transient	JJ	O
ischemic	JJ	O
attack	NN	O
undergoing	JJ	O
TEE	NNP	O
because	IN	O
of	IN	O
presumed	JJ	O
cardioembolic	JJ	O
origin	NN	O
in	IN	O
a	DT	O
specialized	JJ	O
stroke	NN	O
unit	NN	O
of	IN	O
the	DT	O
Johann	NNP	O
Wolfgang	NNP	O
Goethe-University	NNP	O
,	,	O
Frankfurt/Main	NNP	O
,	,	O
Germany	NNP	O
.	.	O

Subjects/Study	NNP	O
interventions	NNS	O
:	:	O
Forty-one	CD	O
(	(	O
41	CD	O
)	)	O
patients	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

Patients	NNS	O
received	VBD	O
single-needle	JJ	PH
acupuncture	NN	PH
with	IN	O
a	DT	O
0.2	CD	O
x	NN	O
13	CD	O
mm	NN	O
disposable	JJ	O
acupuncture	NN	O
needle	NN	O
(	(	O
Suzhou	NNP	O
Medical	NNP	O
Appliances	NNP	O
,	,	O
China	NNP	O
)	)	O
,	,	O
10-mm	JJ	O
deep	NN	O
either	NN	O
at	IN	O
Chengjiang	NNP	O
(	(	O
midline	NN	O
between	IN	O
lower	JJR	O
lip	NN	O
and	CC	O
chin	NN	O
)	)	O
or	CC	O
superficially	RB	O
at	IN	O
a	DT	O
sham	NN	O
point	NN	O
(	(	O
tip	NN	O
of	IN	O
the	DT	O
chin	NN	O
)	)	O
during	IN	O
TEE	NNP	O
or	CC	O
no	DT	PH
acupuncture	NN	PH
for	IN	O
alleviating	VBG	O
gag	NN	O
reflex	NN	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Severity	NNP	O
of	IN	O
gagging	NN	O
was	VBD	O
rated	VBN	O
on	IN	O
a	DT	O
visual-analogue	JJ	O
scale	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
acupuncture	NN	O
group	NN	O
experienced	VBD	O
significantly	RB	O
less	RBR	O
gagging	VBG	O
than	IN	O
the	DT	O
sham	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.037	CD	O
)	)	O
or	CC	O
the	DT	O
nonacupuncture	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Acupuncture	NNP	PH
of	IN	PH
CV24	NNP	PH
is	VBZ	O
an	DT	O
easy	JJ	O
to	TO	O
apply	VB	O
and	CC	O
effective	JJ	O
method	NN	O
to	TO	O
reduce	VB	O
gag	NN	O
reflex	NN	O
during	IN	O
TEE	NNP	O
.	.	O

Rett	NNP	O
syndrome	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
L-carnitine	NNP	PM
.	.	O

Rett	NNP	O
syndrome	NN	O
is	VBZ	O
a	DT	O
severe	JJ	O
neurodevelopmental	JJ	O
disorder	NN	O
of	IN	O
unknown	JJ	O
etiology	NN	O
,	,	O
occurring	VBG	O
almost	RB	O
exclusively	RB	O
in	IN	O
female	JJ	O
patients	NNS	O
.	.	O

The	DT	O
etiology	NN	O
and	CC	O
functional	JJ	O
significance	NN	O
of	IN	O
plasma	JJ	O
carnitine	NN	O
deficiency	NN	O
seen	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

To	TO	O
investigate	VB	O
whether	IN	O
L-carnitine	JJ	PM
might	MD	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
Rett	NNP	O
syndrome	NN	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
of	IN	O
L-carnitine	NNP	PM
has	VBZ	O
been	VBN	O
completed	VBN	O
in	IN	O
35	CD	O
subjects	NNS	O
.	.	O

Eight-week	JJ	O
treatment	NN	O
phases	NNS	O
were	VBD	O
completed	VBN	O
for	IN	O
both	DT	O
a	DT	O
placebo	NN	C
and	CC	O
L-carnitine	NNP	PM
.	.	O

Outcome	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
parents/caregivers	NNS	O
and	CC	O
at	IN	O
medical	JJ	O
follow-up	NN	O
using	VBG	O
three	CD	O
established	VBN	O
tools	NNS	O
:	:	O
the	DT	O
Rett	NNP	O
Syndrome	NNP	O
Motor	NNP	O
Behavioral	NNP	O
Assessment	NNP	O
,	,	O
the	DT	O
Hand	NNP	O
Apraxia	NNP	O
Scale	NNP	O
,	,	O
and	CC	O
the	DT	O
Patient	NNP	O
Well-Being	NNP	O
Index	NNP	O
.	.	O

Analysis	NNP	O
comparing	VBG	O
change	NN	O
between	IN	O
baseline	NN	O
and	CC	O
week	NN	O
8	CD	O
of	IN	O
treatment	NN	O
for	IN	O
L-carnitine	NNP	PM
and	CC	O
the	DT	O
placebo	NN	C
showed	VBD	O
that	IN	O
both	DT	O
parents/caregivers	NNS	O
and	CC	O
medical	JJ	O
follow-up	NN	O
detected	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
subjects	NNS	O
'	POS	O
well-being	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
medical	JJ	O
review	NN	O
showed	VBD	O
an	DT	O
improvement	NN	O
on	IN	O
the	DT	O
Hand	NNP	O
Apraxia	NNP	O
Scale	NNP	O
for	IN	O
a	DT	O
higher	JJR	O
proportion	NN	O
of	IN	O
girls	NNS	O
on	IN	O
L-carnitine	NNP	O
.	.	O

Identification	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
clinical	JJ	O
improvement	NN	O
has	VBZ	O
been	VBN	O
limited	VBN	O
by	IN	O
the	DT	O
power	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
L-carnitine	NNP	PM
is	VBZ	O
of	IN	O
benefit	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
.	.	O

While	IN	O
L-carnitine	NNP	PM
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
major	JJ	O
functional	JJ	O
changes	NNS	O
in	IN	O
ability	NN	O
,	,	O
the	DT	O
type	NN	O
of	IN	O
changes	NNS	O
reported	VBN	O
could	MD	O
still	RB	O
have	VB	O
a	DT	O
substantial	JJ	O
impact	NN	O
on	IN	O
the	DT	O
girls	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
.	.	O

Information	NN	O
is	VBZ	O
still	RB	O
needed	VBN	O
,	,	O
however	RB	O
,	,	O
to	TO	O
determine	VB	O
if	IN	O
only	RB	O
subgroups	NNS	O
of	IN	O
girls	NNS	O
with	IN	O
the	DT	O
disorder	NN	O
are	VBP	O
responsive	JJ	O
to	TO	O
L-carnitine	NNP	PM
and	CC	O
the	DT	O
appropriate	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
.	.	O

FDA	NNP	O
review	NN	O
of	IN	O
a	DT	O
panitumumab	NN	PM
(	(	PM
Vectibix	NNP	PM
)	)	PM
clinical	JJ	O
trial	NN	O
for	IN	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

On	IN	O
September	NNP	O
27	CD	O
,	,	O
2006	CD	O
,	,	O
the	DT	O
U.S.	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
granted	VBD	O
accelerated	VBD	O
approval	NN	O
to	TO	O
panitumumab	VB	PM
(	(	PM
Vectibix	NNP	PM
;	:	PM
Amgen	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Thousand	NNP	O
Oaks	NNP	O
,	,	O
CA	NNP	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor-expressing	NN	O
,	,	O
metastatic	JJ	O
colorectal	NN	O
carcinoma	NN	O
with	IN	O
disease	JJ	O
progression	NN	O
on	IN	O
or	CC	O
following	VBG	O
fluoropyrimidine-	JJ	PM
,	,	O
oxaliplatin-	JJ	O
,	,	O
and	CC	O
irinotecan-containing	JJ	PM
chemotherapy	NN	PM
regimens	NNS	PM
.	.	O

Accelerated	NNP	O
approval	NN	O
was	VBD	O
based	VBN	O
on	IN	O
demonstration	NN	O
of	IN	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
submission	NN	O
summarizes	VBZ	O
a	DT	O
second	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
to	TO	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
panitumumab	JJ	PM
package	NN	O
insert	NN	O
in	IN	O
June	NNP	O
2008	CD	O
,	,	O
of	IN	O
chemotherapy	NN	PM
and	CC	O
bevacizumab	NN	PM
with	IN	PM
and	CC	PM
without	IN	PM
panitumumab	NN	PM
in	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
closed	VBN	O
when	WRB	O
inferior	JJ	O
PFS	NNP	O
and	CC	O
greater	JJR	O
toxicity	NN	O
were	VBD	O
demonstrated	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
planned	VBN	O
interim	NN	O
efficacy	NN	O
analysis	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
panitumumab	NN	PM
in	IN	O
combination	NN	O
with	IN	O
bevacizumab	NN	PM
and	CC	PM
chemotherapy	NN	PM
experienced	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
death	NN	O
(	(	O
9	CD	O
%	NN	O
versus	IN	O
4	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
higher	JJR	O
risk	NN	O
for	IN	O
grade	NN	O
3	CD	O
and	CC	O
4	CD	O
toxicities	NNS	O
than	IN	O
patients	NNS	O
receiving	VBG	O
bevacizumab	NN	PM
and	CC	O
chemotherapy	NN	PM
alone	RB	O
.	.	O

The	DT	O
incidences	NNS	O
of	IN	O
any	DT	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNP	O
grade	VBD	O
3	CD	O
and	CC	O
4	CD	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
87	CD	O
%	NN	O
and	CC	O
72	CD	O
%	NN	O
in	IN	O
the	DT	O
panitumumab	NN	PM
and	CC	O
control	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Grade	VB	O
3	CD	O
and	CC	O
4	CD	O
AEs	NNP	O
occurring	VBG	O
more	JJR	O
commonly	RB	O
in	IN	O
panitumumab-treated	JJ	PM
patients	NNS	O
included	VBD	O
rash/acneiform	NN	O
dermatitis	NN	O
,	,	O
diarrhea	NN	O
,	,	O
dehydration	NN	O
,	,	O
primarily	RB	O
resulting	VBG	O
from	IN	O
diarrhea	NN	O
,	,	O
hypokalemia	NN	O
,	,	O
stomatitis/mucositis	NN	O
,	,	O
and	CC	O
pulmonary	JJ	O
embolism	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
panitumumab	NN	PM
to	TO	PM
bevacizumab	VB	PM
and	CC	PM
chemotherapy	VB	PM
for	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
colorectal	NN	O
cancer	NN	O
was	VBD	O
harmful	JJ	O
when	WRB	O
compared	VBN	O
with	IN	O
bevacizumab	NN	PM
and	CC	PM
chemotherapy	NN	PM
alone	RB	PM
.	.	O

The	DT	O
use	NN	O
of	IN	O
panitumumab	NN	PM
in	IN	O
this	DT	O
setting	NN	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
.	.	O

Gamma-hydroxybutyric	JJ	PM
acid	NN	PM
versus	NN	O
clomethiazole	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
alcohol	NN	O
withdrawal	NN	O
syndrome	NN	O
in	IN	O
a	DT	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
:	:	O
an	DT	O
open	JJ	O
,	,	O
single-center	JJ	O
randomized	VBN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Clomethiazole	NNP	PM
(	(	PM
CLO	NNP	PM
)	)	PM
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
treating	VBG	O
alcohol	NN	O
withdrawal	NN	O
syndrome	NN	O
(	(	O
AWS	NNP	O
)	)	O
.	.	O

Gamma-Hydroxybutyric	JJ	PM
acid	NN	PM
(	(	PM
GHB	NNP	PM
)	)	PM
has	VBZ	O
also	RB	O
been	VBN	O
introduced	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
alcoholic	JJ	O
patients	NNS	O
and	CC	O
is	VBZ	O
effective	JJ	O
in	IN	O
surgical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
ICU	NNP	O
)	)	O
patients	NNS	O
in	IN	O
preventing	VBG	O
and	CC	O
treating	VBG	O
AWS	NNP	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
comparative	JJ	O
studies	NNS	O
between	IN	O
CLO	NNP	PM
and	CC	O
GHB	NNP	PM
in	IN	O
a	DT	O
medical	JJ	O
ICU	NNP	O
setting	NN	O
.	.	O

METHODS	NNP	O
Twenty-six	NNP	O
alcoholic	JJ	O
patients	NNS	O
with	IN	O
severe	JJ	O
AWS	NNP	O
and	CC	O
concomitant	JJ	O
medical	JJ	O
diseases	NNS	O
were	VBD	O
randomally	RB	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

CLO	NNP	PM
was	VBD	O
given	VBN	O
orally	RB	O
to	TO	O
12	CD	O
patients	NNS	O
in	IN	O
a	DT	O
dosage	NN	O
of	IN	O
250	CD	O
mg	NN	O
every	DT	O
4	CD	O
hours	NNS	O
as	IN	O
a	DT	O
liquid	NN	O
;	:	O
GHB	NNP	PM
(	(	O
initially	RB	O
30	CD	O
mg/kg	NNS	O
body	NN	O
weight	NN	O
(	(	O
BW	NNP	O
)	)	O
followed	VBN	O
by	IN	O
15	CD	O
mg/kg	NNS	O
BW	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
to	TO	O
14	CD	O
patients	NNS	O
.	.	O

Four	CD	O
major	JJ	O
AWS	NNP	O
symptoms	NNS	O
(	(	O
tremor	NN	O
,	,	O
sweating	VBG	O
,	,	O
nausea	NN	O
,	,	O
restlessness	NN	O
)	)	O
were	VBD	O
scored	VBN	O
,	,	O
and	CC	O
the	DT	O
administration	NN	O
of	IN	O
additional	JJ	O
medication	NN	O
was	VBD	O
registered	VBN	O
.	.	O

RESULTS	NNP	O
GHB	NNP	PM
was	VBD	O
more	RBR	O
effective	JJ	O
in	IN	O
treating	VBG	O
AWS	NNP	O
symptoms	NNS	O
.	.	O

In	IN	O
the	DT	O
GHB	NNP	PM
group	NN	O
,	,	O
AWS	NNP	O
score	NN	O
dropped	VBD	O
from	IN	O
6.6	CD	O
+/-	JJ	O
2.6	CD	O
to	TO	O
1.8	CD	O
+/-	JJ	O
2.1	CD	O
(	(	O
p	JJ	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
while	IN	O
in	IN	O
the	DT	O
CLO	NNP	PM
group	NN	O
,	,	O
the	DT	O
score	NN	O
dropped	VBD	O
from	IN	O
6	CD	O
+/-	JJ	O
2.5	CD	O
to	TO	O
4.1	CD	O
+/-	JJ	O
2.4	CD	O
(	(	O
n.	JJ	O
s.	NN	O
)	)	O
.	.	O

Differences	NNS	O
between	IN	O
groups	NNS	O
were	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
=.021	NN	O
,	,	O
two-way	JJ	O
ANOVA	NNP	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
did	VBD	O
not	RB	O
alter	VB	O
outcome	NN	O
or	CC	O
the	DT	O
duration	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
.	.	O

No	DT	O
serious	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

CONCLUSION	NNP	O
GHB	NNP	PM
effectively	RB	O
controls	VBZ	O
AWS	NNP	O
symptoms	NNS	O
in	IN	O
medical	JJ	O
ICU	NNP	O
patients	NNS	O
.	.	O

The	DT	O
rapid	JJ	O
initial	JJ	O
treatment	NN	O
response	NN	O
of	IN	O
GHB	NNP	O
in	IN	O
contrast	NN	O
to	TO	O
CLO	NNP	PM
has	VBZ	O
no	DT	O
influence	NN	O
on	IN	O
duration	NN	O
of	IN	O
patient	NN	O
withdrawal	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
schizophrenic	JJ	O
patient	NN	O
functionality	NN	O
on	IN	O
service	NN	O
utilization	NN	O
and	CC	O
cost	NN	O
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
presentation	NN	O
by	IN	O
Sandra	NNP	O
L.	NNP	O
Tunis	NNP	O
,	,	O
PhD	NNP	O
.	.	O

With	IN	O
the	DT	O
advent	NN	O
of	IN	O
atypical	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
schizophrenia	NN	O
,	,	O
physicians	NNS	O
and	CC	O
policy	NN	O
makers	NNS	O
must	MD	O
consider	VB	O
the	DT	O
costs	NNS	O
that	WDT	O
may	MD	O
accompany	VB	O
greater	JJR	O
clinical	JJ	O
efficacy	NN	O
.	.	O

Analyses	VBZ	O
reveal	NN	O
that	WDT	O
olanzapine	NN	PM
shows	VBZ	O
a	DT	O
greater	JJR	O
clinical	JJ	O
cost	NN	O
effectiveness	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
greater	JJR	O
functional	JJ	O
cost	NN	O
effectiveness	NN	O
,	,	O
than	IN	O
haloperidol	NN	PM
,	,	O
and	CC	O
that	IN	O
functional	JJ	O
outcomes	NNS	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
show	VBP	O
promise	NN	O
as	IN	O
important	JJ	O
measures	NNS	O
of	IN	O
effectiveness	NN	O
.	.	O

Functional	JJ	O
outcomes	NNS	O
can	MD	O
help	VB	O
differentiate	VB	O
medications	NNS	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
help	VB	O
demonstrate	VB	O
the	DT	O
cost	NN	O
effectiveness	NN	O
of	IN	O
atypical	JJ	O
agents	NNS	O
.	.	O

Mental	NNP	O
health	NN	O
and	CC	O
physical	JJ	O
health	NN	O
functioning	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
work	NN	O
status	NN	O
,	,	O
are	VBP	O
all	DT	O
measures	NNS	O
of	IN	O
functioning	VBG	O
that	WDT	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
evaluate	VB	O
treatment	NN	O
strategies	NNS	O
.	.	O

When	WRB	O
comparing	VBG	O
olanzapine	NN	PM
with	IN	O
haloperidol	NN	PM
,	,	O
cost	NN	O
savings	NNS	O
are	VBP	O
seen	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
(	(	O
1	CD	O
year	NN	O
)	)	O
,	,	O
with	IN	O
physical	JJ	O
functioning	VBG	O
most	JJS	O
highly	RB	O
affected	VBN	O
over	IN	O
time	NN	O
.	.	O

Functional	JJ	O
outcomes	NNS	O
can	MD	O
therefore	VB	O
serve	VB	O
2	CD	O
purposes	NNS	O
:	:	O
to	TO	O
enhance	VB	O
compliance	NN	O
by	IN	O
improving	VBG	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
to	TO	O
assist	VB	O
in	IN	O
making	VBG	O
both	DT	O
treatment	NN	O
and	CC	O
formulary	JJ	O
decisions	NNS	O
.	.	O

Eye	NNP	O
movements	NNS	O
affirm	NN	O
:	:	O
automatic	JJ	O
overt	NN	O
gaze	NN	O
and	CC	O
arrow	NN	O
cueing	NN	O
for	IN	O
typical	JJ	O
adults	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

People	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
show	NN	O
reduced	VBN	O
interest	NN	O
towards	NNS	O
social	JJ	O
aspects	NNS	O
of	IN	O
the	DT	O
environment	NN	O
and	CC	O
a	DT	O
lesser	JJR	O
tendency	NN	O
to	TO	O
follow	VB	O
other	JJ	O
people	NNS	O
's	POS	O
gaze	NN	O
in	IN	O
the	DT	O
real	JJ	O
world	NN	O
.	.	O

However	RB	O
,	,	O
most	JJS	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
people	NNS	O
with	IN	O
ASD	NNP	O
do	VBP	O
respond	VB	O
to	TO	O
eye-gaze	JJ	O
cues	NNS	O
in	IN	O
experimental	JJ	O
paradigms	NN	O
,	,	O
though	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
this	DT	O
behaviour	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
an	DT	O
atypical	JJ	O
strategy	NN	O
.	.	O

We	PRP	O
tested	VBD	O
this	DT	O
possibility	NN	O
in	IN	O
adults	NNS	O
with	IN	O
ASD	NNP	O
using	VBG	O
a	DT	O
cueing	NN	Ot
task	NN	Ot
combined	VBN	PH
with	IN	PH
eye-movement	JJ	PH
recording	NN	PH
.	.	O

Both	DT	O
eye	NN	O
gaze	NN	O
and	CC	O
arrow	VB	O
pointing	VBG	O
distractors	NNS	O
resulted	VBD	O
in	IN	O
overt	JJ	O
cueing	NN	O
effects	NNS	O
,	,	O
both	DT	O
in	IN	O
terms	NNS	O
of	IN	O
increased	VBN	O
saccadic	JJ	O
reaction	NN	O
times	NNS	O
,	,	O
and	CC	O
in	IN	O
proportions	NNS	O
of	IN	O
saccades	NNS	O
executed	VBN	O
to	TO	O
the	DT	O
cued	VBN	O
direction	NN	O
instead	RB	O
of	IN	O
to	TO	O
the	DT	O
target	NN	O
,	,	O
for	IN	O
both	DT	O
participant	JJ	O
groups	NNS	O
.	.	O

Our	PRP$	O
results	NNS	O
confirm	VBP	O
previous	JJ	O
reports	NNS	O
that	IN	O
eye	NN	O
gaze	NN	O
cues	NNS	O
as	RB	O
well	RB	O
as	IN	O
arrow	NN	O
cues	NNS	O
result	VBP	O
in	IN	O
automatic	JJ	O
orienting	NN	O
of	IN	O
overt	JJ	O
attention	NN	O
.	.	O

Moreover	RB	O
,	,	O
since	IN	O
there	EX	O
were	VBD	O
no	DT	O
group	NN	O
differences	VBZ	O
between	IN	O
arrow	NN	O
and	CC	O
eye	NN	O
gaze	NN	O
cues	NNS	O
,	,	O
we	PRP	O
conclude	VBP	O
that	IN	O
overt	JJ	O
attentional	JJ	O
orienting	NN	O
in	IN	O
ASD	NNP	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
response	NN	O
to	TO	O
centrally	RB	O
presented	VBN	O
schematic	JJ	O
directional	JJ	O
distractors	NNS	O
,	,	O
is	VBZ	O
typical	JJ	O
.	.	O

Prevention	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
comparing	VBG	O
enoxaparin	NN	PM
with	IN	O
warfarin	NN	PM
.	.	PM

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
fixed-dose	JJ	PM
enoxaparin	NN	PM
and	CC	O
adjusted	VBD	PM
dose	JJ	PM
warfarin	NN	PM
in	IN	O
preventing	VBG	O
venous	JJ	O
thromboembolism	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
8	CD	O
university	NN	O
hospitals	NNS	O
.	.	O

PATIENTS	VB	O
670	CD	O
consecutive	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
knee	VBN	O
arthroplasty	RB	O
.	.	O

INTERVENTION	NN	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
enoxaparin	NN	PM
(	(	PM
30	CD	PM
mg	NN	PM
subcutaneously	RB	PM
every	DT	PM
12	CD	PM
hours	NNS	PM
)	)	PM
or	CC	PM
adjusted-dose	JJ	PM
warfarin	NN	PM
(	(	PM
international	JJ	PM
normalized	VBN	PM
ratio	NN	PM
,	,	PM
2.0	CD	PM
to	TO	PM
3.0	CD	PM
)	)	PM
.	.	O

Both	DT	O
regimens	NNS	O
were	VBD	O
started	VBN	O
after	IN	O
surgery	NN	O
.	.	O

MEASUREMENTS	PDT	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
adequate	JJ	O
bilateral	JJ	O
venograms	NNS	O
;	:	O
the	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
hemorrhage	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
417	CD	O
patients	NNS	O
with	IN	O
adequate	JJ	O
venograms	NNS	O
,	,	O
109	CD	O
of	IN	O
211	CD	O
warfarin	NN	PM
recipients	NNS	O
(	(	O
51.7	CD	O
%	NN	O
)	)	O
had	VBD	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
compared	VBN	O
with	IN	O
76	CD	O
of	IN	O
206	CD	O
enoxaparin	NN	PM
recipients	NNS	O
(	(	O
36.9	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
14.8	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
enoxaparin	NN	PM
(	(	O
95	CD	O
%	NN	O
Cl	NNP	O
,	,	O
5.3	CD	O
%	NN	O
to	TO	O
24.1	CD	O
%	NN	O
)	)	O
Twenty-two	NNP	O
warfarin	NN	PM
recipients	NNS	O
(	(	O
10.4	CD	O
%	NN	O
)	)	O
and	CC	O
24	CD	O
enoxaparin	NN	PM
recipients	NNS	O
(	(	O
11.7	CD	O
%	NN	O
)	)	O
had	VBD	O
proximal	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
1.2	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
warfarin	NN	PM
(	(	O
Cl	NNP	O
,	,	O
-7.2	NNP	O
%	NN	O
to	TO	O
4.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
major	JJ	O
bleeding	NN	O
was	VBD	O
1.8	CD	O
%	NN	O
(	(	O
6	CD	O
of	IN	O
334	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
and	CC	O
2.1	CD	O
%	NN	O
(	(	O
7	CD	O
of	IN	O
336	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
enoxaparin	NN	O
group	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
0.3	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
warfarin	NN	O
(	(	O
Cl	NNP	O
,	,	O
-2.4	NNP	O
%	NN	O
to	TO	O
1.8	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
postoperative	JJ	O
,	,	O
fixed-dose	JJ	O
enoxaparin	NN	PM
regimen	NNS	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
adjusted-dose	JJ	O
warfarin	NN	PM
in	IN	O
preventing	VBG	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
proximal	JJ	O
venous	JJ	O
thrombosis	NN	O
or	CC	O
clinically	RB	O
overt	JJ	O
hemorrhage	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
supplemental	JJ	O
arginine	NN	PM
to	TO	O
enhance	VB	O
immune	JJ	O
function	NN	O
in	IN	O
persons	NNS	O
with	IN	O
HIV/AIDS	NNP	O
.	.	O

OBJECTIVE	NNP	O
We	PRP	O
collected	VBD	O
preliminary	JJ	O
data	NNS	O
on	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
supplemental	JJ	O
arginine	NN	PM
to	TO	O
improve	VB	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
persons	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
and	CC	O
acquired	VBD	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
study	NN	O
in	IN	O
an	DT	O
academic	JJ	O
medical	JJ	O
center-based	JJ	O
infectious	JJ	O
disease	NN	O
clinic	NN	O
,	,	O
11	CD	O
clinically	RB	O
stable	JJ	O
,	,	O
HIV-infected	JJ	O
adults	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
highly	RB	O
active	JJ	O
,	,	O
antiretroviral	JJ	PH
therapy	NN	PH
and	CC	O
had	VBD	O
HIV	NNP	O
plasma	NN	O
RNA	NNP	O
levels	NNS	O
of	IN	O
less	JJR	O
than	IN	O
10	CD	O
000	CD	O
copies/mL	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
19.6	CD	PM
g	NN	PM
of	IN	PM
arginine/d	NN	PM
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
for	IN	O
14	CD	O
d.	NN	O
Plasma	NNP	O
HIV	NNP	O
RNA	NNP	O
levels	NNS	O
,	,	O
neuropsychologic	RB	O
functioning	NN	O
,	,	O
and	CC	O
self-reported	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
safety	NN	O
of	IN	O
treatment	NN	O
.	.	O

Efficacy	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
.	.	O

RESULTS	NNP	O
None	NN	O
of	IN	O
the	DT	O
participants	NNS	O
experienced	VBD	O
any	DT	O
adverse	JJ	O
clinical	NN	O
,	,	O
virologic	NN	O
,	,	O
or	CC	O
neuropsychologic	JJ	O
events	NNS	O
that	WDT	O
necessitated	VBD	O
withdrawal	NN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
arginine-supplemented	JJ	PM
group	NN	O
showed	VBD	O
a	DT	O
mean	JJ	O
natural	JJ	O
killer	NN	O
cell	NN	O
cytotoxicity	NN	O
increase	NN	O
of	IN	O
18.9	CD	O
lytic	JJ	O
units	NNS	O
,	,	O
whereas	IN	O
the	DT	O
placebo	NN	O
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
0.3	CD	O
lytic	JJ	O
units	NNS	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.79	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Short-term	JJ	O
arginine	NN	PM
supplementation	NN	O
is	VBZ	O
safe	JJ	O
for	IN	O
persons	NNS	O
with	IN	O
HIV/AIDS	NNP	O
.	.	O

Additional	NNP	O
studies	NNS	O
with	IN	O
larger	JJR	O
samples	NNS	O
and	CC	O
longer	JJR	O
periods	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
arginine	JJ	O
supplementation	NN	O
on	IN	O
other	JJ	O
indices	NNS	O
of	IN	O
immune	JJ	O
function	NN	O
and	CC	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
such	JJ	O
as	IN	O
intercurrent	JJ	O
illnesses	NNS	O
.	.	O

Satisfactory	JJ	O
sampling	NN	O
in	IN	O
cytological	JJ	O
cervical	JJ	O
diagnosis	NN	O
:	:	O
comparison	NN	O
between	IN	O
a	DT	O
conventional	JJ	O
and	CC	O
a	DT	O
new	JJ	O
sampling	NN	PH
device	NN	PH
.	.	O

AIM	NNP	O
Inadequate	NNP	O
cervical	JJ	O
sampling	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
frequent	JJ	O
cause	NN	O
of	IN	O
misdiagnosis	NN	O
in	IN	O
cervical	JJ	O
cancer	NN	O
screening	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
ability	NN	O
of	IN	O
PapCone?	NNP	O
versus	IN	O
the	DT	O
conventional	JJ	O
sampling	NN	O
method	NN	O
(	(	O
Ayre	NNP	O
's	POS	O
spatula	NN	O
plus	CC	O
cytobrush	NN	O
)	)	O
to	TO	O
collect	VB	O
ectocervical	JJ	O
and	CC	O
glandular	JJ	O
cells	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
18	CD	O
healthy	JJ	O
women	NNS	O
,	,	O
two	CD	O
ecto-endocervical	JJ	O
samples	NNS	O
,	,	O
obtained	VBN	O
by	IN	O
two	CD	O
different	JJ	O
methods	NNS	O
,	,	O
were	VBD	O
obtained	VBN	O
at	IN	O
a	DT	O
three-month	JJ	O
interval	NN	O
.	.	O

Qualitative	JJ	O
and	CC	O
quantitative	JJ	O
parameters	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Ultrastructure	NN	O
features	NNS	O
of	IN	O
sampling	VBG	O
devices	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
scanning	VBG	O
electron	NN	O
microscopy	NN	O
(	(	O
SEM	NNP	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
sampling	VBG	O
.	.	O

RESULTS	VB	O
The	DT	O
?	.	O
(	(	O
2	CD	O
)	)	O
test	NN	O
revealed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
:	:	O
PapCone?	NNP	O
caused	VBD	O
less	JJR	O
cell	NN	O
overlap	NN	O
and	CC	O
sampled	VBD	O
less	JJR	O
white	JJ	O
blood	NN	O
cells	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
more	RBR	O
metaplastic	JJ	O
cells	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

SEM	NNP	O
evaluation	NN	O
highlighted	VBD	O
the	DT	O
porous	JJ	O
and	CC	O
spongy	JJ	O
structure	NN	O
of	IN	O
PapCone?	NNP	O
that	WDT	O
was	VBD	O
responsible	JJ	O
for	IN	O
the	DT	O
large	JJ	O
number	NN	O
of	IN	O
glandular	JJ	O
cells	NNS	O
on	IN	O
its	PRP$	O
surface	NN	O
.	.	O

CONCLUSION	NNP	O
Cervical	NNP	O
smears	NNS	O
performed	VBN	O
by	IN	O
PapCone?	NNP	O
were	VBD	O
adequate	JJ	O
and	CC	O
generally	RB	O
easier	JJR	O
to	TO	O
screen	VB	O
than	IN	O
conventionally	RB	O
performed	VBN	O
ones	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
posterior	JJ	O
uveitis	NN	O
with	IN	O
a	DT	O
fluocinolone	NN	PM
acetonide	NN	PM
implant	NN	PM
:	:	O
three-year	JJ	O
clinical	JJ	O
trial	NN	O
results	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
0.59-mg	JJ	O
and	CC	O
2.1-mg	JJ	O
fluocinolone	NN	PM
acetonide	NN	PM
(	(	O
FA	NNP	O
)	)	O
intravitreous	JJ	O
implants	NNS	O
in	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
3-year	JJ	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
historically	RB	O
controlled	VBN	O
trial	NN	O
of	IN	O
the	DT	O
0.59-mg	JJ	PM
FA	NNP	PM
intravitreous	JJ	PM
implant	NN	PM
in	IN	O
110	CD	O
patients	NNS	O
and	CC	O
the	DT	O
2.1-mg	JJ	O
FA	NNP	O
intravitreous	JJ	O
implant	NN	O
in	IN	O
168	CD	O
patients	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Recurrence	NNP	O
rate	NN	O
,	,	O
vision	NN	O
,	,	O
and	CC	O
complications	NNS	O
.	.	O

RESULTS	NNP	O
Uveitis	NNP	O
recurrence	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
implanted	JJ	O
eyes	NNS	O
from	IN	O
62	CD	O
%	NN	O
(	(	O
during	IN	O
the	DT	O
1-year	JJ	O
preimplantation	NN	O
period	NN	O
)	)	O
to	TO	O
4	CD	O
%	NN	O
,	,	O
10	CD	O
%	NN	O
,	,	O
and	CC	O
20	CD	O
%	NN	O
during	IN	O
the	DT	O
1-	JJ	O
,	,	O
2-	JJ	O
,	,	O
and	CC	O
3-year	JJ	O
postimplantation	NN	O
periods	NNS	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
0.59-mg	JJ	O
dose	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
from	IN	O
58	CD	O
%	NN	O
to	TO	O
7	CD	O
%	NN	O
,	,	O
17	CD	O
%	NN	O
,	,	O
and	CC	O
41	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
2.1-mg	JJ	O
dose	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

More	RBR	O
implanted	JJ	O
eyes	NNS	O
than	IN	O
nonimplanted	JJ	O
eyes	NNS	O
had	VBD	O
improved	VBN	O
visual	JJ	O
acuity	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Implanted	VBN	O
eyes	NNS	O
had	VBD	O
higher	JJR	O
incidences	NNS	O
of	IN	O
intraocular	JJ	O
pressure	NN	O
elevation	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
10	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
than	IN	O
nonimplanted	VBN	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
and	CC	O
glaucoma	NN	O
surgery	NN	O
was	VBD	O
required	VBN	O
in	IN	O
40	CD	O
%	NN	O
of	IN	O
implanted	JJ	O
eyes	NNS	O
vs	VBP	O
2	CD	O
%	NN	O
of	IN	O
nonimplanted	JJ	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Cataracts	NNPS	O
were	VBD	O
extracted	VBN	O
in	IN	O
93	CD	O
%	NN	O
of	IN	O
phakic	NN	O
implanted	VBN	O
eyes	NNS	O
vs	VBP	O
20	CD	O
%	NN	O
of	IN	O
phakic	NN	O
nonimplanted	VBN	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
FA	NNP	O
implant	NN	O
significantly	RB	O
reduced	VBN	O
uveitis	JJ	O
recurrence	NN	O
and	CC	O
improved	VBD	O
or	CC	O
stabilized	VBN	O
visual	JJ	O
acuity	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

Most	JJS	O
subjects	NNS	O
required	VBN	O
cataract	JJ	O
extraction	NN	O
,	,	O
and	CC	O
a	DT	O
significant	JJ	O
proportion	NN	O
required	VBN	O
intraocular	JJ	O
pressure-lowering	JJ	O
surgery	NN	O
.	.	O

APPLICATION	NNP	O
TO	NNP	O
CLINICAL	NNP	O
PRACTICE	NNP	O
The	DT	O
FA	NNP	O
implant	NN	O
provides	VBZ	O
an	DT	O
alternative	JJ	O
therapy	NN	O
for	IN	O
prolonged	JJ	O
control	NN	O
of	IN	O
inflammation	NN	O
in	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00407082	NN	O
.	.	O

Possible	JJ	O
etiology	NN	O
of	IN	O
improvements	NNS	O
in	IN	O
both	DT	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
overlapping	VBG	O
gastroesophageal	JJ	O
reflux	JJ	O
disease	NN	O
by	IN	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
treatment	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Symptoms	NNP	O
suggestive	NN	O
of	IN	O
functional	JJ	O
dyspepsia	NN	O
(	(	O
FD	NNP	O
)	)	O
and	CC	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
(	(	O
IBS	NNP	O
)	)	O
frequently	RB	O
overlap	VBP	O
with	IN	O
those	DT	O
of	IN	O
gastroesophageal	JJ	O
reflux	JJ	O
disease	NN	O
.	.	O

Despite	IN	O
the	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
symptomatic	JJ	O
overlap	NN	O
,	,	O
the	DT	O
underlying	JJ	O
etiology	NN	O
remains	VBZ	O
poorly	RB	O
defined	VBN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
correlation	NN	O
of	IN	O
symptomatic	JJ	O
relief	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
HRQoL	NNP	O
)	)	O
with	IN	O
healing	NN	O
of	IN	O
reflux	NN	O
esophagitis	NN	O
to	TO	O
further	RBR	O
derive	JJ	O
insights	NNS	O
into	IN	O
the	DT	O
underlying	JJ	O
etiology	NN	O
.	.	O

METHODS	NNP	O
626	CD	O
patients	NNS	O
with	IN	O
reflux	JJ	O
esophagitis	NN	O
were	VBD	O
enrolled	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
(	(	O
classical	JJ	PH
healing	NN	PH
concept	NN	PH
or	CC	O
the	DT	PH
complete	JJ	PH
remission	NN	PH
concept	NN	PH
)	)	O
to	TO	O
investigate	VB	O
differences	NNS	O
in	IN	O
treatment	NN	O
intensity	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
pantoprazole	NN	PM
until	IN	O
esophageal	JJ	O
mucosal	NN	O
healing	VBG	O
.	.	O

Remission	NN	O
was	VBD	O
followed	VBN	O
for	IN	O
up	RB	O
to	TO	O
6	CD	O
months	NNS	O
without	IN	O
treatment	NN	O
.	.	O

Gastro-intestinal	JJ	O
symptoms	NNS	O
and	CC	O
HRQoL	NNP	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
disease-specific	JJ	O
,	,	O
psychometrically	RB	O
validated	VBN	O
patient-reported	JJ	O
outcome	NN	O
instruments	NNS	O
(	(	O
ReQuest?	NNP	O
,	,	O
GERDyzer?	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Symptomatic	NNP	O
burden	NN	O
reflected	VBN	O
by	IN	O
ReQuest?	NNP	O
substantially	RB	O
decreased	VBD	O
from	IN	O
baseline	NN	O
to	TO	O
end	VB	O
of	IN	O
treatment	NN	O
by	IN	O
83	CD	O
%	NN	O
and	CC	O
88	CD	O
%	NN	O
in	IN	O
either	CC	O
treatment	NN	O
group	NN	O
,	,	O
respectively	RB	O
.	.	O

ReQuest?	NNP	O
scores	VBZ	O
significantly	RB	O
decreased	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
or	CC	O
without	IN	O
heartburn	NN	O
and	CC	O
in	IN	O
those	DT	O
with	IN	O
symptoms	NNS	O
suggestive	JJ	O
of	IN	O
FD	NNP	O
and	CC	O
IBS	NNP	O
,	,	O
indicating	VBG	O
response	NN	O
of	IN	O
all	DT	O
symptom	JJ	O
categories	NNS	O
to	TO	O
treatment	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

Therapy-associated	JJ	O
relief	NN	O
of	IN	O
symptoms	NNS	O
was	VBD	O
paralleled	VBN	O
by	IN	O
substantial	JJ	O
gains	NNS	O
in	IN	O
HRQoL	NNP	O
,	,	O
which	WDT	O
continued	VBD	O
to	TO	O
stabilize	VB	O
post-treatment	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Pantoprazole	NNP	O
is	VBZ	O
effective	JJ	O
in	IN	O
relieving	VBG	O
upper	JJ	O
and	CC	O
lower	JJR	O
gastro-intestinal	NN	O
symptoms	NNS	O
overlapping	VBG	O
with	IN	O
erosive	JJ	O
esophagitis	NN	O
,	,	O
and	CC	O
provides	VBZ	O
sustained	JJ	O
improvement	NN	O
in	IN	O
HRQoL	NNP	O
post-treatment	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
propose	VB	O
a	DT	O
link	NN	O
between	IN	O
both	DT	O
healing	NN	O
of	IN	O
erosive	JJ	O
esophagitis	NN	O
and	CC	O
the	DT	O
slower	JJR	O
remission	NN	O
of	IN	O
upper	JJ	O
and	CC	O
lower	JJR	O
gastro-intestinal	NN	O
symptoms	NNS	O
.	.	O

Since	IN	O
the	DT	O
improvement	NN	O
observed	VBD	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
multifactorial	JJ	O
,	,	O
the	DT	O
possibility	NN	O
for	IN	O
an	DT	O
immune-mediated	JJ	O
etiology	NN	O
and	CC	O
identification	NN	O
of	IN	O
putative	JJ	O
susceptibility	NN	O
factors	NNS	O
by	IN	O
genome-wide	JJ	O
association	NN	O
study	NN	O
may	MD	O
provide	VB	O
focus	NN	O
for	IN	O
future	JJ	O
research	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
identifier	NN	O
:	:	O
NCT00325676	NNP	O
.	.	O

Randomized	VBN	O
Phase	NNP	O
II	NNP	O
trial	NN	O
assessing	VBG	O
estramustine	NN	PM
and	CC	PM
vinblastine	JJ	PM
combination	NN	PM
chemotherapy	NN	PM
vs	JJ	O
estramustine	NN	PM
alone	RB	PM
in	IN	O
patients	NNS	O
with	IN	O
progressive	JJ	O
hormone-escaped	JJ	O
metastatic	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
combined	JJ	O
data	NNS	O
from	IN	O
three	CD	O
North	JJ	O
American	JJ	O
Phase	NNP	O
II	NNP	O
studies	NNS	O
,	,	O
a	DT	O
randomised	JJ	O
Phase	NNP	O
II	NNP	O
study	NN	O
in	IN	O
the	DT	O
same	JJ	O
patient	JJ	O
population	NN	O
was	VBD	O
performed	VBN	O
,	,	O
using	VBG	O
combination	NN	O
chemotherapy	NN	PM
with	IN	PM
estramustine	JJ	PM
phosphate	NN	PM
(	(	PM
EMP	NNP	PM
)	)	PM
and	CC	PM
vinblastine	NN	PM
(	(	PM
VBL	NNP	PM
)	)	PM
in	IN	O
hormone	NN	O
refractory	NN	O
prostate	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

In	IN	O
all	DT	O
,	,	O
92	CD	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
into	IN	O
a	DT	O
Phase	NNP	O
II	NNP	O
study	NN	O
of	IN	O
oral	JJ	PM
EMP	NNP	PM
(	(	PM
10	CD	PM
mg	NNS	PM
kg	JJ	PM
day	NN	PM
continuously	RB	PM
)	)	PM
or	CC	PM
oral	JJ	PM
EMP	NNP	PM
in	IN	PM
combination	NN	PM
with	IN	PM
intravenous	JJ	PM
VBL	NNP	PM
(	(	O
4	CD	O
mg	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
week	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	O
weeks	NNS	O
rest	NN	O
)	)	O
.	.	O

The	DT	O
end	NN	O
points	NNS	O
were	VBD	O
toxicity	NN	O
and	CC	O
PSA	NNP	O
response	NN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
the	DT	O
option	NN	O
to	TO	O
continue	VB	O
the	DT	O
trial	NN	O
as	IN	O
a	DT	O
Phase	NNP	O
III	NNP	O
study	NN	O
with	IN	O
time	NN	O
to	TO	O
progression	NN	O
and	CC	O
survival	NN	O
as	IN	O
end	NN	O
points	NNS	O
,	,	O
if	IN	O
sufficient	JJ	O
responses	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Toxicity	NNP	O
was	VBD	O
unexpectedly	RB	O
high	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
and	CC	O
led	VBD	O
to	TO	O
treatment	NN	O
withdrawal	NN	O
or	CC	O
refusal	NN	O
in	IN	O
49	CD	O
%	NN	O
of	IN	O
all	DT	O
patients	NNS	O
,	,	O
predominantly	RB	O
already	RB	O
during	IN	O
the	DT	O
first	JJ	O
treatment	NN	O
cycle	NN	O
.	.	O

The	DT	O
mean	JJ	O
treatment	NN	O
duration	NN	O
was	VBD	O
10	CD	O
and	CC	O
14	CD	O
weeks	NNS	O
,	,	O
median	JJ	O
time	NN	O
to	TO	O
PSA	NNP	O
progression	NN	O
was	VBD	O
27.2	CD	O
and	CC	O
30.8	CD	O
weeks	NNS	O
,	,	O
median	JJ	O
survival	NN	O
time	NN	O
was	VBD	O
44	CD	O
and	CC	O
50.9	CD	O
weeks	NNS	O
,	,	O
and	CC	O
PSA	NNP	O
response	NN	O
rate	NN	O
was	VBD	O
only	RB	O
24.6	CD	O
and	CC	O
28.9	CD	O
%	NN	O
in	IN	O
the	DT	O
EMP/VBL	NNP	PM
and	CC	O
EMP	NNP	PM
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
correlation	NN	O
between	IN	O
PSA	NNP	O
response	NN	O
and	CC	O
survival	NN	O
.	.	O

While	IN	O
the	DT	O
PSA	NNP	O
response	NN	O
in	IN	O
the	DT	O
patients	NNS	O
tested	VBD	O
was	VBD	O
less	JJR	O
than	IN	O
half	NN	O
that	WDT	O
recorded	VBD	O
in	IN	O
the	DT	O
North	JJ	O
American	JJ	O
studies	NNS	O
,	,	O
the	DT	O
toxicity	NN	O
of	IN	O
EMP	NNP	PM
monotherapy	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
VBL	NNP	PM
was	VBD	O
much	RB	O
higher	JJR	O
than	IN	O
expected	VBN	O
.	.	O

Further	NNP	O
research	NN	O
on	IN	O
more	RBR	O
effective	JJ	O
and	CC	O
less	RBR	O
toxic	JJ	O
treatment	NN	O
strategies	NNS	O
for	IN	O
hormone	NN	O
refractory	NN	O
prostate	NN	O
cancer	NN	O
is	VBZ	O
mandatory	JJ	O
.	.	O

Efficiency	NN	PH
of	IN	PH
adjuvant	JJ	PH
immunochemotherapy	NN	PH
following	VBG	O
curative	JJ	O
resection	NN	O
in	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
curative	JJ	O
resection	NN	O
,	,	O
50	CD	O
%	NN	O
-90	CD	O
%	NN	O
of	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
die	VBP	O
of	IN	O
disease	NN	O
relapse	NN	O
.	.	O

Although	IN	O
some	DT	O
clinical	JJ	O
trials	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
chemotherapy	NN	O
and	CC	O
immunochemotherapy	NN	O
may	MD	O
be	VB	O
effective	JJ	O
modalities	NNS	O
,	,	O
more	RBR	O
recent	JJ	O
studies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
able	JJ	O
to	TO	O
define	VB	O
the	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
adjuvant	JJ	PH
immunochemotherapy	NN	PH
with	IN	PH
the	DT	PH
use	NN	PH
of	IN	PH
BCG	NNP	PM
(	(	PM
bacille	IN	PM
Calmette-Guerin	NNP	PM
)	)	PM
and	CC	O
FAM	NNP	PM
(	(	O
5-fluorouracil	JJ	PM
,	,	O
adriamycin	JJ	PM
,	,	O
mitomycin	JJ	PM
C	NNP	PM
)	)	O
chemotherapy	NN	PM
on	IN	O
the	DT	O
survival	NN	O
of	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	VBN	O
resectable	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
156	CD	O
patients	NNS	O
with	IN	O
stage	NN	O
III	NNP	O
or	CC	O
IV	NNP	O
gastric	JJ	O
cancer	NN	O
who	WP	O
had	VBD	O
undergone	JJ	O
curative	JJ	O
resection	NN	O
were	VBD	O
randomly	RB	PM
assigned	VBN	PM
to	TO	PM
three	CD	PM
treatment	NN	PM
groups	NNS	PM
:	:	PM
BCG	NNP	PM
+	NNP	PM
FAM	NNP	PM
(	(	O
immunochemotherapy	NN	PM
)	)	O
,	,	O
FAM	NNP	O
(	(	O
chemotherapy	NN	PM
)	)	O
,	,	O
and	CC	O
control	NN	S
(	(	S
surgery	NN	S
only	RB	S
)	)	S
.	.	O

Treatment	NN	Ot
was	VBD	Ot
continued	VBN	Ot
for	IN	Ot
2	CD	Ot
years	NNS	Ot
or	CC	Ot
until	IN	Ot
death	NN	Ot
.	.	O

Further	NNP	Ot
postsurgical	JJ	Ot
follow	VBP	Ot
up	RP	Ot
was	VBD	Ot
carried	VBN	Ot
on	IN	Ot
for	IN	Ot
up	IN	Ot
to	TO	Ot
10	CD	Ot
years	NNS	Ot
.	.	O

RESULTS	VB	O
Overall	JJ	O
10-year	JJ	O
survival	NN	O
was	VBD	O
47.1	CD	O
%	NN	O
for	IN	O
the	DT	O
immunochemotherapy	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.037	CD	O
vs	NN	O
FAM	NNP	PH
and	CC	O
P	NNP	O
<	NNP	O
0.0006	CD	O
vs	NNS	O
control	NN	O
)	)	O
,	,	O
30	CD	O
%	NN	O
for	IN	O
the	DT	O
chemotherapy	NN	PH
group	NN	O
(	(	O
vs	FW	O
control	NN	O
,	,	O
NS	NNP	O
)	)	O
,	,	O
and	CC	O
15.2	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
pT2/T3	JJ	O
primary	JJ	O
tumors	NNS	O
,	,	O
10-year	JJ	O
survival	NN	O
was	VBD	O
55.3	CD	O
%	NN	O
for	IN	O
BCG	NNP	PH
+	NNP	PH
FAM	NNP	PH
vs	VBD	O
28.2	CD	O
%	NN	O
for	IN	O
FAM	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
14.6	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.00018	CD	O
)	)	O
.	.	O

BCG	NNP	O
+	NNP	O
FAM	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
survival	NN	O
of	IN	O
patients	NNS	O
with	IN	O
intestinal-type	JJ	O
but	CC	O
not	RB	O
diffuse-type	JJ	O
cancer	NN	O
.	.	O

Immunochemotherapy	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	VB	O
This	DT	O
study	NN	O
,	,	O
based	VBN	O
on	IN	O
a	DT	O
limited	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
,	,	O
indicates	VBZ	O
that	IN	O
adjuvant	JJ	O
immunochemotherapy	NN	O
(	(	O
BCG	NNP	O
+	NNP	O
FAM	NNP	O
)	)	O
may	MD	O
prolong	VB	O
the	DT	O
survival	NN	O
of	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
after	IN	O
curative	JJ	O
gastrectomy	NN	O
;	:	O
in	IN	O
particular	JJ	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
pT2/T3	JJ	O
tumors	NNS	O
and	CC	O
intestinal-type	JJ	O
primary	JJ	O
tumors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
survival	JJ	O
benefit	NN	O
from	IN	O
FAM	NNP	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

Prenatal	JJ	O
depression	NN	O
predicts	VBZ	O
postpartum	JJ	O
maternal	JJ	O
attachment	NN	O
in	IN	O
low-income	JJ	O
Latina	NNP	O
mothers	NNS	O
with	IN	O
infants	NNS	O
.	.	O

Although	IN	O
maternal	JJ	O
attachment	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
predictor	NN	O
of	IN	O
infant	JJ	O
attachment	JJ	O
security	NN	O
and	CC	O
other	JJ	O
developmental	JJ	O
outcomes	NNS	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
formation	NN	O
of	IN	O
maternal	JJ	O
attachment	NN	O
in	IN	O
the	DT	O
first	JJ	O
few	JJ	O
months	NNS	O
of	IN	O
the	DT	O
infant	NN	O
's	POS	O
life	NN	O
,	,	O
particularly	RB	O
among	IN	O
ethnic	JJ	O
minority	NN	O
mothers	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
predictors	NNS	O
of	IN	O
postpartum	JJ	O
maternal	JJ	O
attachment	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
217	CD	O
Latina	NNP	O
women	NNS	O
enrolled	VBD	O
in	IN	O
a	DT	O
perinatal	JJ	O
depression	NN	O
prevention	NN	O
trial	NN	O
.	.	O

Mothers	NNS	O
'	POS	O
attachment	NN	E
to	TO	O
their	PRP$	O
infants	NNS	O
was	VBD	O
measured	VBN	O
at	IN	O
6-8	JJ	E
weeks	NNS	E
postpartum	NN	E
using	VBG	E
the	DT	E
Maternal	NNP	E
Postnatal	NNP	E
Attachment	NNP	E
Scale	NNP	E
.	.	O

A	NNP	O
variety	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
early	JJ	O
attachment	NN	O
were	VBD	O
explored	VBN	O
including	VBG	O
:	:	O
depressive	JJ	O
symptoms	NNS	O
during	IN	O
pregnancy	NN	O
,	,	O
pregnancy	NN	O
intention	NN	O
,	,	O
feelings	NNS	O
about	IN	O
the	DT	O
pregnancy	NN	O
,	,	O
and	CC	O
the	DT	O
quality	NN	O
of	IN	O
the	DT	O
partner	NN	O
relationship	NN	O
.	.	O

The	DT	O
strongest	JJS	O
predictor	NN	O
of	IN	O
lower	JJR	O
maternal	JJ	O
attachment	NN	O
was	VBD	O
depressive	JJ	O
symptoms	NNS	O
late	RB	O
in	IN	O
pregnancy	NN	O
;	:	O
pregnancy	NN	O
intention	NN	O
was	VBD	O
marginally	RB	O
predictive	JJ	O
of	IN	O
attachment	NN	O
,	,	O
with	IN	O
lower	JJR	O
scores	NNS	O
being	VBG	O
associated	VBN	O
with	IN	O
unwanted	JJ	O
pregnancies	NNS	O
.	.	O

The	DT	O
study	NN	O
fills	VBZ	O
a	DT	O
critical	JJ	O
gap	NN	O
in	IN	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
role	NN	O
of	IN	O
depressive	JJ	O
symptoms	NNS	O
during	IN	O
pregnancy	NN	O
in	IN	O
shaping	VBG	O
mothers	NNS	O
'	POS	O
early	JJ	O
attachment	NN	O
to	TO	O
their	PRP$	O
infants	NNS	O
.	.	O

Beneficial	JJ	O
effect	NN	O
of	IN	O
etidronate	NN	PM
therapy	NN	PM
in	IN	O
chronically	RB	O
hospitalized	VBN	O
,	,	O
disabled	JJ	O
patients	NNS	O
with	IN	O
stroke	NN	O
.	.	O

Incidence	NN	O
of	IN	O
hip	NN	O
fractures	NNS	O
is	VBZ	O
high	JJ	O
in	IN	O
chronically	RB	O
hospitalized	VBN	O
,	,	O
disabled	VBD	O
,	,	O
elderly	JJ	O
patients	NNS	O
after	IN	O
stroke	NN	O
.	.	O

Duration	NN	O
of	IN	O
hospitalization	NN	O
was	VBD	O
more	JJR	O
than	IN	O
1	CD	O
year	NN	O
because	IN	O
of	IN	O
insufficiency	NN	O
of	IN	O
nursing	NN	O
homes	NNS	O
.	.	O

Our	PRP$	O
study	NN	O
showed	VBD	O
that	IN	O
immobilization-induced	JJ	O
hypercalcemia	NN	O
and	CC	O
25-hydroxyvitamin	JJ	O
D	NNP	O
deficiency	NN	O
contribute	NN	O
to	TO	O
reduced	VB	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
address	VB	O
the	DT	O
possibility	NN	O
that	WDT	O
treatment	NN	O
with	IN	O
etidronate	NN	PM
may	MD	O
reduce	VB	O
the	DT	O
bone	NN	O
resorption	NN	O
and	CC	O
lower	JJR	O
the	DT	O
incidence	NN	O
of	IN	O
fractures	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
who	WP	O
are	VBP	O
chronically	RB	O
hospitalized	VBN	O
and	CC	O
disabled	VBN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
hemiparesis	NN	O
after	IN	O
stroke	NN	O
.	.	O

Patients	NNS	O
with	IN	O
stroke	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
daily	VB	O
treatment	NN	O
with	IN	O
400	CD	O
mg	NNS	O
of	IN	O
etidronate	NN	PM
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
,	,	O
and	CC	O
followed	VBD	O
up	RB	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
both	DT	O
groups	NNS	O
had	VBD	O
low	JJ	O
BMD	NNP	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
ionized	VBN	O
calcium	NN	O
and	CC	O
urinary	JJ	O
deoxypyridinoline	NN	O
.	.	O

In	IN	O
the	DT	O
etidronate	NN	PM
group	NN	O
,	,	O
serum	NN	O
calcium	NN	O
and	CC	O
urinary	JJ	O
deoxypyridinoline	NN	O
levels	NNS	O
decreased	VBN	O
significantly	RB	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
whereas	IN	O
the	DT	O
levels	NNS	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
were	VBD	O
increased	VBN	O
.	.	O

BMD	NNP	O
on	IN	O
the	DT	O
hemiplegic	JJ	O
side	NN	O
increased	VBN	O
by	IN	O
1.4	CD	O
%	NN	O
in	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
and	CC	O
decreased	VBN	O
by	IN	O
2.2	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Two	CD	O
patients	NNS	O
sustained	VBD	O
hip	JJ	O
fractures	NNS	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
,	,	O
and	CC	O
no	DT	O
hip	NN	O
fracture	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
etidronate	NN	PM
group	NN	O
.	.	O

Treatment	NN	O
with	IN	O
etidronate	NN	PM
increases	NNS	O
BMD	NNP	O
in	IN	O
chronically	RB	O
hospitalized	VBN	O
patients	NNS	O
poststroke	VBD	O
,	,	O
and	CC	O
may	MD	O
prevent	VB	O
hip	NN	O
fracture	NN	O
.	.	O

Chemoprevention	NN	O
of	IN	O
gastric	JJ	O
dysplasia	NN	O
:	:	O
randomized	JJ	O
trial	NN	O
of	IN	O
antioxidant	JJ	PM
supplements	NNS	PM
and	CC	PM
anti-helicobacter	JJ	PM
pylori	NN	PM
therapy	NN	PM
.	.	PM

BACKGROUND	NNP	O
Previous	NNP	O
research	NN	O
has	VBZ	O
identified	VBN	O
a	DT	O
high	JJ	O
risk	NN	O
of	IN	O
gastric	JJ	O
carcinoma	NN	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
cancer	NN	O
precursor	NN	O
lesions	NNS	O
in	IN	O
rural	JJ	O
populations	NNS	O
living	VBG	O
in	IN	O
the	DT	O
province	NN	O
of	IN	O
Nari?o	NNP	O
,	,	O
Colombia	NNP	O
,	,	O
in	IN	O
the	DT	O
Andes	NNP	O
Mountains	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
controlled	VBN	O
chemoprevention	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
subjects	NNS	O
with	IN	O
confirmed	JJ	O
histologic	JJ	O
diagnoses	NNS	O
of	IN	O
multifocal	JJ	O
nonmetaplastic	JJ	O
atrophy	NN	O
and/or	IN	O
intestinal	JJ	O
metaplasia	NN	O
,	,	O
two	CD	O
precancerous	JJ	O
lesions	NNS	O
.	.	O

Individuals	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
anti-Helicobacter	JJ	O
pylori	NN	O
triple	JJ	O
therapy	NN	O
and/or	NN	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
ascorbic	JJ	O
acid	NN	O
,	,	O
beta-carotene	JJ	O
,	,	O
or	CC	O
their	PRP$	O
corresponding	JJ	O
placebos	NN	O
.	.	O

Gastric	NNP	O
biopsy	NN	O
specimens	VBZ	O
taken	VBN	O
at	IN	O
baseline	NN	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
taken	VBN	O
at	IN	O
72	CD	O
months	NNS	O
.	.	O

Relative	JJ	O
risks	NNS	O
of	IN	O
progression	NN	O
,	,	O
no	DT	O
change	NN	O
,	,	O
and	CC	O
regression	NN	O
from	IN	O
multifocal	JJ	O
nonmetaplastic	JJ	O
atrophy	NN	O
and	CC	O
intestinal	JJ	O
metaplasia	NN	O
were	VBD	O
analyzed	VBN	O
with	IN	O
multivariate	NN	O
polytomous	JJ	O
logistic	JJ	O
regression	NN	O
models	NNS	O
to	TO	O
estimate	VB	O
treatment	NN	O
effects	NNS	O
.	.	O

All	DT	O
statistical	JJ	O
tests	NNS	O
were	VBD	O
two-sided	JJ	O
.	.	O

RESULTS	VB	O
All	DT	O
three	CD	O
basic	JJ	O
interventions	NNS	O
resulted	VBD	O
in	IN	O
statistically	RB	O
significant	JJ	O
increases	NNS	O
in	IN	O
the	DT	O
rates	NNS	O
of	IN	O
regression	NN	O
:	:	O
Relative	JJ	O
risks	NNS	O
were	VBD	O
4.8	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
=	NNP	O
1.6-14.2	JJ	O
)	)	O
for	IN	O
anti-H.	JJ	O
pylori	NN	O
treatment	NN	O
,	,	O
5	CD	O
.	.	O

1	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.7-15.0	JJ	O
)	)	O
for	IN	O
beta-carotene	JJ	O
treatment	NN	O
,	,	O
and	CC	O
5.0	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.7-14.4	JJ	O
)	)	O
for	IN	O
ascorbic	JJ	O
acid	JJ	O
treatment	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
atrophy	NN	O
.	.	O

Corresponding	VBG	O
relative	JJ	O
risks	NNS	O
of	IN	O
regression	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
intestinal	JJ	O
metaplasia	NNS	O
were	VBD	O
3.1	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.0-9.3	JJ	O
)	)	O
,	,	O
3.4	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.1-9.8	JJ	O
)	)	O
,	,	O
and	CC	O
3.3	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.1-9.5	JJ	O
)	)	O
.	.	O

Combinations	NNS	O
of	IN	O
treatments	NNS	O
did	VBD	O
not	RB	O
statistically	RB	O
significantly	RB	O
increase	VB	O
the	DT	O
regression	NN	O
rates	NNS	O
.	.	O

Curing	VBG	O
the	DT	O
H.	NNP	O
pylori	NN	O
infection	NN	O
(	(	O
which	WDT	O
occurred	VBD	O
in	IN	O
74	CD	O
%	NN	O
of	IN	O
the	DT	O
treated	JJ	O
subjects	NNS	O
)	)	O
produced	VBD	O
a	DT	O
marked	JJ	O
and	CC	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
regression	NN	O
of	IN	O
the	DT	O
precursor	NN	O
lesions	NNS	O
(	(	O
relative	JJ	O
risks	NNS	O
=	VBP	O
8.7	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
2.7-28.2	JJ	O
]	NN	O
for	IN	O
subjects	NNS	O
with	IN	O
atrophy	NN	O
and	CC	O
5.4	CD	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.7-17.6	JJ	O
]	NN	O
for	IN	O
subjects	NNS	O
with	IN	O
intestinal	JJ	O
metaplasia	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
the	DT	O
very	RB	O
high-risk	JJ	O
population	NN	O
studied	VBN	O
,	,	O
effective	JJ	O
anti-H.	JJ	O
pylori	NN	O
treatment	NN	O
and	CC	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
antioxidant	JJ	O
micronutrients	NNS	O
may	MD	O
interfere	VB	O
with	IN	O
the	DT	O
precancerous	JJ	O
process	NN	O
,	,	O
mostly	RB	O
by	IN	O
increasing	VBG	O
the	DT	O
rate	NN	O
of	IN	O
regression	NN	O
of	IN	O
cancer	NN	O
precursor	NN	O
lesions	NNS	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
strategy	NN	O
to	TO	O
prevent	VB	O
gastric	JJ	O
carcinoma	NN	O
.	.	O

Processing	VBG	O
familiar	JJ	O
and	CC	O
unfamiliar	JJ	O
auditory	NN	O
stimuli	NN	O
during	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

We	PRP	O
tested	VBD	O
memory	NN	O
priming	NN	O
for	IN	O
auditory	JJ	E
stimuli	NNS	E
presented	VBN	O
during	IN	O
general	JJ	PH
propofol-sufentanil	JJ	PH
anesthesia	NN	PH
in	IN	O
58	CD	O
patients	NNS	O
undergoing	JJ	O
day-case	JJ	S
arthroscopic	NN	S
surgery	NN	S
.	.	O

Stimuli	NNP	E
were	VBD	E
presented	VBN	E
via	IN	E
headphones	NNS	E
and	CC	E
consisted	VBN	E
of	IN	E
common	JJ	E
facts	NNS	E
(	(	O
Group	NNP	O
A	NNP	O
,	,	O
29	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
familiar	JJ	E
or	CC	E
unfamiliar	JJ	E
full	JJ	E
names	NNS	E
of	IN	E
fictitious	JJ	E
people	NNS	E
(	(	O
GRoup	NNP	O
B	NNP	O
,	,	O
29	CD	O
patients	NNS	O
)	)	O
.	.	O

Group	NNP	O
A	NNP	O
was	VBD	O
expected	VBN	O
to	TO	O
give	VB	O
more	JJR	O
correct	JJ	O
answers	NNS	O
to	TO	O
questions	NNS	O
about	IN	O
the	DT	O
common	JJ	O
facts	NNS	O
than	IN	O
Group	NNP	O
B	NNP	O
,	,	O
when	WRB	O
tested	VBN	O
postoperatively	RB	O
,	,	O
and	CC	O
Group	NNP	O
B	NNP	O
to	TO	O
attribute	VB	O
more	JJR	O
fame	NN	O
to	TO	O
presented	VBN	O
names	NNS	O
than	IN	O
Group	NNP	O
A	NNP	O
(	(	O
famous	JJ	O
names	RB	O
test	NN	O
)	)	O
.	.	O

Because	IN	O
the	DT	O
process	NN	O
for	IN	O
learning	VBG	O
new	JJ	O
or	CC	O
unfamiliar	JJ	O
stimuli	NNS	O
(	(	O
elaboration	NN	O
)	)	O
in	IN	O
particular	JJ	O
may	MD	O
be	VB	O
impaired	VBN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
,	,	O
more	JJR	O
memory	NN	O
priming	NN	O
was	VBD	O
expected	VBN	O
for	IN	O
familiar	JJ	O
than	IN	O
for	IN	O
unfamiliar	JJ	O
material	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
demonstrated	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
performance	NN	O
on	IN	O
common	JJ	O
facts	NNS	O
or	CC	O
in	IN	O
fame	NN	O
attributed	VBN	O
to	TO	O
the	DT	O
names	NNS	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
memory	NN	O
priming	NN	O
,	,	O
however	RB	O
,	,	O
was	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
measures	NNS	O
of	IN	O
preoperative	JJ	O
anxiety	NN	O
.	.	O

Double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
secretin	NN	PM
:	:	PM
effects	NNS	O
on	IN	O
aberrant	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Secretin	NNP	PM
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
treatment	NN	O
alternative	NN	O
for	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
,	,	O
but	CC	O
empirical	JJ	O
support	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	PM
human	JJ	PM
secretin	NN	PM
on	IN	O
aberrant	JJ	O
behavior	NN	O
.	.	O

Parent	NN	O
and	CC	O
teacher	NN	O
data	NNS	O
from	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
for	IN	O
eight	CD	O
male	JJ	O
children	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
reliable	JJ	O
change	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
replication	NN	O
series	NN	O
.	.	O

By	IN	O
parent	NN	O
and	CC	O
teacher	NN	O
report	NN	O
,	,	O
the	DT	O
majority	NN	O
of	IN	O
change	NN	O
occurred	VBD	O
either	CC	O
on	IN	O
the	DT	O
placebo	NN	C
trial	NN	O
or	CC	O
reflected	VBN	O
deterioration	NN	O
subsequent	NN	O
to	TO	O
secretin	VB	PM
infusion	NN	O
.	.	O

Repeated-measures	JJ	O
multivariate	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
results	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

Results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
other	JJ	O
studies	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
secretin	NN	PM
may	MD	O
not	RB	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
option	NN	O
.	.	O

Amphotericin	NNP	PM
versus	NN	O
pentamidine	NN	PM
in	IN	O
antimony-unresponsive	JJ	O
kala-azar	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
amphotericin	NN	PM
B	NNP	PM
and	CC	O
pentamidine	JJ	PM
isethionate	NN	PM
in	IN	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
trial	NN	O
in	IN	O
120	CD	O
uncomplicated	JJ	O
and	CC	O
parasitologically	RB	O
confirmed	VBN	O
cases	NNS	O
of	IN	O
antimony-unresponsive	JJ	O
kala-azar	NN	O
.	.	O

Doses	NNS	O
were	VBD	O
twenty	JJ	O
intramuscular	JJ	O
injections	NNS	O
of	IN	O
pentamidine	NN	PM
4	CD	O
mg/kg	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
or	CC	O
fourteen	JJ	O
definitive	JJ	O
doses	NNS	O
of	IN	O
amphotericin	JJ	PM
0.5	CD	O
mg/kg	NN	O
infused	VBN	O
in	IN	O
5	CD	O
%	NN	O
dextrose	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
.	.	O

48	CD	O
(	(	O
80	CD	O
%	NN	O
)	)	O
patients	NNS	O
given	VBN	O
pentamidine	VBP	PM
showed	VBN	O
initial	JJ	O
cure	NN	O
and	CC	O
46	CD	O
(	(	O
77	CD	O
%	NN	O
)	)	O
showed	VBD	O
definitive	JJ	O
cure	NN	O
compared	VBN	O
with	IN	O
60	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
and	CC	O
59	CD	O
(	(	O
98	CD	O
%	NN	O
)	)	O
cases	NNS	O
,	,	O
respectively	RB	O
,	,	O
on	IN	O
amphotericin	NN	PM
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Amphotericin	NNP	PM
also	RB	O
brought	VBD	O
about	RB	O
quicker	JJR	O
abatement	NN	O
of	IN	O
fever	NN	O
and	CC	O
more	JJR	O
complete	JJ	O
spleen	JJ	O
regression	NN	O
.	.	O

Arthroscopic	NNP	S
rotator	NN	S
cuff	NN	S
repair	NN	S
with	IN	S
and	CC	O
without	IN	PH
acromioplasty	NN	PH
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
full-thickness	JJ	O
rotator	NN	O
cuff	NN	O
tears	NNS	O
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
to	TO	O
compare	VB	O
functional	JJ	O
and	CC	O
quality-of-life	JJ	O
indices	NNS	O
and	CC	O
rates	NNS	O
of	IN	O
revision	NN	O
surgery	NN	O
in	IN	O
arthroscopic	NN	S
rotator	NN	S
cuff	NN	S
repair	NN	S
with	IN	S
and	CC	O
without	IN	PH
acromioplasty	JJ	PH
.	.	O

METHODS	NNP	O
Eighty-six	JJ	O
patients	NNS	O
consented	VBN	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
intraoperatively	RB	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
study	NN	O
groups	NNS	O
,	,	O
and	CC	O
sixty-eight	NN	O
of	IN	O
them	PRP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
Western	JJ	O
Ontario	NNP	O
Rotator	NNP	O
Cuff	NNP	O
(	(	O
WORC	NNP	O
)	)	O
index	NN	O
.	.	O

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
included	VBD	O
the	DT	O
American	JJ	O
Shoulder	NNP	O
and	CC	O
Elbow	NNP	O
Surgeons	NNP	O
(	(	O
ASES	NNP	O
)	)	O
shoulder	NN	O
assessment	JJ	O
form	NN	O
and	CC	O
a	DT	O
count	NN	O
of	IN	O
revisions	NNS	O
required	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
were	VBD	O
completed	VBN	O
preoperatively	RB	O
and	CC	O
at	IN	O
three	CD	O
,	,	O
six	CD	O
,	,	O
twelve	NN	O
,	,	O
eighteen	NN	O
,	,	O
and	CC	O
twenty-four	JJ	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

RESULTS	NNP	O
WORC	NNP	O
and	CC	O
ASES	NNP	O
scores	VBZ	O
improved	VBN	O
significantly	RB	O
in	IN	O
each	DT	O
group	NN	O
over	IN	O
time	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
WORC	NNP	O
or	CC	O
ASES	NNP	O
scores	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	S
cuff	JJ	S
repair	NN	S
with	IN	S
or	CC	O
without	IN	PH
acromioplasty	JJ	PH
at	IN	O
any	DT	O
time	NN	O
point	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
scores	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
acromion	NN	O
type	NN	O
,	,	O
nor	CC	O
were	VBD	O
any	DT	O
interaction	NN	O
effects	NNS	O
identified	VBN	O
between	IN	O
group	NN	O
and	CC	O
acromion	NN	O
type	NN	O
.	.	O

Four	CD	O
participants	NNS	O
(	(	O
9	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	PH
cuff	JJ	PH
repair	NN	PH
alone	RB	O
,	,	O
one	CD	O
with	IN	O
a	DT	O
Type-2	JJ	O
and	CC	O
three	CD	O
with	IN	O
a	DT	O
Type-3	JJ	O
acromion	NN	O
,	,	O
required	VBN	O
additional	JJ	O
surgery	NN	O
by	IN	O
the	DT	O
twenty-four-month	JJ	O
time	NN	O
point	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
required	VBD	O
additional	JJ	O
surgery	NN	O
was	VBD	O
greater	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
alone	RB	O
than	IN	O
in	IN	O
the	DT	O
group	NN	O
that	WDT	O
had	VBD	O
arthroscopic	VBN	O
cuff	JJ	O
repair	NN	O
and	CC	O
acromioplasty	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
previous	JJ	O
research	NN	O
reports	NNS	O
in	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
functional	JJ	O
and	CC	O
quality-of-life	JJ	O
indices	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
rotator	NN	O
cuff	NN	O
repair	NN	O
with	IN	O
or	CC	O
without	IN	O
acromioplasty	JJ	O
.	.	O

The	DT	O
higher	JJR	O
reoperation	NN	O
rate	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
group	NN	O
without	IN	O
acromioplasty	NN	O
.	.	O

Further	CC	O
study	NN	O
that	WDT	O
includes	VBZ	O
follow-up	JJ	O
imaging	NN	O
and	CC	O
patient-reported	JJ	O
outcomes	NNS	O
over	IN	O
a	DT	O
greater	JJR	O
follow-up	JJ	O
period	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
combination	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
(	(	O
gamma	NN	PM
linolenic	RB	PM
acid	NN	PM
)	)	O
and	CC	O
fish	JJ	O
oil	NN	O
(	(	O
eicosapentaenoic	JJ	PM
+	NNP	PM
docahexaenoic	NN	PM
acid	NN	PM
)	)	O
versus	NN	O
magnesium	NN	PM
,	,	O
and	CC	O
versus	NN	O
placebo	NN	C
in	IN	O
preventing	VBG	O
pre-eclampsia	NN	O
.	.	O

In	IN	O
a	DT	O
placebo	NN	C
controlled	VBN	O
,	,	O
partially	RB	O
double-blinded	JJ	O
,	,	O
clinical	JJ	O
trial	NN	O
,	,	O
a	DT	O
combination	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
and	CC	O
fish	JJ	O
oil	NN	O
was	VBD	O
compared	VBN	O
to	TO	O
Magnesium	NNP	PM
Oxide	NNP	PM
,	,	O
and	CC	O
to	TO	O
a	DT	O
Placebo	NNP	C
in	IN	O
preventing	VBG	O
Pre-Eclampsia	NNP	O
of	IN	O
Pregnancy	NNP	O
.	.	O

All	DT	O
were	VBD	O
given	VBN	O
as	IN	O
nutritional	JJ	O
supplements	NNS	O
for	IN	O
six	CD	O
months	NNS	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
primiparous	JJ	O
and	CC	O
multiparous	JJ	O
pregnant	JJ	O
women	NNS	O
.	.	O

Some	DT	O
of	IN	O
these	DT	O
women	NNS	O
had	VBD	O
personal	JJ	O
or	CC	O
family	NN	O
histories	NNS	O
of	IN	O
hypertension	NN	O
(	(	O
21	CD	O
%	NN	O
)	)	O
.	.	O

Only	RB	O
those	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
prenatal	JJ	O
care	NN	O
at	IN	O
the	DT	O
Central	NNP	O
Maternity	NNP	O
Hospital	NNP	O
for	IN	O
Luanda	NNP	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
Placebo	NNP	C
group	NN	O
(	(	O
29	CD	O
%	NN	O
)	)	O
,	,	O
the	DT	O
group	NN	O
receiving	VBG	O
the	DT	O
mixture	NN	O
of	IN	O
evening	VBG	PM
primrose	JJ	PM
oil	NN	PM
and	CC	O
fish	JJ	PM
oil	NN	PM
containing	VBG	O
Gamma-linolenic	JJ	PM
acid	NN	PM
(	(	PM
GLA	NNP	PM
)	)	PM
,	,	O
Eicosapentaenoic	NNP	PM
acid	NN	PM
(	(	PM
EPA	NNP	PM
)	)	PM
,	,	O
and	CC	O
Docosahexaenoic	NNP	PM
acid	NN	PM
(	(	PM
DHA	NNP	PM
)	)	PM
had	VBD	O
a	DT	O
significantly	RB	O
lower	JJR	O
incidence	NN	O
of	IN	O
edema	NN	O
(	(	O
13	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
group	NN	O
receiving	VBG	O
Magnesium	NNP	PM
Oxide	NNP	PM
had	VBD	O
statistically	RB	O
significant	JJ	O
fewer	JJR	O
subjects	NNS	O
who	WP	O
developed	VBD	O
hypertension	NN	O
of	IN	O
pregnancy	NN	O
.	.	O

There	EX	O
were	VBD	O
3	CD	O
cases	NNS	O
of	IN	O
eclampsia	NN	O
,	,	O
all	DT	O
in	IN	O
the	DT	O
Placebo	NNP	C
group	NN	O
.	.	O

Successful	JJ	O
new	JJ	O
method	NN	O
of	IN	O
extracorporeal	JJ	S
percutaneous	JJ	S
endoscopic	NN	S
gastrostomy	NN	S
(	(	S
E-PEG	NNP	S
)	)	S
.	.	S

BACKGROUND	NNP	O
Although	IN	O
percutaneous	JJ	S
endoscopic	NNS	S
gastrostomy	NN	S
(	(	S
PEG	NNP	S
)	)	S
has	VBZ	O
become	VBN	O
popular	JJ	O
for	IN	O
patients	NNS	O
with	IN	O
swallowing	VBG	O
disorders	NNS	O
as	IN	O
a	DT	O
nutrition	NN	O
support	NN	O
or	CC	O
a	DT	O
decompressant	NN	O
of	IN	O
gastrointestine	NN	O
,	,	O
perioperative	JJ	O
complications	NNS	O
associated	VBN	O
with	IN	O
PEG	NNP	S
have	VBP	O
not	RB	O
decreased	VBN	O
,	,	O
especially	RB	O
peristomal	JJ	O
infections	NNS	O
.	.	O

To	TO	O
reduce	VB	O
peristomal	JJ	O
infections	NNS	O
,	,	O
we	PRP	O
designed	VBD	O
a	DT	O
new	JJ	O
method	NN	O
of	IN	O
gastrostomy	NN	O
by	IN	O
extracorporeal	JJ	O
approach	NN	O
under	IN	O
endoscopic	JJ	O
observation	NN	O
,	,	O
named	VBN	O
as	IN	O
extra-corporeal	JJ	S
PEG	NNP	S
(	(	S
E-PEG	NNP	S
)	)	S
.	.	O

METHODS	NNP	O
Experimental	NNP	O
studies	NNS	O
for	IN	O
E-PEG	NNP	S
were	VBD	O
performed	VBN	O
repeatedly	RB	O
using	VBG	O
pigs	NNS	O
under	IN	O
general	JJ	O
anesthesia	NN	PM
to	TO	O
confirm	VB	O
the	DT	O
safety	NN	O
of	IN	O
its	PRP$	O
procedure	NN	O
for	IN	O
human	JJ	O
use	NN	O
.	.	O

After	IN	O
approval	NN	O
of	IN	O
institutional	JJ	O
ethics	NNS	O
review	VBP	O
board	NN	O
in	IN	O
our	PRP$	O
university	NN	O
,	,	O
thirty	JJ	O
patients	NNS	O
with	IN	O
prior	JJ	O
consent	NN	O
participated	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

The	DT	O
operation	NN	O
time	NN	O
,	,	O
the	DT	O
incidence	NN	O
rate	NN	O
of	IN	O
complications	NNS	O
and	CC	O
the	DT	O
hospital	NN	O
stay	NN	O
were	VBD	O
compared	VBN	O
between	IN	O
E-PEG	NNP	S
and	CC	S
ordinary	JJ	S
pull-method	JJ	S
PEG	NNP	S
groups	NNS	S
.	.	O

RESULTS	NNP	O
Two	CD	O
patients	NNS	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
in	IN	O
E-PEG	NNP	S
group	NN	O
had	VBD	O
postoperative	JJ	O
complications	NNS	O
,	,	O
i.e.	FW	O
,	,	O
aspiration	NN	O
pneumonia	NN	O
and	CC	O
surgical	JJ	O
site	NN	O
infection	NN	O
.	.	O

The	DT	O
operation	NN	O
time	NN	O
of	IN	O
E-PEG	NNP	S
group	NN	O
was	VBD	O
5-16	JJ	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
10.3	CD	O
+/-	JJ	O
2.96	CD	O
)	)	O
min	NN	O
as	IN	O
compared	VBN	O
to	TO	O
14-37	JJ	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
26.9	CD	O
+/-	JJ	O
8.39	CD	O
)	)	O
min	NN	O
with	IN	O
pull-method	JJ	O
PEG	NNP	S
.	.	O

The	DT	O
postoperative	JJ	O
hospital	NN	O
day	NN	O
of	IN	O
E-PEG	NNP	S
was	VBD	O
within	IN	O
two	CD	O
days	NNS	O
except	IN	O
for	IN	O
the	DT	O
two	CD	O
complicated	VBD	O
cases	NNS	O
.	.	O

Significance	NNP	O
differences	NNS	O
of	IN	O
operation	NN	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
and	CC	O
postoperative	JJ	O
hospital	NN	O
stay	NN	O
between	IN	O
those	DT	O
groups	NNS	O
observed	VBD	O
statistically	RB	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
E-PEG	NNP	S
was	VBD	O
safe	JJ	O
,	,	O
tolerable	JJ	O
and	CC	O
speedy	NN	O
when	WRB	O
compared	VBN	O
ordinary	JJ	O
pull-method	JJ	O
PEG	NNP	S
.	.	O

Sustained	JJ	O
effect	NN	O
of	IN	O
SQ-standardized	NNP	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	PM
tablet	NN	PM
on	IN	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
prevalence	NN	O
of	IN	O
allergic	JJ	O
rhinoconjunctivitis	NN	O
has	VBZ	O
increased	VBN	O
significantly	RB	O
over	IN	O
the	DT	O
past	JJ	O
decades	NNS	O
with	IN	O
grass	NN	O
pollen	NN	O
being	VBG	O
a	DT	O
common	JJ	O
trigger	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
allergy	NN	O
on	IN	O
patient	NN	O
's	POS	O
quality	NN	O
of	IN	O
life	NN	O
is	VBZ	O
substantial	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
sustained	JJ	O
effect	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
during	IN	O
the	DT	O
grass	NN	O
pollen	NN	O
season	NN	O
1	CD	O
year	NN	O
after	IN	O
3	CD	O
years	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
the	DT	O
SQ-standardized	JJ	O
grass	NN	PM
allergy	NN	PM
immunotherapy	NN	PM
tablet	NN	PM
(	(	PM
AIT	NNP	PM
)	)	PM
,	,	O
Graza	NNP	O
(	(	O
Phleum	NNP	O
pratense	VBZ	O
75,000	CD	O
SQ-T/2800	JJ	O
BAU	NNP	O
;	:	O
ALK	NNP	O
,	,	O
Denmark	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
adult	NN	O
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
moderate-severe	JJ	O
grass	NN	O
pollen	NN	O
induced	VBD	O
rhinoconjunctivitis	NN	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
.	.	O

Subjects	NNS	O
received	VBD	O
3	CD	O
years	NNS	O
of	IN	O
grass	NN	PM
AIT	NNP	PM
(	(	O
n	JJ	O
=	NNP	O
157	CD	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
126	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
1	CD	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
assessments	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
the	DT	O
standardized	JJ	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
questionnaire	NN	O
(	(	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
)	)	O
;	:	O
completed	VBN	O
weekly	JJ	O
during	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
follow-up	JJ	O
,	,	O
the	DT	O
overall	JJ	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
score	NN	O
for	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
(	(	O
relative	JJ	O
difference	NN	O
to	TO	O
placebo	VB	O
:	:	O
23	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
improvement	NN	O
was	VBD	O
higher	JJR	O
during	IN	O
the	DT	O
peak	NN	O
pollen	NN	O
season	NN	O
(	(	O
28	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
effect	NN	O
of	IN	O
grass	NN	O
AIT	NNP	O
during	IN	O
the	DT	O
follow-up	JJ	O
year	NN	O
and	CC	O
the	DT	O
previous	JJ	O
three	CD	O
treatment	NN	O
years	NNS	O
was	VBD	O
similar	JJ	O
.	.	O

Improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
all	DT	O
seven	CD	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
domains	VBZ	O
.	.	O

The	DT	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
weekly	JJ	O
average	NN	O
pollen	NN	O
counts	VBZ	O
showed	VBD	O
a	DT	O
clear	JJ	O
separation	NN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
subjects	NNS	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
,	,	O
grass	NN	O
AIT	NNP	PM
provided	VBD	O
sustained	VBN	O
and	CC	O
clinically	RB	O
relevant	JJ	O
improvements	NNS	O
in	IN	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
effect	NN	O
increased	VBD	O
with	IN	O
increasing	VBG	O
grass	NN	O
pollen	NN	O
exposure	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
duration	NN	O
on	IN	O
defibrillation	NN	O
efficacy	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
prospectively	RB	O
investigate	VB	O
the	DT	O
influence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
(	(	O
VF	NNP	O
)	)	O
durations	NNS	O
of	IN	O
5	CD	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
s	NN	O
on	IN	O
the	DT	O
defibrillation	NN	O
threshold	NN	O
(	(	O
DFT	NNP	O
)	)	O
during	IN	O
implantable	JJ	O
cardioverter-defibrillator	NN	O
(	(	O
ICD	NNP	O
)	)	O
implantation	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
the	DT	O
DFT	NNP	O
using	VBG	O
monophasic	JJ	O
waveforms	NNS	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
with	IN	O
VF	NNP	O
duration	NN	O
in	IN	O
humans	NNS	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
VF	NNP	O
duration	NN	O
on	IN	O
defibrillation	NN	O
efficacy	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
undergoing	VBG	O
primary	JJ	O
ICD	NNP	O
implantation	NN	O
or	CC	O
pulse	JJ	O
generator	NN	O
replacement	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
have	VB	O
the	DT	O
DFT	NNP	PH
determined	VBD	PH
using	VBG	PH
biphasic	JJ	PH
shocks	NNS	PH
at	IN	O
two	CD	O
durations	NNS	O
of	IN	O
VF	NNP	PH
each	DT	O
(	(	O
5	CD	O
and	CC	O
10	CD	O
s	NN	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
s	NN	O
or	CC	O
5	CD	O
and	CC	O
20	CD	O
s	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
mean	JJ	O
DFT	NNP	O
comparing	VBG	O
VF	NNP	O
durations	NNS	O
of	IN	O
5	CD	O
s	NNS	O
(	(	O
9.5+/-6.0	CD	O
J	NNP	O
)	)	O
and	CC	O
10	CD	O
s	NN	O
(	(	O
10.8+/-7.0	JJ	O
J	NNP	O
)	)	O
(	(	O
p=0.4	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
DFT	NNP	O
significantly	RB	O
increased	VBD	O
from	IN	O
10.9+/-6.1	JJ	O
J	NNP	O
at	IN	O
10	CD	O
s	NN	O
of	IN	O
VF	NNP	O
to	TO	O
12.6+/-5.6	JJ	O
J	NNP	O
(	(	O
p=0.03	NN	O
)	)	O
at	IN	O
20	CD	O
s	NN	O
of	IN	O
VF	NNP	O
,	,	O
and	CC	O
from	IN	O
7.0+/-3.5	JJ	O
J	NNP	O
at	IN	O
5	CD	O
s	NN	O
of	IN	O
VF	NNP	O
to	TO	O
10.5+/-6.3	JJ	O
J	NNP	O
(	(	O
p=0.04	NN	O
)	)	O
at	IN	O
20	CD	O
s	NN	O
of	IN	O
VF	NNP	O
.	.	O

An	DT	O
increase	NN	O
in	IN	O
the	DT	O
DFT	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
14	CD	O
patients	NNS	O
as	IN	O
VF	NNP	O
duration	NN	O
increased	VBD	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
clinical	JJ	O
characteristics	NNS	O
that	WDT	O
differentiated	VBD	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
DFT	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Defibrillation	NNP	O
efficacy	NN	O
decreases	VBZ	O
with	IN	O
increasing	VBG	O
VF	NNP	O
duration	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
.	.	O

Ventricular	JJ	O
fibrillation	NN	O
durations	NNS	O
greater	JJR	O
than	IN	O
10	CD	O
s	NN	O
may	MD	O
negatively	RB	O
affect	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
ICD	NNP	O
therapy	NN	O
.	.	O

Intermittent	NNP	PH
recombinant	JJ	PH
growth	NN	PH
hormone	NN	PH
treatment	NN	PH
in	IN	O
short	JJ	O
children	NNS	O
born	VBP	O
small	JJ	O
for	IN	O
gestational	JJ	O
age	NN	O
:	:	O
four-year	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
two	CD	O
different	JJ	O
treatment	NN	O
regimens	NNS	O
.	.	O

BACKGROUND	NNP	O
Treatment	NNP	O
of	IN	O
short	JJ	O
children	NNS	O
born	VBP	O
small	JJ	O
for	IN	O
gestational	JJ	O
age	NN	O
SGA	NNP	O
with	IN	O
recombinant	JJ	PM
human	JJ	PM
growth	NN	PM
hormone	VBD	PM
r-hGH	JJ	PM
increases	NNS	O
growth	NN	O
velocity	NN	O
during	IN	O
childhood	NN	O
.	.	O

As	IN	O
in	IN	O
other	JJ	O
indications	NNS	O
,	,	O
the	DT	O
growth	NN	O
velocity	NN	O
in	IN	O
these	DT	O
patients	NNS	O
is	VBZ	O
more	JJR	O
marked	JJ	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
treatment	NN	O
and	CC	O
then	RB	O
decreases	VBZ	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
different	JJ	O
r-hGH	JJ	O
treatment	NN	O
schedules	NNS	O
(	(	O
67	CD	O
microg/kg/day	NN	O
in	IN	O
a	DT	O
discontinuous	JJ	O
or	CC	O
continuous	JJ	O
regimen	NNS	O
)	)	O
during	IN	O
the	DT	O
second	JJ	O
year	NN	O
of	IN	O
r-hGH	JJ	O
treatment	NN	O
by	IN	O
comparing	VBG	O
height	JJ	O
velocity	NN	O
changes	NNS	O
and	CC	O
total	JJ	O
gain	NN	O
of	IN	O
height	NN	O
over	IN	O
a	DT	O
4-year	JJ	O
period	NN	O
.	.	O

METHODS	$	O
58	CD	O
growth-retarded	JJ	O
SGA	NNP	O
children	NNS	O
aged	VBN	O
2-5	CD	O
years	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
TOTO	NNP	PM
regimen	NN	PM
(	(	O
4	CD	O
years	NNS	O
alternating	VBG	O
treatment	NN	O
(	(	O
T	NNP	O
)	)	O
and	CC	O
observation	NN	O
(	(	O
O	NNP	O
)	)	O
,	,	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
or	CC	O
a	DT	O
TTOO	JJ	O
regimen	NN	O
(	(	O
2	CD	O
years	NNS	O
'	POS	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	O
years	NNS	O
'	POS	O
observation	NN	O
,	,	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
.	.	O

Height	NNP	O
velocity	NN	O
HV	NNP	O
and	CC	O
total	JJ	O
height	NN	O
gain	NN	O
were	VBD	O
assessed	VBN	O
during	IN	O
the	DT	O
4-year	JJ	O
study	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
both	DT	O
groups	NNS	O
,	,	O
HV	NNP	O
and	CC	O
HV	NNP	O
standard	JJ	O
deviation	NN	O
score	VBD	O
HV-SDSCA	NNP	O
increased	VBD	O
during	IN	O
treatment	NN	O
and	CC	O
decreased	VBD	O
during	IN	O
observation	NN	O
periods	NNS	O
.	.	O

Interruption	NN	O
of	IN	O
treatment	NN	O
in	IN	O
the	DT	O
TOTO	NNP	O
group	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
a	DT	O
better	JJR	O
gain	NN	O
in	IN	O
height	JJ	O
standard	NN	O
deviation	NN	O
score	VBD	O
H-SDSCA	NNP	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
TTOO	NNP	O
group	NN	O
.	.	O

After	IN	O
4	CD	O
years	NNS	O
of	IN	O
study	NN	O
,	,	O
the	DT	O
gain	NN	O
in	IN	O
H-SDSCA	NNP	O
was	VBD	O
1.4	CD	O
+	NN	O
or	CC	O
-	:	O
01	CD	O
in	IN	O
the	DT	O
TOTO	NNP	O
group	NN	O
and	CC	O
1.6	CD	O
+	NN	O
or	CC	O
-	:	O
0.2	CD	O
in	IN	O
the	DT	O
TTOO	NNP	O
group	NN	O
leading	VBG	O
to	TO	O
a	DT	O
mean	JJ	O
height	NN	O
of	IN	O
-2.0	NNP	O
+	NNP	O
or	CC	O
-	:	O
1.0	CD	O
SDS	NNP	O
and	CC	O
-2.0	NNP	O
+	NNP	O
or	CC	O
-	:	O
0.8	CD	O
SDS	NNP	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
bone	NN	O
maturation	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
short	JJ	O
SGA	NNP	O
children	NNS	O
,	,	O
TOTO	NNP	PM
and	CC	O
TTOO	NNP	PM
regimens	NNS	O
produced	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
growth	NN	O
during	IN	O
r-hGH	JJ	PH
treatment	NN	PH
.	.	O

However	RB	O
,	,	O
treatment	NN	O
interruption	NN	O
after	IN	O
1	CD	O
year	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
overall	JJ	O
gain	NN	O
in	IN	O
height	NN	O
SDS	NNP	O
when	WRB	O
compared	VBN	O
with	IN	O
2	CD	O
years	NNS	O
'	POS	O
continuous	JJ	O
treatment	NN	O
.	.	O

Enhancing	VBG	O
implementation	NN	O
of	IN	O
tobacco	NN	E
use	NN	E
prevention	NN	E
and	CC	E
cessation	NN	E
counselling	VBG	E
guideline	NN	E
among	IN	O
dental	JJ	O
providers	NNS	O
:	:	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Tobacco	NNP	O
use	NN	O
adversely	RB	O
affects	VBZ	O
oral	JJ	O
health	NN	O
.	.	O

Tobacco	NNP	E
use	NN	E
prevention	NN	E
and	CC	E
cessation	NN	E
(	(	E
TUPAC	NNP	E
)	)	E
counselling	VBG	E
guidelines	NNS	E
recommend	VBP	O
that	IN	O
healthcare	NN	O
providers	NNS	O
ask	VBP	O
about	IN	O
each	DT	O
patient	NN	O
's	POS	O
tobacco	NN	O
use	NN	O
,	,	O
assess	IN	O
the	DT	O
patient	NN	O
's	POS	O
readiness	NN	O
and	CC	O
willingness	NN	O
to	TO	O
stop	VB	O
,	,	O
document	NN	O
tobacco	NN	O
use	NN	O
habits	NNS	O
,	,	O
advise	VBP	O
the	DT	O
patient	NN	O
to	TO	O
stop	VB	O
,	,	O
assist	NN	O
and	CC	O
help	NN	O
in	IN	O
quitting	NN	O
,	,	O
and	CC	O
arrange	JJ	O
monitoring	NN	O
of	IN	O
progress	NN	O
at	IN	O
follow-up	JJ	O
appointments	NNS	O
.	.	O

Adherence	NN	O
to	TO	O
such	JJ	O
guidelines	NNS	O
,	,	O
especially	RB	O
among	IN	O
dental	JJ	O
providers	NNS	O
,	,	O
is	VBZ	O
poor	JJ	O
.	.	O

To	TO	O
improve	VB	O
guideline	NN	O
implementation	NN	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
to	TO	O
understand	VB	O
factors	NNS	O
influencing	VBG	O
it	PRP	O
and	CC	O
find	VB	O
effective	JJ	O
ways	NNS	O
to	TO	O
influence	VB	O
those	DT	O
factors	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
protocol	NN	O
is	VBZ	O
to	TO	O
introduce	VB	O
a	DT	O
theory-based	JJ	E
approach	NN	E
to	TO	E
diagnose	VB	E
implementation	NN	E
difficulties	NNS	E
of	IN	E
TUPAC	NNP	E
counselling	VBG	E
guidelines	NNS	E
among	IN	E
dental	JJ	E
providers	NNS	E
.	.	E

METHODS	NNP	O
Theories	NNPS	O
of	IN	O
behaviour	NN	O
change	NN	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
identify	VB	O
key	JJ	O
theoretical	JJ	O
domains	NNS	O
relevant	VBP	O
to	TO	O
the	DT	O
behaviours	NN	O
of	IN	O
healthcare	JJ	O
providers	NNS	O
involved	VBN	O
in	IN	O
implementing	VBG	O
clinical	JJ	O
guidelines	NNS	O
.	.	O

These	DT	O
theoretical	JJ	O
domains	NNS	O
will	MD	O
inform	VB	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
questionnaire	NN	O
aimed	VBN	O
at	IN	O
assessing	VBG	O
the	DT	O
implementation	NN	O
of	IN	O
the	DT	O
TUPAC	NNP	E
counselling	VBG	E
guidelines	NNS	E
among	IN	O
Finnish	JJ	O
municipal	JJ	O
dental	JJ	O
providers	NNS	O
.	.	O

Specific	JJ	O
items	NNS	O
will	MD	O
be	VB	O
drawn	VBN	O
from	IN	O
the	DT	O
guidelines	NNS	O
and	CC	O
the	DT	O
literature	NN	O
on	IN	O
TUPAC	NNP	E
studies	NNS	O
.	.	O

After	IN	O
identifying	VBG	O
potential	JJ	O
implementation	NN	O
difficulties	NNS	O
,	,	O
we	PRP	O
will	MD	O
design	VB	O
two	CD	O
interventions	NNS	O
using	VBG	O
theories	NNS	E
of	IN	E
behaviour	JJ	E
change	NN	E
to	TO	O
link	VB	O
them	PRP	O
with	IN	O
relevant	JJ	O
behaviour	NN	O
change	NN	O
techniques	NNS	O
aiming	VBG	O
to	TO	O
improve	VB	O
guideline	NN	E
adherence	NN	E
.	.	E

For	IN	O
assessing	VBG	O
the	DT	O
implementation	NN	O
of	IN	O
TUPAC	NNP	E
guidelines	NNS	E
,	,	O
the	DT	O
electronic	JJ	O
dental	NN	O
record	NN	O
audit	NN	O
and	CC	O
self-reported	JJ	O
questionnaires	NNS	O
will	MD	O
be	VB	O
used	VBN	O
.	.	O

DISCUSSION	NNP	O
To	TO	O
improve	VB	O
guideline	NN	O
adherence	NN	O
,	,	O
the	DT	O
theoretical-domains	NNS	O
approach	NN	O
could	MD	O
provide	VB	O
a	DT	O
comprehensive	JJ	O
basis	NN	O
for	IN	O
assessing	VBG	O
implementation	NN	O
difficulties	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
designing	VBG	O
and	CC	O
evaluating	VBG	O
interventions	NNS	O
.	.	O

After	IN	O
having	VBG	O
identified	VBN	O
implementation	NN	O
difficulties	NNS	O
,	,	O
we	PRP	O
will	MD	O
design	VB	O
and	CC	O
test	VB	O
two	CD	O
interventions	NNS	O
to	TO	O
enhance	VB	O
TUPAC	NNP	E
guideline	JJ	E
adherence	NN	O
.	.	O

Using	VBG	O
the	DT	O
cluster	NN	O
randomised	VBD	O
controlled	JJ	O
design	NN	O
,	,	O
we	PRP	O
aim	VBP	O
to	TO	O
provide	VB	O
further	JJ	O
evidence	NN	O
on	IN	O
intervention	NN	O
effects	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
on	IN	O
the	DT	O
validity	NN	O
and	CC	O
feasibility	NN	O
of	IN	O
the	DT	O
theoretical-domain	JJ	O
approach	NN	O
.	.	O

The	DT	O
empirical	JJ	O
data	NNS	O
collected	VBN	O
within	IN	O
this	DT	O
trial	NN	O
will	MD	O
be	VB	O
useful	JJ	O
in	IN	O
testing	VBG	O
whether	IN	O
this	DT	O
theoretical-domain	JJ	E
approach	NN	E
can	MD	O
improve	VB	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
implementation	NN	O
of	IN	O
TUPAC	NNP	E
guidelines	NNS	E
among	IN	O
dental	JJ	O
providers	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
ISRCTN15427433	NNP	O
.	.	O

Impact	NN	O
of	IN	O
prior	JJ	O
pharmacotherapy	NN	PM
on	IN	O
remission	NN	O
of	IN	O
psychotic	JJ	O
depression	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Having	VBG	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
an	DT	O
adequate	JJ	O
antidepressant	JJ	O
treatment	NN	O
course	NN	O
predicts	VBZ	O
poorer	JJR	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
major	JJ	O
depression	NN	O
.	.	O

However	RB	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
impact	NN	O
of	IN	O
prior	JJ	O
treatment	NN	O
on	IN	O
the	DT	O
outcome	NN	O
of	IN	O
major	JJ	O
depression	NN	O
with	IN	O
psychotic	JJ	O
features	NNS	O
(	(	O
MDpsy	NNP	O
)	)	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
prior	JJ	O
treatment	NN	O
history	NN	O
on	IN	O
the	DT	O
outcome	NN	O
of	IN	O
pharmacotherapy	NN	PM
of	IN	O
MDpsy	NNP	O
in	IN	O
patients	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
the	DT	O
STOPD-PD	NNP	O
study	NN	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
a	DT	O
combination	NN	O
of	IN	O
olanzapine	JJ	PM
plus	CC	PM
sertraline	JJ	PM
vs.	FW	PM
olanzapine	JJ	C
plus	CC	C
placebo	NN	C
.	.	C

The	DT	O
strength	NN	O
of	IN	O
treatment	NN	O
courses	NNS	O
received	VBD	O
prior	RB	O
to	TO	O
randomization	NN	O
was	VBD	O
classified	VBN	O
using	VBG	O
a	DT	O
validated	JJ	O
method	NN	O
.	.	O

A	DT	O
hierarchy	NN	O
of	IN	O
outcomes	NNS	O
was	VBD	O
hypothesized	VBN	O
based	VBN	O
on	IN	O
treatments	NNS	O
received	VBN	O
prior	RB	O
to	TO	O
randomization	NN	O
and	CC	O
randomized	JJ	O
treatment	NN	O
.	.	O

A	DT	O
high	JJ	O
remission	NN	O
rate	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
no	DT	O
prior	JJ	O
treatment	NN	O
or	CC	O
inadequate	JJ	O
treatment	NN	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
olanzapine	NN	PM
and	CC	O
sertraline	NN	PM
.	.	O

A	DT	O
low	JJ	O
remission	NN	O
rate	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
subjects	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
an	DT	O
antidepressant	JJ	O
alone	NN	O
and	CC	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
olanzapine	JJ	PM
monotherapy	NN	O
.	.	O

A	DT	O
low	JJ	O
remission	NN	O
rate	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
subjects	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
a	DT	O
combination	NN	O
of	IN	O
an	DT	O
antipsychotic	JJ	O
and	CC	O
an	DT	O
antidepressant	NN	O
.	.	O

Similar	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
major	JJ	O
depression	NN	O
,	,	O
these	DT	O
results	NNS	O
emphasize	VBP	O
the	DT	O
impact	NN	O
of	IN	O
prior	JJ	O
pharmacotherapy	NN	PM
on	IN	O
treatment	NN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
MDpsy	NNP	O
.	.	O

A	DT	O
randomized	JJ	O
parallel	NN	O
study	NN	O
to	TO	O
assess	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
two	CD	O
different	JJ	O
dosing	VBG	O
regimens	NNS	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
superficial	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
.	.	O

OBJECTIVES	CC	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
two	CD	O
cycled	VBD	O
dosing	VBG	O
regimens	NNS	O
of	IN	O
imiquimod	JJ	PM
5	CD	O
%	NN	O
cream	NN	O
for	IN	O
treatment	NN	O
of	IN	O
superficial	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
(	(	O
sBCC	NN	O
)	)	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
(	(	O
n	JJ	O
=	NNP	O
32	CD	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
regimens	NNS	O
:	:	O
8	CD	PM
weeks	NNS	PM
of	IN	PM
treatment	NN	PM
with	IN	PM
once-daily	JJ	PM
dosing	VBG	PM
for	IN	PM
alternate	JJ	PM
weeks	NNS	PM
(	(	PM
R1	NNP	PM
)	)	PM
and	CC	O
5	CD	O
weeks	NNS	O
of	IN	O
once-daily	JJ	O
dosing	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
interval	NN	O
in	IN	O
the	DT	O
middle	NN	O
of	IN	O
the	DT	O
course	NN	O
(	(	O
R2	NNP	O
)	)	O
.	.	O

Efficacy	NN	O
measures	NNS	O
were	VBD	O
tumour	JJ	O
clearance	NN	O
at	IN	O
weeks	NNS	O
19	CD	O
and	CC	O
52	CD	O
and	CC	O
measures	NNS	O
of	IN	O
patients	NNS	O
'	POS	O
acceptability	NN	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
from	IN	O
30	CD	O
patients	NNS	O
(	(	O
13	CD	O
females	NNS	O
)	)	O
,	,	O
14	CD	O
on	IN	O
R1	NNP	O
and	CC	O
16	CD	O
on	IN	O
R2	NNP	O
,	,	O
were	VBD	O
analysed	VBN	O
.	.	O

The	DT	O
results	NNS	O
revealed	VBD	O
an	DT	O
initial	JJ	O
clearance	NN	O
rate	NN	O
of	IN	O
64	CD	O
%	NN	O
at	IN	O
week	NN	O
19	CD	O
for	IN	O
R1	NNP	O
and	CC	O
81	CD	O
%	NN	O
for	IN	O
R2	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
:	:	O
-14	NN	O
%	NN	O
to	TO	O
45	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
clearance	NN	O
rates	NNS	O
at	IN	O
week	NN	O
52	CD	O
were	VBD	O
significantly	RB	O
different	JJ	O
:	:	O
43	CD	O
%	NN	O
for	IN	O
R1	NNP	O
and	CC	O
88	CD	O
%	NN	O
for	IN	O
R2	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
:	:	O
11	CD	O
%	NN	O
to	TO	O
68	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
acceptability	NN	O
of	IN	O
treatment	NN	O
as	IN	O
measured	VBN	O
by	IN	O
composite	JJ	O
median	JJ	O
visual	JJ	O
analogue	NN	O
scores	NNS	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

CONCLUSION	NNP	O
Five	NNP	O
weeks	NNS	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	PM
cream	NN	O
once	RB	O
daily	JJ	O
with	IN	O
a	DT	O
1-week	JJ	O
interval	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
but	CC	O
as	RB	O
well	RB	O
tolerated	VBN	O
as	IN	O
the	DT	O
8-week	JJ	O
alternate	NN	O
week	NN	O
regimen	NNS	O
for	IN	O
sBCC	NN	O
.	.	O

Utilization	NN	O
patterns	NNS	O
of	IN	O
conventional	JJ	C
and	CC	O
complementary/alternative	JJ	Ot
treatments	NNS	Ot
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
in	IN	O
a	DT	O
population-based	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
utilization	NN	O
of	IN	O
conventional	JJ	C
treatments	NNS	C
and	CC	O
utilization	NN	O
of	IN	O
complementary	JJ	PM
and	CC	PM
alternative	JJ	PM
medicine	NN	PM
in	IN	O
preschoolers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
other	JJ	O
developmental	JJ	O
disabilities	NNS	O
(	(	O
DD	NNP	O
)	)	O
.	.	O

METHODS	JJ	O
Participants	NNS	O
were	VBD	O
578	CD	O
children	NNS	O
who	WP	O
were	VBD	O
part	NN	O
of	IN	O
an	DT	O
ongoing	JJ	O
population-based	JJ	O
,	,	O
case-control	JJ	O
study	NN	O
of	IN	O
2-	JJ	O
to	TO	O
5-year	JJ	O
olds	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
DD	NNP	O
,	,	O
and	CC	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

Parents	NNS	O
completed	VBD	O
an	DT	O
interview	NN	O
on	IN	O
past	JJ	O
and	CC	O
current	JJ	O
services	NNS	O
.	.	O

RESULTS	NNP	O
Four	CD	O
hundred	VBD	O
fifty-three	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
125	CD	O
DD	NNP	O
children	NNS	O
were	VBD	O
included	VBN	O
.	.	O

ASD	NNP	O
families	NNS	O
received	VBD	O
more	RBR	O
hours	NNS	O
of	IN	O
conventional	JJ	PH
services	NNS	PH
compared	VBN	O
with	IN	O
DD	NNP	O
families	NNS	O
(	(	O
17.8	CD	O
vs	RB	O
11	CD	O
;	:	O
p	NN	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
psychotropic	NN	O
medications	NNS	O
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
approximately	RB	O
3	CD	O
%	NN	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
complementary	JJ	PM
and	CC	PM
alternative	JJ	PM
medicine	NN	PM
(	(	PM
CAM	NNP	PM
)	)	PM
use	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
ASD	NNP	O
(	(	O
39	CD	O
%	NN	O
)	)	O
versus	NN	O
DD	NNP	O
(	(	O
30	CD	O
%	NN	O
)	)	O
.	.	O

Hispanic	JJ	O
families	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
used	VBD	O
CAM	NNP	PM
less	RBR	O
often	RB	O
than	IN	O
non-Hispanic	JJ	O
families	NNS	O
.	.	O

Variables	NNS	O
such	JJ	O
as	IN	O
level	NN	O
of	IN	O
function	NN	O
,	,	O
immunization	NN	O
status	NN	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
an	DT	O
identified	VBN	O
neurogenetic	JJ	O
disorder	NN	O
were	VBD	O
not	RB	O
predictive	JJ	O
of	IN	O
CAM	NNP	PM
use	NN	O
.	.	O

A	DT	O
higher	JJR	O
level	NN	O
of	IN	O
parental	JJ	O
education	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
CAM	NNP	PM
use	NN	O
in	IN	O
ASD	NNP	O
and	CC	O
DD	NNP	O
.	.	O

Families	NNS	O
who	WP	O
used	VBD	O
>	$	O
20	CD	O
hours	NNS	O
per	IN	O
week	NN	O
of	IN	O
conventional	JJ	PH
services	NNS	PH
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
CAM	NNP	PM
,	,	O
including	VBG	O
potentially	RB	O
unsafe	JJ	O
or	CC	O
disproven	JJ	O
CAM	NNP	PM
.	.	O

Underimmunized	VBN	O
children	NNS	O
were	VBD	O
marginally	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
CAM	NNP	PM
but	CC	O
not	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
received	VBN	O
potentially	RB	O
unsafe	JJ	O
or	CC	O
disproven	JJ	O
CAM	NNP	PM
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
CAM	NNP	PM
is	VBZ	O
common	JJ	O
in	IN	O
families	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
neurodevelopmental	JJ	O
disorders	NNS	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
predicted	VBN	O
by	IN	O
higher	JJR	O
parental	JJ	O
education	NN	O
and	CC	O
non-Hispanic	JJ	O
ethnicity	NN	O
but	CC	O
not	RB	O
developmental	JJ	O
characteristics	NNS	O
.	.	O

Further	NNP	O
research	NN	O
should	MD	O
address	VB	O
how	WRB	O
health	NN	O
care	NN	O
providers	NNS	O
can	MD	O
support	VB	O
families	NNS	O
in	IN	O
making	VBG	O
decisions	NNS	O
about	IN	O
CAM	NNP	PM
use	NN	O
.	.	O

Salmeterol	NNP	PM
plus	CC	O
fluticasone	JJ	PM
propionate	NN	PM
versus	IN	O
fluticasone	NN	PM
propionate	NN	PM
plus	CC	O
montelukast	NN	PM
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
investigating	VBG	O
the	DT	O
effects	NNS	O
on	IN	O
airway	JJ	O
inflammation	NN	O
in	IN	O
asthma	NN	O
.	.	O

BACKGROUND	NNP	O
Few	NNP	O
studies	NNS	O
have	VBP	O
compared	VBN	O
treatment	NN	O
strategies	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
asthma	JJ	O
poorly	RB	O
controlled	VBN	O
on	IN	O
low	JJ	O
dose	NN	O
inhaled	JJ	O
corticosteroids	NNS	O
,	,	O
and	CC	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
different	JJ	O
treatments	NNS	O
on	IN	O
airway	JJ	O
inflammation	NN	O
.	.	O

In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
salmeterol	NN	PM
plus	CC	PM
fluticasone	NN	PM
propionate	NN	PM
(	(	PM
FP	NNP	PM
)	)	PM
(	(	PM
Seretide	NNP	PM
;	:	PM
SFC	NNP	PM
)	)	PM
and	CC	O
FP	NNP	PM
plus	CC	PM
montelukast	NN	PM
(	(	PM
FP/M	NNP	PM
)	)	PM
on	IN	O
sputum	NN	O
inflammatory	NN	O
markers	NNS	O
,	,	O
airway	RB	O
responsiveness	NN	O
,	,	O
lung	NN	O
function	NN	O
,	,	O
and	CC	O
symptoms	NNS	O
in	IN	O
adult	NN	O
asthmatics	NNS	O
.	.	O

METHODS	NNP	O
Sixty-six	JJ	O
subjects	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
SFC	NNP	PM
or	CC	O
FP/M	NNP	PM
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
changes	NNS	O
in	IN	O
neutrophil	NN	O
,	,	O
eosinophil	NN	O
,	,	O
macrophage	NN	O
,	,	O
lymphocyte	NN	O
,	,	O
and	CC	O
epithelial	JJ	O
cell	NN	O
levels	NNS	O
in	IN	O
induced	JJ	O
sputum	NN	O
.	.	O

Additional	NNP	O
outcomes	NNS	O
included	VBD	O
the	DT	O
change	NN	O
in	IN	O
other	JJ	O
sputum	JJ	O
markers	NNS	O
of	IN	O
airway	JJ	O
inflammation	NN	O
,	,	O
airway	RB	O
responsiveness	NN	O
,	,	O
symptom	NN	O
control	NN	O
,	,	O
and	CC	O
lung	NN	O
function	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
treatments	NNS	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
induced	JJ	O
sputum	NN	O
inflammatory	NN	O
cells	NNS	O
,	,	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
a	DT	O
reduction	NN	O
in	IN	O
sputum	NN	O
eosinophils	NNS	O
.	.	O

Both	DT	O
treatments	NNS	O
significantly	RB	O
improved	VBN	O
airway	RB	O
responsiveness	NN	O
,	,	O
whereas	WP	O
SFC	NNP	PM
generally	RB	O
led	VBD	O
to	TO	O
greater	JJR	O
improvements	NNS	O
in	IN	O
symptom	JJ	O
control	NN	O
and	CC	O
lung	NN	O
function	NN	O
than	IN	O
FP/M	NNP	PM
.	.	O

FP/M	NNP	PM
led	VBD	O
to	TO	O
significantly	RB	O
greater	JJR	O
reductions	NNS	O
in	IN	O
sputum	NN	O
cysteinyl	NN	O
leukotrienes	NNS	O
than	IN	O
SFC	NNP	PM
(	(	O
treatment	NN	O
ratio	NN	O
1.80	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.09	CD	O
,	,	O
2.94	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Both	DT	O
treatments	NNS	O
led	VBD	O
to	TO	O
similar	JJ	O
control	NN	O
of	IN	O
eosinophilic	JJ	O
airway	NN	O
inflammation	NN	O
,	,	O
although	IN	O
PEF	NNP	O
and	CC	O
symptom	VB	O
control	NN	O
were	VBD	O
better	JJR	O
with	IN	O
SFC	NNP	PM
.	.	O

STUDY	NNP	O
NUMBER	NNP	O
:	:	O
SAM40030	NNP	O
(	(	O
SOLTA	NNP	O
)	)	O
.	.	O

Treatment	NN	O
of	IN	O
renal	JJ	O
failure	NN	O
associated	VBN	O
with	IN	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Plasmapheresis	NN	O
,	,	O
hemodialysis	NN	O
,	,	O
and	CC	O
chemotherapy	NN	O
.	.	O

The	DT	O
aims	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
examine	VB	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
plasmapheresis	NN	O
in	IN	O
preventing	VBG	O
irreversible	JJ	O
renal	JJ	O
failure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
multiple	JJ	O
myeloma	NN	O
and	CC	O
to	TO	O
study	VB	O
the	DT	O
renal	JJ	O
biopsy	NN	O
tissues	NNS	O
from	IN	O
such	JJ	O
patients	NNS	O
.	.	O

Twenty-one	CD	O
patients	NNS	O
with	IN	O
active	JJ	O
myeloma	NN	O
and	CC	O
progressive	JJ	O
renal	JJ	O
failure	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
:	:	O
group	NN	O
1	CD	O
,	,	O
forced	VBN	PM
diuresis	NN	PM
and	CC	O
chemotherapy	NN	PM
(	(	O
10	CD	O
patients	NNS	O
)	)	O
,	,	O
and	CC	O
group	NN	O
2	CD	O
,	,	O
forced	VBN	PM
diuresis	NN	PM
,	,	O
chemotherapy	NN	PM
,	,	O
and	CC	O
plasmapheresis	NN	PH
(	(	O
11	CD	O
patients	NNS	O
)	)	O
.	.	O

Plasmapheresis	NN	O
and	CC	O
chemotherapy	NN	O
lowered	VBD	O
the	DT	O
serum	NN	O
myeloma	NN	O
protein	IN	O
value	NN	O
much	RB	O
more	RBR	O
rapidly	RB	O
than	IN	O
chemotherapy	VB	O
alone	JJ	O
.	.	O

Of	IN	O
5	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
oliguric	JJ	O
and	CC	O
undergoing	JJ	O
dialysis	NN	O
at	IN	O
presentation	NN	O
,	,	O
only	RB	O
3	CD	O
who	WP	O
were	VBD	O
treated	VBN	O
by	IN	O
plasmapheresis	NN	O
recovered	VBN	O
.	.	O

Of	IN	O
16	CD	O
polyuric	JJ	O
patients	NNS	O
,	,	O
5	CD	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
7	CD	O
in	IN	O
group	NN	O
2	CD	O
showed	VBD	O
improvement	NN	O
in	IN	O
renal	JJ	O
function	NN	O
.	.	O

The	DT	O
main	JJ	O
factor	NN	O
that	WDT	O
determined	VBD	O
irreversibility	NN	O
of	IN	O
renal	JJ	O
failure	NN	O
was	VBD	O
the	DT	O
severity	NN	O
of	IN	O
myeloma	NN	O
cast	NN	O
formation	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
a	DT	O
spiritually	RB	E
based	VBN	E
and	CC	E
non-spiritually	RB	E
based	VBN	E
educational	JJ	E
intervention	NN	E
for	IN	O
informed	JJ	O
decision	NN	O
making	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
among	IN	O
church-attending	JJ	O
African-American	JJ	O
men	NNS	O
.	.	O

INTRODUCTION	NNP	O
Health	NNP	E
communication	NN	E
interventions	NNS	E
have	VBP	O
been	VBN	O
modestly	RB	O
effective	JJ	O
for	IN	O
increasing	VBG	O
informed	JJ	O
decision	NN	O
making	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
among	IN	O
African-American	JJ	O
men	NNS	O
;	:	O
however	RB	O
,	,	O
knowledge	NN	O
and	CC	O
informed	JJ	O
decision	NN	O
making	NN	O
is	VBZ	O
still	RB	O
questionable	JJ	O
even	RB	O
with	IN	O
screening	VBG	O
.	.	O

Church-based	JJ	O
programs	NNS	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
if	IN	O
they	PRP	O
are	VBP	O
spiritually	RB	O
based	VBN	O
in	IN	O
nature	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aims	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
were	VBD	O
to	TO	O
implement	VB	O
and	CC	O
provide	VB	O
an	DT	O
initial	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
spiritually	RB	O
based	VBN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
informed	JJ	O
decision	NN	O
making	VBG	O
intervention	NN	O
for	IN	O
African-American	JJ	O
men	NNS	O
who	WP	O
attend	VBP	O
church	NN	O
,	,	O
and	CC	O
determine	VB	O
its	PRP$	O
efficacy	NN	O
for	IN	O
increasing	VBG	O
informed	JJ	O
decision	NN	O
making	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
METHOD	NNP	O
Churches	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	CC	O
the	DT	O
spiritually	RB	E
based	VBN	E
or	CC	E
the	DT	E
non-spiritual	JJ	E
intervention	NN	E
.	.	O

Trained	NNP	O
community	NN	O
health	NN	O
advisors	NNS	O
,	,	O
who	WP	O
were	VBD	O
African-American	JJ	O
male	JJ	O
church	NN	O
members	NNS	O
,	,	O
led	VBD	O
an	DT	O
educational	JJ	E
session	NN	E
and	CC	O
distributed	VBD	E
educational	JJ	E
print	NN	E
materials	NNS	E
.	.	E

Participants	NNS	O
completed	VBD	O
baseline	NN	O
and	CC	O
immediate	JJ	O
follow-up	JJ	O
surveys	NNS	O
to	TO	O
assess	VB	O
the	DT	O
intervention	NN	O
impact	NN	O
on	IN	O
study	NN	O
outcomes	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
spiritually	RB	O
based	VBN	O
intervention	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
areas	NNS	O
such	JJ	O
as	IN	O
knowledge	NN	O
,	,	O
and	CC	O
men	NNS	O
read	VBP	O
more	JJR	O
of	IN	O
their	PRP$	O
materials	NNS	O
in	IN	O
the	DT	O
spiritually	RB	O
based	VBN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
non-spiritual	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Further	NNP	O
examination	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
spiritually	RB	O
based	VBN	O
approach	NN	O
to	TO	O
health	NN	O
communication	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
mild	JJ	PH
physical	JJ	PH
exercise	NN	PH
on	IN	O
serum	NN	O
lipoproteins	NNS	O
and	CC	O
metabolites	NNS	O
of	IN	O
arachidonic	JJ	O
acid	NN	O
:	:	O
a	DT	O
controlled	VBN	O
randomised	JJ	O
trial	NN	O
in	IN	O
middle	JJ	O
aged	VBN	O
men	NNS	O
.	.	O

To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
physical	JJ	PH
exercise	NN	PH
on	IN	O
biochemical	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
ischaemic	JJ	O
heart	NN	O
disease	NN	O
31	CD	O
healthy	JJ	O
middle	NNS	O
aged	VBN	O
men	NNS	O
undertook	IN	O
regular	JJ	PH
physical	JJ	PH
exercise	NN	PH
for	IN	PH
two	CD	PH
months	NNS	PH
and	CC	O
29	CD	O
served	VBD	O
as	IN	O
controls	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
trial	NN	O
.	.	O

In	IN	O
the	DT	O
men	NNS	O
taking	VBG	O
regular	JJ	O
exercise	NN	O
serum	NN	O
cholesterol	NN	O
concentrations	NNS	O
increased	VBD	O
26	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
high	JJ	O
density	NN	O
lipoprotein	VBP	O
subfraction	NN	O
two	CD	O
(	(	O
HDL2	NNP	O
)	)	O
and	CC	O
decreased	VBD	O
31	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
subfraction	NN	O
three	CD	O
(	(	O
HDL3	NNP	O
)	)	O
and	CC	O
9	CD	O
%	NN	O
more	JJR	O
in	IN	O
the	DT	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
fraction	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
tendency	NN	O
towards	NNS	O
increased	VBD	O
plasma	JJ	O
6-keto-prostaglandin	JJ	O
F1	NNP	O
alpha	NN	O
concentration	NN	O
and	CC	O
decreased	VBD	O
serum	NN	O
thromboxane	NN	O
B2	NNP	O
concentration	NN	O
was	VBD	O
found	VBN	O
during	IN	O
the	DT	O
period	NN	O
of	IN	O
regular	JJ	O
exercise	NN	PH
,	,	O
but	CC	O
prostaglandin	VBP	O
E2	NNP	O
concentrations	NNS	O
remained	VBD	O
unchanged	JJ	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
plasma	JJ	O
6-keto-prostaglandin	JJ	O
F1	NNP	O
alpha	NN	O
concentration	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	O
HDL2	NNP	O
cholesterol	NN	O
concentration	NN	O
in	IN	O
the	DT	O
group	NN	O
taking	VBG	O
regular	JJ	O
exercise	NN	PH
.	.	O

Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
mild	JJ	PH
regular	JJ	PH
physical	JJ	PH
exercise	NN	PH
favourably	RB	O
influences	VBZ	O
cholesterol	NN	O
distribution	NN	O
in	IN	O
serum	NN	O
lipoproteins	NNS	O
in	IN	O
healthy	JJ	O
middle	NN	O
aged	VBN	O
men	NNS	O
and	CC	O
may	MD	O
have	VB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
circulating	VBG	O
metabolites	NNS	O
of	IN	O
arachidonic	JJ	O
acid	NN	O
.	.	O

Naltrexone	NN	PM
in	IN	O
young	JJ	O
autistic	JJ	O
children	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
crossover	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
naltrexone	NN	PM
,	,	O
an	DT	O
opiate	NN	O
blocker	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
Thirteen	NNP	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBD	O
3.4	CD	O
to	TO	O
8.3	CD	O
years	NNS	O
(	(	O
mean	VB	O
5.4	CD	O
)	)	O
,	,	O
were	VBD	O
studied	VBN	O
in	IN	O
home	NN	O
,	,	O
school	NN	O
,	,	O
and	CC	O
outpatient	JJ	O
laboratory	NN	O
.	.	O

Naltrexone	NNP	PM
,	,	PM
1.0	CD	PM
mg/kg	NN	PM
,	,	O
was	VBD	O
given	VBN	O
daily	RB	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	PH
crossover	NN	PH
design	NN	PH
.	.	O

Dependent	JJ	O
measures	NNS	O
included	VBD	O
parent	NN	O
and	CC	O
teacher	RB	O
Clinical	JJ	O
Global	NNP	O
Impressions	NNP	O
(	(	O
CGI	NNP	O
)	)	O
,	,	O
Conners	NNPS	O
Rating	NNP	O
Scales	NNP	O
,	,	O
and	CC	O
Naltrexone	NNP	O
Side-Effects	NNP	O
(	(	O
SE	NNP	O
)	)	O
Rating	NNP	O
Scale	NNP	O
;	:	O
laboratory	NN	O
CGI	NNP	O
,	,	O
movement	NN	O
actometer	NN	O
readings	NNS	O
,	,	O
and	CC	O
a	DT	O
10-second	JJ	O
interval	NN	O
recording	VBG	O
system	NN	O
analysis	NN	O
of	IN	O
on-task	NN	O
,	,	O
communication	NN	E
initiations	NNS	E
,	,	E
disruptive	JJ	E
behavior	NN	E
,	,	E
and	CC	E
self-stimulation	NN	E
.	.	O

RESULTS	NNP	O
Eight	NNP	O
of	IN	O
13	CD	O
subjects	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
or	CC	O
more	JJR	O
settings	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
parent	NN	O
measures	NNS	O
(	(	O
CGI	NNP	O
,	,	O
Conners	NNP	O
Impulsivity-Hyperactivity	NNP	O
Factor	NNP	O
,	,	O
and	CC	O
SE-Restlessness	NNP	O
)	)	O
and	CC	O
Teacher	NNP	O
CGI	NNP	O
achieved	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

Teacher	CC	O
SE-Restlessness	JJ	O
and	CC	O
initiation	NN	O
of	IN	O
communication	NN	O
in	IN	O
the	DT	O
clinic	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
improvement	NN	O
.	.	O

Actometer	NNP	O
readings	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
children	NNS	O
who	WP	O
were	VBD	O
very	RB	O
active	JJ	O
at	IN	O
baseline	NN	O
.	.	O

Adverse	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
behavioral	JJ	O
,	,	O
mild	JJ	O
,	,	O
and	CC	O
transient	NN	O
.	.	O

Administering	VBG	O
the	DT	O
bitter	JJ	O
tablet	NN	O
was	VBD	O
a	DT	O
challenge	NN	O
.	.	O

CONCLUSIONS	NNP	O
Naltrexone	NNP	PM
offers	VBZ	O
promise	RB	O
as	IN	O
an	DT	O
agent	NN	O
for	IN	O
modest	JJ	O
improvement	NN	O
of	IN	O
behavior	NN	O
and	CC	O
social	JJ	O
communication	NN	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Parent	NN	O
and	CC	O
teacher	NN	O
measures	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
in	IN	O
outpatient	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
change	NN	O
.	.	O

Cardiovascular	JJ	O
safety	NN	O
and	CC	O
gastrointestinal	JJ	O
tolerability	NN	O
of	IN	O
etoricoxib	JJ	O
vs	NN	O
diclofenac	NN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
(	(	O
The	DT	O
MEDAL	NNP	O
study	NN	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
cardiovascular	JJ	O
(	(	O
CV	NNP	O
)	)	O
and	CC	O
other	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
parameters	NNS	O
of	IN	O
etoricoxib	JJ	PM
60	CD	O
and	CC	O
90	CD	O
mg	NN	O
,	,	O
and	CC	O
diclofenac	VBZ	PM
150	CD	O
mg.	NN	O
METHODS	NNP	O
This	DT	O
double-blind	NN	O
study	NN	O
randomized	VBD	O
OA	NNP	O
patients	NNS	O
to	TO	O
etoricoxib	VB	PM
90	CD	O
mg	NN	O
,	,	O
then	RB	O
to	TO	O
60	CD	O
mg	NNS	O
once	RB	O
daily	JJ	O
vs	NNS	O
diclofenac	VBP	PM
75	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
;	:	O
RA	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
etoricoxib	VB	PM
90	CD	O
mg	NNS	O
once	RB	O
daily	JJ	O
or	CC	O
diclofenac	JJ	PM
75	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
non-inferiority	NN	O
of	IN	O
etoricoxib	JJ	PM
vs	NN	O
diclofenac	NN	PM
for	IN	O
thrombotic	JJ	O
CV	NNP	O
events	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
upper	JJ	O
bound	NN	O
of	IN	O
hazard	NN	O
ratio	NN	O
<	NNP	O
1.30	CD	O
)	)	O
.	.	O

Other	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
parameters	NNS	O
were	VBD	O
evaluated	VBN	O
in	IN	O
cohorts	NNS	O
of	IN	O
patients	NNS	O
based	VBN	O
on	IN	O
etoricoxib	NN	PM
dose	NN	O
and	CC	O
disease	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
23	CD	O
504	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
with	IN	O
mean	JJ	O
treatment	NN	O
duration	NN	O
from	IN	O
19.4	CD	O
to	TO	O
20.8	CD	O
months	NNS	O
.	.	O

The	DT	O
thrombotic	JJ	O
CV	NNP	O
risk	NN	O
hazard	NN	O
ratio	NN	O
(	(	O
HR	NNP	O
)	)	O
(	(	O
etoricoxib	UH	PM
to	TO	O
diclofenac	VB	O
)	)	O
was	VBD	O
0.96	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.81	CD	O
,	,	O
1.15	CD	O
)	)	O
,	,	O
consistent	JJ	O
with	IN	O
non-inferiority	NN	O
of	IN	O
etoricoxib	NN	PM
to	TO	O
diclofenac	VB	PM
.	.	O

The	DT	O
cumulative	JJ	O
gastrointestinal	NN	O
(	(	O
GI	NNP	O
)	)	O
/liver	VBP	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
discontinuation	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
etoricoxib	JJR	PM
than	IN	O
diclofenac	NN	PM
in	IN	O
each	DT	O
patient	NN	O
cohort	NN	O
;	:	O
HR	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
of	IN	O
0.46	CD	O
(	(	O
0.39	CD	O
,	,	O
0.54	CD	O
)	)	O
,	,	O
0.52	CD	O
(	(	O
0.42	CD	O
,	,	O
0.63	CD	O
)	)	O
and	CC	O
0.49	CD	O
(	(	O
0.39	CD	O
,	,	O
0.62	CD	O
)	)	O
for	IN	O
the	DT	O
60	CD	O
mg	NN	O
OA	NNP	O
,	,	O
90	CD	O
mg	NN	O
OA	NNP	O
and	CC	O
RA	NNP	O
cohorts	NNS	O
.	.	O

The	DT	O
maximum	JJ	O
average	JJ	O
change	NN	O
in	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
with	IN	O
etoricoxib	NN	PM
was	VBD	O
3.4-3.6	JJ	O
mmHg	NN	O
(	(	O
diastolic	JJ	O
BP	NNP	O
:	:	O
1.0-1.5	JJ	O
mmHg	NN	O
)	)	O
,	,	O
while	IN	O
diclofenac	NN	O
produced	VBD	O
a	DT	O
maximum	JJ	O
average	JJ	O
change	NN	O
of	IN	O
0.9-1.9	JJ	O
mmHg	NN	O
(	(	O
diastolic	JJ	O
BP	NNP	O
:	:	O
0.0-0.5	JJ	O
mmHg	NN	O
)	)	O
.	.	O

Both	DT	O
agents	NNS	O
resulted	VBD	O
in	IN	O
similar	JJ	O
efficacy	NN	O
regardless	NN	O
of	IN	O
etoricoxib	NN	O
dose	NN	O
.	.	O

CONCLUSION	NNP	O
Long-term	NNP	O
etoricoxib	NN	PM
use	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
risk	NN	O
of	IN	O
thrombotic	JJ	O
CV	NNP	O
events	NNS	O
comparable	JJ	O
with	IN	O
that	DT	O
of	IN	O
diclofenac	NN	PM
.	.	O

Compared	VBN	O
with	IN	O
diclofenac	NN	PM
,	,	O
etoricoxib	RB	PM
demonstrated	VBD	O
a	DT	O
greater	JJR	O
risk	NN	O
of	IN	O
renovascular	JJ	O
AEs	NNP	O
,	,	O
but	CC	O
a	DT	O
more	RBR	O
favourable	JJ	O
GI/liver	NNP	O
tolerability	NN	O
profile	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
peer	NN	E
counseling	VBG	E
on	IN	O
smoking	VBG	O
cessation	NN	O
and	CC	O
reduction	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
a	DT	O
peer	NN	E
counseling	VBG	E
intervention	NN	E
for	IN	O
pregnant	JJ	O
smokers	NNS	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
forty-two	NN	O
pregnant	NN	O
,	,	O
predominantly	RB	O
Hispanic	JJ	O
women	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
a	DT	O
peer-led	JJ	E
smoking	NN	E
cessation	NN	E
program	NN	E
or	CC	E
to	TO	E
usual	JJ	E
care	NN	E
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
usual	JJ	E
care	NN	E
,	,	E
peer	NN	E
counseling	NN	E
reduced	VBN	O
smoking	NN	O
(	(	O
-9.1	JJ	O
versus	NN	O
-4.5	NNP	O
cigarettes	VBZ	O
daily	RB	O
,	,	O
P	NNP	O
=.03	NNP	O
)	)	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
absolute	JJ	O
quit	NN	O
rates	NNS	O
(	(	O
24	CD	O
%	NN	O
versus	IN	O
21	CD	O
%	NN	O
)	)	O
at	IN	O
36	CD	O
weeks	NNS	O
'	POS	O
gestation	NN	O
.	.	O

Infant	NNP	O
birth	NN	O
weight	VBD	O
negatively	RB	O
correlated	VBN	O
with	IN	O
cigarettes	NNS	O
smoked	VBN	O
per	IN	O
day	NN	O
(	(	O
r	VB	O
=	NNP	O
-0.29	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
expired	JJ	O
carbon	NN	O
monoxide	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.39	NN	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
at	IN	O
delivery	NN	O
.	.	O

Birth	NNP	O
weight	VBD	O
for	IN	O
infants	NNS	O
born	VBN	O
to	TO	O
women	NNS	O
who	WP	O
quit	VBP	O
smoking	VBG	O
averaged	VBD	O
7.2	CD	O
lb	JJ	O
versus	NN	O
6.8	CD	O
and	CC	O
6.3	CD	O
lb	NN	O
for	IN	O
mothers	NNS	O
smoking	VBG	O
one	CD	O
to	TO	O
six	CD	O
and	CC	O
more	JJR	O
than	IN	O
six	CD	O
cigarettes	NNS	O
per	IN	O
day	NN	O
at	IN	O
delivery	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Peer	NNP	E
counseling	NN	E
reduced	VBD	O
the	DT	O
number	NN	O
of	IN	O
cigarettes	NNS	O
smoked	VBN	O
daily	RB	O
but	CC	O
did	VBD	O
not	RB	O
increase	VB	O
cigarette	NN	O
abstinence	NN	O
rates	NNS	O
.	.	O

Infant	NNP	O
birth	NN	O
weight	NN	O
increases	NNS	O
with	IN	O
both	DT	O
smoking	VBG	O
cessation	NN	O
and	CC	O
smoking	NN	O
reduction	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
peer	NN	E
counseling	VBG	E
intervention	NN	E
programs	NNS	E
may	MD	O
improve	VB	O
newborn	JJR	O
health	NN	O
despite	IN	O
their	PRP$	O
failure	NN	O
to	TO	O
affect	VB	O
smoking	VBG	O
cessation	NN	O
.	.	O

Roles	NNS	O
of	IN	O
adapalene	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	O
versicolor	NN	O
.	.	O

BACKGROUND	NNP	O
Ketoconazole	NNP	PM
is	VBZ	O
a	DT	O
typical	JJ	O
treatment	NN	O
available	JJ	O
for	IN	O
pityriasis	NN	O
versicolor	NN	O
;	:	O
tretinoin	CC	PM
cream	NN	PM
is	VBZ	O
effective	JJ	O
,	,	O
too	RB	O
.	.	O

Adapalene	NNP	PM
gel	NN	PM
is	VBZ	O
a	DT	O
tretinoin	JJ	O
derivative	NN	O
and	CC	O
has	VBZ	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
irritation	NN	O
compared	VBN	O
with	IN	O
other	JJ	O
topical	JJ	O
retinoid	NN	O
products	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
reports	NNS	O
on	IN	O
adapalene	NN	PM
gel	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	O
versicolor	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
adapalene	NN	PM
gel	NN	PM
comparing	VBG	O
the	DT	O
treatment	NN	O
with	IN	O
adapalene	JJ	PM
gel	NNS	PM
and	CC	O
2	CD	PM
%	NN	PM
ketoconazole	JJ	PM
cream	NN	PM
in	IN	O
pityriasis	NN	O
versicolor	NN	O
.	.	O

METHODS	NNP	O
Eighty	NNP	O
patients	NNS	O
suffering	VBG	O
from	IN	O
pityriasis	NN	O
versicolor	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
one	CD	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
2	CD	PM
%	NN	PM
ketoconazole	JJ	PM
cream	NN	PM
topically	RB	O
twice	JJ	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
adapalene	JJ	PM
gel	NN	PM
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
other	JJ	O
group	NN	O
in	IN	O
a	DT	O
similar	JJ	O
fashion	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
efficacy	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

No	DT	O
major	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
either	CC	O
.	.	O

CONCLUSION	NNP	O
Adapalene	NNP	PM
was	VBD	O
the	DT	O
favorable	JJ	O
option	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	O
versicolor	NN	O
.	.	O

The	DT	O
probable	JJ	O
therapeutic	JJ	O
mechanism	NN	O
of	IN	O
adapalene	NN	PM
is	VBZ	O
also	RB	O
discussed	VBN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
soy-based	JJ	PM
dietary	JJ	PM
supplement	NN	PM
on	IN	O
lipid	JJ	O
levels	NNS	O
and	CC	O
cardiovascular	JJ	O
risk	NN	O
markers	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

OBJECTIVE	NNP	O
Consumption	NNP	O
of	IN	O
soy	NN	O
protein	NN	O
has	VBZ	O
recently	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
improve	VB	O
the	DT	O
blood	NN	O
lipid	JJ	O
levels	NNS	O
in	IN	O
nondiabetic	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
if	IN	O
a	DT	O
dietary	JJ	O
supplement	NN	O
of	IN	O
soy	NN	PM
protein	NN	PM
,	,	O
isoflavones	NNS	PM
,	,	O
and	CC	O
cotyledon	VB	PM
fiber	NN	PM
(	(	PM
Abalon	NNP	PM
)	)	PM
affects	VBZ	O
cardiovascular	JJ	O
risk	NN	O
markers	NNS	O
,	,	O
blood	NN	O
glucose	NN	O
,	,	O
and	CC	O
insulin	NN	O
levels	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Twenty	NNP	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
crossover	NN	O
trial	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	JJ	O
supplementation	NN	O
for	IN	O
6	CD	PM
weeks	NNS	PM
with	IN	PM
Abalon	NNP	PM
(	(	PM
soy	JJ	PM
protein	NN	PM
[	VBD	O
50	CD	O
g/day	JJ	O
]	NNP	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
isoflavones	NNS	PM
[	NNP	O
minimum	VBD	O
165	CD	O
mg/day	NN	O
]	NNP	O
and	CC	O
cotyledon	VB	PM
fiber	NN	PM
[	$	O
20	CD	O
g/day	JJ	O
]	NNPS	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
casein	JJ	O
[	VBZ	O
50	CD	O
g/day	NN	O
]	NNP	O
and	CC	O
cellulose	VB	O
[	JJ	O
20	CD	O
g/day	JJ	O
]	NNP	O
)	)	O
,	,	O
separated	VBN	O
by	IN	O
a	DT	O
3-week	JJ	O
wash-out	JJ	O
period	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
results	NNS	O
are	VBP	O
expressed	VBN	O
as	IN	O
means	NNS	O
+/-	JJ	O
SD	NNP	O
.	.	O

The	DT	O
percentage	NN	O
mean	JJ	O
treatment	NN	O
difference	NN	O
between	IN	O
Abalon	NNP	PM
and	CC	O
placebo	NN	C
demonstrated	VBD	O
significantly	RB	O
lower	JJR	O
mean	NN	O
values	NNS	O
after	IN	O
Abalon	NNP	PM
for	IN	O
LDL	NNP	O
cholesterol	NN	O
(	(	O
10	CD	O
+/-	JJ	O
15	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
LDL/UHDL	NNP	O
ratio	NN	O
(	(	O
12	CD	O
+/-	JJ	O
18	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
apolipoprotein	RB	O
(	(	O
apo	NN	O
)	)	O
B100	NNP	O
(	(	O
30	CD	O
+/-	JJ	O
38	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
triglycerides	NNS	O
(	(	O
22	CD	O
+/-	JJ	O
10	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
homocysteine	NN	O
(	(	O
14	CD	O
+/-	JJ	O
21	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
whereas	VBD	O
the	DT	O
total	JJ	O
cholesterol	NN	O
value	NN	O
tended	VBD	O
to	TO	O
be	VB	O
less	RBR	O
significant	JJ	O
but	CC	O
still	RB	O
lower	JJR	O
(	(	O
8	CD	O
+/-	JJ	O
15	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.08	CD	O
)	)	O
.	.	O

No	UH	O
change	NN	O
occurred	VBD	O
in	IN	O
HDL	NNP	O
cholesterol	NN	O
,	,	O
apo	JJ	O
B100/apo	NNP	O
A1	NNP	O
ratio	NN	O
,	,	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
1	CD	O
,	,	O
factor	NN	O
VIIc	NNP	O
,	,	O
von	NNP	O
Willebrand	NNP	O
factor	NN	O
,	,	O
fibrinogen	NN	O
,	,	O
lipoprotein	NN	O
(	(	O
a	DT	O
)	)	O
,	,	O
glucose	JJ	O
,	,	O
HbA1c	NNP	O
,	,	O
or	CC	O
24-h	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
Abalon	NNP	PM
on	IN	O
cardiovascular	JJ	O
risk	NN	O
markers	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
subjects	NNS	O
.	.	O

This	DT	O
improvement	NN	O
is	VBZ	O
seen	VBN	O
even	RB	O
in	IN	O
individuals	NNS	O
with	IN	O
near-normal	JJ	O
lipid	JJ	O
values	NNS	O
.	.	O

Efficacy	NN	O
of	IN	O
amantadine	NN	PM
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
treated	VBD	O
with	IN	O
interferon-alpha	JJ	PM
and	CC	PM
ribavirin	NN	PM
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

AIM	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
amantadine	JJ	O
reduces	NNS	O
deterioration	NN	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
during	IN	O
and	CC	O
after	IN	O
treatment	NN	O
with	IN	O
interferon-alpha	JJ	O
(	(	O
IFN-alpha	NNP	O
)	)	O
and	CC	O
ribavirin	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
multicenter	JJ	O
trial	NN	O
,	,	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
IFN-alpha	NNP	PM
plus	CC	PM
ribavirin	JJ	PM
[	NN	PM
17	CD	PM
]	NN	PM
and	CC	O
randomized	VBN	O
for	IN	O
treatment	NN	O
with	IN	O
amantadine	NN	PM
(	(	O
200	CD	O
mg/day	NN	O
,	,	O
orally	RB	O
,	,	O
n=136	NN	O
)	)	O
or	CC	O
placebo	NN	C
(	(	O
n=131	JJ	O
)	)	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
'Profile	NN	O
of	IN	O
Mood	NNP	O
States	NNPS	O
'	POS	O
scale	NN	O
and	CC	O
the	DT	O
'Everyday	JJ	O
Life	NNP	O
'	POS	O
questionnaire	NN	O
at	IN	O
baseline	NN	O
,	,	O
treatment	NN	O
week	NN	O
(	(	O
TW	NNP	O
)	)	O
8	CD	O
,	,	O
TW24	NNP	O
,	,	O
TW48	NNP	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
.	.	O

RESULTS	VB	O
Early	JJ	O
during	IN	O
treatment	NN	O
at	IN	O
TW8	NNP	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
amantadine	NN	O
group	NN	O
.	.	O

At	IN	O
TW24	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
but	CC	O
not	RB	O
the	DT	O
amantadine	NN	PM
group	NN	O
,	,	O
however	RB	O
,	,	O
showed	VBD	O
significant	JJ	O
deterioration	NN	O
of	IN	O
the	DT	O
modalities	NNS	O
depression	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
vigor	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

Especially	RB	O
,	,	O
nonresponders	NNS	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
lower	JJR	O
deterioration	NN	O
of	IN	O
depression	NN	O
,	,	O
anger	NN	O
,	,	O
mind	NN	O
function	NN	O
,	,	O
everyday	JJ	O
life	NN	O
,	,	O
and	CC	O
zest	JJS	O
for	IN	O
life	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
amantadine	NN	O
disappeared	VBN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
addition	NN	O
of	IN	O
amantadine	NN	PM
to	TO	O
IFN-alpha	NNP	PM
plus	CC	PM
ribavirin	JJ	PM
combination	NN	O
therapy	NN	O
may	MD	O
reduce	VB	O
deterioration	NN	O
of	IN	O
depression	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
vigor	NN	O
during	IN	O
treatment	NN	O
but	CC	O
does	VBZ	O
not	RB	O
affect	JJ	O
quality	NN	O
of	IN	O
life	NN	O
after	IN	O
treatment	NN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
videotape	NN	E
information	NN	E
intervention	NN	E
at	IN	O
discharge	NN	O
on	IN	O
diet	JJ	O
and	CC	O
exercise	NN	O
compliance	NN	O
after	IN	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
relative	JJ	O
effects	NNS	O
on	IN	O
compliance	NN	O
with	IN	O
recommended	JJ	O
lifestyle	JJ	O
changes	NNS	O
of	IN	O
two	CD	O
experimental	JJ	E
videotapes	NNS	E
that	WDT	O
involved	VBD	O
different	JJ	O
approaches	NNS	O
for	IN	O
preparing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
(	(	O
CABG	NNP	O
)	)	O
patients	NNS	O
for	IN	O
the	DT	O
posthospital	JJ	O
recovery	NN	O
period	NN	O
.	.	O

The	DT	O
tapes	NNS	O
differed	VBN	O
in	IN	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
they	PRP	O
portrayed	VBD	O
the	DT	O
recovery	NN	O
period	NN	O
as	IN	O
a	DT	O
steady	JJ	O
,	,	O
forward	JJ	O
progression	NN	O
versus	IN	O
a	DT	O
series	NN	O
of	IN	O
ups	NNS	O
and	CC	O
downs	NNS	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
sixteen	JJ	O
male	NN	O
and	CC	O
female	JJ	O
CABG	NNP	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
either	DT	O
to	TO	O
view	VB	O
one	CD	E
of	IN	E
the	DT	E
two	CD	E
videotapes	NNS	E
before	IN	E
discharge	NN	E
from	IN	E
the	DT	E
hospital	NN	E
or	CC	O
to	TO	E
receive	VB	E
only	RB	E
the	DT	E
standard	JJ	E
discharge	NN	E
preparation	NN	E
provided	VBN	O
by	IN	O
the	DT	O
hospital	NN	O
.	.	O

All	DT	O
patients	NNS	O
completed	VBN	O
measures	NNS	O
of	IN	O
anxiety	NN	O
and	CC	O
self-efficacy	NN	O
at	IN	O
discharge	NN	O
,	,	O
1	CD	O
month	NN	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
discharge	NN	O
from	IN	O
the	DT	O
hospital	NN	O
.	.	O

Patients	NNS	O
also	RB	O
completed	VBD	O
measures	NNS	O
of	IN	O
dietary	JJ	O
fat	JJ	O
consumption	NN	O
and	CC	O
activity	NN	O
level	NN	O
1	CD	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
discharge	NN	O
.	.	O

RESULTS	NNP	O
Relative	NNP	O
to	TO	O
controls	NNS	O
,	,	O
patients	NNS	O
who	WP	O
viewed	VBD	O
either	DT	O
of	IN	O
the	DT	O
videotapes	NNS	E
before	IN	O
hospital	NN	O
release	NN	O
reported	VBD	O
higher	JJR	O
self-efficacy	NN	O
for	IN	O
adhering	VBG	O
to	TO	O
the	DT	O
recommended	VBN	O
low-fat	NN	O
diet	JJ	O
both	DT	O
at	IN	O
discharge	NN	O
and	CC	O
1	CD	O
month	NN	O
after	IN	O
surgery	NN	O
.	.	O

Viewing	VBG	O
either	DT	O
of	IN	O
the	DT	O
videotapes	NNS	O
also	RB	O
resulted	VBD	O
in	IN	O
significantly	RB	O
less	JJR	O
dietary	JJ	O
fat	NN	O
intake	NN	O
1	CD	O
month	NN	O
after	IN	O
hospital	NN	O
release	NN	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
viewed	VBD	O
the	DT	O
tape	NN	O
that	WDT	O
portrayed	VBD	O
the	DT	O
recovery	NN	O
period	NN	O
as	IN	O
consisting	NN	O
of	IN	O
ups	NNS	O
and	CC	O
downs	NNS	O
also	RB	O
reported	VBD	O
significantly	RB	O
more	RBR	O
frequent	JJ	O
moderate	JJ	O
exercise	NN	O
at	IN	O
1	CD	O
month	NN	O
and	CC	O
more	RBR	O
frequent	JJ	O
strenuous	JJ	O
exercise	NN	O
3	CD	O
months	NNS	O
after	IN	O
discharge	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
experimental	JJ	O
videotapes	NNS	E
proved	VBD	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
method	NN	O
for	IN	O
increasing	VBG	O
dietary	JJ	O
and	CC	O
exercise	NN	O
compliance	NN	O
during	IN	O
the	DT	O
first	JJ	O
3	CD	O
months	NNS	O
after	IN	O
CABG	NNP	O
.	.	O

Nasal	NNP	O
oxytocin	MD	PM
for	IN	O
social	JJ	O
deficits	NNS	O
in	IN	O
childhood	NN	O
autism	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

The	DT	O
last	JJ	O
two	CD	O
decades	NNS	O
have	VBP	O
witnessed	VBN	O
a	DT	O
surge	NN	O
in	IN	O
research	NN	O
investigating	VBG	O
the	DT	O
application	NN	O
of	IN	O
oxytocin	NN	O
as	IN	O
a	DT	O
method	NN	O
of	IN	O
enhancing	VBG	O
social	JJ	O
behaviour	NN	O
in	IN	O
humans	NNS	O
.	.	O

Preliminary	JJ	O
evidence	NN	O
suggests	VBZ	O
oxytocin	NN	O
may	MD	O
have	VB	O
potential	NN	O
as	IN	O
an	DT	O
intervention	NN	O
for	IN	O
autism	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
a	DT	O
5-day	JJ	O
'live-in	NN	O
'	POS	O
intervention	NN	O
using	VBG	O
a	DT	O
double-blind	JJ	O
randomized	VBN	O
control	NN	O
trial	NN	O
.	.	O

38	CD	O
male	JJ	O
youths	NNS	O
(	(	O
7-16	CD	O
years	NNS	O
old	JJ	O
)	)	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
were	VBD	O
administered	VBN	O
24	CD	O
or	CC	O
12	CD	O
international	JJ	O
units	NNS	O
(	(	O
depending	VBG	O
on	IN	O
weight	NN	O
)	)	O
intranasal	NN	C
placebo	NN	C
or	CC	O
oxytocin	JJ	PM
once	RB	O
daily	RB	O
over	IN	O
four	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

The	DT	O
oxytocin	NN	O
or	CC	O
placebo	NN	O
was	VBD	O
administered	VBN	O
during	IN	O
parent-child	JJ	O
interaction	NN	O
training	NN	O
sessions	NNS	O
.	.	O

Parent	NN	O
and	CC	O
child	NN	O
behaviours	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
parent	NN	O
reports	NNS	O
,	,	O
clinician	JJ	O
ratings	NNS	O
,	,	O
and	CC	O
independent	JJ	O
observations	NNS	O
,	,	O
at	IN	O
multiple	JJ	O
time	NN	O
points	NNS	O
to	TO	O
measure	VB	O
side-effects	NNS	O
;	:	O
social	JJ	O
interaction	NN	O
skills	NNS	O
;	:	O
repetitive	JJ	O
behaviours	NNS	O
;	:	O
emotion	NN	O
recognition	NN	O
and	CC	O
diagnostic	JJ	O
status	NN	O
.	.	O

Compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
intranasal	VB	O
oxytocin	RB	O
did	VBD	O
not	RB	O
significantly	RB	O
improve	VB	O
emotion	NN	O
recognition	NN	O
,	,	O
social	JJ	O
interaction	NN	O
skills	NNS	O
,	,	O
or	CC	O
general	JJ	O
behavioral	JJ	O
adjustment	NN	O
in	IN	O
male	JJ	O
youths	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
nasal	JJ	O
oxytocin	NN	O
for	IN	O
young	JJ	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
may	MD	O
be	VB	O
more	JJR	O
circumscribed	JJ	O
than	IN	O
suggested	VBN	O
by	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
and	CC	O
suggest	JJS	O
caution	NN	O
in	IN	O
recommending	VBG	O
it	PRP	O
as	IN	O
an	DT	O
intervention	NN	O
that	WDT	O
is	VBZ	O
broadly	RB	O
effective	JJ	O
.	.	O

Weight	NNP	O
and	CC	O
leptin	JJ	O
changes	NNS	O
among	IN	O
risperidone-treated	JJ	PM
youths	NNS	O
with	IN	O
autism	NN	O
:	:	O
6-month	JJ	O
prospective	JJ	O
data	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
authors	NNS	O
examined	VBD	O
the	DT	O
developmental	JJ	O
impact	NN	O
and	CC	O
temporal	JJ	O
characteristics	NNS	O
of	IN	O
risperidone-associated	JJ	PM
weight	NN	O
change	NN	O
.	.	O

METHOD	NNP	O
Weight	NNP	O
change	NN	O
was	VBD	O
measured	VBN	O
for	IN	O
63	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
treated	VBN	O
with	IN	O
risperidone	NN	PM
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Change	NNP	O
in	IN	O
serum	NN	O
leptin	NN	O
levels	NNS	O
after	IN	O
2	CD	O
months	NNS	O
was	VBD	O
examined	VBN	O
as	IN	O
a	DT	O
predictor	NN	O
of	IN	O
final	JJ	O
weight	NN	O
gain	NN	O
in	IN	O
mixed	JJ	O
regression	NN	O
models	NNS	O
that	WDT	O
controlled	VBD	O
for	IN	O
site	NN	O
,	,	O
gender	NN	O
,	,	O
age	NN	O
,	,	O
and	CC	O
risperidone	NN	PM
dose	NN	O
.	.	O

RESULTS	NNP	O
Age-	JJ	O
and	CC	O
gender-standardized	JJ	O
weight	NN	O
increased	VBD	O
after	IN	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
(	(	O
gross	JJ	O
:	:	O
mean=5.6	NN	O
kg	NN	O
[	NNP	O
SD=3.9	NNP	O
]	NNP	O
;	:	O
standardized	VBN	O
:	:	O
mean=0.6	NN	O
z	NN	O
[	NNP	O
SD=0.5	NNP	O
]	NNP	O
)	)	O
and	CC	O
was	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
weight	NN	O
gained	VBN	O
after	IN	O
1	CD	O
month	NN	O
.	.	O

Change	NN	O
in	IN	O
leptin	NN	O
levels	NNS	O
after	IN	O
2	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
(	(	O
mean=-0.3	JJ	O
ng/ml	NN	O
,	,	O
SD=6.2	NNP	O
)	)	O
(	(	O
N=48	NNP	O
)	)	O
did	VBD	O
not	RB	O
predict	JJ	O
final	JJ	O
weight	NN	O
gain	NN	O
.	.	O

CONCLUSIONS	NNP	O
Chronic	NNP	O
risperidone	NN	PM
exposure	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
causes	NNS	O
weight	VBD	O
gain	NN	O
in	IN	O
excess	NN	O
of	IN	O
developmentally	RB	O
expected	VBN	O
norms	NNS	O
that	WDT	O
follows	VBZ	O
a	DT	O
curvilinear	JJ	O
trajectory	NN	O
and	CC	O
decelerates	VBZ	O
over	IN	O
time	NN	O
.	.	O

Serum	NNP	O
leptin	JJ	O
change	NN	O
does	VBZ	O
not	RB	O
reliably	VB	O
predict	JJ	O
risperidone-associated	JJ	O
weight	NN	O
gain	NN	O
.	.	O

Effect	NN	O
of	IN	O
phenylephrine	NN	PM
on	IN	O
the	DT	O
haemodynamic	JJ	O
state	NN	O
and	CC	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
during	IN	O
anaesthesia	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
upright	JJ	O
sitting	NN	O
or	CC	O
beachchair	NN	O
position	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
hypotension	NN	O
,	,	O
risk	NN	O
of	IN	O
cerebral	JJ	O
hypoperfusion	NN	O
,	,	O
and	CC	O
cerebral	JJ	O
injury	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
by	IN	O
increasing	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	JJ	PM
administration	NN	O
,	,	O
cerebral	JJ	O
perfusion	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
recovery	NN	O
would	MD	O
be	VB	O
improved	VBN	O
.	.	O

METHODS	NNP	O
Thirty-four	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
shoulder	NN	O
surgery	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
saline	NN	PM
or	CC	PM
phenylephrine	NN	PM
infusion	NN	PM
(	(	PM
PE	NNP	PM
)	)	PM
5	CD	O
min	NN	O
before	IN	O
being	VBG	O
placed	VBN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

Simultaneous	JJ	O
measurements	NNS	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
,	,	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
velocity	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
function	NN	O
using	VBG	O
transthoracic	JJ	O
echocardiography	NN	O
were	VBD	O
made	VBN	O
.	.	O

Postoperative	JJ	O
neurocognitive	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
commencement	NN	O
of	IN	O
PE	NNP	O
,	,	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
significantly	RB	O
decreased	VBN	O
from	IN	O
77	CD	O
(	(	O
10	CD	O
)	)	O
to	TO	O
67	CD	O
(	(	O
13	CD	O
)	)	O
%	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
,	,	O
and	CC	O
further	RB	O
to	TO	O
59	CD	O
(	(	O
11	CD	O
)	)	O
%	NN	O
on	IN	O
upright	JJ	O
positioning	NN	O
.	.	O

The	DT	O
level	NN	O
of	IN	O
cerebral	JJ	O
saturation	NN	O
upright	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
to	TO	O
patients	NNS	O
receiving	VBG	O
saline	NN	O
(	(	O
P=0.07	NNP	O
)	)	O
,	,	O
with	IN	O
values	NNS	O
remaining	VBG	O
at	IN	O
room-air	JJ	O
levels	NNS	O
.	.	O

Middle	NNP	O
cerebral	JJ	O
artery	RB	O
blood	NN	O
velocity	NN	O
increased	VBN	O
by	IN	O
20	CD	O
%	NN	O
(	(	O
P=0.04	NNP	O
)	)	O
.	.	O

Phenylephrine	NNP	O
prevented	VBD	O
hypotension	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
primarily	RB	O
by	IN	O
maintaining	VBG	O
preload	NN	O
and	CC	O
increasing	VBG	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
(	(	O
P=0.01	NNP	O
)	)	O
,	,	O
and	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

No	DT	O
postoperative	JJ	O
neurocognitive	JJ	O
dysfunction	NN	O
was	VBD	O
identified	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
maintaining	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	NN	PM
,	,	O
cerebral	JJ	O
desaturation	NN	O
occurred	VBD	O
with	IN	O
upright	JJ	O
positioning	VBG	O
.	.	O

Cerebral	NNP	O
oxygen	IN	O
saturation	NN	O
can	MD	O
provide	VB	O
a	DT	O
valuable	JJ	O
endpoint	NN	O
when	WRB	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
vasopressor	NN	O
therapy	NN	O
on	IN	O
cerebral	JJ	O
perfusion	NN	O
.	.	O

Effects	NNS	O
of	IN	O
skin-to-skin	JJ	PH
contact	NN	PH
on	IN	O
autonomic	JJ	O
pain	NN	O
responses	NNS	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

UNLABELLED	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
crossover	NN	O
trial	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
on	IN	O
autonomic	JJ	O
responses	NNS	O
in	IN	O
preterm	JJ	O
infants	NNS	O
of	IN	O
longer	JJR	O
Kangaroo	NNP	PH
Care	NNP	PH
(	(	O
30	CD	O
minutes	NNS	O
,	,	O
KC30	NNP	PH
)	)	O
and	CC	O
shorter	JJR	O
KC	NNP	E
(	(	O
15	CD	O
minutes	NNS	O
,	,	O
KC15	NNP	PH
)	)	O
before	IN	O
and	CC	O
throughout	IN	O
heel	NN	O
stick	NNS	O
compared	VBN	O
with	IN	O
incubator	NN	PH
care	NN	PH
(	(	PH
IC	NNP	PH
)	)	E
.	.	O

Beat-to-beat	JJ	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
and	CC	O
spectral	JJ	O
power	NN	O
analysis	NN	O
of	IN	O
heart	NN	O
rate	NN	O
variability	NN	O
,	,	O
low	JJ	O
frequency	NN	O
power	NN	O
(	(	O
LF	NNP	O
)	)	O
,	,	O
high	JJ	O
frequency	NN	O
power	NN	O
(	(	O
HF	NNP	O
)	)	O
,	,	O
and	CC	O
LF/HF	NNP	O
ratio	NN	O
were	VBD	O
measured	VBN	O
in	IN	O
26	CD	O
infants	NNS	O
.	.	O

HR	NNP	O
changes	NNS	O
from	IN	O
Baseline	NNP	O
to	TO	O
Heel	NNP	O
Stick	NNP	O
were	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
KC30	NNP	O
and	CC	O
KC15	NNP	O
than	IN	O
in	IN	O
IC	NNP	O
,	,	O
and	CC	O
more	JJR	O
infants	NNS	O
had	VBD	O
HR	NNP	O
decrease	NN	O
in	IN	O
IC	NNP	O
than	IN	O
in	IN	O
2	CD	O
KC	NNP	O
conditions	NNS	O
.	.	O

In	IN	O
IC	NNP	O
,	,	O
LF	NNP	O
and	CC	O
HF	NNP	O
significantly	RB	O
increased	VBD	O
from	IN	O
Baseline	NNP	O
to	TO	O
Heel	NNP	O
Stick	NNP	O
and	CC	O
dropped	VBD	O
from	IN	O
Heel	NNP	O
Stick	NNP	O
to	TO	O
Recovery	NNP	O
;	:	O
in	IN	O
2	CD	O
KC	NNP	O
conditions	NNS	O
,	,	O
no	DT	O
changes	NNS	O
across	IN	O
study	NN	O
phases	NNS	O
were	VBD	O
found	VBN	O
.	.	O

During	IN	O
Heel	NNP	O
Stick	NNP	O
,	,	O
LF	NNP	O
and	CC	O
HF	NNP	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
IC	NNP	O
than	IN	O
in	IN	O
KC30	NNP	PH
.	.	O

In	IN	O
all	DT	O
3	CD	O
conditions	NNS	O
,	,	O
LF/HF	NNP	O
ratio	NN	O
decreased	VBD	O
from	IN	O
Baseline	NNP	O
to	TO	O
Heel	NNP	O
Stick	NNP	O
and	CC	O
increased	VBD	O
to	TO	O
Recovery	NNP	O
;	:	O
no	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
IC	NNP	PH
and	CC	O
two	CD	O
KC	NNP	E
conditions	NNS	O
.	.	O

Both	NNP	O
longer	JJR	O
and	CC	O
shorter	JJR	O
KC	NNP	E
before	IN	O
and	CC	O
throughout	IN	O
heel	NN	O
stick	NN	O
can	MD	O
stabilize	VB	O
HR	NNP	O
response	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
,	,	O
and	CC	O
longer	JJR	O
KC	NNP	PH
significantly	RB	O
affected	VBD	O
infants	NNS	O
'	POS	O
sympathetic	JJ	O
and	CC	O
parasympathetic	JJ	O
responses	NNS	O
during	IN	O
heel	NN	O
stick	NNS	O
compared	VBN	O
with	IN	O
incubator	NN	PH
care	NN	PH
.	.	O

PERSPECTIVE	VB	O
This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
KC	NNP	E
has	VBZ	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
reducing	VBG	O
autonomic	JJ	O
pain	NN	O
responses	NNS	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

The	DT	O
findings	NNS	O
support	NN	O
that	IN	O
KC	NNP	E
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
pain	NN	O
intervention	NN	O
in	IN	O
the	DT	O
neonatal	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
.	.	O

Lung	NNP	O
function	NN	O
and	CC	O
respiratory	NN	O
symptoms	NNS	O
in	IN	O
a	DT	O
1-year	JJ	O
randomized	JJ	O
smoking	NN	O
cessation	NN	O
trial	NN	O
of	IN	O
varenicline	NN	PM
in	IN	O
COPD	NNP	O
patients	NNS	O
.	.	O

UNLABELLED	IN	O
There	EX	O
are	VBP	O
few	JJ	O
data	NNS	O
concerning	VBG	O
changes	NNS	O
in	IN	O
lung	NN	O
function	NN	O
and	CC	O
respiratory	NN	O
symptoms	NNS	O
in	IN	O
smokers	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
weeks	NNS	O
to	TO	O
months	NNS	O
after	IN	O
quitting	VBG	O
smoking	NN	O
.	.	O

We	PRP	O
examined	VBD	O
serial	JJ	O
changes	NNS	O
in	IN	O
spirometry	NN	O
and	CC	O
Clinical	NNP	O
COPD	NNP	O
Questionnaire	NNP	O
(	(	O
CCQ	NNP	O
)	)	O
scores	VBZ	O
(	(	O
measuring	VBG	O
respiratory	NN	O
symptoms	NNS	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
)	)	O
in	IN	O
COPD	NNP	O
participants	NNS	O
by	IN	O
smoking	VBG	O
status	NN	O
during	IN	O
a	DT	O
smoking	NN	O
cessation	NN	O
trial	NN	O
.	.	O

In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
,	,	O
smokers	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
varenicline	JJ	PM
1	CD	PM
mg	NN	PM
b.i.d	NN	PM
.	.	PM

or	CC	O
placebo	NN	C
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
followed	VBD	O
to	TO	O
Week	VB	O
52	CD	O
.	.	O

Primary	JJ	O
endpoints	NNS	O
of	IN	O
abstinence	NN	O
were	VBD	O
previously	RB	O
reported	VBN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
were	VBD	O
mean	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
post-bronchodilator	NN	O
forced	VBN	O
expired	JJ	O
volume	NN	O
in	IN	O
1	CD	O
s	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
and	CC	O
CCQ	NNP	O
scores	NNS	O
.	.	O

Change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
post-bronchodilator	NN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
continuous	JJ	O
abstainers	NNS	O
(	(	O
121.8	CD	O
mL	NN	O
)	)	O
vs.	FW	O
continuous	JJ	O
smokers	NNS	O
(	(	O
37.9	CD	O
mL	NN	O
)	)	O
at	IN	O
Week	$	O
12	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.0069	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
Weeks	NNP	O
24	CD	O
or	CC	O
52	CD	O
.	.	O

Mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
at	IN	O
Week	NNP	O
12	CD	O
in	IN	O
CCQ	NNP	O
Total	NNP	O
Score	NNP	O
was	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
continuous	JJ	O
abstainers	NNS	O
(	(	O
-1.04	NN	O
)	)	O
vs.	FW	O
continuous	JJ	O
smokers	NNS	O
(	(	O
-0.53	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
:	:	O
this	DT	O
improvement	NN	O
was	VBD	O
sustained	VBN	O
at	IN	O
Weeks	NNP	O
24	CD	O
and	CC	O
52	CD	O
.	.	O

In	IN	O
a	DT	O
1-year	JJ	O
cessation	NN	O
trial	NN	O
of	IN	O
smokers	NNS	O
with	IN	O
COPD	NNP	O
,	,	O
continuous	JJ	O
abstinence	NN	O
compared	VBN	O
with	IN	O
continuous	JJ	O
smoking	VBG	O
significantly	RB	O
improved	VBN	O
post-bronchodilator	NN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
at	IN	O
Week	$	O
12	CD	O
(	(	O
although	IN	O
the	DT	O
difference	NN	O
narrowed	VBD	O
subsequently	RB	O
)	)	O
and	CC	O
CCQ	NNP	O
Total	NNP	O
Scores	NNP	O
at	IN	O
Week	NNP	O
12	CD	O
,	,	O
with	IN	O
sustained	JJ	O
improvement	NN	O
thereafter	RB	O
.	.	O

(	(	O
TRIAL	NNP	O
REGISTRY	NNP	O
http	NN	O
:	:	O
//www.clinicaltrials.gov	NN	O
;	:	O
trial	NN	O
identifier	NN	O
:	:	O
NCT00285012	NNP	O
)	)	O
.	.	O

Determination	NN	O
of	IN	O
vital	JJ	O
status	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
DIG	NNP	O
trial	NN	O
.	.	O

The	DT	O
Digitalis	NNP	O
Investigation	NNP	O
Group	NNP	O
(	(	O
DIG	NNP	O
)	)	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	C
trial	NN	O
whose	WP$	O
primary	JJ	O
objective	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
digoxin	NN	PM
had	VBD	O
beneficial	JJ	O
,	,	O
harmful	JJ	O
,	,	O
or	CC	O
no	DT	O
effect	NN	O
on	IN	O
total	JJ	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
who	WP	O
were	VBD	O
in	IN	O
sinus	NN	O
rhythm	NN	O
and	CC	O
whose	WP$	O
ejection	NN	O
fraction	NN	O
was	VBD	O
<	JJ	O
/=0.45	NNP	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
large	JJ	O
simple	JJ	O
trial	NN	O
with	IN	O
a	DT	O
large	JJ	O
number	NN	O
of	IN	O
centers	NNS	O
(	(	O
302	CD	O
)	)	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
and	CC	O
Canada	NNP	O
,	,	O
many	JJ	O
of	IN	O
which	WDT	O
were	VBD	O
inexperienced	VBN	O
in	IN	O
research	NN	O
.	.	O

To	TO	O
ensure	VB	O
that	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
trial	NN	O
would	MD	O
be	VB	O
reported	VBN	O
accurately	RB	O
without	IN	O
possible	JJ	O
bias	NN	O
due	JJ	O
to	TO	O
missing	VBG	O
data	NNS	O
,	,	O
the	DT	O
study	NN	O
leadership	NN	O
decided	VBD	O
that	IN	O
no	DT	O
outcome	NN	O
results	NNS	O
would	MD	O
be	VB	O
reported	VBN	O
until	IN	O
the	DT	O
vital	JJ	O
status	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
known	VBN	O
for	IN	O
at	IN	O
least	JJS	O
97	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
participants	NNS	O
.	.	O

Planning	VBG	O
for	IN	O
closeout	NN	O
of	IN	O
the	DT	O
study	NN	O
began	VBD	O
a	DT	O
year	NN	O
prior	RB	O
to	TO	O
the	DT	O
common	JJ	O
end	NN	O
date	NN	O
of	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
and	CC	O
included	VBD	O
plans	NNS	O
for	IN	O
obtaining	VBG	O
vital	JJ	O
status	NN	O
on	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
.	.	O

Participants	NNS	O
were	VBD	O
given	VBN	E
postcards	NNS	E
at	IN	E
their	PRP$	E
final	JJ	E
study	NN	E
visit	NN	E
to	TO	E
be	VB	E
completed	VBN	E
and	CC	E
mailed	VBN	E
on	IN	E
or	CC	E
after	IN	E
January	NNP	E
1	CD	E
,	,	E
1996	CD	E
.	.	O

Of	IN	O
5602	CD	O
postcards	NNS	O
distributed	VBN	O
,	,	O
5070	CD	O
(	(	O
90.5	CD	O
%	NN	O
)	)	O
were	VBD	O
completed	VBN	O
and	CC	O
returned	VBN	O
.	.	O

A	DT	O
contract	NN	O
search	NN	O
agency	NN	O
was	VBD	O
hired	VBN	O
to	TO	O
locate	VB	O
the	DT	O
remaining	VBG	O
participants	NNS	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
7788	CD	O
participants	NNS	O
entered	VBD	O
into	IN	O
the	DT	O
DIG	NNP	O
trial	NN	O
,	,	O
only	RB	O
97	CD	O
participants	NNS	O
(	(	O
1.2	CD	O
%	NN	O
)	)	O
could	MD	O
not	RB	O
have	VB	O
their	PRP$	O
vital	JJ	O
status	NN	O
as	IN	O
of	IN	O
December	NNP	O
31	CD	O
,	,	O
1995	CD	O
determined	VBD	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
investigators	NNS	O
having	VBG	O
an	DT	O
outcome	NN	O
measure	NN	O
with	IN	O
a	DT	O
common	JJ	O
end	NN	O
date	NN	O
include	VBP	O
plans	NNS	O
in	IN	O
their	PRP$	O
protocols	NNS	O
for	IN	O
obtaining	VBG	O
their	PRP$	O
measures	NNS	O
and	CC	O
activate	VBP	O
those	DT	O
plans	NNS	O
as	RB	O
early	RB	O
as	IN	O
possible	JJ	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Interferential	JJ	PH
therapy	NN	PH
electrode	NN	PH
placement	NN	PH
technique	NN	PH
in	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
a	DT	O
preliminary	JJ	O
investigation	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
interferential	JJ	PH
therapy	NN	PH
(	(	PH
IFT	NNP	PH
)	)	PH
electrode	VBP	PH
placement	NN	PH
technique	NN	PH
compared	VBN	O
with	IN	O
a	DT	O
control	NN	C
treatment	NN	C
in	IN	O
subjects	NNS	O
with	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
(	(	O
LBP	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Single-blind	NNP	O
,	,	O
randomized	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
with	IN	O
a	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

SETTING	NN	O
Outpatient	NNP	O
physiotherapy	NN	O
departments	NNS	O
in	IN	O
hospital	NN	O
and	CC	O
university	NN	O
settings	NNS	O
.	.	O

PATIENTS	VB	O
A	DT	O
random	JJ	O
sample	NN	O
of	IN	O
60	CD	O
eligible	JJ	O
patients	NNS	O
with	IN	O
back	JJ	O
pain	NN	O
(	(	O
28	CD	O
men	NNS	O
,	,	O
32	CD	O
women	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
by	IN	O
general	JJ	O
practitioners	NNS	O
and	CC	O
self-referral	JJ	O
for	IN	O
physiotherapy	NN	O
treatment	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
.	.	O

INTERVENTIONS	NNP	O
(	(	O
1	CD	O
)	)	O
IFT	NNP	PM
painful	JJ	PM
area	NN	PM
and	CC	PM
The	DT	PM
Back	NNP	PM
Book	NNP	PM
,	,	O
(	(	O
2	CD	O
)	)	O
IFT	NNP	PH
spinal	JJ	PH
nerve	NN	PH
and	CC	PM
The	DT	PH
Back	NNP	PH
Book	NNP	PH
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
Control	NN	C
,	,	C
The	DT	C
Back	NNP	C
Book	NNP	C
only	RB	O
.	.	O

Standardized	VBN	O
IFT	NNP	PM
stimulation	NN	O
parameters	NNS	O
were	VBD	O
used	VBN	O
:	:	O
carrier	NN	O
frequency	NN	O
3.85	CD	O
kHz	NN	O
;	:	O
140	CD	O
Hz	NNP	O
constant	NN	O
;	:	O
pulse	JJ	O
duration	NN	O
130	CD	O
micros	NN	O
;	:	O
30	CD	O
minutes	NNS	O
'	POS	O
duration	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Pain	NNP	O
Rating	NNP	O
Index	NNP	O
,	,	O
Roland-Morris	NNP	O
Disability	NNP	O
Questionnaire	NNP	O
(	(	O
RMDQ	NNP	O
)	)	O
,	,	O
and	CC	O
EuroQol	NNP	O
were	VBD	O
completed	VBN	O
by	IN	O
subjects	NNS	O
pretreatment	JJ	O
,	,	O
at	IN	O
discharge	NN	O
,	,	O
and	CC	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
groups	NNS	O
had	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
all	DT	O
outcomes	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

Subjects	NNS	O
managed	VBN	O
by	IN	O
IFT	NNP	O
spinal	JJ	O
nerve	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
displayed	VBD	O
both	DT	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
.030	NNP	O
)	)	O
and	CC	O
clinically	RB	O
meaningful	JJ	O
reduction	NN	O
in	IN	O
functional	JJ	O
disability	NN	O
(	(	O
RMDQ	NNP	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
management	NN	O
via	IN	O
IFT	NNP	O
painful	JJ	O
area	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
combined	VBD	O
or	CC	O
The	DT	O
Back	JJ	O
Book	NNP	O
alone	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
showed	VBD	O
that	IN	O
IFT	NNP	PH
electrode	FW	PH
placement	NN	PH
technique	NN	PH
affects	VBZ	O
LBP-specific	JJ	O
functional	JJ	O
disability	NN	O
,	,	O
providing	VBG	O
preliminary	JJ	O
implications	NNS	O
for	IN	O
future	JJ	O
clinical	JJ	O
studies	NNS	O
.	.	O

Self-management	JJ	E
improvement	NN	E
program	NN	E
combined	VBN	E
with	IN	E
community	NN	E
involvement	NN	E
in	IN	O
Thai	NNP	O
hypertensive	JJ	O
population	NN	O
:	:	O
an	DT	O
action	NN	O
research	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
program	NN	E
that	WDT	E
utilizes	VBZ	E
community	NN	E
involvement	NN	E
to	TO	O
improve	VB	O
the	DT	O
self-management	JJ	E
strategies	NNS	E
among	IN	O
people	NNS	O
living	VBG	O
with	IN	O
hypertension	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHOD	NNP	O
Forty-four	NNP	O
subjects	NNS	O
,	,	O
aged	VBD	O
35	CD	O
to	TO	O
59-year-old	JJ	O
,	,	O
with	IN	O
hypertension	NN	O
in	IN	O
Nakhon	NNP	O
Pathom	NNP	O
Province	NNP	O
,	,	O
Thailand	NNP	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	DT	O
an	DT	O
experimental	JJ	E
group	NN	E
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
or	CC	O
a	DT	O
control	NN	C
group	NN	C
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
attended	VBD	O
a	DT	O
program	NN	E
to	TO	E
improve	VB	E
self-management	JJ	E
methods	NNS	E
based	VBN	E
on	IN	E
social	JJ	E
cognitive	JJ	E
theory	NN	E
(	(	E
SCT	NNP	E
)	)	E
.	.	O

The	DT	O
program	NN	O
lasted	VBD	O
12	CD	O
weeks	NNS	O
,	,	O
consisted	VBD	O
of	IN	O
1	CD	O
1/2	CD	O
hours	NNS	O
meeting	VBG	O
once	RB	O
a	DT	O
week	NN	O
,	,	O
including	VBG	O
group	NN	E
meetings	NNS	E
and	CC	O
home	NN	E
visit	NN	E
monitoring	NN	E
.	.	O

Mann-Whitney	NNP	O
U	NNP	O
test	NN	O
and	CC	O
Friedman	NNP	O
test	NN	O
were	VBD	O
employed	VBN	O
to	TO	O
analyze	VB	O
the	DT	O
program	NN	O
's	POS	O
effectiveness	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
the	DT	O
program	NN	O
,	,	O
the	DT	O
mean	JJ	O
rank	NN	O
of	IN	O
the	DT	O
perceived	JJ	O
self-efficacy	NN	O
for	IN	O
the	DT	O
self-management	JJ	O
strategies	NNS	O
was	VBD	O
statistically	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.023	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
,	,	O
after	IN	O
the	DT	O
twelve	NN	O
week	NN	O
,	,	O
the	DT	O
mean	JJ	O
rank	NN	O
of	IN	O
perceived	VBN	O
self-efficacy	NN	O
and	CC	O
outcome	JJ	O
expectancy	NN	O
increased	VBD	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
decreased	VBN	O
after	IN	O
the	DT	O
eight	CD	O
week	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
program	NN	O
applied	VBN	O
social	JJ	E
cognitive	JJ	E
theory	NN	E
(	(	E
SCT	NNP	E
)	)	E
to	TO	O
promote	VB	O
self-management	JJ	E
techniques	NNS	E
,	,	O
increased	VBD	O
the	DT	O
health	NN	O
promoting	VBG	O
behavior	NN	O
among	IN	O
hypertensive	JJ	O
people	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
motor	NN	O
cortex	NN	O
excitability	NN	O
associated	VBN	O
with	IN	O
temporal	JJ	PH
repetitive	JJ	PH
transcranial	JJ	PH
magnetic	JJ	PH
stimulation	NN	PH
in	IN	O
tinnitus	NN	O
:	:	O
hints	NNS	O
for	IN	O
cross-modal	JJ	O
plasticity	NN	O
?	.	O
BACKGROUND	NNP	O
Motor	NNP	O
cortex	VBP	O
excitability	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
changed	VBN	O
after	IN	O
repetitive	JJ	PH
transcranial	JJ	PH
magnetic	JJ	PH
stimulation	NN	PH
(	(	PH
rTMS	NN	PH
)	)	PH
of	IN	O
the	DT	O
temporal	JJ	O
cortex	NN	O
highlighting	VBG	O
the	DT	O
occurrence	NN	O
of	IN	O
cross-modal	JJ	O
plasticity	NN	O
in	IN	O
non-invasive	JJ	O
brain	NN	O
stimulation	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
temporal	JJ	PH
low-frequency	NN	PH
rTMS	NN	PH
on	IN	O
motor	NN	O
cortex	NN	O
plasticity	NN	O
in	IN	O
a	DT	O
large	JJ	O
sample	NN	O
of	IN	O
tinnitus	NN	O
patients	NNS	O
.	.	O

In	IN	O
116	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
tinnitus	NN	O
different	JJ	O
parameters	NNS	O
of	IN	O
cortical	JJ	O
excitability	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
ten	JJ	O
rTMS	JJ	PH
treatment	NN	O
sessions	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
one	CD	O
of	IN	O
three	CD	O
different	JJ	O
protocols	NNS	O
all	DT	O
including	VBG	O
1	CD	O
Hz	NNP	O
rTMS	NN	O
over	IN	O
the	DT	O
left	JJ	O
temporal	JJ	O
cortex	NN	O
.	.	O

Treatment	NNP	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
improvement	NN	O
by	IN	O
at	IN	O
least	JJS	O
five	CD	O
points	NNS	O
in	IN	O
the	DT	O
tinnitus	NN	O
questionnaire	NN	O
(	(	O
TQ	NNP	O
)	)	O
.	.	O

Variables	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
resting	VBG	O
motor	NN	O
threshold	NN	O
(	(	O
RMT	NNP	O
)	)	O
,	,	O
short-interval	JJ	O
intra-cortical	JJ	O
inhibition	NN	O
(	(	O
SICI	NNP	O
)	)	O
,	,	O
intracortical	JJ	O
facilitation	NN	O
(	(	O
ICF	NNP	O
)	)	O
,	,	O
and	CC	O
cortical	JJ	O
silent	JJ	O
period	NN	O
(	(	O
CSP	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
After	IN	O
rTMS	JJ	PH
treatment	NN	O
RMT	NNP	O
was	VBD	O
decreased	VBN	O
by	IN	O
about	IN	O
1	CD	O
%	NN	O
of	IN	O
stimulator	NN	O
output	NN	O
near-significantly	RB	O
in	IN	O
the	DT	O
whole	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

SICI	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
significant	JJ	O
changes	NNS	O
with	IN	O
respect	NN	O
to	TO	O
treatment	NN	O
response	NN	O
.	.	O

The	DT	O
group	NN	O
of	IN	O
treatment	NN	O
responders	NNS	O
showed	VBD	O
a	DT	O
decrease	NN	O
of	IN	O
SICI	NNP	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
group	NN	O
of	IN	O
non-responders	NNS	O
the	DT	O
reverse	NN	O
pattern	NN	O
.	.	O

CONCLUSIONS	NNP	O
Minor	NNP	O
RMT	NNP	O
changes	NNS	O
during	IN	O
rTMS	NN	PH
treatment	NN	O
do	VBP	O
not	RB	O
necessarily	RB	O
suggest	VB	O
the	DT	O
need	NN	O
for	IN	O
systematic	JJ	O
re-examination	NN	O
of	IN	O
the	DT	O
RMT	NNP	O
for	IN	O
safety	NN	O
and	CC	O
efficacy	NN	O
issues	NNS	O
.	.	O

Treatment	NNP	O
response	NN	O
to	TO	O
rTMS	VB	PH
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
related	VBN	O
to	TO	O
changes	NNS	O
in	IN	O
SICI	NNP	O
that	WDT	O
might	MD	O
reflect	VB	O
modulation	NN	O
of	IN	O
GABAergic	NNP	O
mechanisms	FW	O
directly	RB	O
or	CC	O
indirectly	RB	O
related	VBN	O
to	TO	O
rTMS	VB	O
treatment	NN	O
effects	NNS	O
.	.	O

Benzodiazepine	NNP	PM
and	CC	O
opioid	JJ	PM
sedation	NN	PM
attenuate	IN	O
the	DT	O
sympathetic	JJ	O
response	NN	O
to	TO	O
fiberoptic	JJ	O
bronchoscopy	NN	O
.	.	O

Prophylactic	JJ	O
labetalol	NN	O
gave	VBD	O
no	DT	O
additional	JJ	O
benefit	NN	O
.	.	O

Results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Hypertension	NNP	O
and	CC	O
tachycardia	NN	O
are	VBP	O
common	JJ	O
during	IN	O
fiber-optic	JJ	PH
bronchoscopy	NN	PH
(	(	PH
FOB	NNP	PH
)	)	PH
,	,	O
and	CC	O
this	DT	O
may	MD	O
lead	VB	O
to	TO	O
cardiac	JJ	O
ischemia	NN	O
.	.	O

The	DT	O
prophylactic	JJ	O
addition	NN	O
of	IN	O
a	DT	O
beta-adrenergic	JJ	PM
anatagonist	NN	PM
might	MD	O
mask	VB	O
this	DT	O
response	NN	O
and	CC	O
prevent	VB	O
the	DT	O
deleterious	JJ	O
cardiovascular	JJ	O
effects	NNS	O
of	IN	O
FOB	NNP	O
.	.	O

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
labetalol	$	PM
10mg	CD	PM
iv	NN	PM
given	VBN	PM
with	IN	PM
midazolam-alfentanil	JJ	PM
sedation	NN	PM
.	.	O

We	PRP	O
monitored	VBD	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
and	CC	O
systolic/diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
SBP/DBP	NNP	O
)	)	O
throughout	IN	O
the	DT	O
bronchoscopy	NN	O
and	CC	O
calculated	VBD	O
the	DT	O
rate-pressure	JJ	O
product	NN	O
(	(	O
RPP=	NNP	O
(	(	O
HRxSBP	NNP	O
)	)	O
/100	NN	O
)	)	O
.	.	O

One-hundred	JJ	O
twenty	NN	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
rise	NN	O
in	IN	O
HR	NNP	O
,	,	O
SBP	NNP	O
,	,	O
DBP	NNP	O
or	CC	O
RPP	NNP	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
placebo	NN	O
and	CC	O
labetalol	NN	PM
groups	NNS	O
.	.	O

Adverse	JJ	O
events	NNS	O
during	IN	O
bronchoscopy	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

In	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
interventional	JJ	O
bronchoscopy	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
towards	NNS	O
lower	JJR	O
SBP	NNP	O
(	(	O
p=0.06	NN	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Patients	NNPS	O
undergoing	VBG	O
FOB	NNP	O
under	IN	O
adequate	JJ	O
midazolam-alfentanil	JJ	PM
sedation	NN	PM
do	VBP	O
not	RB	O
develop	VB	O
excessive	JJ	O
sympathetic	JJ	O
drive	NN	O
that	WDT	O
may	MD	O
lead	VB	O
to	TO	O
cardiac	JJ	O
stress	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
labetalol	NN	PM
did	VBD	O
not	RB	O
confer	VB	O
additional	JJ	O
benefit	NN	O
or	CC	O
risk	NN	O
to	TO	O
the	DT	O
patients	NNS	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00394537	NNP	O
)	)	O
.	.	O

Accuracy	NN	O
and	CC	O
feasibility	NN	O
of	IN	O
contrast	NN	PH
echocardiography	NN	PH
for	IN	O
detection	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
in	IN	O
routine	JJ	O
practice	NN	O
:	:	O
comparison	NN	O
with	IN	O
wall	JJ	PH
motion	NN	PH
and	CC	PH
technetium-99m	JJ	PH
sestamibi	NN	PH
single-photon	JJ	PH
emission	NN	PH
computed	VBD	PH
tomography	NN	PH
.	.	PH

The	DT	O
Nycomed	NNP	O
NC100100	NNP	O
Investigators	NNP	O
.	.	O

OBJECTIVES	NNP	O
We	PRP	O
sought	VBD	O
to	TO	O
assess	VB	O
the	DT	O
feasibility	NN	O
and	CC	O
accuracy	NN	O
of	IN	O
myocardial	JJ	PH
contrast	NN	PH
echocardiography	NN	PH
(	(	PH
MCE	NNP	PH
)	)	PH
using	VBG	O
standard	JJ	O
imaging	NN	O
approaches	NNS	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Myocardial	NNP	PH
contrast	NN	PH
echocardiography	NN	PH
may	MD	O
be	VB	O
more	JJR	O
versatile	JJ	O
than	IN	O
perfusion	NN	PH
scintigraphy	NN	PH
for	IN	O
identifying	VBG	O
the	DT	O
presence	NN	O
and	CC	O
extent	NN	O
of	IN	O
perfusion	NN	O
defects	NNS	O
after	IN	O
MI	NNP	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
reliability	NN	O
in	IN	O
routine	JJ	O
practice	NN	O
is	VBZ	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
Fundamental	NNP	O
or	CC	O
harmonic	JJ	O
MCE	NNP	O
was	VBD	O
performed	VBN	O
with	IN	O
continuous	JJ	O
or	CC	O
triggered	JJ	O
imaging	NN	O
in	IN	O
203	CD	O
patients	NNS	O
with	IN	O
a	DT	O
previous	JJ	O
MI	NNP	O
using	VBG	O
bolus	JJ	O
doses	NNS	O
of	IN	O
a	DT	O
perfluorocarbon-filled	JJ	PM
contrast	NN	PM
agent	NN	PM
(	(	PM
NC100100	NNP	PM
)	)	PM
.	.	PH

All	DT	O
patients	NNS	O
underwent	JJ	O
single-photon	JJ	PH
emission	NN	PH
computed	VBN	PH
tomography	NN	PH
(	(	PH
SPECT	NNP	PH
)	)	PH
after	IN	O
the	DT	O
injection	NN	O
of	IN	O
technetium-99m	JJ	O
(	(	O
Tc-99m	NNP	O
)	)	O
sestamibi	NN	O
at	IN	O
rest	NN	O
.	.	O

Quantitative	NNP	O
and	CC	O
semiquantitative	JJ	O
SPECT	NNP	PH
,	,	O
wall	NN	O
motion	NN	O
and	CC	O
digitized	JJ	O
echocardiographic	JJ	O
data	NNS	O
were	VBD	O
interpreted	VBN	O
independently	RB	O
.	.	O

The	DT	O
accuracy	NN	O
of	IN	O
MCE	NNP	PH
was	VBD	O
assessed	VBN	O
for	IN	O
detection	NN	O
of	IN	O
segments	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
moderate	JJ	O
and	CC	O
severe	JJ	O
sestamibi-SPECT	JJ	O
defects	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
detection	NN	O
of	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
perfusion	NN	O
defects	NNS	O
(	(	O
>	VB	O
12	CD	O
%	NN	O
of	IN	O
left	JJ	O
ventricle	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
In	IN	O
segments	NNS	O
with	IN	O
diagnostic	JJ	O
MCE	NNP	O
,	,	O
the	DT	O
segmental	JJ	O
sensitivity	NN	O
ranged	VBD	O
from	IN	O
14	CD	O
%	NN	O
to	TO	O
65	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
specificity	NN	O
varied	VBD	O
from	IN	O
78	CD	O
%	NN	O
to	TO	O
95	CD	O
%	NN	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
dose	NN	O
of	IN	O
contrast	NN	O
agent	NN	O
.	.	O

Using	VBG	O
both	DT	O
segment-	JJ	O
and	CC	O
patient-based	JJ	O
analysis	NN	O
,	,	O
the	DT	O
greatest	JJS	O
accuracy	NN	O
and	CC	O
proportion	NN	O
of	IN	O
interpretable	JJ	O
images	NNS	O
were	VBD	O
obtained	VBN	O
using	VBG	O
harmonic	JJ	O
imaging	NN	O
in	IN	O
the	DT	O
triggered	JJ	O
mode	NN	O
.	.	O

For	IN	O
the	DT	O
detection	NN	O
of	IN	O
extensive	JJ	O
defects	NNS	O
,	,	O
the	DT	O
sensitivity	NN	O
varied	VBD	O
from	IN	O
13	CD	O
%	NN	O
to	TO	O
48	CD	O
%	NN	O
,	,	O
with	IN	O
specificity	NN	O
from	IN	O
63	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
.	.	O

Harmonic	NNP	O
imaging	NN	O
remained	VBD	O
the	DT	O
most	RBS	O
accurate	JJ	O
approach	NN	O
.	.	O

Time	NNP	O
since	IN	O
MI	NNP	O
and	CC	O
SPECT	NNP	O
defect	VBP	O
location	NN	O
and	CC	O
intensity	NN	O
were	VBD	O
all	DT	O
determinants	NNS	O
of	IN	O
the	DT	O
MCE	NNP	O
response	NN	O
.	.	O

The	DT	O
extent	NN	O
of	IN	O
defects	NNS	O
on	IN	O
MCE	NNP	O
was	VBD	O
less	JJR	O
than	IN	O
the	DT	O
extent	NN	O
of	IN	O
either	DT	O
abnormal	JJ	O
wall	NN	O
motion	NN	O
or	CC	O
SPECT	NNP	O
abnormalities	NNS	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
wall	JJ	O
motion	NN	O
and	CC	O
MCE	NNP	O
assessment	NN	O
gave	VBD	O
the	DT	O
best	JJS	O
balance	NN	O
of	IN	O
sensitivity	NN	O
(	(	O
46	CD	O
%	NN	O
to	TO	O
55	CD	O
%	NN	O
)	)	O
and	CC	O
specificity	NN	O
(	(	O
82	CD	O
%	NN	O
to	TO	O
83	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
MCE	NNP	O
is	VBZ	O
specific	JJ	O
,	,	O
it	PRP	O
has	VBZ	O
limited	VBN	O
sensitivity	NN	O
for	IN	O
detection	NN	O
of	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
perfusion	NN	O
defects	NNS	O
,	,	O
and	CC	O
it	PRP	O
underestimates	VBZ	O
the	DT	O
extent	NN	O
of	IN	O
SPECT	NNP	O
defects	NNS	O
.	.	O

The	DT	O
best	JJS	O
results	NNS	O
are	VBP	O
obtained	VBN	O
by	IN	O
integration	NN	O
with	IN	O
wall	DT	O
motion	NN	O
.	.	O

More	RBR	O
sophisticated	JJ	O
methods	NNS	O
of	IN	O
acquisition	NN	O
and	CC	O
interpretation	NN	O
are	VBP	O
needed	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
this	DT	O
technique	NN	O
in	IN	O
routine	JJ	O
practice	NN	O
.	.	O

Validation	NN	O
of	IN	O
an	DT	O
FFQ	NNP	O
for	IN	O
evaluation	NN	O
of	IN	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
intake	VBP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
validate	VB	O
an	DT	O
FFQ	NNP	O
for	IN	O
the	DT	O
assessment	NN	O
of	IN	O
dietary	JJ	O
EPA	NNP	PM
and	CC	O
DHA	NNP	PM
against	IN	O
their	PRP$	O
relative	JJ	O
concentrations	NNS	O
in	IN	O
red	JJ	O
blood	NN	O
cells	NNS	O
(	(	O
RBC	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Cross-sectional	JJ	O
analysis	NN	O
of	IN	O
baseline	NN	O
data	NNS	O
.	.	O

Intakes	NNS	O
of	IN	O
marine	NN	PH
food	NN	PH
products	NNS	PH
and	CC	O
EPA	NNP	PM
and	CC	O
DHA	NNP	PM
were	VBD	O
estimated	VBN	O
by	IN	O
FFQ	NNP	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
consumption	NN	O
of	IN	O
marine	NN	PM
food	NN	PM
products	NNS	PM
in	IN	O
the	DT	O
last	JJ	O
month	NN	O
.	.	O

Fatty	NNP	O
acid	JJ	O
composition	NN	O
of	IN	O
RBC	NNP	O
membranes	NNS	O
was	VBD	O
quantified	VBN	O
by	IN	O
GC	NNP	O
.	.	O

SETTING	NNP	O
Saint-Fran?ois	JJ	O
d'Assise	NN	O
Hospital	NNP	O
,	,	O
Qu?bec	NNP	O
,	,	O
Canada	NNP	O
.	.	O

SUBJECTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
sixty-five	JJ	O
middle-aged	JJ	O
women	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

RESULTS	NNP	O
Spearman	NNP	O
's	POS	O
correlation	NN	O
coefficient	NN	O
between	IN	O
intake	NN	O
of	IN	O
EPA	NNP	O
,	,	O
DHA	NNP	O
and	CC	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
and	CC	O
their	PRP$	O
corresponding	JJ	O
concentration	NN	O
in	IN	O
RBC	NNP	O
was	VBD	O
0.46	CD	O
,	,	O
0.40	CD	O
and	CC	O
0.42	CD	O
,	,	O
respectively	RB	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Multiple	JJ	O
regression	NN	O
analysis	NN	O
of	IN	O
EPA+DHA	NNP	O
intake	NN	O
and	CC	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentration	NN	O
indicated	VBD	O
positive	JJ	O
and	CC	O
significant	JJ	O
correlations	NNS	O
for	IN	O
oily	RB	O
fish	JJ	O
(	(	O
beta	JJ	O
=	NN	O
0.44	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.16	CD	O
,	,	O
0.72	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0027	CD	O
)	)	O
,	,	O
total	JJ	O
fish	NN	O
(	(	O
beta	JJ	O
=	NN	O
0.42	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.19	CD	O
,	,	O
0.64	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0005	CD	O
)	)	O
and	CC	O
marine	VB	O
food	NN	O
products	NNS	O
(	(	O
beta	NN	O
=	RB	O
0.42	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.20	CD	O
,	,	O
0.64	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

No	UH	O
other	JJ	O
marine	VB	O
food	NN	O
products	NNS	O
significantly	RB	O
predicted	VBD	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentration	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
present	JJ	O
validation	NN	O
study	NN	O
was	VBD	O
undertaken	VBN	O
among	IN	O
middle-aged	JJ	O
women	NNS	O
with	IN	O
low	JJ	O
consumption	NN	O
of	IN	O
marine	NN	O
food	NN	O
products	NNS	O
(	(	O
<	$	O
3	CD	O
servings/week	NN	O
)	)	O
,	,	O
our	PRP$	O
FFQ	NNP	O
provided	VBD	O
estimates	NNS	O
of	IN	O
EPA	NNP	O
and	CC	O
DHA	NNP	O
intakes	NNS	O
that	WDT	O
correlated	VBD	O
fairly	RB	O
well	RB	O
with	IN	O
their	PRP$	O
RBC	NNP	O
concentrations	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
absence	NN	O
of	IN	O
correlations	NNS	O
between	IN	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
intakes	NNS	O
from	IN	O
different	JJ	O
marine	NN	O
species	NNS	O
suggests	VBZ	O
that	IN	O
a	DT	O
minimum	JJ	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
intake	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
observe	VB	O
a	DT	O
relationship	NN	O
with	IN	O
RBC	NNP	O
EPA	NNP	O
+	NNP	O
DHA	NNP	O
concentrations	NNS	O
.	.	O

A	DT	O
placebo-controlled	JJ	C
,	,	O
fixed-dose	JJ	O
study	NN	O
of	IN	O
aripiprazole	NN	PM
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
aripiprazole	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

METHOD	NNP	O
Two	CD	O
hundred	VBD	O
eighteen	JJ	O
children	NNS	O
and	CC	O
adolescents	NNS	O
(	(	O
aged	VBN	O
6-17	CD	O
years	NNS	O
)	)	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
and	CC	O
with	IN	O
behaviors	NNS	O
such	JJ	O
as	IN	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
self-injurious	JJ	O
behavior	NN	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
these	DT	O
symptoms	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
1:1:1:1	CD	O
to	TO	O
aripiprazole	VB	PM
(	(	PM
5	CD	PM
,	,	PM
10	CD	PM
,	,	PM
or	CC	PM
15	CD	PM
mg/day	NN	PM
)	)	PM
or	CC	O
placebo	NN	C
in	IN	O
this	DT	O
8-week	JJ	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
.	.	O

Efficacy	NNP	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
the	DT	O
caregiver-rated	JJ	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
Irritability	NNP	O
subscale	NN	O
(	(	O
primary	JJ	O
efficacy	NN	O
measure	NN	O
)	)	O
and	CC	O
the	DT	O
clinician-rated	JJ	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NNP	O
score	NN	O
.	.	O

Safety	NNP	O
and	CC	O
tolerability	NN	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
week	NN	O
8	CD	O
,	,	O
all	DT	O
aripiprazole	JJ	PM
doses	NNS	O
produced	VBN	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
than	IN	O
placebo	NN	O
in	IN	O
mean	JJ	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
Irritability	NNP	O
subscale	NN	O
scores	NNS	O
(	(	O
5	CD	O
mg/day	NN	O
,	,	O
-12.4	NNP	O
;	:	O
10	CD	O
mg/day	NN	O
,	,	O
-13.2	NNP	O
;	:	O
15	CD	O
mg/day	NN	O
,	,	O
-14.4	NNP	O
;	:	O
versus	NN	O
placebo	NN	O
,	,	O
-8.4	NNP	O
;	:	O
all	DT	O
p	VBP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

All	DT	O
aripiprazole	JJ	PM
doses	NNS	O
demonstrated	VBN	O
significantly	RB	O
greater	JJR	O
improvements	NNS	O
in	IN	O
mean	JJ	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NNP	O
score	NN	O
than	IN	O
placebo	NN	C
at	IN	O
week	NN	O
8	CD	O
.	.	O

Discontinuation	NN	O
rates	NNS	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
placebo	VB	O
7.7	CD	O
%	NN	O
,	,	O
aripiprazole	JJ	O
5	CD	O
mg/day	JJ	O
9.4	CD	O
%	NN	O
,	,	O
10	CD	O
mg/day	JJ	O
13.6	CD	O
%	NN	O
,	,	O
and	CC	O
15	CD	O
mg/day	JJ	O
7.4	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
event	NN	O
leading	VBG	O
to	TO	O
discontinuation	NN	O
was	VBD	O
sedation	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
:	:	O
presyncope	NN	O
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
and	CC	O
aggression	NN	O
(	(	O
10	CD	O
mg/day	NN	O
)	)	O
.	.	O

At	IN	O
week	NN	O
8	CD	O
,	,	O
mean	JJ	O
weight	NN	O
change	NN	O
(	(	O
last	JJ	O
observation	NN	O
carried	VBD	O
forward	RB	O
)	)	O
was	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
placebo	NN	O
+0.3	NNP	O
kg	NN	O
,	,	O
aripiprazole	JJ	PM
5	CD	O
mg/day	JJ	O
+1.3	NNP	O
kg	NN	O
,	,	O
10	CD	O
mg/day	NN	O
+1.3	NNP	O
kg	NN	O
,	,	O
and	CC	O
15	CD	O
mg/day	NN	O
+1.5	NNP	O
kg	NN	O
;	:	O
all	DT	O
p	VBP	O
<	JJ	O
.05	NNP	O
versus	NN	O
placebo	NN	C
.	.	O

CONCLUSIONS	NNP	O
Aripiprazole	NNP	PM
was	VBD	O
efficacious	JJ	O
and	CC	O
generally	RB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Bilateral	NNP	PM
transversus	NN	PM
abdominis	NN	PM
plane	NN	PM
block	NN	PM
does	VBZ	O
not	RB	O
decrease	VB	O
postoperative	JJ	O
pain	NN	O
after	IN	O
laparoscopic	NN	O
cholecystectomy	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
local	JJ	PM
anesthetic	JJ	PM
infiltration	NN	PM
of	IN	PM
trocar	NN	PM
insertion	NN	PM
sites	NNS	PM
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Transversus	NNP	PM
abdominis	NN	PM
plane	NN	PM
(	(	PM
TAP	NNP	PM
)	)	PM
block	NN	PM
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
pain	NN	O
and	CC	O
analgesic	JJ	O
requirements	NNS	O
after	IN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Our	PRP$	O
hypothesis	NN	O
was	VBD	O
that	IN	O
bilateral	JJ	PM
TAP	NNP	PM
blocks	NNS	PM
decrease	NN	O
pain	NN	O
after	IN	O
laparoscopic	NN	O
cholecystectomy	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
local	JJ	PM
anesthetic	JJ	PM
infiltration	NN	PM
of	IN	O
trocar	NN	O
insertion	NN	O
sites	NNS	O
.	.	O

METHODS	NNP	O
Eighty	NNP	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
bilateral	JJ	PM
TAP	NNP	PM
blocks	NNS	PM
or	CC	O
local	JJ	PM
anesthetic	JJ	PM
infiltration	NN	PM
of	IN	PM
trocar	NN	PM
insertion	NN	PM
sites	VBZ	PM
with	IN	PM
ropivacaine	JJ	PM
0.5	CD	PM
%	NN	PM
.	.	O

Postoperative	JJ	O
pain	NN	O
scores	NNS	O
and	CC	O
analgesic	JJ	O
use	NN	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hrs	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Eighty	NNP	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

After	IN	O
exclusions	NNS	O
,	,	O
data	NNS	O
were	VBD	O
analyzed	VBN	O
on	IN	O
39	CD	O
patients	NNS	O
in	IN	O
group	NN	O
T	NNP	O
(	(	O
bilateral	JJ	O
TAP	NNP	O
block	NN	O
)	)	O
and	CC	O
35	CD	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
(	(	O
infiltration	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
pain	NN	O
scores	NNS	O
on	IN	O
the	DT	O
numeric	JJ	O
analog	NN	O
scale	NN	O
(	(	O
0-10	JJ	O
)	)	O
between	IN	O
the	DT	O
groups	NNS	O
at	IN	O
4	CD	O
hrs	NN	O
after	IN	O
surgery	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.18	CD	O
)	)	O
or	CC	O
during	IN	O
the	DT	O
24	CD	O
hrs	NN	O
after	IN	O
surgery	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.23	CD	O
)	)	O
.	.	O

The	DT	O
time	NN	O
interval	NN	O
from	IN	O
anesthesia	JJ	O
start	NN	O
to	TO	O
surgery	VB	O
start	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
group	NN	O
T	NNP	O
than	IN	O
group	NN	O
I	PRP	O
(	(	O
48	CD	O
vs	RB	O
35	CD	O
mins	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
found	VBD	O
in	IN	O
analgesic	JJ	O
use	NN	O
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
hrs	NN	O
after	IN	O
surgery	NN	O
.	.	O

CONCLUSIONS	NNP	O
Bilateral	NNP	PM
ultrasound-guided	JJ	PM
TAP	NNP	PM
block	NN	PM
is	VBZ	O
equivalent	JJ	O
to	TO	O
local	JJ	PM
anesthetic	JJ	PM
infiltration	NN	PM
of	IN	O
trocar	NN	O
insertion	NN	O
sites	VBZ	O
for	IN	O
overall	JJ	O
postoperative	JJ	O
pain	NN	O
in	IN	O
a	DT	O
heterogeneous	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

Low-intensity	NNP	PH
exercise	NN	PH
and	CC	O
reduction	NN	O
of	IN	O
the	DT	O
risk	NN	O
for	IN	O
falls	NNS	O
among	IN	O
at-risk	JJ	O
elders	NNS	O
.	.	O

BACKGROUND	NNP	O
Among	IN	O
elderly	JJ	O
persons	NNS	O
,	,	O
falls	VBZ	O
account	NN	O
for	IN	O
87	CD	O
%	NN	O
of	IN	O
all	DT	O
fractures	NNS	O
and	CC	O
are	VBP	O
contributing	VBG	O
factors	NNS	O
in	IN	O
many	JJ	O
nursing	NN	O
home	NN	O
admissions	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
easily	RB	O
implemented	VBN	O
,	,	O
low-intensity	JJ	PH
exercise	NN	PH
program	NN	PH
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
falls	NNS	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
first	VB	O
fall	NN	O
among	IN	O
a	DT	O
clinically	RB	O
defined	JJ	O
population	NN	O
of	IN	O
elderly	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

METHODS	VB	O
This	DT	O
community-based	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
compared	VBN	O
the	DT	O
exercise	NN	PH
intervention	NN	PH
with	IN	O
a	DT	O
no-intervention	JJ	C
control	NN	C
.	.	C

The	DT	O
participants	NNS	O
were	VBD	O
294	CD	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
aged	VBD	O
60	CD	O
years	NNS	O
or	CC	O
older	JJR	O
,	,	O
who	WP	O
had	VBD	O
either	CC	O
a	DT	O
hospital	JJ	O
admission	NN	O
or	CC	O
bed	NN	O
rest	NN	O
for	IN	O
2	CD	O
days	NNS	O
or	CC	O
more	JJR	O
within	IN	O
the	DT	O
previous	JJ	O
month	NN	O
.	.	O

Exercise	NN	PH
participants	NNS	O
were	VBD	O
scheduled	VBN	O
to	TO	O
attend	VB	O
exercise	NN	PH
sessions	NNS	PH
lasting	VBG	O
45	CD	O
minutes	NNS	O
,	,	O
including	VBG	O
warm-up	JJ	O
and	CC	O
cool-down	JJ	O
,	,	O
3	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
(	(	O
24	CD	O
sessions	NNS	O
)	)	O
.	.	O

Assessments	NNS	O
included	VBD	O
gait	NN	O
and	CC	O
balance	NN	O
measures	NNS	O
,	,	O
self-reported	JJ	O
physical	JJ	O
function	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
medications	NNS	O
being	VBG	O
taking	VBG	O
at	IN	O
baseline	NN	O
,	,	O
participant	JJ	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
and	CC	O
history	NN	O
of	IN	O
falling	VBG	O
.	.	O

Falls	NNS	O
were	VBD	O
tracked	VBN	O
for	IN	O
1	CD	O
year	NN	O
after	IN	O
each	DT	O
participant	NN	O
's	POS	O
baseline	JJ	O
assessment	NN	O
.	.	O

RESULTS	VB	O
29	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
participants	NNS	O
reported	VBD	O
a	DT	O
fall	NN	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
exercise	NN	PH
in	IN	O
preventing	VBG	O
falls	NNS	O
varied	VBN	O
significantly	RB	O
by	IN	O
baseline	JJ	O
physical	JJ	O
function	NN	O
level	NN	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=.002	NN	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
for	IN	O
falls	NNS	O
decreased	VBN	O
for	IN	O
exercise	NN	O
participants	NNS	O
with	IN	O
low	JJ	O
baseline	NN	O
physical	JJ	O
functioning	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
.51	NN	O
)	)	O
but	CC	O
increased	VBD	O
for	IN	O
exercise	NN	O
participants	NNS	O
with	IN	O
high	JJ	O
baseline	NN	O
physical	JJ	O
functioning	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
3.51	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
easily	RB	O
implemented	VBN	O
,	,	O
low-intensity	JJ	PH
exercise	NN	PH
program	NN	PH
appears	VBZ	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
for	IN	O
falls	NNS	O
among	IN	O
elderly	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
recovering	VBG	O
from	IN	O
recent	JJ	O
hospitalizations	NNS	O
,	,	O
bed	VBD	O
rest	NN	O
,	,	O
or	CC	O
both	DT	O
who	WP	O
have	VBP	O
low	JJ	O
levels	NNS	O
of	IN	O
physical	JJ	O
functioning	NN	O
.	.	O

Insular	JJ	O
and	CC	O
anterior	JJ	O
cingulate	NN	O
circuits	NNS	O
in	IN	O
smokers	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

Schizophrenia	NNP	O
(	(	O
SZ	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
high	JJ	O
rates	NNS	O
of	IN	O
smoking	NN	O
.	.	O

We	PRP	O
previously	RB	O
found	VBD	O
that	IN	O
resting	VBG	O
state	NN	O
functional	JJ	O
connectivity	NN	O
(	(	O
rsFC	NN	O
)	)	O
between	IN	O
the	DT	O
dorsal	NN	O
anterior	JJ	O
cingulate	NN	O
(	(	O
dACC	NN	O
)	)	O
and	CC	O
striatum	NN	O
is	VBZ	O
independently	RB	O
associated	VBN	O
with	IN	O
nicotine	JJ	O
addiction	NN	O
and	CC	O
psychiatric	JJ	O
illness	NN	O
.	.	O

Since	IN	O
the	DT	O
insula	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
nicotine	JJ	O
dependence	NN	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	IN	O
SZ	NNP	O
smokers	NNS	O
will	MD	O
have	VB	O
greater	JJR	O
dysfunction	NN	O
in	IN	O
smoking-related	JJ	O
insular	NN	O
and	CC	O
dACC	NN	O
circuits	NNS	O
than	IN	O
normal	JJ	O
control	NN	O
smokers	NNS	O
(	(	O
NC	NNP	O
)	)	O
independent	JJ	O
of	IN	O
smoking	VBG	O
severity	NN	O
,	,	O
consistent	NN	O
with	IN	O
an	DT	O
inherent	JJ	O
disease-related	JJ	O
weakening	NN	O
of	IN	O
smoking-related	JJ	O
circuits	NNS	O
.	.	O

Nicotine	NNP	O
challenge	NN	O
was	VBD	O
used	VBN	O
to	TO	O
demonstrate	VB	O
that	DT	O
decreased	VBD	O
rsFC	NN	O
in	IN	O
identified	JJ	O
circuits	NNS	O
reflects	VBZ	O
addiction	JJ	O
trait	NN	O
and	CC	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
pharmacological	JJ	O
state	NN	O
.	.	O

Twenty-four	CD	O
NC	NNP	O
smokers	NNS	O
and	CC	O
20	CD	O
smokers	NNS	O
with	IN	O
SZ	NNP	O
matched	VBD	O
on	IN	O
nicotine	JJ	O
addiction	NN	O
severity	NN	O
participated	VBN	O
in	IN	O
a	DT	O
resting	NN	PH
state	NN	PH
fMRI	NN	PH
study	NN	PH
and	CC	PH
were	VBD	PH
scanned	VBN	PH
during	IN	PH
two	CD	PH
separate	JJ	PH
sessions	NNS	PH
while	IN	PH
receiving	VBG	PH
a	DT	PH
placebo	NN	C
or	CC	PH
nicotine	JJ	PM
patch	NN	PM
,	,	PM
in	IN	PH
a	DT	PH
randomized	JJ	PH
,	,	PH
cross-over	JJ	PH
design	NN	PH
.	.	O

Using	VBG	O
individualized	JJ	O
,	,	O
anatomically	RB	O
defined	VBN	O
anterior	JJ	O
and	CC	O
posterior	JJ	O
insula	NN	O
and	CC	O
dACC	NN	O
as	IN	O
regions	NNS	O
of	IN	O
interest	NN	O
(	(	O
ROI	NNP	O
)	)	O
,	,	O
whole	JJ	O
brain	NN	O
rsFC	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
each	DT	O
ROI	NNP	O
as	IN	O
a	DT	O
seed	NN	O
.	.	O

Significant	NNP	O
negative	JJ	O
correlations	NNS	O
between	IN	O
smoking	VBG	O
severity	NN	O
and	CC	O
rsFC	NN	O
between	IN	O
insula	NN	O
,	,	O
dACC	NN	O
and	CC	O
striatum	NN	O
were	VBD	O
found	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
smokers	NNS	O
with	IN	O
SZ	NNP	O
demonstrated	VBD	O
additive	JJ	O
reductions	NNS	O
in	IN	O
circuit	NN	O
strength	NN	O
between	IN	O
the	DT	O
dACC	NN	O
and	CC	O
insula	NN	O
compared	VBN	O
to	TO	O
NC	NNP	O
smokers	NNS	O
independent	JJ	O
of	IN	O
smoking	VBG	O
severity	NN	O
.	.	O

Nicotine	NNP	O
challenge	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
alter	VB	O
rsFC	NN	O
in	IN	O
insula-dACC-striatal	JJ	O
circuits	NNS	O
.	.	O

Reduced	VBN	O
rsFC	JJ	O
strength	NN	O
between	IN	O
the	DT	O
insula	NN	O
,	,	O
dACC	NN	O
and	CC	O
striatum	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
nicotine	JJ	O
addiction	NN	O
severity	NN	O
in	IN	O
both	DT	O
non-psychiatrically	RB	O
ill	NN	O
and	CC	O
in	IN	O
SZ	NNP	O
smokers	NNS	O
.	.	O

Decreased	VBN	O
insula-dACC	JJ	O
rsFC	NN	O
may	MD	O
index	NN	O
overlapping	VBG	O
circuitry	NN	O
associated	VBN	O
with	IN	O
smoking	NN	O
and	CC	O
SZ	NNP	O
.	.	O

Relationship	NN	O
between	IN	O
endogenous	JJ	PM
estrogen	NN	PM
concentrations	NNS	PM
and	CC	O
serum	NN	PM
cholesteryl	NN	PM
ester	NN	PM
transfer	NN	O
protein	NN	O
concentrations	NNS	O
in	IN	O
Chinese	JJ	O
women	NNS	O
.	.	O

BACKGROUND	NNP	O
CETP	NNP	O
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
HDL	NNP	O
metabolism	NN	O
and	CC	O
in	IN	O
the	DT	O
reverse	NN	O
cholesterol	NN	O
transport	NN	O
pathway	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
relationship	NN	O
between	IN	O
the	DT	O
changes	NNS	O
of	IN	O
endogenous	JJ	O
estrogen	NN	O
and	CC	O
the	DT	O
concentration	NN	O
of	IN	O
cholesteryl	NN	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
Chinese	JJ	O
women	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
estradiol	NN	O
(	(	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
,	,	O
follicle-stimulating	JJ	O
hormone	NN	O
(	(	O
FSH	NNP	O
)	)	O
,	,	O
CETP	NNP	O
and	CC	O
lipid	JJ	O
profile	NN	O
were	VBD	O
determined	VBN	O
in	IN	O
196	CD	O
Chinese	JJ	O
women	NNS	O
(	(	O
52	CD	O
premenopausal	NN	O
with	IN	O
ages	NNS	O
ranging	VBG	O
from	IN	O
18	CD	O
to	TO	O
40	CD	O
years	NNS	O
,	,	O
57	CD	O
perimenopausal	NN	O
from	IN	O
41	CD	O
to	TO	O
60	CD	O
years	NNS	O
,	,	O
and	CC	O
87	CD	O
postmenopausal	NN	O
from	IN	O
61	CD	O
to	TO	O
81	CD	O
years	NNS	O
)	)	O
.	.	O

RESULTS	NNP	O
Serum	NNP	O
CETP	NNP	O
concentration	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
perimenopausal	NN	O
and	CC	O
premenopausal	JJ	O
women	NNS	O
(	(	O
1.39+/-1.06	JJ	O
,	,	O
2.36+/-1.50	JJ	O
and	CC	O
2.31+/-1.25	JJ	O
mg/l	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Even	RB	O
in	IN	O
the	DT	O
women	NNS	O
around	IN	O
the	DT	O
menopausal	NN	O
,	,	O
CETP	NNP	O
concentration	NN	O
in	IN	O
postmenopause	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
premenopause	NN	O
(	(	O
1.93+/-1.33	JJ	O
vs.	IN	O
3.42+/-1.35	JJ	O
mg/l	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
CETP	NNP	O
concentration	NN	O
had	VBD	O
a	DT	O
highly	RB	O
positive	JJ	O
correlation	NN	O
with	IN	O
serum	JJ	O
concentration	NN	O
of	IN	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
r=0.243	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
while	IN	O
negative	JJ	O
correlation	NN	O
of	IN	O
CETP	NNP	O
concentration	NN	O
with	IN	O
serum	JJ	O
concentration	NN	O
of	IN	O
FSH	NNP	O
was	VBD	O
found	VBN	O
(	(	O
r=-0.273	JJ	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Estrogen	NNP	O
may	MD	O
affect	VB	O
the	DT	O
concentration	NN	O
of	IN	O
CETP	NNP	O
.	.	O

Line-item	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
:	:	O
results	NNS	O
from	IN	O
two	CD	O
studies	NNS	O
of	IN	O
aripiprazole	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
aripiprazole	NN	PM
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
discrete	JJ	O
symptoms	NNS	O
of	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
symptoms	NNS	O
captured	VBN	O
on	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
post	NN	O
hoc	NN	O
analysis	NN	O
of	IN	O
data	NNS	O
from	IN	O
two	CD	O
8-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
multicenter	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
aripiprazole	NN	PM
dosed	VBN	PM
flexibly	RB	PM
(	(	O
2-15	JJ	O
mg/day	NN	O
,	,	O
n=47	NN	O
)	)	O
or	CC	O
fixed	VBN	O
(	(	O
5	CD	O
,	,	O
10	CD	O
,	,	O
or	CC	O
15	CD	O
mg/day	NN	O
,	,	O
n	JJ	O
=	NNP	O
166	CD	O
)	)	O
versus	NN	O
placebo	NN	C
(	(	O
flexibly	RB	O
dosed	VBN	O
,	,	O
n	JJ	O
=	VBP	O
51	CD	O
;	:	O
fixed	VBN	O
dose	NN	O
,	,	O
n	JJ	O
=	NNP	O
52	CD	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
treatment	NN	O
on	IN	O
the	DT	O
58	CD	O
ABC	NNP	O
items	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Statistically	NNP	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
was	VBD	O
seen	VBN	O
with	IN	O
aripiprazole	JJ	PM
versus	NN	O
placebo	NN	C
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
all	DT	O
arms	NNS	O
in	IN	O
both	DT	O
trials	NNS	O
on	IN	O
the	DT	O
ABC-Irritability	NNP	O
total	JJ	O
subscale	NN	O
score	NN	O
and	CC	O
on	IN	O
the	DT	O
following	JJ	O
individual	JJ	O
ABC-Irritability	NNP	O
items	NNS	O
:	:	O
Mood	NNP	O
changes	NNS	O
quickly	RB	O
,	,	O
cries/screams	NNS	O
inappropriately	RB	O
,	,	O
and	CC	O
stamps	JJ	O
feet/bangs	NNS	O
objects	NNS	O
.	.	O

Several	JJ	O
additional	JJ	O
items	NNS	O
measuring	VBG	O
tantrum-like	JJ	O
behaviors	NNS	O
improved	VBN	O
in	IN	O
the	DT	O
flexibly	RB	O
dosed	VBN	O
trial	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
arm	NN	O
of	IN	O
the	DT	O
fixed-dose	JJ	O
trial	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Measures	NNS	O
of	IN	O
self-injurious	JJ	O
behavior	NN	O
,	,	O
which	WDT	O
had	VBD	O
low	JJ	O
baseline	NN	O
values	NNS	O
,	,	O
demonstrated	VBD	O
numerical	JJ	O
,	,	O
but	CC	O
not	RB	O
statistically	RB	O
significant	JJ	O
,	,	O
improvement	NN	O
in	IN	O
both	DT	O
trials	NNS	O
.	.	O

Statistically	RB	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
in	IN	O
ABC	NNP	O
Stereotypic	NNP	O
Behavior	NNP	O
and	CC	O
Hyperactivity	NNP	O
total	JJ	O
subscale	NN	O
scores	NNS	O
was	VBD	O
also	RB	O
consistent	JJ	O
across	IN	O
all	DT	O
arms	NNS	O
in	IN	O
both	DT	O
trials	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
cluster	NN	O
of	IN	O
items	NNS	O
related	VBN	O
to	TO	O
hyperkinesis	VB	O
that	WDT	O
were	VBD	O
consistently	RB	O
sensitive	JJ	O
to	TO	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Aripiprazole	NNP	PM
is	VBZ	O
efficacious	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
particularly	RB	O
with	IN	O
respect	NN	O
to	TO	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
tantrum	JJ	O
behavior	NN	O
.	.	O

A	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
tamoxifen	NN	PM
with	IN	O
surgical	JJ	S
oophorectomy	NN	S
in	IN	O
premenopausal	NN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

We	PRP	O
randomized	VBD	O
122	CD	O
premenopausal	JJ	O
women	NNS	O
to	TO	O
receive	VB	O
tamoxifen	NN	PM
or	CC	O
to	TO	O
undergo	VB	S
a	DT	S
surgical	JJ	S
oophorectomy	NN	S
.	.	S

Of	IN	O
54	CD	O
evaluable	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
tamoxifen	NN	PM
,	,	O
24	CD	O
%	NN	O
had	VBD	O
an	DT	O
objective	JJ	O
response	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
21	CD	O
%	NN	O
of	IN	O
53	CD	O
women	NNS	O
having	VBG	O
an	DT	O
oophorectomy	NN	S
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
response	NN	O
for	IN	O
tamoxifen	NN	PM
(	(	O
20	CD	O
months	NNS	O
)	)	O
was	VBD	O
longer	JJR	O
than	IN	O
that	DT	O
for	IN	O
surgical	JJ	S
oophorectomy	NN	S
(	(	O
7	CD	O
months	NNS	O
)	)	O
,	,	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
achieve	VB	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
.056	NNP	O
)	)	O
.	.	O

Overall	JJ	O
median	JJ	O
survival	NN	O
was	VBD	O
15	CD	O
months	NNS	O
for	IN	O
58	CD	O
patients	NNS	O
receiving	VBG	O
tamoxifen	NN	O
and	CC	O
25	CD	O
months	NNS	O
for	IN	O
53	CD	O
patients	NNS	O
undergoing	JJ	O
oophorectomy	JJ	O
(	(	O
P	NNP	O
=	NNP	O
.18	NNP	O
)	)	O
.	.	O

Toxicity	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
undergoing	JJ	O
oophorectomy	NN	O
,	,	O
though	IN	O
both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

In	IN	O
those	DT	O
premenopausal	JJ	O
women	NNS	O
for	IN	O
whom	WP	O
hormonal	JJ	O
therapy	NN	O
is	VBZ	O
indicated	VBN	O
,	,	O
tamoxifen	EX	PM
is	VBZ	O
a	DT	O
suitable	JJ	O
alternative	NN	O
to	TO	O
surgical	JJ	S
oophorectomy	NN	S
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
mizolastine	JJ	PM
10	CD	O
mg	NN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	C
comparison	NN	O
with	IN	O
loratadine	NN	PM
in	IN	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NNS	O
:	:	O
results	NNS	O
of	IN	O
the	DT	O
MILOR	NNP	O
Study	NNP	O
.	.	O

BACKGROUND	NNP	O
Mizolastine	NNP	PM
is	VBZ	O
a	DT	O
novel	JJ	O
histamine	NN	O
H1-antagonist	NN	O
registered	VBD	O
in	IN	O
Europe	NNP	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
allergic	JJ	O
rhinitis	NN	O
and	CC	O
urticaria	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
mizolastine	NN	PM
with	IN	PM
loratadine	NN	PM
and	CC	O
placebo	NN	C
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
idiopathic	JJ	O
urticaria	NN	O
(	(	O
CIU	NNP	O
)	)	O
.	.	O

METHODS	CC	O
A	DT	O
multicentre	NN	O
,	,	O
double-blind	NN	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
in	IN	O
which	WDT	O
247	CD	O
patients	NNS	O
with	IN	O
CIU	NNP	O
were	VBD	O
randomised	VBN	O
after	IN	O
a	DT	O
1-week	JJ	O
placebo	NN	C
run-in	JJ	O
period	NN	O
to	TO	O
10	CD	O
mg	NNS	O
daily	JJ	O
mizolastine	NN	PM
(	(	O
n	JJ	O
=	NNP	O
88	CD	O
)	)	O
,	,	O
10	CD	O
mg	JJ	O
daily	JJ	O
loratadine	NN	PM
(	(	O
n	JJ	O
=	NNP	O
79	CD	O
)	)	O
,	,	O
or	CC	O
placebo	NN	C
(	(	O
n	JJ	O
=	NNP	O
80	CD	O
)	)	O
for	IN	O
a	DT	O
4-week	JJ	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	NNP	O
Mizolastine	NNP	PM
and	CC	O
loratadine	VB	PM
both	DT	O
relieved	JJ	O
symptoms	NNS	O
of	IN	O
CIU	NNP	O
.	.	O

After	IN	O
2	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
,	,	O
the	DT	O
severity	NN	O
of	IN	O
pruritus	NN	O
(	(	O
visual	JJ	O
analogue	NN	O
score	NN	O
(	(	O
VAS	NNP	O
)	)	O
assessed	VBN	O
by	IN	O
patients	NNS	O
)	)	O
decreased	VBD	O
significantly	RB	O
in	IN	O
both	CC	O
the	DT	O
mizolastine	NN	PM
and	CC	PM
loratadine	NN	PM
groups	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	C
(	(	O
mizolastine	NN	PM
:	:	O
-36.7	NN	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0001	CD	O
;	:	O
loratadine	NN	PM
:	:	O
-29.8	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0071	CD	O
;	:	O
placebo	NN	C
:	:	O
-16.3	NN	O
)	)	O
;	:	O
this	DT	O
improvement	NN	O
with	IN	O
both	DT	O
active	JJ	O
treatments	NNS	O
was	VBD	O
maintained	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
the	DT	O
difference	NN	O
being	VBG	O
significant	JJ	O
only	RB	O
for	IN	O
the	DT	O
mizolastine	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0090	CD	O
)	)	O
.	.	O

Both	DT	O
active	JJ	O
treatments	NNS	O
were	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
reduced	JJ	O
weekly	JJ	O
episodes	NNS	O
of	IN	O
urticaria	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	C
,	,	O
which	WDT	O
was	VBD	O
significant	JJ	O
after	IN	O
2	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
(	(	O
mizolastine	NN	PM
:	:	O
7.9	CD	O
episodes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0061	CD	O
;	:	O
loratadine	NN	PM
:	:	O
8.3	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0221	CD	O
;	:	O
placebo	NN	C
:	:	O
13.3	CD	O
)	)	O
.	.	O

Angioedema	NNP	O
was	VBD	O
improved	VBN	O
to	TO	O
a	DT	O
clinically	RB	O
significant	JJ	O
extent	NN	O
with	IN	O
mizolastine	NN	PM
,	,	O
and	CC	O
loratadine	NN	PM
compared	VBN	O
with	IN	O
placebo	NN	C
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
this	DT	O
symptom	NN	O
before	IN	O
treatment	NN	O
.	.	O

Overall	JJ	O
tolerability	NN	O
of	IN	O
both	DT	O
treatments	NNS	O
was	VBD	O
similar	JJ	O
to	TO	O
placebo	VB	C
,	,	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
clinically	RB	O
relevant	JJ	O
effects	NNS	O
on	IN	O
cardiac	JJ	O
repolarisation	NN	O
with	IN	O
either	DT	O
mizolastine	NN	PM
or	CC	PM
loratadine	NN	PM
.	.	O

CONCLUSION	NNP	O
Mizolastine	NNP	PM
(	(	O
10	CD	O
mg	NNS	O
daily	RB	O
)	)	O
is	VBZ	O
confirmed	VBN	O
as	IN	O
an	DT	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	JJ	O
agent	NN	O
,	,	O
comparable	JJ	O
to	TO	O
loratadine	VB	O
and	CC	O
superior	VB	O
to	TO	O
placebo	VB	C
,	,	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
CIU	NNP	O
.	.	O

Mizolastine	NNP	PM
acted	VBD	O
as	RB	O
rapidly	RB	O
as	IN	O
loratadine	NN	PM
in	IN	O
improving	VBG	O
urticarial	JJ	O
symptoms	NNS	O
from	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
.	.	O

Antibiotic	JJ	O
therapy	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
using	VBG	O
tetracycline	NN	PM
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
in	IN	O
40	CD	O
patients	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
need	NN	O
for	IN	O
antibiotics	NNS	O
in	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
sufficiently	RB	O
ill	VBN	O
to	TO	O
require	VB	O
hospitalization	NN	O
although	IN	O
none	NN	O
needed	VBD	O
ventilatory	JJ	O
support	NN	O
;	:	O
the	DT	O
presence	NN	O
of	IN	O
pneumonia	NN	O
was	VBD	O
excluded	VBN	O
.	.	O

Treatment	NNP	O
consisted	VBD	O
of	IN	O
bronchodilators	NNS	PM
,	,	O
corticosteroids	NNS	PM
,	,	O
and	CC	O
either	DT	O
tetracycline	NN	PM
,	,	O
500	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	NN	C
by	IN	O
mouth	NN	O
every	DT	O
6	CD	O
hours	NNS	O
for	IN	O
1	CD	O
week	NN	O
.	.	O

Arterial	JJ	O
blood	NN	O
gases	NNS	O
,	,	O
spirometric	JJ	O
tests	NNS	O
,	,	O
bacteriologic	JJ	O
evaluation	NN	O
of	IN	O
sputum	NN	O
,	,	O
and	CC	O
patient	NN	O
and	CC	O
physician	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
illness	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
improved	VBN	O
both	DT	O
symptomatically	RB	O
and	CC	O
by	IN	O
objective	JJ	O
measures	NNS	O
of	IN	O
lung	NN	O
function	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
period	NN	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
those	DT	O
patients	NNS	O
receiving	VBG	O
tetracycline	NN	O
and	CC	O
those	DT	O
receiving	VBG	O
placebo	NN	C
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
antibiotic	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
needed	VBN	O
in	IN	O
moderately	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

Treatment	NN	O
of	IN	O
duodenal	JJ	O
ulcer	NN	O
with	IN	O
low-dose	JJ	PM
antacids	NNS	PM
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
investigation	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
low-dose	JJ	PM
antacid	NN	PM
(	(	PM
Maalox	NNP	PM
70	CD	PM
,	,	O
280	CD	O
mmol/day	NN	O
)	)	O
with	IN	O
that	DT	O
of	IN	O
the	DT	O
H2-receptor	NNP	PM
antagonist	NN	PM
cimetidine	NN	PM
(	(	PM
Tagamet	NNP	PM
,	,	O
200	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
and	CC	O
400	CD	O
mg/day	NN	O
)	)	O
after	IN	O
14	CD	O
and	CC	O
28	CD	O
days	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
duodenal	JJ	O
ulcer	NN	O
.	.	O

The	DT	O
prospective	JJ	O
multicentre	NN	O
study	NN	O
included	VBD	O
171	CD	O
patients	NNS	O
with	IN	O
endoscopically	RB	O
confirmed	VBN	O
duodenal	JJ	O
ulcers	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
groups	NNS	O
with	IN	O
antacid	JJ	PM
containing	VBG	PM
Mg	NNP	PM
and	CC	PM
Al	NNP	PM
hydroxide	NN	PM
(	(	PM
M	NNP	PM
)	)	PM
(	(	PM
4	CD	PM
X	RB	O
70	CD	O
mmol/day	NN	O
;	:	O
n	CC	O
=	VB	O
86	CD	O
)	)	O
or	CC	O
to	TO	O
the	DT	O
group	NN	O
receiving	VBG	O
cimetidine	NN	PM
(	(	O
T	NNP	O
)	)	O
(	(	O
1000	CD	O
mg/day	NN	O
;	:	O
n	CC	O
=	VB	O
85	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
matched	VBN	O
for	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
drinking	NN	O
and	CC	O
smoking	NN	O
habits	NNS	O
,	,	O
and	CC	O
drug	NN	O
use	NN	O
.	.	O

Endoscopic	JJ	O
examinations	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
and	CC	O
14	CD	O
days	NNS	O
later	RB	O
.	.	O

If	IN	O
the	DT	O
ulcer	NN	O
was	VBD	O
still	RB	O
present	JJ	O
at	IN	O
this	DT	O
time	NN	O
,	,	O
the	DT	O
second	JJ	O
endoscopic	NN	O
examination	NN	O
was	VBD	O
done	VBN	O
after	IN	O
a	DT	O
further	JJ	O
14	CD	O
days	NNS	O
.	.	O

Endoscopically	RB	O
,	,	O
the	DT	O
ulcer	NN	O
had	VBD	O
healed	VBN	O
at	IN	O
14	CD	O
days	NNS	O
in	IN	O
38.8	CD	O
%	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
in	IN	O
34.9	CD	O
%	NN	O
(	(	O
T	NNP	O
)	)	O
and	CC	O
at	IN	O
28	CD	O
days	NNS	O
in	IN	O
80.0	CD	O
%	NN	O
(	(	O
M	NNP	O
)	)	O
and	CC	O
74.7	CD	O
%	NN	O
(	(	O
T	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
healing	VBG	O
rate	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Complaints	NNS	O
,	,	O
measured	VBN	O
as	IN	O
percentage	NN	O
of	IN	O
days	NNS	O
per	IN	O
week	NN	O
with	IN	O
upper	JJ	O
abdominal	JJ	O
pain	NN	O
,	,	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
pain	VB	O
relief	NN	O
or	CC	O
side	NN	O
effects	NNS	O
.	.	O

Treatment	NN	O
had	VBD	O
to	TO	O
be	VB	O
abandoned	VBN	O
in	IN	O
one	CD	O
patient	NN	O
receiving	VBG	O
antacid	NN	O
because	IN	O
of	IN	O
diarrhoea	NN	O
and	CC	O
in	IN	O
one	CD	O
patient	NN	O
receiving	VBG	O
cimetidine	NN	O
because	IN	O
of	IN	O
the	DT	O
absence	NN	O
of	IN	O
any	DT	O
response	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Effect	NN	O
of	IN	O
ischemic	JJ	O
postconditioning	NN	O
in	IN	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
.	.	O

Inappropriate	NNP	O
myocardial	JJ	O
protection	NN	O
is	VBZ	O
considered	VBN	O
one	CD	O
of	IN	O
the	DT	O
main	JJ	O
causes	NNS	O
of	IN	O
mortality	NN	O
and	CC	O
morbidity	NN	O
in	IN	O
the	DT	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
(	(	O
TOF	NNP	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
previous	JJ	O
reports	NNS	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
ischemic	JJ	O
postconditioning	NN	O
on	IN	O
myocardial	JJ	O
protection	NN	O
in	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
are	VBP	O
very	RB	O
encouraging	JJ	O
.	.	O

This	DT	O
randomized	JJ	O
and	CC	O
controlled	JJ	O
trial	NN	O
aimed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ischemic	JJ	O
postconditioning	VBG	O
on	IN	O
protection	NN	O
against	IN	O
myocardial	JJ	O
ischemia	NN	O
reperfusion	NN	O
injury	NN	O
in	IN	O
TOF	NNP	O
patients	NNS	O
receiving	VBG	O
cardioplegia	NN	O
.	.	O

From	IN	O
January	NNP	O
2008	CD	O
to	TO	O
June	NNP	O
2010	CD	O
,	,	O
80	CD	O
consecutive	JJ	O
children	NNS	O
undergoing	VBG	O
correction	NN	O
of	IN	O
TOF	NNP	O
were	VBD	O
enrolled	VBN	PH
and	CC	PH
randomly	RB	PH
assigned	VBN	PH
to	TO	PH
either	VB	PH
a	DT	PH
postconditioning	NN	PH
group	NN	PH
(	(	O
three	CD	S
cycles	NNS	S
of	IN	S
30	CD	S
seconds	NNS	S
of	IN	S
ischemia	NN	S
and	CC	S
30	CD	S
seconds	NNS	S
of	IN	S
reperfusion	NN	S
using	VBG	S
re-clamping	JJ	S
and	CC	O
de-clamping	JJ	S
starting	VBG	S
30	CD	S
seconds	NNS	S
after	IN	S
the	DT	S
initial	JJ	S
de-clamping	NN	S
of	IN	S
the	DT	S
aorta	NN	S
,	,	S
n	JJ	S
=	NNP	S
41	CD	S
)	)	O
or	CC	O
a	DT	O
control	NN	C
group	NN	C
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
.	.	O

Cardiac	NNP	O
troponin	NN	O
I	PRP	O
(	(	O
cTnI	NN	O
)	)	O
was	VBD	O
assayed	VBN	O
preoperatively	RB	O
,	,	O
and	CC	O
then	RB	O
4	CD	O
hours	NNS	O
,	,	O
8	CD	O
hours	NNS	O
,	,	O
12	CD	O
hours	NNS	O
,	,	O
20	CD	O
hours	NNS	O
,	,	O
and	CC	O
48	CD	O
hours	NNS	O
after	IN	E
persistent	JJ	E
reperfusion	NN	E
.	.	O

The	DT	O
pre-	JJ	O
,	,	O
intra-	JJ	O
and	CC	O
postoperative	JJ	O
relevant	JJ	O
data	NNS	O
of	IN	O
all	DT	O
selected	VBN	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
ischemic	JJ	O
postconditioning	NN	O
reduced	VBD	O
postoperative	JJ	O
peak	NN	O
release	NN	O
by	IN	O
45	CD	O
%	NN	O
for	IN	O
cTnI	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
0.43	CD	O
?	.	O
0.18	CD	O
ng/mL	JJ	O
versus	NN	O
0.78	CD	O
?	.	O
0.15	CD	O
ng/mL	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Ischemic	NNP	O
postconditioned	VBD	O
patients	NNS	O
had	VBD	O
a	DT	O
lower	JJR	O
peak	NN	O
inotropic	NN	O
score	NN	O
during	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
24	CD	O
hours	NNS	O
(	(	O
5.6	CD	O
?	.	O
2.2	CD	O
?g/kg/minute	JJ	O
versus	NN	O
8.6	CD	O
?	.	O
3.6	CD	O
?g/kg/minute	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
extubation	JJ	O
time	NN	O
(	(	O
21.5	CD	O
?	.	O
7.3	CD	O
hours	NNS	O
versus	IN	O
30.2	CD	O
?	.	O
12.4	CD	O
hours	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0002	CD	O
)	)	O
and	CC	O
length	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
(	(	O
43.4	CD	O
?	.	O
12.6	CD	O
hours	NNS	O
versus	IN	O
56.3	CD	O
?	.	O
17.8	CD	O
hours	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
while	IN	O
they	PRP	O
had	VBD	O
a	DT	O
higher	JJR	O
cardiac	JJ	O
output	NN	O
on	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
day	NN	O
(	(	O
1.41	CD	O
?	.	O
0.26	CD	O
L/minute	NNP	O
versus	NN	O
1.28	CD	O
?	.	O
0.25	CD	O
L/minute	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.0255	CD	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
ischemic	JJ	O
postconditioning	NN	O
may	MD	O
to	TO	O
some	DT	O
extent	NN	O
provide	VBP	O
myocardial	JJ	O
protection	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
correction	NN	O
of	IN	O
tetralogy	NN	O
of	IN	O
Fallot	NNP	O
.	.	O

The	DT	O
Randomised	JJ	O
Intervention	NNP	O
Treatment	NNP	O
of	IN	O
Angina	NNP	O
(	(	O
RITA	NNP	O
)	)	O
Trial	NNP	O
protocol	NN	O
:	:	O
a	DT	O
long	JJ	O
term	NN	O
study	NN	O
of	IN	O
coronary	JJ	S
angioplasty	NN	S
and	CC	O
coronary	JJ	S
artery	NN	S
bypass	NN	S
surgery	NN	S
in	IN	O
patients	NNS	O
with	IN	O
angina	NN	O
.	.	O

The	DT	O
Randomised	JJ	O
Intervention	NNP	O
Treatment	NNP	O
of	IN	O
Angina	NNP	O
(	(	O
RITA	NNP	O
)	)	O
Trial	NNP	O
is	VBZ	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
study	NN	O
to	TO	O
compare	VB	O
the	DT	O
short	JJ	O
term	NN	O
and	CC	O
long	JJ	O
term	NN	O
effects	NNS	O
of	IN	O
percutaneous	JJ	S
transluminal	JJ	S
coronary	NN	S
angioplasty	NN	S
and	CC	O
coronary	JJ	S
artery	NN	S
bypass	NN	S
surgery	NN	S
.	.	O

During	IN	O
the	DT	O
study	NN	O
a	DT	O
register	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	PH
arteriography	NN	PH
at	IN	O
the	DT	O
fourteen	JJ	O
participating	VBG	O
centres	NNS	O
is	VBZ	O
being	VBG	O
maintained	VBN	O
to	TO	O
assess	VB	O
the	DT	O
overall	JJ	O
context	NN	O
of	IN	O
patient	JJ	O
recruitment	NN	O
.	.	O

Patients	NNS	O
with	IN	O
arteriographically	RB	O
proven	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
are	VBP	O
considered	VBN	O
for	IN	O
the	DT	O
trial	NN	O
if	IN	O
the	DT	O
participating	VBG	O
cardiologist	NN	O
and	CC	O
surgeon	NN	O
agree	VBP	O
that	IN	O
equivalent	JJ	O
revascularisation	NN	O
could	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
method	NN	O
.	.	O

Patients	NNS	O
who	WP	O
satisfy	VBP	O
the	DT	O
trial	NN	O
entry	NN	O
criteria	NNS	O
are	VBP	O
randomised	VBN	O
to	TO	O
treatment	NN	O
by	IN	O
coronary	JJ	S
angioplasty	NN	S
or	CC	O
coronary	JJ	S
artery	NN	S
bypass	NN	S
surgery	NN	S
,	,	O
with	IN	O
prospective	JJ	O
stratification	NN	O
into	IN	O
groups	NNS	O
with	IN	O
one	CD	O
,	,	O
two	CD	O
,	,	O
or	CC	O
three	CD	O
treatment	NN	O
vessels	NNS	O
.	.	O

Randomisation	NNP	O
implies	VBZ	O
an	DT	O
intention	NN	O
to	TO	O
treat	VB	O
the	DT	O
patient	NN	O
by	IN	O
the	DT	O
assigned	JJ	O
procedure	NN	O
and	CC	O
the	DT	O
analysis	NN	O
of	IN	O
long	JJ	O
term	NN	O
results	NNS	O
will	MD	O
include	VB	O
all	DT	O
randomised	JJ	O
cases	NNS	O
.	.	O

The	DT	O
trial	NN	O
will	MD	O
recruit	VB	O
at	IN	O
least	JJS	O
1000	CD	O
patients	NNS	O
who	WP	O
will	MD	O
be	VB	O
followed	VBN	O
for	IN	O
five	CD	O
years	NNS	O
.	.	O

The	DT	O
major	JJ	O
trial	NN	O
end	NN	O
points	NNS	O
include	VBP	O
death	NN	O
,	,	O
new	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
new	JJ	O
coronary	JJ	PH
angioplasty	NN	PH
or	CC	O
coronary	JJ	PH
artery	NN	PH
bypass	NN	PH
procedures	NNS	PH
.	.	O

Other	JJ	O
outcome	JJ	O
measures	NNS	O
include	VBP	O
symptom	NN	O
and	CC	O
employment	NN	O
status	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
exercise	NN	O
tolerance	NN	O
,	,	O
and	CC	O
left	VBD	O
ventricular	JJ	O
function	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
fidelity	NN	O
of	IN	O
implementation	NN	O
on	IN	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
the	DT	O
Responsive	NNP	E
Classroom	NNP	E
approach	NN	E
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
direct	JJ	O
and	CC	O
indirect	JJ	O
effects	NNS	O
between	IN	O
training	NN	O
in	IN	O
the	DT	O
Responsive	NNP	O
Classroom?	NNP	O
(	(	O
RC	NNP	O
)	)	O
approach	NN	O
,	,	O
teachers	NNS	O
'	POS	O
uptake	NN	O
of	IN	O
RC	NNP	O
practices	NNS	O
,	,	O
and	CC	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
,	,	O
using	VBG	O
a	DT	O
structural	JJ	O
equation	NN	O
modeling	VBG	O
framework	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
24	CD	O
schools	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
experimental	VB	O
or	CC	O
control	VB	O
conditions	NNS	O
.	.	O

Third-	CD	O
and	CC	O
fourth-grade	JJ	O
teachers	NNS	O
in	IN	O
treatment	NN	O
schools	NNS	O
(	(	O
n=132	NN	O
)	)	O
received	VBD	O
training	NN	O
in	IN	O
the	DT	O
RC	NNP	O
approach	NN	O
,	,	O
whereas	JJ	O
teachers	NNS	O
in	IN	O
control	NN	O
schools	NNS	O
(	(	O
n=107	NN	O
)	)	O
continued	VBD	O
business	NN	C
as	IN	C
usual	JJ	C
.	.	O

Observers	NNS	O
rated	VBD	O
teachers	NNS	O
'	POS	O
fidelity	NN	O
of	IN	O
implementation	NN	O
(	(	O
FOI	NNP	O
)	)	O
of	IN	O
RC	NNP	O
practices	NNS	O
5	CD	O
times	NNS	O
throughout	IN	O
the	DT	O
year	NN	O
using	VBG	O
the	DT	O
Classroom	NNP	O
Practices	NNPS	O
Observation	NNP	O
Measure	NNP	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
teachers	NNS	O
completed	VBD	O
self-report	JJ	O
measures	NNS	O
of	IN	O
FOI	NNP	O
,	,	O
the	DT	O
Classroom	NNP	O
Practices	NNPS	O
Teacher	NNP	O
Survey	NNP	O
and	CC	O
Classroom	NNP	O
Practices	NNP	O
Frequency	NNP	O
Survey	NNP	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
school	NN	O
year	NN	O
.	.	O

Teacher-student	JJ	O
interactions	NNS	O
were	VBD	O
rated	VBN	O
during	IN	O
classroom	NN	O
observations	NNS	O
using	VBG	O
the	DT	O
Classroom	NNP	O
Assessment	NNP	O
Scoring	NNP	O
System	NNP	O
.	.	O

Controlling	VBG	O
for	IN	O
teachers	NNS	O
'	POS	O
grade	NN	O
level	NN	O
and	CC	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
at	IN	O
pretest	JJS	O
,	,	O
RC	NNP	O
training	NN	O
was	VBD	O
expected	VBN	O
to	TO	O
predict	VB	O
posttest	JJS	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
directly	RB	O
and	CC	O
indirectly	RB	O
through	IN	O
FOI	NNP	O
.	.	O

Results	NNP	O
supported	VBD	O
only	RB	O
a	DT	O
significant	JJ	O
indirect	JJ	O
effect	NN	O
,	,	O
?=0.85	NNP	O
,	,	O
p=.002	NN	O
.	.	O

Specifically	RB	O
,	,	O
RC	NNP	O
teachers	NNS	O
had	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
FOI	NNP	O
of	IN	O
RC	NNP	O
practices	NNS	O
,	,	O
?=1.62	NNP	O
,	,	O
p	NN	O
<	NNP	O
.001	NNP	O
,	,	O
R2=.69	NNP	O
.	.	O

In	IN	O
turn	NN	O
,	,	O
FOI	NNP	O
related	VBD	O
to	TO	O
greater	JJR	O
improvement	NN	O
in	IN	O
teacher-student	JJ	O
interaction	NN	O
quality	NN	O
,	,	O
?=0.52	NNP	O
,	,	O
p=.001	NN	O
,	,	O
R2=.32	NNP	O
.	.	O

Discussion	NNP	O
highlights	NNS	O
factors	NNS	O
contributing	VBG	O
to	TO	O
variability	NN	O
in	IN	O
FOI	NNP	O
and	CC	O
school	NN	O
administrators	NNS	O
roles	NNS	O
in	IN	O
supporting	VBG	O
FOI	NNP	O
.	.	O

Fluoroscopic	NNP	O
functional	JJ	O
evaluation	NN	O
of	IN	O
bileaflet	NN	S
prostheses	NNS	S
:	:	O
effect	NN	O
of	IN	O
different	JJ	O
intraoperative	JJ	S
valve	NN	S
orientation	NN	S
.	.	O

Fluoroscopy	NNP	PH
is	VBZ	O
a	DT	O
reliable	JJ	O
,	,	O
easy	JJ	O
,	,	O
and	CC	O
readily	RB	O
available	JJ	O
technique	NN	O
to	TO	O
follow-up	JJ	O
prosthesis	NN	O
functioning	NN	O
after	IN	O
heart	NN	O
valve	NN	O
surgery	NN	O
.	.	O

The	DT	O
different	JJ	O
orientation	NN	O
given	VBN	O
to	TO	O
the	DT	O
prosthesis	NN	O
may	MD	O
represent	VB	O
a	DT	O
limitation	NN	O
of	IN	O
the	DT	O
technique	NN	O
accounting	NN	O
for	IN	O
unsatisfactory	JJ	O
results	NNS	O
in	IN	O
10	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
of	IN	O
the	DT	O
cases	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
whether	IN	O
and	CC	O
to	TO	O
what	WP	O
extent	VB	O
different	JJ	O
intraoperative	JJ	S
valve	NN	S
orientation	NN	S
influence	NN	O
feasibility	NN	O
and	CC	O
accuracy	NN	O
of	IN	O
postoperative	JJ	O
fluoroscopic	JJ	O
evaluation	NN	O
of	IN	O
bileaflet	NN	S
prostheses	NNS	S
.	.	O

We	PRP	O
prospectively	RB	O
evaluated	VBD	O
90	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
aortic	JJ	O
,	,	O
mitral	JJ	O
,	,	O
and/or	JJ	O
tricuspid	JJ	O
valve	FW	O
replacement	NN	O
with	IN	O
Sorin	NNP	PH
Bicarbon	NNP	PH
or	CC	O
CarboMedics	NNPS	PH
bileaflet	NN	PH
prostheses	NNS	PH
.	.	O

Fifty	NNP	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
prostheses	NNS	O
oriented	VBN	O
in	IN	O
a	DT	O
perpendicular	NN	S
or	CC	O
a	DT	O
parallel	JJ	S
position	NN	S
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
ventricular	JJ	O
septum	NN	O
.	.	O

Fluoroscopic	NNP	O
evaluation	NN	O
was	VBD	O
considered	VBN	O
appropriate	JJ	O
when	WRB	O
the	DT	O
prosthesis	NN	O
'	POS	O
tilting	VBG	O
disk	NN	O
projection	NN	O
was	VBD	O
obtained	VBN	O
.	.	O

The	DT	O
valve	NN	O
's	POS	O
hemodynamic	JJ	O
performance	NN	O
was	VBD	O
investigated	VBN	O
through	IN	O
Doppler	NNP	O
study	NN	O
.	.	O

A	DT	O
proper	JJ	O
fluoroscopic	NN	PH
evaluation	NN	PH
was	VBD	O
rapidly	RB	O
(	(	O
15	CD	O
+/-	JJ	O
5	CD	O
seconds	NNS	O
)	)	O
achieved	VBN	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
the	DT	O
former	JJ	O
orientation	NN	O
,	,	O
whereas	IN	O
it	PRP	O
was	VBD	O
impossible	JJ	O
to	TO	O
obtain	VB	O
it	PRP	O
in	IN	O
8	CD	O
of	IN	O
20	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
,	,	O
19	CD	O
of	IN	O
20	CD	O
(	(	O
95	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
4	CD	O
of	IN	O
5	CD	O
(	(	O
80	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
with	IN	O
the	DT	O
latter	JJ	O
orientation	NN	O
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
patients	NNS	O
extremely	RB	O
angulated	VBN	O
,	,	O
uneasy	JJ	O
projection	NN	O
was	VBD	O
often	RB	O
required	VBN	O
to	TO	O
get	VB	O
a	DT	O
correct	JJ	O
fluoroscopic	NN	O
image	NN	O
.	.	O

The	DT	O
Doppler	NNP	O
study	NN	O
showed	VBD	O
a	DT	O
similarly	RB	O
favorable	JJ	O
hemodynamic	JJ	O
performance	NN	O
regardless	NN	O
of	IN	O
valve	JJ	O
orientation	NN	O
.	.	O

Prosthesis	NNP	S
orientation	NN	S
crucially	RB	O
affects	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
success	NN	O
of	IN	O
the	DT	O
fluoroscopic	JJ	O
evaluation	NN	O
.	.	O

The	DT	O
orientation	NN	O
perpendicular	NN	O
to	TO	O
the	DT	O
ventricular	JJ	O
septum	NN	O
greatly	RB	O
facilitates	VBZ	O
the	DT	O
postoperative	JJ	O
feasibility	NN	O
and	CC	O
accuracy	NN	O
of	IN	O
fluoroscopy	NN	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
not	RB	O
detrimental	JJ	O
to	TO	O
the	DT	O
valve	NN	O
's	POS	O
hemodynamic	JJ	O
performance	NN	O
.	.	O

This	DT	O
valve	JJ	S
orientation	NN	S
may	MD	O
provide	VB	O
a	DT	O
better	JJR	O
fluoroscopic	NN	O
window	NN	O
whenever	WRB	O
a	DT	O
valve	NN	O
dysfunction	NN	O
is	VBZ	O
suspected	VBN	O
.	.	O

Microbiologic	JJ	O
yields	NNS	O
and	CC	O
complication	NN	O
rates	NNS	O
of	IN	O
vitreous	JJ	S
needle	JJ	S
aspiration	NN	S
versus	IN	O
mechanized	VBN	S
vitreous	JJ	S
biopsy	NN	S
in	IN	O
the	DT	O
Endophthalmitis	NNP	O
Vitrectomy	NNP	O
Study	NNP	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
microbiologic	JJ	O
yields	NNS	O
and	CC	O
complication	NN	O
rates	NNS	O
associated	VBN	O
with	IN	O
vitreous	JJ	S
needle	JJ	S
tap	NN	S
and	CC	O
vitreous	JJ	PH
biopsy	NN	PH
in	IN	O
the	DT	O
Endophthalmitis	NNP	O
Vitrectomy	NNP	O
Study	NNP	O
(	(	O
EVS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Of	IN	O
420	CD	O
EVS	NNP	O
patients	NNS	O
with	IN	O
postoperative	JJ	O
endophthalmitis	NN	O
,	,	O
201	CD	O
received	VBD	O
immediate	JJ	O
vitreous	JJ	S
tap	NN	S
or	CC	S
biopsy	NN	S
(	(	S
without	IN	S
pars	NNS	S
plana	VBP	S
vitrectomy	NN	S
)	)	S
by	IN	O
random	JJ	O
assignment	NN	O
and	CC	O
193	CD	O
completed	VBN	O
9-12	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

Vitreous	JJ	O
specimens	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
biopsy	NN	O
with	IN	O
a	DT	O
20-gauge	JJ	PH
vitrectomy	NN	PH
cutting	VBG	O
instrument	NN	O
or	CC	O
by	IN	O
needle	JJ	O
tap	NN	O
with	IN	O
a	DT	O
22-27-gauge	JJ	O
needle	NN	O
.	.	O

If	IN	O
resistance	NN	O
to	TO	O
aspiration	NN	O
by	IN	O
needle	JJ	O
tap	NN	O
was	VBD	O
noted	VBN	O
,	,	O
a	DT	O
vitreous	JJ	O
biopsy	NN	O
was	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
201	CD	O
patients	NNS	O
undergoing	JJ	O
tap	NN	O
or	CC	O
biopsy	NN	O
,	,	O
70	CD	O
(	(	O
35	CD	O
%	NN	O
)	)	O
had	VBD	O
needle	JJ	O
tap	NN	O
,	,	O
127	CD	O
(	(	O
63	CD	O
%	NN	O
)	)	O
had	VBD	O
mechanized	VBN	O
biopsy	NN	O
,	,	O
and	CC	O
4	CD	O
(	(	O
2	CD	O
%	NN	O
)	)	O
had	VBD	O
initial	JJ	O
needle	JJ	O
tap	NN	O
that	WDT	O
was	VBD	O
aborted	VBN	O
to	TO	O
mechanized	VBN	O
biopsy	NN	O
(	(	O
abort	JJ	O
eyes	NNS	O
)	)	O
.	.	O

Intraoperative	JJ	O
hyphema	NN	O
occurred	VBD	O
in	IN	O
2	CD	O
tap	JJ	O
eyes	NNS	O
(	(	O
3	CD	O
%	NN	O
)	)	O
,	,	O
3	CD	O
biopsy	NN	O
eyes	NNS	O
(	(	O
2	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
0	CD	O
(	(	O
0	CD	O
%	NN	O
)	)	O
abort	NN	O
eyes	NNS	O
.	.	O

Postoperative	JJ	O
retinal	JJ	O
detachment	NN	O
developed	VBD	O
in	IN	O
8	CD	O
(	(	O
11	CD	O
%	NN	O
)	)	O
tap	NN	O
eyes	NNS	O
,	,	O
10	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
biopsy	NN	O
eyes	NNS	O
,	,	O
and	CC	O
0	CD	O
(	(	O
0	CD	O
%	NN	O
)	)	O
abort	NN	O
eyes	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

Respective	JJ	O
rates	NNS	O
of	IN	O
culture	NN	O
and	CC	O
gram	NN	O
stain	VBP	O
positivity	NN	O
were	VBD	O
69	CD	O
%	NN	O
and	CC	O
42	CD	O
%	NN	O
in	IN	O
tap	JJ	O
eyes	NNS	O
and	CC	O
66	CD	O
%	NN	O
and	CC	O
41	CD	O
%	NN	O
in	IN	O
biopsy	JJ	O
eyes	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
severe	JJ	O
visual	JJ	O
loss	NN	O
(	(	O
final	JJ	O
acuity	NN	O
<	NNP	O
5/200	CD	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
tap	JJ	O
eyes	NNS	O
(	(	O
16	CD	O
eyes	NNS	O
,	,	O
24	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
biopsy	JJ	O
eyes	NNS	O
(	(	O
13	CD	O
eyes	NNS	O
,	,	O
11	CD	O
%	NN	O
)	)	O
and	CC	O
abort	JJ	O
eyes	NNS	O
(	(	O
0	CD	O
eyes	NNS	O
,	,	O
0	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
largely	RB	O
explained	VBN	O
by	IN	O
the	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
virulent	JJ	O
organisms	NNS	O
in	IN	O
the	DT	O
tap	JJ	O
eyes	NNS	O
compared	VBN	O
with	IN	O
biopsy	JJ	O
eyes	NNS	O
.	.	O

When	WRB	O
visual	JJ	O
acuity	NN	O
outcome	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
other	JJ	O
thresholds	NNS	O
(	(	O
20/40	CD	O
and	CC	O
20/100	CD	O
)	)	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
mechanized	VBN	O
vitreous	JJ	O
biopsy	NN	O
and	CC	O
needle	JJ	O
tap	NN	O
with	IN	O
respect	NN	O
to	TO	O
microbiologic	JJ	O
yield	NN	O
,	,	O
operative	JJ	O
complications	NNS	O
,	,	O
short-term	JJ	O
(	(	O
9-12	JJ	O
months	NNS	O
)	)	O
retinal	JJ	O
detachment	NN	O
risk	NN	O
,	,	O
or	CC	O
visual	JJ	O
outcome	NN	O
.	.	O

Choice	NNP	O
of	IN	O
vitreous	JJ	O
sampling	VBG	O
procedure	NN	O
must	MD	O
depend	VB	O
on	IN	O
the	DT	O
clinical	JJ	O
judgment	NN	O
of	IN	O
the	DT	O
surgeon	NN	O
.	.	O

Walking	VBG	O
trials	NNS	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
:	:	O
effect	NN	O
of	IN	O
one	CD	O
vs	NN	O
two	CD	O
daily	JJ	O
bouts	NNS	O
on	IN	O
aerobic	JJ	O
fitness	NN	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
one	CD	PH
vs	NN	PH
two	CD	PH
daily	JJ	PH
bouts	NNS	PH
of	IN	PH
walking	VBG	PH
on	IN	O
aerobic	JJ	O
fitness	NN	O
and	CC	O
body	NN	O
composition	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
thirty-four	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
exercise	NN	O
groups	NNS	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
and	CC	O
130	CD	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
subjects	NNS	O
walked	VBD	E
5	CD	PH
d/week	NN	PH
for	IN	PH
15	CD	PH
weeks	NNS	PH
at	IN	PH
65	CD	PH
%	NN	PH
of	IN	PH
their	PRP$	PH
maximal	NN	PH
aerobic	JJ	PH
power	NN	PH
expending	VBG	PH
300	CD	PH
kcal	JJ	PH
(	(	O
1255	CD	O
kJ	NN	O
)	)	O
in	IN	O
exercise	NN	E
in	IN	O
one	CD	O
(	(	O
Group	NNP	O
S1	NNP	O
)	)	O
or	CC	O
two	CD	O
daily	JJ	O
sessions	NNS	O
(	(	O
Group	NNP	O
S2	NNP	O
)	)	O
.	.	O

VO	NNP	O
(	(	O
2max	CD	O
)	)	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
direct	JJ	PH
maximal	NN	PH
treadmill	NN	PH
test	NN	PH
.	.	O

Body	NNP	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
was	VBD	O
calculated	VBN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
body	NN	O
fat	NN	O
(	(	O
fat	JJ	O
%	NN	O
)	)	O
estimated	VBN	O
using	VBG	O
skinfold	JJ	O
measurements	NNS	O
.	.	O

The	DT	O
net	JJ	O
change	NN	O
in	IN	O
the	DT	O
VO	NNP	O
(	(	O
2max	CD	O
)	)	O
was	VBD	O
2.5	CD	O
mL	NN	O
min/kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.5	CD	O
,	,	O
3.5	CD	O
)	)	O
(	(	O
8.7	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
2.5	CD	O
mL	NN	O
min/kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.5	CD	O
,	,	O
3.5	CD	O
)	)	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

The	DT	O
net	JJ	O
change	NN	O
in	IN	O
body	NN	O
mass	NN	O
was	VBD	O
-1.2	JJ	O
kg	NN	O
(	(	O
95	CD	O
%	NN	O
CI-1.9	NNP	O
,	,	O
-0.5	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
-1.1	NNP	O
kg	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-1.8	NNP	O
,	,	O
-0.4	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

The	DT	O
net	JJ	O
fat	NN	O
%	NN	O
change	NN	O
was	VBD	O
-2.1	JJ	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI-2.7	NNP	O
,	,	O
-1.4	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S1	NNP	O
and	CC	O
-1.7	NNP	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI-2.3	NNP	O
,	,	O
-1.0	NNP	O
)	)	O
in	IN	O
Group	NNP	O
S2	NNP	O
.	.	O

Exercise	NN	O
improved	VBD	O
the	DT	O
maximal	NN	O
aerobic	JJ	O
power	NN	O
and	CC	O
body	NN	O
composition	NN	O
equally	RB	O
when	WRB	O
walking	NN	PH
was	VBD	O
performed	VBN	O
in	IN	O
one	CD	O
or	CC	O
two	CD	O
daily	JJ	O
bouts	NNS	O
.	.	O

Infrared	NNP	PH
LED	NNP	PH
irradiation	NN	PH
applied	VBD	O
during	IN	O
high-intensity	NN	O
treadmill	NN	O
training	VBG	O
improves	NNS	O
maximal	JJ	O
exercise	NN	O
tolerance	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
:	:	O
a	DT	O
6-month	JJ	O
longitudinal	JJ	O
study	NN	O
.	.	O

Reduced	NNP	O
aerobic	JJ	O
fitness	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
diseases	NNS	O
among	IN	O
the	DT	O
older	JJR	O
population	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
LED	NNP	PH
irradiation	NN	PH
(	(	O
850	CD	O
nm	RB	O
)	)	O
applied	VBD	O
during	IN	O
treadmill	JJ	O
training	VBG	O
on	IN	O
the	DT	O
maximal	JJ	O
exercise	NN	O
tolerance	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

At	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
45	CD	O
postmenopausal	JJ	O
women	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
three	CD	O
groups	NNS	O
,	,	O
and	CC	O
30	CD	O
women	NNS	O
completed	VBD	O
the	DT	O
entire	JJ	O
6	CD	O
months	NNS	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
:	:	O
(	(	O
1	CD	O
)	)	O
the	DT	O
LED	NNP	O
group	NN	O
(	(	O
treadmill	IN	O
training	VBG	O
associated	VBN	O
with	IN	O
phototherapy	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
(	(	O
2	CD	O
)	)	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
treadmill	IN	O
training	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
sedentary	JJ	O
group	NN	O
(	(	O
neither	DT	O
physical	JJ	O
training	NN	O
nor	CC	O
phototherapy	NN	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

The	DT	O
training	NN	O
was	VBD	O
performed	VBN	O
for	IN	O
45	CD	O
min	NN	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
6	CD	O
months	NNS	O
at	IN	O
intensities	NNS	O
between	IN	O
85	CD	O
%	NN	O
and	CC	O
90	CD	O
%	NN	O
maximal	JJ	O
heart	NN	O
rate	NN	O
(	(	O
HRmax	NNP	O
)	)	O
.	.	O

The	DT	O
irradiation	NN	O
parameters	NNS	O
were	VBD	O
39	CD	O
mW/cm	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
45	CD	O
min	NN	O
and	CC	O
108	CD	O
J/cm	NNP	O
(	(	O
2	CD	O
)	)	O
.	.	O

The	DT	O
cardiovascular	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

As	IN	O
expected	VBN	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
sedentary	JJ	O
group	NN	O
(	(	O
p	VB	O
?	.	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
time	NN	O
of	IN	O
tolerance	NN	O
(	(	O
Tlim	NNP	O
)	)	O
,	,	O
metabolic	JJ	O
equivalents	NNS	O
(	(	O
METs	NNP	O
)	)	O
and	CC	O
Bruce	NNP	O
stage	NN	O
reached	VBD	O
significantly	RB	O
higher	JJR	O
values	NNS	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
and	CC	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
the	DT	O
HR	NNP	O
,	,	O
double	JJ	O
product	NN	O
and	CC	O
Borg	NNP	O
score	NN	O
at	IN	O
isotime	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
and	CC	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
time	NN	O
of	IN	O
recovery	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
only	RB	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
differences	NNS	O
between	IN	O
before	IN	O
and	CC	O
after	IN	O
training	NN	O
(	(	O
delta	JJ	O
values	NNS	O
)	)	O
for	IN	O
the	DT	O
Tlim	NNP	O
,	,	O
METs	NNP	O
and	CC	O
HR	NNP	O
at	IN	O
isotime	NN	O
were	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
LED	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
with	IN	O
a	DT	O
significant	JJ	O
intergroup	NN	O
difference	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
infrared	JJ	O
LED	NNP	O
irradiation	NN	O
during	IN	O
treadmill	JJ	O
training	NN	O
can	MD	O
improve	VB	O
maximal	JJ	O
performance	NN	O
and	CC	O
post-exercise	JJ	O
recovery	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

Boosting	VBG	O
uptake	NN	O
of	IN	O
influenza	JJ	O
immunisation	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
telephone	NN	O
appointing	VBG	O
in	IN	O
general	JJ	O
practice	NN	O
.	.	O

BACKGROUND	NNP	O
Immunisation	NNP	O
against	IN	O
influenza	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
intervention	NN	O
that	WDT	O
reduces	VBZ	O
serologically	RB	O
confirmed	VBN	O
cases	NNS	O
by	IN	O
between	IN	O
60	CD	O
%	NN	O
and	CC	O
70	CD	O
%	NN	O
.	.	O

Almost	NNP	O
all	DT	O
influenza	JJ	O
immunisation	NN	O
in	IN	O
the	DT	O
UK	NNP	O
is	VBZ	O
done	VBN	O
within	IN	O
general	JJ	O
practice	NN	O
.	.	O

Current	JJ	O
evidence	NN	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
patient	JJ	O
reminders	NNS	O
for	IN	O
all	DT	O
types	NNS	O
of	IN	O
immunisation	NN	O
programmes	NNS	O
is	VBZ	O
largely	RB	O
based	VBN	O
on	IN	O
North	JJ	O
American	JJ	O
studies	NNS	O
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
telephone	NN	Ot
appointments	NNS	Ot
offered	VBD	O
bygeneral	JJ	O
practice	NN	O
receptionists	NNS	O
increase	VBP	O
the	DT	O
uptake	NN	O
of	IN	O
irfluenza	JJ	O
immunisation	NN	O
among	IN	O
the	DT	O
registered	JJ	O
population	NN	O
aged	VBD	O
over	IN	O
65	CD	O
years	NNS	O
in	IN	O
east	JJ	O
London	NNP	O
practices	NNS	O
.	.	O

DESIGN	NNP	O
OF	NNP	O
STUDY	NNP	O
Randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NNP	O
Three	NNP	O
research	NN	O
general	JJ	O
practices	NNS	O
within	IN	O
the	DT	O
East	NNP	O
London	NNP	O
and	CC	O
Essex	NNP	O
network	NN	O
of	IN	O
researchers	NNS	O
(	(	O
ELENoR	NNP	O
)	)	O
.	.	O

METHOD	JJ	O
Participants	NNS	O
were	VBD	O
1,820	CD	O
low-risk	JJ	O
patients	NNS	O
aged	VBD	O
65	CD	O
to	TO	O
74	CD	O
years	NNS	O
who	WP	O
had	VBD	O
not	RB	O
previously	RB	O
been	VBN	O
in	IN	O
a	DT	O
recall	NN	O
system	NN	O
for	IN	O
influenza	JJ	O
immunisation	NN	O
at	IN	O
their	PRP$	O
general	JJ	O
practice	NN	O
.	.	O

The	DT	O
intervention	NN	O
,	,	O
during	IN	O
October	NNP	O
2000	CD	O
,	,	O
was	VBD	O
a	DT	O
telephone	NN	Ot
call	NN	Ot
from	IN	Ot
the	DT	Ot
practice	NN	Ot
receptionist	NN	Ot
to	TO	O
intervention	NN	O
group	NN	O
households	NNS	O
,	,	O
offering	VBG	O
an	DT	O
appointment	NN	O
for	IN	O
influenza	JJ	O
immunisation	NN	O
at	IN	O
a	DT	O
nurse-run	JJ	O
.	.	O

clinic	JJ	O
Main	NNP	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
numbers	NNS	O
of	IN	O
individuals	NNS	O
in	IN	O
each	DT	O
group	NN	O
receiving	VBG	O
immunisation	NN	O
,	,	O
and	CC	O
practice	NN	O
costs	NNS	O
of	IN	O
a	DT	O
telephone-appointing	JJ	O
programme	NN	O
.	.	O

RESULTS	NNP	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
showed	VBD	O
an	DT	O
immunisation	NN	O
rate	NN	O
in	IN	O
the	DT	O
control	NN	C
group	NN	O
of	IN	O
44	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
50	CD	O
%	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
=	JJ	O
1.29	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
=	VBD	O
1.03	CD	O
to	TO	O
1.63	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
making	VBG	O
a	DT	O
telephone	NN	Ot
appointment	NN	Ot
,	,	O
88	CD	O
%	NN	O
recieved	JJ	O
immunisation	NN	O
,	,	O
while	IN	O
22	CD	O
%	NN	O
of	IN	O
those	DT	O
not	RB	O
wanting	VBG	O
an	DT	O
appointment	NN	O
went	VBD	O
on	IN	O
to	TO	O
be	VB	O
immunised	VBN	O
.	.	O

In	IN	O
the	DT	O
controlgroup	NN	C
,	,	O
income	NN	O
generated	VBD	O
was	VBD	O
11.35	CD	O
pounds	NNS	O
per	IN	O
immunisation	NN	O
,	,	O
for	IN	O
each	DT	O
additional	JJ	O
immunisation	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
the	DT	O
income	NN	O
was	VBD	O
5.20	CD	O
pounds	NNS	O
.	.	O

The	DT	O
'number	NNP	O
needed	VBD	O
to	TO	O
telephone	NN	O
'	''	O
was	VBD	O
17	CD	O
.	.	O

CONCLUSION	NNP	O
Uptake	NNP	O
of	IN	O
influenza	JJ	O
immunisation	NN	O
among	IN	O
the	DT	O
low-risk	JJ	O
older	JJR	O
population	NN	O
in	IN	O
inner-city	JJ	O
areas	NNS	O
can	MD	O
be	VB	O
boosted	VBN	O
by	IN	O
around	IN	O
6	CD	O
%	NN	O
using	VBG	O
a	DT	O
simple	JJ	O
intervention	NN	O
by	IN	O
receptionists	NNS	O
.	.	O

Immunisation	NN	O
rates	NNS	O
in	IN	O
this	DT	O
low-risk	JJ	O
group	NN	O
fell	VBD	O
well	RB	O
short	RB	O
of	IN	O
the	DT	O
60	CD	O
%	NN	O
government	NN	O
target	NN	O
.	.	O

Improving	VBG	O
immunisation	NN	O
rates	NNS	O
will	MD	O
require	VB	O
a	DT	O
sustained	JJ	O
public	JJ	O
health	NN	O
campaign	NN	O
.	.	O

Retaining	VBG	O
the	DT	O
item-of-service	JJ	O
payments	NNS	O
to	TO	O
practices	NNS	O
should	MD	O
support	VB	O
costs	NNS	O
of	IN	O
practice-based	JJ	O
interventions	NNS	O
.	.	O

Effect	NN	O
of	IN	O
spinal	JJ	PH
versus	NN	PH
general	JJ	PH
anesthesia	NN	PH
on	IN	O
bladder	NN	O
compliance	NN	O
and	CC	O
intraabdominal	JJ	O
pressure	NN	O
during	IN	O
transurethral	JJ	O
procedures	NNS	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
influence	NN	O
of	IN	O
spinal	JJ	PH
versus	NN	PH
general	JJ	PH
anesthesia	NN	PH
on	IN	O
bladder	NN	O
compliance	NN	O
and	CC	O
intraabdominal	JJ	O
pressure	NN	O
in	IN	O
elderly	JJ	O
males	NNS	O
undergoing	VBG	O
elective	JJ	O
transurethral	JJ	O
resection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
open-label	JJ	O
study	NN	O
.	.	O

SETTING	NN	O
Teaching	NNP	O
hospital	NN	O
.	.	O

PATIENTS	CC	O
21	CD	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
and	CC	O
III	NNP	O
patients	NNS	O
at	IN	O
least	JJS	O
18	CD	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
undergoing	VBG	O
transurethral	JJ	S
surgery	NN	S
.	.	S

INTERVENTIONS	NNP	O
According	VBG	O
to	TO	O
a	DT	O
computer-generated	JJ	O
randomization	NN	O
schedule	NN	O
,	,	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
Group	NNP	O
Spinal	NNP	O
(	(	O
S	NNP	O
)	)	O
,	,	O
10	CD	O
mg	NN	O
of	IN	O
hyperbaric	JJ	PM
tetracaine	NN	PM
was	VBD	O
administered	VBN	O
intrathecally	RB	O
.	.	O

In	IN	O
Group	NNP	O
General	NNP	PH
Anesthesia	NNP	PH
(	(	PH
GA	NNP	PH
)	)	PH
,	,	O
patients	NNS	O
received	VBD	O
,	,	O
fentanyl	RB	PM
intravenous	JJ	PM
(	(	O
i.v	JJ	O
.	.	O

1	CD	O
to	TO	O
2	CD	O
micrograms/kg	NNS	O
and	CC	O
propofol	NN	O
i.v	NN	O
.	.	O

1.0	CD	O
to	TO	O
2.0	CD	O
mg/kg	NN	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	PH
.	.	O

Thereafter	NNP	O
,	,	O
a	DT	O
laryngeal	JJ	O
mask	NN	O
airway	NN	O
was	VBD	O
inserted	VBN	O
and	CC	O
,	,	O
with	IN	O
spontaneous	JJ	O
ventilation	NN	O
,	,	O
anesthesia	NN	PM
was	VBD	O
maintained	VBN	O
by	IN	O
administering	VBG	O
isoflurane	NN	PM
(	(	O
end-tidal	JJ	O
0.7	CD	O
%	NN	O
to	TO	O
1.2	CD	O
%	NN	O
)	)	O
and	CC	O
70	CD	O
%	NN	O
nitrous	JJ	PM
oxide	NN	PM
(	(	PM
N2O	NNP	PM
)	)	PM
in	IN	PM
oxygen	NN	PM
.	.	O

Intraabdominal	JJ	O
pressure	NN	O
and	CC	O
bladder	NN	O
compliance	NN	O
were	VBD	O
recorded	VBN	O
prior	RB	O
to	TO	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	PH
and	CC	O
immediately	RB	O
before	IN	O
the	DT	O
onset	NN	O
of	IN	O
the	DT	O
surgical	JJ	O
procedure	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
demographically	RB	O
comparable	JJ	O
.	.	O

In	IN	O
Group	NNP	O
S	NNP	O
,	,	O
mean	JJ	O
bladder	NN	O
compliance	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
higher	JJR	O
and	CC	O
mean	JJ	O
intraabdominal	JJ	O
pressure	NN	O
significantly	RB	O
lower	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.007	CD	O
)	)	O
when	WRB	O
compared	VBN	O
to	TO	O
baseline	VB	O
preanesthetic	JJ	O
values	NNS	O
.	.	O

In	IN	O
Group	NNP	O
GA	NNP	O
,	,	O
mean	JJ	O
intraabdominal	JJ	O
pressure	NN	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
decreased	VBD	O
when	WRB	O
compared	VBN	O
to	TO	O
baseline	VB	O
preanesthetic	JJ	O
recordings	NNS	O
.	.	O

Following	VBG	O
the	DT	O
induction	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
,	,	O
a	DT	O
small	JJ	O
change	NN	O
in	IN	O
bladder	NN	O
compliance	NN	O
was	VBD	O
noted	VBN	O
.	.	O

However	RB	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
and	CC	O
compared	VBN	O
using	VBG	O
Student	NNP	O
's	POS	O
t-test	NN	O
(	(	O
p	JJ	O
<	NN	O
0.05	CD	O
was	VBD	O
considered	VBN	O
statistically	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
spinal	JJ	PH
and	CC	PH
general	JJ	PH
anesthesia	NN	PH
induced	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
intraabdominal	JJ	O
pressure	NN	O
.	.	O

While	IN	O
both	DT	O
techniques	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
bladder	NN	O
compliance	NN	O
,	,	O
statistical	JJ	O
significance	NN	O
was	VBD	O
demonstrated	VBN	O
only	RB	O
in	IN	O
the	DT	O
spinal	JJ	PH
anesthesia	NN	PH
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
single-dose	JJ	O
metronidazole	JJ	PM
therapy	NN	O
for	IN	O
patients	NNS	O
and	CC	O
their	PRP$	O
partners	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	C
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	IN	O
a	DT	O
2-g	JJ	O
single	JJ	O
dose	NN	O
of	IN	O
metronidazole	NN	PM
for	IN	O
male	JJ	O
partners	NNS	O
of	IN	O
women	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
improving	VBG	O
cure	NN	O
rate	NN	O
and	CC	O
decreasing	VBG	O
recurrence	NN	O
rate	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
2-g	JJ	O
single	JJ	PM
dose	NN	PM
of	IN	PM
metronidazole	NN	PM
was	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
seven-day	JJ	PM
course	NN	PM
of	IN	PM
500	CD	PM
mg	NN	PM
of	IN	PM
metronidazole	JJ	PM
twice	NN	O
a	DT	O
day	NN	O
in	IN	O
patients	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
benefits	NNS	O
of	IN	O
partner	NN	O
treatment	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
cure	NN	O
rate	NN	O
by	IN	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.01	NN	O
)	)	O
and	CC	O
in	IN	O
percentage	NN	O
of	IN	O
women	NNS	O
with	IN	O
symptoms	NNS	O
eight	CD	O
weeks	NNS	O
after	IN	O
initiating	VBG	O
therapy	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.05	NN	O
)	)	O
.	.	O

The	DT	O
seven-day	JJ	O
course	NN	O
of	IN	O
metronidazole	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
single-dose	JJ	O
regimen	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
clue	JJ	O
cells	NNS	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
positive	JJ	O
sniff	NN	O
test	NN	O
at	IN	O
the	DT	O
first	JJ	O
follow-up	JJ	O
visit	NN	O
;	:	O
however	RB	O
,	,	O
differences	NNS	O
in	IN	O
the	DT	O
initial	JJ	O
cure	NN	O
rate	NN	O
assessed	VBN	O
by	IN	O
clinical	JJ	O
criteria	NNS	O
and	CC	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
between	IN	O
the	DT	O
two	CD	O
patient	NN	O
treatment	NN	O
regimens	NNS	O
.	.	O

Recurrence	NN	O
rates	NNS	O
by	IN	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
between	IN	O
patient	NN	O
and	CC	O
partner	NN	O
treatment	NN	O
groups	NNS	O
at	IN	O
five	CD	O
and	CC	O
eight	CD	O
weeks	NNS	O
after	IN	O
initiation	NN	O
of	IN	O
treatment	NN	O
were	VBD	O
also	RB	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
patient	NN	O
regimens	NNS	O
.	.	O

Single-dose	JJ	O
metronidazole	JJ	PM
treatment	NN	O
of	IN	O
the	DT	O
sexual	JJ	O
partner	NN	O
of	IN	O
women	NNS	O
with	IN	O
bacterial	JJ	O
vaginosis	NN	O
improves	VBZ	O
initial	JJ	O
bacterial	JJ	O
vaginosis	NN	O
cure	NN	O
rates	NNS	O
.	.	O

The	DT	O
seven-day	JJ	O
course	NN	O
of	IN	O
metronidazole	NN	O
was	VBD	O
not	RB	O
found	VBN	O
by	IN	O
statistical	JJ	O
analysis	NN	O
to	TO	O
be	VB	O
significantly	RB	O
superior	JJ	O
to	TO	O
single-dose	JJ	O
therapy	NN	O
when	WRB	O
considering	VBG	O
initial	JJ	O
cure	NN	O
rates	NNS	O
by	IN	O
clinical	JJ	O
or	CC	O
Gram-stained	JJ	O
smear	JJ	O
criteria	NNS	O
or	CC	O
recurrence	NN	O
rates	NNS	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Laser-aided	JJ	S
external	JJ	S
drainage	NN	S
of	IN	O
subretinal	JJ	O
fluid	NN	O
:	:	O
prospective	JJ	O
randomized	VBN	O
comparison	NN	O
with	IN	O
needle	JJ	O
drainage	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
of	IN	O
50	CD	O
consecutive	JJ	O
eyes	NNS	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
draining	VBG	O
subretinal	JJ	S
fluid	NN	S
transchoroidally	RB	S
in	IN	O
primary	JJ	O
scleral	JJ	O
buckling	NN	O
for	IN	O
rhegmatogenous	JJ	O
retinal	JJ	O
detachment	NN	O
using	VBG	O
a	DT	O
needle	JJ	Ot
,	,	O
with	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
the	DT	O
same	JJ	O
procedure	NN	O
using	VBG	O
an	DT	O
angulated	VBN	S
endolaser	NN	S
probe	NN	S
set	VBN	O
at	IN	O
1	CD	O
W	NNP	O
for	IN	O
0.2	CD	O
seconds	NNS	O
,	,	O
using	VBG	O
an	DT	O
average	NN	O
of	IN	O
2.4	CD	O
laser	NN	O
burns	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
complications	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
laser-aided	JJ	S
drainage	NN	S
procedures	NNS	O
(	(	O
25	CD	O
eyes	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
transchoroidal	NN	S
needle	JJ	S
drainage	NN	S
procedures	NNS	O
(	(	O
25	CD	O
eyes	NNS	O
)	)	O
,	,	O
subretinal	JJ	O
hemorrhage	NN	O
occurred	VBD	O
in	IN	O
three	CD	O
eyes	NNS	O
and	CC	O
retinal	JJ	O
incarceration	NN	O
in	IN	O
one	CD	O
.	.	O

Thus	VB	O
,	,	O
though	IN	O
our	PRP$	O
numbers	NNS	O
are	VBP	O
small	JJ	O
,	,	O
there	EX	O
appears	VBZ	O
to	TO	O
be	VB	O
some	DT	O
advantage	NN	O
of	IN	O
laser-assisted	JJ	O
drainage	NN	O
in	IN	O
terms	NNS	O
of	IN	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
complications	NNS	O
.	.	O

Prevention	NN	O
of	IN	O
coronary	JJ	O
spasm	NN	O
by	IN	O
nicorandil	NNS	PM
:	:	PM
comparison	NN	O
with	IN	O
nifedipine	NN	PM
.	.	PM

The	DT	O
efficacy	NN	O
of	IN	O
nicorandil	NN	PM
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
nifedipine	NN	PM
in	IN	O
13	CD	O
patients	NNS	O
with	IN	O
vasospastic	JJ	O
angina	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	PH
,	,	O
crossover	NN	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
coronary	JJ	O
spasm	NN	O
during	IN	O
coronary	JJ	O
arteriography	NN	O
,	,	O
either	CC	O
spontaneously	RB	O
or	CC	O
ergometrine-induced	JJ	O
.	.	O

During	IN	O
two	CD	O
consecutive	JJ	O
periods	NNS	O
of	IN	O
2	CD	O
days	NNS	O
,	,	O
patients	NNS	O
received	VBD	O
active	JJ	PM
drugs	NNS	PM
or	CC	O
placebo	NN	PM
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
30	CD	O
mg	NN	O
nicorandil	NN	PM
,	,	O
10	CD	O
mg	NN	O
nifedipine	NN	PM
,	,	O
and	CC	O
,	,	O
on	IN	O
2	CD	O
days	NNS	O
,	,	O
a	DT	O
placebo	NN	PM
.	.	O

One	CD	O
hour	NN	O
after	IN	O
drug	NN	O
intake	NN	O
,	,	O
patients	NNS	O
underwent	VBD	O
an	DT	O
ergometrine	JJ	O
test	NN	O
with	IN	O
increasing	VBG	O
doses	NNS	O
of	IN	O
Methergin	NNP	PM
(	(	PM
ergometrine	NN	PM
)	)	PM
(	(	O
0.05	CD	O
,	,	O
0.10	CD	O
,	,	O
0.20	CD	O
,	,	O
and	CC	O
0.40	CD	O
mg	NN	O
every	DT	O
5	CD	O
min	NN	O
)	)	O
.	.	O

After	IN	O
placebo	NN	PM
,	,	O
the	DT	O
tests	NNS	O
always	RB	O
were	VBD	O
positive	JJ	O
,	,	O
and	CC	O
the	DT	O
ECG	NNP	O
changes	NNS	O
occurred	VBD	O
at	IN	O
the	DT	O
same	JJ	O
+/-	JJ	O
1	CD	O
dose	NN	O
of	IN	O
ergometrine	NN	PM
in	IN	O
10	CD	O
cases	NNS	O
,	,	O
showing	VBG	O
good	JJ	O
reproducibility	NN	O
.	.	O

After	IN	O
nicorandil	NN	PM
,	,	O
the	DT	O
tests	NNS	O
were	VBD	O
negative	JJ	O
in	IN	O
nine	CD	O
patients	NNS	O
and	CC	O
positive	JJ	O
for	IN	O
a	DT	O
higher	JJR	O
or	CC	O
lower	JJR	O
dose	NN	O
of	IN	O
ergometrine	NN	PM
in	IN	O
three	CD	O
and	CC	O
one	CD	O
patient	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	$	O
0.0034	CD	O
vs.	FW	O
placebo	NN	PM
)	)	PM
.	.	O

After	IN	O
nifedipine	NN	PM
,	,	O
the	DT	O
tests	NNS	O
were	VBD	O
negative	JJ	O
in	IN	O
five	CD	O
patients	NNS	O
and	CC	O
positive	JJ	O
for	IN	O
a	DT	O
higher	JJR	O
or	CC	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
ergometrine	NN	PM
in	IN	O
four	CD	O
and	CC	O
four	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	$	O
0.0039	CD	O
vs.	FW	O
placebo	NN	PM
)	)	O
.	.	O

Nifedipine	NNP	PM
(	(	O
10	CD	O
mg	NN	O
)	)	O
and	CC	O
nicorandil	$	O
(	(	O
30	CD	O
mg	NN	O
)	)	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
eight	CD	O
patients	NNS	O
;	:	O
in	IN	O
the	DT	O
remaining	VBG	O
five	CD	O
patients	NNS	O
,	,	O
nicorandil	NNS	PM
had	VBD	O
better	JJR	O
results	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

Nicorandil	NNP	PM
(	(	O
30	CD	O
mg	NN	O
)	)	O
prevents	VBZ	O
ergometrine-induced	JJ	O
coronary	JJ	O
spasm	NN	O
.	.	O

This	DT	O
compound	NN	O
may	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
vasospastic	JJ	O
angina	NN	O
.	.	O

Clofibrate	NNP	PM
and	CC	O
diabetes	VBZ	O
control	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
oral	JJ	PM
hypoglycaemic	JJ	PM
agents	NNS	PM
.	.	O

1	CD	O
.	.	O

Twenty-two	JJ	O
maturity-onset	JJ	O
type	NN	O
diabetics	NNS	O
treated	VBD	O
with	IN	O
oral	JJ	PM
hypoglycaemic	JJ	PM
agents	NNS	PM
entered	VBD	O
a	DT	O
single-blind	JJ	O
crossover	NN	O
study	NN	O
using	VBG	O
placebo	NN	C
(	(	O
periods	VB	O
A	DT	O
and	CC	O
C	NNP	O
,	,	O
2	CD	O
months	NNS	O
each	DT	O
)	)	O
and	CC	O
clofibrate	NN	PM
(	(	O
2	CD	O
g/day	NN	O
;	:	O
period	NN	O
B	NNP	O
;	:	O
2	CD	O
months	NNS	O
)	)	O
.	.	O

2	CD	O
.	.	O

In	IN	O
thirteen	JJ	O
patients	NNS	O
,	,	O
under	IN	O
reasonably	RB	O
good	JJ	O
control	NN	O
,	,	O
clofibrate	NN	PM
did	VBD	O
not	RB	O
reduce	VB	O
fasting	VBG	O
or	CC	O
post-prandial	JJ	O
blood	NN	O
glucose	NN	O
,	,	O
nor	CC	O
24	CD	O
h	NN	O
glycosuria	NN	O
;	:	O
no	DT	O
improvement	NN	O
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
M-value	NNP	O
,	,	O
an	DT	O
index	NN	O
of	IN	O
diabetes	NNS	O
control	NN	O
.	.	O

3	CD	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
in	IN	O
nine	CD	O
patients	NNS	O
,	,	O
with	IN	O
poor	JJ	O
diabetes	NNS	O
control	NN	O
,	,	O
clofibrate	NN	PM
reduced	VBD	O
24	CD	O
h	NN	O
glycosuria	NN	O
and	CC	O
significantly	RB	O
improved	VBD	O
the	DT	O
M-value	NNP	O
.	.	O

4	CD	O
.	.	O

In	IN	O
all	DT	O
patients	NNS	O
,	,	O
clofibrate	JJ	PH
therapy	NN	PH
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
19-23	JJ	O
%	NN	O
reduction	NN	O
in	IN	O
plasma	NN	O
fibrinogen	NN	O
.	.	O

5	CD	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
addition	NN	O
of	IN	O
clofibrate	NN	PM
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
maturity-onset	JJ	O
diabetics	NNS	O
not	RB	O
adequately	RB	O
controlled	VBN	O
by	IN	O
diet	NN	O
combined	VBN	O
with	IN	O
oral	JJ	PM
hypoglycaemic	JJ	PM
agents	NNS	PM
.	.	O

Trachoma	NNP	O
prevalence	NN	O
and	CC	O
associated	VBN	O
risk	NN	O
factors	NNS	O
in	IN	O
the	DT	O
gambia	NN	O
and	CC	O
Tanzania	NNP	O
:	:	O
baseline	NN	O
results	NNS	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Blinding	NNP	O
trachoma	NN	O
,	,	O
caused	VBN	O
by	IN	O
ocular	JJ	O
infection	NN	O
with	IN	O
Chlamydia	NNP	O
trachomatis	NN	O
,	,	O
is	VBZ	O
targeted	VBN	O
for	IN	O
global	JJ	O
elimination	NN	O
by	IN	O
2020	CD	O
.	.	O

Knowledge	NNP	O
of	IN	O
risk	NN	O
factors	NNS	O
can	MD	O
help	VB	O
target	VB	O
control	JJ	O
interventions	NNS	O
.	.	O

METHODOLOGY/PRINCIPAL	NNP	O
FINDINGS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
baseline	NN	O
prevalence	NN	O
of	IN	O
,	,	O
and	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
,	,	O
active	JJ	O
trachoma	NN	O
and	CC	O
ocular	JJ	O
C.	NNP	O
trachomatis	NN	O
infection	NN	O
in	IN	O
randomly	RB	O
selected	VBN	O
children	NNS	O
aged	VBN	O
0-5	CD	O
years	NNS	O
from	IN	O
48	CD	O
Gambian	JJ	O
and	CC	O
36	CD	O
Tanzanian	JJ	O
communities	NNS	O
.	.	O

Both	DT	O
children	NNS	O
's	POS	O
eyes	NNS	O
were	VBD	O
examined	VBN	O
according	VBG	O
to	TO	O
the	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
(	(	O
WHO	NNP	O
)	)	O
simplified	VBD	O
grading	VBG	O
system	NN	O
,	,	O
and	CC	O
an	DT	PH
ocular	JJ	PH
swab	NN	PH
was	VBD	PH
taken	VBN	PH
from	IN	PH
each	DT	PH
child	NN	PH
's	POS	PH
right	JJ	PH
eye	NN	PH
and	CC	PH
processed	VBN	PH
by	IN	PH
Amplicor	NNP	PH
polymerase	NN	PH
chain	NN	PH
reaction	NN	PH
to	TO	PH
test	VB	PH
for	IN	PH
the	DT	PH
presence	NN	PH
of	IN	PH
C.	NNP	PH
trachomatis	NN	O
DNA	NNP	O
.	.	O

Prevalence	NN	O
of	IN	O
active	JJ	O
trachoma	NN	O
was	VBD	O
6.7	CD	O
%	NN	O
(	(	O
335/5033	CD	O
)	)	O
in	IN	O
The	DT	O
Gambia	NNP	O
and	CC	O
32.3	CD	O
%	NN	O
(	(	O
1008/3122	CD	O
)	)	O
in	IN	O
Tanzania	NNP	O
.	.	O

The	DT	O
countries	NNS	O
'	POS	O
corresponding	VBG	O
Amplicor	NNP	O
positive	JJ	O
prevalences	NNS	O
were	VBD	O
0.8	CD	O
%	NN	O
and	CC	O
21.9	CD	O
%	NN	O
.	.	O

After	IN	O
adjustment	NN	O
,	,	O
risk	NN	O
factors	NNS	O
for	IN	O
follicular	JJ	O
trachoma	NN	O
(	(	O
TF	NNP	O
)	)	O
in	IN	O
both	DT	O
countries	NNS	O
were	VBD	O
ocular	JJ	O
or	CC	O
nasal	JJ	O
discharge	NN	O
,	,	O
a	DT	O
low	JJ	O
level	NN	O
of	IN	O
household	NN	O
head	NN	O
education	NN	O
,	,	O
and	CC	O
being	VBG	O
aged	VBN	O
?	.	O
1	CD	O
year	NN	O
.	.	O

Additional	NNP	O
risk	NN	O
factors	NNS	O
in	IN	O
Tanzania	NNP	O
were	VBD	O
flies	NNS	O
on	IN	O
the	DT	O
child	NN	O
's	POS	O
face	NN	O
,	,	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
,	,	O
and	CC	O
crowding	NN	O
(	(	O
the	DT	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
household	NN	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
factors	NNS	O
for	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
in	IN	O
Tanzania	NNP	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
for	IN	O
TF	NNP	O
,	,	O
with	IN	O
the	DT	O
exclusion	NN	O
of	IN	O
flies	NNS	O
and	CC	O
crowding	VBG	O
.	.	O

In	IN	O
The	DT	O
Gambia	NNP	O
,	,	O
only	RB	O
ocular	JJ	O
discharge	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
.	.	O

CONCLUSIONS/SIGNIFICANCE	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
although	IN	O
the	DT	O
prevalence	NN	O
of	IN	O
active	JJ	O
trachoma	NN	O
and	CC	O
Amplicor	NNP	O
positives	NNS	O
were	VBD	O
very	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
countries	NNS	O
,	,	O
the	DT	O
risk	NN	O
factors	NNS	O
for	IN	O
active	JJ	O
trachoma	NN	O
were	VBD	O
similar	JJ	O
but	CC	O
those	DT	O
for	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
were	VBD	O
different	JJ	O
.	.	O

The	DT	O
lack	NN	O
of	IN	O
an	DT	O
association	NN	O
between	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
and	CC	O
TF	NNP	O
in	IN	O
The	DT	O
Gambia	NNP	O
highlights	VBZ	O
the	DT	O
poor	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
trachoma	JJ	O
clinical	JJ	O
signs	NNS	O
and	CC	O
evidence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
infection	NN	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

Only	RB	O
ocular	JJ	O
discharge	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
evidence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
DNA	NN	O
in	IN	O
The	DT	O
Gambia	NNP	O
,	,	O
suggesting	VBG	O
that	IN	O
at	IN	O
this	DT	O
low	JJ	O
endemicity	NN	O
,	,	O
this	DT	O
may	MD	O
be	VB	O
the	DT	O
most	RBS	O
important	JJ	O
risk	NN	O
factor	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
NCT00792922	NNP	O
.	.	O

[	RB	O
Clinical	JJ	O
trial	NN	O
of	IN	O
2	CD	O
tobacco	NN	O
use	NN	O
cessation	NN	PM
interventions	NNS	PM
in	IN	O
primary	JJ	O
care	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
two	CD	O
types	NNS	O
of	IN	O
intervention	NN	O
to	TO	O
stop	VB	O
tobacco	NN	O
dependency	NN	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Primary	NNP	O
care	NN	O
centre	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
OTHER	NNP	O
PARTICIPANTS	NNP	O
Smokers	NNP	O
recruited	VBD	O
from	IN	O
among	IN	O
the	DT	O
health	NN	O
centre	NN	O
users	NNS	O
through	IN	O
the	DT	O
preventive	JJ	O
activities	NNS	O
and	CC	O
health	NN	O
promotion	NN	O
programme	NN	O
.	.	O

INTERVENTIONS	NNP	O
INDEPENDENT	NNP	O
VARIABLE	NNP	O
type	NN	O
of	IN	O
intervention	NN	O
.	.	O

General	JJ	O
variables	NNS	O
:	:	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
marital	JJ	O
status	NN	O
,	,	O
educational	JJ	O
level	NN	O
,	,	O
work	NN	O
situation	NN	O
,	,	O
cohabitation	NN	O
with	IN	O
children	NNS	O
,	,	O
smokers	NNS	O
at	IN	O
home	NN	O
,	,	O
number	NN	O
of	IN	O
years	NNS	O
smoking	VBG	O
,	,	O
type	NN	O
of	IN	O
tobacco	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
types	NNS	O
of	IN	O
intervention	NN	O
:	:	O
a	DT	O
)	)	O
Minimal	NNP	PM
Intervention	NNP	PM
(	(	O
MI	NNP	O
)	)	O
.	.	O

b	NN	O
)	)	O
Advanced	NNP	PM
Intervention	NNP	PM
(	(	O
AI	NNP	O
)	)	O
.	.	O

54	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
,	,	O
with	IN	O
6	CD	O
losses	NNS	O
.	.	O

21	CD	O
were	VBD	O
assigned	VBN	O
at	IN	O
random	NN	O
to	TO	O
the	DT	O
MI	NNP	PM
group	NN	O
and	CC	O
27	CD	O
to	TO	O
the	DT	O
AI	NNP	PM
group	NN	O
.	.	O

Progress	NNP	O
was	VBD	O
measured	VBN	O
at	IN	O
15	CD	O
days	NNS	O
,	,	O
1	CD	O
month	NN	O
,	,	O
3	CD	O
months	NNS	O
,	,	O
6	CD	O
months	NNS	O
and	CC	O
a	DT	O
year	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
MI	NNP	O
,	,	O
23.8	CD	O
%	NN	O
were	VBD	O
abstinent	JJ	O
at	IN	O
15	CD	O
days	NNS	O
;	:	O
the	DT	O
same	JJ	O
percentage	NN	O
at	IN	O
one	CD	O
month	NN	O
and	CC	O
3	CD	O
months	NNS	O
;	:	O
19	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
;	:	O
and	CC	O
14.3	CD	O
%	NN	O
remained	VBD	O
abstinent	JJ	O
after	IN	O
a	DT	O
year	NN	O
.	.	O

In	IN	O
the	DT	O
AI	NNP	O
,	,	O
51.9	CD	O
%	NN	O
were	VBD	O
abstinent	JJ	O
at	IN	O
15	CD	O
days	NNS	O
;	:	O
48.1	CD	O
%	NN	O
at	IN	O
both	DT	O
one	CD	O
and	CC	O
3	CD	O
months	NNS	O
;	:	O
25.9	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
;	:	O
and	CC	O
22.2	CD	O
%	NN	O
were	VBD	O
still	RB	O
not	RB	O
smoking	VBG	O
after	IN	O
a	DT	O
year	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
interventions	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
observations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
do	VBP	O
not	RB	O
show	VB	O
that	IN	O
one	CD	O
intervention	NN	O
is	VBZ	O
better	RBR	O
than	IN	O
the	DT	O
other	JJ	O
.	.	O

With	IN	O
the	DT	O
passage	NN	O
of	IN	O
time	NN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
decreased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Caregiver-mediated	JJ	O
intervention	NN	E
for	IN	O
low-resourced	JJ	O
preschoolers	NNS	O
with	IN	O
autism	NN	O
:	:	O
an	DT	O
RCT	NNP	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
2	CD	O
short-term	JJ	O
,	,	O
community	NN	E
caregiver	RB	E
training	NN	E
interventions	NNS	E
for	IN	O
preschool-aged	JJ	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorder	NNP	O
who	WP	O
had	VBD	O
low	JJ	O
resources	NNS	O
.	.	O

Low	NNP	O
resource	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
the	DT	O
US	NNP	O
Department	NNP	O
of	IN	O
Housing	NNP	O
and	CC	O
Urban	NNP	O
Development	NNP	O
low-income	JJ	O
index	NN	O
or	CC	O
1	CD	O
indicator	NN	O
,	,	O
(	(	O
e.g.	UH	O
,	,	O
Medicaid	NNP	O
eligibility	NN	O
)	)	O
.	.	O

Child	NNP	O
outcomes	NNS	O
focused	VBD	O
on	IN	O
joint	JJ	O
engagement	NN	O
,	,	O
joint	JJ	O
attention	NN	O
,	,	O
and	CC	O
play	NN	O
.	.	O

METHODS	NNP	O
Participants	NNP	O
included	VBD	O
112	CD	O
families	NNS	O
of	IN	O
a	DT	O
child	NN	O
who	WP	O
had	VBD	O
Autism	NNP	O
Spectrum	NNP	O
Disorder	NNP	O
who	WP	O
met	VBD	O
criteria	NNS	O
for	IN	O
being	VBG	O
low-resourced	JJ	O
and	CC	O
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
2	CD	E
3-month	JJ	E
interventions	NNS	E
,	,	O
group	NN	E
caregiver	NN	E
education	NN	E
or	CC	E
individualized	VBN	E
caregiver-mediated	JJ	E
intervention	NN	E
(	(	E
CMM	NNP	E
)	)	E
.	.	O

Children	NNP	O
were	VBD	O
assessed	VBN	O
for	IN	O
social	JJ	O
communication	NN	O
skills	NNS	O
pre-	JJ	O
and	CC	O
post-treatment	JJ	O
,	,	O
and	CC	O
followed	VBD	O
up	RB	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
All	NNP	O
children	NNS	O
improved	VBN	O
in	IN	O
joint	JJ	O
engagement	NN	O
and	CC	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
,	,	O
with	IN	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
by	IN	O
the	DT	O
CMM	NNP	E
group	NN	O
.	.	O

Outcomes	CC	O
on	IN	O
play	NN	O
skills	NNS	O
were	VBD	O
mixed	JJ	O
,	,	O
with	IN	O
improvement	NN	O
of	IN	O
symbolic	JJ	O
play	NN	O
for	IN	O
the	DT	O
CMM	NNP	O
group	NN	O
and	CC	O
no	DT	O
change	NN	O
in	IN	O
functional	JJ	O
play	NN	O
skills	NNS	O
.	.	O

Joint	JJ	O
engagement	NN	O
maintained	VBD	O
over	IN	O
time	NN	O
for	IN	O
the	DT	O
CMM	NNP	E
group	NN	O
,	,	O
and	CC	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
maintained	VBD	O
for	IN	O
both	DT	O
groups	NNS	O
over	IN	O
time	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
is	VBZ	O
among	IN	O
the	DT	O
first	JJ	O
randomized	JJ	O
trials	NNS	O
comparing	VBG	O
2	CD	O
active	JJ	O
interventions	NNS	O
with	IN	O
a	DT	O
large	JJ	O
sample	NN	O
of	IN	O
low-resourced	JJ	O
families	NNS	O
.	.	O

Results	NNP	O
suggest	JJ	O
improvements	NNS	O
in	IN	O
core	NN	O
autism	NN	O
deficits	NNS	O
of	IN	O
joint	JJ	O
engagement	NN	O
,	,	O
joint	JJ	O
attention	NN	O
,	,	O
and	CC	O
symbolic	JJ	O
play	NN	O
with	IN	O
relatively	RB	O
brief	JJ	O
,	,	O
caregiver-mediated	JJ	O
interventions	NNS	O
,	,	O
but	CC	O
additional	JJ	O
support	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
maintain	VB	O
and	CC	O
generalize	VB	O
these	DT	O
gains	NNS	O
over	IN	O
time	NN	O
.	.	O

Parenteral	JJ	O
nutrition	NN	O
and	CC	O
protein	NN	O
sparing	NN	O
after	IN	O
surgery	NN	S
:	:	O
do	VBP	O
we	PRP	O
need	VB	O
glucose	RB	PM
?	.	O
Although	IN	O
capable	JJ	O
of	IN	O
inducing	VBG	O
an	DT	O
anabolic	JJ	O
state	NN	O
after	IN	O
surgery	NN	O
,	,	O
parenteral	JJ	PM
nutrition	NN	PM
,	,	O
including	VBG	O
glucose	NN	PM
,	,	O
leads	VBZ	O
to	TO	O
hyperglycemia	VB	O
.	.	O

Even	RB	O
moderate	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
poor	JJ	O
surgical	JJ	O
outcome	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
amino	NN	PM
acids	NNS	PM
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
glucose	JJ	PM
supply	NN	O
,	,	O
spare	JJ	O
protein	NN	O
while	IN	O
preventing	VBG	O
hyperglycemia	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
,	,	O
14	CD	O
patients	NNS	O
with	IN	O
colonic	JJ	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
a	DT	O
6-hour	JJ	O
stable	JJ	O
isotope	NN	PM
infusion	NN	PM
study	NN	O
(	(	O
3	CD	O
hours	NNS	O
of	IN	O
fasting	VBG	PH
followed	VBN	O
by	IN	O
3-hour	JJ	O
infusions	NNS	O
of	IN	O
amino	NN	PM
acids	NNS	PM
,	,	O
Travasol	NNP	O
[	NNP	O
Baxter	NNP	O
,	,	O
Montreal	NNP	O
,	,	O
Canada	NNP	O
]	VBD	O
10	CD	O
%	NN	O
at	IN	O
0.02	CD	O
mL.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.min	NNP	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
with	IN	PM
or	CC	PM
without	IN	PM
glucose	JJ	PM
at	IN	O
4	CD	O
mg.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.min	NNP	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
on	IN	O
the	DT	O
second	JJ	O
day	NN	O
after	IN	O
colorectal	JJ	O
surgery	NN	O
.	.	O

Protein	NNP	O
breakdown	NN	O
,	,	O
protein	JJ	O
oxidation	NN	O
,	,	O
protein	JJ	O
balance	NN	O
,	,	O
and	CC	O
glucose	JJ	O
production	NN	O
were	VBD	O
assessed	VBN	O
by	IN	O
stable	JJ	O
isotope	NN	O
tracer	NN	O
kinetics	NNS	O
using	VBG	O
l-	JJ	O
[	JJ	O
1-	JJ	O
(	(	O
13	CD	O
)	)	O
C	NNP	O
]	NNP	O
leucine	NN	O
and	CC	O
[	JJ	O
6,6-	JJ	O
(	(	O
2	CD	O
)	)	O
H2	NNP	O
]	NNP	O
glucose	NN	O
.	.	O

Circulating	VBG	O
concentrations	NNS	O
of	IN	O
glucose	NN	O
,	,	O
cortisol	NN	O
,	,	O
insulin	NN	O
,	,	O
and	CC	O
glucagon	NN	O
were	VBD	O
determined	VBN	O
.	.	O

The	DT	O
administration	NN	O
of	IN	O
amino	JJ	PM
acids	NNS	PM
increased	VBD	O
protein	JJ	O
balance	NN	O
from	IN	O
-16+/-4	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
in	IN	O
the	DT	O
fasted	JJ	O
state	NN	O
to	TO	O
16+/-3	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

Combined	VBN	O
infusion	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
and	CC	O
glucose	VB	O
increased	JJ	O
protein	NN	O
balance	NN	O
from	IN	O
-17+/-7	JJ	O
to	TO	O
7+/-5	JJ	O
micromol.kg	NN	O
(	(	O
-1	NNP	O
)	)	O
.h	NNP	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
protein	JJ	O
balance	NN	O
during	IN	O
nutrition	NN	O
was	VBD	O
comparable	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P=.07	NNP	O
)	)	O
.	.	O

Combined	VBN	O
administration	NN	O
of	IN	O
amino	JJ	PM
acids	NNS	PM
and	CC	O
glucose	VB	PM
decreased	VBN	O
endogenous	JJ	O
glucose	JJ	O
production	NN	O
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
stimulated	VBN	O
insulin	NN	O
secretion	NN	O
(	(	O
P=.001	NNP	O
)	)	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
the	DT	O
administration	NN	O
of	IN	O
amino	JJ	PM
acids	NNS	PM
alone	RB	O
.	.	O

Hyperglycemia	NNP	O
(	(	O
blood	NN	O
glucose	NN	O
,	,	O
10.1+/-1.9	JJ	O
micromol/L	NN	O
)	)	O
occurred	VBD	O
only	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
glucose	JJ	PM
infusion	NN	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
excluding	VBG	O
glucose	NN	PM
from	IN	O
a	DT	O
short-term	JJ	O
feeding	NN	O
protocol	NN	O
does	VBZ	O
not	RB	O
diminish	VB	O
the	DT	O
protein-sparing	JJ	O
effect	NN	O
of	IN	O
amino	NN	PM
acids	NNS	PM
and	CC	O
avoids	NNS	O
hyperglycemia	NN	O
.	.	O

Pre-operative	JJ	PH
radiochemotherapy	NN	PH
for	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
pre-operative	JJ	PH
vs.	FW	O
postoperative	JJ	PH
radiochemotherapy	NN	PH
in	IN	O
rectal	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
find	VB	O
out	RP	O
whether	IN	O
pre-operative	JJ	PH
radiochemotherapy	NN	PH
had	VBD	O
any	DT	O
survival	JJ	O
advantage	NN	O
over	IN	O
postoperative	JJ	PH
radiochemotherapy	NN	PH
for	IN	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
without	IN	O
distant	JJ	O
metastasis	NN	O
or	CC	O
peritoneal	JJ	O
carcinomatosis	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
January	NNP	O
1998	CD	O
and	CC	O
December	NNP	O
2003	CD	O
,	,	O
51	CD	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
without	IN	O
distant	JJ	O
metastasis	NN	O
or	CC	O
peritoneal	JJ	O
carcinomatosis	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
pre-operative	JJ	PH
(	(	PH
PRE	NNP	PH
)	)	PH
and	CC	O
postoperative	JJ	PH
(	(	PH
POST	NNP	PH
)	)	PH
radiochemotherapy	NN	PH
groups	NNS	O
.	.	O

Twenty-six	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
PRE	NNP	O
group	NN	O
and	CC	O
were	VBD	O
operated	VBN	O
on	IN	O
5	CD	O
to	TO	O
8	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
completion	NN	O
of	IN	O
radiotherapy	NN	PH
.	.	O

The	DT	O
other	JJ	O
25	CD	O
patients	NNS	O
were	VBD	O
operated	VBN	O
on	IN	O
immediately	RB	O
and	CC	O
received	VBD	O
radiotherapy	NN	O
postoperatively	RB	O
2	CD	O
to	TO	O
4	CD	O
weeks	NNS	O
after	IN	O
surgery	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
between	IN	O
4	CD	O
to	TO	O
51	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
the	DT	O
rates	NNS	O
of	IN	O
disease-free	JJ	O
survival	NN	O
were	VBD	O
92	CD	O
%	NN	O
,	,	O
70	CD	O
%	NN	O
,	,	O
56	CD	O
%	NN	O
and	CC	O
56	CD	O
%	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
3rd	CD	O
and	CC	O
4th	CD	O
years	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
POST	NNP	O
group	NN	O
those	DT	O
percentages	NNS	O
were	VBD	O
83	CD	O
%	NN	O
,	,	O
68	CD	O
%	NN	O
,	,	O
51	CD	O
%	NN	O
and	CC	O
51	CD	O
%	NN	O
at	IN	O
the	DT	O
1st	CD	O
,	,	O
2nd	CD	O
,	,	O
3rd	CD	O
and	CC	O
4th	CD	O
years	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.707	CD	O
)	)	O
.	.	O

One-year	JJ	O
and	CC	O
4-year	JJ	O
overall	JJ	O
survival	NN	O
rates	NNS	O
in	IN	O
the	DT	O
PRE	NNP	O
group	NN	O
were	VBD	O
100	CD	O
%	NN	O
and	CC	O
86	CD	O
%	NN	O
respectively	RB	O
and	CC	O
100	CD	O
%	NN	O
and	CC	O
60	CD	O
%	NN	O
in	IN	O
the	DT	O
POST	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.520	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
statistical	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
survival	JJ	O
rates	NNS	O
of	IN	O
the	DT	O
rectal	JJ	O
carcinoma	NN	O
patients	NNS	O
receiving	VBG	O
radiotherapy	NN	O
either	CC	O
pre-operatively	RB	O
or	CC	O
postoperatively	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
disease-free	JJ	O
survival	NN	O
rates	NNS	O
of	IN	O
the	DT	O
PRE	NNP	PH
group	NN	O
were	VBD	O
higher	JJR	O
than	IN	O
the	DT	O
POST	NNP	PH
group	NN	O
's	POS	O
during	IN	O
each	DT	O
year	NN	O
and	CC	O
overall	JJ	O
survival	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
after	IN	O
the	DT	O
third	JJ	O
and	CC	O
fourth	JJ	O
years	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
pre-operative	JJ	PH
radiotherapy	NN	PH
is	VBZ	O
at	IN	O
least	JJS	O
as	RB	O
effective	JJ	O
as	IN	O
postoperative	JJ	PH
radiotherapy	NN	PH
.	.	O

Sinemet	NNP	PM
CR	NNP	PM
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Sinemet	NNP	PM
CR	NNP	PM
,	,	O
a	DT	O
controlled	JJ	O
release	NN	O
carbidopa/levodopa	NN	PM
preparation	NN	PM
,	,	O
was	VBD	O
compared	VBN	O
to	TO	O
conventional	JJ	O
carbidopa/levodopa	NN	PM
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
.	.	O

Comparable	JJ	O
clinical	JJ	O
benefits	NNS	O
and	CC	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
noted	VBN	O
with	IN	O
the	DT	O
two	CD	O
medications	NNS	O
.	.	O

However	RB	O
significantly	RB	O
less	RBR	O
frequent	JJ	O
dosing	NN	O
was	VBD	O
necessary	JJ	O
with	IN	O
Sinemet	NNP	O
CR	NNP	O
.	.	O

Direct	JJ	O
renin	NN	O
inhibition	NN	O
improves	VBZ	O
parasympathetic	JJ	O
function	NN	O
in	IN	O
diabetes	NNS	O
.	.	O

AIM	VB	O
The	DT	O
renin-angiotensin-aldosterone	NN	O
system	NN	O
(	(	O
RAAS	NNP	O
)	)	O
and	CC	O
autonomic	JJ	O
nervous	JJ	O
system	NN	O
regulate	VB	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
.	.	O

Blockade	NN	O
of	IN	O
the	DT	O
RAAS	NNP	O
may	MD	O
slow	VB	O
the	DT	O
progression	NN	O
of	IN	O
end-organ	JJ	O
damage	NN	O
.	.	O

Direct	JJ	O
renin	NN	O
inhibition	NN	O
offers	VBZ	O
a	DT	O
means	NN	O
for	IN	O
blocking	VBG	O
the	DT	O
RAAS	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
direct	JJ	O
renin	NN	O
inhibition	NN	O
on	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	C
trial	NN	O
,	,	O
60	CD	O
individuals	NNS	O
with	IN	O
diabetes	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
300	CD	O
mg	NN	O
of	IN	O
aliskiren	NN	PM
or	CC	O
placebo	NN	PM
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
change	NN	O
in	IN	O
tests	NNS	O
of	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
.	.	O

Autonomic	NNP	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
power	NN	O
spectral	JJ	O
analysis	NN	O
and	CC	O
RR-variation	NNP	O
during	IN	O
deep	JJ	O
breathing	NN	O
[	JJ	O
i.e	NN	O
.	.	O

mean	VB	O
circular	JJ	O
resultant	NN	O
(	(	O
MCR	NNP	O
)	)	O
,	,	O
expiration/inspiration	NN	O
(	(	O
E/I	NNP	O
)	)	O
ratio	NN	O
]	NN	O
.	.	O

The	DT	O
MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
assess	NN	O
parasympathetic	JJ	O
function	NN	O
.	.	O

Secondary	JJ	O
measures	NNS	O
included	VBD	O
change	NN	O
in	IN	O
biochemical	JJ	O
parameters	NNS	O
[	VBP	O
e.g	NN	O
.	.	O

plasma	JJ	O
renin	NN	O
activity	NN	O
,	,	O
leptin	NN	O
and	CC	O
interleukin-6	JJ	O
]	NN	O
.	.	O

Change	NN	O
in	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
blood	NN	O
analytes	NNS	O
were	VBD	O
analysed	VBN	O
by	IN	O
a	DT	O
mixed	JJ	O
effects	NNS	O
model	NN	O
for	IN	O
repeated	JJ	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
treatment	NN	O
groups	NNS	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
aliskiren	NNS	PM
compared	VBN	O
with	IN	O
placebo	NN	C
,	,	O
blood	NN	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
as	RB	O
well	RB	O
as	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
[	VBP	O
from	IN	O
2.4	CD	O
?	.	O
3.8	CD	O
(	(	O
mean	VB	O
?	.	O
standard	JJ	O
deviation	NN	O
)	)	O
to	TO	O
0.5	CD	O
?	.	O
0.4	CD	O
?g/l/h	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
]	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
(	(	O
aliskiren	VB	O
?	.	O
visit	NN	O
)	)	O
for	IN	O
MCR	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
E/I	NNP	O
ratio	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
indicating	VBG	O
improvement	NN	O
in	IN	O
MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
for	IN	O
those	DT	O
on	IN	O
aliskiren	NNS	O
.	.	O

MCR	NNP	O
means	VBZ	O
,	,	O
baseline	VB	O
vs.	IN	O
follow-up	JJ	O
,	,	O
were	VBD	O
41.8	CD	O
?	.	O
19.7	CD	O
vs.	IN	O
50.8	CD	O
?	.	O
26.1	CD	O
(	(	O
aliskiren	NN	O
)	)	O
and	CC	O
38.2	CD	O
?	.	O
23.6	CD	O
vs.	IN	O
37.5	CD	O
?	.	O
24.1	CD	O
(	(	O
placebo	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Parasympathetic	NNP	O
function	NN	O
(	(	O
i.e	JJ	O
.	.	O

MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
)	)	O
was	VBD	O
enhanced	VBN	O
by	IN	O
downregulation	NN	O
of	IN	O
the	DT	O
RAAS	NNP	O
.	.	O

[	JJ	O
Hemostatic	NNP	O
balance	NN	O
during	IN	O
treatment	NN	O
with	IN	O
the	DT	O
newest	JJS	O
contraceptives	NNS	O
]	RB	O
.	.	O

Thirty-four	CD	O
healthy	JJ	O
young	JJ	O
women	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
12	CD	O
consecutive	JJ	O
cycles	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
monophasic	JJ	PM
combinations	NNS	PM
of	IN	PM
:	:	PM
20	CD	PM
micrograms	NNS	PM
ethinyl	VBP	PM
estradiol	NN	PM
and	CC	O
150	CD	PM
micrograms	NNS	PM
desogestrel	NN	PM
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
or	CC	O
30	CD	PM
micrograms	NNS	PM
ethinyl	VBP	PM
estradiol	NN	PM
and	CC	O
75	CD	PM
micrograms	NNS	PM
gestodene	NN	PM
(	(	O
n	JJ	O
=	NNP	O
19	CD	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
plasma	VBP	O
levels	NNS	O
of	IN	O
fibrinogen	NN	O
and	CC	O
factor	NN	O
VII	NNP	O
increased	VBD	O
while	IN	O
the	DT	O
capacity	NN	O
of	IN	O
coagulation	NN	O
inhibition	NN	O
was	VBD	O
affected	VBN	O
by	IN	O
increased	JJ	O
protein	NN	O
C	NNP	O
and	CC	O
decreased	VBN	O
protein	NN	O
S	NNP	O
levels	NNS	O
.	.	O

Increased	VBN	O
fibrinolytic	JJ	O
capacity	NN	O
was	VBD	O
indicated	VBN	O
by	IN	O
elevated	JJ	O
activity	NN	O
and	CC	O
reduced	JJ	O
antigen	NN	O
levels	NNS	O
of	IN	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
and	CC	O
reduced	JJ	O
activity	NN	O
and	CC	O
concentration	NN	O
of	IN	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
.	.	O

The	DT	O
ratio	NN	O
between	IN	O
thrombin-antithrombin-III-complexes	NNS	O
and	CC	O
fibrin	JJ	O
degradation	NN	O
products	NNS	O
were	VBD	O
unchanged	JJ	O
signifying	VBG	O
no	DT	O
effect	NN	O
of	IN	O
hormonal	JJ	O
intake	NN	O
on	IN	O
the	DT	O
balance	NN	O
between	IN	O
thrombin	JJ	O
formation	NN	O
and	CC	O
fibrin	JJ	O
resolution	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
dynamic	JJ	O
balance	NN	O
between	IN	O
generation	NN	O
and	CC	O
resolution	NN	O
of	IN	O
fibrin	NN	O
was	VBD	O
undisturbed	JJ	O
during	IN	O
treatment	NN	O
with	IN	O
both	DT	O
hormonal	JJ	O
compounds	NNS	O
and	CC	O
our	PRP$	O
findings	NNS	O
do	VBP	O
not	RB	O
provide	VB	O
evidence	NN	O
for	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
thrombosis	NN	O
in	IN	O
normal	JJ	O
women	NNS	O
.	.	O

[	JJ	O
Radiotherapy	NNP	PH
for	IN	O
choroidal	JJ	O
neovascularization	NN	O
in	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
using	VBG	O
low-	JJ	PH
versus	NN	PH
high-dose	JJ	PH
photon	NN	PH
bean	NN	PH
radiation	NN	PH
]	NN	O
.	.	O

PURPOSE	NNP	O
Several	JJ	O
pilot	NN	O
studies	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
low-dose	JJ	PH
radiation	NN	PH
therapy	NN	PH
might	MD	O
have	VB	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
course	NN	O
of	IN	O
choroidal	JJ	O
neovascularization	NN	O
(	(	O
CNV	NNP	O
)	)	O
in	IN	O
age-related	JJ	O
macular	JJ	O
degeneration	NN	O
(	(	O
AMD	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
ascertain	VB	O
whether	IN	O
such	JJ	O
treatment	NN	O
might	MD	O
halt	VB	O
the	DT	O
progression	NN	O
of	IN	O
neovascular	JJ	O
AMD	NNP	O
and	CC	O
whether	IN	O
a	DT	O
low	JJ	O
or	CC	O
a	DT	O
high	JJ	O
radiation	NN	O
dose	NN	O
should	MD	O
be	VB	O
applied	VBN	O
.	.	O

PATIENTS	VB	O
The	DT	O
patients	NNS	O
comprised	VBD	O
some	DT	O
randomized	VBN	O
to	TO	O
0	CD	PH
vs	NNS	PH
10	CD	PH
vs	NNS	PH
36	CD	PH
Gy	NNP	PH
of	IN	PH
radiation	NN	PH
and	CC	O
(	(	O
after	IN	O
a	DT	O
change	NN	O
of	IN	O
the	DT	O
study	NN	O
protocol	NN	O
became	VBD	O
necessary	JJ	O
)	)	O
others	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
controlled	VBD	O
non-randomized	JJ	O
pilot	NN	O
study	NN	O
.	.	O

Enclosed	VBN	O
were	VBD	O
eyes	NNS	O
with	IN	O
visual	JJ	O
acuity	NN	O
of	IN	O
>	NN	O
or	CC	O
=	VB	O
0.1	CD	O
and	CC	O
<	NNP	O
or	CC	O
=	$	O
0.6	CD	O
revealing	VBG	O
a	DT	O
juxta-subfoveal	JJ	O
CNV	NNP	O
either	NN	O
of	IN	O
the	DT	O
occult	NN	O
type	NN	O
(	(	O
type	JJ	O
1	CD	O
)	)	O
or	CC	O
the	DT	O
classic	JJ	O
type	NN	O
(	(	O
isolated	JJ	O
or	CC	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
predominantly	RB	O
occult	JJ	O
lesion	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Eyes	NNP	O
treated	VBD	O
with	IN	O
10	CD	PH
Gy	NNP	PH
for	IN	O
occult	NN	O
CNV	NNP	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
were	VBD	O
subject	JJ	O
to	TO	O
severe	JJ	O
visual	JJ	O
loss	NN	O
in	IN	O
41.6	CD	O
%	NN	O
of	IN	O
the	DT	O
cases	NNS	O
compared	VBN	O
to	TO	O
38.5	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
at	IN	O
12	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

For	IN	O
eyes	NNS	O
treated	VBN	O
with	IN	O
10	CD	PH
Gy	NNP	PH
because	IN	O
of	IN	O
classic	JJ	O
CNV	NNP	O
,	,	O
the	DT	O
corresponding	JJ	O
figures	NNS	O
were	VBD	O
33	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
and	CC	O
57	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
respectively	RB	O
.	.	O

At	IN	O
18	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
the	DT	O
percentages	NNS	O
were	VBD	O
63	CD	O
%	NN	O
and	CC	O
75	CD	O
%	NN	O
respectively	RB	O
.	.	O

Fluorescein	NNP	O
angiographic	JJ	O
growth	NN	O
of	IN	O
classic	JJ	O
and	CC	O
occult	NN	O
CNV	NNP	O
could	MD	O
not	RB	O
be	VB	O
halted	VBN	O
by	IN	O
10	CD	O
Gy	NNP	O
,	,	O
while	IN	O
a	DT	O
temporary	JJ	O
growth	NN	O
retardation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
cases	NNS	O
irradiated	VBN	O
with	IN	O
36	CD	PH
Gy	NNP	PH
.	.	O

CONCLUSION	NNP	O
In	IN	O
the	DT	O
study	NN	O
presented	VBD	O
,	,	O
the	DT	O
natural	JJ	O
course	NN	O
of	IN	O
occult	NN	O
CNV	NNP	O
could	MD	O
not	RB	O
be	VB	O
improved	VBN	O
by	IN	O
irradiation	NN	O
with	IN	O
10	CD	PH
or	CC	PH
36	CD	PH
Gy	NNP	PH
.	.	O

In	IN	O
cases	NNS	O
of	IN	O
classic	JJ	O
CNV	NNP	O
,	,	O
low-dose	JJ	O
irradiation	NN	O
with	IN	O
10	CD	PH
Gy	NNP	PH
postponed	VBD	O
severe	JJ	O
visual	JJ	O
loss	NN	O
by	IN	O
a	DT	O
maximum	NN	O
of	IN	O
18	CD	O
months	NNS	O
.	.	O

A	DT	O
positive	JJ	O
treatment	NN	O
effect	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
cases	NNS	O
irradiated	VBN	O
with	IN	O
36	CD	PH
Gy	NNP	PH
;	:	O
however	RB	O
,	,	O
a	DT	O
25	CD	O
%	NN	O
incidence	NN	O
of	IN	O
radiation	NN	O
retinopathy	NN	O
seems	VBZ	O
unacceptable	JJ	O
.	.	O

Preschoolers	NNS	O
acquire	VB	O
general	JJ	O
knowledge	NN	O
by	IN	O
sharing	VBG	E
in	IN	E
pretense	NN	E
.	.	O

Children	NNP	O
acquire	VB	O
general	JJ	O
knowledge	NN	O
about	IN	O
many	JJ	O
kinds	NNS	O
of	IN	O
things	NNS	O
,	,	O
but	CC	O
there	EX	O
are	VBP	O
few	JJ	O
known	VBN	O
means	NNS	O
by	IN	O
which	WDT	O
this	DT	O
knowledge	NN	O
is	VBZ	O
acquired	VBN	O
.	.	O

In	IN	O
this	DT	O
article	NN	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
children	NNS	O
acquire	VB	O
generic	JJ	O
knowledge	NN	O
by	IN	O
sharing	VBG	O
in	IN	O
pretend	JJ	E
play	NN	E
.	.	O

In	IN	O
Experiment	JJ	O
1	CD	O
,	,	O
twenty-two	JJ	O
3-	JJ	O
to	TO	O
4-year-olds	NNS	O
watched	VBN	E
pretense	NN	E
in	IN	E
which	WDT	E
a	DT	E
puppet	NN	E
represented	VBD	E
a	DT	E
nerp	NN	E
(	(	O
an	DT	O
unfamiliar	JJ	O
kind	NN	O
of	IN	O
animal	NN	O
)	)	O
.	.	O

For	IN	O
instance	NN	O
,	,	O
in	IN	O
one	CD	O
scenario	NN	O
,	,	O
the	DT	O
nerp	JJ	O
ate	NN	O
and	CC	O
disliked	VBD	O
a	DT	O
carrot	NN	O
.	.	O

When	WRB	O
subsequently	RB	O
asked	VBD	O
generic	JJ	O
questions	NNS	O
about	IN	O
real	JJ	O
nerps	NNS	O
,	,	O
children	NNS	O
's	POS	O
responses	NNS	O
suggested	VBD	O
that	IN	O
they	PRP	O
had	VBD	O
learned	VBN	O
general	JJ	O
facts	NNS	O
(	(	O
e.g.	NN	O
,	,	O
nerps	RB	O
dislike	JJ	O
carrots	NNS	O
)	)	O
.	.	O

In	IN	O
Experiment	JJ	O
2	CD	O
,	,	O
thirty-two	JJ	O
4-	JJ	O
to	TO	O
5-year-olds	NNS	O
learned	VBN	O
from	IN	O
scenarios	NNS	E
lacking	VBG	E
pretend	JJ	E
speech	NN	E
or	CC	E
sound	JJ	E
effects	NNS	E
.	.	O

The	DT	O
findings	NNS	O
reveal	VBP	O
a	DT	O
long	JJ	O
overlooked	JJ	O
means	NNS	O
by	IN	O
which	WDT	O
children	NNS	O
can	MD	O
acquire	VB	O
generic	JJ	O
knowledge	NN	O
.	.	O

Stress	NNP	E
reduction	NN	E
prolongs	NNS	O
life	NN	O
in	IN	O
women	NNS	O
with	IN	O
coronary	JJ	O
disease	NN	O
:	:	O
the	DT	O
Stockholm	NNP	O
Women	NNP	O
's	POS	O
Intervention	NNP	O
Trial	NNP	O
for	IN	O
Coronary	NNP	O
Heart	NNP	O
Disease	NNP	O
(	(	O
SWITCHD	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Psychosocial	NNP	O
stress	NN	O
may	MD	O
increase	VB	O
risk	NN	O
and	CC	O
worsen	JJ	O
prognosis	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
in	IN	O
women	NNS	O
.	.	O

Interventions	NNS	O
that	IN	O
counteract	JJ	O
women	NNS	O
's	POS	O
psychosocial	JJ	O
stress	NN	O
have	VBP	O
not	RB	O
previously	RB	O
been	VBN	O
presented	VBN	O
.	.	O

This	DT	O
study	NN	O
implemented	VBD	O
a	DT	O
stress	JJ	E
reduction	NN	E
program	NN	E
for	IN	O
women	NNS	O
and	CC	O
investigated	VBD	O
its	PRP$	O
ability	NN	O
to	TO	O
improve	VB	O
survival	NN	O
in	IN	O
women	NNS	O
coronary	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Two	CD	O
hundred	VBD	O
thirty-seven	JJ	O
consecutive	JJ	O
women	NNS	O
patients	NNS	O
,	,	O
aged	VBD	O
75	CD	O
years	NNS	O
or	CC	O
younger	JJR	O
,	,	O
hospitalized	VBN	O
for	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	NN	O
,	,	O
or	CC	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
group-based	JJ	E
psychosocial	JJ	E
intervention	NN	E
program	NN	E
or	CC	E
usual	JJ	E
care	NN	E
.	.	E

Initiated	VBN	O
4	CD	O
months	NNS	O
after	IN	O
hospitalization	NN	O
,	,	O
intervention	NN	O
groups	NNS	O
of	IN	O
4	CD	O
to	TO	O
8	CD	O
women	NNS	O
met	VBD	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
20	CD	O
sessions	NNS	O
that	WDT	O
were	VBD	O
spread	VBN	O
over	IN	O
a	DT	O
year	NN	O
.	.	O

We	PRP	O
provided	VBD	O
education	NN	E
about	IN	E
risk	NN	E
factors	NNS	E
,	,	O
relaxation	NN	E
training	NN	E
techniques	NNS	E
,	,	O
methods	NNS	E
for	IN	E
self-monitoring	NN	E
and	CC	E
cognitive	JJ	E
restructuring	NN	E
,	,	O
with	IN	O
an	DT	O
emphasis	NN	O
on	IN	O
coping	VBG	E
with	IN	E
stress	JJ	E
exposure	NN	E
from	IN	E
family	NN	E
and	CC	E
work	NN	E
,	,	O
and	CC	O
self-care	NN	E
and	CC	E
compliance	NN	E
with	IN	E
clinical	JJ	E
advice	NN	E
.	.	O

From	IN	O
randomization	NN	O
until	IN	O
end	NN	O
of	IN	O
follow-up	NN	O
(	(	O
mean	JJ	O
duration	NN	O
,	,	O
7.1	CD	O
years	NNS	O
)	)	O
,	,	O
25	CD	O
women	NNS	O
(	(	O
20	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
usual	JJ	O
care	NN	O
and	CC	O
8	CD	O
women	NNS	O
(	(	O
7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
stress	NN	O
reduction	NN	O
died	VBD	O
,	,	O
yielding	VBG	O
an	DT	O
almost	RB	O
3-fold	JJ	O
protective	JJ	O
effect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
(	(	O
odds	NNS	O
ratio	NN	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.15	CD	O
to	TO	O
0.74	CD	O
;	:	O
P=0.007	NNP	O
)	)	O
.	.	O

Introducing	VBG	O
baseline	JJ	O
measures	NNS	O
of	IN	O
clinical	JJ	O
prognostic	JJ	O
factors	NNS	O
,	,	O
including	VBG	O
use	NN	O
of	IN	O
aspirin	NN	PM
,	,	O
beta-blockers	NNS	O
,	,	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
,	,	O
calcium-channel	JJ	O
blockers	NNS	O
,	,	O
and	CC	O
statins	VBZ	O
into	IN	O
multivariate	NN	O
models	NNS	O
confirmed	VBD	O
the	DT	O
unadjusted	JJ	O
results	NNS	O
(	(	O
P=0.009	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
mechanisms	NN	O
remain	VBP	O
unclear	JJ	O
,	,	O
a	DT	O
group-based	JJ	E
psychosocial	JJ	E
intervention	NN	E
program	NN	E
for	IN	O
women	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
may	MD	O
prolong	VB	O
lives	NNS	O
independent	JJ	O
of	IN	O
other	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

Opioid-immune	JJ	O
interactions	NNS	O
in	IN	O
autism	NN	O
:	:	O
behavioural	JJ	O
and	CC	O
immunological	JJ	O
assessment	NN	O
during	IN	O
a	DT	O
double-blind	JJ	O
treatment	NN	O
with	IN	O
naltrexone	NN	PM
.	.	O

The	DT	O
emerging	VBG	O
concept	NN	O
of	IN	O
opioid	JJ	O
peptides	NNS	O
as	IN	O
a	DT	O
new	JJ	O
class	NN	O
of	IN	O
chemical	JJ	O
messengers	NNS	O
of	IN	O
the	DT	O
neuroimmune	JJ	O
axis	NN	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
immunological	JJ	O
abnormalities	NNS	O
in	IN	O
infantile	JJ	O
autism	NN	O
prompted	VBD	O
us	PRP	O
to	TO	O
correlate	VB	O
biological	JJ	O
(	(	O
hormonal	JJ	O
and	CC	O
immunological	JJ	O
)	)	O
determinations	NNS	O
and	CC	O
behavioural	JJ	O
performances	NNS	O
during	IN	O
treatment	NN	O
with	IN	O
the	DT	O
potent	NN	O
opiate	JJ	O
antagonist	NN	O
,	,	O
naltrexone	NN	PM
(	(	PM
NAL	NNP	PM
)	)	PM
.	.	O

Twelve	NNP	O
autistic	JJ	O
patients	NNS	O
ranging	VBG	O
from	IN	O
7	CD	O
to	TO	O
15	CD	O
years	NNS	O
,	,	O
diagnosed	VBD	O
according	VBG	O
to	TO	O
DSM-III-R	NNP	O
,	,	O
entered	VBD	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
with	IN	O
NAL	NNP	PM
at	IN	O
the	DT	O
doses	NNS	O
of	IN	O
0.5	CD	O
,	,	O
1.0	CD	O
and	CC	O
1.5	CD	O
mg/kg	NN	O
every	DT	O
48	CD	O
hours	NNS	O
.	.	O

The	DT	O
behavioural	JJ	O
evaluation	NN	O
was	VBD	O
conducted	VBN	O
using	VBG	O
the	DT	O
specific	JJ	O
BSE	NNP	Ot
and	CC	O
CARS	NNP	Ot
rating	NN	Ot
scales	NNS	Ot
NAL	NNP	PM
treatment	NN	O
produced	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
autistic	JJ	O
symptomatology	NN	O
in	IN	O
seven	CD	O
(	(	O
responders	NNS	O
)	)	O
out	IN	O
of	IN	O
12	CD	O
children	NNS	O
.	.	O

The	DT	O
behavioural	JJ	O
improvement	NN	O
was	VBD	O
accompanied	VBN	O
by	IN	O
alterations	NNS	O
in	IN	O
the	DT	O
distribution	NN	O
of	IN	O
the	DT	O
major	JJ	O
lymphocyte	NN	O
subsets	NNS	O
,	,	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
the	DT	O
T-helper-inducers	NNP	O
(	(	O
CD4+CD8-	NNP	O
)	)	O
and	CC	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
T-cytotoxic-suppressor	NNP	O
(	(	O
CD4-CD8+	NNP	O
)	)	O
resulting	VBG	O
in	IN	O
a	DT	O
normalization	NN	O
of	IN	O
the	DT	O
CD4/CD8	NNP	O
ratio	NN	O
.	.	O

Changes	NNS	O
in	IN	O
natural	JJ	O
killer	NN	O
cells	NNS	O
and	CC	O
activity	NN	O
were	VBD	O
inversely	RB	O
related	VBN	O
to	TO	O
plasma	VB	O
beta-endorphin	JJ	O
levels	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
mechanisms	NNS	O
underlying	VBG	O
opioid-immune	JJ	O
interactions	NNS	O
are	VBP	O
altered	VBN	O
in	IN	O
this	DT	O
population	NN	O
of	IN	O
autistic	JJ	O
children	NNS	O
and	CC	O
that	DT	O
an	DT	O
immunological	JJ	O
screening	NN	O
may	MD	O
have	VB	O
prognostic	JJ	O
value	NN	O
for	IN	O
the	DT	O
pharmacological	JJ	O
therapy	NN	O
with	IN	O
opiate	JJ	PM
antagonists	NNS	PM
.	.	O

Superior	JJ	O
survival	NN	O
with	IN	O
capecitabine	JJ	PM
plus	CC	O
docetaxel	JJ	PM
combination	NN	PM
therapy	NN	PM
in	IN	O
anthracycline-pretreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
phase	NN	O
III	NNP	O
trial	NN	O
results	NNS	O
.	.	O

PURPOSE	NNP	O
Docetaxel	NNP	PM
and	CC	O
capecitabine	NN	PM
,	,	O
a	DT	O
tumor-activated	JJ	O
oral	JJ	O
fluoropyrimidine	NN	O
,	,	O
show	VBP	O
high	JJ	O
single-agent	JJ	O
efficacy	NN	O
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
(	(	O
MBC	NNP	O
)	)	O
and	CC	O
synergy	NN	O
in	IN	O
preclinical	JJ	O
studies	NNS	O
.	.	O

This	DT	O
international	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
compared	VBN	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
capecitabine/docetaxel	JJ	PM
therapy	NN	PM
with	IN	O
single-agent	JJ	PM
docetaxel	NN	PM
in	IN	O
anthracycline-pretreated	JJ	O
patients	NNS	O
with	IN	O
MBC	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
21-day	JJ	O
cycles	NNS	O
of	IN	O
oral	JJ	O
capecitabine	NN	PM
1,250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
twice	RB	O
daily	RB	O
on	IN	O
days	NNS	O
1	CD	O
to	TO	O
14	CD	O
plus	CC	O
docetaxel	JJ	PM
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
255	CD	O
)	)	O
or	CC	O
to	TO	O
docetaxel	VB	PM
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
256	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
Capecitabine/docetaxel	NNP	PM
resulted	VBD	O
in	IN	O
significantly	RB	O
superior	JJ	O
efficacy	NN	O
in	IN	O
time	NN	O
to	TO	O
disease	VB	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.652	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.545	CD	O
to	TO	O
0.780	CD	O
;	:	O
P	NNP	O
=.0001	NNP	O
;	:	O
median	JJ	O
,	,	O
6.1	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
)	)	O
,	,	O
overall	JJ	O
survival	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.775	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.634	CD	O
to	TO	O
0.947	CD	O
;	:	O
P	NNP	O
=.0126	NNP	O
;	:	O
median	JJ	O
,	,	O
14.5	CD	O
v	NN	O
11.5	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
objective	JJ	O
tumor	NN	O
response	NN	O
rate	NN	O
(	(	O
42	CD	O
%	NN	O
v	JJ	O
30	CD	O
%	NN	O
,	,	O
P	NNP	O
=.006	NNP	O
)	)	O
compared	VBN	O
with	IN	O
docetaxel	NN	PM
.	.	O

Gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
and	CC	O
hand-foot	JJ	O
syndrome	NN	O
were	VBD	O
more	JJR	O
common	JJ	O
with	IN	O
combination	NN	PM
therapy	NN	PM
,	,	O
whereas	JJ	O
myalgia	NN	O
,	,	O
arthralgia	NN	O
,	,	O
and	CC	O
neutropenic	JJ	O
fever/sepsis	NN	O
were	VBD	O
more	JJR	O
common	JJ	O
with	IN	O
single-agent	JJ	PM
docetaxel	NN	PM
.	.	O

More	JJR	O
grade	JJ	O
3	CD	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
with	IN	O
combination	NN	O
therapy	NN	O
(	(	O
71	CD	O
%	NN	O
v	JJ	O
49	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
whereas	JJ	O
grade	VBP	O
4	CD	O
events	NNS	O
were	VBD	O
slightly	RB	O
more	RBR	O
common	JJ	O
with	IN	O
docetaxel	NN	PM
(	(	O
31	CD	O
%	NN	O
v	JJ	O
25	CD	O
%	NN	O
with	IN	O
combination	NN	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
significantly	RB	O
superior	JJ	O
TTP	NNP	O
and	CC	O
survival	NN	O
achieved	VBN	O
with	IN	O
the	DT	O
addition	NN	PM
of	IN	PM
capecitabine	NN	PM
to	TO	PM
docetaxel	VB	PM
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
with	IN	O
the	DT	O
manageable	JJ	O
toxicity	NN	O
profile	NN	O
,	,	O
indicate	VBP	O
that	IN	O
this	DT	O
combination	NN	O
provides	VBZ	O
clear	JJ	O
benefits	NNS	O
over	IN	O
single-agent	JJ	PM
docetaxel	NN	PM
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Docetaxel/capecitabine	NNP	PM
therapy	NN	PM
is	VBZ	O
an	DT	O
important	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
women	NNS	O
with	IN	O
anthracycline-pretreated	JJ	O
MBC	NNP	O
.	.	O

Changes	NNS	O
of	IN	O
activated	JJ	O
circulating	VBG	O
endothelial	JJ	O
cells	NNS	O
and	CC	O
survivin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
after	IN	O
antiangiogenesis	NN	PM
therapy	NN	PM
.	.	O

BACKGROUND	NNP	O
Although	IN	O
antiangiogenesis	NN	PM
therapy	NN	PM
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
anti-neoplastic	JJ	O
treatment	NN	O
with	IN	O
its	PRP$	O
recognized	VBN	O
efficacy	NN	O
and	CC	O
slight	JJ	O
adverse	JJ	O
effect	NN	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
define	VB	O
ideal	JJ	O
markers	NNS	O
for	IN	O
predicting	VBG	O
efficacy	NN	O
of	IN	O
antiangiogenic	JJ	PH
therapy	NN	PH
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
changes	NNS	O
of	IN	O
activated	JJ	O
circulating	VBG	O
endothelial	JJ	O
cells	NNS	O
(	(	O
aCECs	NN	O
)	)	O
and	CC	O
survivin	JJ	O
after	IN	O
anti-angiogenesis	JJ	O
therapy	NN	O
and	CC	O
their	PRP$	O
significance	NN	O
in	IN	O
predicting	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
therapy	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
of	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
treated	VBD	O
with	IN	O
chemotherapy	NN	PM
with	IN	PM
or	CC	PM
without	IN	PM
Endostar	NNP	PM
were	VBD	O
observed	VBN	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
activated	JJ	O
CECs	NNP	O
was	VBD	O
detected	VBN	O
by	IN	O
flow	JJ	O
cytometry	NN	O
,	,	O
and	CC	O
the	DT	O
expression	NN	O
of	IN	O
survivin	NN	O
mRNA	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
real-time	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
activated	JJ	O
CECs	NNP	O
decreased	VBD	O
significantly	RB	O
in	IN	O
clinical	JJ	O
benefit	NN	O
cases	NNS	O
(	(	O
P	NNP	O
=	VBZ	O
0.021	CD	O
in	IN	O
chemotherapy	NN	PH
alone	RB	O
,	,	O
P	NNP	O
=	VBZ	O
0.001	CD	O
in	IN	O
chemotherapy	NN	PH
plus	CC	PH
Endostar	NNP	PH
)	)	O
,	,	O
increased	VBN	O
in	IN	O
disease	NN	O
progressive	JJ	O
cases	NNS	O
(	(	O
P	NNP	O
=	VBZ	O
0.015	CD	O
in	IN	O
chemotherapy	NN	PH
alone	RB	O
,	,	O
but	CC	O
P	NNP	O
=	NNP	O
0.293	CD	O
in	IN	O
chemotherapy	NN	PH
with	IN	PH
Endotatar	NNP	PH
)	)	O
.	.	O

After	IN	O
therapy	NN	O
,	,	O
the	DT	O
expression	NN	O
of	IN	O
survivin	JJ	O
mRNA	NN	O
decreased	VBN	O
in	IN	O
clinical	JJ	O
benefit	NN	O
cases	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
and	CC	O
increased	VBN	O
in	IN	O
disease	NN	O
progressive	JJ	O
cases	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.018	CD	O
)	)	O
.	.	O

A	DT	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
activated	VBN	O
CECs	NNP	O
and	CC	O
survivin	NN	O
in	IN	O
the	DT	O
chemotherapy	NN	PH
group	NN	O
pre-	JJ	O
and	CC	O
post-therapy	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
and	CC	O
0.021	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
but	CC	O
only	RB	O
in	IN	O
the	DT	O
chemotherapy	NN	PH
with	IN	PH
Endostar	NNP	PH
group	NN	O
pre-therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.030	CD	O
)	)	O
rather	RB	O
than	IN	O
post-therapy	NN	O
.	.	O

A	DT	O
positive	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
decreased	VBN	O
activated	VBN	O
CECs	NNP	O
after	IN	O
therapy	NN	O
and	CC	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
(	(	O
r	JJ	O
=	NN	O
0.322	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.012	CD	O
)	)	O
;	:	O
a	DT	O
negative	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
amount	NN	O
of	IN	O
survivin	NN	O
mRNA	NN	O
in	IN	O
serum	JJ	O
post-therapy	NN	O
and	CC	O
TTP	NNP	O
(	(	O
r	NN	O
=	NNP	O
-0.291	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.048	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Activated	NNP	O
CECs	NNP	O
and	CC	O
survivin	NN	O
may	MD	O
be	VB	O
ideal	JJ	O
markers	NNS	O
forecasting	VBG	O
efficacy	NN	O
and	CC	O
prognosis	NN	O
of	IN	O
NSCLC	NNP	O
.	.	O

The	DT	O
former	JJ	O
can	MD	O
reflect	VB	O
more	RBR	O
sensitively	RB	O
antiangiogenic	JJ	O
efficacy	NN	O
and	CC	O
the	DT	O
latter	NN	O
is	VBZ	O
more	RBR	O
sensitive	JJ	O
to	TO	O
shrinkage	VB	O
or	CC	O
swelling	VBG	O
of	IN	O
tumors	NNS	O
.	.	O

Their	PRP$	O
combination	NN	O
can	MD	O
evaluate	VB	O
more	RBR	O
accurately	RB	O
the	DT	O
efficacy	NN	O
of	IN	O
antiangiogenic	JJ	PH
therapy	NN	PH
of	IN	O
NSCLC	NNP	O
.	.	O

Dexamethasone	NN	PM
in	IN	O
salbutamol-treated	JJ	O
inpatients	NNS	O
with	IN	O
acute	JJ	O
bronchiolitis	NN	O
:	:	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
clinical	JJ	O
benefit	NN	O
of	IN	O
oral	JJ	O
dexamethasone	NN	O
in	IN	O
children	NNS	O
admitted	VBN	O
to	TO	O
the	DT	O
hospital	NN	O
with	IN	O
bronchiolitis	NN	O
treated	VBN	O
with	IN	O
nebulized	JJ	O
salbutamol	NN	O
.	.	O

METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
the	DT	O
inpatient	JJ	O
wards	NNS	O
of	IN	O
a	DT	O
pediatric	JJ	O
tertiary	NN	O
care	NN	O
hospital	NN	O
.	.	O

The	DT	O
participants	NNS	O
,	,	O
children	NNS	O
aged	VBD	O
6	CD	O
weeks	NNS	O
to	TO	O
15	CD	O
months	NNS	O
,	,	O
admitted	VBN	O
with	IN	O
first-time	JJ	O
wheezing	NN	O
,	,	O
were	VBD	O
eligible	JJ	O
if	IN	O
their	PRP$	O
oxygen	NN	O
saturation	NN	O
was	VBD	O
less	JJR	O
than	IN	O
95	CD	O
%	NN	O
on	IN	O
admission	NN	O
to	TO	O
the	DT	O
hospital	NN	O
and	CC	O
their	PRP$	O
Respiratory	NNP	O
Distress	NNP	O
Assessment	NNP	O
Instrument	NNP	O
(	(	O
RDAI	NNP	O
)	)	O
score	NN	O
was	VBD	O
greater	JJR	O
than	IN	O
6	CD	O
.	.	O

Patients	NNS	O
were	VBD	O
excluded	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
any	DT	O
one	CD	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
an	DT	O
underlying	JJ	O
disease	NN	O
that	WDT	O
might	MD	O
affect	VB	O
cardiopulmonary	JJ	O
status	NN	O
,	,	O
asthma	NN	O
,	,	O
recent	JJ	O
treatment	NN	O
with	IN	O
steroids	NNS	O
(	(	O
within	IN	O
2	CD	O
weeks	NNS	O
)	)	O
,	,	O
or	CC	O
any	DT	O
history	NN	O
of	IN	O
adverse	JJ	O
reaction	NN	O
to	TO	O
steroids	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
orally	RB	O
administered	VBN	O
dexamethasone	NN	PM
with	IN	PM
0.5	CD	PM
mg/kg	NNS	PM
as	IN	O
the	DT	O
first	JJ	O
dose	NN	O
and	CC	O
0.3	CD	O
mg/kg	NN	O
for	IN	O
the	DT	O
next	JJ	O
2	CD	O
mornings	NNS	O
,	,	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
an	DT	O
orally	RB	O
administered	VBN	O
placebo	NN	C
with	IN	O
an	DT	O
identical	JJ	O
appearance	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
nebulized	JJ	O
salbutamol	NN	PM
at	IN	O
0.15	CD	O
mg/kg	NN	O
every	DT	O
4	CD	O
hours	NNS	O
for	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
RDAI	NNP	O
score	NN	O
at	IN	O
24	CD	O
hours	NNS	O
.	.	O

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
oxygen	JJ	O
saturation	NN	O
,	,	O
respiratory	NN	O
rate	NN	O
,	,	O
RDAI	NNP	O
measurement	NN	O
twice	RB	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
4	CD	O
days	NNS	O
,	,	O
and	CC	O
the	DT	O
length	NN	O
of	IN	O
hospitalization	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
24	CD	O
hours	NNS	O
the	DT	O
mean	JJ	O
change	NN	O
(	(	O
SD	NNP	O
)	)	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
RDAI	NNP	O
score	NN	O
was	VBD	O
1.6	CD	O
(	(	O
2.3	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
and	CC	O
1.4	CD	O
(	(	O
2.0	CD	O
)	)	O
in	IN	O
the	DT	O
dexamethasone	NN	O
group	NN	O
(	(	O
n	JJ	O
=	VBZ	O
33	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.74	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
change	NN	O
in	IN	O
oxygen	NN	O
saturation	NN	O
,	,	O
respiratory	NN	O
rate	NN	O
,	,	O
and	CC	O
RDAI	NNP	O
score	NN	O
at	IN	O
any	DT	O
assessment	JJ	O
period	NN	O
.	.	O

The	DT	O
median	JJ	O
length	NN	O
of	IN	O
stay	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
was	VBD	O
48	CD	O
(	(	O
42	CD	O
,	,	O
54	CD	O
)	)	O
hours	NNS	O
compared	VBN	O
with	IN	O
57	CD	O
(	(	O
38	CD	O
,	,	O
76	CD	O
)	)	O
hours	NNS	O
in	IN	O
the	DT	O
dexamethasone	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.19	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Oral	NNP	O
dexamethasone	NN	O
therapy	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
children	NNS	O
hospitalized	VBN	O
with	IN	O
bronchiolitis	NN	O
and	CC	O
therefore	RB	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
in	IN	O
this	DT	O
clinical	JJ	O
situation	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomised	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
dynamic	JJ	Ot
hip	NN	Ot
screw	NN	Ot
and	CC	O
the	DT	O
gamma	NN	Ot
locking	VBG	Ot
nail	NN	Ot
.	.	O

We	PRP	O
made	VBD	O
a	DT	O
randomised	JJ	O
prospective	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
Dynamic	NNP	Ot
Hip	NNP	Ot
Screw	NNP	Ot
and	CC	O
the	DT	PH
Gamma	NNP	Ot
locking	VBG	Ot
nail	NN	Ot
for	IN	O
the	DT	O
internal	JJ	O
fixation	NN	O
of	IN	O
200	CD	O
petrochanteric	JJ	O
femoral	JJ	O
fractures	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
.	.	O

There	EX	O
was	VBD	O
less	RBR	O
intraoperative	JJ	O
blood	NN	O
loss	NN	O
and	CC	O
a	DT	O
lower	JJR	O
rate	NN	O
of	IN	O
wound	NN	O
complications	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
by	IN	O
the	DT	O
Gamma	NNP	Ot
nail	NN	Ot
.	.	O

They	PRP	O
had	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
femoral	JJ	O
shaft	NN	O
fracture	NN	O
which	WDT	O
we	PRP	O
relate	VBP	O
in	IN	O
part	NN	O
to	TO	O
implant	VB	O
design	NN	O
.	.	O

We	PRP	O
do	VBP	O
not	RB	O
recommend	VB	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Gamma	NNP	PH
nail	NN	PH
for	IN	O
these	DT	O
fractures	NNS	O
.	.	O

Management	NN	O
of	IN	O
unstable	JJ	O
angina	NN	O
at	IN	O
rest	NN	O
by	IN	O
verapamil	NN	PM
.	.	O

A	DT	O
double-blind	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
coronary	JJ	O
care	NN	O
unit	NN	O
.	.	O

A	NNP	O
therapeutic	JJ	O
trial	NN	O
with	IN	O
verapamil	NN	PM
,	,	O
a	DT	O
calcium-antagonist	JJ	PM
drug	NN	PM
,	,	O
was	VBD	O
performed	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
admitted	VBN	O
to	TO	O
our	PRP$	O
coronary	JJ	O
care	NN	O
unit	NN	O
because	IN	O
of	IN	O
frequent	JJ	O
daily	JJ	O
attacks	NNS	O
of	IN	O
angina	NN	O
at	IN	O
rest	NN	O
attributed	VBN	O
to	TO	O
coronary	JJ	O
vasospasm	NN	O
.	.	O

After	IN	O
a	DT	O
48-hour	JJ	O
run-in	JJ	O
period	NN	O
,	,	O
oral	JJ	PM
verapamil	NN	PM
480	CD	PM
mg/day	NN	PM
and	CC	O
placebo	NN	C
were	VBD	O
administered	VBN	O
alternately	RB	O
during	IN	O
4	CD	O
randomised	VBD	O
48-hour	CD	O
periods	NNS	O
.	.	O

Transient	NNP	O
ischaemic	JJ	O
attacks	NNS	O
with	IN	O
ST	NNP	O
segment	NN	O
elevation	NN	O
or	CC	O
depression	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
pain	NN	O
,	,	O
were	VBD	O
documented	VBN	O
by	IN	O
continuous	JJ	O
electrocardiographic	JJ	O
monitoring	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
attacks	NNS	O
during	IN	O
the	DT	O
run-in	JJ	O
and	CC	O
2	CD	O
placebo	NN	C
periods	NNS	O
were	VBD	O
128	CD	O
,	,	O
123	CD	O
,	,	O
and	CC	O
130	CD	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
31	CD	O
and	CC	O
23	CD	O
during	IN	O
the	DT	O
2	CD	O
treatment	NN	O
periods	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.006	CD	O
and	CC	O
P	NNP	O
less	JJR	O
than	IN	O
0.003	CD	O
)	)	O
.	.	O

This	DT	O
drug	NN	O
therefore	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
frequent	JJ	O
attacks	NNS	O
of	IN	O
angina	NN	O
at	IN	O
rest	NN	O
.	.	O

Cholesterol-lowering	JJ	O
effect	NN	O
of	IN	O
stanol	NN	PM
ester	NN	PM
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
of	IN	O
mildly	RB	O
hypercholesterolemic	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
stanol	NN	PM
esters	NNS	PM
in	IN	O
lowering	VBG	O
cholesterol	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
After	IN	O
a	DT	O
run-in	JJ	O
phase	NN	O
,	,	O
318	CD	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
margarine-like	JJ	O
spreads	NNS	O
containing	VBG	O
stanol	JJ	PM
ester	NN	PM
or	CC	O
placebo	NN	PH
for	IN	O
8	CD	O
weeks	NNS	O
:	:	O
EU	NNP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	PM
(	(	PM
ester	JJ	PM
form	NN	PM
)	)	PM
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
European	JJ	O
formula	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	PM
(	(	PM
ester	JJ	PM
form	NN	PM
)	)	PM
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
2	CD	O
G	NNP	O
:	:	O
0.67	CD	O
g	NN	O
of	IN	O
stanol	NN	PM
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
or	CC	O
placebo	VB	C
spread	NN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
+/-	JJ	O
SD	NNP	O
baseline	NN	O
total	NN	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
and	CC	O
low-density	JJ	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
LDL-C	NNP	O
)	)	O
levels	NNS	O
were	VBD	O
233+/-20	JJ	O
and	CC	O
153+21	CD	O
mg+/-dL	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
US	NNP	O
3	CD	O
G	NNP	O
group	NN	O
,	,	O
3	CD	O
g	JJ	O
daily	NN	O
of	IN	O
stanol	JJ	PM
esters	NNS	PM
lowered	VBD	O
TC	NNP	O
and	CC	O
LDL-C	NNP	O
levels	NNS	O
by	IN	O
6.4	CD	O
%	NN	O
and	CC	O
10.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose-dependent	JJ	O
response	NN	O
compared	VBN	O
with	IN	O
2	CD	O
g	NNS	O
daily	RB	O
(	(	O
US	PRP	O
2	CD	O
G	NNP	O
)	)	O
.	.	O

Triglyceride	NNP	O
and	CC	O
high-density	NN	O
lipoprotein	NNS	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
unchanged	JJ	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
placebo	NN	C
.	.	O

Serum	NNP	O
vitamin	VBD	O
A	DT	O
and	CC	O
25-hydroxyvitamin	JJ	O
D	NNP	O
levels	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Stanol	NNP	PM
esters	NNS	PM
lowered	VBD	O
TC	NNP	O
and	CC	O
LDL-C	NNP	O
levels	NNS	O
in	IN	O
a	DT	O
mildly	RB	O
hypercholesterolemic	JJ	O
US	NNP	O
population	NN	O
without	IN	O
evidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
dietary	JJ	O
adjunct	NN	O
to	TO	O
lower	VB	O
cholesterol	NN	O
.	.	O

[	JJ	O
Rapidity	NNP	O
of	IN	O
pain	NN	O
relief	NN	O
,	,	O
medication	NN	O
requirement	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
reflux	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
physician	NN	O
's	POS	O
office	NN	O
]	NN	O
.	.	O

Treatment	NN	O
of	IN	O
gastroesophageal	NN	O
reflux	NN	O
disease	NN	O
(	(	O
GERD	NNP	O
)	)	O
with	IN	O
proton	NN	PM
pump	NN	PM
inhibitors	NNS	PM
was	VBD	O
investigated	VBN	O
in	IN	O
three	CD	O
controlled	VBD	O
prospective	JJ	O
,	,	O
randomized	JJ	O
open	JJ	O
studies	NNS	O
.	.	O

Lansoprazole	NNP	PM
,	,	O
omeprazole	JJ	PM
MUPS	NNP	PM
and	CC	O
esomeprazole	NN	PM
were	VBD	O
compared	VBN	O
under	IN	O
doctor	NN	O
's	POS	O
office	NN	O
conditions	NNS	O
.	.	O

The	DT	O
outcomes	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
the	DT	O
rapidity	NN	O
of	IN	O
pain	NN	O
relief	NN	O
achieved	VBN	O
with	IN	O
a	DT	O
single	JJ	O
dose	NN	O
,	,	O
effectiveness	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
on	IN	O
demand	NN	O
therapy	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
,	,	O
180	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
and	CC	O
prolonged	JJ	O
episodes	NNS	O
of	IN	O
reflux	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

Time	NN	O
to	TO	O
pain	VB	O
relief	NN	O
following	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
was	VBD	O
1.1	CD	O
+/-	JJ	O
0.8	CD	O
hours	NNS	O
with	IN	O
30	CD	O
mg	NNS	O
lansoprazole	JJ	PM
,	,	O
3.0	CD	O
+/-	JJ	O
2.5	CD	O
hours	NNS	O
with	IN	O
20	CD	O
mgomeprazole	JJ	PM
MUPS	NNP	O
and	CC	O
2.1	CD	O
+/-	JJ	O
1.2	CD	O
hours	NNS	O
with	IN	O
40	CD	O
mg	NNS	O
esomeprazole	JJ	PM
.	.	O

Studies	NNS	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
designed	VBN	O
as	IN	O
cross-over	NN	O
studies	NNS	O
intended	VBN	O
to	TO	O
investigate	VB	O
drug	NN	O
consumption	NN	O
.	.	O

In	IN	O
study	NN	O
2	CD	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
lansoprazole	NN	PM
consumed	VBN	O
was	VBD	O
approximately	RB	O
50	CD	O
%	NN	O
less	JJR	O
than	IN	O
that	DT	O
of	IN	O
omeprazole	NN	PM
,	,	O
and	CC	O
this	DT	O
translated	VBN	O
to	TO	O
81	CD	O
%	NN	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
lansoprazole	JJ	PM
compared	VBN	O
with	IN	O
only	RB	O
9.5	CD	O
%	NN	O
for	IN	O
omeprazole	NN	PM
.	.	O

In	IN	O
study	NN	O
3	CD	O
comparing	VBG	O
lansoprazole	NN	O
and	CC	O
esomeprazole	NN	PM
,	,	O
consumption	NN	O
of	IN	O
the	DT	O
former	JJ	O
was	VBD	O
85	CD	O
%	NN	O
that	WDT	O
of	IN	O
the	DT	O
latter	NN	O
.	.	O

58	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
opted	VBD	O
to	TO	O
continuetreatment	VB	O
with	IN	O
lansoprazole	NN	PM
,	,	O
compared	VBN	O
with	IN	O
only	RB	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
esomeprazole	NN	PM
.	.	O

The	DT	O
appreciably	RB	O
greater	JJR	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
lansoprazole	NN	PM
was	VBD	O
due	JJ	O
tothe	NN	O
faster	RBR	O
pain	NN	O
relief	NN	O
achieved	VBN	O
with	IN	O
this	DT	O
drug	NN	O
.	.	O

Scaling	VBG	O
clinical	JJ	O
judgments	NNS	O
of	IN	O
symptom	JJ	O
pathology	NN	O
by	IN	O
means	NNS	O
of	IN	O
the	DT	O
psychophysiological	JJ	O
method	NN	O
of	IN	O
magnitude	NN	O
estimation	NN	O
.	.	O

Summing	VBG	O
scores	NNS	O
across	IN	O
heterogeneous	JJ	O
symptom	NN	O
items	NNS	O
without	IN	O
consideration	NN	O
of	IN	O
their	PRP$	O
differing	JJ	O
psychopathological	JJ	O
significance	NN	O
has	VBZ	O
been	VBN	O
criticized	VBN	O
as	IN	O
producing	VBG	O
an	DT	O
inadequate	JJ	O
picture	NN	O
of	IN	O
an	DT	O
individual	NN	O
's	POS	O
clinical	JJ	O
status	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
derive	JJ	O
symptom	JJ	O
item	NN	O
weights	NNS	O
representing	VBG	O
clinically	RB	O
judged	VBN	O
seriousness	NN	O
of	IN	O
each	DT	O
symptom	NN	O
through	IN	O
the	DT	O
application	NN	O
of	IN	O
Steven	NNP	E
's	POS	E
psychophysical	JJ	E
method	NN	E
of	IN	E
magnitude	NN	E
estimation	NN	E
.	.	E

A	DT	O
nationwide	JJ	O
sample	NN	O
of	IN	O
129	CD	O
clinicians	NNS	O
rated	VBD	O
the	DT	O
pathological	JJ	O
significance	NN	O
of	IN	O
221	CD	O
symptom	JJ	O
items	NNS	O
in	IN	O
a	DT	O
design	NN	O
such	JJ	O
that	IN	O
every	DT	O
rater	NN	O
rated	VBD	O
121	CD	O
items	NNS	O
,	,	O
21	CD	O
of	IN	O
which	WDT	O
were	VBD	O
rated	VBN	O
by	IN	O
all	DT	O
raters	NNS	O
and	CC	O
100	CD	O
of	IN	O
which	WDT	O
were	VBD	O
rated	VBN	O
only	RB	O
by	IN	O
the	DT	O
A	NNP	O
or	CC	O
B	NNP	O
subgroup	NN	O
to	TO	O
which	WDT	O
each	DT	O
rater	NN	O
was	VBD	O
randomly	RB	O
assigned	VBN	O
.	.	O

Each	DT	O
item	NN	O
was	VBD	O
rated	VBN	O
as	IN	O
to	TO	O
the	DT	O
seriousness	NN	O
of	IN	O
the	DT	O
pathology	NN	O
it	PRP	O
would	MD	O
represent	VB	O
if	IN	O
manifested	VBN	O
by	IN	O
either	CC	O
a	DT	O
boy	NN	O
child	NN	O
,	,	O
girl	JJ	O
child	NN	O
,	,	O
boy	JJ	O
adolescent	NN	O
,	,	O
or	CC	O
girl	JJ	O
adolescent	NN	O
,	,	O
with	IN	O
one-fourth	NN	O
of	IN	O
the	DT	O
raters	NNS	O
assigned	VBD	O
to	TO	O
each	DT	O
condition	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
211	CD	O
two-way	JJ	O
analyses	NNS	O
of	IN	O
variance	NN	O
revealed	VBD	O
that	IN	O
age	NN	O
and	CC	O
age	NN	O
and	CC	O
sex	NN	O
in	IN	O
interaction	NN	O
,	,	O
but	CC	O
not	RB	O
sex	VB	O
alone	RB	O
,	,	O
significantly	RB	O
influenced	VBD	O
the	DT	O
clinical	JJ	O
ratings	NNS	O
.	.	O

The	DT	O
resulting	VBG	O
magnitude	JJ	O
estimation	NN	O
ratings	NNS	O
of	IN	O
symptom	JJ	O
pathology	NN	O
ranged	VBD	O
from	IN	O
1.0	CD	O
to	TO	O
9.9	CD	O
.	.	O

They	PRP	O
were	VBD	O
demonstrated	VBN	O
to	TO	O
have	VB	O
satisfactoy	VBN	O
reliability	NN	O
and	CC	O
convergent	NN	O
validity	NN	O
and	CC	O
to	TO	O
have	VB	O
the	DT	O
psychophysical	JJ	O
characteristics	NNS	O
of	IN	O
a	DT	O
prothetic	JJ	O
continuum	NN	O
.	.	O

Pethidine	NNP	PM
versus	NN	PM
tramadol	NN	PM
for	IN	O
pain	NN	O
relief	NN	O
during	IN	O
labor	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
and	CC	O
adverse	JJ	O
effects	NNS	O
of	IN	O
tramadol	NN	PM
and	CC	O
pethidine	NN	PM
in	IN	O
labor	NN	O
.	.	O

METHOD	NNP	O
Fifty-nine	NNP	O
full	JJ	O
term	NN	O
parturients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
in	IN	O
active	JJ	O
labor	NN	O
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
100	CD	O
mg	NNS	O
pethidine	VBP	PM
;	:	PM
group	NN	O
2	CD	O
,	,	O
100	CD	O
mg	NN	O
tramadol	NN	PM
,	,	O
intramuscularly	RB	O
.	.	O

Analgesic	JJ	O
efficacy	NN	O
,	,	O
maternal	JJ	O
side	NN	O
effects	NNS	O
,	,	O
changes	NNS	O
in	IN	O
the	DT	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
duration	NN	O
of	IN	O
labor	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULT	NNP	O
At	IN	O
30	CD	O
and	CC	O
60	CD	O
min	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
pain	VBP	O
relief	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
pethidine	NN	PM
group	NN	O
than	IN	O
in	IN	O
tramadol	JJ	PM
group	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
nausea	NN	O
and	CC	O
fatigue	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
tramadol	NN	PM
group	NN	O
.	.	O

Following	VBG	O
drug	NN	O
administration	NN	O
the	DT	O
decrease	NN	O
in	IN	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
heart	NN	O
rate	NN	O
were	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
when	WRB	O
compared	VBN	O
for	IN	O
duration	NN	O
of	IN	O
labor	NN	O
and	CC	O
Apgar	NNP	O
scores	NNS	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
neonates	NNS	O
developed	VBD	O
respiratory	JJ	O
depression	NN	O
.	.	O

CONCLUSION	NNP	O
Pethidine	NNP	PM
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
better	RBR	O
alternative	JJ	O
than	IN	O
tramadol	NN	PM
in	IN	O
obstetric	JJ	O
analgesia	NN	O
because	IN	O
of	IN	O
its	PRP$	O
superiority	NN	O
in	IN	O
analgesic	JJ	O
efficacy	NN	O
and	CC	O
low	JJ	O
incidence	NN	O
of	IN	O
maternal	JJ	O
side	NN	O
effects	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
single-dose	JJ	O
cefixime	NN	PM
with	IN	O
ceftriaxone	NN	PM
as	IN	O
treatment	NN	O
for	IN	O
uncomplicated	JJ	O
gonorrhea	NN	O
.	.	O

The	DT	O
Gonorrhea	NNP	O
Treatment	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
Because	IN	O
of	IN	O
the	DT	O
widespread	JJ	O
existence	NN	O
of	IN	O
Neisseria	NNP	O
gonorrhoeae	NN	O
resistant	NN	O
to	TO	O
penicillin	VB	O
or	CC	O
tetracycline	VB	O
,	,	O
ceftriaxone	NN	O
is	VBZ	O
now	RB	O
recommended	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gonorrhea	NN	O
.	.	O

There	EX	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
a	DT	O
need	NN	O
for	IN	O
effective	JJ	O
antibiotics	NNS	O
that	WDT	O
can	MD	O
be	VB	O
administered	VBN	O
orally	RB	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
ceftriaxone	NN	PM
,	,	O
which	WDT	O
requires	VBZ	O
intramuscular	JJ	O
administration	NN	O
.	.	O

Cefixime	NNP	O
is	VBZ	O
an	DT	O
orally	RB	O
absorbed	JJ	O
cephalosporin	NN	O
that	WDT	O
is	VBZ	O
active	JJ	O
against	IN	O
resistant	JJ	O
gonococci	NN	O
and	CC	O
has	VBZ	O
pharmacokinetic	JJ	O
activity	NN	O
suitable	JJ	O
for	IN	O
single-dose	JJ	O
administration	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
unblinded	JJ	O
multicenter	NN	O
study	NN	O
of	IN	O
209	CD	O
men	NNS	O
and	CC	O
124	CD	O
women	NNS	O
with	IN	O
uncomplicated	JJ	O
gonorrhea	NN	O
,	,	O
we	PRP	O
compared	VBN	O
three	CD	O
single-dose	JJ	O
treatment	NN	O
regimens	NNS	O
:	:	O
400	CD	PM
mg	NN	PM
or	CC	PM
800	CD	PM
mg	NN	PM
of	IN	PM
cefixime	NN	PM
,	,	O
administered	VBN	E
orally	RB	E
,	,	O
and	CC	O
250	CD	PM
mg	NN	PM
of	IN	PM
ceftriaxone	NN	PM
administered	VBN	O
intramuscularly	RB	O
.	.	O

The	DT	O
overall	JJ	O
cure	NN	O
rates	NNS	O
were	VBD	O
96	CD	O
percent	NN	O
for	IN	O
the	DT	O
400-mg	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	PM
(	(	O
89	CD	O
of	IN	O
93	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
93.5	CD	O
percent	NN	O
to	TO	O
97.8	CD	O
percent	NN	O
)	)	O
;	:	O
98	CD	O
percent	NN	O
for	IN	O
the	DT	O
800-mg	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	PM
(	(	O
86	CD	O
of	IN	O
88	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
94.6	CD	O
percent	NN	O
to	TO	O
100	CD	O
percent	NN	O
)	)	O
;	:	O
and	CC	O
98	CD	O
percent	NN	O
for	IN	O
ceftriaxone	NN	PM
(	(	O
92	CD	O
of	IN	O
94	CD	O
patients	NNS	O
)	)	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
94.9	CD	O
to	TO	O
100	CD	O
percent	NN	O
)	)	O
.	.	O

The	DT	O
cure	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
and	CC	O
pharyngeal	JJ	O
infection	NN	O
was	VBD	O
eradicated	VBN	O
in	IN	O
20	CD	O
of	IN	O
22	CD	O
patients	NNS	O
(	(	O
91	CD	O
percent	NN	O
)	)	O
.	.	O

Thirty-nine	JJ	O
percent	NN	O
of	IN	O
303	CD	O
pretreatment	JJ	O
gonococcal	JJ	O
isolates	NNS	O
had	VBD	O
one	CD	O
or	CC	O
more	JJR	O
types	NNS	O
of	IN	O
antimicrobial	JJ	O
resistance	NN	O
;	:	O
the	DT	O
efficacy	NN	O
of	IN	O
all	DT	O
three	CD	O
regimens	NNS	O
was	VBD	O
independent	JJ	O
of	IN	O
the	DT	O
resistance	NN	O
pattern	NN	O
.	.	O

Chlamydia	NNP	O
trachomatis	NN	O
infection	NN	O
persisted	VBN	O
in	IN	O
at	IN	O
least	JJS	O
half	PDT	O
the	DT	O
patients	NNS	O
infected	VBN	O
in	IN	O
each	DT	O
treatment	NN	O
group	NN	O
.	.	O

All	DT	O
three	CD	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
uncomplicated	JJ	O
gonorrhea	NN	O
,	,	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
cefixime	NN	PM
(	(	O
400	CD	O
or	CC	O
800	CD	O
mg	NN	O
)	)	O
given	VBN	O
orally	RB	O
appears	VBZ	O
to	TO	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
the	DT	O
currently	RB	O
recommended	VBN	O
regimen	NNS	O
of	IN	O
ceftriaxone	NN	PM
(	(	O
250	CD	O
mg	NN	O
given	VBN	O
intramuscularly	RB	O
)	)	O
.	.	O

Attenuation	NN	O
of	IN	O
hemodynamic	JJ	O
responses	NNS	O
to	TO	O
laryngoscopy	VB	O
and	CC	O
tracheal	VB	O
intubation	NN	O
during	IN	O
rapid	JJ	O
sequence	NN	O
induction	NN	O
:	:	O
remifentanil	NN	PM
vs.	FW	O
lidocaine	NN	PM
with	IN	PM
esmolol	NN	PM
.	.	O

AIM	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
remifentanil	NN	PM
vs.	FW	O
a	DT	O
lidocaine-esmolol	JJ	PM
combination	NN	O
in	IN	O
blunting	VBG	O
the	DT	O
hemodynamic	JJ	O
response	NN	O
to	TO	O
laryngoscopy	VB	O
and	CC	O
intubation	NN	O
during	IN	O
rapid	JJ	O
sequence	NN	O
induction	NN	O
using	VBG	O
thiopental	JJ	O
and	CC	O
rocuronium	NN	O
in	IN	O
normotensive	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Sixty-six	JJ	O
patients	NNS	O
with	IN	O
American	JJ	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
(	(	O
ASA	NNP	O
)	)	O
physical	JJ	O
status	NN	O
class	NN	O
I	PRP	O
who	WP	O
required	VBD	O
tracheal	JJ	O
intubation	NN	O
for	IN	O
elective	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
R	NNP	O
received	VBD	O
0.9	CD	PM
%	NN	PM
saline	NN	PM
10	CD	PM
ml	NN	PM
and	CC	PM
remifentanil	VB	PM
1	CD	PM
microg/kg	NN	PM
.	.	PM

Group	NNP	O
LE	NNP	O
received	VBD	O
lidocaine	JJ	PM
1.5	CD	PM
mg/kg	NN	PM
and	CC	PM
esmolol	$	PM
1.0	CD	PM
mg/kg	NN	PM
.	.	O

Anesthesia	NNP	O
was	VBD	O
induced	VBN	O
with	IN	O
thiopental	JJ	PM
sodium	NN	PM
5	CD	O
mg/kg	NN	O
,	,	O
followed	VBN	O
by	IN	O
rocuronium	NN	PM
1.0	CD	O
mg/kg	NN	O
.	.	O

Mean	NNP	O
arterial	JJ	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
after	IN	O
induction	NN	O
,	,	O
immediately	RB	O
after	IN	O
intubation	NN	O
and	CC	O
every	DT	O
minute	NN	O
for	IN	O
five	CD	O
minutes	NNS	O
after	IN	O
intubation	NN	O
.	.	O

RESULTS	NNP	O
Changes	NNP	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
over	IN	O
time	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
significantly	RB	O
different	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
maximum	JJ	O
pressor	NN	O
response	NN	O
was	VBD	O
observed	VBN	O
immediately	RB	O
after	IN	O
intubation	NN	O
,	,	O
at	IN	O
which	WDT	O
time	NN	O
the	DT	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
group	NN	O
LE	NNP	O
(	(	O
29.7	CD	O
%	NN	O
)	)	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
116.1	CD	O
,	,	O
121.9	CD	O
)	)	O
was	VBD	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
group	NN	O
R	NNP	O
(	(	O
4.4	CD	O
%	NN	O
)	)	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
92.9	CD	O
,	,	O
98.5	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Two	CD	O
patients	NNS	O
in	IN	O
group	NN	O
R	NNP	O
and	CC	O
15	CD	O
patients	NNS	O
in	IN	O
group	NN	O
LE	NNP	O
developed	VBD	O
hypertension	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NN	O
:	:	O
0.064	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
over	IN	O
time	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
P=0.465	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
remifentanil	VBZ	PM
1	CD	O
mg/kg	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
combination	NN	O
of	IN	O
lidocaine	JJ	PM
1.5	CD	O
mg/kg	NN	O
and	CC	O
esmolol	$	PM
1	CD	O
mg/kg	NN	O
for	IN	O
attenuating	VBG	O
the	DT	O
hemodynamic	JJ	O
responses	NNS	O
to	TO	O
rapid	JJ	O
sequence	NN	O
intubation	NN	O
.	.	O

Effect	NN	O
of	IN	O
cervical	JJ	PH
spine	NN	PH
manipulative	JJ	PH
therapy	NN	PH
on	IN	O
judo	NN	O
athletes	NNS	O
'	POS	O
grip	NN	O
strength	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
perform	VB	O
an	DT	O
investigation	NN	O
evaluating	VBG	O
if	IN	O
cervical	JJ	PH
spinal	JJ	PH
manipulative	JJ	PH
therapy	NN	PH
(	(	PH
SMT	NNP	PH
)	)	PH
can	MD	O
increase	VB	O
grip	JJ	O
strength	NN	O
on	IN	O
judo	NN	O
athletes	NNS	O
in	IN	O
a	DT	O
top	JJ	O
10	CD	O
national-ranked	JJ	O
team	NN	O
.	.	O

METHODS	VB	O
A	DT	O
single-blinded	JJ	O
,	,	O
prospective	JJ	O
,	,	O
comparative	JJ	O
,	,	O
pilot	NN	O
,	,	O
randomized	VBN	O
,	,	O
clinical	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
18	CD	O
athletes	NNS	O
of	IN	O
both	DT	O
sexes	NNS	O
from	IN	O
a	DT	O
judo	NN	O
team	NN	O
currently	RB	O
competing	VBG	O
on	IN	O
a	DT	O
national	JJ	O
level	NN	O
.	.	O

The	DT	O
athletes	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
:	:	O
chiropractic	JJ	PH
SMT	NNP	PH
and	CC	O
sham	NN	C
.	.	O

Three	CD	O
interventions	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
each	DT	O
of	IN	O
the	DT	O
athletes	NNS	O
at	IN	O
different	JJ	O
time	NN	O
points	NNS	O
.	.	O

Force	NN	O
measurements	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
a	DT	O
hydraulic	JJ	O
dynamometer	NN	O
immediately	RB	O
before	IN	O
and	CC	O
after	IN	O
each	DT	O
intervention	NN	O
at	IN	O
the	DT	O
same	JJ	O
period	NN	O
before	IN	O
training	VBG	O
up	RP	O
to	TO	O
3	CD	O
weeks	NNS	O
with	IN	O
at	IN	O
least	JJS	O
36	CD	O
hours	NNS	O
between	IN	O
interventions	NNS	O
.	.	O

RESULTS	NNP	O
Analysis	NNP	O
of	IN	O
grip	NN	O
strength	NN	O
data	NNS	O
revealed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
strength	NN	O
within	IN	O
the	DT	O
treatment	NN	O
group	NN	O
after	IN	O
the	DT	O
first	JJ	O
intervention	NN	O
(	(	O
6.95	CD	O
%	NN	O
right	NN	O
,	,	O
12.61	CD	O
%	NN	O
left	NN	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
second	JJ	O
(	(	O
11.53	CD	O
%	NN	O
right	NN	O
,	,	O
17.02	CD	O
%	NN	O
left	NN	O
)	)	O
and	CC	O
the	DT	O
third	JJ	O
interventions	NNS	O
(	(	O
10.53	CD	O
%	NN	O
right	NN	O
,	,	O
16.81	CD	O
%	NN	O
left	VBD	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
grip	JJ	O
strength	NN	O
comparison	NN	O
within	IN	O
the	DT	O
sham	NN	O
group	NN	O
.	.	O

Overall	JJ	O
differences	NNS	O
in	IN	O
strength	NN	O
were	VBD	O
consistently	RB	O
significant	JJ	O
between	IN	O
the	DT	O
study	NN	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.0025	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
present	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
grip	NN	O
strength	NN	O
of	IN	O
national	JJ	O
level	NN	O
judo	NN	O
athletes	NNS	O
receiving	VBG	O
chiropractic	JJ	PH
SMT	NNP	PH
improved	VBD	O
compared	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
sham	NN	O
.	.	O

Levobunolol	NNP	PM
compared	VBN	O
with	IN	O
timolol	NN	PM
:	:	O
a	DT	O
four-year	JJ	O
study	NN	O
.	.	O

Fifty-one	CD	O
patients	NNS	O
with	IN	O
raised	VBN	O
intraocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
were	VBD	O
treated	VBN	O
for	IN	O
up	IN	O
to	TO	O
four	CD	O
years	NNS	O
with	IN	O
one	CD	O
of	IN	O
three	CD	O
ophthalmic	JJ	O
solutions	NNS	O
:	:	O
0.5	CD	O
%	NN	O
levobunolol	NN	PM
,	,	O
1	CD	O
%	NN	O
levobunolol	NN	PM
,	,	O
or	CC	O
0.5	CD	O
%	NN	O
timolol	NN	PM
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
as	IN	O
a	DT	O
double-masked	JJ	O
,	,	O
randomised	JJ	O
trial	NN	O
in	IN	O
which	WDT	O
medications	NNS	O
were	VBD	O
administered	VBN	O
twice	RB	O
daily	RB	O
to	TO	O
both	DT	O
eyes	NNS	O
.	.	O

Levobunolol	NNP	PM
and	CC	O
timolol	NN	PM
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
overall	JJ	O
mean	JJ	O
IOP	NNP	O
;	:	O
reductions	NNS	O
were	VBD	O
greater	JJR	O
than	IN	O
8.8	CD	O
mmHg	NNS	O
in	IN	O
all	DT	O
three	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
study	NN	O
showed	VBD	O
levobunolol	NNS	PM
to	TO	O
be	VB	O
as	IN	O
safe	JJ	O
and	CC	O
effective	JJ	O
as	IN	O
timolol	NN	PM
in	IN	O
the	DT	O
long-term	JJ	O
control	NN	O
of	IN	O
raised	VBN	O
IOP	NNP	O
.	.	O

Acute	NNP	O
pressor	NN	O
and	CC	O
hormonal	JJ	O
effects	NNS	O
of	IN	O
beta-endorphin	NN	PM
at	IN	O
high	JJ	O
doses	NNS	O
in	IN	O
healthy	JJ	O
and	CC	O
hypertensive	JJ	O
subjects	NNS	O
:	:	O
role	NN	O
of	IN	O
opioid	JJ	O
receptor	NN	O
agonism	NN	O
.	.	O

CONTEXT	VB	O
The	DT	O
opioid	NN	O
system	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
blood	NN	O
pressure	NN	O
regulation	NN	O
in	IN	O
both	DT	O
normal	JJ	O
humans	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
high-dose	JJ	O
infusion	NN	O
of	IN	O
beta-endorphin	NN	PM
,	,	O
an	DT	O
opioid	JJ	O
peptide	NN	O
,	,	O
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
on	IN	O
the	DT	O
hormonal	JJ	O
profile	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
and	CC	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
and	CC	O
the	DT	O
mediation	NN	O
played	VBN	O
by	IN	O
opioid	JJ	O
receptor	NN	O
agonism	NN	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
According	VBG	O
to	TO	O
a	DT	O
randomized	VBN	O
double-blind	NN	O
design	NN	O
,	,	O
11	CD	O
healthy	JJ	O
subjects	NNS	O
(	(	O
controls	NNS	O
)	)	O
and	CC	O
12	CD	O
hypertensive	JJ	O
inpatients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
38.9	CD	O
and	CC	O
40.4	CD	O
yr	NN	O
,	,	O
respectively	RB	O
)	)	O
received	VBD	O
1-h	JJ	PM
iv	JJ	PM
infusion	NN	PM
of	IN	PM
beta-endorphin	JJ	PM
(	(	PM
250	CD	PM
mug/h	NN	PM
)	)	PM
and	CC	O
,	,	O
on	IN	O
another	DT	O
occasion	NN	O
,	,	O
the	DT	O
same	JJ	O
infusion	NN	O
protocol	NN	O
preceded	VBN	O
by	IN	O
the	DT	O
opioid	JJ	PM
antagonist	NN	PM
naloxone	NN	PM
(	(	PM
8	CD	PM
mg	NN	PM
)	)	PM
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Hemodynamic	NNP	O
and	CC	O
hormonal	JJ	O
measurements	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
established	VBN	O
times	NNS	O
during	IN	O
the	DT	O
infusion	NN	O
protocols	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
circulating	VBG	O
beta-endorphin	JJ	O
,	,	O
norepinephrine	JJ	O
,	,	O
and	CC	O
endothelin-1	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

In	IN	O
controls	NNS	O
,	,	O
beta-endorphin	JJ	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
circulating	VBG	O
norepinephrine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
and	CC	O
increased	VBD	O
plasma	JJ	O
atrial	JJ	O
natriuretic	JJ	O
factor	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.003	CD	O
)	)	O
and	CC	O
GH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

In	IN	O
hypertensive	JJ	O
patients	NNS	O
,	,	O
beta-endorphin	JJ	PM
decreased	JJ	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
blood	NN	O
pressure	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
plasma	JJ	O
norepinephrine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
endothelin-1	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
raised	VBD	O
circulating	VBG	O
atrial	JJ	O
natriuretic	JJ	O
factor	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
GH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
IGF-I	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

These	DT	O
hemodynamic	JJ	O
and	CC	O
hormonal	JJ	O
responses	NNS	O
to	TO	O
beta-endorphin	JJ	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
greater	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
but	CC	O
were	VBD	O
annulled	VBN	O
in	IN	O
all	DT	O
individuals	NNS	O
when	WRB	O
naloxone	NN	O
preceded	VBD	O
beta-endorphin	JJ	O
infusion	NN	O
.	.	O

CONCLUSIONS	NNP	O
High	NNP	O
doses	NNS	O
of	IN	O
beta-endorphin	JJ	PM
induce	NN	O
hypotensive	NN	O
and	CC	O
beneficial	JJ	O
hormonal	JJ	O
effects	NNS	O
in	IN	O
humans	NNS	O
,	,	O
which	WDT	O
are	VBP	O
enhanced	VBN	O
in	IN	O
essential	JJ	O
hypertension	NN	O
and	CC	O
are	VBP	O
mediated	VBN	O
by	IN	O
opioid	JJ	O
receptors	NNS	O
.	.	O

Predictors	NNS	O
of	IN	O
survival	NN	O
and	CC	O
eradication	NN	O
of	IN	O
Mycobacterium	NNP	O
avium	NN	O
complex	NN	O
bacteremia	NN	O
(	(	O
MAC	NNP	O
)	)	O
in	IN	O
AIDS	NNP	O
patients	NNS	O
in	IN	O
the	DT	O
Canadian	NNP	O
randomized	VBD	O
MAC	NNP	O
treatment	NN	O
trial	NN	O
.	.	O

Canadian	JJ	O
HIV	NNP	O
Trials	NNP	O
Network	NNP	O
Protocol	NNP	O
010	CD	O
Study	NNP	O
Group	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
importance	NN	O
of	IN	O
baseline	NN	O
characteristics	NNS	O
including	VBG	O
medical	JJ	O
history	NN	O
,	,	O
indicators	NNS	O
of	IN	O
current	JJ	O
disease	NN	O
status	NN	O
,	,	O
therapeutic	JJ	O
drug	NN	O
use	NN	O
,	,	O
in	IN	O
vitro	JJ	O
drug	NN	O
susceptibility	NN	O
,	,	O
immune	JJ	O
status	NN	O
and	CC	O
mycobacterial	JJ	O
load	NN	O
on	IN	O
bacteriologic	JJ	O
response	NN	O
and	CC	O
survival	NN	O
in	IN	O
HIV-positive	JJ	O
patients	NNS	O
with	IN	O
Mycobacterium	NNP	O
avium	NN	O
complex	NN	O
(	(	O
MAC	NNP	O
)	)	O
bacteremia	NN	O
.	.	O

DESIGN	NNP	O
An	DT	O
observational	JJ	O
substudy	NN	O
of	IN	O
an	DT	O
open-label	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
two	CD	O
alternative	JJ	O
therapeutic	JJ	PM
regimens	NNS	PM
for	IN	O
MAC	NNP	O
.	.	O

SETTING	NNP	O
Twenty-four	JJ	O
hospital-based	JJ	O
HIV	NNP	O
clinics	NNS	O
in	IN	O
16	CD	O
Canadian	JJ	O
cities	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
survival	JJ	O
and	CC	O
bacteriologic	JJ	O
response	NN	O
,	,	O
defined	VBN	O
by	IN	O
consecutive	JJ	O
negative	JJ	O
blood	NN	O
cultures	NNS	O
for	IN	O
MAC	NNP	O
at	IN	O
least	JJS	O
2	CD	O
weeks	NNS	O
apart	RB	O
within	IN	O
16	CD	O
weeks	NNS	O
of	IN	O
study	NN	O
entry	NN	O
.	.	O

RESULTS	NNP	O
Prior	NNP	O
AIDS	NNP	O
diagnosis	NN	O
,	,	O
low	JJ	O
Karnofsky	NNP	O
score	NN	O
,	,	O
active	JJ	O
unstable	JJ	O
AIDS-related	JJ	O
conditions	NNS	O
,	,	O
absence	NN	O
of	IN	O
antiretroviral	JJ	O
therapy	NN	O
and	CC	O
absence	NN	O
of	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
prophylaxis	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
shorter	JJR	O
survival	NN	O
by	IN	O
univariate	JJ	O
regression	NN	O
using	VBG	O
the	DT	O
proportional	JJ	O
hazards	NNS	O
model	NN	O
.	.	O

On	IN	O
multivariate	NN	O
analysis	NN	O
,	,	O
antiretroviral	JJ	O
therapy	NN	O
was	VBD	O
not	RB	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
mortality	NN	O
,	,	O
and	CC	O
previous	JJ	O
rifabutin	NN	O
prophylaxis	NN	O
was	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
poor	JJ	O
survival	NN	O
outcomes	NNS	O
,	,	O
a	DT	O
result	NN	O
consistent	JJ	O
across	IN	O
study	NN	O
treatment	NN	O
.	.	O

Using	VBG	O
a	DT	O
logistic	JJ	O
regression	NN	O
model	NN	O
,	,	O
baseline	JJ	O
quantitative	JJ	O
mycobacterial	JJ	O
load	NN	O
[	NNP	O
relative	JJ	O
odds	NNS	O
of	IN	O
clearing	NN	O
,	,	O
1.97	CD	O
for	IN	O
a	DT	O
decrease	NN	O
of	IN	O
1	CD	O
log10	JJ	O
colony	NN	O
forming	VBG	O
count	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
1.36-2.87	JJ	O
;	:	O
P	NNP	O
<	VBD	O
0.001	CD	O
]	NN	O
and	CC	O
Karnofsky	NNP	O
score	NN	O
were	VBD	O
the	DT	O
only	JJ	O
statistically	RB	O
significant	JJ	O
univariate	JJ	O
predictors	NNS	O
of	IN	O
clearance	NN	O
,	,	O
although	IN	O
previous	JJ	O
prophylaxis	NN	O
with	IN	O
rifabutin	NN	O
was	VBD	O
also	RB	O
a	DT	O
significant	JJ	O
predictor	NN	O
in	IN	O
a	DT	O
multivariate	NN	O
model	NN	O
(	(	O
relative	JJ	O
odds	NNS	O
of	IN	O
clearing	NN	O
,	,	O
0.39	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.17-0.88	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
although	IN	O
the	DT	O
level	NN	O
of	IN	O
MAC	NNP	O
bacteremia	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
predictor	NN	O
of	IN	O
clearance	NN	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
survival	NN	O
.	.	O

National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
's	POS	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

The	DT	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
is	VBZ	O
the	DT	O
largest	JJS	O
breast	NN	O
cancer	NN	O
prevention	NN	O
study	NN	O
ever	RB	O
undertaken	RB	O
.	.	O

Administered	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
,	,	O
it	PRP	O
is	VBZ	O
the	DT	O
first	JJ	O
trial	NN	O
seeking	VBG	O
to	TO	O
demonstrate	VB	O
whether	IN	O
a	DT	O
drug	NN	O
,	,	O
tamoxifen	NN	PM
,	,	O
can	MD	O
prevent	VB	O
breast	NN	O
cancer	NN	O
in	IN	O
high-risk	JJ	O
women	NNS	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
trial	NN	O
are	VBP	O
to	TO	O
determine	VB	O
whether	IN	O
tamoxifen	NN	PM
is	VBZ	O
effective	JJ	O
in	IN	O
1	CD	O
)	)	O
reducing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
invasive	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
2	CD	O
)	)	O
reducing	VBG	O
breast	NN	O
cancer	NN	O
mortality	NN	O
,	,	O
3	CD	O
)	)	O
reducing	VBG	O
deaths	NNS	O
from	IN	O
cardiovascular	JJ	O
disease	NN	O
,	,	O
and	CC	O
4	CD	O
)	)	O
reducing	VBG	O
bone	NN	O
fractures	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
study	NN	O
will	MD	O
evaluate	VB	O
side	NN	O
effects	NNS	O
,	,	O
toxicity	NN	O
,	,	O
and	CC	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
all	DT	O
study	NN	O
participants	NNS	O
.	.	O

A	DT	O
good	JJ	O
response	NN	O
to	TO	O
oil	NN	PM
with	IN	PM
medium-	NN	PM
and	CC	PM
long-chain	JJ	PM
fatty	JJ	PM
acids	NNS	PM
in	IN	O
body	NN	O
fat	JJ	O
and	CC	O
blood	NN	O
lipid	JJ	O
profiles	NNS	O
of	IN	O
male	JJ	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

A	DT	O
double	JJ	O
blind	NN	O
clinical	JJ	O
trial	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
clarify	VB	O
the	DT	O
effects	NNS	O
of	IN	O
oil	NN	PM
with	IN	PM
medium-	NN	PM
and	CC	PM
long-chain	JJ	PM
triglyceride	NN	PM
(	(	PM
MLCT	NNP	PM
)	)	PM
on	IN	O
body	NN	O
fat	JJ	O
and	CC	O
blood	NN	O
lipid	JJ	O
profiles	NNS	O
in	IN	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

One-hundred-and-twelve	JJ	O
subjects	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
those	DT	O
that	IN	O
consumed	VBD	O
MLCT	NNP	O
oil	NN	O
and	CC	O
those	DT	O
that	WDT	O
consumed	VBD	O
long-chain	JJ	O
triglyceride	NN	O
(	(	O
LCT	NNP	O
)	)	O
oil	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

All	DT	O
subjects	NNS	O
were	VBD	O
requested	VBN	O
to	TO	O
consume	VB	O
25-30	JJ	O
g	NN	O
of	IN	O
the	DT	O
oils	NNS	O
daily	RB	O
and	CC	O
maintain	VB	O
a	DT	O
fixed	JJ	O
level	NN	O
of	IN	O
energy	NN	O
intake	NN	O
and	CC	O
exercise	NN	O
.	.	O

Anthropometric	NNP	O
and	CC	O
blood	NN	O
biochemical	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
when	WRB	O
the	DT	O
study	NN	O
was	VBD	O
initiated	VBN	O
and	CC	O
completed	VBN	O
.	.	O

The	DT	O
LCT	NNP	PM
group	NN	O
consisted	VBD	O
of	IN	O
50	CD	O
subjects	NNS	O
(	(	O
34	CD	O
men	NNS	O
and	CC	O
16	CD	O
women	NNS	O
)	)	O
,	,	O
while	IN	O
the	DT	O
MLCT	NNP	PM
group	NN	O
consisted	VBD	O
of	IN	O
51	CD	O
subjects	NNS	O
(	(	O
33	CD	O
men	NNS	O
and	CC	O
18	CD	O
women	NNS	O
)	)	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Larger	NNP	O
decreases	VBZ	O
in	IN	O
body	NN	O
weight	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
,	,	O
waist	NN	O
circumference	NN	O
,	,	O
body	NN	O
fat	NN	O
,	,	O
total	JJ	O
fat	JJ	O
area	NN	O
and	CC	O
subcutaneous	JJ	O
fat	JJ	O
area	NN	O
in	IN	O
the	DT	O
abdomen	NNS	O
and	CC	O
serum	NN	O
triglycerides	NNS	O
,	,	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
,	,	O
apolipoprotein	NN	O
B	NNP	O
,	,	O
C2	NNP	O
,	,	O
C3	NNP	O
and	CC	O
E	NNP	O
were	VBD	O
observed	VBN	O
in	IN	O
male	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
MLCT	NNP	PM
group	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
LCT	NNP	PM
group	NN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
these	DT	O
parameters	NNS	O
between	IN	O
the	DT	O
female	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Data	NNS	O
from	IN	O
this	DT	O
study	NN	O
indicate	VBP	O
that	IN	O
consumption	NN	O
of	IN	O
medium-and	JJ	O
long-chain	JJ	O
triglycerides	NNS	O
can	MD	O
reduce	VB	O
body	NN	O
weight	NN	O
and	CC	O
body	NN	O
fat	NN	O
and	CC	O
improve	VB	O
blood	NN	O
lipid	JJ	O
profiles	NNS	O
in	IN	O
male	JJ	O
hypertriglyceridemic	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
sequencing	NN	O
of	IN	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
after	IN	O
conservative	JJ	O
surgery	NN	O
for	IN	O
early-stage	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Patients	NNPS	O
with	IN	O
early-stage	JJ	O
breast	NN	O
cancer	NN	O
who	WP	O
are	VBP	O
at	IN	O
substantial	JJ	O
risk	NN	O
for	IN	O
systemic	JJ	O
metastases	NNS	O
are	VBP	O
increasingly	RB	O
treated	VBN	O
with	IN	O
breast-conserving	JJ	PM
therapy	NN	PM
and	CC	O
adjuvant	JJ	PM
chemotherapy	NN	PM
.	.	O

However	RB	O
,	,	O
the	DT	O
optimal	JJ	O
sequencing	NN	O
of	IN	O
chemotherapy	NN	PM
and	CC	O
radiation	NN	PM
therapy	NN	PM
is	VBZ	O
not	RB	O
clear	JJ	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
forty-four	JJ	O
patients	NNS	O
with	IN	O
stage	NN	O
I	PRP	O
or	CC	O
II	NNP	O
breast	NN	O
cancer	NN	O
who	WP	O
were	VBD	O
at	IN	O
substantial	JJ	O
risk	NN	O
for	IN	O
distant	JJ	O
metastases	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
12-week	JJ	PM
course	NN	PM
of	IN	PM
chemotherapy	NN	PM
either	CC	PM
before	IN	PM
or	CC	PM
after	IN	PM
radiation	NN	PM
therapy	NN	PM
.	.	O

All	DT	O
had	VBD	O
had	VBN	O
breast-conserving	JJ	O
surgery	NN	O
.	.	O

The	DT	O
median	JJ	O
length	NN	O
of	IN	O
follow-up	NN	O
in	IN	O
surviving	VBG	O
patients	NNS	O
was	VBD	O
58	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
10	CD	O
to	TO	O
124	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
five-year	JJ	O
actuarial	JJ	O
rates	NNS	O
of	IN	O
cancer	NN	O
recurrence	NN	O
at	IN	O
any	DT	O
site	NN	O
and	CC	O
of	IN	O
distant	JJ	O
metastases	NNS	O
in	IN	O
the	DT	O
radiotherapy-first	JJ	PM
group	NN	O
and	CC	O
the	DT	O
chemotherapy-first	JJ	PM
group	NN	O
were	VBD	O
38	CD	O
percent	NN	O
and	CC	O
31	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.17	CD	O
)	)	O
and	CC	O
36	CD	O
percent	NN	O
and	CC	O
25	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Overall	JJ	O
survival	NN	O
was	VBD	O
73	CD	O
percent	NN	O
and	CC	O
81	CD	O
percent	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.11	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
five-year	JJ	O
crude	NN	O
rates	NNS	O
of	IN	O
first	JJ	O
recurrence	NN	O
according	VBG	O
to	TO	O
site	NN	O
in	IN	O
the	DT	O
radiotherapy-first	JJ	PM
and	CC	O
chemotherapy-first	JJ	PM
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
5	CD	O
percent	NN	O
and	CC	O
14	CD	O
percent	NN	O
for	IN	O
local	JJ	O
recurrence	NN	O
and	CC	O
32	CD	O
percent	NN	O
and	CC	O
20	CD	O
percent	NN	O
for	IN	O
distant	NN	O
or	CC	O
regional	JJ	O
recurrence	NN	O
or	CC	O
both	DT	O
.	.	O

This	DT	O
difference	NN	O
in	IN	O
the	DT	O
pattern	NN	O
of	IN	O
recurrence	NN	O
was	VBD	O
of	IN	O
borderline	JJ	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
for	IN	O
patients	NNS	O
ar	VBP	O
substantial	JJ	O
risk	NN	O
for	IN	O
systemic	JJ	O
metastases	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
preferable	JJ	O
to	TO	O
give	VB	O
a	DT	O
12-week	JJ	O
course	NN	O
of	IN	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
radiation	NN	PM
therapy	NN	PM
,	,	O
rather	RB	O
than	IN	O
radiation	NN	PM
therapy	NN	PM
followed	VBN	PM
by	IN	PM
chemotherapy	NN	PM
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
orthotic	JJ	PH
heel	NN	PH
lifts	NNS	PH
on	IN	O
Achilles	NNP	O
tendon	NNP	O
force	NN	O
and	CC	O
strain	NN	O
during	IN	O
running	VBG	O
.	.	O

This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
orthotic	JJ	PH
heel	NN	PH
lifts	NNS	PH
on	IN	O
Achilles	NNP	O
tendon	NN	O
(	(	O
AT	NNP	O
)	)	O
force	NN	O
and	CC	O
strain	NN	O
during	IN	O
running	VBG	O
.	.	O

Ten	CD	O
females	NNS	O
ran	VBD	O
barefoot	NN	O
over	IN	O
a	DT	O
force	NN	O
plate	NN	O
in	IN	O
three	CD	O
conditions	NNS	O
:	:	O
no	DT	C
heel	NN	C
lifts	NNS	C
(	(	O
NHL	NNP	O
)	)	O
,	,	O
with	IN	O
12	CD	PH
mm	NNS	PH
heel	JJ	PH
lifts	NNS	PH
(	(	O
12HL	CD	O
)	)	O
and	CC	O
with	IN	O
18	CD	PH
mm	NNS	PH
heel	JJ	PH
lifts	NNS	PH
(	(	O
18HL	CD	O
)	)	O
.	.	O

Kinematics	NNS	O
for	IN	O
the	DT	O
right	JJ	O
lower	JJR	O
limb	NN	O
were	VBD	O
collected	VBN	O
(	(	O
200	CD	O
Hz	NNP	O
)	)	O
.	.	O

AT	NNP	O
force	NN	O
was	VBD	O
calculated	VBN	O
from	IN	O
inverse	JJ	O
dynamics	NNS	O
.	.	O

AT	NNP	O
strain	NN	O
was	VBD	O
determined	VBN	O
from	IN	O
kinematics	NNS	O
and	CC	O
ultrasound	JJ	O
images	NNS	O
of	IN	O
medial	JJ	O
gastrocnemius	NN	O
(	(	O
50	CD	O
Hz	NNP	O
)	)	O
.	.	O

Peak	NNP	O
AT	NNP	O
strain	NN	O
was	VBD	O
less	JJR	O
for	IN	O
18HL	CD	O
(	(	O
5.5	CD	O
?	.	O
4.4	CD	O
%	NN	O
)	)	O
than	IN	O
for	IN	O
NHL	NNP	O
(	(	O
7.4	CD	O
?	.	O
4.2	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
.029	NNP	O
,	,	O
effect	NN	O
size	NN	O
[	NNP	O
ES	NNP	O
]	NNP	O
=	NNP	O
0.44	CD	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
12HL	CD	O
(	(	O
5.8	CD	O
?	.	O
4.8	CD	O
%	NN	O
)	)	O
versus	NN	O
NHL	NNP	O
(	(	O
ES	NNP	O
=	NNP	O
0.35	CD	O
)	)	O
.	.	O

Peak	NNP	O
AT	NNP	O
force	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
.024	NNP	O
,	,	O
ES	NNP	O
=	NNP	O
0.42	CD	O
)	)	O
less	JJR	O
for	IN	O
18HL	CD	O
(	(	O
2382	CD	O
?	.	O
717	CD	O
N	NNP	O
)	)	O
than	IN	O
for	IN	O
NHL	NNP	O
(	(	O
2710	CD	O
?	.	O
830	CD	O
N	NNP	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
12HL	CD	O
(	(	O
2538	CD	O
?	.	O
823	CD	O
N	NNP	O
,	,	O
ES	NNP	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

The	DT	O
18HL	CD	O
reduced	VBD	O
ankle	JJ	O
dorsiflexion	NN	O
but	CC	O
not	RB	O
flexion-extension	JJ	O
ankle	NN	O
moments	NNS	O
and	CC	O
increased	VBD	O
the	DT	O
AT	NNP	O
moment	NN	O
arm	NN	O
compared	VBN	O
with	IN	O
NHL	NNP	O
.	.	O

Thus	NNP	O
,	,	O
18HL	CD	O
reduced	VBN	O
force	NN	O
and	CC	O
strain	NN	O
on	IN	O
the	DT	O
AT	NNP	O
during	IN	O
running	VBG	O
via	IN	O
a	DT	O
reduction	NN	O
in	IN	O
dorsiflexion	NN	O
,	,	O
which	WDT	O
lengthened	VBD	O
the	DT	O
AT	NNP	O
moment	NN	O
arm	NN	O
.	.	O

Therefore	RB	O
,	,	O
heel	NN	O
lifts	NNS	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
reduce	VB	O
AT	NNP	O
loading	NN	O
and	CC	O
strain	NN	O
during	IN	O
the	DT	O
rehabilitation	NN	O
of	IN	O
AT	NNP	O
injuries	NNS	O
.	.	O

Etanercept	NNP	PM
treatment	NN	O
in	IN	O
adults	NNS	O
with	IN	O
established	VBN	O
rheumatoid	NN	O
arthritis	NN	O
:	:	O
7	CD	O
years	NNS	O
of	IN	O
clinical	JJ	O
experience	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
longterm	JJ	O
etanercept	FW	PM
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
disease	NN	O
modifying	VBG	O
antirheumatic	JJ	O
drug	NN	O
(	(	O
DMARD	NNP	O
)	)	O
refractory	NN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Safety	NNP	O
results	NNS	O
are	VBP	O
reported	VBN	O
for	IN	O
714	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
etanercept	RB	PM
in	IN	O
one	CD	O
of	IN	O
7	CD	O
initial	JJ	O
trials	NNS	O
or	CC	O
a	DT	O
longterm	JJ	O
extension	NN	O
.	.	O

Efficacy	NN	O
results	NNS	O
are	VBP	O
reported	VBN	O
for	IN	O
581	CD	O
patients	NNS	O
who	WP	O
enrolled	VBD	O
in	IN	O
the	DT	O
extension	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
714	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
trials	NNS	O
,	,	O
581	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
enrolled	VBN	O
in	IN	O
the	DT	O
extension	NN	O
,	,	O
and	CC	O
388	CD	O
(	(	O
54	CD	O
%	NN	O
)	)	O
patients	NNS	O
are	VBP	O
continuing	VBG	O
to	TO	O
receive	VB	O
etanercept	JJ	PM
therapy	NN	PM
.	.	O

The	DT	O
longest	JJS	O
individual	JJ	O
treatment	NN	O
was	VBD	O
8.2	CD	O
years	NNS	O
,	,	O
with	IN	O
3139	CD	O
total	JJ	O
patient-years	NNS	O
of	IN	O
etanercept	JJ	O
exposure	NN	O
.	.	O

Rates	NNS	O
of	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
overall	JJ	O
rate=14.8	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
serious	JJ	O
infections	NNS	O
(	(	O
overall	JJ	O
rate=4.2	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
cancer	NN	O
(	(	O
overall	JJ	O
rate=1.0	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
,	,	O
and	CC	O
deaths	NNS	O
(	(	O
overall	JJ	O
rate=0.7	NN	O
events/100	IN	O
patient-yrs	NN	O
)	)	O
were	VBD	O
stable	JJ	O
each	DT	O
year	NN	O
,	,	O
through	IN	O
8	CD	O
years	NNS	O
of	IN	O
etanercept	JJ	O
exposure	NN	O
.	.	O

For	IN	O
356	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
6	CD	O
years	NNS	O
of	IN	O
etanercept	JJ	O
treatment	NN	O
,	,	O
response	NN	O
rates	NNS	O
were	VBD	O
ACR20=73	NNP	O
%	NN	O
,	,	O
ACR50=52	NNP	O
%	NN	O
,	,	O
ACR70=27	NNP	O
%	NN	O
,	,	O
DAS28	NNP	O
CRP	NNP	O
good	JJ	O
response=52	NN	O
%	NN	O
,	,	O
and	CC	O
DAS28	NNP	O
CRP	NNP	O
remission=37	VBZ	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Similar	JJ	O
responses	NNS	O
occurred	VBD	O
in	IN	O
167	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
Year	NNP	O
7	CD	O
.	.	O

Doses	NNS	O
of	IN	O
concomitant	JJ	O
methotrexate	NN	O
or	CC	O
corticosteroids	NNS	O
were	VBD	O
reduced	VBN	O
in	IN	O
many	JJ	O
patients	NNS	O
who	WP	O
maintained	VBD	O
clinical	JJ	O
responses	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
safety	NN	O
profile	NN	O
of	IN	O
etanercept	NN	PM
was	VBD	O
consistent	JJ	O
over	IN	O
time	NN	O
,	,	O
with	IN	O
rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
for	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
in	IN	O
general	JJ	O
.	.	O

Durable	JJ	O
clinical	JJ	O
responses	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
for	IN	O
7	CD	O
years	NNS	O
or	CC	O
more	JJR	O
.	.	O

The	DT	O
benefit-to-risk	JJ	O
ratio	NN	O
for	IN	O
longterm	JJ	O
etanercept	JJ	PM
treatment	NN	O
remains	VBZ	O
highly	RB	O
favorable	JJ	O
.	.	O

LEGO	NNP	PS
therapy	NN	PS
and	CC	O
the	DT	O
social	JJ	E
use	NN	E
of	IN	E
language	NN	E
programme	NN	E
:	:	O
an	DT	O
evaluation	NN	O
of	IN	O
two	CD	O
social	JJ	O
skills	NNS	O
interventions	NNS	O
for	IN	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
and	CC	O
Asperger	NNP	O
Syndrome	NNP	O
.	.	O

LEGO	NNP	PS
therapy	NN	PS
and	CC	O
the	DT	O
Social	NNP	E
Use	NNP	E
of	IN	E
Language	NNP	E
Programme	NNP	E
(	(	E
SULP	NNP	E
)	)	E
were	VBD	O
evaluated	VBN	O
as	IN	O
social	JJ	E
skills	NNS	E
interventions	NNS	E
for	IN	O
6-11	JJ	O
year	NN	O
olds	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
and	CC	O
Asperger	NNP	O
Syndrome	NNP	O
.	.	O

Children	NNP	O
were	VBD	O
matched	VBN	O
on	IN	O
CA	NNP	O
,	,	O
IQ	NNP	O
,	,	O
and	CC	O
autistic	JJ	O
symptoms	NNS	O
before	IN	O
being	VBG	O
randomly	RB	O
assigned	VBN	O
to	TO	O
LEGO	NNP	PS
or	CC	O
SULP	NNP	E
.	.	O

Therapy	NNP	O
occurred	VBD	O
for	IN	O
1	CD	O
h/week	NN	O
over	IN	O
18	CD	O
weeks	NNS	O
.	.	O

A	DT	O
no-intervention	JJ	C
control	NN	C
group	NN	C
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
LEGO	NNP	PS
therapy	NN	O
group	NN	O
improved	VBD	O
more	JJR	O
than	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
on	IN	O
autism-specific	JJ	O
social	JJ	O
interaction	NN	O
scores	NNS	O
(	(	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
)	)	O
.	.	O

Maladaptive	JJ	O
behaviour	NN	O
decreased	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
the	DT	O
LEGO	NNP	PS
and	CC	O
SULP	NNP	E
groups	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
non-significant	JJ	O
trend	NN	O
for	IN	O
SULP	NNP	E
and	CC	O
LEGO	NNP	PS
groups	NNS	O
to	TO	O
improve	VB	O
more	JJR	O
than	IN	O
the	DT	O
no-intervention	JJ	C
group	NN	O
in	IN	O
communication	NN	O
and	CC	O
socialisation	NN	O
skills	NNS	O
.	.	O

Warfarin	NNP	PM
versus	NN	O
aspirin	NN	PM
for	IN	O
prevention	NN	O
of	IN	O
thromboembolism	NN	O
in	IN	O
atrial	JJ	O
fibrillation	NN	O
:	:	O
Stroke	NNP	O
Prevention	NNP	O
in	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
II	NNP	O
Study	NNP	O
.	.	O

Warfarin	NNP	PM
is	VBZ	O
an	DT	O
established	JJ	O
treatment	NN	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
,	,	O
but	CC	O
the	DT	O
value	NN	O
of	IN	O
this	DT	O
agent	JJ	O
relative	NN	O
to	TO	O
aspirin	VB	O
in	IN	O
unclear	JJ	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
Stroke	NNP	O
Prevention	NNP	O
in	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
(	(	O
SPAF-I	NNP	O
)	)	O
study	NN	O
,	,	O
direct	JJ	O
comparison	NN	O
of	IN	O
warfarin	NN	PM
with	IN	O
aspirin	NN	PM
was	VBD	O
limited	VBN	O
by	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
thromboembolic	JJ	O
events	NNS	O
.	.	O

SPAF-II	JJ	O
aims	NNS	O
to	TO	O
address	VB	O
this	DT	O
issue	NN	O
and	CC	O
also	RB	O
to	TO	O
assess	VB	O
the	DT	O
differential	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
according	VBG	O
to	TO	O
age	NN	O
.	.	O

We	PRP	O
compared	VBN	O
warfarin	NN	PM
(	(	O
prothrombin	JJ	O
time	NN	O
ratio	JJ	O
1.3-1.8	JJ	O
,	,	O
international	JJ	O
normalised	JJ	O
ratio	NN	O
2.0-4.5	JJ	O
)	)	O
with	IN	O
aspirin	$	PM
325	CD	PM
mg	JJ	PM
daily	RB	PM
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
and	CC	O
systemic	JJ	O
embolism	NN	O
(	(	O
primary	JJ	O
events	NNS	O
)	)	O
in	IN	O
two	CD	O
parallel	NNS	O
randomised	VBD	O
trials	NNS	O
involving	VBG	O
715	CD	O
patients	NNS	O
aged	VBN	O
75	CD	O
years	NNS	O
or	CC	O
less	JJR	O
and	CC	O
385	CD	O
patients	NNS	O
older	JJR	O
than	IN	O
75	CD	O
;	:	O
we	PRP	O
sought	VBD	O
reductions	NNS	O
in	IN	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
warfarin	NNS	PM
compared	VBN	O
with	IN	O
aspirin	NN	PM
of	IN	O
2	CD	O
%	NN	O
per	IN	O
year	NN	O
and	CC	O
4	CD	O
%	NN	O
per	IN	O
year	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
younger	JJR	O
patients	NNS	O
,	,	O
warfarin	NNS	PM
decreased	VBD	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
0.7	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI-0.4	NNP	O
to	TO	O
1.7	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
event	NN	O
rate	NN	O
per	IN	O
year	NN	O
was	VBD	O
1.3	CD	O
%	NN	O
with	IN	O
warfarin	NN	PM
and	CC	O
1.9	CD	O
%	NN	O
with	IN	O
aspirin	NN	PM
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
0.67	CD	O
,	,	O
p	NN	O
=	NNP	O
0.24	CD	O
)	)	O
.	.	O

The	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
in	IN	O
low-risk	JJ	O
younger	NN	O
patients	NNS	O
(	(	O
without	IN	O
hypertension	NN	O
,	,	O
recent	JJ	O
heart	NN	O
failure	NN	O
,	,	O
or	CC	O
previous	JJ	O
thromboembolism	NN	O
)	)	O
on	IN	O
aspirin	NN	PM
was	VBD	O
0.5	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.1	CD	O
to	TO	O
1.9	CD	O
)	)	O
.	.	O

Among	IN	O
older	JJR	O
patients	NNS	O
,	,	O
warfarin	NNS	PM
decreased	VBD	O
the	DT	O
absolute	JJ	O
rate	NN	O
of	IN	O
primary	JJ	O
events	NNS	O
by	IN	O
1.2	CD	O
%	NN	O
per	IN	O
year	NN	O
(	(	O
95	CD	O
%	NN	O
CI-1.7	NNP	O
to	TO	O
4.1	CD	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
event	NN	O
rate	NN	O
per	IN	O
year	NN	O
was	VBD	O
3.6	CD	O
%	NN	O
with	IN	O
warfarin	NN	PM
and	CC	O
4.8	CD	O
%	NN	O
with	IN	O
aspirin	NN	PM
(	(	O
RR	NNP	O
0.73	CD	O
,	,	O
p	NN	O
=	NNP	O
0.39	CD	O
)	)	O
.	.	O

In	IN	O
this	DT	O
older	JJR	O
group	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
all	DT	O
stroke	NN	O
with	IN	O
residual	JJ	O
deficit	NN	O
(	(	O
ischaemic	JJ	O
or	CC	O
haemorrhagic	NN	O
)	)	O
was	VBD	O
4.3	CD	O
%	NN	O
per	IN	O
year	NN	O
with	IN	O
aspirin	NN	O
and	CC	O
4.6	CD	O
%	NN	O
per	IN	O
year	NN	O
with	IN	O
warfarin	NN	O
(	(	O
RR	NNP	O
1.1	CD	O
)	)	O
.	.	O

Warfarin	NNP	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
aspirin	NN	O
for	IN	O
prevention	NN	O
of	IN	O
ischaemic	JJ	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
,	,	O
but	CC	O
the	DT	O
absolute	JJ	O
reduction	NN	O
in	IN	O
stroke	NN	O
rate	NN	O
by	IN	O
warfarin	NN	O
is	VBZ	O
small	JJ	O
.	.	O

Younger	JJR	O
patients	NNS	O
without	IN	O
risk	NN	O
factors	NNS	O
had	VBD	O
a	DT	O
low	JJ	O
rate	NN	O
of	IN	O
stroke	NN	O
when	WRB	O
treated	VBN	O
with	IN	O
aspirin	NN	O
.	.	O

In	IN	O
older	JJR	O
patients	NNS	O
the	DT	O
rate	NN	O
of	IN	O
stroke	NN	O
(	(	O
ischaemic	JJ	O
and	CC	O
haemorrhagic	NN	O
)	)	O
was	VBD	O
substantial	JJ	O
,	,	O
irrespective	NN	O
of	IN	O
which	WDT	O
agent	NN	O
was	VBD	O
given	VBN	O
.	.	O

Patient	JJ	O
age	NN	O
and	CC	O
the	DT	O
inherent	JJ	O
risk	NN	O
of	IN	O
thromboembolism	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
the	DT	O
choice	NN	O
of	IN	O
antithrombotic	JJ	O
prophylaxis	NN	O
for	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

Effects	NNS	O
of	IN	O
an	DT	O
Internet-based	JJ	E
intervention	NN	E
on	IN	O
plasma	NNS	O
glucose	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

This	DT	O
study	NN	O
applied	VBD	O
a	DT	O
12-week	JJ	E
educational	JJ	E
intervention	NN	E
that	WDT	O
used	VBD	O
both	DT	E
the	DT	E
cellular	JJ	E
phone	NN	E
and	CC	E
the	DT	E
Internet	NNP	E
to	TO	E
send	VB	E
short	JJ	E
message	NN	E
service	NN	E
.	.	O

Forty-two	NNP	O
diabetic	JJ	O
patients	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
access	NN	E
a	DT	E
Web	NNP	E
site	NN	E
by	IN	E
using	VBG	E
a	DT	E
cellular	JJ	E
phone	NN	E
or	CC	E
wire	NN	E
Internet	NNP	E
and	CC	E
input	VB	E
their	PRP$	E
blood	NN	E
glucose	NN	E
levels	NNS	E
every	DT	E
day	NN	E
.	.	E

Patients	NNS	O
were	VBD	O
sent	VBN	O
the	DT	O
optimal	JJ	E
recommendations	NNS	E
by	IN	O
both	DT	O
the	DT	O
cellular	JJ	O
phone	NN	O
and	CC	O
the	DT	O
Internet	NNP	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
of	IN	O
28.6	CD	O
mg/dL	NNS	O
in	IN	O
fasting	VBG	O
plasma	NN	O
glucose	NN	O
and	CC	O
78.4	CD	O
mg/dL	NN	O
in	IN	O
2-hour	JJ	O
postprandial	JJ	O
blood	NN	O
sugar	NN	O
levels	NNS	O
and	CC	O
a	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
the	DT	O
care	NN	O
satisfaction	NN	O
score	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
serologic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	O
and	CC	O
injectable	JJ	O
trivalent	NN	PM
poliovirus	NN	PM
vaccines	NNS	PM
.	.	O

United	NNP	O
States	NNPS	O
children	NNS	O
two	CD	O
months	NNS	O
of	IN	O
age	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
that	WDT	O
received	VBD	O
either	RB	O
the	DT	O
commercially	RB	O
available	JJ	O
oral	JJ	PM
trivalent	NN	PM
poliovirus	NN	PM
vaccine	NN	PM
(	(	PM
OPV	NNP	PM
)	)	PM
or	CC	O
an	DT	O
injectable	JJ	PM
(	(	PM
inactivated	VBN	PM
)	)	PM
trivalent	NN	PM
poliovirus	NN	PM
vaccine	NN	PM
(	(	PM
IPV	NNP	PM
)	)	PM
with	IN	O
a	DT	O
confirmed	JJ	O
minimum	JJ	O
D-antigen	NNP	O
content	NN	O
of	IN	O
27	CD	O
,	,	O
3.5	CD	O
,	,	O
and	CC	O
29	CD	O
units	NNS	O
for	IN	O
poliovirus	NN	O
types	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
.	.	O

Vaccine	NNP	O
was	VBD	O
given	VBN	O
at	IN	O
two	CD	O
,	,	O
four	CD	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Sera	NN	O
obtained	VBN	O
from	IN	O
439	CD	O
children	NNS	O
at	IN	O
two	CD	O
,	,	O
four	CD	O
,	,	O
and	CC	O
six	CD	O
months	NNS	O
of	IN	O
age	NN	O
and	CC	O
from	IN	O
85	CD	O
children	NNS	O
at	IN	O
18	CD	O
and	CC	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
neutralizing	VBG	O
antibodies	NNS	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
children	NNS	O
with	IN	O
detectable	JJ	O
antibodies	NNS	O
and	CC	O
the	DT	O
reciprocal	JJ	O
geometric	JJ	O
mean	NN	O
titers	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
at	IN	O
two	CD	O
months	NNS	O
of	IN	O
age	NN	O
for	IN	O
antibodies	NNS	O
to	TO	O
all	DT	O
three	CD	O
poliovirus	NN	O
types	NNS	O
.	.	O

At	IN	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
all	DT	O
children	NNS	O
but	CC	O
one	CD	O
had	VBD	O
detectable	JJ	O
antibodies	NNS	O
to	TO	O
all	DT	O
three	CD	O
poliovirus	NN	O
types	NNS	O
.	.	O

Significantly	RB	O
higher	JJR	O
geometric	JJ	O
mean	NN	O
titers	NNS	O
against	IN	O
types	NNS	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
noted	VBN	O
at	IN	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
for	IN	O
the	DT	O
IPV	NNP	PM
group	NN	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	C
study	NN	O
of	IN	O
L-carnosine	NNP	PM
supplementation	NN	PM
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

L-Carnosine	NNP	PM
,	,	O
a	DT	O
dipeptide	NN	PM
,	,	O
can	MD	O
enhance	VB	O
frontal	JJ	O
lobe	NN	O
function	NN	O
or	CC	O
be	VB	O
neuroprotective	JJ	O
.	.	O

It	PRP	O
can	MD	O
also	RB	O
correlate	VB	O
with	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
(	(	O
GABA	NNP	O
)	)	O
-homocarnosine	NN	O
interaction	NN	O
,	,	O
with	IN	O
possible	JJ	O
anticonvulsive	JJ	O
effects	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
31	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blinded	JJ	O
study	NN	O
to	TO	O
determine	VB	O
if	IN	O
800	CD	O
mg	JJ	O
L-carnosine	JJ	PM
daily	NN	O
would	MD	O
result	VB	O
in	IN	O
observable	JJ	O
changes	NNS	O
versus	VBP	O
placebo	NN	C
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
the	DT	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
Expressive	NNP	O
and	CC	O
Receptive	NNP	O
One-Word	NNP	O
Picture	NNP	O
Vocabulary	NNP	O
tests	NNS	O
,	,	O
and	CC	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
of	IN	O
Change	NNP	O
.	.	O

Children	NNP	O
on	IN	O
placebo	NN	C
did	VBD	O
not	RB	O
show	VB	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
on	IN	O
L-carnosine	NNP	PM
,	,	O
children	NNS	O
showed	VBD	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
on	IN	O
the	DT	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
total	JJ	O
score	NN	O
and	CC	O
the	DT	O
Behavior	NNP	O
,	,	O
Socialization	NNP	O
,	,	O
and	CC	O
Communication	NNP	O
subscales	NNS	O
)	)	O
and	CC	O
the	DT	O
Receptive	JJ	O
One-Word	NNP	O
Picture	NNP	O
Vocabulary	NNP	O
test	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Improved	VBN	O
trends	NNS	O
were	VBD	O
noted	VBN	O
on	IN	O
other	JJ	O
outcome	JJ	O
measures	NNS	O
.	.	O

Although	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
L-carnosine	NNP	PM
is	VBZ	O
not	RB	O
well	RB	O
understood	RB	O
,	,	O
it	PRP	O
may	MD	O
enhance	VB	O
neurologic	JJ	O
function	NN	O
,	,	O
perhaps	RB	O
in	IN	O
the	DT	O
enterorhinal	JJ	O
or	CC	O
temporal	JJ	O
cortex	NN	O
.	.	O

An	DT	O
evaluation	NN	O
of	IN	O
chemical	JJ	O
arthrodesis	NN	O
of	IN	O
the	DT	O
proximal	JJ	O
interphalangeal	NN	O
joint	NN	O
in	IN	O
the	DT	O
horse	NN	O
by	IN	O
using	VBG	O
monoiodoacetate	NN	PM
.	.	O

The	DT	O
use	NN	O
of	IN	O
monoiodoacetate	NN	PM
(	(	PM
MIA	NNP	PM
)	)	PM
for	IN	O
arthrodesis	NN	O
of	IN	O
the	DT	O
proximal	JJ	O
interphalangeal	NN	O
joint	NN	O
(	(	O
PIJ	NNP	O
)	)	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
exercise	NN	O
on	IN	O
the	DT	O
degree	NN	O
of	IN	O
fusion	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

Eight	JJ	O
horses	NNS	O
received	VBD	O
3	CD	O
injections	NNS	O
(	(	O
Weeks	NNP	O
0	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
)	)	O
of	IN	O
MIA	NNP	PM
(	(	O
2	CD	O
mL	NN	O
;	:	O
60	CD	O
mg/mL	NN	O
)	)	O
into	IN	O
the	DT	O
right	NN	O
or	CC	O
left	VBD	O
front	JJ	O
PIJ	NNP	O
.	.	O

Peri-operatively	RB	O
,	,	O
the	DT	O
horses	NNS	O
received	VBD	O
phenylbutazone	NN	PM
,	,	O
butorphanol	NN	PM
,	,	O
and	CC	O
abaxial	JJ	PM
sesamoidean	NN	PM
nerve	NN	PH
blocks	NNS	PH
to	TO	O
relieve	VB	O
pain	NN	O
.	.	O

During	IN	O
the	DT	O
study	NN	O
,	,	O
the	DT	O
horses	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
general	JJ	O
health	NN	O
,	,	O
lameness	NN	O
,	,	O
and	CC	O
swelling	VBG	O
around	IN	O
the	DT	O
injection	NN	O
area	NN	O
.	.	O

Radiographs	NNP	O
were	VBD	O
taken	VBN	O
biweekly	RB	O
to	TO	O
evaluate	VB	O
bony	NN	O
fusion	NN	O
.	.	O

Horses	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
non-exercised	JJ	O
and	CC	O
exercised	JJ	O
groups	NNS	O
.	.	O

Exercise	NNP	PH
consisted	VBD	O
of	IN	O
20	CD	O
minutes	NNS	O
of	IN	O
trotting	VBG	O
on	IN	O
a	DT	O
treadmill	NN	O
(	(	O
4	CD	O
m/s	NN	O
)	)	O
,	,	O
3	CD	O
days	NNS	O
per	IN	O
week	NN	O
for	IN	O
13	CD	O
weeks	NNS	O
.	.	O

The	DT	O
horses	NNS	O
were	VBD	O
euthanized	VBN	O
at	IN	O
24	CD	O
weeks	NNS	O
.	.	O

Slab	NNP	O
sections	NNS	O
of	IN	O
the	DT	O
PIJ	NNP	O
were	VBD	O
evaluated	VBN	O
grossly	RB	O
and	CC	O
radiographically	RB	O
for	IN	O
bony	NN	O
fusion	NN	O
.	.	O

Histologic	JJ	O
examinations	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
articular	JJ	O
cartilage	NN	O
.	.	O

Three	CD	O
horses	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
after	IN	O
developing	VBG	O
soft	JJ	O
tissue	NN	O
necrosis	NN	O
around	IN	O
the	DT	O
injection	NN	O
site	NN	O
,	,	O
septic	JJ	O
arthritis	NN	O
,	,	O
and	CC	O
necrotic	JJ	O
tendinitis	NN	O
.	.	O

The	DT	O
remaining	VBG	O
horses	NNS	O
remained	VBD	O
healthy	JJ	O
,	,	O
developed	VBD	O
a	DT	O
grade	NN	O
1	CD	O
to	TO	O
4	CD	O
lameness	NN	O
with	IN	O
minimal	JJ	O
to	TO	O
severe	VB	O
swelling	VBG	O
in	IN	O
the	DT	O
PIJ	NNP	O
region	NN	O
.	.	O

All	DT	O
5	CD	O
horses	NNS	O
showed	VBD	O
radiographic	JJ	O
evidence	NN	O
of	IN	O
bony	NN	O
fusion	NN	O
,	,	O
however	RB	O
,	,	O
no	DT	O
fusion	NN	O
was	VBD	O
present	JJ	O
when	WRB	O
injected	JJ	O
joints	NNS	O
were	VBD	O
examined	VBN	O
on	IN	O
postmortem	NN	O
examination	NN	O
.	.	O

Histologic	NNP	O
examination	NN	O
revealed	VBD	O
thinning	NN	O
of	IN	O
the	DT	O
cartilage	NN	O
,	,	O
diffuse	VBP	O
necrosis	NN	O
of	IN	O
chondrocytes	NNS	O
,	,	O
with	IN	O
the	DT	O
calcified	JJ	O
zone	NN	O
intact	JJ	O
.	.	O

Subjectively	RB	O
,	,	O
exercise	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
degree	NN	O
of	IN	O
cartilage	NN	O
destruction	NN	O
.	.	O

Based	VBN	O
on	IN	O
this	DT	O
study	NN	O
,	,	O
chemical	JJ	PM
arthrodesis	NN	PM
can	MD	O
not	RB	O
be	VB	O
advocated	VBN	O
in	IN	O
clinical	JJ	O
cases	NNS	O
because	IN	O
of	IN	O
the	DT	O
high	JJ	O
complication	NN	O
rate	NN	O
and	CC	O
lack	NN	O
of	IN	O
bony	NN	O
fusion	NN	O
.	.	O

Dietary	NNP	PM
lignan	NN	PM
and	CC	PM
proanthocyanidin	NN	PM
consumption	NN	PM
and	CC	O
colorectal	JJ	O
adenoma	NN	O
recurrence	NN	O
in	IN	O
the	DT	O
Polyp	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

Lignans	NNPS	O
and	CC	O
proanthocyanidins	NNS	O
are	VBP	O
plant	NN	O
polyphenols	NNS	PM
that	WDT	O
have	VBP	O
shown	VBN	O
protective	JJ	O
properties	NNS	O
against	IN	O
colorectal	JJ	O
neoplasms	NNS	O
in	IN	O
some	DT	O
human	JJ	O
studies	NNS	O
.	.	O

Using	VBG	O
logistic	JJ	O
regression	NN	O
,	,	O
we	PRP	O
estimated	VBD	O
odds	NNS	O
ratios	NNS	O
(	(	O
ORs	NNP	O
)	)	O
and	CC	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
to	TO	O
prospectively	RB	O
evaluate	VB	O
the	DT	O
association	NN	O
between	IN	O
lignan	NN	PM
and	CC	PM
proanthocyanidin	JJ	PM
intake	NN	PM
,	,	O
estimated	VBN	O
from	IN	O
databases	NNS	O
linked	VBN	O
to	TO	O
a	DT	O
food	NN	O
frequency	NN	O
questionnaire	NN	O
,	,	O
and	CC	O
adenoma	JJ	O
recurrence	NN	O
in	IN	O
1,859	CD	O
participants	NNS	O
of	IN	O
the	DT	O
Polyp	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

Overall	NNP	O
,	,	O
individual	NN	O
or	CC	O
total	JJ	O
lignans	NNS	O
or	CC	O
proanthocyanidins	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
colorectal	JJ	O
adenoma	NN	O
recurrence	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
sex-specific	JJ	O
analyses	NNS	O
,	,	O
total	JJ	O
lignan	JJ	O
intake	NN	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
any	DT	O
adenoma	JJ	O
recurrence	NN	O
in	IN	O
women	NNS	O
(	(	O
highest	JJS	O
vs.	NN	O
lowest	JJS	O
lignan	JJ	O
intake	NN	O
quartile	NN	O
OR	NNP	O
=	VBZ	O
2.07	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.22-3.52	JJ	O
,	,	O
p	JJ	O
trend	NN	O
=	VBZ	O
0.004	CD	O
)	)	O
but	CC	O
not	RB	O
in	IN	O
men	NNS	O
(	(	O
p	JJ	O
interaction	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

To	TO	O
conclude	VB	O
,	,	O
dietary	JJ	O
lignan	NN	O
and	CC	O
proanthocyanidin	NN	O
consumption	NN	O
were	VBD	O
not	RB	O
generally	RB	O
related	VBN	O
to	TO	O
colorectal	JJ	O
adenoma	JJ	O
recurrence	NN	O
;	:	O
however	RB	O
,	,	O
high	JJ	O
lignan	NNS	O
intake	VBP	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
adenoma	JJ	O
recurrence	NN	O
in	IN	O
women	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
analgesic	JJ	O
effect	NN	O
of	IN	O
locally	RB	O
and	CC	O
systemically	RB	O
administered	VBN	O
ketorolac	NN	PM
in	IN	O
mastectomy	JJ	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Ketorolac	NNP	PM
is	VBZ	O
a	DT	O
parenteral	JJ	O
nonsteroidal	JJ	O
antiinflammatory	JJ	O
drug	NN	O
(	(	O
NSAID	NNP	O
)	)	O
.	.	O

Two	CD	O
features	NNS	O
have	VBP	O
limited	VBN	O
its	PRP$	O
clinical	JJ	O
utility	NN	O
:	:	O
tendency	NN	O
to	TO	O
elicit	VB	O
kidney	NN	O
failure	NN	O
and	CC	O
inability	NN	O
to	TO	O
produce	VB	O
complete	JJ	O
analgesia	NN	O
.	.	O

Because	IN	O
most	JJS	O
NSAIDs	NNP	PM
are	VBP	O
weak	JJ	O
acids	NNS	O
(	(	O
pKa	IN	O
3-5	NNP	O
)	)	O
and	CC	O
become	VBN	O
concentrated	JJ	O
in	IN	O
acidic	JJ	O
tissues	NNS	O
,	,	O
such	JJ	O
as	IN	O
injured	JJ	O
and	CC	O
inflamed	JJ	O
tissues	NNS	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	IN	O
local	JJ	O
administration	NN	O
may	MD	O
enhance	VB	O
its	PRP$	O
analgesic	JJ	O
efficacy	NN	O
while	IN	O
lowering	VBG	O
the	DT	O
potential	NN	O
for	IN	O
systemic	JJ	O
complications	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
study	NN	O
of	IN	O
60	CD	O
group	NN	O
I-II	NNP	O
(	(	O
American	JJ	O
Society	NNP	O
of	IN	O
Anesthesiology	NNP	O
criteria	NNS	O
)	)	O
mastectomy	NN	O
patients	NNS	O
,	,	O
20	CD	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Near	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
and	CC	O
every	DT	O
6	CD	O
h	NN	O
postoperatively	RB	O
,	,	O
20	CD	O
ml	NN	O
of	IN	O
the	DT	O
study	NN	O
solution	NN	O
containing	VBG	O
normal	JJ	PM
saline	NN	PM
with	IN	PM
or	CC	PM
without	IN	PM
30	CD	PM
mg	NN	PM
of	IN	PM
ketorolac	NN	PM
were	VBD	O
administered	VBN	O
simultaneously	RB	O
either	CC	O
via	IN	O
a	DT	O
Jackson-Pratt	JJ	O
drain	NN	O
or	CC	O
intravenously	RB	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
.	.	O

The	DT	O
quality	NN	O
of	IN	O
pain	NN	O
control	NN	O
,	,	O
the	DT	O
amount	NN	O
and	CC	O
character	NN	O
of	IN	O
the	DT	O
drain	NN	O
fluid	NN	O
,	,	O
incidence	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
length	NN	O
of	IN	O
stay	NN	O
in	IN	O
the	DT	O
postoperative	JJ	O
care	NN	O
unit	NN	O
,	,	O
and	CC	O
amount	NN	O
of	IN	O
morphine	NN	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
break-through	JJ	O
pain	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Intraoperative	NNP	O
administration	NN	O
of	IN	O
ketorolac	NN	PM
resulted	VBD	O
in	IN	O
better	JJR	O
quality	NN	O
of	IN	O
pain	NN	O
control	NN	O
in	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
regardless	NN	O
of	IN	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
nausea	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
drain	NN	O
output	NN	O
in	IN	O
the	DT	O
ketorolac	NN	PM
groups	NNS	O
did	VBD	O
not	RB	O
exceed	VB	O
the	DT	O
output	NN	O
in	IN	O
the	DT	O
placebo	NN	C
group	NN	O
.	.	O

CONCLUSION	NNP	O
Analgesic	NNP	O
of	IN	O
the	DT	O
locally	RB	O
administered	VBN	O
ketorolac	NN	PM
is	VBZ	O
equally	RB	O
effective	JJ	O
to	TO	O
the	DT	O
efficacy	NN	O
of	IN	O
ketorolac	NN	PM
administered	VBN	O
intravenously	RB	O
.	.	O

Double-blind	NNP	O
comparison	NN	O
of	IN	O
ketazolam	NN	PM
,	,	O
diazepam	NN	PM
and	CC	O
placebo	NN	C
in	IN	O
once-a-day	JJ	O
vs	NN	O
t.i.d	NN	O
.	.	O

dosing	VBG	O
.	.	O

Comparison	NNP	O
of	IN	O
ketazolam	NNP	PM
given	VBN	O
once-a-day	JJ	O
with	IN	O
diazepam	NN	PM
given	VBN	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
and	CC	O
placebo	VB	C
given	VBN	O
either	DT	O
once	RB	O
or	CC	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
in	IN	O
101	CD	O
anxious	JJ	O
outpatients	NNS	O
showed	VBD	O
ketazolam	NNS	O
to	TO	O
be	VB	O
significantly	RB	O
better	JJR	O
than	IN	O
placebo	NN	O
in	IN	O
alleviating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
anxiety	NN	O
and	CC	O
,	,	O
on	IN	O
several	JJ	O
measures	NNS	O
of	IN	O
efficacy	NN	O
,	,	O
better	JJR	O
than	IN	O
diazepam	NN	O
as	IN	O
well	RB	O
.	.	O

Significantly	RB	O
fewer	JJR	O
patients	NNS	O
on	IN	O
ketazolam	NN	PM
dropped	VBD	O
out	IN	O
of	IN	O
the	DT	O
study	NN	O
due	JJ	O
to	TO	O
ineffective	JJ	O
medication	NN	O
than	IN	O
on	IN	O
the	DT	O
other	JJ	O
3	CD	O
treatments	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
was	VBD	O
lowest	JJS	O
in	IN	O
the	DT	O
ketazolam	NN	O
group	NN	O
.	.	O

Of	IN	O
particular	JJ	O
note	NN	O
,	,	O
drowsiness	NN	O
was	VBD	O
reported	VBN	O
twice	RB	O
as	RB	O
often	RB	O
by	IN	O
diazepam	JJ	PM
patients	NNS	O
as	IN	O
by	IN	O
ketazolam	NN	PM
patients	NNS	O
.	.	O

Use	NNP	E
of	IN	E
an	DT	E
Internet	NNP	E
portal	NN	E
to	TO	O
improve	VB	O
community-based	JJ	O
pediatric	JJ	O
ADHD	NNP	O
care	NN	O
:	:	O
a	DT	O
cluster	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
quality	NN	E
improvement	NN	E
program	NN	E
to	TO	O
improve	VB	O
pediatricians	NNS	O
'	POS	O
adherence	NN	O
to	TO	O
existing	VBG	O
,	,	O
evidence-based	JJ	O
,	,	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
practice	NN	O
guidelines	NNS	O
.	.	O

METHODS	NNP	O
Forty-nine	JJ	O
community-based	JJ	O
pediatricians	NNS	O
at	IN	O
8	CD	O
practices	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
cluster-randomized	JJ	O
trial	NN	O
.	.	O

Practices	NNS	O
were	VBD	O
matched	VBN	O
according	VBG	O
to	TO	O
the	DT	O
numbers	NNS	O
of	IN	O
pediatricians	NNS	O
and	CC	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
receiving	VBG	O
Medicaid	NNP	O
.	.	O

The	DT	O
medical	JJ	O
charts	NNS	O
for	IN	O
a	DT	O
random	JJ	O
sample	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ADHD	NNP	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
participating	VBG	O
pediatricians	NNS	O
were	VBD	O
examined	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

All	DT	O
practices	NNS	O
participated	VBN	O
in	IN	O
4	CD	O
sessions	NNS	O
of	IN	O
training	NN	E
,	,	E
including	VBG	E
didactic	JJ	E
lectures	NNS	E
and	CC	E
office	NN	E
flow	NN	E
modification	NN	E
workshops	NNS	E
.	.	E

Practices	NNS	O
were	VBD	O
then	RB	O
given	VBN	O
access	NN	O
to	TO	O
an	DT	O
ADHD	NNP	E
Internet	NNP	E
portal	NN	E
that	WDT	O
allowed	VBD	O
parents	NNS	O
,	,	O
teachers	NNS	O
,	,	O
and	CC	O
pediatricians	NNS	O
to	TO	O
input	VB	O
information	NN	O
(	(	O
eg	NN	O
,	,	O
rating	NN	O
scales	NNS	O
)	)	O
about	IN	O
patients	NNS	O
,	,	O
after	IN	O
which	WDT	O
information	NN	O
was	VBD	O
scored	VBN	O
,	,	O
interpreted	VBN	O
,	,	O
and	CC	O
formatted	VBN	O
in	IN	O
a	DT	O
report	NN	O
style	NN	O
that	WDT	O
was	VBD	O
helpful	JJ	O
for	IN	O
assessment	NN	O
and	CC	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ADHD	NNP	O
.	.	O

Physicians	NNPS	O
evaluated	VBD	O
their	PRP$	O
practice	NN	O
behaviors	NNS	O
quarterly	RB	O
and	CC	O
addressed	VBD	O
underperforming	JJ	O
areas	NNS	O
.	.	O

RESULTS	NNP	O
Pediatricians	NNPS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	C
group	NN	O
,	,	O
demonstrated	VBD	O
significantly	RB	O
higher	JJR	O
rates	NNS	O
of	IN	O
many	JJ	O
American	JJ	O
Academy	NNP	O
of	IN	O
Pediatrics-recommended	NNP	O
ADHD	NNP	O
care	NN	O
practices	NNS	O
,	,	O
including	VBG	O
collection	NN	O
of	IN	O
parent	NN	O
(	(	O
Cohen	NNP	O
's	POS	O
d	NN	O
=	VBZ	O
0.69	CD	O
)	)	O
and	CC	O
teacher	$	O
(	(	O
d	JJ	O
=	NNP	O
0.68	CD	O
)	)	O
rating	NN	O
scales	NNS	O
for	IN	O
assessment	NN	O
of	IN	O
children	NNS	O
with	IN	O
ADHD	NNP	O
,	,	O
use	NN	O
of	IN	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
,	,	O
criteria	NNS	O
(	(	O
d	VB	O
=	RB	O
0.85	CD	O
)	)	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
teacher	NN	O
rating	NN	O
scales	NNS	O
to	TO	O
monitor	VB	O
treatment	NN	O
responses	NNS	O
(	(	O
d	VB	O
=	RB	O
1.01	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	E
quality	NN	E
improvement	NN	E
intervention	NN	E
that	WDT	O
can	MD	O
be	VB	O
widely	RB	O
disseminated	VBN	O
by	IN	O
using	VBG	O
Internet-based	JJ	E
information	NN	E
technology	NN	E
significantly	RB	O
improved	VBD	O
the	DT	O
quality	NN	O
of	IN	O
ADHD	NNP	O
care	NN	O
in	IN	O
community-based	JJ	O
pediatric	JJ	O
settings	NNS	O
.	.	O

Effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
inhaled	JJ	O
treprostinil	NN	PM
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pulmonary	JJ	O
arterial	JJ	O
hypertension	NN	O
in	IN	O
children	NNS	O
.	.	O

The	DT	O
introduction	NN	O
of	IN	O
prostanoid	NN	PM
therapy	NN	PM
has	VBZ	O
revolutionized	VBN	O
the	DT	O
treatment	NN	O
of	IN	O
pulmonary	JJ	O
arterial	JJ	O
hypertension	NN	O
(	(	O
PAH	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
continuous	JJ	O
intravenous	JJ	O
prostacyclin	NN	PM
infusion	NN	O
poses	VBZ	O
significant	JJ	O
risks	NNS	O
and	CC	O
challenges	NNS	O
,	,	O
particularly	RB	O
in	IN	O
children	NNS	O
.	.	O

Inhaled	VBN	O
treprostinil	NN	PM
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
efficacious	JJ	O
in	IN	O
adults	NNS	O
.	.	O

This	DT	O
study	NN	O
describes	VBZ	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
inhaled	JJ	O
treprostinil	NN	PM
in	IN	O
children	NNS	O
with	IN	O
PAH	NNP	O
.	.	O

A	NNP	O
retrospective	JJ	O
analysis	NN	O
of	IN	O
29	CD	O
children	NNS	O
treated	VBN	O
with	IN	O
inhaled	JJ	O
treprostinil	NN	PM
for	IN	O
?6	JJ	O
weeks	NNS	O
was	VBD	O
performed	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
inhaled	JJ	O
treprostinil	NN	O
on	IN	O
exercise	NN	O
capacity	NN	O
,	,	O
functional	JJ	O
class	NN	O
,	,	O
and	CC	O
echocardiographic	JJ	O
and	CC	O
hemodynamic	JJ	O
data	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
documented	VBN	O
.	.	O

Patients	NNS	O
received	VBD	O
3	CD	O
to	TO	O
9	CD	O
breaths	NNS	O
(	(	O
6	CD	O
?g/breath	NN	O
)	)	O
of	IN	O
inhaled	VBN	O
treprostinil	NN	O
4	CD	O
times/day	NN	O
.	.	O

All	DT	O
were	VBD	O
receiving	VBG	O
background	NN	O
PAH	NNP	O
therapy	NN	O
;	:	O
12	CD	O
had	VBD	O
previously	RB	O
received	VBN	O
parenteral	JJ	O
prostanoid	NN	O
.	.	O

Inhaled	VBD	O
treprostinil	NN	O
was	VBD	O
discontinued	VBN	O
in	IN	O
4	CD	O
patients	NNS	O
because	IN	O
of	IN	O
symptoms	NNS	O
including	VBG	O
cough	NN	O
and	CC	O
bronchospasm	NN	O
(	(	O
n	JJ	O
=	NNP	O
3	CD	O
)	)	O
and	CC	O
progression	NN	O
of	IN	O
PAH	NNP	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
.	.	O

Mild	JJ	O
side	JJ	O
effects	NNS	O
including	VBG	O
cough	NN	O
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
and	CC	O
sore	$	O
throat	NN	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
did	VBD	O
not	RB	O
require	VB	O
discontinuation	NN	O
of	IN	O
therapy	NN	O
.	.	O

World	NNP	O
Health	NNP	O
Organization	NNP	O
functional	JJ	O
class	NN	O
improved	VBN	O
in	IN	O
19	CD	O
and	CC	O
was	VBD	O
unchanged	JJ	O
in	IN	O
10	CD	O
;	:	O
exercise	NN	O
capacity	NN	O
significantly	RB	O
improved	VBN	O
with	IN	O
the	DT	O
6-minute	JJ	O
walk	NN	O
distance	NN	O
,	,	O
improving	VBG	O
on	IN	O
follow-up	NN	O
from	IN	O
455.7	CD	O
?	.	O
71.5	CD	O
to	TO	O
498	CD	O
?	.	O
70	CD	O
m	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
and	CC	O
peak	JJ	O
oxygen	NN	O
consumption	NN	O
increasing	VBG	O
from	IN	O
25.5	CD	O
?	.	O
10.2	CD	O
to	TO	O
27.4	CD	O
?	.	O
10	CD	O
(	(	O
p	NN	O
=	RB	O
0.04	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
inhaled	VBD	O
treprostinil	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
improvement	NN	O
in	IN	O
exercise	NN	O
capacity	NN	O
and	CC	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
functional	JJ	O
class	NN	O
when	WRB	O
added	VBD	O
to	TO	O
background	VB	O
targeted	JJ	O
PAH	NNP	O
therapy	NN	O
in	IN	O
children	NNS	O
and	CC	O
had	VBD	O
an	DT	O
acceptable	JJ	O
safety	NN	O
profile	NN	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
early	JJ	O
data	NNS	O
,	,	O
further	JJ	O
study	NN	O
of	IN	O
inhaled	JJ	O
treprostinil	NN	O
appears	VBZ	O
warranted	VBN	O
in	IN	O
pediatric	JJ	O
patients	NNS	O
with	IN	O
PAH	NNP	O
.	.	O

Secretin	NNP	O
and	CC	O
autism	NN	O
:	:	O
a	DT	O
two-part	JJ	O
clinical	JJ	O
investigation	NN	O
.	.	O

Recent	JJ	O
anecdotal	JJ	O
reports	NNS	O
have	VBP	O
touted	VBN	O
the	DT	O
gastrointestinal	NN	O
(	(	O
GI	NNP	O
)	)	O
hormone	NN	O
secretin	NN	PH
as	IN	O
a	DT	O
treatment	NN	O
modality	NN	O
for	IN	O
autism	NN	O
,	,	O
though	IN	O
there	EX	O
is	VBZ	O
little	JJ	O
clinical	JJ	O
evidence	NN	O
or	CC	O
literature	NN	O
to	TO	O
support	VB	O
its	PRP$	O
viability	NN	O
.	.	O

We	PRP	O
undertook	VBD	O
a	DT	O
two-part	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
investigate	VB	O
these	DT	O
claims	NNS	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
(	(	O
49	CD	O
boys	NNS	O
,	,	O
7	CD	O
girls	NNS	O
,	,	O
mean	JJ	O
age	NN	O
=	VBD	O
6.4	CD	O
years	NNS	O
,	,	O
SD	NNP	O
=	NNP	O
2.7	CD	O
)	)	O
enrolled	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
trial	NN	O
of	IN	O
secretin	NN	PH
,	,	O
during	IN	O
which	WDT	O
they	PRP	O
received	VBD	O
one	CD	O
injection	NN	O
of	IN	O
the	DT	O
hormone	NN	O
(	(	O
2	CD	O
IU/kg	NNP	O
)	)	O
.	.	O

All	DT	O
subjects	NNS	O
were	VBD	O
evaluated	VBN	O
by	IN	O
their	PRP$	O
parents	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
follow-up	JJ	O
visits	NNS	O
(	(	O
3-6	JJ	O
weeks	NNS	O
later	RB	O
,	,	O
M	NNP	O
=	NNP	O
3.7	CD	O
,	,	O
SD	NNP	O
=	VBZ	O
1.4	CD	O
weeks	NNS	O
)	)	O
with	IN	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scales	NNP	O
(	(	O
CARS	NNP	O
)	)	O
.	.	O

Thirty-four	JJ	O
patients	NNS	O
were	VBD	O
labeled	VBN	O
with	IN	O
Pervasive	NNP	O
Developmental	NNP	O
Disorder	NNP	O
Not	RB	O
Otherwise	NNP	O
Specified	NNP	O
,	,	O
and	CC	O
22	CD	O
met	VBD	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
Autistic	JJ	O
Disorder	NNP	O
.	.	O

Forty-five	JJ	O
patients	NNS	O
were	VBD	O
concurrently	RB	O
on	IN	O
other	JJ	O
drug	NN	O
treatments	NNS	O
.	.	O

At	IN	O
follow-up	NN	O
,	,	O
some	DT	O
reported	VBD	O
minimal	JJ	O
but	CC	O
potentially	RB	O
significant	JJ	O
improvements	NNS	O
including	VBG	O
changes	NNS	O
in	IN	O
GI	NNP	O
symptoms	NNS	O
,	,	O
expressive	JJ	O
and/or	NN	O
receptive	JJ	O
language	NN	O
function	NN	O
,	,	O
and	CC	O
improved	JJ	O
awareness	NN	O
and	CC	O
social	JJ	O
interactions	NNS	O
.	.	O

No	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
reported	VBN	O
or	CC	O
observed	VBN	O
.	.	O

Subsequently	NNP	O
,	,	O
17	CD	O
of	IN	O
the	DT	O
most	RBS	O
responsive	JJ	O
patients	NNS	O
from	IN	O
Study	NNP	O
1	CD	O
began	VBD	O
a	DT	O
double-blind	JJ	O
trial	NN	O
that	WDT	O
also	RB	O
included	VBD	O
8	CD	O
newly	RB	O
enrolled	VBN	O
patients	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
this	DT	O
second	JJ	O
study	NN	O
were	VBD	O
alternatively	RB	O
entered	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
and	CC	O
received	VBD	O
injections	NNS	O
of	IN	O
secretin	NN	O
or	CC	O
placebo	NN	C
with	IN	O
crossover	NN	O
at	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
from	IN	O
Study	NNP	O
1	CD	O
entered	VBD	O
into	IN	O
Study	NNP	O
2	CD	O
at	IN	O
an	DT	O
average	NN	O
of	IN	O
6.5	CD	O
(	(	O
SD	NNP	O
=	NNP	O
0.8	CD	O
)	)	O
weeks	NNS	O
after	IN	O
beginning	VBG	O
Study	NNP	O
1	CD	O
.	.	O

Results	NNS	O
of	IN	O
both	DT	O
inquiries	NNS	O
indicate	VBP	O
that	IN	O
although	IN	O
treatment	NN	O
with	IN	O
secretin	NN	PH
was	VBD	O
reported	VBN	O
to	TO	O
cause	VB	O
transient	JJ	O
changes	NNS	O
in	IN	O
speech	NN	O
and	CC	O
behavior	NN	O
in	IN	O
some	DT	O
children	NNS	O
,	,	O
overall	JJ	O
it	PRP	O
produced	VBD	O
few	JJ	O
clinically	RB	O
meaningful	JJ	O
changes	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
children	NNS	O
given	VBN	O
placebo	JJ	C
injections	NNS	O
.	.	O

New	NNP	O
hope	NN	O
for	IN	O
children	NNS	O
with	IN	O
Kawasaki	NNP	O
disease	NN	O
.	.	O

Kawasaki	NNP	O
disease	NN	O
is	VBZ	O
now	RB	O
the	DT	O
most	RBS	O
common	JJ	O
cause	NN	O
of	IN	O
acquired	VBN	O
heart	NN	O
disease	NN	O
in	IN	O
America	NNP	O
's	POS	O
children	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
an	DT	O
acute	JJ	O
febrile	NN	O
illness	NN	O
that	WDT	O
may	MD	O
cause	VB	O
coronary	JJ	O
artery	NN	O
aneurysm	NN	O
formation	NN	O
in	IN	O
infected	JJ	O
children	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
intravenous	JJ	PM
administration	NN	PM
of	IN	PM
gamma	JJ	PM
globulin	NN	PM
(	(	PM
IVGG	NNP	PM
)	)	PM
plus	CC	O
aspirin	JJ	PM
versus	NN	O
aspirin	NN	PM
alone	RB	PM
upon	IN	O
coronary	JJ	O
aneurysm	NN	O
formation	NN	O
show	VBP	O
a	DT	O
decrease	NN	O
in	IN	O
coronary	JJ	O
aneurysm	NN	O
formation	NN	O
from	IN	O
the	DT	O
usual	JJ	O
20	CD	O
%	NN	O
-30	NN	O
%	NN	O
to	TO	O
3	CD	O
%	NN	O
.	.	O

Administration	NNP	O
of	IN	O
IVGG	NNP	PM
presents	VBZ	O
some	DT	O
unique	JJ	O
challenges	NNS	O
for	IN	O
nurses	NNS	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
pediatric	JJ	O
nurse	NN	O
must	MD	O
educate	VB	O
parents	NNS	O
and	CC	O
children	NNS	O
about	IN	O
this	DT	O
disease	NN	O
to	TO	O
prepare	VB	O
them	PRP	O
for	IN	O
discharge	NN	O
and	CC	O
long-term	JJ	O
follow-up	JJ	O
care	NN	O
.	.	O

Interleukin-6	NNP	O
receptor	NN	O
inhibition	NN	O
with	IN	O
tocilizumab	NN	PM
and	CC	O
attainment	NN	O
of	IN	O
disease	NN	O
remission	NN	O
in	IN	O
rheumatoid	JJ	O
arthritis	NN	O
:	:	O
the	DT	O
role	NN	O
of	IN	O
acute-phase	JJ	O
reactants	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
tocilizumab	NN	PM
on	IN	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
disease	NN	O
activity	NN	O
and	CC	O
remission	NN	O
assessment	NN	O
,	,	O
using	VBG	O
measures	NNS	O
that	WDT	O
do	VBP	O
or	CC	O
do	VB	O
not	RB	O
comprise	VB	O
acute-phase	JJ	O
reactants	NNS	O
.	.	O

METHODS	NNP	O
Simplified	NNP	O
Disease	NNP	O
Activity	NNP	O
Index	NNP	O
(	(	O
SDAI	NNP	O
)	)	O
scores	VBZ	O
,	,	O
Clinical	JJ	O
Disease	NNP	O
Activity	NNP	O
Index	NNP	O
(	(	O
CDAI	NNP	O
)	)	O
scores	VBZ	O
,	,	O
and	CC	O
the	DT	O
Disease	NNP	O
Activity	NNP	O
Score	NNP	O
in	IN	O
28	CD	O
joints	NNS	O
(	(	O
DAS28	NNP	O
)	)	O
were	VBD	O
calculated	VBN	O
using	VBG	O
data	NNS	O
from	IN	O
tocilizumab	JJ	PM
trials	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
in	IN	O
whom	WP	O
disease	NN	O
had	VBD	O
remained	VBN	O
active	JJ	O
despite	IN	O
treatment	NN	O
with	IN	O
disease-modifying	JJ	PM
antirheumatic	JJ	PM
drugs	NNS	PM
.	.	O

The	DT	O
CDAI	NNP	O
does	VBZ	O
not	RB	O
contain	VB	O
an	DT	O
acute-phase	JJ	O
reactant	NN	O
component	NN	O
.	.	O

Disease	NNP	O
activity	NN	O
states	NNS	O
,	,	O
including	VBG	O
remission	NN	O
,	,	O
were	VBD	O
defined	VBN	O
using	VBG	O
established	VBN	O
cut	NN	O
points	NNS	O
;	:	O
for	IN	O
the	DT	O
DAS28	NNP	O
,	,	O
an	DT	O
alternative	JJ	O
cut	NN	O
point	NN	O
of	IN	O
<	$	O
2.4	CD	O
was	VBD	O
also	RB	O
used	VBN	O
.	.	O

RESULTS	JJ	O
Changes	NNS	O
in	IN	O
the	DT	O
DAS28	NNP	O
,	,	O
the	DT	O
SDAI	NNP	O
score	NN	O
,	,	O
and	CC	O
the	DT	O
CDAI	NNP	O
score	NN	O
among	IN	O
patients	NNS	O
receiving	VBG	O
tocilizumab	NN	PM
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
among	IN	O
patients	NNS	O
receiving	VBG	O
placebo	NN	C
,	,	O
and	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
these	DT	O
changes	NNS	O
was	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
SDAI	NNP	O
and	CC	O
the	DT	O
CDAI	NNP	O
.	.	O

Among	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
50	CD	O
%	NN	O
improvement	NN	O
in	IN	O
disease	NN	O
activity	NN	O
according	VBG	O
to	TO	O
the	DT	O
American	NNP	O
College	NNP	O
of	IN	O
Rheumatology	NNP	O
criteria	NNS	O
,	,	O
only	RB	O
?20	VBZ	O
%	NN	O
required	VBN	O
a	DT	O
reduction	NN	O
in	IN	O
acute-phase	JJ	O
reactant	NN	O
values	NNS	O
in	IN	O
order	NN	O
to	TO	O
fulfill	VB	O
the	DT	O
criteria	NNS	O
.	.	O

However	RB	O
,	,	O
DAS28	NNP	O
remission	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
(	(	O
even	RB	O
when	WRB	O
using	VBG	O
the	DT	O
lower	JJR	O
cut	NN	O
point	NN	O
)	)	O
than	IN	O
the	DT	O
SDAI	NNP	O
and	CC	O
CDAI	NNP	O
remission	NN	O
rates	NNS	O
.	.	O

Only	RB	O
a	DT	O
minority	NN	O
of	IN	O
tocilizumab-treated	JJ	PM
patients	NNS	O
with	IN	O
DAS28	NNP	O
remission	NN	O
also	RB	O
had	VBD	O
disease	NN	O
remission	NN	O
according	VBG	O
to	TO	O
the	DT	O
SDAI	NNP	O
(	(	O
26	CD	O
%	NN	O
)	)	O
or	CC	O
CDAI	NNP	O
(	(	O
?21	NNP	O
%	NN	O
)	)	O
.	.	O

With	IN	O
infliximab	JJ	O
treatment	NN	O
,	,	O
SDAI	NNP	O
and	CC	O
CDAI	NNP	O
remission	NN	O
rates	NNS	O
were	VBD	O
of	IN	O
the	DT	O
same	JJ	O
magnitude	NN	O
as	IN	O
those	DT	O
observed	VBN	O
with	IN	O
tocilizumab	JJ	O
treatment	NN	O
,	,	O
and	CC	O
DAS28	NNP	O
remission	NN	O
rates	NNS	O
were	VBD	O
lower	JJR	O
.	.	O

Tocilizumab-treated	JJ	O
patients	NNS	O
with	IN	O
DAS28	NNP	O
remission	NN	O
but	CC	O
without	IN	O
CDAI	NNP	O
remission	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	O
swollen	JJ	O
joint	JJ	O
counts	NNS	O
but	CC	O
lower	JJR	O
erythrocyte	NN	O
sedimentation	NN	O
rates	NNS	O
(	(	O
ESRs	NNP	O
)	)	O
compared	VBN	O
with	IN	O
patients	NNS	O
with	IN	O
SDAI	NNP	O
or	CC	O
CDAI	NNP	O
remission	NN	O
.	.	O

CONCLUSION	NNP	O
Disease	NNP	O
activity	NN	O
in	IN	O
RA	NNP	O
is	VBZ	O
reduced	VBN	O
by	IN	O
tocilizumab	NN	PM
treatment	NN	O
,	,	O
irrespective	NN	O
of	IN	O
the	DT	O
type	NN	O
of	IN	O
composite	JJ	O
measure	NN	O
used	VBN	O
to	TO	O
evaluate	VB	O
disease	NN	O
activity	NN	O
.	.	O

Remission	NN	O
rates	NNS	O
were	VBD	O
much	RB	O
higher	JJR	O
using	VBG	O
the	DT	O
DAS28	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
SDAI	NNP	O
and	CC	O
CDAI	NNP	O
,	,	O
due	JJ	O
to	TO	O
the	DT	O
high	JJ	O
weight	NN	O
of	IN	O
the	DT	O
ESR	NNP	O
in	IN	O
the	DT	O
DAS28	NNP	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
tocilizumab	NN	O
on	IN	O
the	DT	O
ESR	NNP	O
.	.	O

Using	VBG	O
the	DT	O
stringent	NN	O
SDAI	NNP	O
and	CC	O
CDAI	NNP	O
criteria	NNS	O
,	,	O
however	RB	O
,	,	O
remission	NN	O
rates	NNS	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tocilizumab	NNS	O
were	VBD	O
in	IN	O
the	DT	O
same	JJ	O
range	NN	O
as	IN	O
those	DT	O
seen	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
inhibitors	NNS	O
.	.	O

Placebo-controlled	JJ	O
pilot	NN	O
trial	NN	O
of	IN	O
mecamylamine	NN	PM
for	IN	O
treatment	NN	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
possible	JJ	O
benefits	NNS	O
of	IN	O
a	DT	O
nicotinic	JJ	PM
acetylcholine	NN	PM
receptor	NN	PM
(	(	PM
nAChR	JJ	PM
)	)	PM
agent	NN	PM
for	IN	O
autistic	JJ	O
symptoms	NNS	O
based	VBN	O
on	IN	O
postmortem	NN	O
observation	NN	O
of	IN	O
nAChR	JJ	O
abnormalities	NNS	O
(	(	O
deficient	JJ	O
?4?2	NN	O
nAChRs	NN	O
,	,	O
excess	JJ	O
?7	NNP	O
nAChRs	NN	O
)	)	O
in	IN	O
brains	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
Mecamylamine	NNP	O
,	,	O
because	IN	O
of	IN	O
its	PRP$	O
safety	NN	O
record	NN	O
in	IN	O
children	NNS	O
with	IN	O
other	JJ	O
disorders	NNS	O
,	,	O
was	VBD	O
chosen	VBN	O
for	IN	O
this	DT	O
first	JJ	O
exploration	NN	O
.	.	O

Twenty	NNP	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
age	NN	O
4-12	CD	O
years	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
for	IN	O
14	CD	O
weeks	NNS	O
to	TO	O
placebo	VB	O
(	(	O
n=8	NN	O
)	)	O
or	CC	O
mecamylamine	NN	O
(	(	O
n=12	JJ	O
)	)	O
in	IN	O
ascending	VBG	O
fixed	JJ	O
doses	NNS	O
:	:	O
0.5	CD	O
mg/day	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
2.5	CD	O
mg	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
then	RB	O
5	CD	O
mg/day	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Improvement	NNP	O
was	VBD	O
rated	VBN	O
by	IN	O
a	DT	O
blinded	JJ	O
independent	JJ	O
evaluator	NN	O
.	.	O

Because	IN	O
of	IN	O
small	JJ	O
sample	NN	O
,	,	O
data	NNS	O
analysis	NN	O
was	VBD	O
descriptive	JJ	O
.	.	O

RESULTS	NNP	O
Eighteen	JJ	O
participants	NNS	O
(	(	O
10	CD	O
mecamylamine	NN	O
,	,	O
8	CD	O
placebo	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

All	DT	O
doses	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
;	:	O
the	DT	O
only	JJ	O
side	NN	O
effect	NN	O
of	IN	O
note	NN	O
was	VBD	O
constipation	NN	O
(	(	O
50	CD	O
%	NN	O
compared	VBN	O
with	IN	O
25	CD	O
%	NN	O
of	IN	O
placebo	NN	O
group	NN	O
)	)	O
.	.	O

Three	CD	O
children	NNS	O
had	VBD	O
clinically	RB	O
nonsignificant	JJ	O
electrocardiographic	JJ	O
QT	NNP	O
prolongation	NN	O
.	.	O

Both	DT	O
groups	NNS	O
showed	VBD	O
modest	JJ	O
to	TO	O
moderate	VB	O
improvement	NN	O
,	,	O
but	CC	O
differences	NNS	O
between	IN	O
groups	NNS	O
were	VBD	O
negligible	JJ	O
.	.	O

On	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
,	,	O
the	DT	O
Ohio	NNP	O
Autism	NNP	O
Clinical	NNP	O
Impressions	NNP	O
Scale	NNP	O
,	,	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
showed	VBD	O
improvement	NN	O
at	IN	O
some	DT	O
point	NN	O
(	(	O
but	CC	O
only	RB	O
40	CD	O
%	NN	O
sustained	VBD	O
it	PRP	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
62	CD	O
%	NN	O
on	IN	O
placebo	NN	O
.	.	O

Of	IN	O
the	DT	O
four	CD	O
in	IN	O
active	JJ	O
treatment	NN	O
that	WDT	O
sustained	VBD	O
improvement	NN	O
,	,	O
three	CD	O
had	VBD	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
0.13-0.15	JJ	O
mg/kg/day	NN	O
,	,	O
while	IN	O
those	DT	O
who	WP	O
regressed	VBD	O
had	VBD	O
doses	NNS	O
?0.18	JJ	O
mg/kg/day	NN	O
.	.	O

Graphed	VBN	O
means	NNS	O
suggested	VBD	O
better	RBR	O
outcome	NN	O
with	IN	O
lower	JJR	O
mg/kg	NN	O
and	CC	O
longer	JJR	O
medication	NN	O
duration	NN	O
.	.	O

Four	CD	O
parents	NNS	O
spontaneously	RB	O
reported	VBD	O
reduced	JJ	O
hyperactivity	NN	O
and	CC	O
irritability	NN	O
and	CC	O
better	JJR	O
verbalization	NN	O
and	CC	O
continued	JJ	O
mecamylamine	NN	O
at	IN	O
their	PRP$	O
own	JJ	O
expense	NN	O
.	.	O

CONCLUSION	NNP	O
Mecamylamine	NNP	O
appeared	VBD	O
to	TO	O
be	VB	O
safe	JJ	O
,	,	O
but	CC	O
not	RB	O
very	RB	O
effective	JJ	O
in	IN	O
autism	NN	O
.	.	O

The	DT	O
suggestion	NN	O
of	IN	O
better	JJR	O
results	NNS	O
at	IN	O
lower	JJR	O
doses	NNS	O
and	CC	O
longer	JJR	O
exposure	NN	O
warrants	NNS	O
consideration	NN	O
for	IN	O
future	JJ	O
trials	NNS	O
.	.	O

The	DT	O
next	JJ	O
step	NN	O
would	MD	O
be	VB	O
exploration	NN	O
of	IN	O
a	DT	O
more	RBR	O
specific	JJ	O
?4?2	NNP	O
nAChR	JJ	O
agonist	NN	O
,	,	O
such	JJ	O
as	IN	O
varenicline	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
ethnic	JJ	O
matching	VBG	O
between	IN	O
patient	NN	O
and	CC	O
provider	NN	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
brief	NN	PS
alcohol	NN	PS
interventions	NNS	PS
with	IN	O
Hispanics	NNPS	O
.	.	O

BACKGROUND	NNP	O
Evaluating	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
treatments	NNS	O
such	JJ	O
as	IN	O
brief	JJ	O
alcohol	JJ	O
interventions	NNS	O
among	IN	O
Hispanics	NNPS	O
is	VBZ	O
essential	JJ	O
to	TO	O
effectively	RB	O
addressing	VBG	O
their	PRP$	O
treatment	NN	O
needs	NNS	O
.	.	O

Clinicians	NNPS	O
of	IN	O
the	DT	O
same	JJ	O
ethnicity	NN	O
as	IN	O
the	DT	O
client	NN	O
may	MD	O
be	VB	O
more	RBR	O
likely	JJ	O
to	TO	O
understand	VB	O
the	DT	O
culture-specific	JJ	O
values	NNS	O
,	,	O
norms	NNS	O
,	,	O
and	CC	O
attitudes	NNS	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
the	DT	O
intervention	NN	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
.	.	O

Thus	RB	O
,	,	O
in	IN	O
cases	NNS	O
in	IN	O
which	WDT	O
Hispanic	JJ	O
patients	NNS	O
were	VBD	O
provided	VBN	O
intervention	NN	O
by	IN	O
a	DT	O
Hispanic	JJ	O
clinician	NN	O
improved	VBD	O
drinking	NN	O
outcomes	NNS	O
were	VBD	O
expected	VBN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
recruited	VBN	O
from	IN	O
an	DT	O
urban	JJ	O
Level	NN	O
I	PRP	O
Trauma	VBP	O
following	VBG	O
screening	NN	O
for	IN	O
an	DT	O
alcohol-related	JJ	O
injury	NN	O
or	CC	O
alcohol	NN	O
problems	NNS	O
.	.	O

Five	CD	O
hundred	VBD	O
thirty-seven	JJ	O
Hispanics	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
brief	VB	PS
intervention	NN	PS
or	CC	PM
treatment	NN	C
as	IN	C
usual	JJ	C
.	.	O

Hierarchical	JJ	O
linear	JJ	O
modeling	NN	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
ethnic	JJ	O
match	NN	O
on	IN	O
drinking	NN	O
outcomes	NNS	O
including	VBG	O
volume	NN	O
per	IN	O
week	NN	O
,	,	O
maximum	JJ	O
amount	NN	O
,	,	O
and	CC	O
frequency	NN	O
of	IN	O
5	CD	O
or	CC	O
more	JJR	O
drinks	NNS	O
per	IN	O
occasion	NN	O
.	.	O

Analyses	NNS	O
controlled	VBD	O
for	IN	O
level	NN	O
of	IN	O
acculturation	NN	O
and	CC	O
immigration	NN	O
status	NN	O
.	.	O

RESULTS	NNP	O
For	IN	O
Hispanics	NNPS	O
who	WP	O
received	VBD	O
brief	JJ	O
motivational	JJ	O
intervention	NN	O
,	,	O
an	DT	O
ethnic	JJ	O
match	NN	O
between	IN	O
patient	NN	O
and	CC	O
provider	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
drinking	NN	O
outcomes	NNS	O
at	IN	O
12-month	JJ	O
follow-up	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
tendency	NN	O
for	IN	O
ethnic	JJ	O
match	NN	O
to	TO	O
be	VB	O
most	RBS	O
beneficial	JJ	O
to	TO	O
foreign-born	JJ	O
Hispanics	NNPS	O
and	CC	O
less	RBR	O
acculturated	JJ	O
Hispanics	NNPS	O
.	.	O

CONCLUSION	NNP	O
As	IN	O
hypothesized	VBN	O
,	,	O
an	DT	O
ethnic	JJ	O
match	NN	O
between	IN	O
patient	NN	O
and	CC	O
provider	NN	O
significantly	RB	O
enhanced	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
brief	JJ	O
intervention	NN	O
among	IN	O
Hispanics	NNPS	O
.	.	O

Ethnic	JJ	O
concordance	NN	O
between	IN	O
patient	NN	O
and	CC	O
provider	NN	O
may	MD	O
have	VB	O
impacted	VBN	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
intervention	NN	O
through	IN	O
several	JJ	O
mechanisms	NNS	O
including	VBG	O
cultural	JJ	O
scripts	NNS	O
,	,	O
ethnic-specific	JJ	O
perceptions	NNS	O
pertaining	VBG	O
to	TO	O
substance	NN	O
abuse	NN	O
,	,	O
and	CC	O
ethnic-specific	JJ	O
preferred	JJ	O
channels	NNS	O
of	IN	O
communication	NN	O
.	.	O

[	VB	O
A	NNP	O
controlled	JJ	O
study	NN	O
of	IN	O
treating	VBG	O
haemophilia	PRP	O
A	NNP	O
on	IN	O
an	DT	O
out-patient	JJ	O
basis	NN	O
(	(	O
author	NN	O
's	POS	O
transl	NN	O
)	)	O
]	NN	O
.	.	O

For	IN	O
six	CD	O
months	NNS	O
36	CD	PM
U	NNP	PM
factor	NN	PM
VIII	NNP	PM
concentrates	VBZ	PM
per	IN	O
kg	NN	O
bodyweight	NN	O
and	CC	O
week	NN	O
were	VBD	O
administered	VBN	O
to	TO	O
six	CD	O
out-patients	NNS	O
with	IN	O
severe	JJ	O
haemophilia	NN	O
A	NNP	O
.	.	O

The	DT	O
injection	NN	O
regimen	NN	O
was	VBD	O
changed	VBN	O
in	IN	O
every	DT	O
patient	NN	O
every	DT	O
two	CD	O
months	NNS	O
,	,	O
from	IN	O
36	CD	O
U/kg	NNP	O
once	RB	O
to	TO	O
18	CD	O
U/kg	NNP	O
twice	RB	O
and	CC	O
12	CD	O
U/kg	NNP	O
three	CD	O
times	NNS	O
,	,	O
intravenously	RB	O
.	.	O

The	DT	O
six	CD	O
possible	JJ	O
combinations	NNS	O
of	IN	O
these	DT	O
three	CD	O
dosage	NN	O
schedules	NNS	O
were	VBD	O
used	VBN	O
in	IN	O
the	DT	O
patients	NNS	O
in	IN	O
a	DT	O
strictly	RB	O
randomised	JJ	O
manner	NN	O
,	,	O
and	CC	O
all	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
during	IN	O
the	DT	O
same	JJ	O
period	NN	O
.	.	O

In	IN	O
the	DT	O
pre-trial	JJ	O
period	NN	O
(	(	O
treatment	NN	O
as	IN	O
needed	VBN	O
)	)	O
there	EX	O
were	VBD	O
an	DT	O
average	NN	O
of	IN	O
35	CD	O
bleedings	NNS	O
per	IN	O
two	CD	O
months	NNS	O
.	.	O

On	IN	O
continual	JJ	O
treatment	NN	O
there	EX	O
were	VBD	O
21	CD	O
bleedings	NNS	O
on	IN	O
weekly	JJ	O
injections	NNS	O
of	IN	O
36	CD	O
U	NNP	PM
factor	NN	PM
VIII	NNP	PM
per	IN	O
kg	NN	O
,	,	O
14	CD	O
on	IN	O
twice	JJ	O
weekly	JJ	O
18	CD	O
U/kg	NNP	O
and	CC	O
none	NN	O
on	IN	O
12	CD	O
U/kg	NNP	O
,	,	O
three	CD	O
times	NNS	O
weekly	RB	O
.	.	O

The	DT	O
differences	NNS	O
are	VBP	O
statistically	RB	O
significant	JJ	O
.	.	O

The	DT	O
absence	NN	O
of	IN	O
bleeding	VBG	O
on	IN	O
the	DT	O
last	JJ	O
dosage	NN	O
schedule	NN	O
was	VBD	O
achieved	VBN	O
during	IN	O
normal	JJ	O
working	VBG	O
.	.	O

Days	NNPS	O
lost	VBD	O
from	IN	O
work	NN	O
per	IN	O
patient	JJ	O
per	IN	O
month	NN	O
was	VBD	O
zero	NN	O
on	IN	O
three	CD	O
times	NNS	O
12	CD	O
U/kg	NNP	O
,	,	O
0.4	CD	O
day	NN	O
on	IN	O
twice	RB	O
18	CD	O
U/kg	NNP	O
and	CC	O
once	RB	O
36	CD	O
U/kg	NNP	O
,	,	O
while	IN	O
it	PRP	O
had	VBD	O
been	VBN	O
five	CD	O
days	NNS	O
in	IN	O
the	DT	O
pre-trial	JJ	O
period	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
freedom	NN	O
from	IN	O
bleeding	VBG	O
and	CC	O
no	DT	O
lost	JJ	O
days	NNS	O
from	IN	O
work	NN	O
,	,	O
there	EX	O
was	VBD	O
increased	VBN	O
mobility	NN	O
and	CC	O
physical	JJ	O
capacity	NN	O
.	.	O

Symptomatic	JJ	PH
treatment	NN	PH
versus	NN	O
combination	NN	PM
chemotherapy	NN	PM
for	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
non-small	NN	O
cell	NN	O
lung	NN	O
cancer	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
87	CD	O
patients	NNS	O
with	IN	O
inoperable	JJ	O
,	,	O
extensive	JJ	O
non-small	NN	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
combination	NN	PM
chemotherapy	NN	PM
(	(	PM
cisplatin	NN	PM
at	IN	O
70	CD	O
mg/m2	NN	O
intravenously	RB	O
[	NNP	O
i.v	NN	O
.	.	O

]	VB	O
on	IN	O
day	NN	O
1	CD	O
and	CC	O
etoposide	VB	PM
at	IN	O
100	CD	O
mg/m2	NN	O
i.v	NN	O
.	.	O

on	IN	O
day	NN	O
1	CD	O
and	CC	O
200	CD	O
mg/m2	NNS	O
orally	RB	O
on	IN	O
days	NNS	O
2	CD	O
and	CC	O
3	CD	O
)	)	O
or	CC	O
symptomatic	JJ	PH
treatment	NN	PH
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
survival	JJ	O
time	NN	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
techniques	NNS	O
.	.	O

A	DT	O
major	JJ	O
problem	NN	O
in	IN	O
the	DT	O
interpretation	NN	O
of	IN	O
the	DT	O
results	NNS	O
was	VBD	O
the	DT	O
use	NN	O
of	IN	O
semicurative	JJ	O
radiation	NN	O
therapy	NN	O
(	(	O
3000	CD	O
to	TO	O
4200	CD	O
cGy	NN	O
)	)	O
to	TO	O
the	DT	O
primary	JJ	O
tumor	NN	O
and	CC	O
mediastinum	NN	O
,	,	O
which	WDT	O
was	VBD	O
given	VBN	O
with	IN	O
symptomatic	JJ	O
intent	NN	O
.	.	O

Three	CD	O
long-term	JJ	O
survivors	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
latter	JJ	O
group	NN	O
.	.	O

Women	NNP	O
's	POS	O
responses	NNS	O
to	TO	O
information	NN	O
on	IN	O
mammographic	JJ	O
breast	NN	O
density	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
negative	JJ	O
and	CC	O
positive	JJ	O
outcomes	NNS	O
of	IN	O
providing	VBG	O
mammographic	JJ	O
breast	NN	O
density	NN	O
(	(	O
MBD	NNP	O
)	)	O
information	NN	O
to	TO	O
participants	NNS	O
of	IN	O
a	DT	O
screening	JJ	PH
program	NN	PH
.	.	O

A	DT	O
randomized	JJ	O
experiment	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
a	DT	O
sample	NN	O
of	IN	O
618	CD	O
women	NNS	O
50	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
MBD	NNP	O
greater	JJR	O
than	IN	O
50	CD	O
%	NN	O
of	IN	O
breast	NN	O
volume	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
reporting	VBG	PH
the	DT	PH
presence	NN	PH
of	IN	PH
MBD	NNP	PH
in	IN	PH
the	DT	PH
screening	NN	PH
mammography	NN	PH
results	NNS	PH
letter	NN	PH
that	WDT	PH
was	VBD	PH
sent	VBN	PH
along	IN	PH
with	IN	PH
an	DT	PH
information	NN	PH
pamphlet	NN	PH
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
controls	NNS	C
,	,	O
more	JJR	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
described	VBD	O
the	DT	O
term	NN	O
breast	NN	O
density	NN	O
correctly	RB	O
and	CC	O
recognized	VBD	O
it	PRP	O
as	IN	O
a	DT	O
risk	NN	O
factor	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Although	IN	O
at	IN	O
the	DT	O
4-week	JJ	O
follow-up	NN	O
the	DT	O
intervention	NN	O
group	NN	O
indicated	VBD	O
that	IN	O
they	PRP	O
were	VBD	O
very	RB	O
likely	JJ	O
to	TO	O
have	VB	O
an	DT	O
annual	JJ	PH
clinical	JJ	PH
breast	NN	PH
examination	NN	PH
more	RBR	O
frequently	RB	O
than	IN	O
controls	NNS	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
detected	VBN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
on	IN	O
other	JJ	O
behavioural	JJ	O
or	CC	O
psychological	JJ	O
measures	NNS	O
,	,	O
although	IN	O
at	IN	O
the	DT	O
4-week	JJ	O
follow-up	JJ	O
the	DT	O
control	NN	O
group	NN	O
perceived	VBD	O
their	PRP$	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
,	,	O
relative	VBP	O
to	TO	O
other	JJ	O
women	NNS	O
their	PRP$	O
age	NN	O
,	,	O
as	IN	O
a	DT	O
lot	NN	O
lower	JJR	O
than	IN	O
did	VBD	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
a	DT	O
feasible	JJ	O
and	CC	O
non-threatening	JJ	O
way	NN	O
to	TO	O
provide	VB	O
women	NNS	O
with	IN	O
important	JJ	O
personalized	VBN	O
information	NN	O
about	IN	O
breast	NN	O
cancer	NN	O
risk	NN	O
.	.	O

[	RB	O
Perioperative	NNP	O
teicoplanin	NN	PM
prophylaxis	NN	PM
in	IN	O
patients	NNS	O
undergoing	VBG	O
breast	JJ	O
reconstruction	NN	O
with	IN	O
the	DT	O
abdominal	JJ	O
wall	NN	O
.	.	O

A	DT	O
case-control	NN	O
study	NN	O
]	NNP	O
.	.	O

The	DT	O
authors	NNS	O
report	VBP	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
antibiotic	JJ	O
prophylaxis	NN	O
of	IN	O
postoperative	JJ	O
infection	NN	O
following	VBG	O
breast	NN	O
reconstruction	NN	O
by	IN	O
transposition	NN	O
of	IN	O
rectus	NN	O
abdominis	NN	O
myocutaneous	JJ	O
flap	NN	O
(	(	O
TRAMF	NNP	O
)	)	O
.	.	O

The	DT	O
aim	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
short-term	JJ	O
parenteral	JJ	PM
prophylaxis	NN	PM
with	IN	PM
Teicoplanin	NNP	PM
and	CC	O
the	DT	O
end-point	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
the	DT	O
evaluation	NN	O
of	IN	O
wound	NN	O
contamination	NN	O
assessed	VBN	O
by	IN	O
means	NNS	O
of	IN	O
microbiologic	JJ	O
culture	NN	O
of	IN	O
drainage	NN	O
fluid	NN	O
.	.	O

From	IN	O
October	NNP	O
1990	CD	O
to	TO	O
March	NNP	O
1992	CD	O
38	CD	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
:	:	O
20	CD	O
patients	NNS	O
in	IN	O
the	DT	O
antibiotic	JJ	O
prophylaxis	NN	O
arm	NN	O
and	CC	O
18	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Analysis	NN	O
of	IN	O
drainage	NN	O
fluids	NNS	O
showed	VBD	O
a	DT	O
higher	JJR	O
contamination	NN	O
rate	NN	O
(	(	O
15/18	CD	O
=	RB	O
83	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
prophylaxis	NN	O
arm	NN	O
(	(	O
2/20	CD	O
=	RB	O
10	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
11	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
suffered	VBD	O
from	IN	O
fever	NN	O
>	$	O
37.5	CD	O
degrees	NNS	O
C	NNP	O
for	IN	O
at	IN	O
least	JJS	O
3	CD	O
days	NNS	O
as	RB	O
compared	VBN	O
to	TO	O
1	CD	O
patient	NN	O
in	IN	O
the	DT	O
antibiotic	JJ	O
prophylaxis	NN	O
group	NN	O
;	:	O
the	DT	O
postoperative	JJ	O
stay	NN	O
was	VBD	O
13.3	CD	O
+/-	JJ	O
4.3	CD	O
and	CC	O
9.0	CD	O
+/-	JJ	O
1.6	CD	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
antibiotic	JJ	O
arm	NN	O
respectively	RB	O
.	.	O

No	NNP	O
antibiotic	JJ	O
related	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
evidenced	VBN	O
through	IN	O
the	DT	O
study	NN	O
.	.	O

These	DT	O
results	NNS	O
seem	VBP	O
to	TO	O
confirm	VB	O
the	DT	O
value	NN	O
of	IN	O
parenteral	JJ	O
short-term	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
of	IN	O
postoperative	JJ	O
infection	NN	O
in	IN	O
such	JJ	O
kind	NN	O
of	IN	O
clean	JJ	O
operative	JJ	O
procedure	NN	O
.	.	O

Continuous	JJ	O
and	CC	O
cyclical	JJ	PM
clodronate	NN	PM
therapies	NNS	PM
and	CC	O
bone	NN	O
density	NN	O
in	IN	O
postmenopausal	JJ	O
bone	NN	O
loss	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
different	JJ	O
clodronate	NN	PM
regimens	NNS	O
in	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
groups	NNS	O
of	IN	O
20	CD	O
,	,	O
60	CD	O
women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatments	NNS	O
:	:	O
oral	JJ	PM
calcium	NN	PM
,	,	PM
1000	CD	PM
mg/day	NN	PM
;	:	PM
oral	JJ	PM
calcium	NN	PM
plus	CC	PM
oral	JJ	PM
clodronate	NN	PM
,	,	PM
400	CD	PM
mg/day	NN	PM
;	:	PM
oral	JJ	PM
calcium	NN	PM
plus	CC	PM
oral	JJ	PM
clodronate	NN	PM
,	,	PM
400	CD	PM
mg/day	NN	PM
for	IN	PM
30	CD	PM
days	NNS	PM
,	,	PM
followed	VBN	PM
by	IN	PM
a	DT	PM
60-day	JJ	PM
period	NN	PM
of	IN	PM
calcium	JJ	PM
supplement	NN	PM
alone	RB	PM
.	.	PM

This	DT	O
last	JJ	O
regimen	NN	O
was	VBD	O
repeated	VBN	O
four	CD	O
times	NNS	O
in	IN	O
the	DT	O
12-month	JJ	O
study	NN	O
period	NN	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
who	WP	O
received	VBD	O
calcium	NN	PM
alone	RB	PM
showed	VBD	O
a	DT	O
decline	NN	O
in	IN	O
spinal	JJ	O
bone	NN	O
mass	NN	O
,	,	O
both	DT	O
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.03	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
.005	NNP	O
,	,	O
respectively	RB	O
)	)	O
;	:	O
femoral	JJ	O
density	NN	O
in	IN	O
this	DT	O
group	NN	O
also	RB	O
decreased	VBD	O
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.002	NNP	O
and	CC	O
P	NNP	O
<	NNP	O
.05	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
both	DT	O
clodronate-treated	JJ	PM
groups	NNS	O
had	VBD	O
increased	VBN	O
levels	NNS	O
of	IN	O
lumbar	NN	O
bone	NN	O
mass	NN	O
compared	VBN	O
with	IN	O
controls	NNS	O
,	,	O
both	DT	O
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
of	IN	O
therapy	NN	O
.	.	O

However	RB	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
patients	NNS	O
treated	VBD	O
with	IN	O
cyclical	JJ	PM
clodronate	NN	PM
had	VBD	O
higher	JJR	O
spinal	JJ	O
bone	NN	O
mass	NN	O
compared	VBN	O
with	IN	O
those	DT	O
treated	VBN	O
continuously	RB	O
(	(	O
3.32	CD	O
+/-	JJ	O
0.71	CD	O
versus	NN	O
0.43	CD	O
+/-	JJ	O
0.89	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
femoral	JJ	O
bone	NN	O
density	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
both	DT	O
in	IN	O
subjects	NNS	O
treated	VBN	O
with	IN	O
clodronate	NN	O
,	,	O
both	DT	O
cyclically	RB	O
and	CC	O
continuously	RB	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Continuous	JJ	PM
clodronate	NN	PM
treatment	NN	PM
resulted	VBD	O
in	IN	O
a	DT	O
clear	JJ	O
fall	NN	O
in	IN	O
biochemical	JJ	O
indices	NNS	O
of	IN	O
bone	NN	O
resorption	NN	O
,	,	O
together	RB	O
with	IN	O
a	DT	O
consequent	JJ	O
decrease	NN	O
in	IN	O
osteocalcin	NN	O
at	IN	O
6	CD	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
and	CC	O
12	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.003	NNP	O
)	)	O
and	CC	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
parathyroid	JJ	O
hormone	NN	O
after	IN	O
12	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
of	IN	O
therapy	NN	O
.	.	O

CONCLUSION	NNP	O
One-year	JJ	O
treatment	NN	O
with	IN	O
clodronate	NN	PM
induces	NNS	O
a	DT	O
gain	NN	O
in	IN	O
bone	NN	O
mass	NN	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
spine	NN	O
.	.	O

The	DT	O
continuous	JJ	O
regimen	NN	O
does	VBZ	O
not	RB	O
result	VB	O
in	IN	O
any	DT	O
further	JJ	O
benefit	NN	O
in	IN	O
lumbar	NN	O
bone	NN	O
density	NN	O
over	IN	O
the	DT	O
cyclical	JJ	O
one	CD	O
,	,	O
probably	RB	O
because	IN	O
of	IN	O
a	DT	O
greater	JJR	O
suppression	NN	O
of	IN	O
bone	NN	O
turnover	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
once	RB	O
and	CC	O
twice	RB	O
daily	JJ	O
atenolol	NN	PM
for	IN	O
angina	JJ	O
pectoris	NN	O
.	.	O

We	PRP	O
have	VBP	O
studied	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
four	CD	O
doses	NNS	O
of	IN	O
atenolol	NN	PM
in	IN	O
11	CD	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NNS	O
pectoris	VBP	O
using	VBG	O
a	DT	O
symptom-limited	JJ	O
exercise	NN	O
test	NN	O
and	CC	O
angina	NN	O
diaries	NNS	O
.	.	O

The	DT	O
doses	NNS	O
100	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
and	CC	O
50	CD	O
mg	NN	O
,	,	O
100	CD	O
mg	NN	O
and	CC	O
200	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
were	VBD	O
given	VBN	O
double-blind	NNS	O
and	CC	O
randomised	VBD	O
within	IN	O
patients	NNS	O
following	VBG	O
run-in	NN	O
on	IN	O
placebo	NN	C
.	.	O

Measurements	NNS	O
were	VBD	O
made	VBN	O
12	CD	O
hours	NNS	O
after	IN	O
the	DT	O
last	JJ	O
twice	JJ	O
daily	RB	O
dose	JJ	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
last	JJ	O
once	JJ	O
daily	JJ	O
dose	NN	O
.	.	O

Exercise	NN	O
tolerance	NN	O
was	VBD	O
improved	VBN	O
by	IN	O
40-74	JJ	O
%	NN	O
and	CC	O
exercise	NN	O
duration	NN	O
before	IN	O
the	DT	O
onset	NN	O
of	IN	O
angina	NN	O
by	IN	O
61-94	JJ	O
%	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Maximal	JJ	O
heart	NN	O
rate	NN	O
was	VBD	O
reduced	VBN	O
further	RB	O
by	IN	O
a	DT	O
total	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
than	IN	O
by	IN	O
lower	JJR	O
doses	NNS	O
,	,	O
but	CC	O
no	DT	O
extra	JJ	O
benefit	NN	O
was	VBD	O
derived	VBN	O
by	IN	O
giving	VBG	O
the	DT	O
drug	NN	O
twice	RB	O
daily	RB	O
.	.	O

The	DT	O
largest	JJS	O
increase	NN	O
in	IN	O
exercise	NN	O
tolerance	NN	O
was	VBD	O
obtained	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
50	CD	O
mg	NNS	O
once	RB	O
daily	RB	O
.	.	O

Atenolol	NNP	PM
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
anti-anginal	JJ	O
agent	NN	O
when	WRB	O
given	VBN	O
once	RB	O
daily	JJ	O
,	,	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
major	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
doses	NNS	O
studied	VBN	O
.	.	O

Lipoprotein	NNP	O
(	(	O
a	DT	O
)	)	O
serum	NN	O
levels	NNS	O
in	IN	O
post-menopausal	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
oral	JJ	PM
estrogens	NNS	PM
administered	VBN	O
at	IN	O
different	JJ	O
times	NNS	O
.	.	O

The	DT	O
different	JJ	O
effects	NNS	O
on	IN	O
serum	NN	O
lipoprotein	NN	O
(	(	O
a	DT	O
)	)	O
[	NN	O
Lp	NNP	O
(	(	O
a	DT	O
)	)	O
]	NN	O
levels	NNS	O
by	IN	O
administering	VBG	O
estrogens	NNS	PM
at	IN	O
different	JJ	O
times	NNS	O
of	IN	O
the	DT	O
day	NN	O
(	(	O
8	CD	O
a.m.	RB	O
and	CC	O
8	CD	O
p.m.	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
in	IN	O
twenty-four	JJ	O
post-menopausal	JJ	O
women	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
by	IN	O
random	JJ	O
sampling	VBG	O
numbers	NNS	O
.	.	O

Patients	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
received	VBD	O
0.625	CD	O
mg	NNS	O
conjugated	VBN	PM
equine	JJ	PM
estrogens	NNS	PM
daily	JJ	O
per	IN	O
os	NN	O
for	IN	O
21	CD	O
days	NNS	O
.	.	O

Group	NNP	O
A	NNP	O
patients	NNS	O
(	(	O
n	JJ	O
:	:	O
9	CD	O
)	)	O
received	VBD	O
the	DT	O
pill	NN	O
at	IN	O
8	CD	O
a.m.	NN	O
,	,	O
and	CC	O
group	NN	O
B	NNP	O
patients	NNS	O
(	(	O
n	JJ	O
:	:	O
12	CD	O
)	)	O
received	VBD	O
the	DT	O
pill	NN	O
at	IN	O
8	CD	O
p.m	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
as	IN	O
regards	NNS	O
the	DT	O
anthropometric	JJ	O
characteristics	NNS	O
,	,	O
the	DT	O
basal	NN	O
values	NNS	O
of	IN	O
the	DT	O
Lp	NNP	O
(	(	O
a	DT	O
)	)	O
,	,	O
the	DT	O
sex	NN	O
steroid	NN	O
and	CC	O
pituitary	JJ	O
hormone	NN	O
levels	NNS	O
.	.	O

Administration	NN	O
of	IN	O
conjugated	JJ	PM
equine	NN	PM
estrogens	NNS	PM
resulted	VBD	O
in	IN	O
decreased	JJ	O
levels	NNS	O
of	IN	O
Lp	NNP	O
(	(	O
a	DT	O
)	)	O
only	RB	O
in	IN	O
group	NN	O
B	NNP	O
after	IN	O
treatment	NN	O
.	.	O

The	DT	O
different	JJ	O
Lp	NNP	O
(	(	O
a	DT	O
)	)	O
behaviour	NN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
and	CC	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
same	JJ	O
serum	JJ	O
hormonal	NN	O
levels	NNS	O
,	,	O
seems	VBZ	O
to	TO	O
be	VB	O
dependent	JJ	O
on	IN	O
the	DT	O
existence	NN	O
of	IN	O
a	DT	O
circadian	JJ	O
rhythm	NN	O
of	IN	O
the	DT	O
hepatic	JJ	O
responsiveness	NN	O
to	TO	O
estrogens	VB	O
,	,	O
whose	WP$	O
expression	NN	O
is	VBZ	O
higher	JJR	O
during	IN	O
evening	NN	O
hours	NNS	O
.	.	O

Speech	NN	E
following	VBG	E
sign	JJ	E
language	NN	E
training	NN	E
in	IN	O
autistic	JJ	O
children	NNS	O
with	IN	O
minimal	JJ	O
verbal	JJ	O
language	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
test	VB	O
the	DT	O
main	JJ	O
and	CC	O
interaction	JJ	O
effects	NNS	O
of	IN	O
training	VBG	O
condition	NN	O
and	CC	O
pretreatment-elicited	JJ	O
verbal	JJ	O
imitation	NN	O
ability	NN	O
when	WRB	O
predicting	VBG	O
spoken	JJ	O
language	NN	O
use	NN	O
during	IN	O
language	NN	E
training	NN	E
of	IN	O
60	CD	O
minimally	RB	O
verbal	JJ	O
autistic	JJ	O
children	NNS	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
Speech	NNP	E
Alone	NNP	E
,	,	E
Sign	NNP	E
Alone	NNP	E
,	,	E
Simultaneous	NNP	E
Presentation	NNP	E
of	IN	E
Sign	NNP	E
and	CC	E
Speech	NNP	E
,	,	E
and	CC	E
Alternating	NNP	E
Presentation	NNP	E
of	IN	E
Sign	NNP	E
and	CC	E
Speech	NNP	E
training	NN	E
conditions	NNS	E
.	.	E

Speech	NNP	E
Alone	RB	E
,	,	E
Simultaneous	JJ	E
Presentation	NNP	E
,	,	O
and	CC	O
Alternating	NNP	E
Presentation	NNP	E
condition	NN	O
facilitated	VBD	O
more	RBR	O
child-initiated	JJ	O
speech	NN	O
during	IN	O
treatment	NN	O
than	IN	O
did	VBD	O
the	DT	O
Sign	NNP	E
Alone	NNP	E
condition	NN	O
.	.	O

Regardless	NNP	O
of	IN	O
training	VBG	O
condition	NN	O
,	,	O
pretreatment	NN	O
verbal	JJ	O
imitation	NN	O
ability	NN	O
positively	RB	O
predicted	VBD	O
the	DT	O
size	NN	O
of	IN	O
child-initiated	JJ	O
spoken	JJ	O
vocabulary	JJ	O
observed	VBD	O
during	IN	O
training	NN	O
.	.	O

Exploratory	JJ	O
analyses	NNS	O
indicated	VBD	O
that	IN	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
verbal	JJ	O
imitation	NN	O
,	,	O
pretreatment	JJ	O
age	NN	O
and	CC	O
IQ	NNP	O
may	MD	O
also	RB	O
predict	VB	O
spoken	JJ	O
language	NN	O
developed	VBD	O
during	IN	O
training	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	C
cross-over	JJ	O
trial	NN	O
of	IN	O
the	DT	O
impact	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
continuing	VBG	O
dexamethasone	JJ	PM
beyond	IN	O
24	CD	O
h	NN	O
following	VBG	O
adjuvant	JJ	O
chemotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Uncertainty	NN	O
remains	VBZ	O
about	IN	O
the	DT	O
optimal	JJ	O
anti-emetic	JJ	O
regimen	NNS	O
for	IN	O
control	NN	O
of	IN	O
delayed	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
after	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Many	JJ	O
patients	NNS	O
receive	VBP	O
dexamethasone	NN	O
but	CC	O
complain	NN	O
of	IN	O
insomnia	NN	O
,	,	O
anxiety/agitation	NN	O
,	,	O
and	CC	O
indigestion	NN	O
.	.	O

The	DT	O
aim	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
patients	NNS	O
receiving	VBG	O
chemotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
prefer	VBP	O
treatment	NN	O
with	IN	O
dexamethasone	NN	O
or	CC	O
placebo	NN	O
for	IN	O
prophylaxis	NN	O
against	IN	O
delayed	VBN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
and	CC	O
to	TO	O
compare	VB	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
between	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
.	.	O

In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
trial	NN	O
,	,	O
we	PRP	O
compared	VBN	O
oral	JJ	O
dexamethasone	NN	O
(	(	O
4	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
days	NNS	O
)	)	O
versus	VBP	O
placebo	NN	O
for	IN	O
chemotherapy-na?ve	JJ	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
intravenous	JJ	O
granisetron	NN	O
and	CC	O
dexamethasone	NN	O
pre-chemotherapy	NN	O
and	CC	O
oral	JJ	O
granisetron	NN	O
on	IN	O
day	NN	O
2	CD	O
.	.	O

Primary	JJ	O
endpoints	NNS	O
were	VBD	O
:	:	O
(	(	O
i	NN	O
)	)	O
patient	NN	O
preference	NN	O
;	:	O
(	(	O
ii	NN	O
)	)	O
difference	NN	O
between	IN	O
cycles	NNS	O
in	IN	O
change	NN	O
of	IN	O
QOL	NNP	O
from	IN	O
days	NNS	O
1	CD	O
to	TO	O
8	CD	O
.	.	O

Median	JJ	O
age	NN	O
of	IN	O
the	DT	O
94	CD	O
women	NNS	O
was	VBD	O
51	CD	O
years	NNS	O
(	(	O
range	VB	O
27-76	JJ	O
)	)	O
:	:	O
79	CD	O
received	VBD	O
fluorouracil/epirubicin/cyclophosphamide	NN	O
and	CC	O
15	CD	O
received	VBD	O
doxorubicin/cyclophosphamide	NN	O
.	.	O

Thirteen	JJ	O
withdrew	VBD	O
pre-cycle	JJ	O
2	CD	O
with	IN	O
no	DT	O
differences	NNS	O
between	IN	O
arms	NNS	O
.	.	O

Of	IN	O
80	CD	O
patients	NNS	O
stating	VBG	O
a	DT	O
preference	NN	O
,	,	O
31	CD	O
preferred	JJ	O
placebo	NN	O
(	(	O
39	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
28-50	CD	O
%	NN	O
)	)	O
and	CC	O
37	CD	O
(	(	O
46	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
35-58	CD	O
%	NN	O
)	)	O
preferred	VBD	O
dexamethasone	NN	O
;	:	O
12	CD	O
had	VBD	O
no	DT	O
preference	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
intensity	NN	O
of	IN	O
vomiting	VBG	O
,	,	O
nausea	NN	O
,	,	O
or	CC	O
time	NN	O
to	TO	O
onset	VB	O
of	IN	O
vomiting	VBG	O
.	.	O

There	EX	O
was	VBD	O
greater	JJR	O
decrease	NN	O
in	IN	O
global	JJ	O
QOL	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.06	CD	O
)	)	O
when	WRB	O
patients	NNS	O
received	VBD	O
dexamethasone	NN	O
.	.	O

No	DT	O
other	JJ	O
symptom/QOL	NN	O
domains	NNS	O
differed	VBD	O
significantly	RB	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
patient	JJ	O
preference	NN	O
,	,	O
QOL	NNP	O
,	,	O
or	CC	O
symptoms	NNS	O
regardless	RB	O
of	IN	O
whether	IN	O
dexamethasone	NN	O
or	CC	O
placebo	NN	O
was	VBD	O
used	VBN	O
after	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

Effect	NN	O
of	IN	O
extradural	JJ	PM
analgesia	NN	PM
on	IN	O
stress	NN	O
responses	NNS	O
to	TO	O
abdominal	JJ	O
surgery	NN	O
in	IN	O
infants	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
40	CD	O
children	NNS	O
younger	JJR	O
than	IN	O
4	CD	O
yr	NNS	O
having	VBG	O
elective	JJ	O
abdominal	JJ	O
surgery	NN	O
under	IN	O
general	JJ	PM
anaesthesia	NN	PM
supplemented	VBN	O
with	IN	O
either	DT	O
systemic	JJ	PM
opioids	NNS	PM
or	CC	PM
extradural	JJ	PM
bupivacaine	NN	PM
.	.	PM

Venous	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
before	IN	O
tracheal	JJ	O
intubation	NN	O
to	TO	O
measure	VB	O
baseline	JJ	O
concentrations	NNS	O
of	IN	O
adrenaline	NN	O
,	,	O
noradrenaline	NN	O
,	,	O
glucose	NN	O
,	,	O
ACTH	NNP	O
and	CC	O
cortisol	NN	O
.	.	O

Additional	JJ	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
45	CD	O
min	NNS	O
after	IN	O
the	DT	O
start	NN	O
of	IN	O
surgery	NN	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
,	,	O
1	CD	O
h	NN	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
bupivacaine	NN	PM
were	VBD	O
measured	VBN	O
also	RB	O
in	IN	O
the	DT	O
extradural	JJ	O
group	NN	O
at	IN	O
each	DT	O
sampling	VBG	O
time	NN	O
.	.	O

Both	DT	O
techniques	NNS	O
provided	VBN	O
acceptable	JJ	O
analgesia	NN	O
,	,	O
but	CC	O
the	DT	O
perioperative	JJ	O
increases	NNS	O
in	IN	O
adrenaline	NN	O
,	,	O
glucose	NN	O
and	CC	O
ACTH	NNP	O
were	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
opioid	JJ	O
group	NN	O
.	.	O

Noradrenaline	NNP	O
concentrations	NNS	O
decreased	VBD	O
to	TO	O
less	JJR	O
than	IN	O
baseline	NN	O
values	NNS	O
in	IN	O
the	DT	O
extradural	JJ	O
group	NN	O
and	CC	O
were	VBD	O
significantly	RB	O
less	JJR	O
than	IN	O
in	IN	O
the	DT	O
opioid	JJ	O
group	NN	O
.	.	O

The	DT	O
perioperative	JJ	O
increase	NN	O
in	IN	O
cortisol	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
despite	IN	O
the	DT	O
differences	NNS	O
in	IN	O
ACTH	NNP	O
responses	NNS	O
.	.	O

Most	JJS	O
responses	NNS	O
returned	VBN	O
to	TO	O
the	DT	O
baseline	NN	O
values	NNS	O
within	IN	O
24	CD	O
h.	NN	O
Plasma	NNP	O
bupivacaine	NN	PM
concentrations	NNS	O
remained	VBD	O
within	IN	O
safe	JJ	O
limits	NNS	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
but	CC	O
systemic	JJ	O
concentrations	NNS	O
increased	VBD	O
in	IN	O
some	DT	O
of	IN	O
the	DT	O
patients	NNS	O
during	IN	O
postoperative	JJ	O
infusion	NN	O
with	IN	O
0.125	CD	O
%	NN	O
bupivacaine	NN	O
.	.	O

Efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
donepezil	NN	PM
in	IN	O
vascular	JJ	O
dementia	NN	O
:	:	O
positive	JJ	O
results	NNS	O
of	IN	O
a	DT	O
24-week	JJ	O
,	,	O
multicenter	NN	O
,	,	O
international	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	C
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Clinical	NNP	O
observations	NNS	O
suggest	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
vascular	JJ	O
dementia	NN	O
(	(	O
VaD	NNP	O
)	)	O
may	MD	O
benefit	VB	O
from	IN	O
treatment	NN	O
with	IN	O
cholinesterase	NN	PM
inhibitors	NNS	PM
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
donepezil	NN	PM
for	IN	O
relieving	VBG	O
symptoms	NNS	O
of	IN	O
dementia	NN	O
in	IN	O
VaD	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
(	(	O
n=603	JJ	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
73.9	CD	O
years	NNS	O
;	:	O
55.2	CD	O
%	NN	O
men	NNS	O
)	)	O
with	IN	O
probable	JJ	O
(	(	O
70.5	CD	O
%	NN	O
)	)	O
or	CC	O
possible	JJ	O
(	(	O
29.5	CD	O
%	NN	O
)	)	O
VaD	NNP	O
,	,	O
according	VBG	O
to	TO	O
criteria	NNS	O
of	IN	O
the	DT	O
National	NNP	O
Institute	NNP	O
of	IN	O
Neurological	NNP	O
Disorders	NNP	O
and	CC	O
Stroke	NNP	O
(	(	O
NINDS	NNP	O
)	)	O
and	CC	O
the	DT	O
Association	NNP	O
Internationale	NNP	O
pour	VBP	O
la	NN	O
Recherche	NNP	O
et	CC	O
l'Enseignement	JJ	O
en	NN	O
Neurosciences	NNP	O
(	(	O
AIREN	NNP	O
)	)	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
donepezil	JJ	PM
5	CD	O
mg/d	NN	O
(	(	O
n=198	JJ	O
)	)	O
,	,	O
donepezil	$	PM
10	CD	O
mg/d	NN	O
(	(	O
5	CD	O
mg/d	NN	O
for	IN	O
first	JJ	O
28	CD	O
days	NNS	O
;	:	O
n=206	CC	O
)	)	O
,	,	O
or	CC	O
placebo	NN	C
(	(	O
n=199	JJ	O
)	)	O
.	.	O

Analyses	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
week	NN	O
24	CD	O
,	,	O
both	DT	O
donepezil	NN	PM
groups	NNS	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
cognition	NN	O
versus	NN	O
placebo	NN	O
on	IN	O
the	DT	O
Alzheimer	NNP	O
's	POS	O
Disease	NNP	O
Assessment	NNP	O
Scale-cognitive	JJ	O
subscale	NN	O
(	(	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
score	NN	O
effect	NN	O
size	NN	O
:	:	O
donepezil	NN	PM
5	CD	O
mg/d	NN	O
,	,	O
-1.90	NNP	O
;	:	O
P=0.001	NNP	O
;	:	O
donepezil	VBZ	PM
10	CD	O
mg/d	NN	O
,	,	O
-2.33	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Significant	JJ	O
improvements	NNS	O
in	IN	O
patients	NNS	O
'	POS	O
global	JJ	O
function	NN	O
were	VBD	O
seen	VBN	O
versus	NN	O
placebo	NN	O
at	IN	O
week	NN	O
24	CD	O
(	(	O
observed	JJ	O
cases	NNS	O
)	)	O
,	,	O
on	IN	O
the	DT	O
Clinician	NNP	O
's	POS	O
Interview-Based	JJ	O
Impression	NN	O
of	IN	O
Change-Plus	NNP	O
version	NN	O
only	RB	O
for	IN	O
patients	NNS	O
on	IN	O
donepezil	JJ	PM
5	CD	O
mg/d	NN	O
(	(	O
P=0.014	NNP	O
)	)	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
Sum	NNP	O
of	IN	O
the	DT	O
Boxes	NNP	O
of	IN	O
the	DT	O
Clinical	NNP	O
Dementia	NNP	O
Rating	NNP	O
only	RB	O
for	IN	O
patients	NNS	O
on	IN	O
10	CD	O
mg/d	NN	O
(	(	O
P=0.007	NNP	O
)	)	O
.	.	O

Donepezil-treated	JJ	O
patients	NNS	O
showed	VBD	O
significant	JJ	O
benefits	NNS	O
in	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
over	IN	O
placebo	NN	O
on	IN	O
the	DT	O
Alzheimer	NNP	O
's	POS	O
Disease	NNP	O
Functional	NNP	O
Assessment	NNP	O
and	CC	O
Change	NNP	O
Scale	NNP	O
(	(	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
score	NN	O
effect	NN	O
size	NN	O
at	IN	O
week	NN	O
24	CD	O
:	:	O
donepezil	NN	O
5	CD	O
mg/d	NN	O
,	,	O
-1.31	NNP	O
,	,	O
P=0.02	NNP	O
;	:	O
donepezil	VBZ	O
10	CD	O
mg/d	NN	O
,	,	O
-1.31	NNP	O
,	,	O
P=0.02	NNP	O
)	)	O
.	.	O

Donepezil	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Withdrawal	NNP	O
rates	NNS	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
were	VBD	O
relatively	RB	O
low	JJ	O
(	(	O
placebo	NN	O
,	,	O
11.1	CD	O
%	NN	O
;	:	O
donepezil	CC	O
5	CD	O
mg/d	NN	O
,	,	O
11.1	CD	O
%	NN	O
;	:	O
donepezil	CC	O
10	CD	O
mg/d	NN	O
,	,	O
21.8	CD	O
%	NN	O
;	:	O
P=0.005	NNP	O
versus	IN	O
placebo	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
donepezil	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
VaD	NNP	O
and	CC	O
show	VB	O
it	PRP	O
may	MD	O
have	VB	O
an	DT	O
important	JJ	O
place	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
this	DT	O
condition	NN	O
.	.	O

Improved	VBN	O
acidosis	NN	O
correction	NN	O
and	CC	O
recovery	NN	O
of	IN	O
mesothelial	JJ	O
cell	NN	O
mass	NN	O
with	IN	O
neutral-pH	JJ	PM
bicarbonate	JJ	PM
dialysis	NN	PM
solution	NN	PM
among	IN	O
children	NNS	O
undergoing	VBG	O
automated	VBN	PH
peritoneal	JJ	PH
dialysis	NN	PH
.	.	O

Acid-base	JJ	O
balance	NN	O
and	CC	O
peritoneal	JJ	O
membrane	NN	O
longevity	NN	O
are	VBP	O
of	IN	O
utmost	JJ	O
relevance	NN	O
for	IN	O
pediatric	JJ	O
patients	NNS	O
undergoing	VBG	O
peritoneal	JJ	PH
dialysis	NN	PH
(	(	PH
PD	NNP	PH
)	)	PH
.	.	O

PD	NNP	O
fluids	NNS	O
with	IN	O
neutral	JJ	O
pH	NN	O
and	CC	O
reduced	VBD	O
glucose	JJ	O
degradation	NN	O
product	NN	O
contents	NNS	O
are	VBP	O
considered	VBN	O
more	RBR	O
biocompatible	JJ	O
,	,	O
because	IN	O
they	PRP	O
preserve	VBP	O
peritoneal	JJ	O
cell	NN	O
functions	NNS	O
in	IN	O
vitro	NN	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
clinical	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
novel	JJ	PM
PD	NNP	PM
fluid	NN	PM
buffered	VBD	PM
with	IN	PM
34	CD	PM
mM	NNS	PM
pure	JJ	PM
bicarbonate	NN	PM
at	IN	PM
neutral	JJ	PM
pH	NN	PM
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
crossover	JJ	O
comparison	NN	O
with	IN	O
conventional	JJ	PM
,	,	PM
acidic	JJ	PM
,	,	PM
35	CD	PM
mM	NN	PM
lactate	NN	PM
PD	NNP	PM
fluid	NN	PM
was	VBD	O
performed	VBN	O
for	IN	O
two	CD	O
consecutive	JJ	O
12-wk	JJ	O
periods	NNS	O
with	IN	O
28	CD	O
children	NNS	O
(	(	O
age	NN	O
,	,	O
6	CD	O
mo	NN	O
to	TO	O
15	CD	O
yr	NN	O
)	)	O
undergoing	NN	O
automated	VBN	PH
PD	NNP	PH
(	(	PH
APD	NNP	PH
)	)	PH
.	.	O

Blood	NNP	O
bicarbonate	NN	O
levels	NNS	O
and	CC	O
arterial	JJ	O
pH	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
after	IN	O
3	CD	O
mo	NN	O
of	IN	O
bicarbonate	NN	PM
PD	NNP	PM
(	(	O
24.6	CD	O
+/-	JJ	O
2.3	CD	O
mM	NN	O
and	CC	O
7.43	CD	O
+/-	JJ	O
0.06	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
lactate	JJ	PM
PD	NNP	PM
(	(	O
22.8	CD	O
+/-	JJ	O
3.9	CD	O
mM	NN	O
and	CC	O
7.38	CD	O
+/-	JJ	O
0.05	CD	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

This	DT	O
effect	NN	O
was	VBD	O
reversible	JJ	O
among	IN	O
patients	NNS	O
who	WP	O
returned	VBD	O
from	IN	O
bicarbonate	NN	O
to	TO	O
lactate	VB	O
fluid	NN	O
.	.	O

Low	JJ	O
initial	JJ	O
pH	NN	O
and	CC	O
young	JJ	O
patient	NN	O
age	NN	O
independently	RB	O
predicted	VBD	O
increased	VBN	O
blood	NN	O
pH	NN	O
during	IN	O
bicarbonate	NN	O
APD	NNP	O
.	.	O

Peritoneal	NNP	O
equilibration	NN	O
tests	NNS	O
revealed	VBD	O
subtle	JJ	O
changes	NNS	O
in	IN	O
solute	NN	O
transport	NN	O
,	,	O
with	IN	O
a	DT	O
less	RBR	O
steep	JJ	O
creatinine	NN	O
equilibration	NN	O
curve	NN	O
during	IN	O
bicarbonate	JJ	O
dialysis	NN	O
,	,	O
suggesting	VBG	O
reduced	VBN	O
peritoneal	JJ	O
vasodilation	NN	O
.	.	O

The	DT	O
peritoneal	JJ	O
release	NN	O
of	IN	O
carcinogen	JJ	O
antigen-125	NNS	O
increased	VBD	O
twofold	NN	O
during	IN	O
bicarbonate	NN	O
APD	NNP	O
(	(	O
29	CD	O
+/-	JJ	O
15	CD	O
versus	NN	O
15	CD	O
+/-	JJ	O
8	CD	O
U/ml	NNP	O
per	IN	O
4	CD	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
consistent	JJ	O
with	IN	O
recovery	NN	O
of	IN	O
the	DT	O
mesothelial	JJ	O
cell	NN	O
layer	NN	O
.	.	O

This	DT	O
effect	NN	O
was	VBD	O
fully	RB	O
reversed	VBN	O
when	WRB	O
the	DT	O
patients	NNS	O
returned	VBD	O
to	TO	O
lactate	VB	O
fluid	NN	O
.	.	O

Effluent	JJ	O
carcinogen	NN	O
antigen-125	JJ	O
levels	NNS	O
were	VBD	O
inversely	RB	O
correlated	VBN	O
with	IN	O
peritoneal	JJ	O
glucose	JJ	O
exposure	NN	O
during	IN	O
lactate	NN	O
but	CC	O
not	RB	O
bicarbonate	VB	O
APD	NNP	O
,	,	O
indicating	VBG	O
improved	VBN	O
in	IN	O
vivo	JJ	O
mesothelial	NN	O
cell	NN	O
tolerance	NN	O
of	IN	O
high-dose	JJ	O
glucose	NN	O
with	IN	O
the	DT	O
neutral-pH	JJ	PM
PD	NNP	PM
fluid	NN	PM
with	IN	PM
reduced	VBN	PM
glucose	JJ	PM
degradation	NN	PM
product	NN	PM
content	NN	PM
.	.	O

Among	IN	O
children	NNS	O
undergoing	VBG	O
APD	NNP	PM
,	,	PM
neutral-pH	JJ	PM
,	,	PM
bicarbonate-buffered	JJ	PM
PD	NNP	PM
fluid	NN	PM
provides	VBZ	O
more	RBR	O
effective	JJ	O
correction	NN	O
of	IN	O
metabolic	JJ	O
acidosis	NN	O
and	CC	O
better	JJR	O
preservation	NN	O
of	IN	O
peritoneal	NN	O
cell	NN	O
mass	NN	O
than	IN	O
do	VBP	O
conventional	JJ	PM
,	,	PM
acidic	JJ	PM
,	,	PM
lactate-based	JJ	PM
fluids	NNS	PM
.	.	O

Lack	NN	O
of	IN	O
interaction	NN	O
between	IN	O
pantoprazole	NN	PM
and	CC	PM
digoxin	NN	PM
at	IN	O
therapeutic	JJ	O
doses	NNS	O
in	IN	O
man	NN	O
.	.	O

Substituted	JJ	PM
benzimidazole	JJ	PM
inhibitors	NNS	PM
of	IN	O
the	DT	O
gastric	JJ	O
H+/K+ATPase	NNP	O
may	MD	O
interact	VB	O
with	IN	O
the	DT	O
cytochrome	NN	O
P450	NNP	O
enzyme	NN	O
system	NN	O
and	CC	O
alter	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
coadministered	JJ	O
drugs	NNS	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
changes	NNS	O
in	IN	O
intragastric	JJ	O
pH	NN	O
might	MD	O
alter	VB	O
the	DT	O
absorption	NN	O
of	IN	O
other	JJ	O
drugs	NNS	O
.	.	O

The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
pantoprazole	JJ	PM
modifies	NNS	O
the	DT	O
steady-state	JJ	O
serum	NN	O
concentrations	NNS	O
of	IN	O
orally	RB	O
administered	VBN	O
digoxin	NN	PM
.	.	O

Secondary	JJ	O
aims	NNS	O
were	VBD	O
the	DT	O
influence	NN	O
of	IN	O
digoxin	NN	PM
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
pantoprazole	NN	PM
as	RB	O
well	RB	O
as	IN	O
safety	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Eighteen	NNP	O
healthy	JJ	O
volunteers	NNS	O
received	VBD	O
a	DT	O
single	JJ	O
oral	JJ	PM
dose	NN	PM
of	IN	PM
pantoprazole	NN	PM
(	(	PM
40	CD	PM
mg	NN	PM
)	)	PM
and	CC	O
serum	JJ	O
concentrations	NNS	O
were	VBD	O
determined	VBN	O
.	.	O

Three	CD	O
to	TO	O
10	CD	O
days	NNS	O
later	RB	O
,	,	O
subjects	NNS	O
received	VBD	O
in	IN	O
a	DT	O
single-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	JJ	O
fashion	NN	O
oral	JJ	O
beta-acetyldigoxin	NN	PM
(	(	O
0.2	CD	O
mg	NN	O
)	)	O
twice	RB	O
daily	RB	O
and	CC	O
concomitant	JJ	PM
oral	JJ	PM
pantoprazole	NN	PM
(	(	O
40	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	JJ	C
once	RB	O
daily	JJ	O
for	IN	O
5	CD	O
days	NNS	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
pantoprazole	NN	PM
and	CC	O
digoxin	NN	PM
were	VBD	O
determined	VBN	O
on	IN	O
day	NN	O
5	CD	O
.	.	O

Primary	JJ	O
characteristics	NNS	O
for	IN	O
confirmative	JJ	O
assessment	NN	O
of	IN	O
no	DT	O
interaction	NN	O
were	VBD	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
of	IN	O
digoxin	NN	PM
.	.	O

Lack	NNP	O
of	IN	O
interaction	NN	O
in	IN	O
the	DT	O
sense	NN	O
of	IN	O
equivalence	NN	O
was	VBD	O
concluded	VBN	O
for	IN	O
both	DT	O
digoxin	NN	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
pantoprazole	NN	PM
)	)	O
and	CC	O
pantoprazole	JJ	PM
(	(	O
with	IN	O
and	CC	O
without	IN	O
digoxin	NN	PM
)	)	O
as	IN	O
the	DT	O
90	CD	O
%	NN	O
-confidence	NN	O
intervals	NNS	O
of	IN	O
the	DT	O
respective	JJ	O
AUC-	NNP	O
and	CC	O
Cmax-ratios	NNP	O
were	VBD	O
within	IN	O
the	DT	O
equivalence	NN	O
range	NN	O
of	IN	O
0.8-1.25	NNP	O
.	.	O

Pantoprazole	NNP	PM
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
characteristic	JJ	O
ECG	NNP	O
modifications	NNS	O
(	(	O
T-wave	NNP	O
)	)	O
caused	VBN	O
by	IN	O
digoxin	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
no	DT	O
adverse	JJ	O
events	NNS	O
or	CC	O
clinically	RB	O
relevant	JJ	O
alterations	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
or	CC	O
clinical	JJ	O
laboratory	NN	O
parameters	NNS	O
were	VBD	O
observed	VBN	O
during	IN	O
treatment	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
pantoprazole	NN	PM
and	CC	O
digoxin	NN	PM
may	MD	O
be	VB	O
administered	VBN	O
concomitantly	RB	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
dose	JJ	O
adjustment	NN	O
.	.	O

A	DT	O
multi-component	JJ	E
social	JJ	E
skills	NNS	E
intervention	NN	E
for	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
:	:	O
the	DT	O
Junior	NNP	E
Detective	NNP	E
Training	NNP	E
Program	NNP	E
.	.	O

BACKGROUND	NNP	O
The	DT	O
study	NN	O
aimed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
new	JJ	O
multi-component	JJ	E
social	JJ	E
skills	NNS	E
intervention	NN	E
for	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	O
syndrome	NN	O
(	(	O
AS	IN	O
)	)	O
:	:	O
The	DT	E
Junior	NNP	E
Detective	NNP	E
Training	NNP	E
Program	NNP	E
.	.	E

This	DT	O
7-week	JJ	O
program	NN	O
included	VBD	O
a	DT	O
computer	NN	O
game	NN	O
,	,	O
small	JJ	O
group	NN	O
sessions	NNS	O
,	,	O
parent	NN	O
training	NN	O
sessions	NNS	O
and	CC	O
teacher	NN	O
handouts	NNS	O
.	.	O

METHOD	NNP	O
Forty-nine	JJ	O
children	NNS	O
with	IN	O
AS	NNP	O
were	VBD	O
recruited	VBN	O
to	TO	O
participate	VB	O
and	CC	O
randomly	VB	O
assigned	VBN	O
to	TO	O
intervention	NN	E
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
or	CC	O
wait-list	JJ	C
control	NN	C
(	(	O
n	JJ	O
=	NNP	O
23	CD	O
)	)	O
conditions	NNS	O
.	.	O

RESULTS	NNP	O
Relative	NNP	O
to	TO	O
children	NNS	O
in	IN	O
the	DT	O
wait-list	JJ	O
group	NN	O
,	,	O
program	NN	O
participants	NNS	O
showed	VBD	O
greater	JJR	O
improvements	NNS	O
in	IN	O
social	JJ	O
skills	NNS	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
intervention	NN	O
,	,	O
as	IN	O
indicated	VBN	O
by	IN	O
parent-report	JJ	O
measures	NNS	O
.	.	O

Teacher-report	NNP	O
data	NNS	O
also	RB	O
confirmed	VBD	O
that	IN	O
children	NNS	O
receiving	VBG	O
the	DT	O
intervention	NN	O
made	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
social	JJ	O
functioning	NN	O
from	IN	O
pre-	JJ	O
to	TO	O
post-treatment	JJ	O
.	.	O

Treatment	NNP	O
group	NN	O
participants	NNS	O
were	VBD	O
better	RBR	O
able	JJ	O
to	TO	O
suggest	VB	O
appropriate	JJ	O
emotion-management	JJ	O
strategies	NNS	O
for	IN	O
story	NN	O
characters	NNS	O
at	IN	O
post-intervention	NN	O
than	IN	O
at	IN	O
pre-intervention	NN	O
,	,	O
whereas	NNS	O
control	VBP	O
participants	NNS	O
were	VBD	O
not	RB	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
improvements	NNS	O
made	VBN	O
by	IN	O
children	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
conditions	NNS	O
on	IN	O
facial	JJ	O
expression	NN	O
and	CC	O
body-posture	NN	O
recognition	NN	O
measures	NNS	O
.	.	O

Follow-up	NNP	O
data	NN	O
suggested	VBD	O
that	IN	O
treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
by	IN	O
children	NNS	O
at	IN	O
5-months	JJ	O
post-intervention	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	E
Junior	NNP	E
Detective	NNP	E
Training	NNP	E
Program	NNP	E
appeared	VBD	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
enhancing	VBG	O
the	DT	O
social	JJ	O
skills	NNS	O
and	CC	O
emotional	JJ	O
understanding	NN	O
of	IN	O
children	NNS	O
with	IN	O
AS	NNP	O
.	.	O

Limitations	NNS	O
and	CC	O
suggestions	NNS	O
for	IN	O
future	JJ	O
research	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Enhanced	NNP	O
inotropic	NN	O
state	NN	O
of	IN	O
the	DT	O
failing	NN	O
left	VBD	O
ventricle	NN	O
by	IN	O
cardiac	JJ	PH
contractility	NN	PH
modulation	NN	PH
electrical	JJ	PH
signals	NNS	PH
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
increased	JJ	O
myocardial	JJ	O
oxygen	NN	O
consumption	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	NNP	O
studies	NNS	O
in	IN	O
patients	NNS	O
and	CC	O
in	IN	O
dogs	NNS	O
with	IN	O
experimentally	RB	O
induced	JJ	O
heart	NN	O
failure	NN	O
(	(	O
HF	NNP	O
)	)	O
showed	VBD	O
that	IN	O
electrical	JJ	PH
signals	NNS	PH
applied	VBN	O
to	TO	O
the	DT	O
failing	VBG	O
myocardium	NN	O
during	IN	O
the	DT	O
absolute	JJ	O
refractory	NN	O
period	NN	O
improved	VBD	O
left	JJ	O
ventricular	NN	O
(	(	O
LV	NNP	O
)	)	O
function	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
these	DT	O
same	JJ	O
cardiac	NN	PH
contractility	NN	PH
modulating	NN	PH
(	(	PH
CCM	NNP	PH
)	)	PH
electrical	JJ	PH
signals	NNS	PH
on	IN	O
myocardial	JJ	O
oxygen	NN	O
consumption	NN	O
(	(	O
MVO	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
in	IN	O
both	DT	O
patients	NNS	O
and	CC	O
dogs	NNS	O
with	IN	O
chronic	JJ	O
HF	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Six	NNP	O
dogs	NNS	O
with	IN	O
microembolizations-induced	JJ	PH
HF	NNP	PH
and	CC	O
9	CD	O
HF	NNP	O
patients	NNS	O
underwent	JJ	O
CCM	NNP	PH
leads	NNS	PH
and	CC	PH
generator	NN	PH
(	(	PH
OPTIMIZER	NNP	PH
II	NNP	PH
)	)	PH
implantation	NN	PH
.	.	O

After	IN	O
baseline	NN	O
measurements	NNS	O
,	,	O
CCM	NNP	PH
signals	NNS	PH
were	VBD	O
delivered	VBN	O
continuously	RB	O
for	IN	O
2	CD	O
hours	NNS	O
in	IN	O
dogs	NNS	O
and	CC	O
for	IN	O
30	CD	O
minutes	NNS	O
in	IN	O
patients	NNS	O
.	.	O

MVO	NNP	O
(	(	O
2	CD	O
)	)	O
was	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
after	IN	O
CCM	NNP	PH
therapy	NN	PH
.	.	O

In	IN	O
dogs	NNS	O
,	,	O
CCM	NNP	PH
therapy	NN	PH
increased	VBD	O
LV	NNP	O
ejection	NN	O
fraction	NN	O
at	IN	O
2	CD	O
hours	NNS	O
(	(	O
26	CD	O
+/-	JJ	O
1	CD	O
versus	NN	O
31	CD	O
+/-	JJ	O
2	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
without	IN	O
increasing	VBG	O
MVO	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
257	CD	O
+/-	JJ	O
41	CD	O
versus	NN	O
180	CD	O
+/-	JJ	O
34	CD	O
micromol/min	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
,	,	O
CCM	NNP	PH
therapy	NN	PH
increased	VBD	O
LV	NNP	O
peak	NN	O
+dP/dt	NN	O
by	IN	O
10.1	CD	O
+/-	JJ	O
1.5	CD	O
%	NN	O
.	.	O

As	IN	O
with	IN	O
dogs	NNS	O
,	,	O
the	DT	O
increase	NN	O
in	IN	O
LV	NNP	O
function	NN	O
after	IN	O
30	CD	O
minutes	NNS	O
of	IN	O
CCM	NNP	PH
therapy	NN	PH
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
increased	VBN	O
MVO	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
13.6	CD	O
+/-	JJ	O
9.7	CD	O
versus	NN	O
12.5	CD	O
+/-	JJ	O
7.2	CD	O
mL	NN	O
O	NNP	O
(	(	O
2	CD	O
)	)	O
/min	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
study	NN	O
results	NNS	O
suggest	VBP	O
that	IN	O
unlike	IN	O
cAMP-dependent	JJ	O
positive	JJ	O
inotropic	NN	O
drugs	NNS	O
,	,	O
the	DT	O
increase	NN	O
in	IN	O
LV	NNP	O
function	NN	O
during	IN	O
CCM	NNP	PH
therapy	NN	PH
is	VBZ	O
elicited	VBN	O
without	IN	O
increasing	VBG	O
MVO	NNP	O
(	(	O
2	CD	O
)	)	O
.	.	O

Kata	NNP	PH
techniques	NNS	PH
training	VBG	PH
consistently	RB	O
decreases	VBZ	O
stereotypy	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
14	CD	O
weeks	NNS	O
of	IN	O
Kata	NNP	PH
techniques	NNS	PH
training	VBG	PH
on	IN	O
stereotypic	JJ	O
behaviors	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
were	VBD	O
investigated	VBN	O
.	.	O

The	DT	O
study	NN	O
included	VBD	O
30	CD	O
eligible	JJ	O
(	(	O
diagnosed	JJ	O
ASD	NNP	O
,	,	O
school	NN	O
age	NN	O
)	)	O
children	NNS	O
with	IN	O
ages	NNS	O
ranging	VBG	O
from	IN	O
5	CD	O
to	TO	O
16	CD	O
years	NNS	O
whom	WP	O
they	PRP	O
assigned	VBD	O
to	TO	O
an	DT	O
exercise	NN	O
(	(	O
n=15	JJ	O
)	)	O
or	CC	O
a	DT	O
no-exercise	JJ	C
control	NN	C
group	NN	C
(	(	O
n=15	RB	O
)	)	O
.	.	O

Participants	NNS	O
of	IN	O
the	DT	O
exercise	NN	O
group	NN	O
received	VBD	O
Kata	NNP	PH
techniques	NNS	PH
instruction	VBP	PH
four	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
14	CD	O
weeks	NNS	O
(	(	O
56	CD	O
sessions	NNS	O
)	)	O
.	.	O

Stereotypy	NNP	PH
was	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
(	(	O
pre-intervention	NN	O
)	)	O
,	,	O
week	NN	O
14	CD	O
(	(	O
post-intervention	NN	O
)	)	O
,	,	O
and	CC	O
at	IN	O
one	CD	O
month	NN	O
follow	VB	O
up	RP	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
Kata	NNP	O
techniques	NNS	O
training	VBG	O
significantly	RB	O
reduced	VBN	O
stereotypy	NN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
.	.	O

Following	VBG	O
participation	NN	O
in	IN	O
Kata	NNP	O
techniques	NNS	O
training	NN	O
,	,	O
stereotypy	NN	O
decreased	VBN	O
from	IN	O
baseline	NN	O
levels	NNS	O
by	IN	O
a	DT	O
M	NNP	O
of	IN	O
42.54	CD	O
%	NN	O
across	IN	O
participants	NNS	O
.	.	O

Interestingly	NNP	O
,	,	O
after	IN	O
30	CD	O
days	NNS	O
of	IN	O
no	DT	O
practice	NN	O
,	,	O
stereotypy	NN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
remained	VBD	O
significantly	RB	O
decreased	VBN	O
compared	VBN	O
to	TO	O
pre-intervention	NN	O
time	NN	O
.	.	O

The	DT	O
participants	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
did	VBD	O
not	RB	O
show	VB	O
significant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
stereotypy	NN	O
.	.	O

Teaching	VBG	O
martial	JJ	O
arts	NNS	O
techniques	NNS	O
to	TO	O
children	NNS	O
with	IN	O
ASD	NNP	O
for	IN	O
a	DT	O
long	JJ	O
period	NN	O
of	IN	O
time	NN	O
consistently	RB	O
decreased	VBN	O
their	PRP$	O
stereotypic	NN	O
behaviors	NNS	O
.	.	O

Acid	NNP	O
resistance	NN	O
of	IN	O
enamel	JJ	O
subsurface	NN	O
lesions	NNS	O
remineralized	VBN	O
by	IN	O
a	DT	O
sugar-free	JJ	PM
chewing	NN	PM
gum	NN	PM
containing	VBG	O
casein	JJ	O
phosphopeptide-amorphous	JJ	O
calcium	NN	O
phosphate	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
clinical	JJ	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
acid	JJ	O
resistance	NN	O
of	IN	O
enamel	JJ	O
lesions	NNS	O
remineralized	VBN	O
in	IN	O
situ	NN	O
by	IN	O
a	DT	O
sugar-free	JJ	PM
chewing	NN	PM
gum	NN	PM
containing	VBG	O
casein	JJ	O
phosphopeptide-amorphous	JJ	O
calcium	NN	O
phosphate	NN	O
nanocomplexes	NNS	O
(	(	O
CPP-ACP	JJ	O
:	:	O
Recaldent	NN	O
)	)	O
.	.	O

The	DT	O
study	NN	O
utilized	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	VB	O
design	NN	O
with	IN	O
two	CD	O
treatments	NNS	O
:	:	O
(	(	O
i	NN	O
)	)	O
sugar-free	JJ	PM
gum	NN	PM
containing	VBG	O
18.8	CD	O
mg	NN	O
of	IN	O
CPP-ACP	NNP	PM
,	,	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
sugar-free	JJ	C
gum	NN	C
not	RB	C
containing	VBG	C
CPP-ACP	NNP	C
as	IN	O
control	NN	O
.	.	O

Subjects	NNS	O
wore	RBR	O
removable	JJ	O
palatal	JJ	O
appliances	NNS	O
with	IN	O
insets	NNS	O
of	IN	O
human	JJ	O
enamel	NN	O
containing	VBG	O
demineralized	JJ	O
subsurface	NN	O
lesions	NNS	O
and	CC	O
chewed	VBD	O
the	DT	O
gum	NN	PM
for	IN	PM
20	CD	O
min	NN	O
4	CD	O
times	NNS	O
per	IN	O
day	NN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

After	IN	O
each	DT	O
treatment	NN	O
the	DT	O
enamel	NN	O
slabs	NN	O
were	VBD	O
removed	VBN	O
and	CC	O
half	NN	O
of	IN	O
each	DT	O
lesion	NN	O
challenged	VBD	O
with	IN	O
acid	NN	O
in	IN	O
vitro	NN	O
for	IN	O
8	CD	O
or	CC	O
16	CD	O
h.	VBP	O
The	DT	O
level	NN	O
of	IN	O
remineralization	NN	O
was	VBD	O
determined	VBN	O
using	VBG	O
microradiography	NN	O
.	.	O

The	DT	O
gum	NN	PM
containing	VBG	PM
CPP-ACP	NNP	PM
produced	VBD	O
approximately	RB	O
twice	JJ	O
the	DT	O
level	NN	O
of	IN	O
remineralization	NN	O
as	IN	O
the	DT	O
control	NN	O
sugar-free	JJ	O
gum	NN	O
.	.	O

The	DT	O
8-	JJ	O
and	CC	O
16-hour	JJ	O
acid	NN	O
challenge	NN	O
of	IN	O
the	DT	O
lesions	NNS	O
remineralized	VBN	O
with	IN	O
the	DT	O
control	NN	C
gum	NN	C
resulted	VBD	O
in	IN	O
65.4	CD	O
and	CC	O
88.0	CD	O
%	NN	O
reductions	NNS	O
,	,	O
respectively	RB	O
,	,	O
of	IN	O
deposited	JJ	O
mineral	NN	O
,	,	O
while	IN	O
for	IN	O
the	DT	O
CPP-ACP-remineralized	JJ	O
lesions	NNS	O
the	DT	O
corresponding	JJ	O
reductions	NNS	O
were	VBD	O
30.5	CD	O
and	CC	O
41.8	CD	O
%	NN	O
.	.	O

The	DT	O
acid	NN	O
challenge	NN	O
after	IN	O
in	IN	O
situ	JJ	O
remineralization	NN	O
for	IN	O
both	DT	O
control	NN	O
and	CC	O
CPP-ACP-treated	JJ	O
lesions	NNS	O
resulted	VBD	O
in	IN	O
demineralization	NN	O
underneath	IN	O
the	DT	O
remineralized	JJ	O
zone	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
remineralized	JJ	O
mineral	NN	O
was	VBD	O
more	RBR	O
resistant	JJ	O
to	TO	O
subsequent	JJ	O
acid	NN	O
challenge	NN	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
sugar-free	JJ	PM
gum	NN	PM
containing	VBG	PM
CPP-ACP	NNP	PM
is	VBZ	O
superior	JJ	O
to	TO	O
an	DT	O
equivalent	JJ	O
gum	NN	C
not	RB	O
containing	VBG	O
CPP-ACP	NNP	O
in	IN	O
remineralization	NN	O
of	IN	O
enamel	JJ	O
subsurface	NN	O
lesions	NNS	O
in	IN	O
situ	NN	O
with	IN	O
mineral	NN	O
that	WDT	O
is	VBZ	O
more	RBR	O
resistant	JJ	O
to	TO	O
subsequent	JJ	O
acid	NN	O
challenge	NN	O
.	.	O

A	DT	O
pharmacy	NN	Ot
discharge	NN	Ot
plan	NN	Ot
for	IN	O
hospitalized	JJ	O
elderly	JJ	O
patients	NNS	O
--	:	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
to	TO	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
pharmacy	NN	Ot
discharge	NN	Ot
plan	NN	O
in	IN	O
elderly	JJ	O
hospitalized	JJ	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SUBJECTS	NNP	O
AND	CC	O
SETTINGS	NNP	O
we	PRP	O
randomized	VBD	O
patients	NNS	O
aged	VBN	O
75	CD	O
years	NNS	O
and	CC	O
older	JJR	O
on	IN	O
four	CD	O
or	CC	O
more	JJR	O
medicines	NNS	O
who	WP	O
had	VBD	O
been	VBN	O
discharged	VBN	O
from	IN	O
three	CD	O
acute	JJ	O
general	JJ	O
and	CC	O
one	CD	O
long-stay	JJ	O
hospital	NN	O
to	TO	O
a	DT	O
pharmacy	NN	O
intervention	NN	O
or	CC	O
usual	JJ	O
care	NN	O
.	.	O

INTERVENTIONS	VBZ	O
the	DT	O
hospital	NN	Ot
pharmacist	NN	Ot
developed	VBD	Ot
discharge	NN	Ot
plans	NNS	Ot
which	WDT	O
gave	VBD	O
details	NNS	O
of	IN	O
medication	NN	O
and	CC	O
support	NN	O
required	VBN	O
by	IN	O
the	DT	O
patient	NN	O
.	.	O

A	DT	O
copy	NN	O
was	VBD	O
given	VBN	O
to	TO	O
the	DT	O
patient	NN	O
and	CC	O
to	TO	O
all	DT	O
relevant	JJ	O
professionals	NNS	O
and	CC	O
carers	NNS	O
.	.	O

This	DT	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
domiciliary	JJ	O
assessment	NN	O
by	IN	O
a	DT	O
community	NN	O
pharmacist	NN	O
.	.	O

In	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
patients	NNS	O
were	VBD	O
discharged	VBN	Ot
from	IN	Ot
hospital	NN	Ot
following	VBG	Ot
standard	JJ	Ot
procedures	NNS	Ot
that	WDT	O
included	VBD	O
a	DT	O
discharge	NN	O
letter	NN	O
to	TO	O
the	DT	O
general	JJ	O
practitioner	NN	O
listing	VBG	O
current	JJ	O
medications	NNS	O
.	.	O

OUTCOMES	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
re-admission	NN	O
to	TO	O
hospital	VB	O
within	IN	O
6	CD	O
months	NNS	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
the	DT	O
number	NN	O
of	IN	O
deaths	NNS	O
,	,	O
attendance	NN	O
at	IN	O
hospital	JJ	O
outpatient	NN	O
clinics	NNS	O
and	CC	O
general	JJ	O
practice	NN	O
and	CC	O
proportion	NN	O
of	IN	O
days	NNS	O
in	IN	O
hospital	NN	O
over	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
,	,	O
together	RB	O
with	IN	O
patients	NNS	O
'	POS	O
general	JJ	O
well-being	NN	O
,	,	O
satisfaction	NN	O
with	IN	O
the	DT	O
service	NN	O
and	CC	O
knowledge	NN	O
of	IN	O
and	CC	O
adherence	NN	O
to	TO	O
prescribed	VB	O
medication	NN	O
.	.	O

RESULTS	NNP	O
we	PRP	O
recruited	VBD	O
362	CD	O
patients	NNS	O
,	,	O
of	IN	O
whom	WP	O
181	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
each	DT	O
group	NN	O
.	.	O

We	PRP	O
collected	VBD	O
hospital	NN	O
and	CC	O
general	JJ	O
practice	NN	O
data	NNS	O
on	IN	O
at	IN	O
least	JJS	O
91	CD	O
and	CC	O
72	CD	O
%	NN	O
of	IN	O
patients	NNS	O
respectively	RB	O
at	IN	O
each	DT	O
follow-up	JJ	O
point	NN	O
and	CC	O
interviewed	VBD	O
between	IN	O
43	CD	O
and	CC	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
subjects	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
re-admitted	JJ	O
to	TO	O
hospital	VB	O
between	IN	O
baseline	NN	O
and	CC	O
3	CD	O
months	NNS	O
or	CC	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
we	PRP	O
found	VBD	O
no	DT	O
evidence	NN	O
to	TO	O
suggest	VB	O
that	IN	O
the	DT	O
co-ordinated	JJ	O
hospital	NN	O
and	CC	O
community	NN	Ot
pharmacy	NN	Ot
care	NN	Ot
discharge	NN	Ot
plans	NNS	Ot
in	IN	O
elderly	JJ	O
patients	NNS	O
in	IN	O
this	DT	O
study	NN	O
influence	NN	O
outcomes	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
polyvinylpyrrolidone-iodine	NN	PM
as	IN	O
an	DT	O
disinfectant	NN	O
in	IN	O
eye	NN	O
surgery	NN	O
.	.	O

105	CD	O
patients	NNS	O
admitted	VBN	O
for	IN	O
cataract	NN	O
surgery	NN	O
were	VBD	O
treated	VBN	O
pre-operatively	RB	O
with	IN	O
polyvinylpyrrolidone-iodine	JJ	PM
(	(	PM
PVP-I	NNP	PM
)	)	PM
as	IN	O
a	DT	O
disinfectant	NN	O
,	,	O
and	CC	O
consecutive	JJ	O
bacterial	JJ	O
cultures	NNS	O
were	VBD	O
obtained	VBN	O
before	IN	O
initiating	VBG	O
surgery	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
operation	NN	O
.	.	O

A	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
99	CD	O
)	)	O
only	RB	O
had	VBD	O
a	DT	O
standard	JJ	E
disinfection	NN	E
procedure	NN	E
of	IN	O
the	DT	O
eye	NN	O
(	(	O
including	VBG	O
instillation	NN	O
of	IN	O
Terramycin	NNP	PM
cum	NN	PM
polymyxin	NN	PM
B	NNP	PM
cream	NN	PM
in	IN	O
the	DT	O
conjunctival	NN	O
sac	VBD	O
the	DT	O
evening	NN	O
before	IN	O
surgery	NN	O
)	)	O
.	.	O

The	DT	O
cultures	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
principally	RB	O
showed	VBD	O
growth	NN	O
of	IN	O
Staph	NNP	O
.	.	O

albus	NN	O
and	CC	O
Staph	NNP	O
.	.	O

aureus	NN	O
,	,	O
and	CC	O
to	TO	O
a	DT	O
minor	JJ	O
degree	NN	O
diphtheroids	NNS	O
(	(	O
Corynebacterium	NNP	O
species	NNS	O
)	)	O
.	.	O

Proteus	NNP	O
mirabilis	NN	O
,	,	O
Escherichia	NNP	O
coli	NN	O
and	CC	O
micrococci	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
quantitative	JJ	O
diminished	VBN	O
growth	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
of	IN	O
bacteria	NN	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
PVP-I	NNP	PM
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Concerning	VBG	O
the	DT	O
growth	NN	O
of	IN	O
Staph	NNP	O
.	.	O

albus	NN	O
,	,	O
this	DT	O
was	VBD	O
reduced	VBN	O
to	TO	O
almost	RB	O
one	CD	O
third	JJ	O
and	CC	O
other	JJ	O
bacteria	NNS	O
were	VBD	O
almost	RB	O
eliminated	VBN	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
PVP-I	NNP	PM
.	.	O

As	IN	O
we	PRP	O
disclosed	VBD	O
no	DT	O
toxic	NN	O
or	CC	O
allergic	JJ	O
reaction	NN	O
post-operatively	RB	O
which	WDT	O
could	MD	O
be	VB	O
related	VBN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
PVP-I	NNP	PM
as	IN	O
a	DT	O
disinfectant	NN	O
,	,	O
this	DT	O
agent	NN	O
seems	VBZ	O
to	TO	O
constitute	VB	O
an	DT	O
effective	JJ	O
pre-operative	JJ	O
antimicrobial	JJ	O
treatment	NN	O
,	,	O
taking	VBG	O
into	IN	O
consideration	NN	O
the	DT	O
broad	JJ	O
antimicrobial	JJ	O
spectrum	NN	O
of	IN	O
PVP-I	NNP	PM
shown	VBN	O
by	IN	O
other	JJ	O
authors	NNS	O
.	.	O

Long-term	JJ	O
follow-up	NN	O
of	IN	O
the	DT	O
Stockholm	NNP	O
randomized	VBD	O
trials	NNS	O
of	IN	O
postoperative	JJ	PH
radiation	NN	PH
therapy	NN	PH
versus	NN	O
adjuvant	JJ	PH
chemotherapy	NN	PH
among	IN	O
'high	JJ	O
risk	NN	O
'	POS	O
pre-	NN	O
and	CC	O
postmenopausal	NN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

For	IN	O
many	JJ	O
years	NNS	O
,	,	O
loco-regional	JJ	O
radiotherapy	NN	O
was	VBD	O
the	DT	O
standard	JJ	O
postoperative	JJ	O
treatment	NN	O
for	IN	O
node	JJ	O
positive	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
in	IN	O
Sweden	NNP	O
.	.	O

Because	IN	O
of	IN	O
encouraging	VBG	O
results	NNS	O
from	IN	O
trials	NNS	O
of	IN	O
adjuvant	JJ	PH
chemotherapy	NN	PH
in	IN	O
the	DT	O
mid	NN	O
1970s	CD	O
,	,	O
the	DT	O
Stockholm	NNP	O
Breast	NNP	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
decided	VBD	O
to	TO	O
directly	RB	O
compare	VB	O
postoperative	JJ	PH
radiation	NN	PH
(	(	O
RT	NNP	O
)	)	O
with	IN	O
adjuvant	JJ	PH
CMF-type	JJ	PH
chemotherapy	NN	PH
(	(	O
CT	NNP	O
)	)	O
.	.	O

Long-term	JJ	O
results	NNS	O
are	VBP	O
presented	VBN	O
from	IN	O
two	CD	O
randomized	JJ	O
trials	NNS	O
of	IN	O
RT	NNP	PM
versus	NN	O
CT	NNP	PM
in	IN	O
pre-	NN	O
(	(	O
n	JJ	O
=	NNP	O
547	CD	O
)	)	O
and	CC	O
postmenopausal	NN	O
(	(	O
n	JJ	O
=	NNP	O
679	CD	O
)	)	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
node	JJ	O
positive	JJ	O
disease	NN	O
or	CC	O
a	DT	O
tumour	JJ	O
diameter	NN	O
>	VBD	O
30	CD	O
mm	NN	O
.	.	O

RT	NNP	O
substantially	RB	O
reduced	VBD	O
loco-regional	JJ	O
recurrences	NNS	O
among	IN	O
both	DT	O
pre-	JJ	O
and	CC	O
postmenopausal	JJ	O
patients	NNS	O
(	(	O
relative	JJ	O
hazard	NN	O
RT	NNP	O
versus	NN	O
CT	NNP	O
:	:	O
0.67	CD	O
and	CC	O
0.43	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Among	IN	O
premenopausal	JJ	O
patients	NNS	O
distant	JJ	O
metastases	NNS	O
occurred	VBD	O
less	RBR	O
frequently	RB	O
in	IN	O
the	DT	O
CT	NNP	O
group	NN	O
(	(	O
relative	JJ	O
hazard	NN	O
:	:	O
1.68	CD	O
,	,	O
p	NN	O
>	NNP	O
0.001	CD	O
)	)	O
resulting	VBG	O
in	IN	O
an	DT	O
improved	JJ	O
recurrence-free	JJ	O
survival	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Overall	JJ	O
survival	NN	O
was	VBD	O
also	RB	O
better	RB	O
with	IN	O
CT	NNP	O
(	(	O
cumulative	JJ	O
survival	NN	O
at	IN	O
15	CD	O
years	NNS	O
:	:	O
50	CD	O
%	NN	O
and	CC	O
44	CD	O
%	NN	O
in	IN	O
the	DT	O
CT	NNP	O
and	CC	O
RT	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
but	CC	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Among	IN	O
the	DT	O
postmenopausal	NN	O
patients	NNS	O
there	EX	O
were	VBD	O
no	DT	O
substantial	JJ	O
differences	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
recurrence-free	NN	O
or	CC	O
overall	JJ	O
survival	NN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
a	DT	O
second	JJ	O
primary	JJ	O
malignancy	NN	O
,	,	O
however	RB	O
,	,	O
was	VBD	O
doubled	VBN	O
in	IN	O
the	DT	O
RT	NNP	O
group	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
pronounced	JJ	O
excess	NN	O
concerned	JJ	O
second	JJ	O
lung	NN	O
cancers	NNS	O
occurring	VBG	O
after	IN	O
10	CD	O
years	NNS	O
.	.	O

The	DT	O
cumulative	JJ	O
incidence	NN	O
at	IN	O
20	CD	O
years	NNS	O
was	VBD	O
estimated	VBN	O
at	IN	O
0.3	CD	O
%	NN	O
and	CC	O
3.7	CD	O
%	NN	O
in	IN	O
the	DT	O
CT	NNP	O
and	CC	O
RT	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
trials	NNS	O
illustrate	VBP	O
the	DT	O
role	NN	O
of	IN	O
radiotherapy	NN	O
in	IN	O
preventing	VBG	O
loco-regional	JJ	O
recurrences	NNS	O
among	IN	O
high-risk	JJ	O
patients	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
need	NN	O
for	IN	O
systemic	JJ	O
treatment	NN	O
to	TO	O
control	VB	O
the	DT	O
disease	NN	O
systemically	RB	O
.	.	O

Depressive	JJ	O
mood	NN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
ovarian	JJ	O
suppression	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
if	IN	O
sertraline	NN	PM
is	VBZ	O
helpful	JJ	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
depressive	NN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
ovarian	JJ	O
suppression	NN	O
during	IN	O
GnRH	NNP	PM
agonist	JJ	PM
therapy	NN	PM
as	IN	O
compared	VBN	O
with	IN	O
a	DT	O
placebo-controlled	JJ	C
group	NN	O
.	.	O

DESIGN	NNP	O
Double-blind	JJ	O
placebo-controlled	JJ	O
prospective	JJ	O
study	NN	O
design	NN	O
.	.	O

SETTING	NN	O
An	DT	O
obstetrics/gynecological	JJ	O
office	NN	O
specializing	VBG	O
in	IN	O
infertility	NN	O
in	IN	O
an	DT	O
academic	JJ	O
environment	NN	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Premenstrual	NNP	O
women	NNS	O
with	IN	O
laparoscopically	RB	O
diagnosed	VBN	O
endometriosis	NN	O
who	WP	O
required	VBD	O
GnRH	NNP	PM
agonist	JJ	PM
therapy	NN	PM
for	IN	O
treatment	NN	O
and	CC	O
did	VBD	O
not	RB	O
have	VB	O
significant	JJ	O
depressive	JJ	O
or	CC	O
premenstrual	JJ	O
mood	NN	O
symptoms	NNS	O
at	IN	O
baseline	NN	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
Participants	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
the	DT	O
sertraline	JJ	O
treatment	NN	O
group	NN	O
or	CC	O
to	TO	O
the	DT	O
placebo	NN	O
group	NN	O
for	IN	O
the	DT	O
3-month	JJ	O
duration	NN	O
of	IN	O
the	DT	O
GnRH	NNP	PM
agonist	NN	PM
therapy	NN	PM
.	.	PM

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
The	DT	O
21-item	JJ	O
Hamilton	NNP	O
Rating	NNP	O
Scale	NNP	O
for	IN	O
Depression	NNP	O
(	(	O
HRSD	NNP	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
an	DT	O
instrument	NN	O
designed	VBN	O
to	TO	O
assess	VB	O
depressive	JJ	O
symptomatology	NN	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
Hotellings	NNP	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
test	NN	O
for	IN	O
repeated	VBN	O
measure	NN	O
analysis	NN	O
indicated	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
between-group	NN	O
difference	NN	O
across	IN	O
time	NN	O
for	IN	O
the	DT	O
HRSD	NNP	O
(	(	O
T	NNP	O
(	(	O
2	CD	O
)	)	O
=	NN	O
13.3	CD	O
;	:	O
F	NNP	O
[	VBZ	O
3	CD	O
,	,	O
28	CD	O
]	NN	O
=	NN	O
4.1	CD	O
;	:	O
P=.02	NNP	O
)	)	O
with	IN	O
the	DT	O
sertraline	NN	PM
treatment	NN	O
group	NN	O
manifesting	VBG	O
significantly	RB	O
fewer	JJR	O
depressive	NN	O
symptoms	NNS	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
The	DT	O
results	NNS	O
indicate	VBP	O
that	DT	O
sertraline	NN	PM
is	VBZ	O
an	DT	O
effective	JJ	O
option	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
depressive	JJ	O
mood	NN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
ovarian	JJ	O
suppression	NN	O
during	IN	O
GnRH	NNP	PM
agonist	JJ	PM
therapy	NN	PM
.	.	PM

[	NN	O
Erythropoietin	NNP	PM
therapy	NN	O
during	IN	O
frequent	JJ	O
autologous	JJ	O
blood	NN	O
donations	NNS	O
.	.	O

Dose-finding	NN	O
study	NN	O
]	NNP	O
.	.	O

Avoidance	NN	O
of	IN	O
homologous	JJ	O
blood	NN	O
products	NNS	O
and	CC	O
patients	NNS	O
'	POS	O
demand	NN	O
for	IN	O
preoperative	JJ	O
autologous	JJ	O
blood	NN	O
donation	NN	O
programs	NNS	O
are	VBP	O
increasing	VBG	O
.	.	O

As	IN	O
many	JJ	O
of	IN	O
these	DT	O
patients	NNS	O
are	VBP	O
older	JJR	O
,	,	O
with	IN	O
a	DT	O
compromised	VBN	O
cardiovascular	NN	O
system	NN	O
and	CC	O
a	DT	O
slow	JJ	O
response	NN	O
of	IN	O
the	DT	O
erythropoietic	JJ	O
system	NN	O
when	WRB	O
anemia	NN	O
occurs	VBZ	O
,	,	O
the	DT	O
feasibility	NN	O
and	CC	O
benefit	NN	O
of	IN	O
autologous	JJ	O
blood	NN	O
donation	NN	O
is	VBZ	O
often	RB	O
limited	JJ	O
.	.	O

Augmentation	NN	O
of	IN	O
preoperative	JJ	O
blood	NN	O
donation	NN	O
by	IN	O
therapy	NN	O
with	IN	O
recombinant	JJ	PM
human	JJ	PM
erythropoietin	NN	PM
(	(	O
rHuEPO	NN	O
)	)	O
has	VBZ	O
been	VBN	O
described	VBN	O
in	IN	O
animal	JJ	O
models	NNS	O
and	CC	O
in	IN	O
patients	NNS	O
.	.	O

METHODS	NNP	O
.	.	O

In	IN	O
a	DT	O
multicenter	NN	O
,	,	O
controlled	VBN	O
,	,	O
randomized	VBN	O
trial	NN	O
,	,	O
49	CD	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
orthopaedic	JJ	O
or	CC	O
vascular	JJ	O
surgery	NN	O
received	VBD	O
0	CD	O
(	(	O
control	NN	O
group	NN	O
,	,	O
n	RB	O
=	VBZ	O
9	CD	O
)	)	O
,	,	O
200	CD	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
300	CD	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
,	,	O
400	CD	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
500	CD	O
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
U/kg	NNP	O
rHuEPO	NN	PM
(	(	O
Erypo	NNP	PM
,	,	O
Cilag	NNP	PM
,	,	O
Sulzbach	NNP	PM
,	,	O
distributor	NN	PM
Fresenius	NNP	PM
,	,	O
Oberursel	NNP	PM
,	,	O
Germany	NNP	O
)	)	O
subcutaneously	RB	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
while	IN	O
every	DT	O
week	NN	O
450	CD	O
ml	NN	O
blood	NN	O
was	VBD	O
collected	VBN	O
.	.	O

Iron	NNP	PM
sulphate	NN	PM
100	CD	PM
mg	NN	PM
was	VBD	O
prescribed	VBN	O
orally	RB	O
twice	RB	O
a	DT	O
day	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
ineligible	JJ	O
if	IN	O
they	PRP	O
had	VBD	O
uncontrolled	VBN	O
hypertension	NN	O
,	,	O
recent	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
haematological	JJ	O
disorders	NNS	O
or	CC	O
a	DT	O
history	NN	O
of	IN	O
seizures	NNS	O
.	.	O

Blood	NNP	O
donation	NN	O
had	VBD	O
to	TO	O
be	VB	O
cancelled	VBN	O
if	IN	O
the	DT	O
haematocrit	NN	O
was	VBD	O
below	IN	O
30	CD	O
%	NN	O
.	.	O

RESULTS	NNP	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
ANOVA	NNP	O
)	)	O
drop	NN	O
of	IN	O
the	DT	O
haematocrit	NN	O
value	NN	O
only	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
and	CC	O
end-point	NN	O
values	NNS	O
for	IN	O
haematocrit	NN	O
and	CC	O
haemoglobin	NN	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
in	IN	O
the	DT	O
400	CD	O
and	CC	O
500	CD	O
U/kg	NNP	O
groups	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
Table	NNP	O
9	CD	O
)	)	O
.	.	O

DISCUSSION	NNP	O
.	.	O

The	DT	O
erythropoietic	JJ	O
stimulus	NN	O
of	IN	O
phlebotomy	NN	O
for	IN	O
autologous	JJ	O
blood	NN	O
donations	NNS	O
is	VBZ	O
often	RB	O
not	RB	O
efficient	JJ	O
enough	RB	O
to	TO	O
guarantee	VB	O
a	DT	O
constant	JJ	O
haematocrit	NN	O
.	.	O

Lowering	VBG	O
of	IN	O
the	DT	O
preoperative	JJ	O
haematocrit	NN	O
jeopardizes	VBZ	O
the	DT	O
aim	NN	O
of	IN	O
avoidance	NN	O
of	IN	O
homologous	JJ	O
blood	NN	O
transfusions	NNS	O
.	.	O

rHuEPO	NN	O
increased	VBD	O
the	DT	O
efficiency	NN	O
of	IN	O
autologous	JJ	O
blood	NN	O
collections	NNS	O
,	,	O
as	IN	O
predonation	NN	O
haematocrit	NN	O
values	NNS	O
could	MD	O
be	VB	O
preserved	VBN	O
in	IN	O
the	DT	O
high-dosage	NN	O
groups	NNS	O
.	.	O

As	IN	O
a	DT	O
consequence	NN	O
,	,	O
homologous	JJ	O
transfusions	NNS	O
could	MD	O
be	VB	O
avoided	VBN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
broad	JJ	O
interindividual	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
erythropoietic	JJ	O
response	NN	O
,	,	O
possibly	RB	O
due	JJ	O
to	TO	O
limitations	NNS	O
in	IN	O
iron	NN	O
availability	NN	O
.	.	O

Adverse	JJ	O
effects	NNS	O
of	IN	O
rHuEPO	NN	PM
therapy	NN	O
,	,	O
such	JJ	O
as	IN	O
hypertension	NN	O
,	,	O
thrombosis	NN	O
or	CC	O
neurologic	JJ	O
disorders	NNS	O
,	,	O
are	VBP	O
mostly	RB	O
reported	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
terminal	JJ	O
kidney	NN	O
failure	NN	O
.	.	O

No	DT	O
such	JJ	O
disturbances	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
.	.	O

CONCLUSION	NNP	O
.	.	O

rHuEPO	NN	O
ameliorates	VBZ	O
the	DT	O
preoperative	JJ	O
decrease	NN	O
of	IN	O
haemoglobin	NN	O
and	CC	O
haematocrit	NN	O
values	NNS	O
due	JJ	O
to	TO	O
autologous	JJ	O
blood	NN	O
donations	NNS	O
in	IN	O
a	DT	O
dose-related	JJ	O
fashion	NN	O
.	.	O

The	DT	O
individually	RB	O
adjusted	VBN	O
dosage	NN	O
of	IN	O
rHuEPO	NN	O
and	CC	O
iron	NN	O
supplementation	NN	O
merits	NNS	O
further	JJ	O
investigation	NN	O
.	.	O

No	DT	O
association	NN	O
between	IN	O
dinucleotide	JJ	O
repeat	NN	O
polymorphism	NN	O
in	IN	O
intron	NN	O
1	CD	O
of	IN	O
the	DT	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
gene	NN	O
EGFR	NNP	O
and	CC	O
risk	NN	O
of	IN	O
lung	NN	O
cancer	NN	O
.	.	O

The	DT	O
tyrosine	JJ	O
kinase	NN	O
receptor	NN	O
EGFR	NNP	O
pathway	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
oncogenic	JJ	O
signaling	NN	O
cascades	NNS	O
involved	VBN	O
in	IN	O
lung	NN	O
cancer	NN	O
,	,	O
mediating	VBG	O
the	DT	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
gene	NN	O
EGFR	NNP	O
.	.	O

First-intron	NNP	PH
polymorphisms	NN	PH
with	IN	O
greater	JJR	O
numbers	NNS	O
of	IN	O
CA	NNP	O
dinucleotide	NN	O
repeats	NNS	O
tend	VBP	O
to	TO	O
downregulate	VB	O
EGFR	NNP	O
expression	NN	O
,	,	O
which	WDT	O
suggests	VBZ	O
that	IN	O
this	DT	O
polymorphism	NN	PH
may	MD	O
modulate	VB	O
susceptibility	NN	O
to	TO	O
lung	NN	O
cancer	NN	O
.	.	O

The	DT	O
present	JJ	O
hospital-based	JJ	PH
case-control	NN	PH
study	NN	PH
evaluated	VBD	PH
the	DT	PH
possible	JJ	PH
association	NN	PH
of	IN	PH
CA	NNP	PH
repeat	NN	PH
polymorphism	NN	PH
in	IN	PH
the	DT	PH
EGFR	NNP	PH
gene	NN	PH
with	IN	O
risk	NN	O
of	IN	O
lung	NN	O
cancer	NN	O
in	IN	O
a	DT	O
Korean	JJ	O
population	NN	O
.	.	O

A	DT	O
bimodal	JJ	O
pattern	NN	O
appeared	VBD	O
,	,	O
with	IN	O
a	DT	O
frequency	NN	O
of	IN	O
57.1	CD	O
%	NN	O
for	IN	O
20	CD	O
CA	NNP	O
repeats	NNS	O
and	CC	O
18.6	CD	O
%	NN	O
for	IN	O
16	CD	O
CA	NNP	O
repeats	NNS	O
.	.	O

There	EX	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
distribution	NN	O
of	IN	O
allele	JJ	O
genotypes	NNS	O
between	IN	O
all	DT	O
lung	NN	O
cancer	NN	O
cases	NNS	O
and	CC	O
the	DT	O
controls	NNS	O
,	,	O
nor	CC	O
among	IN	O
histological	JJ	O
types	NNS	O
for	IN	O
the	DT	O
cases	NNS	O
.	.	O

Pilot	NNP	O
study	NN	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
weighted	JJ	PH
vests	NNS	PH
.	.	O

OBJECTIVE	NN	O
In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
we	PRP	O
determined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
weighted	JJ	PH
vest	NN	PH
on	IN	O
attention	NN	O
to	TO	O
task	VB	O
for	IN	O
second-grade	JJ	O
general	JJ	O
education	NN	O
students	NNS	O
with	IN	O
difficulty	NN	O
attending	VBG	O
.	.	O

METHOD	NNP	O
We	PRP	O
used	VBD	O
an	DT	O
intervention	NN	PH
and	CC	O
a	DT	O
control	NN	C
group	NN	O
and	CC	O
an	DT	O
ABA	NNP	O
design	NN	O
to	TO	O
compare	VB	O
participants	NNS	O
'	POS	O
percentage	NN	O
of	IN	O
time	NN	O
on	IN	O
task	NN	O
with	IN	Ot
and	CC	Ot
without	IN	Ot
a	DT	Ot
vest	NN	Ot
.	.	O

Ten	CD	O
participants	NNS	O
from	IN	O
nine	CD	O
elementary	JJ	O
schools	NNS	O
in	IN	O
a	DT	O
suburban	JJ	O
Texas	NNP	O
school	NN	O
district	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	PH
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Control	NNP	O
group	NN	O
participants	NNS	O
wore	VBD	O
a	DT	O
nonweighted	JJ	Ot
vest	NN	Ot
.	.	O

Participants	NNS	O
,	,	O
classroom	NN	O
teachers	NNS	O
,	,	O
and	CC	O
research	NN	O
assistants	NNS	O
who	WP	O
coded	VBD	O
the	DT	O
data	NNS	O
were	VBD	O
blind	RB	O
as	IN	O
to	TO	O
the	DT	O
group	NN	O
to	TO	O
which	WDT	O
the	DT	O
participants	NNS	O
were	VBD	O
assigned	VBN	O
.	.	O

RESULTS	VB	O
A	NNP	O
repeated	JJ	O
measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
indicated	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
or	CC	O
between	IN	O
baseline	NN	O
,	,	O
intervention	NN	O
,	,	O
and	CC	O
withdrawal	NN	O
conditions	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
weighted	JJ	PH
vests	NNS	PH
were	VBD	O
not	RB	O
effective	JJ	O
in	IN	O
increasing	VBG	O
time	NN	O
on	IN	O
task	NN	O
.	.	O

These	DT	O
results	NNS	O
should	MD	O
be	VB	O
generalized	VBN	O
cautiously	RB	O
owing	VBG	O
to	TO	O
the	DT	O
small	JJ	O
sample	NN	O
size	NN	O
and	CC	O
participant	JJ	O
selection	NN	O
process	NN	O
.	.	O

